S-834	0,97 % 0,40 %
T-834	0.97 %
H-834	-0.005315866786986589	0.97 %
D-834	-0.005315866786986589	0.97 %
P-834	-0.0047 -0.0025 -0.0015 -0.0126
S-652	d ) 487 Days
T-652	d ) 487 Days
H-652	-0.003644001204520464	d ) 487 Days
D-652	-0.003644001204520464	d ) 487 Days
P-652	-0.0011 -0.0015 -0.0029 -0.0013 -0.0135 -0.0014
S-1693	Christiaens B.V
T-1693	Christiaens B. V
H-1693	-0.029106050729751587	Christiaens B. V
D-1693	-0.029106050729751587	Christiaens B. V
P-1693	-0.0083 -0.0019 -0.0021 -0.0144 -0.0040 -0.1439
S-590	40 ( 53 % )
T-590	40 ( 53 % )
H-590	-0.002165718236938119	40 ( 53 % )
D-590	-0.002165718236938119	40 ( 53 % )
P-590	-0.0052 -0.0014 -0.0020 -0.0015 -0.0014 -0.0015
S-1471	R03D C03
T-1471	R03D C03
H-1471	-0.7314103245735168	FIN S
D-1471	-0.7314103245735168	FIN S
P-1471	-2.7848 -0.0145 -0.0551 -0.0713
S-346	Efexor XL
T-346	Efexor XL
H-346	-0.002842994872480631	Efexor XL
D-346	-0.002842994872480631	Efexor XL
P-346	-0.0097 -0.0013 -0.0008 -0.0016 -0.0020 -0.0017
S-588	9,3 ± 2,2
T-588	9.3 ± 2.2
H-588	-0.04712996259331703	9.3 ± 2.2
D-588	-0.04712996259331703	9.3 ± 2.2
P-588	-0.2558 -0.0119 -0.0099 -0.0021 -0.0015 -0.0016
S-114	Videokonferenzen
T-114	Video @-@ conferencing
H-114	-0.005661303177475929	Video @-@ conferencing
D-114	-0.005661303177475929	Video @-@ conferencing
P-114	-0.0079 -0.0143 -0.0063 -0.0007 -0.0018 -0.0030
S-1185	ALT @-@ Anstieg :
T-1185	ALT flare :
H-1185	-0.008553211577236652	ALT flare :
D-1185	-0.008553211577236652	ALT flare :
P-1185	-0.0137 -0.0013 -0.0145 -0.0060 -0.0144 -0.0014
S-189	213,892.23
T-189	213,892.23
H-189	-0.8894392251968384	158
D-189	-0.8894392251968384	158
P-189	-2.5476 -0.0181 -0.1026
S-1165	Selten Palpitationen
T-1165	Rare Palpitations
H-1165	-0.08786366879940033	Rare Palpitations
D-1165	-0.08786366879940033	Rare Palpitations
P-1165	-0.0027 -0.0247 -0.0116 -0.0009 -0.0018 -0.4855
S-1555	Deutschland Luxembourg / Luxemburg
T-1555	Deutschland Luxembourg / Luxemburg
H-1555	-0.006054094061255455	Deutschland Luxembourg / Luxemburg
D-1555	-0.006054094061255455	Deutschland Luxembourg / Luxemburg
P-1555	-0.0146 -0.0018 -0.0009 -0.0050 -0.0126 -0.0014
S-824	N03A X15
T-824	N03A X15
H-824	-1.4872349500656128	R075 100
D-824	-1.4872349500656128	R075 100
P-824	-5.7341 -0.0145 -0.6038 -1.0768 -0.0070
S-1567	Prämedikation :
T-1567	Premedication regimen :
H-1567	-0.11419475823640823	Premedication regimen :
D-1567	-0.11419475823640823	Premedication regimen :
P-1567	-0.0098 -0.0046 -0.6182 -0.0496 -0.0017 -0.0013
S-1612	Syndrom * *
T-1612	syndrome * *
H-1612	-0.003981595393270254	syndrome * *
D-1612	-0.003981595393270254	syndrome * *
P-1612	-0.0143 -0.0008 -0.0019 -0.0015 -0.0014
S-712	ANHANG I
T-712	ANNEX I
H-712	-0.001901392824947834	ANNEX I
D-712	-0.001901392824947834	ANNEX I
P-712	-0.0059 -0.0003 -0.0006 -0.0013 -0.0014
S-1402	Hunde , Katzen .
T-1402	Dogs , cats
H-1402	-0.05710135027766228	Dogs , cats
D-1402	-0.05710135027766228	Dogs , cats
P-1402	-0.0017 -0.0010 -0.0101 -0.0013 -0.2713
S-642	771 000 700 000
T-642	49 000 000
H-642	-0.0765344426035881	49 000 000
D-642	-0.0765344426035881	49 000 000
P-642	-0.0152 -0.0143 -0.1596 -0.1170
S-1571	30 mg / 3 ml
T-1571	30 mg / 3 ml
H-1571	-0.0025185563135892153	30 mg / 3 ml
D-1571	-0.0025185563135892153	30 mg / 3 ml
P-1571	-0.0095 -0.0003 -0.0015 -0.0015 -0.0007 -0.0016
S-922	Arzneistoffen zu erwarten .
T-922	ho death / re @-@ MI at Day 30 were not statistically different : respectively , 8.3 % vs 8.7 % ( hazard ratio 0.94 , 95 % CI , 0.79 , 1.11 p = 0.460 ) .
H-922	-1.9695918560028076	ho death .
D-922	-1.9695918560028076	ho death .
P-922	-0.0242 -0.0145 -7.8376 -0.0021
S-713	116 Patienten empfohlen .
T-713	106 treatment and close observation of the patient are recommended in cases of overdose .
H-713	-0.6385873556137085	106 treatment and close observation of the patient .
D-713	-0.6385873556137085	106 treatment and close observation of the patient .
P-713	-0.0145 -0.0145 -0.0144 -0.0145 -0.0145 -0.0014 -0.0140 -0.0126 -0.0128 -6.9099 -0.0014
S-418	Polysorbat 80 .
T-418	Docetaxel Winthrop vial : polysorbate 80 .
H-418	-0.395401269197464	Docetaxel vial : polysorbate 80 .
D-418	-0.395401269197464	Docetaxel vial : polysorbate 80 .
P-418	-0.0145 -0.0146 -0.0145 -0.0141 -0.0111 -5.7290 -0.0125 -0.0158 -0.0180 -0.0024 -0.0027 -0.0016 -0.0762 -0.0024 -0.0014
S-159	Wirtschaftlichkeit Jährlichkeit
T-159	s Cost @-@ effectiveness s Annuality
H-159	-0.009358604438602924	s Cost @-@ effectiveness s Annuality
D-159	-0.009358604438602924	s Cost @-@ effectiveness s Annuality
P-159	-0.0145 -0.0145 -0.0005 -0.0107 -0.0066 -0.0010 -0.0186 -0.0147 -0.0031 -0.0116 -0.0073
S-773	• Halten Sie den
T-773	Holder to collect air at top .
H-773	-0.012945328839123249	Holder to collect air at top .
D-773	-0.012945328839123249	Holder to collect air at top .
P-773	-0.0146 -0.0136 -0.0145 -0.0145 -0.0146 -0.0145 -0.0145 -0.0144 -0.0015
S-1343	Anschlußersuchen )
T-1343	( 1 + 2 follow @-@ up )
H-1343	-1.1569029092788696	( 1 + 2 follow up )
D-1343	-1.1569029092788696	( 1 + 2 follow up )
P-1343	-0.0143 -0.0145 -0.0146 -0.0122 -0.0147 -9.1743 -0.0092 -0.0015
S-1789	{ Nummer } 14 .
T-1789	{ number } ng lo 14 .
H-1789	-0.03193613141775131	{ number } ng lo 14 .
D-1789	-0.03193613141775131	{ number } ng lo 14 .
P-1789	-0.0007 -0.0085 -0.0012 -0.0313 -0.0145 -0.1307 -0.0976 -0.0016 -0.0014
S-591	19 Psychiatrische Erkrankungen
T-591	Psychiatric disorders
H-591	-0.005642239470034838	Psychiatric disorders
D-591	-0.005642239470034838	Psychiatric disorders
P-591	-0.0146 -0.0019 -0.0011 -0.0110 -0.0010 -0.0043
S-1433	CA Woche 13 @-@ 52
T-1433	CA wk 13 @-@ 52
H-1433	-0.005131726153194904	CA wk 13 @-@ 52
D-1433	-0.005131726153194904	CA wk 13 @-@ 52
P-1433	-0.0038 -0.0145 -0.0125 -0.0014 -0.0014 -0.0010 -0.0014
S-721	10 ( 1,8 % )
T-721	10 ( 1.8 % )
H-721	-0.0016620132373645902	10 ( 1.8 % )
D-721	-0.0016620132373645902	10 ( 1.8 % )
P-721	-0.0032 -0.0015 -0.0012 -0.0014 -0.0016 -0.0014 -0.0015
S-1223	ANHÄNGE
T-1223	ANNE S XE
H-1223	-0.932013213634491	ANNE S
D-1223	-0.932013213634491	ANNE S
P-1223	-0.0105 -0.0145 -0.0145 -0.0153 -4.6052
S-616	Polypropylen-
T-616	Bottle ( PP )
H-616	-0.012595869600772858	Bottle ( PP )
D-616	-0.012595869600772858	Bottle ( PP )
P-616	-0.0220 -0.0139 -0.0092 -0.0145 -0.0145 -0.0092 -0.0049
S-1651	Weibliche Lachsartige
T-1651	Female salmonid fish
H-1651	-0.010952691547572613	Female salmonid fish
D-1651	-0.010952691547572613	Female salmonid fish
P-1651	-0.0119 -0.0025 -0.0085 -0.0080 -0.0136 -0.0216 -0.0106
S-609	3 @-@ 4 @-@ 5
T-609	3 @-@ 4 @-@ 5
H-609	-0.004878242965787649	3 @-@ 4 @-@ 5
D-609	-0.004878242965787649	3 @-@ 4 @-@ 5
P-609	-0.0204 -0.0020 -0.0021 -0.0015 -0.0015 -0.0018
S-157	261 Systemorgan-
T-157	Gastrointestinal Disorders
H-157	-1.4004400968551636	Gastrointestinal system
D-157	-1.4004400968551636	Gastrointestinal system
P-157	-0.0146 -0.0053 -0.0085 -0.0005 -0.0004 -9.4831 -0.2907
S-113	Cerezyme
T-113	Cerezyme
H-113	-0.003833177499473095	Cerezyme
D-113	-0.003833177499473095	Cerezyme
P-113	-0.0103 -0.0006 -0.0055 -0.0008 -0.0019
S-246	Rapinyl4
T-246	Rapinyl 4
H-246	-0.037292592227458954	Rapinyl 4
D-246	-0.037292592227458954	Rapinyl 4
P-246	-0.0086 -0.0017 -0.0130 -0.0095 -0.1537
S-1715	( 16,5 )
T-1715	( 16.5 )
H-1715	-0.016060780733823776	( 16.5 )
D-1715	-0.016060780733823776	( 16.5 )
P-1715	-0.0468 -0.0114 -0.0191 -0.0015 -0.0016
S-1749	Biliranin
T-1749	Biliranin
H-1749	-0.002808957127854228	Biliranin
D-1749	-0.002808957127854228	Biliranin
P-1749	-0.0061 -0.0010 -0.0015 -0.0039 -0.0015
S-1309	Oral * *
T-1309	Oral * *
H-1309	-0.002084731822833419	Oral * *
D-1309	-0.002084731822833419	Oral * *
P-1309	-0.0038 -0.0002 -0.0033 -0.0016 -0.0015
S-1790	6c 7d
T-1790	6c 7d
H-1790	-0.004773951601237059	6c 7d
D-1790	-0.004773951601237059	6c 7d
P-1790	-0.0168 -0.0013 -0.0034 -0.0009 -0.0015
S-272	Für mittelgroße Hunde
T-272	for medium sized dogs
H-272	-0.03477803245186806	for medium sized dogs
D-272	-0.03477803245186806	for medium sized dogs
P-272	-0.0140 -0.0021 -0.0102 -0.0014 -0.1462
S-343	- - 40 -
T-343	<<unk>> <<unk>> 40 <<unk>>
H-343	-0.1483364850282669	<unk> <unk> 40 <unk>
D-343	-0.1483364850282669	<unk> <unk> 40 <unk>
P-343	-0.6924 -0.0135 -0.0143 -0.0145 -0.0070
S-1694	0,0 6,2
T-1694	14.0 0.0
H-1694	-0.6663088798522949	2 447
D-1694	-0.6663088798522949	2 447
P-1694	-2.6174 -0.0188 -0.0145 -0.0145
S-1602	200 Hartkapseln
T-1602	200 hard capsules
H-1602	-1.9640787839889526	200 Hands After
D-1602	-1.9640787839889526	200 Hands After
P-1602	-0.0025 -9.2904 -0.2279 -0.2944 -0.0052
S-1157	Meldungen aus Drittländern
T-1157	Non @-@ EU reports
H-1157	-0.027395857498049736	Non @-@ EU reports
D-1157	-0.027395857498049736	Non @-@ EU reports
P-1157	-0.0145 -0.0018 -0.0065 -0.0139 -0.1002
S-1966	KINERET
T-1966	KINERET
H-1966	-0.031302765011787415	KINERET
D-1966	-0.031302765011787415	KINERET
P-1966	-0.1465 -0.0040 -0.0030 -0.0010 -0.0020
S-125	n = 157
T-125	N = 157
H-125	-0.188096284866333	N = 157
D-125	-0.188096284866333	N = 157
P-125	-0.9161 -0.0012 -0.0202 -0.0015 -0.0014
S-1412	n = 257
T-1412	n = 257
H-1412	-0.1844387948513031	n = 257
D-1412	-0.1844387948513031	n = 257
P-1412	-0.8901 -0.0011 -0.0280 -0.0015 -0.0014
S-1952	23 25 23 -
T-1952	23 25 23 <<unk>>
H-1952	-0.34458887577056885	23 25 23 <unk>
D-1952	-0.34458887577056885	23 25 23 <unk>
P-1952	-1.6774 -0.0146 -0.0079 -0.0177 -0.0053
S-439	Actos 45 mg
T-439	Actos 45 mg
H-439	-0.0024297665804624557	Actos 45 mg
D-439	-0.0024297665804624557	Actos 45 mg
P-439	-0.0010 -0.0012 -0.0080 -0.0005 -0.0015
S-390	105,000 105,000
T-390	105,000 105,000
H-390	-0.31817689538002014	105,000 105,000
D-390	-0.31817689538002014	105,000 105,000
P-390	-1.5711 -0.0031 -0.0143 -0.0009 -0.0014
S-1812	1,6 mg / ml
T-1812	1.6 mg / ml
H-1812	-0.002283396665006876	1.6 mg / ml
D-1812	-0.002283396665006876	1.6 mg / ml
P-1812	-0.0070 -0.0004 -0.0015 -0.0010 -0.0015
S-977	( Wochen ) :
T-977	( weeks ) :
H-977	-0.004195389803498983	( weeks ) :
D-977	-0.004195389803498983	( weeks ) :
P-977	-0.0092 -0.0074 -0.0015 -0.0014 -0.0014
S-532	e sp 9 .
T-532	nd 9 .
H-532	-0.007302355021238327	nd 9 .
D-532	-0.007302355021238327	nd 9 .
P-532	-0.0145 -0.0104 -0.0029 -0.0014
S-177	Feldene Lipo
T-177	Feldene Lipo
H-177	-0.05061476305127144	Feldene Lipo
D-177	-0.05061476305127144	Feldene Lipo
P-177	-0.0138 -0.0142 -0.0075 -0.0005 -0.2170
S-1883	50 % 80 %
T-1883	17 % 29 % 79 % 50 % 80 %
H-1883	-0.3204314410686493	17 % 29 % 79 % 50 % 80 %
D-1883	-0.3204314410686493	17 % 29 % 79 % 50 % 80 %
P-1883	-0.1290 -0.0052 -0.0154 -0.0015 -0.5890 -0.0015 -0.9362 -0.0016 -1.0246 -0.0016 -0.8190
S-1172	Uveitis )
T-1172	Careful monitoring of full blood counts and adverse events to rifabutin ( e. g. uveitis ) is recommended when rifabutin is coadministered with voriconazole .
H-1172	-0.6717434525489807	Careful monitoring of full blood counts and adverse events .
D-1172	-0.6717434525489807	Careful monitoring of full blood counts and adverse events .
P-1172	-0.0145 -0.0145 -0.0145 -0.0127 -0.0145 -0.0141 -0.0145 -0.0179 -0.0145 -0.0072 -0.0106 -8.5815 -0.0018
S-1049	198 Liter .
T-1049	Distribution The mean volume of distribution at steady state following a single 100 @-@ mg intravenous dose of sitagliptin to healthy subjects is approximately 198 litres .
H-1049	-1.1993507146835327	Distribution The mean .
D-1049	-1.1993507146835327	Distribution The mean .
P-1049	-0.0148 -0.0095 -0.0145 -0.0145 -7.1414 -0.0014
S-1354	5.2 Gegenanzeigen
T-1354	5.2 Contraindications and warnings in respect of other products used in the host , immunological status of host and physiological status of host
H-1354	-0.17135345935821533	5.2 Contraindications
D-1354	-0.17135345935821533	5.2 Contraindications
P-1354	-0.0031 -0.0017 -0.0062 -0.0028 -0.0042 -0.0012 -1.1802
S-1124	April 2005 wieder .
T-1124	The information given in this document and Annexes reflect only the CHMP Opinion dated 21 April 2005 .
H-1124	-0.4713851809501648	The Marketing Authorisation Holder provided supplementary information .
D-1124	-0.4713851809501648	The Marketing Authorisation Holder provided supplementary information .
P-1124	-0.0144 -6.2873 -0.0145 -0.0129 -0.0061 -0.0145 -0.0178 -0.0165 -0.0145 -0.0089 -0.0014 -0.0087 -0.1806 -0.0014
S-1285	November 2008 erwartet .
T-1285	The sixth and seventh 6 @-@ monthly safety update reports are expected in May 2008 and November 2008 , respectively .
H-1285	-0.5970867872238159	The sixth and seventh 6 @-@ monthly safety update reports are expected Nov.
D-1285	-0.5970867872238159	The sixth and seventh 6 @-@ monthly safety update reports are expected Nov.
P-1285	-0.0145 -0.0360 -0.0143 -0.0143 -0.0145 -0.0068 -0.0145 -0.0145 -0.0145 -0.0145 -0.0133 -0.0062 -8.1799 -0.0014
S-358	Clofarabin
T-358	International non @-@ proprietary name ( INN ) : clofarabine
H-358	-1.3782086372375488	Clofarabine
D-358	-1.3782086372375488	Clofarabine
P-358	-6.8841 -0.0006 -0.0014 -0.0035 -0.0015
S-555	Mai 2007 verlängert .
T-555	The marketing authorisation was renewed on 22 May 2002 and 22 May 2007 .
H-555	-0.17362868785858154	The marketing authorisation was renewed on 22 May 2002 and 22 May 2007 .
D-555	-0.17362868785858154	The marketing authorisation was renewed on 22 May 2002 and 22 May 2007 .
P-555	-0.0145 -0.0165 -0.0145 -0.0041 -0.0101 -0.0115 -0.0134 -0.0504 -0.3444 -0.2199 -1.3050 -0.0143 -0.0404 -0.1648 -0.5527 -0.0014
S-319	vermindern .
T-319	Nifedipine can lower the chance of conception .
H-319	-1.0333224534988403	Nifedipine .
D-319	-1.0333224534988403	Nifedipine .
P-319	-0.0145 -0.0145 -0.0145 -0.0145 -0.0144 -7.1595 -0.0014
S-1348	2034 / 96
T-1348	Commission Regulation ( EEC ) No 2034 / 96
H-1348	-0.9029392004013062	Commission Regulation ( EEC )
D-1348	-0.9029392004013062	Commission Regulation ( EEC )
P-1348	-0.0465 -0.0145 -0.0491 -0.0148 -0.0136 -0.0102 -0.0014 -7.0734
S-1458	Häufig Infektion
T-1458	Common Infection Common Hypotension , Flushing
H-1458	-0.1454942524433136	Common Infection
D-1458	-0.1454942524433136	Common Infection
P-1458	-0.0245 -0.0012 -0.0144 -0.0045 -0.6829
S-1832	STUDIE 2
T-1832	STUDY 2
H-1832	-0.003599689807742834	STUDY 2
D-1832	-0.003599689807742834	STUDY 2
P-1832	-0.0145 -0.0009 -0.0010 -0.0011 -0.0025 -0.0015
S-463	Juli 1961 , Franzose
T-463	40 EMEA Work Programme 2001 @-@ 2002
H-463	-1.067750096321106	40 EMEA Work Programme
D-463	-1.067750096321106	40 EMEA Work Programme
P-463	-0.0145 -0.0145 -0.0145 -0.0120 -0.0148 -0.0145 -7.3894
S-899	( morgens ) :
T-899	atazanavir ( am ) :
H-899	-0.010715904645621777	atazanavir ( am ) :
D-899	-0.010715904645621777	atazanavir ( am ) :
P-899	-0.0188 -0.0145 -0.0145 -0.0145 -0.0137 -0.0123 -0.0144 -0.0015 -0.0016 -0.0014
S-42	Peter JONES
T-42	Head of Unit Peter JONES
H-42	-1.1831597089767456	Head of Unit Peter Jones
D-42	-1.1831597089767456	Head of Unit Peter Jones
P-42	-0.0146 -0.0058 -0.0145 -0.0122 -0.0116 -8.2216 -0.0018
S-1038	Verschwommensehen
T-1038	Very Common : vision blurred
H-1038	-1.5673575401306152	Very Common :
D-1038	-1.5673575401306152	Very Common :
P-1038	-0.0145 -0.0145 -0.0017 -0.0145 -7.7916
S-1414	34 % 25 %
T-1414	34 % 25 % 34 %
H-1414	-0.11458167433738708	34 % 25 % 34 %
D-1414	-0.11458167433738708	34 % 25 % 34 %
P-1414	-0.0859 -0.0012 -0.0090 -0.0013 -0.3138 -0.0017 -0.3892
S-1703	ge Selten :
T-1703	89 pain Rarely :
H-1703	-0.6992045640945435	89 pain Rare :
D-1703	-0.6992045640945435	89 pain Rare :
P-1703	-0.0145 -0.0145 -0.0145 -4.1438 -0.0066 -0.0014
S-1569	Kapsel oder Lösung
T-1569	Capsule or Solution
H-1569	-0.003832725342363119	Capsule or Solution
D-1569	-0.003832725342363119	Capsule or Solution
P-1569	-0.0062 -0.0008 -0.0018 -0.0020 -0.0136 -0.0009 -0.0015
S-1974	Referatsleiter :
T-1974	Head of Unit :
H-1974	-0.0020027339924126863	Head of Unit :
D-1974	-0.0020027339924126863	Head of Unit :
P-1974	-0.0026 -0.0015 -0.0039 -0.0012 -0.0015 -0.0014
S-374	934 11,57
T-374	12,934 11.57
H-374	-0.7202011346817017	2 447
D-374	-0.7202011346817017	2 447
P-374	-2.8322 -0.0197 -0.0144 -0.0145
S-4	Zahl der Delegierten
T-4	Number of delegates
H-4	-0.0030597643926739693	Number of delegates
D-4	-0.0030597643926739693	Number of delegates
P-4	-0.0026 -0.0015 -0.0064 -0.0018
S-106	197 1 .
T-106	170 1 .
H-106	-0.12137524038553238	170 1 .
D-106	-0.12137524038553238	170 1 .
P-106	-0.4683 -0.0133 -0.0025 -0.0014
S-599	544 6 .
T-599	is 6 .
H-599	-0.058477044105529785	is 6 .
D-599	-0.058477044105529785	is 6 .
P-599	-0.2153 -0.0142 -0.0029 -0.0014
S-1553	Andere Wirkstoffe :
T-1553	Other agents :
H-1553	-0.004506029188632965	Other agents :
D-1553	-0.004506029188632965	Other agents :
P-1553	-0.0015 -0.0133 -0.0018 -0.0014
S-1081	Zurückgezo-
T-1081	Withdrawn
H-1081	-0.007496913895010948	Withdrawn
D-1081	-0.007496913895010948	Withdrawn
P-1081	-0.0138 -0.0015 -0.0072
S-268	Arzneimittels reagieren .
T-268	medicine .
H-268	-0.011001117527484894	medicine .
D-268	-0.011001117527484894	medicine .
P-268	-0.0254 -0.0061 -0.0015
S-504	150 Mikrogramm
T-504	150 micrograms
H-504	-0.0019675130024552345	150 micrograms
D-504	-0.0019675130024552345	150 micrograms
P-504	-0.0016 -0.0022 -0.0026 -0.0015
S-1839	03.04.2006
T-1839	03.04.2006
H-1839	-0.3568432927131653	03.04.2006
D-1839	-0.3568432927131653	03.04.2006
P-1839	-1.3006 -0.0020 -0.0117 -0.1131
S-1452	58 7 .
T-1452	54 7 .
H-1452	-0.031929709017276764	54 7 .
D-1452	-0.031929709017276764	54 7 .
P-1452	-0.1122 -0.0123 -0.0019 -0.0014
S-839	FIN S
T-839	FIN S
H-839	-0.43158620595932007	FIN S
D-839	-0.43158620595932007	FIN S
P-839	-1.7058 -0.0106 -0.0083 -0.0017
S-1084	21.11.2008
T-1084	21.11.2008
H-1084	-0.071714386343956	21.11.2008
D-1084	-0.071714386343956	21.11.2008
P-1084	-0.2785 -0.0050 -0.0018 -0.0015
S-404	as 14 .
T-404	or 14 .
H-404	-0.006761600729078054	or 14 .
D-404	-0.006761600729078054	or 14 .
P-404	-0.0145 -0.0092 -0.0020 -0.0014
S-443	1 , 10
T-443	1 , 10
H-443	-0.0925789549946785	1 , 10
D-443	-0.0925789549946785	1 , 10
P-443	-0.3592 -0.0032 -0.0047 -0.0033
S-1964	Ältere Menschen
T-1964	Geriatric
H-1964	-0.008940287865698338	Geriatric
D-1964	-0.008940287865698338	Geriatric
P-1964	-0.0145 -0.0002 -0.0161 -0.0050
S-1030	&gt; 105 kg
T-1030	&gt; 105 kg
H-1030	-0.006268254481256008	&gt; 105 kg
D-1030	-0.006268254481256008	&gt; 105 kg
P-1030	-0.0157 -0.0062 -0.0018 -0.0015
S-142	4 / 30
T-142	4 / 28
H-142	-0.11239825934171677	4 / 28
D-142	-0.11239825934171677	4 / 28
P-142	-0.4034 -0.0015 -0.0316 -0.0131
S-1526	Bild 1 .
T-1526	Picture 1 .
H-1526	-0.003909064456820488	Picture 1 .
D-1526	-0.003909064456820488	Picture 1 .
P-1526	-0.0104 -0.0023 -0.0015 -0.0014
S-1779	0,42 *
T-1779	0.42 *
H-1779	-0.08922841399908066	0.42 *
D-1779	-0.08922841399908066	0.42 *
P-1779	-0.3478 -0.0016 -0.0061 -0.0015
S-680	69 / 75
T-680	67 / 72
H-680	-0.04357926547527313	67 / 72
D-680	-0.04357926547527313	67 / 72
P-680	-0.1429 -0.0049 -0.0149 -0.0117
S-1781	21 Tage nach
T-1781	21 Days After
H-1781	-0.00976300798356533	21 Days After
D-1781	-0.00976300798356533	21 Days After
P-1781	-0.0166 -0.0142 -0.0068 -0.0015
S-1051	14.11.2007
T-1051	14.11.2007
H-1051	-0.12025779485702515	14.11.2007
D-1051	-0.12025779485702515	14.11.2007
P-1051	-0.4698 -0.0036 -0.0062 -0.0015
S-661	68 / 69
T-661	60 / 61
H-661	-0.041104789823293686	60 / 61
D-661	-0.041104789823293686	60 / 61
P-661	-0.1337 -0.0035 -0.0145 -0.0128
S-1910	92 B .
T-1910	86 B .
H-1910	-0.010434145107865334	86 B .
D-1910	-0.010434145107865334	86 B .
P-1910	-0.0170 -0.0097 -0.0137 -0.0014
S-398	ECU .
T-398	The European
H-398	-0.015710555016994476	The European
D-398	-0.015710555016994476	The European
P-398	-0.0147 -0.0182 -0.0143
S-1750	158 66
T-1750	158
H-1750	-0.6613739132881165	2.09
D-1750	-0.6613739132881165	2.09
P-1750	-2.5825 -0.0310 -0.0208 -0.0111
S-915	Mehl :
T-915	Meal :
H-915	-0.005991986487060785	Meal :
D-915	-0.005991986487060785	Meal :
P-915	-0.0144 -0.0064 -0.0018 -0.0013
S-873	61 Mitgliedsstaat
T-873	61 Member State
H-873	-0.006696345750242472	61 Member State
D-873	-0.006696345750242472	61 Member State
P-873	-0.0046 -0.0143 -0.0063 -0.0016
S-208	48 Stunden .
T-208	Following application of EVRA , norelgestromin and ethinyl estradiol levels in serum reach a plateau by approximately 48 hours .
H-208	-0.829679012298584	Following application of EVRA .
D-208	-0.829679012298584	Following application of EVRA .
P-208	-0.0145 -0.0145 -0.0143 -0.0145 -0.0141 -0.0144 -0.0138 -7.3656 -0.0014
S-422	Juli 2002 .
T-422	As the company had supplied the additional information requested , the <<unk>> Exceptional Circumstances <<unk>> ended on 11 July 2002 .
H-422	-1.2115741968154907	As the company had supplied .
D-422	-1.2115741968154907	As the company had supplied .
P-422	-0.0147 -0.0143 -0.0145 -0.0144 -0.0145 -0.0009 -9.6179 -0.0014
S-1501	Dosen )
T-1501	40 mg / day ( 3 doses ) 80 mg / day ( 3 dose )
H-1501	-1.4027589559555054	40 mg / day )
D-1501	-1.4027589559555054	40 mg / day )
P-1501	-0.0145 -0.0145 -0.0162 -0.0144 -7.9822 -0.3748
S-1070	September 2008 .
T-1070	A Decision was issued by the European Commission on 23 September 2008 .
H-1070	-1.7809782028198242	A Sept .
D-1070	-1.7809782028198242	A Sept .
P-1070	-0.0145 -7.1066 -0.0015 -0.0013
S-1622	Auftropfen
T-1622	Spot @-@ on solution Dogs Spot @-@ on use
H-1622	-0.2057104855775833	Spot @-@ on solution
D-1622	-0.2057104855775833	Spot @-@ on solution
P-1622	-0.0145 -0.0141 -0.0140 -0.0143 -0.0203 -1.1571
S-101	10 / 18
T-101	AMENDMENTS
H-101	-0.08642710745334625	AMENDMENTS
D-101	-0.08642710745334625	AMENDMENTS
P-101	-0.5480 -0.0144 -0.0138 -0.0088 -0.0026 -0.0144 -0.0031
S-1726	22 Lebensqualität
T-1726	Quality of Life
H-1726	-0.007350344210863113	Quality of Life
D-1726	-0.007350344210863113	Quality of Life
P-1726	-0.0148 -0.0011 -0.0016 -0.0137 -0.0056
S-890	- Milch :
T-890	- Milk :
H-890	-0.003021130571141839	- Milk :
D-890	-0.003021130571141839	- Milk :
P-890	-0.0043 -0.0064 -0.0010 -0.0021 -0.0014
S-1998	12 / 23
T-1998	12 / 22
H-1998	-0.10514263808727264	12 / 22
D-1998	-0.10514263808727264	12 / 22
P-1998	-0.3783 -0.0019 -0.0273 -0.0131
S-444	37,1
T-444	37.1
H-444	-0.46117332577705383	37.1
D-444	-0.46117332577705383	37.1
P-444	-1.8127 -0.0070 -0.0160 -0.0090
S-1849	20,8 %
T-1849	20.8 %
H-1849	-0.09122180938720703	20.8 %
D-1849	-0.09122180938720703	20.8 %
P-1849	-0.2487 -0.0356 -0.0015 -0.0791
S-1841	20 9 .
T-1841	19 9 .
H-1841	-0.15106318891048431	19 9 .
D-1841	-0.15106318891048431	19 9 .
P-1841	-0.5859 -0.0139 -0.0031 -0.0014
S-1557	50 Dosen
T-1557	50 doses
H-1557	-0.0053672329522669315	50 doses
D-1557	-0.0053672329522669315	50 doses
P-1557	-0.0051 -0.0142 -0.0008 -0.0015
S-417	0,4 mg
T-417	0.4 mg
H-417	-0.012410899624228477	0.4 mg
D-417	-0.012410899624228477	0.4 mg
P-417	-0.0367 -0.0107 -0.0009 -0.0014
S-794	3 / 75
T-794	3 / 72
H-794	-0.06687285006046295	3 / 72
D-794	-0.06687285006046295	3 / 72
P-794	-0.2338 -0.0016 -0.0180 -0.0140
S-1989	Roxene
T-1989	Roxene
H-1989	-0.0033584334887564182	Roxene
D-1989	-0.0033584334887564182	Roxene
P-1989	-0.0090 -0.0019 -0.0008 -0.0017
S-878	400mg
T-878	400mg
H-878	-0.009916207753121853	400mg
D-878	-0.009916207753121853	400mg
P-878	-0.0276 -0.0008 -0.0014
S-465	20 g
T-465	20 g
H-465	-0.1889139711856842	20 g
D-465	-0.1889139711856842	20 g
P-465	-0.5618 -0.0030 -0.0019
S-1976	15 1
T-1976	15 1
H-1976	-0.6557714343070984	2 447
D-1976	-0.6557714343070984	2 447
P-1976	-2.5766 -0.0172 -0.0145 -0.0148
S-1389	nicht verfügbar
T-1389	recommendation
H-1389	-0.010021572932600975	recommendation
D-1389	-0.010021572932600975	recommendation
P-1389	-0.0149 -0.0017 -0.0135
S-1576	Seldane
T-1576	Seldane
H-1576	-0.004418855533003807	Seldane
D-1576	-0.004418855533003807	Seldane
P-1576	-0.0101 -0.0016 -0.0016
S-550	47 %
T-550	47 %
H-550	-0.45594415068626404	47 %
D-550	-0.45594415068626404	47 %
P-550	-1.3001 -0.0013 -0.0665
S-491	4,2
T-491	26.2 4.2
H-491	-0.3516182601451874	26.2 4.2
D-491	-0.3516182601451874	26.2 4.2
P-491	-1.6297 -0.0113 -0.0403 -0.0688 -0.0080
S-84	Seite 20
T-84	Page 19
H-84	-0.009661847725510597	Page 19
D-84	-0.009661847725510597	Page 19
P-84	-0.0059 -0.0216 -0.0014
S-1322	6,0
T-1322	6.0
H-1322	-0.5143495202064514	6.0
D-1322	-0.5143495202064514	6.0
P-1322	-1.5268 -0.0122 -0.0041
S-790	24,5
T-790	24.5
H-790	-0.48137304186820984	24.5
D-790	-0.48137304186820984	24.5
P-790	-1.3840 -0.0275 -0.0326
S-1667	300 250
T-1667	300 250
H-1667	-0.6212911605834961	2.09
D-1667	-0.6212911605834961	2.09
P-1667	-2.4397 -0.0158 -0.0183 -0.0114
S-1244	300 ml
T-1244	300 ml
H-1244	-0.17252492904663086	300 ml
D-1244	-0.17252492904663086	300 ml
P-1244	-0.5157 -0.0003 -0.0016
S-1946	216
T-1946	216
H-1946	-0.40603184700012207	216
D-1946	-0.40603184700012207	216
P-1946	-1.1895 -0.0142 -0.0144
S-655	Bulgarien :
T-655	Bulgaria :
H-655	-0.0010267632314935327	Bulgaria :
D-655	-0.0010267632314935327	Bulgaria :
P-655	-0.0004 -0.0013 -0.0013
S-1201	Hund .
T-1201	Dogs .
H-1201	-0.029131054878234863	Dogs .
D-1201	-0.029131054878234863	Dogs .
P-1201	-0.0035 -0.0143 -0.0974 -0.0014
S-673	137
T-673	Raynaud <<unk>> s disease , flushing , pallor
H-673	-0.5358962416648865	150 149 100
D-673	-0.5358962416648865	150 149 100
P-673	-2.4703 -0.1745 -0.0137 -0.0172 -0.0038
S-1579	1120
T-1579	112 Further training , language courses and retraining for staff 1120
H-1579	-0.6572277545928955	2.09
D-1579	-0.6572277545928955	2.09
P-1579	-2.5605 -0.0236 -0.0349 -0.0099
S-328	Gutachten Gutachten
T-328	Designations granted by the Commission
H-328	-1.2587085962295532	300 149 100
D-328	-1.2587085962295532	300 149 100
P-328	-6.2097 -0.0252 -0.0152 -0.0338 -0.0096
S-1662	20 16
T-1662	20 16 14 6 16
H-1662	-0.6493327617645264	2.09
D-1662	-0.6493327617645264	2.09
P-1662	-2.5478 -0.0250 -0.0143 -0.0102
S-1640	192
T-1640	150 149 100
H-1640	-0.41272708773612976	150 149 100
D-1640	-0.41272708773612976	150 149 100
P-1640	-2.0074 -0.0225 -0.0137 -0.0162 -0.0038
S-1111	Mai 1999
T-1111	28 May 1999 .
H-1111	-0.15832582116127014	28 May 1999
D-1111	-0.15832582116127014	28 May 1999
P-1111	-0.0358 -0.0064 -0.0044 -0.5866
S-83	Erwachsene .
T-83	6 Adults .
H-83	-0.012650130316615105	6 Adults .
D-83	-0.012650130316615105	6 Adults .
P-83	-0.0146 -0.0144 -0.0148 -0.0182 -0.0014
S-1217	2,44
T-1217	2.09
H-1217	-0.29828134179115295	2.09
D-1217	-0.29828134179115295	2.09
P-1217	-1.1565 -0.0145 -0.0140 -0.0082
S-1362	2447
T-1362	2 447
H-1362	-0.37357068061828613	2.09
D-1362	-0.37357068061828613	2.09
P-1362	-1.4486 -0.0176 -0.0188 -0.0093
S-1510	1500 IE
T-1510	1500 IU
H-1510	-0.18467290699481964	1500 IU
D-1510	-0.18467290699481964	1500 IU
P-1510	-0.7124 -0.0129 -0.0118 -0.0016
S-459	Anwendung :
T-459	How to use
H-459	-0.011102408170700073	How to use
D-459	-0.011102408170700073	How to use
P-459	-0.0145 -0.0049 -0.0079 -0.0171
S-983	191
T-983	98 191
H-983	-0.41052308678627014	150 149 100
D-983	-0.41052308678627014	150 149 100
P-983	-1.9758 -0.0370 -0.0138 -0.0223 -0.0037
S-339	1984
T-339	1984
H-339	-0.5026506781578064	2.09
D-339	-0.5026506781578064	2.09
P-339	-1.9687 -0.0172 -0.0166 -0.0081
S-215	000
T-215	320 000 333 000 359 000 85 000 190 000
H-215	-0.5836885571479797	320 000 333 000 359 000
D-215	-0.5836885571479797	320 000 333 000 359 000
P-215	-1.6554 -0.0145 -0.0150 -0.0633 -0.0128 -0.1300 -0.0763 -0.0159 -3.2699
S-99	mindestens
T-99	at least 10 days , it
H-99	-1.8351012468338013	at least 10
D-99	-1.8351012468338013	at least 10
P-99	-0.0216 -0.0016 -0.0209 -7.2963
S-1894	Vorbereitung
T-1894	KwikPen
H-1894	-0.026159504428505898	KwikPen
D-1894	-0.026159504428505898	KwikPen
P-1894	-0.0836 -0.0145 -0.0144 -0.0145 -0.0038
S-466	Personal
T-466	MRAs in force
H-466	-0.01527768187224865	MRAs in force
D-466	-0.01527768187224865	MRAs in force
P-466	-0.0264 -0.0145 -0.0177 -0.0144 -0.0033
S-247	170
T-247	170
H-247	-0.49270641803741455	170
D-247	-0.49270641803741455	170
P-247	-0.9775 -0.0079
S-958	HBV @-@ DNA in Woche 24
T-958	HBV DNA at week 24
H-958	-0.025804754346609116	HBV DNA at week 24
D-958	-0.025804754346609116	HBV DNA at week 24
P-958	-0.0002 -0.1519 -0.0082 -0.0165 -0.0014 -0.0011 -0.0014
S-124	ZYPREXA 15 mg
T-124	ZYPREXA 15 mg
H-124	-0.0032557682134211063	ZYPREXA 15 mg
D-124	-0.0032557682134211063	ZYPREXA 15 mg
P-124	-0.0117 -0.0015 -0.0003 -0.0009 -0.0013 -0.0082 -0.0005 -0.0015
S-1142	Was ist Bondronat ?
T-1142	What is Bondronat ?
H-1142	-0.005893823225051165	What is Bondronat ?
D-1142	-0.005893823225051165	What is Bondronat ?
P-1142	-0.0013 -0.0015 -0.0117 -0.0011 -0.0145 -0.0142 -0.0015 -0.0014
S-430	Was ist Actrapid ?
T-430	What is Actrapid ?
H-430	-0.0015662942314520478	What is Actrapid ?
D-430	-0.0015662942314520478	What is Actrapid ?
P-430	-0.0016 -0.0017 -0.0037 -0.0008 -0.0008 -0.0011 -0.0015 -0.0014
S-1818	74,8 ( 3,6 )
T-1818	74.8 ( 3.6 )
H-1818	-0.004950602538883686	74.8 ( 3.6 )
D-1818	-0.004950602538883686	74.8 ( 3.6 )
P-1818	-0.0198 -0.0051 -0.0019 -0.0015 -0.0072 -0.0014 -0.0013 -0.0014
S-1367	76 35041 Marburg Deutschland
T-1367	76 35 041 Marburg Germany
H-1367	-0.06503905355930328	76 35 041 Marburg Germany
D-1367	-0.06503905355930328	76 35 041 Marburg Germany
P-1367	-0.0005 -0.4972 -0.0131 -0.0050 -0.0015 -0.0005 -0.0012 -0.0014
S-45	4 ( 4 ) Häufig :
T-45	4 ( 4 ) Common :
H-45	-0.002589720068499446	4 ( 4 ) Common :
D-45	-0.002589720068499446	4 ( 4 ) Common :
P-45	-0.0014 -0.0014 -0.0016 -0.0014 -0.0106 -0.0013 -0.0016 -0.0014
S-991	23 Resorption entfällt .
T-991	Absorption Not applicable .
H-991	-0.007134916726499796	Absorption Not applicable .
D-991	-0.007134916726499796	Absorption Not applicable .
P-991	-0.0145 -0.0024 -0.0018 -0.0145 -0.0145 -0.0013 -0.0066 -0.0015
S-1159	Xolair N = 209
T-1159	Xolair N = 209
H-1159	-0.004405197687447071	Xolair N = 209
D-1159	-0.004405197687447071	Xolair N = 209
P-1159	-0.0023 -0.0015 -0.0010 -0.0013 -0.0015 -0.0249 -0.0014 -0.0015
S-1786	Was ist Replagal ?
T-1786	What is Replagal ?
H-1786	-0.002083825645968318	What is Replagal ?
D-1786	-0.002083825645968318	What is Replagal ?
P-1786	-0.0020 -0.0020 -0.0075 -0.0009 -0.0007 -0.0007 -0.0015 -0.0014
S-1685	- Erbrechen , Übelkeit
T-1685	- vomiting , nausea
H-1685	-0.0025880252942442894	- vomiting , nausea
D-1685	-0.0025880252942442894	- vomiting , nausea
P-1685	-0.0020 -0.0115 -0.0002 -0.0013 -0.0017 -0.0010 -0.0004 -0.0027
S-836	EDS ( MWT )
T-836	EDS ( MWT )
H-836	-0.002747907768934965	EDS ( MWT )
D-836	-0.002747907768934965	EDS ( MWT )
P-836	-0.0115 -0.0006 -0.0017 -0.0025 -0.0015 -0.0013 -0.0014 -0.0015
S-1724	0,5 1,0 1,5 2,0 2,5
T-1724	0.5 1.0 1.5 2.0 2.5
H-1724	-0.004286912735551596	0.5 1.0 1.5 2.0 2.5
D-1724	-0.004286912735551596	0.5 1.0 1.5 2.0 2.5
P-1724	-0.0112 -0.0120 -0.0010 -0.0014 -0.0007 -0.0021 -0.0017
S-1459	25 Anwendung des Impfstoffs :
T-1459	To administer the vaccine :
H-1459	-0.005373434163630009	To administer the vaccine :
D-1459	-0.005373434163630009	To administer the vaccine :
P-1459	-0.0146 -0.0145 -0.0006 -0.0027 -0.0013 -0.0027 -0.0014
S-194	- &lt; 0,001
T-194	p &lt; 0.001
H-194	-0.9588049054145813	<unk> <unk> 40 <unk>
D-194	-0.9588049054145813	<unk> <unk> 40 <unk>
P-194	-4.7397 -0.0131 -0.0154 -0.0172 -0.0086
S-1304	Placebo n = 72
T-1304	Vehicle N = 72
H-1304	-0.008279291912913322	Vehicle N = 72
D-1304	-0.008279291912913322	Vehicle N = 72
P-1304	-0.0145 -0.0144 -0.0143 -0.0008 -0.0017 -0.0039
S-1595	Veränderung des geistigen Zustandes §
T-1595	Mental status change §
H-1595	-0.008419157937169075	Mental status change §
D-1595	-0.008419157937169075	Mental status change §
P-1595	-0.0145 -0.0006 -0.0144 -0.0072 -0.0123 -0.0014
S-658	Wirksamkeit des Impfstoffs *
T-658	efficacy *
H-658	-0.024281926453113556	efficacy *
D-658	-0.024281926453113556	efficacy *
P-658	-0.0145 -0.0005 -0.0008 -0.1022 -0.0035
S-1173	Suspension zum Eingeben .
T-1173	Oral suspension .
H-1173	-0.009220373816788197	Oral suspension .
D-1173	-0.009220373816788197	Oral suspension .
P-1173	-0.0145 -0.0145 -0.0080 -0.0078 -0.0014
S-1748	69,46 % 19,84 %
T-1748	1 9.84 %
H-1748	-0.019258828833699226	1 9.84 %
D-1748	-0.019258828833699226	1 9.84 %
P-1748	-0.0246 -0.0145 -0.0516 -0.0016 -0.0039
S-1481	16 Nicht zutreffend .
T-1481	Not applicable
H-1481	-0.01063840463757515	Not applicable
D-1481	-0.01063840463757515	Not applicable
P-1481	-0.0128 -0.0138 -0.0014 -0.0146
S-887	Mündlishe Konsultationen
T-887	consultations
H-887	-0.00956520065665245	consultations
D-887	-0.00956520065665245	consultations
P-887	-0.0145 -0.0010 -0.0131
S-1944	ONW = Oberer Normwert
T-1944	ULN = Upper Limit of Normal
H-1944	-0.009956707246601582	ULN = Upper Limit of Normal
D-1944	-0.009956707246601582	ULN = Upper Limit of Normal
P-1944	-0.0146 -0.0139 -0.0005 -0.0076 -0.0014 -0.0145 -0.0101 -0.0152 -0.0133 -0.0090 -0.0094
S-708	In einigen , jedoch t lä
T-708	clinical exposure levels and with possible relevance to clinical use were as follows : uc
H-708	-0.9853063225746155	clinical exposure levels and with possible relevance .
D-708	-0.9853063225746155	clinical exposure levels and with possible relevance .
P-708	-0.0408 -0.0145 -0.0186 -0.0264 -0.0145 -0.0145 -0.0145 -0.0015 -9.7037 -0.0040
S-219	Anwendung von Nevirapin mit
T-219	nevirapine with REYATAZ / ritonavir is
H-219	-0.8147670030593872	nevirapine with REYATAZ
D-219	-0.8147670030593872	nevirapine with REYATAZ
P-219	-0.0146 -0.0011 -0.0006 -0.0736 -0.0105 -0.0147 -0.0145 -0.0145 -0.0145 -7.9892
S-1954	% des Körpergewichts )
T-1954	Cl ( ml / min / kg ) Vss ( % BW )
H-1954	-0.9129374027252197	Cl ( % BW )
D-1954	-0.9129374027252197	Cl ( % BW )
P-1954	-0.0266 -0.0145 -0.0146 -6.2782 -0.0535 -0.0015 -0.0016
S-1590	Bindehautentzündung .
T-1590	Eye Disorders Common : - conjunctivitis .
H-1590	-0.8975268602371216	Eye Disorders Common : -
D-1590	-0.8975268602371216	Eye Disorders Common : -
P-1590	-0.0145 -0.0118 -0.0145 -0.0072 -0.0148 -0.0043 -0.0145 -0.0146 -7.9815
S-1907	Schiedsverfahren nach Artikel 33 der Richtlinie
T-1907	Type of referral Article 33 Directive 2001 / 82 / EC
H-1907	-0.24246226251125336	Type of referral Article 33 Directive 2001 / 82
D-1907	-0.24246226251125336	Type of referral Article 33 Directive 2001 / 82
P-1907	-0.0145 -0.0126 -0.0145 -0.0006 -0.0144 -0.0009 -0.0143 -0.0028 -0.0285 -0.0282 -0.0147 -2.7635
S-1439	311 − Lösungsmittel :
T-1439	monohydrate , and human albumin solution .
H-1439	-0.011362294666469097	monohydrate , and human albumin solution .
D-1439	-0.011362294666469097	monohydrate , and human albumin solution .
P-1439	-0.0192 -0.0145 -0.0095 -0.0045 -0.0108 -0.0145 -0.0145 -0.0147 -0.0145 -0.0069 -0.0027 -0.0163 -0.0151 -0.0014
S-1634	Erwachsene und Jugendliche über 16 Jahre :
T-1634	Adults and adolescents over the age of 16 years :
H-1634	-0.011237363331019878	Adults and adolescents over the age of 16 years :
D-1634	-0.011237363331019878	Adults and adolescents over the age of 16 years :
P-1634	-0.0011 -0.0517 -0.0023 -0.0130 -0.0006 -0.0007 -0.0054 -0.0296 -0.0013 -0.0014 -0.0012 -0.0316 -0.0161 -0.0014
S-659	12 Fertigspritzen + 12 Nadeln
T-659	12 pre @-@ filled syringes + 12 needles
H-659	-0.0025829896330833435	12 pre @-@ filled syringes + 12 needles
D-659	-0.0025829896330833435	12 pre @-@ filled syringes + 12 needles
P-659	-0.0009 -0.0120 -0.0014 -0.0085 -0.0004 -0.0003 -0.0014 -0.0012 -0.0013 -0.0009 -0.0012 -0.0015
S-133	se Behandlungsperiode .
T-133	hydrocortisone acetate ointment .
H-133	-0.39120638370513916	hydrocortisone acetate .
D-133	-0.39120638370513916	hydrocortisone acetate .
P-133	-0.0145 -0.0145 -0.0053 -0.0018 -0.0145 -0.0035 -0.0064 -3.4589 -0.0014
S-158	Labyrinths Häufig :
T-158	ed Ear and labyrinth Common :
H-158	-0.008679070509970188	ed Ear and labyrinth Common :
D-158	-0.008679070509970188	ed Ear and labyrinth Common :
P-158	-0.0145 -0.0145 -0.0145 -0.0143 -0.0145 -0.0021 -0.0097 -0.0004 -0.0145 -0.0014 -0.0025 -0.0014
S-728	Warum wurde Cystadane zugelassen ?
T-728	Why has Cystadane been approved ?
H-728	-0.003781467443332076	Why has Cystadane been approved ?
D-728	-0.003781467443332076	Why has Cystadane been approved ?
P-728	-0.0014 -0.0119 -0.0095 -0.0003 -0.0008 -0.0013 -0.0060 -0.0015 -0.0014
S-1350	Wie wurde Xolair untersucht ?
T-1350	How has Xolair been studied ?
H-1350	-0.003925018012523651	How has Xolair been studied ?
D-1350	-0.003925018012523651	How has Xolair been studied ?
P-1350	-0.0015 -0.0128 -0.0021 -0.0010 -0.0009 -0.0014 -0.0129 -0.0014 -0.0014
S-1075	Wie wurde Intanza untersucht ?
T-1075	How has Intanza been studied ?
H-1075	-0.004145191516727209	How has Intanza been studied ?
D-1075	-0.004145191516727209	How has Intanza been studied ?
P-1075	-0.0015 -0.0132 -0.0039 -0.0005 -0.0013 -0.0017 -0.0122 -0.0015 -0.0014
S-1154	Wechselwirkungen mit Abacavir
T-1154	Interactions relevant to abacavir
H-1154	-0.04481363296508789	Interactions relevant to abacavir
D-1154	-0.04481363296508789	Interactions relevant to abacavir
P-1154	-0.0048 -0.3002 -0.0849 -0.0038 -0.0053 -0.0010 -0.0011 -0.0009 -0.0014
S-103	Gastrointestinale Symptome :
T-103	Gastrointestinal Symptoms :
H-103	-0.0024536186829209328	Gastrointestinal Symptoms :
D-103	-0.0024536186829209328	Gastrointestinal Symptoms :
P-103	-0.0017 -0.0009 -0.0004 -0.0005 -0.0009 -0.0143 -0.0004 -0.0016 -0.0014
S-520	5 mg ( 250 kIE )
T-520	5 mg ( 250 KIU )
H-520	-0.00854702852666378	5 mg ( 250 KIU )
D-520	-0.00854702852666378	5 mg ( 250 KIU )
P-520	-0.0061 -0.0004 -0.0015 -0.0028 -0.0382 -0.0146 -0.0105 -0.0014 -0.0015
S-594	Wie wirkt Ebixa ?
T-594	How does Ebixa work ?
H-594	-0.0016114759491756558	How does Ebixa work ?
D-594	-0.0016114759491756558	How does Ebixa work ?
P-594	-0.0032 -0.0016 -0.0017 -0.0011 -0.0010 -0.0015 -0.0016 -0.0015 -0.0014
S-1646	Wie wirkt Yondelis ?
T-1646	How does Yondelis work ?
H-1646	-0.0056230369955301285	How does Yondelis work ?
D-1646	-0.0056230369955301285	How does Yondelis work ?
P-1646	-0.0349 -0.0027 -0.0022 -0.0010 -0.0009 -0.0013 -0.0046 -0.0015 -0.0014
S-470	Weitere Informationen über Renagel :
T-470	Other information about Renagel :
H-470	-0.005362328141927719	Other information about Renagel :
D-470	-0.005362328141927719	Other information about Renagel :
P-470	-0.0194 -0.0028 -0.0134 -0.0011 -0.0014 -0.0006 -0.0028 -0.0014
S-1808	sichelähnliche Form annehmen ) .
T-1808	of the red blood cells ) .
H-1808	-0.009681383147835732	of the red blood cells ) .
D-1808	-0.009681383147835732	of the red blood cells ) .
P-1808	-0.0145 -0.0109 -0.0147 -0.0145 -0.0138 -0.0061 -0.0017 -0.0014
S-176	60 % ) eliminiert .
T-176	Excretion Brinzolamide is eliminated primarily by renal excretion ( approximately 60 % ) .
H-176	-0.25736314058303833	Excretion Brinzolamide is eliminated .
D-176	-0.25736314058303833	Excretion Brinzolamide is eliminated .
P-176	-0.0145 -0.0145 -0.0136 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0135 -0.0143 -0.0063 -0.0011 -3.4514 -0.0014
S-556	Bruxicam 0,5 %
T-556	Bruxicam 0,5 %
H-556	-0.0030691700521856546	Bruxicam 0,5 %
D-556	-0.0030691700521856546	Bruxicam 0,5 %
P-556	-0.0018 -0.0009 -0.0005 -0.0016 -0.0139 -0.0013 -0.0014
S-657	Was ist Gliolan ?
T-657	What is Gliolan ?
H-657	-0.002197028137743473	What is Gliolan ?
D-657	-0.002197028137743473	What is Gliolan ?
P-657	-0.0012 -0.0016 -0.0064 -0.0010 -0.0021 -0.0016 -0.0014
S-526	Firazyr 30 mg
T-526	Firazyr 30 mg
H-526	-0.001561493263579905	Firazyr 30 mg
D-526	-0.001561493263579905	Firazyr 30 mg
P-526	-0.0029 -0.0010 -0.0009 -0.0015 -0.0026 -0.0005 -0.0015
S-1979	3 ml / h / kg
T-1979	3 ml / h / kg
H-1979	-0.013193679973483086	3 ml / h / kg
D-1979	-0.013193679973483086	3 ml / h / kg
P-1979	-0.0334 -0.0010 -0.0015 -0.0530 -0.0014 -0.0007 -0.0015
S-522	Antikonvulsiva :
T-522	Anticonvulsants :
H-522	-0.0030526877380907536	Anticonvulsants :
D-522	-0.0030526877380907536	Anticonvulsants :
P-522	-0.0031 -0.0013 -0.0001 -0.0010 -0.0127 -0.0018 -0.0014
S-334	Was ist Avonex ?
T-334	What is Avonex ?
H-334	-0.0021972472313791513	What is Avonex ?
D-334	-0.0021972472313791513	What is Avonex ?
P-334	-0.0015 -0.0016 -0.0026 -0.0004 -0.0064 -0.0015 -0.0014
S-5	Was ist Fertavid ?
T-5	What is Fertavid ?
H-5	-0.002671843161806464	What is Fertavid ?
D-5	-0.002671843161806464	What is Fertavid ?
P-5	-0.0020 -0.0020 -0.0079 -0.0035 -0.0004 -0.0015 -0.0014
S-1036	General considerations for clinical trials
T-1036	General considerations for clinical trials
H-1036	-0.0037575692404061556	General considerations for clinical trials
D-1036	-0.0037575692404061556	General considerations for clinical trials
P-1036	-0.0041 -0.0145 -0.0014 -0.0019 -0.0007 -0.0022 -0.0015
S-1206	Was ist Riprazo ?
T-1206	What is Riprazo ?
H-1206	-0.0029190622735768557	What is Riprazo ?
D-1206	-0.0029190622735768557	What is Riprazo ?
P-1206	-0.0016 -0.0016 -0.0130 -0.0008 -0.0006 -0.0014 -0.0014
S-894	Was ist Yentreve ?
T-894	What is Yentreve ?
H-894	-0.001663321745581925	What is Yentreve ?
D-894	-0.001663321745581925	What is Yentreve ?
P-894	-0.0020 -0.0019 -0.0030 -0.0005 -0.0013 -0.0015 -0.0014
S-953	Was ist Glustin ?
T-953	What is Glustin ?
H-953	-0.004435800481587648	What is Glustin ?
D-953	-0.004435800481587648	What is Glustin ?
P-953	-0.0014 -0.0017 -0.0145 -0.0004 -0.0101 -0.0015 -0.0014
S-832	Efient 5 mg :
T-832	Efient 5 mg :
H-832	-0.0025731173809617758	Efient 5 mg :
D-832	-0.0025731173809617758	Efient 5 mg :
P-832	-0.0047 -0.0026 -0.0011 -0.0061 -0.0004 -0.0017 -0.0014
S-1610	n = 94 ( % )
T-1610	N = 94 ( % )
H-1610	-0.0036915093660354614	N = 94 ( % )
D-1610	-0.0036915093660354614	N = 94 ( % )
P-1610	-0.0153 -0.0012 -0.0034 -0.0015 -0.0016 -0.0014 -0.0014
S-447	Was ist Luminity ?
T-447	What is Luminity ?
H-447	-0.001504118088632822	What is Luminity ?
D-447	-0.001504118088632822	What is Luminity ?
P-447	-0.0014 -0.0016 -0.0027 -0.0006 -0.0014 -0.0015 -0.0014
S-956	Glass ( braun )
T-956	Glass ( brown )
H-956	-0.0022324121091514826	Glass ( brown )
D-956	-0.0022324121091514826	Glass ( brown )
P-956	-0.0025 -0.0006 -0.0020 -0.0053 -0.0015 -0.0014
S-947	Maltitol @-@ Lösung
T-947	Maltitol liquid
H-947	-0.004944979213178158	Maltitol liquid
D-947	-0.004944979213178158	Maltitol liquid
P-947	-0.0010 -0.0011 -0.0008 -0.0011 -0.0154 -0.0102
S-69	Histologisches Ansprechen2
T-69	Histological response2
H-69	-0.004398374352604151	Histological response2
D-69	-0.004398374352604151	Histological response2
P-69	-0.0009 -0.0067 -0.0116 -0.0038 -0.0020 -0.0014
S-1996	Bitte informieren Sie Ihren Arzt :
T-1996	Please tell your doctor :
H-1996	-0.03688976913690567	Please tell your doctor :
D-1996	-0.03688976913690567	Please tell your doctor :
P-1996	-0.0247 -0.0276 -0.1618 -0.0020 -0.0038 -0.0014
S-1628	- Veränderungen des Blutdrucks
T-1628	- changes in blood pressure
H-1628	-0.04203632101416588	- changes in blood pressure
D-1628	-0.04203632101416588	- changes in blood pressure
P-1628	-0.0015 -0.0089 -0.0654 -0.0037 -0.0009 -0.1718
S-857	Lokalreaktionen ( % )
T-857	Local symptoms ( % )
H-857	-0.0038816588930785656	Local symptoms ( % )
D-857	-0.0038816588930785656	Local symptoms ( % )
P-857	-0.0028 -0.0145 -0.0016 -0.0015 -0.0014 -0.0014
S-864	Beide Fälle heilten aus .
T-864	Both cases resolved .
H-864	-0.0054018800146877766	Both cases resolved .
D-864	-0.0054018800146877766	Both cases resolved .
P-864	-0.0015 -0.0035 -0.0144 -0.0063 -0.0014
S-259	Klinische Resistenz :
T-259	Clinical resistance :
H-259	-0.007809466682374477	Clinical resistance :
D-259	-0.007809466682374477	Clinical resistance :
P-259	-0.0015 -0.0010 -0.0047 -0.0305 -0.0014
S-1123	Es ist bekannt , dass sich
T-1123	It is known that there is a potential
H-1123	-1.1226794719696045	It is known that there is
D-1123	-1.1226794719696045	It is known that there is
P-1123	-0.0058 -0.0020 -0.0051 -0.0045 -0.0142 -0.0098 -7.8173
S-1208	Hyperthyreose
T-1208	Thyroid dysfunction most often presenting as hypothyroidism or hyperthyroidism
H-1208	-0.4046815037727356	Thyroid dysfunction
D-1208	-0.4046815037727356	Thyroid dysfunction
P-1208	-0.0146 -0.0013 -0.0004 -0.0117 -0.0144 -0.0006 -2.7897
S-1085	November 2007 und am 22 .
T-1085	The Marketing Authorisation Holder provided supplementary information on 23 November 2007 and 22 April 2008 .
H-1085	-0.02936774119734764	The Marketing Authorisation Holder provided supplementary information on 23 November 2007 and 22 April 2008 .
D-1085	-0.02936774119734764	The Marketing Authorisation Holder provided supplementary information on 23 November 2007 and 22 April 2008 .
P-1085	-0.0144 -0.0356 -0.0145 -0.0137 -0.0070 -0.0145 -0.0189 -0.0145 -0.0145 -0.0080 -0.0013 -0.0069 -0.0129 -0.0145 -0.0152 -0.0780 -0.1036 -0.0072 -0.0402 -0.1463 -0.0630 -0.0014
S-1425	Nieren Leber Blase
T-1425	5.06 2.41 2.11 --- --- 0.85 0.30 0.26 0.11
H-1425	-0.43877938389778137	5.06 2.41 2.11 --- --- 0.85 0.30 0.11
D-1425	-0.43877938389778137	5.06 2.41 2.11 --- --- 0.85 0.30 0.11
P-1425	-0.0146 -0.0142 -0.0140 -0.0146 -0.1095 -0.0693 -0.3669 -0.1252 -0.7657 -0.7321 -0.6453 -0.0148 -1.4097 -0.0253 -1.6491 -1.0502
S-675	Dieser wird erst Dunkler Ring
T-675	You will push it in when you are ready to self @-@ inject the Dark ring
H-675	-0.6793503165245056	You will push it in when you are ready .
D-675	-0.6793503165245056	You will push it in when you are ready .
P-675	-0.0266 -0.0132 -0.0145 -0.0132 -0.0144 -0.0145 -0.0090 -0.0130 -0.0137 -7.3393 -0.0014
S-1115	2 siehe Abschnitt 4.4 :
T-1115	See Section 4.4 pancreatitis and lipids
H-1115	-0.750058650970459	See Section 4.4 pancreatitis :
D-1115	-0.750058650970459	See Section 4.4 pancreatitis :
P-1115	-0.0283 -0.1899 -0.0007 -0.0021 -0.0018 -0.0147 -0.0145 -0.0137 -0.0134 -7.9702 -0.0014
S-1833	Injektionssets1
T-1833	EU / 1 / 00 / 131 / 005
H-1833	-1.771409034729004	Injection set 2
D-1833	-1.771409034729004	Injection set 2
P-1833	-7.2068 -0.0062 -0.3073 -1.0802 -0.2565
S-645	• Patientencharakteristika
T-645	10 • Characteristics in patients
H-645	-1.0144468545913696	10 • Characteristics
D-645	-1.0144468545913696	10 • Characteristics
P-645	-0.0147 -0.0145 -0.0142 -0.0004 -0.0007 -0.0007 -0.0013 -8.0692
S-495	Informationen über Gürtelrose
T-495	Disease information on shingles :
H-495	-0.009277358651161194	Disease information on shingles :
D-495	-0.009277358651161194	Disease information on shingles :
P-495	-0.0145 -0.0126 -0.0038 -0.0077 -0.0128 -0.0062 -0.0001 -0.0006 -0.0330 -0.0015
S-784	Spritze warm werden lassen
T-784	Leave the syringe to warm up
H-784	-0.7508376240730286	Leave the syringe to warm
D-784	-0.7508376240730286	Leave the syringe to warm
P-784	-0.0141 -0.0107 -0.0011 -0.0003 -0.0002 -0.0110 -0.0057 -5.9635
S-565	Gute Klinische Praxis 3 .
T-565	Good Clinical Practice 3 .
H-565	-0.0012658940395340323	Good Clinical Practice 3 .
D-565	-0.0012658940395340323	Good Clinical Practice 3 .
P-565	-0.0012 -0.0023 -0.0009 -0.0007 -0.0002 -0.0016 -0.0017 -0.0014 -0.0014
S-633	April 1949 , Deutscher Bildung :
T-633	German Education :
H-633	-0.011764883063733578	German Education :
D-633	-0.011764883063733578	German Education :
P-633	-0.0144 -0.0052 -0.0131 -0.0144
S-50	20.11.2002 18.12.2002
T-50	• 20.11.2002 • 18.12.2002
H-50	-0.0058274175971746445	• 20.11.2002 • 18.12.2002
D-50	-0.0058274175971746445	• 20.11.2002 • 18.12.2002
P-50	-0.0153 -0.0130 -0.0013 -0.0018 -0.0150 -0.0028 -0.0008 -0.0009 -0.0015
S-580	Bearbeitungszeit 5 Tage
T-580	Submissions dealt with in 5 days
H-580	-0.007968212477862835	Submissions dealt with in 5 days
D-580	-0.007968212477862835	Submissions dealt with in 5 days
P-580	-0.0145 -0.0144 -0.0145 -0.0017 -0.0136 -0.0020 -0.0015 -0.0016
S-883	SkyePharma PLC
T-883	• SkyePharma PLC
H-883	-0.005059344694018364	• SkyePharma PLC
D-883	-0.005059344694018364	• SkyePharma PLC
P-883	-0.0244 -0.0085 -0.0014 -0.0022 -0.0006 -0.0016 -0.0004 -0.0015
S-545	Wie wurde Actos untersucht ?
T-545	How has Actos been studied ?
H-545	-0.004349038936197758	How has Actos been studied ?
D-545	-0.004349038936197758	How has Actos been studied ?
P-545	-0.0017 -0.0124 -0.0014 -0.0004 -0.0016 -0.0145 -0.0015 -0.0014
S-1235	Urtikaria Überempfindlichkeit
T-1235	Urticaria Hypersensitivity
H-1235	-0.025104572996497154	Urticaria Hypersensitivity
D-1235	-0.025104572996497154	Urticaria Hypersensitivity
P-1235	-0.0014 -0.0005 -0.0005 -0.0135 -0.0008 -0.0010 -0.0003 -0.1829
S-822	Wie wirkt Advasure ?
T-822	How does Advasure work ?
H-822	-0.0029943448025733232	How does Advasure work ?
D-822	-0.0029943448025733232	How does Advasure work ?
P-822	-0.0111 -0.0030 -0.0026 -0.0012 -0.0008 -0.0024 -0.0015 -0.0014
S-1654	- Hypokaliämie
T-1654	- Hypokalaemia
H-1654	-0.05596169829368591	- Hypokalaemia
D-1654	-0.05596169829368591	- Hypokalaemia
P-1654	-0.0022 -0.0055 -0.0008 -0.0037 -0.0115 -0.0008 -0.0013 -0.4219
S-628	Kinder unter Hämodialyse
T-628	Children receiving haemodialysis
H-628	-0.004381242673844099	Children receiving haemodialysis
D-628	-0.004381242673844099	Children receiving haemodialysis
P-628	-0.0030 -0.0144 -0.0126 -0.0007 -0.0008 -0.0004 -0.0012 -0.0021
S-1811	Kinder und Jugendliche : itte
T-1811	Chidren and adolescents :
H-1811	-0.6370638608932495	Chidren and adolescent
D-1811	-0.6370638608932495	Chidren and adolescent
P-1811	-0.0145 -0.0108 -0.0081 -0.0131 -0.0012 -3.4034 -1.0083
S-1920	582,833.55
T-1920	582,833.55
H-1920	-0.7553679943084717	2.09
D-1920	-0.7553679943084717	2.09
P-1920	-2.6947 -0.0778 -0.2328 -0.0163
S-718	Protopic 0,03 % Salbe
T-718	Protopic 0.03 % ointment
H-718	-0.018511194735765457	Protopic 0.03 % ointment
D-718	-0.018511194735765457	Protopic 0.03 % ointment
P-718	-0.0009 -0.0008 -0.0010 -0.0060 -0.0014 -0.0015 -0.0067 -0.0002 -0.0013 -0.1655
S-1924	Die Infusion sollte 3 Stunden dauern .
T-1924	The infusion should last 3 hours .
H-1924	-0.039421480149030685	The infusion should last 3 hours .
D-1924	-0.039421480149030685	The infusion should last 3 hours .
P-1924	-0.0037 -0.0026 -0.0009 -0.0026 -0.0166 -0.0066 -0.0012 -0.0017 -0.3189
S-826	STRONGHOLD 30 mg
T-826	STRONGHOLD 30 mg
H-826	-0.0011183652095496655	STRONGHOLD 30 mg
D-826	-0.0011183652095496655	STRONGHOLD 30 mg
P-826	-0.0016 -0.0011 -0.0007 -0.0009 -0.0010 -0.0007 -0.0020 -0.0006 -0.0015
S-1289	Tel : + 39 02 96 54 1
T-1289	Tel : + 39 02 96 54 1
H-1289	-0.01205423939973116	Tel : + 39 02 96 54 1
D-1289	-0.01205423939973116	Tel : + 39 02 96 54 1
P-1289	-0.0036 -0.0036 -0.0013 -0.0009 -0.0011 -0.0007 -0.0940 -0.0016 -0.0015
S-552	- Lymphadenopathie
T-552	- lymphadenopathy .
H-552	-0.098680280148983	- lymphadenopathy
D-552	-0.098680280148983	- lymphadenopathy
P-552	-0.0018 -0.0122 -0.0014 -0.0008 -0.0014 -0.0008 -0.0015 -0.7695
S-583	Tony HUMPHREYS
T-583	Tony HUMPHREYS
H-583	-1.5452746152877808	Tony Humphyloride
D-583	-1.5452746152877808	Tony Humphyloride
P-583	-0.0025 -0.0105 -9.3477 -2.1091 -0.1535 -0.1215 -0.6156 -0.0018
S-477	155 ( 46,4 % )
T-477	155 ( 46.4 % )
H-477	-0.0018322461983188987	155 ( 46.4 % )
D-477	-0.0018322461983188987	155 ( 46.4 % )
P-477	-0.0046 -0.0012 -0.0015 -0.0015 -0.0018 -0.0013 -0.0017 -0.0014 -0.0015
S-1258	00420222807232
T-1258	00420222807232
H-1258	-1.262343406677246	2.06
D-1258	-1.262343406677246	2.06
P-1258	-4.7451 -0.0237 -0.2622 -0.0185
S-889	IAP / NQMI :
T-889	UA / NQMI :
H-889	-0.004856275860220194	UA / NQMI :
D-889	-0.004856275860220194	UA / NQMI :
P-889	-0.0146 -0.0145 -0.0025 -0.0043 -0.0011 -0.0016 -0.0015 -0.0023 -0.0014
S-1538	Norfloxacine Biogaran
T-1538	Norfloxacine Biogaran
H-1538	-0.0025171684101223946	Norfloxacine Biogaran
D-1538	-0.0025171684101223946	Norfloxacine Biogaran
P-1538	-0.0022 -0.0005 -0.0013 -0.0010 -0.0078 -0.0030 -0.0011 -0.0041 -0.0015
S-461	Nur zur intrathekalen Anwendung
T-461	For intrathecal use only
H-461	-0.021564610302448273	For intrathecal use only
D-461	-0.021564610302448273	For intrathecal use only
P-461	-0.0075 -0.0024 -0.0469 -0.0058 -0.0005 -0.0011 -0.0060 -0.0014 -0.1223
S-243	Bicalutamide Peseri
T-243	Bicalutamide Peseri
H-243	-0.0037350349593907595	Bicalutamide Peseri
D-243	-0.0037350349593907595	Bicalutamide Peseri
P-243	-0.0127 -0.0010 -0.0009 -0.0037 -0.0052 -0.0036 -0.0045 -0.0005 -0.0015
S-619	Was ist TRISENOX ?
T-619	What is TRISENOX ?
H-619	-0.0012531167594715953	What is TRISENOX ?
D-619	-0.0012531167594715953	What is TRISENOX ?
P-619	-0.0013 -0.0014 -0.0012 -0.0010 -0.0013 -0.0013 -0.0009 -0.0015 -0.0014
S-1135	Anweisungen zur Herstellung siehe Abschnitt 12 .
T-1135	For instructions for preparation , see section 12 .
H-1135	-0.006720162928104401	For instructions for preparation , see section 12 .
D-1135	-0.006720162928104401	For instructions for preparation , see section 12 .
P-1135	-0.0110 -0.0052 -0.0127 -0.0143 -0.0082 -0.0047 -0.0067 -0.0013 -0.0017 -0.0014
S-331	Ihre Augen müssen eventuell regelmäßig kontrolliert werden .
T-331	Your eyes may need regular check @-@ ups .
H-331	-0.00379455485381186	Your eyes may need regular check @-@ ups .
D-331	-0.00379455485381186	Your eyes may need regular check @-@ ups .
P-331	-0.0033 -0.0010 -0.0035 -0.0036 -0.0048 -0.0129 -0.0035 -0.0022 -0.0018 -0.0014
S-1830	- wenn Sie an Durchfall leiden .
T-1830	- if you suffer from diarrhoea .
H-1830	-0.07554217427968979	- if you suffer from diarrhoea .
D-1830	-0.07554217427968979	- if you suffer from diarrhoea .
P-1830	-0.0043 -0.0043 -0.0017 -0.3532 -0.0023 -0.0014 -0.0004 -0.0094 -0.0005 -0.4521 -0.0014
S-40	Fertigspritze aus Typ I Glas .
T-40	Type I glass pre @-@ filled syringe .
H-40	-0.009539277292788029	Type I glass pre @-@ filled syringe .
D-40	-0.009539277292788029	Type I glass pre @-@ filled syringe .
P-40	-0.0141 -0.0511 -0.0079 -0.0118 -0.0015 -0.0118 -0.0029 -0.0003 -0.0002 -0.0021 -0.0014
S-370	Vicari trat 1997 zehnmal zusammen .
T-370	Vicari , met on 10 occasions in 1997 .
H-370	-0.005808639340102673	Vicari , met on 10 occasions in 1997 .
D-370	-0.005808639340102673	Vicari , met on 10 occasions in 1997 .
P-370	-0.0030 -0.0014 -0.0145 -0.0145 -0.0143 -0.0080 -0.0007 -0.0034 -0.0011 -0.0016 -0.0014
S-322	Box 23490 Nicosia Zypern
T-322	Box 23490 Nicosia Cyprus
H-322	-0.0012882007285952568	Box 23490 Nicosia Cyprus
D-322	-0.0012882007285952568	Box 23490 Nicosia Cyprus
P-322	-0.0026 -0.0023 -0.0013 -0.0010 -0.0006 -0.0012 -0.0006 -0.0019 -0.0005 -0.0008 -0.0014
S-162	Anwendung bei Hämodialyse @-@ Patienten
T-162	28 Use in patients undergoing haemodialysis
H-162	-0.006495463661849499	28 Use in patients undergoing haemodialysis
D-162	-0.006495463661849499	28 Use in patients undergoing haemodialysis
P-162	-0.0146 -0.0143 -0.0037 -0.0144 -0.0118 -0.0005 -0.0133 -0.0005 -0.0012 -0.0008 -0.0008 -0.0019
S-970	Salzsäure ( 0,04 M )
T-970	Hydrochloric acid ( 0.04 M )
H-970	-0.001534954528324306	Hydrochloric acid ( 0.04 M )
D-970	-0.001534954528324306	Hydrochloric acid ( 0.04 M )
P-970	-0.0036 -0.0003 -0.0004 -0.0004 -0.0006 -0.0009 -0.0014 -0.0013 -0.0026 -0.0014 -0.0041 -0.0014 -0.0014
S-1674	Start der Betriebsphase für Anfang 2003 geplant
T-1674	Mutual recognition agreement ( MRA ) implementation status and coverage
H-1674	-0.018671266734600067	Mutual recognition agreement ( MRA ) implementation status and coverage
D-1674	-0.018671266734600067	Mutual recognition agreement ( MRA ) implementation status and coverage
P-1674	-0.0145 -0.0015 -0.0145 -0.0146 -0.0153 -0.0145 -0.0138 -0.0536 -0.0165 -0.0276 -0.0257 -0.0145 -0.0161
S-1137	Die Dosierung sollte individuell angepasst werden .
T-1137	Individual adjustment of dosage should be considered .
H-1137	-0.009622960351407528	Individual adjustment of dosage should be considered .
D-1137	-0.009622960351407528	Individual adjustment of dosage should be considered .
P-1137	-0.0224 -0.0032 -0.0147 -0.0007 -0.0079 -0.0055 -0.0094 -0.0408 -0.0022 -0.0080 -0.0022 -0.0143 -0.0019 -0.0014
S-940	0,15 &#91; 95 % C.I .
T-940	0.03 ; 0.22 &#93; percentage points and by 0.15 &#91; 95 % C. I .
H-940	-0.018650447949767113	0.03 ; 0.22 &#93; percentage points and by 0.15 &#91; 95 % C. I .
D-940	-0.018650447949767113	0.03 ; 0.22 &#93; percentage points and by 0.15 &#91; 95 % C. I .
P-940	-0.0165 -0.0180 -0.0166 -0.0118 -0.1120 -0.0157 -0.0145 -0.0123 -0.0145 -0.0145 -0.0132 -0.0580 -0.0130 -0.0017 -0.0015 -0.0145 -0.0026 -0.0019 -0.0014
S-1121	ProQuad ist ein Impfstoff .
T-1121	ProQuad is a vaccine .
H-1121	-0.014299982227385044	ProQuad is a vaccine .
D-1121	-0.014299982227385044	ProQuad is a vaccine .
P-1121	-0.0032 -0.0016 -0.0007 -0.0016 -0.0102 -0.0014 -0.0942 -0.0014
S-1400	• Erkrankungen der Leber ; Ar
T-1400	liver disease ; ic
H-1400	-0.010759972967207432	liver disease ; ic
D-1400	-0.010759972967207432	liver disease ; ic
P-1400	-0.0148 -0.0115 -0.0051 -0.0145 -0.0079
S-400	Unkontrollierter Bluthochdruck .
T-400	Uncontrolled hypertension .
H-400	-0.03561205044388771	Uncontrolled hypertension .
D-400	-0.03561205044388771	Uncontrolled hypertension .
P-400	-0.0013 -0.0033 -0.0249 -0.0017 -0.1811 -0.0014
S-955	alli darf nicht angewendet werden ,
T-955	Do not take alli
H-955	-0.00868215411901474	Do not take alli
D-955	-0.00868215411901474	Do not take alli
P-955	-0.0145 -0.0014 -0.0148 -0.0074 -0.0013 -0.0127
S-871	Minimum von Minimum von 10 1
T-871	minimum of minimum of 10 1
H-871	-0.006526757497340441	minimum of minimum of 10 1
D-871	-0.006526757497340441	minimum of minimum of 10 1
P-871	-0.0135 -0.0045 -0.0060 -0.0079 -0.0098 -0.0024 -0.0016
S-1053	Keine besonderen Anforderungen an die Lagerung .
T-1053	There are no special storage instructions .
H-1053	-0.009070482105016708	There are no special storage instructions .
D-1053	-0.009070482105016708	There are no special storage instructions .
P-1053	-0.0144 -0.0274 -0.0015 -0.0054 -0.0048 -0.0145 -0.0032 -0.0014
S-1334	Exazerbationen während der Behandlung :
T-1334	Exacerbations during treatment :
H-1334	-0.004060508217662573	Exacerbations during treatment :
D-1334	-0.004060508217662573	Exacerbations during treatment :
P-1334	-0.0073 -0.0024 -0.0022 -0.0011 -0.0020 -0.0141 -0.0019 -0.0014
S-1754	Pritor 20 mg Tabletten
T-1754	Pritor 20 mg tablets
H-1754	-0.0353701151907444	Pritor 20 mg tablets
D-1754	-0.0353701151907444	Pritor 20 mg tablets
P-1754	-0.0022 -0.0003 -0.0012 -0.0067 -0.0006 -0.0060 -0.2642 -0.0017
S-80	Wie wird Ranexa angewendet ?
T-80	How is Ranexa used ?
H-80	-0.002783067524433136	How is Ranexa used ?
D-80	-0.002783067524433136	How is Ranexa used ?
P-80	-0.0014 -0.0070 -0.0010 -0.0013 -0.0014 -0.0072 -0.0015 -0.0014
S-669	Waschen Sie sich gründlich die Hände
T-669	Wash Hands Thoroughly
H-669	-0.004023429937660694	Wash Hands Thoroughly
D-669	-0.004023429937660694	Wash Hands Thoroughly
P-669	-0.0059 -0.0003 -0.0145 -0.0003 -0.0085 -0.0005 -0.0005 -0.0017
S-799	Wie wird Alimta angewendet ?
T-799	How is Alimta used ?
H-799	-0.0030015655793249607	How is Alimta used ?
D-799	-0.0030015655793249607	How is Alimta used ?
P-799	-0.0015 -0.0056 -0.0013 -0.0016 -0.0006 -0.0104 -0.0015 -0.0014
S-78	b ) .... c ) P art A
T-78	b ) .... c ) Part A
H-78	-0.003503310726955533	b ) .... c ) Part A
D-78	-0.003503310726955533	b ) .... c ) Part A
P-78	-0.0020 -0.0014 -0.0012 -0.0011 -0.0013 -0.0146 -0.0032 -0.0032
S-1089	Johnson &amp; Johnson s.r.o .
T-1089	Johnson &amp; Johnson s. r. o .
H-1089	-0.038706161081790924	Johnson &amp; Johnson s. r. o .
D-1089	-0.038706161081790924	Johnson &amp; Johnson s. r. o .
P-1089	-0.2746 -0.0013 -0.0005 -0.0147 -0.0130 -0.0027 -0.0014 -0.0014
S-1103	Wie wird Liprolog angewendet ?
T-1103	How is Liprolog used ?
H-1103	-0.004783379379659891	How is Liprolog used ?
D-1103	-0.004783379379659891	How is Liprolog used ?
P-1103	-0.0015 -0.0195 -0.0017 -0.0013 -0.0016 -0.0097 -0.0015 -0.0014
S-1711	7 / 20 ANHANG II
T-1711	7 / 20 ANNEX II
H-1711	-0.00973002053797245	7 / 20 ANNEX II
D-1711	-0.00973002053797245	7 / 20 ANNEX II
P-1711	-0.0450 -0.0014 -0.0014 -0.0116 -0.0003 -0.0007 -0.0160 -0.0015
S-1351	Wie wird Ventavis angewendet ?
T-1351	How is Ventavis used ?
H-1351	-0.0025666402652859688	How is Ventavis used ?
D-1351	-0.0025666402652859688	How is Ventavis used ?
P-1351	-0.0017 -0.0051 -0.0010 -0.0013 -0.0014 -0.0072 -0.0015 -0.0014
S-118	• eine Schwangerschaft planen. ch
T-118	or • plan to get pregnant .
H-118	-0.012527643702924252	or • plan to get pregnant .
D-118	-0.012527643702924252	or • plan to get pregnant .
P-118	-0.0145 -0.0356 -0.0175 -0.0146 -0.0036 -0.0042 -0.0079 -0.0025
S-1253	14 / 33 ANHANG III
T-1253	14 / 33 ANNEX III
H-1253	-0.005664042197167873	14 / 33 ANNEX III
D-1253	-0.005664042197167873	14 / 33 ANNEX III
P-1253	-0.0203 -0.0014 -0.0010 -0.0099 -0.0002 -0.0007 -0.0103 -0.0015
S-544	Ziconotid erhalten .
T-544	Only a small number of patients have received systemic chemotherapy and IT ziconotide .
H-544	-0.5968555212020874	Only a small number of patients have received syphile .
D-544	-0.5968555212020874	Only a small number of patients have received syphile .
P-544	-0.0145 -0.0139 -0.0135 -0.0140 -0.0078 -0.0137 -0.0131 -0.0115 -0.0145 -7.2708 -0.2604 -0.1099 -0.0014
S-312	Brivudin behandelt wurden .
T-312	Xeloda should also not be used in the following groups : • patients who have had severe and unexpected reactions to fluoropyrimidine therapy ( a group of anticancer medicines ) ; 2 / 3 • patients with dihydropyrimidine dehydrogenase deficiency ( low levels of an enzyme ) ; • pregnant or breast @-@ feeding women ; • patients with severe leucopenia , neutropenia , or thrombocytopenia ( low levels of white cells or platelets in the blood ) ; • patients with severe liver or kidney disease ; • patients treated with sorivudine or similar anticancer medicines such as brivudine within the last four weeks .
H-312	-0.12241000682115555	Xeloda should also not be used in the following groups :
D-312	-0.12241000682115555	Xeloda should also not be used in the following groups :
P-312	-0.0145 -0.0145 -0.0136 -0.0145 -0.0222 -0.0232 -0.0062 -0.0139 -0.0136 -0.0126 -0.0145 -0.0145 -0.0862 -1.4498
S-1382	Über diesen Minimalwert hinausgehende
T-1382	The recommendation of a minimum yield of ≥ 2.0 x 106 CD34 + cells / kg is based on published experience resulting in adequate haematologic reconstitution .
H-1382	-0.020103516057133675	The recommendation of a minimum yield of ≥ 2.0 x 106 CD34 + cells / kg is based on published experience resulting in adequate haematologic reconstitution .
D-1382	-0.020103516057133675	The recommendation of a minimum yield of ≥ 2.0 x 106 CD34 + cells / kg is based on published experience resulting in adequate haematologic reconstitution .
P-1382	-0.0145 -0.0145 -0.0013 -0.0142 -0.0140 -0.0125 -0.0145 -0.0135 -0.0145 -0.0146 -0.0152 -0.0145 -0.0156 -0.0145 -0.0144 -0.0145 -0.1263 -0.0143 -0.1766 -0.0144 -0.0022 -0.0145 -0.0145 -0.0146 -0.0119 -0.0145 -0.0145 -0.0143 -0.0019 -0.0138 -0.0024 -0.0144 -0.0145 -0.0058 -0.0014
S-396	441 ng / g .
T-396	The active metabolite 3 @-@ AT has a mean concentration of 57.9 ng / g and 441 ng / g , respectively .
H-396	-0.1517464816570282	The active metabolite 3 @-@ AT has a mean concentration of 57.9 ng / g , respectively .
D-396	-0.1517464816570282	The active metabolite 3 @-@ AT has a mean concentration of 57.9 ng / g , respectively .
P-396	-0.0146 -0.0151 -0.0145 -0.0062 -0.0477 -0.0145 -0.0138 -0.0145 -0.0143 -0.0136 -0.0145 -0.0144 -0.0022 -0.0143 -0.0143 -0.0604 -0.0138 -0.0010 -0.0028 -0.0009 -3.3175 -0.0141 -0.0016 -0.0014
S-1190	TRAVATAN allein .
T-1190	DuoTrav was more effective at reducing IOP than timolol on its own , or TRAVATAN on its own .
H-1190	-0.5508086681365967	DuoTrav was more effective at reducing IOP .
D-1190	-0.5508086681365967	DuoTrav was more effective at reducing IOP .
P-1190	-0.0145 -0.0145 -0.0145 -0.0142 -0.0144 -0.0145 -0.0145 -0.0144 -0.0145 -0.0145 -0.0144 -7.0003 -0.0014
S-457	36 Handhabung des Pens
T-457	36 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet .
H-457	-0.18743304908275604	36 Handling of the pen
D-457	-0.18743304908275604	36 Handling of the pen
P-457	-0.0014 -0.0129 -0.0018 -0.0092 -0.0038 -0.0022 -1.2808
S-926	EU / 1 / 08 / 447 / 003
T-926	EU / 1 / 08 / 447 / 003
H-926	-0.0014474253403022885	EU / 1 / 08 / 447 / 003
D-926	-0.0014474253403022885	EU / 1 / 08 / 447 / 003
P-926	-0.0018 -0.0018 -0.0017 -0.0015 -0.0013 -0.0014 -0.0012 -0.0008 -0.0015 -0.0016 -0.0015 -0.0015
S-971	Omnitrope @-@ Injektionslösung befindet .
T-971	solution .
H-971	-0.014059819281101227	solution .
D-971	-0.014059819281101227	solution .
P-971	-0.0145 -0.0142 -0.0135
S-1269	• Erkrankun gen der Leber ; oder el
T-1269	Special warnings ro
H-1269	-0.014494452625513077	Special warnings ro
D-1269	-0.014494452625513077	Special warnings ro
P-1269	-0.0145 -0.0145 -0.0145 -0.0145
S-1220	Auftreten einer Invagination wahrscheinlicher machen könnte
T-1220	intussusception .
H-1220	-0.011746025644242764	intussusception .
D-1220	-0.011746025644242764	intussusception .
P-1220	-0.0145 -0.0145 -0.0131 -0.0065 -0.0077 -0.0145 -0.0115
S-32	2 / 3 Weitere Informationen über Xelevia :
T-32	Other information about Xelevia :
H-32	-0.008359557949006557	Other information about Xelevia :
D-32	-0.008359557949006557	Other information about Xelevia :
P-32	-0.0497 -0.0057 -0.0078 -0.0013 -0.0014 -0.0007 -0.0013 -0.0054 -0.0020
S-1758	Prüfen Sie das Aussehen von Neupopeg .
T-1758	Check the appearance of Neupopeg .
H-1758	-0.0027492824010550976	Check the appearance of Neupopeg .
D-1758	-0.0027492824010550976	Check the appearance of Neupopeg .
P-1758	-0.0031 -0.0027 -0.0078 -0.0015 -0.0028 -0.0029 -0.0004 -0.0021 -0.0015
S-7	Für weitere Informationen wenden Sie sich bitte an den Hersteller .
T-7	For more information , contact the manufacturer .
H-7	-0.007027598097920418	For more information , contact the manufacturer .
D-7	-0.007027598097920418	For more information , contact the manufacturer .
P-7	-0.0051 -0.0249 -0.0037 -0.0055 -0.0142 -0.0024 -0.0031 -0.0028 -0.0015
S-1480	44 5 @-@ HT3 @-@ Antagonisten :
T-1480	5 @-@ HT3 antagonists :
H-1480	-0.0036607873626053333	5 @-@ HT3 antagonists :
D-1480	-0.0036607873626053333	5 @-@ HT3 antagonists :
P-1480	-0.0173 -0.0024 -0.0017 -0.0014 -0.0015 -0.0035 -0.0005 -0.0040 -0.0029 -0.0015
S-625	- Gelenk- oder Muskelschmerzen , Muskelschwäche
T-625	- painful joints or muscles , muscle weakness
H-625	-0.01567057892680168	- painful joints or muscles , muscle weakness
D-625	-0.01567057892680168	- painful joints or muscles , muscle weakness
P-625	-0.0016 -0.0159 -0.0015 -0.0005 -0.1267 -0.0028 -0.0021 -0.0029 -0.0007 -0.0019
S-638	- wenn Sie an einer Lebererkrankung leiden ;
T-638	- if you suffer from any liver problems ;
H-638	-0.137856587767601	- if you suffer from any liver problems ;
D-638	-0.137856587767601	- if you suffer from any liver problems ;
P-638	-0.2877 -0.0039 -0.0016 -0.7864 -0.0017 -0.0366 -0.0033 -0.0318 -0.2242 -0.0014
S-635	Apidra ist eine klare Insulinlösung .
T-635	Apidra is a clear insulin .
H-635	-0.0036922406870871782	Apidra is a clear insulin .
D-635	-0.0036922406870871782	Apidra is a clear insulin .
P-635	-0.0028 -0.0008 -0.0003 -0.0017 -0.0020 -0.0031 -0.0018 -0.0006 -0.0224 -0.0014
S-1558	Enthält Aspartam ( E951 ) .
T-1558	Aspartame ( E951 ) .
H-1558	-0.004079976584762335	Aspartame ( E951 ) .
D-1558	-0.004079976584762335	Aspartame ( E951 ) .
P-1558	-0.0169 -0.0023 -0.0010 -0.0042 -0.0038 -0.0014 -0.0018 -0.0014 -0.0064 -0.0015
S-445	18 Remissionsraten sind in Tabelle 6 dargestellt .
T-445	16 Response rates are presented in Table 6 .
H-445	-0.023098498582839966	16 Response rates are presented in Table 6 .
D-445	-0.023098498582839966	16 Response rates are presented in Table 6 .
P-445	-0.0145 -0.0128 -0.0023 -0.0027 -0.0025 -0.0165 -0.0016 -0.1956 -0.0017 -0.0023 -0.0014
S-1293	Alapis România S.R.L .
T-1293	Alapis România S. R. L .
H-1293	-0.009888182394206524	Alapis România S. R. L .
D-1293	-0.009888182394206524	Alapis România S. R. L .
P-1293	-0.0050 -0.0013 -0.0013 -0.0012 -0.0011 -0.0004 -0.0145 -0.0761 -0.0047 -0.0017 -0.0014
S-563	Entfernen Sie die Spritze und Nadel .
T-563	Remove the syringe and needle .
H-563	-0.008160747587680817	Remove the syringe and needle .
D-563	-0.008160747587680817	Remove the syringe and needle .
P-563	-0.0847 -0.0007 -0.0010 -0.0022 -0.0010 -0.0003 -0.0001 -0.0015 -0.0021 -0.0011 -0.0017 -0.0014
S-846	EU / 1 / 04 / 276 / 004
T-846	EU / 1 / 04 / 276 / 004
H-846	-0.0014416002668440342	EU / 1 / 04 / 276 / 004
D-846	-0.0014416002668440342	EU / 1 / 04 / 276 / 004
P-846	-0.0019 -0.0018 -0.0017 -0.0014 -0.0010 -0.0014 -0.0010 -0.0013 -0.0015 -0.0015 -0.0014 -0.0015
S-612	EU / 1 / 97 / 030 / 070
T-612	EU / 1 / 97 / 030 / 070
H-612	-0.001420381711795926	EU / 1 / 97 / 030 / 070
D-612	-0.001420381711795926	EU / 1 / 97 / 030 / 070
P-612	-0.0018 -0.0018 -0.0017 -0.0014 -0.0007 -0.0014 -0.0014 -0.0014 -0.0014 -0.0013 -0.0011 -0.0015
S-1421	EU / 1 / 03 / 249 / 006
T-1421	EU / 1 / 03 / 249 / 006
H-1421	-0.0015455613611266017	EU / 1 / 03 / 249 / 006
D-1421	-0.0015455613611266017	EU / 1 / 03 / 249 / 006
P-1421	-0.0017 -0.0018 -0.0016 -0.0014 -0.0010 -0.0014 -0.0021 -0.0015 -0.0015 -0.0015 -0.0015 -0.0015
S-1247	EU / 1 / 04 / 291 / 001
T-1247	EU / 1 / 04 / 291 / 001
H-1247	-0.0014663570327684283	EU / 1 / 04 / 291 / 001
D-1247	-0.0014663570327684283	EU / 1 / 04 / 291 / 001
P-1247	-0.0019 -0.0018 -0.0016 -0.0014 -0.0009 -0.0014 -0.0013 -0.0013 -0.0015 -0.0016 -0.0014 -0.0015
S-1264	CPMP / 3257 / 03 5 .
T-1264	CPMP / 3257 / 03 5 .
H-1264	-0.003362608142197132	CPMP / 3257 / 03 5 .
D-1264	-0.003362608142197132	CPMP / 3257 / 03 5 .
P-1264	-0.0144 -0.0058 -0.0007 -0.0035 -0.0041 -0.0031 -0.0011 -0.0015 -0.0010 -0.0020 -0.0017 -0.0014
S-910	Cytochrom P450 @-@ Enzyme :
T-910	Cytochrome P450 enzymes :
H-910	-0.0019444989738985896	Cytochrome P450 enzymes :
D-910	-0.0019444989738985896	Cytochrome P450 enzymes :
P-910	-0.0019 -0.0010 -0.0009 -0.0033 -0.0020 -0.0044 -0.0023 -0.0012 -0.0012 -0.0019 -0.0014
S-1967	Wofür wird Prepandrix angewendet ?
T-1967	What is Prepandrix used for ?
H-1967	-0.0023103347048163414	What is Prepandrix used for ?
D-1967	-0.0023103347048163414	What is Prepandrix used for ?
P-1967	-0.0047 -0.0042 -0.0032 -0.0004 -0.0009 -0.0010 -0.0014 -0.0052 -0.0016 -0.0013 -0.0014
S-1401	- Erhöhte Kreatininwerte im Blut
T-1401	- Elevated creatinine in blood
H-1401	-0.01464358251541853	- Elevated creatinine in blood
D-1401	-0.01464358251541853	- Elevated creatinine in blood
P-1401	-0.0027 -0.0139 -0.0013 -0.0012 -0.0031 -0.0010 -0.0220 -0.0014 -0.0147 -0.0970 -0.0028
S-1177	EMEA / H / C / 757
T-1177	EMEA / H / C / 757
H-1177	-0.004136659204959869	EMEA / H / C / 757
D-1177	-0.004136659204959869	EMEA / H / C / 757
P-1177	-0.0078 -0.0005 -0.0012 -0.0019 -0.0011 -0.0014 -0.0010 -0.0015 -0.0014 -0.0264 -0.0015
S-135	Pharma @-@ Cos House Triq C .
T-135	Pharma @-@ Cos House Triq C .
H-135	-0.7370487451553345	Pharma 070 House Triq C .
D-135	-0.7370487451553345	Pharma 070 House Triq C .
P-135	-0.0025 -0.0005 -4.9548 -1.7891 -0.6097 -0.0045 -0.0014 -0.0028 -0.0038 -0.0014
S-672	PUREVAX RCPCH
T-672	PUREVAX RCPCH
H-672	-1.4960118532180786	Roxene RCPCH
D-672	-1.4960118532180786	Roxene RCPCH
P-672	-11.5766 -0.0141 -0.0200 -0.3508 -0.0023 -0.0008 -0.0011 -0.0024
S-1483	EU / 1 / 07 / 400 / 017
T-1483	EU / 1 / 07 / 400 / 017
H-1483	-0.0014417734928429127	EU / 1 / 07 / 400 / 017
D-1483	-0.0014417734928429127	EU / 1 / 07 / 400 / 017
P-1483	-0.0020 -0.0018 -0.0018 -0.0014 -0.0012 -0.0014 -0.0008 -0.0015 -0.0014 -0.0012 -0.0015
S-1104	Tel : + 351 21 434 61 00
T-1104	Tel : + 351 21 434 61 00
H-1104	-0.004052038304507732	Tel : + 351 21 434 61 00
D-1104	-0.004052038304507732	Tel : + 351 21 434 61 00
P-1104	-0.0034 -0.0039 -0.0012 -0.0275 -0.0012 -0.0011 -0.0012 -0.0011 -0.0009 -0.0015 -0.0015
S-386	ge Rheumatoide Arthritis
T-386	tho Rheumatoid arthritis
H-386	-0.007827475666999817	tho Rheumatoid arthritis
D-386	-0.007827475666999817	tho Rheumatoid arthritis
P-386	-0.0145 -0.0145 -0.0128 -0.0033 -0.0008 -0.0009 -0.0005 -0.0118 -0.0007 -0.0010 -0.0253
S-37	Gummi- Balken dichtschei be
T-37	Important information for use of OptiSet :
H-37	-0.012146281078457832	Important information for use of OptiSet :
D-37	-0.012146281078457832	Important information for use of OptiSet :
P-37	-0.0145 -0.0144 -0.0022 -0.0139 -0.0142 -0.0147 -0.0139 -0.0145 -0.0145 -0.0144 -0.0023
S-577	EU / 1 / 01 / 185 / 022
T-577	EU / 1 / 01 / 185 / 022
H-577	-0.0013954881578683853	EU / 1 / 01 / 185 / 022
D-577	-0.0013954881578683853	EU / 1 / 01 / 185 / 022
P-577	-0.0015 -0.0017 -0.0018 -0.0014 -0.0014 -0.0014 -0.0007 -0.0015 -0.0013 -0.0012 -0.0014
S-1822	150 mg / ml Olanzapin .
T-1822	150 mg / ml olanzapine .
H-1822	-0.015538472682237625	150 mg / ml olanzapine .
D-1822	-0.015538472682237625	150 mg / ml olanzapine .
P-1822	-0.0022 -0.0005 -0.0015 -0.0011 -0.0044 -0.0008 -0.0006 -0.0013 -0.1416 -0.0014
S-637	Wofür wird Pradaxa angewendet ?
T-637	What is Pradaxa used for ?
H-637	-0.0020463017281144857	What is Pradaxa used for ?
D-637	-0.0020463017281144857	What is Pradaxa used for ?
P-637	-0.0045 -0.0031 -0.0010 -0.0010 -0.0010 -0.0014 -0.0042 -0.0016 -0.0013 -0.0014
S-1445	Ac Helcor S.R.L .
T-1445	Ac Helcor S. R. L .
H-1445	-0.0060052634216845036	Ac Helcor S. R. L .
D-1445	-0.0060052634216845036	Ac Helcor S. R. L .
P-1445	-0.0018 -0.0012 -0.0015 -0.0013 -0.0013 -0.0145 -0.0263 -0.0090 -0.0017 -0.0014
S-725	Wofür wird Atripla angewendet ?
T-725	What is Atripla used for ?
H-725	-0.00224728393368423	What is Atripla used for ?
D-725	-0.00224728393368423	What is Atripla used for ?
P-725	-0.0057 -0.0035 -0.0019 -0.0008 -0.0011 -0.0013 -0.0038 -0.0016 -0.0014 -0.0014
S-490	Wofür wird Trizivir angewendet ?
T-490	What is Trizivir used for ?
H-490	-0.00955482292920351	What is Trizivir used for ?
D-490	-0.00955482292920351	What is Trizivir used for ?
P-490	-0.0039 -0.0032 -0.0107 -0.0105 -0.0579 -0.0006 -0.0044 -0.0017 -0.0013 -0.0014
S-1392	Gutachten nach Erteilung der Zulassung 1999 @-@ 2001
T-1392	Post @-@ authorisation opinions 1999 @-@ 2001
H-1392	-0.030362283810973167	Post @-@ authorisation opinions 1999 @-@ 2001
D-1392	-0.030362283810973167	Post @-@ authorisation opinions 1999 @-@ 2001
P-1392	-0.0145 -0.0049 -0.0116 -0.0010 -0.0118 -0.0020 -0.0021 -0.0019 -0.2236
S-1260	56 Geschlecht , Rasse und ältere Patienten :
T-1260	47 Gender , race , elderly :
H-1260	-0.04638422653079033	47 Gender , race , elderly :
D-1260	-0.04638422653079033	47 Gender , race , elderly :
P-1260	-0.0145 -0.0048 -0.0007 -0.0014 -0.0045 -0.3620 -0.0146 -0.0132 -0.0018
S-308	Besondere Vorsichtsmaßnahmen für die Anwendung bei Tieren
T-308	Special precautions for use in animals
H-308	-0.008832352235913277	Special precautions for use in animals
D-308	-0.008832352235913277	Special precautions for use in animals
P-308	-0.0308 -0.0053 -0.0004 -0.0023 -0.0030 -0.0061 -0.0283 -0.0015 -0.0018
S-630	100 Glasfläschchen ( Mehrdosen )
T-630	100 vials ( multidose )
H-630	-0.007872534915804863	100 vials ( multidose )
D-630	-0.007872534915804863	100 vials ( multidose )
P-630	-0.0031 -0.0144 -0.0020 -0.0103 -0.0126 -0.0139 -0.0035 -0.0033
S-1978	Durchsichtiges gelbes Gel , 60 g
T-1978	Clear yellow gel , 60 g
H-1978	-0.0033661455381661654	Clear yellow gel , 60 g
D-1978	-0.0033661455381661654	Clear yellow gel , 60 g
P-1978	-0.0141 -0.0008 -0.0024 -0.0023 -0.0023 -0.0019 -0.0013 -0.0017
S-1143	- Retention des Mageninhaltes .
T-1143	- Gastric retention .
H-1143	-0.004047214053571224	- Gastric retention .
D-1143	-0.004047214053571224	- Gastric retention .
P-1143	-0.0017 -0.0145 -0.0009 -0.0008 -0.0088 -0.0004 -0.0038 -0.0014
S-663	Wenn Ihnen Glukagon gegeben wurde , sollten
T-663	Using glucagon t uc
H-663	-0.011714055202901363	Using glucagon t uc
D-663	-0.011714055202901363	Using glucagon t uc
P-663	-0.0310 -0.0033 -0.0011 -0.0005 -0.0145 -0.0145 -0.0145 -0.0142
S-435	3 Durchstechflaschen mit Lösungsmittel .
T-435	3 vials of solvent .
H-435	-0.018830234184861183	3 vials of solvent .
D-435	-0.018830234184861183	3 vials of solvent .
P-435	-0.1215 -0.0065 -0.0009 -0.0112 -0.0028 -0.0023 -0.0039 -0.0015
S-1417	Es wurde kein Rebound @-@ Effekt beobachtet .
T-1417	No rebound was observed .
H-1417	-0.013171248137950897	No rebound was observed .
D-1417	-0.013171248137950897	No rebound was observed .
P-1417	-0.0067 -0.0026 -0.0003 -0.0130 -0.0664 -0.0018 -0.0014
S-1540	10 Tabletten je Blister- packung
T-1540	PVC / aluminium blisters
H-1540	-0.06364885717630386	PVC / aluminium blisters
D-1540	-0.06364885717630386	PVC / aluminium blisters
P-1540	-0.0369 -0.0146 -0.0451 -0.0145 -0.0103 -0.0272 -0.3465 -0.0141
S-412	Es muss für Kinder unzugänglich aufbewahrt werden .
T-412	It must be kept out of the sight and reach of children .
H-412	-0.08341781795024872	It must be kept out of the sight and reach of children .
D-412	-0.08341781795024872	It must be kept out of the sight and reach of children .
P-412	-0.0037 -0.0125 -0.0024 -0.0038 -0.0094 -0.0014 -0.0098 -0.0145 -0.7215 -0.0074 -0.3769 -0.0015 -0.0016 -0.0014
S-972	Lisinopril + Amlodipin
T-972	OPINION FOLLOWING AN ARTICLE 29 ( 4 ) 1 REFERRAL FOR Lisonorm and associated names International Non @-@ Proprietary Name ( INN ) : lisinopril + amlodipine
H-972	-0.39166319370269775	OPINION FOLLOWING AN ARTICLE 29 ( 4 ) 1 .
D-972	-0.39166319370269775	OPINION FOLLOWING AN ARTICLE 29 ( 4 ) 1 .
P-972	-0.0145 -0.0141 -0.0145 -0.0155 -0.0141 -0.0053 -0.0025 -0.0085 -0.0226 -0.0146 -0.0125 -0.0080 -0.0039 -0.0265 -0.0178 -0.0144 -0.0022 -0.0170 -7.6029 -0.0020
S-1466	Jedoch kann der Schweregrad erhöht sein .
T-1466	In general , the adverse events seen in overdose cases involving PegIntron are consistent with the known safety profile for PegIntron ; however , the severity of the events may be increased .
H-1466	-0.14563623070716858	In general , the adverse events seen in overdose cases involving PegIntron are consistent with the known safety profile for PegIntron ;
D-1466	-0.14563623070716858	In general , the adverse events seen in overdose cases involving PegIntron are consistent with the known safety profile for PegIntron ;
P-1466	-0.0146 -0.0152 -0.0046 -0.0096 -0.0145 -0.0033 -0.0133 -0.0152 -0.0112 -0.0145 -0.0097 -0.0140 -0.0147 -0.0145 -0.0145 -0.0145 -0.0145 -0.0134 -0.0126 -0.0145 -0.0152 -0.0123 -0.0145 -0.0144 -0.0145 -0.0336 -0.0145 -0.0016 -0.0102 -0.0011 -0.0027 -0.0146 -4.4040
S-1396	Bei Ratten und Mäusen verringerte es jedoch
T-1396	Rotigotine did not influence male fertility in rats , but clearly reduced female fertility in rats and mice , because of the effects on prolactin levels which are particularly significant in rodents .
H-1396	-0.17931510508060455	Rotigotine did not influence male fertility in rats , but clearly reduced female fertility in mice , because of the effects on prolactin levels which are particularly significant in rodents .
D-1396	-0.17931510508060455	Rotigotine did not influence male fertility in rats , but clearly reduced female fertility in mice , because of the effects on prolactin levels which are particularly significant in rodents .
P-1396	-0.0145 -0.0145 -0.0107 -0.0137 -0.0144 -0.0137 -0.0150 -0.0145 -0.0145 -0.0056 -0.0061 -0.0012 -0.0270 -0.0114 -0.0152 -0.0112 -0.0144 -0.0017 -0.0022 -0.0078 -7.0052 -0.0006 -0.0888 -0.0146 -0.0121 -0.0101 -0.0141 -0.0138 -0.0145 -0.0145 -0.0010 -0.0025 -0.0131 -0.0152 -0.0139 -0.0145 -0.0144 -0.0108 -0.0145 -0.0049 -0.0073 -0.0014
S-1938	17 Handhabungshinweise siehe Abschnitt 6.6
T-1938	17 Exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopoenia or bleeding disorders .
H-1938	-0.4115581214427948	17 Exceptionally , the vaccine may be administered subcutaneously in patients .
D-1938	-0.4115581214427948	17 Exceptionally , the vaccine may be administered subcutaneously in patients .
P-1938	-0.0012 -0.0145 -0.0144 -0.0149 -0.0142 -0.0144 -0.0145 -0.0143 -0.0096 -0.0143 -0.0011 -0.0150 -0.0144 -0.0013 -0.0016 -0.0602 -0.0156 -0.0143 -7.9800 -0.0014
S-1648	L 147 vom 9.6.1975 , S .
T-1648	1 ) • Council Directive 75 / 319 / EEC as amended ( OJ L 147 , 9.6.1975 , p .
H-1648	-0.36960074305534363	1 ) • Council Directive 75 / 319 / EEC as amended ( OJ L 147 ) .
D-1648	-0.36960074305534363	1 ) • Council Directive 75 / 319 / EEC as amended ( OJ L 147 ) .
P-1648	-0.0175 -0.0137 -0.0365 -0.0346 -0.0144 -0.0015 -0.0145 -0.0055 -0.0150 -0.0144 -0.0051 -0.0115 -0.0003 -0.0146 -0.0060 -0.0004 -0.0148 -0.0100 -0.0015 -0.0115 -0.0031 -0.0014 -8.3874 -0.6036 -0.0014
S-252	15 mg oder 30 mg täglich für 4 Wochen .
T-252	Treatment of heartburn and acid regurgitation : one 15 mg or 30 mg capsule for 4 weeks .
H-252	-0.03163428232073784	Treatment of heartburn and acid regurgitation : one 15 mg or 30 mg capsule for 4 weeks .
D-252	-0.03163428232073784	Treatment of heartburn and acid regurgitation : one 15 mg or 30 mg capsule for 4 weeks .
P-252	-0.0147 -0.0043 -0.0016 -0.0137 -0.0145 -0.0024 -0.0140 -0.0145 -0.0145 -0.0025 -0.0000 -0.0025 -0.0143 -0.0145 -0.0145 -0.0035 -0.0115 -0.0013 -0.0010 -0.3727 -0.0012 -0.0035 -0.3060 -0.0058 -0.0010 -0.0027 -0.0014
S-1484	Prequenza Te Prequenza
T-1484	Prequenza Prequenza Prequenza Prequenza Te Prequenza
H-1484	-0.3814316689968109	Prequenza Prequenza Prequenza
D-1484	-0.3814316689968109	Prequenza Prequenza Prequenza
P-1484	-0.0108 -0.0013 -0.0021 -0.0014 -0.0145 -0.0016 -0.0016 -0.0014 -0.1336 -0.0014 -0.0016 -0.0014 -4.7860
S-1709	Beobachtungsanalyse FPV / RTV BID
T-1709	Observed analysis Observed analysis FPV / RTV BID LPV / RTV BID
H-1709	-0.16328109800815582	Observed analysis Observed analysis FPV / RTV BID
D-1709	-0.16328109800815582	Observed analysis Observed analysis FPV / RTV BID
P-1709	-0.0022 -0.0145 -0.0087 -0.7504 -0.0145 -0.0193 -0.6810 -0.2111 -0.0017 -0.0014 -0.0011 -0.0045 -0.0008 -0.5749
S-1262	n Dynepo 5.000 IE / 0,5 ml
T-1262	Dynepo 5,000 IU / 0.5 ml injection Epoetin delta
H-1262	-0.4174579083919525	Dynepo 5,000 IU / 0.5 ml injection Epoxy delta
D-1262	-0.4174579083919525	Dynepo 5,000 IU / 0.5 ml injection Epoxy delta
P-1262	-0.0143 -0.0031 -0.0011 -0.0123 -0.0126 -0.0001 -0.0015 -0.0090 -0.0006 -0.0188 -0.0120 -0.0145 -0.0144 -6.7003 -0.2591 -0.0101 -0.0132
S-1019	Xyrem kann eine Atemdepression verursachen .
T-1019	Xyrem has the potential to induce respiratory depression
H-1019	-0.14425452053546906	Xyrem has the potential to induce respiratory depression
D-1019	-0.14425452053546906	Xyrem has the potential to induce respiratory depression
P-1019	-0.0008 -0.0014 -0.0013 -0.3533 -0.0107 -0.0029 -0.0016 -0.0185 -0.0011 -0.0060 -0.0006 -0.0008 -0.0015 -1.6189
S-880	Diese Zusammenfassung wurde zuletzt im December 2008 aktualisiert .
T-880	This summary was last updated in December 2008 .
H-880	-0.02365499921143055	This summary was last updated in December 2008 .
D-880	-0.02365499921143055	This summary was last updated in December 2008 .
P-880	-0.0055 -0.0056 -0.0052 -0.0022 -0.0016 -0.0011 -0.0025 -0.0012 -0.0020 -0.2319 -0.0014
S-782	häufige Miktion , Harninkontinenz
T-782	Micturition frequency , urinary incontinence
H-782	-0.6654157042503357	Micturition , urinary incontinence
D-782	-0.6654157042503357	Micturition , urinary incontinence
P-782	-0.0145 -0.0140 -0.0067 -0.0026 -7.2720 -0.0031 -0.0014 -0.0012 -0.0003 -0.0010 -0.0030
S-698	Patienten mit schwerer Leberinsuffizienz .
T-698	Patients with severe hepatic insufficiency .
H-698	-0.0033269270788878202	Patients with severe hepatic insufficiency .
D-698	-0.0033269270788878202	Patients with severe hepatic insufficiency .
P-698	-0.0025 -0.0009 -0.0023 -0.0026 -0.0142 -0.0008 -0.0012 -0.0126 -0.0006 -0.0009 -0.0012 -0.0021 -0.0014
S-1679	- Eine schwere psychische Erkrankung wie Psychose .
T-1679	- any form of severe mental disorder like psychosis
H-1679	-0.04557923972606659	- any form of severe mental disorder like psychosis
D-1679	-0.04557923972606659	- any form of severe mental disorder like psychosis
P-1679	-0.0028 -0.0145 -0.0147 -0.0014 -0.0114 -0.0047 -0.0142 -0.0128 -0.0019 -0.0005 -0.0009 -0.4672
S-695	45 Wie Iscover aussieht und Inhalt der Packung
T-695	What Iscover looks like and contents of the pack
H-695	-0.0073607563972473145	What Iscover looks like and contents of the pack
D-695	-0.0073607563972473145	What Iscover looks like and contents of the pack
P-695	-0.0144 -0.0016 -0.0012 -0.0031 -0.0015 -0.0022 -0.0088 -0.0010 -0.0019 -0.0039 -0.0076 -0.0412
S-1222	Hinweise für stillende Frauen siehe Abschnitt 4.6 .
T-1222	For breast @-@ feeding women , see section 4.6 .
H-1222	-0.0065278285183012486	For breast @-@ feeding women , see section 4.6 .
D-1222	-0.0065278285183012486	For breast @-@ feeding women , see section 4.6 .
P-1222	-0.0078 -0.0143 -0.0221 -0.0010 -0.0111 -0.0060 -0.0026 -0.0077 -0.0012 -0.0014 -0.0018 -0.0014
S-1795	Die hauptsächlichen Ziele für 2003 sind :
T-1795	Requirement for more efficient evaluation procedures
H-1795	-0.012514187023043633	Requirement for more efficient evaluation procedures
D-1795	-0.012514187023043633	Requirement for more efficient evaluation procedures
P-1795	-0.0148 -0.0143 -0.0139 -0.0125 -0.0145 -0.0145 -0.0145 -0.0012 -0.0007 -0.0164 -0.0204
S-182	EMEA / H / C / 267
T-182	EMEA / H / C / 267
H-182	-0.0021517532877624035	EMEA / H / C / 267
D-182	-0.0021517532877624035	EMEA / H / C / 267
P-182	-0.0093 -0.0005 -0.0012 -0.0018 -0.0011 -0.0014 -0.0009 -0.0016 -0.0031 -0.0013 -0.0015
S-1307	EMEA / H / C / 528
T-1307	EMEA / H / C / 528
H-1307	-0.001808647415600717	EMEA / H / C / 528
D-1307	-0.001808647415600717	EMEA / H / C / 528
P-1307	-0.0075 -0.0005 -0.0012 -0.0018 -0.0010 -0.0014 -0.0009 -0.0015 -0.0014 -0.0012 -0.0015
S-1024	EU / 1 / 08 / 450 / 002
T-1024	EU / 1 / 08 / 450 / 002
H-1024	-0.0018377354135736823	EU / 1 / 08 / 450 / 002
D-1024	-0.0018377354135736823	EU / 1 / 08 / 450 / 002
P-1024	-0.0018 -0.0018 -0.0017 -0.0015 -0.0013 -0.0014 -0.0044 -0.0015 -0.0018 -0.0015 -0.0015
S-1344	Welches Risiko ist mit ORENCIA verbunden ?
T-1344	What is the risk associated with ORENCIA ?
H-1344	-0.0026011320296674967	What is the risk associated with ORENCIA ?
D-1344	-0.0026011320296674967	What is the risk associated with ORENCIA ?
P-1344	-0.0034 -0.0083 -0.0019 -0.0024 -0.0057 -0.0014 -0.0010 -0.0009 -0.0006 -0.0015 -0.0014
S-1150	( 3 @-@ 5 ) ( 3 @-@ 7 )
T-1150	28 ( 7 @-@ 33 )
H-1150	-0.009799235500395298	28 ( 7 @-@ 33 )
D-1150	-0.009799235500395298	28 ( 7 @-@ 33 )
P-1150	-0.0146 -0.0090 -0.0142 -0.0019 -0.0145 -0.0015 -0.0128
S-424	Nicht bekannt Stevens @-@ Johnson @-@ Syndrom ;
T-424	not known
H-424	-0.010029844008386135	not known
D-424	-0.010029844008386135	not known
P-424	-0.0132 -0.0024 -0.0145
S-451	Miete / Nebenkosten Ausgaben für die Datenverarbeitung
T-451	Building / equipment
H-451	-0.014063882641494274	Building / equipment
D-451	-0.014063882641494274	Building / equipment
P-451	-0.0145 -0.0128 -0.0145 -0.0145
S-1847	8 / 12 Besondere Patientengruppen :
T-1847	Special Populations :
H-1847	-0.08144791424274445	Special Populations :
D-1847	-0.08144791424274445	Special Populations :
P-1847	-0.3643 -0.0145 -0.0099 -0.0057 -0.0128
S-1690	13 % * * * 20 % * * *
T-1690	13 % * * *
H-1690	-0.004967320244759321	13 % * * *
D-1690	-0.004967320244759321	13 % * * *
P-1690	-0.0046 -0.0020 -0.0018 -0.0013 -0.0013 -0.0188
S-1913	90 95 p = 0,016 nach 48 Monaten
T-1913	95 p = 0.016
H-1913	-0.009576300159096718	95 p = 0.016
D-1913	-0.009576300159096718	95 p = 0.016
P-1913	-0.0251 -0.0115 -0.0012 -0.0037 -0.0013 -0.0146
S-572	Kapsel 120 mg 6 Packungsgrößen
T-572	120 mg 6 presentations
H-572	-0.009968944825232029	120 mg 6 presentations
D-572	-0.009968944825232029	120 mg 6 presentations
P-572	-0.0136 -0.0003 -0.0140 -0.0145 -0.0130 -0.0045 -0.0098
S-1980	Magensaftresistente Tablette
T-1980	Gastro resistant tablet
H-1980	-0.032441768795251846	Gastro resistant tablet
D-1980	-0.032441768795251846	Gastro resistant tablet
P-1980	-0.0089 -0.0150 -0.0144 -0.0010 -0.0016 -0.1846 -0.0017
S-1568	5 Behältnisse 5 Behältnisse
T-1568	5 vials 5 vials
H-1568	-0.003918375354260206	5 vials 5 vials
D-1568	-0.003918375354260206	5 vials 5 vials
P-1568	-0.0019 -0.0145 -0.0010 -0.0021 -0.0057 -0.0005 -0.0018
S-1686	- wenn Sie an einer Lebererkrankung leiden
T-1686	- if you have liver problems
H-1686	-0.17921259999275208	- if you suffer from any liver problems
D-1686	-0.17921259999275208	- if you suffer from any liver problems
P-1686	-0.2174 -0.0038 -0.0015 -0.9121 -0.0017 -0.0459 -0.0030 -0.0263 -0.4012
S-180	Dies sollte mit Ihrem Arzt besprochen werden .
T-180	This can be discussed with your doctor .
H-180	-0.009654756635427475	This can be discussed with your doctor .
D-180	-0.009654756635427475	This can be discussed with your doctor .
P-180	-0.0032 -0.0176 -0.0040 -0.0038 -0.0018 -0.0502 -0.0028 -0.0020 -0.0014
S-1118	Tel : + 370 5 269 17 96
T-1118	Tel : + 370 5 269 17 96
H-1118	-0.0020663514733314514	Tel : + 370 5 269 17 96
D-1118	-0.0020663514733314514	Tel : + 370 5 269 17 96
P-1118	-0.0040 -0.0044 -0.0012 -0.0004 -0.0017 -0.0010 -0.0016 -0.0014 -0.0035 -0.0016
S-961	Fieber Reaktionen an der Injektionsstelle
T-961	Fever Injection site reaction Pain
H-961	-0.00855917390435934	Fever Injection site reaction Pain
D-961	-0.00855917390435934	Fever Injection site reaction Pain
P-961	-0.0088 -0.0010 -0.0150 -0.0011 -0.0050 -0.0131 -0.0152 -0.0124 -0.0055
S-134	136 Nicht über 25ºC lagern .
T-134	Do not store above 25 ° C .
H-134	-0.08615707606077194	Do not store above 25 ° C .
D-134	-0.08615707606077194	Do not store above 25 ° C .
P-134	-0.7372 -0.0016 -0.0018 -0.0051 -0.0131 -0.0084 -0.0022 -0.0046 -0.0015
S-892	Wofür wird Imprida angewendet ?
T-892	What is Imprida used for ?
H-892	-0.002318903338164091	What is Imprida used for ?
D-892	-0.002318903338164091	What is Imprida used for ?
P-892	-0.0049 -0.0043 -0.0011 -0.0012 -0.0007 -0.0042 -0.0017 -0.0013 -0.0014
S-1197	Wofür wird Easotic angewendet ?
T-1197	What is Easotic used for ?
H-1197	-0.002367146546021104	What is Easotic used for ?
D-1197	-0.002367146546021104	What is Easotic used for ?
P-1197	-0.0047 -0.0038 -0.0026 -0.0011 -0.0006 -0.0042 -0.0016 -0.0014 -0.0014
S-1013	Dies wird von Ihrem Arzt abgeklärt werden .
T-1013	This will be checked by your doctor .
H-1013	-0.011874266900122166	This will be checked by your doctor .
D-1013	-0.011874266900122166	This will be checked by your doctor .
P-1013	-0.0026 -0.0090 -0.0013 -0.0129 -0.0109 -0.0652 -0.0019 -0.0016 -0.0014
S-1042	Die Nadel kann verstopft sein .
T-1042	Your needle may be clogged .
H-1042	-0.00535544753074646	Your needle may be clogged .
D-1042	-0.00535544753074646	Your needle may be clogged .
P-1042	-0.0147 -0.0017 -0.0012 -0.0088 -0.0061 -0.0099 -0.0011 -0.0033 -0.0014
S-1270	Norfloxacine CF 400 mg
T-1270	Norfloxacine CF 400 mg
H-1270	-0.003717294428497553	Norfloxacine CF 400 mg
D-1270	-0.003717294428497553	Norfloxacine CF 400 mg
P-1270	-0.0010 -0.0006 -0.0013 -0.0009 -0.0233 -0.0045 -0.0018 -0.0018 -0.0005 -0.0015
S-1805	Cambrex Bio Science Baltimore , Inc .
T-1805	Cambrex Bio Science Baltimore , Inc .
H-1805	-0.0010370895033702254	Cambrex Bio Science Baltimore , Inc .
D-1805	-0.0010370895033702254	Cambrex Bio Science Baltimore , Inc .
P-1805	-0.0008 -0.0012 -0.0013 -0.0008 -0.0009 -0.0005 -0.0014 -0.0006 -0.0015 -0.0014
S-8	136 Nicht über 30 ° C lagern .
T-8	135 Do not store above 30 ° C .
H-8	-0.08071832358837128	135 Do not store above 30 ° C .
D-8	-0.08071832358837128	135 Do not store above 30 ° C .
P-8	-0.7819 -0.0021 -0.0015 -0.0018 -0.0077 -0.0016 -0.0015 -0.0020 -0.0056 -0.0014
S-1006	0,89 ( 0,76 - 1,03 )
T-1006	0.89 ( 0.76 @-@ 1.03 )
H-1006	-0.012318843975663185	0.89 ( 0.76 @-@ 1.03 )
D-1006	-0.012318843975663185	0.89 ( 0.76 @-@ 1.03 )
P-1006	-0.0115 -0.0122 -0.0015 -0.0053 -0.0013 -0.0853 -0.0022 -0.0010 -0.0014 -0.0014
S-82	Erkrankungen der Atemwege , des Brustraums
T-82	Skin and subcutaneous tissue
H-82	-0.016567742452025414	Skin and subcutaneous tissue
D-82	-0.016567742452025414	Skin and subcutaneous tissue
P-82	-0.0944 -0.0110 -0.0131 -0.0145 -0.0021 -0.0004 -0.0011 -0.0016 -0.0145 -0.0130
S-1957	Suboxone 8 mg / 2 mg
T-1957	Suboxone 8 mg / 2 mg
H-1957	-0.013602256774902344	Suboxone 8 mg / 2 mg
D-1957	-0.013602256774902344	Suboxone 8 mg / 2 mg
P-1957	-0.0064 -0.0051 -0.0009 -0.0229 -0.0018 -0.0003 -0.0015 -0.0950 -0.0006 -0.0015
S-1992	Jede Dosis von 4,31 g enthält :
T-1992	Each 4.31g dose contains :
H-1992	-0.006024961359798908	Each 4.31g dose contains :
D-1992	-0.006024961359798908	Each 4.31g dose contains :
P-1992	-0.0019 -0.0137 -0.0272 -0.0005 -0.0021 -0.0031 -0.0028 -0.0015 -0.0014
S-1279	Wofür wird Optisulin angewendet ?
T-1279	What is Optisulin used for ?
H-1279	-0.0031968343537300825	What is Optisulin used for ?
D-1279	-0.0031968343537300825	What is Optisulin used for ?
P-1279	-0.0047 -0.0031 -0.0026 -0.0035 -0.0054 -0.0051 -0.0016 -0.0013 -0.0014
S-827	Es liegen keine Daten zu älteren Patienten vor .
T-827	No data is available on elderly patients .
H-827	-0.010646791197359562	No data is available on elderly patients .
D-827	-0.010646791197359562	No data is available on elderly patients .
P-827	-0.0131 -0.0018 -0.0334 -0.0019 -0.0189 -0.0223 -0.0013 -0.0016 -0.0014
S-1821	Wofür wird IDflu angewendet ?
T-1821	What is IDflu used for ?
H-1821	-0.0025523549411445856	What is IDflu used for ?
D-1821	-0.0025523549411445856	What is IDflu used for ?
P-1821	-0.0057 -0.0036 -0.0038 -0.0013 -0.0003 -0.0039 -0.0016 -0.0013 -0.0014
S-1876	7 / 214 ( 3,3 % )
T-1876	( 0 % ) 3 / 95
H-1876	-0.0224007461220026	( 0 % ) 3 / 95
D-1876	-0.0224007461220026	( 0 % ) 3 / 95
P-1876	-0.1098 -0.0180 -0.0100 -0.0026 -0.0150 -0.0030 -0.0147 -0.0062
S-1139	- Sie haben eine Nierenerkrankung .
T-1139	- You have kidney disease .
H-1139	-0.02658449485898018	- You have kidney disease .
D-1139	-0.02658449485898018	- You have kidney disease .
P-1139	-0.0060 -0.0035 -0.0076 -0.1230 -0.0008 -0.0684 -0.0019 -0.0014
S-92	5 Durchstechflaschen ( 17 ml )
T-92	5 vials ( 17 ml )
H-92	-0.0030734085012227297	5 vials ( 17 ml )
D-92	-0.0030734085012227297	5 vials ( 17 ml )
P-92	-0.0025 -0.0126 -0.0010 -0.0034 -0.0014 -0.0008 -0.0015 -0.0015
S-1430	Der Verwaltungsrat tagte 2002 viermal .
T-1430	Overview of the Management Board
H-1430	-0.010436583310365677	Overview of the Management Board
D-1430	-0.010436583310365677	Overview of the Management Board
P-1430	-0.0146 -0.0099 -0.0131 -0.0076 -0.0143 -0.0018 -0.0119
S-1122	43 ETIKETTIERUNG
T-1122	41 LABELLING
H-1122	-0.007437827531248331	41 LABELLING
D-1122	-0.007437827531248331	41 LABELLING
P-1122	-0.0145 -0.0132 -0.0027 -0.0088 -0.0066 -0.0001 -0.0061
S-1564	Lassen Sie den Kolben nicht los ..
T-1564	Do not release plunger .
H-1564	-0.007334908004850149	Do not release plunger .
D-1564	-0.007334908004850149	Do not release plunger .
P-1564	-0.0112 -0.0015 -0.0120 -0.0156 -0.0010 -0.0082 -0.0018
S-682	Neulasta darf nicht angewendet werden :
T-682	Do not use Neulasta
H-682	-0.00861272495239973	Do not use Neulasta
D-682	-0.00861272495239973	Do not use Neulasta
P-682	-0.0144 -0.0015 -0.0119 -0.0139 -0.0019 -0.0005 -0.0163
S-561	Obstipation Dyspepsie ,
T-561	constipation , a
H-561	-0.008408346213400364	constipation , a
D-561	-0.008408346213400364	constipation , a
P-561	-0.0117 -0.0004 -0.0007 -0.0014 -0.0151 -0.0151 -0.0144
S-1381	Führen Sie die Injektion sofort durch
T-1381	Inject straight away .
H-1381	-0.009404772892594337	Inject straight away .
D-1381	-0.009404772892594337	Inject straight away .
P-1381	-0.0144 -0.0117 -0.0145 -0.0012 -0.0131 -0.0016
S-1848	Paroxetine &apos; Copyfarm &quot;
T-1848	Paroxetine <<unk>> Copyfarm <<unk>>
H-1848	-0.02734236791729927	Paroxetine <unk> Copyfarm <unk>
D-1848	-0.02734236791729927	Paroxetine <unk> Copyfarm <unk>
P-1848	-0.0044 -0.0004 -0.0007 -0.1659 -0.0146 -0.0104 -0.0015 -0.0010 -0.0459 -0.0286
S-1313	März 17. , 18. , 19. / 20 .
T-1313	21 , 22 18 , 19 18 , 19 15 , 16 13 , 14 17 , 18 22 , 23
H-1313	-0.49158528447151184	21 , 22 18 , 19 18 , 19 15 , 16 13 , 14 17 , 23
D-1313	-0.49158528447151184	21 , 22 18 , 19 18 , 19 15 , 16 13 , 14 17 , 23
P-1313	-0.0147 -0.0271 -0.0143 -0.1633 -0.1205 -0.0433 -0.1045 -0.1146 -0.3950 -0.3570 -0.2675 -0.9161 -0.8927 -0.0984 -1.4419 -1.2083 -0.0535 -1.8060 -1.3015
S-1017	Durchfall , Übelkeit , Erbrechen
T-1017	Respiratory , thoracic and mediastinal disorders : uncommon : dyspnoea
H-1017	-0.12011750042438507	Respiratory , thoracic and mediastinal disorders : uncommon : dyspnoea
D-1017	-0.12011750042438507	Respiratory , thoracic and mediastinal disorders : uncommon : dyspnoea
P-1017	-0.0145 -0.0072 -0.0002 -0.0135 -0.0163 -0.0064 -0.0010 -0.0137 -0.0145 -0.0145 -0.0145 -0.0143 -0.0009 -0.1255 -0.6733 -0.0145 -0.0144 -0.6490 -0.0126 -0.0140 -0.0004 -1.0073
S-1838	März 2001 bei der EMEA statt .
T-1838	Other areas for support will be explored with the heads of agencies groups in 2001 .
H-1838	-0.05470316484570503	Other areas for support will be explored with the heads of agencies groups in 2001 .
D-1838	-0.05470316484570503	Other areas for support will be explored with the heads of agencies groups in 2001 .
P-1838	-0.0145 -0.0145 -0.0143 -0.0144 -0.0141 -0.0081 -0.0144 -0.0037 -0.0149 -0.0119 -0.0145 -0.0029 -0.0144 -0.3236 -0.3497 -0.0145 -0.1390 -0.0014
S-349	Dokumentation - Modul 3 ( Qualität ) ;
T-349	and harmonisation of the pharmaceutical documentation <<unk>> module 3 ( quality )
H-349	-0.5256906151771545	and harmonisation of the pharmaceutical documentation <unk> module ( quality )
D-349	-0.5256906151771545	and harmonisation of the pharmaceutical documentation <unk> module ( quality )
P-349	-0.0145 -0.0145 -0.0136 -0.0127 -0.0129 -0.0163 -0.0028 -0.0023 -0.0140 -0.0008 -0.0160 -0.0065 -0.0010 -8.7519 -0.0073 -0.0016 -0.0480
S-347	Sehr selten ( ≤ 1 / 10.000 ) :
T-347	Subject Incidence Very rare ( ≤ 1 / 10,000 ) :
H-347	-0.007274496369063854	Subject Incidence Very rare ( ≤ 1 / 10,000 ) :
D-347	-0.007274496369063854	Subject Incidence Very rare ( ≤ 1 / 10,000 ) :
P-347	-0.0196 -0.0141 -0.0145 -0.0117 -0.0121 -0.0112 -0.0095 -0.0014 -0.0001 -0.0014 -0.0016 -0.0075 -0.0015 -0.0018 -0.0014
S-821	Johnson &amp; Johnson , s.r.o .
T-821	Slovenská republika Johnson &amp; Johnson , s. r. o .
H-821	-0.3216140866279602	Johnson &amp; Johnson , s. r. o .
D-821	-0.3216140866279602	Johnson &amp; Johnson , s. r. o .
P-821	-2.7178 -0.0014 -0.0005 -0.1399 -0.0145 -0.0117 -0.0058 -0.0015 -0.0014
S-707	Nicht anwenden bei Hautgeschwüren .
T-707	Do not use on cutaneous ulcers .
H-707	-0.005054432433098555	Do not use on cutaneous ulcers .
D-707	-0.005054432433098555	Do not use on cutaneous ulcers .
P-707	-0.0047 -0.0014 -0.0147 -0.0153 -0.0144 -0.0014 -0.0016 -0.0013 -0.0011 -0.0055 -0.0010 -0.0020 -0.0014
S-1263	Maximal können 2 Kits verwendet werden .
T-1263	However , a maximum of 2 kits may be used .
H-1263	-0.005180571228265762	However , a maximum of 2 kits may be used .
D-1263	-0.005180571228265762	However , a maximum of 2 kits may be used .
P-1263	-0.0145 -0.0043 -0.0094 -0.0016 -0.0016 -0.0110 -0.0036 -0.0012 -0.0141 -0.0015 -0.0014 -0.0017 -0.0014
S-1055	12 Patienten mit eingeschränkter Nierenfunktion :
T-1055	11 Patients with renal impairment :
H-1055	-0.007370431441813707	11 Patients with renal impairment :
D-1055	-0.007370431441813707	11 Patients with renal impairment :
P-1055	-0.0145 -0.0137 -0.0010 -0.0018 -0.0430 -0.0009 -0.0065 -0.0013 -0.0006 -0.0013 -0.0024 -0.0014
S-1203	Piroxicam Disper Cf
T-1203	Piroxicam Disper Cf 20 mg
H-1203	-0.058868128806352615	Piroxicam Disper Cf
D-1203	-0.058868128806352615	Piroxicam Disper Cf
P-1203	-0.0063 -0.0010 -0.0011 -0.0006 -0.0017 -0.0112 -0.0075 -0.0015 -0.0029 -0.5548
S-742	3 Durchstechflaschen 3 Ampullen
T-742	Package size 3 vials + 3 ampoules
H-742	-0.5426507592201233	3 vials 3 ampoules
D-742	-0.5426507592201233	3 vials 3 ampoules
P-742	-3.6677 -0.0065 -0.0010 -0.4979 -0.1159 -0.0001 -0.0015 -0.0506
S-1923	Wie wurde Aerinaze untersucht ?
T-1923	How has Aerinaze been studied ?
H-1923	-0.004174195695668459	How has Aerinaze been studied ?
D-1923	-0.004174195695668459	How has Aerinaze been studied ?
P-1923	-0.0017 -0.0126 -0.0034 -0.0010 -0.0016 -0.0064 -0.0023 -0.0016 -0.0124 -0.0015 -0.0014
S-1836	ZOTON ZOTON ZOTON
T-1836	ZOTON ZOTON ZOTON
H-1836	-1.5982304811477661	R07.0
D-1836	-1.5982304811477661	R07.0
P-1836	-5.8117 -0.0145 -0.5517 -0.7915 -0.8217
S-1294	0,63 ( 0,52 - 0,75 )
T-1294	0.63 ( 0.52 @-@ 0.75 )
H-1294	-0.012137002311646938	0.63 ( 0.52 @-@ 0.75 )
D-1294	-0.012137002311646938	0.63 ( 0.52 @-@ 0.75 )
P-1294	-0.0095 -0.0100 -0.0016 -0.0023 -0.0010 -0.0908 -0.0013 -0.0020 -0.0014 -0.0015
S-1194	13 ( 0,5 ) 4 ( 0,2 )
T-1194	13 ( 0.5 ) 4 ( 0.2 )
H-1194	-0.002712021814659238	13 ( 0.5 ) 4 ( 0.2 )
D-1194	-0.002712021814659238	13 ( 0.5 ) 4 ( 0.2 )
P-1194	-0.0067 -0.0015 -0.0093 -0.0014 -0.0014 -0.0013 -0.0013 -0.0014 -0.0014 -0.0014
S-494	Was Rasilez HCT enthält
T-494	What Rasilez HCT contains
H-494	-0.006819866597652435	What Rasilez HCT contains
D-494	-0.006819866597652435	What Rasilez HCT contains
P-494	-0.0021 -0.0036 -0.0010 -0.0009 -0.0010 -0.0013 -0.0012 -0.0010 -0.0044 -0.0516
S-1011	( 35,8 ; 50,9 )
T-1011	( 35.8 , 50.9 )
H-1011	-0.013501877896487713	( 35.8 , 50.9 )
D-1011	-0.013501877896487713	( 35.8 , 50.9 )
P-1011	-0.0300 -0.0100 -0.0105 -0.0012 -0.0746 -0.0025 -0.0021 -0.0012 -0.0015 -0.0015
S-502	Leukopenie Neutropenie
T-502	Leucopenia Neutropenia
H-502	-0.021255671977996826	Leucopenia Neutropenia
D-502	-0.021255671977996826	Leucopenia Neutropenia
P-502	-0.0020 -0.0121 -0.0009 -0.0005 -0.0136 -0.0003 -0.0009 -0.0010 -0.0007 -0.1805
S-1503	EMEA / H / C / 190
T-1503	EMEA / H / C / 190
H-1503	-0.0018125928472727537	EMEA / H / C / 190
D-1503	-0.0018125928472727537	EMEA / H / C / 190
P-1503	-0.0077 -0.0006 -0.0012 -0.0016 -0.0010 -0.0014 -0.0009 -0.0015 -0.0007 -0.0016
S-1171	Wie ist CIALIS einzunehmen ?
T-1171	How to take CIALIS 4 .
H-1171	-0.00528626749292016	How to take CIALIS 4 .
D-1171	-0.00528626749292016	How to take CIALIS 4 .
P-1171	-0.0046 -0.0035 -0.0049 -0.0026 -0.0015 -0.0009 -0.0011 -0.0176 -0.0146 -0.0016
S-1127	103 office building Sofia Tower , fl .
T-1127	103 office building Sofia Tower , fl .
H-1127	-0.002550835721194744	103 office building Sofia Tower , fl .
D-1127	-0.002550835721194744	103 office building Sofia Tower , fl .
P-1127	-0.0014 -0.0137 -0.0007 -0.0009 -0.0012 -0.0014 -0.0022 -0.0007 -0.0018 -0.0014
S-377	Was Olanzapin Teva enthält
T-377	What Olanzapine Teva contains
H-377	-0.00916967447847128	What Olanzapine Teva contains
D-377	-0.00916967447847128	What Olanzapine Teva contains
P-377	-0.0023 -0.0111 -0.0006 -0.0010 -0.0005 -0.0009 -0.0015 -0.0008 -0.0040 -0.0690
S-716	Thalidomide Celgene 50 mg
T-716	Thalidomide Celgene 50mg
H-716	-0.007410042453557253	Thalidomide Celgene 50mg
D-716	-0.007410042453557253	Thalidomide Celgene 50mg
P-716	-0.0027 -0.0006 -0.0008 -0.0007 -0.0041 -0.0015 -0.0004 -0.0612 -0.0006 -0.0015
S-1169	Wie ist Cyanokit anzuwenden ?
T-1169	How to use Cyanokit 4 .
H-1169	-0.011839468032121658	How to use Cyanokit 4 .
D-1169	-0.011839468032121658	How to use Cyanokit 4 .
P-1169	-0.0019 -0.0096 -0.0065 -0.0130 -0.0030 -0.0026 -0.0122 -0.0527 -0.0151 -0.0018
S-1592	43,3 % ( 13 / 30 )
T-1592	43.3 % ( 13 / 30 )
H-1592	-0.02440698817372322	43.3 % ( 13 / 30 )
D-1592	-0.02440698817372322	43.3 % ( 13 / 30 )
P-1592	-0.0145 -0.0070 -0.2114 -0.0017 -0.0014 -0.0022 -0.0014 -0.0017 -0.0014 -0.0014
S-97	Informieren Sie bitte Ihren Arzt .
T-97	If any of the above applies to you , do not take Rasilez HCT and talk to your doctor .
H-97	-0.41200265288352966	If any of the above applies to you , do not take Rasilez .
D-97	-0.41200265288352966	If any of the above applies to you , do not take Rasilez .
P-97	-0.0308 -0.0144 -0.0133 -0.0595 -0.0093 -0.0142 -0.0126 -0.0096 -0.0043 -0.0145 -0.0041 -0.0145 -0.0145 -0.0145 -0.0144 -0.0143 -7.1558 -0.0014
S-510	Es darf auch nicht bei Frauen itte
T-510	Zenapax should not be used in people who may be hypersensitive ( allergic ) to daclizumab or any of lon the other ingredients .
H-510	-0.2147025763988495	Zenapax should not be used in people who may be hypersensitive to daclizumab or any of lon the other ingredients .
D-510	-0.2147025763988495	Zenapax should not be used in people who may be hypersensitive to daclizumab or any of lon the other ingredients .
P-510	-0.0145 -0.0145 -0.0145 -0.0118 -0.0041 -0.0044 -0.0065 -0.0147 -0.0148 -0.0134 -0.0145 -0.0108 -0.0145 -0.0043 -6.1142 -0.0145 -0.0145 -0.0145 -0.0144 -0.0001 -0.0002 -0.0147 -0.0142 -0.0137 -0.0145 -0.0145 -0.0144 -0.0144 -0.0098 -0.0014
S-1275	Mai 2006 schriftliche Erklärungen ab .
T-1275	Written explanations were provided by the Marketing Authorisation Holders on 29 August 2005 , 6 January 2006 , 3 April 2006 and 11 May 2006 .
H-1275	-0.19970490038394928	Written explanations were provided by the Marketing Authorisation Holders on 29 August 2005 , 6 January 2006 , 3 April 2006 and 11 May 2006 .
D-1275	-0.19970490038394928	Written explanations were provided by the Marketing Authorisation Holders on 29 August 2005 , 6 January 2006 , 3 April 2006 and 11 May 2006 .
P-1275	-0.0138 -0.0008 -0.0141 -0.0015 -0.0136 -0.0144 -0.0141 -0.0125 -0.0145 -0.0145 -0.0117 -0.0066 -0.0145 -0.0160 -0.0129 -0.0274 -0.2523 -0.9300 -0.5297 -0.2935 -0.2108 -0.3356 -0.6721 -0.3735 -0.2064 -0.1699 -1.3881 -0.0144 -0.1437 -0.1456 -0.5207 -0.0014
S-1887	( siehe Abschnitt 4.2 . ) .
T-1887	Suspension or modification of therapy should be considered when drug @-@ induced bone marrow depression is detected ( see section 4.2 ) .
H-1887	-0.514663577079773	Suspension or modification of therapy should be considered .
D-1887	-0.514663577079773	Suspension or modification of therapy should be considered .
P-1887	-0.0145 -0.0129 -0.0098 -0.0145 -0.0145 -0.0071 -0.0121 -0.0145 -0.0145 -0.0041 -0.0114 -6.5594 -0.0014
S-1544	7,9 µmol / l .
T-1544	Ki values in human liver microsomes were 27 , 7.5 and 7.9 µmol / l , respectively .
H-1544	-0.018304327502846718	Ki values in human liver microsomes were 27 , 7.5 and 7.9 µmol / l , respectively .
D-1544	-0.018304327502846718	Ki values in human liver microsomes were 27 , 7.5 and 7.9 µmol / l , respectively .
P-1544	-0.0145 -0.0144 -0.0145 -0.0142 -0.0145 -0.0145 -0.0145 -0.0116 -0.0139 -0.0015 -0.0139 -0.0145 -0.0145 -0.0145 -0.0080 -0.0141 -0.1942 -0.0114 -0.0016 -0.0012 -0.0024 -0.0028 -0.0513 -0.0004 -0.0016 -0.0014
S-1856	- Enthält Sucrosemonopalmitat :
T-1856	- Contains sucrose palmitate :
H-1856	-0.0072938669472932816	- Contains sucrose palmitate :
D-1856	-0.0072938669472932816	- Contains sucrose palmitate :
P-1856	-0.0115 -0.0097 -0.0005 -0.0074 -0.0099 -0.0035 -0.0142 -0.0130 -0.0073 -0.0018 -0.0014
S-0	Packungsgrößen zu 1 und 3 Pens .
T-0	Pack size of 1 and 3 pens .
H-0	-0.00572732649743557	Pack size of 1 and 3 pens .
D-0	-0.00572732649743557	Pack size of 1 and 3 pens .
P-0	-0.0164 -0.0028 -0.0141 -0.0131 -0.0022 -0.0028 -0.0015 -0.0046 -0.0012 -0.0030 -0.0015
S-1730	1 g Valnemulin - Base je 100 g
T-1730	1 g valnemulin base per 100 g
H-1730	-0.004111809656023979	1 g valnemulin base per 100 g
D-1730	-0.004111809656023979	1 g valnemulin base per 100 g
P-1730	-0.0040 -0.0013 -0.0128 -0.0022 -0.0015 -0.0016 -0.0120 -0.0057 -0.0011 -0.0014 -0.0017
S-248	• den Verwendungszweck des Laborstandards .
T-248	The purpose of the laboratory standard .
H-248	-0.004765263758599758	The purpose of the laboratory standard .
D-248	-0.004765263758599758	The purpose of the laboratory standard .
P-248	-0.0145 -0.0080 -0.0041 -0.0047 -0.0039 -0.0010 -0.0027 -0.0027 -0.0015
S-1303	Arbeitsprogramm 2001 @-@ 2002 2.7 Erarbeitung von Leitlinien
T-1303	2.7 Guideline development
H-1303	-0.010136542841792107	2.7 Guideline development
D-1303	-0.010136542841792107	2.7 Guideline development
P-1303	-0.0143 -0.0029 -0.0118 -0.0140 -0.0013 -0.0121 -0.0145
S-442	Welche Nebenwirkungen hat EQUIOXX ?
T-442	What are the side @-@ effects of EQUIOXX ?
H-442	-0.04704459756612778	What are the side @-@ effects of EQUIOXX ?
D-442	-0.04704459756612778	What are the side @-@ effects of EQUIOXX ?
P-442	-0.0058 -0.0106 -0.0023 -0.0023 -0.6488 -0.0246 -0.0023 -0.0015 -0.0008 -0.0013 -0.0005 -0.0010 -0.0010 -0.0015 -0.0014
S-317	Jeder Umkarton enthält 1 Durchstechflasche .
T-317	Each cardboard outer contains 1 vial .
H-317	-0.03874592110514641	Each cardboard outer contains 1 vial .
D-317	-0.03874592110514641	Each cardboard outer contains 1 vial .
P-317	-0.0013 -0.0141 -0.0238 -0.0015 -0.0145 -0.0022 -0.0145 -0.0346 -0.0006 -0.0007 -0.0375 -0.3196
S-1927	Myocet kann Schwindel verursachen .
T-1927	Myocet has been reported to cause dizziness .
H-1927	-0.25124335289001465	Myocet has been reported to cause dizziness
D-1927	-0.25124335289001465	Myocet has been reported to cause dizziness
P-1927	-0.0022 -0.0005 -0.0040 -0.0012 -0.2570 -0.0167 -0.0143 -0.0025 -0.0074 -0.0043 -0.0004 -0.0011 -2.9546
S-1878	Wie wurde Purevax RCPCh untersucht ?
T-1878	How has Purevax RCPCh been studied ?
H-1878	-0.0030995458364486694	How has Purevax RCPCh been studied ?
D-1878	-0.0030995458364486694	How has Purevax RCPCh been studied ?
P-1878	-0.0013 -0.0127 -0.0017 -0.0015 -0.0004 -0.0041 -0.0013 -0.0008 -0.0013 -0.0012 -0.0112 -0.0014 -0.0014
S-378	Joseph , Missouri , 64506 U.S.A .
T-378	Joseph , Missouri , 64506 U. S. A .
H-378	-0.004629656206816435	Joseph , Missouri , 64506 U. S. A .
D-378	-0.004629656206816435	Joseph , Missouri , 64506 U. S. A .
P-378	-0.0031 -0.0061 -0.0005 -0.0017 -0.0018 -0.0009 -0.0014 -0.0142 -0.0125 -0.0015 -0.0132 -0.0016 -0.0016
S-238	Wie viel Synagis wird meinem Kind verabreicht ?
T-238	How often will Synagis be given to my child ?
H-238	-0.0056272242218256	How often will Synagis be given to my child ?
D-238	-0.0056272242218256	How often will Synagis be given to my child ?
P-238	-0.0017 -0.0268 -0.0137 -0.0096 -0.0012 -0.0014 -0.0019 -0.0082 -0.0019 -0.0019 -0.0020 -0.0015 -0.0014
S-117	Tryptose und NZ @-@ Amine :
T-117	Tryptose and NZ @-@ Amines :
H-117	-0.011633027344942093	Tryptose and NZ @-@ Amines :
D-117	-0.011633027344942093	Tryptose and NZ @-@ Amines :
P-117	-0.0037 -0.0006 -0.0129 -0.0009 -0.1050 -0.0016 -0.0011 -0.0056 -0.0131 -0.0020 -0.0014 -0.0019 -0.0014
S-314	33 • wenn Sie Sichelzellanämie habe
T-314	• if you have sickle cell anaemia ;
H-314	-0.02099251188337803	• if you have sickle cell anaemia ;
D-314	-0.02099251188337803	• if you have sickle cell anaemia ;
P-314	-0.0166 -0.0062 -0.0014 -0.0019 -0.0007 -0.0011 -0.0009 -0.0016 -0.0134 -0.0003 -0.0012 -0.2262 -0.0015
S-227	Sehr häufig ( mehr als 10 % der Patienten ) :
T-227	Very common ( more than 10 % of the patients ) :
H-227	-0.008551864884793758	Very common ( more than 10 % of the patients ) :
D-227	-0.008551864884793758	Very common ( more than 10 % of the patients ) :
P-227	-0.0503 -0.0103 -0.0018 -0.0035 -0.0015 -0.0014 -0.0015 -0.0024 -0.0311 -0.0026 -0.0016 -0.0018 -0.0014
S-1869	EU / 1 / 97 / 046 / 031
T-1869	EU / 1 / 97 / 046 / 031
H-1869	-0.001712800352834165	EU / 1 / 97 / 046 / 031
D-1869	-0.001712800352834165	EU / 1 / 97 / 046 / 031
P-1869	-0.0018 -0.0018 -0.0017 -0.0014 -0.0007 -0.0014 -0.0012 -0.0051 -0.0015 -0.0015 -0.0011 -0.0015
S-1566	20 , 50 ml ( 10 , 25 Dosen )
T-1566	20 , 50ml ( 10 , 25 doses )
H-1566	-0.05737258493900299	20 , 50ml ( 10 , 25 doses )
D-1566	-0.05737258493900299	20 , 50ml ( 10 , 25 doses )
P-1566	-0.0031 -0.0054 -0.6538 -0.0009 -0.0015 -0.0014 -0.0022 -0.0020 -0.0142 -0.0011 -0.0014 -0.0015
S-1867	Es ist als längliche Tabletten ( weiß :
T-1867	It is available as oblong tablets ( white :
H-1867	-0.0041549657471477985	It is available as oblong tablets ( white :
D-1867	-0.0041549657471477985	It is available as oblong tablets ( white :
P-1867	-0.0062 -0.0090 -0.0073 -0.0073 -0.0108 -0.0004 -0.0016 -0.0010 -0.0014 -0.0015 -0.0019 -0.0014
S-1655	Jede Kapsel enthält 75 mg Bexaroten .
T-1655	Each capsule contains 75 mg of bexarotene .
H-1655	-0.0032134205102920532	Each capsule contains 75 mg of bexarotene .
D-1655	-0.0032134205102920532	Each capsule contains 75 mg of bexarotene .
P-1655	-0.0021 -0.0016 -0.0006 -0.0010 -0.0023 -0.0035 -0.0010 -0.0087 -0.0144 -0.0019 -0.0014 -0.0043 -0.0001 -0.0039 -0.0014
S-1972	Atosiban darf nicht angewendet werden bei :
T-1972	TRACTOCILE should not be used in the following conditions :
H-1972	-0.014961294829845428	TRACTOCILE should not be used in the following conditions :
D-1972	-0.014961294829845428	TRACTOCILE should not be used in the following conditions :
P-1972	-0.0145 -0.0197 -0.0138 -0.0145 -0.0144 -0.0125 -0.0143 -0.0018 -0.0016 -0.0784 -0.0133 -0.0126 -0.0106 -0.0144 -0.0016 -0.0014
S-1722	Die Patrone ist fest verbunden mit einem Fertigpen .
T-1722	The cartridge is sealed in a disposable pre @-@ filled pen .
H-1722	-0.014983341097831726	The cartridge is sealed in a disposable pre @-@ filled pen .
D-1722	-0.014983341097831726	The cartridge is sealed in a disposable pre @-@ filled pen .
P-1722	-0.0031 -0.0037 -0.0003 -0.0007 -0.0018 -0.0146 -0.0142 -0.0115 -0.0145 -0.0028 -0.0408 -0.0018 -0.0140 -0.0350 -0.0794 -0.0014
S-1066	9.8.2001 12.6.2002 120 days 187 days
T-1066	• 9.8.2001 • 12.6.2002 • 120 days • 187 days
H-1066	-0.014046726748347282	• 9.8.2001 • 12.6.2002 • 120 days • 187 days
D-1066	-0.014046726748347282	• 9.8.2001 • 12.6.2002 • 120 days • 187 days
P-1066	-0.0544 -0.0252 -0.0010 -0.0008 -0.0170 -0.0023 -0.0011 -0.0035 -0.0619 -0.0359 -0.0011 -0.0145 -0.0020 -0.0015 -0.0012 -0.0014
S-1498	Jede Kapsel enthält 289 mg Lactose .
T-1498	Each capsule contains 289 mg of anhydrous lactose .
H-1498	-0.07842210680246353	Each capsule contains 289 mg of anhydrous lactose .
D-1498	-0.07842210680246353	Each capsule contains 289 mg of anhydrous lactose .
P-1498	-0.0018 -0.0013 -0.0007 -0.0010 -0.0023 -0.0014 -0.0026 -0.0009 -1.0513 -0.0251 -0.0119 -0.0024 -0.0032 -0.0008 -0.0008 -0.2242 -0.0014
S-1514	Dieses überarbeitete Gutachten wurde im Oktober 2007 erneut behandelt .
T-1514	The final opinion was converted into a Decision by the European Commission on 18 January 2008 .
H-1514	-0.04116726294159889	The final opinion was converted into a Decision by the European Commission on 18 January 2008 .
D-1514	-0.04116726294159889	The final opinion was converted into a Decision by the European Commission on 18 January 2008 .
P-1514	-0.0225 -0.0145 -0.0118 -0.0031 -0.0145 -0.0108 -0.0099 -0.0145 -0.0045 -0.0021 -0.0142 -0.0078 -0.0134 -0.0103 -0.0167 -0.0143 -0.1985 -0.2439 -0.1947 -0.0014
S-546	Ausspülen mit reichlich Wasser begegnet werden .
T-546	13 Accidental contact with the skin , eyes or mucous membranes must be treated immediately with copious amounts of water .
H-546	-0.1102105900645256	13 Accidental contact with the skin , eyes or mucous membranes must be treated immediately .
D-546	-0.1102105900645256	13 Accidental contact with the skin , eyes or mucous membranes must be treated immediately .
P-546	-0.0145 -0.0145 -0.0132 -0.0120 -0.0145 -0.0095 -0.0137 -0.0142 -0.0142 -0.0145 -0.0125 -0.0145 -0.0138 -0.0027 -0.0054 -0.0004 -0.0071 -0.0148 -0.0020 -0.0133 -0.0145 -2.2979 -0.0014
S-392	Infanrix Hexa enthält geringe Mengen von :
T-392	The polysaccharides are chemically attached ( conjugated ) to tetanus toxoid as a carrier protein because this improves the response to the vaccine .
H-392	-0.32125163078308105	The polysaccharides are chemically attached ( conjugated ) to tetanus toxoid .
D-392	-0.32125163078308105	The polysaccharides are chemically attached ( conjugated ) to tetanus toxoid .
P-392	-0.0168 -0.0145 -0.0137 -0.0024 -0.0001 -0.0002 -0.0112 -0.0142 -0.0145 -0.0022 -0.0145 -0.0400 -0.0145 -0.0145 -0.0076 -0.0063 -0.0030 -0.0324 -0.0145 -0.0144 -0.0009 -0.0147 -0.0145 -7.7483 -0.0015
S-554	Diese Substanzen sind mit Vitamin A verwandt .
T-554	The active substance in Panretin , alitretinoin , is an anticancer agent that belongs to the group of retinoids , substances that are derived from vitamin A .
H-554	-0.2524559497833252	The active substance in Panretin , alitretinoin , is an anticancer agent that belongs to the group .
D-554	-0.2524559497833252	The active substance in Panretin , alitretinoin , is an anticancer agent that belongs to the group .
P-554	-0.0473 -0.0144 -0.0140 -0.0144 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0127 -0.0088 -0.0041 -0.0086 -0.0031 -0.0145 -0.0121 -0.0144 -0.0066 -0.0164 -0.0568 -0.0145 -0.0008 -0.0025 -0.0132 -0.0141 -6.9250 -0.0014
S-1047	ESAs sind für die Anwendung in die ser Patientenpopulation
T-1047	• er shortened time to tumour progression in patients with advanced head and neck cancer receiving ng radiation therapy when administered to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) , ESAs are not indicated for use in this patient population. lo
H-1047	-0.013812626712024212	• er shortened time to tumour progression in patients with advanced head and neck cancer receiving ng radiation therapy when administered to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) , ESAs are not indicated for use in this patient population. lo
D-1047	-0.013812626712024212	• er shortened time to tumour progression in patients with advanced head and neck cancer receiving ng radiation therapy when administered to target a haemoglobin of greater than 14 g / dl ( 8.7 mmol / l ) , ESAs are not indicated for use in this patient population. lo
P-1047	-0.0256 -0.0430 -0.0145 -0.0099 -0.0046 -0.0145 -0.0134 -0.0145 -0.0105 -0.0145 -0.0012 -0.0141 -0.0120 -0.0145 -0.0143 -0.0145 -0.0121 -0.0085 -0.0135 -0.0272 -0.0145 -0.0145 -0.0145 -0.0135 -0.0154 -0.0145 -0.0515 -0.0135 -0.0145 -0.0142 -0.0145 -0.0134 -0.0023 -0.0010 -0.0145 -0.0145 -0.0144 -0.0145 -0.0145 -0.0142 -0.0145 -0.0237 -0.0145 -0.0241 -0.0141 -0.0108 -0.0003 -0.0107 -0.0098 -0.0314 -0.0140 -0.0145 -0.0020 -0.0073 -0.0143 -0.0146 -0.0074 -0.0107 -0.0040 -0.0146 -0.0064 -0.0144 -0.0119 -0.0131 -0.0076 -0.0146 -0.0046
S-1941	Midazolam zur Injektion ) .
T-1941	Examples include the cholesterol @-@ reducing agent atorvastatin , the antibiotics rifabutin and clarithromycin , the asthma treatment theophylline , the antidepressants desipramine , trazodone and bupropion ( also used for smoking cessation ) , the anticonvulsants carbamazepine , phenobarbital and phenytoin , the proton pump inhibitors omeprazole and esomeprazole and sedative agents ( e. g. midazolam administered by injection ) .
H-1941	-0.10021233558654785	Examples include the cholesterol @-@ reducing agent atorvastatin , the antibiotics rifabutin and clarithromycin , the asthma treatment theophylline , trazodone and bupropion ( also used for smoking cessation ) .
D-1941	-0.10021233558654785	Examples include the cholesterol @-@ reducing agent atorvastatin , the antibiotics rifabutin and clarithromycin , the asthma treatment theophylline , trazodone and bupropion ( also used for smoking cessation ) .
P-1941	-0.0145 -0.0136 -0.0103 -0.0143 -0.0145 -0.0021 -0.0008 -0.0127 -0.0144 -0.0144 -0.0147 -0.0033 -0.0002 -0.0002 -0.0148 -0.0144 -0.0189 -0.0249 -0.0281 -0.0153 -0.0145 -0.0145 -0.0053 -0.0250 -0.0218 -0.0145 -0.0016 -0.0001 -0.0002 -0.0364 -0.0145 -0.0927 -0.0088 -0.0003 -0.0141 -0.0191 -0.0140 -0.0126 -0.0144 -0.0143 -0.0593 -3.0084 -0.0145 -0.0142 -0.3960 -0.1430 -0.0143 -0.0141 -0.0129 -0.2114 -0.0284 -0.0144 -0.0129 -0.0145 -0.0146 -0.0060 -0.0023 -0.0044 -1.4407 -0.0014
S-1710	EU / 2 / 08 / 081 / 001
T-1710	EU / 2 / 08 / 081 / 001
H-1710	-0.001497946330346167	EU / 2 / 08 / 081 / 001
D-1710	-0.001497946330346167	EU / 2 / 08 / 081 / 001
P-1710	-0.0016 -0.0018 -0.0018 -0.0015 -0.0013 -0.0014 -0.0016 -0.0008 -0.0015 -0.0019 -0.0014 -0.0014
S-1475	EU / 1 / 00 / 156 / 002
T-1475	EU / 1 / 00 / 156 / 002
H-1475	-0.001631569699384272	EU / 1 / 00 / 156 / 002
D-1475	-0.001631569699384272	EU / 1 / 00 / 156 / 002
P-1475	-0.0016 -0.0018 -0.0016 -0.0014 -0.0014 -0.0014 -0.0027 -0.0014 -0.0014 -0.0016 -0.0017 -0.0015
S-885	EU / 1 / 98 / 058 / 002
T-885	EU / 1 / 98 / 058 / 002
H-885	-0.0014180775033310056	EU / 1 / 98 / 058 / 002
D-885	-0.0014180775033310056	EU / 1 / 98 / 058 / 002
P-885	-0.0018 -0.0018 -0.0016 -0.0014 -0.0009 -0.0014 -0.0015 -0.0007 -0.0015 -0.0016 -0.0015 -0.0015
S-812	EU / 2 / 05 / 054 / 022
T-812	EU / 2 / 05 / 054 / 022
H-812	-0.021128518506884575	EU / 2 / 05 / 054 / 022
D-812	-0.021128518506884575	EU / 2 / 05 / 054 / 022
P-812	-0.0015 -0.0017 -0.0018 -0.0014 -0.0012 -0.0014 -0.0018 -0.2373 -0.0015 -0.0012 -0.0012 -0.0014
S-1179	EU / 2 / 00 / 022 / 011
T-1179	EU / 2 / 00 / 022 / 011
H-1179	-0.0015311040915548801	EU / 2 / 00 / 022 / 011
D-1179	-0.0015311040915548801	EU / 2 / 00 / 022 / 011
P-1179	-0.0015 -0.0017 -0.0020 -0.0014 -0.0014 -0.0014 -0.0017 -0.0013 -0.0015 -0.0017 -0.0013 -0.0015
S-481	EU / 1 / 08 / 469 / 012
T-481	EU / 1 / 08 / 469 / 012
H-481	-0.0015409172046929598	EU / 1 / 08 / 469 / 012
D-481	-0.0015409172046929598	EU / 1 / 08 / 469 / 012
P-481	-0.0017 -0.0017 -0.0016 -0.0015 -0.0013 -0.0014 -0.0019 -0.0013 -0.0015 -0.0016 -0.0014 -0.0014
S-1857	EU / 1 / 09 / 506 / 008
T-1857	EU / 1 / 09 / 506 / 008
H-1857	-0.0033838856033980846	EU / 1 / 09 / 506 / 008
D-1857	-0.0033838856033980846	EU / 1 / 09 / 506 / 008
P-1857	-0.0017 -0.0018 -0.0018 -0.0014 -0.0240 -0.0014 -0.0012 -0.0013 -0.0015 -0.0015 -0.0015 -0.0015
S-1290	EU / 1 / 02 / 231 / 034
T-1290	EU / 1 / 02 / 231 / 034
H-1290	-0.0016052313148975372	EU / 1 / 02 / 231 / 034
D-1290	-0.0016052313148975372	EU / 1 / 02 / 231 / 034
P-1290	-0.0016 -0.0018 -0.0017 -0.0014 -0.0009 -0.0014 -0.0015 -0.0009 -0.0014 -0.0014 -0.0038 -0.0014
S-1196	- Savene sollte bei Kindern nicht angewendet werden .
T-1196	- Savene should not be administered to children .
H-1196	-0.05059746280312538	- Savene should not be administered to children .
D-1196	-0.05059746280312538	- Savene should not be administered to children .
P-1196	-0.0026 -0.0036 -0.0012 -0.0026 -0.0017 -0.0014 -0.4809 -0.0008 -0.1073 -0.0015 -0.0022 -0.0014
S-1816	31 Sehr häufig juckt die behandelte Haut leicht .
T-1816	Very commonly the treated skin may be slightly itchy .
H-1816	-0.019977832213044167	Very commonly the treated skin may be slightly itchy .
D-1816	-0.019977832213044167	Very commonly the treated skin may be slightly itchy .
P-1816	-0.0144 -0.0221 -0.0087 -0.0034 -0.0010 -0.0144 -0.0135 -0.0133 -0.0003 -0.0008 -0.1464 -0.0014
S-10	Tel : + 420 272 937 381
T-10	Tel : + 420 272 937 381
H-10	-0.0016317297704517841	Tel : + 420 272 937 381
D-10	-0.0016317297704517841	Tel : + 420 272 937 381
P-10	-0.0032 -0.0036 -0.0013 -0.0015 -0.0012 -0.0009 -0.0014 -0.0015 -0.0011 -0.0009 -0.0014 -0.0015
S-1508	0049 ( 0 ) 81 41 3572 329
T-1508	0049 ( 0 ) 81 41 3572 329
H-1508	-1.2253960371017456	81 41 3572 329 ( 0 )
D-1508	-1.2253960371017456	81 41 3572 329 ( 0 )
P-1508	-9.6457 -0.0010 -0.0010 -0.0013 -0.1982 -0.0026 -2.3891 -0.0022 -0.0014 -0.0116
S-1680	EU / 1 / 97 / 031 / 038
T-1680	EU / 1 / 97 / 031 / 038
H-1680	-0.0013755096588283777	EU / 1 / 97 / 031 / 038
D-1680	-0.0013755096588283777	EU / 1 / 97 / 031 / 038
P-1680	-0.0018 -0.0018 -0.0017 -0.0014 -0.0007 -0.0014 -0.0015 -0.0010 -0.0014 -0.0012 -0.0010 -0.0015
S-483	Points to consider on multiplicity issues in clinical trials
T-483	Points to consider on multiplicity issues in clinical trials
H-483	-0.002616364974528551	Points to consider on multiplicity issues in clinical trials
D-483	-0.002616364974528551	Points to consider on multiplicity issues in clinical trials
P-483	-0.0014 -0.0018 -0.0031 -0.0015 -0.0027 -0.0037 -0.0005 -0.0010 -0.0051 -0.0006 -0.0086 -0.0015
S-1904	EU / 2 / 98 / 008 / 001
T-1904	EU / 2 / 98 / 008 / 001
H-1904	-0.001524703111499548	EU / 2 / 98 / 008 / 001
D-1904	-0.001524703111499548	EU / 2 / 98 / 008 / 001
P-1904	-0.0019 -0.0018 -0.0018 -0.0014 -0.0008 -0.0015 -0.0017 -0.0013 -0.0015 -0.0016 -0.0014 -0.0015
S-1358	EU / 1 / 08 / 457 / 013
T-1358	EU / 1 / 08 / 457 / 013
H-1358	-0.005723931826651096	EU / 1 / 08 / 457 / 013
D-1358	-0.005723931826651096	EU / 1 / 08 / 457 / 013
P-1358	-0.0017 -0.0018 -0.0016 -0.0014 -0.0012 -0.0014 -0.0012 -0.0527 -0.0014 -0.0016 -0.0013 -0.0014
S-1368	EU / 1 / 97 / 030 / 056
T-1368	EU / 1 / 97 / 030 / 056
H-1368	-0.0013902634382247925	EU / 1 / 97 / 030 / 056
D-1368	-0.0013902634382247925	EU / 1 / 97 / 030 / 056
P-1368	-0.0018 -0.0019 -0.0017 -0.0014 -0.0007 -0.0014 -0.0014 -0.0014 -0.0014 -0.0013 -0.0008 -0.0015
S-1427	EU / 1 / 06 / 341 / 006
T-1427	EU / 1 / 06 / 341 / 006
H-1427	-0.0016109892167150974	EU / 1 / 06 / 341 / 006
D-1427	-0.0016109892167150974	EU / 1 / 06 / 341 / 006
P-1427	-0.0015 -0.0018 -0.0015 -0.0014 -0.0038 -0.0014 -0.0013 -0.0006 -0.0014 -0.0015 -0.0015 -0.0015
S-1597	L61 vom 18.03.1995 3 OJ No .
T-1597	L61 of 18.03.1995 3 OJ No .
H-1597	-0.002438831841573119	L61 of 18.03.1995 3 OJ No .
D-1597	-0.002438831841573119	L61 of 18.03.1995 3 OJ No .
P-1597	-0.0038 -0.0010 -0.0079 -0.0064 -0.0005 -0.0016 -0.0014 -0.0018 -0.0006 -0.0014 -0.0014 -0.0014
S-356	EU / 1 / 00 / 157 / 061
T-356	EU / 1 / 00 / 157 / 061
H-356	-0.0015108681982383132	EU / 1 / 00 / 157 / 061
D-356	-0.0015108681982383132	EU / 1 / 00 / 157 / 061
P-356	-0.0015 -0.0017 -0.0015 -0.0014 -0.0014 -0.0014 -0.0024 -0.0012 -0.0014 -0.0016 -0.0011 -0.0014
S-1661	EU / 1 / 06 / 352 / 002
T-1661	EU / 1 / 06 / 352 / 002
H-1661	-0.0016647086013108492	EU / 1 / 06 / 352 / 002
D-1661	-0.0016647086013108492	EU / 1 / 06 / 352 / 002
P-1661	-0.0016 -0.0018 -0.0017 -0.0014 -0.0040 -0.0014 -0.0012 -0.0008 -0.0015 -0.0016 -0.0015 -0.0015
S-1168	- Halsschmerzen , laufende Nase , Fieber .
T-1168	- sore throat , runny nose , fever
H-1168	-0.06260963529348373	- sore throat , runny nose , fever
D-1168	-0.06260963529348373	- sore throat , runny nose , fever
P-1168	-0.0028 -0.0131 -0.0006 -0.0010 -0.0014 -0.0008 -0.0002 -0.0005 -0.0019 -0.0110 -0.0008 -0.7172
S-476	EU / 1 / 02 / 205 / 002
T-476	EU / 1 / 02 / 205 / 002
H-476	-0.0026089276652783155	EU / 1 / 02 / 205 / 002
D-476	-0.0026089276652783155	EU / 1 / 02 / 205 / 002
P-476	-0.0017 -0.0018 -0.0018 -0.0014 -0.0009 -0.0014 -0.0151 -0.0013 -0.0015 -0.0015 -0.0015 -0.0015
S-1965	EU / 1 / 08 / 505 / 006
T-1965	EU / 1 / 08 / 505 / 006
H-1965	-0.0014943864662200212	EU / 1 / 08 / 505 / 006
D-1965	-0.0014943864662200212	EU / 1 / 08 / 505 / 006
P-1965	-0.0017 -0.0018 -0.0017 -0.0015 -0.0013 -0.0014 -0.0013 -0.0013 -0.0015 -0.0014 -0.0016 -0.0015
S-1727	EU / 1 / 96 / 027 / 005
T-1727	EU / 1 / 96 / 027 / 005
H-1727	-0.0014482042752206326	EU / 1 / 96 / 027 / 005
D-1727	-0.0014482042752206326	EU / 1 / 96 / 027 / 005
P-1727	-0.0019 -0.0019 -0.0016 -0.0015 -0.0008 -0.0014 -0.0014 -0.0010 -0.0015 -0.0015 -0.0014 -0.0015
S-1523	EU / 1 / 08 / 452 / 001
T-1523	EU / 1 / 08 / 452 / 001
H-1523	-0.0014399598585441709	EU / 1 / 08 / 452 / 001
D-1523	-0.0014399598585441709	EU / 1 / 08 / 452 / 001
P-1523	-0.0017 -0.0018 -0.0016 -0.0015 -0.0013 -0.0014 -0.0012 -0.0007 -0.0015 -0.0017 -0.0014 -0.0015
S-384	Was ist Aloxi und wofür wird es angewendet ?
T-384	What Aloxi is and what it is used for .
H-384	-0.06011141836643219	What Aloxi is and what it is used for 2 .
D-384	-0.06011141836643219	What Aloxi is and what it is used for 2 .
P-384	-0.0018 -0.3667 -0.0004 -0.0017 -0.0029 -0.0041 -0.0136 -0.0054 -0.0042 -0.0014 -0.3631 -0.0141 -0.0020
S-656	EU / 2 / 03 / 039 / 004
T-656	EU / 2 / 03 / 039 / 004
H-656	-0.0014483837876468897	EU / 2 / 03 / 039 / 004
D-656	-0.0014483837876468897	EU / 2 / 03 / 039 / 004
P-656	-0.0016 -0.0017 -0.0019 -0.0014 -0.0011 -0.0014 -0.0015 -0.0009 -0.0015 -0.0015 -0.0013 -0.0015
S-1386	- wenn Sie Lebererkrankungen in der eigenen Vorgeschichte haben ,
T-1386	87 PACKAGE LEAFLET :
H-1386	-0.1155877336859703	87 PACKAGE LEAFLET :
D-1386	-0.1155877336859703	87 PACKAGE LEAFLET :
P-1386	-1.1165 -0.0146 -0.0145 -0.0095 -0.0030 -0.0085 -0.0828 -0.0145 -0.0145 -0.0142 -0.0803 -0.0143
S-613	Stanhope Gate 15 London W1K 1LN United Kingdom
T-613	Stanhope Gate 15 London W1K 1LN United Kingdom
H-613	-0.0031164877582341433	Stanhope Gate 15 London W1K 1LN United Kingdom
D-613	-0.0031164877582341433	Stanhope Gate 15 London W1K 1LN United Kingdom
P-613	-0.0003 -0.0008 -0.0016 -0.0015 -0.0010 -0.0013 -0.0012 -0.0013 -0.0011 -0.0015 -0.0015 -0.0009 -0.0309 -0.0006 -0.0014
S-595	Anti @-@ HBs ( 10 mI.E. / ml ) †
T-595	Anti @-@ HBs ( 10 mIU / ml ) †
H-595	-0.0026667106430977583	Anti @-@ HBs ( 10 mIU / ml ) †
D-595	-0.0026667106430977583	Anti @-@ HBs ( 10 mIU / ml ) †
P-595	-0.0045 -0.0017 -0.0008 -0.0016 -0.0016 -0.0022 -0.0028 -0.0016 -0.0145 -0.0014 -0.0010 -0.0014 -0.0008 -0.0014
S-327	Wenn Sie vergessen , FORCALTONIN anzuwenden :
T-327	If you forget to take FORCALTONIN :
H-327	-0.002935466356575489	If you forget to take FORCALTONIN :
D-327	-0.002935466356575489	If you forget to take FORCALTONIN :
P-327	-0.0073 -0.0017 -0.0020 -0.0015 -0.0144 -0.0031 -0.0006 -0.0014 -0.0008 -0.0018 -0.0008 -0.0020 -0.0023 -0.0014
S-843	Bei diesen Patienten darf keine vorhergehende HIV @-@ Therapie versagt haben .
T-843	Patients must not have experienced failure of a previous HIV therapy .
H-843	-0.008344326168298721	Patients must not have experienced failure of a previous HIV therapy .
D-843	-0.008344326168298721	Patients must not have experienced failure of a previous HIV therapy .
P-843	-0.0145 -0.0010 -0.0123 -0.0050 -0.0046 -0.0143 -0.0135 -0.0129 -0.0139 -0.0102 -0.0038 -0.0076 -0.0018 -0.0014
S-1072	Falls dies eintritt , sollte der Patient einen Arzt konsultieren .
T-1072	If this occurs , the patient should consult a doctor .
H-1072	-0.014256537891924381	If this occurs , the patient should consult a doctor .
D-1072	-0.014256537891924381	If this occurs , the patient should consult a doctor .
P-1072	-0.0045 -0.0649 -0.0102 -0.0007 -0.0029 -0.0096 -0.0012 -0.0020 -0.0174 -0.0007 -0.0696 -0.0128 -0.0017 -0.0014
S-1864	IVAX Pharmaceuticals s.r.o .
T-1864	IVAX Pharmaceuticals s. r. o .
H-1864	-0.004926186054944992	IVAX Pharmaceuticals s. r. o .
D-1864	-0.004926186054944992	IVAX Pharmaceuticals s. r. o .
P-1864	-0.0006 -0.0012 -0.0008 -0.0013 -0.0004 -0.0011 -0.0006 -0.0009 -0.0012 -0.0365 -0.0206 -0.0010 -0.0014 -0.0014
S-1937	Die Immunität setzt nach zwei Wochen ein und hält sechs Monate an .
T-1937	Immunity starts after 14 days and lasts for 6 months .
H-1937	-0.009171448647975922	Immunity starts after 14 days and lasts for 6 months .
D-1937	-0.009171448647975922	Immunity starts after 14 days and lasts for 6 months .
P-1937	-0.0026 -0.0013 -0.0120 -0.0050 -0.0558 -0.0170 -0.0052 -0.0023 -0.0006 -0.0079 -0.0137 -0.0018 -0.0017 -0.0014
S-493	Norvir kann Schläfrigkeit und Schwindel hervorrufen .
T-493	Norvir can cause sleepiness and dizziness .
H-493	-0.06967867910861969	Norvir can cause sleepiness and dizziness .
D-493	-0.06967867910861969	Norvir can cause sleepiness and dizziness .
P-493	-0.0008 -0.0009 -0.0014 -0.6067 -0.0089 -0.0357 -0.0003 -0.0020 -0.0017 -0.0023 -0.0007 -0.0010 -0.3118 -0.0014
S-981	ISENTRESS stoppt die Wirkung des Enzyms .
T-981	ISENTRESS stops this enzyme working .
H-981	-0.0034982317592948675	ISENTRESS stops this enzyme working .
D-981	-0.0034982317592948675	ISENTRESS stops this enzyme working .
P-981	-0.0017 -0.0012 -0.0012 -0.0012 -0.0006 -0.0050 -0.0146 -0.0018 -0.0009 -0.0012 -0.0122 -0.0025 -0.0014
S-1465	Hand @-@ Fuß @-@ Syndrom ( siehe Abschnitt 4.4 ) :
T-1465	Hand @-@ foot syndrome ( see section 4.4 ) :
H-1465	-0.0027667854446917772	Hand @-@ foot syndrome ( see section 4.4 ) :
D-1465	-0.0027667854446917772	Hand @-@ foot syndrome ( see section 4.4 ) :
P-1465	-0.0009 -0.0061 -0.0077 -0.0024 -0.0008 -0.0015 -0.0021 -0.0061 -0.0014 -0.0014 -0.0016 -0.0025 -0.0014
S-57	Suizid / Suizidgedanken oder klinische Verschlechterung
T-57	Suicide / suicidal thoughts or clinical worsening
H-57	-0.5600203275680542	Suicide / suicidal thoughts or clinical deterioration
D-57	-0.5600203275680542	Suicide / suicidal thoughts or clinical deterioration
P-57	-0.0084 -0.0003 -0.0023 -0.0021 -0.0030 -0.0005 -0.0019 -0.0019 -0.0017 -6.6947 -0.0014 -0.0019
S-1926	22 Mikrogramm ( 6 Millionen I.E. ) / 0,5ml
T-1926	22 micrograms ( 6 million IU ) / 0.5 ml
H-1926	-0.004556931089609861	22 micrograms ( 6 million IU ) / 0.5 ml
D-1926	-0.004556931089609861	22 micrograms ( 6 million IU ) / 0.5 ml
P-1926	-0.0083 -0.0035 -0.0045 -0.0014 -0.0024 -0.0063 -0.0029 -0.0110 -0.0018 -0.0020 -0.0114 -0.0020 -0.0018
S-547	Rebif 44 Mikrogramm Injektionslösung in einer Fertigspritze
T-547	Rebif 44 micrograms solution for injection in pre @-@ filled syringe
H-547	-0.0444025881588459	Rebif 44 micrograms solution for injection in pre @-@ filled syringe
D-547	-0.0444025881588459	Rebif 44 micrograms solution for injection in pre @-@ filled syringe
P-547	-0.0007 -0.0012 -0.0017 -0.0044 -0.0075 -0.0129 -0.0142 -0.0037 -0.0017 -0.0028 -0.6881 -0.0014 -0.0097 -0.0011 -0.0020 -0.0001 -0.0017
S-1338	28 GEBRAUCHSINFORMATION :
T-1338	28 PACKAGE LEAFLET :
H-1338	-0.011453834362328053	28 PACKAGE LEAFLET :
D-1338	-0.011453834362328053	28 PACKAGE LEAFLET :
P-1338	-0.0051 -0.0144 -0.0144 -0.0016 -0.0004 -0.0364 -0.0148 -0.0144 -0.0145 -0.0135 -0.0065 -0.0014
S-797	Kivexa wird nicht zur Anwendung in der Schwangerschaft empfohlen .
T-797	Kivexa is not recommended during pregnancy .
H-797	-0.008446168154478073	Kivexa is not recommended during pregnancy .
D-797	-0.008446168154478073	Kivexa is not recommended during pregnancy .
P-797	-0.0013 -0.0010 -0.0012 -0.0015 -0.0020 -0.0015 -0.0016 -0.0782 -0.0013 -0.0017 -0.0015
S-1045	• Injizieren Sie das Insulin unter die Haut .
T-1045	• Inject the insulin under the skin .
H-1045	-0.008759805001318455	• Inject the insulin under the skin .
D-1045	-0.008759805001318455	• Inject the insulin under the skin .
P-1045	-0.0045 -0.0013 -0.0006 -0.0104 -0.0006 -0.0005 -0.0058 -0.0034 -0.0010 -0.0666 -0.0015
S-719	5 / 19 Nach dem Öffnen nicht über 25 ° C lagern .
T-719	Once opened do not store above 25 ° C .
H-719	-0.006078638602048159	Once opened do not store above 25 ° C .
D-719	-0.006078638602048159	Once opened do not store above 25 ° C .
P-719	-0.0163 -0.0027 -0.0127 -0.0013 -0.0067 -0.0080 -0.0021 -0.0015 -0.0023 -0.0105 -0.0027
S-521	Besondere Vorsicht bei der Anwendung von BYETTA ist erforderlich ,
T-521	Take special care with BYETTA :
H-521	-0.029200877994298935	Take special care with BYETTA :
D-521	-0.029200877994298935	Take special care with BYETTA :
P-521	-0.1106 -0.0093 -0.0015 -0.0518 -0.0201 -0.0013 -0.0008 -0.0004 -0.0918 -0.0043
S-589	Achten Sie darauf , dass Sie den Behandlungsverlauf vollständig durchführen .
T-589	Be sure to complete your course of treatment .
H-589	-0.01705581322312355	Be sure to complete your course of treatment .
D-589	-0.01705581322312355	Be sure to complete your course of treatment .
P-589	-0.1097 -0.0034 -0.0111 -0.0095 -0.0142 -0.0134 -0.0019 -0.0021 -0.0039 -0.0015
S-644	Besondere Vorsicht bei der Anwendung von Myocet ist erforderlich :
T-644	Take special care with Myocet .
H-644	-0.047740690410137177	Take special care with Myocet .
D-644	-0.047740690410137177	Take special care with Myocet .
P-644	-0.2951 -0.0091 -0.0015 -0.0482 -0.0209 -0.0006 -0.0013 -0.0010 -0.0898 -0.0100
S-1369	Besondere Vorsicht bei der Einnahme von Galvus ist erforderlich :
T-1369	25 Take special care with Galvus :
H-1369	-0.10565396398305893	Take special care with Galvus :
D-1369	-0.10565396398305893	Take special care with Galvus :
P-1369	-0.8929 -0.0095 -0.0022 -0.0138 -0.0133 -0.0008 -0.0016 -0.0116 -0.0051
S-811	* spiegelt Patienten wider , für die 12 Wochen @-@ Daten verfügbar waren
T-811	* reflects patients with 12 week data available
H-811	-0.00709226680919528	* reflects patients with 12 week data available
D-811	-0.00709226680919528	* reflects patients with 12 week data available
P-811	-0.0030 -0.0101 -0.0025 -0.0140 -0.0035 -0.0162 -0.0030 -0.0045 -0.0071
S-315	2 @-@ 4 @-@ 6- Monate ; 3 @-@ 4 @-@ 5-
T-315	Antibody ( cut @-@ off )
H-315	-0.013189510442316532	Antibody ( cut @-@ off )
D-315	-0.013189510442316532	Antibody ( cut @-@ off )
P-315	-0.0162 -0.0139 -0.0144 -0.0145 -0.0123 -0.0076 -0.0120 -0.0145
S-1282	Alle Schweregrade n = 318 ( 1 @-@ 5 % )
T-1282	( 1 @-@ 5 % )
H-1282	-0.006897562183439732	( 1 @-@ 5 % )
D-1282	-0.006897562183439732	( 1 @-@ 5 % )
P-1282	-0.0145 -0.0105 -0.0030 -0.0016 -0.0016 -0.0026 -0.0145
S-1804	EU / 2 / 06 / 062 / 001 Cerenia
T-1804	Cerenia
H-1804	-0.1634058803319931	EU / 2 / 06 / 062 / 001 MI
D-1804	-0.1634058803319931	EU / 2 / 06 / 062 / 001 MI
P-1804	-0.8472 -0.0016 -0.0018 -0.0014 -0.0046 -0.0014 -0.0017 -0.0625 -0.0014 -0.0017 -0.0014 -1.2827 -0.0682 -0.0099
S-748	48 % ( 38 @-@ 59 ) 38 % ( 27 @-@ 50 )
T-748	48 % ( 38 @-@ 59 ) 38 % ( 27 @-@ 50 )
H-748	-0.005906112492084503	48 % ( 38 @-@ 59 ) 38 % ( 27 @-@ 50 )
D-748	-0.005906112492084503	48 % ( 38 @-@ 59 ) 38 % ( 27 @-@ 50 )
P-748	-0.0023 -0.0017 -0.0014 -0.0013 -0.0694 -0.0009 -0.0015 -0.0008 -0.0014 -0.0013 -0.0011 -0.0014 -0.0012 -0.0014 -0.0014
S-1960	Packungen zu 30 , 90 , 100 oder 300 Ampullen .
T-1960	Packages containing 30 , 90 , 100 or 300 ampoules .
H-1960	-0.04015575349330902	Packages containing 30 , 90 , 100 or 300 ampoules .
D-1960	-0.04015575349330902	Packages containing 30 , 90 , 100 or 300 ampoules .
P-1960	-0.0096 -0.0136 -0.0150 -0.0017 -0.0016 -0.0013 -0.0015 -0.0011 -0.5394 -0.0011 -0.0097 -0.0002 -0.0014 -0.0038 -0.0014
S-313	Amprenavir , Lopinavir , Saquinavir :
T-313	Amprenavir , lopinavir , saquinavir :
H-313	-0.0032802370842546225	Amprenavir , lopinavir , saquinavir :
D-313	-0.0032802370842546225	Amprenavir , lopinavir , saquinavir :
P-313	-0.0082 -0.0005 -0.0013 -0.0010 -0.0014 -0.0144 -0.0136 -0.0016 -0.0009 -0.0017 -0.0007 -0.0010 -0.0022 -0.0009 -0.0017 -0.0014
S-1295	Jede Pulver @-@ Durchstechflasche enthält 250 I.E .
T-1295	Each powder vial contains 250 IU octocog alfa .
H-1295	-0.011211484670639038	Each powder vial contains 250 IU octocog alfa .
D-1295	-0.011211484670639038	Each powder vial contains 250 IU octocog alfa .
P-1295	-0.0023 -0.0103 -0.0014 -0.0009 -0.0023 -0.0010 -0.0025 -0.0141 -0.0612 -0.0144 -0.0145 -0.0145 -0.0145 -0.0145 -0.0096 -0.0014
S-1615	Studien zur Morbidität und Mortalität sind noch nicht abgeschlossen .
T-1615	Studies on morbidity and mortality have not yet been terminated .
H-1615	-0.007483507040888071	Studies on morbidity and mortality have not yet been terminated .
D-1615	-0.007483507040888071	Studies on morbidity and mortality have not yet been terminated .
P-1615	-0.0040 -0.0096 -0.0015 -0.0009 -0.0013 -0.0014 -0.0010 -0.0009 -0.0126 -0.0038 -0.0483 -0.0157 -0.0147 -0.0012 -0.0016 -0.0014
S-720	Was ist Insuman Basal und wofür wird es angewendet ?
T-720	What Insuman Basal is and what it is used for 2 .
H-720	-0.10330692678689957	What Insuman Basal is and what it is used for 2 .
D-720	-0.10330692678689957	What Insuman Basal is and what it is used for 2 .
P-720	-0.0013 -1.2683 -0.0011 -0.0016 -0.0010 -0.0014 -0.0019 -0.0032 -0.0031 -0.0137 -0.0052 -0.0036 -0.0014 -0.3297 -0.0143 -0.0022
S-1281	Levetiracetam geht in die Muttermilch über .
T-1281	Levetiracetam is excreted in human breast milk .
H-1281	-0.08118366450071335	Levetiracetam is excreted in human breast milk .
D-1281	-0.08118366450071335	Levetiracetam is excreted in human breast milk .
P-1281	-0.0023 -0.0007 -0.0010 -0.0006 -0.0009 -0.0014 -0.0101 -0.0145 -0.0033 -0.0009 -0.3031 -0.1620 -0.7935 -0.0014 -0.0017 -0.0014
S-1205	Meda AB Pipers väg 2 170 73 Solna Schweden
T-1205	Meda AB Pipers väg 2A 170 73 Solna Sweden
H-1205	-0.056292999535799026	Meda AB Pipers väg 2A 170 73 Solna Sweden
D-1205	-0.056292999535799026	Meda AB Pipers väg 2A 170 73 Solna Sweden
P-1205	-0.0009 -0.0008 -0.0004 -0.0016 -0.0011 -0.0010 -0.0003 -0.0011 -0.8718 -0.0145 -0.0013 -0.0012 -0.0012 -0.0006 -0.0014 -0.0014
S-1395	Tenofovirdisoproxilfumarat :
T-1395	Tenofovir disoproxil fumarate :
H-1395	-0.0038160330150276423	Tenofovir disoproxil fumarate :
D-1395	-0.0038160330150276423	Tenofovir disoproxil fumarate :
P-1395	-0.0171 -0.0013 -0.0012 -0.0060 -0.0073 -0.0046 -0.0012 -0.0019 -0.0055 -0.0077 -0.0010 -0.0005 -0.0014 -0.0011 -0.0020 -0.0014
S-1718	74 Ísland GlaxoSmithKline ehf .
T-1718	67 Ísland GlaxoSmithKline ehf .
H-1718	-0.003147864481434226	67 Ísland GlaxoSmithKline ehf .
D-1718	-0.003147864481434226	67 Ísland GlaxoSmithKline ehf .
P-1718	-0.0145 -0.0145 -0.0050 -0.0011 -0.0004 -0.0011 -0.0011 -0.0003 -0.0011 -0.0013 -0.0011 -0.0008 -0.0008 -0.0026 -0.0014
S-1744	DepoCyte 50 mg Injektionssuspension Cytarabin
T-1744	DepoCyte 50 mg suspension for injection Cytarabine
H-1744	-0.004268893040716648	DepoCyte 50 mg suspension for injection Cytarabine
D-1744	-0.004268893040716648	DepoCyte 50 mg suspension for injection Cytarabine
P-1744	-0.0026 -0.0011 -0.0009 -0.0014 -0.0055 -0.0005 -0.0144 -0.0130 -0.0084 -0.0056 -0.0066 -0.0005 -0.0008 -0.0012 -0.0016
S-1665	Das Idealgewicht ( IBW ) wird wie folgt berechnet :
T-1665	Ideal body weight ( IBW ) is calculated as follows :
H-1665	-0.0032682756427675486	Ideal body weight ( IBW ) is calculated as follows :
D-1665	-0.0032682756427675486	Ideal body weight ( IBW ) is calculated as follows :
P-1665	-0.0141 -0.0004 -0.0146 -0.0014 -0.0017 -0.0022 -0.0011 -0.0014 -0.0026 -0.0016 -0.0012 -0.0022 -0.0014 -0.0016 -0.0014
S-1148	MIRCERA 50 Mikrogramm / ml Injektionslösung
T-1148	MIRCERA 50 micrograms / ml solution for injection
H-1148	-0.005543963983654976	MIRCERA 50 micrograms / ml solution for injection
D-1148	-0.005543963983654976	MIRCERA 50 micrograms / ml solution for injection
P-1148	-0.0031 -0.0007 -0.0014 -0.0009 -0.0013 -0.0277 -0.0058 -0.0066 -0.0016 -0.0008 -0.0125 -0.0134 -0.0025 -0.0023 -0.0027
S-1092	Karel de Neef Stephen Fairchild Beatrice Fayl ........
T-1092	Karel de Neef Stephen Fairchild Beatrice Fayl ........
H-1092	-0.0017862871754914522	Karel de Neef Stephen Fairchild Beatrice Fayl ........
D-1092	-0.0017862871754914522	Karel de Neef Stephen Fairchild Beatrice Fayl ........
P-1092	-0.0039 -0.0010 -0.0034 -0.0010 -0.0002 -0.0007 -0.0007 -0.0014 -0.0008 -0.0036 -0.0002 -0.0010 -0.0017 -0.0058 -0.0014
S-1575	86 % 98 % ( 83 ; 88 ) ( 97 ; 99 )
T-1575	86 % 98 % ( 83 , 88 ) ( 97 , 99 )
H-1575	-0.012769418768584728	86 % 98 % ( 83 , 88 ) ( 97 , 99 )
D-1575	-0.012769418768584728	86 % 98 % ( 83 , 88 ) ( 97 , 99 )
P-1575	-0.0016 -0.0013 -0.0014 -0.0013 -0.0014 -0.0007 -0.1083 -0.0011 -0.0015 -0.0013 -0.0007 -0.0672 -0.0007 -0.0015 -0.0014
S-1132	Lagerungsbedingungen wie in Abschnitt 5 in dieser Gebrauchsinformation beschrieben .
T-1132	For storage conditions , please see section 5 of this leaflet .
H-1132	-0.007364262826740742	For storage conditions , please see section 5 of this leaflet .
D-1132	-0.007364262826740742	For storage conditions , please see section 5 of this leaflet .
P-1132	-0.0145 -0.0052 -0.0052 -0.0121 -0.0127 -0.0109 -0.0085 -0.0119 -0.0066 -0.0032 -0.0145 -0.0004 -0.0007 -0.0026 -0.0014
S-507	Was ist Diacomit und wofür wird es angewendet 2 .
T-507	What Diacomit is and what it is used for 2 .
H-507	-0.03709094598889351	What Diacomit is and what it is used for 2 .
D-507	-0.03709094598889351	What Diacomit is and what it is used for 2 .
P-507	-0.0022 -0.4963 -0.0010 -0.0142 -0.0048 -0.0021 -0.0032 -0.0035 -0.0097 -0.0038 -0.0038 -0.0016 -0.0071 -0.0015 -0.0014
S-1178	Ihr Arzt wird entscheiden , wie viele dieser Behandlungszyklen Sie benötigen .
T-1178	Your doctor will determine how many cycles of treatment you will need .
H-1178	-0.005849395878612995	Your doctor will determine how many cycles of treatment you will need .
D-1178	-0.005849395878612995	Your doctor will determine how many cycles of treatment you will need .
P-1178	-0.0054 -0.0028 -0.0017 -0.0159 -0.0022 -0.0132 -0.0143 -0.0007 -0.0027 -0.0114 -0.0019 -0.0092 -0.0032 -0.0018 -0.0014
S-641	Gardasil sollte entsprechend den offiziellen Empfehlungen angewendet werden .
T-641	Gardasil should be used in accordance with official guidelines .
H-641	-0.017601676285266876	Gardasil should be used in accordance with official guidelines .
D-641	-0.017601676285266876	Gardasil should be used in accordance with official guidelines .
P-641	-0.0008 -0.0010 -0.0008 -0.0010 -0.0014 -0.0018 -0.0052 -0.0512 -0.0052 -0.0011 -0.0014 -0.1755 -0.0147 -0.0017 -0.0014
S-1583	EU / 1 / 07 / 407 / 001 @-@ 010
T-1583	EU / 1 / 07 / 407 / 001 @-@ 010
H-1583	-0.0014561479911208153	EU / 1 / 07 / 407 / 001 @-@ 010
D-1583	-0.0014561479911208153	EU / 1 / 07 / 407 / 001 @-@ 010
P-1583	-0.0020 -0.0018 -0.0015 -0.0014 -0.0011 -0.0014 -0.0012 -0.0011 -0.0014 -0.0015 -0.0015 -0.0015 -0.0016 -0.0014 -0.0015
S-969	Dies wird durch eine von der Europäischen Kommission verabschiedete Verordnung eingeführt werden .
T-969	This will be introduced by a Regulation adopted by the European Commission .
H-969	-0.00981427077203989	This will be introduced by a Regulation adopted by the European Commission .
D-969	-0.00981427077203989	This will be introduced by a Regulation adopted by the European Commission .
P-969	-0.0072 -0.0029 -0.0018 -0.0082 -0.0269 -0.0038 -0.0081 -0.0012 -0.0030 -0.0507 -0.0014 -0.0277 -0.0013 -0.0016 -0.0014
S-1629	Die Clearance von Ciclosporin A blieb unverändert .
T-1629	Clearance of ciclosporin A was unchanged .
H-1629	-0.004016172606498003	Clearance of ciclosporin A was unchanged .
D-1629	-0.004016172606498003	Clearance of ciclosporin A was unchanged .
P-1629	-0.0108 -0.0015 -0.0014 -0.0020 -0.0097 -0.0004 -0.0005 -0.0006 -0.0120 -0.0017 -0.0123 -0.0030 -0.0013 -0.0016 -0.0014
S-136	Klare , farblose Lösung , frei von Partikeln .
T-136	Clear , colourless solution , free of particulate matter .
H-136	-0.05658899247646332	Clear , colourless solution , free of particulate matter .
D-136	-0.05658899247646332	Clear , colourless solution , free of particulate matter .
P-136	-0.0016 -0.0008 -0.0034 -0.0050 -0.0008 -0.0012 -0.0022 -0.0092 -0.0025 -0.0059 -0.0025 -0.8083 -0.0016 -0.0024 -0.0014
S-27	Über seltene Fälle von hypertropher Granulation wurde berichtet .
T-27	Rare cases of hypertrophic granulation have been reported .
H-27	-0.009872435592114925	Rare cases of hypertrophic granulation have been reported .
D-27	-0.009872435592114925	Rare cases of hypertrophic granulation have been reported .
P-27	-0.0030 -0.0029 -0.0013 -0.0015 -0.0013 -0.0010 -0.0008 -0.0003 -0.0009 -0.0011 -0.1087 -0.0016 -0.0204 -0.0018 -0.0014
S-237	Irbesartan BMS 150 mg Filmtabletten .
T-237	Irbesartan BMS 150 mg film @-@ coated tablets .
H-237	-0.014512190595269203	Irbesartan BMS 150 mg film @-@ coated tablets .
D-237	-0.014512190595269203	Irbesartan BMS 150 mg film @-@ coated tablets .
P-237	-0.0176 -0.0003 -0.0005 -0.0012 -0.0053 -0.0012 -0.0027 -0.0009 -0.0186 -0.0809 -0.0145 -0.0019 -0.0819 -0.0015 -0.0018 -0.0014
S-859	- Die gebrauchsfertige Lösung muss vor der Anwendung visuell
T-859	- Inspect the reconstituted solution visually prior to administration .
H-859	-0.007715058512985706	- Inspect the reconstituted solution visually prior to administration .
D-859	-0.007715058512985706	- Inspect the reconstituted solution visually prior to administration .
P-859	-0.0017 -0.0145 -0.0145 -0.0058 -0.0047 -0.0145 -0.0114 -0.0025 -0.0030 -0.0041 -0.0013 -0.0122 -0.0017 -0.0145 -0.0153 -0.0017
S-536	- wenn Sie bereits andere Arzneimittel zur Behandlung von Diabetes einnehmen
T-536	- If you are already taking other medicines for the treatment of diabetes .
H-536	-0.06400954723358154	- If you are already taking other medicines for the treatment of diabetes .
D-536	-0.06400954723358154	- If you are already taking other medicines for the treatment of diabetes .
P-536	-0.0884 -0.0177 -0.0016 -0.0232 -0.0246 -0.0114 -0.0042 -0.0036 -0.0029 -0.0091 -0.0110 -0.0012 -0.0014 -0.0006 -0.8218 -0.0014
S-1825	Stoffwechsel- und Ernährungsstörungen Häufig Psychiatrische Erkrankungen
T-1825	Metabolism and nutrition disorders Common Psychiatric disorders
H-1825	-0.005045515950769186	Metabolism and nutrition disorders Common Psychiatric disorders
D-1825	-0.005045515950769186	Metabolism and nutrition disorders Common Psychiatric disorders
P-1825	-0.0011 -0.0003 -0.0152 -0.0017 -0.0086 -0.0076 -0.0027 -0.0010 -0.0105 -0.0013 -0.0129 -0.0021 -0.0012 -0.0119 -0.0010 -0.0015
S-47	3 für die Behandlungstage 13 , 15 und 17 verwenden .
T-47	3 for treatment days 13 , 15 and 17 Use blue triple pack No .
H-47	-0.04387892037630081	3 for treatment days 13 , 15 and 17 Use blue triple pack No .
D-47	-0.04387892037630081	3 for treatment days 13 , 15 and 17 Use blue triple pack No .
P-47	-0.0063 -0.0059 -0.0085 -0.0025 -0.0017 -0.0015 -0.0011 -0.5505 -0.0010 -0.0588 -0.0145 -0.0145 -0.0145 -0.0145 -0.0049 -0.0015
S-48	29,8 % 2,2 % 0,2 % 0,0 %
T-48	0.1mg 29.8 % 2.2 % 0.2 % 0.0 %
H-48	-0.015830468386411667	0.1mg 29.8 % 2.2 % 0.2 % 0.0 %
D-48	-0.015830468386411667	0.1mg 29.8 % 2.2 % 0.2 % 0.0 %
P-48	-0.0155 -0.0968 -0.0145 -0.0133 -0.0072 -0.0014 -0.0056 -0.0769 -0.0014 -0.0020 -0.0101 -0.0014 -0.0026 -0.0015 -0.0015 -0.0016
S-1214	Wenn Sie Thrombasthenie Glanzmann haben :
T-1214	If you have Glanzmann <<unk>> s thrombasthenia :
H-1214	-0.009645357728004456	If you have Glanzmann <unk> s thrombasthenia :
D-1214	-0.009645357728004456	If you have Glanzmann <unk> s thrombasthenia :
P-1214	-0.0137 -0.0016 -0.0032 -0.0135 -0.0002 -0.0381 -0.0139 -0.0497 -0.0008 -0.0038 -0.0010 -0.0009 -0.0011 -0.0016 -0.0014
S-1961	Wirkungen von Posaconazol auf andere Arzneimittel :
T-1961	Effects of posaconazole on other medicinal products :
H-1961	-0.02929091826081276	Effects of posaconazole on other medicinal products :
D-1961	-0.02929091826081276	Effects of posaconazole on other medicinal products :
P-1961	-0.0067 -0.0008 -0.0014 -0.0129 -0.0011 -0.0011 -0.0005 -0.0007 -0.0015 -0.0013 -0.0003 -0.4076 -0.0006 -0.0015 -0.0014
S-475	Katzen erhalten eine intramuskuläre Injektion .
T-475	In cats , it is given by intramuscular injection .
H-475	-0.005842513404786587	In cats , it is given by intramuscular injection .
D-475	-0.005842513404786587	In cats , it is given by intramuscular injection .
P-475	-0.0145 -0.0040 -0.0103 -0.0142 -0.0055 -0.0092 -0.0150 -0.0053 -0.0013 -0.0007 -0.0006 -0.0019 -0.0020 -0.0018 -0.0014
S-376	Ein ml Lösung enthält 0,3 mg Bimatoprost
T-376	One ml of solution contains 0.3 mg bimatoprost
H-376	-0.03372493013739586	One ml of solution contains 0.3 mg bimatoprost
D-376	-0.03372493013739586	One ml of solution contains 0.3 mg bimatoprost
P-376	-0.0055 -0.0022 -0.0304 -0.0029 -0.0014 -0.0034 -0.0030 -0.0008 -0.0180 -0.0009 -0.0011 -0.0009 -0.0019 -0.0001 -0.4332
S-891	Was ist NEVANAC und wofür wird es angewendet ?
T-891	What NEVANAC is and what it is used for 2 .
H-891	-0.10005474090576172	What NEVANAC is and what it is used for 2 .
D-891	-0.10005474090576172	What NEVANAC is and what it is used for 2 .
P-891	-0.0016 -1.0071 -0.0013 -0.0919 -0.0009 -0.0018 -0.0033 -0.0044 -0.0139 -0.0062 -0.0040 -0.0014 -0.3467 -0.0143 -0.0021
S-1915	Was ist Zevalin und wofür wird es angewendet ?
T-1915	What Zevalin is and what it is used for 2 .
H-1915	-0.11815919727087021	What Zevalin is and what it is used for 2 .
D-1915	-0.11815919727087021	What Zevalin is and what it is used for 2 .
P-1915	-0.0014 -1.3814 -0.0005 -0.0011 -0.0014 -0.0016 -0.0028 -0.0033 -0.0138 -0.0043 -0.0032 -0.0014 -0.3400 -0.0141 -0.0020
S-702	Quixidar enthält keine tierischen Produkte. eim
T-702	ra What Quixidar looks like and contents of the pack
H-702	-0.009761644527316093	ra What Quixidar looks like and contents of the pack
D-702	-0.009761644527316093	ra What Quixidar looks like and contents of the pack
P-702	-0.0145 -0.0145 -0.0126 -0.0025 -0.0009 -0.0007 -0.0145 -0.0025 -0.0145 -0.0145 -0.0009 -0.0148 -0.0146 -0.0145 -0.0101
S-379	Falls Sie Ihr Kind stillen , sollten Sie Ihren Arzt informieren .
T-379	You should consult your doctor if you are breast @-@ feeding your child .
H-379	-0.011996399611234665	You should consult your doctor if you are breast @-@ feeding your child .
D-379	-0.011996399611234665	You should consult your doctor if you are breast @-@ feeding your child .
P-379	-0.0865 -0.0124 -0.0208 -0.0006 -0.0235 -0.0042 -0.0047 -0.0018 -0.0044 -0.0169 -0.0055 -0.0007 -0.0030 -0.0037 -0.0017 -0.0014
S-1061	Jede Filmtablette enthält 71,3 mg Lactose .
T-1061	Each film @-@ coated tablet contains 71.3 mg lactose .
H-1061	-0.11791642010211945	Each film @-@ coated tablet contains 71.3 mg lactose .
D-1061	-0.11791642010211945	Each film @-@ coated tablet contains 71.3 mg lactose .
P-1061	-0.0019 -0.0044 -0.8245 -0.0145 -0.0021 -0.0392 -0.0011 -0.0018 -0.0035 -0.0033 -0.0012 -0.8116 -0.0006 -0.0007 -0.1748 -0.0014
S-1058	- wenn Sie Schwierigkeiten beim Wasserlassen haben oder schon einmal hatten .
T-1058	- if you have , or have ever had , difficulties in passing urine .
H-1058	-0.00663434574380517	- if you have , or have ever had , difficulties in passing urine .
D-1058	-0.00663434574380517	- if you have , or have ever had , difficulties in passing urine .
P-1058	-0.0044 -0.0041 -0.0015 -0.0050 -0.0144 -0.0020 -0.0074 -0.0149 -0.0095 -0.0033 -0.0131 -0.0131 -0.0113 -0.0023 -0.0012 -0.0038 -0.0014
S-1376	Die meisten Reaktionen klangen nach 1 bis 3 Tagen spontan ab .
T-1376	Most reactions resolved spontaneously within 1 to 3 days after onset .
H-1376	-0.030019495636224747	Most reactions resolved spontaneously within 1 to 3 days after onset .
D-1376	-0.030019495636224747	Most reactions resolved spontaneously within 1 to 3 days after onset .
P-1376	-0.0022 -0.0057 -0.0006 -0.0144 -0.0013 -0.0008 -0.0403 -0.0175 -0.0095 -0.1936 -0.0013 -0.0013 -0.2009 -0.0146 -0.0013 -0.0037 -0.0014
S-766	Selten kam es zu Ileus und Darmverschluss .
T-766	Rare cases of ileus and intestinal obstruction have been reported .
H-766	-0.007103778421878815	Rare cases of ileus and intestinal obstruction have been reported .
D-766	-0.007103778421878815	Rare cases of ileus and intestinal obstruction have been reported .
P-766	-0.0106 -0.0199 -0.0140 -0.0067 -0.0001 -0.0016 -0.0097 -0.0066 -0.0021 -0.0008 -0.0050 -0.0007 -0.0144 -0.0145 -0.0110 -0.0016 -0.0014
S-1136	184 jeder Injektion die Injektionsstelle wechseln .
T-1136	Changing the site with each injection may help to prevent such skin changes .
H-1136	-0.009358013048768044	Changing the site with each injection may help to prevent such skin changes .
D-1136	-0.009358013048768044	Changing the site with each injection may help to prevent such skin changes .
P-1136	-0.0145 -0.0008 -0.0082 -0.0054 -0.0144 -0.0149 -0.0069 -0.0018 -0.0005 -0.0145 -0.0119 -0.0143 -0.0137 -0.0144 -0.0145 -0.0143 -0.0021 -0.0014
S-41	Statut der Beamten der Europäischen Gemeinschaften , insbesondere Artikel 34 .
T-41	Staff Regulations of officials of the European Communities , and in particular Article 34 thereof .
H-41	-0.009957721456885338	Staff Regulations of officials of the European Communities , and in particular Article 34 thereof .
D-41	-0.009957721456885338	Staff Regulations of officials of the European Communities , and in particular Article 34 thereof .
P-41	-0.0012 -0.0020 -0.0346 -0.0083 -0.0104 -0.0016 -0.0014 -0.0035 -0.0023 -0.0004 -0.0013 -0.0024 -0.0156 -0.0069 -0.0011 -0.0019 -0.0010 -0.0125 -0.0010 -0.0014 -0.1067 -0.0014
S-948	Geben Sie kein anderes Insulin in die Patrone .
T-948	Do not re @-@ fill and re @-@ use empty cartridges . Do not add any other insulin to the cartridge .
H-948	-0.03143264725804329	Do not re @-@ fill and re @-@ use empty cartridges .
D-948	-0.03143264725804329	Do not re @-@ fill and re @-@ use empty cartridges .
P-948	-0.0037 -0.0014 -0.0145 -0.0016 -0.0173 -0.0170 -0.0142 -0.0015 -0.0162 -0.0163 -0.0132 -0.0003 -0.0176 -0.0058 -0.3309
S-1900	Parästhesie , Benommenheit , Schwindel
T-1900	Nervous system disorders Very common : headache Uncommon : paraesthesia , somnolence , dizziness
H-1900	-0.14249759912490845	Nervous system disorders Very common : headache Uncommon : paraesthesia
D-1900	-0.14249759912490845	Nervous system disorders Very common : headache Uncommon : paraesthesia
P-1900	-0.0145 -0.0053 -0.0030 -0.0144 -0.0215 -0.0010 -0.0337 -0.0137 -0.0134 -0.0164 -0.0002 -0.0093 -0.5950 -0.0145 -0.0128 -0.0147 -0.0020 -0.0009 -0.0004 -2.0633
S-1422	Der Pen muss dann sofort in den Kühlschrank zurückgelegt werden .
T-1422	After each use , the injection needle must be discarded safely and the pen must be returned immediately to the refrigerator .
H-1422	-0.014409235678613186	After each use , the injection needle must be discarded safely and the pen must be returned immediately to the refrigerator .
D-1422	-0.014409235678613186	After each use , the injection needle must be discarded safely and the pen must be returned immediately to the refrigerator .
P-1422	-0.0144 -0.0145 -0.0143 -0.0068 -0.0055 -0.0211 -0.0132 -0.0145 -0.0136 -0.0077 -0.0041 -0.0963 -0.0001 -0.0011 -0.0366 -0.0377 -0.0145 -0.0046 -0.0118 -0.0034 -0.0528 -0.0139 -0.0131 -0.0016 -0.0089 -0.0008 -0.0008 -0.0015 -0.0016 -0.0014
S-895	Schwindel Parästhesien Kopfschmerzen Angstgefühle
T-895	CPMP / 4514 / 02 / Final 1 TRADE NAME OF THE MEDICINAL PRODUCT
H-895	-0.03937360644340515	CPMP / 4514 / 02 / Final 1 TRADE NAME OF THE MEDICINAL PRODUCT
D-895	-0.03937360644340515	CPMP / 4514 / 02 / Final 1 TRADE NAME OF THE MEDICINAL PRODUCT
P-895	-0.0231 -0.0145 -0.0145 -0.0144 -0.0145 -0.0145 -0.0144 -0.0149 -0.0484 -0.0165 -0.0145 -0.0468 -0.0219 -0.0078 -0.4122 -0.0141 -0.0116 -0.3689 -0.0032 -0.0143 -0.0148 -0.0136 -0.0046 -0.0129 -0.0130 -0.0144 -0.0124 -0.0121 -0.0003 -0.0123 -0.0051
S-1902	70 Stunden ( von 7 bis 300 Stunden ) zu berücksichtigen ist .
T-1902	Patients should be evaluated for infections before , during , and after treatment with Enbrel , taking into consideration that the mean elimination half @-@ life of etanercept is approximately 70 hours ( range 7 to 300 hours ) .
H-1902	-0.32409796118736267	Patients should be evaluated for infections before , during , and after treatment with Enbrel , taking into consideration 70 hours .
D-1902	-0.32409796118736267	Patients should be evaluated for infections before , during , and after treatment with Enbrel , taking into consideration 70 hours .
P-1902	-0.0145 -0.0016 -0.0130 -0.0122 -0.0145 -0.0020 -0.0084 -0.0145 -0.0100 -0.0144 -0.0145 -0.0073 -0.0169 -0.0076 -0.0022 -0.0116 -0.0332 -0.0145 -0.0145 -0.0007 -0.0150 -0.0145 -0.0100 -0.0338 -8.4333 -0.0015 -0.3372 -0.0014
S-91	UMKARTON FÜR SPRITZE
T-91	CARDBOARD BOX FOR SYRINGE
H-91	-0.012185693718492985	CARDBOARD BOX FOR SYRINGE
D-91	-0.012185693718492985	CARDBOARD BOX FOR SYRINGE
P-91	-0.0141 -0.0109 -0.0407 -0.0036 -0.0001 -0.0156 -0.0116 -0.0039 -0.0007 -0.0050 -0.0019 -0.0026 -0.0002 -0.0144 -0.0574
S-1071	Was ist VISTIDE und wofür wird es angewendet ?
T-1071	What VISTIDE is and what it is used for 2 .
H-1071	-0.10201967507600784	What VISTIDE is and what it is used for 2 .
D-1071	-0.10201967507600784	What VISTIDE is and what it is used for 2 .
P-1071	-0.0015 -1.1297 -0.0008 -0.0010 -0.0008 -0.0017 -0.0033 -0.0040 -0.0138 -0.0058 -0.0044 -0.0014 -0.3459 -0.0142 -0.0020
S-296	Berichtszeit gemeldet wurden , sowie die kumulative Anzahl .
T-296	cumulatively .
H-296	-0.0988193154335022	cumulatively .
D-296	-0.0988193154335022	cumulatively .
P-296	-0.0145 -0.0007 -0.4501 -0.0144 -0.0145
S-1888	- Optisulin - insulin glargine - A
T-1888	Members of the Management Board
H-1888	-0.014228145591914654	Members of the Management Board
D-1888	-0.014228145591914654	Members of the Management Board
P-1888	-0.0372 -0.0085 -0.0061 -0.0145 -0.0046 -0.0144
S-990	Besondere Vorsicht bei der Einnahme von Riprazo ist erforderlich
T-990	Take special care with Riprazo
H-990	-0.04139422997832298	Take special care with Riprazo
D-990	-0.04139422997832298	Take special care with Riprazo
P-990	-0.2761 -0.0109 -0.0022 -0.0141 -0.0134 -0.0008 -0.0006 -0.0131
S-1100	Alle Behandlungen wurden bis zur Progression der Erkrankung fortgesetzt .
T-1100	All treatments were continued until disease progression .
H-1100	-0.005483721382915974	All treatments were continued until disease progression .
D-1100	-0.005483721382915974	All treatments were continued until disease progression .
P-1100	-0.0028 -0.0055 -0.0078 -0.0061 -0.0122 -0.0134 -0.0011 -0.0021 -0.0025 -0.0014
S-1347	4 Beim Menschen liegen keine Erfahrungen mit einer Überdosierung vor .
T-1347	There is no human experience of overdose .
H-1347	-0.008849219419062138	There is no human experience of overdose .
D-1347	-0.008849219419062138	There is no human experience of overdose .
P-1347	-0.0151 -0.0082 -0.0015 -0.0151 -0.0055 -0.0204 -0.0121 -0.0065 -0.0025 -0.0015
S-694	Darüber hinaus ist die Halbwertszeit länger als bei Erwachsenen .
T-694	Moreover half life is longer than in adults .
H-694	-0.008613069541752338	Moreover half life is longer than in adults .
D-694	-0.008613069541752338	Moreover half life is longer than in adults .
P-694	-0.0133 -0.0373 -0.0128 -0.0036 -0.0013 -0.0021 -0.0093 -0.0033 -0.0016 -0.0014
S-617	38,7 % ( 36,8 ; 40,6 )
T-617	( 75.3 ; 78.6 )
H-617	-0.1320245862007141	( 75.3 ; 78.6 )
D-617	-0.1320245862007141	( 75.3 ; 78.6 )
P-617	-0.0208 -0.0286 -0.0142 -0.5617 -0.0329 -0.0140 -0.0152 -0.6037 -0.0266 -0.0024
S-102	Versuchen Sie nicht , Erbrechen auszulösen. el
T-102	au not try to induce vomiting .
H-102	-0.005904860328882933	au not try to induce vomiting .
D-102	-0.005904860328882933	au not try to induce vomiting .
P-102	-0.0151 -0.0144 -0.0033 -0.0018 -0.0091 -0.0017 -0.0018 -0.0003 -0.0029 -0.0049 -0.0097
S-1882	Koloniestimulierende Faktoren , ATC @-@ Code :
T-1882	Colony stimulating factors , ATC code :
H-1882	-0.004498601425439119	Colony stimulating factors , ATC code :
D-1882	-0.004498601425439119	Colony stimulating factors , ATC code :
P-1882	-0.0013 -0.0004 -0.0073 -0.0261 -0.0011 -0.0025 -0.0010 -0.0012 -0.0054 -0.0018 -0.0014
S-1424	EMG ( Elektromyographie ) , angewendet werden .
T-1424	EMG ( electromyography ) .
H-1424	-0.0025648605078458786	EMG ( electromyography ) .
D-1424	-0.0025648605078458786	EMG ( electromyography ) .
P-1424	-0.0058 -0.0010 -0.0020 -0.0045 -0.0010 -0.0015 -0.0007 -0.0008 -0.0014 -0.0080 -0.0015
S-1845	Erkrankungen des Blutes und des Lymphsystems Selten :
T-1845	Blood and the lymphatic system disorders
H-1845	-0.007878400385379791	Blood and the lymphatic system disorders
D-1845	-0.007878400385379791	Blood and the lymphatic system disorders
P-1845	-0.0129 -0.0011 -0.0023 -0.0169 -0.0136 -0.0113 -0.0005 -0.0020 -0.0112 -0.0011 -0.0139
S-292	Das Verfahren zur gegenseitigen Anerkennung ist 1998 sehr gut vorangekommen .
T-292	The mutual recognition procedure has made considerable progress during 1998 .
H-292	-0.0060753715224564075	The mutual recognition procedure has made considerable progress during 1998 .
D-292	-0.0060753715224564075	The mutual recognition procedure has made considerable progress during 1998 .
P-292	-0.0069 -0.0042 -0.0008 -0.0057 -0.0108 -0.0096 -0.0140 -0.0017 -0.0151 -0.0014 -0.0014 -0.0014
S-1826	Protaphane ist ein lang wirkendes Insulin .
T-1826	Protaphane is a long @-@ acting insulin .
H-1826	-0.001735998084768653	Protaphane is a long @-@ acting insulin .
D-1826	-0.001735998084768653	Protaphane is a long @-@ acting insulin .
P-1826	-0.0010 -0.0020 -0.0004 -0.0017 -0.0023 -0.0025 -0.0055 -0.0007 -0.0007 -0.0008 -0.0020 -0.0014
S-564	Packungsgröße 30 Tabletten 3 x 30 Tabletten
T-564	Package size 30 tablets 3 x 30 tablets
H-564	-0.0025557861663401127	Package size 30 tablets 3 x 30 tablets
D-564	-0.0025557861663401127	Package size 30 tablets 3 x 30 tablets
P-564	-0.0087 -0.0018 -0.0028 -0.0023 -0.0033 -0.0017 -0.0023 -0.0010 -0.0014 -0.0016 -0.0021 -0.0017
S-304	* hergestellt durch rekombinante DNA @-@ Technologie in CHO
T-304	Produced by recombinant DNA technology in CHO
H-304	-0.012749966233968735	Produced by recombinant DNA technology in CHO
D-304	-0.012749966233968735	Produced by recombinant DNA technology in CHO
P-304	-0.0172 -0.0004 -0.1298 -0.0031 -0.0007 -0.0006 -0.0015 -0.0010 -0.0032 -0.0029 -0.0011 -0.0014 -0.0029
S-687	Jede Durchstechflasche enthält 100 mg Anakinra .
T-687	Each vial contains 100 mg of anakinra .
H-687	-0.018716873601078987	Each vial contains 100 mg of anakinra .
D-687	-0.018716873601078987	Each vial contains 100 mg of anakinra .
P-687	-0.0018 -0.0024 -0.0006 -0.1532 -0.0023 -0.0011 -0.0064 -0.0052 -0.0020 -0.0013 -0.0021 -0.0634 -0.0014
S-1656	Brechen Sie den Ampullenspieß nach hinten ab .
T-1656	Take hold of the stem and snap off away from you .
H-1656	-0.017790991812944412	Take hold of the stem and snap off away from you .
D-1656	-0.017790991812944412	Take hold of the stem and snap off away from you .
P-1656	-0.0145 -0.0146 -0.0020 -0.0032 -0.0145 -0.0128 -0.0145 -0.0158 -0.0584 -0.0599 -0.0149 -0.0051 -0.0014
S-764	Zu diesem Zweck ist von ihnen eine entsprechende Erklärung zu unterzeichnen .
T-764	To this effect , they undersign a public declaration of interests .
H-764	-0.010812205262482166	To this effect , they undersign a public declaration of interests .
D-764	-0.010812205262482166	To this effect , they undersign a public declaration of interests .
P-764	-0.0099 -0.0054 -0.0141 -0.0048 -0.0097 -0.0179 -0.0145 -0.0037 -0.0145 -0.0042 -0.0012 -0.0267 -0.0145 -0.0197 -0.0014
S-1776	Der Anteil der betroffenen Patienten nimmt mit weiteren Infusionen ab .
T-1776	The proportion of affected patients decreases with subsequent infusions .
H-1776	-0.004485371056944132	The proportion of affected patients decreases with subsequent infusions .
D-1776	-0.004485371056944132	The proportion of affected patients decreases with subsequent infusions .
P-1776	-0.0040 -0.0056 -0.0043 -0.0110 -0.0013 -0.0057 -0.0010 -0.0070 -0.0143 -0.0026 -0.0022 -0.0008 -0.0015 -0.0014
S-1635	OMRIX biopharmaceuticals Ltd .
T-1635	OMRIX biopharmaceuticals Ltd .
H-1635	-0.0010426482185721397	OMRIX biopharmaceuticals Ltd .
D-1635	-0.0010426482185721397	OMRIX biopharmaceuticals Ltd .
P-1635	-0.0012 -0.0004 -0.0014 -0.0009 -0.0021 -0.0009 -0.0005 -0.0009 -0.0006 -0.0011 -0.0011 -0.0007 -0.0017 -0.0014
S-1763	Equilis Te , Injektionssuspension , für Pferde
T-1763	Equilis Te , suspension for injection , for horses
H-1763	-0.0037769731134176254	Equilis Te , suspension for injection , for horses
D-1763	-0.0037769731134176254	Equilis Te , suspension for injection , for horses
P-1763	-0.0004 -0.0005 -0.0013 -0.0016 -0.0014 -0.0019 -0.0141 -0.0093 -0.0047 -0.0073 -0.0054 -0.0024 -0.0009 -0.0017
S-1316	Panzytopenie , Thrombozytopenie
T-1316	pancytopenia , thrombocytopenia
H-1316	-0.001969300676137209	pancytopenia , thrombocytopenia
D-1316	-0.001969300676137209	pancytopenia , thrombocytopenia
P-1316	-0.0138 -0.0032 -0.0003 -0.0009 -0.0009 -0.0005 -0.0016 -0.0010 -0.0007 -0.0009 -0.0004 -0.0011 -0.0005 -0.0017
S-127	11 Erkrankungen der Haut und des Unterhautzellgewebes
T-127	r ge Skin and subcutaneous tissue disorders
H-127	-0.007465614937245846	r ge Skin and subcutaneous tissue disorders
D-127	-0.007465614937245846	r ge Skin and subcutaneous tissue disorders
P-127	-0.0157 -0.0253 -0.0262 -0.0013 -0.0020 -0.0104 -0.0013 -0.0005 -0.0012 -0.0015 -0.0040 -0.0120 -0.0012 -0.0019
S-759	Tel : + 44 208 600 1400 ( United Kingdom )
T-759	Tel : + 44 208 600 1400 ( United Kingdom )
H-759	-0.005266897846013308	Tel : + 44 208 600 1400 ( United Kingdom )
D-759	-0.005266897846013308	Tel : + 44 208 600 1400 ( United Kingdom )
P-759	-0.0024 -0.0024 -0.0014 -0.0007 -0.0352 -0.0012 -0.0008 -0.0171 -0.0011 -0.0026 -0.0047 -0.0009 -0.0015 -0.0016
S-1043	Τηλ . : + 30 2 10 75 17 981
T-1043	Τηλ . : + 30 2 10 75 17 981
H-1043	-0.021646995097398758	Τηλ . : + 30 2 10 75 17 981
D-1043	-0.021646995097398758	Τηλ . : + 30 2 10 75 17 981
P-1043	-0.0145 -0.0118 -0.0015 -0.1313 -0.0014 -0.0014 -0.0012 -0.1331 -0.0015 -0.0008 -0.0013 -0.0011 -0.0006 -0.0015
S-1698	Aktive , schwere Infektionen ( siehe Abschnitt 4.4 ) .
T-1698	Active , severe infections ( see section 4.4 ) .
H-1698	-0.0025119816418737173	Active , severe infections ( see section 4.4 ) .
D-1698	-0.0025119816418737173	Active , severe infections ( see section 4.4 ) .
P-1698	-0.0028 -0.0011 -0.0043 -0.0056 -0.0019 -0.0006 -0.0016 -0.0022 -0.0073 -0.0013 -0.0015 -0.0016 -0.0019 -0.0014
S-228	Luxembourg Mariette BACKES @-@ LIES
T-228	Luxembourg Mariette BACKES @-@ LIES
H-228	-0.0019030048279091716	Luxembourg Mariette BACKES @-@ LIES
D-228	-0.0019030048279091716	Luxembourg Mariette BACKES @-@ LIES
P-228	-0.0090 -0.0008 -0.0033 -0.0008 -0.0004 -0.0021 -0.0007 -0.0013 -0.0016 -0.0017 -0.0014 -0.0009 -0.0011 -0.0015
S-1231	Teil einer Packung mit 300 Ampullen zu 2 ml .
T-1231	Part of a box containing 300 ampoules with 2 ml .
H-1231	-0.007201353088021278	Part of a box containing 300 ampoules with 2 ml .
D-1231	-0.007201353088021278	Part of a box containing 300 ampoules with 2 ml .
P-1231	-0.0029 -0.0015 -0.0059 -0.0144 -0.0312 -0.0017 -0.0114 -0.0002 -0.0016 -0.0163 -0.0033 -0.0009 -0.0081 -0.0015
S-1277	Welchen Nutzen hat Zavesca in diesen Studien gezeigt ?
T-1277	What benefit has Zavesca shown during the studies ?
H-1277	-0.007757405750453472	What benefit has Zavesca shown during the studies ?
D-1277	-0.007757405750453472	What benefit has Zavesca shown during the studies ?
P-1277	-0.0233 -0.0104 -0.0077 -0.0014 -0.0009 -0.0012 -0.0008 -0.0051 -0.0149 -0.0244 -0.0077 -0.0015 -0.0014
S-172	- Sehr schneller Herzschlag ( Tachykardie ) .
T-172	- Very fast heart rate ( tachycardia ) .
H-172	-0.0035593274515122175	- Very fast heart rate ( tachycardia ) .
D-172	-0.0035593274515122175	- Very fast heart rate ( tachycardia ) .
P-172	-0.0052 -0.0039 -0.0026 -0.0166 -0.0104 -0.0015 -0.0008 -0.0008 -0.0011 -0.0012 -0.0003 -0.0014 -0.0027 -0.0014
S-1705	Wichtige Information über bestimmte sonstige Bestandteile von Zerene
T-1705	Important information about some of the ingredients of Zerene
H-1705	-0.007922652177512646	Important information about some of the ingredients of Zerene
D-1705	-0.007922652177512646	Important information about some of the ingredients of Zerene
P-1705	-0.0015 -0.0007 -0.0012 -0.0051 -0.0374 -0.0140 -0.0155 -0.0034 -0.0147 -0.0040 -0.0023 -0.0008 -0.0022
S-1777	22 Hunde Einmalige Sedierung und Analgesie
T-1777	Dogs Single @-@ use sedation and analgesia
H-1777	-0.018954571336507797	Dogs Single @-@ use sedation and analgesia
D-1777	-0.018954571336507797	Dogs Single @-@ use sedation and analgesia
P-1777	-0.0215 -0.0020 -0.0070 -0.0130 -0.0081 -0.0033 -0.0009 -0.0851 -0.0019 -0.0011 -0.0007 -0.0018 -0.0998
S-1660	Die klinische Relevanz dieser Erhöhung wurde nicht untersucht .
T-1660	The clinical relevance of this increase has not been established .
H-1660	-0.012950974516570568	The clinical relevance of this increase has not been established .
D-1660	-0.012950974516570568	The clinical relevance of this increase has not been established .
P-1660	-0.0043 -0.0014 -0.0022 -0.0012 -0.0015 -0.0498 -0.0035 -0.0092 -0.0015 -0.0015 -0.0890 -0.0016 -0.0014
S-842	CPMP / BWP / 388 / 95
T-842	CPMP / BWP / 388 / 95
H-842	-0.016206301748752594	CPMP / BWP / 388 / 95
D-842	-0.016206301748752594	CPMP / BWP / 388 / 95
P-842	-0.0172 -0.0019 -0.0006 -0.0017 -0.0023 -0.0013 -0.1752 -0.0018 -0.0032 -0.0015 -0.0016 -0.0008 -0.0015
S-46	Sie müssen sofort zu Ihrem Arzt gehen , da dies in sehr
T-46	See your doctor immediately as very occasionally this may become serious .
H-46	-0.011449841782450676	See your doctor immediately as very occasionally this may become serious .
D-46	-0.011449841782450676	See your doctor immediately as very occasionally this may become serious .
P-46	-0.0154 -0.0018 -0.0026 -0.0257 -0.0189 -0.0149 -0.0145 -0.0050 -0.0125 -0.0144 -0.0144 -0.0073 -0.0014
S-1742	58,6 ( 51,0 @-@ 65,8 )
T-1742	58.6 ( 51.0 @-@ 65.8 )
H-1742	-0.004441481549292803	58.6 ( 51.0 @-@ 65.8 )
D-1742	-0.004441481549292803	58.6 ( 51.0 @-@ 65.8 )
P-1742	-0.0164 -0.0052 -0.0018 -0.0016 -0.0028 -0.0014 -0.0013 -0.0211 -0.0013 -0.0008 -0.0013 -0.0014 -0.0014
S-1341	Wyeth Pharmaceuticals B.V .
T-1341	Wyeth Pharmaceuticals B. V .
H-1341	-0.002621064195409417	Wyeth Pharmaceuticals B. V .
D-1341	-0.002621064195409417	Wyeth Pharmaceuticals B. V .
P-1341	-0.0016 -0.0007 -0.0025 -0.0012 -0.0004 -0.0010 -0.0007 -0.0010 -0.0011 -0.0146 -0.0053 -0.0026 -0.0014
S-758	-0,70 % ( -1,1 ; -0,2 )
T-758	-0.70 % ( -1.1 , -0.2 )
H-758	-0.006318562664091587	-0.70 % ( -1.1 , -0.2 )
D-758	-0.006318562664091587	-0.70 % ( -1.1 , -0.2 )
P-758	-0.0016 -0.0020 -0.0015 -0.0014 -0.0015 -0.0015 -0.0025 -0.0630 -0.0012 -0.0016 -0.0014 -0.0015 -0.0015
S-1800	EMEA / HMPWP / 21 / 00
T-1800	EMEA / HMPWP / 21 / 00
H-1800	-0.3246995806694031	EMEA / HMPWP21 / 00
D-1800	-0.3246995806694031	EMEA / HMPWP21 / 00
P-1800	-0.0064 -0.0005 -0.0011 -0.0019 -0.0032 -0.0012 -0.0013 -3.7218 -0.1540 -0.0021 -0.0015 -0.0015
S-606	Sterrebaan 14 3606 EB Maarssen
T-606	Sterrebaan 14 3606 EB Maarssen
H-606	-0.0022381371818482876	Sterrebaan 14 3606 EB Maarssen
D-606	-0.0022381371818482876	Sterrebaan 14 3606 EB Maarssen
P-606	-0.0007 -0.0012 -0.0007 -0.0013 -0.0146 -0.0006 -0.0025 -0.0014 -0.0010 -0.0017 -0.0012 -0.0007 -0.0015
S-792	Porcilis AR @-@ T DF enthält Mineralöl .
T-792	Porcilis AR @-@ T DF contains mineral oil .
H-792	-0.018759766593575478	Porcilis AR @-@ T DF contains mineral oil .
D-792	-0.018759766593575478	Porcilis AR @-@ T DF contains mineral oil .
P-792	-0.0015 -0.0017 -0.0003 -0.0009 -0.2156 -0.0011 -0.0005 -0.0145 -0.0019 -0.0010 -0.0016 -0.0019 -0.0014
S-534	Recombinant human C1- inhibitor
T-534	Recombinant human C1 @-@ inhibitor
H-534	-0.01819707080721855	Recombinant human C1 @-@ inhibitor
D-534	-0.01819707080721855	Recombinant human C1 @-@ inhibitor
P-534	-0.0029 -0.0007 -0.0006 -0.0013 -0.0015 -0.0017 -0.1924 -0.0281 -0.0029 -0.0008 -0.0009 -0.0014 -0.0015
S-11	( -5,6 % ; -0,6 % ) e
T-11	( -5.6 % ; -0.6 % ) e
H-11	-0.0466119684278965	( -5.6 % ; -0.6 % ) e
D-11	-0.0466119684278965	( -5.6 % ; -0.6 % ) e
P-11	-0.0017 -0.0014 -0.0053 -0.2017 -0.0013 -0.3768 -0.0009 -0.0022 -0.0014 -0.0012 -0.0015 -0.0091 -0.0014
S-1644	Die Lösung vor der Infusion sanft schwenken .
T-1644	The solution is to be mixed gently for infusion .
H-1644	-0.011328144930303097	The solution is to be mixed gently for infusion .
D-1644	-0.011328144930303097	The solution is to be mixed gently for infusion .
P-1644	-0.0145 -0.0021 -0.0135 -0.0177 -0.0097 -0.0332 -0.0059 -0.0209 -0.0139 -0.0012 -0.0019 -0.0014
S-1606	- Der erste Data Lock Point ist 14 Tage später .
T-1606	- First data @-@ lock point is 14 days later .
H-1606	-0.01059762667864561	- First data @-@ lock point is 14 days later .
D-1606	-0.01059762667864561	- First data @-@ lock point is 14 days later .
P-1606	-0.0024 -0.0139 -0.0114 -0.0554 -0.0250 -0.0041 -0.0048 -0.0026 -0.0012 -0.0022 -0.0027 -0.0014
S-1125	ZYPREXA 5 mg überzogene Tabletten
T-1125	ZYPREXA 5 mg coated tablets
H-1125	-0.0035427759867161512	ZYPREXA 5 mg coated tablets
D-1125	-0.0035427759867161512	ZYPREXA 5 mg coated tablets
P-1125	-0.0063 -0.0014 -0.0004 -0.0008 -0.0013 -0.0021 -0.0006 -0.0137 -0.0007 -0.0079 -0.0054 -0.0018
S-154	2,5 mg zweimal täglich ( 5 Tropfen zweimal täglich ) .
T-154	2.5 mg twice daily ( 5 drops twice daily ) .
H-154	-0.038002680987119675	2.5 mg twice daily ( 5 drops twice daily ) .
D-154	-0.038002680987119675	2.5 mg twice daily ( 5 drops twice daily ) .
P-154	-0.0067 -0.0022 -0.0019 -0.2547 -0.0016 -0.0020 -0.0009 -0.0017 -0.1790 -0.0014 -0.0024 -0.0014
S-1461	- Der Wirkstoff ist Insulin lispro .
T-1461	- The active substance is insulin lispro .
H-1461	-0.0036111881490796804	- The active substance is insulin lispro .
D-1461	-0.0036111881490796804	- The active substance is insulin lispro .
P-1461	-0.0119 -0.0036 -0.0021 -0.0129 -0.0018 -0.0022 -0.0005 -0.0034 -0.0005 -0.0014 -0.0016 -0.0014
S-1230	Wofür wird VASOVIST angewendet ?
T-1230	What is VASOVIST used for ?
H-1230	-0.04323174059391022	What is VASOVIST used for ?
D-1230	-0.04323174059391022	What is VASOVIST used for ?
P-1230	-0.0054 -0.0038 -0.0033 -0.4917 -0.0013 -0.0014 -0.0012 -0.0011 -0.0053 -0.0016 -0.0014 -0.0014
S-348	Ausschlag Entzündungen im Wundbereich Ödem
T-348	Rash Wound site inflammation edema
H-348	-0.019448822364211082	Rash Wound site inflammation edema
D-348	-0.019448822364211082	Rash Wound site inflammation edema
P-348	-0.0137 -0.0012 -0.0146 -0.0018 -0.0146 -0.0051 -0.0006 -0.0017 -0.0069 -0.0003 -0.0002 -0.1727
S-1842	Zyanid ist eine hochgiftige Chemikalie .
T-1842	Cyanide is a highly poisonous chemical .
H-1842	-0.0022842464968562126	Cyanide is a highly poisonous chemical .
D-1842	-0.0022842464968562126	Cyanide is a highly poisonous chemical .
P-1842	-0.0005 -0.0005 -0.0010 -0.0015 -0.0017 -0.0026 -0.0132 -0.0010 -0.0014 -0.0011 -0.0016 -0.0014
S-1451	Ariclaim kann unabhängig von der Nahrungsaufnahme eingenommen werden .
T-1451	Ariclaim can be taken with or without food .
H-1451	-0.02646232582628727	Ariclaim can be taken with or without food .
D-1451	-0.02646232582628727	Ariclaim can be taken with or without food .
P-1451	-0.0022 -0.0104 -0.1168 -0.0014 -0.0068 -0.1181 -0.0132 -0.0011 -0.0092 -0.0105 -0.0014
S-1366	Eine Magenspülung kann erwogen werden .
T-1366	Gastric lavage may be considered .
H-1366	-0.004673571325838566	Gastric lavage may be considered .
D-1366	-0.004673571325838566	Gastric lavage may be considered .
P-1366	-0.0134 -0.0001 -0.0010 -0.0128 -0.0019 -0.0052 -0.0093 -0.0019 -0.0027 -0.0016 -0.0014
S-330	Granulozytenzahl ( x 106 / l )
T-330	Absolute granulocyte count ( x 106 / l )
H-330	-0.003738629398867488	Absolute granulocyte count ( x 106 / l )
D-330	-0.003738629398867488	Absolute granulocyte count ( x 106 / l )
P-330	-0.0145 -0.0026 -0.0129 -0.0022 -0.0009 -0.0005 -0.0099 -0.0025 -0.0015 -0.0013 -0.0008 -0.0017 -0.0018 -0.0014 -0.0015
S-1760	Durchgeführte Inspektionen für zentralisierte Verfahren 1998 @-@ 2000
T-1760	The significant expansion in 2000 of specific post @-@ authorisation activities reflects the increase in the number of applications for variations to centralised procedures and extensions / modifications to MRLs as compared to previous years .
H-1760	-0.04150667041540146	The significant expansion in 2000 of specific post @-@ authorisation activities reflects the increase in the number of applications for variations to centralised procedures and extensions / modifications to MRLs as compared to previous years .
D-1760	-0.04150667041540146	The significant expansion in 2000 of specific post @-@ authorisation activities reflects the increase in the number of applications for variations to centralised procedures and extensions / modifications to MRLs as compared to previous years .
P-1760	-0.0145 -0.0145 -0.0145 -0.0137 -0.0398 -0.0088 -0.0903 -0.0151 -0.0039 -0.0145 -0.0042 -0.0149 -0.0240 -0.0080 -0.0145 -0.0047 -0.0120 -0.0073 -0.0032 -0.0144 -0.0166 -0.0145 -0.0153 -0.0213 -0.0188 -0.0008 -0.0027 -0.0060 -0.1932 -0.0145 -0.0072 -0.4969 -0.0144 -0.0061 -0.4741 -0.0185 -0.0144 -0.0037 -0.1465 -0.0143 -0.0060 -0.0139 -0.0033 -0.0068 -0.0014
S-768	Alteplase ( etwa 15 000 Patienten ) .
T-768	Rapilysin reduced the incidence of heart failure better than streptokinase and was equally effective in reducing death , and as effective as alteplase at preventing death and strokes .
H-768	-0.3145146369934082	Rapilysin reduced the incidence of heart failure better than streptokinase and was equally effective .
D-768	-0.3145146369934082	Rapilysin reduced the incidence of heart failure better than streptokinase and was equally effective .
P-768	-0.0145 -0.0145 -0.0145 -0.0144 -0.0145 -0.0109 -0.0175 -0.0006 -0.0034 -0.0144 -0.0122 -0.0150 -0.0115 -0.0145 -0.0140 -0.0117 -0.0145 -0.0071 -0.0148 -0.0145 -0.0145 -0.0067 -7.2769 -0.0014
S-169	Innerhalb von 1 bis 3 Tagen klingen diese Symptome wieder ab .
T-169	Reduced feed intake and listlessness may occur in approximately 10 % of the animals on the day of vaccination , but returns to normal within 1 @-@ 3 days .
H-169	-0.3735639452934265	Reduced feed intake and listlessness may occur in approximately 10 % of the animals .
D-169	-0.3735639452934265	Reduced feed intake and listlessness may occur in approximately 10 % of the animals .
P-169	-0.0146 -0.0096 -0.0145 -0.0144 -0.0041 -0.0142 -0.0145 -0.0119 -0.0012 -0.0144 -0.0107 -0.0143 -0.0143 -0.0153 -0.0142 -0.0046 -0.0122 -0.0144 -7.2564 -0.0014
S-1524	2377 / 90 des Rates gemäß folgender Tabelle enthalten :
T-1524	Gamithromycin is included in Annex III of Council Regulation ( EEC ) No 2377 / 90 in accordance with the following table :
H-1524	-0.014149236492812634	Gamithromycin is included in Annex III of Council Regulation ( EEC ) No 2377 / 90 in accordance with the following table :
D-1524	-0.014149236492812634	Gamithromycin is included in Annex III of Council Regulation ( EEC ) No 2377 / 90 in accordance with the following table :
P-1524	-0.0145 -0.0145 -0.0145 -0.0114 -0.0075 -0.0075 -0.0142 -0.0122 -0.0063 -0.0154 -0.0042 -0.0450 -0.0108 -0.0084 -0.0145 -0.0224 -0.1080 -0.0140 -0.0079 -0.0014 -0.0755 -0.0041 -0.0010 -0.0014 -0.0009 -0.0140 -0.0122 -0.0011 -0.0015 -0.0029 -0.0073 -0.0010 -0.0019 -0.0014
S-1403	Die tägliche Einnahme über einen längeren Zeitraum wird nicht empfohlen .
T-1403	Tadalafil 10 mg and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous daily use .
H-1403	-0.24593405425548553	Tadalafil 10 mg and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous use .
D-1403	-0.24593405425548553	Tadalafil 10 mg and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous use .
P-1403	-0.0145 -0.0145 -0.0141 -0.0019 -0.0059 -0.0145 -0.0135 -0.0145 -0.0143 -0.0037 -0.0137 -0.0156 -0.0051 -0.0130 -0.0145 -0.0014 -0.0145 -0.0145 -0.0120 -0.0217 -0.0145 -0.0062 -0.0124 -0.0005 -0.0137 -0.0145 -0.0017 -7.0744 -0.0016 -0.0014
S-406	Wiederholungsimpfungen im Abstand von 6 Wochen erfolgen .
T-406	For prolonged immunity , chickens should be revaccinated every 6 weeks after the initial administration .
H-406	-0.032638225704431534	For prolonged immunity , chickens should be revaccinated every 6 weeks after the initial administration .
D-406	-0.032638225704431534	For prolonged immunity , chickens should be revaccinated every 6 weeks after the initial administration .
P-406	-0.0145 -0.0145 -0.0141 -0.0006 -0.0140 -0.0370 -0.0100 -0.0145 -0.0144 -0.0057 -0.0099 -0.0029 -0.0144 -0.0077 -0.0009 -0.0085 -0.0091 -0.0010 -0.5425 -0.0141 -0.0140 -0.0145 -0.0032 -0.0014
S-1687	OptiSet ist beschädigt , verwenden Sie einen neuen OptiSet .
T-1687	• Difference is more than 2 units OptiSet is damaged , use a new OptiSet .
H-1687	-0.5275360345840454	• OptiSet is damaged , use a new OptiSet .
D-1687	-0.5275360345840454	• OptiSet is damaged , use a new OptiSet .
P-1687	-0.0167 -6.7719 -0.0009 -0.0028 -0.0071 -0.0410 -0.0054 -0.0051 -0.0015 -0.0005 -0.0010 -0.0029 -0.0015
S-88	09.01.97 06.05.98 180 T age 508 Tage
T-88	a ) 9.1.1997 b ) 6.5.1998 c ) 180 days d ) 508 days
H-88	-0.02010270580649376	a ) 9.1.1997 b ) 6.5.1998 c ) 180 days d ) 508 days
D-88	-0.02010270580649376	a ) 9.1.1997 b ) 6.5.1998 c ) 180 days d ) 508 days
P-88	-0.0147 -0.0097 -0.0146 -0.0129 -0.0258 -0.0186 -0.0040 -0.0189 -0.0086 -0.0312 -0.0156 -0.0013 -0.0014 -0.0089 -0.1984 -0.0025 -0.0108 -0.0013 -0.0014 -0.0013
S-701	bis 27,0 ) 14,7 bis 26,9 )
T-701	15.42 ( 3.9 , 27.0 ) 14.7 ( 2.5 , 26.9 ) -
H-701	-0.06855030357837677	15.42 ( 3.9 , 27.0 ) 14.7 ( 2.5 , 26.9 ) -
D-701	-0.06855030357837677	15.42 ( 3.9 , 27.0 ) 14.7 ( 2.5 , 26.9 ) -
P-701	-0.0145 -0.2301 -0.0372 -0.0149 -0.1167 -0.1165 -0.0168 -0.0024 -0.1059 -0.0090 -0.0016 -0.0201 -0.0172 -0.1264 -0.0159 -0.0026 -0.0594 -0.3856 -0.0098
S-571	Schwangeres Personal darf dieses Arzneimittel nicht handhaben .
T-571	Pregnant staff should be excluded from handling the medicinal product .
H-571	-0.5274615287780762	Pregnant staff should be excluded from handling the medicines .
D-571	-0.5274615287780762	Pregnant staff should be excluded from handling the medicines .
P-571	-0.0037 -0.0003 -0.0012 -0.0082 -0.0125 -0.0213 -0.0141 -0.0009 -0.0017 -0.0088 -0.0134 -0.0136 -7.8090 -0.0020 -0.0014
S-141	Paroxetin STADA 20 mg Filmtabletten
T-141	Paroxetin STADA 20 mg Filmtabletten
H-141	-0.07434790581464767	Paroxetine STADA 20 mg Filmtabletten
D-141	-0.07434790581464767	Paroxetine STADA 20 mg Filmtabletten
P-141	-0.0024 -0.0005 -0.0006 -0.7373 -0.0017 -0.0004 -0.0055 -0.0007 -0.1800 -0.0074 -0.0138 -0.0144 -0.0018
S-415	- wenn Sie starken Bluthochdruck haben oder hatten .
T-415	- if you have , or have had , severe high blood pressure .
H-415	-0.1884191334247589	- if you have , or have had , severe high blood pressure
D-415	-0.1884191334247589	- if you have , or have had , severe high blood pressure
P-415	-0.1931 -0.0043 -0.0014 -0.0062 -0.0140 -0.0014 -0.0085 -0.0038 -0.0038 -0.0096 -0.0359 -0.0011 -0.0009 -2.3536
S-1067	Warum wurde Clopidogrel Winthrop zugelassen ?
T-1067	Why has Clopidogrel Winthrop been approved ?
H-1067	-0.0021177504677325487	Why has Clopidogrel Winthrop been approved ?
D-1067	-0.0021177504677325487	Why has Clopidogrel Winthrop been approved ?
P-1067	-0.0014 -0.0108 -0.0034 -0.0009 -0.0010 -0.0004 -0.0010 -0.0026 -0.0002 -0.0012 -0.0014 -0.0022 -0.0017 -0.0014
S-1684	80 mg gegeben als eine subkutane Injektion
T-1684	80 mg administered as one subcutaneous injection
H-1684	-0.007459784392267466	80 mg administered as one subcutaneous injection
D-1684	-0.007459784392267466	80 mg administered as one subcutaneous injection
P-1684	-0.0028 -0.0015 -0.0144 -0.0009 -0.0033 -0.0699 -0.0032 -0.0008 -0.0005 -0.0014 -0.0014 -0.0018 -0.0005 -0.0019
S-1308	Deshalb muss eine Überwachung bei überdosierten Patienten gewährleistet sein .
T-1308	Monitoring of overdosed patients is warranted .
H-1308	-0.008152516558766365	Monitoring of overdosed patients is warranted .
D-1308	-0.008152516558766365	Monitoring of overdosed patients is warranted .
P-1308	-0.0132 -0.0012 -0.0011 -0.0089 -0.0048 -0.0356 -0.0107 -0.0012 -0.0123 -0.0145 -0.0003 -0.0010 -0.0080 -0.0014
S-747	Falls diese auftreten , sollten Sie umgehend Ihren Arzt aufsuchen .
T-747	Should these occur , you should promptly consult your doctor .
H-747	-0.0494425930082798	Should these occur , you should promptly consult your doctor .
D-747	-0.0494425930082798	Should these occur , you should promptly consult your doctor .
P-747	-0.2235 -0.0066 -0.0021 -0.0032 -0.0087 -0.0014 -0.4241 -0.0008 -0.0136 -0.0006 -0.0021 -0.0023 -0.0016 -0.0014
S-676	Capsules 200mg , 400mg 5 Presentations
T-676	C apsules 200mg , 400mg 5 Presentations
H-676	-0.0034853448159992695	C apsules 200mg , 400mg 5 Presentations
D-676	-0.0034853448159992695	C apsules 200mg , 400mg 5 Presentations
P-676	-0.0145 -0.0144 -0.0009 -0.0015 -0.0015 -0.0005 -0.0019 -0.0036 -0.0006 -0.0017 -0.0040 -0.0010 -0.0013 -0.0015
S-1147	Diese Karte sollten Sie ablösen und immer bei sich tragen .
T-1147	This card should be removed and kept with you at all times .
H-1147	-0.005445956252515316	This card should be removed and kept with you at all times .
D-1147	-0.005445956252515316	This card should be removed and kept with you at all times .
P-1147	-0.0111 -0.0040 -0.0078 -0.0039 -0.0109 -0.0042 -0.0142 -0.0052 -0.0014 -0.0089 -0.0008 -0.0008 -0.0017 -0.0014
S-1	Wirkungen von Tadalafil auf andere Arzneimittel
T-1	Effects of tadalafil on other medicinal products
H-1	-0.06892328709363937	Effects of tadalafil on other medicinal products
D-1	-0.06892328709363937	Effects of tadalafil on other medicinal products
P-1	-0.0071 -0.0008 -0.0014 -0.0080 -0.0010 -0.0010 -0.0007 -0.0011 -0.0015 -0.0016 -0.0006 -0.7747 -0.0008 -0.1646
S-1221	GONAL @-@ f bedarf einer ärztlichen Verschreibung .
T-1221	GONAL @-@ f can only be obtained with a prescription .
H-1221	-0.029351644217967987	GONAL @-@ f can only be obtained with a prescription .
D-1221	-0.029351644217967987	GONAL @-@ f can only be obtained with a prescription .
P-1221	-0.0057 -0.0008 -0.0008 -0.0014 -0.0024 -0.0145 -0.0105 -0.0018 -0.0142 -0.0134 -0.0042 -0.0081 -0.0125 -0.3205
S-1110	- Ritonavir ( zur Behandlung von AIDS )
T-1110	- ritonavir ( used to treat AIDS )
H-1110	-0.019624076783657074	- ritonavir ( used to treat AIDS )
D-1110	-0.019624076783657074	- ritonavir ( used to treat AIDS )
P-1110	-0.0024 -0.0158 -0.0022 -0.0008 -0.0011 -0.0015 -0.0113 -0.2132 -0.0013 -0.0014 -0.0008 -0.0015 -0.0017
S-875	Es liegen keine Angaben über die Behandlung einer Überdosierung mit Karvea vor .
T-875	No specific information is available on the treatment of overdose with Karvea .
H-875	-0.008558543398976326	No specific information is available on the treatment of overdose with Karvea .
D-875	-0.008558543398976326	No specific information is available on the treatment of overdose with Karvea .
P-875	-0.0144 -0.0159 -0.0112 -0.0186 -0.0022 -0.0163 -0.0083 -0.0019 -0.0024 -0.0119 -0.0076 -0.0045 -0.0247 -0.0006 -0.0014 -0.0022 -0.0014
S-94	von Levitra sind ( siehe die sonstigen Bestandteile in Abschnitt 6 ) .
T-94	ingredients in section 6 .
H-94	-0.013778387568891048	ingredients in section 6 .
D-94	-0.013778387568891048	ingredients in section 6 .
P-94	-0.0145 -0.0136 -0.0146 -0.0124 -0.0130 -0.0145
S-1189	WIE IST BONDRONAT ANZUWENDEN ?
T-1189	HOW TO USE BONDRONAT
H-1189	-0.014822632074356079	HOW TO USE BONDRONAT
D-1189	-0.014822632074356079	HOW TO USE BONDRONAT
P-1189	-0.0022 -0.0005 -0.1187 -0.0070 -0.0006 -0.0059 -0.0006 -0.0023 -0.0006 -0.0103 -0.0143
S-1880	WIE IST EUCREAS EINZUNEHMEN ?
T-1880	HOW TO TAKE EUCREAS
H-1880	-0.0054163518361747265	HOW TO TAKE EUCREAS
D-1880	-0.0054163518361747265	HOW TO TAKE EUCREAS
P-1880	-0.0033 -0.0004 -0.0132 -0.0141 -0.0027 -0.0006 -0.0087 -0.0016 -0.0006 -0.0007 -0.0137
S-472	9 Erkrankungen der Geschlechtsorgane und der Brustdrüse Gelegentlich Unbekannt
T-472	Reproductive system and breast disorders Uncommon Not known
H-472	-0.010790565982460976	Reproductive system and breast disorders Uncommon Not known
D-472	-0.010790565982460976	Reproductive system and breast disorders Uncommon Not known
P-472	-0.0147 -0.0008 -0.0138 -0.0107 -0.0136 -0.0144 -0.0011 -0.0144 -0.0144 -0.0156 -0.0112 -0.0049
S-1669	Bitte informieren Sie Ihren Arzt , wenn Sie an einer Nierenkrankheit leiden .
T-1669	Please tell your doctor if you have a kidney disorder .
H-1669	-0.08296197652816772	Please tell your doctor if you have a kidney disorder .
D-1669	-0.08296197652816772	Please tell your doctor if you have a kidney disorder .
P-1669	-0.4078 -0.0734 -0.0017 -0.0022 -0.0019 -0.0012 -0.3355 -0.0856 -0.0010 -0.0005 -0.0178 -0.1485 -0.0014
S-52	Die EMEA wird sich auch 2006 an diesem regelmäßigen Zyklus beteiligen .
T-52	The Agency <<unk>> s involvement in this cycle will continue in 2006 .
H-52	-0.010352673009037971	The Agency <unk> s involvement in this cycle will continue in 2006 .
D-52	-0.010352673009037971	The Agency <unk> s involvement in this cycle will continue in 2006 .
P-52	-0.0294 -0.0366 -0.0145 -0.0053 -0.0134 -0.0047 -0.0059 -0.0129 -0.0046 -0.0049 -0.0083 -0.0014 -0.0015 -0.0014
S-706	Der Inhaber der Genehmigung für das Inverkehrbringen ist INO Therapeutics AB .
T-706	The marketing authorisation holder is INO Therapeutics AB .
H-706	-0.013088177889585495	The marketing authorisation holder is INO Therapeutics AB .
D-706	-0.013088177889585495	The marketing authorisation holder is INO Therapeutics AB .
P-706	-0.0032 -0.0171 -0.0039 -0.0014 -0.0035 -0.0018 -0.0012 -0.0010 -0.0003 -0.0006 -0.0022 -0.0012 -0.1444 -0.0014
S-856	Den vollständigen Wortlaut des EPAR für Ebixa finden Sie hier .
T-856	The full EPAR for Ebixa can be found here .
H-856	-0.00363356014713645	The full EPAR for Ebixa can be found here .
D-856	-0.00363356014713645	The full EPAR for Ebixa can be found here .
P-856	-0.0088 -0.0020 -0.0119 -0.0010 -0.0056 -0.0020 -0.0011 -0.0010 -0.0014 -0.0106 -0.0013 -0.0024 -0.0016 -0.0025 -0.0014
S-1193	Bei älteren Patienten ( &gt; 75 Jahren ) liegen nur begrenzte klinische Erfahrungen vor .
T-1193	In elderly patients ( &gt; 75 years ) there is limited clinical experience .
H-1193	-0.02761179208755493	In elderly patients ( &gt; 75 years ) there is limited clinical experience .
D-1193	-0.02761179208755493	In elderly patients ( &gt; 75 years ) there is limited clinical experience .
P-1193	-0.0110 -0.0373 -0.0014 -0.0022 -0.0048 -0.0010 -0.1823 -0.1410 -0.0116 -0.0042 -0.0092 -0.0015 -0.0022 -0.0032 -0.0014
S-204	Die empfohlene Dosis von APTIVUS beträgt 500 mg zweimal täglich .
T-204	The recommended dose of APTIVUS is 500 mg twice a day .
H-204	-0.05260869860649109	The recommended dose of APTIVUS is 500 mg twice daily .
D-204	-0.05260869860649109	The recommended dose of APTIVUS is 500 mg twice daily .
P-204	-0.0165 -0.0011 -0.0037 -0.0225 -0.0013 -0.0013 -0.0008 -0.0009 -0.0016 -0.0052 -0.0015 -0.0028 -0.7268 -0.0016 -0.0014
S-1162	Eine Bewertung der pharmakokinetischen Eigenschaften ist für Impfstoffe nicht erforderlich .
T-1162	Evaluation of pharmacokinetic properties is not available for vaccines .
H-1162	-0.0356617346405983	Evaluation of pharmacokinetic properties is not available for vaccines .
D-1162	-0.0356617346405983	Evaluation of pharmacokinetic properties is not available for vaccines .
P-1162	-0.0139 -0.0031 -0.0015 -0.0064 -0.0006 -0.0003 -0.2021 -0.0033 -0.0058 -0.0018 -0.2898 -0.0365 -0.0012 -0.0011 -0.0018 -0.0014
S-1517	Daten über Fisteln wurden mittels der PCDAI @-@ Scores erhoben .
T-1517	Data about fistulas were derived from PCDAI scores .
H-1517	-0.01206198800355196	Data about fistulas were derived from PCDAI scores .
D-1517	-0.01206198800355196	Data about fistulas were derived from PCDAI scores .
P-1517	-0.0034 -0.0146 -0.0013 -0.0008 -0.0043 -0.0013 -0.0139 -0.0145 -0.0013 -0.0745 -0.0102 -0.0006 -0.0014 -0.0013 -0.0037 -0.0564 -0.0014
S-474	WIE IST Helixate NexGen 1000 I.E .
T-474	HOW TO USE Helixate NexGen 1000 IU
H-474	-0.00696035660803318	HOW TO USE Helixate NexGen 1000 IU
D-474	-0.00696035660803318	HOW TO USE Helixate NexGen 1000 IU
P-474	-0.0019 -0.0005 -0.0143 -0.0138 -0.0005 -0.0082 -0.0012 -0.0015 -0.0016 -0.0025 -0.0009 -0.0015 -0.0016 -0.0021 -0.0042 -0.0145 -0.0475
S-1738	Diese Verbesserung hielt bei Patienten , die Macugen erhielten , zwei Jahre lang an .
T-1738	This improvement lasted for patients who were given Macugen for 2 years .
H-1738	-0.03478448465466499	This improvement lasted for patients who were given Macugen for 2 years .
D-1738	-0.03478448465466499	This improvement lasted for patients who were given Macugen for 2 years .
P-1738	-0.0058 -0.0019 -0.0120 -0.0055 -0.1184 -0.1811 -0.0479 -0.0051 -0.0028 -0.0010 -0.0008 -0.0019 -0.1682 -0.0015 -0.0015 -0.0014
S-1174	Bei Katzen können während der Sedierung Hornhauttrübungen auftreten .
T-1174	In cats , corneal opacities may occur during sedation .
H-1174	-0.005080049857497215	In cats , corneal opacities may occur during sedation .
D-1174	-0.005080049857497215	In cats , corneal opacities may occur during sedation .
P-1174	-0.0080 -0.0014 -0.0107 -0.0111 -0.0001 -0.0031 -0.0112 -0.0039 -0.0061 -0.0103 -0.0047 -0.0019 -0.0049 -0.0008 -0.0017 -0.0014
S-1126	Die Behandlung mit Ratiograstim wird über 4 bis 5 Tage durchgeführt .
T-1126	Ratiograstim treatment will last for 4 to 5 days .
H-1126	-0.017442915588617325	Ratiograstim treatment will last for 4 to 5 days .
D-1126	-0.017442915588617325	Ratiograstim treatment will last for 4 to 5 days .
P-1126	-0.0132 -0.0008 -0.0012 -0.0007 -0.0018 -0.0011 -0.0099 -0.0139 -0.0176 -0.0125 -0.0039 -0.1967 -0.0014 -0.0014 -0.0017 -0.0014
S-709	- Arzneimittel zur Behandlung von psychischen Störungen ( Neuroleptika )
T-709	- medicines used for treating psychological disorders ( neuroleptics )
H-709	-0.07682742923498154	- medicines used for treating psychological disorders ( neuroleptics )
D-709	-0.07682742923498154	- medicines used for treating psychological disorders ( neuroleptics )
P-709	-0.0023 -0.0101 -0.0064 -0.0156 -0.9354 -0.0134 -0.0129 -0.0024 -0.0009 -0.0014 -0.0083 -0.0012 -0.0013 -0.0021 -0.0014 -0.2141
S-156	Neoclarityn 5 mg Tabletten Desloratadin
T-156	Neoclarityn 5 mg tablet desloratadine
H-156	-0.03346589207649231	Neoclarityn 5 mg tablets desloratadine
D-156	-0.03346589207649231	Neoclarityn 5 mg tablets desloratadine
P-156	-0.0019 -0.0014 -0.0006 -0.0016 -0.0009 -0.0009 -0.0066 -0.0006 -0.0095 -0.4916 -0.0124 -0.0002 -0.0013 -0.0024 -0.0017 -0.0019
S-636	Diese zeigten keine nachteilige Wirkung auf den Gelenkknorpel .
T-636	These have shown no deleterious effect on joint cartilage .
H-636	-0.005335615947842598	These have shown no deleterious effect on joint cartilage .
D-636	-0.005335615947842598	These have shown no deleterious effect on joint cartilage .
P-636	-0.0161 -0.0142 -0.0115 -0.0017 -0.0145 -0.0005 -0.0001 -0.0011 -0.0091 -0.0017 -0.0095 -0.0011 -0.0011 -0.0003 -0.0015 -0.0014
S-1735	Daher darf Docetaxel während der Schwangerschaft nicht angewandt werden .
T-1735	Therefore , docetaxel must not be used during pregnancy .
H-1735	-0.040113236755132675	Therefore , docetaxel must not be used during pregnancy .
D-1735	-0.040113236755132675	Therefore , docetaxel must not be used during pregnancy .
P-1735	-0.0056 -0.0009 -0.0071 -0.0048 -0.0013 -0.0008 -0.0006 -0.0009 -0.5920 -0.0016 -0.0014 -0.0035 -0.0173 -0.0013 -0.0015 -0.0014
S-1265	5 ml ( 2,5 mg ) Aerius Lösung zum Einnehmen einmal täglich .
T-1265	5 ml ( 2.5 mg ) Aerius oral solution once a day .
H-1265	-0.04984546825289726	5 ml ( 2.5 mg ) Aerius oral solution once a day .
D-1265	-0.04984546825289726	5 ml ( 2.5 mg ) Aerius oral solution once a day .
P-1265	-0.0040 -0.0024 -0.0015 -0.0057 -0.0013 -0.0015 -0.0086 -0.0006 -0.0011 -0.0147 -0.0064 -0.0084 -0.7359 -0.0014 -0.0025 -0.0015
S-762	Demnach kann ADENURIC unabhängig von den Mahlzeiten eingenommen werden .
T-762	Thus , ADENURIC may be taken without regard to food .
H-762	-0.025281285867094994	Thus , ADENURIC may be taken without regard to food .
D-762	-0.025281285867094994	Thus , ADENURIC may be taken without regard to food .
P-762	-0.0137 -0.0108 -0.0026 -0.0010 -0.0008 -0.0006 -0.1184 -0.0014 -0.0057 -0.1899 -0.0137 -0.0016 -0.0143 -0.0034 -0.0014
S-193	Die tägliche Gesamtdosis kann in zwei oder drei Dosen eingenommen werden .
T-193	You can divide the total daily dose in two or three intakes .
H-193	-0.00791423860937357	You can divide the total daily dose in two or three intakes .
D-193	-0.00791423860937357	You can divide the total daily dose in two or three intakes .
P-193	-0.0142 -0.0145 -0.0145 -0.0055 -0.0096 -0.0048 -0.0038 -0.0135 -0.0030 -0.0028 -0.0031 -0.0145 -0.0116 -0.0018 -0.0014
S-1625	40 Actrapid InnoLet darf nur von einer Person benutzt werden .
T-1625	Actrapid InnoLet is for single person use only .
H-1625	-0.0070261708460748196	Actrapid InnoLet is for single person use only .
D-1625	-0.0070261708460748196	Actrapid InnoLet is for single person use only .
P-1625	-0.0145 -0.0008 -0.0009 -0.0009 -0.0022 -0.0029 -0.0026 -0.0136 -0.0129 -0.0135 -0.0131 -0.0147 -0.0094 -0.0020 -0.0015
S-302	Bei 6 von diesen Patienten beträgt der Follow @-@ up jetzt mehr als 4 Jahre .
T-302	In 6 of these patients follow @-@ up now exceeds 4 years .
H-302	-0.012634803541004658	In 6 of these patients follow @-@ up now exceeds 4 years .
D-302	-0.012634803541004658	In 6 of these patients follow @-@ up now exceeds 4 years .
P-302	-0.0088 -0.0047 -0.0034 -0.0038 -0.0018 -0.0137 -0.0030 -0.0017 -0.0124 -0.0098 -0.0010 -0.0428 -0.0288 -0.0523 -0.0014
S-1052	Eine Eliminationshalbwertzeit von 5,8 Stunden wurde beobachtet .
T-1052	A half @-@ life time of 5.8 hours has been observed .
H-1052	-0.009341700002551079	A half @-@ life time of 5.8 hours has been observed .
D-1052	-0.009341700002551079	A half @-@ life time of 5.8 hours has been observed .
P-1052	-0.0113 -0.0071 -0.0065 -0.0034 -0.0143 -0.0150 -0.0055 -0.0013 -0.0019 -0.0144 -0.0015 -0.0456 -0.0017 -0.0014
S-391	Jedoch folgt einer Dosisreduktion nicht unbedingt eine Verbesserung der Symptome .
T-391	However , dose reduction is not necessarily followed by improvement of symptoms .
H-391	-0.015787342563271523	However , dose reduction is not necessarily followed by improvement of symptoms .
D-391	-0.015787342563271523	However , dose reduction is not necessarily followed by improvement of symptoms .
P-391	-0.0038 -0.0031 -0.0125 -0.0036 -0.0124 -0.0016 -0.0034 -0.0025 -0.0016 -0.0120 -0.1576 -0.0039 -0.0015 -0.0014
S-387	14 AIDS @-@ assoziiertes Kaposi @-@ Sarkom :
T-387	AIDS @-@ related Kaposi <<unk>> s sarcoma :
H-387	-0.008031276054680347	AIDS @-@ related Kaposi <unk> s sarcoma :
D-387	-0.008031276054680347	AIDS @-@ related Kaposi <unk> s sarcoma :
P-387	-0.0192 -0.0005 -0.0021 -0.0134 -0.0053 -0.0000 -0.0012 -0.0309 -0.0142 -0.0186 -0.0011 -0.0017 -0.0028 -0.0014
S-1706	Den vollständigen Wortlaut des EPAR für Alimta finden Sie hier .
T-1706	The full EPAR for Alimta can be found here .
H-1706	-0.0036164585035294294	The full EPAR for Alimta can be found here .
D-1706	-0.0036164585035294294	The full EPAR for Alimta can be found here .
P-1706	-0.0080 -0.0021 -0.0115 -0.0008 -0.0057 -0.0018 -0.0013 -0.0007 -0.0093 -0.0014 -0.0026 -0.0016 -0.0024 -0.0014
S-1336	Sie dürfen ihn nicht einweichen , waschen oder mit einem Schmiermittel behandeln .
T-1336	Do not soak it , wash or lubricate it .
H-1336	-0.005308949388563633	Do not soak it , wash or lubricate it .
D-1336	-0.005308949388563633	Do not soak it , wash or lubricate it .
P-1336	-0.0119 -0.0014 -0.0038 -0.0008 -0.0126 -0.0046 -0.0006 -0.0153 -0.0138 -0.0004 -0.0017 -0.0029 -0.0029 -0.0015
S-928	VIRAMUNE 50 mg / 5 ml Suspension zum Einnehmen
T-928	VIRAMUNE 50 mg / 5 ml oral suspension
H-928	-0.003047994105145335	VIRAMUNE 50 mg / 5 ml oral suspension
D-928	-0.003047994105145335	VIRAMUNE 50 mg / 5 ml oral suspension
P-928	-0.0035 -0.0007 -0.0008 -0.0011 -0.0012 -0.0066 -0.0005 -0.0017 -0.0016 -0.0009 -0.0145 -0.0031 -0.0034
S-1359	Die Nadel muss sorgfältig und gerade am Pen befestigt werden .
T-1359	The needle should be carefully attached straight onto the pen .
H-1359	-0.0072726658545434475	The needle should be carefully attached straight onto the pen .
D-1359	-0.0072726658545434475	The needle should be carefully attached straight onto the pen .
P-1359	-0.0044 -0.0051 -0.0012 -0.0163 -0.0020 -0.0131 -0.0133 -0.0119 -0.0169 -0.0017 -0.0055 -0.0017 -0.0014
S-1440	1 Beutel enthält 500 mg ( E ) -Stiripentol .
T-1440	1 sachet contains 500 mg stiripentol .
H-1440	-0.009250263683497906	1 sachet contains 500 mg stiripentol .
D-1440	-0.009250263683497906	1 sachet contains 500 mg stiripentol .
P-1440	-0.0099 -0.0040 -0.0011 -0.0025 -0.0030 -0.0007 -0.0150 -0.0017 -0.0015 -0.0008 -0.0716 -0.0069 -0.0015
S-605	Der Inhalt von teilweise aufgebrauchten Durchstechflaschen muss vernichtet werden .
T-605	Partially used vials must be discarded .
H-605	-0.004946676082909107	Partially used vials must be discarded .
D-605	-0.004946676082909107	Partially used vials must be discarded .
P-605	-0.0145 -0.0010 -0.0032 -0.0070 -0.0051 -0.0053 -0.0024 -0.0145 -0.0001 -0.0010 -0.0037 -0.0015
S-621	und danach im Berliner Büro des Instituts , das er von 1972 bis 1976 leitete .
T-621	office , which he headed from 1972 to 1976 .
H-621	-0.006535569671541452	office , which he headed from 1972 to 1976 .
D-621	-0.006535569671541452	office , which he headed from 1972 to 1976 .
P-621	-0.0145 -0.0121 -0.0104 -0.0019 -0.0085 -0.0026 -0.0007 -0.0136 -0.0006 -0.0036 -0.0032
S-772	Faltschachtel und Etikett ( Packung mit einer Flasche ) :
T-772	Carton and label bottle pack ( 1 bottle ) :
H-772	-0.01095825806260109	Carton and label bottle pack ( 1 bottle ) :
D-772	-0.01095825806260109	Carton and label bottle pack ( 1 bottle ) :
P-772	-0.0134 -0.0014 -0.0045 -0.0021 -0.0573 -0.0139 -0.0072 -0.0123 -0.0065 -0.0081 -0.0024 -0.0023
S-850	Die übrigen 9 Fälle von YEL- AND traten bei Jugendlichen und Erwachsenen auf .
T-850	The remaining 9 cases of YEL @-@ AND developed in adolescent and adults .
H-850	-0.034813132137060165	The remaining 9 cases of YEL @-@ AND developed in adolescents and adults .
D-850	-0.034813132137060165	The remaining 9 cases of YEL @-@ AND developed in adolescents and adults .
P-850	-0.0028 -0.0050 -0.0048 -0.0098 -0.0021 -0.0029 -0.0107 -0.0072 -0.0027 -0.0145 -0.0033 -0.0058 -0.0010 -0.5473 -0.0016 -0.0020 -0.0016 -0.0014
S-831	Serumferritin &gt; 1.000 µg / l ) begonnen wird .
T-831	It is recommended that treatment be started after the transfusion of approximately 20 units ( about 100 ml / kg ) of packed red blood cells or when there is evidence from clinical monitoring that chronic iron overload is present ( e. g. serum ferritin &gt; 1,000 µg / l ) .
H-831	-0.0830860584974289	It is recommended that treatment be started after the transfusion of approximately 20 units ( about 100 ml ) of packed red blood cells or when there is evidence from clinical monitoring that chronic iron overload is present ( e. g. serum ferritin &gt; 1,000 µg / l ) .
D-831	-0.0830860584974289	It is recommended that treatment be started after the transfusion of approximately 20 units ( about 100 ml ) of packed red blood cells or when there is evidence from clinical monitoring that chronic iron overload is present ( e. g. serum ferritin &gt; 1,000 µg / l ) .
P-831	-0.0145 -0.0074 -0.0096 -0.0110 -0.0144 -0.0127 -0.0059 -0.0145 -0.0127 -0.0146 -0.0109 -0.0073 -0.0722 -0.0344 -0.0149 -0.0163 -0.0144 -0.0414 -0.0141 -3.9670 -0.0195 -0.0677 -0.0145 -0.0131 -0.0067 -0.0161 -0.0145 -0.0145 -0.0041 -0.0145 -0.0145 -0.0144 -0.0145 -0.0143 -0.0145 -0.0145 -0.0145 -0.0018 -0.0094 -0.0142 -0.0301 -0.0145 -0.0088 -0.0046 -0.0130 -0.0018 -0.0057 -0.0005 -0.0015 -0.0024 -0.0052 -0.0076 -0.0011 -0.0017 -0.0018 -0.0020 -0.0933 -0.0014
S-649	Patienten mit Genotyp 2 und 3 ) kann eine Behandlung ohne zn
T-649	6 All patients in the chronic hepatitis C studies had a liver biopsy before inclusion , but in certain cases ( i. e. patients with genotype 2 and 3 ) , treatment may be possible without histological confirmation .
H-649	-0.012291068211197853	6 All patients in the chronic hepatitis C studies had a liver biopsy before inclusion , but in certain cases ( i. e. patients with genotype 2 and 3 ) , treatment may be possible without histological confirmation .
D-649	-0.012291068211197853	6 All patients in the chronic hepatitis C studies had a liver biopsy before inclusion , but in certain cases ( i. e. patients with genotype 2 and 3 ) , treatment may be possible without histological confirmation .
P-649	-0.0146 -0.0153 -0.0036 -0.0156 -0.0140 -0.0145 -0.0144 -0.0024 -0.0076 -0.0068 -0.0145 -0.0145 -0.0129 -0.0145 -0.0145 -0.0044 -0.0001 -0.0144 -0.0145 -0.0012 -0.0143 -0.0132 -0.0149 -0.0145 -0.0109 -0.0215 -0.0141 -0.0143 -0.0090 -0.0919 -0.0142 -0.0060 -0.0034 -0.0109 -0.0008 -0.0032 -0.0067 -0.0040 -0.0020 -0.0247 -0.0120 -0.0140 -0.0076 -0.0135 -0.0052 -0.0145 -0.0144 -0.0145 -0.0087 -0.0015
S-211	{ HANDELSNAME } 80 mg darf nicht eingenommen werden ,
T-211	Take special care with { PRODUCT NAME } 80 mg The following are reasons why { PRODUCT NAME } may not be suitable for you : − If you have kidney problems
H-211	-0.16337403655052185	Take special care with { PRODUCT NAME } 80 mg The following are reasons why { PRODUCT NAME } may not be suitable :
D-211	-0.16337403655052185	Take special care with { PRODUCT NAME } 80 mg The following are reasons why { PRODUCT NAME } may not be suitable :
P-211	-0.0145 -0.0145 -0.0142 -0.0143 -0.0144 -0.0144 -0.0062 -0.0071 -0.0003 -0.0073 -0.0125 -0.0005 -0.0011 -0.0008 -0.0057 -0.0007 -0.0145 -0.0144 -0.0144 -0.0145 -0.0134 -0.0145 -0.0136 -0.0094 -0.0013 -0.0002 -0.0057 -0.0143 -0.0004 -0.0011 -0.0012 -0.0136 -0.0032 -0.0021 -0.0145 -5.2569 -0.4931
S-1227	Hypoästhesien * , Parästhesien * , Schwindel
T-1227	Nervous system disorders Common : drowsiness , headache Rare : hypoaesthesia * , paraesthesia * , dizziness
H-1227	-0.1580430418252945	Nervous system disorders Common : drowsiness Rare : hypoaesthesia * , paraesthesia * , dizziness
D-1227	-0.1580430418252945	Nervous system disorders Common : drowsiness Rare : hypoaesthesia * , paraesthesia * , dizziness
P-1227	-0.0148 -0.0061 -0.0013 -0.0144 -0.0336 -0.0007 -0.0417 -0.0041 -0.0135 -0.0176 -0.0082 -0.0007 -0.0001 -4.5987 -0.0145 -0.0138 -0.0105 -0.0106 -0.0011 -0.0047 -0.1155 -0.0164 -0.0147 -0.0046 -0.0009 -0.0011 -0.0213 -0.0594 -0.0090 -0.0003 -0.0012 -0.0023
S-1002	Während einer Langzeitanwendung ist der Calciumspiegel im Blut zu kontrollieren .
T-1002	Calcichew @-@ D3 ( and associated names ) tablets contain aspartame and should be avoided by patients with phenylketonuria .
H-1002	-0.19329901039600372	Calcium in the blood should be checked during long @-@ term treatment .
D-1002	-0.19329901039600372	Calcium in the blood should be checked during long @-@ term treatment .
P-1002	-0.0117 -0.0007 -0.4906 -1.6248 -0.8135 -0.0011 -0.0125 -0.0015 -0.0181 -0.0028 -0.0567 -0.0032 -0.0013 -0.0513 -0.0017 -0.0014
S-1352	Die Anwendung von Viani Evohaler sollte währenddessen fortgeführt werden .
T-1352	Symptomatic candidiasis can be treated with topical anti- fungal therapy whilst still continuing with the Viani Evohaler .
H-1352	-0.023892700672149658	Symptomatic candidiasis can be treated with topical anti- fungal therapy whilst still continuing with the Viani Evohaler .
D-1352	-0.023892700672149658	Symptomatic candidiasis can be treated with topical anti- fungal therapy whilst still continuing with the Viani Evohaler .
P-1352	-0.0145 -0.0141 -0.0066 -0.0145 -0.0143 -0.1999 -0.2834 -0.0020 -0.0136 -0.0085 -0.0128 -0.0088 -0.0146 -0.0004 -0.0141 -0.0146 -0.0145 -0.0010 -0.0035 -0.0125 -0.0154 -0.0134 -0.0144 -0.0136 -0.0126 -0.0115 -0.0007 -0.0021 -0.0007 -0.0008 -0.0099 -0.0014
S-717	33 Angstgefühle , Verwirrung , Konzentrationsschwierigkeiten .
T-717	r headache ; rapid heart beat ; feeling sick ; feeling very hungry ; temporary changes in vision ; drowsiness ;
H-717	-0.09654782712459564	r headache ; rapid heart beat ; feeling sick ; feeling very hungry ; temporary changes in vision ; drowsiness ;
D-717	-0.09654782712459564	r headache ; rapid heart beat ; feeling sick ; feeling very hungry ; temporary changes in vision ; drowsiness ;
P-717	-0.0147 -0.0146 -0.0010 -0.0117 -0.0710 -0.0146 -0.0145 -0.0144 -0.0085 -0.0149 -0.3564 -0.0094 -0.1411 -0.2700 -0.0144 -0.0122 -0.1374 -0.0145 -0.0101 -0.0143 -0.0417 -0.6712 -0.0058 -0.0050 -0.0001 -0.0340 -0.6893
S-316	1 Fertigspritze mit 0,7 ml 6 Fertigspritzen mit je 0,7 ml
T-316	1 pre @-@ filled syringe of 0.7 ml 6 pre @-@ filled syringes of 0.7 ml
H-316	-0.0037434911355376244	1 pre @-@ filled syringe of 0.7 ml 6 pre @-@ filled syringes of 0.7 ml
D-316	-0.0037434911355376244	1 pre @-@ filled syringe of 0.7 ml 6 pre @-@ filled syringes of 0.7 ml
P-316	-0.0012 -0.0130 -0.0014 -0.0089 -0.0005 -0.0005 -0.0002 -0.0143 -0.0079 -0.0014 -0.0010 -0.0031 -0.0021 -0.0013 -0.0048 -0.0004 -0.0016 -0.0013 -0.0054 -0.0012 -0.0014 -0.0007 -0.0125
S-221	Januvia wurde nicht bei Patienten mit schwerer Leberinsuffizienz untersucht .
T-221	Januvia has not been studied in patients with severe hepatic insufficiency .
H-221	-0.023121803998947144	Januvia has not been studied in patients with severe hepatic insufficiency .
D-221	-0.023121803998947144	Januvia has not been studied in patients with severe hepatic insufficiency .
P-221	-0.0007 -0.0100 -0.0084 -0.0016 -0.0012 -0.1951 -0.0023 -0.0016 -0.1853 -0.0019 -0.0132 -0.0010 -0.0011 -0.0108 -0.0006 -0.0006 -0.0010 -0.0016 -0.0014
S-1302	Im Laufe der Zeit nimmt die Anzahl dieser infusionsbedingten Reaktionen ab .
T-1302	Over time the number of these infusion @-@ associated reactions decreases .
H-1302	-0.0364815890789032	Over time the number of these infusion @-@ associated reactions decreases .
D-1302	-0.0364815890789032	Over time the number of these infusion @-@ associated reactions decreases .
P-1302	-0.0062 -0.0015 -0.0146 -0.0031 -0.1680 -0.0054 -0.0032 -0.0010 -0.0034 -0.3566 -0.0122 -0.0005 -0.0040 -0.0011 -0.0015 -0.0014
S-1314	Eine Behandlung öfter als alle drei Monate erbringt normalerweise keinen zusätzlichen therapeutischen Effekt .
T-1314	Normally no additional benefit is conferred by treating more frequently than every three months .
H-1314	-0.007569869514554739	Normally no additional benefit is conferred by treating more frequently than every three months .
D-1314	-0.007569869514554739	Normally no additional benefit is conferred by treating more frequently than every three months .
P-1314	-0.0145 -0.0011 -0.0144 -0.0040 -0.0147 -0.0090 -0.0145 -0.0024 -0.0049 -0.0140 -0.0126 -0.0148 -0.0018 -0.0062 -0.0032 -0.0014 -0.0016 -0.0014
S-1527	4,3 % ) ; Neutropenie ( G3 / 4 :
T-1527	4.3 % ) ; Neutropenia ( G3 / 4 :
H-1527	-0.002204829128459096	4.3 % ) ; Neutropenia ( G3 / 4 :
D-1527	-0.002204829128459096	4.3 % ) ; Neutropenia ( G3 / 4 :
P-1527	-0.0036 -0.0015 -0.0015 -0.0015 -0.0034 -0.0094 -0.0005 -0.0007 -0.0011 -0.0034 -0.0015 -0.0013 -0.0014 -0.0015 -0.0013 -0.0027 -0.0014
S-1909	Bexal Produtos Farmacêuticos S.A .
T-1909	Bexal Produtos Farmacêuticos S. A .
H-1909	-0.0022143132518976927	Bexal Produtos Farmacêuticos S. A .
D-1909	-0.0022143132518976927	Bexal Produtos Farmacêuticos S. A .
P-1909	-0.0032 -0.0006 -0.0016 -0.0053 -0.0012 -0.0007 -0.0011 -0.0012 -0.0010 -0.0002 -0.0012 -0.0011 -0.0005 -0.0145 -0.0014 -0.0016 -0.0014
S-123	Bei Fortbestehen der Symptome sollte die Behandlung mit DepoCyte abgebrochen werden .
T-123	If it persists , treatment with DepoCyte should be discontinued .
H-123	-0.01294022612273693	If it persists , treatment with DepoCyte should be discontinued .
D-123	-0.01294022612273693	If it persists , treatment with DepoCyte should be discontinued .
P-123	-0.0075 -0.0245 -0.0071 -0.0014 -0.0068 -0.0074 -0.0023 -0.0032 -0.0010 -0.0012 -0.0016 -0.0020 -0.0018 -0.1490 -0.0002 -0.0015 -0.0014
S-1140	Patienten mit ACR20 Ansprechen / ausgewertete Patienten ( % ) c
T-1140	Patients with ACR20 response / Patients evaluated ( % ) c
H-1140	-0.0028233753982931376	Patients with ACR20 response / Patients evaluated ( % ) c
D-1140	-0.0028233753982931376	Patients with ACR20 response / Patients evaluated ( % ) c
P-1140	-0.0053 -0.0011 -0.0034 -0.0020 -0.0015 -0.0014 -0.0028 -0.0019 -0.0145 -0.0012 -0.0040 -0.0013 -0.0018 -0.0016 -0.0014 -0.0014 -0.0014
S-976	Weitere Informationen sind der Packungsbeilage des anderen Arzneimittels zu entnehmen .
T-976	See the Package Leaflet provided with the other medicine for full details .
H-976	-0.007732876110821962	See the Package Leaflet provided with the other medicine for full details .
D-976	-0.007732876110821962	See the Package Leaflet provided with the other medicine for full details .
P-976	-0.0200 -0.0051 -0.0148 -0.0022 -0.0144 -0.0002 -0.0016 -0.0212 -0.0077 -0.0032 -0.0017 -0.0082 -0.0018 -0.0190 -0.0071 -0.0018 -0.0014
S-325	Legen Sie FORSTEO unmittelbar nach Gebrauch in den Kühlschrank .
T-325	Place FORSTEO in the refrigerator immediately after use .
H-325	-0.0028302210848778486	Place FORSTEO in the refrigerator immediately after use .
D-325	-0.0028302210848778486	Place FORSTEO in the refrigerator immediately after use .
P-325	-0.0083 -0.0046 -0.0008 -0.0009 -0.0012 -0.0009 -0.0048 -0.0016 -0.0096 -0.0008 -0.0007 -0.0013 -0.0043 -0.0036 -0.0015 -0.0017 -0.0014
S-1491	Es gibt keine Erfahrungen bezüglich der Anwendung von Imprida bei schwangeren Frauen .
T-1491	There is no experience on the use of Imprida in pregnant women .
H-1491	-0.010183685459196568	There is no experience on the use of Imprida in pregnant women .
D-1491	-0.010183685459196568	There is no experience on the use of Imprida in pregnant women .
P-1491	-0.0045 -0.0037 -0.0019 -0.0055 -0.1214 -0.0063 -0.0044 -0.0014 -0.0023 -0.0010 -0.0009 -0.0041 -0.0011 -0.0015 -0.0016 -0.0014
S-1803	Nach Resuspension : gleichmäßig milchig weiße Suspension .
T-1803	After re @-@ suspension , milky white suspension .
H-1803	-0.007840229198336601	After re @-@ suspension , milky white suspension .
D-1803	-0.007840229198336601	After re @-@ suspension , milky white suspension .
P-1803	-0.0047 -0.0143 -0.0017 -0.0100 -0.0174 -0.0141 -0.0006 -0.0060 -0.0042 -0.0116 -0.0017
S-562	Via San Martino 12 I @-@ 20122 Mailand Italien rz ge än
T-562	Via San Martino 12 M
H-562	-0.09267257153987885	Via San Martino 12 M
D-562	-0.09267257153987885	Via San Martino 12 M
P-562	-0.0009 -0.0013 -0.0009 -0.0004 -0.0013 -0.0012 -0.2849 -0.4505
S-1245	Bitte wenden Sie sich dann an Ihren Arzt oder Ihre Diabetesberaterin ..
T-1245	Contact your Health Care Professional .
H-1245	-0.024236155673861504	Contact your Health Care Professional .
D-1245	-0.024236155673861504	Contact your Health Care Professional .
P-1245	-0.0276 -0.0022 -0.1073 -0.0104 -0.0118 -0.0062 -0.0138 -0.0145
S-185	Sehr häufige Nebenwirkungen ( bei mehr als 1 von 10 Behandelten ) el
T-185	Side effects reported very commonly
H-185	-0.014672130346298218	Side effects reported very commonly
D-185	-0.014672130346298218	Side effects reported very commonly
P-185	-0.0152 -0.0042 -0.0145 -0.0128 -0.0150 -0.0263
S-1207	Equilis Prequenza , Injektionssuspension , für Pferde
T-1207	Equilis Prequenza , suspension for injection , for horses
H-1207	-0.003508594585582614	Equilis Prequenza , suspension for injection , for horses
D-1207	-0.003508594585582614	Equilis Prequenza , suspension for injection , for horses
P-1207	-0.0004 -0.0005 -0.0013 -0.0013 -0.0010 -0.0005 -0.0014 -0.0023 -0.0139 -0.0100 -0.0058 -0.0073 -0.0053 -0.0026 -0.0009 -0.0018
S-413	AZILECT 1mg Tabletten Rasagilin
T-413	AZILECT 1 mg tablets Rasagiline
H-413	-0.03409472852945328	AZILECT 1 mg tablets Rasagiline
D-413	-0.03409472852945328	AZILECT 1 mg tablets Rasagiline
P-413	-0.0035 -0.0018 -0.0013 -0.0009 -0.0013 -0.0010 -0.0142 -0.0009 -0.0075 -0.3929 -0.0032 -0.0010 -0.0007 -0.0795 -0.0017
S-1331	10 Durchstechflaschen + 10 Fertigspritzen mit beigelegter Nadel
T-1331	10 vials + 10 pre @-@ filled syringes with attached needle
H-1331	-0.005151453893631697	10 vials + 10 pre @-@ filled syringes with attached needle
D-1331	-0.005151453893631697	10 vials + 10 pre @-@ filled syringes with attached needle
P-1331	-0.0339 -0.0058 -0.0008 -0.0023 -0.0013 -0.0086 -0.0014 -0.0064 -0.0006 -0.0004 -0.0013 -0.0022 -0.0130 -0.0015 -0.0012 -0.0018
S-1530	1 ml enthält Ibritumomab * -Tiuxetan
T-1530	One ml contains ibritumomab * tiuxetan .
H-1530	-0.02486407198011875	One ml contains ibritumomab * tiuxetan .
D-1530	-0.02486407198011875	One ml contains ibritumomab * tiuxetan .
P-1530	-0.0168 -0.0016 -0.0017 -0.0021 -0.0014 -0.0012 -0.0009 -0.0008 -0.0017 -0.0139 -0.0015 -0.0010 -0.0009 -0.0138 -0.3373 -0.0014
S-1529	Leber und Nieren erwiesen sich als die Hauptzielorgane .
T-1529	The liver and kidney were found to be the major target organs .
H-1529	-0.028739050030708313	The liver and kidney were found to be the major target organs .
D-1529	-0.028739050030708313	The liver and kidney were found to be the major target organs .
P-1529	-0.0055 -0.0012 -0.0014 -0.0023 -0.3958 -0.0116 -0.0111 -0.0014 -0.0016 -0.0022 -0.0141 -0.0045 -0.0028 -0.0013 -0.0016 -0.0014
S-488	Die Infusion kann über eine periphere Vene verabreicht werden .
T-488	The infusion may be given through a peripheral vein .
H-488	-0.003961287438869476	The infusion may be given through a peripheral vein .
D-488	-0.003961287438869476	The infusion may be given through a peripheral vein .
P-488	-0.0051 -0.0020 -0.0005 -0.0144 -0.0043 -0.0136 -0.0104 -0.0020 -0.0006 -0.0007 -0.0013 -0.0013 -0.0004 -0.0016 -0.0014
S-775	Unbekannt : allergische Reaktionen ( einschließlich schwere allergische Reaktionen mit Schock )
T-775	Not known : allergic reactions ( sometimes severe , including shock )
H-775	-0.03266448155045509	Not known : allergic reactions ( sometimes severe , including shock )
D-775	-0.03266448155045509	Not known : allergic reactions ( sometimes severe , including shock )
P-775	-0.0145 -0.0063 -0.0015 -0.0030 -0.0005 -0.0241 -0.0006 -0.0016 -0.2098 -0.0068 -0.0144 -0.0131 -0.0057 -0.0113 -0.1768
S-1438	Alle Patienten erlitten eine ausgeprägte Myelosuppression .
T-1438	All patients experienced a profound myelosuppression .
H-1438	-0.005474864970892668	All patients experienced a profound myelosuppression .
D-1438	-0.005474864970892668	All patients experienced a profound myelosuppression .
P-1438	-0.0112 -0.0028 -0.0138 -0.0115 -0.0144 -0.0003 -0.0014 -0.0029 -0.0113 -0.0024 -0.0047 -0.0008 -0.0014 -0.0020 -0.0014
S-1975	• Schwächegefühl , Müdigkeit • unangenehmer Geschmack im Mund
T-1975	severe or life threatening skin • serious allergic reaction ( anaphy
H-1975	-0.030345086008310318	severe or life threatening skin • serious allergic reaction ( anaphy
D-1975	-0.030345086008310318	severe or life threatening skin • serious allergic reaction ( anaphy
P-1975	-0.0145 -0.0906 -0.0145 -0.0098 -0.0145 -0.0122 -0.0146 -0.1935 -0.0043 -0.0116 -0.0145 -0.0145 -0.0145 -0.0145 -0.0173
S-1456	Eine symptomatische orthostatische Hypotonie tritt selten auf .
T-1456	Symptomatic postural hypotension is infrequent .
H-1456	-0.004636465571820736	Symptomatic postural hypotension is infrequent .
D-1456	-0.004636465571820736	Symptomatic postural hypotension is infrequent .
P-1456	-0.0006 -0.0018 -0.0007 -0.0145 -0.0086 -0.0015 -0.0009 -0.0003 -0.0010 -0.0052 -0.0079 -0.0216 -0.0016 -0.0017 -0.0014
S-1086	Verwerfen Sie BYETTA , das eingefroren war .
T-1086	Throw away any BYETTA pen that has been frozen .
H-1086	-0.006257806904613972	Throw away any BYETTA pen that has been frozen .
D-1086	-0.006257806904613972	Throw away any BYETTA pen that has been frozen .
P-1086	-0.0143 -0.0009 -0.0083 -0.0143 -0.0108 -0.0011 -0.0008 -0.0005 -0.0147 -0.0058 -0.0139 -0.0028 -0.0020 -0.0021 -0.0014
S-671	Die Pharmakokinetik von Ritonavir wurde nicht beeinflusst .
T-671	The pharmacokinetics of ritonavir remained unchanged .
H-671	-0.005154883489012718	The pharmacokinetics of ritonavir remained unchanged .
D-671	-0.005154883489012718	The pharmacokinetics of ritonavir remained unchanged .
P-671	-0.0057 -0.0022 -0.0004 -0.0012 -0.0018 -0.0017 -0.0036 -0.0013 -0.0007 -0.0009 -0.0389 -0.0021 -0.0139 -0.0016 -0.0014
S-1101	ETIKETT DER PATRONE für OptiClik
T-1101	CARTRIDGE LABEL for OptiClik
H-1101	-0.020661870017647743	CARTRIDGE LABEL for OptiClik
D-1101	-0.020661870017647743	CARTRIDGE LABEL for OptiClik
P-1101	-0.0144 -0.0139 -0.0161 -0.0125 -0.0079 -0.0004 -0.0814 -0.0016 -0.0076 -0.1268 -0.0019 -0.0017 -0.0014 -0.0017
S-1870	Kumulierte 2 @-@ Jahres @-@ Daten der Studie BM 16549
T-1870	Two year cumulative data in study BM 16549
H-1870	-0.053770605474710464	Two year cumulative data in study BM 16549
D-1870	-0.053770605474710464	Two year cumulative data in study BM 16549
P-1870	-0.0144 -0.0811 -0.0022 -0.0043 -0.4352 -0.0043 -0.0143 -0.0126 -0.0021 -0.0010 -0.0012 -0.0012 -0.0009 -0.1779
S-373	Es gab keine relevante Änderung der Cmin von Tipranavir .
T-373	There was no relevant change in TPV Cmin .
H-373	-0.013070003129541874	There was no relevant change in TPV Cmin .
D-373	-0.013070003129541874	There was no relevant change in TPV Cmin .
P-373	-0.0055 -0.0782 -0.0017 -0.0049 -0.0037 -0.0054 -0.0145 -0.0141 -0.0139 -0.0144 -0.0017 -0.0104 -0.0014
S-1460	In knapp der Hälfte der betreffenden Fälle wurden mehrere Arzneimittel eingenommen .
T-1460	Nearly half of the cases involved multiple drug ingestions .
H-1460	-0.007401890587061644	Nearly half of the cases involved multiple drug ingestions .
D-1460	-0.007401890587061644	Nearly half of the cases involved multiple drug ingestions .
P-1460	-0.0123 -0.0016 -0.0038 -0.0075 -0.0029 -0.0084 -0.0087 -0.0142 -0.0124 -0.0125 -0.0089 -0.0015 -0.0014
S-1163	Verbleibende Restmengen sind nach der Verabreichung zu verwerfen .
T-1163	Any remaining contents should be discarded after use .
H-1163	-0.011320086196064949	Any remaining contents should be discarded after use .
D-1163	-0.011320086196064949	Any remaining contents should be discarded after use .
P-1163	-0.0106 -0.0085 -0.0187 -0.0019 -0.0135 -0.0017 -0.0034 -0.0003 -0.0011 -0.0158 -0.0684 -0.0019 -0.0014
S-1156	158 GEBRAUCHSINFORMATION :
T-1156	146 PACKAGE LEAFLET :
H-1156	-0.015780063346028328	146 PACKAGE LEAFLET :
D-1156	-0.015780063346028328	146 PACKAGE LEAFLET :
P-1156	-0.0145 -0.0530 -0.0144 -0.0145 -0.0022 -0.0005 -0.0399 -0.0146 -0.0144 -0.0145 -0.0135 -0.0076 -0.0014
S-1204	Quadrisol 100 mg / ml Gel zum Eingeben für Pferde
T-1204	Quadrisol 100 mg / ml oral gel for horses
H-1204	-0.0028838838916271925	Quadrisol 100 mg / ml oral gel for horses
D-1204	-0.0028838838916271925	Quadrisol 100 mg / ml oral gel for horses
P-1204	-0.0007 -0.0011 -0.0016 -0.0010 -0.0035 -0.0004 -0.0015 -0.0008 -0.0145 -0.0068 -0.0020 -0.0018 -0.0019
S-1044	Soweit erforderlich sollte mit den Patienten die weitere Familienplanung besprochen werden .
T-1044	Family planning should be discussed with patients as appropriate .
H-1044	-0.006013741251081228	Family planning should be discussed with patients as appropriate .
D-1044	-0.006013741251081228	Family planning should be discussed with patients as appropriate .
P-1044	-0.0144 -0.0005 -0.0037 -0.0036 -0.0018 -0.0037 -0.0072 -0.0133 -0.0147 -0.0017 -0.0014
S-1246	Iscover ist ein Plättchenaggregationshemmer .
T-1246	Iscover is an inhibitor of platelet aggregation .
H-1246	-0.007311326451599598	Iscover is an inhibitor of platelet aggregation .
D-1246	-0.007311326451599598	Iscover is an inhibitor of platelet aggregation .
P-1246	-0.0035 -0.0010 -0.0018 -0.0399 -0.0143 -0.0003 -0.0006 -0.0015 -0.0066 -0.0020 -0.0004 -0.0418 -0.0046 -0.0012 -0.0017 -0.0016 -0.0014
S-1120	Kopfschmerzen , Somnolenz , Reaktionen an der Injektionsstelle
T-1120	4 Common Gastro @-@ intestinal disorders : nausea , abdominal pain , pelvic pain Reproductive system and breast disorders : ovarian hyperstimulation syndrome , ovarian cyst , breast pain General disorders and administration site conditions : headache , somnolence , injection site reaction
H-1120	-0.07241733372211456	4 Common Gastro @-@ intestinal disorders : nausea , abdominal pain , pelvic pain Reproductive system and breast disorders : ovarian hyperstimulation syndrome , ovarian cyst , breast pain General disorders and administration site conditions : headache , somnolence , injection site reaction
D-1120	-0.07241733372211456	4 Common Gastro @-@ intestinal disorders : nausea , abdominal pain , pelvic pain Reproductive system and breast disorders : ovarian hyperstimulation syndrome , ovarian cyst , breast pain General disorders and administration site conditions : headache , somnolence , injection site reaction
P-1120	-0.0203 -0.0145 -0.0016 -0.0145 -0.0144 -0.0038 -0.0129 -0.0008 -0.0012 -0.0130 -0.0011 -0.0122 -0.0149 -0.0001 -0.0027 -0.0641 -0.0025 -0.0008 -0.0047 -0.6689 -0.0484 -0.0007 -0.0045 -0.8603 -0.0147 -0.0129 -0.0173 -0.0156 -0.0603 -0.0009 -0.3598 -0.0450 -0.0130 -0.0063 -0.1893 -0.0145 -0.0009 -0.0466 -0.0003 -0.5099 -0.2389 -0.0061 -0.0024 -0.0470 -0.0136 -0.0133 -0.2044 -0.0246 -0.2056 -0.0145 -0.0010 -0.4716 -0.0154 -0.0146 -0.0145 -0.3303 -0.0436 -0.0006 -0.0060 -0.0082 -0.0131 -0.0026 -0.0007 -0.0018 -0.1455 -0.0168 -0.0068 -0.0008 -0.0138 -0.1007
S-1069	Eine Fertigspritze enthält 8 ml Wasser für Injektionszwecke .
T-1069	One pre- filled syringe contains 8 ml of water for injections . − The other ingredients are L @-@ arginine , phosphoric acid and polysorbate 20 . − The METALYSE solvent is water for injections .
H-1069	-0.024771176278591156	One pre- filled syringe contains 8 ml of water for injections .
D-1069	-0.024771176278591156	One pre- filled syringe contains 8 ml of water for injections .
P-1069	-0.0093 -0.0134 -0.0145 -0.0128 -0.0010 -0.0003 -0.0002 -0.0021 -0.0017 -0.0005 -0.0202 -0.0019 -0.0035 -0.0026 -0.0141 -0.0023 -0.3208
S-1753	Dadurch wird ein verbessertes Signal @-@ zu @-@ Rausch @-@ Verhältnis erreicht .
T-1753	SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood , which results in an improved signal to noise ratio .
H-1753	-0.2774987518787384	SonoVue is for use with ultrasound imaging to enhance the signal to noise ratio .
D-1753	-0.2774987518787384	SonoVue is for use with ultrasound imaging to enhance the signal to noise ratio .
P-1753	-0.0146 -0.0141 -0.0144 -0.0145 -0.0138 -0.0145 -0.0142 -0.0094 -0.0145 -0.0007 -0.0132 -0.0141 -0.0005 -0.0144 -0.0142 -0.0010 -0.0128 -6.1485 -0.0334 -0.0011 -0.0015 -0.0017 -0.0014
S-1113	Pro Injektionsstelle dürfen nicht mehr als 50 Einheiten appliziert werden .
T-1113	CPMP / 4260 / 03 treatment , initial dosing in a naïve patient should U should be given at any one site .
H-1113	-0.012864080257713795	CPMP / 4260 / 03 treatment , initial dosing in a naïve patient should U should be given at any one site .
D-1113	-0.012864080257713795	CPMP / 4260 / 03 treatment , initial dosing in a naïve patient should U should be given at any one site .
P-1113	-0.0145 -0.0144 -0.0144 -0.0144 -0.0145 -0.0145 -0.0133 -0.0146 -0.0146 -0.0143 -0.0145 -0.0143 -0.0121 -0.0144 -0.0140 -0.0145 -0.0130 -0.0014 -0.0143 -0.0143 -0.0145 -0.0145 -0.0125 -0.0144 -0.0137 -0.0143 -0.0143 -0.0142 -0.0018 -0.0014
S-1624	Aclasta ( N = 1.065 ) Placebo Absolute
T-1624	Aclasta Placebo Absolute reduction ( N = 1,065 ) ( N = 1,062 ) in fracture event
H-1624	-0.07724684476852417	Aclasta Placebo Absolute reduction ( N = 1,065 ) ( N = 1,062 ) in fracture event
D-1624	-0.07724684476852417	Aclasta Placebo Absolute reduction ( N = 1,065 ) ( N = 1,062 ) in fracture event
P-1624	-0.0047 -0.0005 -0.0007 -0.3934 -0.0013 -0.0007 -0.0012 -0.0027 -0.0007 -0.0145 -0.0063 -0.0013 -0.0015 -0.0102 -0.0059 -0.0341 -0.0015 -0.6457 -0.0143 -0.0089 -0.0095 -0.2438 -0.0710 -0.0017 -0.7172 -0.0145 -0.0122 -0.0145 -0.0052
S-1520	Europäischen Agentur für die Beurteilung von Arzneimitteln ( &quot; die Agentur &quot; )
T-1520	Between National competent authority and The European Agency for the Evaluation of Medicinal Products ( <<unk>> the Agency <<unk>> )
H-1520	-0.010704387910664082	Between National competent authority and The European Agency for the Evaluation of Medicinal Products ( <unk> the Agency <unk> )
D-1520	-0.010704387910664082	Between National competent authority and The European Agency for the Evaluation of Medicinal Products ( <unk> the Agency <unk> )
P-1520	-0.0145 -0.0145 -0.0145 -0.0141 -0.0143 -0.0072 -0.0145 -0.0042 -0.0033 -0.0015 -0.0018 -0.0013 -0.0011 -0.0014 -0.0003 -0.0008 -0.0004 -0.0011 -0.0048 -0.0145 -0.0109 -0.0018 -0.0223 -0.0021 -0.1004
S-1012	Es wurden keine Studien zu Nieren- und Leberfunktionsstörungen durchgeführt .
T-1012	Studies have not been conducted to examine the effects of renal or hepatic impairment .
H-1012	-0.03304661810398102	Studies have not been conducted to examine the effects of renal or hepatic impairment .
D-1012	-0.03304661810398102	Studies have not been conducted to examine the effects of renal or hepatic impairment .
P-1012	-0.0457 -0.0176 -0.0018 -0.0020 -0.4480 -0.0162 -0.0138 -0.0139 -0.0127 -0.0031 -0.0137 -0.0011 -0.0140 -0.0898 -0.0027 -0.0012 -0.0148 -0.0044 -0.0003 -0.0066 -0.0022 -0.0014
S-815	Solche Effekte können im Zusammenwirken mit Alkohol verstärkt in Erscheinung treten .
T-815	This effect may be enhanced if &lt; Invented name &gt; is administered in association with alcohol .
H-815	-0.009380577132105827	This effect may be enhanced if &lt; Invented name &gt; is administered in association with alcohol .
D-815	-0.009380577132105827	This effect may be enhanced if &lt; Invented name &gt; is administered in association with alcohol .
P-815	-0.0142 -0.0118 -0.0117 -0.0119 -0.0136 -0.0155 -0.0145 -0.0006 -0.0010 -0.0145 -0.0136 -0.0145 -0.0142 -0.0069 -0.0145 -0.0014 -0.0123 -0.0140 -0.0015 -0.0012 -0.0017 -0.0014
S-1594	für Kinder &lt; 8 Jahren ( Dosierung 7 mg / kg )
T-1594	patients &lt; 8 yrs of age on a body weight basis receiving 7 mg / kg .
H-1594	-0.014305410906672478	patients &lt; 8 yrs of age on a body weight basis receiving 7 mg / kg .
D-1594	-0.014305410906672478	patients &lt; 8 yrs of age on a body weight basis receiving 7 mg / kg .
P-1594	-0.0145 -0.0035 -0.0003 -0.0011 -0.0024 -0.1405 -0.0014 -0.0152 -0.0010 -0.0265 -0.0113 -0.0145 -0.0110 -0.0142 -0.0167 -0.0074 -0.0008 -0.0020 -0.0009 -0.0136 -0.0015
S-1141	- Wie andere Arzneimittel dieser Klasse kann auch Neupro Spielzwang und erhöhten
T-1141	- As with other medicines in this class , Neupro may cause excessive gambling and increased sex
H-1141	-0.008521344512701035	- As with other medicines in this class , Neupro may cause excessive gambling and increased sex
D-1141	-0.008521344512701035	- As with other medicines in this class , Neupro may cause excessive gambling and increased sex
P-1141	-0.0037 -0.0120 -0.0126 -0.0085 -0.0096 -0.0042 -0.0056 -0.0018 -0.0018 -0.0042 -0.0065 -0.0023 -0.0117 -0.0143 -0.0145 -0.0142 -0.0105 -0.0067 -0.0145 -0.0114
S-1949	MHK Cefovecin ( µg / ml ) Anzahl
T-1949	Cefovecin MIC ( µg / ml ) No. of
H-1949	-0.004498543683439493	Cefovecin MIC ( µg / ml ) No. of
D-1949	-0.004498543683439493	Cefovecin MIC ( µg / ml ) No. of
P-1949	-0.0132 -0.0017 -0.0010 -0.0013 -0.0010 -0.0014 -0.0126 -0.0145 -0.0019 -0.0016 -0.0010 -0.0015 -0.0010 -0.0015 -0.0142 -0.0020 -0.0032 -0.0064
S-1286	Blister für Velmetia 50 mg / 1000 mg Filmtabletten
T-1286	Blister for Velmetia 50 mg / 1,000 mg film @-@ coated tablets
H-1286	-0.037714242935180664	Blister for Velmetia 50 mg / 1,000 mg film @-@ coated tablets
D-1286	-0.037714242935180664	Blister for Velmetia 50 mg / 1,000 mg film @-@ coated tablets
P-1286	-0.0025 -0.1355 -0.0026 -0.0019 -0.0029 -0.0003 -0.0055 -0.0006 -0.0015 -0.0225 -0.0009 -0.1903 -0.2036 -0.0145 -0.0010 -0.0888 -0.0023 -0.0016
S-1947	Jede Rebetol Kapsel enthält 200 mg Ribavirin .
T-1947	Each Rebetol capsule contains 200 mg of ribavirin .
H-1947	-0.0333331860601902	Each Rebetol capsule contains 200 mg of ribavirin .
D-1947	-0.0333331860601902	Each Rebetol capsule contains 200 mg of ribavirin .
P-1947	-0.0024 -0.0034 -0.0021 -0.0011 -0.0010 -0.0022 -0.0007 -0.0011 -0.0021 -0.0022 -0.0010 -0.0107 -0.0035 -0.0007 -0.0004 -0.0026 -0.2419 -0.3208
S-1280	Verwenden Sie nur Nadeln , die für SoloStar geeignet sind .
T-1280	Only use needles that are compatible for use with SoloStar .
H-1280	-0.035264622420072556	Only use needles that are compatible for use with SoloStar .
D-1280	-0.035264622420072556	Only use needles that are compatible for use with SoloStar .
P-1280	-0.0086 -0.0017 -0.0019 -0.0014 -0.0073 -0.0021 -0.0143 -0.0006 -0.0011 -0.2698 -0.1231 -0.0068 -0.1549 -0.0007 -0.0007 -0.0033 -0.0015
S-518	Pulver / ml und Lösungsmittel zur Herstellung einer Injektionslösung
T-518	Viraferon 1 million IU / ml powder and solvent for solution for injection
H-518	-0.44197988510131836	Viraferon / ml powder and solvent for solution for injection
D-518	-0.44197988510131836	Viraferon / ml powder and solvent for solution for injection
P-518	-0.0145 -0.0147 -0.0145 -0.0145 -6.6579 -0.0048 -0.2874 -0.0169 -0.0013 -0.0031 -0.0058 -0.0145 -0.0141 -0.0034 -0.0015 -0.0028
S-287	unter Chemotherapie , Strahlentherapie oder Immunsuppression stehen .
T-287	are receiving chemotherapy , radiation treatment or immunosuppression ;
H-287	-0.04438571631908417	are receiving chemotherapy , radiation treatment or immunosuppression ;
D-287	-0.04438571631908417	are receiving chemotherapy , radiation treatment or immunosuppression ;
P-287	-0.0124 -0.0143 -0.0016 -0.0005 -0.1641 -0.0015 -0.0775 -0.0136 -0.3695 -0.0014 -0.0008 -0.0008 -0.0005 -0.0010 -0.0020 -0.0185 -0.0747
S-611	128 Hersteller Novartis Farmacéutica , S.A .
T-611	Manufacturer Novartis Farmacéutica , S. A .
H-611	-0.03765343129634857	Manufacturer Novartis Farmacéutica , S. A .
D-611	-0.03765343129634857	Manufacturer Novartis Farmacéutica , S. A .
P-611	-0.0144 -0.0007 -0.5898 -0.0030 -0.0027 -0.0004 -0.0012 -0.0019 -0.0020 -0.0011 -0.0011 -0.0002 -0.0024 -0.0145 -0.0016 -0.0016 -0.0014
S-974	Instituto Luso @-@ Fármaco , Lda .
T-974	Instituto Luso @-@ Fármaco , Lda .
H-974	-0.00278891040943563	Instituto Luso @-@ Fármaco , Lda .
D-974	-0.00278891040943563	Instituto Luso @-@ Fármaco , Lda .
P-974	-0.0115 -0.0014 -0.0041 -0.0014 -0.0015 -0.0021 -0.0042 -0.0015 -0.0082 -0.0012 -0.0004 -0.0016 -0.0017 -0.0008 -0.0015 -0.0015
S-1374	SmithKline Beecham Phramaceuticals UK
T-1374	7 Replaced John PSOMAS as of the 20 December 2000 meeting .
H-1374	-0.013636618852615356	7 Replaced John PSOMAS as of the 20 December 2000 meeting .
D-1374	-0.013636618852615356	7 Replaced John PSOMAS as of the 20 December 2000 meeting .
P-1374	-0.0155 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0144 -0.0145 -0.0145 -0.0145 -0.0144 -0.0145 -0.0133 -0.0144 -0.0145 -0.0134 -0.0015
S-1991	Juli 2007 EMEA / CHMP / 247760 / 2007
T-1991	London , 30 July 2007 EMEA / CHMP / 247760 / 2007
H-1991	-0.004587125964462757	London , 30 July 2007 EMEA / CHMP / 247760 / 2007
D-1991	-0.004587125964462757	London , 30 July 2007 EMEA / CHMP / 247760 / 2007
P-1991	-0.0146 -0.0132 -0.0145 -0.0120 -0.0028 -0.0031 -0.0006 -0.0012 -0.0017 -0.0016 -0.0005 -0.0019 -0.0050 -0.0013 -0.0030 -0.0016 -0.0026 -0.0015
S-607	Das Änderungsverfahren im Rahmen der gegenseitigen Anerkennung wurde am 7 .
T-607	This Mutual Recognition variation procedure was started on 7 December 2006 .
H-607	-0.016652686521410942	This Mutual Recognition variation procedure was started on 7 December 2006 .
D-607	-0.016652686521410942	This Mutual Recognition variation procedure was started on 7 December 2006 .
P-607	-0.0164 -0.0140 -0.0010 -0.0011 -0.0004 -0.0004 -0.0011 -0.0145 -0.0067 -0.0087 -0.0023 -0.0145 -0.0025 -0.0054 -0.0656 -0.1411 -0.0026 -0.0014
S-1672	Wie Infanrix hexa aussieht und Inhalt der Packung
T-1672	37 What Infanrix hexa looks like and contents of the pack
H-1672	-0.00390440016053617	37 What Infanrix hexa looks like and contents of the pack
D-1672	-0.00390440016053617	37 What Infanrix hexa looks like and contents of the pack
P-1672	-0.0152 -0.0140 -0.0041 -0.0003 -0.0010 -0.0013 -0.0024 -0.0014 -0.0013 -0.0014 -0.0013 -0.0019 -0.0075 -0.0010 -0.0017 -0.0057 -0.0071 -0.0016
S-155	Die Wirkungsdauer von Nifedipin kann sich verkürzen .
T-155	The duration of action of nifedipine can be shortened .
H-155	-0.003906849771738052	The duration of action of nifedipine can be shortened .
D-155	-0.003906849771738052	The duration of action of nifedipine can be shortened .
P-155	-0.0038 -0.0038 -0.0014 -0.0014 -0.0110 -0.0021 -0.0122 -0.0007 -0.0008 -0.0022 -0.0012 -0.0155 -0.0051 -0.0042 -0.0006 -0.0013 -0.0016 -0.0014
S-1813	- Weitere Impfungen sollten entsprechend den offiziellen Empfehlungen verabreicht werden .
T-1813	- Subsequent doses of vaccine should be given according to the locally recommended vaccination
H-1813	-0.02833804115653038	- Subsequent doses of vaccine should be given according to the locally recommended vaccination
D-1813	-0.02833804115653038	- Subsequent doses of vaccine should be given according to the locally recommended vaccination
P-1813	-0.0035 -0.0145 -0.0006 -0.0149 -0.0005 -0.0187 -0.0448 -0.0069 -0.0022 -0.0102 -0.0455 -0.0015 -0.2202 -0.0151 -0.0124 -0.0079 -0.0141 -0.0908 -0.0143
S-1184	Ihr Kind wird drei Dosen im Abstand von mindestens 4 Wochen erhalten .
T-1184	21 Your child will receive 3 doses of RotaTeq given at least four weeks apart .
H-1184	-0.008708396926522255	21 Your child will receive 3 doses of RotaTeq given at least four weeks apart .
D-1184	-0.008708396926522255	21 Your child will receive 3 doses of RotaTeq given at least four weeks apart .
P-1184	-0.0219 -0.0140 -0.0041 -0.0033 -0.0057 -0.0141 -0.0012 -0.0008 -0.0143 -0.0145 -0.0140 -0.0141 -0.0145 -0.0145 -0.0064 -0.0043 -0.0142 -0.0011 -0.0023 -0.0022 -0.0014
S-927	Dinatrium @-@ hydrogenphosphate Polysorbat 80f
T-927	Potassium chloride Potassium dihydrogen phosphatec Sodium chlorided
H-927	-0.03136897832155228	Potassium chloride Potassium dihydrogen phosphatec Sodium chlorided
D-927	-0.03136897832155228	Potassium chloride Potassium dihydrogen phosphatec Sodium chlorided
P-927	-0.0145 -0.0010 -0.0015 -0.0145 -0.0024 -0.0002 -0.2294 -0.0152 -0.0020 -0.0011 -0.0157 -0.0140 -0.0065 -0.0039 -0.0009 -0.0001 -0.2607 -0.0147 -0.0003 -0.0137 -0.0006 -0.0003 -0.1260 -0.0137
S-140	Die Relevanz für die klinische Anwendung wird als gering bewertet .
T-140	Effects in non @-@ clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure , indicating little relevance to clinical use .
H-140	-0.372823566198349	Effects in non @-@ clinical studies were observed only at exposures considered sufficiently in excess .
D-140	-0.372823566198349	Effects in non @-@ clinical studies were observed only at exposures considered sufficiently in excess .
P-140	-0.0146 -0.0102 -0.0141 -0.0148 -0.0020 -0.0032 -0.0144 -0.0140 -0.0145 -0.0146 -0.0141 -0.0145 -0.0104 -0.0009 -0.0145 -0.0145 -0.0025 -0.0014 -0.0145 -0.0144 -7.9827 -0.0014
S-1986	Als neuer Termin wurde zunächst der Beginn des Jahres 2002 ins Auge gefasst .
T-1986	The rise is due to a combination of an increasing number of centrally authorised medicines and the number of variations , extensions and renewals for these authorisations .
H-1986	-0.012272566556930542	The rise is due to a combination of an increasing number of centrally authorised medicines and the number of variations , extensions and renewals for these authorisations .
D-1986	-0.012272566556930542	The rise is due to a combination of an increasing number of centrally authorised medicines and the number of variations , extensions and renewals for these authorisations .
P-1986	-0.0079 -0.0145 -0.0144 -0.0139 -0.0043 -0.0144 -0.0145 -0.0016 -0.0143 -0.0144 -0.0114 -0.0017 -0.0145 -0.0126 -0.0496 -0.0145 -0.0013 -0.0145 -0.0203 -0.0101 -0.0141 -0.0144 -0.0014 -0.0145 -0.0185 -0.0156 -0.0145 -0.0145 -0.0042 -0.0145 -0.0047 -0.0177 -0.0144 -0.0145 -0.0107 -0.0010 -0.0110 -0.0014
S-1945	Ranitidin oder Cimetidin ) verringert sein .
T-1945	Serum levels of amprenavir can be reduced by concomitant use of histamine H2 receptor antagonists ( for example ranitidine and cimetidine ) .
H-1945	-0.272671639919281	Serum levels of amprenavir can be reduced by concomitant use of histamine H2 receptor .
D-1945	-0.272671639919281	Serum levels of amprenavir can be reduced by concomitant use of histamine H2 receptor .
P-1945	-0.0145 -0.0109 -0.0138 -0.0121 -0.0145 -0.0145 -0.0145 -0.0130 -0.0141 -0.0044 -0.0069 -0.0106 -0.0145 -0.0142 -0.0070 -0.0032 -0.0144 -0.0035 -0.0145 -0.0075 -0.0175 -0.0143 -0.0164 -0.0003 -0.0076 -7.0822 -0.0014
S-993	Tenofovirdiphosphat phosphoryliert .
T-993	10 Emtricitabine and tenofovir are phosphorylated by cellular enzymes to form emtricitabine triphosphate and tenofovir diphosphate , respectively .
H-993	-0.0861433818936348	10 Emtricitabine and tenofovir are phosphorylated by cellular enzymes .
D-993	-0.0861433818936348	10 Emtricitabine and tenofovir are phosphorylated by cellular enzymes .
P-993	-0.0283 -0.0145 -0.0145 -0.0146 -0.0144 -0.0097 -0.0143 -0.0133 -0.0013 -0.0012 -0.0019 -0.0015 -0.0144 -0.0141 -0.0017 -0.0016 -0.0010 -0.0020 -0.0307 -0.0145 -0.0072 -0.0145 -0.0045 -0.0014 -2.0012 -0.0014
S-996	Entacapon verstärkt die Wirkung von Levodopa .
T-996	Entacapone enhances the effects of levodopa .
H-996	-0.014887958765029907	Entacapone enhances the effects of levodopa .
D-996	-0.014887958765029907	Entacapone enhances the effects of levodopa .
P-996	-0.0008 -0.0011 -0.0007 -0.2058 -0.0115 -0.0007 -0.0013 -0.0026 -0.0111 -0.0015 -0.0080 -0.0010 -0.0014 -0.0011 -0.0014 -0.0017 -0.0014
S-1027	Erkrankungen des Gastrointestinaltrakts Sehr selten ( &lt; 1 / 10.000 )
T-1027	Gastrointestinal disorders Very rare ( &lt; 1 / 10,000 )
H-1027	-0.0025513372384011745	Gastrointestinal disorders Very rare ( &lt; 1 / 10,000 )
D-1027	-0.0025513372384011745	Gastrointestinal disorders Very rare ( &lt; 1 / 10,000 )
P-1027	-0.0058 -0.0006 -0.0003 -0.0006 -0.0007 -0.0137 -0.0011 -0.0021 -0.0026 -0.0015 -0.0067 -0.0004 -0.0013 -0.0019 -0.0018 -0.0019 -0.0014 -0.0014
S-1598	- Vor der Anwendung von REGRANEX sind die Hände sorgfältig zu waschen .
T-1598	- Hands should be washed thoroughly before applying REGRANEX .
H-1598	-0.00972847267985344	- Hands should be washed thoroughly before applying REGRANEX .
D-1598	-0.00972847267985344	- Hands should be washed thoroughly before applying REGRANEX .
P-1598	-0.0028 -0.0145 -0.0005 -0.0105 -0.0016 -0.0061 -0.0007 -0.0103 -0.0005 -0.0006 -0.1151 -0.0107 -0.0026 -0.0008 -0.0011 -0.0014 -0.0011 -0.0027 -0.0015
S-1884	Welchen Nutzen hat M @-@ M @-@ RVAXPRO in den Studien gezeigt ?
T-1884	What benefit has M @-@ M @-@ RVAXPRO shown during the studies ?
H-1884	-0.01835131086409092	What benefit has M @-@ M @-@ RVAXPRO shown during the studies ?
D-1884	-0.01835131086409092	What benefit has M @-@ M @-@ RVAXPRO shown during the studies ?
P-1884	-0.0030 -0.0120 -0.0100 -0.0026 -0.2718 -0.0011 -0.0015 -0.0016 -0.0014 -0.0013 -0.0010 -0.0006 -0.0013 -0.0059 -0.0183 -0.0065 -0.0061 -0.0014 -0.0014
S-650	- Acetylsalicylsäure oder andere entzündungshemmende Arzneimittel
T-650	- Acetylsalcylic acid or other anti @-@ inflammatory medicines
H-650	-0.07102464884519577	- Acetylsalicylic acid or other anti @-@ inflammatory medicines
D-650	-0.07102464884519577	- Acetylsalicylic acid or other anti @-@ inflammatory medicines
P-650	-0.0019 -0.0035 -0.0007 -0.0969 -0.0007 -0.8149 -0.0027 -0.0009 -0.0011 -0.1207 -0.0017 -0.0028 -0.0014 -0.0006 -0.0007 -0.0006 -0.0017 -0.0055 -0.1829 -0.1787
S-263	24 Ketoconazol ( CYP3A4 @-@ Inhibitor ) :
T-263	Ketoconazole ( CYP3A4 inhibitor ) :
H-263	-0.02086923085153103	Ketoconazole ( CYP3A4 inhibitor ) :
D-263	-0.02086923085153103	Ketoconazole ( CYP3A4 inhibitor ) :
P-263	-0.0166 -0.0012 -0.0014 -0.0004 -0.0004 -0.0015 -0.0022 -0.0012 -0.3218 -0.0012 -0.0006 -0.0191 -0.0010 -0.0007 -0.0014 -0.0014 -0.0021 -0.0014
S-1188	Nierentransplantation Es gibt keine Erfahrungen bei Patienten mit kürzlich erfolgter Nierentranplantation .
T-1188	Renal transplantation There is no experience in patients with recent kidney transplantation .
H-1188	-0.004786568693816662	Renal transplantation There is no experience in patients with recent kidney transplantation .
D-1188	-0.004786568693816662	Renal transplantation There is no experience in patients with recent kidney transplantation .
P-1188	-0.0140 -0.0010 -0.0047 -0.0079 -0.0042 -0.0040 -0.0016 -0.0060 -0.0128 -0.0030 -0.0041 -0.0073 -0.0036 -0.0005 -0.0008 -0.0069 -0.0023 -0.0014
S-1918	- we nn bei Ihnen schwere Beeinträchtigungen des Nervensystems oder Geistesstörungen aufgetreten
T-1918	- if you are pregnant or planning to become pregnant ( see Pregnancy ) .
H-1918	-0.010813473723828793	- if you are pregnant or planning to become pregnant ( see Pregnancy ) .
D-1918	-0.010813473723828793	- if you are pregnant or planning to become pregnant ( see Pregnancy ) .
P-1918	-0.0037 -0.0143 -0.0050 -0.0140 -0.0145 -0.0126 -0.0145 -0.0076 -0.0139 -0.0059 -0.0146 -0.0144 -0.0145 -0.0091 -0.0071 -0.0135 -0.0139 -0.0017
S-1119	Die Sicherheit von VASOVIST bei Personen unter 18 Jahren wurde noch nicht geprüft .
T-1119	The safety of Vasovist in persons under 18 has not yet been tested .
H-1119	-0.059082597494125366	The safety of VASOVIST in persons under 18 has not yet been tested .
D-1119	-0.059082597494125366	The safety of VASOVIST in persons under 18 has not yet been tested .
P-1119	-0.0069 -0.0014 -0.0021 -0.0017 -0.5925 -0.0013 -0.0013 -0.0011 -0.0009 -0.0123 -0.0078 -0.0529 -0.0970 -0.0142 -0.0021 -0.3683 -0.0013 -0.0134 -0.0017 -0.0014
S-345	Jede überzogene Tablette enthält 161.3 mg Lactose @-@ Monohydrat
T-345	Each coated tablet contains 161.3 mg lactose monohydrate
H-345	-0.06345289200544357	Each coated tablet contains 161.3 mg lactose monohydrate
D-345	-0.06345289200544357	Each coated tablet contains 161.3 mg lactose monohydrate
P-345	-0.0016 -0.0114 -0.0006 -0.0225 -0.0011 -0.3425 -0.0011 -0.0013 -0.0007 -0.2445 -0.0005 -0.0006 -0.0013 -0.0008 -0.0014 -0.0010 -0.0013 -0.5081
S-1951	Eine sichere Anwendung von CELSENTRI während der Schwangerschaft wurde bisher nicht nachgewiesen .
T-1951	The safe use of CELSENTRI in pregnancy has not been established .
H-1951	-0.01253605168312788	The safe use of CELSENTRI in pregnancy has not been established .
D-1951	-0.01253605168312788	The safe use of CELSENTRI in pregnancy has not been established .
P-1951	-0.0139 -0.0031 -0.0043 -0.0014 -0.0030 -0.0009 -0.0013 -0.0011 -0.0015 -0.0015 -0.0420 -0.0016 -0.0036 -0.0979 -0.0221 -0.0141 -0.0110 -0.0014
S-902	Die empfohlene Dosierung beträgt 0,5 ml / kg Körpergewicht für Erwachsene und ältere Personen .
T-902	0.5 ml / kg body weight is the recommended dosage for adults and elderly .
H-902	-0.009009293280541897	0.5 ml / kg body weight is the recommended dosage for adults and elderly .
D-902	-0.009009293280541897	0.5 ml / kg body weight is the recommended dosage for adults and elderly .
P-902	-0.0783 -0.0015 -0.0030 -0.0012 -0.0097 -0.0011 -0.0071 -0.0119 -0.0011 -0.0155 -0.0007 -0.0011 -0.0020 -0.0036 -0.0017 -0.0094 -0.0117 -0.0014
S-1087	Andere häufige Nebenwirkungen Von diesen Nebenwirkungen sind wahrscheinlich mehr als 1 von 100 Patienten betroffen :
T-1087	Other common side effects These are likely to affect more than 1 in every 100 people :
H-1087	-0.019023826345801353	Other common side effects These are likely to affect more than 1 in every 100 people :
D-1087	-0.019023826345801353	Other common side effects These are likely to affect more than 1 in every 100 people :
P-1087	-0.0020 -0.0047 -0.0301 -0.0020 -0.0094 -0.0159 -0.0076 -0.0015 -0.0026 -0.0029 -0.0014 -0.0024 -0.0042 -0.1582 -0.0775 -0.0145 -0.0041 -0.0015
S-276	Synkopen sind nach Impfung mit Silgard aufgetreten ( siehe Abschnitt 4.8 ) .
T-276	Syncope , sometimes associated with falling , has occurred after vaccination with Silgard ( See section 4.8 ) .
H-276	-0.02992510423064232	Syncope , sometimes associated with falling , has occurred after vaccination with Silgard ( see section 4.8 ) .
D-276	-0.02992510423064232	Syncope , sometimes associated with falling , has occurred after vaccination with Silgard ( see section 4.8 ) .
P-276	-0.0010 -0.0134 -0.0145 -0.0145 -0.0145 -0.0019 -0.0146 -0.0143 -0.0137 -0.0100 -0.0143 -0.0069 -0.0011 -0.0042 -0.0013 -0.0003 -0.0026 -0.5612 -0.0063 -0.0012 -0.0015 -0.0019 -0.0016 -0.0014
S-1586	Zur Beurteilung eines neuen Antrags benötigt der CHMP in der Regel bis zu 210 Tage .
T-1586	The CHMP normally takes up to 210 days to evaluate a new application .
H-1586	-0.0035878203343600035	The CHMP normally takes up to 210 days to evaluate a new application .
D-1586	-0.0035878203343600035	The CHMP normally takes up to 210 days to evaluate a new application .
P-1586	-0.0111 -0.0006 -0.0005 -0.0120 -0.0032 -0.0041 -0.0014 -0.0005 -0.0013 -0.0017 -0.0112 -0.0011 -0.0028 -0.0018 -0.0046 -0.0016 -0.0014
S-992	Die Behandlung mit Zarzio sollte bis zur letztmaligen Gewinnung von Stammzellen fortgesetzt werden .
T-992	Treatment with Zarzio should be maintained until the last stem cell collection .
H-992	-0.013314646668732166	Treatment with Zarzio should be maintained until the last stem cell collection .
D-992	-0.013314646668732166	Treatment with Zarzio should be maintained until the last stem cell collection .
P-992	-0.0073 -0.0008 -0.0012 -0.0026 -0.0017 -0.0005 -0.0036 -0.1110 -0.0304 -0.0222 -0.0045 -0.0056 -0.0122 -0.0039 -0.0138 -0.0037 -0.0014
S-160	In allen Tabellen sind die generischen und nicht die produktspezifischen Daten anzuführen .
T-160	- All tables will be based on generic and not product @-@ specific data .
H-160	-0.006513046100735664	- All tables will be based on generic and not product @-@ specific data .
D-160	-0.006513046100735664	- All tables will be based on generic and not product @-@ specific data .
P-160	-0.0149 -0.0098 -0.0033 -0.0144 -0.0135 -0.0141 -0.0016 -0.0044 -0.0006 -0.0116 -0.0018 -0.0038 -0.0081 -0.0018 -0.0031 -0.0027 -0.0014
S-264	Bei Patienten mit schweren Leberproblemen wird die Anwendung von Zonegran nicht empfohlen .
T-264	It is not recommended for use in patients who have severe problems with their liver .
H-264	-0.06068352982401848	It is not recommended for use in patients who have severe problems with their liver .
D-264	-0.06068352982401848	It is not recommended for use in patients who have severe problems with their liver .
P-264	-0.0141 -0.0017 -0.0016 -0.0014 -0.0125 -0.1045 -0.0071 -0.0402 -0.7916 -0.0048 -0.0073 -0.0266 -0.0025 -0.0108 -0.0020 -0.0017 -0.0014
S-1068	Es wird empfohlen , bei der Handhabung der Köder Gummihandschuhe zu tragen .
T-1068	It is recommended to wear rubber gloves when handling the bait .
H-1068	-0.003666136646643281	It is recommended to wear rubber gloves when handling the bait .
D-1068	-0.003666136646643281	It is recommended to wear rubber gloves when handling the bait .
P-1068	-0.0059 -0.0016 -0.0032 -0.0095 -0.0021 -0.0022 -0.0005 -0.0011 -0.0068 -0.0020 -0.0069 -0.0035 -0.0064 -0.0018 -0.0015
S-710	Öffnen Sie die Flasche durch Niederdrücken und Drehen des kindergesicherten Verschlusses .
T-710	Push down and turn child resistant closure to open bottle .
H-710	-0.013914757408201694	Push down and turn child resistant closure to open bottle .
D-710	-0.013914757408201694	Push down and turn child resistant closure to open bottle .
P-710	-0.0144 -0.0043 -0.0083 -0.0028 -0.0066 -0.0146 -0.1070 -0.0008 -0.0141 -0.0043 -0.0020 -0.0111 -0.0028 -0.0016
S-573	Timolol ist ein Betablocker , der die Kammerwasserbildung im Auge verringert .
T-573	The two ingredients work together to reduce pressure within the eye .
H-573	-0.010746708139777184	The two ingredients work together to reduce pressure within the eye .
D-573	-0.010746708139777184	The two ingredients work together to reduce pressure within the eye .
P-573	-0.0145 -0.0145 -0.0144 -0.0145 -0.0066 -0.0084 -0.0124 -0.0145 -0.0144 -0.0020 -0.0048 -0.0081 -0.0107
S-848	WIE IST SIKLOS AUFZUBEWAHREN ?
T-848	HOW TO STORE SIKLOS
H-848	-0.0225335955619812	HOW TO STORE SIKLOS
D-848	-0.0225335955619812	HOW TO STORE SIKLOS
P-848	-0.0021 -0.0005 -0.0124 -0.0141 -0.0141 -0.0123 -0.0048 -0.0016 -0.0131 -0.1504
S-344	WIE IST ABSEAMED AUFZUBEWAHREN ?
T-344	HOW TO STORE ABSEAMED
H-344	-0.029167748987674713	HOW TO STORE ABSEAMED
D-344	-0.029167748987674713	HOW TO STORE ABSEAMED
P-344	-0.0014 -0.0006 -0.0112 -0.0142 -0.0137 -0.0065 -0.0014 -0.0011 -0.0003 -0.2412
S-1145	Abgeschlossene wissenschaftliche Beratung und Unterstützung bei der Erstellung von Prüfplänen ( Output )
T-1145	of supplementary expertise
H-1145	-0.011117188259959221	of supplementary expertise
D-1145	-0.011117188259959221	of supplementary expertise
P-1145	-0.0145 -0.0145 -0.0063 -0.0022 -0.0145 -0.0148
S-803	Bei Patienten mit leichter Nierenfunktionsstörung ist keine Dosisanpassung erforderlich .
T-803	No dose adjustment is required in patients with mild renal impairment .
H-803	-0.057523734867572784	No dose adjustment is necessary in patients with mild renal impairment .
D-803	-0.057523734867572784	No dose adjustment is necessary in patients with mild renal impairment .
P-803	-0.0122 -0.0044 -0.0027 -0.0008 -0.0018 -0.0233 -0.8506 -0.0070 -0.0012 -0.0017 -0.0054 -0.0060 -0.0009 -0.1660 -0.0042 -0.0005 -0.0013 -0.0016 -0.0014
S-433	Bei Patienten mit möglicher Hyperglykämie ist Nifedipin mit Vorsicht einzusetzen .
T-433	In patients with possible hyperglycaemia , nifedipine should be given with caution .
H-433	-0.015864545479416847	In patients with possible hyperglycaemia , nifedipine should be given with caution .
D-433	-0.015864545479416847	In patients with possible hyperglycaemia , nifedipine should be given with caution .
P-433	-0.0081 -0.0088 -0.2575 -0.0064 -0.0011 -0.0011 -0.0006 -0.0115 -0.0018 -0.0012 -0.0058 -0.0037 -0.0008 -0.0008 -0.0032 -0.0010 -0.0064 -0.0016 -0.0343 -0.0029 -0.0034 -0.0014 -0.0014
S-1565	Darüber hinaus wurden Studien an Patienten mit Rückenmarksverletzungen und an Diabetikern durchgeführt .
T-1565	The main measure of effectiveness was based on the ability of the men to get and maintain an erection .
H-1565	-0.01114346832036972	The main measure of effectiveness was based on the ability of the men to get and maintain an erection .
D-1565	-0.01114346832036972	The main measure of effectiveness was based on the ability of the men to get and maintain an erection .
P-1565	-0.0144 -0.0145 -0.0145 -0.0092 -0.0143 -0.0010 -0.0106 -0.0146 -0.0017 -0.0103 -0.0144 -0.0206 -0.0109 -0.0145 -0.0081 -0.0144 -0.0144 -0.0137 -0.0143 -0.0143 -0.0037 -0.0063 -0.0014
S-270	Die Sicherheit und Wirksamkeit von PritorPlus bei Patienten unter 18 Jahren wurden nicht untersucht .
T-270	The safety and effectiveness of PritorPlus have not been established in patients below 18 years of age .
H-270	-0.11191956698894501	The safety and effectiveness of PritorPlus have not been established in patients below 18 years of age .
D-270	-0.11191956698894501	The safety and effectiveness of PritorPlus have not been established in patients below 18 years of age .
P-270	-0.0066 -0.0008 -0.0015 -0.3412 -0.0009 -0.0014 -0.0018 -0.0003 -0.0014 -0.0006 -0.0210 -0.0014 -0.0013 -0.4257 -0.0040 -0.0017 -0.6357 -0.3987 -0.0032 -0.7211 -0.0010 -0.0015 -0.0014
S-181	Die Verträglichkeit und Wirksamkeit bei Kindern und Jugendlich unter 18 Jahren sind nicht belegt .
T-181	Safety and efficacy in paediatric patients below the age of 18 years have not been established .
H-181	-0.05801556631922722	Safety and efficacy in paediatric patients below the age of 18 years have not been established .
D-181	-0.05801556631922722	Safety and efficacy in paediatric patients below the age of 18 years have not been established .
P-181	-0.0145 -0.0030 -0.0437 -0.0005 -0.0007 -0.0084 -0.1108 -0.0023 -0.0016 -0.0992 -0.0085 -0.0281 -0.9624 -0.0014 -0.0014 -0.0014 -0.0137 -0.0096 -0.0019 -0.0016 -0.0165 -0.0018 -0.0014
S-126	Metaboliten werden mit dem Urin oder biliär über die Fäzes ausgeschieden .
T-126	Metabolites are excreted in urine and via biliary excretion in faeces .
H-126	-0.008550513535737991	Metabolites are excreted in urine and via biliary excretion in faeces .
D-126	-0.008550513535737991	Metabolites are excreted in urine and via biliary excretion in faeces .
P-126	-0.0019 -0.0005 -0.0003 -0.0029 -0.0042 -0.0004 -0.0012 -0.0132 -0.0091 -0.0010 -0.0669 -0.0139 -0.0185 -0.0007 -0.0136 -0.0004 -0.0077 -0.0139 -0.0213 -0.0001 -0.0019 -0.0017 -0.0014
S-1033	Nifedipine Pharmamatch retard 30 mg Retardtabletten
T-1033	Nifedipine Pharmamatch retard 30 mg prolonged @-@ release tablets
H-1033	-0.003948702942579985	Nifedipine Pharmamatch retard 30 mg prolonged @-@ release tablets
D-1033	-0.003948702942579985	Nifedipine Pharmamatch retard 30 mg prolonged @-@ release tablets
P-1033	-0.0011 -0.0013 -0.0011 -0.0007 -0.0011 -0.0017 -0.0004 -0.0054 -0.0014 -0.0012 -0.0141 -0.0010 -0.0021 -0.0007 -0.0145 -0.0141 -0.0014 -0.0141 -0.0027 -0.0031 -0.0022 -0.0018
S-28	Schellack , Eisen ( II , III ) -oxid ( E 172 ) .
T-28	The printing ink contains : shellac glaze , iron oxide black ( E172 ) .
H-28	-0.038282476365566254	The printing ink contains : shellac glaze , iron oxide black ( E172 ) .
D-28	-0.038282476365566254	The printing ink contains : shellac glaze , iron oxide black ( E172 ) .
P-28	-0.0145 -0.0145 -0.0099 -0.0145 -0.0142 -0.0145 -0.0021 -0.0008 -0.0019 -0.3571 -0.0060 -0.3245 -0.0023 -0.0064 -0.0193 -0.0045 -0.0135 -0.0011 -0.0015 -0.0017 -0.0160 -0.0014
S-729	Leberfunktionstests sollten vor Behandlungsbeginn und danach in regelmäßigen Abständen durchgeführt werden .
T-729	Liver function tests should be performed before the initiation of treatment and periodically thereafter .
H-729	-0.008858182467520237	Liver function tests should be performed before the initiation of treatment and periodically thereafter .
D-729	-0.008858182467520237	Liver function tests should be performed before the initiation of treatment and periodically thereafter .
P-729	-0.0022 -0.0007 -0.0014 -0.0027 -0.0015 -0.0015 -0.0109 -0.0068 -0.0109 -0.0145 -0.0013 -0.0022 -0.0120 -0.0097 -0.0140 -0.0875 -0.0013 -0.0085 -0.0010 -0.0013 -0.0014 -0.0014
S-1320	Dosierungen über 2000 mg / 40 mg täglich wurden nicht untersucht und werden daher nicht empfohlen .
T-1320	Daily doses greater than 2000 mg / 40 mg have not been studied and therefore are not recommended .
H-1320	-0.01739666238427162	Daily doses greater than 2000 mg / 40 mg have not been studied and therefore are not recommended .
D-1320	-0.01739666238427162	Daily doses greater than 2000 mg / 40 mg have not been studied and therefore are not recommended .
P-1320	-0.0168 -0.0014 -0.1624 -0.0136 -0.0016 -0.0039 -0.0008 -0.0017 -0.0015 -0.0013 -0.0091 -0.0016 -0.0014 -0.1119 -0.0069 -0.0183 -0.0049 -0.0015 -0.0016 -0.0016 -0.0014
S-670	- Zusätzlich enthalten die verschiedenen ZYPREXA Tablettenstärken die folgenden Bestandteile :
T-670	• In addition the different ZYPREXA tablet strengths also contain the following ingredients :
H-670	-0.012437697499990463	• In addition the different ZYPREXA tablet strengths also contain the following ingredients :
D-670	-0.012437697499990463	• In addition the different ZYPREXA tablet strengths also contain the following ingredients :
P-670	-0.0281 -0.0081 -0.0011 -0.0127 -0.0091 -0.0070 -0.0014 -0.0004 -0.0008 -0.0014 -0.0029 -0.0040 -0.0113 -0.0012 -0.0928 -0.0600 -0.0075 -0.0011 -0.0072 -0.0016 -0.0014
S-1729	Dieses Arzneimittel ist nur für Sie , verwenden Sie nur Ihren eigenen BYETTA Pen .
T-1729	Use a new injection needle for each injection and dispose of it after each use .
H-1729	-0.011243218556046486	Use a new injection needle for each injection and dispose of it after each use .
D-1729	-0.011243218556046486	Use a new injection needle for each injection and dispose of it after each use .
P-1729	-0.0147 -0.0144 -0.0144 -0.0145 -0.0079 -0.0145 -0.0011 -0.0139 -0.0144 -0.0143 -0.0058 -0.0141 -0.0145 -0.0133 -0.0027 -0.0129 -0.0145 -0.0141 -0.0142 -0.0039 -0.0022
S-1793	Wenn Sie gleichzeitig gerinnungshemmende Mittel vom Kumarin @-@ Typ ( wie z.B .
T-1793	In case you are using coumarin anticoagulants ( e. g .
H-1793	-0.018692096695303917	In case you are using coumarin anticoagulants ( e. g .
D-1793	-0.018692096695303917	In case you are using coumarin anticoagulants ( e. g .
P-1793	-0.0151 -0.0128 -0.0029 -0.0120 -0.0112 -0.0135 -0.0000 -0.0016 -0.0141 -0.0020 -0.0001 -0.0016 -0.0020 -0.0051 -0.0145 -0.0019 -0.0051 -0.2383 -0.0014
S-1099	Die Zusatzstudien zeigten , dass die Antikörper mindestens vier Jahre lang erhalten blieben .
T-1099	The additional studies showed that the presence of antibodies was maintained for at least four years .
H-1099	-0.011246603913605213	The additional studies showed that the presence of antibodies was maintained for at least four years .
D-1099	-0.011246603913605213	The additional studies showed that the presence of antibodies was maintained for at least four years .
P-1099	-0.0054 -0.0073 -0.0107 -0.0135 -0.0039 -0.0151 -0.0331 -0.0015 -0.0181 -0.0009 -0.0126 -0.0037 -0.0022 -0.0047 -0.0010 -0.0663 -0.0110 -0.0015 -0.0014
S-1443	España Ms Carmen COLLADO ALVAREZ Prof .
T-1443	España Ms Carmen COLLADO ALVAREZ Prof .
H-1443	-0.0020332245621830225	España Ms Carmen COLLADO ALVAREZ Prof .
D-1443	-0.0020332245621830225	España Ms Carmen COLLADO ALVAREZ Prof .
P-1443	-0.0105 -0.0009 -0.0004 -0.0014 -0.0077 -0.0004 -0.0015 -0.0012 -0.0012 -0.0011 -0.0010 -0.0010 -0.0014 -0.0011 -0.0012 -0.0008 -0.0036 -0.0009 -0.0020 -0.0014
S-341	In peri- / postnatalen Studien an Ratten wurde eine verlängerte Tragzeit beobachtet .
T-341	In peri / postnatal studies in rats , an increased gestation time was observed .
H-341	-0.012371538206934929	In peri / postnatal studies in rats , an increased gestation time was observed .
D-341	-0.012371538206934929	In peri / postnatal studies in rats , an increased gestation time was observed .
P-341	-0.0096 -0.0140 -0.0008 -0.0110 -0.0019 -0.0003 -0.0013 -0.0023 -0.0159 -0.0008 -0.0074 -0.0107 -0.0142 -0.0003 -0.0496 -0.0113 -0.0033 -0.0898 -0.0015 -0.0014
S-828	Dolorgiet GmbH &amp; Co KG Otto @-@ von @-@ Guericke @-@ Str .
T-828	Dolorgiet GmbH &amp; Co KG Otto @-@ von @-@ Guericke @-@ Str .
H-828	-0.015918776392936707	Dolorgiet GmbH &amp; Co KG Otto @-@ von @-@ Guericke @-@ Str .
D-828	-0.015918776392936707	Dolorgiet GmbH &amp; Co KG Otto @-@ von @-@ Guericke @-@ Str .
P-828	-0.0035 -0.0011 -0.0015 -0.0002 -0.0009 -0.0010 -0.0009 -0.0005 -0.0047 -0.0219 -0.0006 -0.2728 -0.0010 -0.0005 -0.0007 -0.0014 -0.0015 -0.0009 -0.0015 -0.0014
S-205	Bekannte Überempfindlichkeit gegen Paroxetin oder gegen einen der sonstigen Bestandteile .
T-205	Known hypersensitivity to paroxetine or any of the excipients .
H-205	-0.024479037150740623	Known hypersensitivity to paroxetine or any of the excipients .
D-205	-0.024479037150740623	Known hypersensitivity to paroxetine or any of the excipients .
P-205	-0.0028 -0.0003 -0.0023 -0.0004 -0.0007 -0.0019 -0.0017 -0.0005 -0.0014 -0.1748 -0.0023 -0.1021 -0.0047 -0.0071 -0.1644 -0.0104 -0.0013 -0.0060 -0.0029 -0.0014
S-567	Ruhrpharm AG Heidsieker Heide 114 D @-@ 33739 Bielefeld Deutschland
T-567	Ruhrpharm AG Heidsieker Heide 114 D @-@ 33739 Bielefeld Germany
H-567	-0.01931176148355007	Ruhrpharm AG Heidsieker Heide 114 D @-@ 33739 Bielefeld Germany
D-567	-0.01931176148355007	Ruhrpharm AG Heidsieker Heide 114 D @-@ 33739 Bielefeld Germany
P-567	-0.0001 -0.0013 -0.0001 -0.0009 -0.0007 -0.0011 -0.0004 -0.0020 -0.0011 -0.0011 -0.0012 -0.0011 -0.0009 -0.3639 -0.0061 -0.0012 -0.0009 -0.0001 -0.0008 -0.0014
S-1621	Ihr Arzt wird vor und während der Behandlung mit Zavesca die folgenden Tests durchführen :
T-1621	20 Your doctor will perform the following tests before treatment and during treatment with Zavesca :
H-1621	-0.014468326233327389	20 Your doctor will perform the following tests before treatment and during treatment with Zavesca :
D-1621	-0.014468326233327389	20 Your doctor will perform the following tests before treatment and during treatment with Zavesca :
P-1621	-0.0241 -0.0143 -0.0028 -0.0020 -0.0033 -0.0020 -0.0010 -0.0019 -0.0062 -0.0918 -0.1015 -0.0020 -0.0071 -0.0211 -0.0019 -0.0010 -0.0012 -0.0006 -0.0022 -0.0014
S-622	Was Humalog Mix25 100 E / ml KwikPen Injektionssuspension enthält
T-622	What Humalog Mix25 100 U / ml KwikPen , suspension for injection contains
H-622	-0.006274790968745947	What Humalog Mix25 100 U / ml KwikPen , suspension for injection contains
D-622	-0.006274790968745947	What Humalog Mix25 100 U / ml KwikPen , suspension for injection contains
P-622	-0.0034 -0.0056 -0.0006 -0.0010 -0.0016 -0.0013 -0.0023 -0.0185 -0.0015 -0.0008 -0.0062 -0.0013 -0.0026 -0.0005 -0.0146 -0.0143 -0.0145 -0.0024 -0.0082 -0.0096 -0.0212
S-861	Daher darf intranasales Calcitonin bei diesen Patienten nicht angewendet werden .
T-861	Therefore , intranasal calcitonin is not to be administered to such patients .
H-861	-0.04603414982557297	Therefore , intranasal calcitonin is not to be administered to such patients .
D-861	-0.04603414982557297	Therefore , intranasal calcitonin is not to be administered to such patients .
P-861	-0.0055 -0.0009 -0.0080 -0.0046 -0.0008 -0.0008 -0.0015 -0.0016 -0.0007 -0.0011 -0.0013 -0.5074 -0.0024 -0.0130 -0.0013 -0.3420 -0.0008 -0.0864 -0.0284 -0.0012 -0.0015 -0.0014
S-853	Antiepileptika , soll Betaferon mit Vorsicht angewendet werden .
T-853	Caution should be exercised when Betaferon is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance , e. g. anti @-@ epileptics .
H-853	-0.12659645080566406	Caution should be exercised when Betaferon is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system .
D-853	-0.12659645080566406	Caution should be exercised when Betaferon is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system .
P-853	-0.0145 -0.0106 -0.0054 -0.0018 -0.0131 -0.0010 -0.0110 -0.0145 -0.0011 -0.0007 -0.0092 -0.0032 -0.0131 -0.0009 -0.0140 -0.0097 -0.0015 -0.0145 -0.0303 -0.0106 -0.0160 -0.0139 -0.0129 -0.0145 -0.0144 -0.0014 -0.0145 -0.0151 -0.0116 -0.0145 -0.0145 -0.0033 -0.0117 -0.0145 -0.0094 -0.0126 -0.0145 -0.0126 -0.0144 -0.0132 -0.0145 -0.0145 -0.0145 -5.2218 -0.0014
S-1209	Addendum to &apos; Dose selection for carcinogenicity studies of
T-1209	Addendum to <<unk>> Dose selection for carcinogenicity studies of CPMP / ICH / 366 / 95 ( S1C ( R ) )
H-1209	-0.07550164312124252	Addendum to <unk> Dose selection for carcinogenicity studies of CPMP / 366 / 95 ( S1C ( R ) )
D-1209	-0.07550164312124252	Addendum to <unk> Dose selection for carcinogenicity studies of CPMP / 366 / 95 ( S1C ( R ) )
P-1209	-0.0009 -0.0007 -0.0012 -0.0011 -0.0035 -0.0145 -0.0116 -0.0022 -0.0024 -0.0016 -0.0015 -0.0003 -0.0013 -0.0015 -0.0011 -0.0010 -0.0010 -0.0027 -0.0146 -0.0144 -0.0144 -0.0153 -2.1879 -0.0145 -0.0667 -0.0147 -0.0739 -0.0147 -0.0144 -0.0144 -0.0145 -0.0144 -0.0408 -0.0404 -0.0225
S-1129	s Quintanrix darf unter keinen Umständen intravasal verabreicht werden .
T-1129	ris febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post vaccination .
H-1129	-0.19165489077568054	ris febrile convulsions should never be given intravascularly .
D-1129	-0.19165489077568054	ris febrile convulsions should never be given intravascularly .
P-1129	-0.0145 -0.0145 -0.0145 -0.0021 -0.0050 -0.0145 -0.0144 -0.0071 -0.0135 -3.3016 -0.0020 -0.1240 -0.0813 -0.0005 -0.0012 -0.0159 -0.0051 -0.0084 -0.0014
S-1921	ICH Q3C ( M ) Maintenance document for guidance on impurities :
T-1921	CPMP / ICH / 1940 / 00 ICH Q3C ( M ) Maintenance document for guidance on impurities :
H-1921	-0.054589297622442245	CPMP / ICH / 1940 / 00 ICH Q3C ( M ) Maintenance document for guidance on impurities :
D-1921	-0.054589297622442245	CPMP / ICH / 1940 / 00 ICH Q3C ( M ) Maintenance document for guidance on impurities :
P-1921	-0.0145 -0.0144 -0.0145 -0.0149 -0.2889 -0.0032 -0.2440 -0.2327 -0.1314 -0.0145 -0.2209 -0.0026 -0.3563 -0.0015 -0.0011 -0.0078 -0.0012 -0.0014 -0.0019 -0.0005 -0.0027 -0.0016 -0.0006 -0.0017 -0.0030 -0.0006 -0.0010 -0.0021 -0.0014
S-409	Anschließend wurde das Arzneimittel zwölf Wochen lang in einer stabilen Dosis verabreicht .
T-409	The main measure of effectiveness was the change in pain levels between the start of the study and the last four weeks on the stable dose .
H-409	-0.2503417730331421	The main measure of effectiveness was the change in pain levels between the start of the study and the last four weeks .
D-409	-0.2503417730331421	The main measure of effectiveness was the change in pain levels between the start of the study and the last four weeks .
P-409	-0.0088 -0.0212 -0.0145 -0.0120 -0.0141 -0.0011 -0.0071 -0.0108 -0.0145 -0.0044 -0.0145 -0.0143 -0.0148 -0.0119 -0.0145 -0.0106 -0.0089 -0.0143 -0.0046 -0.0074 -0.0145 -0.0144 -0.0051 -5.9989 -0.0014
S-917	Polyethylenglykol , Polysorbat 80 , Blau Nr .
T-917	The 375 mg tablets are pale blue and are engraved with CVT375 on one side .
H-917	-0.012697869911789894	The 375 mg tablets are pale blue and are engraved with CVT375 on one side .
D-917	-0.012697869911789894	The 375 mg tablets are pale blue and are engraved with CVT375 on one side .
P-917	-0.0249 -0.0175 -0.0144 -0.0143 -0.0145 -0.0109 -0.0114 -0.0168 -0.0145 -0.0090 -0.0134 -0.0140 -0.0216 -0.0140 -0.0017 -0.0048 -0.0145 -0.0145 -0.0145 -0.0144 -0.0144 -0.0145 -0.0144 -0.0043 -0.0056 -0.0014
S-128	Im nächsten Behandlungszyklus wird Ihnen Ihr Arzt eine niedrigere Dosierung verschreiben .
T-128	For the following cycle , your doctor will prescribe a dosage lower than that of the previous cycle .
H-128	-0.010713508352637291	For the following cycle , your doctor will prescribe a dosage lower than that of the previous cycle .
D-128	-0.010713508352637291	For the following cycle , your doctor will prescribe a dosage lower than that of the previous cycle .
P-128	-0.0139 -0.0026 -0.0223 -0.0169 -0.0084 -0.0023 -0.0017 -0.0019 -0.0015 -0.0009 -0.0049 -0.0726 -0.0025 -0.0014 -0.0135 -0.0087 -0.0134 -0.0139 -0.0114 -0.0140 -0.0139 -0.0023 -0.0014
S-1578	Nekrotisierende Enterokolitis , Darmperforation Gelegentlich :
T-1578	Necrotizing enterocolitis , Intestinal perforation Uncommon :
H-1578	-0.0033325159456580877	Necrotizing enterocolitis , Intestinal perforation Uncommon :
D-1578	-0.0033325159456580877	Necrotizing enterocolitis , Intestinal perforation Uncommon :
P-1578	-0.0017 -0.0007 -0.0003 -0.0010 -0.0073 -0.0015 -0.0011 -0.0033 -0.0023 -0.0008 -0.0027 -0.0141 -0.0010 -0.0006 -0.0019 -0.0009 -0.0014 -0.0145 -0.0096 -0.0017 -0.0014
S-1237	Antikörperkonzentrationen gegen &quot; fremde &quot; Zellen von anderen Menschen haben .
T-1237	transplantation. uc
H-1237	-0.016417035833001137	transplantation. uc
D-1237	-0.016417035833001137	transplantation. uc
P-1237	-0.0145 -0.0289 -0.0142 -0.0140 -0.0145 -0.0145 -0.0144
S-202	49 / 161 ( 30,4 ) 137 / 870 ( 15,7 )
T-202	122 / 849 ( 14.4 )
H-202	-0.05571615323424339	122 / 849 ( 14.4 )
D-202	-0.05571615323424339	122 / 849 ( 14.4 )
P-202	-0.0149 -0.0135 -0.0044 -0.0141 -0.0282 -0.0021 -0.0145 -0.4497 -0.0016 -0.0143
S-1824	WIE IST STALEVO EINZUNEHMEN ?
T-1824	HOW TO TAKE STALEVO
H-1824	-0.00480571249499917	HOW TO TAKE STALEVO
D-1824	-0.00480571249499917	HOW TO TAKE STALEVO
P-1824	-0.0014 -0.0005 -0.0131 -0.0144 -0.0035 -0.0005 -0.0054 -0.0010 -0.0012 -0.0014 -0.0011 -0.0142
S-36	WIE IST PEGASYS ANZUWENDEN ?
T-36	HOW TO USE PEGASYS
H-36	-0.02667895145714283	HOW TO USE PEGASYS
D-36	-0.02667895145714283	HOW TO USE PEGASYS
P-36	-0.0017 -0.0005 -0.2875 -0.0037 -0.0006 -0.0028 -0.0013 -0.0010 -0.0007 -0.0052 -0.0009 -0.0142
S-1641	WIE WIRD AVONEX INJIZIERT ?
T-1641	HOW TO INJECT AVONEX
H-1641	-0.0041702440939843655	HOW TO INJECT AVONEX
D-1641	-0.0041702440939843655	HOW TO INJECT AVONEX
P-1641	-0.0013 -0.0006 -0.0141 -0.0020 -0.0004 -0.0125 -0.0010 -0.0038 -0.0012 -0.0010 -0.0013 -0.0008 -0.0142
S-1713	WIE IST Infanrix Penta ANZUWENDEN ?
T-1713	HOW Infanrix Penta IS GIVEN
H-1713	-0.10493283718824387	HOW Infanrix Penta IS GIVEN
D-1713	-0.10493283718824387	HOW Infanrix Penta IS GIVEN
P-1713	-0.0019 -0.0005 -1.3030 -0.0005 -0.0014 -0.0012 -0.0017 -0.0014 -0.0036 -0.0154 -0.0115 -0.0078 -0.0141
S-1297	Die Nahrungsaufnahme im Rahmen der Diät sollte auf drei Hauptmahlzeiten verteilt sein .
T-1297	The food in the diet should be spread over three main meals .
H-1297	-0.007066642865538597	The food in the diet should be spread over three main meals .
D-1297	-0.007066642865538597	The food in the diet should be spread over three main meals .
P-1297	-0.0117 -0.0094 -0.0144 -0.0032 -0.0127 -0.0018 -0.0015 -0.0112 -0.0078 -0.0191 -0.0018 -0.0013 -0.0016 -0.0014
S-351	Binocrit 7000 I.E. / 0,7 ml Injektionszubereitung
T-351	Binocrit 7000 IU / 0.7 ml injection
H-351	-0.003954244311898947	Binocrit 7000 IU / 0.7 ml injection
D-351	-0.003954244311898947	Binocrit 7000 IU / 0.7 ml injection
P-351	-0.0003 -0.0012 -0.0010 -0.0014 -0.0006 -0.0012 -0.0145 -0.0015 -0.0065 -0.0015 -0.0008 -0.0092 -0.0015 -0.0143
S-68	HDPE @-@ Flaschen mit kindergesicherter Verschlusskappe aus Kunststoff .
T-68	HDPE bottles with a child @-@ resistant polypropylene closure .
H-68	-0.37426578998565674	HDPE bottles with a child resistant polypropylene closure .
D-68	-0.37426578998565674	HDPE bottles with a child resistant polypropylene closure .
P-68	-0.0009 -0.0005 -0.0044 -0.0020 -0.0140 -0.0042 -5.5310 -0.0006 -0.0161 -0.0126 -0.0009 -0.0004 -0.0158 -0.0092 -0.0014
S-18	1 x 360 Tabletten 2 x 360 Tabletten 3 x 360 Tabletten
T-18	1 x 360 tablets 2 x 360 tablets 3 x 360 tablets
H-18	-0.0014046208234503865	1 x 360 tablets 2 x 360 tablets 3 x 360 tablets
D-18	-0.0014046208234503865	1 x 360 tablets 2 x 360 tablets 3 x 360 tablets
P-18	-0.0030 -0.0013 -0.0006 -0.0021 -0.0014 -0.0024 -0.0013 -0.0004 -0.0006 -0.0010 -0.0013 -0.0011 -0.0005 -0.0030 -0.0010 -0.0015
S-901	Fahren Sie bei Schwindelgefühl nicht Auto und bedienen Sie keine Werkzeuge oder Maschinen .
T-901	Do not drive or use any tools or machines if you feel dizzy .
H-901	-0.007306193001568317	Do not drive or use any tools or machines if you feel dizzy .
D-901	-0.007306193001568317	Do not drive or use any tools or machines if you feel dizzy .
P-901	-0.0080 -0.0014 -0.0009 -0.0107 -0.0269 -0.0110 -0.0027 -0.0020 -0.0104 -0.0134 -0.0043 -0.0185 -0.0020 -0.0008 -0.0023 -0.0014
S-1796	Eventuell muss Ihnen Ihr Arzt auch ein anderes krampflösendes Mittel geben .
T-1796	Your doctor may need to consider giving you a different anticonvulsant .
H-1796	-0.01077832467854023	Your doctor may need to consider giving you a different anticonvulsant .
D-1796	-0.01077832467854023	Your doctor may need to consider giving you a different anticonvulsant .
P-1796	-0.0080 -0.0020 -0.0886 -0.0125 -0.0018 -0.0145 -0.0125 -0.0027 -0.0142 -0.0020 -0.0041 -0.0118 -0.0002 -0.0006 -0.0011 -0.0051 -0.0014
S-841	Targretin ist ein Arzneimittel , das den Wirkstoff Bexaroten enthält .
T-841	Targretin is a medicine containing the active substance bexarotene .
H-841	-0.05313984304666519	Targretin is a medicine containing the active substance bexarotene .
D-841	-0.05313984304666519	Targretin is a medicine containing the active substance bexarotene .
P-841	-0.0004 -0.0008 -0.0018 -0.0015 -0.0057 -0.0052 -0.8503 -0.0023 -0.0012 -0.0104 -0.0145 -0.0028 -0.0013 -0.0019 -0.0003 -0.0017 -0.0014
S-903	n se Nespo 150 µg Darbepoetin alfa IV / SC
T-903	Nespo 150 µg Darbepoetin alfa IV / SC
H-903	-0.0027724215760827065	Nespo 150 µg Darbepoetin alfa IV / SC
D-903	-0.0027724215760827065	Nespo 150 µg Darbepoetin alfa IV / SC
P-903	-0.0147 -0.0032 -0.0015 -0.0052 -0.0028 -0.0010 -0.0031 -0.0035 -0.0013 -0.0009 -0.0021 -0.0017 -0.0004 -0.0012 -0.0015 -0.0007 -0.0024
S-1416	Gelöstes Xeomin ist für Injektionen in den Muskel bestimmt .
T-1416	Dissolved Xeomin is intended for injections into the muscle .
H-1416	-0.011829575523734093	Dissolved Xeomin is intended for injections into the muscle .
D-1416	-0.011829575523734093	Dissolved Xeomin is intended for injections into the muscle .
P-1416	-0.0025 -0.0003 -0.0010 -0.0056 -0.0022 -0.0008 -0.0020 -0.0019 -0.0123 -0.1322 -0.0040 -0.0206 -0.0050 -0.0058 -0.0016 -0.0018 -0.0014
S-385	Metaflumizon 499,5 mg und Amitraz 499,5 mg
T-385	Metaflumizone 499.5 mg and amitraz 499.5 mg
H-385	-0.002507438650354743	Metaflumizone 499.5 mg and amitraz 499.5 mg
D-385	-0.002507438650354743	Metaflumizone 499.5 mg and amitraz 499.5 mg
P-385	-0.0016 -0.0014 -0.0007 -0.0010 -0.0063 -0.0006 -0.0073 -0.0015 -0.0006 -0.0021 -0.0134 -0.0013 -0.0022 -0.0004 -0.0011 -0.0013 -0.0008 -0.0015
S-681	Erhöhte Leberenzyme , Gelbsucht , Hepatitis .
T-681	Elevated liver enzymes , jaundice , hepatitis
H-681	-0.02432483807206154	Elevated liver enzymes , jaundice , hepatitis
D-681	-0.02432483807206154	Elevated liver enzymes , jaundice , hepatitis
P-681	-0.0049 -0.0011 -0.0011 -0.0017 -0.0003 -0.0008 -0.0013 -0.0015 -0.0007 -0.0002 -0.0001 -0.0012 -0.0017 -0.0023 -0.0005 -0.0007 -0.3936
S-1536	FORZAAR 100 mg + 25 mg compresse rivestite con film
T-1536	FORZAAR 100 mg + 25 100 mg mg compresse rivestite con film
H-1536	-0.10959269851446152	FORZAAR 100 mg + 25 100 mg mg compresse rivestite con film
D-1536	-0.10959269851446152	FORZAAR 100 mg + 25 100 mg mg compresse rivestite con film
P-1536	-0.0043 -0.0009 -0.0017 -0.0014 -0.0013 -0.0016 -0.0005 -0.0014 -0.0014 -0.8402 -0.1110 -0.6555 -0.6716 -0.0020 -0.0016 -0.0013 -0.0003 -0.0009 -0.0001 -0.0010 -0.0015
S-1761	51 Wie M @-@ M @-@ RVAXPRO aussieht und Inhalt der Packung
T-1761	57 What M @-@ M @-@ RVAXPRO looks like and contents of the pack
H-1761	-0.01781538873910904	57 What M @-@ M @-@ RVAXPRO looks like and contents of the pack
D-1761	-0.01781538873910904	57 What M @-@ M @-@ RVAXPRO looks like and contents of the pack
P-1761	-0.0146 -0.0072 -0.0024 -0.2999 -0.0011 -0.0016 -0.0015 -0.0014 -0.0013 -0.0009 -0.0006 -0.0011 -0.0025 -0.0015 -0.0024 -0.0106 -0.0010 -0.0026 -0.0071 -0.0106 -0.0022
S-234	Efexor sollte normalerweise nicht bei Kindern und Jugendlichen unter 18 Jahren angewendet werden .
T-234	Efexor should normally not be used for children and adolescents under 18 years .
H-234	-0.1157621443271637	Efexor should normally not be used in children and adolescents under 18 years .
D-234	-0.1157621443271637	Efexor should normally not be used in children and adolescents under 18 years .
P-234	-0.0028 -0.0012 -0.0006 -0.0013 -0.0024 -0.0421 -0.0017 -0.0014 -0.2519 -0.9278 -0.1241 -0.0126 -0.0060 -0.0007 -0.0009 -0.0715 -0.1050 -0.0042 -0.7556 -0.0014
S-597	Überwiegend handelt es sich um oberflächliche Blutungen an der Injektionsstelle .
T-597	The type of haemorrhage is predominantly superficial at the injection site .
H-597	-0.005834126379340887	The type of haemorrhage is predominantly superficial at the injection site .
D-597	-0.005834126379340887	The type of haemorrhage is predominantly superficial at the injection site .
P-597	-0.0125 -0.0145 -0.0056 -0.0141 -0.0010 -0.0002 -0.0034 -0.0081 -0.0116 -0.0015 -0.0020 -0.0029 -0.0003 -0.0073 -0.0048 -0.0215 -0.0008 -0.0018 -0.0015 -0.0014
S-614	Es gibt kein spezifisches Antidot gegen Raloxifenhydrochlorid .
T-614	There is no specific antidote for raloxifene hydrochloride .
H-614	-0.0078072636388242245	There is no specific antidote for raloxifene hydrochloride .
D-614	-0.0078072636388242245	There is no specific antidote for raloxifene hydrochloride .
P-614	-0.0037 -0.0762 -0.0017 -0.0015 -0.0038 -0.0024 -0.0034 -0.0324 -0.0036 -0.0009 -0.0031 -0.0143 -0.0001 -0.0014 -0.0014 -0.0013 -0.0009 -0.0010 -0.0017 -0.0014
S-129	Was ist Suvaxyn Aujeszky 783 + O / W ?
T-129	What is Suvaxyn Aujeszky 783 + O / W ?
H-129	-0.011611715890467167	What is Suvaxyn Aujeszky 783 + O / W ?
D-129	-0.011611715890467167	What is Suvaxyn Aujeszky 783 + O / W ?
P-129	-0.0013 -0.1967 -0.0015 -0.0011 -0.0005 -0.0005 -0.0009 -0.0012 -0.0011 -0.0009 -0.0005 -0.0014 -0.0006 -0.0015 -0.0048 -0.0015 -0.0012 -0.0019 -0.0015
S-1432	Bündelpackung bestehend aus 3 Packungen mit jeweils 112 Filmtabletten .
T-1432	Multipack comprising 3 packs , each containing 112 film @-@ coated tablets .
H-1432	-0.01744888164103031	Multipack comprising 3 packs , each containing 112 film @-@ coated tablets .
D-1432	-0.01744888164103031	Multipack comprising 3 packs , each containing 112 film @-@ coated tablets .
P-1432	-0.0145 -0.0071 -0.0140 -0.0023 -0.0096 -0.0048 -0.0009 -0.0172 -0.0054 -0.0081 -0.0007 -0.0021 -0.1345 -0.0145 -0.0010 -0.0898 -0.0012 -0.0024 -0.0014
S-1551	Ribavirin induziert Genotoxizität ( siehe Abschnitt 5.3 ) .
T-1551	Ribavirin induces genotoxicity ( see section 5.3 ) .
H-1551	-0.0019430542597547174	Ribavirin induces genotoxicity ( see section 5.3 ) .
D-1551	-0.0019430542597547174	Ribavirin induces genotoxicity ( see section 5.3 ) .
P-1551	-0.0084 -0.0006 -0.0006 -0.0018 -0.0019 -0.0011 -0.0008 -0.0005 -0.0011 -0.0007 -0.0011 -0.0016 -0.0019 -0.0075 -0.0013 -0.0014 -0.0017 -0.0017 -0.0014
S-1146	Danmark Sanofi Pasteur MSD sa / nv Tél :
T-1146	Danmark Sanofi Pasteur MSD sa / nv Tél :
H-1146	-0.0014174191746860743	Danmark Sanofi Pasteur MSD sa / nv Tél :
D-1146	-0.0014174191746860743	Danmark Sanofi Pasteur MSD sa / nv Tél :
P-1146	-0.0023 -0.0006 -0.0009 -0.0013 -0.0004 -0.0004 -0.0003 -0.0021 -0.0014 -0.0011 -0.0006 -0.0014 -0.0014 -0.0048 -0.0015 -0.0021 -0.0011 -0.0017 -0.0014
S-86	Während der Behandlung mit Betaferon sind Reaktionen an der Injektionsstelle wahrscheinlich .
T-86	During Betaferon treatment you are likely to experience injection site reactions .
H-86	-0.0169291440397501	During Betaferon treatment you are likely to experience injection site reactions .
D-86	-0.0169291440397501	During Betaferon treatment you are likely to experience injection site reactions .
P-86	-0.0071 -0.0143 -0.0009 -0.0008 -0.0066 -0.0089 -0.0145 -0.0106 -0.0042 -0.0013 -0.0069 -0.0143 -0.0020 -0.0010 -0.0030 -0.0005 -0.2062 -0.0014
S-519	Bei älteren Patienten ist keine Dosisanpassung für FABLYN erforderlich .
T-519	No dose adjustment for FABLYN is necessary in elderly patients .
H-519	-0.04556266590952873	No dose adjustment for FABLYN is necessary in elderly patients .
D-519	-0.04556266590952873	No dose adjustment for FABLYN is necessary in elderly patients .
P-519	-0.0131 -0.0054 -0.0028 -0.0008 -0.0019 -0.0594 -0.0019 -0.0007 -0.0013 -0.0013 -0.0018 -0.0026 -0.5741 -0.0567 -0.0920 -0.0013 -0.0018 -0.0014
S-1769	Primäre Hypercholesterinämie und gemischte Dyslipidämie
T-1769	Primary hypercholesterolaemia and mixed dyslipidaemia
H-1769	-0.043714843690395355	Primary hypercholesterolaemia and mixed dyslipidaemia
D-1769	-0.043714843690395355	Primary hypercholesterolaemia and mixed dyslipidaemia
P-1769	-0.0022 -0.0004 -0.3406 -0.0680 -0.0008 -0.0006 -0.0282 -0.0006 -0.0013 -0.0972 -0.0037 -0.0016 -0.0008 -0.0113 -0.0019 -0.0033 -0.0013 -0.2232
S-1908	Nach ein bis zwei Wochen kann Ihr Arzt die Dosis auf 20 mg / Tag erhöhen .
T-1908	After one to two weeks , your doctor may increase the dose to 20mg / day .
H-1908	-0.008368280716240406	After one to two weeks , your doctor may increase the dose to 20mg / day .
D-1908	-0.008368280716240406	After one to two weeks , your doctor may increase the dose to 20mg / day .
P-1908	-0.0034 -0.0200 -0.0223 -0.0013 -0.0010 -0.0057 -0.0017 -0.0010 -0.0204 -0.0026 -0.0031 -0.0031 -0.0016 -0.0642 -0.0006 -0.0023 -0.0018 -0.0014 -0.0014
S-1039	Die zusätzliche Anwendung weiterer Arzneimittel neben Humalog Pen muss mit dem Arzt abgestimmt werden .
T-1039	The physician should be consulted when using other medications in addition to Humalog Pen .
H-1039	-0.0370812714099884	The physician should be consulted when using other medicines in addition to Humalog Pen .
D-1039	-0.0370812714099884	The physician should be consulted when using other medicines in addition to Humalog Pen .
P-1039	-0.0089 -0.0145 -0.0015 -0.0123 -0.0108 -0.0088 -0.0012 -0.0141 -0.0105 -0.0108 -0.0047 -0.6223 -0.0117 -0.0007 -0.0014 -0.0026 -0.0004 -0.0011 -0.0017 -0.0014
S-326	Nespo 40 Mikrogramm I njektionslösung in einer Fertigspritze .
T-326	Nespo 40 micrograms solution for injection in a pre @-@ filled syringe .
H-326	-0.03021285869181156	Nespo 40 micrograms solution for injection in a pre @-@ filled syringe .
D-326	-0.03021285869181156	Nespo 40 micrograms solution for injection in a pre @-@ filled syringe .
P-326	-0.0019 -0.0017 -0.0014 -0.0034 -0.0046 -0.0102 -0.0128 -0.0139 -0.0046 -0.0013 -0.0035 -0.5215 -0.0088 -0.0014 -0.0078 -0.0011 -0.0005 -0.0002 -0.0025 -0.0014
S-301	Zum Einlass von Kohlendioxid in den Analysator sind mehrere Systeme denkbar .
T-301	For introduction of the carbon dioxide into the analyser many sample inlet systems are available .
H-301	-0.007478026673197746	For introduction of the carbon dioxide into the analyser many sample inlet systems are available .
D-301	-0.007478026673197746	For introduction of the carbon dioxide into the analyser many sample inlet systems are available .
P-301	-0.0137 -0.0145 -0.0017 -0.0171 -0.0032 -0.0010 -0.0005 -0.0035 -0.0017 -0.0012 -0.0108 -0.0144 -0.0145 -0.0144 -0.0139 -0.0025 -0.0039 -0.0143 -0.0016 -0.0014
S-551	Es gibt keine therapeutische Erfahrung bei Patienten mit schwerer Einschränkung der Leberfunktion .
T-551	There is no therapeutic experience in patients with severe hepatic impairment .
H-551	-0.0034474236890673637	There is no therapeutic experience in patients with severe hepatic impairment .
D-551	-0.0034474236890673637	There is no therapeutic experience in patients with severe hepatic impairment .
P-551	-0.0031 -0.0024 -0.0015 -0.0083 -0.0012 -0.0023 -0.0083 -0.0019 -0.0024 -0.0018 -0.0141 -0.0016 -0.0011 -0.0096 -0.0011 -0.0004 -0.0014 -0.0017 -0.0014
S-64	Die Dosierung von Levemir muss entsprechend dem Bedarf des Patienten individuell angepasst werden .
T-64	The dose of Levemir should be titrated based on individual patients <<unk>> needs .
H-64	-0.012517917901277542	The dose of Levemir should be titrated based on individual patients <unk> needs .
D-64	-0.012517917901277542	The dose of Levemir should be titrated based on individual patients <unk> needs .
P-64	-0.0115 -0.0130 -0.0022 -0.0028 -0.0007 -0.0006 -0.0140 -0.0016 -0.0153 -0.0145 -0.0035 -0.0147 -0.0875 -0.0136 -0.0141 -0.0145 -0.0107 -0.0017 -0.0014
S-816	Aufgrund dieser Merkmale ist keine Anpassung der Micafungindosis erforderlich .
T-816	No dose adjustment of micafungin is required based on gender or race .
H-816	-0.041944898664951324	No dose adjustment of micafungin is required based on gender or race .
D-816	-0.041944898664951324	No dose adjustment of micafungin is required based on gender or race .
P-816	-0.0142 -0.0145 -0.0059 -0.0007 -0.0020 -0.0716 -0.0139 -0.0145 -0.0012 -0.0028 -0.0075 -0.5755 -0.0143 -0.0017 -0.0185 -0.0145 -0.0133 -0.0089 -0.0014
S-1046	Die Daten für den Endpunkt &quot; schwere Blutung &quot; sind in Tabelle 6 enthalten .
T-1046	Data for adjudicated major bleeding endpoints are shown in tables 6 below .
H-1046	-0.026170123368501663	Data for adjudicated major bleeding endpoints are shown in tables 6 below .
D-1046	-0.026170123368501663	Data for adjudicated major bleeding endpoints are shown in tables 6 below .
P-1046	-0.0077 -0.0036 -0.0145 -0.0143 -0.0136 -0.0143 -0.0048 -0.0022 -0.0092 -0.0261 -0.0057 -0.0186 -0.0018 -0.3114 -0.0030 -0.0171 -0.0017 -0.0014
S-1741	14 Novem 20 mg / ml Injektionslösung für Rinder und Schweine
T-1741	14 Novem 20 mg / ml solution for injection for cattle and pigs
H-1741	-0.005773826502263546	14 Novem 20 mg / ml solution for injection for cattle and pigs
D-1741	-0.005773826502263546	14 Novem 20 mg / ml solution for injection for cattle and pigs
P-1741	-0.0075 -0.0016 -0.0011 -0.0013 -0.0003 -0.0015 -0.0006 -0.0142 -0.0031 -0.0115 -0.0031 -0.0138 -0.0057 -0.0007 -0.0295 -0.0053 -0.0015 -0.0016
S-1633	174 Pharmazeutischer Unternehmer Otsuka Pharmaceutical Europe Ltd .
T-1633	Marketing Authorisation Holder Otsuka Pharmaceutical Europe Ltd .
H-1633	-0.0054250117391347885	Marketing Authorisation Holder Otsuka Pharmaceutical Europe Ltd .
D-1633	-0.0054250117391347885	Marketing Authorisation Holder Otsuka Pharmaceutical Europe Ltd .
P-1633	-0.0145 -0.0145 -0.0139 -0.0139 -0.0145 -0.0132 -0.0014 -0.0009 -0.0008 -0.0013 -0.0004 -0.0011 -0.0005 -0.0010 -0.0017 -0.0005 -0.0021 -0.0014
S-1890	Gekühlte Lösungen müssen vor dem Gebrauch auf Raumtemperatur erwärmt werden .
T-1890	Refrigerated solutions should be allowed to warm to room temperature prior to use .
H-1890	-0.010268855839967728	Refrigerated solutions should be allowed to warm to room temperature prior to use .
D-1890	-0.010268855839967728	Refrigerated solutions should be allowed to warm to room temperature prior to use .
P-1890	-0.0102 -0.0005 -0.0007 -0.0013 -0.0023 -0.0138 -0.0017 -0.0145 -0.0017 -0.0130 -0.0045 -0.0018 -0.0013 -0.0878 -0.0014 -0.0255 -0.0015 -0.0014
S-863	Dies betrifft auch u nbekannte oder neuartige Viren und andere Infektionsarten .
T-863	This also applies to any unknown or emerging viruses or other types of infections. lp
H-863	-0.03879164531826973	This also applies to any unknown or emerging viruses or other types of infections. lp
D-863	-0.03879164531826973	This also applies to any unknown or emerging viruses or other types of infections. lp
P-863	-0.0033 -0.0059 -0.0086 -0.0016 -0.0145 -0.0126 -0.0031 -0.0144 -0.0082 -0.0010 -0.5487 -0.0024 -0.0067 -0.0014 -0.0095 -0.1219 -0.0145 -0.0040 -0.0146 -0.0143 -0.0034
S-337	verschwommenes Sehen ( siehe Abschnitt 4.7 ) , Augenschmerz .
T-337	Eye disorders Common : vision blurred ( see section 4.7 ) , eye pain .
H-337	-0.025547780096530914	Eye disorders Common : vision blurred ( see section 4.7 ) , eye pain .
D-337	-0.025547780096530914	Eye disorders Common : vision blurred ( see section 4.7 ) , eye pain .
P-337	-0.0166 -0.0019 -0.0157 -0.0012 -0.0145 -0.0024 -0.0124 -0.0251 -0.0057 -0.0101 -0.0020 -0.0024 -0.0074 -0.0014 -0.0014 -0.0017 -0.0050 -0.0070 -0.0050 -0.3963 -0.0014
S-1630	Liprolog BASAL weist gegenüber Normalinsulin eine verlängerte Wirkung auf .
T-1630	Liprolog Basal has a prolonged mode of action compared to soluble insulin .
H-1630	-0.02785734087228775	Liprolog Basal has a prolonged mode of action compared to soluble insulin .
D-1630	-0.02785734087228775	Liprolog Basal has a prolonged mode of action compared to soluble insulin .
P-1630	-0.0035 -0.0015 -0.0018 -0.0145 -0.0014 -0.0059 -0.0096 -0.0040 -0.0005 -0.0008 -0.0152 -0.0017 -0.0010 -0.0083 -0.4862 -0.0145 -0.0101 -0.0010 -0.0005 -0.0017 -0.0014
S-1131	Trimethoprim 28,89 % Gew . / Ge w .
T-1131	Trimethoprim 5.78 % w / w Sulfadiazine 28.89 % w / w
H-1131	-0.018838122487068176	Trimethoprim 5.78 % w / w Sulfadiazine 28.89 % w / w
D-1131	-0.018838122487068176	Trimethoprim 5.78 % w / w Sulfadiazine 28.89 % w / w
P-1131	-0.0052 -0.0004 -0.0011 -0.0015 -0.0012 -0.0145 -0.0855 -0.0027 -0.0140 -0.0022 -0.0126 -0.0639 -0.0145 -0.0145 -0.0141 -0.0139 -0.0148 -0.0382 -0.0018 -0.0097 -0.0030 -0.0107 -0.0931
S-361	Neben diesen Effekten wurden weitere Nebenwirkungen nach Markteinführung wie folgt berichtet :
T-361	Next to these effects , there are further adverse reactions reported after the introduction of the product to the market as follows :
H-361	-0.00991698820143938	Next to these effects , there are further adverse reactions reported after the introduction of the product to the market as follows :
D-361	-0.00991698820143938	Next to these effects , there are further adverse reactions reported after the introduction of the product to the market as follows :
P-361	-0.0144 -0.0015 -0.0079 -0.0036 -0.0042 -0.0143 -0.0510 -0.0120 -0.0119 -0.0004 -0.0111 -0.0008 -0.0049 -0.0096 -0.0137 -0.0143 -0.0099 -0.0068 -0.0087 -0.0266 -0.0022 -0.0010 -0.0233 -0.0011 -0.0015 -0.0014
S-1984	Die Arbeit an detaillierten Spezifikationen zu beiden Dantenbanken hat gerade begonnen .
T-1984	The average time for processing of reimbursement claims was reduced , with payment calculations for all meetings completed within one week .
H-1984	-0.01310962438583374	The average time for processing of reimbursement claims was reduced , with payment calculations for all meetings completed within one week .
D-1984	-0.01310962438583374	The average time for processing of reimbursement claims was reduced , with payment calculations for all meetings completed within one week .
P-1984	-0.0136 -0.0145 -0.0144 -0.0128 -0.0145 -0.0134 -0.0150 -0.0015 -0.0002 -0.0105 -0.0139 -0.0139 -0.0144 -0.0144 -0.0141 -0.0145 -0.0145 -0.0012 -0.0413 -0.0140 -0.0141 -0.0145 -0.0152 -0.0142 -0.0142 -0.0115 -0.0151 -0.0014
S-1877	ECU sowie Gebühreneinnahmen aus der Industrie in Höhe von 19,6 Mio .
T-1877	ECU 14 million , and fees from industry amounting to ECU 19.6 million , representing a 40 percent increase on fee revenue compared to 1997 .
H-1877	-0.2676427662372589	ECU 14 million , and fees from industry amounting to ECU 19.6 million .
D-1877	-0.2676427662372589	ECU 14 million , and fees from industry amounting to ECU 19.6 million .
P-1877	-0.0086 -0.0010 -0.0145 -0.0040 -0.0116 -0.0096 -0.0144 -0.0081 -0.0037 -0.0130 -0.0021 -0.0014 -0.0036 -0.0006 -0.0045 -0.0018 -0.0018 -4.9796 -0.0014
S-995	Jede Filmtablette enthält 60 mg Raloxifenhydrochlorid .
T-995	Each film coated tablet contains 60 mg raloxifene hydrochloride , equivalent to 56 mg raloxifene free base .
H-995	-0.0831054151058197	Each film @-@ coated tablet contains 60 mg raloxifene hydrochloride .
D-995	-0.0831054151058197	Each film @-@ coated tablet contains 60 mg raloxifene hydrochloride .
P-995	-0.0022 -0.0038 -1.1511 -0.0145 -0.0024 -0.0307 -0.0012 -0.0020 -0.0049 -0.0009 -0.0121 -0.0011 -0.0029 -0.0143 -0.0002 -0.0012 -0.0014 -0.0013 -0.0009 -0.0010 -0.5768 -0.0014
S-1018	Informieren Sie sofort Ihren Arzt , falls Sie eines dieser Anzeichen bei sich bemerken
T-1018	Deep , rapid breathing Drowsiness Nausea ( feeling sick ) , vomiting and stomach pain notice any of these symptoms , tell your doctor immediately .
H-1018	-0.4587855041027069	Deep , rapid breathing Drowsiness Nausea ( feeling sick ) , vomiting
D-1018	-0.4587855041027069	Deep , rapid breathing Drowsiness Nausea ( feeling sick ) , vomiting
P-1018	-0.0189 -0.0144 -0.0145 -0.0145 -0.0145 -0.0149 -0.0145 -0.0107 -0.0139 -0.0173 -0.0118 -0.0151 -0.0145 -0.0139 -0.0040 -0.0143 -0.0141 -0.0053 -0.0018 -8.9328
S-662	Deshalb ist eine Dosisanpassung von CHAMPIX nicht erforderlich .
T-662	Furthermore since metabolism of varenicline represents less than 10 % of its clearance , active substances known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline ( see section 5.2 ) and therefore a dose adjustment of CHAMPIX would not be required .
H-662	-0.14868499338626862	Furthermore since metabolism of varenicline represents less than 10 % of its clearance , active substances known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline .
D-662	-0.14868499338626862	Furthermore since metabolism of varenicline represents less than 10 % of its clearance , active substances known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline .
P-662	-0.0145 -0.0009 -0.0013 -0.0145 -0.0145 -0.0091 -0.0770 -0.0133 -0.0147 -0.0145 -0.0129 -0.0139 -0.0145 -0.0144 -0.0128 -0.0141 -0.0072 -0.0058 -0.0145 -0.0145 -0.0029 -0.0131 -0.0145 -0.0142 -0.0015 -0.0148 -0.0139 -0.0143 -0.0106 -0.0147 -0.0086 -0.0140 -0.0103 -0.0145 -0.0145 -0.0144 -0.0091 -0.0145 -0.0074 -0.0145 -0.0122 -0.0145 -0.0153 -0.0010 -0.0123 -0.0143 -0.0144 -0.0062 -0.0039 -0.0035 -7.0973 -0.0014
S-1164	Eine thrombolytische Behandlung kann einen unregelmäßigen Herzschlag verursachen .
T-1164	Thrombolytic treatment may cause the heart to beat irregularly .
H-1164	-0.010554076172411442	Thrombolytic treatment may cause the heart to beat irregularly .
D-1164	-0.010554076172411442	Thrombolytic treatment may cause the heart to beat irregularly .
P-1164	-0.0083 -0.0005 -0.0008 -0.0012 -0.0013 -0.0011 -0.0030 -0.0724 -0.0502 -0.0145 -0.0086 -0.0021 -0.0102 -0.0016 -0.0007 -0.0016 -0.0014
S-1699	Beachten Sie auch die Warnung unter 2 Was müssen Sie vor der Anwendung von Actraphane beachten ?
T-1699	See also warning in 2 Before you use Actraphane .
H-1699	-0.009693893603980541	See also warning in 2 Before you use Actraphane .
D-1699	-0.009693893603980541	See also warning in 2 Before you use Actraphane .
P-1699	-0.0229 -0.0118 -0.0208 -0.0104 -0.0060 -0.0145 -0.0135 -0.0059 -0.0017 -0.0008 -0.0007 -0.0005 -0.0140 -0.0123
S-1133	Häufig Injektionsstelle : vorübergehender Schmerz , Rötung , Verhärtung .
T-1133	Common Application site : transient soreness , erythema , induration
H-1133	-0.03864942863583565	Common Application site : transient soreness , erythema , induration
D-1133	-0.03864942863583565	Common Application site : transient soreness , erythema , induration
P-1133	-0.0132 -0.0015 -0.0145 -0.0055 -0.0777 -0.0126 -0.0016 -0.0131 -0.0011 -0.1573 -0.0207 -0.0004 -0.0015 -0.0146 -0.0009 -0.0017 -0.0024 -0.0141 -0.0041 -0.0019 -0.4513
S-1489	Jede überzogene Tablette enthält 238 mg Lactose @-@ Monohydrat .
T-1489	Each coated tablet conatins 238 mg lactose monohydrate .
H-1489	-0.05748918280005455	Each coated tablet contains 238 mg lactose monohydrate .
D-1489	-0.05748918280005455	Each coated tablet contains 238 mg lactose monohydrate .
P-1489	-0.0021 -0.0118 -0.0006 -0.0172 -0.0011 -0.5665 -0.0059 -0.0009 -0.0009 -0.1431 -0.0005 -0.0006 -0.0011 -0.0008 -0.0013 -0.0010 -0.0014 -0.3339 -0.0014
S-1765	Darminfektionen , verursacht durch Escherichia coli und Salmonella spp .
T-1765	Intestinal infections caused by Escherichia coli and Salmonella spp .
H-1765	-0.0033572290558367968	Intestinal infections caused by Escherichia coli and Salmonella spp .
D-1765	-0.0033572290558367968	Intestinal infections caused by Escherichia coli and Salmonella spp .
P-1765	-0.0076 -0.0015 -0.0005 -0.0031 -0.0006 -0.0040 -0.0014 -0.0052 -0.0003 -0.0004 -0.0010 -0.0010 -0.0012 -0.0332 -0.0010 -0.0022 -0.0006 -0.0016 -0.0012 -0.0016 -0.0014
S-269	Jalra gehört zur Arzneimittelgruppe der sogenannten &quot; oralen Antidiabetika &quot; .
T-269	Jalra belongs to a group of medicines called <<unk>> oral antidiabetics <<unk>> .
H-269	-0.018876850605010986	Jalra belongs to a group of medicines called <unk> oral antidiabetics <unk> .
D-269	-0.018876850605010986	Jalra belongs to a group of medicines called <unk> oral antidiabetics <unk> .
P-269	-0.0016 -0.0012 -0.0008 -0.0037 -0.0009 -0.0014 -0.0214 -0.0028 -0.0087 -0.0076 -0.0071 -0.0082 -0.0172 -0.0063 -0.0037 -0.0019 -0.0005 -0.2488 -0.0439 -0.0074 -0.0014
S-1391	10 ml ( nach Rekonstitution ) Jede Flasche enthält 852 mg Cefovecin
T-1391	10 ml ( after reconstitution ) Each vial contains 852 mg cefovecin .
H-1391	-0.03179547190666199	10 ml ( after reconstitution ) Each vial contains 852 mg cefovecin .
D-1391	-0.03179547190666199	10 ml ( after reconstitution ) Each vial contains 852 mg cefovecin .
P-1391	-0.0158 -0.0010 -0.0018 -0.0076 -0.0070 -0.0005 -0.0015 -0.0077 -0.0145 -0.0004 -0.0013 -0.0013 -0.0011 -0.0013 -0.0080 -0.0010 -0.0012 -0.0009 -0.0014 -0.5910 -0.0015
S-1872	Abbott SRL I @-@ 04010 Campoverde di Aprilia ( Latina ) Italien
T-1872	AbbottSRL I 04011 Campoverde di Aprilia , ( Latina ) Italy
H-1872	-0.09228828549385071	AbbottSRL I @-@ 04011 Campoverde di Aprilia ( Latina ) Italy
D-1872	-0.09228828549385071	AbbottSRL I @-@ 04011 Campoverde di Aprilia ( Latina ) Italy
P-1872	-0.0147 -0.0143 -0.0073 -0.0013 -0.0014 -0.1153 -0.4843 -0.0015 -0.0038 -0.6410 -0.0079 -0.0001 -0.0014 -0.0021 -0.0003 -0.0006 -0.7253 -0.0014 -0.0014 -0.0014 -0.0021 -0.0015
S-1477	TEXT FALTSCHACHTEL Puregon 100 IE 5 Ampullen
T-1477	OUTER CARTON TEXT Puregon 100 IU 5 ampoules
H-1477	-0.012438442558050156	OUTER CARTON TEXT Puregon 100 IU 5 ampoules
D-1477	-0.012438442558050156	OUTER CARTON TEXT Puregon 100 IU 5 ampoules
P-1477	-0.0147 -0.0126 -0.0051 -0.0139 -0.0408 -0.0135 -0.0143 -0.0143 -0.0598 -0.0013 -0.0013 -0.0446 -0.0006 -0.0014 -0.0010 -0.0140 -0.0001 -0.0021 -0.0139 -0.0003 -0.0016 -0.0023
S-1472	Nehmen Sie morgens zwei 100 mg INTELENCE Tabletten nach dem Essen ein .
T-1472	In the morning , take two 100 milligram INTELENCE tablets , following a meal .
H-1472	-0.05144069716334343	In the morning , take two 100 milligram INTELENCE tablets , following a meal .
D-1472	-0.05144069716334343	In the morning , take two 100 milligram INTELENCE tablets , following a meal .
P-1472	-0.0160 -0.0030 -0.0021 -0.0088 -0.0012 -0.0031 -0.0076 -0.6959 -0.0103 -0.0060 -0.0014 -0.0009 -0.0009 -0.0004 -0.0036 -0.0011 -0.0200 -0.0138 -0.0127 -0.0015 -0.0016 -0.3198
S-100	CellCept ist bei stillenden Frauen kontraindiziert ( siehe Abschnitt 4.6 ) .
T-100	CellCept is contraindicated in women who are breastfeeding ( see section 4.6 ) .
H-100	-0.002985440194606781	CellCept is contraindicated in women who are breastfeeding ( see section 4.6 ) .
D-100	-0.002985440194606781	CellCept is contraindicated in women who are breastfeeding ( see section 4.6 ) .
P-100	-0.0024 -0.0008 -0.0018 -0.0000 -0.0019 -0.0008 -0.0003 -0.0047 -0.0131 -0.0112 -0.0037 -0.0055 -0.0005 -0.0009 -0.0015 -0.0019 -0.0071 -0.0012 -0.0014 -0.0018 -0.0016 -0.0014
S-907	Die Dosierung für Kinder mit eingeschränkter Nieren- und / oder Leberfunktion wurde nicht untersucht .
T-907	Dosing in children with impaired renal and / or hepatic function has not been studied .
H-907	-0.02565017156302929	Dosing in children with impaired renal and / or hepatic function has not been studied .
D-907	-0.02565017156302929	Dosing in children with impaired renal and / or hepatic function has not been studied .
P-907	-0.0099 -0.0219 -0.0142 -0.0024 -0.0015 -0.1215 -0.0003 -0.0121 -0.0011 -0.0119 -0.0018 -0.0012 -0.1392 -0.0031 -0.0013 -0.0038 -0.0186 -0.0015 -0.0013 -0.1928 -0.0016 -0.0014
S-749	Was ist Ceftriaxon Tyrol Pharma 1g und wofür wird es angewendet ?
T-749	What Ceftriaxone Tyrol Pharma 1g is and what it is used for 2 .
H-749	-0.08539941906929016	What Ceftriaxone Tyrol Pharma 1g is and what it is used for 2 .
D-749	-0.08539941906929016	What Ceftriaxone Tyrol Pharma 1g is and what it is used for 2 .
P-749	-0.0014 -1.4918 -0.0005 -0.0008 -0.0005 -0.0103 -0.0006 -0.0006 -0.0007 -0.0007 -0.0011 -0.0011 -0.0020 -0.0031 -0.0033 -0.0140 -0.0050 -0.0031 -0.0015 -0.3193 -0.0143 -0.0033
S-1688	Vorsicht ist geboten bei gleichzeitiger Einnahme von Kaletra und Rosuvastatin .
T-1688	Caution should be exercised when Kaletra is co @-@ administered with rosuvastatin .
H-1688	-0.007292169611901045	Caution should be exercised when Kaletra is co @-@ administered with rosuvastatin .
D-1688	-0.007292169611901045	Caution should be exercised when Kaletra is co @-@ administered with rosuvastatin .
P-1688	-0.0021 -0.0010 -0.0127 -0.0016 -0.0083 -0.0013 -0.0088 -0.0145 -0.0013 -0.0005 -0.0733 -0.0146 -0.0015 -0.0072 -0.0009 -0.0040 -0.0075 -0.0016 -0.0010 -0.0004 -0.0005 -0.0016 -0.0014
S-1506	Pankreatitis1,3 , Leberversagen , gastrointestinale Störungen1
T-1506	Pancreatitis1,3 , Hepatic Failure , Gastrointestinal Disorder1
H-1506	-0.004388527479022741	Pancreatitis1,3 , Hepatic Failure , Gastrointestinal Disorder1
D-1506	-0.004388527479022741	Pancreatitis1,3 , Hepatic Failure , Gastrointestinal Disorder1
P-1506	-0.0015 -0.0008 -0.0027 -0.0111 -0.0007 -0.0014 -0.0145 -0.0015 -0.0112 -0.0108 -0.0006 -0.0011 -0.0018 -0.0059 -0.0005 -0.0004 -0.0006 -0.0007 -0.0025 -0.0145 -0.0004 -0.0143 -0.0015
S-489	Wenn die Knochenaufnahme positiv und LeukoScan negativ ist , ist eine Infektion unwahrscheinlich .
T-489	When a bone scan is positive and imaging with LeukoScan is negative , infection is unlikely .
H-489	-0.00564792612567544	When a bone scan is positive and imaging with LeukoScan is negative , infection is unlikely .
D-489	-0.00564792612567544	When a bone scan is positive and imaging with LeukoScan is negative , infection is unlikely .
P-489	-0.0143 -0.0144 -0.0008 -0.0145 -0.0011 -0.0021 -0.0007 -0.0021 -0.0146 -0.0104 -0.0145 -0.0091 -0.0012 -0.0021 -0.0008 -0.0081 -0.0009 -0.0038 -0.0070 -0.0016 -0.0025 -0.0019 -0.0014
S-226	Fondaparinux wird unverändert über die Nieren ( 64- 77 % ) ausgeschieden .
T-226	Fondaparinux is excreted to 64 <<unk>> 77 % by the kidney as unchanged compound .
H-226	-0.014718652702867985	Fondaparinux is excreted to 64 <unk> 77 % by the kidney as unchanged compound .
D-226	-0.014718652702867985	Fondaparinux is excreted to 64 <unk> 77 % by the kidney as unchanged compound .
P-226	-0.0030 -0.0016 -0.0003 -0.0012 -0.0006 -0.0040 -0.0064 -0.0006 -0.0009 -0.0145 -0.0145 -0.0315 -0.0016 -0.0030 -0.0123 -0.0027 -0.0016 -0.2005 -0.0141 -0.0143 -0.0023 -0.0177 -0.0025 -0.0014
S-665	Dyspnoe , Belastungsdyspnoe , Husten , Dysphonie .
T-665	Common : dyspnoea , dyspnoea exertional , cough , dysphonia .
H-665	-0.04060904681682587	Common : dyspnoea , dyspnoea exertional , cough , dysphonia .
D-665	-0.04060904681682587	Common : dyspnoea , dyspnoea exertional , cough , dysphonia .
P-665	-0.0145 -0.0019 -0.0143 -0.0112 -0.0014 -0.0129 -0.0011 -0.0018 -0.0144 -0.0014 -0.0135 -0.0011 -0.0145 -0.0144 -0.0109 -0.0049 -0.0004 -0.0022 -0.0045 -0.0031 -0.0012 -0.0007 -0.8270 -0.0014
S-1743	Wenn die Ergebnisse bekannt sind , ist die antimy- kotische Therapie jedoch entsprechend anzupassen .
T-1743	2 The dose regimen of Mycamine depends on the body weight of the patient as given in the following tables :
H-1743	-0.015280093066394329	2 The dose regimen of Mycamine depends on the body weight of the patient as given in the following tables :
D-1743	-0.015280093066394329	2 The dose regimen of Mycamine depends on the body weight of the patient as given in the following tables :
P-1743	-0.0162 -0.0851 -0.0145 -0.0147 -0.0023 -0.0138 -0.0145 -0.0145 -0.0143 -0.0145 -0.0029 -0.0061 -0.0144 -0.0142 -0.0127 -0.0045 -0.0055 -0.0145 -0.0145 -0.0120 -0.0062 -0.0145 -0.0145 -0.0383 -0.0028
S-776	Busilvex und Busulfan wurden nicht an Patienten mit Leberfunktionsstörungen untersucht .
T-776	Busilvex as well as busulfan has not been studied in patients with hepatic impairment .
H-776	-0.028982996940612793	Busilvex as well as busulfan has not been studied in patients with hepatic impairment .
D-776	-0.028982996940612793	Busilvex as well as busulfan has not been studied in patients with hepatic impairment .
P-776	-0.0052 -0.0004 -0.0010 -0.0012 -0.4389 -0.0018 -0.0015 -0.0144 -0.0012 -0.0009 -0.0192 -0.0018 -0.0011 -0.0497 -0.0070 -0.0024 -0.0809 -0.0142 -0.0018 -0.0010 -0.0943 -0.0034 -0.0005 -0.0068 -0.0016 -0.0014
S-1335	Die Nebenwirkungen waren im Allgemeinen leicht und vorübergehend und erforderten nur selten einen Therapieabbruch .
T-1335	Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy .
H-1335	-0.022561945021152496	Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy .
D-1335	-0.022561945021152496	Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy .
P-1335	-0.0140 -0.0014 -0.0336 -0.0006 -0.0171 -0.0050 -0.0014 -0.0045 -0.0033 -0.0087 -0.0005 -0.0334 -0.2288 -0.0020 -0.1452 -0.0130 -0.0144 -0.0145 -0.0012 -0.0051 -0.0126 -0.0021 -0.0015 -0.0040 -0.0383 -0.0015 -0.0014
S-511	Calcobutrol @-@ Natrium , Trometamol , Salzsäure und Wasser für
T-511	- The other ingredients are calcobutrol sodium , trometamol , hydrochloric acid and water for injections
H-511	-0.007674431893974543	- The other ingredients are calcobutrol sodium , trometamol , hydrochloric acid and water for injections
D-511	-0.007674431893974543	- The other ingredients are calcobutrol sodium , trometamol , hydrochloric acid and water for injections
P-511	-0.0546 -0.0333 -0.0146 -0.0127 -0.0121 -0.0090 -0.0016 -0.0008 -0.0007 -0.0075 -0.0005 -0.0016 -0.0051 -0.0014 -0.0009 -0.0016 -0.0017 -0.0018 -0.0006 -0.0006 -0.0005 -0.0011 -0.0014 -0.0120 -0.0023 -0.0059 -0.0145 -0.0143 -0.0078
S-1312	5 Filmtabletten 10 Filmtabletten 30 Filmtabletten 100 Filmtabletten
T-1312	5 film @-@ coated tablets 10 film @-@ coated tablets 30 film @-@ coated tablets 100 film @-@ coated tablets
H-1312	-0.0029450315050780773	5 film @-@ coated tablets 10 film @-@ coated tablets 30 film @-@ coated tablets 100 film @-@ coated tablets
D-1312	-0.0029450315050780773	5 film @-@ coated tablets 10 film @-@ coated tablets 30 film @-@ coated tablets 100 film @-@ coated tablets
P-1312	-0.0036 -0.0087 -0.0144 -0.0158 -0.0062 -0.0017 -0.0011 -0.0020 -0.0026 -0.0018 -0.0013 -0.0006 -0.0008 -0.0010 -0.0022 -0.0015 -0.0020 -0.0006 -0.0004 -0.0010 -0.0011 -0.0045 -0.0024 -0.0036 -0.0005 -0.0005 -0.0008 -0.0011 -0.0017
S-1732	Thrombozytentransfusionsbedürftigkeit ) bei 100 % der Patienten auf .
T-1732	In children , thrombocytopenia ( &lt; 25x109 / l or requiring platelet transfusion ) occurred in 100 % of patients .
H-1732	-0.008098218590021133	In children , thrombocytopenia ( &lt; 25x109 / l or requiring platelet transfusion ) occurred in 100 % of patients .
D-1732	-0.008098218590021133	In children , thrombocytopenia ( &lt; 25x109 / l or requiring platelet transfusion ) occurred in 100 % of patients .
P-1732	-0.0143 -0.0145 -0.0127 -0.0145 -0.0016 -0.0009 -0.0209 -0.0076 -0.0011 -0.0091 -0.0145 -0.0002 -0.0010 -0.0145 -0.0145 -0.0142 -0.0145 -0.0144 -0.0145 -0.0145 -0.0145 -0.0081 -0.0007 -0.0055 -0.0033 -0.0016 -0.0018 -0.0134 -0.0022 -0.0030 -0.0016 -0.0017 -0.0092 -0.0015 -0.0014
S-423	Tritt eine Verschlechterung ein , muss die Therapie abgebrochen werden ( siehe Abschnitt 4.2 ) .
T-423	Cardiac status must be assessed before start of therapy and monitored clinically during therapy ; if any deterioration occurs , therapy must be stopped ( see section 4.2 ) .
H-423	-0.2244655191898346	Cardiac status must be assessed before start of therapy ; if any deterioration occurs , therapy must be stopped ( see section 4.2 ) .
D-423	-0.2244655191898346	Cardiac status must be assessed before start of therapy ; if any deterioration occurs , therapy must be stopped ( see section 4.2 ) .
P-423	-0.0338 -0.0092 -0.0145 -0.0137 -0.0027 -0.0143 -0.0007 -0.0183 -0.0145 -0.0030 -0.0128 -5.9309 -0.0138 -0.0144 -0.0054 -0.0018 -0.0050 -0.0007 -0.0035 -0.0261 -0.0077 -0.0018 -0.4942 -0.0032 -0.0025 -0.0069 -0.0012 -0.0014 -0.0017 -0.2971 -0.0014
S-1409	Daher werden die Informationen zu oralem Olanzapin im Folgenden als Referenz angegeben .
T-1409	However , systemic concentrations in these studies were generally less than that seen at effect levels in the oral studies ; thus the information on oral olanzapine is provided below for reference .
H-1409	-0.01055221538990736	However , systemic concentrations in these studies were generally less than that seen at effect levels in the oral studies ; thus the information on oral olanzapine is provided below for reference .
D-1409	-0.01055221538990736	However , systemic concentrations in these studies were generally less than that seen at effect levels in the oral studies ; thus the information on oral olanzapine is provided below for reference .
P-1409	-0.0147 -0.0023 -0.0145 -0.0071 -0.0022 -0.0145 -0.0063 -0.0007 -0.0141 -0.0143 -0.0140 -0.0140 -0.0169 -0.0159 -0.0109 -0.0140 -0.0143 -0.0149 -0.0145 -0.0147 -0.0105 -0.0123 -0.0144 -0.0145 -0.0146 -0.0224 -0.0123 -0.0111 -0.0105 -0.0022 -0.0032 -0.0007 -0.0007 -0.0009 -0.0046 -0.0136 -0.0090 -0.0356 -0.0017 -0.0017 -0.0014
S-1802	Das hängt davon ab , welche Krankheit bei Ihnen behandelt wird und wie Sie auf die Behandlung ansprechen .
T-1802	Your doctor may also advise you to start or stop taking other medicines , depending on what condition you <<unk>> re being treated for and the way you respond to treatment . • Swallow your tablets whole .
H-1802	-0.022665632888674736	Your doctor may also advise you to start or stop taking other medicines , depending on what condition you <unk> re being treated for and the way you respond to treatment .
D-1802	-0.022665632888674736	Your doctor may also advise you to start or stop taking other medicines , depending on what condition you <unk> re being treated for and the way you respond to treatment .
P-1802	-0.0159 -0.0145 -0.0131 -0.0689 -0.0892 -0.0010 -0.0069 -0.0095 -0.0144 -0.0145 -0.0060 -0.0136 -0.0188 -0.0070 -0.0109 -0.0148 -0.0110 -0.0017 -0.0151 -0.0124 -0.0048 -0.0145 -0.0140 -0.0136 -0.0009 -0.0021 -0.0109 -0.0136 -0.0103 -0.0038 -0.0050 -0.0105 -0.0045 -0.0016 -0.3241
S-1114	Gelenkschmerzen , Muskelkrämpfe , Gliederschmerzen , Rückenschmerzen Gelenkerkrankungen
T-1114	pruritus , rash , alopecias , acne , sweating increased dermatitis , photosensitivity toxic epidermal necrolysis ( Lyell <<unk>> s syndrome )
H-1114	-0.10420794039964676	pruritus , rash , alopecias , acne , sweating increased dermatitis , photosensitivity toxic epidermal necrolysis
D-1114	-0.10420794039964676	pruritus , rash , alopecias , acne , sweating increased dermatitis , photosensitivity toxic epidermal necrolysis
P-1114	-0.0169 -0.0145 -0.0123 -0.0098 -0.0059 -0.0200 -0.0106 -0.0026 -0.0269 -0.0097 -0.0145 -0.0139 -0.0030 -0.1377 -0.0121 -0.0066 -0.1077 -0.0092 -0.0156 -0.0145 -0.0028 -0.0002 -0.1190 -0.0261 -0.0141 -0.0072 -0.0012 -0.0054 -0.0234 -0.0145 -0.0124 -0.0020 -0.0102 -0.0145 -0.0112 -0.0144 -0.0022 -3.2154
S-360	Antidepressiva wurden in allen Studien mit Ausnahme der Studie 2 vor der aktiven Behandlung abgesetzt .
T-360	The effectiveness of sodium oxybate for the treatment of narcolepsy symptoms was established in four multicentre , randomised , double @-@ blind , placebo @-@ controlled , parallel @-@ group trials ( Trial 1 , 2 , 3 and 4 ) in patients with narcolepsy with cataplexy except for trial 2 where cataplexy was not required for enrolment Concomitant stimulant use was permitted in all trials ( except for the active @-@ treatment phase of Trial 2 ) ; antidepressants were withdrawn prior to active treatment in all trials with the exception of Trial 2 .
H-360	-0.046081412583589554	The effectiveness of sodium oxybate for the treatment of narcolepsy symptoms was established in four multicentre , randomised , double @-@ blind , placebo @-@ controlled , parallel @-@ group trials ( Trial 1 , 2 , 3 and 4 ) in patients with narcolepsy with cataplexy except for trial 2 where cataplexy was not required for enrolment Concomitant stimulant use was permitted in all trials ( except for the active @-@ treatment phase of Trial 2 ) ; antidepressants were withdrawn prior to active treatment in all trials with the exception of Trial 2 .
D-360	-0.046081412583589554	The effectiveness of sodium oxybate for the treatment of narcolepsy symptoms was established in four multicentre , randomised , double @-@ blind , placebo @-@ controlled , parallel @-@ group trials ( Trial 1 , 2 , 3 and 4 ) in patients with narcolepsy with cataplexy except for trial 2 where cataplexy was not required for enrolment Concomitant stimulant use was permitted in all trials ( except for the active @-@ treatment phase of Trial 2 ) ; antidepressants were withdrawn prior to active treatment in all trials with the exception of Trial 2 .
P-360	-0.0145 -0.0145 -0.0017 -0.0329 -0.0145 -0.0068 -0.0144 -0.0145 -0.0127 -0.0141 -0.0124 -0.0115 -0.0042 -0.0145 -0.0129 -0.0002 -0.0005 -0.0457 -0.0214 -0.0144 -0.0065 -0.0173 -0.0145 -0.0098 -0.0143 -0.0014 -0.0145 -0.0145 -0.0118 -0.0000 -0.0011 -0.0132 -0.2385 -0.0079 -0.0090 -0.0137 -0.4885 -0.0007 -0.0001 -0.0015 -0.0101 -0.0111 -0.0158 -0.3522 -0.0139 -0.0132 -0.0128 -0.0630 -0.0145 -0.0014 -0.0176 -0.0160 -0.0123 -0.3570 -0.0127 -0.4080 -0.0108 -0.0357 -0.2735 -0.0146 -0.0114 -0.2911 -0.0108 -0.0001 -0.0006 -0.0159 -0.3937 -0.0144 -0.0145 -0.0120 -0.0159 -0.0083 -0.0149 -0.0065 -0.0203 -0.0145 -0.0089 -0.0085 -0.0083 -0.0075 -0.0884 -0.0147 -0.1853 -0.0145 -0.0135 -0.0010 -0.0012 -0.0425 -0.0145 -0.0013 -0.0014 -0.0145 -0.0109 -0.0083 -0.0895 -0.1366 -0.0002 -0.1321 -0.0136 -0.0124 -0.1304 -0.0146 -0.0117 -0.0141 -0.0145 -0.0143 -0.0139 -0.0140 -0.0143 -0.0145 -0.0009 -0.0092 -0.0095 -0.5289 -0.1701 -0.0013 -0.0008 -0.0094 -0.0086 -0.0140 -0.0009 -0.0155 -0.0014 -0.0125 -0.0033 -0.3005 -0.0126 -0.0100 -0.2771 -0.0142 -0.0145 -0.0927 -0.0152 -0.0019 -0.0109 -0.0210 -0.0014
S-1794	Im Mai 2000 erfolgte seine Wahl zum Vorsitzenden des Ausschusses für Arzneimittel für seltene Leiden .
T-1794	He was elected Chairperson of the Committee for Orphan Medicinal Products in May 2000 .
H-1794	-0.008048324845731258	He was elected Chairperson of the Committee for Orphan Medicinal Products in May 2000 .
D-1794	-0.008048324845731258	He was elected Chairperson of the Committee for Orphan Medicinal Products in May 2000 .
P-1794	-0.0110 -0.0024 -0.0013 -0.0144 -0.0043 -0.0016 -0.0017 -0.0030 -0.1135 -0.0020 -0.0002 -0.0008 -0.0020 -0.0008 -0.0005 -0.0012 -0.0035 -0.0014 -0.0008 -0.0015 -0.0014
S-1226	WIE IST VANIQA AUFZUBEWAHREN ?
T-1226	HOW TO STORE Vaniqa
H-1226	-0.0563027486205101	HOW TO STORE Vaniqa
D-1226	-0.0563027486205101	HOW TO STORE Vaniqa
P-1226	-0.0018 -0.0005 -0.0119 -0.0141 -0.0139 -0.0068 -0.3029 -0.0022 -0.0017 -0.2072
S-568	Besonderer Beitrag für Arzneimittel für seltene Leiden ( Orphan Medicinal Products )
T-568	Special contribution for orphan medicinal products
H-568	-0.010033173486590385	Special contribution for orphan medicinal products
D-568	-0.010033173486590385	Special contribution for orphan medicinal products
P-568	-0.0049 -0.0068 -0.0064 -0.0034 -0.0002 -0.0012 -0.0007 -0.0616 -0.0006 -0.0145
S-289	WIE IST ARIXTRA AUFZUBEWAHREN ?
T-289	HOW TO STORE ARIXTRA
H-289	-0.030151115730404854	HOW TO STORE ARIXTRA
D-289	-0.030151115730404854	HOW TO STORE ARIXTRA
P-289	-0.0018 -0.0005 -0.0124 -0.0142 -0.0139 -0.0052 -0.0013 -0.0015 -0.0023 -0.0012 -0.2773
S-1249	WIE IST COAPROVEL AUFZUBEWAHREN ?
T-1249	HOW TO STORE COAPROVEL
H-1249	-0.029874907806515694	HOW TO STORE COAPROVEL
D-1249	-0.029874907806515694	HOW TO STORE COAPROVEL
P-1249	-0.0016 -0.0006 -0.0121 -0.0142 -0.0138 -0.0118 -0.0009 -0.0012 -0.0013 -0.0008 -0.2704
S-1885	WIE IST REVATIO AUFZUBEWAHREN ?
T-1885	HOW TO STORE REVATIO
H-1885	-0.03234599530696869	HOW TO STORE REVATIO
D-1885	-0.03234599530696869	HOW TO STORE REVATIO
P-1885	-0.0014 -0.0006 -0.0115 -0.0143 -0.0137 -0.0103 -0.0012 -0.0007 -0.0017 -0.0013 -0.2993
S-732	WIE IST TRUDEXA AUFZUBEWAHREN ?
T-732	HOW TO STORE TRUDEXA
H-732	-0.030963676050305367	HOW TO STORE TRUDEXA
D-732	-0.030963676050305367	HOW TO STORE TRUDEXA
P-732	-0.0020 -0.0005 -0.0121 -0.0142 -0.0138 -0.0066 -0.0012 -0.0017 -0.0014 -0.0013 -0.2859
S-1977	WIE IST ZIMULTI AUFZUBEWAHREN ?
T-1977	HOW TO STORE ZIMULTI dic
H-1977	-0.05396971479058266	HOW TO STORE ZIMULTI
D-1977	-0.05396971479058266	HOW TO STORE ZIMULTI
P-1977	-0.0018 -0.0005 -0.0115 -0.0141 -0.0140 -0.0135 -0.0009 -0.0010 -0.0019 -0.0015 -0.5329
S-500	Bitte informieren Sie Ihren Arzt , wenn Sie eines der folgenden Arzneimittel einnehmen oder einnehmen möchten :
T-500	Tell your doctor if you take or wish to take :
H-500	-0.06516560167074203	Tell your doctor if you take or wish to take :
D-500	-0.06516560167074203	Tell your doctor if you take or wish to take :
P-500	-0.5717 -0.0006 -0.0017 -0.0017 -0.0025 -0.0014 -0.0338 -0.0170 -0.0086 -0.0015 -0.0054 -0.1996 -0.0017
S-369	IDflu kann zeitgleich mit anderen Impfstoffen in unterschiedliche Extremitäten verabreicht werden .
T-369	Immunisation should be carried out on separate limbs .
H-369	-0.00979947205632925	Immunisation should be carried out on separate limbs .
D-369	-0.00979947205632925	Immunisation should be carried out on separate limbs .
P-369	-0.0146 -0.0140 -0.0144 -0.0054 -0.0137 -0.0016 -0.0143 -0.0144 -0.0079 -0.0010 -0.0012 -0.0146 -0.0103
S-951	In den klinischen Studien wurden die Dosierungen in Schritten von 50 mg herabgesetzt .
T-951	In the clinical studies doses were reduced by 50 mg steps .
H-951	-0.060910437256097794	In the clinical studies doses were reduced by 50 mg steps .
D-951	-0.060910437256097794	In the clinical studies doses were reduced by 50 mg steps .
P-951	-0.0059 -0.1197 -0.0020 -0.5557 -0.0112 -0.1146 -0.0055 -0.0044 -0.0146 -0.0042 -0.0009 -0.0110 -0.0017 -0.0014
S-332	Sagen Sie der Person , die sich um Sie kümmert , dass Sie Exelon einnehmen .
T-332	Tell your caregiver that you are taking Exelon .
H-332	-0.004059056751430035	Tell your caregiver that you are taking Exelon .
D-332	-0.004059056751430035	Tell your caregiver that you are taking Exelon .
P-332	-0.0023 -0.0006 -0.0169 -0.0081 -0.0049 -0.0021 -0.0087 -0.0017 -0.0045 -0.0033 -0.0015 -0.0009 -0.0014 -0.0020 -0.0018
S-1420	Es muss eine klare , farblose oder leicht perlmuttfarbene Flüssigkeit sein .
T-1420	It must be a clear , colourless or slightly pearly liquid .
H-1420	-0.02297152392566204	It must be a clear , colourless or slightly pearly liquid .
D-1420	-0.02297152392566204	It must be a clear , colourless or slightly pearly liquid .
P-1420	-0.0046 -0.0074 -0.0014 -0.0040 -0.0018 -0.0025 -0.0055 -0.0008 -0.0013 -0.0033 -0.0047 -0.0069 -0.0074 -0.0060 -0.3086 -0.0014
S-1542	Zusammenfassung der Sicherheitsdaten von Patienten mit nicht vorbehandeltem multiplem Myelom :
T-1542	Summary of safety data in patients with previously untreated multiple myeloma :
H-1542	-0.003536697942763567	Summary of safety data in patients with previously untreated multiple myeloma :
D-1542	-0.003536697942763567	Summary of safety data in patients with previously untreated multiple myeloma :
P-1542	-0.0035 -0.0196 -0.0050 -0.0008 -0.0010 -0.0138 -0.0038 -0.0016 -0.0021 -0.0018 -0.0006 -0.0009 -0.0003 -0.0008 -0.0003 -0.0027 -0.0014
S-342	Dompé Biotec S.p.A. tl ch ni el itt m ei zn Ar
T-342	Dompé Biotec S. p . A. no ct du ro ed M
H-342	-0.044121965765953064	Dompé Biotec S. p . A. no ct du ro ed M
D-342	-0.044121965765953064	Dompé Biotec S. p . A. no ct du ro ed M
P-342	-0.0024 -0.0020 -0.0013 -0.0016 -0.0009 -0.0003 -0.0145 -0.3518 -0.0122 -0.0117 -0.0145 -0.0145 -0.0151 -0.0145 -0.1697 -0.1086 -0.0144
S-1216	Die klinische Erfahrung bei Patienten mit einer mäßigen Einschränkung der Nierenfunktion ist sehr begrenzt .
T-1216	The clinical experience in patients with moderate renal impairment is very limited .
H-1216	-0.00424768403172493	The clinical experience in patients with moderate renal impairment is very limited .
D-1216	-0.00424768403172493	The clinical experience in patients with moderate renal impairment is very limited .
P-1216	-0.0110 -0.0011 -0.0022 -0.0086 -0.0016 -0.0021 -0.0075 -0.0142 -0.0009 -0.0119 -0.0008 -0.0005 -0.0014 -0.0018 -0.0064 -0.0017 -0.0015 -0.0014
S-1088	Es wird in einem mit 3 ml vorgefüllten Fertigpen ( genannt FlexPen ) geliefert .
T-1088	It comes in a 3 ml pre @-@ filled pen ( called FlexPen ) .
H-1088	-0.0062539479695260525	It comes in a 3 ml pre @-@ filled pen ( called FlexPen ) .
D-1088	-0.0062539479695260525	It comes in a 3 ml pre @-@ filled pen ( called FlexPen ) .
P-1088	-0.0030 -0.0114 -0.0037 -0.0028 -0.0133 -0.0020 -0.0089 -0.0018 -0.0011 -0.0133 -0.0400 -0.0026 -0.0024 -0.0011 -0.0004 -0.0014 -0.0019 -0.0014
S-737	Jede Packung enthält 56 Tabletten ( 4 Blister mit jeweils 14 Tabletten ) .
T-737	Each package contains 56 tablets ( 4 blister cards of 14 tablets each ) .
H-737	-0.009067488834261894	Each package contains 56 tablets ( 4 blister cards of 14 tablets each ) .
D-737	-0.009067488834261894	Each package contains 56 tablets ( 4 blister cards of 14 tablets each ) .
P-737	-0.0017 -0.0983 -0.0019 -0.0011 -0.0039 -0.0016 -0.0015 -0.0025 -0.0011 -0.0174 -0.0145 -0.0119 -0.0022 -0.0037 -0.0011 -0.0032 -0.0016 -0.0017 -0.0014
S-1022	Aranesp 40 Mikrogramm Injektionslösung in einem vorgefüllten Injektor .
T-1022	Aranesp 40 micrograms solution for injection in a pre @-@ filled pen .
H-1022	-0.005143085494637489	Aranesp 40 micrograms solution for injection in a pre @-@ filled pen .
D-1022	-0.005143085494637489	Aranesp 40 micrograms solution for injection in a pre @-@ filled pen .
P-1022	-0.0023 -0.0006 -0.0011 -0.0009 -0.0046 -0.0044 -0.0084 -0.0127 -0.0142 -0.0036 -0.0018 -0.0041 -0.0070 -0.0085 -0.0018 -0.0011 -0.0149 -0.0042 -0.0015
S-354	Falls klinisch zu rechtfertigen , kann eine anschließende Einstellung auf eine höhere Dosis erfolgen .
T-354	Subsequent titration to a higher dose may be initiated as warranted clinically
H-354	-0.01807042770087719	Subsequent titration to a higher dose may be initiated as warranted clinically
D-354	-0.01807042770087719	Subsequent titration to a higher dose may be initiated as warranted clinically
P-354	-0.0218 -0.0012 -0.0145 -0.0145 -0.0012 -0.0045 -0.0036 -0.0018 -0.0037 -0.0093 -0.0038 -0.0145 -0.0019 -0.0158 -0.0159 -0.0002 -0.0011 -0.0089 -0.0012 -0.2222
S-1276	Ist Wismut nicht verfügbar , sollte eine auf PPI basierende Tripletherapie verabreicht werden .
T-1276	If bismuth is not available , PPI @-@ based triple therapies should be used .
H-1276	-0.004185779485851526	If bismuth is not available , PPI @-@ based triple therapies should be used .
D-1276	-0.004185779485851526	If bismuth is not available , PPI @-@ based triple therapies should be used .
P-1276	-0.0043 -0.0014 -0.0001 -0.0002 -0.0019 -0.0039 -0.0011 -0.0027 -0.0130 -0.0008 -0.0046 -0.0014 -0.0126 -0.0143 -0.0011 -0.0021 -0.0015 -0.0135 -0.0019 -0.0014
S-144	Die Dosen werden gemäß dem Ansprechen angepasst , und die Behandlung kann bis zu 5 Wochen dauern .
T-144	Doses are adjusted according to the response , and treatment may continue for up to 5 weeks .
H-144	-0.006473066750913858	Doses are adjusted according to the response , and treatment may continue for up to 5 weeks .
D-144	-0.006473066750913858	Doses are adjusted according to the response , and treatment may continue for up to 5 weeks .
P-144	-0.0055 -0.0005 -0.0051 -0.0042 -0.0100 -0.0014 -0.0221 -0.0023 -0.0077 -0.0021 -0.0109 -0.0117 -0.0230 -0.0043 -0.0018 -0.0014 -0.0114 -0.0011 -0.0016 -0.0014
S-1632	6 ( 3,8 ) 1 ( 0,6 ) 0 ( 0,0 ) 0 ( 0,0 )
T-1632	6 ( 3.8 ) 1 ( 0.6 ) 0 ( 0.0 ) 0 ( 0.0 )
H-1632	-0.0022925646044313908	6 ( 3.8 ) 1 ( 0.6 ) 0 ( 0.0 ) 0 ( 0.0 )
D-1632	-0.0022925646044313908	6 ( 3.8 ) 1 ( 0.6 ) 0 ( 0.0 ) 0 ( 0.0 )
P-1632	-0.0057 -0.0014 -0.0133 -0.0016 -0.0014 -0.0015 -0.0013 -0.0024 -0.0015 -0.0014 -0.0012 -0.0013 -0.0026 -0.0013 -0.0014 -0.0012 -0.0013 -0.0023 -0.0013 -0.0014 -0.0014
S-1397	las Novo Nordisk A / S DK @-@ 2880 Bagsværd Dänemark
T-1397	au Novo Nordisk A / S DK @-@ 2880 Bagsværd Denmark
H-1397	-0.01193301472812891	au Novo Nordisk A / S DK @-@ 2880 Bagsværd Denmark
D-1397	-0.01193301472812891	au Novo Nordisk A / S DK @-@ 2880 Bagsværd Denmark
P-1397	-0.0145 -0.0014 -0.0014 -0.0011 -0.0015 -0.0010 -0.0018 -0.0014 -0.0011 -0.0027 -0.0010 -0.2010 -0.0011 -0.0011 -0.0084 -0.0018 -0.0014 -0.0004 -0.0008 -0.0037 -0.0019
S-1697	Es wird in einem mit 3 ml vorgefüllten Fertigpen genannt FlexPen , geliefert .
T-1697	It comes in a 3 ml pre @-@ filled pen , called FlexPen - see overleaf for detailed instructions .
H-1697	-0.08798776566982269	It comes in a 3 ml pre @-@ filled pen , called FlexPen .
D-1697	-0.08798776566982269	It comes in a 3 ml pre @-@ filled pen , called FlexPen .
P-1697	-0.0027 -0.0093 -0.0032 -0.0021 -0.0129 -0.0591 -0.0087 -0.0017 -0.0014 -0.0126 -0.0186 -0.0032 -0.0053 -0.0012 -0.0005 -1.3518 -0.0015
S-688	Die Anwenderin sollte deshalb vor der Anwendung von EVRA ihren Arzt aufsuchen .
T-688	If more than 7 days elapse after taking the last active oral contraceptive tablet , the woman may have ovulated and should , therefore , be advised to consult a physician before initiating treatment with EVRA .
H-688	-0.0628213882446289	If more than 7 days elapse after taking the last active oral contraceptive tablet , the woman may have ovulated and should , therefore , be advised to consult a physician before initiating treatment .
D-688	-0.0628213882446289	If more than 7 days elapse after taking the last active oral contraceptive tablet , the woman may have ovulated and should , therefore , be advised to consult a physician before initiating treatment .
P-688	-0.0145 -0.0151 -0.0098 -0.0146 -0.0138 -0.0144 -0.0002 -0.0101 -0.0141 -0.0141 -0.0138 -0.0145 -0.0145 -0.0145 -0.0125 -0.0029 -0.0012 -0.0143 -0.0086 -0.0055 -0.0116 -0.0145 -0.0142 -0.0135 -0.0145 -0.0140 -0.0143 -0.0144 -0.0148 -0.0068 -0.0016 -0.0163 -0.0135 -0.0051 -0.0126 -0.0006 -0.0205 -0.0184 -0.0008 -0.0475 -0.0145 -0.0019 -0.0138 -2.3028 -0.0014
S-1008	Lactose @-@ Monohydrat , Magnesiumstearat ( E
T-1008	- The other ingredients in the tablet core are : lactose monohydrate , magnesium stearate ( E 470 B ) ,
H-1008	-0.023507757112383842	- The other ingredients in the tablet core are : lactose monohydrate , magnesium stearate ( E 470 B ) ,
D-1008	-0.023507757112383842	- The other ingredients in the tablet core are : lactose monohydrate , magnesium stearate ( E 470 B ) ,
P-1008	-0.0284 -0.0260 -0.0145 -0.0143 -0.0139 -0.0110 -0.0145 -0.0105 -0.0435 -0.0341 -0.0393 -0.0241 -0.0007 -0.0006 -0.0019 -0.0005 -0.0013 -0.0008 -0.0013 -0.0024 -0.0011 -0.0009 -0.1933 -0.0008 -0.0011 -0.0012 -0.0031 -0.0015 -0.1550 -0.0144 -0.0145 -0.0096 -0.1113 -0.0078
S-967	Cetuximab hat eine lange Eliminationshalbwertszeit von 70
T-967	Cetuximab has a long elimination half @-@ life with values ranging from 70 to 100 hours at the target dose .
H-967	-0.247064471244812	Cetuximab has a long elimination half @-@ life of 70 to 100 hours at the target dose .
D-967	-0.247064471244812	Cetuximab has a long elimination half @-@ life of 70 to 100 hours at the target dose .
P-967	-0.0026 -0.0009 -0.0008 -0.0004 -0.0009 -0.0010 -0.0027 -0.0025 -0.0024 -0.0028 -0.0014 -0.0016 -0.0107 -0.0074 -5.9532 -0.0013 -0.0188 -0.0141 -0.0153 -0.0851 -0.0126 -0.0144 -0.0127 -0.0094 -0.0014
S-938	Falls Sie eines der genannten Arzneimittel anwenden , sprechen Sie bitte sofort mit Ihrem Arzt . ... &#91; &#93; ....
T-938	- If any of these applies to you tell your doctor immediately . <<unk>>
H-938	-0.028794730082154274	- If any of these applies to you tell your doctor immediately . <unk>
D-938	-0.028794730082154274	- If any of these applies to you tell your doctor immediately . <unk>
P-938	-0.0923 -0.0077 -0.2147 -0.0022 -0.0134 -0.0147 -0.0101 -0.0062 -0.0172 -0.0023 -0.0036 -0.0097 -0.0093 -0.0145 -0.0141
S-985	- Wenn Sie an einer Infektion mit Fieber leiden , sollte die Impfung verschoben werden , bis Sie wieder
T-985	Vaccination should be postponed until after you have
H-985	-0.020566577091813087	Vaccination should be postponed until after you have
D-985	-0.020566577091813087	Vaccination should be postponed until after you have
P-985	-0.2044 -0.0010 -0.0022 -0.0035 -0.0017 -0.0047 -0.0011 -0.0014 -0.0033 -0.0132 -0.0051 -0.0113 -0.0145
S-1109	Enalaprilat ist mit einer Rate von 62 ml / min dialysierbar .
T-1109	The dialysis clearance is 62 ml / min .
H-1109	-0.0067614479921758175	The dialysis clearance is 62 ml / min .
D-1109	-0.0067614479921758175	The dialysis clearance is 62 ml / min .
P-1109	-0.0144 -0.0131 -0.0010 -0.0116 -0.0145 -0.0014 -0.0134 -0.0047 -0.0024 -0.0016 -0.0015 -0.0039 -0.0043
S-870	INNENETIKETT DER LÖSUNGSMITTELFLASCHE
T-870	SOLVENT LABEL
H-870	-0.009714542888104916	SOLVENT LABEL
D-870	-0.009714542888104916	SOLVENT LABEL
P-870	-0.0144 -0.0072 -0.0137 -0.0118 -0.0043 -0.0139 -0.0058 -0.0019 -0.0145
S-1410	- Neupro kann Halluzinationen ( Sehen oder Hören von Dingen , die nicht wirklich sind )
T-1410	If you notice such
H-1410	-0.013599827885627747	If you notice such
D-1410	-0.013599827885627747	If you notice such
P-1410	-0.0145 -0.0100 -0.0145 -0.0145 -0.0145
S-282	Luminity sollte nicht bei Kindern und Jugendlichen angewendet werden , da keine Untersuchungen in diesen Gruppen vorliegen .
T-282	Luminity should not be used in children and adolescents as it has not been studied in these groups .
H-282	-0.03711424767971039	Luminity should not be used in children and adolescents as it has not been studied in these groups .
D-282	-0.03711424767971039	Luminity should not be used in children and adolescents as it has not been studied in these groups .
P-282	-0.0030 -0.0006 -0.0014 -0.0020 -0.0015 -0.0014 -0.1413 -0.3427 -0.0016 -0.1669 -0.0037 -0.0010 -0.0008 -0.1737 -0.0138 -0.0091 -0.0034 -0.0016 -0.0079 -0.0026 -0.0055 -0.0019 -0.0018 -0.0014
S-195	Wie alle Arzneimittel kann Simulect Nebenwirkungen haben , die aber nicht bei jedem auftreten müssen .
T-195	Like all medicines , Simulect can cause side effects , although not everybody gets them .
H-195	-0.01832408271729946	Like all medicines , Simulect can cause side effects , although not everybody gets them .
D-195	-0.01832408271729946	Like all medicines , Simulect can cause side effects , although not everybody gets them .
P-195	-0.0052 -0.0077 -0.0060 -0.2207 -0.0028 -0.0022 -0.0015 -0.0010 -0.0013 -0.0390 -0.0120 -0.0025 -0.0022 -0.0153 -0.0160 -0.0072 -0.0142 -0.0144 -0.0106 -0.0016 -0.0014
S-1158	Aus mikrobiologischer Sicht sind rekonstituierte und verdünnte Lösungen sofort anzuwenden .
T-1158	From a microbiological point of view , the reconstituted and diluted solutions should be used immediately .
H-1158	-0.003883291967213154	From a microbiological point of view , the reconstituted and diluted solutions should be used immediately .
D-1158	-0.003883291967213154	From a microbiological point of view , the reconstituted and diluted solutions should be used immediately .
P-1158	-0.0049 -0.0056 -0.0007 -0.0011 -0.0013 -0.0063 -0.0013 -0.0007 -0.0032 -0.0144 -0.0123 -0.0006 -0.0010 -0.0029 -0.0019 -0.0008 -0.0027 -0.0087 -0.0020 -0.0104 -0.0037 -0.0014 -0.0014
S-1267	- Bei HBeAg @-@ positiven Patienten ohne Zirrhose sollte die Behandlung mindestens 6 @-@ 12 Monate
T-1267	- In HBeAg positive patients without cirrhosis , treatment should be administered for at least
H-1267	-0.007666955702006817	- In HBeAg positive patients without cirrhosis , treatment should be administered for at least
D-1267	-0.007666955702006817	- In HBeAg positive patients without cirrhosis , treatment should be administered for at least
P-1267	-0.0031 -0.0101 -0.0079 -0.0018 -0.0012 -0.0012 -0.0122 -0.0022 -0.0053 -0.0014 -0.0006 -0.0003 -0.0008 -0.0093 -0.0044 -0.0015 -0.0130 -0.0144 -0.0008 -0.0026 -0.0051 -0.0010 -0.0763
S-497	Ritonavir / Efavirenz ( 500 mg zweimal täglich / 600 mg einmal täglich )
T-497	Ritonavir / Efavirenz ( 500 mg twice daily / 600 mg once daily )
H-497	-0.015358293429017067	Ritonavir / Efavirenz ( 500 mg twice daily / 600 mg once daily )
D-497	-0.015358293429017067	Ritonavir / Efavirenz ( 500 mg twice daily / 600 mg once daily )
P-497	-0.0040 -0.0014 -0.0007 -0.0010 -0.0016 -0.0090 -0.0007 -0.0011 -0.0004 -0.0018 -0.0015 -0.0025 -0.0016 -0.0025 -0.2299 -0.0016 -0.0007 -0.0009 -0.0009 -0.0710 -0.0015 -0.0016
S-1016	Sonstiger Bestandteil Ein ml enthält 0,15 mmol ( 3,45 mg ) Natrium .
T-1016	Excipient Each ml contains 0.15 mmol ( 3.45 mg ) of sodium .
H-1016	-0.014278762973845005	Excipient Each ml contains 0.15 mmol ( 3.45 mg ) of sodium .
D-1016	-0.014278762973845005	Excipient Each ml contains 0.15 mmol ( 3.45 mg ) of sodium .
P-1016	-0.0145 -0.0143 -0.0022 -0.0013 -0.0144 -0.0036 -0.0011 -0.0022 -0.0017 -0.0012 -0.0010 -0.0009 -0.0016 -0.0049 -0.0388 -0.0012 -0.0015 -0.0087 -0.0010 -0.0004 -0.1963 -0.0014
S-1614	Nach der Injektion von PhotoBarr wird Porfimer in Zellen überall im Körper aufgenommen .
T-1614	When PhotoBarr is injected , porfimer is absorbed into cells throughout the body .
H-1614	-0.004297452978789806	When PhotoBarr is injected , porfimer is absorbed into cells throughout the body .
D-1614	-0.004297452978789806	When PhotoBarr is injected , porfimer is absorbed into cells throughout the body .
P-1614	-0.0143 -0.0059 -0.0014 -0.0012 -0.0022 -0.0022 -0.0009 -0.0028 -0.0090 -0.0069 -0.0020 -0.0019 -0.0025 -0.0076 -0.0009 -0.0185 -0.0013 -0.0069 -0.0017 -0.0015 -0.0016 -0.0014
S-1032	a ) 26.07.96 b ) 08.01.97 c ) OJ L 5 , 09.1.1997
T-1032	a ) 26.7.1996 b ) 8.1.1997 c ) OJ L 5 , 09.1.1997
H-1032	-0.023850973695516586	a ) 26.7.1996 b ) 8.1.1997 c ) OJ L 5 , 09.1.1997
D-1032	-0.023850973695516586	a ) 26.7.1996 b ) 8.1.1997 c ) OJ L 5 , 09.1.1997
P-1032	-0.0035 -0.0014 -0.0143 -0.0044 -0.1291 -0.0014 -0.0013 -0.0142 -0.0071 -0.3211 -0.0011 -0.0014 -0.0019 -0.0007 -0.0016 -0.0013 -0.0014 -0.0056 -0.0011 -0.0014 -0.0078 -0.0014
S-389	Č eská republika Pfizer Animal Health Tel : + 420 283 004 111
T-389	Česká republika Pfizer Animal Health Tel : + 420 283 004 111
H-389	-0.00378608051687479	Česká republika Pfizer Animal Health Tel : + 420 283 004 111
D-389	-0.00378608051687479	Česká republika Pfizer Animal Health Tel : + 420 283 004 111
P-389	-0.0145 -0.0127 -0.0010 -0.0099 -0.0133 -0.0130 -0.0002 -0.0007 -0.0005 -0.0010 -0.0008 -0.0028 -0.0018 -0.0010 -0.0015 -0.0013 -0.0009 -0.0012 -0.0013 -0.0014 -0.0006 -0.0017
S-723	Schwangerschaft und Stillzeit Informieren Sie Ihren Arzt , wenn Sie schwanger sind oder werden möchten .
T-723	Pregnancy and breast feeding Tell your doctor if you are pregnant or planning to become pregnant .
H-723	-0.025449449196457863	Pregnancy and breast feeding Tell your doctor if you are pregnant or planning to become pregnant .
D-723	-0.025449449196457863	Pregnancy and breast feeding Tell your doctor if you are pregnant or planning to become pregnant .
P-723	-0.0065 -0.0004 -0.0007 -0.0025 -0.0144 -0.4265 -0.0112 -0.0007 -0.0015 -0.0014 -0.0021 -0.0013 -0.0019 -0.0079 -0.0264 -0.0144 -0.0024 -0.0042 -0.0044 -0.0020 -0.0015
S-516	- Das Hauptkriterium für einen Wirkungsvergleich ist die Reduktion der Eizahl bzw. der
T-516	- The principle criteria used for a comparison of effect is egg count reduction / larval identification or
H-516	-0.01040052343159914	- The principle criteria used for a comparison of effect is egg count reduction / larval identification or
D-516	-0.01040052343159914	- The principle criteria used for a comparison of effect is egg count reduction / larval identification or
P-516	-0.0026 -0.0032 -0.0153 -0.0128 -0.0186 -0.0166 -0.0108 -0.0067 -0.0052 -0.0137 -0.0044 -0.0145 -0.0089 -0.0069 -0.0148 -0.0157 -0.0077 -0.0145 -0.0012 -0.0145 -0.0097
S-1537	Gerinnungshemmung bei Erwachsenen mit HIT Typ II und thromboembolischer Erkrankung :
T-1537	Anticoagulation in adult patients with HIT type II and thromboembolic disease :
H-1537	-0.027472488582134247	Anticoagulation in adult patients with HIT type II and thromboembolic disease :
D-1537	-0.027472488582134247	Anticoagulation in adult patients with HIT type II and thromboembolic disease :
P-1537	-0.0086 -0.0016 -0.0002 -0.0083 -0.0031 -0.0247 -0.0066 -0.0809 -0.0042 -0.0008 -0.0049 -0.0597 -0.0019 -0.0002 -0.0004 -0.0005 -0.0009 -0.3612 -0.0040 -0.0028 -0.0014
S-1657	Kleinkindalter muss eine Auffrischimpfung mit Hib und MenC verabreicht werden .
T-1657	After primary vaccination in infancy , booster doses of Hib and MenC must be administered .
H-1657	-0.008524617180228233	After primary vaccination in infancy , booster doses of Hib and MenC must be administered .
D-1657	-0.008524617180228233	After primary vaccination in infancy , booster doses of Hib and MenC must be administered .
P-1657	-0.0145 -0.0145 -0.0144 -0.0022 -0.0144 -0.0090 -0.0565 -0.0061 -0.0143 -0.0052 -0.0144 -0.0003 -0.0042 -0.0029 -0.0016 -0.0016 -0.0006 -0.0018 -0.0103 -0.0015 -0.0100 -0.0009 -0.0022 -0.0014
S-1815	Parenterale Lösungen sollten vor der Anwendung auf Partikel und auf Farbveränderungen visuell geprüft werden .
T-1815	Parenteral solutions should be inspected visually for particulate matter and discoloration prior to administration .
H-1815	-0.035923250019550323	Parenteral solutions should be inspected visually for particulate matter and discoloration prior to administration .
D-1815	-0.035923250019550323	Parenteral solutions should be inspected visually for particulate matter and discoloration prior to administration .
P-1815	-0.0019 -0.0006 -0.0015 -0.0018 -0.0027 -0.0017 -0.0141 -0.0013 -0.0051 -0.0011 -0.0057 -0.0017 -0.7130 -0.0070 -0.0189 -0.0145 -0.0040 -0.0052 -0.0025 -0.0115 -0.0014 -0.0418 -0.0017 -0.0014
S-524	127 ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG
T-524	123 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
H-524	-0.039794959127902985	123 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
D-524	-0.039794959127902985	123 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
P-524	-0.0149 -0.0145 -0.0121 -0.0017 -0.0137 -0.0094 -0.0095 -0.0142 -0.0145 -0.0130 -0.0099 -0.0137 -0.0139 -0.0041 -0.0043 -0.0050 -0.0016 -0.0103 -0.0144 -0.0143 -0.0034 -0.0007 -0.0072 -0.7349
S-1095	Die Leberenzyme sind bei allen Patienten vor Beginn der Therapie mit Tandemact zu kontrollieren .
T-1095	Liver enzymes should be checked prior to the initiation of therapy with Tandemact in all patients .
H-1095	-0.004817734006792307	Liver enzymes should be checked prior to the initiation of therapy with Tandemact in all patients .
D-1095	-0.004817734006792307	Liver enzymes should be checked prior to the initiation of therapy with Tandemact in all patients .
P-1095	-0.0116 -0.0007 -0.0005 -0.0007 -0.0013 -0.0128 -0.0016 -0.0111 -0.0171 -0.0014 -0.0110 -0.0142 -0.0015 -0.0015 -0.0088 -0.0048 -0.0012 -0.0011 -0.0005 -0.0070 -0.0014 -0.0012 -0.0015 -0.0014
S-1060	- verringerte Zahl von Blutzellen , einschließlich weißer Blutzellen ( die bei Fieber gebildet
T-1060	- decreased number of cells in the blood , these include white cells ( which may occur with a fever ) ,
H-1060	-0.06914456933736801	- decreased number of cells in the blood , these include white cells ( which may occur with a fever ) ,
D-1060	-0.06914456933736801	- decreased number of cells in the blood , these include white cells ( which may occur with a fever ) ,
P-1060	-0.0023 -0.0106 -0.2205 -0.0037 -0.0014 -0.0156 -0.0139 -0.0048 -0.0020 -0.0032 -0.1426 -0.0107 -0.0020 -0.0617 -0.0027 -0.0108 -0.0144 -0.0141 -0.0136 -0.0138 -0.0032 -0.0010 -0.0084 -1.1495 -0.0021
S-1649	Leberfunktionsstörungen Tasigna wurde bisher nicht an Patienten mit eingeschränkter Leberfunktion untersucht .
T-1649	Hepatic impairment Tasigna has not been investigated in patients with hepatic impairment .
H-1649	-0.009411491453647614	Hepatic impairment Tasigna has not been investigated in patients with hepatic impairment .
D-1649	-0.009411491453647614	Hepatic impairment Tasigna has not been investigated in patients with hepatic impairment .
P-1649	-0.0142 -0.0013 -0.0112 -0.0143 -0.0038 -0.0005 -0.0033 -0.0042 -0.0005 -0.0004 -0.0028 -0.0708 -0.0041 -0.0580 -0.0072 -0.0013 -0.0015 -0.0319 -0.0014 -0.0011 -0.0017 -0.0005 -0.0005 -0.0020 -0.0048 -0.0014
S-984	Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-984	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-984	-0.016724398359656334	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
D-984	-0.016724398359656334	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
P-984	-0.0145 -0.0139 -0.0145 -0.0145 -0.0630 -0.0340 -0.0142 -0.0668 -0.0362 -0.0150 -0.0083 -0.0188 -0.0649 -0.0247 -0.1078 -0.0140 -0.0190 -0.0011 -0.0014 -0.0012 -0.0022 -0.0008 -0.0041 -0.0123 -0.0008 -0.0006 -0.0016 -0.0131 -0.0106 -0.0005 -0.0018 -0.0008 -0.0014 -0.0009 -0.0014 -0.0017
S-1287	Die Gabe von Aktivkohle oder eine Magenspülung sollten ebenfalls erwogen werden .
T-1287	In the postmarketing period with Remeron very rare cases of agranulocytosis have been reported , mostly reversible , but in some cases fatal .
H-1287	-0.013033297844231129	In the postmarketing period with Remeron very rare cases of agranulocytosis have been reported , mostly reversible , but in some cases fatal .
D-1287	-0.013033297844231129	In the postmarketing period with Remeron very rare cases of agranulocytosis have been reported , mostly reversible , but in some cases fatal .
P-1287	-0.0145 -0.0150 -0.0145 -0.0145 -0.0135 -0.0145 -0.0145 -0.0145 -0.0142 -0.0145 -0.0144 -0.0138 -0.0229 -0.0145 -0.0145 -0.0145 -0.0097 -0.0144 -0.0137 -0.0017 -0.0211 -0.0093 -0.0090 -0.0145 -0.0213 -0.0145 -0.0142 -0.0010 -0.0143 -0.0219 -0.0144 -0.0137 -0.0046 -0.0128 -0.0027 -0.0014
S-786	462 ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG
T-786	400 PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE @-@ FILLED PEN CARTON
H-786	-0.050347693264484406	400 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
D-786	-0.050347693264484406	400 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
P-786	-0.0146 -0.0145 -0.0126 -0.0041 -0.0135 -0.0106 -0.0095 -0.0143 -0.0145 -0.0129 -0.0094 -0.0136 -0.0132 -0.0037 -0.0044 -0.0049 -0.0016 -0.0098 -0.0144 -0.0143 -0.0035 -0.0007 -0.0074 -0.9864
S-1063	Tween 80 ( Polyoxyethylen @-@ Sorbitan- monooleat )
T-1063	Pharmacologically active substance Mineral oils Arlacel 83V ( sorbitan sesquioleate ) Tween 80 ( polyoxyethylene sorbitan monooleate )
H-1063	-0.10678346455097198	Pharmacologically active substance Mineral oils Arlacel 83V ( sorbitan sesquioleate ) Tween 80
D-1063	-0.10678346455097198	Pharmacologically active substance Mineral oils Arlacel 83V ( sorbitan sesquioleate ) Tween 80
P-1063	-0.0160 -0.0144 -0.0022 -0.0151 -0.0119 -0.0119 -0.0145 -0.0318 -0.0092 -0.0144 -0.0030 -0.0550 -0.0145 -0.0145 -0.0248 -0.0143 -0.0145 -0.0180 -0.0163 -0.0007 -0.0138 -0.0149 -0.0145 -0.0145 -0.0006 -0.0019 -0.3597 -0.0000 -0.0029 -2.4636
S-14	- wenn Sie ein Leberversagen haben ( mit Beschwerden wie beispielsweise Übelkeit , Durchfall ,
T-14	Stop taking the capsules and tell your doctor immediately − If you have an allergic reaction such as skin rash , swelling of the face , wheezing or difficulty breathing − If you have heart problems such as pain in the chest − If you have liver failure ( symptoms may include nausea ( feeling sick ) , diarrhoea , jaundice ( your skin or the whites of your eyes look yellow ) ) − If you have blistering or peeling of the skin − If you have severe stomach pain or any sign of bleeding in the stomach or intestines , such as passing black or bloodstained bowel movements , or vomiting blood
H-14	-0.1073717251420021	Stop taking the capsules and tell your doctor immediately − If you have an allergic reaction such as skin rash , swelling of the face , wheezing or difficulty breathing − If you have heart problems such as pain in the chest − If you have liver failure ( symptoms may include nausea ( feeling sick ) , diarrhoea , jaundice ( your skin or the whites of your eyes look yellow ) − If you have severe stomach pain or any sign of bleeding in the stomach or intestines , or vomiting blood
D-14	-0.1073717251420021	Stop taking the capsules and tell your doctor immediately − If you have an allergic reaction such as skin rash , swelling of the face , wheezing or difficulty breathing − If you have heart problems such as pain in the chest − If you have liver failure ( symptoms may include nausea ( feeling sick ) , diarrhoea , jaundice ( your skin or the whites of your eyes look yellow ) − If you have severe stomach pain or any sign of bleeding in the stomach or intestines , or vomiting blood
P-14	-0.5829 -0.0141 -0.0145 -0.0145 -0.0008 -0.3420 -0.0142 -0.0145 -0.0098 -0.0079 -0.0298 -0.0186 -0.0138 -0.0016 -0.0019 -0.0145 -0.0145 -0.0005 -0.0028 -0.0150 -0.0025 -0.0326 -0.0144 -0.0070 -0.0307 -0.0525 -0.0010 -0.0230 -0.0044 -0.0143 -0.0442 -0.1068 -0.0078 -0.0058 -0.0155 -0.0145 -0.0083 -0.0165 -0.0144 -0.0079 -0.0083 -0.1216 -0.0143 -0.0295 -0.0030 -0.0446 -0.0145 -0.0048 -0.0144 -0.0265 -0.0145 -0.0107 -0.0113 -0.4007 -0.0068 -0.1743 -0.0408 -0.0146 -0.0119 -0.0095 -0.0006 -0.2794 -0.0386 -0.0135 -0.1005 -1.2929 -0.2643 -0.0008 -0.0092 -0.0003 -0.2399 -0.2974 -0.0076 -0.0008 -0.0008 -0.2082 -0.0158 -0.0145 -0.0142 -0.0147 -0.0145 -0.0133 -0.0076 -0.0104 -0.0130 -0.0149 -0.0145 -0.0128 -1.3607 -0.0144 -0.0101 -0.0101 -1.3801 -0.0145 -0.0145 -0.3719 -0.2298 -0.0145 -0.0045 -0.0153 -0.0005 -0.1563 -0.0107 -0.0145 -0.4329 -0.0725 -0.0032 -0.0093 -0.1347 -1.2359 -0.5382 -0.0011 -0.0012 -0.8385 -0.0141
S-76	Folgende Nebenwirkungen sind bei einigen Patienten unter Behandlung mit Actos 45 mg Tabletten aufgetreten :
T-76	The following side effects have been experienced by some patients taking Actos 45mg tablets :
H-76	-0.01556071825325489	The following side effects have been experienced by some patients taking Actos 45mg tablets :
D-76	-0.01556071825325489	The following side effects have been experienced by some patients taking Actos 45mg tablets :
P-76	-0.0061 -0.0036 -0.0195 -0.0018 -0.0044 -0.0111 -0.0116 -0.1934 -0.0036 -0.0018 -0.0167 -0.0009 -0.0003 -0.0123 -0.0006 -0.0034 -0.0014 -0.0017 -0.0014
S-813	Folgende Warnhinweise gelten , wenn Norvir in der vollständigen Dosierung eingenommen wird .
T-813	The following warnings apply when Norvir is taken as a full dose .
H-813	-0.005886084865778685	The following warnings apply when Norvir is taken as a full dose .
D-813	-0.005886084865778685	The following warnings apply when Norvir is taken as a full dose .
P-813	-0.0028 -0.0024 -0.0040 -0.0051 -0.0304 -0.0059 -0.0010 -0.0011 -0.0018 -0.0026 -0.0145 -0.0083 -0.0044 -0.0050 -0.0034 -0.0014
S-540	In klinischen Studien wurden keine Torsade @-@ de @-@ Pointes @-@ Episoden beobachtet .
T-540	No episodes of torsade de pointes were observed in clinical studies .
H-540	-0.04798801243305206	No episodes of torsade de pointes were observed in clinical studies .
D-540	-0.04798801243305206	No episodes of torsade de pointes were observed in clinical studies .
P-540	-0.0060 -0.0122 -0.0016 -0.0027 -0.0030 -0.0011 -0.0132 -0.0101 -0.0017 -0.0058 -0.0208 -0.0018 -0.0823 -0.6024 -0.0015 -0.0014
S-1009	Bei Hochrisikopatienten sollte , wenn klinisch angezeigt , eine EKG @-@ Überwachung erfolgen .
T-1009	ECG monitoring should be performed in high @-@ risk patients as clinically indicated .
H-1009	-0.00707927206531167	ECG monitoring should be performed in high @-@ risk patients as clinically indicated .
D-1009	-0.00707927206531167	ECG monitoring should be performed in high @-@ risk patients as clinically indicated .
P-1009	-0.0137 -0.0008 -0.0029 -0.0058 -0.0031 -0.0191 -0.0186 -0.0025 -0.0091 -0.0111 -0.0012 -0.0164 -0.0066 -0.0012 -0.0053 -0.0016 -0.0014
S-1531	Es wurden keine Studien zur Auswirkung auf die Verkehrstüchtigkeit und das Bedienen von Maschinen durchgeführt .
T-1531	No studies on the effects on ability to drive and use machines have been performed .
H-1531	-0.0318220779299736	No studies on the effects on ability to drive and use machines have been performed .
D-1531	-0.0318220779299736	No studies on the effects on ability to drive and use machines have been performed .
P-1531	-0.0495 -0.0016 -0.0262 -0.0043 -0.0131 -0.0055 -0.0166 -0.0085 -0.0089 -0.0126 -0.0139 -0.0115 -0.0392 -0.0014 -0.3250 -0.0018 -0.0014
S-962	In keinem Fall wurden klinisch signifikante pharmakokinetische Wechselwirkungen festgestellt .
T-962	No clinically significant pharmacokinetic interactions were found in each case .
H-962	-0.023394444957375526	No clinically significant pharmacokinetic interactions were found in each case .
D-962	-0.023394444957375526	No clinically significant pharmacokinetic interactions were found in each case .
P-962	-0.0109 -0.0025 -0.0009 -0.0010 -0.0012 -0.0007 -0.0005 -0.0015 -0.0023 -0.1238 -0.0120 -0.1816 -0.0365 -0.0145 -0.0048 -0.0015 -0.0014
S-1659	Vergewissern Sie sich , dass Sie das von Ihrem Arzt ver- schriebene Humalog erhalten .
T-1659	Make sure you get the Humalog that your doctor has told you to use .
H-1659	-0.4552804231643677	Make sure you get the Humalog that your doctor has prescribed .
D-1659	-0.4552804231643677	Make sure you get the Humalog that your doctor has prescribed .
P-1659	-0.0127 -0.0014 -0.0239 -0.0108 -0.0041 -0.0103 -0.0011 -0.0141 -0.0041 -0.0019 -0.0102 -6.7270 -0.0010 -0.0049 -0.0017
S-273	Bei Ratten wurden Studien zur Reproduktion sowie zur perinatalen und postnatalen Entwicklung durchgeführt .
T-273	Reproduction , peri- and postnatal development studies were conducted in rats .
H-273	-0.008733858354389668	Reproduction , peri- and postnatal development studies were conducted in rats .
D-273	-0.008733858354389668	Reproduction , peri- and postnatal development studies were conducted in rats .
P-273	-0.0133 -0.0031 -0.0124 -0.0145 -0.0144 -0.0058 -0.0045 -0.0005 -0.0012 -0.0015 -0.0038 -0.0062 -0.0585 -0.0042 -0.0014 -0.0016 -0.0014
S-184	10 % Imidacloprid Lösung zum und 2,5 % Auftropfen Moxidectin
T-184	10 % imidacloprid &amp; 2.5 % moxidectin
H-184	-0.007303550373762846	10 % imidacloprid &amp; 2.5 % moxidectin
D-184	-0.007303550373762846	10 % imidacloprid &amp; 2.5 % moxidectin
P-184	-0.0022 -0.0014 -0.0058 -0.0016 -0.0010 -0.0012 -0.0011 -0.0692 -0.0148 -0.0035 -0.0011 -0.0025 -0.0021 -0.0009 -0.0006 -0.0031 -0.0122
S-820	Die beobachteten Symptome beinhalteten Dyspnoe , Herzinsuffizienz und Palpitationen .
T-820	Observed symptoms included dyspnoea , cardiac failure and palpitations .
H-820	-0.03037993609905243	Observed symptoms included dyspnoea , cardiac failure and palpitations .
D-820	-0.03037993609905243	Observed symptoms included dyspnoea , cardiac failure and palpitations .
P-820	-0.0139 -0.0050 -0.0012 -0.2497 -0.0145 -0.0011 -0.0126 -0.0013 -0.0014 -0.0210 -0.0009 -0.0114 -0.0059 -0.0007 -0.0011 -0.0031 -0.2007 -0.0014
S-448	Ihr Actrapid NovoLet ist für eine sehr genaue und sichere Funktionsweise entwickelt worden .
T-448	Your Actrapid NovoLet is designed to work accurately and safely .
H-448	-0.006114986725151539	Your Actrapid NovoLet is designed to work accurately and safely .
D-448	-0.006114986725151539	Your Actrapid NovoLet is designed to work accurately and safely .
P-448	-0.0060 -0.0017 -0.0010 -0.0008 -0.0010 -0.0013 -0.0010 -0.0031 -0.0103 -0.0059 -0.0400 -0.0112 -0.0137 -0.0010 -0.0018 -0.0069 -0.0018 -0.0014
S-484	Vor der Anwendung muss die Aranesp @-@ Lösung auf sichtbare Schwebeteilchen untersucht werden .
T-484	Before administration the Aranesp solution should be inspected for visible particles .
H-484	-0.030757565051317215	Before administration the Aranesp solution should be inspected for visible particles .
D-484	-0.030757565051317215	Before administration the Aranesp solution should be inspected for visible particles .
P-484	-0.0071 -0.0294 -0.0121 -0.0029 -0.0007 -0.0012 -0.0010 -0.0023 -0.0274 -0.0015 -0.0137 -0.0013 -0.0021 -0.0025 -0.0133 -0.4286 -0.0054 -0.0014
S-1846	Entfernen Sie die Luft aus der Spritze und überprüfen Sie , dass die Dosis korrekt ist .
T-1846	Expel any air from the syringe and check that the dose is correct .
H-1846	-0.012698210775852203	Expel any air from the syringe and check that the dose is correct .
D-1846	-0.012698210775852203	Expel any air from the syringe and check that the dose is correct .
P-1846	-0.1541 -0.0133 -0.0145 -0.0039 -0.0028 -0.0023 -0.0020 -0.0002 -0.0002 -0.0062 -0.0093 -0.0052 -0.0035 -0.0043 -0.0020 -0.0015 -0.0017 -0.0015
S-1404	Die Relevanz dieser Ergebnisse ist nicht bekannt , doch wurden sie mit Entwicklungsverzögerungen in Zusammenhang gebracht .
T-1404	The significance of these findings is unknown , but they have been associated with delayed development .
H-1404	-0.015301961451768875	The significance of these findings is unknown , but they have been associated with delayed development .
D-1404	-0.015301961451768875	The significance of these findings is unknown , but they have been associated with delayed development .
P-1404	-0.0035 -0.0143 -0.0014 -0.0290 -0.0113 -0.0042 -0.1413 -0.0268 -0.0070 -0.0023 -0.0027 -0.0014 -0.0099 -0.0014 -0.0143 -0.0017 -0.0018 -0.0014
S-61	Das Virus wurde zuerst inaktiviert ( abgetötet ) , damit es keine Erkrankungen verursachen kann .
T-61	This may help to protect against the disease caused by the virus .
H-61	-0.010477924719452858	This may help to protect against the disease caused by the virus .
D-61	-0.010477924719452858	This may help to protect against the disease caused by the virus .
P-61	-0.0144 -0.0145 -0.0160 -0.0112 -0.0140 -0.0105 -0.0123 -0.0139 -0.0143 -0.0018 -0.0086 -0.0055 -0.0076 -0.0022
S-686	Behandlungsdauer bei Kombinationstherapie mit pegyliertem Interferon alfa @-@ 2b
T-686	Duration of treatment in combination with pegylated interferon alfa @-@ 2b
H-686	-0.0029601878486573696	Duration of treatment in combination with pegylated interferon alfa @-@ 2b
D-686	-0.0029601878486573696	Duration of treatment in combination with pegylated interferon alfa @-@ 2b
P-686	-0.0032 -0.0013 -0.0017 -0.0070 -0.0126 -0.0007 -0.0067 -0.0034 -0.0006 -0.0001 -0.0096 -0.0006 -0.0013 -0.0016 -0.0005 -0.0014 -0.0011 -0.0011 -0.0016
S-1664	Ziehen Sie an dieser farbigen Lasche und drehen Sie dabei den Kolben ggf. weiter .
T-1664	Pull on the coloured tab while continuing to rotate the plunger as needed .
H-1664	-0.007109554950147867	Pull on the coloured tab while continuing to rotate the plunger as needed .
D-1664	-0.007109554950147867	Pull on the coloured tab while continuing to rotate the plunger as needed .
P-1664	-0.0050 -0.0003 -0.0102 -0.0143 -0.0071 -0.0033 -0.0006 -0.0210 -0.0125 -0.0051 -0.0078 -0.0013 -0.0022 -0.0123 -0.0012 -0.0147 -0.0133 -0.0015 -0.0014
S-1936	Hunde vertrugen orale Einzeldosen von bis zu 100 mg / kg Körpergewicht ohne Todesfälle .
T-1936	Dogs tolerated single oral doses up to 100 mg / kg without mortality .
H-1936	-0.008420348167419434	Dogs tolerated single oral doses up to 100 mg / kg without mortality .
D-1936	-0.008420348167419434	Dogs tolerated single oral doses up to 100 mg / kg without mortality .
P-1936	-0.0016 -0.0008 -0.0036 -0.0014 -0.0076 -0.0019 -0.0014 -0.0008 -0.0134 -0.0014 -0.0058 -0.0007 -0.0015 -0.0008 -0.0978 -0.0143 -0.0019 -0.0019 -0.0014
S-1291	Er / Sie könnte auch ansprechen , ob Sie eine andere Verhütungsmethode anwenden müssen .
T-1291	He / she may also talk about whether you need to use another method of contraception .
H-1291	-0.007247232366353273	He / she may also talk about whether you need to use another method of contraception .
D-1291	-0.007247232366353273	He / she may also talk about whether you need to use another method of contraception .
P-1291	-0.0057 -0.0140 -0.0020 -0.0326 -0.0028 -0.0153 -0.0035 -0.0042 -0.0034 -0.0082 -0.0031 -0.0052 -0.0273 -0.0100 -0.0017 -0.0019 -0.0008 -0.0002 -0.0017 -0.0014
S-336	In den meisten Fällen können Sie die Behandlung mit Replagal fortsetzen , auch wenn solche Symptome auftreten .
T-336	Most of the time you can still be given Replagal even if these symptoms occur .
H-336	-0.008236367255449295	Most of the time you can still be given Replagal even if these symptoms occur .
D-336	-0.008236367255449295	Most of the time you can still be given Replagal even if these symptoms occur .
P-336	-0.0156 -0.0103 -0.0027 -0.0043 -0.0074 -0.0209 -0.0145 -0.0157 -0.0143 -0.0075 -0.0006 -0.0007 -0.0011 -0.0120 -0.0083 -0.0131 -0.0023 -0.0105 -0.0016 -0.0014
S-1233	Blutuntersuchungen können verringerte Kalium- und Natriumwerte in Ihrem Blut zeigen .
T-1233	Blood tests may show lowered levels of potassium and sodium in your blood .
H-1233	-0.0036173968110233545	Blood tests may show lowered levels of potassium and sodium in your blood .
D-1233	-0.0036173968110233545	Blood tests may show lowered levels of potassium and sodium in your blood .
P-1233	-0.0010 -0.0008 -0.0091 -0.0098 -0.0063 -0.0139 -0.0008 -0.0077 -0.0014 -0.0030 -0.0002 -0.0013 -0.0014 -0.0008 -0.0005 -0.0016 -0.0083 -0.0014 -0.0017 -0.0014
S-419	Aufgrund von Berichten über tödliche Leberschädigungen wurde die Genehmigung für das Inverkehrbringen am 11 .
T-419	Because of reports of fatal liver injury , the marketing authorisation was suspended on 11 December 1998 .
H-419	-0.016901560127735138	Because of reports of fatal liver injury , the marketing authorisation was suspended on 11 December 1998 .
D-419	-0.016901560127735138	Because of reports of fatal liver injury , the marketing authorisation was suspended on 11 December 1998 .
P-419	-0.0144 -0.0016 -0.0021 -0.0020 -0.0065 -0.0041 -0.0361 -0.0043 -0.0082 -0.0069 -0.0033 -0.0011 -0.0040 -0.0137 -0.0025 -0.0064 -0.0807 -0.1366 -0.0021 -0.0014
S-777	Ihr Blutzucker kann zu hoch ansteigen ( dies wird Hyperglykämie genannt ) .
T-777	Your blood sugar may get too high ( this is called hyperglycaemia ) .
H-777	-0.009815691038966179	Your blood sugar may get too high ( this is called hyperglycaemia ) .
D-777	-0.009815691038966179	Your blood sugar may get too high ( this is called hyperglycaemia ) .
P-777	-0.0049 -0.0012 -0.1252 -0.0097 -0.0166 -0.0027 -0.0019 -0.0019 -0.0038 -0.0014 -0.0045 -0.0011 -0.0011 -0.0006 -0.0121 -0.0019 -0.0012 -0.0015 -0.0017 -0.0014
S-523	Es wurden keine Fälle von Überdosierung berichtet , dies ist bei Anwendung am Auge auch nicht zu erwarten .
T-523	No case of overdose has been reported , and is unlikely to occur after ocular administration .
H-523	-0.01074440311640501	No case of overdose has been reported , and is unlikely to occur after ocular administration .
D-523	-0.01074440311640501	No case of overdose has been reported , and is unlikely to occur after ocular administration .
P-523	-0.0026 -0.0141 -0.0018 -0.0250 -0.0026 -0.0110 -0.0014 -0.0010 -0.0200 -0.0122 -0.0139 -0.0146 -0.0086 -0.0063 -0.0291 -0.0145 -0.0005 -0.0144 -0.0198 -0.0014
S-814	Bei versehentlichem Kontakt des Arzneimittels mit den Augen unverzüglich mit reichlich Wasser spülen .
T-814	If accidental eye contact occurs , flush immediately with copious amounts of water .
H-814	-0.00594222079962492	If accidental eye contact occurs , flush immediately with copious amounts of water .
D-814	-0.00594222079962492	If accidental eye contact occurs , flush immediately with copious amounts of water .
P-814	-0.0114 -0.0137 -0.0082 -0.0143 -0.0018 -0.0133 -0.0010 -0.0049 -0.0128 -0.0009 -0.0096 -0.0019 -0.0144 -0.0003 -0.0011 -0.0039 -0.0013 -0.0010 -0.0016 -0.0014
S-174	Anti @-@ Polio @-@ Typ 3 ( 1 / 8 Verdünnung ) † N = Anzahl der Kinder
T-174	Anti @-@ Polio type 3 ( 1 / 8 dilution ) † N = number of subjects
H-174	-0.003983034752309322	Anti @-@ Polio type 3 ( 1 / 8 dilution ) † N = number of subjects
D-174	-0.003983034752309322	Anti @-@ Polio type 3 ( 1 / 8 dilution ) † N = number of subjects
P-174	-0.0048 -0.0017 -0.0122 -0.0012 -0.0139 -0.0018 -0.0015 -0.0041 -0.0016 -0.0020 -0.0045 -0.0004 -0.0015 -0.0006 -0.0010 -0.0014 -0.0063 -0.0014 -0.0152 -0.0025
S-1652	Makrolide gelten im Allgemeinen als bakteriostatisch und mykoplasmastatisch .
T-1652	Macrolides are generally considered bacteriostatic and mycoplasmastatic .
H-1652	-0.005308343097567558	Macrolides are generally considered bacteriostatic and mycoplasmastatic .
D-1652	-0.005308343097567558	Macrolides are generally considered bacteriostatic and mycoplasmastatic .
P-1652	-0.0030 -0.0011 -0.0012 -0.0028 -0.0023 -0.0023 -0.0056 -0.0087 -0.0005 -0.0004 -0.0006 -0.0018 -0.0014 -0.0010 -0.0007 -0.0061 -0.0034 -0.0005 -0.0614 -0.0014
S-959	Jede Buccaltablette enthält 200 Mikrogramm Fentanyl ( als Citrat ) .
T-959	Each buccal tablet contains 200 micrograms fentanyl ( as citrate ) .
H-959	-0.017613403499126434	Each buccal tablet contains 200 micrograms fentanyl ( as citrate ) .
D-959	-0.017613403499126434	Each buccal tablet contains 200 micrograms fentanyl ( as citrate ) .
P-959	-0.0025 -0.0054 -0.0113 -0.0005 -0.0300 -0.0013 -0.2810 -0.0015 -0.0013 -0.0019 -0.0139 -0.0006 -0.0005 -0.0010 -0.0019 -0.0065 -0.0030 -0.0013 -0.0015 -0.0016 -0.0014
S-1455	Alle in die Studien einbezogenen Kinder erhielten entweder Phenytoin oder Benzodiazepine .
T-1455	In children studied patients received either phenytoin or benzodiazepines .
H-1455	-0.010343858040869236	In children studied patients received either phenytoin or benzodiazepines .
D-1455	-0.010343858040869236	In children studied patients received either phenytoin or benzodiazepines .
P-1455	-0.0198 -0.0146 -0.0144 -0.0145 -0.0106 -0.0017 -0.0011 -0.0011 -0.0014 -0.0029 -0.0973 -0.0012 -0.0008 -0.0009 -0.0005 -0.0006 -0.0100 -0.0018 -0.0014
S-840	Auch bei künftigen Leistungsvergleichen mit anderen international anerkannten Zulassungsstellen wird diese Initiative eine wichtige Rolle spielen .
T-840	It is also important in the context of any future benchmarking exercise with other internationally recognised regulatory bodies .
H-840	-0.007411154452711344	It is also important in the context of any future benchmarking exercise with other internationally recognised regulatory bodies .
D-840	-0.007411154452711344	It is also important in the context of any future benchmarking exercise with other internationally recognised regulatory bodies .
P-840	-0.0148 -0.0155 -0.0065 -0.0136 -0.0114 -0.0169 -0.0091 -0.0015 -0.0172 -0.0046 -0.0068 -0.0013 -0.0045 -0.0104 -0.0062 -0.0018 -0.0018 -0.0010 -0.0048 -0.0142 -0.0035 -0.0016 -0.0014
S-397	Zubereitung von Viraferon , Pulver zur Herstellung einer Injektionslösung , zur parenteralen
T-397	Reconstitution of Viraferon , powder for solution for injection , for parenteral administration :
H-397	-0.2742655575275421	Reconstitution of Viraferon , powder for injection solution for parenteral administration :
D-397	-0.2742655575275421	Reconstitution of Viraferon , powder for injection solution for parenteral administration :
P-397	-0.0145 -0.0145 -0.0015 -0.0050 -0.0010 -0.0009 -0.0032 -0.0053 -0.0033 -0.0050 -3.6112 -0.0013 -1.5412 -0.2261 -0.0121 -0.0006 -0.0012 -0.0144 -0.0199 -0.0033
S-603	Pädiatrische Patienten Es wurden keine Studien mit Sitagliptin bei pädiatrischen Patienten durchgeführt .
T-603	Paediatric No studies with sitagliptin have been performed in paediatric patients .
H-603	-0.03096713311970234	Paediatric No studies with sitagliptin have been performed in paediatric patients .
D-603	-0.03096713311970234	Paediatric No studies with sitagliptin have been performed in paediatric patients .
P-603	-0.0128 -0.0005 -0.0005 -0.0013 -0.0145 -0.0039 -0.0570 -0.0049 -0.0031 -0.0007 -0.0024 -0.0101 -0.0012 -0.5469 -0.0049 -0.0093 -0.0007 -0.0005 -0.0013 -0.0014 -0.0017 -0.0014
S-1494	Häufige Kontrollen des großen Blutbildes sollten bei allen Patienten , die Docetaxel erhalten , erfolgen .
T-1494	Frequent monitoring of complete blood counts should be conducted on all patients receiving docetaxel .
H-1494	-0.013320929370820522	Frequent monitoring of complete blood counts should be conducted on all patients receiving docetaxel .
D-1494	-0.013320929370820522	Frequent monitoring of complete blood counts should be conducted on all patients receiving docetaxel .
P-1494	-0.0040 -0.0005 -0.0381 -0.0139 -0.0019 -0.0144 -0.0021 -0.0071 -0.0031 -0.0091 -0.0251 -0.1222 -0.0018 -0.0012 -0.0407 -0.0012 -0.0012 -0.0008 -0.0004 -0.0010 -0.0019 -0.0014
S-353	Die Konzentrations @-@ Wirkungsbeziehung nach Anwendung von Fosaprepitant wurde nicht ausgewertet .
T-353	The relationship between concentration and effect has not been evaluated after administration of fosaprepitant .
H-353	-0.0049942778423428535	The relationship between concentration and effect has not been evaluated after administration of fosaprepitant .
D-353	-0.0049942778423428535	The relationship between concentration and effect has not been evaluated after administration of fosaprepitant .
P-353	-0.0033 -0.0144 -0.0073 -0.0022 -0.0016 -0.0120 -0.0145 -0.0015 -0.0015 -0.0066 -0.0013 -0.0050 -0.0145 -0.0015 -0.0134 -0.0007 -0.0007 -0.0019 -0.0013 -0.0018 -0.0017 -0.0014
S-364	Dennoch sollte bei jeder verabreichten Infusion das Risiko einer Überempfindlichkeitsreaktion in Betracht gezogen werden .
T-364	However , the risk of hypersensitivity reactions should be considered for every infusion administered .
H-364	-0.008934318087995052	However , the risk of hypersensitivity reactions should be considered for every infusion administered .
D-364	-0.008934318087995052	However , the risk of hypersensitivity reactions should be considered for every infusion administered .
P-364	-0.0097 -0.0020 -0.0083 -0.0015 -0.0865 -0.0066 -0.0015 -0.0006 -0.0138 -0.0011 -0.0025 -0.0020 -0.0097 -0.0134 -0.0132 -0.0043 -0.0004 -0.0066 -0.0009 -0.0016 -0.0014
S-1861	Fort Dodge Animal Health , Flanders Road , Hedge End , Southampton , UK SO30 4QH
T-1861	Fort Dodge Animal Health Ltd Flanders Road Hedge End Southampton UK SO30 4QH
H-1861	-0.04299381747841835	Fort Dodge Animal Health Ltd Flanders Road Hedge End Southampton UK SO30 4QH
D-1861	-0.04299381747841835	Fort Dodge Animal Health Ltd Flanders Road Hedge End Southampton UK SO30 4QH
P-1861	-0.0017 -0.0012 -0.0005 -0.0007 -0.0006 -0.0007 -0.2968 -0.0185 -0.0012 -0.0013 -0.4938 -0.0003 -0.0011 -0.0626 -0.0140 -0.0013 -0.0013 -0.0018 -0.0009 -0.0010 -0.0018
S-1094	Es wurde gezeigt , dass Purevax RC unter Laborbedingungen Schutz vor den oben aufgeführten Krankheiten bietet .
T-1094	In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above .
H-1094	-0.006495904177427292	In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above .
D-1094	-0.006495904177427292	In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above .
P-1094	-0.0144 -0.0055 -0.0007 -0.0046 -0.0102 -0.0011 -0.0004 -0.0019 -0.0014 -0.0147 -0.0148 -0.0050 -0.0113 -0.0017 -0.0093 -0.0026 -0.0091 -0.0054 -0.0194 -0.0015 -0.0014
S-1787	Helicobacter Test INFAI für Kinder im Alter von 3 @-@ 11 darf nicht eingenommen werden ,
T-1787	Do not take Helicobacter Test INFAI for children of the age 3 @-@ 11
H-1787	-0.016757305711507797	Do not take Helicobacter Test INFAI for children of the age 3 @-@ 11
D-1787	-0.016757305711507797	Do not take Helicobacter Test INFAI for children of the age 3 @-@ 11
P-1787	-0.0128 -0.0017 -0.0044 -0.0107 -0.0008 -0.0005 -0.0012 -0.0013 -0.0028 -0.0017 -0.0007 -0.0012 -0.0029 -0.0026 -0.0173 -0.0107 -0.0035 -0.0132 -0.2480 -0.0014 -0.0125
S-111	Desirudin ist ein rekombinantes DNS @-@ Produkt , das aus Hefezellen hergestellt wird .
T-111	Desirudin is a recombinant DNA product derived from yeast cells .
H-111	-0.011673119850456715	Desirudin is a recombinant DNA product derived from yeast cells .
D-111	-0.011673119850456715	Desirudin is a recombinant DNA product derived from yeast cells .
P-111	-0.0011 -0.0009 -0.0055 -0.0077 -0.0016 -0.0016 -0.0012 -0.0012 -0.0006 -0.0015 -0.0015 -0.0028 -0.0146 -0.0013 -0.0273 -0.0008 -0.0008 -0.0013 -0.1587 -0.0014
S-1728	Das Pulver zur Herstellung einer Injektionslösung muss mit Wasser für Injektionszwecke aufgelöst werden .
T-1728	The powder for solution for injection has to be reconstituted with water for injection .
H-1728	-0.023241130635142326	The powder for solution for injection has to be reconstituted with water for injection .
D-1728	-0.023241130635142326	The powder for solution for injection has to be reconstituted with water for injection .
P-1728	-0.0038 -0.0009 -0.0117 -0.0228 -0.0144 -0.0033 -0.0012 -0.0130 -0.0014 -0.0017 -0.0146 -0.0075 -0.0006 -0.0102 -0.0019 -0.0032 -0.0028 -0.3392 -0.0091 -0.0014
S-767	30 % höher als die Cmax- und AUC ( 0 @-@ t ) -Werte an Tag 1 .
T-767	On the day 1 , 3 , and 5 schedule , Cmax and AUC ( 0 @-@ t ) values on day 3 were approximately 50 % and 30 % , respectively , greater than Cmax and AUC ( 0 @-@ t ) values on day 1 .
H-767	-0.061901699751615524	On the day 1 , 3 , and 5 schedule , Cmax and AUC ( 0 @-@ t ) values on day 3 were approximately 50 % and 30 % , respectively .
D-767	-0.061901699751615524	On the day 1 , 3 , and 5 schedule , Cmax and AUC ( 0 @-@ t ) values on day 3 were approximately 50 % and 30 % , respectively .
P-767	-0.0146 -0.0139 -0.0112 -0.0059 -0.0053 -0.1164 -0.0141 -0.0200 -0.0249 -0.0148 -0.0092 -0.0905 -0.0046 -0.0033 -0.0006 -0.0010 -0.0040 -0.0026 -0.0034 -0.0049 -0.0014 -0.0106 -0.0911 -0.0108 -0.0768 -0.0433 -0.0145 -0.0146 -0.0025 -0.0443 -0.0056 -0.0013 -0.0593 -0.0002 -1.4856 -0.0014
S-1906	Ältere Patienten sollten sorgfältig auf Anzeichen einer Fentanyl @-@ Toxizität überwacht werden .
T-1906	Elderly patients should be observed carefully for signs of fentanyl toxicity .
H-1906	-0.013485166244208813	Elderly patients should be observed carefully for signs of fentanyl toxicity .
D-1906	-0.013485166244208813	Elderly patients should be observed carefully for signs of fentanyl toxicity .
P-1906	-0.0069 -0.0008 -0.0018 -0.0019 -0.0017 -0.0184 -0.0064 -0.0014 -0.0025 -0.0014 -0.0006 -0.0006 -0.0004 -0.0010 -0.0010 -0.0008 -0.0009 -0.2062 -0.0014
S-1225	Sie dürfen keine Werkzeuge benutzen und keine Maschinen bedienen , wenn Sie Schwindel oder Schläfrigkeit verspüren .
T-1225	Do not use any tools or machines if you experience dizziness or sleepiness .
H-1225	-0.010833382606506348	Do not use any tools or machines if you experience dizziness or sleepiness .
D-1225	-0.010833382606506348	Do not use any tools or machines if you experience dizziness or sleepiness .
P-1225	-0.0134 -0.0014 -0.0018 -0.0112 -0.0025 -0.0045 -0.0107 -0.0121 -0.0017 -0.0328 -0.0043 -0.0009 -0.0010 -0.0900 -0.0125 -0.0003 -0.0015 -0.0018 -0.0015
S-896	Sie können , während Sie das Pflaster tragen , ganz normal duschen , baden , schwimmen und Sport treiben .
T-896	You may shower , bath , swim and exercise as normal while wearing the patch .
H-896	-0.013794361613690853	You may shower , bath , swim and exercise as normal while wearing the patch .
D-896	-0.013794361613690853	You may shower , bath , swim and exercise as normal while wearing the patch .
P-896	-0.0098 -0.0273 -0.0062 -0.0022 -0.0937 -0.0017 -0.0489 -0.0056 -0.0092 -0.0101 -0.0095 -0.0051 -0.0051 -0.0032 -0.0052 -0.0022 -0.0019 -0.0015
S-1273	Falls eine Frau während der Behandlung mit dem Arzneimittel schwanger wird , sollte sie ihren Arzt zu Rate ziehen .
T-1273	If a woman becomes pregnant while taking the medicine , she should consult her doctor .
H-1273	-0.01290295273065567	If a woman becomes pregnant while taking the medicine , she should consult her doctor .
D-1273	-0.01290295273065567	If a woman becomes pregnant while taking the medicine , she should consult her doctor .
P-1273	-0.0176 -0.0035 -0.0020 -0.0082 -0.0009 -0.0629 -0.0176 -0.0048 -0.0157 -0.0042 -0.0038 -0.0020 -0.0051 -0.0006 -0.0766 -0.0029 -0.0023 -0.0015
S-1599	Nehmen Sie die Injektionsnadel mit gelber Markierung und entfernen Sie die äußere Verpackung .
T-1599	Take the injection needle with the yellow mark and remove the wrapping .
H-1599	-0.005113382823765278	Take the injection needle with the yellow mark and remove the wrapping .
D-1599	-0.005113382823765278	Take the injection needle with the yellow mark and remove the wrapping .
P-1599	-0.0081 -0.0024 -0.0091 -0.0012 -0.0022 -0.0010 -0.0051 -0.0126 -0.0012 -0.0091 -0.0021 -0.0018 -0.0029 -0.0145 -0.0074 -0.0048 -0.0015
S-1850	Durch die Blockade dieser Rezeptoren trägt Glivec dazu bei , die Zellteilung einzudämmen .
T-1850	By blocking these receptors , Glivec helps to control cell division .
H-1850	-0.0030755256302654743	By blocking these receptors , Glivec helps to control cell division .
D-1850	-0.0030755256302654743	By blocking these receptors , Glivec helps to control cell division .
P-1850	-0.0023 -0.0015 -0.0027 -0.0010 -0.0007 -0.0051 -0.0033 -0.0016 -0.0005 -0.0012 -0.0060 -0.0063 -0.0139 -0.0021 -0.0011 -0.0016 -0.0014
S-139	Ihr Arzt , Apotheker oder das Pflegepersonal wissen , wie Aclasta ordnungsgemäß aufbewahrt werden muss .
T-139	Your doctor , pharmacist or nurse knows how to store Aclasta properly .
H-139	-0.008091731928288937	Your doctor , pharmacist or nurse knows how to store Aclasta properly .
D-139	-0.008091731928288937	Your doctor , pharmacist or nurse knows how to store Aclasta properly .
P-139	-0.0028 -0.0024 -0.0018 -0.0017 -0.0008 -0.0825 -0.0099 -0.0098 -0.0024 -0.0033 -0.0086 -0.0030 -0.0006 -0.0008 -0.0037 -0.0019 -0.0016
S-825	WIE IST CIPROFLOXACIN KABI ANZUWENDEN ?
T-825	HOW TO USE CIPROFLOXACIN KABI
H-825	-0.010267175734043121	HOW TO USE CIPROFLOXACIN KABI
D-825	-0.010267175734043121	HOW TO USE CIPROFLOXACIN KABI
P-825	-0.0015 -0.0006 -0.1389 -0.0030 -0.0007 -0.0028 -0.0009 -0.0013 -0.0015 -0.0013 -0.0012 -0.0013 -0.0018 -0.0021 -0.0011 -0.0002 -0.0143
S-383	- Sagen Sie es dem Arzt oder der Schwester , falls Sie sich nach der Injektion schwindlig oder
T-383	You will probably need to lie down until you feel better .
H-383	-0.016223926097154617	You will probably need to lie down until you feel better .
D-383	-0.016223926097154617	You will probably need to lie down until you feel better .
P-383	-0.0187 -0.0312 -0.0214 -0.0352 -0.0063 -0.0145 -0.0066 -0.0144 -0.0121 -0.0129 -0.0142 -0.0089 -0.0144
S-1082	Nummer ( n ) der Genehmigung für das Inverkehrbringen EU / 2 / 00 / 022 / 09 @-@ 12
T-1082	Marketing Authorisation number ( s )
H-1082	-0.00800460483878851	Marketing Authorisation number ( s )
D-1082	-0.00800460483878851	Marketing Authorisation number ( s )
P-1082	-0.0144 -0.0140 -0.0076 -0.0014 -0.0114 -0.0046 -0.0016 -0.0014 -0.0156
S-960	Mannitol ( Ph.Eur. ) , Natriumcitrat Ampulle mit Lösungsmittel :
T-960	Mannitol Sodium citrate
H-960	-0.027947617694735527	Mannitol Sodium citrate
D-960	-0.027947617694735527	Mannitol Sodium citrate
P-960	-0.0012 -0.0008 -0.1067 -0.0853 -0.0003 -0.0141 -0.0008 -0.0145
S-817	In zwei Langzeit @-@ Follow @-@ up @-@ Studien blieb die Wirksamkeit von Imprida über ein Jahr erhalten .
T-817	In two long @-@ term follow @-@ up studies the effect of Imprida was maintained for over one year .
H-817	-0.010758700780570507	In two long @-@ term follow @-@ up studies the effect of Imprida was maintained for over one year .
D-817	-0.010758700780570507	In two long @-@ term follow @-@ up studies the effect of Imprida was maintained for over one year .
P-817	-0.0107 -0.0020 -0.0020 -0.0505 -0.0018 -0.0014 -0.0017 -0.0012 -0.0325 -0.0114 -0.0735 -0.0015 -0.0009 -0.0012 -0.0009 -0.0063 -0.0059 -0.0064 -0.0231 -0.0082 -0.0013 -0.0015 -0.0014
S-734	Wenn Sie eine stark eingeschränkte Nierenfunktion haben , nehmen Sie abwechselnd Tagesdosen von t lä
T-734	The recommended dose of Levviax for adults and children of 12 years and older is two tablets of 400 mg once daily ( 800 mg once daily ) .
H-734	-0.016432611271739006	The recommended dose of Levviax for adults and children of 12 years and older is two tablets of 400 mg once daily ( 800 mg once daily ) .
D-734	-0.016432611271739006	The recommended dose of Levviax for adults and children of 12 years and older is two tablets of 400 mg once daily ( 800 mg once daily ) .
P-734	-0.0276 -0.0144 -0.0113 -0.0113 -0.0145 -0.0145 -0.0145 -0.0141 -0.0145 -0.0848 -0.0041 -0.0754 -0.0144 -0.0112 -0.0142 -0.0104 -0.0123 -0.0144 -0.0136 -0.0016 -0.0121 -0.0145 -0.0038 -0.0145 -0.0122 -0.0239 -0.0145 -0.0062 -0.0149 -0.0070 -0.0072 -0.0114 -0.0071
S-789	Ferner unterstützt der Bereich den Direktor in seinen Bemühungen um die Genehmigungen der EU @-@ Beiträge durch die Haushaltsbehörde .
T-789	The Sector is also responsible for assisting the Executive Director in the process to obtain the approval of the budgetary authority for the EU contribution .
H-789	-0.01444037351757288	The Sector is also responsible for assisting the Executive Director in the process to obtain the approval of the budgetary authority for the EU contribution .
D-789	-0.01444037351757288	The Sector is also responsible for assisting the Executive Director in the process to obtain the approval of the budgetary authority for the EU contribution .
P-789	-0.0120 -0.0143 -0.0015 -0.0139 -0.0041 -0.0150 -0.0016 -0.0090 -0.0010 -0.0024 -0.0145 -0.0031 -0.0033 -0.0136 -0.0125 -0.0147 -0.0092 -0.0117 -0.0035 -0.0020 -0.0085 -0.1086 -0.0006 -0.0007 -0.0012 -0.0122 -0.0086 -0.1300 -0.0114 -0.0018 -0.0014
S-170	Im ersten Halbjahr wurde an alle Abonnenten eine aktualisierte und verbesserte Version der CD @-@ ROM herausgegeben .
T-170	An updated and improved version of the CD @-@ ROM was issued to all subscribers during the first half of the year .
H-170	-0.003291268600150943	An updated and improved version of the CD @-@ ROM was issued to all subscribers during the first half of the year .
D-170	-0.003291268600150943	An updated and improved version of the CD @-@ ROM was issued to all subscribers during the first half of the year .
P-170	-0.0115 -0.0010 -0.0025 -0.0024 -0.0018 -0.0017 -0.0024 -0.0019 -0.0015 -0.0013 -0.0013 -0.0040 -0.0110 -0.0025 -0.0031 -0.0028 -0.0008 -0.0107 -0.0016 -0.0018 -0.0042 -0.0044 -0.0051 -0.0012 -0.0015 -0.0014
S-1311	Im Urin und den Faeces wurden noch kleinere Metaboliten gefunden , im Plasma jedoch nicht .
T-1311	Minor metabolites were identified in urine and faeces , but generally were not found in plasma .
H-1311	-0.0055092135444283485	Minor metabolites were identified in urine and faeces , but generally were not found in plasma .
D-1311	-0.0055092135444283485	Minor metabolites were identified in urine and faeces , but generally were not found in plasma .
P-1311	-0.0140 -0.0013 -0.0018 -0.0009 -0.0003 -0.0040 -0.0145 -0.0059 -0.0287 -0.0011 -0.0017 -0.0027 -0.0000 -0.0014 -0.0059 -0.0043 -0.0190 -0.0151 -0.0027 -0.0075 -0.0016 -0.0041 -0.0004 -0.0011 -0.0017 -0.0014
S-975	Überempfindlichkeit gegen Tacrolimus oder andere Macrolide oder einen der sonstigen Bestandteile .
T-975	Hypersensitivity to tacrolimus or other macrolides or to any of the excipients .
H-975	-0.02686670981347561	Hypersensitivity to tacrolimus or other macrolides or to any of the excipients .
D-975	-0.02686670981347561	Hypersensitivity to tacrolimus or other macrolides or to any of the excipients .
P-975	-0.0044 -0.0015 -0.0016 -0.0009 -0.0020 -0.0018 -0.0013 -0.0013 -0.0002 -0.1110 -0.0141 -0.0011 -0.0011 -0.0010 -0.0071 -0.0028 -0.4120 -0.0179 -0.0055 -0.0037 -0.0845 -0.0103 -0.0011 -0.0054 -0.0035 -0.0014
S-570	Titandioxid Hypromellose Macrogol 400 Polysorbat 80 ( E433 )
T-570	Titanium dioxide Hypromellose Macrogol 400 Polysorbate 80 ( E433 )
H-570	-0.006943649146705866	Titanium dioxide Hypromellose Macrogol 400 Polysorbate 80 ( E433 )
D-570	-0.006943649146705866	Titanium dioxide Hypromellose Macrogol 400 Polysorbate 80 ( E433 )
P-570	-0.0069 -0.0005 -0.0012 -0.0116 -0.0005 -0.0058 -0.1295 -0.0010 -0.0035 -0.0012 -0.0010 -0.0010 -0.0009 -0.0009 -0.0011 -0.0011 -0.0005 -0.0021 -0.0014 -0.0009 -0.0016 -0.0012 -0.0011 -0.0010 -0.0014 -0.0015
S-1541	Im Falle hämorrhagischer Komplikationen ist die Behandlung abzubrechen und die Blutungsquelle festzustellen .
T-1541	In the event of haemorrhagic complications , treatment must be discontinued and the source of bleeding investigated .
H-1541	-0.013714633882045746	In the event of haemorrhagic complications , treatment must be discontinued and the source of bleeding investigated .
D-1541	-0.013714633882045746	In the event of haemorrhagic complications , treatment must be discontinued and the source of bleeding investigated .
P-1541	-0.0062 -0.1077 -0.0093 -0.0015 -0.0115 -0.0007 -0.0004 -0.0012 -0.0011 -0.0011 -0.0016 -0.0050 -0.0111 -0.0168 -0.0021 -0.0364 -0.0004 -0.0027 -0.0031 -0.0032 -0.0014 -0.0086 -0.0010 -0.0145 -0.1065 -0.0014
S-297	Im Zusammenhang mit der Anwendung des in diesem Arzneimittel enthaltenen Wirkstoff wurde bisher noch kein solcher Fall berichtet .
T-297	Nevertheless , in view of this rare but serious risk which could be a class effect , it must be emphasized that :
H-297	-0.010887579061090946	Nevertheless , in view of this rare but serious risk which could be a class effect , it must be emphasized that :
D-297	-0.010887579061090946	Nevertheless , in view of this rare but serious risk which could be a class effect , it must be emphasized that :
P-297	-0.0145 -0.0014 -0.0025 -0.0138 -0.0145 -0.0014 -0.0156 -0.0145 -0.0145 -0.0142 -0.0145 -0.0144 -0.0144 -0.0108 -0.0140 -0.0145 -0.0145 -0.0071 -0.0169 -0.0145 -0.0032 -0.0143 -0.0007 -0.0022 -0.0159 -0.0043
S-469	UCB Pharma GmbH ( AT ) Jacquingasse , 16 @-@ 18 / 3.OG 1030 Wien
T-469	UCB Pharma GmbH ( AT ) Jacquingasse , 16 @-@ 18 / 3 . OG 1030 Wien
H-469	-0.005870008375495672	UCB Pharma GmbH ( AT ) Jacquingasse , 16 @-@ 18 / 3 . OG 1030 Wien
D-469	-0.005870008375495672	UCB Pharma GmbH ( AT ) Jacquingasse , 16 @-@ 18 / 3 . OG 1030 Wien
P-469	-0.0005 -0.0010 -0.0006 -0.0007 -0.0011 -0.0746 -0.0012 -0.0014 -0.0024 -0.0014 -0.0033 -0.0004 -0.0024 -0.0025 -0.0015 -0.0013 -0.0015 -0.0144 -0.0115 -0.0042 -0.0008 -0.0013 -0.0014 -0.0135 -0.0019
S-279	Die Abgabe von Lenalidomid an gebärfähige Frauen soll innerhalb von 7 Tagen nach Verschreibung erfolgen .
T-279	Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription .
H-279	-0.014001951552927494	Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription .
D-279	-0.014001951552927494	Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription .
P-279	-0.0145 -0.0021 -0.0025 -0.0256 -0.0158 -0.0010 -0.0008 -0.0003 -0.0011 -0.0028 -0.0084 -0.0030 -0.0395 -0.0004 -0.0145 -0.0065 -0.0224 -0.0010 -0.0090 -0.0014 -0.1561 -0.0110 -0.0057 -0.0032 -0.0014
S-482	- Laktatazidose ( 0,03 Fälle / 1000 Patientenjahre ) ist sehr selten ( siehe 4.4 .
T-482	- Lactic acidosis ( 0.03 cases / 1000 patient @-@ years ) is very rare ( see 4.4 .
H-482	-0.009368738159537315	- Lactic acidosis ( 0.03 cases / 1000 patient @-@ years ) is very rare ( see 4.4 .
D-482	-0.009368738159537315	- Lactic acidosis ( 0.03 cases / 1000 patient @-@ years ) is very rare ( see 4.4 .
P-482	-0.0027 -0.0131 -0.0127 -0.0006 -0.0007 -0.0008 -0.0020 -0.0030 -0.0014 -0.0017 -0.0047 -0.0038 -0.0024 -0.0291 -0.0114 -0.0014 -0.0016 -0.0143 -0.0019 -0.0018 -0.0656 -0.0079 -0.0013 -0.0467 -0.0014
S-631	Schwere Leberfunktionsstörungen Eine Dosisanpassung für Fondaparinux ist nicht erforderlich .
T-631	Severe hepatic impairment Dosing adjustment of fondaparinux is not necessary .
H-631	-0.02450527809560299	Severe hepatic impairment Dosing adjustment of fondaparinux is not necessary .
D-631	-0.02450527809560299	Severe hepatic impairment Dosing adjustment of fondaparinux is not necessary .
P-631	-0.0045 -0.0013 -0.0139 -0.0020 -0.0012 -0.0846 -0.0036 -0.0004 -0.0075 -0.0131 -0.0355 -0.0027 -0.0009 -0.0040 -0.0182 -0.0143 -0.0027 -0.0003 -0.0012 -0.0007 -0.0025 -0.0015 -0.3926 -0.0020 -0.0014
S-44	Überblick über das EMEA @-@ Arbeitsprogramm 2006 EMEA / 145874 / 2006 Anhänge 1 .
T-44	Summary of the EMEA work programme 2006 EMEA / 62913 / 2006 Annexes 1 .
H-44	-0.01552125159651041	Summary of the EMEA work programme 2006 EMEA / 62913 / 2006 Annexes 1 .
D-44	-0.01552125159651041	Summary of the EMEA work programme 2006 EMEA / 62913 / 2006 Annexes 1 .
P-44	-0.0139 -0.0016 -0.0015 -0.0038 -0.0089 -0.0008 -0.0012 -0.0118 -0.0019 -0.0038 -0.0030 -0.0008 -0.0012 -0.0014 -0.2517 -0.0144 -0.0147 -0.0020 -0.0025 -0.0025 -0.0212 -0.0026 -0.0038 -0.0014
S-71	Portugal Smith Kline &amp; French Portuguesa , Produtos Farmacêuticos , Lda .
T-71	Portugal Smith Kline &amp; French Portuguesa , Produtos Farmacêuticos , Lda .
H-71	-0.0012292189057916403	Portugal Smith Kline &amp; French Portuguesa , Produtos Farmacêuticos , Lda .
D-71	-0.0012292189057916403	Portugal Smith Kline &amp; French Portuguesa , Produtos Farmacêuticos , Lda .
P-71	-0.0028 -0.0008 -0.0014 -0.0011 -0.0013 -0.0019 -0.0008 -0.0003 -0.0016 -0.0033 -0.0013 -0.0006 -0.0009 -0.0010 -0.0011 -0.0001 -0.0012 -0.0011 -0.0003 -0.0015 -0.0013 -0.0008 -0.0016 -0.0014
S-771	Es liegen begrenzte klinische Daten zur Sicherheit und Wirksamkeit weiterer Behandlungszyklen mit MabThera vor .
T-771	There are limited clinical data on the safety and efficacy of further courses of therapy with MabThera .
H-771	-0.016019307076931	There are limited clinical data on the safety and efficacy of further courses of therapy with MabThera .
D-771	-0.016019307076931	There are limited clinical data on the safety and efficacy of further courses of therapy with MabThera .
P-771	-0.0030 -0.1801 -0.0013 -0.0014 -0.0019 -0.0092 -0.0039 -0.0008 -0.0014 -0.1317 -0.0008 -0.0008 -0.0016 -0.0058 -0.0134 -0.0015 -0.0147 -0.0031 -0.0019 -0.0008 -0.0009 -0.0014 -0.0016 -0.0014
S-1720	Januar 2001 erteilte die Europäische Kommission eine Genehmigung für das Inverkehrbringen von Pirsue in der gesamten Europäischen Union .
T-1720	The European Commission granted a marketing authorisation valid throughout the European Union , for Pirsue on 29 January 2001 .
H-1720	-0.06947972625494003	The European Commission granted a marketing authorisation valid throughout the EU , for Pirsue on 29 January 2001 .
D-1720	-0.06947972625494003	The European Commission granted a marketing authorisation valid throughout the EU , for Pirsue on 29 January 2001 .
P-1720	-0.0133 -0.0039 -0.0012 -0.0117 -0.0130 -0.0028 -0.0030 -0.0010 -0.0145 -0.0017 -0.0102 -0.0016 -0.7768 -0.1230 -0.0127 -0.0140 -0.0001 -0.0133 -0.0274 -0.5263 -0.0234 -0.0017 -0.0014
S-87	Bei 2 bis 8 oC ist die rekonstituierte Lösung über 24 Stunden chemisch und physikalisch stabil .
T-87	Chemical and physical in @-@ use stability has been demonstrated for 24 hours at 2 ° C to 8 ° C .
H-87	-0.00770885543897748	Chemical and physical in @-@ use stability has been demonstrated for 24 hours at 2 ° C to 8 ° C .
D-87	-0.00770885543897748	Chemical and physical in @-@ use stability has been demonstrated for 24 hours at 2 ° C to 8 ° C .
P-87	-0.0145 -0.0134 -0.0018 -0.0026 -0.0146 -0.0132 -0.0145 -0.0041 -0.0145 -0.0033 -0.0143 -0.0117 -0.0043 -0.0018 -0.0070 -0.0047 -0.0204 -0.0034 -0.0043 -0.0018 -0.0008 -0.0045 -0.0081 -0.0014
S-1935	Wie alle Arzneimittel kann TESLASCAN Nebenwirkungen haben , die aber nicht bei jedem auftreten müssen .
T-1935	Like all medicines , TESLASCAN can cause side effects , although not everybody gets them .
H-1935	-0.023471901193261147	Like all medicines , TESLASCAN can cause side effects , although not everybody gets them .
D-1935	-0.023471901193261147	Like all medicines , TESLASCAN can cause side effects , although not everybody gets them .
P-1935	-0.0074 -0.0078 -0.0063 -0.2184 -0.0030 -0.0020 -0.0016 -0.0013 -0.1592 -0.0015 -0.0006 -0.0363 -0.0107 -0.0029 -0.0024 -0.0136 -0.0157 -0.0068 -0.0142 -0.0144 -0.0106 -0.0017 -0.0014
S-365	Einige dieser Nebenwirkungen stehen unter Umständen eher mit der Depression des Patienten in Zusammenhang als mit Valdoxan selbst .
T-365	Some of these side effects may be linked to the patient <<unk>> s depression rather than Valdoxan itself .
H-365	-0.013434028252959251	Some of these side effects may be linked to the patient <unk> s depression rather than Valdoxan itself .
D-365	-0.013434028252959251	Some of these side effects may be linked to the patient <unk> s depression rather than Valdoxan itself .
P-365	-0.0037 -0.0019 -0.0160 -0.0272 -0.0025 -0.0057 -0.0025 -0.0132 -0.0055 -0.0079 -0.0027 -0.0145 -0.0013 -0.0007 -0.0069 -0.0014 -0.0122 -0.0007 -0.0014 -0.0047 -0.0035 -0.1714 -0.0014
S-1931	Gardasil schützt nicht vor anderen Erkrankungen , die nicht durch humane Papillomviren ausgelöst werden .
T-1931	Gardasil will not protect against other diseases that are not caused by Human Papillomavirus .
H-1931	-0.007674557622522116	Gardasil will not protect against other diseases that are not caused by Human Papillomavirus .
D-1931	-0.007674557622522116	Gardasil will not protect against other diseases that are not caused by Human Papillomavirus .
P-1931	-0.0012 -0.0010 -0.0010 -0.0009 -0.1014 -0.0016 -0.0030 -0.0023 -0.0037 -0.0077 -0.0079 -0.0024 -0.0018 -0.0034 -0.0014 -0.0144 -0.0030 -0.0006 -0.0092 -0.0011 -0.0035 -0.0026 -0.0014
S-1010	Das Ausmaß der antihypertensiven Wirkung ist nach Verabreichung der Anfangsdosis genau zu überwachen .
T-1010	The magnitude of antihypertensive effect should be closely monitored after administering the initial dose .
H-1010	-0.007710535079240799	The magnitude of antihypertensive effect should be closely monitored after administering the initial dose .
D-1010	-0.007710535079240799	The magnitude of antihypertensive effect should be closely monitored after administering the initial dose .
P-1010	-0.0034 -0.0144 -0.0005 -0.0006 -0.0014 -0.0125 -0.0008 -0.0004 -0.0010 -0.0086 -0.0129 -0.0015 -0.0235 -0.0020 -0.0009 -0.0246 -0.0192 -0.0015 -0.0021 -0.0362 -0.0065 -0.0017 -0.0014
S-1932	Die Dosierungen in diesen Studien führten zu ähnlichen Expositionen wie die in der humantherapeutischen Anwendung .
T-1932	Animal toxicology studies have been conducted at exposures up to clinical exposure levels with darunavir alone , in mice , rats and dogs and in combination with ritonavir in rats and dogs .
H-1932	-0.20270223915576935	Animal toxicology studies have been conducted at exposures up to clinical exposure levels with darunavir alone .
D-1932	-0.20270223915576935	Animal toxicology studies have been conducted at exposures up to clinical exposure levels with darunavir alone .
P-1932	-0.0162 -0.0012 -0.0145 -0.0059 -0.0121 -0.0120 -0.0133 -0.0134 -0.0103 -0.0135 -0.0144 -0.0006 -0.0004 -0.0186 -0.0015 -0.0145 -0.0145 -0.0098 -0.0171 -0.0145 -0.0145 -0.0145 -0.0102 -0.0145 -4.9967 -0.0014
S-884	Bereichsspezifische Tätigkeiten 1 % Erstbewertung 13 % Allgemeine Tätigkeiten 18 % Folgeverfahren 6 %
T-884	ActiTrack data for veterinary medicines evaluation in 2000 Overheads ( specific unit / sector ) 1 % Initial evaluation 13 % Overheads ( all sectors ) 18 % Specific post- authorisation 6 %
H-884	-0.012312652543187141	ActiTrack data for veterinary medicines evaluation in 2000 Overheads ( specific unit / sector ) 1 % Initial evaluation 13 % Overheads ( all sectors ) 18 % Specific post- authorisation 6 %
D-884	-0.012312652543187141	ActiTrack data for veterinary medicines evaluation in 2000 Overheads ( specific unit / sector ) 1 % Initial evaluation 13 % Overheads ( all sectors ) 18 % Specific post- authorisation 6 %
P-884	-0.0142 -0.0009 -0.0145 -0.0140 -0.0145 -0.0140 -0.0145 -0.0011 -0.0145 -0.0227 -0.0184 -0.0008 -0.0009 -0.0211 -0.0145 -0.0145 -0.0145 -0.0144 -0.0145 -0.0145 -0.0454 -0.0133 -0.0258 -0.0057 -0.0014 -0.0096 -0.0015 -0.0035 -0.0010 -0.0007 -0.0033 -0.0012 -0.0145 -0.0138 -0.0735 -0.0145 -0.0144 -0.0024 -0.0367 -0.0013 -0.0145 -0.0009 -0.0145 -0.0142 -0.0145 -0.0028 -0.0028 -0.0014 -0.0014
S-845	Die chemische und physikalische Stabilität nach Zubereitung wurde für 2 Stunden bei 25ºC nachgewiesen .
T-845	Chemical and physical in @-@ use stability has been demonstrated for 2 hours at 25ºC .
H-845	-0.00925485324114561	Chemical and physical in @-@ use stability has been demonstrated for 2 hours at 25ºC .
D-845	-0.00925485324114561	Chemical and physical in @-@ use stability has been demonstrated for 2 hours at 25ºC .
P-845	-0.0087 -0.0014 -0.0019 -0.0012 -0.0173 -0.0072 -0.0143 -0.0045 -0.0140 -0.0015 -0.0115 -0.0064 -0.0075 -0.0024 -0.0100 -0.0680 -0.0018 -0.0012 -0.0029 -0.0014
S-63	Die Kapseln werden in den Mund genommen und im Ganzen geschluckt , ohne sie zu kauen .
T-63	The capsules should always be taken by mouth , and swallowed whole and not chewed .
H-63	-0.01842450723052025	The capsules should always be taken by mouth , and swallowed whole and not chewed .
D-63	-0.01842450723052025	The capsules should always be taken by mouth , and swallowed whole and not chewed .
P-63	-0.0048 -0.0014 -0.0006 -0.0013 -0.0150 -0.1110 -0.1625 -0.0097 -0.0140 -0.0011 -0.0266 -0.0099 -0.0036 -0.0007 -0.0010 -0.0100 -0.0148 -0.0102 -0.0021 -0.0010 -0.0024 -0.0014
S-79	Bei Lagerung ist in der Suspension eine weiße Ablagerung und ein klarer Überstand zu beobachten .
T-79	Upon storage , a fine white deposit with a clear colourless supernatant can be observed .
H-79	-0.009988131001591682	Upon storage , a fine white deposit with a clear colourless supernatant can be observed .
D-79	-0.009988131001591682	Upon storage , a fine white deposit with a clear colourless supernatant can be observed .
P-79	-0.0144 -0.0015 -0.0018 -0.0069 -0.0079 -0.0146 -0.0030 -0.0110 -0.0145 -0.0061 -0.0027 -0.0483 -0.0089 -0.0142 -0.0326 -0.0015 -0.0020 -0.0105 -0.0014 -0.0034 -0.0111 -0.0014
S-1191	EMEA / MB / 002 / 97 2.3 Zentralisierte Anträge auf Genehmigung für das Inverkehrbringen
T-1191	EMEA / MB / 002 / 97 2.3 Centralised applications for marketing authorisations
H-1191	-0.00361822871491313	EMEA / MB / 002 / 97 2.3 Centralised applications for marketing authorisations
D-1191	-0.00361822871491313	EMEA / MB / 002 / 97 2.3 Centralised applications for marketing authorisations
P-1191	-0.0019 -0.0006 -0.0012 -0.0012 -0.0006 -0.0014 -0.0013 -0.0014 -0.0014 -0.0006 -0.0012 -0.0014 -0.0014 -0.0004 -0.0054 -0.0074 -0.0017 -0.0037 -0.0015 -0.0414 -0.0009 -0.0016
S-1317	Kuvan ist ein Arzneimittel , das den Wirkstoff Sapropterindihydrochlorid enthält .
T-1317	Kuvan is a medicine that contains the active substance sapropterin dihydrochloride .
H-1317	-0.06533220410346985	Kuvan is a medicine that contains the active substance sapropterin dihydrochloride .
D-1317	-0.06533220410346985	Kuvan is a medicine that contains the active substance sapropterin dihydrochloride .
P-1317	-0.0012 -0.0002 -0.0017 -0.0019 -0.0054 -0.8758 -0.0037 -0.0031 -0.0009 -0.0106 -0.0025 -0.0011 -0.0013 -0.0145 -0.0111 -0.0015 -0.0012 -0.0012 -0.0005 -0.0010 -0.4953 -0.0014
S-1613	Der Wirkstoff in Bonviva , Ibandronsäure , ist ein Bisphosphonat .
T-1613	The active substance in Bonviva , ibandronic acid , is a bisphosphonate .
H-1613	-0.016208890825510025	The active substance in Bonviva , ibandronic acid , is a bisphosphonate .
D-1613	-0.016208890825510025	The active substance in Bonviva , ibandronic acid , is a bisphosphonate .
P-1613	-0.0029 -0.0020 -0.0116 -0.0029 -0.0012 -0.0009 -0.0009 -0.0026 -0.0010 -0.0003 -0.0031 -0.0009 -0.0007 -0.0021 -0.0014 -0.0025 -0.0012 -0.0004 -0.0013 -0.0002 -0.3152 -0.0014
S-1953	Lebendimpfstoffe sollen nicht zusammen mit STELARA gegeben werden ( siehe Abschnitt 4.4 ) .
T-1953	Live vaccines should not be given concurrently with STELARA ( see section 4.4 ) .
H-1953	-0.010175595991313457	Live vaccines should not be given concurrently with STELARA ( see section 4.4 ) .
D-1953	-0.010175595991313457	Live vaccines should not be given concurrently with STELARA ( see section 4.4 ) .
P-1953	-0.0018 -0.0015 -0.0021 -0.0062 -0.0015 -0.0015 -0.0093 -0.1615 -0.0127 -0.0021 -0.0018 -0.0008 -0.0011 -0.0013 -0.0019 -0.0026 -0.0064 -0.0013 -0.0015 -0.0017 -0.0017 -0.0014
S-399	Dies hängt mit der verminderten Nierenfunktion in dieser Personengruppe zusammen ( siehe Abschnitt 4.2 ) .
T-399	This is related to the decrease in renal function in this population ( see section 4.2 ) .
H-399	-0.04947078600525856	This is related to the decrease in renal function in this population ( see section 4.2 ) .
D-399	-0.04947078600525856	This is related to the decrease in renal function in this population ( see section 4.2 ) .
P-399	-0.0022 -0.0030 -0.0100 -0.0015 -0.0098 -0.0114 -0.9545 -0.0039 -0.0098 -0.0010 -0.0009 -0.0455 -0.0023 -0.0141 -0.0025 -0.0020 -0.0069 -0.0012 -0.0014 -0.0016 -0.0015 -0.0014
S-58	Es liegen keine Erfahrungen zur Verabreichung von Karvea bei Patienten kurz nach Nierentransplantation vor .
T-58	There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation .
H-58	-0.010576693341135979	There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation .
D-58	-0.010576693341135979	There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation .
P-58	-0.0047 -0.0044 -0.0020 -0.0073 -0.0436 -0.0062 -0.0049 -0.0014 -0.0129 -0.0006 -0.0013 -0.0055 -0.0013 -0.0144 -0.0136 -0.0144 -0.0021 -0.0005 -0.0011 -0.0873 -0.0018 -0.0014
S-146	Wie alle Arzneimittel kann CELVAPAN Nebenwirkungen haben , die aber nicht bei jedem auftreten müssen .
T-146	Like all medicines , CELVAPAN can cause side effects , although not everybody gets them .
H-146	-0.018956920132040977	Like all medicines , CELVAPAN can cause side effects , although not everybody gets them .
D-146	-0.018956920132040977	Like all medicines , CELVAPAN can cause side effects , although not everybody gets them .
P-146	-0.0079 -0.0086 -0.0064 -0.2095 -0.0033 -0.0047 -0.0008 -0.0012 -0.0008 -0.0012 -0.0766 -0.0111 -0.0026 -0.0022 -0.0148 -0.0155 -0.0071 -0.0142 -0.0144 -0.0110 -0.0017 -0.0014
S-982	Falls Sie eine allergische Reaktion haben , setzen sie Janumet ab und rufen Sie Ihren Arzt sofort an .
T-982	If you have an allergic reaction , stop taking Janumet and call your doctor right away .
H-982	-0.007104829419404268	If you have an allergic reaction , stop taking Janumet and call your doctor right away .
D-982	-0.007104829419404268	If you have an allergic reaction , stop taking Janumet and call your doctor right away .
P-982	-0.0102 -0.0013 -0.0121 -0.0021 -0.0010 -0.0007 -0.0010 -0.0025 -0.0058 -0.0114 -0.0023 -0.0009 -0.0011 -0.0026 -0.0026 -0.0233 -0.0020 -0.0609 -0.0024 -0.0016 -0.0014
S-1155	Rekonstituierte Arzneimittel sollten vor der Verabreichung visuell auf Schwebstoffe untersucht werden .
T-1155	Reconstituted products should be inspected visually for particulate matter prior to administration .
H-1155	-0.007384764961898327	Reconstituted products should be inspected visually for particulate matter prior to administration .
D-1155	-0.007384764961898327	Reconstituted products should be inspected visually for particulate matter prior to administration .
P-1155	-0.0042 -0.0030 -0.0005 -0.0008 -0.0240 -0.0024 -0.0018 -0.0140 -0.0013 -0.0041 -0.0010 -0.0023 -0.0131 -0.0251 -0.0003 -0.0158 -0.0014 -0.0296 -0.0017 -0.0014
S-1767	CVMP und Verfahren für Tierarzneimittel Unbedenklichkeit von Rückständen ( MRLs )
T-1767	Head of Unit CVMP and veterinary procedures Safety of residues ( MRLs )
H-1767	-0.005614308174699545	Head of Unit CVMP and veterinary procedures Safety of residues ( MRLs )
D-1767	-0.005614308174699545	Head of Unit CVMP and veterinary procedures Safety of residues ( MRLs )
P-1767	-0.0145 -0.0127 -0.0145 -0.0014 -0.0128 -0.0020 -0.0009 -0.0025 -0.0127 -0.0010 -0.0143 -0.0144 -0.0018 -0.0063 -0.0010 -0.0016 -0.0019 -0.0004 -0.0023 -0.0015 -0.0014 -0.0015
S-340	Die Durchstechflasche darf auf keinen Fall geöffnet werden ; die Bleiabschirmung darf nicht entfernt werden .
T-340	7 The vial should never be opened and must be kept inside its lead shielding .
H-340	-0.01731020212173462	7 The vial should never be opened and must be kept inside its lead shielding .
D-340	-0.01731020212173462	7 The vial should never be opened and must be kept inside its lead shielding .
P-340	-0.0145 -0.0136 -0.0125 -0.1008 -0.0131 -0.0716 -0.0016 -0.0016 -0.0133 -0.0145 -0.0166 -0.0122 -0.0144 -0.0144 -0.0088 -0.0049 -0.0124 -0.0015 -0.0024 -0.0014
S-1513	Emtricitabin empfiehlt sich nicht als Monotherapeutikum zur Behandlung einer HIV @-@ Infektion .
T-1513	Emtricitabine is not recommended as monotherapy for the treatment of HIV infection .
H-1513	-0.003999687265604734	Emtricitabine is not recommended as monotherapy for the treatment of HIV infection .
D-1513	-0.003999687265604734	Emtricitabine is not recommended as monotherapy for the treatment of HIV infection .
P-1513	-0.0015 -0.0010 -0.0005 -0.0010 -0.0011 -0.0184 -0.0017 -0.0034 -0.0052 -0.0143 -0.0019 -0.0048 -0.0065 -0.0067 -0.0010 -0.0014 -0.0027 -0.0042 -0.0015 -0.0014
S-138	Wenn Ihnen die Nebenwirkungen zu unangenehm werden , fragen Sie bitte Ihren Arzt so rasch wie möglich um Rat .
T-138	If your side effects become too uncomfortable , ask your doctor for advice as soon as possible .
H-138	-0.013976422138512135	If your side effects become too uncomfortable , ask your doctor for advice as soon as possible .
D-138	-0.013976422138512135	If your side effects become too uncomfortable , ask your doctor for advice as soon as possible .
P-138	-0.1061 -0.0140 -0.0048 -0.0033 -0.0114 -0.0037 -0.0113 -0.0054 -0.0752 -0.0022 -0.0024 -0.0048 -0.0032 -0.0036 -0.0083 -0.0013 -0.0015 -0.0015 -0.0014
S-2	• Ihr Arzt wird Ihnen Truvada in Kombination mit anderen antiretroviralen Arzneimitteln verschreiben .
T-2	• Your doctor will prescribe Truvada with other antiretroviral medicines .
H-2	-0.004491910338401794	• Your doctor will prescribe Truvada with other antiretroviral medicines .
D-2	-0.004491910338401794	• Your doctor will prescribe Truvada with other antiretroviral medicines .
P-2	-0.0061 -0.0021 -0.0018 -0.0027 -0.0009 -0.0009 -0.0024 -0.0012 -0.0005 -0.0345 -0.0048 -0.0030 -0.0011 -0.0006 -0.0010 -0.0123 -0.0053 -0.0027 -0.0014
S-295	Die Vildagliptin @-@ vermittelte Hemmung von DPP @-@ 4 ist altersunabhängig .
T-295	DPP @-@ 4 inhibition by vildagliptin is not affected by age .
H-295	-0.0055266208946704865	DPP @-@ 4 inhibition by vildagliptin is not affected by age .
D-295	-0.0055266208946704865	DPP @-@ 4 inhibition by vildagliptin is not affected by age .
P-295	-0.0145 -0.0006 -0.0015 -0.0013 -0.0100 -0.0019 -0.0142 -0.0113 -0.0014 -0.0010 -0.0003 -0.0078 -0.0036 -0.0143 -0.0142 -0.0014 -0.0022 -0.0020 -0.0014
S-167	Bei Bewegung an der Stelle der Pseudarthrosenbildung kann der Frakturheilungsprozess gestört werden .
T-167	Motion in the non @-@ union site may disrupt the fracture healing process .
H-167	-0.018304690718650818	Motion in the non @-@ union site may disrupt the fracture healing process .
D-167	-0.018304690718650818	Motion in the non @-@ union site may disrupt the fracture healing process .
P-167	-0.0110 -0.0134 -0.0138 -0.0030 -0.0145 -0.0021 -0.0145 -0.0128 -0.0115 -0.0120 -0.0006 -0.0024 -0.0089 -0.0002 -0.0018 -0.0009 -0.0016 -0.2213 -0.0014
S-1228	Ihr Mixtard 10 NovoLet ist für eine sehr genaue und sichere Funktionsweise entwickelt worden .
T-1228	Your Mixtard 10 NovoLet is designed to work accurately and safely .
H-1228	-0.005665498785674572	Your Mixtard 10 NovoLet is designed to work accurately and safely .
D-1228	-0.005665498785674572	Your Mixtard 10 NovoLet is designed to work accurately and safely .
P-1228	-0.0069 -0.0013 -0.0012 -0.0019 -0.0009 -0.0016 -0.0012 -0.0009 -0.0028 -0.0095 -0.0064 -0.0345 -0.0106 -0.0136 -0.0010 -0.0019 -0.0080 -0.0019 -0.0015
S-1905	Liprolog Mix25 wirkt sehr rasch , die Wirkung hält längere Zeit an als bei Normalinsulin .
T-1905	Liprolog Mix25 works very quickly and longer than soluble insulin .
H-1905	-0.006031692959368229	Liprolog Mix25 works very quickly and longer than soluble insulin .
D-1905	-0.006031692959368229	Liprolog Mix25 works very quickly and longer than soluble insulin .
P-1905	-0.0025 -0.0013 -0.0015 -0.0009 -0.0013 -0.0012 -0.0102 -0.0033 -0.0068 -0.0218 -0.0145 -0.0126 -0.0145 -0.0101 -0.0010 -0.0005 -0.0030 -0.0016
S-1535	Halten Sie die Spritze und die Durchstechflasche gut fest ( siehe Abbildung 3 ) .
T-1535	Hold the syringe and vial firmly ( see Figure 3 ) .
H-1535	-0.0028889758978039026	Hold the syringe and vial firmly ( see Figure 3 ) .
D-1535	-0.0028889758978039026	Hold the syringe and vial firmly ( see Figure 3 ) .
P-1535	-0.0041 -0.0007 -0.0039 -0.0008 -0.0002 -0.0002 -0.0020 -0.0068 -0.0009 -0.0119 -0.0045 -0.0022 -0.0069 -0.0010 -0.0014 -0.0015 -0.0016 -0.0015
S-329	Enthält als sonstige Bestandteile unter anderem E216 , E218 und Maltitol .
T-329	Other ingredients include E216 , E218 and maltitol .
H-329	-0.02720608003437519	Other ingredients include E216 , E218 and maltitol .
D-329	-0.02720608003437519	Other ingredients include E216 , E218 and maltitol .
P-329	-0.0109 -0.0092 -0.0086 -0.0031 -0.0012 -0.0012 -0.0015 -0.0016 -0.0012 -0.0013 -0.3641 -0.0081 -0.0013 -0.0010 -0.0011 -0.0455 -0.0015
S-1627	Bei einigen Patienten kommt es während der Behandlung des Bluthochdrucks zu Schwindel oder Müdigkeit .
T-1627	Some people feel dizzy or tired when they are treated for high blood pressure .
H-1627	-0.0070568774826824665	Some people feel dizzy or tired when they are treated for high blood pressure .
D-1627	-0.0070568774826824665	Some people feel dizzy or tired when they are treated for high blood pressure .
P-1627	-0.0047 -0.0149 -0.0141 -0.0021 -0.0014 -0.0030 -0.0082 -0.0333 -0.0117 -0.0065 -0.0080 -0.0020 -0.0047 -0.0012 -0.0012 -0.0017 -0.0014
S-1550	España Frau Carmen COLLADO ALVAREZ ( 2 ) Prof .
T-1550	España Ms Carmen COLLADO ALVAREZ ( 2 ) Prof .
H-1550	-0.001911698840558529	España Ms Carmen COLLADO ALVAREZ ( 2 ) Prof .
D-1550	-0.001911698840558529	España Ms Carmen COLLADO ALVAREZ ( 2 ) Prof .
P-1550	-0.0040 -0.0007 -0.0005 -0.0014 -0.0137 -0.0006 -0.0014 -0.0013 -0.0012 -0.0011 -0.0009 -0.0009 -0.0015 -0.0010 -0.0012 -0.0007 -0.0013 -0.0013 -0.0015 -0.0037 -0.0008 -0.0018 -0.0014
S-1522	Die Inzidenz variierte in den Zielindikationsstudien zwischen 0 % und 9,6 % .
T-1522	Overall , measurable HACA titres were noted in 3.4 % of the patients studied , with incidences ranging from 0 % to 9.6 % in the target indication studies .
H-1522	-0.1161179468035698	Overall , measurable HACA titres were noted in 3.4 % of the patients studied , with incidence ranging from 0 % to 9.6 % in the target indication studies .
D-1522	-0.1161179468035698	Overall , measurable HACA titres were noted in 3.4 % of the patients studied , with incidence ranging from 0 % to 9.6 % in the target indication studies .
P-1522	-0.0145 -0.0190 -0.0160 -0.0192 -0.0030 -0.0192 -0.0144 -0.0142 -0.0145 -0.0145 -0.0086 -0.0133 -0.0145 -0.0120 -0.0147 -0.0767 -0.0111 -0.0078 -0.0115 -0.0133 -0.0144 -0.0145 -0.0135 -0.0144 -4.1641 -0.0109 -0.0038 -0.0066 -0.0020 -0.0020 -0.0013 -0.0019 -0.0012 -0.0283 -0.0072 -0.0059 -0.0133 -0.0045 -0.0015 -0.0014
S-1005	Bei Patienten mit Leber- oder Nierenproblemen bzw. bei älteren Patienten wurde Luminity nicht untersucht .
T-1005	After activation , the medicine contains microspheres of perflutren gas in a fatty layer of phospholipids .
H-1005	-0.018573010340332985	After activation , the medicine contains microspheres of perflutren gas in a fatty layer of phospholipids .
D-1005	-0.018573010340332985	After activation , the medicine contains microspheres of perflutren gas in a fatty layer of phospholipids .
P-1005	-0.0145 -0.0145 -0.0149 -0.0091 -0.0118 -0.0147 -0.0146 -0.0192 -0.0132 -0.0123 -0.0045 -0.0042 -0.0144 -0.0145 -0.0145 -0.0145 -0.0145 -0.0729 -0.0925 -0.0141 -0.0145 -0.0008 -0.0138 -0.0352 -0.0144 -0.0101 -0.0127 -0.0055 -0.0016 -0.0661 -0.0014
S-904	Sportler Hydrochlorothiazid kann bei Dopingtests zu einem positiven Analyseergebnis führen .
T-904	17 Athletes Hydrochlorothiazide may produce a positive analytic result in the anti @-@ doping test .
H-904	-0.006203840021044016	17 Athletes Hydrochlorothiazide may produce a positive analytic result in the anti @-@ doping test .
D-904	-0.006203840021044016	17 Athletes Hydrochlorothiazide may produce a positive analytic result in the anti @-@ doping test .
P-904	-0.0145 -0.0143 -0.0031 -0.0126 -0.0005 -0.0011 -0.0003 -0.0012 -0.0007 -0.0014 -0.0002 -0.0009 -0.0119 -0.0142 -0.0052 -0.0008 -0.0143 -0.0140 -0.0019 -0.0093 -0.0144 -0.0145 -0.0017 -0.0003 -0.0107 -0.0021 -0.0014
S-779	Üblicherweise ist eine lebenslange Therapie mit KOGENATE Bayer 1000 I.E. erforderlich .
T-779	Usually , the substitution therapy with KOGENATE Bayer 1000 IU is a life @-@ time treatment .
H-779	-0.0064758420921862125	Usually , the substitution therapy with KOGENATE Bayer 1000 IU is a life @-@ time treatment .
D-779	-0.0064758420921862125	Usually , the substitution therapy with KOGENATE Bayer 1000 IU is a life @-@ time treatment .
P-779	-0.0102 -0.0009 -0.0012 -0.0095 -0.0144 -0.0145 -0.0132 -0.0154 -0.0084 -0.0031 -0.0012 -0.0013 -0.0008 -0.0004 -0.0010 -0.0007 -0.0013 -0.0046 -0.0143 -0.0034 -0.0135 -0.0117 -0.0041 -0.0138 -0.0082 -0.0023 -0.0014
S-997	Überempfindlichkeit gegen den Wirkstoff oder einen der Bestandteile des Arzneimittels ( siehe Abschnitt 6.1 ) .
T-997	Hypersensitivity to the active substances or to any of the excipients ( see section 6.1 ) .
H-997	-0.017204005271196365	Hypersensitivity to the active substances or to any of the excipients ( see section 6.1 ) .
D-997	-0.017204005271196365	Hypersensitivity to the active substances or to any of the excipients ( see section 6.1 ) .
P-997	-0.0069 -0.0008 -0.0009 -0.0006 -0.0019 -0.0030 -0.0015 -0.3051 -0.0044 -0.0022 -0.0121 -0.0036 -0.0047 -0.0017 -0.0146 -0.0041 -0.0005 -0.0175 -0.0235 -0.0023 -0.0092 -0.0192 -0.0014 -0.0025 -0.0018 -0.0014
S-1418	• Halten Sie die Spritze mit der Nadel nach oben , um Luftbläschen zu entfernen .
T-1418	● To remove air bubbles from the syringe , hold the syringe with the needle pointing up .
H-1418	-0.022829694673419	● To remove air bubbles from the syringe , hold the syringe with the needle pointing up .
D-1418	-0.022829694673419	● To remove air bubbles from the syringe , hold the syringe with the needle pointing up .
P-1418	-0.0152 -0.0147 -0.0023 -0.0112 -0.0010 -0.0007 -0.0281 -0.0044 -0.0034 -0.0003 -0.0001 -0.0193 -0.0037 -0.0031 -0.2701 -0.0002 -0.0001 -0.0125 -0.0023 -0.1444 -0.0012 -0.0177 -0.0106 -0.0029 -0.0015
S-1985	- Carbamazepin ( Arzneimittel zur Vorbeugung von Krampfanfällen oder zur Behandlung von
T-1985	- carbamazepine ( medicine to prevent seizures or to treat certain types of nerve pain ) .
H-1985	-0.043883662670850754	- carbamazepine ( medicine to prevent seizures or to treat certain types of nerve pain ) .
D-1985	-0.043883662670850754	- carbamazepine ( medicine to prevent seizures or to treat certain types of nerve pain ) .
P-1985	-0.0021 -0.0100 -0.0013 -0.0007 -0.0004 -0.0033 -0.0016 -0.0139 -0.0195 -0.0015 -0.0039 -0.1292 -0.0009 -0.0020 -0.0089 -0.0013 -0.0145 -0.0130 -0.0018 -0.0150 -0.0136 -0.0112 -0.7821 -0.0014
S-1215	Nur ein kleiner Teil ( 3 % ) wurde als unverändertes Darifenacin ausgeschieden .
T-1215	Only a small percentage of the excreted dose was unchanged darifenacin ( 3 % ) .
H-1215	-0.007460139691829681	Only a small percentage of the excreted dose was unchanged darifenacin ( 3 % ) .
D-1215	-0.007460139691829681	Only a small percentage of the excreted dose was unchanged darifenacin ( 3 % ) .
P-1215	-0.0020 -0.0016 -0.0025 -0.0138 -0.0414 -0.0093 -0.0144 -0.0004 -0.0104 -0.0141 -0.0148 -0.0119 -0.0062 -0.0145 -0.0089 -0.0002 -0.0012 -0.0013 -0.0024 -0.0017 -0.0016 -0.0016 -0.0016 -0.0014
S-416	Glaxo Group Ltd Berkeley Avenue , Greenford Middlesex TW8 9GS United Kingdom
T-416	Glaxo Group Ltd Berkeley Avenue , Greenford Middlesex TW8 9GS United Kingdom
H-416	-0.009707008488476276	Glaxo Group Ltd Berkeley Avenue , Greenford Middlesex TW8 9GS United Kingdom
D-416	-0.009707008488476276	Glaxo Group Ltd Berkeley Avenue , Greenford Middlesex TW8 9GS United Kingdom
P-416	-0.0004 -0.0011 -0.0013 -0.0010 -0.0006 -0.0020 -0.0004 -0.0006 -0.0011 -0.2014 -0.0006 -0.0007 -0.0004 -0.0012 -0.0007 -0.0016 -0.0014 -0.0012 -0.0013 -0.0003 -0.0017 -0.0007 -0.0014
S-338	Die vorübergehenden Ereignisse umfassten Übelkeit , Schwäche / Lethargie und Hypotension .
T-338	Transient events reported have included nausea , weakness / lethargy and hypotension .
H-338	-0.011801019310951233	Transient events reported have included nausea , weakness / lethargy and hypotension .
D-338	-0.011801019310951233	Transient events reported have included nausea , weakness / lethargy and hypotension .
P-338	-0.0141 -0.0012 -0.0418 -0.0030 -0.1708 -0.0145 -0.0018 -0.0009 -0.0003 -0.0015 -0.0017 -0.0018 -0.0019 -0.0010 -0.0017 -0.0008 -0.0067 -0.0015 -0.0005 -0.0010 -0.0001 -0.0016 -0.0014
S-1948	Fenturogenox 100 µg / h - transdermales Matrixpflaster
T-1948	Fenturogenox 100 µg / h - transdermales Matrixpflaster
H-1948	-0.03614521026611328	Fenturogenox 100 µg / h - transdermales Matrixpflaster
D-1948	-0.03614521026611328	Fenturogenox 100 µg / h - transdermales Matrixpflaster
P-1948	-0.0020 -0.0002 -0.0010 -0.0008 -0.0012 -0.0012 -0.0015 -0.0021 -0.0012 -0.0015 -0.0013 -0.0196 -0.0039 -0.0009 -0.5669 -0.0085 -0.0141 -0.0009 -0.1724 -0.0145 -0.0114 -0.0027 -0.0017
S-964	Daten des MEDAL @-@ Studienprogramms zur gastrointestinalen ( GI ) Verträglichkeit :
T-964	MEDAL Program Gastrointestinal Tolerability Results :
H-964	-0.027828866615891457	MEDAL Program Gastrointestinal Tolerability Results :
D-964	-0.027828866615891457	MEDAL Program Gastrointestinal Tolerability Results :
P-964	-0.0144 -0.0008 -0.0011 -0.0138 -0.0145 -0.0007 -0.0005 -0.0007 -0.0008 -0.0144 -0.3368 -0.0145 -0.0007 -0.0022 -0.0015
S-691	RISPERDAL und zugehörige Namen ( siehe Anhang I ) 6 mg Filmtabletten
T-691	RISPERDAL and associated names ( see Annex I ) 6 mg film @-@ coated tablets
H-691	-0.021147731691598892	RISPERDAL and associated names ( see Annex I ) 6 mg film @-@ coated tablets
D-691	-0.021147731691598892	RISPERDAL and associated names ( see Annex I ) 6 mg film @-@ coated tablets
P-691	-0.0012 -0.0006 -0.0009 -0.0009 -0.0009 -0.0019 -0.0110 -0.0018 -0.0016 -0.3026 -0.0079 -0.0012 -0.0016 -0.0016 -0.0037 -0.0004 -0.0419 -0.0483 -0.0145 -0.0016 -0.0368 -0.0016 -0.0019
S-265	Brexidol 20 Mg Granulat Zur Herstellung Einer Lösung Zum Einnehmen 27116.00.01
T-265	Brexidol 20 Mg Granulat Zur Herstellung Einer Lösung Zum Einnehmen 27116.00.01
H-265	-0.006222989410161972	Brexidol 20 Mg Granulat Zur Herstellung Einer Lösung Zum Einnehmen 27116.00.01
D-265	-0.006222989410161972	Brexidol 20 Mg Granulat Zur Herstellung Einer Lösung Zum Einnehmen 27116.00.01
P-265	-0.0009 -0.0007 -0.0003 -0.0026 -0.0133 -0.0013 -0.0047 -0.0135 -0.0144 -0.0145 -0.0131 -0.0145 -0.0038 -0.0129 -0.0099 -0.0053 -0.0010 -0.0012 -0.0105 -0.0009 -0.0009 -0.0014 -0.0015
S-1814	EU / 1 / 97 / 040 / 001 EU / 1 / 97 / 040 / 002
T-1814	EU / 1 / 97 / 040 / 001 EU / 1 / 97 / 040 / 002
H-1814	-0.0013426466612145305	EU / 1 / 97 / 040 / 001 EU / 1 / 97 / 040 / 002
D-1814	-0.0013426466612145305	EU / 1 / 97 / 040 / 001 EU / 1 / 97 / 040 / 002
P-1814	-0.0018 -0.0016 -0.0014 -0.0015 -0.0007 -0.0014 -0.0014 -0.0011 -0.0014 -0.0014 -0.0015 -0.0015 -0.0015 -0.0013 -0.0015 -0.0005 -0.0014 -0.0011 -0.0010 -0.0014 -0.0015 -0.0014 -0.0015
S-685	Bitte beachten Sie daher auch die Einnahmehinweise in den Packungsbeilagen dieser anderen Arzneimittel .
T-685	Please refer to the Package Leaflets of these other medicines for guidance on how to take them .
H-685	-0.018547791987657547	Please refer to the Package Leaflets of these other medicines for guidance on how to take them .
D-685	-0.018547791987657547	Please refer to the Package Leaflets of these other medicines for guidance on how to take them .
P-685	-0.0067 -0.0142 -0.0054 -0.0024 -0.0145 -0.0036 -0.0139 -0.0003 -0.0428 -0.0265 -0.0045 -0.0032 -0.0056 -0.2163 -0.0079 -0.0144 -0.0124 -0.0110 -0.0017 -0.0042 -0.0107 -0.0029 -0.0014
S-1834	EU / 1 / 07 / 432 / 017 EU / 1 / 07 / 432 / 020
T-1834	EU / 1 / 07 / 432 / 017 EU / 1 / 07 / 432 / 020
H-1834	-0.0013194507919251919	EU / 1 / 07 / 432 / 017 EU / 1 / 07 / 432 / 020
D-1834	-0.0013194507919251919	EU / 1 / 07 / 432 / 017 EU / 1 / 07 / 432 / 020
P-1834	-0.0016 -0.0016 -0.0013 -0.0015 -0.0011 -0.0014 -0.0012 -0.0013 -0.0014 -0.0014 -0.0010 -0.0014 -0.0015 -0.0014 -0.0015 -0.0009 -0.0014 -0.0011 -0.0012 -0.0014 -0.0013 -0.0012 -0.0015
S-441	România Torrex Chiesi Pharma GmbH Tel : + 40 729 995 020
T-441	România Torrex Chiesi Pharma GmbH Tel : + 40 729 995 020
H-441	-0.0014976707752794027	România Torrex Chiesi Pharma GmbH Tel : + 40 729 995 020
D-441	-0.0014976707752794027	România Torrex Chiesi Pharma GmbH Tel : + 40 729 995 020
P-441	-0.0021 -0.0006 -0.0005 -0.0014 -0.0013 -0.0012 -0.0010 -0.0011 -0.0013 -0.0020 -0.0008 -0.0034 -0.0035 -0.0024 -0.0011 -0.0016 -0.0013 -0.0013 -0.0012 -0.0007 -0.0016 -0.0013 -0.0019
S-1365	Wenn Ihre Packung Atripla zu Ende geht , bitten Sie Ihren Arzt um ein neues Rezept .
T-1365	When your supply of Atripla starts to run low , get more from your doctor or pharmacist .
H-1365	-0.03399571031332016	When your supply of Atripla starts to run low , get more from your doctor or pharmacist .
D-1365	-0.03399571031332016	When your supply of Atripla starts to run low , get more from your doctor or pharmacist .
P-1365	-0.0054 -0.0028 -0.0144 -0.0022 -0.0024 -0.0010 -0.0010 -0.0014 -0.0145 -0.0069 -0.0068 -0.0144 -0.0039 -0.0517 -0.0145 -0.0140 -0.0265 -0.0023 -0.3038 -0.0126 -0.0009 -0.2770 -0.0014
S-925	Česká republika Amgen s.r.o Tel : + 420 2 21 773 500
T-925	52 eská republika Amgen s.r.o Tel : + 420 2 21 773 500
H-925	-0.01912730373442173	52 eská republika Amgen s.r.o Tel : + 420 2 21 773 500
D-925	-0.01912730373442173	52 eská republika Amgen s.r.o Tel : + 420 2 21 773 500
P-925	-0.0145 -0.0146 -0.0032 -0.0015 -0.0008 -0.0013 -0.0033 -0.0005 -0.0050 -0.0110 -0.2482 -0.0024 -0.0067 -0.0040 -0.0011 -0.0016 -0.0013 -0.1120 -0.0009 -0.0016 -0.0009 -0.0013 -0.0023
S-987	France Laboratoires Takeda Tél : + 33 ( 0 ) 1 46 25 16 16
T-987	France Laboratoires Takeda Tél : + 33 ( 0 ) 1 46 25 16 16
H-987	-0.0018792498158290982	France Laboratoires Takeda Tél : + 33 ( 0 ) 1 46 25 16 16
D-987	-0.0018792498158290982	France Laboratoires Takeda Tél : + 33 ( 0 ) 1 46 25 16 16
P-987	-0.0038 -0.0038 -0.0012 -0.0010 -0.0012 -0.0006 -0.0034 -0.0003 -0.0022 -0.0010 -0.0010 -0.0016 -0.0015 -0.0011 -0.0013 -0.0013 -0.0014 -0.0013 -0.0087 -0.0013 -0.0012 -0.0013 -0.0016
S-877	Latvija Generics &#91; UK &#93; Ltd Tel : + 44 1707 853000 ( United Kingdom )
T-877	Latvija Generics &#91; UK &#93; Ltd Tel : + 44 1707 853000 ( United Kingdom )
H-877	-0.0021919209975749254	Latvija Generics &#91; UK &#93; Ltd Tel : + 44 1707 853000 ( United Kingdom )
D-877	-0.0021919209975749254	Latvija Generics &#91; UK &#93; Ltd Tel : + 44 1707 853000 ( United Kingdom )
P-877	-0.0023 -0.0013 -0.0006 -0.0005 -0.0011 -0.0104 -0.0063 -0.0014 -0.0007 -0.0038 -0.0018 -0.0010 -0.0006 -0.0011 -0.0009 -0.0011 -0.0011 -0.0008 -0.0019 -0.0075 -0.0009 -0.0014 -0.0019
S-515	Berechnen Sie die Gesamtdosis und die Anzahl der benötigten Durchstechflaschen Elaprase .
T-515	Calculate the total dose to be administered and number of Elaprase vials needed .
H-515	-0.010217687115073204	Calculate the total dose to be administered and number of Elaprase vials needed .
D-515	-0.010217687115073204	Calculate the total dose to be administered and number of Elaprase vials needed .
P-515	-0.0039 -0.0006 -0.0013 -0.0034 -0.0028 -0.0032 -0.1259 -0.0099 -0.0138 -0.0010 -0.0104 -0.0140 -0.0015 -0.0143 -0.0007 -0.0011 -0.0013 -0.0020 -0.0007 -0.0095 -0.0022 -0.0014
S-132	WIE IST INSULIN HUMAN WINTHROP BASAL ANZUWENDEN ?
T-132	HOW TO USE INSULIN HUMAN WINTHROP BASAL
H-132	-0.020757155492901802	HOW TO USE INSULIN HUMAN WINTHROP BASAL
D-132	-0.020757155492901802	HOW TO USE INSULIN HUMAN WINTHROP BASAL
P-132	-0.0016 -0.0006 -0.2517 -0.0044 -0.0007 -0.0030 -0.0012 -0.0016 -0.0007 -0.0014 -0.0005 -0.0009 -0.0014 -0.0018 -0.0007 -0.1207 -0.0039 -0.0019 -0.0022 -0.0143
S-59	Die Zuständigkeit für die Koordinierung der Übersetzungsdienstleistungen wurde vom Konferenzdienst auf diesen Bereich übertragen .
T-59	The responsibility for co @-@ ordinating translation services was transferred from conference services to this sector .
H-59	-0.013143462128937244	The responsibility for co @-@ ordinating translation services was transferred from conference services to this sector .
D-59	-0.013143462128937244	The responsibility for co @-@ ordinating translation services was transferred from conference services to this sector .
P-59	-0.0075 -0.0129 -0.0028 -0.0133 -0.1136 -0.0009 -0.0319 -0.0048 -0.0016 -0.0035 -0.0124 -0.0028 -0.0073 -0.0141 -0.0105 -0.0028 -0.0048 -0.0126 -0.0015 -0.0014
S-1871	Besondere Vorsicht bei der Einnahme von Tredaptive ist erforderlich Informieren Sie Ihren Arzt über alle gesundheitlichen Probleme .
T-1871	Take special care with Tredaptive Tell your doctor about all of your medical conditions .
H-1871	-0.015594846569001675	Take special care with Tredaptive Tell your doctor about all of your medical conditions .
D-1871	-0.015594846569001675	Take special care with Tredaptive Tell your doctor about all of your medical conditions .
P-1871	-0.1703 -0.0117 -0.0024 -0.0143 -0.0129 -0.0014 -0.0008 -0.0007 -0.0141 -0.0007 -0.0015 -0.0029 -0.0148 -0.0100 -0.0148 -0.0060 -0.0145 -0.0142 -0.0022 -0.0016
S-1994	WAS IST COAPROVEL UND WOFÜR WIRD ES ANGEWENDET ?
T-1994	WHAT COAPROVEL IS AND WHAT IT IS USED FOR
H-1994	-0.07991716265678406	WHAT COAPROVEL IS AND WHAT IT IS USED FOR
D-1994	-0.07991716265678406	WHAT COAPROVEL IS AND WHAT IT IS USED FOR
P-1994	-0.0014 -0.0009 -1.3515 -0.0010 -0.0015 -0.0012 -0.0009 -0.0071 -0.0096 -0.0024 -0.0091 -0.0141 -0.0032 -0.0102 -0.0015 -0.0079 -0.0006 -0.0143
S-1875	WAS IST TELZIR UND WOFÜR WIRD ES ANGEWENDET ?
T-1875	WHAT TELZIR IS AND WHAT IT IS USED FOR
H-1875	-0.20962023735046387	WHAT COX IS AND WHAT IT IS USED FOR
D-1875	-0.20962023735046387	WHAT COX IS AND WHAT IT IS USED FOR
P-1875	-0.0014 -0.0009 -2.7081 -0.3369 -0.0079 -0.0212 -0.0028 -0.0086 -0.0142 -0.0067 -0.0105 -0.0020 -0.0082 -0.0005 -0.0144
S-1930	WAS IST ZALASTA UND WOFÜR WIRD ES ANGEWENDET ?
T-1930	WHAT ZALASTA IS AND WHAT IT IS USED FOR
H-1930	-0.07576138526201248	WHAT ZALASTA IS AND WHAT IT IS USED FOR
D-1930	-0.07576138526201248	WHAT ZALASTA IS AND WHAT IT IS USED FOR
P-1930	-0.0015 -0.0009 -1.2791 -0.0017 -0.0014 -0.0008 -0.0012 -0.0052 -0.0083 -0.0026 -0.0096 -0.0141 -0.0032 -0.0098 -0.0015 -0.0081 -0.0006 -0.0143
S-275	Erkrankungen der Atemwege , des Brustraums und Mediastinums Gelegentlich Erkrankungen des Gastrointestinaltrakts
T-275	Uncommon Gastrointestinal disorders
H-275	-0.011552786454558372	Uncommon Gastrointestinal disorders
D-275	-0.011552786454558372	Uncommon Gastrointestinal disorders
P-275	-0.0557 -0.0128 -0.0145 -0.0006 -0.0005 -0.0009 -0.0007 -0.0142 -0.0011 -0.0145
S-1327	România Takeda Global R &amp; D Centre ( Europe ) Tel : + 44 ( 0 ) 20 3116 8000
T-1327	România Takeda Global R &amp; D Centre ( Europe ) Tel : + 44 ( 0 ) 20 3116 8000
H-1327	-0.210371732711792	România Takeda Global R &amp; D Centre ( Europe ) Tel : + 44 ( 0 ) 20 35 8
D-1327	-0.210371732711792	România Takeda Global R &amp; D Centre ( Europe ) Tel : + 44 ( 0 ) 20 35 8
P-1327	-0.0070 -0.0028 -0.0006 -0.0007 -0.0003 -0.0007 -0.0013 -0.0011 -0.0011 -0.0012 -0.0274 -0.0019 -0.0014 -0.0036 -0.0018 -0.0011 -0.0006 -0.0022 -0.0011 -0.0014 -0.0012 -3.5997 -1.2473 -0.1415
S-528	Klinische Studie 1 , 6 Indexläsionen ; Klinische Studie 2 , bis zu 8 Indexläsionen 2 .
T-528	Study 1 , 6 index lesions ; Study 2 , up to 8 index lesions 2 .
H-528	-0.004039636813104153	Study 1 , 6 index lesions ; Study 2 , up to 8 index lesions 2 .
D-528	-0.004039636813104153	Study 1 , 6 index lesions ; Study 2 , up to 8 index lesions 2 .
P-528	-0.0157 -0.0006 -0.0021 -0.0033 -0.0022 -0.0063 -0.0027 -0.0002 -0.0048 -0.0141 -0.0007 -0.0208 -0.0023 -0.0017 -0.0014 -0.0015 -0.0006 -0.0020 -0.0005 -0.0017 -0.0022 -0.0014
S-1473	Magyarország GE Healthcare SCE Handels GmbH Hungary Representative Office Akron u.2 .
T-1473	Magyarország GE Healthcare SCE Handels GmbH Hungary Representative Office Akron u.2 .
H-1473	-0.0016803996404632926	Magyarország GE Healthcare SCE Handels GmbH Hungary Representative Office Akron u.2 .
D-1473	-0.0016803996404632926	Magyarország GE Healthcare SCE Handels GmbH Hungary Representative Office Akron u.2 .
P-1473	-0.0066 -0.0013 -0.0012 -0.0015 -0.0003 -0.0007 -0.0010 -0.0004 -0.0005 -0.0011 -0.0011 -0.0015 -0.0005 -0.0015 -0.0008 -0.0030 -0.0007 -0.0009 -0.0011 -0.0010 -0.0010 -0.0003 -0.0020 -0.0108 -0.0017 -0.0014
S-1057	Falls Sie während der Behandlungsdauer Herzklopfen oder Herzrhythmusstörungen bemerken , suchen Sie bitte sofort Ihren Arzt auf .
T-1057	If you experience palpitations or irregular heart beat during the period of treatment , you should inform your doctor immediately .
H-1057	-0.026577258482575417	If you experience palpitations or irregular heart beat during the period of treatment , you should inform your doctor immediately .
D-1057	-0.026577258482575417	If you experience palpitations or irregular heart beat during the period of treatment , you should inform your doctor immediately .
P-1057	-0.0988 -0.0040 -0.0111 -0.0018 -0.0003 -0.0025 -0.0019 -0.0106 -0.0007 -0.0058 -0.0147 -0.0052 -0.0148 -0.0148 -0.0023 -0.0085 -0.0092 -0.0306 -0.0047 -0.3910 -0.0097 -0.0019 -0.0026 -0.0404 -0.0016 -0.0014
S-679	- Patienten mit exudativer ( feuchter ) altersbezogener Makuladegeneration ( AMD ) mit
T-679	- patients with exudative ( wet ) age @-@ related macular degeneration ( AMD ) with predominantly
H-679	-0.0036648535169661045	- patients with exudative ( wet ) age @-@ related macular degeneration ( AMD ) with predominantly
D-679	-0.0036648535169661045	- patients with exudative ( wet ) age @-@ related macular degeneration ( AMD ) with predominantly
P-679	-0.0023 -0.0119 -0.0019 -0.0019 -0.0013 -0.0018 -0.0008 -0.0017 -0.0075 -0.0014 -0.0010 -0.0058 -0.0034 -0.0011 -0.0012 -0.0016 -0.0007 -0.0019 -0.0011 -0.0011 -0.0014 -0.0043 -0.0145 -0.0141 -0.0020 -0.0079
S-192	Danmark Eisai AB Tlf : + 46 ( 0 ) 8 501 01 600 ( Sverige )
T-192	Danmark Eisai AB Tlf : + 46 ( 0 ) 8 501 01 600 ( Sverige )
H-192	-0.0078063043765723705	Danmark Eisai AB Tlf : + 46 ( 0 ) 8 501 01 600 ( Sverige )
D-192	-0.0078063043765723705	Danmark Eisai AB Tlf : + 46 ( 0 ) 8 501 01 600 ( Sverige )
P-192	-0.0063 -0.0006 -0.0036 -0.0014 -0.0013 -0.0007 -0.0019 -0.0011 -0.0009 -0.0014 -0.0013 -0.1617 -0.0013 -0.0014 -0.0014 -0.0015 -0.0027 -0.0014 -0.0012 -0.0007 -0.0014 -0.0019 -0.0028 -0.0001 -0.0014 -0.0015
S-1232	Die vorgelegten Informationen waren nicht ausreichend , um die Anwendung von Dukoral bei Reisediarrhö zu stützen .
T-1232	The information presented was not sufficient to support the use of Dukoral in traveller <<unk>> s diarrhoea .
H-1232	-0.004920939449220896	The information presented was not sufficient to support the use of Dukoral in traveller <unk> s diarrhoea .
D-1232	-0.004920939449220896	The information presented was not sufficient to support the use of Dukoral in traveller <unk> s diarrhoea .
P-1232	-0.0042 -0.0050 -0.0127 -0.0032 -0.0066 -0.0038 -0.0016 -0.0015 -0.0037 -0.0060 -0.0014 -0.0022 -0.0004 -0.0015 -0.0053 -0.0127 -0.0050 -0.0192 -0.0137 -0.0031 -0.0002 -0.0068 -0.0006 -0.0017 -0.0014
S-1673	13 Volumen ( ml ) = BSA ( m2 ) x individuelle Dosis ( mg / m2 ) 0,05 mg / ml
T-1673	Volume ( ml ) = BSA ( m2 ) x individual dose ( mg / m2 ) 0.05 mg / ml
H-1673	-0.008426751010119915	Volume ( ml ) = BSA ( m2 ) x individual dose ( mg / m2 ) 0.05 mg / ml
D-1673	-0.008426751010119915	Volume ( ml ) = BSA ( m2 ) x individual dose ( mg / m2 ) 0.05 mg / ml
P-1673	-0.0161 -0.0007 -0.0077 -0.0021 -0.0014 -0.0022 -0.0017 -0.0008 -0.0015 -0.0806 -0.0014 -0.0019 -0.0028 -0.0027 -0.0014 -0.0004 -0.0014 -0.0755 -0.0014 -0.0011 -0.0014 -0.0003 -0.0015 -0.0008 -0.0015
S-12	INTELENCE und Lopinavir / Ritonavir können ohne Dosisanpassungen angewendet werden .
T-12	INTELENCE and lopinavir / ritonavir can be used without dose adjustments .
H-12	-0.0419670008122921	INTELENCE and lopinavir / ritonavir can be used without dose adjustments .
D-12	-0.0419670008122921	INTELENCE and lopinavir / ritonavir can be used without dose adjustments .
P-12	-0.0012 -0.0013 -0.0007 -0.0010 -0.0004 -0.0335 -0.0104 -0.0135 -0.0007 -0.0011 -0.0025 -0.0011 -0.0015 -0.0007 -0.0010 -0.0041 -0.0015 -0.0165 -0.0025 -0.1381 -0.0031 -0.0006 -0.8088 -0.0019 -0.0014
S-1919	Die vollständige Beschreibung der im Zusammenhang mit Actraphane berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-1919	For the full description of the side effects reported with Actraphane , please see the Package Leaflet .
H-1919	-0.043152399361133575	For the full description of the side effects reported with Actraphane , see the Package Leaflet .
D-1919	-0.043152399361133575	For the full description of the side effects reported with Actraphane , see the Package Leaflet .
P-1919	-0.0122 -0.0091 -0.0043 -0.0118 -0.0015 -0.0152 -0.0115 -0.0022 -0.0025 -0.0129 -0.0021 -0.0009 -0.0007 -0.0004 -0.0044 -0.9031 -0.0054 -0.0148 -0.0019 -0.0143 -0.0002 -0.0011 -0.0018 -0.0015
S-763	Es ist nicht bekannt , ob Botulinum Neurotoxin Typ A in die Muttermilch übergeht .
T-763	It is not known whether Botulinum neurotoxin type A is excreted into the breast milk .
H-763	-0.06746058911085129	It is not known whether Botulinum neurotoxin type A is excreted into the breast milk .
D-763	-0.06746058911085129	It is not known whether Botulinum neurotoxin type A is excreted into the breast milk .
P-763	-0.0025 -0.0017 -0.0524 -0.0018 -0.0087 -0.0089 -0.0009 -0.0015 -0.0011 -0.0042 -0.0004 -0.0013 -0.0013 -0.0025 -0.0014 -0.0094 -0.0145 -0.0062 -0.0012 -0.8039 -0.7500 -0.0054 -0.0022 -0.0018 -0.0014
S-1828	Das kann zu Theophyllin @-@ verursachten Nebenwirkungen führen , die selten lebensbedrohlich oder tödlich sein können .
T-1828	This can lead to theophylline @-@ induced side effects that may rarely be life threatening or fatal .
H-1828	-0.016289183869957924	This can lead to theophylline @-@ induced side effects that may rarely be life threatening or fatal .
D-1828	-0.016289183869957924	This can lead to theophylline @-@ induced side effects that may rarely be life threatening or fatal .
P-1828	-0.0044 -0.0235 -0.0188 -0.0014 -0.0041 -0.0009 -0.0009 -0.0018 -0.0016 -0.0017 -0.0152 -0.0011 -0.0239 -0.0040 -0.0585 -0.0144 -0.0063 -0.0013 -0.0015 -0.0873 -0.1086 -0.0070 -0.0015 -0.0014
S-1332	Tricyclische Antidepressiva / Antipsychotika / Anästhetika / Narkotika :
T-1332	Tricyclic antidepressants / antipsychotics / anaesthetics / narcotics :
H-1332	-0.003396266605705023	Tricyclic antidepressants / antipsychotics / anaesthetics / narcotics :
D-1332	-0.003396266605705023	Tricyclic antidepressants / antipsychotics / anaesthetics / narcotics :
P-1332	-0.0033 -0.0007 -0.0015 -0.0060 -0.0005 -0.0009 -0.0109 -0.0015 -0.0027 -0.0012 -0.0006 -0.0197 -0.0013 -0.0017 -0.0032 -0.0029 -0.0008 -0.0013 -0.0046 -0.0007 -0.0088 -0.0021 -0.0014
S-1436	Die Zahl der 2002 bearbeiteten Folgemaßnahmen und besonderer Bedingungen erhöhte sich signifikant und lag über den Planungsannahmen .
T-1436	follow @-@ up measures and specific obligations processed in 2002 increased significantly and was greater than initial forecasts .
H-1436	-0.007035968825221062	follow @-@ up measures and specific obligations processed in 2002 increased significantly and was greater than initial forecasts .
D-1436	-0.007035968825221062	follow @-@ up measures and specific obligations processed in 2002 increased significantly and was greater than initial forecasts .
P-1436	-0.0145 -0.0025 -0.0024 -0.0118 -0.0035 -0.0097 -0.0146 -0.0015 -0.0134 -0.0007 -0.0023 -0.0010 -0.0079 -0.0016 -0.0045 -0.0143 -0.0140 -0.0014 -0.0145 -0.0139 -0.0034 -0.0014
S-596	Bei Schizophrenie beträgt die empfohlene Anfangsdosis zum Einnehmen 10 oder 15 mg pro Tag .
T-596	For schizophrenia , the recommended starting dose is 10 or 15 mg by mouth per day .
H-596	-0.010000479407608509	For schizophrenia , the recommended starting dose is 10 or 15 mg by mouth per day .
D-596	-0.010000479407608509	For schizophrenia , the recommended starting dose is 10 or 15 mg by mouth per day .
P-596	-0.0114 -0.0011 -0.0006 -0.0009 -0.0004 -0.0006 -0.0065 -0.0018 -0.0021 -0.0523 -0.0032 -0.0205 -0.0033 -0.0027 -0.0022 -0.0027 -0.0746 -0.0145 -0.0143 -0.0015 -0.0016 -0.0014
S-1983	Wenn auch die 60 @-@ Minuten @-@ Infusion gut vertragen wird , können alle folgenden Infusionen über 30 Minuten erfolgen .
T-1983	If the 60 @-@ minute infusion is well tolerated , all subsequent infusions may be administered over 30 @-@ minutes .
H-1983	-0.035478852689266205	If the 60 @-@ minute infusion is well tolerated , all subsequent infusions may be administered over 30 @-@ minutes .
D-1983	-0.035478852689266205	If the 60 @-@ minute infusion is well tolerated , all subsequent infusions may be administered over 30 @-@ minutes .
P-1983	-0.0097 -0.0050 -0.0019 -0.0203 -0.0231 -0.0022 -0.0006 -0.0023 -0.0055 -0.0021 -0.0012 -0.0045 -0.0053 -0.0080 -0.0021 -0.0008 -0.0010 -0.0120 -0.0160 -0.0135 -0.0008 -0.0096 -0.0037 -0.7957 -0.0076 -0.0022 -0.0014
S-1292	Retacrit 2000 I.E. / 0,6 ml Injektionslösung in Fertigspritze Epoetin zeta
T-1292	Retacrit 2000 IU / 0.6ml solution for injection in pre @-@ filled syringe Epoetin zeta
H-1292	-0.03130422905087471	Retacrit 2000 IU / 0.6 ml solution for injection in pre @-@ filled syringe Epoetin zeta
D-1292	-0.03130422905087471	Retacrit 2000 IU / 0.6 ml solution for injection in pre @-@ filled syringe Epoetin zeta
P-1292	-0.0008 -0.0014 -0.0037 -0.0009 -0.0016 -0.0145 -0.0017 -0.0080 -0.7552 -0.0006 -0.0129 -0.0131 -0.0097 -0.0019 -0.0093 -0.0128 -0.0014 -0.0081 -0.0009 -0.0005 -0.0001 -0.0107 -0.0012 -0.0007 -0.0015 -0.0012 -0.0005 -0.0016
S-1897	Insulin Human Winthrop Rapid gibt es in Patronen mit 3 ml Lösung ( 300 I.E. ) .
T-1897	452 Insulin Human Winthrop Rapid is supplied in cartridges containing 3 ml solution ( 300 IU ) .
H-1897	-0.005663365591317415	452 Insulin Human Winthrop Rapid is supplied in cartridges containing 3 ml solution ( 300 IU ) .
D-1897	-0.005663365591317415	452 Insulin Human Winthrop Rapid is supplied in cartridges containing 3 ml solution ( 300 IU ) .
P-1897	-0.0270 -0.0145 -0.0119 -0.0004 -0.0006 -0.0021 -0.0008 -0.0002 -0.0011 -0.0010 -0.0072 -0.0203 -0.0010 -0.0026 -0.0066 -0.0004 -0.0013 -0.0144 -0.0064 -0.0012 -0.0145 -0.0018 -0.0012 -0.0014 -0.0137 -0.0019 -0.0018 -0.0014
S-1509	Für die Behandlung anorektischer Kälber sollte das Präparat in einem halben Liter Elektrolytlösung verabreicht werden .
T-1509	For treatment of anorexic calves , the product should be administered in half a litre of an electrolyte solution .
H-1509	-0.025021320208907127	For treatment of anorexic calves , the product should be administered in half a litre of an electrolyte solution .
D-1509	-0.025021320208907127	For treatment of anorexic calves , the product should be administered in half a litre of an electrolyte solution .
P-1509	-0.0057 -0.0129 -0.0015 -0.0023 -0.0012 -0.0137 -0.0025 -0.0014 -0.0012 -0.0078 -0.0038 -0.0130 -0.0018 -0.0014 -0.0119 -0.0010 -0.0040 -0.0056 -0.0017 -0.0019 -0.0062 -0.0029 -0.0142 -0.0008 -0.0007 -0.0007 -0.0014 -0.0076 -0.3000 -0.3197
S-178	Grauweiße kapselförmige Filmtabletten , auf einer Seite bedruckt mit &quot; Cholestagel &quot; .
T-178	Off @-@ white , capsule @-@ shaped film @-@ coated tablets imprinted with <<unk>> Cholestagel <<unk>> on one side .
H-178	-0.007926194928586483	Off @-@ white , capsule @-@ shaped film @-@ coated tablets imprinted with <unk> Cholestagel <unk> on one side .
D-178	-0.007926194928586483	Off @-@ white , capsule @-@ shaped film @-@ coated tablets imprinted with <unk> Cholestagel <unk> on one side .
P-178	-0.0145 -0.0073 -0.0064 -0.0172 -0.0026 -0.0006 -0.0025 -0.0026 -0.0059 -0.0066 -0.0330 -0.0145 -0.0018 -0.0236 -0.0013 -0.0147 -0.0017 -0.0024 -0.0145 -0.0142 -0.0011 -0.0016 -0.0042 -0.0004 -0.0144 -0.0028 -0.0015 -0.0199 -0.0023 -0.0014
S-1886	zu Wenn Sie mehr ACOMPLIA eingenommen haben , als Sie sollten , informieren Sie Ihren Arzt oder Apotheker .
T-1886	If you take more ACOMPLIA than you should If you take more ACOMPLIA than you should tell a doctor or pharmacist .
H-1886	-0.05453838035464287	If you take more ACOMPLIA than you should If you take more ACOMPLIA than you should tell a doctor or pharmacist .
D-1886	-0.05453838035464287	If you take more ACOMPLIA than you should If you take more ACOMPLIA than you should tell a doctor or pharmacist .
P-1886	-0.0126 -0.0014 -0.0170 -0.0023 -0.0024 -0.0010 -0.0005 -0.0014 -0.0004 -0.0019 -0.0016 -0.0017 -0.5918 -0.0033 -0.0131 -0.0125 -0.0030 -0.0011 -0.0005 -0.0015 -0.0004 -0.0138 -0.0020 -0.0019 -0.2622 -0.7764 -0.0042 -0.0066 -0.0018 -0.0010 -0.0025 -0.0015
S-1243	Dazu werden die Röhrchen oder Beutel verwendet , die dem Helicobacter Test INFAI beiliegen .
T-1243	Firstly , the patient collects two breath samples , using the tubes or bags supplied with Helicobacter Test INFAI .
H-1243	-0.017146460711956024	Firstly , the patient collects two breath samples , using the tubes or bags supplied with Helicobacter Test INFAI .
D-1243	-0.017146460711956024	Firstly , the patient collects two breath samples , using the tubes or bags supplied with Helicobacter Test INFAI .
P-1243	-0.0145 -0.0013 -0.0061 -0.0089 -0.1861 -0.0145 -0.0006 -0.0152 -0.0145 -0.0111 -0.0132 -0.0144 -0.0069 -0.1814 -0.0012 -0.0016 -0.0038 -0.0080 -0.0129 -0.0008 -0.0022 -0.0141 -0.0009 -0.0006 -0.0010 -0.0011 -0.0044 -0.0020 -0.0006 -0.0013 -0.0018 -0.0014
S-1588	Mastschweine älter als 10 Wochen werden jedoch mit einer Dosis intramuskulär geimpft. itte
T-1588	For fattening pigs over the age of 10 weeks , however , one intramuscular injection with one dose is administered. od
H-1588	-0.035556383430957794	For fattening pigs over the age of 10 weeks , however , one intramuscular injection with one dose is administered .
D-1588	-0.035556383430957794	For fattening pigs over the age of 10 weeks , however , one intramuscular injection with one dose is administered .
P-1588	-0.0144 -0.0121 -0.0002 -0.0054 -0.0011 -0.0014 -0.0130 -0.0229 -0.0010 -0.0014 -0.0018 -0.0016 -0.0032 -0.0164 -0.0014 -0.0318 -0.0222 -0.0021 -0.0005 -0.0015 -0.0147 -0.0074 -0.0146 -0.0114 -0.0147 -0.0064 -0.0143 -0.8247 -0.0019 -0.0014
S-1255	• Das Aufklärungsmaterial sollte Ärzte dazu anhalten , schwerwiegende und bestimmte ausgewählte UAWs zu berichten wie :
T-1255	Significant changes found in auditory or ophthalmological testing Gallstones Unexpected ADRs according to the SPC .
H-1255	-0.011148902587592602	Significant changes found in auditory or ophthalmological testing Gallstones Unexpected ADRs according to the SPC .
D-1255	-0.011148902587592602	Significant changes found in auditory or ophthalmological testing Gallstones Unexpected ADRs according to the SPC .
P-1255	-0.0145 -0.0045 -0.0016 -0.0144 -0.0145 -0.0054 -0.0145 -0.0114 -0.0145 -0.0145 -0.0004 -0.0008 -0.0113 -0.0033 -0.0142 -0.0146 -0.0144 -0.0272 -0.0145 -0.0100 -0.0098 -0.0038 -0.0145 -0.0138 -0.0012 -0.0362 -0.0014 -0.0103 -0.0145 -0.0138 -0.0133 -0.0037
S-1528	FÜR DEN WIDERRUF DER GENEHMIGUNGEN FÜR
T-1528	GROUNDS FOR WITHDRAWAL OF THE MARKETING AUTHORISATIONS Whereas ,
H-1528	-0.01063504721969366	GROUNDS FOR WITHDRAWAL OF THE MARKETING AUTHORISATIONS Whereas ,
D-1528	-0.01063504721969366	GROUNDS FOR WITHDRAWAL OF THE MARKETING AUTHORISATIONS Whereas ,
P-1528	-0.0145 -0.0127 -0.0141 -0.0049 -0.0129 -0.0009 -0.0146 -0.0094 -0.0145 -0.0102 -0.0134 -0.0141 -0.0139 -0.0011 -0.0189 -0.0277 -0.0074 -0.0056 -0.0144 -0.0150 -0.0068 -0.0019 -0.0135 -0.0125 -0.0050 -0.0005 -0.0008 -0.0160 -0.0145 -0.0038 -0.0059 -0.0181 -0.0114
S-1211	Der Aufbau des Sekretariats der Agentur hat sich 1996 gefestigt und wird 1997 und 1998 voraussichtlich weitgehend unverändert bleiben .
T-1211	The structure of the EMEA Secretariat became more stable by the end of 1996 and it is anticipated that it will remain largely unchanged during 1997 and 1998 .
H-1211	-0.008247972466051579	The structure of the EMEA Secretariat became more stable by the end of 1996 and it is anticipated that it will remain largely unchanged during 1997 and 1998 .
D-1211	-0.008247972466051579	The structure of the EMEA Secretariat became more stable by the end of 1996 and it is anticipated that it will remain largely unchanged during 1997 and 1998 .
P-1211	-0.0029 -0.0122 -0.0014 -0.0018 -0.0153 -0.0145 -0.0003 -0.0126 -0.0008 -0.0013 -0.0140 -0.0118 -0.0136 -0.0348 -0.0231 -0.0055 -0.0013 -0.0360 -0.0038 -0.0140 -0.0026 -0.0139 -0.0023 -0.0077 -0.0015 -0.0050 -0.0062 -0.0026 -0.0019 -0.0143 -0.0038 -0.0016 -0.0014 -0.0015 -0.0014
S-1911	Vorgesehen sind dabei unter anderem die Teilnahme an bestimmten Sitzungen und Lehrgängen sowie die Durchführung spezieller Konferenzen .
T-1911	Similar activities will start under the PHARE multi @-@ beneficiary programme on participation of Croatia and Turkey in certain Community Agencies , in order to support preparation of these countries for accession .
H-1911	-0.011365332640707493	Similar activities will start under the PHARE multi @-@ beneficiary programme on participation of Croatia and Turkey in certain Community Agencies , in order to support preparation of these countries for accession .
D-1911	-0.011365332640707493	Similar activities will start under the PHARE multi @-@ beneficiary programme on participation of Croatia and Turkey in certain Community Agencies , in order to support preparation of these countries for accession .
P-1911	-0.0145 -0.0064 -0.0139 -0.0106 -0.0145 -0.0145 -0.0069 -0.0145 -0.0134 -0.0138 -0.0145 -0.0015 -0.0145 -0.0017 -0.0032 -0.0132 -0.0145 -0.0145 -0.0201 -0.0145 -0.0156 -0.0144 -0.0148 -0.0113 -0.0145 -0.0145 -0.0006 -0.0130 -0.0144 -0.0145 -0.0018 -0.0143 -0.0145 -0.0083 -0.0144 -0.0142 -0.0130 -0.0145 -0.0005 -0.0063 -0.0014
S-807	Lietuva GlaxoSmithKline Lietuva UAB Tel . + 370 264 90 00 Ar
T-807	r ge Lietuva GlaxoSmithKline Lietuva UAB Tel . + 370 264 90 00 info. lt @ gsk. com lon This leaflet was last approved on : no
H-807	-0.09429207444190979	r ge Lietuva GlaxoSmithKline Lietuva UAB Tel . + 370 264 90 00 info. lt @ gsk. com
D-807	-0.09429207444190979	r ge Lietuva GlaxoSmithKline Lietuva UAB Tel . + 370 264 90 00 info. lt @ gsk. com
P-807	-0.0147 -0.0171 -0.0161 -0.0014 -0.0010 -0.0009 -0.0012 -0.0012 -0.0004 -0.0011 -0.0013 -0.0009 -0.0025 -0.0016 -0.0009 -0.0016 -0.0003 -0.0050 -0.2812 -0.0013 -0.0004 -0.0008 -0.0012 -0.0009 -0.0015 -0.0148 -0.0144 -0.0126 -0.0145 -0.0145 -0.0145 -0.0145 -0.0139 -2.7355
S-1561	Es wirkt nicht als ein Inhibitor der mitochondrialen DNA @-@ Polymerase gamma .
T-1561	It has a very low potential to decrease mitochondrial DNA content , is not permanently incorporated into mitochondrial DNA , and does not act as an inhibitor of mitochondrial DNA polymerase gamma .
H-1561	-0.16762016713619232	It has a very low potential to decrease mitochondrial DNA content , is not permanently incorporated into mitochondrial DNA , and does not act as an inhibitor .
D-1561	-0.16762016713619232	It has a very low potential to decrease mitochondrial DNA content , is not permanently incorporated into mitochondrial DNA , and does not act as an inhibitor .
P-1561	-0.0046 -0.0153 -0.0155 -0.0144 -0.0098 -0.0144 -0.0099 -0.0145 -0.0009 -0.0137 -0.0003 -0.0012 -0.0012 -0.0007 -0.0009 -0.0031 -0.0160 -0.0139 -0.0155 -0.0097 -0.0145 -0.0082 -0.0145 -0.0016 -0.0098 -0.0144 -0.0006 -0.0009 -0.0011 -0.0008 -0.0023 -0.0019 -0.0141 -0.0082 -0.0125 -0.0016 -0.0082 -0.0016 -0.0034 -0.0012 -0.0005 -0.0004 -0.0013 -7.2423 -0.0014
S-25	Ethanol 96 % Benzylalkohol Propylenglycol Arginin Wasser für Injektionszwecke
T-25	Ethanol Benzyl alcohol Propylene glycol Arginine Water for injections
H-25	-0.011530120857059956	Ethanol Benzyl alcohol Propylene glycol Arginine Water for injections
D-25	-0.011530120857059956	Ethanol Benzyl alcohol Propylene glycol Arginine Water for injections
P-25	-0.0077 -0.0002 -0.0307 -0.0365 -0.0013 -0.0014 -0.0337 -0.0008 -0.0006 -0.0063 -0.0006 -0.0009 -0.0011 -0.0018 -0.0003 -0.0910 -0.0067 -0.0022 -0.0026 -0.0139 -0.0020
S-359	Konzentrat zur Herstellung einer Infusionslösung 10 Ampullen zu je 10 ml ( 10 mg / 10 ml )
T-359	concentrate for solution for infusion 10 ampoules of 10 ml ( 10 mg / 10 ml )
H-359	-0.005492947995662689	concentrate for solution for infusion 10 ampoules of 10 ml ( 10 mg / 10 ml )
D-359	-0.005492947995662689	concentrate for solution for infusion 10 ampoules of 10 ml ( 10 mg / 10 ml )
P-359	-0.0136 -0.0074 -0.0145 -0.0143 -0.0086 -0.0023 -0.0052 -0.0067 -0.0006 -0.0016 -0.0074 -0.0032 -0.0015 -0.0115 -0.0020 -0.0006 -0.0015 -0.0014 -0.0006 -0.0015 -0.0091
S-420	Erythropoetine sind Wachstumsfaktoren , die in erster Linie die Produktion roter Blutzellen anregen .
T-420	Erythropoietins are growth factors that primarily stimulate red blood cell production .
H-420	-0.013837217353284359	Erythropoietins are growth factors that primarily stimulate red blood cell production .
D-420	-0.013837217353284359	Erythropoietins are growth factors that primarily stimulate red blood cell production .
P-420	-0.0017 -0.0012 -0.0002 -0.0013 -0.0124 -0.0140 -0.0005 -0.0016 -0.0021 -0.0008 -0.0064 -0.0076 -0.0019 -0.0010 -0.0105 -0.0022 -0.0019 -0.0017 -0.2066 -0.0014
S-43	Die Einnahme von Stocrin zu den Mahlzeiten kann zu einem Anstieg der Häufigkeit von Nebenwirkungen führen .
T-43	Taking Stocrin with food may lead to an increase in the frequency of side effects .
H-43	-0.015604543499648571	Taking Stocrin with food may lead to an increase in the frequency of side effects .
D-43	-0.015604543499648571	Taking Stocrin with food may lead to an increase in the frequency of side effects .
P-43	-0.0099 -0.0047 -0.0024 -0.0012 -0.0058 -0.0144 -0.0098 -0.0230 -0.0014 -0.0052 -0.0020 -0.0017 -0.0051 -0.0169 -0.0011 -0.0014 -0.0063 -0.0026 -0.1958 -0.0014
S-120	Wenn Sie während der Behandlung mit &lt; Cozaar &gt; schwanger werden , teilen Sie dies unmittelbar Ihrem Arzt mit .
T-120	If you become pregnant while on losartan , tell your doctor immediately .
H-120	-0.009397607296705246	If you become pregnant while on losartan , tell your doctor immediately .
D-120	-0.009397607296705246	If you become pregnant while on losartan , tell your doctor immediately .
P-120	-0.0057 -0.0055 -0.0089 -0.0007 -0.0236 -0.0163 -0.0145 -0.0041 -0.0027 -0.0132 -0.0103 -0.0276 -0.0024 -0.0099 -0.0032 -0.0017
S-931	Unter der Behandlung mit Soliris traten weniger thrombotische Ereignisse auf als während desselben Zeitraums vor der Behandlung .
T-931	There were fewer thrombotic events with Soliris treatment than during the same period of time prior to treatment .
H-931	-0.012288767844438553	There were fewer thrombotic events with Soliris treatment than during the same period of time prior to treatment .
D-931	-0.012288767844438553	There were fewer thrombotic events with Soliris treatment than during the same period of time prior to treatment .
P-931	-0.0126 -0.0416 -0.0014 -0.0003 -0.0003 -0.0017 -0.0017 -0.0131 -0.0036 -0.0005 -0.0149 -0.0087 -0.0045 -0.0027 -0.0016 -0.0069 -0.0735 -0.0039 -0.0797 -0.0014 -0.0051 -0.0015 -0.0014
S-1236	Die Tablette löst sich im Mund innerhalb von Sekunden auf und kann dann mit oder ohne Wasser geschluckt werden .
T-1236	The tablet begins breaking up in the mouth within seconds and can then be swallowed with or without water .
H-1236	-0.008849440142512321	The tablet begins breaking up in the mouth within seconds and can then be swallowed with or without water .
D-1236	-0.008849440142512321	The tablet begins breaking up in the mouth within seconds and can then be swallowed with or without water .
P-1236	-0.0036 -0.0018 -0.0013 -0.0145 -0.0145 -0.0113 -0.0056 -0.0040 -0.0007 -0.0035 -0.0016 -0.0185 -0.0052 -0.0590 -0.0314 -0.0012 -0.0011 -0.0010 -0.0026 -0.0237 -0.0013 -0.0018 -0.0016 -0.0015
S-525	Daher sollte die gemeinsame Anwendung vermieden werden , sofern diese nicht als unbedingt notwendig angesehen wird ( siehe Abschnitt 4.5 ) .
T-525	Therefore , this co @-@ administration should be avoided unless judged strictly necessary ( see section 4.5 ) .
H-525	-0.008546913973987103	Therefore , this co @-@ administration should be avoided unless judged strictly necessary ( see section 4.5 ) .
D-525	-0.008546913973987103	Therefore , this co @-@ administration should be avoided unless judged strictly necessary ( see section 4.5 ) .
P-525	-0.0093 -0.0009 -0.0099 -0.0154 -0.0143 -0.0640 -0.0145 -0.0027 -0.0017 -0.0009 -0.0136 -0.0145 -0.0121 -0.0008 -0.0009 -0.0018 -0.0025 -0.0086 -0.0012 -0.0014 -0.0027 -0.0015 -0.0014
S-1102	Es stehen nur begrenzt pharmakokinetische Informationen bei Kindern und Jugendlichen zur Verfügung ( siehe Abschnitt 5.2 ) .
T-1102	Limited pharmacokinetic information is available in children and adolescents ( see section 5.2 ) .
H-1102	-0.0028364642057567835	Limited pharmacokinetic information is available in children and adolescents ( see section 5.2 ) .
D-1102	-0.0028364642057567835	Limited pharmacokinetic information is available in children and adolescents ( see section 5.2 ) .
P-1102	-0.0131 -0.0013 -0.0005 -0.0005 -0.0018 -0.0023 -0.0044 -0.0025 -0.0083 -0.0017 -0.0015 -0.0029 -0.0010 -0.0008 -0.0017 -0.0021 -0.0088 -0.0012 -0.0014 -0.0016 -0.0015 -0.0014
S-403	Die Bolusdosis sollte von der oben beschriebenen Dosierung bei ACS oder PCI nicht verändert werden .
T-403	The bolus dose should not be changed from the posology described under ACS or PCI above .
H-403	-0.011094686575233936	The bolus dose should not be changed from the posology described under ACS or PCI above .
D-403	-0.011094686575233936	The bolus dose should not be changed from the posology described under ACS or PCI above .
P-403	-0.0045 -0.0059 -0.0011 -0.0054 -0.0036 -0.0022 -0.0026 -0.0070 -0.0062 -0.0025 -0.0145 -0.0145 -0.0055 -0.1167 -0.0028 -0.0011 -0.0277 -0.0009 -0.0015 -0.0147 -0.0016 -0.0014
S-798	Die so erhaltene Lösung hat eine Konzentration von 0,05 mg / ml und ist nur zur einmaligen Anwendung gedacht .
T-798	The solution obtained has a concentration of 0.05 mg / ml and is for single @-@ use only .
H-798	-0.006491732783615589	The solution obtained has a concentration of 0.05 mg / ml and is for single @-@ use only .
D-798	-0.006491732783615589	The solution obtained has a concentration of 0.05 mg / ml and is for single @-@ use only .
P-798	-0.0031 -0.0064 -0.0076 -0.0106 -0.0018 -0.0004 -0.0014 -0.0020 -0.0018 -0.0007 -0.0015 -0.0011 -0.0486 -0.0023 -0.0142 -0.0106 -0.0131 -0.0008 -0.0053 -0.0016 -0.0015
S-1078	Jede Packung enthält Blisterpackungen mit 14 , 30 , 42 , 56 , 90 oder 100 Tabletten .
T-1078	Each pack contains blisters of 14 , 30 , 42 , 56 , 90 or 100 tablets .
H-1078	-0.08747341483831406	Each pack contains blisters of 14 , 30 , 42 , 56 , 90 or 100 tablets .
D-1078	-0.08747341483831406	Each pack contains blisters of 14 , 30 , 42 , 56 , 90 or 100 tablets .
P-1078	-0.0029 -0.1575 -0.0040 -0.0010 -1.0642 -0.0110 -0.0014 -0.0014 -0.0011 -0.0014 -0.0021 -0.0014 -0.0007 -0.0014 -0.0012 -0.5758 -0.0010 -0.0027 -0.0012 -0.0019 -0.0015
S-498	Wenn die rote Leuchtanzeige zu blinken beginnt , können Sie bei Bedarf jederzeit eine weitere Dosis auslösen .
T-498	When the red light starts to flash , you may start another dose at any time you need it .
H-498	-0.007315884344279766	When the red light starts to flash , you may start another dose at any time you need it .
D-498	-0.007315884344279766	When the red light starts to flash , you may start another dose at any time you need it .
P-498	-0.0124 -0.0022 -0.0027 -0.0125 -0.0051 -0.0107 -0.0023 -0.0042 -0.0027 -0.0248 -0.0141 -0.0107 -0.0013 -0.0074 -0.0020 -0.0019 -0.0150 -0.0080 -0.0104 -0.0019 -0.0015
S-1268	Reinigen Sie den Gummistopfen an der Oberseite der Durchstechflasche erneut mit einem Alkoholtupfer .
T-1268	Clean the rubber stopper on the top of the vial with an alcohol swab again .
H-1268	-0.004529231693595648	Clean the rubber stopper on the top of the vial with an alcohol swab again .
D-1268	-0.004529231693595648	Clean the rubber stopper on the top of the vial with an alcohol swab again .
P-1268	-0.0075 -0.0015 -0.0032 -0.0031 -0.0051 -0.0011 -0.0076 -0.0065 -0.0021 -0.0019 -0.0017 -0.0041 -0.0013 -0.0103 -0.0135 -0.0022 -0.0091 -0.0010 -0.0094 -0.0015 -0.0014
S-666	Zwei Patienten ( 0,7 % ) hatten schwere Nebenwirkungen , die möglicherweise in Zusammenhang mit der Studienmedikation standen .
T-666	Two patients ( 0.7 % ) experienced Serious Adverse Events potentially related to study drug .
H-666	-0.006463023368269205	Two patients ( 0.7 % ) experienced Serious Adverse Events potentially related to study drug .
D-666	-0.006463023368269205	Two patients ( 0.7 % ) experienced Serious Adverse Events potentially related to study drug .
P-666	-0.0015 -0.0024 -0.0017 -0.0015 -0.0012 -0.0015 -0.0014 -0.0106 -0.0147 -0.0014 -0.0137 -0.0004 -0.0140 -0.0141 -0.0079 -0.0015 -0.0133 -0.0134 -0.0116 -0.0014
S-258	Zu mehreren Zeitpunkten wurden Serumproben von erwachsenen Patienten auf die Entwicklung von Autoantikörpern untersucht .
T-258	Adult patients had serum samples tested for autoantibodies at multiple timepoints .
H-258	-0.012263420037925243	Adult patients had serum samples tested for autoantibodies at multiple timepoints .
D-258	-0.012263420037925243	Adult patients had serum samples tested for autoantibodies at multiple timepoints .
P-258	-0.0152 -0.0014 -0.0144 -0.0141 -0.0037 -0.0011 -0.0018 -0.0100 -0.0055 -0.0105 -0.0011 -0.1026 -0.0083 -0.0128 -0.0145 -0.0016 -0.0110 -0.0018 -0.0014
S-726	28 VORBEREITUNG FÜR DIE INJEKTION VON CEPLENE
T-726	PREPARATION FOR INJECTION OF CEPLENE
H-726	-0.003713760292157531	PREPARATION FOR INJECTION OF CEPLENE
D-726	-0.003713760292157531	PREPARATION FOR INJECTION OF CEPLENE
P-726	-0.0195 -0.0005 -0.0029 -0.0013 -0.0037 -0.0010 -0.0143 -0.0011 -0.0032 -0.0012 -0.0007 -0.0045 -0.0012 -0.0016 -0.0014 -0.0013 -0.0011 -0.0062
S-186	Hemmer ( ACE = Angiotensin Converting Enzyme ) ( siehe Abschnitt 6.1 )
T-186	Converting Enzyme ) inhibitors ( see section 6.1 )
H-186	-0.013864612206816673	Converting Enzyme ) inhibitors ( see section 6.1 )
D-186	-0.013864612206816673	Converting Enzyme ) inhibitors ( see section 6.1 )
P-186	-0.0148 -0.0032 -0.0041 -0.0131 -0.0135 -0.0050 -0.0151 -0.0232 -0.0004 -0.0005 -0.0033 -0.0015 -0.0073 -0.0097 -0.0299 -0.0014 -0.0019 -0.1017
S-26	Nplate 250 μg Pulver zur Herstellung einer Injektionszubereitung Romiplostim s.c .
T-26	Nplate 250 µg powder for injection romiplostim SC
H-26	-0.02213127352297306	Nplate 250 µg powder for injection romiplostim SC
D-26	-0.02213127352297306	Nplate 250 µg powder for injection romiplostim SC
P-26	-0.0022 -0.0007 -0.0012 -0.0124 -0.0011 -0.0062 -0.0045 -0.2802 -0.0010 -0.0145 -0.0012 -0.0003 -0.0010 -0.0008 -0.0145 -0.0123
S-1820	Die opportunistischen Infektionen , über die bei mit Remicade therapierten Patienten berichtet wurde , schlossen u.a .
T-1820	Some of these infections have been fatal .
H-1820	-0.011072796769440174	Some of these infections have been fatal .
D-1820	-0.011072796769440174	Some of these infections have been fatal .
P-1820	-0.0145 -0.0032 -0.0160 -0.0146 -0.0006 -0.0145 -0.0046 -0.0145 -0.0138 -0.0145
S-576	Die vollständige Liste aller im Zusammenhang mit ProQuad berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-576	For the full list of all side effects reported with ProQuad , see the Package Leaflet .
H-576	-0.032424554228782654	For the full list of all side effects reported with ProQuad , see the Package Leaflet .
D-576	-0.032424554228782654	For the full list of all side effects reported with ProQuad , see the Package Leaflet .
P-576	-0.0120 -0.0074 -0.0051 -0.0031 -0.0014 -0.0225 -0.0206 -0.0020 -0.0023 -0.0118 -0.0014 -0.0024 -0.0009 -0.0037 -0.6088 -0.0051 -0.0147 -0.0019 -0.0142 -0.0001 -0.0010 -0.0019 -0.0015
S-1328	Falls sich die Klebstoffreste nicht abwaschen lassen , können sie auch mit ein wenig Babyöl entfernt werden .
T-1328	You can also use a small amount of baby oil to remove any adhesive that won <<unk>> t wash off .
H-1328	-0.011194025166332722	You can also use a small amount of baby oil to remove any adhesive that won <unk> t wash off .
D-1328	-0.011194025166332722	You can also use a small amount of baby oil to remove any adhesive that won <unk> t wash off .
P-1328	-0.0271 -0.0366 -0.0321 -0.0370 -0.0103 -0.0143 -0.0033 -0.0014 -0.0021 -0.0015 -0.0072 -0.0106 -0.0125 -0.0127 -0.0007 -0.0014 -0.0135 -0.0143 -0.0167 -0.0008 -0.0030 -0.0059 -0.0025 -0.0014
S-1288	Die Behandlung sollte von einem entsprechend qualifizierten Transplantationsspezialisten initiiert werden und unter dessen Leitung verbleiben .
T-1288	Treatment should be initiated by and remain under the guidance of an appropriately qualified specialist in transplantation .
H-1288	-0.005568009335547686	Treatment should be initiated by and remain under the guidance of an appropriately qualified specialist in transplantation .
D-1288	-0.005568009335547686	Treatment should be initiated by and remain under the guidance of an appropriately qualified specialist in transplantation .
P-1288	-0.0087 -0.0007 -0.0011 -0.0016 -0.0016 -0.0008 -0.0014 -0.0142 -0.0126 -0.0069 -0.0027 -0.0019 -0.0121 -0.0015 -0.0110 -0.0033 -0.0009 -0.0018 -0.0144 -0.0060 -0.0037 -0.0209 -0.0023 -0.0014
S-1898	März 1997 erteilte die Europäische Kommission eine Genehmigung für das Inverkehrbringen von Refludan in der gesamten Europäischen Union .
T-1898	The European Commission granted a marketing authorisation valid throughout the European Union , for Refludan on 13 March 1997 .
H-1898	-0.06770742684602737	The European Commission granted a marketing authorisation valid throughout the EU , for Refludan on 13 March 1997 .
D-1898	-0.06770742684602737	The European Commission granted a marketing authorisation valid throughout the EU , for Refludan on 13 March 1997 .
P-1898	-0.0134 -0.0040 -0.0012 -0.0122 -0.0131 -0.0021 -0.0032 -0.0010 -0.0145 -0.0021 -0.0107 -0.0016 -0.7626 -0.2010 -0.0121 -0.0069 -0.0006 -0.0010 -0.0135 -0.0255 -0.5055 -0.0141 -0.0016 -0.0014
S-288	EU / 1 / 04 / 301 / 003 EU / 1 / 04 / 301 / 004 ln
T-288	EU / 1 / 04 / 301 / 003 EU / 1 / 04 / 301 / 004 lP
H-288	-0.019896432757377625	EU / 1 / 04 / 301 / 003 EU / 1 / 04 / 301 / 004 lP
D-288	-0.019896432757377625	EU / 1 / 04 / 301 / 003 EU / 1 / 04 / 301 / 004 lP
P-288	-0.0013 -0.0016 -0.0014 -0.0015 -0.0010 -0.0014 -0.0010 -0.0013 -0.0014 -0.0012 -0.0015 -0.1923 -0.0015 -0.0014 -0.0015 -0.0008 -0.0014 -0.0009 -0.0013 -0.0014 -0.0011 -0.0012 -0.0032 -0.2703 -0.0044
S-998	Proposal for a core @-@ data for Lupuli flos ( Hop strobile ) ( * )
T-998	Proposal for a core @-@ data for Lupuli flos ( Hop strobile ) ( * )
H-998	-0.020609019324183464	Proposal for a core @-@ data for Lupuli flos ( Hop strobile ) ( * )
D-998	-0.020609019324183464	Proposal for a core @-@ data for Lupuli flos ( Hop strobile ) ( * )
P-998	-0.0017 -0.0004 -0.0012 -0.0014 -0.0014 -0.0007 -0.2570 -0.0012 -0.0014 -0.0022 -0.0004 -0.0012 -0.0010 -0.0003 -0.2329 -0.0008 -0.0010 -0.0003 -0.0012 -0.0007 -0.0014 -0.0015 -0.0010 -0.0014 -0.0014
S-778	Der Impfstoff wird als tiefe Injektion in einen Muskel , vorzugsweise den Oberschenkel , verabreicht .
T-778	Quintanrix can also be used to boost previous vaccinations against diphtheria , tetanus and na
H-778	-0.02276383340358734	Quintanrix can also be used to boost previous vaccinations against diphtheria , tetanus and na
D-778	-0.02276383340358734	Quintanrix can also be used to boost previous vaccinations against diphtheria , tetanus and na
P-778	-0.0161 -0.0139 -0.0145 -0.0145 -0.0144 -0.0144 -0.0933 -0.1098 -0.0116 -0.0157 -0.0145 -0.0145 -0.0144 -0.1095 -0.0143 -0.0145 -0.0143 -0.0002 -0.0006 -0.0129 -0.0145 -0.0113 -0.0003 -0.0087 -0.0145 -0.0145
S-15	Nach dem Auflösen enthält die Lösung 40 Einheiten Imiglucerase pro ml ( 400 Einheiten / 10 ml ) .
T-15	After reconstitution , the solution contains 40 units of imiglucerase per ml ( 400 U / 10 ml ) .
H-15	-0.004920952953398228	After reconstitution , the solution contains 40 units of imiglucerase per ml ( 400 U / 10 ml ) .
D-15	-0.004920952953398228	After reconstitution , the solution contains 40 units of imiglucerase per ml ( 400 U / 10 ml ) .
P-15	-0.0069 -0.0145 -0.0145 -0.0057 -0.0041 -0.0023 -0.0021 -0.0021 -0.0054 -0.0040 -0.0119 -0.0011 -0.0010 -0.0005 -0.0007 -0.0178 -0.0018 -0.0016 -0.0012 -0.0183 -0.0022 -0.0023 -0.0016 -0.0015 -0.0016 -0.0014
S-1468	Bei normaler Anwendung ist die Behandlung von mehr als ein oder zwei Zyklen Broilern in einem Jahr äußerst unwahrscheinlich .
T-1468	It is highly unlikely that in normal use more than one or two cycles of broilers would be treated in any one year .
H-1468	-0.006553306709975004	It is highly unlikely that in normal use more than one or two cycles of broilers would be treated in any one year .
D-1468	-0.006553306709975004	It is highly unlikely that in normal use more than one or two cycles of broilers would be treated in any one year .
P-1468	-0.0142 -0.0040 -0.0102 -0.0018 -0.0077 -0.0143 -0.0037 -0.0057 -0.0130 -0.0014 -0.0025 -0.0016 -0.0016 -0.0018 -0.0006 -0.0125 -0.0128 -0.0103 -0.0221 -0.0029 -0.0026 -0.0046 -0.0151 -0.0054 -0.0017 -0.0016 -0.0014
S-108	Sobald Sie gut eingestellt sind , werden Sie regelmäßige Dosen von Epoetin alfa HEXAL erhalten .
T-108	When your condition has been brought under control , you will receive regular doses of Epoetin alfa HEXAL .
H-108	-0.00530846556648612	When your condition has been brought under control , you will receive regular doses of Epoetin alfa HEXAL .
D-108	-0.00530846556648612	When your condition has been brought under control , you will receive regular doses of Epoetin alfa HEXAL .
P-108	-0.0144 -0.0144 -0.0145 -0.0132 -0.0111 -0.0145 -0.0136 -0.0006 -0.0043 -0.0023 -0.0033 -0.0071 -0.0022 -0.0011 -0.0012 -0.0016 -0.0103 -0.0010 -0.0006 -0.0014 -0.0025 -0.0004 -0.0017 -0.0011 -0.0015 -0.0018 -0.0014
S-1056	CRIXIVAN Hartkapseln dürfen nur an Kinder verabreicht werden , die Hartkapseln schlucken können .
T-1056	CRIXIVAN hard capsules should only be given to children who are able to swallow hard capsules .
H-1056	-0.009051761589944363	CRIXIVAN hard capsules should only be given to children who are able to swallow hard capsules .
D-1056	-0.009051761589944363	CRIXIVAN hard capsules should only be given to children who are able to swallow hard capsules .
P-1056	-0.0030 -0.0007 -0.0011 -0.0008 -0.0006 -0.0054 -0.0029 -0.0010 -0.0013 -0.0166 -0.0840 -0.0014 -0.0905 -0.0014 -0.0042 -0.0034 -0.0114 -0.0041 -0.0013 -0.0013 -0.0009 -0.0011 -0.0009 -0.0008 -0.0012 -0.0017 -0.0014
S-1589	71 Desitin Pharma AB Krokslätts Torg 5 43137 Mölndal Sweden Tel :
T-1589	FI / SE Desitin Pharma AB Krokslätts Torg 5 43137 Mölndal Sweden Tel :
H-1589	-0.003981465008109808	FI / SE Desitin Pharma AB Krokslätts Torg 5 43137 Mölndal Sweden Tel :
D-1589	-0.003981465008109808	FI / SE Desitin Pharma AB Krokslätts Torg 5 43137 Mölndal Sweden Tel :
P-1589	-0.0162 -0.0145 -0.0185 -0.0145 -0.0193 -0.0012 -0.0008 -0.0016 -0.0006 -0.0005 -0.0006 -0.0006 -0.0001 -0.0008 -0.0007 -0.0011 -0.0015 -0.0009 -0.0010 -0.0012 -0.0024 -0.0004 -0.0011 -0.0002 -0.0011 -0.0050 -0.0031 -0.0018
S-427	Blähungen , Verstopfung , Diarrhoe , Übelkeit , Erbrechen , Abdominalschmerzen
T-427	Rare : flatulence , constipation , diarrhoea , nausea , vomiting , abdominal pain
H-427	-0.0046080038882792	Rare : flatulence , constipation , diarrhoea , nausea , vomiting , abdominal pain
D-427	-0.0046080038882792	Rare : flatulence , constipation , diarrhoea , nausea , vomiting , abdominal pain
P-427	-0.0174 -0.0144 -0.0134 -0.0155 -0.0001 -0.0015 -0.0015 -0.0013 -0.0002 -0.0006 -0.0013 -0.0015 -0.0016 -0.0003 -0.0087 -0.0006 -0.0015 -0.0012 -0.0003 -0.0015 -0.0374 -0.0003 -0.0014 -0.0020 -0.0018 -0.0003 -0.0007 -0.0026 -0.0028
S-1671	Katzenleukosevirus ) des Kanarienpockenvirus ( Stamm vCP97 ) enthält .
T-1671	Purevax FeLV is a vaccine containing feline leukaemia virus ( FeLV ) recombinant canarypox virus ( vCP97 ) .
H-1671	-0.012040887959301472	Purevax FeLV is a vaccine containing feline leukaemia virus ( FeLV ) recombinant canarypox virus ( vCP97 ) .
D-1671	-0.012040887959301472	Purevax FeLV is a vaccine containing feline leukaemia virus ( FeLV ) recombinant canarypox virus ( vCP97 ) .
P-1671	-0.0145 -0.0145 -0.0145 -0.0148 -0.0145 -0.0143 -0.0146 -0.0083 -0.0145 -0.0123 -0.0145 -0.0010 -0.0008 -0.0137 -0.0003 -0.0013 -0.0032 -0.0253 -0.0148 -0.0143 -0.0075 -0.0040 -0.0324 -0.0143 -0.0056 -0.0058 -0.0139 -0.0144 -0.0133 -0.0053 -0.0007 -0.0020 -0.0024 -0.0127 -0.0015 -0.1029 -0.0007 -0.0130 -0.0018 -0.0014
S-1423	Candidiasis , Ohr @-@ Infektion , Herpes simplex , Zahn @-@ Infektion
T-1423	Infections Common : influenza like symptoms , respiratory tract infection ( e. g bronchitis ) , urinary tract infection Uncommon : candidiasis , ear infection , herpes simplex , tooth infection
H-1423	-0.04948221892118454	Infections Common : influenza like symptoms , respiratory tract infection ( e. g bronchitis ) , urinary tract infection Uncommon : candidiasis , ear infection , herpes simplex , tooth infection
D-1423	-0.04948221892118454	Infections Common : influenza like symptoms , respiratory tract infection ( e. g bronchitis ) , urinary tract infection Uncommon : candidiasis , ear infection , herpes simplex , tooth infection
P-1423	-0.0145 -0.0108 -0.0145 -0.0019 -0.0132 -0.0171 -0.0009 -0.0013 -0.0145 -0.0145 -0.0111 -0.0159 -0.0006 -0.0009 -0.0137 -0.0009 -0.0040 -0.2426 -0.0148 -0.0145 -0.0073 -0.8247 -0.0085 -0.0049 -0.0437 -0.2538 -0.0333 -0.0014 -0.0031 -0.0001 -0.0021 -0.4540 -0.0131 -0.0119 -0.0137 -0.0013 -0.0308 -0.0014 -0.0014 -0.0587 -0.0114 -0.0017 -0.3213 -0.0043 -0.0004 -0.0004 -0.0013 -0.0011 -0.0757 -0.0092 -0.0006 -0.0015 -0.0020
S-1600	U. zu den geeignetsten Kandidaten für eine lang wirkende injizierbare Medikation gehören .
T-1600	The MAH provided further justifications , being of the position that restricting the use of Risperdal Consta to patients with an initial treatment response to oral risperidone would be unjustified and would introduce an unnecessary and potentially prolonged additional step for the prescribing physicians , delaying access of Risperdal Consta to those patients who may not be adherent to their oral medication and who may be among the most suitable candidates for a long @-@ acting injectable medication .
H-1600	-0.12170474976301193	The MAH provided further justifications , being of the position that restricting the use of Risperdal Consta to patients with an initial treatment response to oral risperidone would be unjustified and would introduce an unnecessary and potentially prolonged additional step for the prescribing physicians , delaying access of Risperdal Consta .
D-1600	-0.12170474976301193	The MAH provided further justifications , being of the position that restricting the use of Risperdal Consta to patients with an initial treatment response to oral risperidone would be unjustified and would introduce an unnecessary and potentially prolonged additional step for the prescribing physicians , delaying access of Risperdal Consta .
P-1600	-0.0143 -0.0145 -0.0144 -0.0145 -0.0145 -0.0145 -0.0141 -0.0142 -0.0145 -0.0145 -0.0098 -0.0145 -0.0131 -0.0145 -0.0128 -0.0102 -0.0115 -0.0017 -0.0145 -0.0144 -0.0105 -0.0324 -0.0145 -0.0217 -0.0139 -0.0110 -0.0181 -0.0145 -0.0144 -0.0145 -0.0141 -0.0143 -0.0145 -0.0145 -0.0144 -0.0138 -0.0137 -0.0094 -0.0145 -0.0140 -0.0366 -0.0119 -0.0148 -0.0142 -0.0142 -0.0146 -0.0151 -0.0187 -0.0060 -0.0010 -0.0150 -0.0192 -0.0141 -0.0124 -0.0145 -0.0101 -0.0145 -0.0137 -0.0153 -0.0145 -0.0012 -0.0145 -0.0145 -0.0146 -0.0066 -0.0054 -0.0157 -0.0145 -7.5770 -0.0014
S-1806	Die theoretische spezifische Aktivität liegt bei 20 GBq / Mikrogramm Yttrium @-@ 90 ( siehe Abschnitt 6.5 ) .
T-1806	The theoretical specific activity is 20 GBq / microgram of Yttrium ( 90Y ) ( see section 6.5 ) .
H-1806	-0.037455927580595016	The theoretical specific activity is 20 GBq / microgram of Yttrium ( 90Y ) ( see section 6.5 ) .
D-1806	-0.037455927580595016	The theoretical specific activity is 20 GBq / microgram of Yttrium ( 90Y ) ( see section 6.5 ) .
P-1806	-0.0050 -0.0013 -0.0054 -0.0053 -0.0030 -0.0039 -0.0051 -0.0016 -0.0019 -0.0006 -0.0018 -0.0136 -0.3432 -0.0073 -0.0124 -0.0003 -0.0011 -0.0012 -0.4049 -0.2246 -0.0145 -0.0054 -0.0030 -0.0023 -0.0105 -0.0020 -0.0019 -0.0016 -0.0014
S-253	Nebenwirkungen bemerken , die nicht in dieser Gebrauchsinformation angegeben sind , informieren Sie bitte Ihren Arzt , Apotheker oder das Pflegepersonal .
T-253	please tell your doctor , pharmacist or nurse .
H-253	-0.012272707186639309	please tell your doctor , pharmacist or nurse .
D-253	-0.012272707186639309	please tell your doctor , pharmacist or nurse .
P-253	-0.0145 -0.0242 -0.0015 -0.0039 -0.0458 -0.0020 -0.0009 -0.0028 -0.0105 -0.0145 -0.0145
S-1896	Wenn Sie aufhören , Atripla zu nehmen , kann das schwere Auswirkungen darauf haben , wie Sie auf die weitere Behandlung ansprechen .
T-1896	Stopping Atripla can seriously affect your response to future treatment .
H-1896	-0.009338255040347576	Stopping Atripla can seriously affect your response to future treatment .
D-1896	-0.009338255040347576	Stopping Atripla can seriously affect your response to future treatment .
P-1896	-0.0145 -0.0001 -0.0128 -0.0008 -0.0010 -0.0013 -0.0070 -0.0143 -0.0045 -0.0170 -0.0093 -0.0277 -0.0144 -0.0027 -0.0081 -0.0138
S-1310	Viraferon ist während der Schwangerschaft nur anzuwenden , wenn der potentielle Nutzen die Gefahren für den Fetus rechtfertigt .
T-1310	used during pregnancy only if the potential benefit justifies the potential risk to the foetus .
H-1310	-0.010015218518674374	used during pregnancy only if the potential benefit justifies the potential risk to the foetus .
D-1310	-0.010015218518674374	used during pregnancy only if the potential benefit justifies the potential risk to the foetus .
P-1310	-0.0165 -0.0046 -0.0015 -0.0067 -0.0324 -0.0048 -0.0013 -0.0080 -0.0035 -0.0009 -0.0026 -0.0169 -0.0135 -0.0073 -0.0019 -0.0133 -0.0002 -0.0156 -0.0469 -0.0018
S-802	Da insbesondere für Patienten mit mäßiger Leberfunktionsstörung nur begrenzte klinische Erfahrungen vorliegen , ist Vorsicht bei der Behandlung angebracht .
T-802	Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised .
H-802	-0.04922940954566002	Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised .
D-802	-0.04922940954566002	Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised .
P-802	-0.0145 -0.0012 -0.0032 -0.0048 -0.0091 -0.0449 -0.0115 -0.0027 -0.4395 -0.0027 -0.0172 -0.0024 -0.0014 -0.3645 -0.0009 -0.0657 -0.0087 -0.0109 -0.0137 -0.0130 -0.0014
S-560	Übelkeit / Erbrechen sind seltener , wenn die Injek- tionen am Abend oder nach einer Mahlzeit gegeben werden .
T-560	Nausea / vomiting are less frequent when the injection is done in the evening and after meals .
H-560	-0.038545314222574234	Nausea / vomiting are less frequent when the injection is done in the evening and after meals .
D-560	-0.038545314222574234	Nausea / vomiting are less frequent when the injection is done in the evening and after meals .
P-560	-0.0029 -0.0003 -0.0023 -0.0502 -0.0002 -0.0013 -0.0067 -0.0050 -0.0156 -0.1035 -0.0090 -0.0013 -0.0306 -0.0022 -0.0144 -0.0031 -0.0014 -0.0019 -0.5777 -0.0028 -0.0511 -0.0017 -0.0014
S-368	Blutungen ( schwere Blutungen / Blutungen insgesamt ) in den pivotalen Studien zum Hüft- und Kniegelenksersatz
T-368	Table 1 Bleeding events broken down to major and any bleeding in the pivotal hip and knee study
H-368	-0.009330899454653263	Table 1 Bleeding events broken down to major and any bleeding in the pivotal hip and knee study
D-368	-0.009330899454653263	Table 1 Bleeding events broken down to major and any bleeding in the pivotal hip and knee study
P-368	-0.0154 -0.0136 -0.0140 -0.0010 -0.0151 -0.0164 -0.0083 -0.0150 -0.0142 -0.0142 -0.0145 -0.0081 -0.0014 -0.0095 -0.0101 -0.0010 -0.0038 -0.0014 -0.0130 -0.0037 -0.0009 -0.0145 -0.0056
S-200	Es wurden drei Studien ermittelt , in denen der Ausgang von Loratadin @-@ exponierten Schwangerschaften mit Kontrollen verglichen wurde .
T-200	Three studies comparing the outcomes of loratadine @-@ exposed pregnancies to controls were identified .
H-200	-0.005323808174580336	Three studies comparing the outcomes of loratadine @-@ exposed pregnancies to controls were identified .
D-200	-0.005323808174580336	Three studies comparing the outcomes of loratadine @-@ exposed pregnancies to controls were identified .
P-200	-0.0013 -0.0056 -0.0141 -0.0018 -0.0036 -0.0116 -0.0012 -0.0019 -0.0037 -0.0010 -0.0097 -0.0035 -0.0035 -0.0013 -0.0009 -0.0009 -0.0009 -0.0379 -0.0020 -0.0063 -0.0068 -0.0016 -0.0014
S-485	Ihr Arzt oder sein / e Assistent / in wird Ihnen zeigen , wie Sie die Selbstinjektion von IntronA vornehmen .
T-485	Your doctor or his / her assistant will instruct you how to self- inject IntronA .
H-485	-0.004798829555511475	Your doctor or his / her assistant will instruct you how to self- inject IntronA .
D-485	-0.004798829555511475	Your doctor or his / her assistant will instruct you how to self- inject IntronA .
P-485	-0.0053 -0.0044 -0.0022 -0.0122 -0.0076 -0.0012 -0.0021 -0.0016 -0.0144 -0.0009 -0.0016 -0.0134 -0.0023 -0.0145 -0.0028 -0.0119 -0.0024 -0.0005 -0.0023 -0.0008 -0.0013 -0.0028 -0.0019
S-161	Nach wiederholter täglicher Einnahme über 7 Tage wird eine Hemmung der Magensäuresekretion um etwa 90 % erzielt .
T-161	After repeated daily administration for seven days , about 90 % inhibition of gastric acid secretion is achieved .
H-161	-0.005418323911726475	After repeated daily administration for seven days , about 90 % inhibition of gastric acid secretion is achieved .
D-161	-0.005418323911726475	After repeated daily administration for seven days , about 90 % inhibition of gastric acid secretion is achieved .
P-161	-0.0055 -0.0026 -0.0016 -0.0150 -0.0088 -0.0144 -0.0014 -0.0065 -0.0145 -0.0011 -0.0016 -0.0133 -0.0023 -0.0017 -0.0036 -0.0003 -0.0008 -0.0014 -0.0009 -0.0191 -0.0021 -0.0085 -0.0015 -0.0014
S-60	In einer anderen Studie hatte Grapefruit @-@ Saft keine Auswirkung auf die Verfügbarkeit von Desloratadin .
T-60	In another study , grapefruit juice had no effect on the disposition of desloratadine .
H-60	-0.0052817040123045444	In another study , grapefruit juice had no effect on the disposition of desloratadine .
D-60	-0.0052817040123045444	In another study , grapefruit juice had no effect on the disposition of desloratadine .
P-60	-0.0022 -0.0062 -0.0017 -0.0029 -0.0013 -0.0007 -0.0006 -0.0013 -0.0006 -0.0243 -0.0017 -0.0032 -0.0015 -0.0033 -0.0148 -0.0129 -0.0321 -0.0057 -0.0002 -0.0015 -0.0021 -0.0028 -0.0016 -0.0014
S-1733	Die Einnahme von Nahrung beeinflusst die AUC oder Cmax von Rivaroxaban bei der 10 mg @-@ Dosis nicht .
T-1733	Intake with food does not affect rivaroxaban AUC or Cmax at the 10 mg dose .
H-1733	-0.011495545506477356	Intake with food does not affect rivaroxaban AUC or Cmax at the 10 mg dose .
D-1733	-0.011495545506477356	Intake with food does not affect rivaroxaban AUC or Cmax at the 10 mg dose .
P-1733	-0.0142 -0.0056 -0.0761 -0.0034 -0.0047 -0.0014 -0.0216 -0.0147 -0.0002 -0.0013 -0.0011 -0.0010 -0.0050 -0.0010 -0.1010 -0.0018 -0.0008 -0.0052 -0.0062 -0.0043 -0.0007 -0.0011 -0.0019 -0.0015
S-1116	Für dosisabhängige Nebenwirkungen bezieht sich die Häufigkeitsangabe auf die höhere Rosiglitazondosis .
T-1116	For dose @-@ related adverse reactions the frequency category reflects the higher dose of rosiglitazone .
H-1116	-0.011245517991483212	For dose @-@ related adverse reactions the frequency category reflects the higher dose of rosiglitazone .
D-1116	-0.011245517991483212	For dose @-@ related adverse reactions the frequency category reflects the higher dose of rosiglitazone .
P-1116	-0.0039 -0.0017 -0.0043 -0.0137 -0.0829 -0.0005 -0.0847 -0.0012 -0.0117 -0.0039 -0.0009 -0.0145 -0.0145 -0.0034 -0.0017 -0.0082 -0.0017 -0.0070 -0.0005 -0.0009 -0.0010 -0.0038 -0.0018 -0.0014
S-741	22 unten angeführten Tabellen 2 und 3 beschreiben die Nebenwirkungen , die mit den einzelnen Bestandteilen von Karvezide berichtet wurden .
T-741	Tables 2 and 3 below detail the adverse reactions reported with the individual components of Karvezide .
H-741	-0.01167434174567461	Tables 2 and 3 below detail the adverse reactions reported with the individual components of Karvezide .
D-741	-0.01167434174567461	Tables 2 and 3 below detail the adverse reactions reported with the individual components of Karvezide .
P-741	-0.0111 -0.0011 -0.0072 -0.0020 -0.0015 -0.0065 -0.0144 -0.0055 -0.0144 -0.0003 -0.1516 -0.0010 -0.0042 -0.0092 -0.0075 -0.0096 -0.0068 -0.0015 -0.0145 -0.0008 -0.0005 -0.0047 -0.0029 -0.0015
S-994	Bei Patienten mit einem Körpergewicht unter 100 kg zeigten sich zwischen den beiden Dosierungen von Stelara keine Unterschiede bei den Ansprechraten .
T-994	There was no difference in response rates between the two doses of Stelara in patients weighing below 100 kg .
H-994	-0.020968258380889893	There was no difference in response rates between the two doses of Stelara in patients weighing below 100 kg .
D-994	-0.020968258380889893	There was no difference in response rates between the two doses of Stelara in patients weighing below 100 kg .
P-994	-0.0131 -0.3615 -0.0017 -0.0014 -0.0019 -0.0021 -0.0027 -0.0121 -0.0041 -0.0019 -0.0017 -0.0069 -0.0021 -0.0018 -0.0011 -0.0011 -0.0056 -0.0025 -0.0180 -0.0013 -0.0662 -0.0046 -0.0025 -0.0047 -0.0014
S-1112	Im Jahre 1995 wurde sie Leiterin des Referats für pharmakotoxisch @-@ klinische Evaluation bei der französischen Arzneimittelbehörde .
T-1112	In 1995 she joined the French Medicines Agency as Head of Unit for pharmaco @-@ toxico @-@ clinical assessment .
H-1112	-0.006885952316224575	In 1995 she joined the French Medicines Agency as Head of Unit for pharmaco @-@ toxico @-@ clinical assessment .
D-1112	-0.006885952316224575	In 1995 she joined the French Medicines Agency as Head of Unit for pharmaco @-@ toxico @-@ clinical assessment .
P-1112	-0.0037 -0.0010 -0.0074 -0.0239 -0.0031 -0.0057 -0.0090 -0.0029 -0.0060 -0.0069 -0.0073 -0.0015 -0.0143 -0.0011 -0.0036 -0.0145 -0.0115 -0.0015 -0.0077 -0.0181 -0.0028 -0.0012 -0.0141 -0.0022 -0.0014
S-620	Durchstechflaschen Gadovist sollte erst unmittelbar vor der Anwendung aus der Durchstechflasche in die Spritze aufgezogen werden .
T-620	Vials Gadovist should not be drawn up into the syringe from the vial until immediately before use .
H-620	-0.010759674943983555	Vials Gadovist should not be drawn up into the syringe from the vial until immediately before use .
D-620	-0.010759674943983555	Vials Gadovist should not be drawn up into the syringe from the vial until immediately before use .
P-620	-0.0099 -0.0096 -0.0009 -0.0003 -0.0012 -0.0028 -0.0375 -0.0058 -0.0108 -0.0506 -0.0329 -0.0025 -0.0011 -0.0004 -0.0003 -0.0283 -0.0020 -0.0008 -0.0016 -0.0253 -0.0077 -0.0035 -0.0305 -0.0015 -0.0014
S-1702	Luxembourg / Luxemburg Novartis Pharma GmbH Allemagne / Deutschland Tél / Tel : + 49 911 273 0
T-1702	Luxembourg / Luxemburg Novartis Pharma GmbH Allemagne / Deutschland Tél / Tel : + 49 911 273 0
H-1702	-0.002181907882913947	Luxembourg / Luxemburg Novartis Pharma GmbH Allemagne / Deutschland Tél / Tel : + 49 911 273 0
D-1702	-0.002181907882913947	Luxembourg / Luxemburg Novartis Pharma GmbH Allemagne / Deutschland Tél / Tel : + 49 911 273 0
P-1702	-0.0031 -0.0007 -0.0016 -0.0142 -0.0006 -0.0005 -0.0012 -0.0007 -0.0007 -0.0009 -0.0003 -0.0011 -0.0008 -0.0014 -0.0153 -0.0015 -0.0009 -0.0011 -0.0014 -0.0041 -0.0020 -0.0013 -0.0008 -0.0011 -0.0010 -0.0007 -0.0013 -0.0014 -0.0015
S-218	UAB Magnum Veterinarija UAB Magnum Veterinarija Fort Dodge Animal Health Benelux B.V .
T-218	UAB Magnum Veterinarija UAB Magnum Veterinarija Fort Dodge Animal Health Benelux B. V .
H-218	-0.0014399492647498846	UAB Magnum Veterinarija UAB Magnum Veterinarija Fort Dodge Animal Health Benelux B. V .
D-218	-0.0014399492647498846	UAB Magnum Veterinarija UAB Magnum Veterinarija Fort Dodge Animal Health Benelux B. V .
P-218	-0.0015 -0.0005 -0.0008 -0.0013 -0.0007 -0.0016 -0.0011 -0.0008 -0.0017 -0.0004 -0.0005 -0.0012 -0.0006 -0.0014 -0.0011 -0.0008 -0.0008 -0.0013 -0.0006 -0.0004 -0.0007 -0.0009 -0.0006 -0.0009 -0.0004 -0.0145 -0.0014 -0.0017 -0.0014
S-1666	Novartis Healthcare A / S , Tlf / Tel / Puh : + 45 @-@ 39 16 84 00 Deutschland :
T-1666	Novartis Healthcare A / S , Tlf / Tel / Puh : + 45 @-@ 39 16 84 00 Deutschland :
H-1666	-0.00292171910405159	Novartis Healthcare A / S , Tlf / Tel / Puh : + 45 @-@ 39 16 84 00 Deutschland :
D-1666	-0.00292171910405159	Novartis Healthcare A / S , Tlf / Tel / Puh : + 45 @-@ 39 16 84 00 Deutschland :
P-1666	-0.0029 -0.0004 -0.0012 -0.0008 -0.0011 -0.0011 -0.0016 -0.0014 -0.0010 -0.0020 -0.0059 -0.0014 -0.0010 -0.0016 -0.0026 -0.0020 -0.0062 -0.0009 -0.0017 -0.0016 -0.0213 -0.0025 -0.0009 -0.0015 -0.0005 -0.0013 -0.0146 -0.0023 -0.0015
S-919	UCB Pharma SA ( BRAINE ) Chemin du Foriest Braine @-@ l &apos; Alleud B @-@ 1420 Belgien
T-919	UCB Pharma SA ( BRAINE ) Chemin du Foriest Braine @-@ l &apos;Alleud B @-@ 1420 Belgium
H-919	-0.10732848197221756	UCB Pharma SA ( BRAINE ) Chemin du Foriest Braine @-@ l &apos;Alleud B 041 Belgium
D-919	-0.10732848197221756	UCB Pharma SA ( BRAINE ) Chemin du Foriest Braine @-@ l &apos;Alleud B 041 Belgium
P-919	-0.0003 -0.0009 -0.0004 -0.0007 -0.0007 -0.0013 -0.0012 -0.0008 -0.0012 -0.0011 -0.0014 -0.0003 -0.0012 -0.0005 -0.0012 -0.0057 -0.0008 -0.0014 -0.2115 -0.0011 -0.0012 -0.0003 -0.0004 -0.0010 -2.6694 -0.0444 -0.0530 -0.0017
S-1518	Humalog Pen 100 E / ml Injektionslösung Insulin lispro Zur subkutanen und intravenösen Anwendung
T-1518	Humalog Pen 100 U / ml solution for injection Insulin lispro Subcutaneous and intravenous use
H-1518	-0.012853734195232391	Humalog Pen 100 U / ml solution for injection Insulin lispro Subcutaneous and intravenous use
D-1518	-0.012853734195232391	Humalog Pen 100 U / ml solution for injection Insulin lispro Subcutaneous and intravenous use
P-1518	-0.0008 -0.0004 -0.0005 -0.0018 -0.0151 -0.0015 -0.0009 -0.0145 -0.0154 -0.0063 -0.0037 -0.0073 -0.0004 -0.0006 -0.0039 -0.0006 -0.0012 -0.0137 -0.0012 -0.0006 -0.0012 -0.2582 -0.0046 -0.0055 -0.0014 -0.0005 -0.0011 -0.0082 -0.0017
S-1340	19 Die Durchstechflasche ist zusätzlich mit einer Schutzkappe aus Polypropylen verschlossen , die Manipulationen sofort erkennen lässt .
T-1340	The closed vials are equipped with a tamper @-@ evident snap @-@ off cap which is made of polypropylene .
H-1340	-0.025111664086580276	The closed vials are equipped with a tamper @-@ evident snap @-@ off cap which is made of polypropylene .
D-1340	-0.025111664086580276	The closed vials are equipped with a tamper @-@ evident snap @-@ off cap which is made of polypropylene .
P-1340	-0.0146 -0.0589 -0.0089 -0.4457 -0.0054 -0.0142 -0.0017 -0.0038 -0.0145 -0.0005 -0.0016 -0.0085 -0.0129 -0.0011 -0.0216 -0.0108 -0.0144 -0.0162 -0.0141 -0.0092 -0.0048 -0.0103 -0.0027 -0.0007 -0.0006 -0.0008 -0.0032 -0.0015
S-1766	Wiederholter Kontakt mit Quecksilber aus Quellen wie Arzneimitteln und Lebensmittel kann zu dessen Anreicherung in den Organen führen .
T-1766	Repeated exposure to mercury from sources such as medicines and foods could lead to it building up in the organs .
H-1766	-0.01983679085969925	Repeated exposure to mercury from sources such as medicines and foods could lead to it building up in the organs .
D-1766	-0.01983679085969925	Repeated exposure to mercury from sources such as medicines and foods could lead to it building up in the organs .
P-1766	-0.0029 -0.0006 -0.0017 -0.0095 -0.2188 -0.0017 -0.0005 -0.0012 -0.0019 -0.0010 -0.0040 -0.0014 -0.0051 -0.0029 -0.0018 -0.0112 -0.2351 -0.0064 -0.0014 -0.0133 -0.0143 -0.0031 -0.0027 -0.0063 -0.0025 -0.0013 -0.0016 -0.0014
S-1858	Weiß , länglich , mit Bruchkerbe und Prägung des Codes &quot; ucb &quot; und &quot; 1000 &quot; auf einer Seite .
T-1858	White , oblong , scored and debossed with the code <<unk>> ucb <<unk>> and <<unk>> 1000 <<unk>> on one side .
H-1858	-0.007541792467236519	White , oblong , scored and debossed with the code <unk> ucb <unk> and <unk> 1000 <unk> on one side .
D-1858	-0.007541792467236519	White , oblong , scored and debossed with the code <unk> ucb <unk> and <unk> 1000 <unk> on one side .
P-1858	-0.0022 -0.0025 -0.0109 -0.0006 -0.0056 -0.0145 -0.0134 -0.0145 -0.0087 -0.0057 -0.0074 -0.0072 -0.0109 -0.0146 -0.0035 -0.0014 -0.0012 -0.0143 -0.0037 -0.0132 -0.0043 -0.0137 -0.0024 -0.0019 -0.0214 -0.0025 -0.0014
S-780	Juni 2007 erteilte die Europäische Kommission dem Unternehmen Merial eine Genehmigung für das Inverkehrbringen von Circovac in der gesamten Europäischen Union .
T-780	The European Commission granted a marketing authorisation valid throughout the European Union for Circovac to Merial on 21 June 2007 .
H-780	-0.08492434024810791	The European Commission granted a marketing authorisation valid throughout the European Union for Circovac to Merial on 21 June 2007 .
D-780	-0.08492434024810791	The European Commission granted a marketing authorisation valid throughout the European Union for Circovac to Merial on 21 June 2007 .
P-780	-0.0140 -0.0033 -0.0013 -0.0124 -0.0130 -0.0048 -0.0032 -0.0009 -0.0145 -0.0019 -0.0114 -0.0017 -0.7418 -0.0016 -0.0105 -0.0028 -0.0011 -0.0002 -0.0557 -0.0074 -0.0002 -0.0134 -1.1623 -0.1613 -0.0493 -0.0017 -0.0014
S-753	Lamivudin und Zidovudin sind Nukleosidanaloga , die Aktivität gegen HIV aufweisen .
T-753	Lamivudine and zidovudine are nucleoside analogues which have activity against HIV .
H-753	-0.008336292579770088	Lamivudine and zidovudine are nucleoside analogues which have activity against HIV .
D-753	-0.008336292579770088	Lamivudine and zidovudine are nucleoside analogues which have activity against HIV .
P-753	-0.0012 -0.0010 -0.0009 -0.0011 -0.0034 -0.1411 -0.0058 -0.0009 -0.0009 -0.0011 -0.0039 -0.0016 -0.0006 -0.0007 -0.0017 -0.0013 -0.0010 -0.0004 -0.0059 -0.0128 -0.0118 -0.0075 -0.0056 -0.0014 -0.0016 -0.0014
S-604	Es hat außerdem eine flache Dosis @-@ Wirkungs @-@ Kurve , d. h. seine Wirksamkeit ist größtenteils dosisunabhängig .
T-604	It also has a flat dose / response curve i. e. its efficacy is largely independent of the dose .
H-604	-0.010542282834649086	It also has a flat dose / response curve i. e. its efficacy is largely independent of the dose .
D-604	-0.010542282834649086	It also has a flat dose / response curve i. e. its efficacy is largely independent of the dose .
P-604	-0.0106 -0.0044 -0.0015 -0.0016 -0.0021 -0.0034 -0.0139 -0.0077 -0.0013 -0.0008 -0.0220 -0.0142 -0.0023 -0.1178 -0.0035 -0.0263 -0.0005 -0.0008 -0.0023 -0.0049 -0.0144 -0.0043 -0.0071 -0.0026 -0.0023 -0.0014
S-1676	( PET ) Polyethylenterephthalat @-@ Flaschen mit Gummistopfen und Aluminiumkapseln
T-1676	Polyethylene terephtalate ( PET ) bottles with rubber closures and aluminium capsules
H-1676	-0.012104101479053497	Polyethylene terephtalate ( PET ) bottles with rubber closures and aluminium capsules
D-1676	-0.012104101479053497	Polyethylene terephtalate ( PET ) bottles with rubber closures and aluminium capsules
P-1676	-0.0170 -0.0007 -0.0011 -0.0006 -0.0011 -0.0048 -0.0004 -0.0351 -0.0014 -0.0768 -0.0016 -0.0005 -0.0014 -0.0307 -0.0020 -0.0024 -0.1054 -0.0045 -0.0017 -0.0015 -0.0036 -0.0044 -0.0008 -0.0012 -0.0021
S-449	Die Nebenwirkungen von Alli betreffen in erster Linie das Verdauungssystem und treten bei fettreduzierter Ernährung seltener auf .
T-449	Most of the side effects with Alli affect the digestive system and are less likely to occur with a low fat diet .
H-449	-0.014195453375577927	Most of the side effects with Alli affect the digestive system and are less likely to occur with a low fat diet .
D-449	-0.014195453375577927	Most of the side effects with Alli affect the digestive system and are less likely to occur with a low fat diet .
P-449	-0.0144 -0.0038 -0.0118 -0.0026 -0.0037 -0.0144 -0.0008 -0.0109 -0.0021 -0.0022 -0.0005 -0.0017 -0.0017 -0.0214 -0.0062 -0.0069 -0.0163 -0.0067 -0.0026 -0.0177 -0.0069 -0.0061 -0.0131 -0.0009 -0.1923 -0.0014
S-38	Überempfindlichkeit Immunsystems Thromboembolie Gefäßerkrankungen ( bei intravaskulärer Anwendung ) Allgemeine Erkrankungen
T-38	( cannot be estimated from the available data ) Thromboembolism ( if applied intravascularly )
H-38	-0.0077545722015202045	( cannot be estimated from the available data ) Thromboembolism ( if applied intravascularly )
D-38	-0.0077545722015202045	( cannot be estimated from the available data ) Thromboembolism ( if applied intravascularly )
P-38	-0.0148 -0.0145 -0.0066 -0.0145 -0.0145 -0.0110 -0.0144 -0.0116 -0.0047 -0.0145 -0.0008 -0.0003 -0.0006 -0.0008 -0.0060 -0.0006 -0.0135 -0.0140 -0.0125 -0.0014 -0.0008 -0.0011 -0.0127 -0.0007 -0.0016 -0.0131
S-874	Falls unter der erhöhten Dosierung nach 3 Wochen keine bessere Wirksamkeit zu sehen ist , sollte Ihr Arzt die Behandlung mit Tasmar beenden .
T-874	If you do not get better at the higher dose after a total of 3 weeks , your doctor should stop your treatment with Tasmar .
H-874	-0.011806488037109375	If you do not get better at the higher dose after a total of 3 weeks , your doctor should stop your treatment with Tasmar .
D-874	-0.011806488037109375	If you do not get better at the higher dose after a total of 3 weeks , your doctor should stop your treatment with Tasmar .
P-874	-0.0044 -0.0133 -0.0099 -0.0013 -0.0143 -0.0105 -0.0144 -0.0077 -0.0120 -0.0099 -0.0057 -0.1166 -0.0144 -0.0030 -0.0262 -0.0011 -0.0038 -0.0040 -0.0020 -0.0200 -0.0066 -0.0142 -0.0075 -0.0029 -0.0007 -0.0009 -0.0018 -0.0014
S-1854	Österreich Wyeth @-@ Lederle Pharma GmbH Tel : + 43 1 891140 Fax : + 43 1 89 114600
T-1854	Österreich Wyeth @-@ Lederle Pharma GmbH Tel : + 43 1 891140 Fax : + 43 1 89 114600
H-1854	-0.0036235132720321417	Österreich Wyeth @-@ Lederle Pharma GmbH Tel : + 43 1 891140 Fax : + 43 1 89 114600
D-1854	-0.0036235132720321417	Österreich Wyeth @-@ Lederle Pharma GmbH Tel : + 43 1 891140 Fax : + 43 1 89 114600
P-1854	-0.0145 -0.0014 -0.0006 -0.0040 -0.0016 -0.0005 -0.0011 -0.0008 -0.0007 -0.0014 -0.0039 -0.0022 -0.0015 -0.0015 -0.0015 -0.0075 -0.0012 -0.0010 -0.0009 -0.0014 -0.0012 -0.0010 -0.0014 -0.0167 -0.0015 -0.0280 -0.0009 -0.0016
S-333	Möglicherweise lässt sich das Dosierungsschema so anpassen , dass ein Behandlungsintervall von wenigstens 6 Monaten erreicht werden kann .
T-333	It may be possible to adapt the dosage regimen to obtain an interval of at least six months between treatment sessions .
H-333	-0.06847973167896271	It may be possible to adapt the dosing regimen to obtain an interval of at least six months between treatment sessions .
D-333	-0.06847973167896271	It may be possible to adapt the dosing regimen to obtain an interval of at least six months between treatment sessions .
P-333	-0.0114 -0.1982 -0.0018 -0.0023 -0.0292 -0.0128 -0.0012 -0.0018 -0.0026 -1.3855 -0.0132 -0.0012 -0.0131 -0.0149 -0.0119 -0.0020 -0.0004 -0.0016 -0.0102 -0.0014 -0.0884 -0.0014 -0.0168 -0.0083 -0.0145 -0.0016 -0.0014
S-781	Hviezdoslavova 19 SK @-@ 903 01 Senec Tel . + 421 245 646 322
T-781	Hviezdoslavova 19 SK @-@ 903 01 Senec Tel . + 421 245 646 322
H-781	-0.022257406264543533	Hviezdoslavova 19 SK @-@ 903 01 Senec Tel . + 421 245 646 322
D-781	-0.022257406264543533	Hviezdoslavova 19 SK @-@ 903 01 Senec Tel . + 421 245 646 322
P-781	-0.0033 -0.0006 -0.0011 -0.0015 -0.0004 -0.0008 -0.0009 -0.0015 -0.0019 -0.0008 -0.0014 -0.0014 -0.0009 -0.0010 -0.0023 -0.0009 -0.0065 -0.4033 -0.0014 -0.0014 -0.0011 -0.0012 -0.1112 -0.0012 -0.0048 -0.0676 -0.0011 -0.0018
S-1151	Wenn Sie Insuline mischen , befolgen Sie die im Abschnitt II ) und 6.2 aufgeführten Anweisungen für das Mischen .
T-1151	If mixing insulins , refer to the instructions for mixing that follow in Section ( ii ) and 6.2 .
H-1151	-0.008412428200244904	If mixing insulins , refer to the instructions for mixing that follow in Section ( ii ) and 6.2 .
D-1151	-0.008412428200244904	If mixing insulins , refer to the instructions for mixing that follow in Section ( ii ) and 6.2 .
P-1151	-0.0096 -0.0141 -0.0005 -0.0114 -0.0141 -0.0025 -0.0034 -0.0145 -0.0015 -0.0041 -0.0088 -0.0055 -0.0014 -0.0005 -0.0143 -0.0145 -0.0068 -0.0100 -0.0005 -0.0425 -0.0324 -0.0016 -0.0014 -0.0017 -0.0087 -0.0014 -0.0065 -0.0014
S-206	Ambirix ist in Packungen zu 1 und 10 mit oder ohne Nadeln und in Packungen zu 50 ohne Nadeln erhältlich .
T-206	Ambirix is available in packs of 1 and 10 with or without needles and in a pack size of 50 without needles .
H-206	-0.017002739012241364	Ambirix is available in packs of 1 and 10 with or without needles and in a pack size of 50 without needles .
D-206	-0.017002739012241364	Ambirix is available in packs of 1 and 10 with or without needles and in a pack size of 50 without needles .
P-206	-0.0011 -0.0010 -0.0012 -0.0025 -0.1503 -0.0016 -0.0061 -0.0007 -0.0029 -0.0020 -0.0024 -0.0013 -0.0047 -0.0022 -0.0012 -0.0011 -0.0013 -0.0997 -0.0049 -0.0148 -0.0054 -0.1029 -0.0185 -0.0546 -0.0037 -0.0005 -0.0011 -0.0016 -0.0015
S-1756	Milch oder Antazida sollten zur Bindung von Bonviva gegeben werden , und jede Nebenwirkung symptomatisch behandelt werden .
T-1756	Milk or antacids should be given to bind Bonviva , and any adverse reactions treated symptomatically .
H-1756	-0.007616940885782242	Milk or antacids should be given to bind Bonviva , and any adverse reactions treated symptomatically .
D-1756	-0.007616940885782242	Milk or antacids should be given to bind Bonviva , and any adverse reactions treated symptomatically .
P-1756	-0.0007 -0.0011 -0.1032 -0.0006 -0.0025 -0.0013 -0.0017 -0.0014 -0.0081 -0.0035 -0.0020 -0.0008 -0.0032 -0.0009 -0.0006 -0.0273 -0.0017 -0.0018 -0.0153 -0.0003 -0.0136 -0.0012 -0.0140 -0.0059 -0.0007 -0.0033 -0.0011 -0.0015 -0.0014
S-1997	- Hemmer des Angiotensin umwandelnden Enzyms ( ACE @-@ Hemmer ) ( zur Behandlung bestimmter
T-1997	- angiotensin converting enzyme ( ACE ) inhibitors ( used to treat certain heart conditions or high
H-1997	-0.02293461188673973	- angiotensin converting enzyme ( ACE ) inhibitors ( used to treat certain heart conditions or high
D-1997	-0.02293461188673973	- angiotensin converting enzyme ( ACE ) inhibitors ( used to treat certain heart conditions or high
P-1997	-0.0025 -0.0146 -0.0010 -0.0009 -0.0006 -0.0014 -0.0105 -0.0032 -0.0012 -0.0036 -0.0010 -0.0228 -0.0010 -0.3765 -0.0197 -0.0252 -0.0006 -0.0004 -0.0050 -0.0019 -0.0103 -0.0804 -0.0010 -0.0038 -0.0145 -0.0131 -0.0196 -0.0145 -0.0144
S-456	- wenn Sie überempfindlich ( allergisch ) gegen Bimatoprost , Timolol oder einen der sonstigen
T-456	- if you are allergic ( hypersensitive ) to bimatoprost , timolol or any of the other ingredients of
H-456	-0.009154556319117546	- if you are allergic ( hypersensitive ) to bimatoprost , timolol or any of the other ingredients of
D-456	-0.009154556319117546	- if you are allergic ( hypersensitive ) to bimatoprost , timolol or any of the other ingredients of
P-456	-0.0031 -0.0042 -0.0016 -0.0026 -0.1542 -0.0010 -0.0115 -0.0100 -0.0006 -0.0018 -0.0018 -0.0063 -0.0008 -0.0010 -0.0009 -0.0011 -0.0001 -0.0018 -0.0016 -0.0004 -0.0010 -0.0031 -0.0066 -0.0038 -0.0035 -0.0043 -0.0144 -0.0152 -0.0073
S-668	Danmark Merck Sharp &amp; Dohme , Tlf : + 45 43 28 77 66 dkmail @ merck.com
T-668	Danmark Merck Sharp &amp; Dohme , Tlf : + 45 43 28 77 66 dkmail @ merck. com
H-668	-0.002784377196803689	Danmark Merck Sharp &amp; Dohme , Tlf : + 45 43 28 77 66 dkmail @ merck. com
D-668	-0.002784377196803689	Danmark Merck Sharp &amp; Dohme , Tlf : + 45 43 28 77 66 dkmail @ merck. com
P-668	-0.0044 -0.0007 -0.0015 -0.0014 -0.0011 -0.0011 -0.0013 -0.0004 -0.0014 -0.0019 -0.0041 -0.0012 -0.0011 -0.0020 -0.0014 -0.0106 -0.0012 -0.0011 -0.0010 -0.0012 -0.0012 -0.0025 -0.0008 -0.0010 -0.0015 -0.0024 -0.0147 -0.0144 -0.0021
S-586	Wärmen sie Neupopeg keinesfalls auf eine andere Weise auf ( beispielsweise im Mikrowellengerät oder in heißem Wasser ) .
T-586	not warm Neupopeg in any other way ( for example , do not warm it in a microwave or in hot water ) . in ic
H-586	-0.02021929621696472	not warm Neupopeg in any other way ( for example , do not warm it in a microwave or in hot water ) .
D-586	-0.02021929621696472	not warm Neupopeg in any other way ( for example , do not warm it in a microwave or in hot water ) .
P-586	-0.0145 -0.0106 -0.0108 -0.0048 -0.0001 -0.0063 -0.0053 -0.0021 -0.0021 -0.0021 -0.0082 -0.0029 -0.0380 -0.0149 -0.0081 -0.0129 -0.0104 -0.0079 -0.0070 -0.0005 -0.0008 -0.0048 -0.0244 -0.0210 -0.0012 -0.0017 -0.0026 -0.3403
S-930	Ein Flüssigkeits- und / oder Natriummangel sollte vor Verabreichung von Irbesartan BMS ausgeglichen werden .
T-930	Intravascular volume depletion : volume and / or sodium depletion should be corrected prior to administration of Irbesartan BMS .
H-930	-0.008512125350534916	Intravascular volume depletion : volume and / or sodium depletion should be corrected prior to administration of Irbesartan BMS .
D-930	-0.008512125350534916	Intravascular volume depletion : volume and / or sodium depletion should be corrected prior to administration of Irbesartan BMS .
P-930	-0.0145 -0.0145 -0.0141 -0.0002 -0.0145 -0.0148 -0.0046 -0.0016 -0.0152 -0.0145 -0.0144 -0.0313 -0.0013 -0.0292 -0.0004 -0.0137 -0.0012 -0.0013 -0.0029 -0.0014 -0.0137 -0.0013 -0.0326 -0.0015 -0.0107 -0.0018 -0.0132 -0.0003 -0.0004 -0.0011 -0.0022 -0.0013 -0.0023 -0.0014
S-674	Darüber hinaus lieferte die Studie keine Informationen darüber , ob höhere Dosen von Losartan ( über 50 mg ) die Wirksamkeit verbessern .
T-674	Furthermore , the study provided no information on the effect that higher doses of losartan ( greater than 50mg ) could have on improving efficacy .
H-674	-0.2270260751247406	Furthermore , the study provided no information on the effect that higher doses of losartan ( above 50mg ) could have on improving efficacy .
D-674	-0.2270260751247406	Furthermore , the study provided no information on the effect that higher doses of losartan ( above 50mg ) could have on improving efficacy .
P-674	-0.0123 -0.0008 -0.0013 -0.0022 -0.0025 -0.0034 -0.0130 -0.0016 -0.0033 -0.0083 -0.0149 -0.0131 -0.0140 -0.0025 -0.0015 -0.0008 -0.0016 -0.0007 -0.0004 -0.0013 -0.0025 -7.5251 -0.0402 -0.0008 -0.0016 -0.0142 -0.0032 -0.0062 -0.0144 -0.0062 -0.0009 -0.0010 -0.0017 -0.0014
S-240	5 Notwendigkeit für die Gabe von Antaziden , ein signifikanter Unterschied bezüglich der Symptome wurde jedoch nicht aufgezeigt .
T-240	Compared with placebo , lansoprazole only reduced the need for antacids in one of the studies but significant difference with regard to symptoms was not shown .
H-240	-0.021792273968458176	Compared with placebo , lansoprazole only reduced the need for antacids in one of the studies but significant difference with regard to symptoms was not shown .
D-240	-0.021792273968458176	Compared with placebo , lansoprazole only reduced the need for antacids in one of the studies but significant difference with regard to symptoms was not shown .
P-240	-0.0187 -0.0135 -0.3242 -0.0145 -0.0013 -0.0003 -0.0024 -0.0083 -0.0145 -0.0145 -0.0125 -0.0020 -0.0145 -0.0145 -0.0071 -0.0334 -0.1284 -0.0031 -0.0029 -0.0024 -0.0143 -0.0145 -0.0143 -0.0070 -0.0143 -0.0141 -0.0145 -0.0138 -0.0144 -0.0131 -0.0015 -0.0118 -0.0100 -0.0017 -0.0109 -0.0018 -0.0015
S-190	Der Inhaber der Genehmigung für das Inverkehrbringen legte die folgenden Informationen vor : • Eine aktualisierte Bewertung der Umweltrisiken •
T-190	The Marketing Authorisation Holder provided the following information : • An updated Environmental Risk Assessment • The complete information submitted to the Reference Member State and the CMD ( v ) in respect to environmental risk assessment .
H-190	-0.011841134168207645	The Marketing Authorisation Holder provided the following information : • An updated Environmental Risk Assessment • The complete information submitted to the Reference Member State and the CMD ( v ) in respect to environmental risk assessment .
D-190	-0.011841134168207645	The Marketing Authorisation Holder provided the following information : • An updated Environmental Risk Assessment • The complete information submitted to the Reference Member State and the CMD ( v ) in respect to environmental risk assessment .
P-190	-0.0025 -0.0178 -0.0022 -0.0057 -0.0016 -0.0074 -0.0010 -0.0066 -0.0025 -0.0012 -0.0019 -0.0026 -0.0026 -0.0030 -0.0035 -0.0141 -0.0007 -0.0008 -0.0023 -0.0012 -0.0007 -0.0008 -0.0028 -0.1003 -0.0145 -0.0139 -0.0145 -0.0133 -0.0043 -0.0145 -0.0113 -0.0145 -0.0211 -0.0208 -0.0083 -0.0145 -0.0141 -0.0143 -0.0205 -0.0145 -0.0029 -0.0201 -0.0143 -0.0875 -0.0144 -0.0098 -0.0061 -0.0087 -0.0018
S-1234	Der Patient wurde komatös und hatte eine Atemdepression , kam jedoch fünf Tage später wieder zu Bewusstsein und hatte keine Folgeerscheinungen .
T-1234	A very high plasma concentration of 100.1 μ g / ml zonisamide was recorded approximately 31 hours after a patient took an overdose of Zonegran and clonazepam ; the patient became comatose and had respiratory depression , but recovered consciousness five days later and had no sequelae .
H-1234	-0.015918483957648277	A very high plasma concentration of 100.1 μ g / ml zonisamide was recorded approximately 31 hours after a patient took an overdose of Zonegran and clonazepam ; the patient became comatose and had respiratory depression , but recovered consciousness five days later and had no sequelae .
D-1234	-0.015918483957648277	A very high plasma concentration of 100.1 μ g / ml zonisamide was recorded approximately 31 hours after a patient took an overdose of Zonegran and clonazepam ; the patient became comatose and had respiratory depression , but recovered consciousness five days later and had no sequelae .
P-1234	-0.0148 -0.0145 -0.0144 -0.0145 -0.0137 -0.0003 -0.0140 -0.0142 -0.0145 -0.0142 -0.0264 -0.0145 -0.1076 -0.2039 -0.0138 -0.1318 -0.0145 -0.0145 -0.0129 -0.0101 -0.0131 -0.0143 -0.0152 -0.0147 -0.0139 -0.0102 -0.0144 -0.0140 -0.0144 -0.0139 -0.0141 -0.0006 -0.0132 -0.0146 -0.0145 -0.0144 -0.0139 -0.0142 -0.0145 -0.0145 -0.0144 -0.0125 -0.0015 -0.0148 -0.0144 -0.0094 -0.0122 -0.0027 -0.0004 -0.0004 -0.0037 -0.0081 -0.0072 -0.0006 -0.0012 -0.0024 -0.0233 -0.0027 -0.0138 -0.0012 -0.0013 -0.0025 -0.0011 -0.0012 -0.0194 -0.0061 -0.0017 -0.0145 -0.0030 -0.0000 -0.0016 -0.0014
S-1364	Aufgrund der Ausscheidung des unveränderten Arzneimittels im Urin wurde die Bioverfügbarkeit auf mindestens 70 % geschätzt .
T-1364	Based on urinary excretion of unchanged drug , the bioavailability has been estimated to be at least 70 % .
H-1364	-0.005784847307950258	Based on urinary excretion of unchanged drug , the bioavailability has been estimated to be at least 70 % .
D-1364	-0.005784847307950258	Based on urinary excretion of unchanged drug , the bioavailability has been estimated to be at least 70 % .
P-1364	-0.0121 -0.0017 -0.0152 -0.0100 -0.0052 -0.0002 -0.0023 -0.0026 -0.0130 -0.0120 -0.0097 -0.0069 -0.0126 -0.0030 -0.0009 -0.0121 -0.0013 -0.0015 -0.0131 -0.0020 -0.0024 -0.0010 -0.0011 -0.0019 -0.0051 -0.0014
S-1584	92 Eesti Österreich TIBOTEC , JANSSEN @-@ CILAG Polska Sp. z o.o .
T-1584	Eesti TIBOTEC , JANSSEN @-@ CILAG Polska Sp. z o.o .
H-1584	-0.00475687300786376	Eesti TIBOTEC , JANSSEN @-@ CILAG Polska Sp. z o.o .
D-1584	-0.00475687300786376	Eesti TIBOTEC , JANSSEN @-@ CILAG Polska Sp. z o.o .
P-1584	-0.0145 -0.0023 -0.0014 -0.0145 -0.0007 -0.0013 -0.0008 -0.0027 -0.0013 -0.0292 -0.0005 -0.0009 -0.0014 -0.0012 -0.0008 -0.0005 -0.0027 -0.0006 -0.0014 -0.0014 -0.0008 -0.0015 -0.0370 -0.0015 -0.0014 -0.0014
S-1299	Drehen Sie die Injekti- onsnadel ab und werfen Sie sie in den speziell dafür vorgesehenen Abfallbehälter .
T-1299	Twist off the needle and discard it properly .
H-1299	-0.015849828720092773	Twist off the needle and discard it properly .
D-1299	-0.015849828720092773	Twist off the needle and discard it properly .
P-1299	-0.0144 -0.0008 -0.0124 -0.0052 -0.0232 -0.0014 -0.0043 -0.0132 -0.0009 -0.0066 -0.0596 -0.0497 -0.0143
S-1970	TEXT AUF DEM ETIKETT DER DURCHSTECHFLASCHE ( 45 mg )
T-1970	VIAL LABEL TEXT ( 45 mg )
H-1970	-0.00935779046267271	VIAL LABEL TEXT ( 45 mg )
D-1970	-0.00935779046267271	VIAL LABEL TEXT ( 45 mg )
P-1970	-0.0146 -0.0145 -0.0328 -0.0040 -0.0034 -0.0278 -0.0015 -0.0014 -0.0042 -0.0042 -0.0010 -0.0016 -0.0108
S-220	Das Arzneimittel wird bei Patienten mit ausgewachsenem Skelett angewendet ( bei denen das Knochenwachstum abgeschlossen ist ) .
T-220	It is used in skeletally mature patients ( who have stopped growing ) .
H-220	-0.05067813768982887	It is used in skeletally mature patients ( who have stopped growing ) .
D-220	-0.05067813768982887	It is used in skeletally mature patients ( who have stopped growing ) .
P-220	-0.0135 -0.0020 -0.0175 -0.3387 -0.0145 -0.0007 -0.0016 -0.4499 -0.0066 -0.0036 -0.0073 -0.0123 -0.0057 -0.0143 -0.0067 -0.0139 -0.0020 -0.0015
S-900	Die Anzahl der Blutzellen kehrt in der Regel binnen zwei Wochen nach der Behandlung mit Siklos wieder auf die normalen Werte zurück .
T-900	Blood cell counts normally return to normal within two weeks of stopping Siklos treatment .
H-900	-0.02328549139201641	Blood cell counts normally return to normal within two weeks of stopping Siklos treatment .
D-900	-0.02328549139201641	Blood cell counts normally return to normal within two weeks of stopping Siklos treatment .
P-900	-0.0136 -0.0010 -0.0061 -0.0093 -0.0168 -0.0025 -0.0016 -0.0019 -0.0093 -0.0612 -0.0012 -0.2773 -0.0146 -0.0138 -0.0027 -0.0003 -0.0059 -0.0017 -0.0015
S-266	WAS IST CYMBALTA UND WOFÜR WIRD ES ANGEWENDET ?
T-266	WHAT CYMBALTA IS AND WHAT IT IS USED FOR
H-266	-0.08408103138208389	WHAT CYMBALTA IS AND WHAT IT IS USED FOR
D-266	-0.08408103138208389	WHAT CYMBALTA IS AND WHAT IT IS USED FOR
P-266	-0.0014 -0.0008 -1.5101 -0.0026 -0.0020 -0.0016 -0.0009 -0.0005 -0.0060 -0.0086 -0.0023 -0.0097 -0.0139 -0.0024 -0.0100 -0.0016 -0.0080 -0.0006 -0.0143
S-801	Informieren Sie Ihren Arzt , wenn Sie zu viel Betaferon oder Betaferon zu häufig injiziert haben .
T-801	Talk to your doctor if you inject too much Betaferon or injected too often .
H-801	-0.021453408524394035	Talk to your doctor if you inject too much Betaferon or injected too often .
D-801	-0.021453408524394035	Talk to your doctor if you inject too much Betaferon or injected too often .
P-801	-0.1564 -0.0025 -0.0015 -0.0014 -0.0018 -0.0014 -0.0171 -0.0135 -0.0020 -0.1237 -0.0142 -0.0012 -0.0008 -0.0109 -0.0534 -0.0192 -0.0098 -0.0072 -0.0092 -0.0020 -0.0014
S-1574	Daher sollten Frauen , die schwanger sind oder eine Schwangerschaft planen , eine andere Methode zur Entfernung von Gesichtshaar anwenden .
T-1574	Therefore , women who are pregnant or planning pregnancy should use an alternative means to manage facial hair .
H-1574	-0.018229534849524498	Therefore , women who are pregnant or planning pregnancy should use an alternative means to manage facial hair .
D-1574	-0.018229534849524498	Therefore , women who are pregnant or planning pregnancy should use an alternative means to manage facial hair .
P-1574	-0.0068 -0.0009 -0.0039 -0.0031 -0.0029 -0.0019 -0.0010 -0.0467 -0.0063 -0.0129 -0.0027 -0.0061 -0.1770 -0.0037 -0.0143 -0.0537 -0.0146 -0.0074 -0.0015 -0.0140 -0.0014
S-1492	Falls eine Kapsel versehentlich geöffnet wird , waschen Sie jegliches Pulver von Ihrer Haut mit Wasser und Seife ab .
T-1492	If a capsule breaks open accidentally , wash any powder from your skin with soap and water .
H-1492	-0.004540450405329466	If a capsule breaks open accidentally , wash any powder from your skin with soap and water .
D-1492	-0.004540450405329466	If a capsule breaks open accidentally , wash any powder from your skin with soap and water .
P-1492	-0.0059 -0.0054 -0.0011 -0.0007 -0.0010 -0.0145 -0.0104 -0.0093 -0.0018 -0.0018 -0.0054 -0.0067 -0.0026 -0.0085 -0.0037 -0.0013 -0.0027 -0.0058 -0.0019 -0.0062 -0.0017 -0.0016
S-285	Interferone sind eine Familie natürlich vorkommender Proteine , die vom Körper als Reaktion auf Virusinfektionen produziert werden .
T-285	Interferons are a family of naturally occurring proteins that are produced in response to viral infections .
H-285	-0.00439537363126874	Interferons are a family of naturally occurring proteins that are produced in response to viral infections .
D-285	-0.00439537363126874	Interferons are a family of naturally occurring proteins that are produced in response to viral infections .
P-285	-0.0019 -0.0007 -0.0018 -0.0016 -0.0018 -0.0015 -0.0014 -0.0005 -0.0023 -0.0011 -0.0008 -0.0005 -0.0113 -0.0048 -0.0018 -0.0455 -0.0098 -0.0016 -0.0014 -0.0020 -0.0005 -0.0050 -0.0014
S-1083	In diesem Konzentrationsbereich scheint der Anteil von ungebundenem Tipranavir unabhängig von der Gesamtkonzentration zu sein .
T-1083	The unbound fraction of tipranavir appeared to be independent of total drug concentration over this concentration range .
H-1083	-0.00729045644402504	The unbound fraction of tipranavir appeared to be independent of total drug concentration over this concentration range .
D-1083	-0.00729045644402504	The unbound fraction of tipranavir appeared to be independent of total drug concentration over this concentration range .
P-1083	-0.0141 -0.0144 -0.0026 -0.0147 -0.0010 -0.0016 -0.0056 -0.0013 -0.0011 -0.0007 -0.0144 -0.0028 -0.0019 -0.0038 -0.0264 -0.0142 -0.0183 -0.0062 -0.0146 -0.0037 -0.0056 -0.0034 -0.0015 -0.0014
S-1390	Während und bis zu 2 Wochen nach der Behandlung mit CYP3A4 @-@ Induktoren sollte Ketek nicht angewendet werden .
T-1390	Ketek should not be used during and 2 weeks after treatment with CYP3A4 inducers .
H-1390	-0.041941266506910324	Ketek should not be used during and 2 weeks after treatment with CYP3A4 inducers .
D-1390	-0.041941266506910324	Ketek should not be used during and 2 weeks after treatment with CYP3A4 inducers .
P-1390	-0.0076 -0.0010 -0.0012 -0.0614 -0.0017 -0.0013 -0.0050 -0.0084 -0.0053 -0.0143 -0.0012 -0.1816 -0.0087 -0.0019 -0.0024 -0.0011 -0.6812 -0.0011 -0.0007 -0.0022 -0.0005 -0.0136 -0.0016 -0.0014
S-632	Wie bei allen Patienten , die Erythropoetin erhalten , kann unter Behandlung mit Silapo der Blutdruck ansteigen .
T-632	Like in all patients receiving erythropoietin , blood pressure may rise during treatment with Silapo .
H-632	-0.0064552295953035355	Like in all patients receiving erythropoietin , blood pressure may rise during treatment with Silapo .
D-632	-0.0064552295953035355	Like in all patients receiving erythropoietin , blood pressure may rise during treatment with Silapo .
P-632	-0.0129 -0.0171 -0.0065 -0.0022 -0.0350 -0.0028 -0.0013 -0.0003 -0.0010 -0.0000 -0.0014 -0.0027 -0.0089 -0.0014 -0.0095 -0.0102 -0.0181 -0.0074 -0.0018 -0.0089 -0.0010 -0.0013 -0.0017 -0.0014
S-626	Wenn der Patient nach der dritten Dosis kein Ansprechen zeigt , sollte die Infliximab @-@ Therapie nicht fortgeführt werden .
T-626	If a patient does not respond after 3 doses , no additional treatment with infliximab should be given .
H-626	-0.005991935729980469	If a patient does not respond after 3 doses , no additional treatment with infliximab should be given .
D-626	-0.005991935729980469	If a patient does not respond after 3 doses , no additional treatment with infliximab should be given .
P-626	-0.0037 -0.0138 -0.0011 -0.0070 -0.0014 -0.0090 -0.0048 -0.0152 -0.0043 -0.0008 -0.0021 -0.0145 -0.0145 -0.0127 -0.0101 -0.0059 -0.0003 -0.0011 -0.0011 -0.0029 -0.0015 -0.0124 -0.0019 -0.0014
S-804	Nicht anwenden vor Rückgang auf Grad &lt; 2 und anschließend Reduktion der Dosis um 25 % für alle nachfolgenden Anwendungen .
T-804	Do not dose until recovered to Grade &lt; 2 and reduce dose by 25 % for all subsequent doses .
H-804	-0.007636941038072109	Do not dose until recovered to Grade &lt; 2 and reduce dose by 25 % for all subsequent doses .
D-804	-0.007636941038072109	Do not dose until recovered to Grade &lt; 2 and reduce dose by 25 % for all subsequent doses .
P-804	-0.0039 -0.0014 -0.0218 -0.0144 -0.0145 -0.0040 -0.0081 -0.0011 -0.0013 -0.0006 -0.0012 -0.0497 -0.0061 -0.0144 -0.0057 -0.0045 -0.0013 -0.0016 -0.0054 -0.0040 -0.0040 -0.0144 -0.0040 -0.0022 -0.0015
S-509	Fieber von mehr als 39 ° C wurde für 3,3 % der Kinder berichtet , verglichen mit 1,2 % in der Kontrollgruppe .
T-509	Fever of &gt; 39 ° C was reported in 3.3 % of children compared to 1.2 % in the control group .
H-509	-0.05294743925333023	Fever of &gt; 39 ° C was reported in 3.3 % of children compared to 1.2 % in the control group .
D-509	-0.05294743925333023	Fever of &gt; 39 ° C was reported in 3.3 % of children compared to 1.2 % in the control group .
P-509	-0.0056 -0.0004 -0.0107 -0.0145 -0.0015 -0.0024 -0.0013 -0.0054 -0.0067 -0.0056 -0.0019 -0.0014 -0.0019 -0.0016 -0.0053 -0.0659 -0.9841 -0.0006 -0.0014 -0.0286 -0.0025 -0.0015 -0.1698 -0.0017 -0.0014
S-1064	Je nach Ansprechen des Patienten auf die Behandlung und den auftretenden Nebenwirkungen kann die Behandlung ausgesetzt oder die Dosis angepasst werden .
T-1064	Depending on the patient <<unk>> s response to treatment and side effects , the treatment may be suspended or the dose adjusted .
H-1064	-0.020972756668925285	Depending on the patient <unk> s response to treatment and side effects , the treatment may be suspended or the dose adjusted .
D-1064	-0.020972756668925285	Depending on the patient <unk> s response to treatment and side effects , the treatment may be suspended or the dose adjusted .
P-1064	-0.0063 -0.0006 -0.2596 -0.0048 -0.0048 -0.0145 -0.0018 -0.0046 -0.0226 -0.0049 -0.0291 -0.0129 -0.0031 -0.0086 -0.0187 -0.0022 -0.0074 -0.0018 -0.0040 -0.0793 -0.0064 -0.0137 -0.0097 -0.0017 -0.0014
S-514	Da es sich um ein Generikum handelt , besteht nach Ansicht des Antragstellers zudem kein zusätzliches Umweltrisiko .
T-514	In addition , he considers that since this is a generic , there will not be an additional risk to the environment .
H-514	-0.009916279464960098	In addition , he considers that since this is a generic , there will not be an additional risk to the environment .
D-514	-0.009916279464960098	In addition , he considers that since this is a generic , there will not be an additional risk to the environment .
P-514	-0.0142 -0.0018 -0.0021 -0.0145 -0.0115 -0.0026 -0.0152 -0.0120 -0.0053 -0.0026 -0.0029 -0.0007 -0.0126 -0.0037 -0.0568 -0.0346 -0.0085 -0.0119 -0.0026 -0.0135 -0.0124 -0.0015 -0.0014 -0.0016 -0.0014
S-1490	Februar 2008 befassten die Tschechische Republik und Lettland die EMEA mit den Gründen für die abweichenden Meinungen .
T-1490	The Czech Republic and Latvia referred the reasons for disagreement to the EMEA on 1 February 2008 .
H-1490	-0.00783294253051281	The Czech Republic and Latvia referred the reasons for disagreement to the EMEA on 1 February 2008 .
D-1490	-0.00783294253051281	The Czech Republic and Latvia referred the reasons for disagreement to the EMEA on 1 February 2008 .
P-1490	-0.0137 -0.0121 -0.0013 -0.0159 -0.0011 -0.0012 -0.0125 -0.0067 -0.0038 -0.0022 -0.0143 -0.0040 -0.0027 -0.0033 -0.0024 -0.0007 -0.0012 -0.0091 -0.0209 -0.0436 -0.0044 -0.0017 -0.0014
S-920	Die Anwendung von Tarceva bei Patienten mit schwerer Leberfunktionsstörung wird nicht empfohlen ( siehe Abschnitt 5.2 ) .
T-920	Use of Tarceva in patients with severe hepatic impairment is not recommended ( see section 5.2 ) .
H-920	-0.014146176166832447	Use of Tarceva in patients with severe hepatic impairment is not recommended ( see section 5.2 ) .
D-920	-0.014146176166832447	Use of Tarceva in patients with severe hepatic impairment is not recommended ( see section 5.2 ) .
P-920	-0.0131 -0.0015 -0.0007 -0.0012 -0.0003 -0.0057 -0.0022 -0.1587 -0.0029 -0.0160 -0.0026 -0.0010 -0.1463 -0.0036 -0.0005 -0.0016 -0.0017 -0.0015 -0.0017 -0.0017 -0.0017 -0.0084 -0.0013 -0.0014 -0.0018 -0.0015 -0.0014
S-428	Bronchospasmus , allergische Alveolitis / eosinophile Pneumonie , Sinusitis
T-428	Bronchospasm , Allergic alveolitis / Eosinophilic pneumonia , Sinusitis
H-428	-0.0027975270058959723	Bronchospasm , Allergic alveolitis / Eosinophilic pneumonia , Sinusitis
D-428	-0.0027975270058959723	Bronchospasm , Allergic alveolitis / Eosinophilic pneumonia , Sinusitis
P-428	-0.0049 -0.0014 -0.0011 -0.0006 -0.0021 -0.0017 -0.0151 -0.0007 -0.0134 -0.0005 -0.0007 -0.0015 -0.0019 -0.0130 -0.0006 -0.0013 -0.0005 -0.0005 -0.0023 -0.0007 -0.0007 -0.0006 -0.0018 -0.0053 -0.0003 -0.0006 -0.0017
S-949	Merck Sharp &amp; Dohme BV ( Merck Manufacturing Division ) Waarderweg 39 P.O .
T-949	Merck Sharp &amp; Dohme BV ( Merck Manufacturing Division ) Waarderweg 39 P. O .
H-949	-0.002764214528724551	Merck Sharp &amp; Dohme BV ( Merck Manufacturing Division ) Waarderweg 39 P. O .
D-949	-0.002764214528724551	Merck Sharp &amp; Dohme BV ( Merck Manufacturing Division ) Waarderweg 39 P. O .
P-949	-0.0011 -0.0013 -0.0022 -0.0012 -0.0013 -0.0007 -0.0014 -0.0027 -0.0012 -0.0137 -0.0008 -0.0013 -0.0016 -0.0010 -0.0018 -0.0006 -0.0014 -0.0116 -0.0012 -0.0011 -0.0003 -0.0013 -0.0142 -0.0039 -0.0016 -0.0014
S-230	MRA @-@ Untersuchungen vaskulärer Strukturen sind bis zu einer Stunde nach Verabreichung dieses Arzneimittels in hoher Auflösung möglich .
T-230	High resolution MRA scans of vascular structures are obtained up to one hour after administration of the medicinal product .
H-230	-0.0212502870708704	High resolution MRA scans of vascular structures are obtained up to one hour after administration of the medicinal product .
D-230	-0.0212502870708704	High resolution MRA scans of vascular structures are obtained up to one hour after administration of the medicinal product .
P-230	-0.0144 -0.0085 -0.0003 -0.0017 -0.0140 -0.0032 -0.0022 -0.0029 -0.0010 -0.0006 -0.0012 -0.0033 -0.0146 -0.0041 -0.0014 -0.0070 -0.0011 -0.2651 -0.0150 -0.0023 -0.0397 -0.0147 -0.0060 -0.0021 -0.1246 -0.0014
S-1183	Abhängig vom Ansprechen und der individuellen Verträglichkeit , kann die Dosis nach einer Woche auf 300 mg täglich erhöht werden .
T-1183	Based on individual patient response and tolerability , the dosage may be increased to 300 mg per day after 1 week .
H-1183	-0.031432148069143295	Based on individual patient response and tolerability , the dosage may be increased to 300 mg per day after 1 week .
D-1183	-0.031432148069143295	Based on individual patient response and tolerability , the dosage may be increased to 300 mg per day after 1 week .
P-1183	-0.1802 -0.0017 -0.0263 -0.0150 -0.0131 -0.0057 -0.0017 -0.2846 -0.0035 -0.0050 -0.0705 -0.0022 -0.0013 -0.0992 -0.0026 -0.0067 -0.0046 -0.0029 -0.0015 -0.0235 -0.0012 -0.0156 -0.0176 -0.0012 -0.0284 -0.0015
S-311	Advasure enthält das KSP @-@ Antigen E2 ( eine Substanz , die eine Immunreaktion auslöst ) .
T-311	Advasure contains an antigen <<unk>> E2 ( a substance that stimulates an immune response ) to CSF .
H-311	-0.006000888999551535	Advasure contains an antigen <unk> E2 ( a substance that stimulates an immune response ) to CSF .
D-311	-0.006000888999551535	Advasure contains an antigen <unk> E2 ( a substance that stimulates an immune response ) to CSF .
P-311	-0.0015 -0.0010 -0.0010 -0.0018 -0.0143 -0.0124 -0.0003 -0.0145 -0.0059 -0.0016 -0.0062 -0.0051 -0.0041 -0.0042 -0.0144 -0.0015 -0.0051 -0.0011 -0.0052 -0.0016 -0.0242 -0.0145 -0.0037 -0.0032 -0.0014
S-1488	Eine Dosisanpassung ist nicht erforderlich , wenn Efavirenz mit VIRACEPT angewendet wird .
T-1488	A dose adjustment is not needed when efavirenz is administered with VIRACEPT .
H-1488	-0.03491731733083725	A dose adjustment is not needed when efavirenz is administered with VIRACEPT .
D-1488	-0.03491731733083725	A dose adjustment is not needed when efavirenz is administered with VIRACEPT .
P-1488	-0.0121 -0.0041 -0.0021 -0.0008 -0.0013 -0.0026 -0.0016 -0.6418 -0.1542 -0.0119 -0.0005 -0.0015 -0.0042 -0.0025 -0.0051 -0.0145 -0.0009 -0.0035 -0.0015 -0.0005 -0.0007 -0.0008 -0.0011 -0.0017 -0.0014
S-1482	Auch die Einnahme von anderen Arzneimitteln sollte 1 Stunde vor und nach der Einnahme von DUKORAL vermieden werden .
T-1482	Oral administration of other medicinal products should be avoided within 1 hour before and after administration of DUKORAL .
H-1482	-0.04602358490228653	Oral administration of other medicinal products should be avoided within 1 hour before and after administration of DUKORAL .
D-1482	-0.04602358490228653	Oral administration of other medicinal products should be avoided within 1 hour before and after administration of DUKORAL .
P-1482	-0.0147 -0.0143 -0.0143 -0.0060 -0.0062 -0.0082 -0.9077 -0.0028 -0.0028 -0.0115 -0.0014 -0.0142 -0.0061 -0.0012 -0.0082 -0.1002 -0.0019 -0.0144 -0.0029 -0.0021 -0.0006 -0.0039 -0.0009 -0.0028 -0.0015
S-1556	Niederlande Niederlande Polen Portugal Portugal Portugal Portugal Portugal Portugal Portugal Portugal Rumänien Slowenien Slowenien Slowenien Spanien Spanien Spanien Schweden Schweden Schweden Schweden Vereinigtes Königreich
T-1556	Netherlands Netherlands Poland Portugal Portugal Portugal Portugal Portugal Portugal Portugal Portugal Romania Slovenia Slovenia Slovenia Spain Spain
H-1556	-0.2008385807275772	Netherlands Netherlands Poland Portugal Portugal Portugal Portugal Portugal Portugal Portugal Portugal Romania Slovenia Slovenia Slovenia Spain Spain
D-1556	-0.2008385807275772	Netherlands Netherlands Poland Portugal Portugal Portugal Portugal Portugal Portugal Portugal Portugal Romania Slovenia Slovenia Slovenia Spain Spain
P-1556	-0.0024 -0.3967 -0.5935 -0.0009 -0.0005 -0.0005 -0.0005 -0.0004 -0.0004 -0.0006 -0.5568 -0.6170 -0.0006 -0.0006 -0.0012 -0.0289 -0.0006 -0.0012 -0.8011 -0.0007 -0.0012 -0.8744 -0.5569 -0.3825
S-75	Patienten , bei denen während der Therapie eine Überempfindlichkeit diagnostiziert wird , MÜSSEN Ziagen sofort absetzen .
T-75	Patients who are diagnosed with a hypersensitivity reaction whilst on therapy MUST discontinue Ziagen immediately .
H-75	-0.32203367352485657	Patients who are diagnosed with a hypersensitivity reaction whilst on therapy MUST stop Ziagen immediately .
D-75	-0.32203367352485657	Patients who are diagnosed with a hypersensitivity reaction whilst on therapy MUST stop Ziagen immediately .
P-75	-0.0038 -0.0009 -0.0100 -0.0063 -0.0019 -0.0041 -0.0147 -0.0022 -0.0006 -0.0008 -0.0145 -0.0145 -0.0128 -0.0081 -0.0048 -0.0004 -0.0003 -7.2856 -0.0140 -0.0008 -0.0028 -0.0016 -0.0014
S-440	Für die meisten Patienten ( bis zu 75 kg Körpergewicht ) genügen zwei Durchstechflaschen von PhotoBarr 75 mg .
T-440	For most patients ( up to 75 kg ) two vials of PhotoBarr 75 mg will suffice .
H-440	-0.00453319912776351	For most patients ( up to 75 kg ) two vials of PhotoBarr 75 mg will suffice .
D-440	-0.00453319912776351	For most patients ( up to 75 kg ) two vials of PhotoBarr 75 mg will suffice .
P-440	-0.0054 -0.0023 -0.0024 -0.0023 -0.0054 -0.0014 -0.0066 -0.0016 -0.0243 -0.0095 -0.0083 -0.0011 -0.0021 -0.0004 -0.0015 -0.0012 -0.0035 -0.0009 -0.0120 -0.0081 -0.0007 -0.0018 -0.0015
S-934	Die Anzeichen und Symptome einer Überdosierung mit Salmeterol sind Tremor , Kopfschmerzen und Tachykardie .
T-934	Both salmeterol and fluticasone propionate are excreted into breast milk in rats .
H-934	-0.012292416766285896	Both salmeterol and fluticasone propionate are excreted into breast milk in rats .
D-934	-0.012292416766285896	Both salmeterol and fluticasone propionate are excreted into breast milk in rats .
P-934	-0.0146 -0.0145 -0.0010 -0.0143 -0.0117 -0.0145 -0.0145 -0.0122 -0.0050 -0.0365 -0.0143 -0.0082 -0.0137 -0.0145 -0.0130 -0.0065 -0.0144 -0.0145 -0.0050 -0.0143 -0.0145 -0.0085 -0.0028
S-963	Für beide Anwendungsarten sollte die maximale Dosis von 720 I.E. / kg und Woche nicht überschritten werden .
T-963	For both routes of administration , the maximum dose should not exceed 720 IU / kg per week .
H-963	-0.010059176944196224	For both routes of administration , the maximum dose should not exceed 720 IU / kg per week .
D-963	-0.010059176944196224	For both routes of administration , the maximum dose should not exceed 720 IU / kg per week .
P-963	-0.0068 -0.0026 -0.0145 -0.0413 -0.0135 -0.0352 -0.0037 -0.0017 -0.0078 -0.0129 -0.0480 -0.0068 -0.0010 -0.0027 -0.0014 -0.0011 -0.0097 -0.0027 -0.0013 -0.0123 -0.0010 -0.0017 -0.0014
S-255	Wenn ein solcher Fall eintritt , und der Verdacht eines Zusammenhangs mit Extavia besteht , soll die Behandlung abgebrochen werden .
T-255	If this occurs and a relationship to Extavia is suspected , treatment should be discontinued .
H-255	-0.013071020133793354	If this occurs and a relationship to Extavia is suspected , treatment should be discontinued .
D-255	-0.013071020133793354	If this occurs and a relationship to Extavia is suspected , treatment should be discontinued .
P-255	-0.0094 -0.0236 -0.0089 -0.0008 -0.0151 -0.0137 -0.0144 -0.0117 -0.0021 -0.0009 -0.0227 -0.0021 -0.0008 -0.0023 -0.0299 -0.0329 -0.0020 -0.0777 -0.0004 -0.0016 -0.0014
S-800	Bei schwerwiegenden respiratorischen Erkrankungen kann die Dosis auf 5 mg / kg Körpergewicht / Tag verdoppelt werden .
T-800	For complicated respiratory disease the dose can be doubled to 5 mg / kg bodyweight / day .
H-800	-0.015220374800264835	For complicated respiratory disease the dose can be doubled to 5 mg / kg bodyweight / day .
D-800	-0.015220374800264835	For complicated respiratory disease the dose can be doubled to 5 mg / kg bodyweight / day .
P-800	-0.0112 -0.0162 -0.0010 -0.0006 -0.0009 -0.0143 -0.0105 -0.0359 -0.0958 -0.0015 -0.0013 -0.0029 -0.0024 -0.0006 -0.0016 -0.0011 -0.1162 -0.0008 -0.0154 -0.0016 -0.0018 -0.0014
S-1700	Außerdem wurde Neoclarityn Schmelztablette in einer Mehrfach @-@ Dosis Studie gut vertragen .
T-1700	In addition , Neoclarityn orodispersible tablets were well tolerated in a multiple dose trial .
H-1700	-0.0458044670522213	In addition , Neoclarityn orodispersible tablets were well tolerated in a multiple dose trial .
D-1700	-0.0458044670522213	In addition , Neoclarityn orodispersible tablets were well tolerated in a multiple dose trial .
P-1700	-0.0125 -0.0014 -0.0031 -0.0026 -0.0017 -0.0007 -0.0014 -0.0009 -0.0019 -0.0145 -0.0140 -0.0145 -0.0045 -0.0142 -0.0080 -1.0099 -0.0040 -0.0029 -0.0017 -0.0011 -0.0087 -0.0058 -0.0062 -0.0047 -0.0150 -0.0795 -0.0014
S-1670	In bestimmten Fällen können Injektionen unter die Haut ( subkutan ) auch von Ihnen selbst oder Ihrem Partner durchgeführt werden .
T-1670	Injections under the skin ( subcutaneous ) may , in some cases , be given by you or your partner .
H-1670	-0.0224904827773571	Injections under the skin ( subcutaneous ) may , in some cases , be given by you or your partner .
D-1670	-0.0224904827773571	Injections under the skin ( subcutaneous ) may , in some cases , be given by you or your partner .
P-1670	-0.0148 -0.0022 -0.0081 -0.0020 -0.0010 -0.0069 -0.0030 -0.0005 -0.0005 -0.0015 -0.4589 -0.0017 -0.0089 -0.0198 -0.0020 -0.0108 -0.0020 -0.0015 -0.0102 -0.0142 -0.0044 -0.0121 -0.0115 -0.0031 -0.0018 -0.0024 -0.0014
S-1356	In zwei Vorstudien wurden einigen Patienten mit Röhrenknochenfrakturen vor und nach der Operation Serumproben entnommen .
T-1356	In two exploratory studies , pre- and post @-@ surgery serum samples were collected from a few long @-@ bone fracture patients .
H-1356	-0.007594327908009291	In two exploratory studies , pre- and post @-@ surgery serum samples were collected from a few long @-@ bone fracture patients .
D-1356	-0.007594327908009291	In two exploratory studies , pre- and post @-@ surgery serum samples were collected from a few long @-@ bone fracture patients .
P-1356	-0.0084 -0.0017 -0.0145 -0.0007 -0.0085 -0.0103 -0.0147 -0.0035 -0.0016 -0.0040 -0.0016 -0.0109 -0.0008 -0.0011 -0.0014 -0.0020 -0.0332 -0.0156 -0.0127 -0.0124 -0.0145 -0.0045 -0.0142 -0.0126 -0.0033 -0.0009 -0.0015 -0.0014
S-819	Die Kombination von Tenofovirdisoproxil und Emtricitabin wurde 2005 als Truvada zugelassen .
T-819	The combination of tenofovir disoproxil and emtricitabine has been approved as Truvada since 2005 .
H-819	-0.0024021610151976347	The combination of tenofovir disoproxil and emtricitabine has been approved as Truvada since 2005 .
D-819	-0.0024021610151976347	The combination of tenofovir disoproxil and emtricitabine has been approved as Truvada since 2005 .
P-819	-0.0035 -0.0014 -0.0016 -0.0028 -0.0012 -0.0009 -0.0024 -0.0023 -0.0017 -0.0011 -0.0017 -0.0018 -0.0013 -0.0017 -0.0018 -0.0009 -0.0004 -0.0009 -0.0010 -0.0142 -0.0022 -0.0018 -0.0055 -0.0010 -0.0012 -0.0005 -0.0114 -0.0010 -0.0014 -0.0014
S-750	Besonderes Augenmerk wird 2000 @-@ 2001 auf die Kosten für die Beurteilungs- und Inspektionsleistungen der nationalen Behörden gerichtet .
T-750	Particular attention will be paid in 2000 @-@ 2001 to looking at national authorities <<unk>> costs for the provision of evaluation and inspection services .
H-750	-0.02077009715139866	Particular attention will be paid in 2000 @-@ 2001 to looking at national authorities <unk> costs for the provision of evaluation and inspection services .
D-750	-0.02077009715139866	Particular attention will be paid in 2000 @-@ 2001 to looking at national authorities <unk> costs for the provision of evaluation and inspection services .
P-750	-0.0097 -0.0008 -0.0009 -0.0028 -0.0044 -0.0017 -0.0047 -0.0088 -0.0036 -0.0471 -0.0039 -0.0254 -0.1049 -0.0051 -0.2960 -0.0052 -0.0145 -0.0140 -0.0071 -0.0280 -0.0145 -0.0014 -0.0168 -0.0009 -0.0008 -0.0015 -0.0017 -0.0077 -0.0070 -0.0016 -0.0014
S-1916	Diese Kinder erhielten PROCOMVAX im Alter von 2 bis 3 , 4 bis 5 und 12 bis 15 Monaten .
T-1916	These infants nominally received PROCOMVAX at 2 @-@ 3 , 4 @-@ 5 , and 12 @-@ 15 months of age
H-1916	-0.056523483246564865	These infants nominally received PROCOMVAX at 2 @-@ 3 , 4 @-@ 5 , and 12 @-@ 15 months of age
D-1916	-0.056523483246564865	These infants nominally received PROCOMVAX at 2 @-@ 3 , 4 @-@ 5 , and 12 @-@ 15 months of age
P-1916	-0.0105 -0.0147 -0.0020 -0.0260 -0.0087 -0.0031 -0.0138 -0.0032 -0.0010 -0.0017 -0.0014 -0.0014 -0.0014 -0.0011 -0.0070 -0.0115 -0.1457 -0.0013 -0.0020 -0.0015 -0.1707 -0.0013 -0.1593 -0.0335 -0.0013 -0.1441 -0.0012 -0.0016 -0.0176 -0.0012 -0.9615
S-1835	38 zurück , ohne dass eine Unterbrechung der Behandlung mit Fosamprenavir mit Ritonavir erforderlich ist .
T-1835	The rash generally will resolve spontaneously without the necessity of discontinuing treatment with the fosamprenavir with ritonavir .
H-1835	-0.011606327258050442	The rash generally will resolve spontaneously without the necessity of discontinuing treatment with the fosamprenavir with ritonavir .
D-1835	-0.011606327258050442	The rash generally will resolve spontaneously without the necessity of discontinuing treatment with the fosamprenavir with ritonavir .
P-1835	-0.0145 -0.0147 -0.0135 -0.0145 -0.0144 -0.0144 -0.0145 -0.0006 -0.0469 -0.0112 -0.0129 -0.0138 -0.0006 -0.0009 -0.1101 -0.0160 -0.0117 -0.0046 -0.0021 -0.0144 -0.0131 -0.0007 -0.0006 -0.0003 -0.0039 -0.0012 -0.0077 -0.0026 -0.0013 -0.0008 -0.0011 -0.0018 -0.0014
S-876	Die vollständige Auflistung aller im Zusammenhang mit Karvea berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-876	For the full list of all side effects reported with Irbesartan Hydrochlorothiazide BMS , see the Package Leaflet .
H-876	-0.021588662639260292	For the full list of all side effects reported with Irbesartan Hydrochlorothiazide BMS , see the Package Leaflet .
D-876	-0.021588662639260292	For the full list of all side effects reported with Irbesartan Hydrochlorothiazide BMS , see the Package Leaflet .
P-876	-0.0124 -0.0098 -0.0071 -0.0117 -0.0015 -0.0113 -0.0197 -0.0021 -0.0026 -0.0133 -0.0242 -0.0145 -0.0145 -0.0131 -0.0221 -0.0087 -0.0142 -0.0118 -0.0067 -0.0138 -0.0088 -0.0015 -0.0010 -0.0274 -0.0140 -0.0125 -0.4142 -0.0055 -0.0149 -0.0020 -0.0144 -0.0002 -0.0009 -0.0017 -0.0014
S-575	172 ( 57,1 % ) a 242 ( 80,4 % ) a 274 ( 91,0 % )
T-575	172 ( 57.1 % ) a 242 ( 80.4 % ) a 274 ( 91.0 % ) 242 ( 82.9 % ) ab
H-575	-0.03223157301545143	172 ( 57.1 % ) a 242 ( 80.4 % ) a 274 ( 91.0 % ) 242 ( 82.9 % ) ab
D-575	-0.03223157301545143	172 ( 57.1 % ) a 242 ( 80.4 % ) a 274 ( 91.0 % ) 242 ( 82.9 % ) ab
P-575	-0.0023 -0.0014 -0.0014 -0.0015 -0.0038 -0.0014 -0.0014 -0.0014 -0.0038 -0.0012 -0.0014 -0.0013 -0.0014 -0.0013 -0.0012 -0.0013 -0.0014 -0.0015 -0.0010 -0.0012 -0.0013 -0.0012 -0.0015 -0.0013 -0.0013 -0.0014 -0.5454 -0.0078 -0.0022 -0.0034 -0.1038 -0.3857 -0.0017 -0.0014 -0.0565 -0.0116
S-1167	Untersuchungen mit &lt; HANDELSNAME &gt; beobachtet wurde , sollten die Patienten bei Therapiebeginn darauf hingewiesen werden .
T-1167	In view of the fact that drowsiness has been observed in clinical trials with &lt; TRADENAME &gt; , patients should be warned of this possibility at the start of treatment .
H-1167	-0.0075033423490822315	In view of the fact that drowsiness has been observed in clinical trials with &lt; TRADENAME &gt; , patients should be warned of this possibility at the start of treatment .
D-1167	-0.0075033423490822315	In view of the fact that drowsiness has been observed in clinical trials with &lt; TRADENAME &gt; , patients should be warned of this possibility at the start of treatment .
P-1167	-0.0143 -0.0145 -0.0014 -0.0092 -0.0141 -0.0023 -0.0145 -0.0123 -0.0101 -0.0010 -0.0127 -0.0065 -0.0046 -0.0097 -0.0144 -0.0027 -0.0101 -0.0009 -0.0004 -0.0011 -0.0139 -0.0060 -0.0144 -0.0145 -0.0010 -0.0005 -0.0041 -0.0029 -0.0018 -0.0016 -0.0140 -0.0119 -0.0065 -0.0144 -0.0084 -0.0093 -0.0093 -0.0014 -0.0118 -0.0016 -0.0014
S-854	3 / 4 2 Injektionsset = Injektionsspritze + Injektionsnadel + Reinigungstupfer
T-854	l no 1 injection set = injection syringe + 2 injection needles + cleansing swab 2 injection set = injection syringe + injection needle + cleansing swab
H-854	-0.13115456700325012	l no 1 injection set = injection syringe + 2 injection needle + cleansing swab
D-854	-0.13115456700325012	l no 1 injection set = injection syringe + 2 injection needle + cleansing swab
P-854	-0.0452 -0.0161 -0.0143 -0.0156 -0.0017 -0.0119 -0.0051 -0.0120 -0.0022 -0.0027 -0.0004 -0.0001 -0.0015 -0.0460 -0.0161 -0.0012 -0.0017 -1.0274 -0.0020 -0.0142 -0.0032 -0.0145 -0.0008 -1.8918
S-150	Daher kann ein Vergleich der Inzidenz der Antikörperbildung mit der anderer Präparate irreführend sein .
T-150	The observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling , concomitant medications and underlying disease , therefore , comparison of the incidence of antibodies to other products may be misleading .
H-150	-0.05202402547001839	The observed incidence of antibodies in an assay may be influenced by several factors including sample handling , concomitant medications and underlying disease , therefore , comparison of the incidence of antibodies to other products may be misleading .
D-150	-0.05202402547001839	The observed incidence of antibodies in an assay may be influenced by several factors including sample handling , concomitant medications and underlying disease , therefore , comparison of the incidence of antibodies to other products may be misleading .
P-150	-0.0143 -0.0156 -0.0111 -0.0008 -0.0028 -0.0034 -1.5166 -0.0131 -0.0145 -0.0143 -0.0059 -0.0123 -0.0103 -0.0177 -0.0012 -0.0027 -0.0145 -0.0101 -0.0145 -0.0166 -0.0145 -0.0104 -0.0175 -0.0142 -0.0051 -0.0072 -0.0146 -0.0433 -0.0104 -0.0163 -0.0143 -0.0144 -0.0149 -0.0126 -0.0144 -0.0108 -0.0122 -0.0080 -0.0008 -0.0089 -0.0067 -0.6155 -0.0130 -0.0047 -0.0125 -0.0083 -0.0016 -0.0102 -0.0007 -0.0014 -0.0014
S-796	In solchen Situationen ist eine sorgfältige Nutzen @-@ Schaden @-@ Abwägung erforderlich und es sollte eine engmaschige Überwachung erfolgen .
T-796	Creatine phosphokinase measurement Creatine phosphokinase ( CPK ) should not be measured following strenuous exercise or in the presence of any plausible alternative cause of CPK increase as this makes value interpretation difficult .
H-796	-0.10557076334953308	Creatine phosphokinase measurement Creatine phosphokinase ( CPK ( and associated names ) tablets contain aspartame and should be avoided by patients with phenylketonuria .
D-796	-0.10557076334953308	Creatine phosphokinase measurement Creatine phosphokinase ( CPK ( and associated names ) tablets contain aspartame and should be avoided by patients with phenylketonuria .
P-796	-0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0141 -0.0145 -0.0093 -0.0147 -0.0121 -0.0088 -0.0145 -0.0105 -0.0095 -0.0202 -0.0013 -0.0062 -0.0134 -0.0018 -0.0177 -0.0132 -0.0134 -0.0144 -3.3150 -0.1454 -0.0173 -0.0146 -0.0043 -0.0537 -0.0139 -0.0887 -0.2860 -0.0144 -0.0041 -0.0140 -0.0145 -0.5113 -0.0223 -0.0147 -0.0149 -0.0165 -0.2356 -0.0133 -0.0145 -0.0145 -0.0144 -0.0136 -0.0183 -0.0014
S-145	Wie bei allen Impfstoffen kann es sein , dass Infanrix hexa möglicherweise nicht jeden Geimpften vollständig schützt .
T-145	After control of the disease the vaccine should be administered . • if your child has a bleeding problem or bruises easily • if your child has a tendency to seizures / fits due to a fever , or if there is a history in the family of this As with all vaccines , Infanrix hexa may not completely protect all people who are vaccinated .
H-145	-0.09996826946735382	After control of the disease the vaccine should be administered . • if your child has a bleeding problem or bruises easily • if your child has a tendency to seizures / fits due to a fever , or if there is a history in the family of this As with all vaccines , Infanrix hexa may not completely protect all people .
D-145	-0.09996826946735382	After control of the disease the vaccine should be administered . • if your child has a bleeding problem or bruises easily • if your child has a tendency to seizures / fits due to a fever , or if there is a history in the family of this As with all vaccines , Infanrix hexa may not completely protect all people .
P-145	-0.0205 -0.0146 -0.0095 -0.0087 -0.0196 -0.0142 -0.0160 -0.0143 -0.0059 -0.0140 -0.0010 -0.0143 -0.0154 -0.0153 -0.0144 -0.0138 -0.0112 -0.0128 -0.0147 -0.0046 -0.0140 -0.0153 -0.0181 -0.0189 -0.0156 -0.0145 -0.0053 -0.0433 -0.0053 -0.0082 -0.0085 -0.0150 -0.0058 -0.0022 -0.0145 -0.0145 -0.0011 -0.0148 -0.0144 -0.0145 -0.0015 -0.0139 -0.0156 -0.0004 -0.0143 -0.0162 -0.0147 -0.0386 -0.0054 -0.0092 -0.0167 -0.0160 -0.0106 -0.0138 -0.0140 -0.0144 -0.0145 -0.0132 -0.0085 -0.0014 -0.0018 -0.0150 -0.0175 -0.0005 -0.0014 -0.0014 -0.0035 -0.0015 -0.0014 -0.0059 -0.0064 -0.0143 -0.0064 -0.0142 -0.0143 -6.8193 -0.0014
S-1879	Hypromellose , Titandioxid ( E 171 ) , Lactose @-@ Monohydrat , Triacetin .
T-1879	Film coat : hypromellose , titanium dioxide ( E171 ) , lactose monohydrate , glycerol triacetate
H-1879	-0.0209339689463377	Film coat : hypromellose , titanium dioxide ( E171 ) , lactose monohydrate , glycerol triacetate
D-1879	-0.0209339689463377	Film coat : hypromellose , titanium dioxide ( E171 ) , lactose monohydrate , glycerol triacetate
P-1879	-0.0281 -0.0148 -0.0139 -0.0131 -0.0786 -0.0008 -0.0030 -0.0007 -0.0019 -0.0024 -0.0009 -0.0011 -0.0013 -0.0005 -0.0017 -0.2000 -0.0009 -0.0014 -0.0014 -0.0015 -0.0068 -0.0005 -0.0006 -0.0015 -0.0005 -0.0012 -0.0010 -0.0012 -0.0018 -0.0323 -0.0014 -0.0128 -0.0035 -0.0168 -0.0010 -0.0007 -0.0194 -0.3244
S-651	Seamus HEALY Assistant Secretary Department of Agriculture , Food and Rural Development Agriculture House Kildare Street IRL - Dublin 2 Tel .
T-651	Dublin 2 Ireland Tel .
H-651	-0.013355680741369724	Dublin 2 Ireland Tel .
D-651	-0.013355680741369724	Dublin 2 Ireland Tel .
P-651	-0.0145 -0.0141 -0.0159 -0.0158 -0.0046 -0.0152
S-646	Nach 6 aufeinanderfolgenden Wochen mit aufgebrachtem Pflaster muss ein pflasterfreies Intervall von 7 Tagen eingelegt werden .
T-646	After 6 consecutive weeks of patch wear , there should be a patch free interval of 7 days .
H-646	-0.006122179329395294	After 6 consecutive weeks of patch wear , there should be a patch free interval of 7 days .
D-646	-0.006122179329395294	After 6 consecutive weeks of patch wear , there should be a patch free interval of 7 days .
P-646	-0.0036 -0.0045 -0.0035 -0.0009 -0.0086 -0.0142 -0.0090 -0.0145 -0.0037 -0.0143 -0.0181 -0.0014 -0.0048 -0.0093 -0.0025 -0.0145 -0.0053 -0.0006 -0.0015 -0.0015 -0.0013 -0.0019 -0.0015
S-1001	Das Pflaster sollte unmittelbar nach dem Öffnen des Beutels und dem Entfernen der beiden Hälften der Schutzfolie aufgebracht werden .
T-1001	The patch should be applied immediately after opening the sachet and removing both parts of the protective release liner .
H-1001	-0.010896971449255943	The patch should be applied immediately after opening the sachet and removing both parts of the protective release liner .
D-1001	-0.010896971449255943	The patch should be applied immediately after opening the sachet and removing both parts of the protective release liner .
P-1001	-0.0049 -0.0108 -0.0018 -0.0020 -0.0075 -0.0051 -0.0045 -0.0020 -0.0038 -0.0025 -0.0143 -0.0013 -0.0017 -0.0045 -0.0092 -0.0141 -0.0015 -0.0015 -0.0032 -0.0145 -0.0120 -0.1263 -0.0015
S-1682	Trat erneut keine Reaktion auf , wurde die Infusion während der nächsten Stunde beendet , so dass die Gesamt @-@ Infusionszeit 90 Minuten betrug .
T-1682	If tolerated , the infusion was completed over the next hour for a total infusion time of 90 minutes .
H-1682	-0.023224709555506706	If tolerated , the infusion was completed over the next hour for a total infusion time of 90 minutes .
D-1682	-0.023224709555506706	If tolerated , the infusion was completed over the next hour for a total infusion time of 90 minutes .
P-1682	-0.0070 -0.0145 -0.0180 -0.0116 -0.0038 -0.0026 -0.0007 -0.0058 -0.0142 -0.0144 -0.0020 -0.0054 -0.0012 -0.0146 -0.0067 -0.0015 -0.0079 -0.0008 -0.0034 -0.0014 -0.0019 -0.4146 -0.0018 -0.0017
S-1889	Dieses Arzneimittel verringerte in klinischen Studien die Lahmheit und Entzündung bei Hunden mit chronischer Osteoarthritis .
T-1889	This product reduced in clinical trials the lameness and inflammation of dogs with chronic osteoarthritis .
H-1889	-0.017549408599734306	This product reduced in clinical trials the lameness and inflammation of dogs with chronic osteoarthritis .
D-1889	-0.017549408599734306	This product reduced in clinical trials the lameness and inflammation of dogs with chronic osteoarthritis .
P-1889	-0.0022 -0.0150 -0.0111 -0.0213 -0.0174 -0.2549 -0.0363 -0.0007 -0.0005 -0.0014 -0.0012 -0.0006 -0.0013 -0.0581 -0.0010 -0.0022 -0.0021 -0.0032 -0.0009 -0.0013 -0.0017 -0.0007 -0.0007 -0.0015 -0.0014
S-1028	Im Falle einer Inkompatibilität kann ein Adapter verwendet werden , der sofort nach der Verabreichung zusammen mit der Glasspritze entfernt wird .
T-1028	In case of incompatibility an adaptor can be used and removed together with the glass syringe immediately after administration
H-1028	-0.05711156874895096	In case of incompatibility an adaptor can be used and removed together with the glass syringe immediately after administration
D-1028	-0.05711156874895096	In case of incompatibility an adaptor can be used and removed together with the glass syringe immediately after administration
P-1028	-0.0063 -0.1418 -0.0015 -0.0041 -0.0008 -0.0005 -0.0015 -0.0102 -0.0008 -0.4750 -0.0053 -0.0013 -0.0016 -0.0141 -0.0088 -0.0166 -0.0014 -0.0027 -0.0092 -0.0015 -0.0002 -0.0002 -0.0051 -0.0031 -0.0495 -0.7218
S-1855	Um das Photosensitivitätsrisiko zu verringern , sollten die Patienten vor direktem oder künstlichem ( Solarium ) Sonnenlicht gewarnt werden .
T-1855	To reduce the risk of photosensitivity , patients should be warned against exposure to direct and solarium sunlight .
H-1855	-0.011861984618008137	To reduce the risk of photosensitivity , patients should be warned against exposure to direct and solarium sunlight .
D-1855	-0.011861984618008137	To reduce the risk of photosensitivity , patients should be warned against exposure to direct and solarium sunlight .
P-1855	-0.0100 -0.0148 -0.0033 -0.0052 -0.1023 -0.0030 -0.0003 -0.0010 -0.0007 -0.0012 -0.0046 -0.0035 -0.0019 -0.0017 -0.0029 -0.0064 -0.0207 -0.0630 -0.0183 -0.0158 -0.0145 -0.0011 -0.0074 -0.0011 -0.0021 -0.0014
S-1379	Die Restmengenskala auf dem transparenten Insulinbehälter zeigt an , wie viel Insulin ungefähr noch im OptiSet vorhanden ist .
T-1379	The residual insulin scale on the transparent insulin reservoir shows approximately how much insulin remains in the OptiSet .
H-1379	-0.006429512053728104	The residual insulin scale on the transparent insulin reservoir shows approximately how much insulin remains in the OptiSet .
D-1379	-0.006429512053728104	The residual insulin scale on the transparent insulin reservoir shows approximately how much insulin remains in the OptiSet .
P-1379	-0.0022 -0.0037 -0.0007 -0.0328 -0.0008 -0.0313 -0.0031 -0.0016 -0.0007 -0.0007 -0.0010 -0.0144 -0.0008 -0.0008 -0.0085 -0.0131 -0.0024 -0.0288 -0.0005 -0.0008 -0.0137 -0.0046 -0.0020 -0.0002 -0.0013 -0.0017 -0.0014
S-1388	Halten Sie den Reco @-@ Pen dicht an der Kanüle , stechen Sie die Kanüle schnell und kräftig in die Hautfalte .
T-1388	Holding the Reco @-@ Pen near the needle , insert the needle into the skin fold with a quick , firm action .
H-1388	-0.006591531913727522	Holding the Reco @-@ Pen near the needle , insert the needle into the skin fold with a quick , firm action .
D-1388	-0.006591531913727522	Holding the Reco @-@ Pen near the needle , insert the needle into the skin fold with a quick , firm action .
P-1388	-0.0158 -0.0023 -0.0027 -0.0014 -0.0024 -0.0006 -0.0144 -0.0048 -0.0129 -0.0010 -0.0022 -0.0145 -0.0006 -0.0025 -0.0028 -0.0011 -0.0135 -0.0015 -0.0049 -0.0013 -0.0145 -0.0119 -0.0101 -0.0142 -0.0135 -0.0142 -0.0015 -0.0014
S-886	In den einjährigen klinischen Studien wurden Größe und sexuelle Entwicklung von pädiatrischen Patienten , die mit EXJADE behandelt wurden , nicht beeinflusst .
T-886	In the 1 @-@ year clinical studies growth and sexual development of paediatric patients treated with EXJADE were not affected .
H-886	-0.007521049119532108	In the 1 @-@ year clinical studies growth and sexual development of paediatric patients treated with EXJADE were not affected .
D-886	-0.007521049119532108	In the 1 @-@ year clinical studies growth and sexual development of paediatric patients treated with EXJADE were not affected .
P-886	-0.0086 -0.0047 -0.0137 -0.0089 -0.0015 -0.0022 -0.0707 -0.0145 -0.0023 -0.0015 -0.0019 -0.0058 -0.0125 -0.0007 -0.0006 -0.0016 -0.0015 -0.0121 -0.0017 -0.0008 -0.0036 -0.0008 -0.0010 -0.0146 -0.0018 -0.0174 -0.0019 -0.0014
S-1929	Im Fall einer Überdosierung oder Vergiftung wird Colestyramin oder Kohle empfohlen , um die Ausscheidung zu beschleunigen .
T-1929	In the event of an overdose or toxicity , colestyramine or charcoal is recommended to accelerate elimination .
H-1929	-0.016087878495454788	In the event of an overdose or toxicity , colestyramine or charcoal is recommended to accelerate elimination .
D-1929	-0.016087878495454788	In the event of an overdose or toxicity , colestyramine or charcoal is recommended to accelerate elimination .
P-1929	-0.0037 -0.2101 -0.0076 -0.0015 -0.0743 -0.0014 -0.0007 -0.0018 -0.0142 -0.0045 -0.0081 -0.0046 -0.0066 -0.0007 -0.0015 -0.0010 -0.0004 -0.0536 -0.0127 -0.0005 -0.0032 -0.0021 -0.0224 -0.0097 -0.0012 -0.0137 -0.0013 -0.0021 -0.0014
S-1337	Es liegen keine ausreichenden Daten vor , um die Anwendung von Mitotan bei Patienten mit stark eingeschränkter Leber- oder Nierenfunktion zu unterstützen .
T-1337	There are insufficient data to support the use of mitotane in patients with severe hepatic or renal impairment .
H-1337	-0.0136488638818264	There are insufficient data to support the use of mitotane in patients with severe hepatic or renal impairment .
D-1337	-0.0136488638818264	There are insufficient data to support the use of mitotane in patients with severe hepatic or renal impairment .
P-1337	-0.0105 -0.2625 -0.0122 -0.0014 -0.0018 -0.0084 -0.0009 -0.0032 -0.0037 -0.0014 -0.0143 -0.0010 -0.0095 -0.0022 -0.0022 -0.0019 -0.0137 -0.0142 -0.0017 -0.0011 -0.0045 -0.0054 -0.0011 -0.0104 -0.0013 -0.0005 -0.0019 -0.0016 -0.0014
S-1152	Die gleichzeitige Anwendung von REYATAZ mit Nevirapin oder Efavirenz wird nicht empfohlen ( siehe Abschnitt 4.5 ) .
T-1152	Co @-@ administration of REYATAZ with nevirapine or efavirenz is not recommended ( see section 4.5 ) .
H-1152	-0.009126923978328705	Co @-@ administration of REYATAZ with nevirapine or efavirenz is not recommended ( see section 4.5 ) .
D-1152	-0.009126923978328705	Co @-@ administration of REYATAZ with nevirapine or efavirenz is not recommended ( see section 4.5 ) .
P-1152	-0.0145 -0.0014 -0.0118 -0.0039 -0.0017 -0.0011 -0.0008 -0.0005 -0.0024 -0.0033 -0.0018 -0.0005 -0.0898 -0.1005 -0.0070 -0.0006 -0.0016 -0.0010 -0.0038 -0.0020 -0.0016 -0.0020 -0.0019 -0.0021 -0.0086 -0.0012 -0.0015 -0.0020 -0.0016 -0.0014
S-557	Nach Gabe von G @-@ CSFs wurde über seltene pulmonale Nebenwirkungen , insbesondere interstitielle Pneumonie , berichtet .
T-557	Rare pulmonary undesirable effects , in particular interstitial pneumonia , have been reported after G- CSF administration .
H-557	-0.012141238898038864	Rare pulmonary undesirable effects , in particular interstitial pneumonia , have been reported after G- CSF administration .
D-557	-0.012141238898038864	Rare pulmonary undesirable effects , in particular interstitial pneumonia , have been reported after G- CSF administration .
P-557	-0.0103 -0.0011 -0.0022 -0.0009 -0.0050 -0.0238 -0.0130 -0.0082 -0.0087 -0.0061 -0.0212 -0.0011 -0.0023 -0.0006 -0.0005 -0.0024 -0.0007 -0.0008 -0.0004 -0.0108 -0.0293 -0.0015 -0.0578 -0.0262 -0.0145 -0.0141 -0.0010 -0.0127 -0.0048 -0.0929 -0.0014
S-437	Folglich sollte die Dosistitration für Effentora bis zum Erreichen des gewünschten Effekts individuell erfolgen ( siehe Abschnitt 4.2 ) .
T-437	As a result , the dose of Effentora should be individually titrated to achieve the desired effect ( see section 4.2 ) .
H-437	-0.006036995444446802	As a result , the dose of Effentora should be individually titrated to achieve the desired effect ( see section 4.2 ) .
D-437	-0.006036995444446802	As a result , the dose of Effentora should be individually titrated to achieve the desired effect ( see section 4.2 ) .
P-437	-0.0137 -0.0021 -0.0074 -0.0030 -0.0061 -0.0089 -0.0134 -0.0011 -0.0009 -0.0010 -0.0022 -0.0019 -0.0121 -0.0033 -0.0145 -0.0143 -0.0011 -0.0490 -0.0052 -0.0017 -0.0014 -0.0020 -0.0015 -0.0017 -0.0023 -0.0079 -0.0012 -0.0014 -0.0020 -0.0014 -0.0014
S-1093	Während der ersten 12 Wochen der Doppelblind @-@ Phase erhielten die Patienten Plazebo oder eine der oben genannten drei Enbrel @-@ Dosierungen .
T-1093	During the first 12 weeks of the double @-@ blind treatment period , patients received placebo or one of the above three Enbrel doses .
H-1093	-0.006800275761634111	During the first 12 weeks of the double @-@ blind treatment period , patients received placebo or one of the above three Enbrel doses .
D-1093	-0.006800275761634111	During the first 12 weeks of the double @-@ blind treatment period , patients received placebo or one of the above three Enbrel doses .
P-1093	-0.0076 -0.0016 -0.0015 -0.0014 -0.0014 -0.0017 -0.0037 -0.0018 -0.0429 -0.0577 -0.0145 -0.0123 -0.0042 -0.0039 -0.0089 -0.0061 -0.0012 -0.0007 -0.0012 -0.0020 -0.0050 -0.0014 -0.0023 -0.0076 -0.0028 -0.0092 -0.0009 -0.0009 -0.0014 -0.0069 -0.0016 -0.0014
S-929	Podleś na 83 PL @-@ 05 @-@ 552 Wólka Kosowska Tel : + 48 ( 22 ) 702 8200
T-929	Podleś na 83 PL @-@ 05 @-@ 552 Wólka Kosowska Tel : + 48 ( 22 ) 702 8200
H-929	-0.005679348949342966	Podleś na 83 PL @-@ 05 @-@ 552 Wólka Kosowska Tel : + 48 ( 22 ) 702 8200
D-929	-0.005679348949342966	Podleś na 83 PL @-@ 05 @-@ 552 Wólka Kosowska Tel : + 48 ( 22 ) 702 8200
P-929	-0.0022 -0.0015 -0.0011 -0.0001 -0.0011 -0.0007 -0.0019 -0.0012 -0.1299 -0.0011 -0.0014 -0.0012 -0.0008 -0.0118 -0.0022 -0.0013 -0.0005 -0.0006 -0.0010 -0.0006 -0.0045 -0.0030 -0.0012 -0.0011 -0.0014 -0.0012 -0.0014 -0.0011 -0.0008 -0.0011 -0.0011 -0.0017
S-1784	In einer klinischen Studie wurde gezeigt , dass VASOVIST die nicht gebundene Fraktion von Warfarin im Plasma nicht beeinflusst .
T-1784	In a clinical study , it was shown that VASOVIST does not affect the unbound fraction of warfarin in plasma .
H-1784	-0.019275179132819176	In a clinical study , it was shown that VASOVIST does not affect the unbound fraction of warfarin in plasma .
D-1784	-0.019275179132819176	In a clinical study , it was shown that VASOVIST does not affect the unbound fraction of warfarin in plasma .
P-1784	-0.0098 -0.0092 -0.0008 -0.0076 -0.0086 -0.0111 -0.0208 -0.0067 -0.0041 -0.0033 -0.4248 -0.0012 -0.0014 -0.0013 -0.0008 -0.0064 -0.0014 -0.0790 -0.0026 -0.0053 -0.0035 -0.0047 -0.0012 -0.0016 -0.0012 -0.0007 -0.0013 -0.0020 -0.0093 -0.0006 -0.0009 -0.0016 -0.0014
S-478	Abhängig von den Ergebnissen kann das Arzneimittel vorsichtig abgesetzt werden , um Entzugssymptome und einen erneuten illegalen Drogenabusus zu verhindern .
T-478	Depending upon the findings , the medicinal product may be discontinued cautiously so as to prevent withdrawal symptoms and to prevent a return to illicit drug use .
H-478	-0.02581051178276539	Depending on the findings , the medicinal product may be discontinued cautiously so as to prevent withdrawal symptoms and to prevent a return to illicit drug use .
D-478	-0.02581051178276539	Depending on the findings , the medicinal product may be discontinued cautiously so as to prevent withdrawal symptoms and to prevent a return to illicit drug use .
P-478	-0.0274 -0.0006 -0.4915 -0.0033 -0.0141 -0.0047 -0.0034 -0.0511 -0.0071 -0.0021 -0.0114 -0.0027 -0.0117 -0.0001 -0.0086 -0.0006 -0.0010 -0.1149 -0.0020 -0.0014 -0.0233 -0.0016 -0.0012 -0.0018 -0.0368 -0.0031 -0.0553 -0.0143 -0.0058 -0.0120 -0.0010 -0.0015 -0.0049 -0.0041 -0.0015 -0.0014
S-1704	Der Hilfsstoff Benzalkoniumchlorid kann Reizungen der Nasenschleimhaut hervorrufen . ( Firmen - spezifisch )
T-1704	The excipient benzalkonium chloride is an irritant and may cause irritation of the nasal mucosa ( company @-@ specific ) .
H-1704	-0.06265080720186234	The excipient benzalkonium chloride is an irritant and may cause irritation of the nasal mucosa ( company @-@ specific )
D-1704	-0.06265080720186234	The excipient benzalkonium chloride is an irritant and may cause irritation of the nasal mucosa ( company @-@ specific )
P-1704	-0.0039 -0.0131 -0.0004 -0.0011 -0.0018 -0.0017 -0.0035 -0.0013 -0.0104 -0.0002 -0.0012 -0.0010 -0.0006 -0.0010 -0.1644 -0.0141 -0.0051 -0.0017 -0.0146 -0.0129 -0.0042 -0.0023 -0.0032 -0.0502 -0.0035 -0.0030 -0.0005 -0.0014 -0.0038 -0.0939 -0.0013 -0.4709 -0.0135 -0.0128 -0.0005 -0.0016 -1.3971
S-197	Leichte oder mittelschwere infusionsbedingte Reaktionen * ; leichte bis mittelschwere Mukositis , die zu Epistaxis führen kann .
T-197	Mild or moderate infusion @-@ related reactions * ; mild to moderate mucositis which may lead to epistaxis .
H-197	-0.03164000064134598	Mild or moderate infusion @-@ related reactions * ; mild to moderate mucositis which may lead to epistaxis .
D-197	-0.03164000064134598	Mild or moderate infusion @-@ related reactions * ; mild to moderate mucositis which may lead to epistaxis .
P-197	-0.0049 -0.0009 -0.0052 -0.0040 -0.0068 -0.0005 -0.0045 -0.1820 -0.0053 -0.0006 -0.0012 -0.0063 -0.0019 -0.0061 -0.0028 -0.0088 -0.4191 -0.0015 -0.0007 -0.0126 -0.0434 -0.0074 -0.0015 -0.0008 -0.0010 -0.0012 -0.0005 -0.1847 -0.0014
S-1678	Bei Säuglingen , Kindern und Jugendlichen beträgt die Anfangsdosis Cyanokit 70 mg / kg Körpergewicht , aber maximal 5 g .
T-1678	In infants to adolescents , the initial dose of Cyanokit is 70 mg / kg body weight not exceeding 5 g .
H-1678	-0.03073321282863617	In infants to adolescents , the initial dose of Cyanokit is 70 mg / kg body weight not exceeding 5 g .
D-1678	-0.03073321282863617	In infants to adolescents , the initial dose of Cyanokit is 70 mg / kg body weight not exceeding 5 g .
P-1678	-0.0104 -0.0045 -0.0333 -0.3782 -0.0144 -0.0008 -0.2564 -0.0088 -0.0030 -0.0528 -0.0033 -0.0043 -0.0117 -0.0016 -0.0033 -0.0050 -0.0031 -0.0034 -0.0005 -0.0018 -0.0008 -0.0790 -0.0009 -0.0241 -0.0073 -0.0007 -0.0020 -0.0032 -0.0019 -0.0014
S-806	Fragen Sie Ihren Arzt , wenn die zu impfende Person schwanger ist , versucht schwanger zu werden oder während der Impfserie schwanger wird .
T-806	Consult your doctor if the person to be vaccinated is pregnant , trying to become pregnant or becomes pregnant during the course of vaccination .
H-806	-0.0250987708568573	Consult your doctor if the person to be vaccinated is pregnant , trying to become pregnant or becomes pregnant during the course of vaccination .
D-806	-0.0250987708568573	Consult your doctor if the person to be vaccinated is pregnant , trying to become pregnant or becomes pregnant during the course of vaccination .
P-806	-0.0119 -0.0003 -0.0025 -0.0025 -0.0033 -0.0058 -0.0027 -0.0090 -0.0033 -0.0021 -0.0008 -0.0019 -0.0012 -0.2473 -0.0090 -0.0014 -0.0116 -0.0007 -0.1069 -0.0109 -0.0008 -0.0295 -0.1162 -0.0142 -0.0014 -0.1245 -0.0019 -0.0027 -0.0014
S-1160	Juni 2007 erteilte die Europäische Kommission dem Unternehmen Addmedica eine Genehmigung für das Inverkehrbringen von Siklos in der gesamten Europäischen Union .
T-1160	The European Commission granted a marketing authorisation valid throughout the EU for Siklos to Addmedica on 29 June 2007 .
H-1160	-0.08206792920827866	The European Commission granted a marketing authorisation valid throughout the European Union for Siklos to Addmedica on 29 June 2007 .
D-1160	-0.08206792920827866	The European Commission granted a marketing authorisation valid throughout the European Union for Siklos to Addmedica on 29 June 2007 .
P-1160	-0.0139 -0.0029 -0.0012 -0.0125 -0.0138 -0.0044 -0.0034 -0.0009 -0.0145 -0.0019 -0.0115 -0.0017 -0.7462 -0.0015 -0.0110 -0.0069 -0.0010 -0.0006 -0.0415 -0.0075 -0.0012 -0.0008 -0.0012 -0.0137 -1.2165 -0.1834 -0.0614 -0.0016 -0.0014
S-704	Wenn Fluoxetin über lange Zeit und / oder in hoher Dosierung verordnet wurde , sollte ein längerer Zeitraum in Betracht gezogen werden .
T-704	If fluoxetine has been prescribed chronically and / or at a high dose , a longer interval should be considered .
H-704	-0.01601487211883068	If fluoxetine has been prescribed chronically and / or at a high dose , a longer interval should be considered .
D-704	-0.01601487211883068	If fluoxetine has been prescribed chronically and / or at a high dose , a longer interval should be considered .
P-704	-0.0050 -0.0039 -0.0005 -0.0007 -0.3065 -0.0080 -0.0015 -0.0027 -0.0008 -0.0147 -0.0110 -0.0037 -0.0018 -0.0013 -0.0106 -0.0225 -0.0025 -0.0094 -0.0031 -0.0052 -0.0053 -0.0144 -0.0008 -0.0053 -0.0014 -0.0027 -0.0016 -0.0014
S-844	Arbeitsgruppe Sicherheit Die Arbeitsgruppe Sicherheit tagte 2002 dreimal und war mit 12 Leitlinien betraut , von denen 1 neu war und 5 veröffentlicht wurden .
T-844	guidelines , 1 concept paper and released 3 guidelines for public consultation ( one of which concerned both human and veterinary medicinal products ) .
H-844	-0.013431594707071781	guidelines , 1 concept paper and released 3 guidelines for public consultation ( one of which concerned both human and veterinary medicinal products ) .
D-844	-0.013431594707071781	guidelines , 1 concept paper and released 3 guidelines for public consultation ( one of which concerned both human and veterinary medicinal products ) .
P-844	-0.0145 -0.0143 -0.0106 -0.0145 -0.0149 -0.0064 -0.0152 -0.0146 -0.0144 -0.0168 -0.0144 -0.0144 -0.0151 -0.0144 -0.0113 -0.0038 -0.0145 -0.0148 -0.0152 -0.0129 -0.0145 -0.0015 -0.0145 -0.0549 -0.0051 -0.0037 -0.0136 -0.0014
S-684	Docetaxel ist eine lipophile Substanz ; es ist jedoch nicht bekannt , ob es in die Muttermilch übergeht .
T-684	Docetaxel is a lipophilic substance but it is not known whether it is excreted in human milk .
H-684	-0.0644482970237732	Docetaxel is a lipophilic substance but it is not known whether it is excreted in human milk .
D-684	-0.0644482970237732	Docetaxel is a lipophilic substance but it is not known whether it is excreted in human milk .
P-684	-0.0014 -0.0012 -0.0009 -0.0005 -0.0012 -0.0016 -0.0019 -0.0015 -0.0006 -0.0006 -0.0008 -0.0027 -0.0663 -0.0054 -0.0017 -0.0396 -0.0017 -0.0094 -0.0018 -0.0117 -0.0145 -0.0034 -0.0009 -0.6072 -0.2475 -0.7753 -0.0017 -0.0014
S-1587	Die Endkonzentration an Interferon in der physiologischen Kochsalzlösung darf nicht weniger als 1 x 105 I.E. / ml betragen .
T-1587	Final concentration of interferon in sodium chloride solution must not be less than 1 x 105 IU / ml .
H-1587	-0.006242393050342798	Final concentration of interferon in sodium chloride solution must not be less than 1 x 105 IU / ml .
D-1587	-0.006242393050342798	Final concentration of interferon in sodium chloride solution must not be less than 1 x 105 IU / ml .
P-1587	-0.0143 -0.0060 -0.0021 -0.0121 -0.0005 -0.0015 -0.0028 -0.0144 -0.0012 -0.0028 -0.0001 -0.0001 -0.0111 -0.0085 -0.0099 -0.0593 -0.0040 -0.0020 -0.0015 -0.0021 -0.0017 -0.0009 -0.0019 -0.0078 -0.0016 -0.0012 -0.0021 -0.0015
S-1752	Wenn Sie Erbitux in Kombination mit einer Strahlentherapie erhalten , beginnt die Behandlung mit Erbitux normalerweise eine Woche vor der Bestrahlung .
T-1752	If you receive Erbitux in combination with radiation therapy , treatment with Erbitux is usually started one week before radiation therapy .
H-1752	-0.005104653537273407	If you receive Erbitux in combination with radiation therapy , treatment with Erbitux is usually started one week before radiation therapy .
D-1752	-0.005104653537273407	If you receive Erbitux in combination with radiation therapy , treatment with Erbitux is usually started one week before radiation therapy .
P-1752	-0.0053 -0.0022 -0.0116 -0.0014 -0.0007 -0.0007 -0.0074 -0.0011 -0.0014 -0.0114 -0.0076 -0.0023 -0.0070 -0.0025 -0.0012 -0.0005 -0.0007 -0.0143 -0.0078 -0.0087 -0.0084 -0.0011 -0.0048 -0.0113 -0.0123 -0.0030 -0.0014
S-1497	Die EMEA beteiligte sich weiterhin aktiv an der Arbeitsgruppe der Europäischen Kommission zur Erstellung von Dokumenten , die im Rahmen der Richtlinie benötigt werden .
T-1497	EMEA continued to participate actively in the European Commission Working Party on the preparation of other documents needed under the Directive .
H-1497	-0.006631310097873211	EMEA continued to participate actively in the European Commission Working Party on the preparation of other documents needed under the Directive .
D-1497	-0.006631310097873211	EMEA continued to participate actively in the European Commission Working Party on the preparation of other documents needed under the Directive .
P-1497	-0.0369 -0.0006 -0.0012 -0.0068 -0.0027 -0.0097 -0.0022 -0.0018 -0.0019 -0.0042 -0.0012 -0.0111 -0.0012 -0.0122 -0.0062 -0.0064 -0.0083 -0.0014 -0.0145 -0.0031 -0.0124 -0.0212 -0.0022 -0.0035 -0.0030 -0.0016 -0.0014
S-479	• Warum kann ich keine Dosis einstellen , um auch den kleinen Rest Insulin zu nutzen , der noch in der Patrone verblieben ist ?
T-479	• Why can I not dial the dose to use the small amount of insulin that remains in my cartridge ?
H-479	-0.00633048452436924	• Why can I not dial the dose to use the small amount of insulin that remains in my cartridge ?
D-479	-0.00633048452436924	• Why can I not dial the dose to use the small amount of insulin that remains in my cartridge ?
P-479	-0.0055 -0.0016 -0.0037 -0.0130 -0.0021 -0.0146 -0.0085 -0.0133 -0.0077 -0.0068 -0.0081 -0.0059 -0.0070 -0.0061 -0.0018 -0.0008 -0.0006 -0.0096 -0.0096 -0.0030 -0.0166 -0.0041 -0.0005 -0.0011 -0.0113 -0.0016
S-918	Seit Markteinführung wurden diese Symptome auch bei Patienten mit der Parkinson @-@ Krankeit beobachtet , die mit AZILECT behandelt wurden .
T-918	In post marketing experience these symptoms have also been observed in Parkinson &apos;s disease patients treated with AZILECT .
H-918	-0.015574511140584946	In post marketing experience these symptoms have also been observed in Parkinson &apos;s disease patients treated with AZILECT .
D-918	-0.015574511140584946	In post marketing experience these symptoms have also been observed in Parkinson &apos;s disease patients treated with AZILECT .
P-918	-0.0145 -0.0145 -0.0150 -0.0145 -0.0133 -0.0023 -0.0069 -0.1411 -0.0772 -0.0189 -0.0030 -0.0124 -0.0005 -0.0332 -0.0072 -0.0020 -0.0128 -0.0022 -0.0036 -0.0019 -0.0013 -0.0009 -0.0014 -0.0010 -0.0019 -0.0014
S-1507	Patienten , die Alli einnehmen und nach 12 Wochen keine Gewichtsabnahme verzeichnen können , sollten sich an ihren Arzt oder Apotheker wenden .
T-1507	If patients taking Alli have been unable to lose weight after 12 weeks , they should speak to their doctor or pharmacist .
H-1507	-0.007406042888760567	If patients taking Alli have been unable to lose weight after 12 weeks , they should speak to their doctor or pharmacist .
D-1507	-0.007406042888760567	If patients taking Alli have been unable to lose weight after 12 weeks , they should speak to their doctor or pharmacist .
P-1507	-0.0157 -0.0117 -0.0142 -0.0013 -0.0138 -0.0143 -0.0051 -0.0014 -0.0072 -0.0038 -0.0040 -0.0015 -0.0009 -0.0046 -0.0065 -0.0020 -0.0232 -0.0029 -0.0398 -0.0039 -0.0016 -0.0018 -0.0008 -0.0020 -0.0014
S-35	20 Nicht einfrieren Das Behältnis im Umkarton aufbewahren Nach Anbruch : nicht im Kühlschrank oder über 25 ° C aufbewahren
T-35	ed Keep the container in the outer carton During use : do not refrigerate or store above 25 ° C
H-35	-0.006761500611901283	ed Keep the container in the outer carton During use : do not refrigerate or store above 25 ° C
D-35	-0.006761500611901283	ed Keep the container in the outer carton During use : do not refrigerate or store above 25 ° C
P-35	-0.0145 -0.0143 -0.0073 -0.0034 -0.0030 -0.0066 -0.0144 -0.0012 -0.0095 -0.0023 -0.0145 -0.0145 -0.0035 -0.0081 -0.0014 -0.0131 -0.0010 -0.0006 -0.0015 -0.0029 -0.0136 -0.0121 -0.0021 -0.0019 -0.0019 -0.0065
S-299	Modell @-@ Impfstoffe enthalten Influenza @-@ Antigene , die sich von denen der gegenwärtig zirkulierenden Influenzaviren unterscheiden .
T-299	Mock @-@ up vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses .
H-299	-0.019340280443429947	Mock @-@ up vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses .
D-299	-0.019340280443429947	Mock @-@ up vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses .
P-299	-0.0144 -0.0142 -0.1930 -0.0110 -0.2570 -0.0008 -0.0027 -0.0032 -0.0004 -0.0014 -0.0017 -0.0008 -0.0079 -0.0090 -0.0043 -0.0066 -0.0049 -0.0132 -0.0074 -0.0095 -0.0007 -0.0008 -0.0013 -0.0042 -0.0005 -0.0014 -0.0044 -0.0007 -0.0015 -0.0014
S-462	24 Ελλάδα ΦΑΡΜΑΣΕΡΒ -ΛΙΛΛΥ Α .Ε .Β .Ε .
T-462	Ελλάδα ΦΑΡΜΑΣΕΡΒ -ΛΙΛΛΥ Α .Ε .Β .Ε .
H-462	-0.10302558541297913	Ελλάδα ΦΑΡΜΑΣΕΡΒ -ΛΙΛΛΥ Α .Ε .Β .
D-462	-0.10302558541297913	Ελλάδα ΦΑΡΜΑΣΕΡΒ -ΛΙΛΛΥ Α .Ε .Β .
P-462	-0.0146 -0.0005 -0.1162 -0.1003 -0.0011 -0.0005 -0.0018 -0.0025 -0.0145 -0.0113 -0.0046 -0.0150 -0.0227 -0.0209 -0.0147 -0.0077 -0.0143 -0.0278 -0.0354 -0.3489 -0.4630 -0.0145 -0.0031 -0.0165 -0.0148 -0.3448 -1.2506 -0.0021
S-1240	Die Zeit bis zum Eintreten einer Wirkung war kurz ( nur 2 Wochen ) und das Ausmaß des Ansprechens nahm während der Dauer der Behandlung weiter zu .
T-1240	Time to onset was rapid ( as early as week 2 ) and the magnitude of response continued to improve with duration of treatment .
H-1240	-0.009277265518903732	Time to onset was rapid ( as early as week 2 ) and the magnitude of response continued to improve with duration of treatment .
D-1240	-0.009277265518903732	Time to onset was rapid ( as early as week 2 ) and the magnitude of response continued to improve with duration of treatment .
P-1240	-0.0144 -0.0047 -0.0143 -0.0018 -0.0134 -0.0145 -0.0020 -0.0152 -0.0144 -0.0014 -0.0455 -0.0059 -0.0018 -0.0337 -0.0070 -0.0144 -0.0008 -0.0007 -0.0015 -0.0080 -0.0071 -0.0016 -0.0143 -0.0156 -0.0130 -0.0013 -0.0015 -0.0052 -0.0017 -0.0014
S-70	Lamivudin hat keinen Einfluss auf die Pharmakokinetik von Trimethoprim und Sulfamethoxazol .
T-70	Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulfamethoxazole .
H-70	-0.024264810606837273	Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulfamethoxazole .
D-70	-0.024264810606837273	Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulfamethoxazole .
P-70	-0.0012 -0.0010 -0.0009 -0.0009 -0.0012 -0.0482 -0.0016 -0.0110 -0.0017 -0.0030 -0.0012 -0.0005 -0.0006 -0.0012 -0.0015 -0.0064 -0.0005 -0.0009 -0.0010 -0.0015 -0.6106 -0.0230 -0.0007 -0.0017 -0.0002 -0.0012 -0.0005 -0.0008 -0.0017 -0.0014
S-746	Č eská republika Na Př íkopě 25 Praha 1 CZ @-@ 110 00 + 420 @-@ 221 771 250
T-746	Č eská republika Na Př íkopě 25 Praha 1 CZ @-@ 110 00 + 420 @-@ 221 771 250
H-746	-0.007421006448566914	Č eská republika Na Př íkopě 25 Praha 1 CZ @-@ 110 00 + 420 @-@ 221 771 250
D-746	-0.007421006448566914	Č eská republika Na Př íkopě 25 Praha 1 CZ @-@ 110 00 + 420 @-@ 221 771 250
P-746	-0.0146 -0.0060 -0.0030 -0.0011 -0.0011 -0.0028 -0.0042 -0.0065 -0.0132 -0.0046 -0.0036 -0.0014 -0.0019 -0.0016 -0.0105 -0.0020 -0.0014 -0.0012 -0.1341 -0.0019 -0.0010 -0.0011 -0.0015 -0.0013 -0.0014 -0.0010 -0.0009 -0.0016 -0.0006 -0.0013 -0.0015
S-335	Dieser Patient erhielt jedoch gleichzeitig eine Ganzhirnbestrahlung und hatte vorher Methotrexat intraventrikulär erhalten .
T-335	This patient , however , was also receiving concomitant whole brain irradiation and had previously received intraventricular methotrexate .
H-335	-0.006597576662898064	This patient , however , was also receiving concomitant whole brain irradiation and had previously received intraventricular methotrexate .
D-335	-0.006597576662898064	This patient , however , was also receiving concomitant whole brain irradiation and had previously received intraventricular methotrexate .
P-335	-0.0110 -0.0014 -0.0214 -0.0017 -0.0014 -0.0182 -0.0173 -0.0317 -0.0150 -0.0136 -0.0003 -0.0025 -0.0105 -0.0088 -0.0118 -0.0009 -0.0036 -0.0029 -0.0063 -0.0059 -0.0130 -0.0010 -0.0018 -0.0012 -0.0003 -0.0003 -0.0010 -0.0017 -0.0010 -0.0008 -0.0016 -0.0014
S-1607	Patienten mit Extravasation durch einen zentralvenösen Zugang ( CVAD ) wurden nicht in die Wirksamkeitsuntersuchung aufgenommen .
T-1607	Patients with extravasations from a central venous access device ( CVAD ) were not included in the efficacy evaluation .
H-1607	-0.004920791834592819	Patients with extravasations from a central venous access device ( CVAD ) were not included in the efficacy evaluation .
D-1607	-0.004920791834592819	Patients with extravasations from a central venous access device ( CVAD ) were not included in the efficacy evaluation .
P-1607	-0.0016 -0.0010 -0.0037 -0.0013 -0.0033 -0.0006 -0.0173 -0.0141 -0.0118 -0.0054 -0.0016 -0.0006 -0.0070 -0.0145 -0.0017 -0.0013 -0.0016 -0.0006 -0.0014 -0.0249 -0.0014 -0.0024 -0.0035 -0.0023 -0.0030 -0.0006 -0.0008 -0.0143 -0.0010 -0.0008 -0.0109 -0.0014
S-1798	Hyponatriämie Selten und überwiegend bei älteren Patienten wurden Hyponatriämien bei der Anwendung von CYMBALTA berichtet .
T-1798	Hyponatremia Hyponatremia has been reported rarely , predominantly in the elderly , when administering CYMBALTA .
H-1798	-0.02062404900789261	Hyponatremia Hyponatremia has been reported rarely , predominantly in the elderly , when administering CYMBALTA .
D-1798	-0.02062404900789261	Hyponatremia Hyponatremia has been reported rarely , predominantly in the elderly , when administering CYMBALTA .
P-1798	-0.0012 -0.0008 -0.0017 -0.0009 -0.0010 -0.0145 -0.0009 -0.0012 -0.0005 -0.0025 -0.0115 -0.0039 -0.0093 -0.0114 -0.0170 -0.0139 -0.0012 -0.0021 -0.0053 -0.1111 -0.0016 -0.0112 -0.0096 -0.0144 -0.4202 -0.0019 -0.0024 -0.0015 -0.0014 -0.0007 -0.0004 -0.0019 -0.0014
S-290	Behandlung von invasiver Candidose Behandlung der ösophagealen Candidose Prophylaxe von Candida @-@ Infektionen
T-290	Treatment of invasive candidiasis Treatment of oesophageal candidiasis Prophylaxis of Candida infection
H-290	-0.03374581038951874	Treatment of invasive candidiasis Treatment of oesophageal candidiasis Prophylaxis of Candida infection
D-290	-0.03374581038951874	Treatment of invasive candidiasis Treatment of oesophageal candidiasis Prophylaxis of Candida infection
P-290	-0.0022 -0.0012 -0.0012 -0.0015 -0.0045 -0.0007 -0.0008 -0.0022 -0.0034 -0.1256 -0.1322 -0.0017 -0.0006 -0.0010 -0.0011 -0.0014 -0.0136 -0.0005 -0.0020 -0.0009 -0.0008 -0.0015 -0.0012 -0.0033 -0.3747 -0.5592 -0.0015 -0.0048 -0.0008 -0.0013 -0.0008 -0.0010 -0.0016 -0.0148 -0.0017 -0.0008 -0.0127 -0.0017
S-1511	Kortison ) , Medikamenten gegen Krebs ( Chemotherapie ) , Bestrahlungen oder andere Behandlungen , die das Immunsystem beeinträchtigen .
T-1511	response such as corticosteroids ( for example cortisone ) , medicines against cancer ( chemotherapy ) , radiotherapy or other medicines affecting the immune system .
H-1511	-0.034847892820835114	response such as corticosteroids ( for example cortisone ) , medicines against cancer ( chemotherapy ) , radiotherapy or other medicines affecting the immune system .
D-1511	-0.034847892820835114	response such as corticosteroids ( for example cortisone ) , medicines against cancer ( chemotherapy ) , radiotherapy or other medicines affecting the immune system .
P-1511	-0.0145 -0.0145 -0.0016 -0.0101 -0.3458 -0.0079 -0.0000 -0.0214 -0.0004 -0.0724 -0.0144 -0.0103 -0.0135 -0.4833 -0.0013 -0.0024 -0.0018 -0.0117 -0.0069 -0.0125 -0.0012 -0.0016 -0.0022 -0.0006 -0.1516 -0.0015 -0.0822 -0.0139 -0.0023 -0.0054 -0.0031 -0.0145 -0.0098 -0.0140 -0.0034 -0.0006 -0.0015 -0.0018 -0.0014
S-171	Vorausgegangen war ein Atemstillstand mit Krampfanfällen , der in eine tödlich verlaufende Aspirationspneumonie mündete .
T-171	Only one recorded death has been published : after an overdose of 469 mg / kg , a 16 @-@ month old child developed an apnoeic episode with seizures and a fatal aspiration pneumonia .
H-171	-0.11914949119091034	Only one recorded death has been published : after an overdose of 469 mg , a 16 @-@ month old child developed an apnoeic episode with seizures and a fatal aspiration pneumonia .
D-171	-0.11914949119091034	Only one recorded death has been published : after an overdose of 469 mg , a 16 @-@ month old child developed an apnoeic episode with seizures and a fatal aspiration pneumonia .
P-171	-0.0145 -0.0138 -0.0145 -0.0144 -0.0144 -0.0070 -0.0145 -0.0141 -0.0144 -0.0136 -0.0145 -0.0096 -0.0086 -0.0148 -0.0140 -0.0117 -4.8685 -0.0131 -0.0145 -0.0083 -0.0127 -0.0144 -0.0140 -0.0144 -0.0138 -0.0145 -0.0144 -0.0145 -0.0096 -0.0144 -0.0191 -0.0141 -0.0142 -0.0008 -0.0204 -0.0129 -0.0100 -0.0103 -0.0025 -0.0022 -0.0013 -0.0007 -0.0005 -0.0017 -0.0014
S-1020	{ ( Name ( Phantasiebezeichnung ) } enthält weiterhin Propylenglykol , das Hautirritationen hervorrufen kann .
T-1020	&lt; Invented Name &gt; contains cetyl alcohol and stearyl alcohol which may cause local skin reactions . &lt; Invented Name &gt; also contains propylene glycol , which may cause skin irritation .
H-1020	-0.030531998723745346	&lt; Invented Name &gt; contains cetyl alcohol and stearyl alcohol which may cause local skin reactions . &lt; Invented Name &gt; also contains propylene glycol , which may cause skin irritation .
D-1020	-0.030531998723745346	&lt; Invented Name &gt; contains cetyl alcohol and stearyl alcohol which may cause local skin reactions . &lt; Invented Name &gt; also contains propylene glycol , which may cause skin irritation .
P-1020	-0.0145 -0.0002 -0.0010 -0.0145 -0.0117 -0.0144 -0.0143 -0.0133 -0.0146 -0.0141 -0.0134 -0.0141 -0.0765 -0.0145 -0.0131 -0.0141 -0.0135 -0.0928 -0.0121 -0.0039 -0.0764 -0.0071 -0.2599 -0.0110 -0.0047 -0.0901 -0.0003 -0.0011 -0.0145 -0.0059 -0.0145 -0.0142 -0.0145 -0.0029 -0.0029 -0.0006 -0.0007 -0.0013 -0.0007 -0.0014 -0.0010 -0.0156 -0.0055 -0.0120 -0.0035 -0.1447 -0.3749 -0.0049 -0.0576 -0.0014
S-1181	Makrophagen @-@ Aktivierungs @-@ Syndrom * , anti @-@ neutrophile Antikörper @-@ positive Vaskulitis
T-1181	Allergic reactions ( see Skin and subcutaneous tissue disorders ) , autoantibody formation * Serious allergic / anaphylactic reactions ( including angioedema , bronchospasm ) Macrophage activation syndrome * , anti @-@ neutrophilic cytoplasmic antibody positive vasculitis
H-1181	-0.09167429804801941	Allergic reactions ( see Skin and subcutaneous tissue disorders ) , autoantibody formation * Serious allergic / anaphylactic reactions ( including angioedema , bronchospasm )
D-1181	-0.09167429804801941	Allergic reactions ( see Skin and subcutaneous tissue disorders ) , autoantibody formation * Serious allergic / anaphylactic reactions ( including angioedema , bronchospasm )
P-1181	-0.0145 -0.0064 -0.0145 -0.0111 -0.0158 -0.0146 -0.0145 -0.0107 -0.0139 -0.0145 -0.0040 -0.0004 -0.0012 -0.0017 -0.0131 -0.0145 -0.0010 -0.0032 -0.0128 -0.0145 -0.0143 -0.0056 -0.0179 -0.0102 -0.1424 -0.0028 -0.0145 -0.0040 -0.0154 -0.0144 -0.0143 -0.0053 -0.0005 -0.0013 -0.0143 -0.0013 -0.1102 -0.0146 -0.0142 -0.0145 -0.0145 -0.0008 -0.0004 -0.0210 -0.0150 -0.0399 -0.0136 -0.0135 -0.0117 -0.0160 -3.9005
S-1090	In der &quot; per @-@ protocol &quot; -Analyse war der Einfluss des Impfstoffes eine 9 % ige Reduktion ( 95 % CI :
T-1090	The effect of the vaccine in the per @-@ protocol analysis was a 9 % reduction ( 95 % CI :
H-1090	-0.0045132748782634735	The effect of the vaccine in the per @-@ protocol analysis was a 9 % reduction ( 95 % CI :
D-1090	-0.0045132748782634735	The effect of the vaccine in the per @-@ protocol analysis was a 9 % reduction ( 95 % CI :
P-1090	-0.0134 -0.0116 -0.0019 -0.0032 -0.0018 -0.0099 -0.0055 -0.0094 -0.0138 -0.0045 -0.0009 -0.0010 -0.0019 -0.0021 -0.0032 -0.0029 -0.0019 -0.0029 -0.0022 -0.0011 -0.0015 -0.0069 -0.0016 -0.0060 -0.0015
S-286	Nehmen Sie die nächste Tablette am folgenden Tag ein und fahren Sie dann mit der normalen Einnahme von einer Tablette einmal täglich fort .
T-286	Take the next tablet on the following day and then carry on taking a tablet once a day as normal .
H-286	-0.03307430446147919	Take the next tablet on the following day and then carry on taking a tablet once a day as normal .
D-286	-0.03307430446147919	Take the next tablet on the following day and then carry on taking a tablet once a day as normal .
P-286	-0.0121 -0.0033 -0.0082 -0.0052 -0.0009 -0.0128 -0.0021 -0.0045 -0.0018 -0.0278 -0.0464 -0.0511 -0.0024 -0.0095 -0.0139 -0.0112 -0.0009 -0.0040 -0.5528 -0.0013 -0.0114 -0.0070 -0.0016 -0.0015
S-756	26 Hypertonie In kontrollierten klinischen Studien zu essenzieller Hypertonie mit Losartan wurde über folgende Nebenwirkungen berichtet .
T-756	Hypertension In controlled clinical trials for essential hypertension with losartan the following adverse events were reported
H-756	-0.04279958829283714	Hypertension In controlled clinical trials for essential hypertension with losartan the following adverse events were reported
D-756	-0.04279958829283714	Hypertension In controlled clinical trials for essential hypertension with losartan the following adverse events were reported
P-756	-0.0145 -0.0008 -0.0003 -0.0098 -0.0030 -0.0007 -0.4156 -0.0121 -0.0033 -0.0024 -0.0001 -0.0074 -0.0008 -0.0004 -0.0013 -0.0117 -0.0022 -0.0438 -0.0004 -0.1017 -0.0750 -0.0009 -0.2761
S-1785	Die Einnahme von Glubrava mit oder unmittelbar nach der Mahlzeit kann die mit Metformin verbundenen Magenprobleme verringern .
T-1785	Taking Glubrava with or just after food may reduce any stomach problems caused by metformin .
H-1785	-0.007512637879699469	Taking Glubrava with or just after food may reduce any stomach problems caused by metformin .
D-1785	-0.007512637879699469	Taking Glubrava with or just after food may reduce any stomach problems caused by metformin .
P-1785	-0.0093 -0.0083 -0.0006 -0.0010 -0.0007 -0.0034 -0.0017 -0.0167 -0.0028 -0.0475 -0.0215 -0.0061 -0.0144 -0.0030 -0.0054 -0.0144 -0.0014 -0.0017 -0.0004 -0.0014 -0.0021 -0.0015
S-34	Zeffix ist auch als Lösung zum Einnehmen erhältlich , so dass Ihr Arzt Ihnen , wenn nötig , eine geringere Dosis verschreiben kann .
T-34	This means that your doctor can prescribe a lower dose for you if necessary .
H-34	-0.01507822796702385	This means that your doctor can prescribe a lower dose for you if necessary .
D-34	-0.01507822796702385	This means that your doctor can prescribe a lower dose for you if necessary .
P-34	-0.0167 -0.0145 -0.0050 -0.0122 -0.0020 -0.0327 -0.0036 -0.0010 -0.0068 -0.0941 -0.0029 -0.0164 -0.0043 -0.0060 -0.0196 -0.0044 -0.0142
S-1385	Falls vom Arzt nicht anders verordnet , beträgt die übliche Dosis 60 mg , d.h. eine Tablette ist 1 mal täglich einzunehmen .
T-1385	The usual dose is 60 mg tablet taken orally , once daily .
H-1385	-0.024980520829558372	The usual dose is 60 mg tablet taken orally , once daily .
D-1385	-0.024980520829558372	The usual dose is 60 mg tablet taken orally , once daily .
P-1385	-0.0155 -0.0080 -0.0135 -0.0083 -0.0049 -0.0017 -0.0249 -0.0036 -0.0205 -0.0145 -0.0015 -0.0130 -0.0145 -0.2255 -0.0153 -0.0144
S-1982	Bündelpackung aus 10 Packungen mit jeweils 1 Durchstechflasche mit je 5 ml Konzentrat zur Herstellung einer Infusionslösung .
T-1982	Multipack comprising ten packs , each containing one vial .
H-1982	-0.0131436288356781	Multipack comprising ten packs , each containing one vial .
D-1982	-0.0131436288356781	Multipack comprising ten packs , each containing one vial .
P-1982	-0.0145 -0.0040 -0.0143 -0.0019 -0.0160 -0.0069 -0.0011 -0.0196 -0.0032 -0.0095 -0.0737 -0.0023 -0.0008 -0.0149 -0.0145
S-434	se Erhöhung , Reduktion oder Abbruch ) und einer signifikanten Änderung des Hämoglobinwertes ein Zeitraum von ungefähr 4 Wochen liegen .
T-434	In consequence , dose adjustment should not
H-434	-0.010936585254967213	In consequence , dose adjustment should not
D-434	-0.010936585254967213	In consequence , dose adjustment should not
P-434	-0.0140 -0.0157 -0.0019 -0.0081 -0.0145 -0.0144 -0.0005 -0.0084 -0.0142 -0.0139 -0.0145
S-1716	26 % ( 24 % ) 44 % ( 28 % ) 13 % ( 10 % ) 36 % ( 37 % ) 0 % ( 0 % )
T-1716	Urinary incontinence Urinary urgency
H-1716	-0.013540031388401985	Urinary incontinence Urinary urgency
D-1716	-0.013540031388401985	Urinary incontinence Urinary urgency
P-1716	-0.0171 -0.0145 -0.0144 -0.0136 -0.0010 -0.0160 -0.0141 -0.0147 -0.0141 -0.0158
S-1596	Avaglim wird zur Behandlung von erwachsenen Patienten mit Typ @-@ 2 @-@ Diabetes ( nicht insulinabhängigem Diabetes ) angewendet .
T-1596	Avaglim is used to treat adult patients who have type 2 diabetes ( non @-@ insulin @-@ dependent diabetes ) .
H-1596	-0.025549162179231644	Avaglim is used to treat adult patients who have type 2 diabetes ( non @-@ insulin @-@ dependent diabetes ) .
D-1596	-0.025549162179231644	Avaglim is used to treat adult patients who have type 2 diabetes ( non @-@ insulin @-@ dependent diabetes ) .
P-1596	-0.0011 -0.0010 -0.0011 -0.0012 -0.0019 -0.0030 -0.1150 -0.0007 -0.0018 -0.0017 -0.4929 -0.0050 -0.0018 -0.0015 -0.0088 -0.0021 -0.0030 -0.0017 -0.0012 -0.0006 -0.0089 -0.0024 -0.0017 -0.0014 -0.0016 -0.0014
S-1330	Basierend auf den konventionellen Studien zur chronischen Toxizität lassen die präklinischen Daten keine besonderen Gefahren für den Menschen erkennen .
T-1330	Non @-@ clinical data revealed no special hazard for humans based on conventional studies of repeated dose toxicity .
H-1330	-0.03533347323536873	Non @-@ clinical data revealed no special hazard for humans based on conventional studies of repeated dose toxicity .
D-1330	-0.03533347323536873	Non @-@ clinical data revealed no special hazard for humans based on conventional studies of repeated dose toxicity .
P-1330	-0.5040 -0.0018 -0.0125 -0.0043 -0.1430 -0.0084 -0.0139 -0.0130 -0.0130 -0.0115 -0.0040 -0.0058 -0.0016 -0.0077 -0.0074 -0.0120 -0.0150 -0.0145 -0.0136 -0.0009 -0.0009 -0.0024 -0.0014
S-1108	• Blutungen im Magen @-@ Darm @-@ Trakt oder im Bereich der Harn- oder Geschlechtsorgane innerhalb der letzten 10 Tage
T-1108	• bleeding in the gastrointestinal , urinary or genital tract within the past 10 days
H-1108	-0.0060470267198979855	• bleeding in the gastrointestinal , urinary or genital tract within the past 10 days
D-1108	-0.0060470267198979855	• bleeding in the gastrointestinal , urinary or genital tract within the past 10 days
P-1108	-0.0039 -0.0108 -0.0009 -0.0060 -0.0023 -0.0021 -0.0012 -0.0002 -0.0007 -0.0007 -0.0452 -0.0015 -0.0008 -0.0202 -0.0107 -0.0011 -0.0048 -0.0026 -0.0074 -0.0033 -0.0117 -0.0022 -0.0014 -0.0035
S-699	Die Wirkung von Leflunomid auf die Verbesserung der funktionsbezogenen Lebensqualität und die Reduzierung von Hautläsionen waren mäßig .
T-699	The effect of leflunomide on improvement of function and on reduction of skin lesions was modest .
H-699	-0.01985221542418003	The effect of leflunomide on improvement of function and on reduction of skin lesions was modest .
D-699	-0.01985221542418003	The effect of leflunomide on improvement of function and on reduction of skin lesions was modest .
P-699	-0.0041 -0.0070 -0.0015 -0.0018 -0.0016 -0.0035 -0.0004 -0.0009 -0.0022 -0.0151 -0.3118 -0.0163 -0.0165 -0.0224 -0.0219 -0.0015 -0.0042 -0.0010 -0.0006 -0.0049 -0.0143 -0.0016 -0.0014
S-112	Wird nicht vor jeder Injektion entlüftet , kann es passieren , dass zu viel oder zu wenig Insulin gespritzt wird .
T-112	If you do not prime before each injection , you may get too much or too little insulin .
H-112	-0.005819878075271845	If you do not prime before each injection , you may get too much or too little insulin .
D-112	-0.005819878075271845	If you do not prime before each injection , you may get too much or too little insulin .
P-112	-0.0046 -0.0141 -0.0051 -0.0013 -0.0145 -0.0144 -0.0076 -0.0023 -0.0006 -0.0036 -0.0118 -0.0062 -0.0128 -0.0049 -0.0048 -0.0028 -0.0026 -0.0025 -0.0020 -0.0007 -0.0073 -0.0015
S-19	- durch sehr langsame anfängliche Injektionsrate von 0,01 - 0,02 ml / kg / min. sichergestellt wird , dass die
T-19	- that patients are not sensitive to human normal immunoglobulin by first injecting the product
H-19	-0.012376387603580952	- that patients are not sensitive to human normal immunoglobulin by first injecting the product
D-19	-0.012376387603580952	- that patients are not sensitive to human normal immunoglobulin by first injecting the product
P-19	-0.0026 -0.0147 -0.0145 -0.0113 -0.0144 -0.0145 -0.0030 -0.0145 -0.0145 -0.0145 -0.0070 -0.0139 -0.0005 -0.0018 -0.0127 -0.0145 -0.0078 -0.0540 -0.0015 -0.0124 -0.0135 -0.0145
S-1773	Während der Dauer der Behandlung mit TRISENOX brauchen Sie keine Einschränkungen in Bezug auf den Verzehr von Nahrungsmitteln oder Getränken beachten .
T-1773	- no restrictions on your food or drink are needed while you are receiving TRISENOX .
H-1773	-0.009235800243914127	- no restrictions on your food or drink are needed while you are receiving TRISENOX .
D-1773	-0.009235800243914127	- no restrictions on your food or drink are needed while you are receiving TRISENOX .
P-1773	-0.0145 -0.0145 -0.0053 -0.0112 -0.0148 -0.0126 -0.0040 -0.0146 -0.0144 -0.0138 -0.0225 -0.0109 -0.0047 -0.0131 -0.0079 -0.0011 -0.0014 -0.0015 -0.0010 -0.0075 -0.0026
S-1623	Für Dosi eru ngen , die ganzen Umdrehungen en tsprechen , sollte die Dosierungsanzeige mit der Ar
T-1623	For doses corresponding to full turns , the scale should line up with the correct dose marking .
H-1623	-0.008228913880884647	For doses corresponding to full turns , the scale should line up with the correct dose marking .
D-1623	-0.008228913880884647	For doses corresponding to full turns , the scale should line up with the correct dose marking .
P-1623	-0.0038 -0.0033 -0.0103 -0.0142 -0.0011 -0.0019 -0.0133 -0.0141 -0.0039 -0.0022 -0.0148 -0.0103 -0.0145 -0.0067 -0.0022 -0.0023 -0.0145 -0.0136 -0.0145 -0.0072 -0.0043
S-654	WAS IST RISPERDAL CONSTA UND WOFÜR WIRD ES ANGEWENDET ?
T-654	WHAT RISPERDAL CONSTA IS AND WHAT IT IS USED FOR
H-654	-0.06543881446123123	WHAT RISPERDAL CONSTA IS AND WHAT IT IS USED FOR
D-654	-0.06543881446123123	WHAT RISPERDAL CONSTA IS AND WHAT IT IS USED FOR
P-654	-0.0014 -0.0008 -1.2880 -0.0006 -0.0011 -0.0007 -0.0008 -0.0007 -0.0008 -0.0013 -0.0073 -0.0099 -0.0025 -0.0089 -0.0142 -0.0026 -0.0086 -0.0012 -0.0080 -0.0006 -0.0143
S-937	ZEFFIX 5 MG / ML LÖSUNG ZUM EINNEHMEN Lamivudin
T-937	Zeffix 5 mg / ml oral solution Lamivudine
H-937	-0.008253632113337517	Zeffix 5 mg / ml oral solution Lamivudine
D-937	-0.008253632113337517	Zeffix 5 mg / ml oral solution Lamivudine
P-937	-0.0144 -0.0145 -0.0126 -0.0023 -0.0145 -0.0016 -0.0027 -0.0145 -0.0120 -0.0144 -0.0010 -0.0009 -0.0011 -0.0055 -0.0117
S-1441	HERSTELLUNGSERLAUBNIS , VERANTWORTLICH IST / SIND
T-1441	Manufacturer of the biological active substance :
H-1441	-0.012115848250687122	Manufacturer of the biological active substance :
D-1441	-0.012115848250687122	Manufacturer of the biological active substance :
P-1441	-0.0146 -0.0006 -0.0153 -0.0034 -0.0145 -0.0126 -0.0145 -0.0138 -0.0145 -0.0128 -0.0143 -0.0145
S-1942	Jede Durchstechflasche Nplate 500 Mikrogramm Pulver zur Herstellung einer Injektionslösung enthält 500 Mikrogramm Romiplostim .
T-1942	Each vial of Nplate 500 micrograms powder for solution for injection contains 500 micrograms of romiplostim .
H-1942	-0.010534520260989666	Each vial of Nplate 500 micrograms powder for solution for injection contains 500 micrograms of romiplostim .
D-1942	-0.010534520260989666	Each vial of Nplate 500 micrograms powder for solution for injection contains 500 micrograms of romiplostim .
P-1942	-0.0017 -0.0051 -0.0009 -0.0039 -0.0021 -0.0006 -0.0011 -0.0035 -0.0084 -0.0123 -0.0088 -0.0145 -0.0142 -0.0044 -0.0017 -0.0021 -0.0015 -0.0008 -0.0011 -0.0036 -0.0067 -0.0010 -0.0004 -0.0101 -0.0010 -0.1715 -0.0014
S-1239	25,5 - 32,8 Tage ) , kann sich Herceptin nach Absetzen der Behandlung noch bis zu 24 Wochen im Kreislauf befinden .
T-1239	Because the half @-@ life of Herceptin is approximately 28.5 days ( 95 % confidence interval , 25.5 <<unk>> 32.8 days ) , Herceptin may persist in the circulation for up to 24 weeks after stopping Herceptin treatment .
H-1239	-0.013299787417054176	Because the half @-@ life of Herceptin is approximately 28.5 days ( 95 % confidence interval , 25.5 <unk> 32.8 days ) , Herceptin may persist in the circulation for up to 24 weeks after stopping Herceptin treatment .
D-1239	-0.013299787417054176	Because the half @-@ life of Herceptin is approximately 28.5 days ( 95 % confidence interval , 25.5 <unk> 32.8 days ) , Herceptin may persist in the circulation for up to 24 weeks after stopping Herceptin treatment .
P-1239	-0.0145 -0.0129 -0.0145 -0.0044 -0.0129 -0.0110 -0.0073 -0.0002 -0.0005 -0.0099 -0.0143 -0.0145 -0.0531 -0.1483 -0.0095 -0.0150 -0.0143 -0.0145 -0.0145 -0.0051 -0.0127 -0.0036 -0.0014 -0.1201 -0.0100 -0.0011 -0.0014 -0.0016 -0.0016 -0.0027 -0.0075 -0.0003 -0.0005 -0.0099 -0.0144 -0.0006 -0.0048 -0.0079 -0.0092 -0.0009 -0.0028 -0.0019 -0.0014 -0.0010 -0.0011 -0.0522 -0.0136 -0.0145 -0.0003 -0.0006 -0.0089 -0.0016 -0.0014
S-1495	Es ist ein zellselektiver Inhibitor der Produktion und Freisetzung von pro- inflammatorischen Zytokinen .
T-1495	Pimecrolimus binds with high affinity to macrophilin @-@ 12 and inhibits the calcium @-@ dependent phosphatase calcineurin .
H-1495	-0.019024088978767395	Pimecrolimus binds with high affinity to macrophilin @-@ 12 and inhibits the calcium @-@ dependent phosphatase calcineurin .
D-1495	-0.019024088978767395	Pimecrolimus binds with high affinity to macrophilin @-@ 12 and inhibits the calcium @-@ dependent phosphatase calcineurin .
P-1495	-0.0374 -0.0145 -0.0144 -0.0145 -0.0137 -0.0140 -0.0145 -0.0106 -0.0141 -0.0220 -0.0145 -0.0077 -0.0014 -0.0067 -0.0249 -0.0015 -0.0145 -0.0145 -0.0150 -0.0145 -0.0145 -0.0144 -0.0002 -0.0018 -0.0079 -0.0147 -0.0048 -0.0031 -0.0119 -0.0145 -0.0145 -0.0124 -0.0062 -0.0137 -0.1421 -0.0155 -0.0132 -0.0145 -0.1551 -0.0014
S-1638	- Haarausfall , trockene Haut , Ekzem , schuppige Haut , Hautausschlag mit flachen roten Pusteln ,
T-1638	General disorders : chest pain , chest pain substernal , chills , fever , flu syndrome , malaise , peripheral oedema , drug interaction ,
H-1638	-0.16435886919498444	General disorders : chest pain , chest pain substernal , chills , fever , flu syndrome , malaise , peripheral oedema , drug interaction ,
D-1638	-0.16435886919498444	General disorders : chest pain , chest pain substernal , chills , fever , flu syndrome , malaise , peripheral oedema , drug interaction ,
P-1638	-0.0151 -0.0145 -0.0011 -0.0120 -0.0146 -0.0108 -0.4245 -0.4933 -0.0088 -0.5252 -0.0145 -0.0137 -0.0144 -0.5016 -0.0143 -0.0497 -0.7310 -0.0004 -0.0030 -0.5337 -0.0149 -0.0003 -0.0235 -0.6727 -0.0139 -0.0046 -0.8418 -0.0085 -0.0020 -0.0145 -0.0003 -0.0001 -0.0488 -0.8030 -0.0145 -0.0133 -0.0138 -0.3593
S-1559	Übelkeit , Erbrechen , Diarrhoe , Mukositis , Konstipation , Stomatitis , Bauchschmerzen
T-1559	Very common : nausea , vomiting , diarrhoea , mucosal inflammation , constipation , stomatitis , abdominal pain
H-1559	-0.05286656692624092	Very common : nausea , vomiting , diarrhoea , mucositis , constipation , stomatitis , abdominal pain
D-1559	-0.05286656692624092	Very common : nausea , vomiting , diarrhoea , mucositis , constipation , stomatitis , abdominal pain
P-1559	-0.0168 -0.0144 -0.0105 -0.0072 -0.0005 -0.0014 -0.1016 -0.0002 -0.0014 -0.0015 -0.0019 -0.0003 -0.0092 -0.0006 -0.0014 -0.0087 -1.5926 -0.0014 -0.0007 -0.0015 -0.0033 -0.0002 -0.0008 -0.0015 -0.0016 -0.0001 -0.0007 -0.0009 -0.0021 -0.0062 -0.0003 -0.0009 -0.0023 -0.0028
S-1611	32 INTELENCE soll nicht bei Kindern oder Jugendlichen angewendet werden , weil es bei Patienten unter 18 Jahren noch nicht ausreichend untersucht wurde .
T-1611	INTELENCE is not for use in children or adolescents , because it has not been sufficiently studied in patients under 18 years of age .
H-1611	-0.056489378213882446	INTELENCE is not for use in children or adolescents , because it has not been sufficiently studied in patients under 18 years of age .
D-1611	-0.056489378213882446	INTELENCE is not for use in children or adolescents , because it has not been sufficiently studied in patients under 18 years of age .
P-1611	-0.0145 -0.0014 -0.0008 -0.0010 -0.0005 -0.0143 -0.0030 -0.0159 -0.0021 -0.0995 -0.0288 -0.2726 -0.0036 -0.0009 -0.0009 -0.2458 -0.0202 -0.0044 -0.0062 -0.0017 -0.0119 -0.0100 -0.0007 -0.0010 -0.0105 -0.0032 -0.0023 -0.3674 -0.0066 -0.0055 -0.6826 -0.0011 -0.0780 -0.0014
S-1658	Glustin 30 mg Tabletten werden zur Behandlung von Diabetes mellitus vom Typ 2 ( nicht insulinpflichtig ) angewendet .
T-1658	Glustin 30 mg tablets are an anti @-@ diabetic medicine used to treat type 2 ( non @-@ insulin dependent ) diabetes mellitus .
H-1658	-0.2124442607164383	Glustin 30 mg tablets are used to treat type 2 ( non @-@ insulin dependent ) diabetes mellitus .
D-1658	-0.2124442607164383	Glustin 30 mg tablets are used to treat type 2 ( non @-@ insulin dependent ) diabetes mellitus .
P-1658	-0.0031 -0.0003 -0.0113 -0.0026 -0.0009 -0.0042 -0.0015 -0.0034 -4.8733 -0.3787 -0.0010 -0.0058 -0.0018 -0.1225 -0.0108 -0.0026 -0.0032 -0.0004 -0.0136 -0.0014 -0.0348 -0.0413 -0.0011 -0.0002 -0.0022 -0.0015
S-1736	Danmark Eli Lilly Industries Ltd Elanco Animal Health Priestley Road Basingstoke RG24 9NL
T-1736	Danmark Eli Lilly Industries Ltd Elanco Animal Health Priestley Road Basingstoke RG24 9NL
H-1736	-0.0011365782702341676	Danmark Eli Lilly Industries Ltd Elanco Animal Health Priestley Road Basingstoke RG24 9NL
D-1736	-0.0011365782702341676	Danmark Eli Lilly Industries Ltd Elanco Animal Health Priestley Road Basingstoke RG24 9NL
P-1736	-0.0019 -0.0006 -0.0011 -0.0013 -0.0003 -0.0013 -0.0004 -0.0012 -0.0004 -0.0031 -0.0005 -0.0011 -0.0006 -0.0008 -0.0008 -0.0012 -0.0007 -0.0010 -0.0011 -0.0006 -0.0027 -0.0006 -0.0019 -0.0012 -0.0014 -0.0011 -0.0013 -0.0013 -0.0010 -0.0014
S-372	In weiteren Studien wurde außerdem die Wirksamkeit von Hepsera bei Patienten untersucht , deren Erkrankung gegen Lamivudin resistent ist .
T-372	Studies have also examined the effectiveness of Hepsera in patients whose disease was resistant to lamivudine .
H-372	-0.00744391605257988	Studies have also examined the effectiveness of Hepsera in patients whose disease was resistant to lamivudine .
D-372	-0.00744391605257988	Studies have also examined the effectiveness of Hepsera in patients whose disease was resistant to lamivudine .
P-372	-0.0145 -0.0055 -0.0052 -0.0142 -0.0024 -0.1067 -0.0008 -0.0014 -0.0040 -0.0005 -0.0006 -0.0013 -0.0024 -0.0013 -0.0092 -0.0022 -0.0145 -0.0014 -0.0006 -0.0017 -0.0028 -0.0011 -0.0009 -0.0010 -0.0017 -0.0015 -0.0014
S-467	- Blutuntersuchungen mit erhöhten Leberenzymwerten oder Creatinphosphokinasewerten ( CPK ) .
T-467	- Blood testing showing higher levels of liver enzymes or creatine phosphokinase ( CPK ) .
H-467	-0.007596385665237904	- Blood testing showing higher levels of liver enzymes or creatine phosphokinase ( CPK ) .
D-467	-0.007596385665237904	- Blood testing showing higher levels of liver enzymes or creatine phosphokinase ( CPK ) .
P-467	-0.0030 -0.0048 -0.0009 -0.0240 -0.0144 -0.0145 -0.0091 -0.0013 -0.0019 -0.0005 -0.0056 -0.0013 -0.1028 -0.0042 -0.0013 -0.0027 -0.0016 -0.0009 -0.0012 -0.0006 -0.0005 -0.0032 -0.0016 -0.0016 -0.0010 -0.0014 -0.0052 -0.0014
S-405	30 Genotypische Entecavir @-@ Resistenzen bis Jahr 5 , Studien mit Lamivudin refraktären Patienten
T-405	26 Genotypic Entecavir Resistance Through Year 5 , Lamivudine @-@ Refractory Studies
H-405	-0.013452988117933273	26 Genotypic Entecavir Resistance Through Year 5 , Lamivudine @-@ Refractory Studies
D-405	-0.013452988117933273	26 Genotypic Entecavir Resistance Through Year 5 , Lamivudine @-@ Refractory Studies
P-405	-0.0146 -0.0118 -0.0062 -0.0041 -0.0076 -0.0011 -0.0006 -0.2317 -0.0010 -0.0055 -0.0015 -0.0145 -0.0004 -0.0015 -0.0023 -0.0140 -0.0010 -0.0009 -0.0011 -0.0029 -0.0138 -0.0076 -0.0006 -0.0010 -0.0007 -0.0136 -0.0021
S-1361	Es ist wichtig , dass Sie Ihren Arzt informieren , wenn Sie eines der folgenden Medikamente einnehmen ( fragen Sie Ihren Arzt , wenn Sie sich nicht
T-1361	It is important that you tell your doctor if you are taking any of the following medicines ( ask your doctor if you are not sure ) .
H-1361	-0.014357202686369419	It is important that you tell your doctor if you are taking any of the following medicines ( ask your doctor if you are not sure ) .
D-1361	-0.014357202686369419	It is important that you tell your doctor if you are taking any of the following medicines ( ask your doctor if you are not sure ) .
P-1361	-0.0059 -0.0017 -0.0332 -0.0577 -0.0013 -0.0106 -0.0015 -0.0030 -0.0048 -0.0012 -0.0125 -0.0087 -0.1682 -0.0015 -0.0021 -0.0005 -0.0043 -0.0121 -0.0017 -0.0099 -0.0252 -0.0017 -0.0014 -0.0014 -0.0076 -0.0030 -0.0125 -0.0142 -0.0193 -0.0019
S-209	Insulin Human Winthrop Comb 15 100 I.E. / ml Injektionssuspension in einem Fertigpen Insulin human
T-209	Insulin Human Winthrop Comb 15 100 IU / ml suspension for injection in a pre @-@ filled pen Insulin human
H-209	-0.01440148614346981	Insulin Human Winthrop Comb 15 100 IU / ml suspension for injection in a pre @-@ filled pen Insulin human
D-209	-0.01440148614346981	Insulin Human Winthrop Comb 15 100 IU / ml suspension for injection in a pre @-@ filled pen Insulin human
P-209	-0.0184 -0.0004 -0.0007 -0.0036 -0.0007 -0.0002 -0.0011 -0.0012 -0.0011 -0.0014 -0.0014 -0.0010 -0.0144 -0.0015 -0.0007 -0.0144 -0.0149 -0.0041 -0.0028 -0.0077 -0.0026 -0.0142 -0.0015 -0.0113 -0.0086 -0.0035 -0.0014 -0.0007 -0.0017 -0.2948
S-1539	Arixtra 5 mg / 0,4 ml ist in Packungsgrößen zu 2 , 7 , 10 und 20 Fertigspritzen zugelassen .
T-1539	Arixtra 5 mg / 0.4 ml is available in pack sizes of 2 , 7 , 10 and 20 pre @-@ filled syringes .
H-1539	-0.007326097227632999	Arixtra 5 mg / 0.4 ml is available in pack sizes of 2 , 7 , 10 and 20 pre @-@ filled syringes .
D-1539	-0.007326097227632999	Arixtra 5 mg / 0.4 ml is available in pack sizes of 2 , 7 , 10 and 20 pre @-@ filled syringes .
P-1539	-0.0008 -0.0013 -0.0004 -0.0037 -0.0004 -0.0017 -0.0062 -0.0028 -0.0009 -0.0020 -0.0141 -0.0024 -0.0103 -0.0152 -0.0009 -0.0062 -0.0018 -0.0014 -0.0011 -0.0014 -0.0013 -0.1231 -0.0012 -0.0106 -0.0014 -0.0088 -0.0009 -0.0003 -0.0013 -0.0018 -0.0014
S-852	Schwangerschaft ( siehe auch Abschnitte 4.3 und 4.4 ) Lenalidomid ist strukturverwandt zu Thalidomid .
T-852	Pregnancy ( see also sections 4.3 and 4.4 ) Lenalidomide is structurally related to thalidomide .
H-852	-0.00873554591089487	Pregnancy ( see also sections 4.3 and 4.4 ) Lenalidomide is structurally related to thalidomide .
D-852	-0.00873554591089487	Pregnancy ( see also sections 4.3 and 4.4 ) Lenalidomide is structurally related to thalidomide .
P-852	-0.0030 -0.0006 -0.0008 -0.0018 -0.0032 -0.0074 -0.0067 -0.0011 -0.0014 -0.0017 -0.0012 -0.0013 -0.0016 -0.0011 -0.0009 -0.0009 -0.0003 -0.0013 -0.0018 -0.0015 -0.0005 -0.0009 -0.0022 -0.0015 -0.0038 -0.0008 -0.0010 -0.0004 -0.0011 -0.2175 -0.0014
S-62	Der Inhaber der Zulassung verpflichtet sich , die im Pharmakovigilanzplan vorgesehenen Aktivitäten zur Pharmakovigilanz durchzuführen .
T-62	The Marketing Authorisation Holder commits to performing the pharmacovigilance activities detailed in the Pharmacovigilance Plan .
H-62	-0.0034458073787391186	The Marketing Authorisation Holder commits to performing the pharmacovigilance activities detailed in the Pharmacovigilance Plan .
D-62	-0.0034458073787391186	The Marketing Authorisation Holder commits to performing the pharmacovigilance activities detailed in the Pharmacovigilance Plan .
P-62	-0.0031 -0.0146 -0.0004 -0.0070 -0.0015 -0.0018 -0.0008 -0.0131 -0.0006 -0.0055 -0.0141 -0.0040 -0.0038 -0.0008 -0.0003 -0.0009 -0.0013 -0.0014 -0.0148 -0.0018 -0.0018 -0.0045 -0.0003 -0.0009 -0.0009 -0.0002 -0.0010 -0.0011 -0.0011 -0.0019 -0.0014
S-175	Rasilez HCT 150 mg / 25 mg Filmtabletten Aliskiren / Hydrochlorothiazid
T-175	Rasilez HCT 150 mg / 25 mg film @-@ coated tablets Aliskiren / hydrochlorothiazide
H-175	-0.009850962087512016	Rasilez HCT 150 mg / 25 mg film @-@ coated tablets Aliskiren / hydrochlorothiazide
D-175	-0.009850962087512016	Rasilez HCT 150 mg / 25 mg film @-@ coated tablets Aliskiren / hydrochlorothiazide
P-175	-0.0022 -0.0016 -0.0009 -0.0010 -0.0014 -0.0012 -0.0011 -0.0037 -0.0006 -0.0017 -0.0016 -0.1951 -0.0101 -0.0273 -0.0145 -0.0012 -0.0141 -0.0025 -0.0025 -0.0000 -0.0009 -0.0022 -0.0099 -0.0012 -0.0003 -0.0013 -0.0005 -0.0019 -0.0001 -0.0011 -0.0017
S-855	Die Impfung kann bei dem Tier eine leichte Erhöhung der Körpertemperatur verursachen ( weniger als 1,5 ° C während höchstens 24 Stunden ) .
T-855	Vaccination may cause a slight rise in the animal <<unk>> s body temperature ( less than 1.5 ° C during a maximum period of 24 hours ) .
H-855	-0.005475816782563925	Vaccination may cause a slight rise in the animal <unk> s body temperature ( less than 1.5 ° C during a maximum period of 24 hours ) .
D-855	-0.005475816782563925	Vaccination may cause a slight rise in the animal <unk> s body temperature ( less than 1.5 ° C during a maximum period of 24 hours ) .
P-855	-0.0103 -0.0003 -0.0017 -0.0133 -0.0047 -0.0071 -0.0024 -0.0124 -0.0038 -0.0057 -0.0082 -0.0151 -0.0081 -0.0036 -0.0012 -0.0018 -0.0043 -0.0014 -0.0019 -0.0016 -0.0013 -0.0152 -0.0095 -0.0024 -0.0136 -0.0114 -0.0014 -0.0015 -0.0015 -0.0017 -0.0014
S-905	Umgekehrt kann aufgrund des Aliskiren @-@ Anteils in Rasilez HCT eine Hyperkaliämie auftreten .
T-905	Conversely , due to the aliskiren component of Rasilez HCT , hyperkalaemia might occur .
H-905	-0.004706527106463909	Conversely , due to the aliskiren component of Rasilez HCT , hyperkalaemia might occur .
D-905	-0.004706527106463909	Conversely , due to the aliskiren component of Rasilez HCT , hyperkalaemia might occur .
P-905	-0.0071 -0.0010 -0.0008 -0.0028 -0.0115 -0.0014 -0.0032 -0.0144 -0.0145 -0.0023 -0.0011 -0.0130 -0.0011 -0.0141 -0.0028 -0.0011 -0.0009 -0.0010 -0.0013 -0.0013 -0.0011 -0.0052 -0.0029 -0.0019 -0.0126 -0.0004 -0.0013 -0.0166 -0.0042 -0.0016 -0.0014
S-761	Bei Mäusen , die vor oder zum Zeitpunkt der Schließung des harten Gaumens Azacitidin erhielten , wurden Hirnentwicklungsstörungen festgestellt .
T-761	Developmental abnormalities in the brain have been detected in mice given azacitidine on or before closure of the hard palate .
H-761	-0.00908043421804905	Developmental abnormalities in the brain have been detected in mice given azacitidine on or before closure of the hard palate .
D-761	-0.00908043421804905	Developmental abnormalities in the brain have been detected in mice given azacitidine on or before closure of the hard palate .
P-761	-0.0145 -0.0008 -0.0143 -0.0010 -0.0002 -0.0012 -0.0128 -0.0190 -0.0072 -0.0155 -0.0013 -0.1116 -0.0010 -0.0017 -0.0092 -0.0009 -0.0135 -0.0009 -0.0029 -0.0020 -0.0048 -0.0187 -0.0069 -0.0030 -0.0127 -0.0018 -0.0025 -0.0020 -0.0030 -0.0008 -0.0015 -0.0014
S-257	- Die sonstigen Bestandteile sind Trometamol , Natriumchlorid , Natriumhydroxid ( zur Einstellung
T-257	- The other ingredients are trometamol , sodium chloride , sodium hydroxide ( for pH adjustment ) ,
H-257	-0.014249395579099655	- The other ingredients are trometamol , sodium chloride , sodium hydroxide ( for pH adjustment ) ,
D-257	-0.014249395579099655	- The other ingredients are trometamol , sodium chloride , sodium hydroxide ( for pH adjustment ) ,
P-257	-0.0035 -0.0084 -0.0025 -0.0098 -0.0026 -0.0108 -0.0021 -0.0011 -0.0020 -0.0015 -0.0011 -0.0006 -0.0014 -0.0009 -0.0010 -0.0011 -0.0023 -0.0013 -0.0005 -0.0007 -0.0007 -0.0011 -0.0022 -0.0087 -0.0145 -0.0133 -0.0105 -0.0008 -0.0018 -0.0130 -0.3280 -0.0060
S-1862	Der Wirkstoff in MabCampath , Alemtuzumab , ist ein monoklonaler Antikörper .
T-1862	Reproduction is authorised provided the source is acknowledged. sugar molecules ) called CD52 that is found on the surface of lymphocytes .
H-1862	-0.011688354425132275	Reproduction is authorised provided the source is acknowledged. sugar molecules ) called CD52 that is found on the surface of lymphocytes .
D-1862	-0.011688354425132275	Reproduction is authorised provided the source is acknowledged. sugar molecules ) called CD52 that is found on the surface of lymphocytes .
P-1862	-0.0145 -0.0145 -0.0138 -0.0145 -0.0020 -0.0145 -0.0131 -0.0145 -0.0136 -0.0145 -0.0144 -0.0145 -0.0145 -0.0144 -0.0009 -0.0116 -0.0146 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0141 -0.0156 -0.0122 -0.0143 -0.0031 -0.0167 -0.0095 -0.0011 -0.0023 -0.0086 -0.0014
S-618	Diese Zellen spielen bei der Erkennung von &quot; fremden &quot; Zellen und der Abstoßung von transplantierten Organen eine wichtige Rolle .
T-618	Both studies compared the effects of adding Zenapax or placebo ( a dummy treatment ) to other immunosuppressive medicines .
H-618	-0.010994039475917816	Both studies compared the effects of adding Zenapax or placebo ( a dummy treatment ) to other immunosuppressive medicines .
D-618	-0.010994039475917816	Both studies compared the effects of adding Zenapax or placebo ( a dummy treatment ) to other immunosuppressive medicines .
P-618	-0.0230 -0.0145 -0.0145 -0.0104 -0.0143 -0.0026 -0.0145 -0.0145 -0.0145 -0.0145 -0.0349 -0.0145 -0.0087 -0.0001 -0.0015 -0.0196 -0.0140 -0.0145 -0.0031 -0.0144 -0.0066 -0.0079 -0.0143 -0.0145 -0.0127 -0.0016 -0.0000 -0.0017 -0.0075 -0.0142 -0.0091 -0.0088 -0.0015
S-1580	Dagegen gibt es bei den Ergebnissen aus verschiedenen Studien ( HOPE , EUROPA , PEACE und PART 2 ) Unterschiede .
T-1580	There are differences , however , in the results obtained from various trials ( HOPE , EUROPA , PEACE , and PART 2 ) .
H-1580	-0.013694170862436295	There are differences , however , in the results obtained from various trials ( HOPE , EUROPA , PEACE , and PART 2 ) .
D-1580	-0.013694170862436295	There are differences , however , in the results obtained from various trials ( HOPE , EUROPA , PEACE , and PART 2 ) .
P-1580	-0.0130 -0.0116 -0.0066 -0.0152 -0.0065 -0.0014 -0.0096 -0.0031 -0.0037 -0.0119 -0.0139 -0.0098 -0.0157 -0.0021 -0.0011 -0.0006 -0.0015 -0.0017 -0.0011 -0.0085 -0.0014 -0.0013 -0.0014 -0.0009 -0.0011 -0.2079 -0.0120 -0.0030 -0.0013 -0.0787 -0.0015 -0.0015 -0.0014
S-1479	14 Eine tägliche Anpassung der BYETTA @-@ Dosis an den vom Patienten selbst gemessenen Blutzuckerspiegel ist nicht erforderlich .
T-1479	The dose of BYETTA does not need to be adjusted on a day @-@ by @-@ day basis depending on self- monitored glycaemia .
H-1479	-0.02449735626578331	The dose of BYETTA does not need to be adjusted on a day @-@ by @-@ day basis depending on self- monitored glycaemia .
D-1479	-0.02449735626578331	The dose of BYETTA does not need to be adjusted on a day @-@ by @-@ day basis depending on self- monitored glycaemia .
P-1479	-0.0356 -0.0132 -0.0024 -0.0016 -0.0012 -0.0007 -0.0003 -0.0127 -0.0015 -0.0093 -0.0022 -0.0012 -0.0045 -0.0136 -0.0013 -0.0143 -0.0045 -0.0125 -0.0014 -0.0013 -0.0007 -0.0146 -0.2534 -0.0145 -0.0017 -0.0035 -0.0145 -0.0012 -0.0148 -0.0010 -0.0116 -0.3758 -0.0013 -0.0121 -0.0014
S-1695	Kinder und Jugendliche ( unter 18 Jahren ) Die Anwendung von Lucentis wurde bei Kindern und Jugendlichen nicht untersucht und wird deshalb nicht empfohlen .
T-1695	22 Children and adolescents ( below 18 years of age ) The use of Lucentis in children and adolescents has not been studied and is therefore not recommended .
H-1695	-0.015868181362748146	22 Children and adolescents ( below 18 years of age ) The use of Lucentis in children and adolescents has not been studied and is therefore not recommended .
D-1695	-0.015868181362748146	22 Children and adolescents ( below 18 years of age ) The use of Lucentis in children and adolescents has not been studied and is therefore not recommended .
P-1695	-0.0145 -0.0149 -0.0039 -0.0065 -0.0008 -0.0008 -0.0031 -0.0144 -0.1239 -0.0274 -0.1746 -0.0011 -0.0014 -0.0067 -0.0035 -0.0014 -0.0018 -0.0015 -0.0004 -0.0013 -0.0169 -0.0283 -0.0024 -0.0032 -0.0009 -0.0009 -0.0116 -0.0016 -0.0014 -0.0916 -0.0053 -0.0039 -0.0093 -0.0014 -0.0014 -0.0017 -0.0015
S-791	Dennoch ist es wichtig , Ihren Arzt davon in Kenntnis zu setzen , dass Sie diese Arzneimittel einnehmen , bevor Sie Xolair erhalten .
T-791	Taking other medicines Xolair can be used together with inhaled corticosteroids and other medicines for allergic asthma , but it is still important to tell your doctor that you are taking them before you are given Xolair .
H-791	-0.08952219039201736	Taking other medicines Xolair can be used together with inhaled corticosteroids for allergic asthma , but it is still important to tell your doctor that you are taking them before you are given Xolair .
D-791	-0.08952219039201736	Taking other medicines Xolair can be used together with inhaled corticosteroids for allergic asthma , but it is still important to tell your doctor that you are taking them before you are given Xolair .
P-791	-0.0147 -0.0145 -0.0036 -0.0054 -0.0145 -0.0010 -0.0011 -0.0129 -0.0126 -0.0130 -0.0153 -0.0034 -0.0145 -0.0111 -0.0145 -0.0018 -0.0055 -0.0000 -0.0144 -0.0003 -3.8505 -0.0146 -0.0088 -0.0144 -0.0018 -0.0004 -0.0131 -0.0116 -0.0025 -0.0022 -0.1321 -0.0770 -0.0876 -0.0104 -0.0014 -0.0022 -0.0067 -0.0013 -0.0028 -0.0052 -0.0150 -0.0049 -0.0090 -0.0140 -0.0072 -0.0009 -0.0008 -0.0007 -0.0015 -0.0014
S-1837	Da keine Daten zur Wirksamkeit und Sicherheit vorliegen , sollte das Präparat bei Kindern nicht angewendet werden ( siehe unter Abschnitt 4.3 ) .
T-1837	Therefore , safety and efficacy have not been established and the product should not be used in children ( see section 4.3 ) .
H-1837	-0.0150527972728014	Therefore , safety and efficacy have not been established and the product should not be used in children ( see section 4.3 ) .
D-1837	-0.0150527972728014	Therefore , safety and efficacy have not been established and the product should not be used in children ( see section 4.3 ) .
P-1837	-0.0268 -0.0009 -0.0066 -0.0145 -0.0044 -0.0050 -0.0006 -0.0009 -0.0145 -0.0029 -0.0016 -0.0109 -0.0103 -0.0089 -0.0108 -0.0140 -0.0017 -0.0016 -0.0829 -0.1939 -0.0015 -0.0023 -0.0020 -0.0080 -0.0012 -0.0014 -0.0038 -0.0016 -0.0014
S-921	Weder eine Zunahme in der Häufigkeit noch in der Schwere dieser unerwünschten Wirkungen wurde mit zunehmender Anzahl der verabreichten Impfdosen beobachtet .
T-921	No increase in the incidence or severity of these undesirable events was seen with subsequent doses of the primary vaccination schedule .
H-921	-0.015329125337302685	No increase in the incidence or severity of these undesirable events was seen with subsequent doses of the primary vaccination schedule .
D-921	-0.015329125337302685	No increase in the incidence or severity of these undesirable events was seen with subsequent doses of the primary vaccination schedule .
P-921	-0.0123 -0.0020 -0.0026 -0.0080 -0.0173 -0.0010 -0.1133 -0.0020 -0.0012 -0.0014 -0.0041 -0.0134 -0.0140 -0.0018 -0.0211 -0.0045 -0.1075 -0.0058 -0.0145 -0.0098 -0.0013 -0.0054 -0.0196 -0.0145 -0.0126 -0.0137 -0.0145 -0.0039 -0.0014
S-1774	Vor dem Mischen mit dem Lösungsmittel liegt das Impfstoff @-@ Pulver als weißer bis blassgelber kompakter kristalliner Kuchen vor .
T-1774	Before mixing with the solvent , the powder vaccine is a white to pale yellow compact crystalline cake .
H-1774	-0.005957486107945442	Before mixing with the solvent , the powder vaccine is a white to pale yellow compact crystalline cake .
D-1774	-0.005957486107945442	Before mixing with the solvent , the powder vaccine is a white to pale yellow compact crystalline cake .
P-1774	-0.0060 -0.0031 -0.0006 -0.0051 -0.0022 -0.0016 -0.0008 -0.0052 -0.0022 -0.0157 -0.0140 -0.0043 -0.0137 -0.0065 -0.0066 -0.0022 -0.0005 -0.0015 -0.0026 -0.0006 -0.0023 -0.0006 -0.0008 -0.0013 -0.0006 -0.0587 -0.0014
S-867	Tritt eine derartige Reaktion während der Behandlung mit PegIntron auf , ist die Behandlung sofort abzusetzen und es sind geeignete therapeutische Maßnahmen zu ergreifen .
T-867	If such a reaction develops during treatment with PegIntron , discontinue treatment and institute appropriate medical therapy immediately .
H-867	-0.008943754248321056	If such a reaction develops during treatment with PegIntron , discontinue treatment and institute appropriate medical therapy immediately .
D-867	-0.008943754248321056	If such a reaction develops during treatment with PegIntron , discontinue treatment and institute appropriate medical therapy immediately .
P-867	-0.0150 -0.0149 -0.0022 -0.0022 -0.0151 -0.0013 -0.0131 -0.0111 -0.0019 -0.0021 -0.0012 -0.0015 -0.0005 -0.0012 -0.0025 -0.0409 -0.0092 -0.0104 -0.0242 -0.0145 -0.0074 -0.0032 -0.0141 -0.0144 -0.0144 -0.0017 -0.0015
S-426	Die abrupte Beendigung einer Behandlung mit Stalevo wie auch anderen Antiparkinson @-@ Arzneimitteln kann zum Auftreten unerwünschter Nebenwirkungen führen .
T-426	Abrupt discontinuation of Stalevo and other antiparkinsonian medicines may result in unwanted side effects .
H-426	-0.01959543488919735	Abrupt discontinuation of Stalevo and other antiparkinsonian medicines may result in unwanted side effects .
D-426	-0.01959543488919735	Abrupt discontinuation of Stalevo and other antiparkinsonian medicines may result in unwanted side effects .
P-426	-0.0096 -0.0027 -0.0128 -0.0009 -0.0016 -0.0015 -0.0139 -0.0008 -0.0011 -0.0104 -0.0034 -0.0087 -0.0062 -0.0134 -0.0005 -0.0140 -0.0191 -0.2420 -0.0862 -0.0327 -0.0015 -0.0107 -0.0128 -0.0164 -0.0030 -0.0016 -0.0014
S-888	Aus dieser Studie geht ebenfalls hervor , dass Zavesca keine oder nur eine begrenzte Auswirkung auf die Pharmakokinetik von Cerezyme hat .
T-888	This study also indicated that Zavesca has no or limited effect on the pharmacokinetics of Cerezyme .
H-888	-0.0036081576254218817	This study also indicated that Zavesca has no or limited effect on the pharmacokinetics of Cerezyme .
D-888	-0.0036081576254218817	This study also indicated that Zavesca has no or limited effect on the pharmacokinetics of Cerezyme .
P-888	-0.0088 -0.0026 -0.0026 -0.0142 -0.0020 -0.0016 -0.0008 -0.0011 -0.0007 -0.0086 -0.0083 -0.0045 -0.0087 -0.0092 -0.0018 -0.0062 -0.0007 -0.0008 -0.0007 -0.0014 -0.0019 -0.0039 -0.0006 -0.0008 -0.0007 -0.0028 -0.0015
S-505	Braunglasflasche ( hydrolytische Klasse III ) mit kindergesichertem Verschluß , Steigrohr und selbstzentrierendem Stopfen .
T-505	Type III amber glass bottle with a child @-@ resistant cap , dip tube and self aligning plug .
H-505	-0.007496018894016743	Type III amber glass bottle with a child @-@ resistant cap , dip tube and self aligning plug .
D-505	-0.007496018894016743	Type III amber glass bottle with a child @-@ resistant cap , dip tube and self aligning plug .
P-505	-0.0145 -0.0019 -0.0032 -0.0006 -0.0031 -0.0036 -0.0110 -0.0195 -0.0080 -0.0052 -0.0122 -0.0007 -0.0097 -0.0022 -0.0145 -0.0048 -0.0365 -0.0023 -0.0147 -0.0011 -0.0014 -0.0119 -0.0009 -0.0022 -0.0015
S-256	Die empfohlene Anfangsdosierung beträgt einmal täglich 4 Kapseln Lansoprazol AbZ 15 mg ( entsprechend 60 mg Lansoprazol ) .
T-256	The recommended initial dosage is 4 capsules once daily ( equivalent to 60 mg lansoprazole ) .
H-256	-0.02833469584584236	The recommended initial dosage is 4 capsules once daily ( equivalent to 60 mg lansoprazole ) .
D-256	-0.02833469584584236	The recommended initial dosage is 4 capsules once daily ( equivalent to 60 mg lansoprazole ) .
P-256	-0.0040 -0.0016 -0.2583 -0.0579 -0.0006 -0.0012 -0.0032 -0.0049 -0.0029 -0.0006 -0.0012 -0.0164 -0.3093 -0.0159 -0.0060 -0.0017 -0.0019 -0.0011 -0.0085 -0.0002 -0.0004 -0.0002 -0.0018 -0.0073 -0.0015
S-1643	Da in den Studien nur wenige Patienten über 75 Jahre und Asiaten / Orientalen vertreten waren , können für diese Patientengruppen keine definitiven Aussagen gemacht werden .
T-1643	No conclusions can be drawn with regard to effects in patients over 75 years or in Asian / Oriental patients lp
H-1643	-0.011306856758892536	No conclusions can be drawn with regard to effects in patients over 75 years or in Asian / Oriental patients lp
D-1643	-0.011306856758892536	No conclusions can be drawn with regard to effects in patients over 75 years or in Asian / Oriental patients lp
P-1643	-0.0212 -0.0125 -0.0161 -0.0046 -0.0014 -0.0112 -0.0142 -0.0112 -0.0014 -0.0197 -0.0136 -0.0183 -0.0088 -0.0051 -0.0062 -0.0277 -0.0131 -0.0083 -0.0052 -0.0060 -0.0008 -0.0129 -0.0145 -0.0145 -0.0143
S-137	Die Herstellerfirma von Galvus hat ihre Zustimmung dazu gegeben , dass die wissenschaftlichen Daten zu Galvus auch für Jalra herangezogen werden können .
T-137	The company that makes Galvus has agreed that its scientific data can be used for Jalra .
H-137	-0.007156184408813715	The company that makes Galvus has agreed that its scientific data can be used for Jalra .
D-137	-0.007156184408813715	The company that makes Galvus has agreed that its scientific data can be used for Jalra .
P-137	-0.0051 -0.0138 -0.0105 -0.0131 -0.0024 -0.0011 -0.0013 -0.0055 -0.0131 -0.0060 -0.0143 -0.0019 -0.0022 -0.0082 -0.0230 -0.0049 -0.0086 -0.0035 -0.0012 -0.0012 -0.0120 -0.0046
S-1819	Beim Menschen kann die Anwendung von Tigecyclin während des Zahnwachstums zu einer dauerhaften Zahnverfärbung führen ( siehe Abschnitt 4.8 ) .
T-1819	Tigecycline may be associated with permanent tooth discolouration in humans if used during tooth development ( see section 4.8 ) .
H-1819	-0.005703524220734835	Tigecycline may be associated with permanent tooth discolouration in humans if used during tooth development ( see section 4.8 ) .
D-1819	-0.005703524220734835	Tigecycline may be associated with permanent tooth discolouration in humans if used during tooth development ( see section 4.8 ) .
P-1819	-0.0144 -0.0009 -0.0010 -0.0023 -0.0089 -0.0121 -0.0122 -0.0145 -0.0018 -0.0044 -0.0120 -0.0005 -0.0030 -0.0085 -0.0019 -0.0012 -0.0056 -0.0058 -0.0181 -0.0105 -0.0044 -0.0053 -0.0009 -0.0144 -0.0021 -0.0021 -0.0066 -0.0012 -0.0013 -0.0019 -0.0015 -0.0014
S-1645	Fügen Sie die hergestellte Remicade @-@ Lösung langsam zu der 250 @-@ ml @-@ Infusionsflasche oder dem Infusionsbeutel hinzu .
T-1645	Slowly add the total volume of reconstituted Remicade solution to the 250 @-@ ml infusion bottle or bag .
H-1645	-0.03551366552710533	Slowly add the total volume of reconstituted Remicade solution to the 250 @-@ ml infusion bottle or bag .
D-1645	-0.03551366552710533	Slowly add the total volume of reconstituted Remicade solution to the 250 @-@ ml infusion bottle or bag .
P-1645	-0.0018 -0.0009 -0.0014 -0.0035 -0.0148 -0.0145 -0.0033 -0.0149 -0.0131 -0.0014 -0.0061 -0.0004 -0.0006 -0.0084 -0.0065 -0.0037 -0.0055 -0.4929 -0.0177 -0.0109 -0.0014 -0.0025 -0.2805 -0.0134 -0.0020 -0.0015
S-487	Eine retrograde transsynaptische Passage des aktiven Botulinum Neurotoxins Typ A in das zentrale Nervensystem wurde dagegen nicht gefunden .
T-487	Retrograde transsynaptic passage of active Botulinum neurotoxin type A into the central nervous system however has not been found .
H-487	-0.004136753734201193	Retrograde transsynaptic passage of active Botulinum neurotoxin type A into the central nervous system however has not been found .
D-487	-0.004136753734201193	Retrograde transsynaptic passage of active Botulinum neurotoxin type A into the central nervous system however has not been found .
P-487	-0.0141 -0.0025 -0.0005 -0.0056 -0.0011 -0.0007 -0.0008 -0.0035 -0.0017 -0.0138 -0.0127 -0.0008 -0.0015 -0.0010 -0.0042 -0.0004 -0.0011 -0.0014 -0.0040 -0.0014 -0.0042 -0.0023 -0.0019 -0.0005 -0.0013 -0.0167 -0.0138 -0.0020 -0.0015 -0.0123 -0.0016 -0.0014
S-147	Aripiprazol und andere antipsychotischen Arzneimittel sollten mit Vorsicht bei Patienten mit einem Risiko für Aspirationspneumonie angewendet werden ,
T-147	Aripiprazole and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia .
H-147	-0.018215356394648552	Aripiprazole and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia .
D-147	-0.018215356394648552	Aripiprazole and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia .
P-147	-0.0016 -0.0010 -0.0028 -0.0006 -0.0001 -0.0016 -0.0015 -0.0070 -0.0010 -0.0007 -0.0008 -0.0415 -0.0014 -0.0016 -0.0181 -0.1300 -0.0009 -0.0010 -0.0037 -0.0016 -0.0134 -0.0011 -0.1974 -0.0019 -0.0034 -0.0025 -0.0010 -0.0007 -0.0003 -0.1230 -0.0015
S-1023	Zalasta 7,5 mg Tabletten sind in Packungen mit 14 , 28 , 35 , 56 und 70 Tabletten in Blisterpackungen erhältlich .
T-1023	Zalasta 7.5 mg tablets : available in boxes of 14 , 28 , 35 , 56 and 70 tablets in blister packs .
H-1023	-0.02229064516723156	Zalasta 7.5 mg tablets : available in boxes of 14 , 28 , 35 , 56 and 70 tablets in blister packs .
D-1023	-0.02229064516723156	Zalasta 7.5 mg tablets : available in boxes of 14 , 28 , 35 , 56 and 70 tablets in blister packs .
P-1023	-0.0024 -0.0011 -0.0008 -0.0015 -0.0050 -0.0007 -0.0057 -0.0018 -0.0190 -0.0115 -0.0015 -0.0152 -0.0229 -0.0013 -0.0014 -0.0010 -0.0014 -0.0491 -0.0014 -0.0008 -0.2041 -0.0010 -0.0067 -0.0014 -0.0047 -0.0014 -0.3160 -0.0051 -0.0007 -0.0028 -0.0016
S-395	Wenn Sie an dieser Krankheit leiden , sollten Sie sich an Ihren Arzt wenden . • Myasthenia gravis ( eine besondere Art von Muskelschwäche ) .
T-395	If you suffer from this disease , you should consult your doctor . • myastenia gravis ( a particular type of muscle weakness ) .
H-395	-0.017078634351491928	If you suffer from this disease , you should consult your doctor . • myastenia gravis ( a particular type of muscle weakness ) .
D-395	-0.017078634351491928	If you suffer from this disease , you should consult your doctor . • myastenia gravis ( a particular type of muscle weakness ) .
P-395	-0.0086 -0.0013 -0.2281 -0.0019 -0.0023 -0.0069 -0.0050 -0.0090 -0.0022 -0.0102 -0.0006 -0.0029 -0.0023 -0.0026 -0.0009 -0.0145 -0.2003 -0.0016 -0.0007 -0.0010 -0.0004 -0.0015 -0.0021 -0.0088 -0.0043 -0.0014 -0.0022 -0.0008 -0.0015 -0.0020 -0.0015
S-1278	Die Durchführung des zentralen EudraVigilance @-@ Projekts hat nach erfolgreichen Tests bei den zuständigen nationalen Behörden und einer Reihe von Genehmigungsinhabern begonnen .
T-1278	the context of biological threats , the success of the implementation of the legislation on orphan drugs or the development of the scientific advice procedure .
H-1278	-0.019353065639734268	the context of biological threats , the success of the implementation of the legislation on orphan drugs or the development of the scientific advice procedure .
D-1278	-0.019353065639734268	the context of biological threats , the success of the implementation of the legislation on orphan drugs or the development of the scientific advice procedure .
P-1278	-0.0145 -0.1136 -0.0053 -0.0149 -0.0134 -0.0145 -0.0129 -0.0107 -0.1419 -0.0029 -0.0070 -0.0158 -0.0019 -0.0054 -0.0147 -0.0230 -0.0145 -0.0106 -0.0099 -0.0143 -0.0193 -0.0120 -0.0142 -0.0018 -0.0134 -0.0145 -0.0145 -0.0145 -0.0132 -0.0016
S-1161	Daher sollte Ciprofloxacin bei Patienten mit Erkrankungen des zentralen Nervensystems , die für Krampfanfälle prädisponieren , mit Vorsicht angewendet werden .
T-1161	Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure .
H-1161	-0.02539796195924282	Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure .
D-1161	-0.02539796195924282	Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure .
P-1161	-0.0140 -0.0002 -0.0009 -0.0011 -0.0009 -0.0013 -0.0059 -0.0133 -0.0131 -0.0603 -0.0050 -0.0038 -0.0040 -0.3638 -0.0145 -0.0017 -0.0113 -0.0009 -0.0129 -0.0141 -0.0091 -0.0059 -0.0003 -0.0011 -0.0023 -0.0009 -0.1926 -0.0021 -0.0033 -0.0015
S-1891	Sie dürfen das Arzneimittel nach dem auf der Flasche und dem Umkarton nach { Verwendbar bis } angegebenen Verfalldatum nicht mehr anwenden .
T-1891	Do not use Emtriva after the expiry date which is stated on the bottle and outer carton after { EXP } .
H-1891	-0.016977472230792046	Do not use Emtriva after the expiry date which is stated on the bottle and outer carton after { EXP } .
D-1891	-0.016977472230792046	Do not use Emtriva after the expiry date which is stated on the bottle and outer carton after { EXP } .
P-1891	-0.0141 -0.0015 -0.0033 -0.0145 -0.0145 -0.0146 -0.0082 -0.0026 -0.0020 -0.0076 -0.0019 -0.2784 -0.0056 -0.0118 -0.0018 -0.0020 -0.0012 -0.0168 -0.0148 -0.0010 -0.0099 -0.0016 -0.0131 -0.0021 -0.0145 -0.0144 -0.0144 -0.0025 -0.0015
S-1300	5,00 % 4,50 % 4,00 % 3,50 % 3,00 % 2,50 % 2,00 % 1,50 % 1,00 % 0,50 % 0,00 %
T-1300	5.0 % 4.5 % 4.0 % 3.5 % 3.0 % 2.5 % 2.0 % 1.5 % 1.0 % 0.5 % 0 %
H-1300	-0.25364571809768677	5.0 % 4.5 % 4.0 % 3.5 % 3.0 % 2.5 % 2.0 % 1.5 % 1.0 % 0.5 % 0 %
D-1300	-0.25364571809768677	5.0 % 4.5 % 4.0 % 3.5 % 3.0 % 2.5 % 2.0 % 1.5 % 1.0 % 0.5 % 0 %
P-1300	-0.0146 -0.1741 -0.0025 -0.0170 -0.8624 -0.0018 -0.4391 -0.7370 -0.0015 -0.3949 -0.0019 -0.4686 -0.0566 -0.0013 -0.6693 -0.0014 -0.5721 -0.0013 -0.3854 -0.0013 -0.4907 -0.0024 -0.0014 -0.7053 -0.0013 -0.7619 -0.0020 -0.3331
S-1238	August 2002 erteilte die Europäische Kommission dem Unternehmen Orion Corporation eine Genehmigung für das Inverkehrbringen von DEXDOMITOR in der gesamten Europäischen Union .
T-1238	The European Commission granted a marketing authorisation valid throughout the European Union for DEXDOMITOR on 30 August 2002 .
H-1238	-0.055779460817575455	The European Commission granted a marketing authorisation valid throughout the EU for DEXDOMITOR on 30 August 2002 .
D-1238	-0.055779460817575455	The European Commission granted a marketing authorisation valid throughout the EU for DEXDOMITOR on 30 August 2002 .
P-1238	-0.0136 -0.0041 -0.0012 -0.0127 -0.0132 -0.0041 -0.0033 -0.0009 -0.0145 -0.0020 -0.0103 -0.0019 -0.7531 -0.0099 -0.0040 -0.0009 -0.0012 -0.0013 -0.0010 -0.0014 -0.0008 -0.1681 -0.0186 -0.4325 -0.0188 -0.0115 -0.0014
S-986	Amlodipin Amlodipin wird nach oraler Verabreichung langsam und fast vollständig aus dem Magen @-@ Darm @-@ Trakt resorbiert .
T-986	19 Amlodipine is slowly and almost completely absorbed from the gastrointestinal tract following oral administration .
H-986	-0.007897059433162212	19 Amlodipine is slowly and almost completely absorbed from the gastrointestinal tract following oral administration .
D-986	-0.007897059433162212	19 Amlodipine is slowly and almost completely absorbed from the gastrointestinal tract following oral administration .
P-986	-0.0146 -0.0145 -0.0009 -0.0011 -0.0021 -0.0010 -0.0147 -0.0072 -0.0023 -0.0026 -0.0064 -0.0035 -0.0009 -0.0057 -0.0016 -0.0021 -0.0012 -0.0003 -0.0007 -0.0008 -0.0443 -0.0007 -0.0779 -0.0010 -0.0015 -0.0021 -0.0015
S-153	Der Insulinspiegel kehrt innerhalb von 3- 4 Stunden zum Ausgangswert zurück und verringert dabei nach der Mahlzeit die Hyperinsulinämie .
T-153	Insulin levels return to baseline within 3 to 4 hours , reducing post @-@ meal hyperinsulinaemia .
H-153	-0.027682894840836525	Insulin levels return to baseline within 3 to 4 hours , reducing post @-@ meal hyperinsulinaemia .
D-153	-0.027682894840836525	Insulin levels return to baseline within 3 to 4 hours , reducing post @-@ meal hyperinsulinaemia .
P-153	-0.0090 -0.0005 -0.0005 -0.0018 -0.0060 -0.0018 -0.0040 -0.0016 -0.0077 -0.0141 -0.6085 -0.0014 -0.0013 -0.0077 -0.0098 -0.0135 -0.0017 -0.0021 -0.0020 -0.0004 -0.0048 -0.0143 -0.0006 -0.0012 -0.0020 -0.0014
S-1840	In Studie VI waren die ACR @-@ Ansprechraten in Kombination mit Methotrexat und ohne Methotrexat- Begleittherapie ähnlich .
T-1840	N / A not applicable
H-1840	-0.011314447037875652	N / A not applicable
D-1840	-0.011314447037875652	N / A not applicable
P-1840	-0.0148 -0.0140 -0.0058 -0.0145 -0.0145 -0.0012 -0.0145
S-1745	Die Dauer vom Beginn der Gabe von Sugammadex oder Neostigmin bis zur Erholung des T4 / T1 Verhältnisses auf 0,9 betrug :
T-1745	The time from start of administration of sugammadex or neostigmine to recovery of the T4 / T1 ratio to 0.9 was :
H-1745	-0.005989182274788618	The time from start of administration of sugammadex or neostigmine to recovery of the T4 / T1 ratio to 0.9 was :
D-1745	-0.005989182274788618	The time from start of administration of sugammadex or neostigmine to recovery of the T4 / T1 ratio to 0.9 was :
P-1745	-0.0049 -0.0124 -0.0088 -0.0136 -0.0022 -0.0076 -0.0021 -0.0145 -0.0140 -0.0111 -0.0006 -0.0393 -0.0015 -0.0023 -0.0006 -0.0034 -0.0056 -0.0032 -0.0022 -0.0070 -0.0036 -0.0012 -0.0019 -0.0012 -0.0014 -0.0027 -0.0122 -0.0027 -0.0012 -0.0030 -0.0022 -0.0014
S-865	April 2004 erteilte die Europäische Kommission dem Unternehmen SBL Vaccin AB eine Genehmigung für das Inverkehrbringen von Dukoral in der gesamten Europäischen Union .
T-865	The European Commission granted a marketing authorisation valid throughout the European Union for Dukoral to SBL Vaccin AB on 28 April 2004 .
H-865	-0.05121767520904541	The European Commission granted a marketing authorisation valid throughout the European Union for Dukoral to SBL Vaccin AB on 28 April 2004 .
D-865	-0.05121767520904541	The European Commission granted a marketing authorisation valid throughout the European Union for Dukoral to SBL Vaccin AB on 28 April 2004 .
P-865	-0.0139 -0.0043 -0.0013 -0.0128 -0.0135 -0.0062 -0.0031 -0.0009 -0.0145 -0.0024 -0.0113 -0.0018 -0.7369 -0.0018 -0.0111 -0.0040 -0.0004 -0.0015 -0.0167 -0.0081 -0.0014 -0.0012 -0.0013 -0.0008 -0.0014 -0.0004 -0.0120 -0.0738 -0.6551 -0.0220 -0.0018 -0.0014
S-231	217 Glucosegehalt Ciprofloxacin Bayer Infusionslösung enthält 10 g Glucose in 200 ml Infusionslösung .
T-231	Glucose Load Ciprofloxacin Bayer solution for infusion contains 10 g glucose in 200 mL solution for infusion .
H-231	-0.04973649978637695	Glucose Load Ciprofloxacin Bayer solution for infusion contains 10 g glucose in 200 ml solution for infusion .
D-231	-0.04973649978637695	Glucose Load Ciprofloxacin Bayer solution for infusion contains 10 g glucose in 200 ml solution for infusion .
P-231	-0.0145 -0.0009 -0.0010 -0.0015 -0.0145 -0.0141 -0.0143 -0.0002 -0.0010 -0.0011 -0.0010 -0.0013 -0.0012 -0.0142 -0.0459 -0.0104 -0.0025 -0.0082 -0.0032 -0.0032 -0.0058 -0.0010 -0.0008 -0.0022 -0.0011 -1.3907 -0.0102 -0.0168 -0.0042 -0.0009 -0.0025 -0.0014
S-1562	Deshalb sollte vor einer Verordnung von Tadalafil Lilly der verschreibende Arzt eine sorgfältige , individuelle Nutzen @-@ Risiko Abwägung durchführen :
T-1562	If Tadalafil Lilly is prescribed , a careful individual benefit / risk evaluation should be undertaken by the prescribing physician .
H-1562	-0.005992392543703318	If Tadalafil Lilly is prescribed , a careful individual benefit / risk evaluation should be undertaken by the prescribing physician .
D-1562	-0.005992392543703318	If Tadalafil Lilly is prescribed , a careful individual benefit / risk evaluation should be undertaken by the prescribing physician .
P-1562	-0.0147 -0.0142 -0.0013 -0.0010 -0.0007 -0.0011 -0.0106 -0.0011 -0.0050 -0.0029 -0.0009 -0.0078 -0.0136 -0.0151 -0.0124 -0.0059 -0.0119 -0.0010 -0.0142 -0.0009 -0.0007 -0.0041 -0.0050 -0.0141 -0.0006 -0.0036 -0.0042 -0.0010 -0.0086 -0.0027 -0.0006 -0.0130 -0.0032
S-1048	EU / 2 / 08 / 082 / 001 EU / 2 / 08 / 082 / 002 EU / 2 / 08 / 082 / 003
T-1048	EU / 2 / 08 / 082 / 001 EU / 2 / 08 / 082 / 002 EU / 2 / 08 / 082 / 003
H-1048	-0.010951387695968151	EU / 2 / 08 / 082 / 001 EU / 2 / 08 / 082 / 002 EU / 2 / 08 / 082 / 003
D-1048	-0.010951387695968151	EU / 2 / 08 / 082 / 001 EU / 2 / 08 / 082 / 002 EU / 2 / 08 / 082 / 003
P-1048	-0.0015 -0.0015 -0.0016 -0.0015 -0.0013 -0.0014 -0.0017 -0.0005 -0.0015 -0.0015 -0.0016 -0.3278 -0.0015 -0.0014 -0.0015 -0.0012 -0.0014 -0.0015 -0.0005 -0.0014 -0.0013 -0.0015 -0.0012 -0.0015 -0.0014 -0.0015 -0.0011 -0.0014 -0.0014 -0.0005 -0.0014 -0.0015 -0.0014 -0.0014
S-310	Eine Seite enthält eine Prägung mit dem Code &quot; 54 193 &quot; , wobei &quot; 54 &quot; und &quot; 193 &quot; durch eine Mittellinie getrennt sind .
T-310	One side is embossed with the code <<unk>> 54 193 <<unk>> , with a single bisect separating the <<unk>> 54 <<unk>> and <<unk>> 193 <<unk>> .
H-310	-0.007578243967145681	One side is embossed with the code <unk> 54 193 <unk> , with a single bisect separating the <unk> 54 <unk> and <unk> 193 <unk> .
D-310	-0.007578243967145681	One side is embossed with the code <unk> 54 193 <unk> , with a single bisect separating the <unk> 54 <unk> and <unk> 193 <unk> .
P-310	-0.0053 -0.0127 -0.0141 -0.0075 -0.0001 -0.0012 -0.0016 -0.0031 -0.0019 -0.0151 -0.0061 -0.0025 -0.0015 -0.0146 -0.0081 -0.0086 -0.0143 -0.0145 -0.0146 -0.0141 -0.0054 -0.0113 -0.0013 -0.0135 -0.0145 -0.0030 -0.0143 -0.0023 -0.0070 -0.0015 -0.0017 -0.0093 -0.0097 -0.0014
S-245	EU / 1 / 04 / 291 / 001 EU / 1 / 04 / 291 / 002 EU / 1 / 04 / 291 / 003
T-245	EU / 1 / 04 / 291 / 001 EU / 1 / 04 / 291 / 002 EU / 1 / 04 / 291 / 003
H-245	-0.010016570799052715	EU / 1 / 04 / 291 / 001 EU / 1 / 04 / 291 / 002 EU / 1 / 04 / 291 / 003
D-245	-0.010016570799052715	EU / 1 / 04 / 291 / 001 EU / 1 / 04 / 291 / 002 EU / 1 / 04 / 291 / 003
P-245	-0.0017 -0.0015 -0.0013 -0.0015 -0.0010 -0.0014 -0.0010 -0.0014 -0.0014 -0.0013 -0.0015 -0.2969 -0.0015 -0.0013 -0.0014 -0.0008 -0.0014 -0.0009 -0.0014 -0.0014 -0.0011 -0.0015 -0.0013 -0.0015 -0.0014 -0.0014 -0.0008 -0.0014 -0.0010 -0.0013 -0.0014 -0.0012 -0.0015 -0.0015
S-770	EU / 1 / 04 / 279 / 023 EU / 1 / 04 / 279 / 024 EU / 1 / 04 / 279 / 025
T-770	EU / 1 / 04 / 279 / 023 EU / 1 / 04 / 279 / 024 EU / 1 / 04 / 279 / 025
H-770	-0.010538648813962936	EU / 1 / 04 / 279 / 023 EU / 1 / 04 / 279 / 024 EU / 1 / 04 / 279 / 025
D-770	-0.010538648813962936	EU / 1 / 04 / 279 / 023 EU / 1 / 04 / 279 / 024 EU / 1 / 04 / 279 / 025
P-770	-0.0017 -0.0015 -0.0014 -0.0015 -0.0010 -0.0014 -0.0008 -0.0012 -0.0014 -0.0016 -0.0122 -0.3055 -0.0015 -0.0014 -0.0014 -0.0008 -0.0014 -0.0008 -0.0012 -0.0014 -0.0012 -0.0011 -0.0013 -0.0015 -0.0014 -0.0014 -0.0008 -0.0014 -0.0008 -0.0012 -0.0014 -0.0012 -0.0011 -0.0015
S-65	12,3 0,80 ( 0,70 @-@ 0,90 ) 8,1 0,74 ( 0,64 @-@ 0,87 ) 4,9 0,68 ( 0,56 @-@ 0,84 )
T-65	0.78 ( 0.70 @-@ 0.86 ) 0.80 ( 0.70 @-@ 0.90 ) 0.74 ( 0.64 @-@ 0.87 ) 0.68 ( 0.56 @-@ 0.84 )
H-65	-0.07536409795284271	0.78 ( 0.70 @-@ 0.86 ) 0.80 ( 0.70 @-@ 0.90 ) 0.74 ( 0.64 @-@ 0.87 ) 0.68 ( 0.56 @-@ 0.84 )
D-65	-0.07536409795284271	0.78 ( 0.70 @-@ 0.86 ) 0.80 ( 0.70 @-@ 0.90 ) 0.74 ( 0.64 @-@ 0.87 ) 0.68 ( 0.56 @-@ 0.84 )
P-65	-0.0145 -0.0472 -0.0112 -0.0036 -0.3407 -0.0147 -0.0008 -0.3589 -0.0013 -0.0089 -0.7271 -0.0027 -0.0011 -0.0375 -0.0014 -0.0011 -0.2506 -0.0013 -0.0059 -0.6558 -0.0014 -0.0009 -0.0096 -0.0014 -0.0011 -0.0319 -0.0013 -0.0055 -0.2291 -0.0014 -0.0008 -0.0009 -0.0014 -0.0010 -0.0082 -0.0014 -0.0049
S-700	Die meisten dieser Patienten erreichten die HR unter Tasigna rasch ( Median 1,0 Monate ) und nachhhaltig ( Median noch nicht erreicht ) .
T-700	Most responders achieved a HR early with Tasigna treatment ( median 1.0 months ) and these have been durable ( median duration has not been reached ) .
H-700	-0.010835659690201283	Most responders achieved a HR early with Tasigna treatment ( median 1.0 months ) and these have been durable ( median duration has not been reached ) .
D-700	-0.010835659690201283	Most responders achieved a HR early with Tasigna treatment ( median 1.0 months ) and these have been durable ( median duration has not been reached ) .
P-700	-0.0031 -0.0151 -0.0134 -0.0122 -0.0143 -0.0144 -0.0007 -0.0145 -0.0143 -0.0058 -0.0005 -0.0004 -0.0268 -0.0389 -0.0010 -0.0012 -0.0064 -0.0012 -0.0020 -0.0016 -0.0147 -0.0145 -0.0144 -0.0137 -0.0145 -0.0073 -0.0033 -0.0018 -0.0012 -0.0292 -0.0253 -0.0553 -0.0022 -0.0103 -0.0031 -0.0097 -0.0017 -0.0014
S-1959	Für den Fall eines signifikanten Blutdruckabfalls sollten weitere Plasmaexpander ( kristalloide oder kolloidale Lösungen ) bereitstehen .
T-1959	This is to ensure optimal haemodynamic conditions and ensure a high urinary output , especially after the perfusion , to allow for rapid clearance of any residual Beromun .
H-1959	-0.01620618626475334	This is to ensure optimal haemodynamic conditions and ensure a high urinary output , especially after the perfusion , to allow for rapid clearance of any residual Beromun .
D-1959	-0.01620618626475334	This is to ensure optimal haemodynamic conditions and ensure a high urinary output , especially after the perfusion , to allow for rapid clearance of any residual Beromun .
P-1959	-0.0160 -0.0128 -0.0144 -0.0140 -0.0676 -0.0145 -0.0047 -0.0142 -0.0144 -0.0206 -0.0145 -0.0854 -0.0133 -0.0145 -0.0055 -0.0144 -0.0205 -0.0210 -0.0142 -0.0131 -0.0146 -0.0037 -0.0139 -0.0146 -0.0143 -0.0148 -0.0160 -0.0145 -0.0019 -0.0094 -0.0143 -0.0144 -0.0028 -0.0145 -0.0145 -0.0145 -0.0123 -0.0015
S-460	Cetirizindihydrochlorid ) können den Juckreiz lindern und das Abklingen des Hautausschlages beschleunigen .
T-460	Appropriate antihistamines ( e. g. cetirizine dihydrochloride ) may reduce pruritus and hasten the resolution of rash .
H-460	-0.007556676398962736	Appropriate antihistamines ( e. g. cetirizine dihydrochloride ) may reduce pruritus and hasten the resolution of rash .
D-460	-0.007556676398962736	Appropriate antihistamines ( e. g. cetirizine dihydrochloride ) may reduce pruritus and hasten the resolution of rash .
P-460	-0.0145 -0.0056 -0.0138 -0.0064 -0.0140 -0.0140 -0.0057 -0.0006 -0.0068 -0.0141 -0.0531 -0.0072 -0.0028 -0.0014 -0.0011 -0.0017 -0.0045 -0.0068 -0.0014 -0.0013 -0.0010 -0.0005 -0.0012 -0.0017 -0.0106 -0.0133 -0.0152 -0.0007 -0.0020 -0.0010 -0.0022 -0.0144 -0.0004 -0.0049 -0.0145 -0.0015 -0.0134 -0.0225 -0.0029 -0.0014
S-1318	Kombination mit Efavirenz eine Dosiserhöhung , von Atazanavir und auch Ritonavir auf 400 mg bzw .
T-1318	the dose of both atazanavir and ritonavir to 400 mg and 200 mg , respectively , in combination with efavirenz could be considered with close clinical monitoring .
H-1318	-0.006480894051492214	the dose of both atazanavir and ritonavir to 400 mg and 200 mg , respectively , in combination with efavirenz could be considered with close clinical monitoring .
D-1318	-0.006480894051492214	the dose of both atazanavir and ritonavir to 400 mg and 200 mg , respectively , in combination with efavirenz could be considered with close clinical monitoring .
P-1318	-0.0143 -0.0130 -0.0045 -0.0144 -0.0033 -0.0007 -0.0011 -0.0006 -0.0012 -0.0017 -0.0017 -0.0015 -0.0007 -0.0012 -0.0124 -0.0033 -0.0008 -0.0127 -0.0143 -0.0046 -0.0109 -0.0018 -0.0146 -0.0102 -0.0012 -0.0016 -0.0070 -0.0005 -0.0018 -0.0007 -0.0018 -0.0159 -0.0045 -0.0145 -0.0145 -0.0145 -0.0144 -0.0144 -0.0050 -0.0014
S-1166	Lansoprazol 30 mg in Kombination mit Clarithromycin 250 oder 500 mg und Amoxicillin 1 g bzw .
T-1166	Lansoprazole 30 mg combined with clarithromycin 250 or 500 mg and amoxicillin 1g , or clarithromycin 250 and metronidazole 400 @-@ 500 mg twice daily was associated with eradication rates meeting the above described requirements .
H-1166	-0.05204854905605316	Lansoprazole 30 mg combined with clarithromycin 250 or 500 mg and amoxicillin 1g , or clarithromycin 250 and metronidazole 400 mg twice daily was associated with eradication rates meeting the above described requirements .
D-1166	-0.05204854905605316	Lansoprazole 30 mg combined with clarithromycin 250 or 500 mg and amoxicillin 1g , or clarithromycin 250 and metronidazole 400 mg twice daily was associated with eradication rates meeting the above described requirements .
P-1166	-0.0006 -0.0002 -0.0004 -0.0001 -0.0022 -0.0006 -0.0261 -0.0014 -0.0082 -0.0002 -0.0006 -0.0009 -0.0011 -0.0013 -0.0547 -0.0023 -0.0006 -0.0025 -0.0005 -0.0011 -0.0011 -0.0010 -0.0012 -0.0192 -0.0015 -0.0214 -0.0129 -0.0145 -0.0007 -0.0003 -0.0009 -0.0009 -0.2402 -0.0521 -0.0145 -0.0145 -0.0141 -0.0101 -0.0005 -0.0005 -0.3684 -1.9347 -0.0171 -0.0141 -0.0161 -0.0144 -0.0033 -0.0146 -0.0128 -0.0022 -0.0145 -0.0146 -0.0115 -0.0145 -0.0146 -0.0133 -0.0088 -0.0014
S-629	Arzneimittel Agentur ( EMEA ) http : / / www.emea.europa.eu / verfügbar. ich ln itte eim zn Ar
T-629	http : / / www.emea.europa.eu / i dic Me
H-629	-0.1346362829208374	http : / / www.emea. europa.eu / i dic Me
D-629	-0.1346362829208374	http : / / www.emea. europa.eu / i dic Me
P-629	-0.0145 -0.0013 -0.0014 -0.0014 -0.3284 -0.0005 -0.9966 -0.0005 -0.6125 -0.0033 -0.0015 -0.0144 -0.0145 -0.0146 -0.0142
S-1689	WAS MÜSSEN SIE VOR DER ANWENDUNG VON NAGLAZYME BEACHTEN ?
T-1689	BEFORE YOU USE NAGLAZYME
H-1689	-0.009034008719027042	BEFORE YOU USE NAGLAZYME
D-1689	-0.009034008719027042	BEFORE YOU USE NAGLAZYME
P-1689	-0.0620 -0.0009 -0.0002 -0.0143 -0.0007 -0.0009 -0.0119 -0.0003 -0.0024 -0.0020 -0.0027 -0.0160 -0.0016 -0.0052 -0.0145
S-818	Das Verfallsdatum bezieht sich auf den letzten Tag des Monats.VIRAMUNE sollte innerhalb von 6 Monaten nach dem Öffnen aufgebraucht werden .
T-818	VIRAMUNE should be used within 6 months of opening the bottle .
H-818	-0.013697339221835136	VIRAMUNE should be used within 6 months of opening the bottle .
D-818	-0.013697339221835136	VIRAMUNE should be used within 6 months of opening the bottle .
P-818	-0.0141 -0.0007 -0.0008 -0.0013 -0.0014 -0.0133 -0.0023 -0.0037 -0.0094 -0.0209 -0.0018 -0.1102 -0.0047 -0.0132 -0.0141 -0.0066 -0.0145
S-1653	Berühren Sie nicht die klebrige Seite des Systems oder die Gele , oder lassen Sie die Gele nicht mit Ihrem Mund in Berührung kommen .
T-1653	Do not touch the sticky side of the system or the gels or allow gels to touch your mouth .
H-1653	-0.0047538853250443935	Do not touch the sticky side of the system or the gels or allow gels to touch your mouth .
D-1653	-0.0047538853250443935	Do not touch the sticky side of the system or the gels or allow gels to touch your mouth .
P-1653	-0.0046 -0.0014 -0.0028 -0.0019 -0.0012 -0.0006 -0.0021 -0.0020 -0.0021 -0.0021 -0.0037 -0.0050 -0.0018 -0.0199 -0.0133 -0.0163 -0.0020 -0.0130 -0.0026 -0.0014 -0.0019 -0.0028
S-584	Bitte fragen Sie bei Ihrem Arzt oder Apotheker nach , wenn Sie sich nicht ganz sicher sind , wie Sie Ciprofloxacin Bayer einnehmen sollen .
T-584	Ask your doctor or pharmacist if you are not sure how to take Ciprofloxacin Bayer .
H-584	-0.004516452085226774	Ask your doctor or pharmacist if you are not sure how to take Ciprofloxacin Bayer .
D-584	-0.004516452085226774	Ask your doctor or pharmacist if you are not sure how to take Ciprofloxacin Bayer .
P-584	-0.0509 -0.0010 -0.0019 -0.0029 -0.0017 -0.0018 -0.0009 -0.0040 -0.0015 -0.0022 -0.0028 -0.0081 -0.0042 -0.0063 -0.0040 -0.0039 -0.0002 -0.0009 -0.0012 -0.0010 -0.0013 -0.0010 -0.0024 -0.0026
S-1650	Ist Ihre Injektion beendet , entsorgen Sie unverzüglich die gebrauchten Spritzen , vorzugsweise in einem für spitze Gegenstände vorgesehenen Behälter .
T-1650	Once you have finished your injection , immediately discard the syringes used safely , preferably in a sharp container .
H-1650	-0.007021681405603886	Once you have finished your injection , immediately discard the syringes used safely , preferably in a sharp container .
D-1650	-0.007021681405603886	Once you have finished your injection , immediately discard the syringes used safely , preferably in a sharp container .
P-1650	-0.0097 -0.0126 -0.0052 -0.0025 -0.0127 -0.0020 -0.0010 -0.0032 -0.0132 -0.0145 -0.0021 -0.0042 -0.0097 -0.0005 -0.0013 -0.0131 -0.0292 -0.0134 -0.0011 -0.0009 -0.0020 -0.0024 -0.0145 -0.0079 -0.0021 -0.0014
S-979	Die Dosen von Ceplene und IL @-@ 2 sind erforderlichenfalls auf der Basis der Verträglichkeit der Behandlung des einzelnen Patienten zu ändern .
T-979	Doses of Ceplene and IL @-@ 2 should be modified as necessary based on individual patient tolerance to treatment .
H-979	-0.03736312687397003	Doses of Ceplene and IL @-@ 2 should be modified as necessary based on individual patient tolerance to treatment .
D-979	-0.03736312687397003	Doses of Ceplene and IL @-@ 2 should be modified as necessary based on individual patient tolerance to treatment .
P-979	-0.0070 -0.0007 -0.0016 -0.0038 -0.0008 -0.0015 -0.0009 -0.1322 -0.0008 -0.0014 -0.0014 -0.0119 -0.0047 -0.0110 -0.0011 -0.0139 -0.0055 -0.0128 -0.2657 -0.0142 -0.0014 -0.0056 -0.4796 -0.0213 -0.0046 -0.0018 -0.0014
S-810	Die Plasmaproteinbindung von Voriconazol war bei Patienten mit verschieden stark ausgeprägter Niereninsuffizienz ähnlich .
T-810	The plasma protein binding of voriconazole was similar in subjects with different degrees of renal impairment .
H-810	-0.009015824645757675	The plasma protein binding of voriconazole was similar in subjects with different degrees of renal impairment .
D-810	-0.009015824645757675	The plasma protein binding of voriconazole was similar in subjects with different degrees of renal impairment .
P-810	-0.0069 -0.0057 -0.0005 -0.0013 -0.0012 -0.0132 -0.0011 -0.0017 -0.0008 -0.0003 -0.0004 -0.0004 -0.0165 -0.0038 -0.0030 -0.0294 -0.0021 -0.0121 -0.0071 -0.0014 -0.0016 -0.0011 -0.1350 -0.0010 -0.0008 -0.0013 -0.0015 -0.0014
S-425	Wenn Anzeichen oder Symptome einer Nephrolithiasis auftreten , kann eine vorübergehende Unterbrechung oder ein Abbruch der Therapie erwogen werden .
T-425	If signs or symptoms of nephrolithiasis occur , temporary interruption or discontinuation of treatment may be considered .
H-425	-0.006022239103913307	If signs or symptoms of nephrolithiasis occur , temporary interruption or discontinuation of treatment may be considered .
D-425	-0.006022239103913307	If signs or symptoms of nephrolithiasis occur , temporary interruption or discontinuation of treatment may be considered .
P-425	-0.0075 -0.0071 -0.0167 -0.0008 -0.0023 -0.0018 -0.0013 -0.0012 -0.0012 -0.0006 -0.0005 -0.0011 -0.0106 -0.0024 -0.0136 -0.0071 -0.0009 -0.0031 -0.0095 -0.0010 -0.0018 -0.0020 -0.0584 -0.0084 -0.0014 -0.0033 -0.0015 -0.0014
S-9	12 Einzeldosis @-@ Durchstechflaschen , 12 Injektionsspritzen , 12 Injektionsnadeln und 12 Reinigungstupfer ln
T-9	12 single dose vials , 12 injection syringes , 12 injection needles and 12 cleansing swabs uc rod
H-9	-0.009998905472457409	12 single dose vials , 12 injection syringes , 12 injection needles and 12 cleansing swabs uc rod
D-9	-0.009998905472457409	12 single dose vials , 12 injection syringes , 12 injection needles and 12 cleansing swabs uc rod
P-9	-0.0012 -0.0035 -0.0117 -0.0055 -0.0007 -0.0017 -0.0010 -0.0136 -0.0018 -0.0013 -0.0006 -0.0013 -0.0015 -0.0009 -0.0306 -0.0011 -0.0015 -0.0012 -0.1098 -0.0010 -0.0139 -0.0040 -0.0145 -0.0004 -0.0148 -0.0145 -0.0176 -0.0089
S-847	Xiliarx darf nicht zur Behandlung von Patienten mit Typ @-@ 1 @-@ Diabetes oder zur Behandlung einer diabetischen Ketoazidose angewendet werden .
T-847	Xiliarx should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis .
H-847	-0.06116748973727226	Xiliarx should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis .
D-847	-0.06116748973727226	Xiliarx should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis .
P-847	-0.0011 -0.0008 -0.0012 -0.0013 -0.0095 -0.0014 -0.0013 -0.3912 -0.4951 -0.0130 -0.3275 -0.0017 -0.0603 -0.0006 -0.0020 -0.0103 -0.0070 -0.0010 -0.0014 -0.0010 -0.0005 -0.0011 -0.0007 -0.4385 -0.0002 -0.0004 -0.0009 -0.0016 -0.0014
S-54	September 2008 erteilte die Europäische Kommission dem Unternehmen CT Arzneimittel GmbH eine Genehmigung für das Inverkehrbringen von Biograstim in der gesamten Europäischen Union .
T-54	The European Commission granted a marketing authorisation valid throughout the EU for Biograstim to CT Arzneimittel GmbH on 15 September 2008 .
H-54	-0.05260954424738884	The European Commission granted a marketing authorisation valid throughout the European Union for Biograstim to CT Arzneimittel GmbH on 15 September 2008 .
D-54	-0.05260954424738884	The European Commission granted a marketing authorisation valid throughout the European Union for Biograstim to CT Arzneimittel GmbH on 15 September 2008 .
P-54	-0.0138 -0.0029 -0.0012 -0.0126 -0.0124 -0.0026 -0.0029 -0.0008 -0.0145 -0.0021 -0.0107 -0.0017 -0.7509 -0.0018 -0.0102 -0.0055 -0.0012 -0.0026 -0.0011 -0.0176 -0.0076 -0.0013 -0.0007 -0.0003 -0.0010 -0.0129 -0.0899 -0.6276 -0.0173 -0.0017 -0.0014
S-1751	Jedoch sollte zur Prävention von skelettbezogenen Ereignissen bei Patienten mit Brustkrebs und Knochenmetastasen den folgenden Empfehlungen gefolgt werden :
T-1751	However , for the prevention of skeletal events in patients with breast cancer and bone metastases the following recommendations should be followed :
H-1751	-0.011129279620945454	However , for the prevention of skeletal events in patients with breast cancer and bone metastases the following recommendations should be followed :
D-1751	-0.011129279620945454	However , for the prevention of skeletal events in patients with breast cancer and bone metastases the following recommendations should be followed :
P-1751	-0.0030 -0.0023 -0.0124 -0.0046 -0.0009 -0.0013 -0.0014 -0.0016 -0.0008 -0.0013 -0.1831 -0.0040 -0.0023 -0.0041 -0.0766 -0.0018 -0.0010 -0.0017 -0.0014 -0.0016 -0.0026 -0.0011 -0.0113 -0.0012 -0.0019 -0.0020 -0.0015 -0.0020 -0.0017 -0.0014
S-542	Patienten , die unter ALL leiden und auf mindestens zwei vorangegangene Behandlungen nicht angesprochen bzw. einen Rückfall erlitten haben , haben sehr geringe Überlebenschancen .
T-542	Patients with ALL who have not responded to or who have relapsed after receiving at least two treatments have a very poor chance of survival .
H-542	-0.017166197299957275	Patients with ALL who have not responded to or who have relapsed after receiving at least two treatments have a very poor chance of survival .
D-542	-0.017166197299957275	Patients with ALL who have not responded to or who have relapsed after receiving at least two treatments have a very poor chance of survival .
P-542	-0.0035 -0.0010 -0.0174 -0.0008 -0.0040 -0.0033 -0.0066 -0.0016 -0.0066 -0.0220 -0.0223 -0.0143 -0.0158 -0.0003 -0.0014 -0.0143 -0.0146 -0.0500 -0.0011 -0.0053 -0.0144 -0.0068 -0.0081 -0.0019 -0.0133 -0.0027 -0.0874 -0.0020 -0.1708 -0.0014
S-1202	Die Behandlung mit Bonviva kann mit einer Osteonekrose des Kiefers ( Abbau der Knochensubstanz im Kiefer ) einhergehen .
T-1202	Bonviva treatment may be linked to osteonecrosis of the jaw ( collapse of bone tissue in the jaw ) .
H-1202	-0.009510873816907406	Bonviva treatment may be linked to osteonecrosis of the jaw ( collapse of bone tissue in the jaw ) .
D-1202	-0.009510873816907406	Bonviva treatment may be linked to osteonecrosis of the jaw ( collapse of bone tissue in the jaw ) .
P-1202	-0.0113 -0.0011 -0.0008 -0.0064 -0.0093 -0.0064 -0.0223 -0.1594 -0.0070 -0.0007 -0.0013 -0.0007 -0.0008 -0.0006 -0.0059 -0.0015 -0.0013 -0.0011 -0.0018 -0.0145 -0.0016 -0.0051 -0.0133 -0.0033 -0.0015 -0.0009 -0.0012 -0.0014 -0.0015 -0.0014
S-166	Apidra 100 Einheiten / ml Injektionslösung in einer Durchstechflasche ist eine klare , farblose Lösung , die keine Partikel enthält .
T-166	Apidra 100 Units / ml solution for injection in a vial is a clear , colourless solution with no particles visible .
H-166	-0.027171457186341286	Apidra 100 Units / ml solution for injection in a vial is a clear , colourless solution with no particles visible .
D-166	-0.027171457186341286	Apidra 100 Units / ml solution for injection in a vial is a clear , colourless solution with no particles visible .
P-166	-0.0028 -0.0009 -0.0003 -0.0036 -0.0078 -0.0011 -0.0015 -0.0011 -0.0135 -0.0137 -0.0049 -0.0019 -0.0043 -0.0042 -0.0022 -0.0008 -0.0029 -0.0032 -0.0026 -0.0055 -0.0040 -0.0009 -0.0012 -0.0018 -0.0198 -0.0023 -0.0020 -0.7105 -0.0145 -0.0052 -0.0015
S-1608	Die Häufigkeit der Nebenwirkungen bei der Mutter und ihrem Säugling war in der Silgard @-@ Gruppe und in der Placebogruppe vergleichbar .
T-1608	In breastfeeding mothers given Silgard or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable between the vaccination and the placebo groups .
H-1608	-0.060641877353191376	In breastfeeding mothers given Silgard or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable .
D-1608	-0.060641877353191376	In breastfeeding mothers given Silgard or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable .
P-1608	-0.0143 -0.0150 -0.0029 -0.0021 -0.0133 -0.0145 -0.0194 -0.0003 -0.0144 -0.0100 -0.0013 -0.0003 -0.0012 -0.0145 -0.0134 -0.0145 -0.0019 -0.0103 -0.0792 -0.0124 -0.0148 -0.0138 -0.1492 -0.0142 -0.0037 -0.0059 -0.0002 -0.0357 -0.0005 -0.0148 -0.0086 -0.0041 -0.0019 -0.0137 -0.0156 -0.0081 -0.0116 -0.0083 -0.0020 -0.0030 -0.0107 -0.0013 -2.0699 -0.0014
S-752	Unter solchen Umständen kann eine Hämodialyse wirksam sein , die aber nur bei einer schweren Vergiftung durch Hydroxocobalamin angezeigt ist .
T-752	Haemodialysis may be effective in such a circumstance , but is only indicated in the event of significant hydroxocobalamin- related toxicity .
H-752	-0.0074807326309382915	Haemodialysis may be effective in such a circumstance , but is only indicated in the event of significant hydroxocobalamin- related toxicity .
D-752	-0.0074807326309382915	Haemodialysis may be effective in such a circumstance , but is only indicated in the event of significant hydroxocobalamin- related toxicity .
P-752	-0.0143 -0.0017 -0.0005 -0.0005 -0.0008 -0.0091 -0.0024 -0.0027 -0.0057 -0.0092 -0.0145 -0.0124 -0.0006 -0.0260 -0.0145 -0.0125 -0.0047 -0.0031 -0.0045 -0.0107 -0.0099 -0.0015 -0.0145 -0.0125 -0.0011 -0.0017 -0.0012 -0.0006 -0.0144 -0.0144 -0.0142 -0.0143 -0.0158 -0.0036 -0.0038 -0.0016 -0.0014
S-1577	Bei pädiatrischen klinischen Studien wurde Neoclarityn Sirup insgesamt 246 Kindern im Alter zwischen 6 Monaten und 11 Jahren verabreicht .
T-1577	In clinical trials in a paediatric population , Neoclarityn syrup was administered to a total of 246 children aged 6 months through 11 years .
H-1577	-0.016362760215997696	In clinical trials in a paediatric population , Neoclarityn syrup was administered to a total of 246 children aged 6 months through 11 years .
D-1577	-0.016362760215997696	In clinical trials in a paediatric population , Neoclarityn syrup was administered to a total of 246 children aged 6 months through 11 years .
P-1577	-0.0061 -0.0167 -0.0141 -0.0135 -0.0162 -0.0115 -0.0006 -0.0006 -0.0020 -0.0145 -0.0075 -0.0096 -0.0019 -0.0007 -0.0014 -0.0008 -0.0008 -0.0086 -0.0011 -0.0029 -0.0097 -0.0009 -0.0030 -0.0091 -0.0017 -0.0019 -0.0011 -0.0012 -0.0025 -0.0134 -0.0102 -0.0870 -0.2931 -0.0015 -0.0015 -0.0351 -0.0014
S-1852	35 ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG UND AUF DEM BEHÄLTNIS
T-1852	32 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
H-1852	-0.012424087151885033	32 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
D-1852	-0.012424087151885033	32 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
P-1852	-0.0151 -0.0145 -0.0130 -0.0028 -0.0131 -0.0100 -0.0089 -0.0142 -0.0145 -0.0131 -0.0103 -0.0134 -0.0134 -0.0048 -0.0049 -0.0046 -0.0015 -0.0115 -0.0141 -0.0142 -0.0043 -0.0006 -0.0090 -0.0007 -0.0119 -0.0145 -0.0109 -0.0005 -0.0002 -0.0125 -0.0178 -0.0143 -0.0017 -0.0001 -0.0129 -0.1236
S-1778	78 ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG UND AUF DEM BEHÄLTNIS
T-1778	72 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
H-1778	-0.01273062452673912	72 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
D-1778	-0.01273062452673912	72 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
P-1778	-0.0146 -0.0145 -0.0126 -0.0025 -0.0130 -0.0095 -0.0098 -0.0142 -0.0145 -0.0132 -0.0103 -0.0135 -0.0133 -0.0048 -0.0051 -0.0047 -0.0015 -0.0114 -0.0142 -0.0142 -0.0042 -0.0006 -0.0090 -0.0007 -0.0119 -0.0145 -0.0108 -0.0005 -0.0002 -0.0125 -0.0166 -0.0143 -0.0017 -0.0001 -0.0130 -0.1363
S-978	Gelatine Eisenoxid ( E172 ) Siliciumdioxid Natriumdodecylsulfat Titandioxid ( E171 )
T-978	Gelatin Iron oxide colorant ( E172 ) Silicon dioxide Sodium laurilsulphate Titanium dioxide ( E171 )
H-978	-0.009345836006104946	Gelatin Iron oxide colorant ( E172 ) Silicon dioxide Sodium laurilsulphate Titanium dioxide ( E171 )
D-978	-0.009345836006104946	Gelatin Iron oxide colorant ( E172 ) Silicon dioxide Sodium laurilsulphate Titanium dioxide ( E171 )
P-978	-0.0007 -0.0059 -0.0032 -0.0088 -0.0772 -0.0134 -0.0111 -0.0068 -0.0136 -0.0014 -0.0016 -0.0015 -0.0044 -0.0040 -0.0014 -0.0006 -0.0026 -0.0003 -0.0277 -0.0110 -0.0145 -0.0140 -0.0859 -0.0012 -0.0028 -0.0005 -0.0011 -0.0014 -0.0005 -0.0016 -0.0013 -0.0010 -0.0014 -0.0014 -0.0015
S-1843	Jana Pawł a II 29 PL @-@ 00- 867 Warszawa Tel . : + 48 ( 0 ) 22 653 68 00
T-1843	Jana Paw ł a II 29 PL @-@ 00- 867 Warszawa Tel . : + 48 ( 0 ) 22 653 68 00
H-1843	-0.024937322363257408	Jana Paw ł a II 29 PL @-@ 00- 867 Warszawa Tel . : + 48 ( 0 ) 22 653 68 00
D-1843	-0.024937322363257408	Jana Paw ł a II 29 PL @-@ 00- 867 Warszawa Tel . : + 48 ( 0 ) 22 653 68 00
P-1843	-0.0028 -0.0014 -0.0048 -0.0136 -0.0145 -0.0051 -0.0048 -0.0011 -0.0016 -0.0010 -0.0015 -0.0013 -0.1263 -0.0011 -0.0007 -0.0009 -0.0122 -0.0004 -0.0005 -0.0072 -0.6062 -0.0014 -0.0011 -0.0011 -0.0014 -0.0013 -0.0014 -0.0011 -0.0012 -0.0006 -0.0006 -0.0013 -0.0016
S-535	MIRCERA 200 Mikrogramm / ml Injektionslösung Methoxy @-@ Polyethylenglycol @-@ Epoetin beta
T-535	MIRCERA 200 micrograms / ml solution for injection methoxy polyethylene glycol @-@ epoetin beta
H-535	-0.0035378304310142994	MIRCERA 200 micrograms / ml solution for injection methoxy polyethylene glycol @-@ epoetin beta
D-535	-0.0035378304310142994	MIRCERA 200 micrograms / ml solution for injection methoxy polyethylene glycol @-@ epoetin beta
P-535	-0.0022 -0.0007 -0.0014 -0.0009 -0.0013 -0.0034 -0.0050 -0.0067 -0.0016 -0.0009 -0.0135 -0.0144 -0.0071 -0.0022 -0.0093 -0.0130 -0.0083 -0.0007 -0.0010 -0.0008 -0.0006 -0.0012 -0.0007 -0.0011 -0.0008 -0.0080 -0.0020 -0.0012 -0.0007 -0.0019 -0.0007 -0.0014 -0.0018
S-1853	In einigen EU @-@ Mitgliedstaaten sind Viani Evohaler und damit verbundene Bezeichnungen im Rahmen des Verfahrens der gegenseitigen Anerkennung ( MRP ) zugelassen .
T-1853	In several EU Member States Viani Evohaler and associated names are approved through the Mutual Recognition Procedure ( MRP ) .
H-1853	-0.00806120689958334	In several EU Member States Viani Evohaler and associated names are approved through the Mutual Recognition Procedure ( MRP ) .
D-1853	-0.00806120689958334	In several EU Member States Viani Evohaler and associated names are approved through the Mutual Recognition Procedure ( MRP ) .
P-1853	-0.0077 -0.0168 -0.0029 -0.0045 -0.0014 -0.0106 -0.0007 -0.0010 -0.0006 -0.0014 -0.0026 -0.0113 -0.0114 -0.0029 -0.0115 -0.0389 -0.0022 -0.0091 -0.0008 -0.0012 -0.0005 -0.0007 -0.0011 -0.0024 -0.0048 -0.0005 -0.0018 -0.0003 -0.1017 -0.0014 -0.0017 -0.0014
S-1469	Hämatologische unerwünschte Reaktionen Eine hämatologische Toxizität wurde in klinischen Prüfungen sehr häufig beobachtet und ist dosislimitierend .
T-1469	Haematological adverse reactions Haematological toxicity has been very commonly observed in clinical trials , and is dose @-@ limiting .
H-1469	-0.010187585838139057	Haematological adverse reactions Haematological toxicity has been very commonly observed in clinical trials , and is dose @-@ limiting .
D-1469	-0.010187585838139057	Haematological adverse reactions Haematological toxicity has been very commonly observed in clinical trials , and is dose @-@ limiting .
P-1469	-0.0114 -0.0009 -0.0009 -0.0037 -0.0050 -0.0004 -0.0028 -0.0004 -0.0068 -0.0010 -0.0010 -0.0030 -0.0004 -0.0008 -0.0008 -0.0062 -0.0022 -0.0135 -0.0139 -0.0041 -0.0026 -0.0391 -0.0355 -0.1219 -0.0038 -0.0048 -0.0012 -0.0166 -0.0174 -0.0010 -0.0016 -0.0014
S-183	Bestimmen Sie die zu verabreichende Dosis von Caelyx ( gemäß der empfohlenen Dosis und der Körperoberfläche des Patienten ) .
T-183	Determine the dose of Caelyx to be administered ( based upon the recommended dose and the patient <<unk>> s body surface area ) .
H-183	-0.023681655526161194	Determine the dose of Caelyx to be administered ( based on the recommended dose and the patient <unk> s body surface area ) .
D-183	-0.023681655526161194	Determine the dose of Caelyx to be administered ( based on the recommended dose and the patient <unk> s body surface area ) .
P-183	-0.0062 -0.0011 -0.0002 -0.0022 -0.0047 -0.0021 -0.0018 -0.0011 -0.0014 -0.0013 -0.0064 -0.0038 -0.0104 -0.0009 -0.0031 -0.0129 -0.5299 -0.0030 -0.0021 -0.0018 -0.0779 -0.0078 -0.0104 -0.0145 -0.0026 -0.0089 -0.0039 -0.0067 -0.0016 -0.0020 -0.0014
S-1619	Das transdermale Pflaster besteht aus drei Schichten : einer Deckfolie , einer Klebe- / Arzneimittelschicht und einer Schutzfolie .
T-1619	The transdermal patch is composed of three layers : a backing film , an adhesive / drug layer and a release liner .
H-1619	-0.025312475860118866	The transdermal patch is composed of three layers : a backing film , an adhesive / drug layer and a release liner .
D-1619	-0.025312475860118866	The transdermal patch is composed of three layers : a backing film , an adhesive / drug layer and a release liner .
P-1619	-0.0039 -0.0012 -0.0008 -0.2729 -0.0033 -0.0013 -0.0140 -0.0109 -0.0006 -0.0017 -0.0126 -0.0025 -0.0008 -0.0042 -0.0060 -0.0144 -0.0068 -0.0015 -0.0058 -0.0006 -0.0006 -0.0011 -0.0020 -0.0085 -0.0030 -0.2119 -0.0016 -0.0148 -0.0131 -0.1609 -0.0014
S-213	Juni 2000 erteilte die Europäische Kommission dem Unternehmen Intervet International B.V. eine Genehmigung für das Inverkehrbringen von Ibaflin in der gesamten Europäischen Union .
T-213	The European Commission granted a marketing authorisation valid throughout the European Union for Ibaflin to Intervet International B. V. on 13 June 2000 .
H-213	-0.0696723684668541	The European Commission granted a marketing authorisation valid throughout the EU for Ibaflin to Intervet International B. V. on 13 June 2000 .
D-213	-0.0696723684668541	The European Commission granted a marketing authorisation valid throughout the EU for Ibaflin to Intervet International B. V. on 13 June 2000 .
P-213	-0.0140 -0.0047 -0.0012 -0.0127 -0.0137 -0.0067 -0.0027 -0.0009 -0.0145 -0.0020 -0.0105 -0.0017 -0.7538 -0.0106 -0.0088 -0.0015 -0.0010 -0.0043 -0.0959 -0.0049 -0.0005 -0.0011 -0.0145 -0.0119 -0.0125 -0.9019 -0.1766 -0.0021 -0.0018 -0.0014
S-1810	Es wurde nachgewiesen , dass er primär über einen äquilibrierenden Nukleosid @-@ Transporter des es @-@ Typs erfolgt .
T-1810	Ribavirin transport in non @-@ plasma compartments has been most extensively studied in red cells , and has been identified to be primarily via an es @-@ type equilibrative nucleoside transporter .
H-1810	-0.012193682603538036	Ribavirin transport in non @-@ plasma compartments has been most extensively studied in red cells , and has been identified to be primarily via an es @-@ type equilibrative nucleoside transporter .
D-1810	-0.012193682603538036	Ribavirin transport in non @-@ plasma compartments has been most extensively studied in red cells , and has been identified to be primarily via an es @-@ type equilibrative nucleoside transporter .
P-1810	-0.0152 -0.0145 -0.0143 -0.0092 -0.0145 -0.0144 -0.0145 -0.0016 -0.0144 -0.0081 -0.0050 -0.0144 -0.0141 -0.0016 -0.0123 -0.0023 -0.0626 -0.0144 -0.0008 -0.0147 -0.0168 -0.0146 -0.0137 -0.0132 -0.0129 -0.0130 -0.0059 -0.0629 -0.0167 -0.0068 -0.0147 -0.0150 -0.0046 -0.0140 -0.0039 -0.0008 -0.0033 -0.0023 -0.0142 -0.0133 -0.0027 -0.0007 -0.0016 -0.0020 -0.0018 -0.0042 -0.0455 -0.0014
S-98	Die Wirksamkeit von Revasc als Gerinnungshemmer wurde in vier Studien mit insgesamt 1 621 Patienten getestet , die Revasc erhielten .
T-98	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged problems ) and the rate of deep vein thrombosis ( the formation of a blood clot in one of the deep veins of the body , usually in the leg ) .
H-98	-0.07720731943845749	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged problems ) .
D-98	-0.07720731943845749	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged problems ) .
P-98	-0.0145 -0.0145 -0.0146 -0.0144 -0.0089 -0.0145 -0.0145 -0.0155 -0.0981 -0.0988 -0.0144 -0.0144 -0.0093 -0.0144 -0.0069 -0.0158 -0.0547 -0.6499 -0.4554 -0.5457 -0.0129 -0.0119 -0.0131 -0.0145 -0.0058 -0.0145 -0.0145 -0.0199 -0.0145 -0.0154 -0.0144 -0.0429 -0.0014 -0.0015 -0.0014 -0.0144 -0.0078 -0.0136 -0.0613 -0.0145 -0.0981 -0.0145 -0.0111 -0.0028 -0.0329 -0.0145 -0.0141 -0.0014 -0.0144 -0.0147 -0.0144 -0.0142 -0.0145 -0.0016 -0.0145 -0.0128 -0.0145 -0.0143 -0.0144 -0.0145 -0.0027 -0.0145 -0.0145 -0.0145 -0.0134 -0.0153 -0.0408 -0.0145 -0.0145 -0.0003 -0.0005 -0.0144 -0.0145 -0.0147 -0.0145 -2.9925 -0.0014
S-1771	Barbara van Zwieten @-@ Boot trat 1998 fünfmal zusammen , wobei jedoch zusätzliche Nebenbesprechungen und Ad- hoc @-@ Sitzungen stattfanden .
T-1771	The efficacy working party ( EWP ) , chaired by Professor Alfred Hildebrandt and co @-@ chaired by Dr Barbara van Zwieten @-@ Boot met on five occasions in 1998 with a number of break @-@ out and ad hoc meetings .
H-1771	-0.013936279341578484	The efficacy working party ( EWP ) , chaired by Professor Alfred Hildebrandt and co @-@ chaired by Dr Barbara van Zwieten @-@ Boot met on five occasions in 1998 with a number of break @-@ out and ad hoc meetings .
D-1771	-0.013936279341578484	The efficacy working party ( EWP ) , chaired by Professor Alfred Hildebrandt and co @-@ chaired by Dr Barbara van Zwieten @-@ Boot met on five occasions in 1998 with a number of break @-@ out and ad hoc meetings .
P-1771	-0.0143 -0.0145 -0.0136 -0.0029 -0.0392 -0.0141 -0.0487 -0.0144 -0.0145 -0.0126 -0.1574 -0.0265 -0.0145 -0.0003 -0.0020 -0.0277 -0.0333 -0.0145 -0.0141 -0.0014 -0.0139 -0.0141 -0.0015 -0.0114 -0.0003 -0.0030 -0.0368 -0.0156 -0.0028 -0.0012 -0.0002 -0.0006 -0.0016 -0.0004 -0.0354 -0.0141 -0.0037 -0.0010 -0.0032 -0.0009 -0.0192 -0.0146 -0.0110 -0.0014 -0.0147 -0.0042 -0.0144 -0.0132 -0.0039 -0.0036 -0.0013 -0.0041 -0.0035 -0.0014
S-1496	Fieber , Husten , Halsschmerzen , brennende Schmerzen beim Wasserlassen , oder wenn Sie beginnen , sich schwach oder allgemein unwohl zu fühlen .
T-1496	Infections Tell your doctor after your MabThera treatment if you get any symptoms of an infection , for example fever , cough , sore throat , burning pain when passing urine , or you start to feel weak or generally unwell .
H-1496	-0.009375937283039093	Infections Tell your doctor after your MabThera treatment if you get any symptoms of an infection , for example fever , cough , sore throat , burning pain when passing urine , or you start to feel weak or generally unwell .
D-1496	-0.009375937283039093	Infections Tell your doctor after your MabThera treatment if you get any symptoms of an infection , for example fever , cough , sore throat , burning pain when passing urine , or you start to feel weak or generally unwell .
P-1496	-0.0157 -0.0114 -0.0146 -0.0143 -0.0138 -0.0065 -0.0182 -0.0144 -0.0145 -0.0145 -0.0145 -0.0120 -0.0144 -0.0138 -0.0045 -0.0170 -0.0145 -0.0136 -0.0327 -0.0144 -0.0126 -0.0408 -0.0146 -0.0043 -0.0074 -0.0006 -0.0018 -0.0023 -0.0005 -0.0021 -0.0022 -0.0006 -0.0005 -0.0023 -0.0019 -0.0066 -0.0088 -0.0120 -0.0041 -0.0012 -0.0067 -0.0037 -0.0144 -0.0054 -0.0064 -0.0016 -0.0037 -0.0208 -0.0077 -0.0064 -0.0007 -0.0016 -0.0014
S-1747	Deshalb kann das Risiko einer Lithiumtoxizität durch Irbesartan Hydrochlorothiazide Winthrop erhöht werden .
T-1747	Furthermore , renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with Irbesartan Hydrochlorothiazide Winthrop .
H-1747	-0.006380491890013218	Furthermore , renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with Irbesartan Hydrochlorothiazide Winthrop .
D-1747	-0.006380491890013218	Furthermore , renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with Irbesartan Hydrochlorothiazide Winthrop .
P-1747	-0.0155 -0.0009 -0.0012 -0.0053 -0.0145 -0.0111 -0.0145 -0.0018 -0.0134 -0.0118 -0.0007 -0.0012 -0.0137 -0.0144 -0.0095 -0.0145 -0.0135 -0.0009 -0.0225 -0.0145 -0.0113 -0.0024 -0.0046 -0.0042 -0.0005 -0.0013 -0.0015 -0.0010 -0.0008 -0.0142 -0.0029 -0.0041 -0.0365 -0.0137 -0.0002 -0.0004 -0.0014 -0.0095 -0.0008 -0.0012 -0.0004 -0.0013 -0.0007 -0.0010 -0.0003 -0.0082 -0.0015 -0.0002 -0.0011 -0.0017 -0.0014
S-121	Dieser Anhang enthält auch eine vollständige Liste der Entscheidungen über gemeinschaftliche Genehmigungsverfahren für das Inverkehrbringen , die von der Kommission 1997 verabschiedet wurden .
T-121	Information on the number of marketing authorisations and variation applications received , and opinions granted in 1997 are shown in Annex 7 , together with a full list of Community authorisation Decisions , as approved by the Commission in 1997 .
H-121	-0.0203230082988739	Information on the number of marketing authorisations and variation applications received , and opinions granted in 1997 are shown in Annex 7 , together with a full list of Community authorisation Decisions , as approved by the Commission in 1997 .
D-121	-0.0203230082988739	Information on the number of marketing authorisations and variation applications received , and opinions granted in 1997 are shown in Annex 7 , together with a full list of Community authorisation Decisions , as approved by the Commission in 1997 .
P-121	-0.0150 -0.0094 -0.0086 -0.0145 -0.0024 -0.0151 -0.0014 -0.0540 -0.0010 -0.0157 -0.0156 -0.0303 -0.0145 -0.0170 -0.0153 -0.0129 -0.0151 -0.0145 -0.0162 -0.0091 -0.0140 -0.0144 -0.0028 -0.0144 -0.0013 -0.0144 -0.0137 -0.0139 -0.0014 -0.0068 -0.0089 -0.0017 -0.0016 -0.0139 -0.0097 -0.1603 -0.0144 -0.0012 -0.0016 -0.0145 -0.0142 -0.0143 -0.0073 -0.0014 -0.0196 -0.0086 -0.0011 -0.3051 -0.0014
S-222	Bei Beendigung der inhalativen Behandlung mit Iloprost sollte der Patient sorgfältig überwacht und eine Alternativbehandlung bei kritisch kranken Patienten in Betracht gezogen werden .
T-222	Careful monitoring of the patient should be performed , when inhaled iloprost therapy is stopped and an alternative treatment should be considered in critically ill patients .
H-222	-0.008169246837496758	Careful monitoring of the patient should be performed , when inhaled iloprost therapy is stopped and an alternative treatment should be considered in critically ill patients .
D-222	-0.008169246837496758	Careful monitoring of the patient should be performed , when inhaled iloprost therapy is stopped and an alternative treatment should be considered in critically ill patients .
P-222	-0.0147 -0.0101 -0.0038 -0.0096 -0.0051 -0.0019 -0.0110 -0.0030 -0.0137 -0.0158 -0.0130 -0.0115 -0.0143 -0.0145 -0.0028 -0.0132 -0.0002 -0.0141 -0.0053 -0.0142 -0.0276 -0.0105 -0.0009 -0.0023 -0.0105 -0.0015 -0.0018 -0.0195 -0.0051 -0.0011 -0.0015 -0.0009 -0.0015 -0.0014
S-1218	Ramilich comp 2.5 mg / 12.5 mg 2.5 mg / 12.5mg Taletten Ramilich comp 5 mg / 25 mg 5 mg / 25mg Tabletten
T-1218	Ramilich comp 5 mg / 25 mg Tabletten
H-1218	-0.02557765133678913	Ramilich comp 5 mg / 25 mg Tabletten
D-1218	-0.02557765133678913	Ramilich comp 5 mg / 25 mg Tabletten
P-1218	-0.0024 -0.0016 -0.0017 -0.0016 -0.0011 -0.0164 -0.0005 -0.0018 -0.0054 -0.2019 -0.0144 -0.0800 -0.0145 -0.0147
S-298	Wenn Sie rauchen , ist die Insulinmenge , die Ihr Körper durch die Lunge aufnimmt , erhöht und Sie haben ein höheres Risiko für Unterzuckerungen .
T-298	If you smoke , the amount of insulin your body absorbs will be increased and you will have a greater od
H-298	-0.006540058646351099	If you smoke , the amount of insulin your body absorbs will be increased and you will have a greater od
D-298	-0.006540058646351099	If you smoke , the amount of insulin your body absorbs will be increased and you will have a greater od
P-298	-0.0068 -0.0015 -0.0011 -0.0026 -0.0035 -0.0043 -0.0013 -0.0003 -0.0010 -0.0083 -0.0011 -0.0035 -0.0011 -0.0152 -0.0075 -0.0063 -0.0138 -0.0022 -0.0098 -0.0115 -0.0026 -0.0144 -0.0229 -0.0145
S-1470	Chinidin hat eine geringe therapeutische Breite und ist aufgrund der möglichen Hemmung von CYP3A durch REYATAZ / Ritonavir kontraindiziert .
T-1470	contraindicated due to potential inhibition of CYP3A by REYATAZ / ritonavir .
H-1470	-0.015077855437994003	contraindicated due to potential inhibition of CYP3A by REYATAZ / ritonavir .
D-1470	-0.015077855437994003	contraindicated due to potential inhibition of CYP3A by REYATAZ / ritonavir .
P-1470	-0.0145 -0.0003 -0.0122 -0.0014 -0.0137 -0.0028 -0.0015 -0.0017 -0.0018 -0.0012 -0.2867 -0.0012 -0.0013 -0.0034 -0.0024 -0.0012 -0.0007 -0.0006 -0.0016 -0.0110 -0.0014 -0.0007 -0.0010 -0.0065 -0.0062
S-1692	perforierten Blistern zur Abgabe von Einzeldosen mit 70 x 1 Tablette und in weißen Plastikflaschen mit 28 , 98 oder 500 Tabletten. ln
T-1692	ise blister packs containing 70 x 1 tablets , and in white plastic bottles containing 28 , 98 and 500 tablets .
H-1692	-0.027815524488687515	ise blister packs containing 70 x 1 tablets , and in white plastic bottles containing 28 , 98 and 500 tablets .
D-1692	-0.027815524488687515	ise blister packs containing 70 x 1 tablets , and in white plastic bottles containing 28 , 98 and 500 tablets .
P-1692	-0.0145 -0.0125 -0.0843 -0.0138 -0.0066 -0.0145 -0.0108 -0.0014 -0.0014 -0.0037 -0.0072 -0.0134 -0.0098 -0.0104 -0.0031 -0.0012 -0.0017 -0.0090 -0.0023 -0.0015 -0.0008 -0.5087 -0.0015 -0.0010 -0.0068 -0.0041 -0.0051
S-1463	Es liegen keine hinreichenden tierexperimentellen Studien in Bezug auf die Auswirkungen auf Schwangerschaft und embryonale / fetale Entwicklung vor ( siehe Abschnitt 5.3 ) .
T-1463	Animal studies are insufficient with respect to effects on pregnancy and embryofoetal development ( see section 5.3 ) .
H-1463	-0.0115243811160326	Animal studies are insufficient with respect to effects on pregnancy and embryofoetal development ( see section 5.3 ) .
D-1463	-0.0115243811160326	Animal studies are insufficient with respect to effects on pregnancy and embryofoetal development ( see section 5.3 ) .
P-1463	-0.0223 -0.0014 -0.0015 -0.0137 -0.0121 -0.0055 -0.0140 -0.0127 -0.0014 -0.0126 -0.0019 -0.0013 -0.0017 -0.0042 -0.0008 -0.1715 -0.0145 -0.0043 -0.0011 -0.0033 -0.0021 -0.0020 -0.0092 -0.0012 -0.0013 -0.0020 -0.0016 -0.0014
S-731	Es wird empfohlen , dass bei Patienten mit kardialen Begleiterkrankungen und / oder mit Karzinomen im fortgeschrittenen Stadium vor und während der Behandlung wiederholt ein itte
T-731	It is recommended that those patients who have pre @-@ existing cardiac abnormalities and / or are in advanced stages of cancer have
H-731	-0.009906630963087082	It is recommended that those patients who have pre @-@ existing cardiac abnormalities and / or are in advanced stages of cancer have
D-731	-0.009906630963087082	It is recommended that those patients who have pre @-@ existing cardiac abnormalities and / or are in advanced stages of cancer have
P-731	-0.0069 -0.0019 -0.0024 -0.0026 -0.0145 -0.0361 -0.0785 -0.0055 -0.0145 -0.0016 -0.0018 -0.0074 -0.0010 -0.0145 -0.0006 -0.0003 -0.0012 -0.0028 -0.0013 -0.0012 -0.0142 -0.0125 -0.0060 -0.0108 -0.0031 -0.0058 -0.0138 -0.0145
S-1988	Bei den Parallelvertriebsanzeigen kam es 2000 zu einem starken Anstieg des Arbeitspensums , der die Erwartungen des Arbeitsprogramms 1999 @-@ 2000 bei weitem übertraf .
T-1988	The workload for parallel distribution notifications increased significantly in 2000 , greatly in excess of the level foreseen in the Work Programme 1999 @-@ 2000 .
H-1988	-0.007556620053946972	The workload for parallel distribution notifications increased significantly in 2000 , greatly in excess of the level foreseen in the Work Programme 1999 @-@ 2000 .
D-1988	-0.007556620053946972	The workload for parallel distribution notifications increased significantly in 2000 , greatly in excess of the level foreseen in the Work Programme 1999 @-@ 2000 .
P-1988	-0.0108 -0.0145 -0.0026 -0.0132 -0.0040 -0.0124 -0.0139 -0.0117 -0.0096 -0.0127 -0.0123 -0.0016 -0.0054 -0.0140 -0.0144 -0.0040 -0.0014 -0.0072 -0.0145 -0.0137 -0.0004 -0.0038 -0.0015 -0.0136 -0.0011 -0.0044 -0.0017 -0.0031 -0.0015 -0.0014
S-6	Die EDGE- und EDGE @-@ II @-@ Studien verglichen die gastrointestinale Verträglichkeit von Etoricoxib mit der von Diclofenac .
T-6	The EDGE and EDGE II studies compared the gastrointestinal tolerability of etoricoxib versus diclofenac .
H-6	-0.016304971650242805	The EDGE and EDGE II studies compared the gastrointestinal tolerability of etoricoxib versus diclofenac .
D-6	-0.016304971650242805	The EDGE and EDGE II studies compared the gastrointestinal tolerability of etoricoxib versus diclofenac .
P-6	-0.0053 -0.0008 -0.0007 -0.0049 -0.0007 -0.0006 -0.0094 -0.0027 -0.0020 -0.0027 -0.0019 -0.0084 -0.0003 -0.0007 -0.0009 -0.0031 -0.3778 -0.0015 -0.0044 -0.0022 -0.0007 -0.0004 -0.0011 -0.0472 -0.0046 -0.0002 -0.0004 -0.0006 -0.0017 -0.0014
S-830	Während der Phase 3 berichtete ADRs , die bei 39 bis zu 6 Monate behandelten Patienten auftraten , sind in untenstehender Tabelle nach Organsystemen sortiert aufgeführt .
T-830	ADRs reported during the Phase 3 study , in 39 patients treated up to 6 months , are listed in the table below by Body System .
H-830	-0.00802319310605526	ADRs reported during the Phase 3 study , in 39 patients treated up to 6 months , are listed in the table below by Body System .
D-830	-0.00802319310605526	ADRs reported during the Phase 3 study , in 39 patients treated up to 6 months , are listed in the table below by Body System .
P-830	-0.0139 -0.0015 -0.0013 -0.0047 -0.0100 -0.0346 -0.0088 -0.0018 -0.0107 -0.0096 -0.0138 -0.0029 -0.0053 -0.0041 -0.0137 -0.0014 -0.0278 -0.0014 -0.0038 -0.0024 -0.0081 -0.0101 -0.0040 -0.0041 -0.0018 -0.0124 -0.0145 -0.0075 -0.0031 -0.0015
S-740	Die Knochenresorption infolge einer bösartigen Erkrankung ist als übermäßige Knochenresorption gekennzeichnet , die nicht durch entsprechende Knochenbildung ausgeglichen wird .
T-740	Bone resorption due to malignant disease is characterized by excessive bone resorption that is not balanced with appropriate bone formation .
H-740	-0.008712107315659523	Bone resorption due to malignant disease is characterized by excessive bone resorption that is not balanced with appropriate bone formation .
D-740	-0.008712107315659523	Bone resorption due to malignant disease is characterized by excessive bone resorption that is not balanced with appropriate bone formation .
P-740	-0.0025 -0.0007 -0.0051 -0.0012 -0.0006 -0.0097 -0.0014 -0.0098 -0.0009 -0.0026 -0.0038 -0.0017 -0.0046 -0.0527 -0.0766 -0.0036 -0.0010 -0.0037 -0.0013 -0.0006 -0.0138 -0.0030 -0.0016 -0.0134 -0.0291 -0.0110 -0.0012 -0.0010 -0.0016 -0.0014
S-946	Wenn bei Ihrem Kind bei der Umstellung von den Kapseln auf das Pulver zur Herstellung einer Suspension zum Einnehmen - oder umgekehrt - Probleme auftreten , informieren Sie bitte Ihren Arzt .
T-946	If your child experiences any problems when switching from taking the capsules to the powder for oral suspension or vice versa please inform your doctor .
H-946	-0.019596124067902565	If your child experiences any problems when switching from taking the capsules to the powder for oral suspension or vice versa please inform your doctor .
D-946	-0.019596124067902565	If your child experiences any problems when switching from taking the capsules to the powder for oral suspension or vice versa please inform your doctor .
P-946	-0.0376 -0.0041 -0.0018 -0.0123 -0.0113 -0.0039 -0.0127 -0.0079 -0.0026 -0.0890 -0.0553 -0.0036 -0.0010 -0.0012 -0.0021 -0.0088 -0.0012 -0.0110 -0.0147 -0.0061 -0.0104 -0.0011 -0.0007 -0.0013 -0.0273 -0.1773 -0.0006 -0.0942 -0.0026 -0.0019 -0.0015
S-1257	Die geänderte Indikation für die Behandlung von gastrointestinalen endoparasitären Infektionen bei Pferden war mit den vorgelegten Daten nicht belegt worden .
T-1257	The amended indication for the treatment of gastrointestinal endoparasitic infections in horses had not been demonstrated by the data provided .
H-1257	-0.00434463145211339	The amended indication for the treatment of gastrointestinal endoparasitic infections in horses had not been demonstrated by the data provided .
D-1257	-0.00434463145211339	The amended indication for the treatment of gastrointestinal endoparasitic infections in horses had not been demonstrated by the data provided .
P-1257	-0.0032 -0.0132 -0.0009 -0.0035 -0.0027 -0.0046 -0.0013 -0.0014 -0.0010 -0.0074 -0.0002 -0.0005 -0.0008 -0.0015 -0.0008 -0.0009 -0.0010 -0.0025 -0.0026 -0.0007 -0.0068 -0.0019 -0.0278 -0.0016 -0.0014 -0.0177 -0.0088 -0.0028 -0.0051 -0.0110 -0.0019 -0.0014
S-744	Besondere Patientengruppen Die Pharmakokinetik von Sitagliptin war bei gesunden Probanden und Typ @-@ 2 @-@ Diabetikern im Allgemeinen ähnlich .
T-744	Characteristics in patients The pharmacokinetics of sitagliptin were generally similar in healthy subjects and in patients with type 2 diabetes .
H-744	-0.008647417649626732	Characteristics in patients The pharmacokinetics of sitagliptin were generally similar in healthy subjects and in patients with type 2 diabetes .
D-744	-0.008647417649626732	Characteristics in patients The pharmacokinetics of sitagliptin were generally similar in healthy subjects and in patients with type 2 diabetes .
P-744	-0.0145 -0.0005 -0.0030 -0.0006 -0.0102 -0.0143 -0.0119 -0.0076 -0.0013 -0.0006 -0.0009 -0.0017 -0.0018 -0.0052 -0.0046 -0.0009 -0.0017 -0.0066 -0.0108 -0.0022 -0.0051 -0.0020 -0.1260 -0.0021 -0.0144 -0.0152 -0.0022 -0.0013 -0.0017 -0.0025 -0.0016 -0.0014
S-757	Injektionslösung 10 ml ( 1 , 10 Durchstechflaschen ) 15 ml ( 1 , 10 Durchstechflaschen ) 20 ml ( 1 , 10 Durchstechflaschen )
T-757	Solution for injection 10 ml ( 1 , 10 vials ) 15 ml ( 1 , 10 vials ) 20 ml ( 1 , 10 vials )
H-757	-0.001960821682587266	Solution for injection 10 ml ( 1 , 10 vials ) 15 ml ( 1 , 10 vials ) 20 ml ( 1 , 10 vials )
D-757	-0.001960821682587266	Solution for injection 10 ml ( 1 , 10 vials ) 15 ml ( 1 , 10 vials ) 20 ml ( 1 , 10 vials )
P-757	-0.0145 -0.0009 -0.0113 -0.0039 -0.0018 -0.0016 -0.0008 -0.0014 -0.0014 -0.0034 -0.0012 -0.0007 -0.0006 -0.0013 -0.0013 -0.0007 -0.0014 -0.0013 -0.0014 -0.0012 -0.0001 -0.0006 -0.0014 -0.0011 -0.0007 -0.0013 -0.0012 -0.0014 -0.0012 -0.0002 -0.0006 -0.0014 -0.0014
S-131	Kinzalmono darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen Telmisartan oder einen der sonstigen Bestandteile sind .
T-131	Kinzalmono should not be used in people who may be hypersensitive ( allergic ) to telmisartan or any of the other ingredients .
H-131	-0.03301914408802986	Kinzalmono should not be used in people who may be hypersensitive ( allergic ) to telmisartan or any of the other ingredients .
D-131	-0.03301914408802986	Kinzalmono should not be used in people who may be hypersensitive ( allergic ) to telmisartan or any of the other ingredients .
P-131	-0.0006 -0.0010 -0.0008 -0.0007 -0.0012 -0.0082 -0.0015 -0.0013 -0.8160 -0.0051 -0.0299 -0.0028 -0.0037 -0.0021 -0.0128 -0.0007 -0.0033 -0.0015 -0.0007 -0.0015 -0.0015 -0.0021 -0.0008 -0.0006 -0.0016 -0.0890 -0.0539 -0.0027 -0.0079 -0.0251 -0.0058 -0.0019 -0.0014
S-1446	Bei versehentlicher Selbstinjektion des Implantates ist umgehend ärztlicher Rat einzuholen und dem Arzt die Packungsbeilage oder das Etikett zu zeigen .
T-1446	In case of accidental self @-@ administration of the implant , seek medical advice immediately and show the package leaflet or the label to the physician .
H-1446	-0.006624746602028608	In case of accidental self @-@ administration of the implant , seek medical advice immediately and show the package leaflet or the label to the physician .
D-1446	-0.006624746602028608	In case of accidental self @-@ administration of the implant , seek medical advice immediately and show the package leaflet or the label to the physician .
P-1446	-0.0094 -0.0387 -0.0027 -0.0054 -0.0008 -0.0032 -0.0116 -0.0282 -0.0032 -0.0028 -0.0012 -0.0015 -0.0041 -0.0138 -0.0041 -0.0009 -0.0120 -0.0020 -0.0019 -0.0040 -0.0145 -0.0080 -0.0008 -0.0011 -0.0015 -0.0118 -0.0019 -0.0050 -0.0044 -0.0141 -0.0011 -0.0015 -0.0014
S-1097	Die Daten über Influenza @-@ Impfungen bei schwangeren Frauen weisen im Allgemeinen auf keine negativen Folgen für Föten und Mutter hin , die auf den Impfstoff zurückzuführen sind .
T-1097	In general data from influenza vaccinations in pregnant women do not indicate adverse fetal and maternal outcomes attributable to the vaccine .
H-1097	-0.006575899198651314	In general data from influenza vaccinations in pregnant women do not indicate adverse fetal and maternal outcomes attributable to the vaccine .
D-1097	-0.006575899198651314	In general data from influenza vaccinations in pregnant women do not indicate adverse fetal and maternal outcomes attributable to the vaccine .
P-1097	-0.0134 -0.0017 -0.0153 -0.0168 -0.0028 -0.0004 -0.0014 -0.0022 -0.0598 -0.0057 -0.0011 -0.0013 -0.0103 -0.0014 -0.0073 -0.0110 -0.0003 -0.0142 -0.0024 -0.0051 -0.0014 -0.0004 -0.0013 -0.0099 -0.0007 -0.0136 -0.0064 -0.0010 -0.0014 -0.0025 -0.0014 -0.0016 -0.0014
S-923	HBVAXPRO darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen den Wirkstoff oder einen der sonstigen Bestandteile sind .
T-923	HBVAXPRO should not be given to people who may be hypersensitive ( allergic ) to the active substance or any of the other ingredients .
H-923	-0.039687082171440125	HBVAXPRO should not be used in people who may be hypersensitive ( allergic ) to the active substance or any of the other ingredients .
D-923	-0.039687082171440125	HBVAXPRO should not be used in people who may be hypersensitive ( allergic ) to the active substance or any of the other ingredients .
P-923	-0.0013 -0.0011 -0.0014 -0.0010 -0.0006 -0.0011 -0.0091 -0.0016 -0.0014 -1.0188 -0.0045 -0.0267 -0.0028 -0.0033 -0.0023 -0.0108 -0.0006 -0.0038 -0.0018 -0.0008 -0.0015 -0.0016 -0.0035 -0.0067 -0.1461 -0.0018 -0.0142 -0.0029 -0.0087 -0.0184 -0.0060 -0.0021 -0.0014
S-207	20 Menschen kann nicht mit letzter Sicherheit ausgeschlossen werden , da das Potential einer lokalen Immunsuppression bei Langzeitanwendung von Pimecrolimus Creme nicht bekannt ist .
T-207	19 out as the potential for local immunosuppression with the long @-@ term use of pimecrolimus cream is unknown .
H-207	-0.018167685717344284	19 out as the potential for local immunosuppression with the long @-@ term use of pimecrolimus cream is unknown .
D-207	-0.018167685717344284	19 out as the potential for local immunosuppression with the long @-@ term use of pimecrolimus cream is unknown .
P-207	-0.0145 -0.0145 -0.3821 -0.0091 -0.0024 -0.0089 -0.0079 -0.0025 -0.0012 -0.0010 -0.0007 -0.0007 -0.0017 -0.0130 -0.0141 -0.0026 -0.0046 -0.0014 -0.0105 -0.0014 -0.0136 -0.0013 -0.0013 -0.0011 -0.0011 -0.0006 -0.0025 -0.0041 -0.0391 -0.0021 -0.0018
S-96	Das Register soll helfen , die klinische Anwendung von Ziconotid zu definieren , z.B. das optimale Dosierungsschema und eine mögliche Toleranzentwicklung .
T-96	The registry will help to define the use of ziconotide in the clinical setting e. g. optimal dosing regimen , the possible development of tolerance .
H-96	-0.02803371660411358	The registry will help to define the use of ziconotide in the clinical setting e. g. optimal dosing regimen , the possible development of tolerance .
D-96	-0.02803371660411358	The registry will help to define the use of ziconotide in the clinical setting e. g. optimal dosing regimen , the possible development of tolerance .
P-96	-0.0042 -0.0082 -0.0011 -0.0124 -0.0032 -0.0096 -0.0044 -0.0044 -0.0150 -0.0019 -0.0124 -0.0011 -0.0015 -0.0002 -0.0090 -0.0137 -0.0032 -0.0040 -0.0283 -0.0014 -0.0038 -0.0139 -0.0019 -0.4688 -0.0079 -0.0038 -0.1291 -0.0144 -0.0129 -0.0125 -0.0015 -0.0007 -0.1625 -0.0069 -0.0014
S-1552	In allen Fällen wird die letzte Dosis ( und bei der Wiederholungsimpfung die einzige Dosis ) mindestens zwei Wochen vor dem erwarteten Abferkeltermin verabreicht .
T-1552	In all cases the last dose ( and only dose , in case of re @-@ vaccination ) is given at least two weeks before the expected date of farrowing .
H-1552	-0.0053884112276136875	In all cases the last dose ( and only dose , in case of re @-@ vaccination ) is given at least two weeks before the expected date of farrowing .
D-1552	-0.0053884112276136875	In all cases the last dose ( and only dose , in case of re @-@ vaccination ) is given at least two weeks before the expected date of farrowing .
P-1552	-0.0034 -0.0027 -0.0018 -0.0097 -0.0036 -0.0021 -0.0034 -0.0033 -0.0142 -0.0084 -0.0145 -0.0103 -0.0110 -0.0016 -0.0144 -0.0014 -0.0039 -0.0013 -0.0015 -0.0058 -0.0088 -0.0020 -0.0009 -0.0133 -0.0010 -0.0060 -0.0021 -0.0029 -0.0084 -0.0086 -0.0102 -0.0022 -0.0003 -0.0020 -0.0014
S-1457	Bei der Behandlung von Osteoporose war Evista hinsichtlich der Verringerung der Anzahl von vertebralen Frakturen wirksamer als Placebo .
T-1457	When used to treat osteoporosis , Evista was more effective than placebo in reducing the number of vertebral fractures .
H-1457	-0.003126715775579214	When used to treat osteoporosis , Evista was more effective than placebo in reducing the number of vertebral fractures .
D-1457	-0.003126715775579214	When used to treat osteoporosis , Evista was more effective than placebo in reducing the number of vertebral fractures .
P-1457	-0.0134 -0.0143 -0.0259 -0.0010 -0.0019 -0.0008 -0.0009 -0.0011 -0.0015 -0.0008 -0.0021 -0.0018 -0.0012 -0.0004 -0.0033 -0.0029 -0.0018 -0.0077 -0.0022 -0.0010 -0.0009 -0.0012 -0.0037 -0.0035 -0.0024 -0.0019 -0.0014 -0.0010 -0.0012 -0.0009 -0.0012 -0.0003 -0.0009 -0.0017 -0.0014
S-1324	Da intranasales Calcitonin zur Anwendung bei postmenopausalen Frauen vorgesehen ist , wurden keine entsprechenden Studien bei schwangeren Frauen oder stillenden Müttern durchgeführt .
T-1324	As intranasal calcitonin is indicated for postmenopausal women , no studies have been carried out in pregnant women or nursing mothers .
H-1324	-0.028686366975307465	As intranasal calcitonin is indicated for postmenopausal women , no studies have been carried out in pregnant women or nursing mothers .
D-1324	-0.028686366975307465	As intranasal calcitonin is indicated for postmenopausal women , no studies have been carried out in pregnant women or nursing mothers .
P-1324	-0.0184 -0.0030 -0.0009 -0.0009 -0.0014 -0.0015 -0.0007 -0.0011 -0.0013 -0.0022 -0.0179 -0.0557 -0.0137 -0.0005 -0.0011 -0.0003 -0.0014 -0.0018 -0.0029 -0.0028 -0.0076 -0.0638 -0.0014 -0.7256 -0.0015 -0.0171 -0.0018 -0.0083 -0.0018 -0.0107 -0.0009 -0.0019 -0.0020 -0.0014
S-647	Der Anteil der Patienten mit einem Visusverlust kleiner 1,5 Zeilen betrug für Visudyne 64 % und 49 % für Plazebo ( p = 0.106 ) .
T-647	The percentage of patients who lost less than 1.5 lines was 64 % for Visudyne and 49 % for placebo ( p = 0.106 ) .
H-647	-0.003420119406655431	The percentage of patients who lost less than 1.5 lines was 64 % for Visudyne and 49 % for placebo ( p = 0.106 ) .
D-647	-0.003420119406655431	The percentage of patients who lost less than 1.5 lines was 64 % for Visudyne and 49 % for placebo ( p = 0.106 ) .
P-647	-0.0052 -0.0193 -0.0017 -0.0030 -0.0146 -0.0111 -0.0119 -0.0017 -0.0015 -0.0019 -0.0090 -0.0012 -0.0015 -0.0079 -0.0012 -0.0013 -0.0007 -0.0009 -0.0020 -0.0007 -0.0013 -0.0015 -0.0012 -0.0012 -0.0007 -0.0011 -0.0017 -0.0011 -0.0014 -0.0013 -0.0007 -0.0014 -0.0019 -0.0014
S-1917	Neugeborene weisen eine verringerte MetHb @-@ Reduktaseaktivität auf und könnten daher einem größeren Methämoglobinämierisiko ausgesetzt sein .
T-1917	Neonates have diminished MetHb reductase activity and could therefore be at greater risk of developing methaemoglobinaemia .
H-1917	-0.01606515236198902	Neonates have diminished MetHb reductase activity and could therefore be at greater risk of developing methaemoglobinaemia .
D-1917	-0.01606515236198902	Neonates have diminished MetHb reductase activity and could therefore be at greater risk of developing methaemoglobinaemia .
P-1917	-0.0144 -0.0037 -0.0091 -0.0156 -0.0007 -0.0013 -0.0124 -0.0011 -0.0011 -0.0034 -0.0012 -0.0003 -0.0008 -0.0014 -0.0116 -0.0121 -0.0084 -0.0073 -0.0075 -0.0108 -0.0021 -0.2388 -0.0158 -0.0142 -0.0139 -0.0101 -0.0003 -0.0102 -0.0105 -0.0009 -0.0011 -0.0867 -0.0014
S-916	Bei gleichzeitiger Anwendung von Medikamenten , die den Magen @-@ pH erhöhen , nimmt die Bioverfügbarkeit von Cefuroximaxetil ab .
T-916	Simultaneous use of medicines enhancing the pH of the stomach decreases the bioavailability of cefuroxime axetil .
H-916	-0.009384231641888618	Simultaneous use of medicines enhancing the pH of the stomach decreases the bioavailability of cefuroxime axetil .
D-916	-0.009384231641888618	Simultaneous use of medicines enhancing the pH of the stomach decreases the bioavailability of cefuroxime axetil .
P-916	-0.0147 -0.0005 -0.0010 -0.1558 -0.0049 -0.0014 -0.0087 -0.0094 -0.0145 -0.0039 -0.0096 -0.0141 -0.0006 -0.0065 -0.0016 -0.0024 -0.0108 -0.0013 -0.0019 -0.0015 -0.0014 -0.0015 -0.0007 -0.0035 -0.0009 -0.0112 -0.0020 -0.0008 -0.0028 -0.0073 -0.0017 -0.0015
S-436	Zerit 20 mg Hartkapseln sind braun und mit der Prägung &quot; BMS 1965 &quot; auf der einen Seite und &quot; 20 &quot; auf der anderen Seite gekennzeichnet .
T-436	Zerit 20 mg hard capsules are brown and marked with <<unk>> BMS 1965 <<unk>> on one side and <<unk>> 20 <<unk>> on the other side .
H-436	-0.02199554443359375	Zerit 20 mg hard capsules are brown and marked with <unk> BMS 1965 <unk> on one side and <unk> 20 <unk> on the other side .
D-436	-0.02199554443359375	Zerit 20 mg hard capsules are brown and marked with <unk> BMS 1965 <unk> on one side and <unk> 20 <unk> on the other side .
P-436	-0.0012 -0.0017 -0.0038 -0.0008 -0.0055 -0.0092 -0.0008 -0.0012 -0.0022 -0.0029 -0.0074 -0.0105 -0.0035 -0.0148 -0.0017 -0.0013 -0.0007 -0.0139 -0.0040 -0.0025 -0.1851 -0.1294 -0.0043 -0.0026 -0.0041 -0.0025 -0.0014 -0.0015 -0.2583 -0.0018 -0.0014
S-1096	Möglicherweise war die verminderte Bioverfügbarkeit in dieser Studie auf eine verzögerte Passage von Ribavirin oder einen veränderten pH @-@ Wert zurückzuführen .
T-1096	It is possible that the decreased bioavailability in this study was due to delayed transit of ribavirin or modified pH .
H-1096	-0.028495144098997116	It is possible that the decreased bioavailability in this study was due to delayed transit of ribavirin or modified pH .
D-1096	-0.028495144098997116	It is possible that the decreased bioavailability in this study was due to delayed transit of ribavirin or modified pH .
P-1096	-0.0124 -0.1059 -0.0034 -0.0024 -0.0030 -0.0106 -0.6302 -0.0011 -0.0014 -0.0045 -0.0020 -0.0013 -0.0039 -0.0057 -0.0015 -0.0089 -0.0140 -0.0029 -0.0021 -0.0013 -0.0007 -0.0007 -0.0020 -0.0027 -0.0142 -0.0070 -0.0016 -0.0007 -0.0055 -0.0014
S-1525	EU / 1 / 01 / 184 / 045 ( 1 @-@ er Packung ) EU / 1 / 01 / 184 / 057 ( 4 @-@ er Packung )
T-1525	EU / 1 / 01 / 184 / 027 1 Pack EU / 1 / 01 / 184 / 028 4 pack lo no
H-1525	-0.08205132186412811	EU / 1 / 01 / 184 / 027 1 Pack EU / 1 / 01 / 184 / 028 4 pack lo no
D-1525	-0.08205132186412811	EU / 1 / 01 / 184 / 027 1 Pack EU / 1 / 01 / 184 / 028 4 pack lo no
P-1525	-0.0148 -0.0015 -0.0014 -0.0014 -0.0014 -0.0014 -0.0009 -0.0014 -0.0014 -0.0011 -0.5527 -0.0148 -0.7302 -0.0009 -0.0045 -0.0015 -0.0016 -0.0014 -0.0015 -0.0014 -0.0010 -0.0014 -0.0016 -0.0010 -0.3341 -0.0084 -0.0144 -0.7344 -0.0148 -0.0134
S-697	Die perinatale Sterblichkeit war erhöht , das mittlere Fetengewicht war bei den F1 @-@ Tieren in der Hochdosis- Gruppe während der Stillzeit reduziert .
T-697	Perinatal mortality was increased and mean pup weight was decreased during the lactation period in high @-@ dose F1 animals .
H-697	-0.01178174652159214	Perinatal mortality was increased and mean pup weight was decreased during the lactation period in high @-@ dose F1 animals .
D-697	-0.01178174652159214	Perinatal mortality was increased and mean pup weight was decreased during the lactation period in high @-@ dose F1 animals .
P-697	-0.0093 -0.0012 -0.0009 -0.0012 -0.0019 -0.0010 -0.0022 -0.0080 -0.0173 -0.0096 -0.0147 -0.0145 -0.0052 -0.0044 -0.0370 -0.0410 -0.0500 -0.0554 -0.0116 -0.0006 -0.0012 -0.0104 -0.0160 -0.0140 -0.0097 -0.0069 -0.0015 -0.0036 -0.0018 -0.0015
S-952	Der Hauptindikator für die Wirksamkeit war der Anteil der Neugeborenen , die verstarben oder eine ECMO im Laufe der ersten 120 Tage im Krankenhaus benötigten .
T-952	The main measure of effectiveness was the proportion of neonates who died or needed ECMO over the first 120 days in hospital .
H-952	-0.004020492546260357	The main measure of effectiveness was the proportion of neonates who died or needed ECMO over the first 120 days in hospital .
D-952	-0.004020492546260357	The main measure of effectiveness was the proportion of neonates who died or needed ECMO over the first 120 days in hospital .
P-952	-0.0030 -0.0071 -0.0144 -0.0016 -0.0085 -0.0010 -0.0023 -0.0019 -0.0050 -0.0014 -0.0135 -0.0010 -0.0032 -0.0034 -0.0025 -0.0019 -0.0077 -0.0017 -0.0018 -0.0017 -0.0136 -0.0024 -0.0034 -0.0007 -0.0013 -0.0045 -0.0028 -0.0016 -0.0014
S-1248	Allerdings sollte zur Vermeidung einer möglichen und plötzlichen klinischen Verschlechterung während des Absetzens eine allmähliche Dosisreduktion in Erwägung gezogen werden .
T-1248	However to avoid the possible occurrence of sudden clinical deterioration during withdrawal , a gradual dose reduction should be considered .
H-1248	-0.005844064988195896	However to avoid the possible occurrence of sudden clinical deterioration during withdrawal , a gradual dose reduction should be considered .
D-1248	-0.005844064988195896	However to avoid the possible occurrence of sudden clinical deterioration during withdrawal , a gradual dose reduction should be considered .
P-1248	-0.0042 -0.0182 -0.0114 -0.0158 -0.0119 -0.0145 -0.0014 -0.0006 -0.0012 -0.0023 -0.0078 -0.0040 -0.0110 -0.0012 -0.0046 -0.0130 -0.0046 -0.0055 -0.0048 -0.0013 -0.0082 -0.0008 -0.0025 -0.0015 -0.0024 -0.0016 -0.0014
S-164	EU / 1 / 01 / 184 / 054 ( 1 @-@ er Packung ) EU / 1 / 01 / 184 / 066 ( 4 @-@ er Packung )
T-164	EU / 1 / 01 / 184 / 072 1 pack EU / 1 / 01 / 184 / 073 4 pack ct
H-164	-0.078128382563591	EU / 1 / 01 / 184 / 054 1 Pack EU / 1 / 01 / 184 / 066 4 pack lo no
D-164	-0.078128382563591	EU / 1 / 01 / 184 / 054 1 Pack EU / 1 / 01 / 184 / 066 4 pack lo no
P-164	-0.0153 -0.0015 -0.0014 -0.0014 -0.0014 -0.0014 -0.0009 -0.0013 -0.0014 -0.0012 -0.7863 -0.1800 -0.5639 -0.0008 -0.0050 -0.0015 -0.0014 -0.0014 -0.0013 -0.0014 -0.0008 -0.0014 -0.0013 -0.0011 -0.0213 -0.0032 -0.0144 -0.7017 -0.0147 -0.0134
S-1380	Zur Sicherheit von Fibrinklebern / Hämostatika bei der Anwendung während der Schwangerschaft beim Menschen oder in der Stillzeit liegen keine kontrollierten klinischen Studien vor .
T-1380	3 The safety of fibrin sealants / haemostatics for use in human pregnancy or during breast @-@ feeding has not been established in controlled clinical trials .
H-1380	-0.02022213116288185	3 The safety of fibrin sealants / haemostatics for use in human pregnancy or during breast @-@ feeding has not been established in controlled clinical trials .
D-1380	-0.02022213116288185	3 The safety of fibrin sealants / haemostatics for use in human pregnancy or during breast @-@ feeding has not been established in controlled clinical trials .
P-1380	-0.0146 -0.0146 -0.0006 -0.0018 -0.0017 -0.0037 -0.0018 -0.0145 -0.0109 -0.0021 -0.0099 -0.0097 -0.0004 -0.0126 -0.0009 -0.0197 -0.0044 -0.0334 -0.0082 -0.0069 -0.0033 -0.0573 -0.0495 -0.0795 -0.0008 -0.0128 -0.0015 -0.0019 -0.0144 -0.0067 -0.0046 -0.0007 -0.2991 -0.0017 -0.0014
S-1252	Wie andere Arzneimittel , die NRTIs enthalten , kann Atripla eine Laktatazidose ( Ansammlung von Milchsäure im Körper ) verursachen .
T-1252	As with other medicines containing NRTIs , Atripla may also cause lactic acidosis ( a build @-@ up of lactic acid in the body ) .
H-1252	-0.04147777706384659	As with other medicines containing NRTIs , Atripla may also cause lactic acidosis ( a build @-@ up of lactic acid in the body ) .
D-1252	-0.04147777706384659	As with other medicines containing NRTIs , Atripla may also cause lactic acidosis ( a build @-@ up of lactic acid in the body ) .
P-1252	-0.0177 -0.0066 -0.0077 -0.0073 -0.2391 -0.0146 -0.0021 -0.0011 -0.0013 -0.0017 -0.0107 -0.0005 -0.0011 -0.0013 -0.3326 -0.3529 -0.2403 -0.0009 -0.0135 -0.0070 -0.0010 -0.0008 -0.0020 -0.0136 -0.0025 -0.0569 -0.0012 -0.0014 -0.0015 -0.0007 -0.0006 -0.0025 -0.0018 -0.0015 -0.0015 -0.1837 -0.0014
S-148	Bedfont Cross , Stanwell Road Feltham , Middlesex TW 14 8NX United Kingdom Tel : + 44 @-@ 208 @-@ 818 @-@ 7200
T-148	Bedfont Cross , Stanwell Road Feltham , Middlesex TW 14 8NX United Kingdom Tel : + 44 @-@ 208 @-@ 818 @-@ 7200
H-148	-0.007879222743213177	Bedfont Cross , Stanwell Road Feltham , Middlesex TW 14 8NX United Kingdom Tel : + 44 @-@ 208 @-@ 818 @-@ 7200
D-148	-0.007879222743213177	Bedfont Cross , Stanwell Road Feltham , Middlesex TW 14 8NX United Kingdom Tel : + 44 @-@ 208 @-@ 818 @-@ 7200
P-148	-0.0018 -0.0012 -0.0008 -0.0002 -0.0013 -0.0957 -0.0004 -0.0011 -0.0010 -0.0011 -0.0002 -0.0932 -0.0003 -0.0012 -0.0008 -0.0014 -0.0009 -0.0014 -0.0013 -0.0013 -0.0010 -0.0053 -0.0006 -0.0021 -0.0015 -0.0012 -0.0006 -0.0424 -0.0198 -0.0013 -0.0014 -0.0010 -0.0011 -0.0014 -0.0014 -0.0010 -0.0017
S-1823	EU / 1 / 98 / 086 / 001 @-@ 003 EU / 1 / 98 / 086 / 007 EU / 1 / 98 / 086 / 009
T-1823	EU / 1 / 98 / 086 / 001 @-@ 003 EU / 1 / 98 / 086 / 007 EU / 1 / 98 / 086 / 009
H-1823	-0.0964442789554596	EU / 1 / 98 / 086 / 001 @-@ 003 1 / 98 / 086 / 007 EU / 1 / 98 / 086 / 009
D-1823	-0.0964442789554596	EU / 1 / 98 / 086 / 001 @-@ 003 1 / 98 / 086 / 007 EU / 1 / 98 / 086 / 009
P-1823	-0.0017 -0.0015 -0.0013 -0.0014 -0.0008 -0.0015 -0.0017 -0.0005 -0.0014 -0.0013 -0.0014 -0.0014 -0.0010 -0.0015 -2.4300 -0.0978 -0.0055 -0.0016 -0.0024 -0.0010 -0.0015 -0.0023 -0.0018 -0.7954 -0.0023 -0.0014 -0.0014 -0.0008 -0.0015 -0.0023 -0.0007 -0.0015 -0.0019 -0.0015 -0.0022
S-765	Kivexa darf Erwachsenen oder Jugendlichen , die weniger als 40 kg wiegen , nicht gegeben werden , da es eine fixe Kombination ist , deren Dosis nicht reduziert werden kann .
T-765	Kivexa should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed @-@ dose tablet that cannot be dose reduced .
H-765	-0.011637087911367416	Kivexa should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed @-@ dose tablet that cannot be dose reduced .
D-765	-0.011637087911367416	Kivexa should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed @-@ dose tablet that cannot be dose reduced .
P-765	-0.0027 -0.0010 -0.0011 -0.0015 -0.0098 -0.0017 -0.0014 -0.1287 -0.0008 -0.0019 -0.0077 -0.0026 -0.0072 -0.0006 -0.0009 -0.0122 -0.0025 -0.0855 -0.0014 -0.0065 -0.0036 -0.0232 -0.0036 -0.0015 -0.0024 -0.0013 -0.0313 -0.0017 -0.0433 -0.0006 -0.0119 -0.0034 -0.0014 -0.0145 -0.0061 -0.0017 -0.0014
S-1106	Die Anwendung von Dafiro bei Patienten mit Leberfunktionsstörungen oder Gallenwegsobstruktion ( Gallenabflussprobleme ) sollte mit Vorsicht erfolgen .
T-1106	Dafiro should be used with caution in patients who have problems with their liver or biliary obstructive disorders ( problems with the elimination of bile ) .
H-1106	-0.02844919264316559	Dafiro should be used with caution in patients who have problems with their liver or biliary obstructive disorders ( problems with the elimination of bile ) .
D-1106	-0.02844919264316559	Dafiro should be used with caution in patients who have problems with their liver or biliary obstructive disorders ( problems with the elimination of bile ) .
P-1106	-0.0098 -0.0006 -0.0016 -0.0011 -0.0048 -0.0018 -0.0240 -0.0622 -0.0042 -0.0043 -0.0103 -0.7359 -0.0057 -0.0144 -0.0024 -0.0144 -0.0017 -0.0105 -0.0143 -0.0013 -0.0140 -0.0144 -0.0144 -0.0144 -0.0011 -0.0122 -0.0107 -0.0039 -0.0142 -0.0145 -0.0012 -0.0014 -0.0017 -0.0004 -0.0058 -0.0015 -0.0014
S-908	Danmark JANSSEN @-@ CILAG A / S Hammerbakken 19 DK @-@ 3460 Birkerød Tlf : + 45 45 94 82 82
T-908	Danmark JANSSEN @-@ CILAG A / S Hammerbakken 19 DK @-@ 3460 Birkerød Tlf : + 45 45 94 82 82
H-908	-0.002190100261941552	Danmark JANSSEN @-@ CILAG A / S Hammerbakken 19 DK @-@ 3460 Birkerød Tlf : + 45 45 94 82 82
D-908	-0.002190100261941552	Danmark JANSSEN @-@ CILAG A / S Hammerbakken 19 DK @-@ 3460 Birkerød Tlf : + 45 45 94 82 82
P-908	-0.0035 -0.0007 -0.0025 -0.0010 -0.0006 -0.0007 -0.0016 -0.0013 -0.0007 -0.0006 -0.0016 -0.0014 -0.0011 -0.0023 -0.0004 -0.0005 -0.0015 -0.0021 -0.0010 -0.0014 -0.0008 -0.0019 -0.0093 -0.0009 -0.0004 -0.0011 -0.0021 -0.0013 -0.0008 -0.0015 -0.0011 -0.0262 -0.0007 -0.0008 -0.0005 -0.0031 -0.0017
S-468	Karzinogenese / Mutagenese Es sind keine Langzeitstudien im Tiermodell zur Beurteilung des karzinogenen Potenzials von Cladribin durchgeführt worden .
T-468	Carcinogenesis / mutagenesis Long @-@ term studies in animals to evaluate the carcinogenic potential of cladribine have not been conducted .
H-468	-0.009986639022827148	Carcinogenesis / mutagenesis Long @-@ term studies in animals to evaluate the carcinogenic potential of cladribine have not been conducted .
D-468	-0.009986639022827148	Carcinogenesis / mutagenesis Long @-@ term studies in animals to evaluate the carcinogenic potential of cladribine have not been conducted .
P-468	-0.0058 -0.0006 -0.0012 -0.0013 -0.0008 -0.0015 -0.0084 -0.0002 -0.0023 -0.0007 -0.0142 -0.0664 -0.0012 -0.0026 -0.0084 -0.0138 -0.0105 -0.0154 -0.0012 -0.0035 -0.0017 -0.0004 -0.0014 -0.0006 -0.0010 -0.0014 -0.0015 -0.0017 -0.0008 -0.0064 -0.0008 -0.0048 -0.0018 -0.0015 -0.1805 -0.0018 -0.0015
S-696	In einer Studie wurde eine Abnahme der Fertilität bei weiblichen Meerschweinchen in Dosierungen beobachtet , die über der beim Menschen zum Einsatz kommenden Dosis lagen .
T-696	Reductions in female guinea pig fertility were observed in one study at doses in excess of the human dose ; natalizumab did not affect male fertility .
H-696	-0.009584551677107811	Reductions in female guinea pig fertility were observed in one study at doses in excess of the human dose ; natalizumab did not affect male fertility .
D-696	-0.009584551677107811	Reductions in female guinea pig fertility were observed in one study at doses in excess of the human dose ; natalizumab did not affect male fertility .
P-696	-0.0160 -0.0121 -0.0301 -0.0134 -0.0113 -0.0003 -0.0121 -0.0013 -0.0022 -0.0011 -0.0065 -0.0280 -0.0139 -0.0112 -0.0022 -0.0092 -0.0041 -0.0066 -0.0142 -0.0001 -0.0014 -0.0111 -0.0094 -0.0044 -0.0155 -0.0280 -0.0144 -0.0142 -0.0007 -0.0002 -0.0144 -0.0035 -0.0144 -0.0143 -0.0131 -0.0010 -0.0069 -0.0014
S-486	Bei den meisten Patienten mit einer Parkinson @-@ Erkrankung im Frühstadium wird die geeignete Dosis innerhalb von drei bis vier Wochen mit Dosierungen von 6 mg bzw .
T-486	For most patients with early stage Parkinson <<unk>> s disease , the right dose is reached within 3 or 4 weeks , at doses of 6 mg per day or 8 mg per day respectively .
H-486	-0.02277488261461258	For most patients with early stage Parkinson <unk> s disease , the right dose is reached within 3 or 4 weeks , at doses of 6 mg per day or 8 mg per day respectively .
D-486	-0.02277488261461258	For most patients with early stage Parkinson <unk> s disease , the right dose is reached within 3 or 4 weeks , at doses of 6 mg per day or 8 mg per day respectively .
P-486	-0.0124 -0.0035 -0.0066 -0.0214 -0.0014 -0.0125 -0.0013 -0.0004 -0.0616 -0.0109 -0.0032 -0.0038 -0.0044 -0.0136 -0.0027 -0.0049 -0.0141 -0.0054 -0.0115 -0.4045 -0.0014 -0.0012 -0.0126 -0.0106 -0.0043 -0.1242 -0.0021 -0.0046 -0.0012 -0.0280 -0.0103 -0.0325 -0.0144 -0.0016 -0.0039 -0.0041 -0.0274 -0.0022 -0.0014
S-1546	7,0 mm , runde , normal gewölbte weiße Filmtabletten mit der Markierung &quot; OZ 2,5 &quot; auf der einen und &quot; G &quot; auf der anderen Seite .
T-1546	7.0 mm , round , normal convex , white film @-@ coated tablets debossed <<unk>> OZ 2.5 <<unk>> on one side and <<unk>> G <<unk>> on the other side .
H-1546	-0.020495444536209106	7.0 mm , round , normal convex , white film @-@ coated tablets debossed <unk> OZ 2.5 <unk> on one side and <unk> G <unk> on the other side .
D-1546	-0.020495444536209106	7.0 mm , round , normal convex , white film @-@ coated tablets debossed <unk> OZ 2.5 <unk> on one side and <unk> G <unk> on the other side .
P-1546	-0.0037 -0.0019 -0.0046 -0.0034 -0.0035 -0.0039 -0.0133 -0.0136 -0.0023 -0.0010 -0.0172 -0.0018 -0.0076 -0.0693 -0.0144 -0.0011 -0.0473 -0.0015 -0.0150 -0.0145 -0.0084 -0.0149 -0.0124 -0.0014 -0.0069 -0.0143 -0.0037 -0.0028 -0.1171 -0.0522 -0.0141 -0.0011 -0.0109 -0.0139 -0.0014 -0.0015 -0.2780 -0.0022 -0.0014
S-1062	Lietuva Abbott Laboratories Baltics Vienī bas 87h LV @-@ 1004 Rī ga Latvia Tel : + 371 67605580
T-1062	Lietuva Abbott Laboratories Baltics Vienī bas 87h LV @-@ 1004 , Rī ga Latvija Tel : + 371 67605580
H-1062	-0.00898720882833004	Lietuva Abbott Laboratories Baltics Vienī bas 87h LV @-@ 1004 , Rī ga Latvija Tel : + 371 67605580
D-1062	-0.00898720882833004	Lietuva Abbott Laboratories Baltics Vienī bas 87h LV @-@ 1004 , Rī ga Latvija Tel : + 371 67605580
P-1062	-0.0008 -0.0012 -0.0009 -0.0006 -0.0007 -0.0013 -0.0010 -0.0009 -0.0334 -0.0012 -0.0327 -0.0052 -0.0099 -0.0055 -0.0053 -0.0123 -0.0013 -0.0022 -0.1131 -0.0014 -0.0050 -0.0007 -0.0145 -0.0121 -0.0140 -0.0013 -0.0024 -0.0415 -0.0140 -0.0028 -0.0015 -0.0010 -0.0014 -0.0005 -0.0009 -0.0026 -0.0007 -0.0010 -0.0020
S-805	Sicherheit und Wirksamkeit von BOTOX bei der Behandlung der primären Hyperhidrosis axillaris wurden nicht bei Kindern und Jugendlichen unter 18 Jahren untersucht .
T-805	The safety and effectiveness of BOTOX in the treatment of primary hyperhidrosis of the axillae have not been investigated in children and adolescents under 18 years .
H-805	-0.04707873985171318	The safety and effectiveness of BOTOX in the treatment of primary hyperhidrosis of the axillae have not been investigated in children and adolescents under 18 years .
D-805	-0.04707873985171318	The safety and effectiveness of BOTOX in the treatment of primary hyperhidrosis of the axillae have not been investigated in children and adolescents under 18 years .
P-805	-0.0093 -0.0006 -0.0016 -0.2404 -0.0008 -0.0014 -0.0025 -0.0026 -0.0015 -0.0009 -0.0033 -0.0064 -0.0016 -0.0014 -0.0022 -0.0105 -0.0009 -0.0004 -0.0007 -0.0144 -0.0064 -0.0013 -0.0146 -0.0134 -0.0034 -0.0080 -0.0014 -0.0015 -0.5004 -0.0027 -0.0232 -0.0054 -0.0038 -0.0009 -0.0009 -0.0644 -0.0820 -0.0041 -0.8405 -0.0014
S-1995	In klinischen Studien war das Ausmaß der HbA1c @-@ Senkungen unter Vildagliptin größer bei Patienten mit hohen HbA1c @-@ Ausgangswerten .
T-1995	In a 52 @-@ week double @-@ blind controlled trial , vildagliptin ( 50 mg twice daily ) reduced baseline HbA1c by -1 % compared to -1.6 % for metformin ( titrated to 2 g / day ) statistical non @-@ inferiority was not achieved .
H-1995	-0.0723668560385704	In clinical trials , vildagliptin ( 50 mg twice daily ) reduced baseline HbA1c by -1 % compared to -1.6 % for metformin ( titrated to 2 g / day ) statistical non @-@ inferiority was not achieved .
D-1995	-0.0723668560385704	In clinical trials , vildagliptin ( 50 mg twice daily ) reduced baseline HbA1c by -1 % compared to -1.6 % for metformin ( titrated to 2 g / day ) statistical non @-@ inferiority was not achieved .
P-1995	-0.0034 -2.1970 -0.8953 -0.0054 -0.0144 -0.0018 -0.0012 -0.0003 -0.0026 -0.0182 -0.0145 -0.0109 -0.0164 -0.0118 -0.0047 -0.0336 -0.0145 -0.0016 -0.0056 -0.0010 -0.0015 -0.0012 -0.0013 -0.0140 -0.0145 -0.0137 -0.0103 -0.0145 -0.5179 -0.0145 -0.0167 -0.0078 -0.0132 -0.0148 -0.0140 -0.0016 -0.0136 -0.0178 -0.0143 -0.0144 -0.0144 -0.0144 -0.0146 -0.0131 -0.0141 -0.0050 -0.0145 -0.0149 -0.0145 -0.0015 -0.0145 -0.0106 -0.0158 -0.0145 -0.0152 -0.0144 -0.0041 -0.0014
S-634	Die hohe Nummer der Ausweisungen , welche im Jahr 2001 gewährt wurden , wird in eine Anzahl von Zulassungsanträgen in 2002 resultieren , die höher als erwartet sein wird .
T-634	The large number of designations granted in 2001 will result in a higher than anticipated number of orphan marketing applications in 2002 .
H-634	-0.005327207036316395	The large number of designations granted in 2001 will result in a higher than anticipated number of orphan marketing applications in 2002 .
D-634	-0.005327207036316395	The large number of designations granted in 2001 will result in a higher than anticipated number of orphan marketing applications in 2002 .
P-634	-0.0037 -0.0131 -0.0009 -0.0013 -0.0070 -0.0020 -0.0022 -0.0025 -0.0023 -0.0024 -0.0032 -0.0015 -0.0029 -0.0093 -0.0086 -0.0133 -0.0010 -0.0014 -0.0145 -0.0139 -0.0071 -0.0143 -0.0050 -0.0057 -0.0015 -0.0017 -0.0014
S-1791	Bei den 11 AP @-@ Patienten , die für die Wirksamkeitsbeurteilung betrachtet wurden , führte die Therapie zu einer Gesamt @-@ HR @-@ Rate von 36 % .
T-1791	In 11 AP patients , evaluated for efficacy , treatment induced a 36 % overall HR rate .
H-1791	-0.006132121197879314	In 11 AP patients , evaluated for efficacy , treatment induced a 36 % overall HR rate .
D-1791	-0.006132121197879314	In 11 AP patients , evaluated for efficacy , treatment induced a 36 % overall HR rate .
P-1791	-0.0082 -0.0135 -0.0012 -0.0028 -0.0144 -0.0147 -0.0016 -0.0039 -0.0068 -0.0009 -0.0011 -0.0086 -0.0137 -0.0147 -0.0013 -0.0098 -0.0086 -0.0018 -0.0055 -0.0047 -0.0008 -0.0037 -0.0025 -0.0021
S-1737	Grippeähn- liche Symp- tome , ein- schließlich Fieber , Kopfschmer- zen , Schüt- telfrost , Übelkeit und Muskel- schmerzen
T-1737	Flu @-@ like symptoms including fever , headaches , chills , nausea and myalgia
H-1737	-0.009503587149083614	Flu @-@ like symptoms including fever , headaches , chills , nausea and myalgia
D-1737	-0.009503587149083614	Flu @-@ like symptoms including fever , headaches , chills , nausea and myalgia
P-1737	-0.0103 -0.0004 -0.0025 -0.0022 -0.0040 -0.0299 -0.0029 -0.0008 -0.0015 -0.0007 -0.0004 -0.1163 -0.0014 -0.0015 -0.0002 -0.0015 -0.0014 -0.0004 -0.0032 -0.0146 -0.0089 -0.0038 -0.0099
S-407	WAS MÜSSEN SIE VOR DER EINNAHME VON CIPROFLOXACIN BAYER BEACHTEN ?
T-407	BEFORE YOU TAKE CIPROFLOXACIN BAYER
H-407	-0.005295965354889631	BEFORE YOU TAKE CIPROFLOXACIN BAYER
D-407	-0.005295965354889631	BEFORE YOU TAKE CIPROFLOXACIN BAYER
P-407	-0.0419 -0.0009 -0.0004 -0.0142 -0.0009 -0.0008 -0.0143 -0.0004 -0.0005 -0.0076 -0.0008 -0.0012 -0.0016 -0.0013 -0.0012 -0.0012 -0.0015 -0.0028 -0.0017 -0.0018 -0.0144
S-1406	Übermäßige Blutdrucksenkung trat gelegentlich ( 0,1 % ) bei Patienten mit unkomplizierter Hypertonie auf , die mit Tekturna allein behandelt wurden .
T-1406	Excessive hypotension was uncommonly ( 0.1 % ) seen in patients with uncomplicated hypertension treated with Tekturna alone .
H-1406	-0.004655309487134218	Excessive hypotension was uncommonly ( 0.1 % ) seen in patients with uncomplicated hypertension treated with Tekturna alone .
D-1406	-0.004655309487134218	Excessive hypotension was uncommonly ( 0.1 % ) seen in patients with uncomplicated hypertension treated with Tekturna alone .
P-1406	-0.0017 -0.0011 -0.0009 -0.0145 -0.0004 -0.0011 -0.0017 -0.0137 -0.0145 -0.0145 -0.0122 -0.0022 -0.0014 -0.0017 -0.0014 -0.0123 -0.0020 -0.0026 -0.0031 -0.0080 -0.0021 -0.0007 -0.0002 -0.0151 -0.0021 -0.0082 -0.0005 -0.0004 -0.0012 -0.0016 -0.0014
S-119	Im Vergleich zu den 20 % mit einem Placebo behandelten Tieren , die in Studie ACE129801 kontinent wurden , wirken diese Zahlen sehr überzeugend .
T-119	These results were convincing when compared to the 20 % placebo treated animals that became continent in study ACE129801 .
H-119	-0.02628873847424984	These results were convincing when compared to the 20 % placebo treated animals that became continent in study ACE129801 .
D-119	-0.02628873847424984	These results were convincing when compared to the 20 % placebo treated animals that became continent in study ACE129801 .
P-119	-0.0073 -0.0142 -0.0138 -0.0142 -0.0140 -0.0007 -0.5700 -0.0031 -0.0013 -0.0029 -0.0141 -0.0011 -0.0007 -0.0013 -0.0113 -0.0029 -0.0139 -0.0145 -0.0145 -0.0033 -0.0073 -0.0010 -0.0019 -0.0019 -0.0006 -0.0009 -0.0020 -0.0014
S-410	Je nachdem wie Ihre Anämie auf die Behandlung anspricht , wird die Dosis in ungefähr vierwöchigen Abständen angepasst , bis Ihre Anämie unter Kontrolle ist .
T-410	Depending on how your anaemia responds to treatment , the dose may be adjusted approximately every 4 weeks until your condition is controlled .
H-410	-0.023790430277585983	Depending on how your anaemia responds to treatment , the dose may be adjusted approximately every 4 weeks until your condition is controlled .
D-410	-0.023790430277585983	Depending on how your anaemia responds to treatment , the dose may be adjusted approximately every 4 weeks until your condition is controlled .
P-410	-0.0743 -0.0006 -0.2295 -0.0109 -0.0022 -0.1433 -0.0106 -0.0006 -0.0013 -0.0036 -0.0009 -0.0077 -0.0026 -0.0026 -0.0042 -0.0155 -0.0145 -0.0026 -0.0045 -0.0147 -0.0126 -0.0141 -0.0013 -0.0123 -0.0039 -0.1053 -0.0026 -0.0120 -0.0016 -0.0014
S-1958	Verkehrstüchtigkeit und das Bedienen von Maschinen Der Einfluss von Invirase auf die Fahrtüchtigkeit und die Fähigkeit zum Bedienen von Maschinen wurde nicht geprüft .
T-1958	Driving and using machines Invirase has not been tested for its effect on your ability to drive a car or operate machinery .
H-1958	-0.008203928358852863	Driving and using machines Invirase has not been tested for its effect on your ability to drive a car or operate machinery .
D-1958	-0.008203928358852863	Driving and using machines Invirase has not been tested for its effect on your ability to drive a car or operate machinery .
P-1958	-0.0144 -0.0130 -0.0101 -0.0144 -0.0059 -0.0125 -0.0011 -0.0010 -0.0010 -0.0133 -0.0025 -0.0019 -0.0063 -0.0091 -0.0050 -0.0137 -0.0017 -0.0175 -0.0126 -0.0184 -0.0024 -0.0167 -0.0112 -0.0094 -0.0114 -0.0140 -0.0010 -0.0010 -0.0022 -0.0015
S-835	Begrenzte Sicherheitsdaten ( n = 51 ) sind bei koinfizierten Patienten mit einer CD4 + Zellzahl &lt; 200 / Mikroliter verfügbar .
T-835	Limited safety data ( N = 51 ) are available in co- infected patients with CD4 + cell counts &lt; 200 / µl .
H-835	-0.013690371066331863	Limited safety data ( N = 51 ) are available in co- infected patients with CD4 + cell counts &lt; 200 / µl .
D-835	-0.013690371066331863	Limited safety data ( N = 51 ) are available in co- infected patients with CD4 + cell counts &lt; 200 / µl .
P-835	-0.0018 -0.0009 -0.0014 -0.0022 -0.2237 -0.0010 -0.0018 -0.0015 -0.0090 -0.0023 -0.0062 -0.0092 -0.0150 -0.0015 -0.0015 -0.0024 -0.0083 -0.0015 -0.0013 -0.0018 -0.0125 -0.0011 -0.0009 -0.0013 -0.0013 -0.0027 -0.0500 -0.0042 -0.0411 -0.0014
S-1315	Dieser Anteil wird zwar 1998 wieder abnehmen , doch wird die Aktualisierung von ICH- Leitlinien und rein europäischer CPMP @-@ Leitlinien einer der Arbeitsschwerpunkte bleiben .
T-1315	While this will reduce in 1998 , updating ICH @-@ derived and purely European CPMP guidelines will remain a considerable task .
H-1315	-0.008118219673633575	While this will reduce in 1998 , updating ICH @-@ derived and purely European CPMP guidelines will remain a considerable task .
D-1315	-0.008118219673633575	While this will reduce in 1998 , updating ICH @-@ derived and purely European CPMP guidelines will remain a considerable task .
P-1315	-0.0124 -0.0045 -0.0138 -0.0143 -0.0109 -0.0010 -0.0019 -0.0102 -0.0004 -0.0137 -0.0067 -0.0318 -0.0145 -0.0022 -0.0213 -0.0076 -0.0008 -0.0016 -0.0028 -0.0015 -0.0018 -0.0110 -0.0028 -0.0035 -0.0092 -0.0145 -0.0144 -0.0030 -0.0014
S-1349	Eingeschränkte Leberfunktion Für Patienten mit eingeschränkter Leberfunktion liegen keine Daten mit intranasal angewendeten Fluticasonfuroat vor .
T-1349	There are no data with intranasal fluticasone furoate in patients with hepatic impairment .
H-1349	-0.014294154942035675	There are no data with intranasal fluticasone furoate in patients with hepatic impairment .
D-1349	-0.014294154942035675	There are no data with intranasal fluticasone furoate in patients with hepatic impairment .
P-1349	-0.0138 -0.2394 -0.0018 -0.0031 -0.0421 -0.0039 -0.0011 -0.0009 -0.0063 -0.0048 -0.0020 -0.0005 -0.0034 -0.0071 -0.0027 -0.0019 -0.0138 -0.0013 -0.0019 -0.0292 -0.0018 -0.0010 -0.0038 -0.0072 -0.0006 -0.0011 -0.0023 -0.0014
S-1213	Die einzigen Variablen mit statistisch signifikanter Korrelation zu den Blutungen waren die Avastin Therapie und die Plattenepithel @-@ Histologie .
T-1213	The only variables that showed statistically significant correlations with bleeding were Avastin therapy and squamous cell histology .
H-1213	-0.004036757629364729	The only variables that showed statistically significant correlations with bleeding were Avastin therapy and squamous cell histology .
D-1213	-0.004036757629364729	The only variables that showed statistically significant correlations with bleeding were Avastin therapy and squamous cell histology .
P-1213	-0.0046 -0.0011 -0.0011 -0.0014 -0.0130 -0.0130 -0.0127 -0.0012 -0.0014 -0.0012 -0.0014 -0.0134 -0.0150 -0.0110 -0.0009 -0.0015 -0.0026 -0.0006 -0.0013 -0.0027 -0.0017 -0.0014 -0.0003 -0.0039 -0.0007 -0.0011 -0.0016 -0.0014
S-85	Die Dosierung bei Hunden richtet sich nach der Größe der Körperoberfläche ( die mittels des Körpergewichts bestimmt wird ) , bei Katzen nach dem Körpergewicht .
T-85	The dose depends on the body surface area in dogs ( caluclated using body weight ) and body weight in cats .
H-85	-0.010106222704052925	The dose depends on the body surface area in dogs ( caluclated using body weight ) and body weight in cats .
D-85	-0.010106222704052925	The dose depends on the body surface area in dogs ( caluclated using body weight ) and body weight in cats .
P-85	-0.0150 -0.0137 -0.0137 -0.0019 -0.0026 -0.0144 -0.0063 -0.0199 -0.0310 -0.0027 -0.0022 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0063 -0.0011 -0.0020 -0.0357 -0.0122 -0.0014 -0.0017 -0.0010 -0.0038 -0.0017
S-74	Eine Dosis wurde eingestellt , der Injektionsknopf wurde herausgezogen und wieder eingedrückt - versehentlich , ohne dass eine Nadel befestigt war .
T-74	Dose has been selected and the injection button has been pulled out and pressed in again without a needle attached .
H-74	-0.007495244964957237	Dose has been selected and the injection button has been pulled out and pressed in again without a needle attached .
D-74	-0.007495244964957237	Dose has been selected and the injection button has been pulled out and pressed in again without a needle attached .
P-74	-0.0143 -0.0135 -0.0142 -0.0016 -0.0145 -0.0137 -0.0030 -0.0059 -0.0015 -0.0072 -0.0092 -0.0016 -0.0053 -0.0026 -0.0057 -0.0092 -0.0131 -0.0072 -0.0145 -0.0081 -0.0018 -0.0011 -0.0113 -0.0058 -0.0016
S-318	Wenn Sie die Einnahme von ORACEA vergessen haben Nehmen Sie nicht die doppelte Dosis ein , wenn Sie die vorherige Einnahme einer Kapsel vergessen haben .
T-318	If you forget to take ORACEA Do not take a double dose to make up for a forgotten capsule .
H-318	-0.006257717497646809	If you forget to take ORACEA Do not take a double dose to make up for a forgotten capsule .
D-318	-0.006257717497646809	If you forget to take ORACEA Do not take a double dose to make up for a forgotten capsule .
P-318	-0.0018 -0.0014 -0.0106 -0.0013 -0.0009 -0.0018 -0.0007 -0.0004 -0.0144 -0.0013 -0.0007 -0.0144 -0.0028 -0.0016 -0.0145 -0.0144 -0.0143 -0.0013 -0.0144 -0.0145 -0.0137 -0.0005 -0.0011 -0.0099 -0.0036
S-1149	Nplate sollte bei Patienten , die Probleme mit der Leber oder den Nieren haben , mit Vorsicht angewendet werden , da es bei dieser Gruppe nicht formell untersucht wurde .
T-1149	Romiplostim is a protein that has been <<unk>> engineered <<unk>> ( specifically designed ) so that it can
H-1149	-0.2717902660369873	Romiplostim is a protein that has been <unk> engineered so that it can
D-1149	-0.2717902660369873	Romiplostim is a protein that has been <unk> engineered so that it can
P-1149	-0.0145 -0.0144 -0.0145 -0.0145 -0.0145 -0.0144 -0.0130 -0.0145 -0.0097 -0.0128 -0.0050 -0.0145 -0.0145 -0.0008 -4.9502 -0.0089 -0.0076 -0.0113 -0.0145
S-13	Daher sind bei Patienten mit leichter bis mittelgradiger Leberfunktionsstörung unveränderte Konzentrationen von ungebundenem Fondaparinux zu erwarten .
T-13	22 resulting in increased renal clearance of fondaparinux .
H-13	-0.009254478849470615	22 resulting in increased renal clearance of fondaparinux .
D-13	-0.009254478849470615	22 resulting in increased renal clearance of fondaparinux .
P-13	-0.0146 -0.0155 -0.0062 -0.0145 -0.0145 -0.0005 -0.0145 -0.0021 -0.0126 -0.0144 -0.0085 -0.0007 -0.0012 -0.0014 -0.0125 -0.0145
S-1593	Eine Reduzierung der Olanzapin @-@ Dosis muss in Betracht gezogen werden , wenn eine Behandlung mit einem CYP1A2 Hemmer begonnen wird .
T-1593	A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated .
H-1593	-0.03130555897951126	A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated .
D-1593	-0.03130555897951126	A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated .
P-1593	-0.0082 -0.0142 -0.0011 -0.0044 -0.0099 -0.0135 -0.0015 -0.0023 -0.0006 -0.0004 -0.0011 -0.0125 -0.0015 -0.0036 -0.2740 -0.0072 -0.0046 -0.0174 -0.0024 -0.0004 -0.0009 -0.0014 -0.0054 -0.0019 -0.0012 -0.6506 -0.0012 -0.0013 -0.0014 -0.0025 -0.0114 -0.0014 -0.0015 -0.0014
S-999	Sie soll über den Zeitraum der Verabreichung von Gonadotropinen fortgeführt werden , bis zum Vorabend des Tages , an dem der Eisprung ausgelöst werden soll .
T-999	Treatment with Cetrotide 0.25 mg should begin on day 5 of ovarian stimulation ( approximately 96 to 108 hours after start of ovarian stimulation ) with urinary or recombinant gonadotropins and is to be continued throughout the gonadotropin treatment period until the evening prior to the day of ovulation induction .
H-999	-0.11610228568315506	Treatment with Cetrotide 0.25 mg should begin on day 5 of ovarian stimulation ( approximately 96 to 108 hours after start of ovarian stimulation ) with urinary or recombinant gonadotropin .
D-999	-0.11610228568315506	Treatment with Cetrotide 0.25 mg should begin on day 5 of ovarian stimulation ( approximately 96 to 108 hours after start of ovarian stimulation ) with urinary or recombinant gonadotropin .
P-999	-0.0146 -0.0014 -0.0015 -0.0153 -0.0145 -0.0179 -0.0145 -0.0145 -0.0145 -0.0149 -0.0138 -0.0137 -0.1339 -0.0107 -0.0144 -0.0144 -0.0069 -0.0148 -0.0023 -0.0025 -0.0144 -0.0006 -0.0141 -0.0145 -0.0147 -0.0360 -0.0145 -0.0175 -0.0134 -0.0153 -0.0030 -0.0142 -0.0016 -0.0022 -0.0143 -0.0005 -0.0035 -0.0367 -0.0145 -0.0106 -0.0144 -0.0144 -0.0145 -0.0016 -0.0036 -0.0143 -0.0007 -0.0006 -0.0008 -0.0037 -3.1609 -2.3155 -0.0014
S-1037	Thrombolytika , Acetylsalicylsäure , Beta @-@ Blocker , Statine und Diuretika angewendet werden .
T-1037	Valsartan may be used in patients treated with other post @-@ myocardial infarction therapies , e. g. thrombolytics , acetylsalicylic acid , beta blockers , statins , and diuretics .
H-1037	-0.032460398972034454	Valsartan may be used in patients treated with other post @-@ myocardial infarction therapies , e. g. thrombolytics , acetylsalicylic acid , beta blockers , statins , and diuretics .
D-1037	-0.032460398972034454	Valsartan may be used in patients treated with other post @-@ myocardial infarction therapies , e. g. thrombolytics , acetylsalicylic acid , beta blockers , statins , and diuretics .
P-1037	-0.0145 -0.0145 -0.0142 -0.0141 -0.0142 -0.0030 -0.0066 -0.0160 -0.0142 -0.0144 -0.0018 -0.0163 -0.0145 -0.0041 -0.0145 -0.0100 -0.0067 -0.0036 -0.0144 -0.0141 -0.0030 -0.0144 -0.0010 -0.0110 -0.0148 -0.0135 -0.0035 -0.0135 -0.0009 -0.0011 -0.0015 -0.0051 -0.0014 -0.0015 -0.0008 -0.0601 -0.0006 -0.6927 -0.0021 -0.0008 -0.0009 -0.0014 -0.0009 -0.0015 -0.0104 -0.0013 -0.0015 -0.0009 -0.0008 -0.6396 -0.0028 -0.0009 -0.0005 -0.0822 -0.0016 -0.0014
S-1603	7 Filmtabletten 14 Filmtabletten 28 Filmtabletten 30 Filmtabletten 50 Filmtabletten 56 Filmtabletten 90 Filmtabletten
T-1603	7 film @-@ coated tablets 14 film @-@ coated tablets 28 film @-@ coated tablets 30 film @-@ coated tablets 50 film @-@ coated tablets 56 film @-@ coated tablets 90 film @-@ coated tablets
H-1603	-0.0025066486559808254	7 film @-@ coated tablets 14 film @-@ coated tablets 28 film @-@ coated tablets 30 film @-@ coated tablets 50 film @-@ coated tablets 56 film @-@ coated tablets 90 film @-@ coated tablets
D-1603	-0.0025066486559808254	7 film @-@ coated tablets 14 film @-@ coated tablets 28 film @-@ coated tablets 30 film @-@ coated tablets 50 film @-@ coated tablets 56 film @-@ coated tablets 90 film @-@ coated tablets
P-1603	-0.0143 -0.0105 -0.0144 -0.0149 -0.0066 -0.0012 -0.0011 -0.0048 -0.0034 -0.0016 -0.0020 -0.0008 -0.0008 -0.0011 -0.0012 -0.0028 -0.0013 -0.0010 -0.0004 -0.0009 -0.0012 -0.0012 -0.0024 -0.0015 -0.0008 -0.0005 -0.0008 -0.0012 -0.0015 -0.0023 -0.0017 -0.0006 -0.0005 -0.0006 -0.0012 -0.0025 -0.0023 -0.0018 -0.0005 -0.0004 -0.0007 -0.0011 -0.0026 -0.0026 -0.0028 -0.0006 -0.0005 -0.0008 -0.0011 -0.0016
S-188	ANGABEN AUF DER DURCHSTECHFLASCHE LÖSUNGSMITTEL FÜR ZYPADHERA
T-188	69 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label Solvent for ZYPADHERA
H-188	-0.011593284085392952	69 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label Solvent for ZYPADHERA
D-188	-0.011593284085392952	69 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label Solvent for ZYPADHERA
P-188	-0.0147 -0.0144 -0.0103 -0.0143 -0.0014 -0.0007 -0.0211 -0.0110 -0.0040 -0.0134 -0.0133 -0.0115 -0.0155 -0.0363 -0.0123 -0.0068 -0.0127 -0.0140 -0.0261 -0.0083 -0.0145 -0.0136 -0.0004 -0.0005 -0.0136 -0.0322 -0.0144 -0.0043 -0.0007 -0.0319 -0.0202 -0.0136 -0.0071 -0.0165 -0.0143 -0.0145 -0.0037 -0.0179 -0.0148 -0.0137 -0.0127 -0.0022 -0.0014 -0.0007 -0.0003 -0.0013 -0.0018
S-1829	Wenden Sie Arixtra so lange an , wie es Ihnen Ihr Arzt verordnet hat , da Arixtra der Entwicklung schwerwiegender Komplikationen vorbeugt .
T-1829	How long should Arixtra be taken for You should continue Arixtra treatment for as long as your doctor has told you , since Arixtra prevents development of a serious condition .
H-1829	-0.007853556424379349	How long should Arixtra be taken for You should continue Arixtra treatment for as long as your doctor has told you , since Arixtra prevents development of a serious condition .
D-1829	-0.007853556424379349	How long should Arixtra be taken for You should continue Arixtra treatment for as long as your doctor has told you , since Arixtra prevents development of a serious condition .
P-1829	-0.0145 -0.0104 -0.0112 -0.0141 -0.0011 -0.0004 -0.0041 -0.0145 -0.0142 -0.0145 -0.0145 -0.0144 -0.0145 -0.0012 -0.0004 -0.0145 -0.0138 -0.0054 -0.0017 -0.0015 -0.0113 -0.0017 -0.0077 -0.0144 -0.0013 -0.0112 -0.0115 -0.0018 -0.0012 -0.0005 -0.0058 -0.0011 -0.0147 -0.0015 -0.0159 -0.0042 -0.0145 -0.0037 -0.0014
S-1192	Bei den behandlungserfahrenen Patienten ließen sich die Ergebnisse der ersten Studie mit Reyataz nicht interpretieren , da ein Großteil der Patienten die Studie vor deren Abschluss verließ .
T-1192	In treatment @-@ experienced patients , the results of the first study could not be interpreted , as a large number of patients left the study before its planned end .
H-1192	-0.006565052550286055	In treatment @-@ experienced patients , the results of the first study could not be interpreted , as a large number of patients left the study before its planned end .
D-1192	-0.006565052550286055	In treatment @-@ experienced patients , the results of the first study could not be interpreted , as a large number of patients left the study before its planned end .
P-1192	-0.0113 -0.0143 -0.0089 -0.0016 -0.0013 -0.0038 -0.0039 -0.0028 -0.0034 -0.0017 -0.0028 -0.0082 -0.0160 -0.0014 -0.0012 -0.0010 -0.0013 -0.0133 -0.0112 -0.0085 -0.0055 -0.0117 -0.0017 -0.0054 -0.0042 -0.0033 -0.0024 -0.0069 -0.0118 -0.0221 -0.0206 -0.0016 -0.0014
S-869	KRKA , d.d. , Novo mesto , Š marješ ka cesta 6 , 8501 Novo mesto , Slovenien
T-869	KRKA , d. d . , Novo mesto , Š marješ ka cesta 6 , 8501 Novo mesto , Slovenia
H-869	-0.0070330919697880745	KRKA , d. d . , Novo mesto , Š marješ ka cesta 6 , 8501 Novo mesto , Slovenia
D-869	-0.0070330919697880745	KRKA , d. d . , Novo mesto , Š marješ ka cesta 6 , 8501 Novo mesto , Slovenia
P-869	-0.0024 -0.0016 -0.0005 -0.0014 -0.0143 -0.0048 -0.2015 -0.0013 -0.0007 -0.0015 -0.0016 -0.0007 -0.0012 -0.0014 -0.0005 -0.0007 -0.0013 -0.0003 -0.0010 -0.0014 -0.0007 -0.0013 -0.0016 -0.0014 -0.0008 -0.0023 -0.0015 -0.0008 -0.0013 -0.0011 -0.0006 -0.0011 -0.0014 -0.0009 -0.0005 -0.0010 -0.0016
S-67	TEVA Pharmaceutical Works Private Limited Company H @-@ 2100 Gödöllő , Táncsics Mihály út 82 Ungarn
T-67	TEVA Pharmaceutical Works Private Limited Company H @-@ 2100 Gödöll ő , Táncsics Mihály út 82 Hungary
H-67	-0.010712935589253902	TEVA Pharmaceutical Works Private Limited Company H @-@ 2100 Gödöll ő , Táncsics Mihály út 82 Hungary
D-67	-0.010712935589253902	TEVA Pharmaceutical Works Private Limited Company H @-@ 2100 Gödöll ő , Táncsics Mihály út 82 Hungary
P-67	-0.0005 -0.0011 -0.0023 -0.0003 -0.0011 -0.0007 -0.0010 -0.0009 -0.0013 -0.0010 -0.0006 -0.0007 -0.0013 -0.3100 -0.0012 -0.0015 -0.0068 -0.0016 -0.0145 -0.0131 -0.0143 -0.0015 -0.0035 -0.0011 -0.0011 -0.0011 -0.0013 -0.0009 -0.0020 -0.0003 -0.0007 -0.0011 -0.0004 -0.0012 -0.0008 -0.0018 -0.0017
S-163	Auch die Anzahl von varizellenartigem Ausschlag innerhalb von 42 Tagen nach Impfung war bei den Probanden der SP @-@ Studie gering ( n = 59 ) .
T-163	Within the same 42 @-@ day postvaccination reporting period in the SPS , the number ( n = 59 ) of reported varicella @-@ like rashes was also small .
H-163	-0.037536002695560455	Within the same 42 @-@ day postvaccination reporting period in the SPS , the number ( n = 59 ) of reported varicella @-@ like rashes was also small .
D-163	-0.037536002695560455	Within the same 42 @-@ day postvaccination reporting period in the SPS , the number ( n = 59 ) of reported varicella @-@ like rashes was also small .
P-163	-0.0145 -0.0140 -0.0142 -0.0142 -0.1758 -0.0032 -0.0144 -0.0065 -0.0013 -0.0145 -0.0029 -0.0145 -0.0096 -0.0142 -0.0124 -0.0144 -0.0065 -0.0043 -0.7748 -0.0012 -0.0011 -0.0011 -0.0017 -0.0034 -0.0219 -0.0183 -0.0034 -0.0042 -0.0068 -0.0027 -0.0038 -0.0486 -0.0043 -0.0392 -0.0651 -0.0345 -0.0014
S-408	50 -100 Holmers Farm Way , High Wycombe , Buckinghamshire , HP12 4EG Tel : + 44 1 494 567 567
T-408	50 -100 Holmers Farm Way , High Wycombe , Buckinghamshire , HP12 4EG Tel : + 44 1 494 567 567
H-408	-0.008102728985249996	50 -100 Holmers Farm Way , High Wycombe , Buckinghamshire , HP12 4EG Tel : + 44 1 494 567 567
D-408	-0.008102728985249996	50 -100 Holmers Farm Way , High Wycombe , Buckinghamshire , HP12 4EG Tel : + 44 1 494 567 567
P-408	-0.0050 -0.0840 -0.0012 -0.0006 -0.0006 -0.0005 -0.0006 -0.0013 -0.0010 -0.0003 -0.0025 -0.0013 -0.0977 -0.0002 -0.0012 -0.0010 -0.0010 -0.0005 -0.0022 -0.0028 -0.0627 -0.0013 -0.0013 -0.0056 -0.0032 -0.0018 -0.0010 -0.0006 -0.0013 -0.0013 -0.0008 -0.0012 -0.0005 -0.0013 -0.0006 -0.0017
S-352	54,0 ; 69,5 ) deutlich geringer , da Silgard keinen Einfluss auf den Verlauf von Infektionen oder Erkrankungen hat , die bereits zu Beginn der Impfserie bestehen .
T-352	54.0 , 69.5 ) , respectively , as Silgard does not impact the course of infections or disease that are present at vaccination onset .
H-352	-0.012751657515764236	54.0 , 69.5 ) , respectively , as Silgard does not impact the course of infections or disease that are present at vaccination onset .
D-352	-0.012751657515764236	54.0 , 69.5 ) , respectively , as Silgard does not impact the course of infections or disease that are present at vaccination onset .
P-352	-0.0038 -0.0043 -0.0013 -0.0590 -0.0016 -0.0010 -0.0013 -0.0016 -0.0160 -0.0516 -0.0039 -0.0763 -0.0008 -0.0002 -0.0724 -0.0014 -0.0219 -0.0087 -0.0032 -0.0014 -0.0027 -0.0005 -0.0028 -0.0142 -0.0088 -0.0138 -0.0121 -0.0074 -0.0187 -0.0016 -0.0145 -0.0016 -0.0018 -0.0014
S-667	Colecalciferol In Tierstudien wurden bei weit höheren Dosen als der therapeutischen Dosis beim Menschen reproduktionstoxische Wirkungen beobachtet .
T-667	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
H-667	-0.010797610506415367	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
D-667	-0.010797610506415367	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
P-667	-0.0051 -0.0011 -0.0013 -0.0010 -0.0009 -0.1028 -0.0142 -0.0107 -0.0017 -0.0059 -0.0037 -0.0016 -0.0083 -0.0143 -0.0049 -0.0013 -0.0167 -0.0037 -0.0041 -0.0066 -0.0060 -0.0024 -0.0013 -0.0118 -0.0013 -0.0787 -0.0166 -0.0023 -0.0016 -0.0015 -0.0014
S-1788	274 Pharmazeutischer Unternehmer und Hersteller Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW Vereinigtes Königreich
T-1788	Marketing Authorisation Holder Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom
H-1788	-0.005298105534166098	Marketing Authorisation Holder Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom
D-1788	-0.005298105534166098	Marketing Authorisation Holder Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom
P-1788	-0.0449 -0.0145 -0.0128 -0.0112 -0.0179 -0.0122 -0.0103 -0.0007 -0.0009 -0.0010 -0.0004 -0.0014 -0.0005 -0.0005 -0.0010 -0.0015 -0.0007 -0.0006 -0.0005 -0.0187 -0.0005 -0.0005 -0.0010 -0.0008 -0.0014 -0.0012 -0.0013 -0.0010 -0.0021 -0.0007 -0.0016
S-1940	Vorsicht ist angezeigt bei Patienten , die zuvor mit Simulect behandelt worden sind und denen erneut Simulect während eines weiteren Behandlungszyklus verabreicht wird .
T-1940	Caution should be exercised when patients previously given Simulect are re @-@ exposed to a subsequent course of therapy with this medicinal product .
H-1940	-0.013985210098326206	Caution should be exercised when patients previously given Simulect are re @-@ exposed to a subsequent course of therapy with this medicinal product .
D-1940	-0.013985210098326206	Caution should be exercised when patients previously given Simulect are re @-@ exposed to a subsequent course of therapy with this medicinal product .
P-1940	-0.0077 -0.0009 -0.0153 -0.0017 -0.0073 -0.0013 -0.0761 -0.0114 -0.0138 -0.0145 -0.0021 -0.0020 -0.0010 -0.0012 -0.0118 -0.0138 -0.0014 -0.0144 -0.0033 -0.0209 -0.0141 -0.0050 -0.0021 -0.0144 -0.0628 -0.0196 -0.0145 -0.0074 -0.0037 -0.0666 -0.0014
S-1775	Informationen über die Ausgangsmaterialien von Privigen Privigen wird aus menschlichem Blutplasma ( das ist der flüssige Bestandteil des Blutes ) hergestellt .
T-1775	Information on the starting material of Privigen Privigen is made from human blood plasma ( this is the liquid part of the blood ) .
H-1775	-0.008893688209354877	Information on the starting material of Privigen Privigen is made from human blood plasma ( this is the liquid part of the blood ) .
D-1775	-0.008893688209354877	Information on the starting material of Privigen Privigen is made from human blood plasma ( this is the liquid part of the blood ) .
P-1775	-0.0027 -0.0710 -0.0040 -0.0112 -0.0140 -0.0035 -0.0105 -0.0003 -0.0145 -0.0013 -0.0005 -0.0145 -0.0032 -0.0305 -0.0359 -0.0026 -0.0043 -0.0015 -0.0005 -0.0012 -0.0026 -0.0143 -0.0014 -0.0038 -0.0017 -0.0141 -0.0016 -0.0120 -0.0013 -0.0015 -0.0015 -0.0014
S-33	In einer Zusatzstudie an 27 Patienten wurde festgestellt , dass die Exelon @-@ Kapseln und die Lösung zum Einnehmen ähnliche Wirkstoffspiegel im Blut ergaben .
T-33	An additional study in 27 patients was used to show that Exelon capsules and oral solution produced similar levels of the active substance in the blood .
H-33	-0.009750253520905972	An additional study in 27 patients was used to show that Exelon capsules and oral solution produced similar levels of the active substance in the blood .
D-33	-0.009750253520905972	An additional study in 27 patients was used to show that Exelon capsules and oral solution produced similar levels of the active substance in the blood .
P-33	-0.0135 -0.0021 -0.0026 -0.0259 -0.0015 -0.0015 -0.0144 -0.0147 -0.0047 -0.0138 -0.0032 -0.0128 -0.0010 -0.0015 -0.0024 -0.0007 -0.0012 -0.0020 -0.0145 -0.0112 -0.0136 -0.0024 -0.0035 -0.0793 -0.0116 -0.0065 -0.0123 -0.0022 -0.0309 -0.0014 -0.0016 -0.0014
S-224	Dieser Botenstoff ist am Entzündungsgeschehen beteiligt und findet sich in hohen Konzentrationen bei Patienten mit den Erkrankungen , die mit Remicade behandelt werden .
T-224	This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Remicade is used to treat .
H-224	-0.006999365985393524	This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Remicade is used to treat .
D-224	-0.006999365985393524	This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Remicade is used to treat .
P-224	-0.0035 -0.0057 -0.0004 -0.0009 -0.0086 -0.0023 -0.0019 -0.0149 -0.0041 -0.0006 -0.0016 -0.0088 -0.0064 -0.0057 -0.0268 -0.0143 -0.0229 -0.0016 -0.0017 -0.0201 -0.0057 -0.0075 -0.0113 -0.0144 -0.0007 -0.0004 -0.0081 -0.0076 -0.0122 -0.0003 -0.0015 -0.0014
S-579	199 France BRISTOL @-@ MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
T-579	France BRISTOL @-@ MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
H-579	-0.0016982853412628174	France BRISTOL @-@ MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
D-579	-0.0016982853412628174	France BRISTOL @-@ MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
P-579	-0.0149 -0.0032 -0.0010 -0.0012 -0.0012 -0.0016 -0.0014 -0.0011 -0.0008 -0.0012 -0.0015 -0.0008 -0.0012 -0.0009 -0.0010 -0.0016 -0.0010 -0.0010 -0.0015 -0.0009 -0.0010 -0.0016 -0.0013 -0.0011 -0.0014 -0.0013 -0.0014 -0.0010 -0.0013 -0.0012 -0.0015 -0.0014 -0.0016
S-585	Die Möglichkeit , dass Gadograf bei einzelnen Patienten Torsades @-@ des- pointes @-@ Arrhythmien auslösen könnte , kann folglich nicht ausgeschlossen werden .
T-585	Therefore , the possibility that Gadograf may cause torsade de pointes arrhythmias in an individual patient can not be excluded .
H-585	-0.0055287922732532024	Therefore , the possibility that Gadograf may cause torsade de pointes arrhythmias in an individual patient can not be excluded .
D-585	-0.0055287922732532024	Therefore , the possibility that Gadograf may cause torsade de pointes arrhythmias in an individual patient can not be excluded .
P-585	-0.0136 -0.0010 -0.0056 -0.0037 -0.0023 -0.0060 -0.0062 -0.0017 -0.0029 -0.0021 -0.0154 -0.0120 -0.0020 -0.0016 -0.0142 -0.0140 -0.0078 -0.0015 -0.0008 -0.0004 -0.0031 -0.0130 -0.0020 -0.0145 -0.0009 -0.0012 -0.0140 -0.0024 -0.0012 -0.0113 -0.0010 -0.0016 -0.0014
S-1799	Eine verminderte Calciumausscheidung im Urin geht häufig mit einer nicht behandlungsbedürftigen Abnahme des Serumphosphatspiegels einher .
T-1799	Frequently , decreased renal calcium excretion is accompanied by a fall in serum phosphate levels not requiring therapeutic measures .
H-1799	-0.014500913210213184	Frequently , decreased renal calcium excretion is accompanied by a fall in serum phosphate levels not requiring therapeutic measures .
D-1799	-0.014500913210213184	Frequently , decreased renal calcium excretion is accompanied by a fall in serum phosphate levels not requiring therapeutic measures .
P-1799	-0.0145 -0.0003 -0.0196 -0.0082 -0.0158 -0.0021 -0.0146 -0.0116 -0.0086 -0.0009 -0.2498 -0.0123 -0.0008 -0.0013 -0.0131 -0.0139 -0.0018 -0.0043 -0.0145 -0.0030 -0.0034 -0.0010 -0.0054 -0.0005 -0.0010 -0.0038 -0.0149 -0.0040 -0.0145 -0.0018 -0.0143 -0.0015 -0.0014
S-517	Inkeysa , S.A , Juan XXIII , 15 - 19 , 3ª planta , Esplugas de Llobregat , 08950 Spanien
T-517	Inkeysa , S. A , Juan XXIII , 15 - 19 , 3ª planta , Esplugas de Llobregat , 08950 Spain
H-517	-0.006095089949667454	Inkeysa , S. A , Juan XXIII , 15 - 19 , 3ª planta , Esplugas de Llobregat , 08950 Spain
D-517	-0.006095089949667454	Inkeysa , S. A , Juan XXIII , 15 - 19 , 3ª planta , Esplugas de Llobregat , 08950 Spain
P-517	-0.0028 -0.0019 -0.0007 -0.0014 -0.0144 -0.0041 -0.0014 -0.0008 -0.0007 -0.0011 -0.0014 -0.0014 -0.1564 -0.0010 -0.0014 -0.0029 -0.0000 -0.0008 -0.0006 -0.0014 -0.0005 -0.0014 -0.0013 -0.0012 -0.0012 -0.0011 -0.0006 -0.0010 -0.0013 -0.0014 -0.0006 -0.0011 -0.0012 -0.0013 -0.0015
S-355	Er war ab 1987 Leiter der medizinischen Abteilung der niederländischen Herzstiftung und ging 1990 als Abteilungsleiter für klinische Beurteilungen zur niederländischen Beurteilungs- stelle für Arzneimittel .
T-355	He was Head of Medical Affairs of the Netherlands Heart Foundation from 1987 and moved to the Netherlands Medicines Evaluation Board in 1990 as Head of Department for Clinical Assessment .
H-355	-0.00728607177734375	He was Head of Medical Affairs of the Netherlands Heart Foundation from 1987 and moved to the Netherlands Medicines Evaluation Board in 1990 as Head of Department for Clinical Assessment .
D-355	-0.00728607177734375	He was Head of Medical Affairs of the Netherlands Heart Foundation from 1987 and moved to the Netherlands Medicines Evaluation Board in 1990 as Head of Department for Clinical Assessment .
P-355	-0.0068 -0.0132 -0.0099 -0.0015 -0.0124 -0.0136 -0.0119 -0.0029 -0.0107 -0.0020 -0.0008 -0.0045 -0.0006 -0.0070 -0.0141 -0.0044 -0.0022 -0.0052 -0.0111 -0.0035 -0.0056 -0.0007 -0.0115 -0.0071 -0.0007 -0.0060 -0.0038 -0.0030 -0.0372 -0.0073 -0.0257 -0.0007 -0.0083 -0.0008 -0.0098 -0.0018 -0.0014
S-1004	Stillen In klinischen Studien gab es keine Hinweise , dass Stillen den durch Rotarix aufgebauten Schutz vor Rotavirus @-@ Gastroenteritis reduziert .
T-1004	Breast @-@ feeding Based on evidence generated in clinical trials , breast @-@ feeding does not reduce the protection against rotavirus gastro @-@ enteritis afforded by Rotarix .
H-1004	-0.016054781153798103	Breast @-@ feeding Based on evidence generated in clinical trials , breast @-@ feeding does not reduce the protection against rotavirus gastro @-@ enteritis afforded by Rotarix .
D-1004	-0.016054781153798103	Breast @-@ feeding Based on evidence generated in clinical trials , breast @-@ feeding does not reduce the protection against rotavirus gastro @-@ enteritis afforded by Rotarix .
P-1004	-0.0045 -0.0166 -0.0056 -0.0011 -0.0145 -0.0062 -0.0158 -0.0145 -0.0224 -0.0131 -0.3565 -0.0020 -0.0121 -0.0058 -0.0011 -0.0140 -0.0017 -0.0044 -0.0091 -0.0051 -0.0125 -0.0043 -0.0013 -0.0011 -0.0010 -0.0306 -0.0020 -0.0004 -0.0010 -0.0006 -0.0144 -0.0063 -0.0020 -0.0011 -0.0010 -0.0011 -0.0017 -0.0014
S-56	Topotecan , der Wirkstoff in Hycamtin , ist ein Arzneimittel gegen Krebs und gehört zur Gruppe der Topoisomerase @-@ Hemmer .
T-56	The active substance in Hycamtin , topotecan , is an anticancer medicine that belongs to the group <<unk>> topoisomerase inhibitors <<unk>> .
H-56	-0.028645239770412445	The active substance in Hycamtin , topotecan , is an anticancer medicine that belongs to the group <unk> topoisomerase inhibitors .
D-56	-0.028645239770412445	The active substance in Hycamtin , topotecan , is an anticancer medicine that belongs to the group <unk> topoisomerase inhibitors .
P-56	-0.0144 -0.0021 -0.0109 -0.0029 -0.0118 -0.0007 -0.0007 -0.0040 -0.0072 -0.0016 -0.0014 -0.0012 -0.0023 -0.0014 -0.0182 -0.0113 -0.0002 -0.0006 -0.0096 -0.0146 -0.0023 -0.0008 -0.0014 -0.0113 -0.0037 -0.0750 -0.0040 -0.0014 -0.0007 -0.0008 -0.0010 -0.0006 -0.0026 -0.0005 -0.0005 -0.0014 -0.8621 -0.0014
S-860	Hyprolose ( E 463 ) Titandioxid ( E 171 ) Macrogol ( 400 ) Hypromellose ( E 464 )
T-860	Hydroxypropyl cellulose ( E463 ) Titanium dioxide ( E171 ) Macrogol Hypromellose ( E464 )
H-860	-0.058839160948991776	Hydroxypropyl cellulose ( E463 ) Titanium dioxide ( E171 ) Macrogol Hypromellose ( E464 )
D-860	-0.058839160948991776	Hydroxypropyl cellulose ( E463 ) Titanium dioxide ( E171 ) Macrogol Hypromellose ( E464 )
P-860	-0.3328 -0.9144 -0.0145 -0.0048 -0.0145 -0.0128 -0.0146 -0.0046 -0.0001 -0.0025 -0.0543 -0.0464 -0.1014 -0.0014 -0.0085 -0.0006 -0.0011 -0.0075 -0.0006 -0.0616 -0.0873 -0.0012 -0.0014 -0.0014 -0.0036 -0.0011 -0.0013 -0.0009 -0.5024 -0.0115 -0.0130 -0.0052 -0.0001 -0.0177 -0.0423 -0.0010 -0.0014 -0.0014 -0.0016
S-1444	EU / 1 / 04 / 305 / 001 30 Filmtabletten EU / 1 / 04 / 305 / 002 3 x 30 Filmtabletten
T-1444	EU / 1 / 04 / 305 / 001 30 film @-@ coated tablets EU / 1 / 04 / 305 / 002 3 x 30 film @-@ coated tablets
H-1444	-0.007372443564236164	EU / 1 / 04 / 305 / 001 30 film @-@ coated tablets EU / 1 / 04 / 305 / 002 3 x 30 film @-@ coated tablets
D-1444	-0.007372443564236164	EU / 1 / 04 / 305 / 001 30 film @-@ coated tablets EU / 1 / 04 / 305 / 002 3 x 30 film @-@ coated tablets
P-1444	-0.0038 -0.0014 -0.0014 -0.0014 -0.0010 -0.0014 -0.0010 -0.0012 -0.0014 -0.0013 -0.0015 -0.0031 -0.0069 -0.0371 -0.0144 -0.0008 -0.0129 -0.0013 -0.0015 -0.0014 -0.0014 -0.0014 -0.0009 -0.0014 -0.0009 -0.0012 -0.0014 -0.0012 -0.0014 -0.0023 -0.0015 -0.0014 -0.0018 -0.0041 -0.0016 -0.0006 -0.0012 -0.0011 -0.1646
S-452	Um dieses Problem zu minimieren , ist beim Einsetzen des Implantats besonders darauf zu achten , dass das Implantat direkt unter die Haut appliziert wird ,
T-452	To minimise this problem , caution needs to be exercised to ensure that the implant is administered by subcutaneous injection , particularly in dogs with pronounced depots of subcutaneous fat .
H-452	-0.010462386533617973	To minimise this problem , caution needs to be exercised to ensure that the implant is administered by subcutaneous injection , particularly in dogs with pronounced depots of subcutaneous fat .
D-452	-0.010462386533617973	To minimise this problem , caution needs to be exercised to ensure that the implant is administered by subcutaneous injection , particularly in dogs with pronounced depots of subcutaneous fat .
P-452	-0.0079 -0.0131 -0.0105 -0.0022 -0.0017 -0.0031 -0.0145 -0.0143 -0.0015 -0.0014 -0.0134 -0.0010 -0.0158 -0.0103 -0.0051 -0.0024 -0.0014 -0.0014 -0.0017 -0.0145 -0.0010 -0.0148 -0.0145 -0.0075 -0.0002 -0.0017 -0.1181 -0.0143 -0.0141 -0.0107 -0.0145 -0.0127 -0.0145 -0.0141 -0.0145 -0.0032 -0.0145 -0.0145 -0.0149 -0.0145 -0.0010 -0.0003 -0.0010 -0.0019 -0.0145 -0.0057 -0.0015
S-795	Die Häufigkeit der Nebenwirkungen bei der Mutter und ihrem Säugling war in der Gardasil @-@ Gruppe und in der Placebogruppe vergleichbar .
T-795	In breastfeeding mothers given Gardasil or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable between the vaccination and the placebo groups .
H-795	-0.06006059795618057	In breastfeeding mothers given Gardasil or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable .
D-795	-0.06006059795618057	In breastfeeding mothers given Gardasil or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable .
P-795	-0.0143 -0.0163 -0.0026 -0.0018 -0.0136 -0.0145 -0.0096 -0.0009 -0.0008 -0.0010 -0.0144 -0.0079 -0.0012 -0.0002 -0.0012 -0.0145 -0.0134 -0.0145 -0.0019 -0.0094 -0.0981 -0.0124 -0.0146 -0.0138 -0.1069 -0.0141 -0.0037 -0.0055 -0.0002 -0.0383 -0.0005 -0.0151 -0.0084 -0.0045 -0.0017 -0.0139 -0.0158 -0.0077 -0.0114 -0.0071 -0.0021 -0.0026 -0.0138 -0.0012 -2.1939 -0.0014
S-602	Aspirin ) vor der Einnahme von Trevaclyn anwenden , wird das Auftreten von Flush nicht weiter vermindert als unter Trevaclyn allein .
T-602	This will lower your chance of flushing ( redness of the skin , feeling warm , itching , or tingling , particularly in your head , neck , chest and upper back ) . • Taking aspirin before you take Trevaclyn does not reduce your flushing more than taking Trevaclyn alone .
H-602	-0.06639907509088516	This will lower your chance of flushing ( redness of the skin , feeling warm , itching , or tingling , particularly in your head , neck , chest and upper back ) .
D-602	-0.06639907509088516	This will lower your chance of flushing ( redness of the skin , feeling warm , itching , or tingling , particularly in your head , neck , chest and upper back ) .
P-602	-0.0145 -0.0140 -0.0144 -0.0142 -0.0167 -0.0357 -0.0080 -0.0116 -0.0135 -0.0145 -0.0024 -0.0126 -0.0059 -0.0138 -0.0116 -0.0148 -0.0147 -0.0107 -0.0178 -0.0105 -0.0096 -0.0408 -0.0188 -0.0063 -0.0005 -0.0139 -0.0152 -0.0124 -0.0142 -0.0144 -0.0140 -0.0144 -0.0430 -0.0248 -0.0621 -0.0239 -0.0137 -0.0030 -0.0080 -2.0312
S-216	33 Telmisartan senkt bei Patienten mit Hypertonie den systolischen und diastolischen Blutdruck , ohne die Pulsfrequenz zu beeinflussen .
T-216	28 In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate .
H-216	-0.011933272704482079	28 In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate .
D-216	-0.011933272704482079	28 In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate .
P-216	-0.0146 -0.0131 -0.0072 -0.0969 -0.0013 -0.0003 -0.0138 -0.0008 -0.0007 -0.0015 -0.0119 -0.0012 -0.0723 -0.0813 -0.0010 -0.0004 -0.0016 -0.0012 -0.0007 -0.0007 -0.0010 -0.0019 -0.0010 -0.0043 -0.0097 -0.0089 -0.0008 -0.0042 -0.0019 -0.0017
S-559	Sehr häufig : trockene Haut , Ausschlag , Unbekannt : schwere Hautreaktionen , Haarausfall , dunklere Hautfarbe , eingewachsene Zehennägel mit oder ohne Infektion
T-559	Very common : dry skin ; rash Not known : severe skin reactions ; hair loss ; darkening skin colour ; ingrown toenails with or without infection
H-559	-0.023565623909235	Very common : dry skin ; rash Not known : severe skin reactions ; hair loss ; darkening skin colour ; ingrown toenails with or without infection
D-559	-0.023565623909235	Very common : dry skin ; rash Not known : severe skin reactions ; hair loss ; darkening skin colour ; ingrown toenails with or without infection
P-559	-0.0017 -0.0050 -0.0015 -0.0052 -0.0011 -0.5120 -0.0040 -0.0009 -0.0395 -0.0026 -0.0015 -0.0014 -0.0029 -0.0044 -0.0012 -0.0872 -0.0052 -0.0022 -0.0053 -0.0027 -0.0142 -0.0110 -0.0039 -0.0115 -0.0226 -0.0006 -0.0001 -0.0001 -0.0024 -0.0003 -0.0004 -0.0042 -0.0014 -0.0012 -0.0024 -0.0848
S-1321	Diese Reaktion sollte bei der Differentialdiagnose von Fällen schwerer oder persistierender Diarrhoe berücksichtigt werden , die während oder kurz nach der Behandlung mit Paclitaxel auftreten .
T-1321	This reaction should be considered in the differential diagnosis of cases of severe or persistent diarrhoea occurring during or shortly after treatment with paclitaxel .
H-1321	-0.003797773504629731	This reaction should be considered in the differential diagnosis of cases of severe or persistent diarrhoea occurring during or shortly after treatment with paclitaxel .
D-1321	-0.003797773504629731	This reaction should be considered in the differential diagnosis of cases of severe or persistent diarrhoea occurring during or shortly after treatment with paclitaxel .
P-1321	-0.0034 -0.0085 -0.0022 -0.0016 -0.0096 -0.0102 -0.0063 -0.0008 -0.0008 -0.0014 -0.0018 -0.0067 -0.0015 -0.0011 -0.0023 -0.0005 -0.0008 -0.0015 -0.0004 -0.0096 -0.0008 -0.0112 -0.0013 -0.0016 -0.0017 -0.0109 -0.0128 -0.0138 -0.0017 -0.0001 -0.0012 -0.0007 -0.0010 -0.0016 -0.0014
S-201	Aufgrund des bekannten Missbrauchspotentials von Fentanyl , sollten die Ärzte die Patienten hinsichtlich eines Drogenmissbrauchs in der Anamnese beurteilen ( siehe Abschnitt 4.4 ) .
T-201	Due to the well known potential of abuse of fentanyl physicians should evaluate patients for a history of drug abuse ( see section 4.4 ) .
H-201	-0.005427713040262461	Due to the well known potential of abuse of fentanyl physicians should evaluate patients for a history of drug abuse ( see section 4.4 ) .
D-201	-0.005427713040262461	Due to the well known potential of abuse of fentanyl physicians should evaluate patients for a history of drug abuse ( see section 4.4 ) .
P-201	-0.0098 -0.0007 -0.0014 -0.0035 -0.0126 -0.0116 -0.0054 -0.0126 -0.0139 -0.0050 -0.0016 -0.0006 -0.0005 -0.0012 -0.0155 -0.0010 -0.0017 -0.0086 -0.0012 -0.0076 -0.0129 -0.0146 -0.0098 -0.0014 -0.0075 -0.0029 -0.0021 -0.0025 -0.0077 -0.0012 -0.0014 -0.0017 -0.0015 -0.0014
S-1305	Packung mit 90 x 1 perforierten PVC / Aluminium Einzeldosis @-@ Blisterpackung ( 3 eingesiegelte Schalen ) und 2 Ersatz @-@ Freisetzungs @-@ Einheiten ch
T-1305	90 x 1 PVC / Aluminium perforated unit dose blisters ( 3 pouches ) and 2 spare Insulin uc
H-1305	-0.030091913416981697	90 x 1 PVC / Aluminium perforated unit dose blisters ( 3 pouches ) and 2 spare Insulin uc
D-1305	-0.030091913416981697	90 x 1 PVC / Aluminium perforated unit dose blisters ( 3 pouches ) and 2 spare Insulin uc
P-1305	-0.0142 -0.0017 -0.0014 -0.0156 -0.0014 -0.0032 -0.0136 -0.0081 -0.0120 -0.0010 -0.0013 -0.0156 -0.0171 -0.0035 -0.6392 -0.0090 -0.0020 -0.0144 -0.0141 -0.0029 -0.0101 -0.0064 -0.0030 -0.0113 -0.0149 -0.0132 -0.0143 -0.0150 -0.0145 -0.0085
S-942	Die empfohlene Anfangsdosis beträgt 5 mg pro Tag und wird schrittweise über die ersten 4 Wochen der Behandlung erhöht , bis die empfohlene Erhaltungsdosis wie folgt erreicht wird :
T-942	The recommended starting dose is 5 mg per day which is stepwise increased over the first 4 weeks of treatment reaching the recommended maintenance dose as follows :
H-942	-0.011828610673546791	The recommended starting dose is 5 mg per day which is stepwise increased over the first 4 weeks of treatment reaching the recommended maintenance dose as follows :
D-942	-0.011828610673546791	The recommended starting dose is 5 mg per day which is stepwise increased over the first 4 weeks of treatment reaching the recommended maintenance dose as follows :
P-942	-0.0083 -0.0028 -0.0581 -0.0024 -0.0021 -0.0045 -0.0013 -0.0912 -0.0015 -0.0593 -0.0060 -0.0146 -0.0007 -0.0038 -0.0116 -0.0016 -0.0019 -0.0027 -0.0010 -0.0021 -0.0042 -0.0559 -0.0021 -0.0017 -0.0010 -0.0020 -0.0048 -0.0024 -0.0017 -0.0014
S-913	Zenapax zeigte bei der Verabreichung zusammen mit anderen Immunsuppresiva in Bezug auf die Verringerung der Abstoßungsrate eine größere Wirksamkeit als ein Placebo .
T-913	Zenapax was more effective than placebo in reducing the rate of rejection when added to immunosuppressive therapy .
H-913	-0.005675171967595816	Zenapax was more effective than placebo in reducing the rate of rejection when added to immunosuppressive therapy .
D-913	-0.005675171967595816	Zenapax was more effective than placebo in reducing the rate of rejection when added to immunosuppressive therapy .
P-913	-0.0056 -0.0009 -0.0011 -0.0126 -0.0094 -0.0016 -0.0097 -0.0095 -0.0010 -0.0008 -0.0012 -0.0095 -0.0044 -0.0106 -0.0051 -0.0014 -0.0021 -0.0006 -0.0038 -0.0182 -0.0071 -0.0154 -0.0018 -0.0004 -0.0003 -0.0009 -0.0167 -0.0143 -0.0030 -0.0014
S-95	Trudexa 40 mg Injektionslösung in Fertigspritze mit Stichschutz @-@ System wird als sterile Lösung von 40 mg Adalimumab in 0,8 ml Lösung geliefert .
T-95	Trudexa 40 mg solution for injection in pre @-@ filled syringe with needleguard is supplied as a sterile
H-95	-0.02820209041237831	Trudexa 40 mg solution for injection in pre @-@ filled syringe with needleguard is supplied as a sterile
D-95	-0.02820209041237831	Trudexa 40 mg solution for injection in pre @-@ filled syringe with needleguard is supplied as a sterile
P-95	-0.0014 -0.0012 -0.0012 -0.0015 -0.0036 -0.0008 -0.0139 -0.0125 -0.0082 -0.0019 -0.0074 -0.0126 -0.0015 -0.0114 -0.0008 -0.0008 -0.0001 -0.0031 -0.0145 -0.6464 -0.0140 -0.0129 -0.0073 -0.0013 -0.0156 -0.0050 -0.0016 -0.0007 -0.0147
S-1516	Ein Messlöffel oder eine Applikationsspritze fûr Zubereitung zum Einnehmen mit Skalierungen von 2,5 ml- und 5 ml @-@ Dosen ist beigelegt .
T-1516	A measuring spoon or an oral measuring syringe is provided , marked for doses of 2.5 ml and 5 ml .
H-1516	-0.007035528775304556	A measuring spoon or an oral measuring syringe is provided , marked for doses of 2.5 ml and 5 ml .
D-1516	-0.007035528775304556	A measuring spoon or an oral measuring syringe is provided , marked for doses of 2.5 ml and 5 ml .
P-1516	-0.0058 -0.0022 -0.0059 -0.0010 -0.0014 -0.0018 -0.0114 -0.0145 -0.0146 -0.0103 -0.0022 -0.0004 -0.0002 -0.0121 -0.0242 -0.0142 -0.0145 -0.0139 -0.0143 -0.0093 -0.0049 -0.0045 -0.0027 -0.0035 -0.0015 -0.0006 -0.0033 -0.0017
S-73	− Der CHMP befasste sich mit dem Verfahren gemäß Artikel 31 der Richtlinie 2001 / 83 / EG in der geänderten Fassung für Arzneimittel , die Piroxicam enthalten .
T-73	− The CHMP considered the referral made under article 31of Directive 2001 / 83 / EC , as amended , for medicinal products containing piroxicam .
H-73	-0.011425463482737541	− The CHMP considered the referral made under article 31of Directive 2001 / 83 / EC , as amended , for medicinal products containing piroxicam .
D-73	-0.011425463482737541	− The CHMP considered the referral made under article 31of Directive 2001 / 83 / EC , as amended , for medicinal products containing piroxicam .
P-73	-0.0076 -0.0048 -0.0008 -0.0008 -0.0131 -0.0022 -0.0145 -0.0002 -0.0145 -0.0087 -0.0394 -0.1741 -0.0097 -0.0031 -0.0089 -0.0036 -0.0008 -0.0014 -0.0006 -0.0022 -0.0017 -0.0077 -0.0031 -0.0026 -0.0010 -0.0020 -0.0076 -0.0018 -0.0756 -0.0009 -0.0086 -0.0019 -0.0011 -0.0009 -0.0006 -0.0015 -0.0030 -0.0014
S-293	Besondere Patientengruppen Es liegen nur begrenzte Erfahrungen zur Anwendung von Lantus bei Kindern unter 6 Jahren und bei Patienten , deren Leber oder Nieren nicht vollständig arbeiten , vor .
T-293	There is limited experience with the use of Lantus in children less than 6 years old and in patients whose liver or kidneys do not function well .
H-293	-0.027281027287244797	There is limited experience with the use of Lantus in children less than 6 years old and in patients whose liver or kidneys do not function well .
D-293	-0.027281027287244797	There is limited experience with the use of Lantus in children less than 6 years old and in patients whose liver or kidneys do not function well .
P-293	-0.0139 -0.0032 -0.0046 -0.0043 -0.0798 -0.0090 -0.0040 -0.0014 -0.0029 -0.0006 -0.0012 -0.0033 -0.0091 -0.1557 -0.0014 -0.0048 -0.0025 -0.0295 -0.0543 -0.0073 -0.0029 -0.0038 -0.0017 -0.0029 -0.0019 -0.4540 -0.0003 -0.0099 -0.0013 -0.0104 -0.0144 -0.0023 -0.0017
S-906	Zu den vierteljährlichen Informationstreffen mit Mitgliedern des CVMP und den regelmäßigen gemeinsamen Infotagen mit der Industrie finden sich nach wie vor Interessenten aus den unterschiedlichsten Bereichen ein .
T-906	Interested parties from a wide sphere continue to attend quarterly briefing meetings with members of CVMP regularly and also the regular Info @-@ days held jointly with industry .
H-906	-0.00972223561257124	Interested parties from a wide sphere continue to attend quarterly briefing meetings with members of CVMP regularly and also the regular Info @-@ days held jointly with industry .
D-906	-0.00972223561257124	Interested parties from a wide sphere continue to attend quarterly briefing meetings with members of CVMP regularly and also the regular Info @-@ days held jointly with industry .
P-906	-0.0117 -0.0008 -0.0018 -0.0037 -0.0055 -0.0109 -0.0052 -0.0145 -0.0028 -0.0105 -0.0014 -0.0136 -0.0104 -0.0010 -0.0144 -0.0033 -0.0028 -0.0081 -0.0016 -0.0620 -0.0012 -0.0004 -0.0296 -0.0115 -0.0236 -0.0230 -0.0102 -0.0151 -0.0145 -0.0145 -0.0139 -0.0127 -0.0011 -0.0008 -0.0015 -0.0059 -0.0024 -0.0014
S-881	Oxybutynin kann zu verminderter Speichelbildung führen , was Zahnkaries , Parodontose oder orale Candidiasis zur Folge haben kann .
T-881	Oxybutynin may lead to suppressed salivary secretions which could result in dental caries , parodontosis or oral candidiasis .
H-881	-0.03675346076488495	Oxybutynin may lead to suppressed salivary secretions which could result in dental caries , parodontosis or oral candidiasis .
D-881	-0.03675346076488495	Oxybutynin may lead to suppressed salivary secretions which could result in dental caries , parodontosis or oral candidiasis .
P-881	-0.0005 -0.0011 -0.0005 -0.0014 -0.0021 -0.2113 -0.0141 -0.0015 -0.0188 -0.0012 -0.0020 -0.0003 -0.0139 -0.0014 -0.0144 -0.0428 -0.0137 -0.0191 -0.0179 -0.0015 -0.0093 -0.0060 -0.0003 -0.0015 -0.0145 -0.0013 -0.0010 -0.0024 -0.0011 -0.6070 -0.0014 -0.0014 -0.0014 -0.0333 -0.0489 -0.0012 -0.2838 -0.0014
S-569	Bei anderen Alpha- Rezeptorenblockern sollte ein zeitlicher Abstand der Gabe berücksichtigt werden , wenn Vardenafil als Begleitbehandlung verordnet wird ( siehe Abschnitt 4.4 ) .
T-569	With other alpha blockers a time separation of dosing should be considered when vardenafil is prescribed concomitantly ( see section 4.4 ) .
H-569	-0.015860477462410927	With other alpha blockers a time separation of dosing should be considered when vardenafil is prescribed concomitantly ( see section 4.4 ) .
D-569	-0.015860477462410927	With other alpha blockers a time separation of dosing should be considered when vardenafil is prescribed concomitantly ( see section 4.4 ) .
P-569	-0.0128 -0.0022 -0.0012 -0.0002 -0.0013 -0.0164 -0.0013 -0.0118 -0.0079 -0.0145 -0.0012 -0.0082 -0.0136 -0.0060 -0.0015 -0.0014 -0.0094 -0.1611 -0.0104 -0.0006 -0.0008 -0.0011 -0.0019 -0.0043 -0.0008 -0.0159 -0.0047 -0.0002 -0.2544 -0.0021 -0.0021 -0.0083 -0.0013 -0.0013 -0.0016 -0.0015 -0.0014
S-506	Es zerfällt durch Emission von Betastrahlung von 2,281 MeV ( 99,98 % ) maximaler Energie in stabiles Zirkonium ( 90Zr ) .
T-506	It decay by emission of beta radiation of 2.281 MeV ( 99.98 % ) of maximal energy to stable Zirconium ( 90Zr ) .
H-506	-0.01522392313927412	It decay by emission of beta radiation of 2.281 MeV ( 99.98 % ) of maximal energy to stable Zirconium ( 90Zr ) .
D-506	-0.01522392313927412	It decay by emission of beta radiation of 2.281 MeV ( 99.98 % ) of maximal energy to stable Zirconium ( 90Zr ) .
P-506	-0.0054 -0.0056 -0.0142 -0.0117 -0.0055 -0.0052 -0.0015 -0.0070 -0.0014 -0.0019 -0.0028 -0.0068 -0.0009 -0.0014 -0.0028 -0.1513 -0.0015 -0.0013 -0.0032 -0.0006 -0.0014 -0.0014 -0.0092 -0.0139 -0.0013 -0.0172 -0.0018 -0.0132 -0.0013 -0.0017 -0.0016 -0.1111 -0.0009 -0.0010 -0.0014 -0.1515 -0.0014
S-1549	Ihr Kind kann nach der Impfung aufgefordert werden , noch für kurze Zeit im Sprechzimmer oder im Impfraum zu bleiben , um sicherzustellen , dass es zu keiner sofortigen allergischen Reaktion kommt .
T-1549	Your child may be asked to stay in the surgery or vaccination area for a short time after vaccination to check that he or she does not have an immediate allergic reaction .
H-1549	-0.0053788539953529835	Your child may be asked to stay in the surgery or vaccination area for a short time after vaccination to check that he or she does not have an immediate allergic reaction .
D-1549	-0.0053788539953529835	Your child may be asked to stay in the surgery or vaccination area for a short time after vaccination to check that he or she does not have an immediate allergic reaction .
P-1549	-0.0068 -0.0021 -0.0044 -0.0026 -0.0063 -0.0034 -0.0066 -0.0055 -0.0035 -0.0143 -0.0053 -0.0097 -0.0018 -0.0144 -0.0021 -0.0025 -0.0023 -0.0093 -0.0046 -0.0036 -0.0011 -0.0103 -0.0145 -0.0066 -0.0139 -0.0099 -0.0014 -0.0101 -0.0013 -0.0073 -0.0030 -0.0019 -0.0012 -0.0007 -0.0013 -0.0018 -0.0014
S-1500	Da der pharmakologische Effekt von Amlodipin erst langsam einsetzt , führt Amlodipin zu keiner akuten Hypotonie oder Reflextachykardie .
T-1500	As the pharmacological effect of amlodipine is of slow onset it does not cause acute hypotension or reflex tachycardia .
H-1500	-0.014153609052300453	As the pharmacological effect of amlodipine is of slow onset it does not cause acute hypotension or reflex tachycardia .
D-1500	-0.014153609052300453	As the pharmacological effect of amlodipine is of slow onset it does not cause acute hypotension or reflex tachycardia .
P-1500	-0.0112 -0.0046 -0.0010 -0.0020 -0.0052 -0.0015 -0.0018 -0.0010 -0.0010 -0.0007 -0.0010 -0.0070 -0.0145 -0.0101 -0.0073 -0.0004 -0.0146 -0.0042 -0.0014 -0.0142 -0.0081 -0.0005 -0.0010 -0.0003 -0.0012 -0.0082 -0.1587 -0.0008 -0.0055 -0.0010 -0.0011 -0.0012 -0.0015 -0.0005 -0.2138 -0.0014
S-1448	Eine Ampulle enthält 5 ml Lösungsmittel ( Wasser für Injektionszwecke mit Benzylalkohol und Benzalkoniumchlorid als Konservierungsmittel ) .
T-1448	One ampoule contains 5 ml solvent ( water for injections with benzyl alcohol and benzalkonium chloride as preservatives ) .
H-1448	-0.0059446413069963455	One ampoule contains 5 ml solvent ( water for injections with benzyl alcohol and benzalkonium chloride as preservatives ) .
D-1448	-0.0059446413069963455	One ampoule contains 5 ml solvent ( water for injections with benzyl alcohol and benzalkonium chloride as preservatives ) .
P-1448	-0.0093 -0.0054 -0.0004 -0.0009 -0.0020 -0.0022 -0.0009 -0.0108 -0.0033 -0.0017 -0.0051 -0.0038 -0.0022 -0.1074 -0.0063 -0.0012 -0.0036 -0.0006 -0.0012 -0.0019 -0.0006 -0.0038 -0.0020 -0.0068 -0.0002 -0.0016 -0.0009 -0.0008 -0.0011 -0.0043 -0.0045 -0.0017 -0.0106 -0.0015 -0.0020 -0.0014
S-1616	Klare , farblose bis weißliche Injektionslösung , die für das Produkt typische , durchsichtige bis weißliche , nicht @-@ kristalline Partikel enthalten kann .
T-1616	Clear , colourless @-@ to @-@ white solution for injection that may contain some product @-@ related translucent @-@ to- white amorphous particles .
H-1616	-0.024579674005508423	Clear , colourless @-@ to @-@ white solution for injection that may contain some product @-@ related translucent @-@ to- white amorphous particles .
D-1616	-0.024579674005508423	Clear , colourless @-@ to @-@ white solution for injection that may contain some product @-@ related translucent @-@ to- white amorphous particles .
P-1616	-0.0020 -0.0007 -0.0056 -0.0045 -0.0008 -0.0011 -0.1115 -0.0160 -0.0015 -0.0342 -0.0142 -0.0130 -0.0034 -0.0025 -0.0121 -0.0082 -0.0026 -0.0169 -0.0161 -0.0080 -0.0144 -0.0147 -0.0002 -0.0011 -0.0151 -0.0197 -0.0095 -0.0143 -0.0209 -0.0132 -0.0003 -0.0006 -0.0131 -0.4665 -0.0047 -0.0015
S-529	Die Wirkungen von Preotact auf die Knochenarchitektur wurden mithilfe der quantitativen Computertomographie ( QCT ) und der peripheren QCT untersucht .
T-529	The effects of Preotact on bone architecture were evaluated using quantitative computed tomography ( QCT ) and peripheral QCT .
H-529	-0.004011207260191441	The effects of Preotact on bone architecture were evaluated using quantitative computed tomography ( QCT ) and peripheral QCT .
D-529	-0.004011207260191441	The effects of Preotact on bone architecture were evaluated using quantitative computed tomography ( QCT ) and peripheral QCT .
P-529	-0.0040 -0.0021 -0.0015 -0.0033 -0.0011 -0.0010 -0.0019 -0.0037 -0.0030 -0.0092 -0.0320 -0.0012 -0.0427 -0.0036 -0.0014 -0.0009 -0.0039 -0.0010 -0.0003 -0.0010 -0.0006 -0.0016 -0.0012 -0.0014 -0.0013 -0.0014 -0.0018 -0.0013 -0.0005 -0.0014 -0.0026 -0.0013 -0.0012 -0.0023 -0.0014
S-610	Nobilis IB 4 @-@ 91 enthält das lebende IBV @-@ Virus , das attenuiert ( abgeschwächt ) wurde , so dass es keine Krankheitserscheinungen mehr hervorrufen kann .
T-610	Nobilis IB 4 @-@ 91 contains the live IBV virus that has been attenuated ( altered ) so that it does not cause the disease .
H-610	-0.004856733605265617	Nobilis IB 4 @-@ 91 contains the live IBV virus that has been attenuated ( altered ) so that it does not cause the disease .
D-610	-0.004856733605265617	Nobilis IB 4 @-@ 91 contains the live IBV virus that has been attenuated ( altered ) so that it does not cause the disease .
P-610	-0.0027 -0.0003 -0.0013 -0.0018 -0.0013 -0.0018 -0.0014 -0.0009 -0.0019 -0.0036 -0.0071 -0.0018 -0.0012 -0.0013 -0.0117 -0.0036 -0.0016 -0.0002 -0.0004 -0.0016 -0.0231 -0.0145 -0.0007 -0.0015 -0.0169 -0.0042 -0.0017 -0.0141 -0.0023 -0.0043 -0.0144 -0.0097 -0.0089 -0.0015
S-943	Die Gabe von Lamivudin zusammen mit den Mahlzeiten führt zu einer Verzögerung von tmax und einer Verringerung von Cmax ( um bis zu 47 % ) .
T-943	Co @-@ administration of lamivudine with food resulted in a delay of tmax and a lower Cmax ( decreased by up to 47 % ) .
H-943	-0.01735350675880909	Co @-@ administration of lamivudine with food resulted in a delay of tmax and a lower Cmax ( decreased by up to 47 % ) .
D-943	-0.01735350675880909	Co @-@ administration of lamivudine with food resulted in a delay of tmax and a lower Cmax ( decreased by up to 47 % ) .
P-943	-0.0145 -0.0018 -0.0015 -0.0021 -0.0057 -0.0010 -0.0010 -0.0010 -0.0014 -0.0056 -0.0144 -0.0147 -0.0015 -0.0038 -0.0030 -0.0162 -0.0018 -0.0008 -0.0051 -0.0041 -0.0150 -0.0045 -0.0007 -0.0035 -0.0148 -0.4356 -0.0036 -0.0029 -0.0015 -0.0012 -0.0014 -0.0015 -0.0016 -0.0015
S-1229	Es wurde eine mäßige und für gewöhnlich reversible Senkung der drei Blutzellreihen - weiße Blutzellen , rote Blutzellen und Blutplättchen - beobachtet .
T-1229	Moderate and usually reversible reduction in all three blood elements @-@ white blood cells , red blood cells and platelets , has been reported .
H-1229	-0.023934336379170418	Moderate and usually reversible reduction in all three blood elements @-@ white blood cells , red blood cells and platelets , has been reported .
D-1229	-0.023934336379170418	Moderate and usually reversible reduction in all three blood elements @-@ white blood cells , red blood cells and platelets , has been reported .
P-1229	-0.0059 -0.0011 -0.0031 -0.0054 -0.0014 -0.0006 -0.0009 -0.0121 -0.0097 -0.0145 -0.0016 -0.0068 -0.0145 -0.0145 -0.0014 -0.0044 -0.0107 -0.0015 -0.0012 -0.0102 -0.0075 -0.2887 -0.0012 -0.0003 -0.0031 -0.0121 -0.0138 -0.0016 -0.2889 -0.0018 -0.0014
S-1105	Sonstiges 17 Klinische Daten über die Verabreichung von ProQuad an Personen mit nachgewiesener HIV @-@ Infektion ohne Hinweis auf eine Immunsuppression liegen nicht vor .
T-1105	Other No clinical data are available for ProQuad in individuals who are known to be infected with human immunodeficiency viruses without evidence of immunosuppression .
H-1105	-0.011144357733428478	Other No clinical data are available for ProQuad in individuals who are known to be infected with human immunodeficiency viruses without evidence of immunosuppression .
D-1105	-0.011144357733428478	Other No clinical data are available for ProQuad in individuals who are known to be infected with human immunodeficiency viruses without evidence of immunosuppression .
P-1105	-0.0112 -0.0155 -0.0126 -0.0258 -0.0205 -0.0018 -0.0632 -0.0141 -0.0014 -0.0009 -0.0143 -0.0133 -0.0291 -0.0134 -0.0144 -0.0017 -0.0133 -0.0041 -0.0020 -0.0155 -0.0137 -0.0441 -0.0134 -0.0011 -0.0015 -0.0145 -0.0006 -0.0149 -0.0088 -0.0025 -0.0037 -0.0102 -0.0006 -0.0002 -0.0007 -0.0015 -0.0020 -0.0015
S-1609	Bei Gabe mit Efavirenz 600 mg einmal täglich , sollte die Dosierung Lopinavir / Ritonavir Tabletten auf 500 / 125 mg zweimal täglich erhöht werden .
T-1609	lopinavir / ritonavir tablets should be increased to 500 / 125 mg twice daily when co @-@ administered with efavirenz 600 mg once daily .
H-1609	-0.02278733067214489	lopinavir / ritonavir tablets should be increased to 500 / 125 mg twice daily when co @-@ administered with efavirenz 600 mg once daily .
D-1609	-0.02278733067214489	lopinavir / ritonavir tablets should be increased to 500 / 125 mg twice daily when co @-@ administered with efavirenz 600 mg once daily .
P-1609	-0.0145 -0.0132 -0.0011 -0.0011 -0.0063 -0.0013 -0.0015 -0.0009 -0.0011 -0.0027 -0.0016 -0.0060 -0.0017 -0.0056 -0.0036 -0.0018 -0.0014 -0.0027 -0.0016 -0.0043 -0.3811 -0.0127 -0.0145 -0.0015 -0.0047 -0.0865 -0.0023 -0.0090 -0.0005 -0.0014 -0.0003 -0.0015 -0.0033 -0.0013 -0.0028 -0.2650 -0.0019 -0.0015
S-1266	Stickstoffhaltige Abfallprodukte in Form von Ammoniak wirken vor allem hirntoxisch und führen in schweren Fällen zu Bewusstseinsstörungen oder Koma .
T-1266	Nitrogen waste , in the form of ammonia , is especially toxic for the brain and leads , in severe cases , to reduced levels of consciousness and to coma .
H-1266	-0.011897643096745014	Nitrogen waste , in the form of ammonia , is especially toxic for the brain and leads , in severe cases , to reduced levels of consciousness and to coma .
D-1266	-0.011897643096745014	Nitrogen waste , in the form of ammonia , is especially toxic for the brain and leads , in severe cases , to reduced levels of consciousness and to coma .
P-1266	-0.0052 -0.0008 -0.0010 -0.0061 -0.0144 -0.0145 -0.0058 -0.0031 -0.0011 -0.0014 -0.0008 -0.0010 -0.0005 -0.0017 -0.0061 -0.0131 -0.0103 -0.0188 -0.0020 -0.0015 -0.0182 -0.0136 -0.0143 -0.0014 -0.0033 -0.0011 -0.0015 -0.0015 -0.0144 -0.0154 -0.0017 -0.0024 -0.0009 -0.2372 -0.0141 -0.0051 -0.0055 -0.0017 -0.0014
S-93	Diese Reaktionen waren nach Reduzierung der Dosis oder Absetzen von Vigabatrin vollständig reversibel ( siehe Abschnitt 4.4 Warnhinweise und Vorsichtsmaßnahmen für die Anwendung ) .
T-93	Such reactions have been fully reversible following dose reduction or discontinuation of vigabatrin ( see Section 4.4 Special warnings and special precautions for use ) .
H-93	-0.00872237142175436	Such reactions have been fully reversible following dose reduction or discontinuation of vigabatrin ( see Section 4.4 Special warnings and special precautions for use ) .
D-93	-0.00872237142175436	Such reactions have been fully reversible following dose reduction or discontinuation of vigabatrin ( see Section 4.4 Special warnings and special precautions for use ) .
P-93	-0.0152 -0.0045 -0.0005 -0.0336 -0.0020 -0.0091 -0.0011 -0.0004 -0.0010 -0.0410 -0.0062 -0.0028 -0.0558 -0.0104 -0.0017 -0.0020 -0.0022 -0.0144 -0.0106 -0.0008 -0.0039 -0.0017 -0.0020 -0.0533 -0.0007 -0.0009 -0.0016 -0.0145 -0.0106 -0.0018 -0.0163 -0.0023 -0.0004 -0.0021 -0.0042 -0.0036 -0.0017 -0.0017 -0.0014
S-705	Kinder mit Turner @-@ Syndrom Spritzen Sie 0,045 - 0,050 Milligramm ( mg ) pro Kilogramm Körpergewicht einmal täglich unter die Haut ( subkutan ) .
T-705	Children with Turner syndrome Inject 0.045 - 0.050 milligrams ( mg ) for each kilogramme of body weight once daily under the skin ( subcutaneously ) .
H-705	-0.030172260478138924	Children with Turner syndrome Inject 0.045 - 0.050 milligrams ( mg ) for each kilogramme of body weight once daily under the skin ( subcutaneous ) .
D-705	-0.030172260478138924	Children with Turner syndrome Inject 0.045 - 0.050 milligrams ( mg ) for each kilogramme of body weight once daily under the skin ( subcutaneous ) .
P-705	-0.0064 -0.0116 -0.0006 -0.0060 -0.0010 -0.0145 -0.0014 -0.0019 -0.1407 -0.0585 -0.0013 -0.0788 -0.0048 -0.0017 -0.0016 -0.0006 -0.0014 -0.0259 -0.0108 -0.0040 -0.0016 -0.0643 -0.0006 -0.0026 -0.0029 -0.0011 -0.0168 -0.1255 -0.0221 -0.0032 -0.0009 -0.0018 -0.0027 -0.0003 -0.0005 -0.0016 -0.5803 -0.0017 -0.0017 -0.0014
S-909	Italia Eli Lilly Italia S.p.A Elanco Animal Health Via Gramsci , 733 SestoFiorentino I @-@ 50019 Firenze
T-909	Italia Eli Lilly Italia S. p . A Elanco Animal Health Via Gramsci , 733 SestoFiorentino I @-@ 50019 Firenze
H-909	-0.009532217867672443	Italia Eli Lilly Italia S. p . A Elanco Animal Health Via Gramsci , 733 SestoFiorentino I @-@ 50019 Firenze
D-909	-0.009532217867672443	Italia Eli Lilly Italia S. p . A Elanco Animal Health Via Gramsci , 733 SestoFiorentino I @-@ 50019 Firenze
P-909	-0.0006 -0.0013 -0.0010 -0.0013 -0.0003 -0.0012 -0.0004 -0.0013 -0.0145 -0.0177 -0.0068 -0.0016 -0.0024 -0.0005 -0.0011 -0.0007 -0.0009 -0.0007 -0.0016 -0.0013 -0.0003 -0.0021 -0.0013 -0.0014 -0.0013 -0.0010 -0.0020 -0.0006 -0.0019 -0.0010 -0.0010 -0.0007 -0.0009 -0.0316 -0.2717 -0.0009 -0.0011 -0.0013 -0.0002 -0.0016
S-1701	Die kardiovaskuläre Funktion des Hundes sollten sorgfältig geprüft werden , bevor die Behandlung mit Enurace 50 begonnen wird , und sind auch während der Behandlung regelmäßig zu überwachen
T-1701	The dog <<unk>> s cardiovascular functionality should be carefully assessed before the start of the treatment with Enurace 50 and it should be periodically monitored during the treatment .
H-1701	-0.0181971937417984	The dog <unk> s cardiovascular functionality should be carefully assessed before the start of the treatment with Enurace 50 and it should be periodically monitored during the treatment .
D-1701	-0.0181971937417984	The dog <unk> s cardiovascular functionality should be carefully assessed before the start of the treatment with Enurace 50 and it should be periodically monitored during the treatment .
P-1701	-0.0078 -0.0160 -0.0145 -0.0020 -0.0023 -0.0005 -0.0008 -0.0007 -0.0209 -0.0138 -0.0012 -0.0015 -0.0013 -0.0042 -0.0128 -0.0008 -0.0036 -0.0139 -0.0975 -0.0013 -0.0162 -0.2251 -0.0021 -0.0007 -0.0022 -0.0009 -0.0189 -0.1457 -0.0145 -0.0100 -0.0117 -0.0144 -0.0317 -0.0013 -0.0011 -0.0010 -0.0072 -0.0142 -0.0014 -0.0068 -0.0014
S-104	Bei Patienten mit Fructoseintoleranz , Glucose @-@ Malabsorption und Sucrose @-@ Isomaltase @-@ Mangel darf dieses Medikament nicht angewendet werden ..
T-104	Patients with rare hereditary problems of fructose intolerance , glucose malabsorption or sucrose- isomaltase insufficiency should not take this medicine
H-104	-0.02977856807410717	Patients with rare hereditary problems of fructose intolerance , glucose malabsorption or sucrose- isomaltase insufficiency should not take this medicine
D-104	-0.02977856807410717	Patients with rare hereditary problems of fructose intolerance , glucose malabsorption or sucrose- isomaltase insufficiency should not take this medicine
P-104	-0.0112 -0.0009 -0.0088 -0.0153 -0.0145 -0.0095 -0.0013 -0.0144 -0.0142 -0.0036 -0.0006 -0.0009 -0.0015 -0.0008 -0.0010 -0.0018 -0.0015 -0.0010 -0.0005 -0.0012 -0.0007 -0.0008 -0.6816 -0.0015 -0.2359 -0.0139 -0.0137 -0.0003 -0.0008 -0.0009 -0.0008 -0.0221 -0.0024 -0.0006 -0.0015 -0.0090 -0.0024 -0.0113 -0.0023 -0.0071 -0.1063
S-1130	Wenn ein Fertigpen aus dem Kühlschrank entnommen wurde und Raumtemperatur ( nicht über 30 ° C ) erreicht hat , muss er entweder innerhalb von 3 Tagen angewendet oder verworfen werden .
T-1130	Once a pre @-@ filled pen has been removed from the refrigerator and has reached room temperature ( not above 30 ° C ) it must either be used within 3 days or disposed of .
H-1130	-0.006150176282972097	Once a pre @-@ filled pen has been removed from the refrigerator and has reached room temperature ( not above 30 ° C ) it must either be used within 3 days or disposed of .
D-1130	-0.006150176282972097	Once a pre @-@ filled pen has been removed from the refrigerator and has reached room temperature ( not above 30 ° C ) it must either be used within 3 days or disposed of .
P-1130	-0.0136 -0.0088 -0.0144 -0.0014 -0.0117 -0.0094 -0.0052 -0.0015 -0.0047 -0.0016 -0.0019 -0.0082 -0.0007 -0.0007 -0.0013 -0.0032 -0.0095 -0.0011 -0.0014 -0.0013 -0.0017 -0.0052 -0.0115 -0.0019 -0.0016 -0.0015 -0.0021 -0.0135 -0.0185 -0.0262 -0.0014 -0.0062 -0.0036 -0.0032 -0.0013 -0.0292 -0.0143 -0.0027 -0.0016 -0.0020 -0.0015
S-1453	Dies zeigen die Unterschiede in den Zusammenfassungen der Merkmale des Arzneimittels , Etikettierungen und Packungsbeilagen in den Ländern , in denen das Arzneimittel in Verkehr ist .
T-1453	Diovan has been identified as needing harmonisation by the Co @-@ ordination Group on the Mutual and Decentralised Procedures <<unk>> Human ( CMD ( h ) ) .
H-1453	-0.025067033246159554	Diovan has been identified as needing harmonisation by the Co @-@ ordination Group on the Mutual and Decentralised Procedures <unk> Human ( CMD ( h ) ) .
D-1453	-0.025067033246159554	Diovan has been identified as needing harmonisation by the Co @-@ ordination Group on the Mutual and Decentralised Procedures <unk> Human ( CMD ( h ) ) .
P-1453	-0.0234 -0.0145 -0.0145 -0.0143 -0.0139 -0.0141 -0.0126 -0.0145 -0.0015 -0.0145 -0.0071 -0.0144 -0.0093 -0.0145 -0.0016 -0.0136 -0.0101 -0.0142 -0.0146 -0.0112 -0.0145 -0.0038 -0.0144 -0.0145 -0.0144 -0.0068 -0.0143 -0.0100 -0.0087 -0.0155 -0.0145 -0.0145 -0.0126 -0.0134 -0.0135 -0.5362 -0.0145 -0.0065 -0.0150 -0.0199 -0.0018
S-1026	Aufgrund des seltenen Auftretens von Hämophilie A bei Frauen liegen über die Anwendung von Helixate NexGen während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-1026	Based on the rare occurrence of haemophilia A in women , experience regarding the use of Helixate NexGen during pregnancy and breast @-@ feeding is not available .
H-1026	-0.02196303941309452	Based on the rare occurrence of haemophilia A in women , experience regarding the use of Helixate NexGen during pregnancy and breast @-@ feeding is not available .
D-1026	-0.02196303941309452	Based on the rare occurrence of haemophilia A in women , experience regarding the use of Helixate NexGen during pregnancy and breast @-@ feeding is not available .
P-1026	-0.0150 -0.0016 -0.0028 -0.0045 -0.0060 -0.0008 -0.0007 -0.0011 -0.0015 -0.0115 -0.0008 -0.0002 -0.0010 -0.0018 -0.0030 -0.0698 -0.0050 -0.0141 -0.0142 -0.0033 -0.0033 -0.0014 -0.0058 -0.0011 -0.0013 -0.0017 -0.0015 -0.0010 -0.0016 -0.0021 -0.0504 -0.0014 -0.0020 -0.4834 -0.1619 -0.0008 -0.0075 -0.0065 -0.0039 -0.0017 -0.0014
S-1581	In Langzeitstudien in einer Population von Kindern und Jugendlichen mit Verhaltensstörung und anderen störenden Verhaltensweisen erhöhte sich das Gewicht nach 12 Monaten Behandlung im Mittel um 7,3 kg .
T-1581	In a population of children and adolescents with conduct and other disruptive behaviour disorders , in long- term studies , weight increased by a mean of 7.3 kg after 12 months of treatment .
H-1581	-0.030389469116926193	In a population of children and adolescents with conduct and other disruptive behaviour disorders , in long- term studies , weight increased by a mean of 7.3 kg after 12 months of treatment .
D-1581	-0.030389469116926193	In a population of children and adolescents with conduct and other disruptive behaviour disorders , in long- term studies , weight increased by a mean of 7.3 kg after 12 months of treatment .
P-1581	-0.0050 -0.4989 -0.0107 -0.0025 -0.0037 -0.0022 -0.0035 -0.0009 -0.0008 -0.0034 -0.0145 -0.0118 -0.0017 -0.0122 -0.0020 -0.0134 -0.0145 -0.0008 -0.0043 -0.0209 -0.5186 -0.0136 -0.0012 -0.0057 -0.0071 -0.0139 -0.0049 -0.0032 -0.0154 -0.0061 -0.0040 -0.0035 -0.0022 -0.0023 -0.0068 -0.0020 -0.0014 -0.0022 -0.0014 -0.0015 -0.0014
S-1570	Wichtige Informationen über bestimmte sonstige Bestandteile von Nifedipine Pharmamatch retard Nifedipine Pharmamatch retard enthält Laktose .
T-1570	Important information about some of the ingredients of Nifedipine Pharmamatch retard 36 / 44 Nifedipine Pharmamatch retard contains lactose .
H-1570	-0.0038712178356945515	Important information about some of the ingredients of Nifedipine Pharmamatch retard 36 / 44 Nifedipine Pharmamatch retard contains lactose .
D-1570	-0.0038712178356945515	Important information about some of the ingredients of Nifedipine Pharmamatch retard 36 / 44 Nifedipine Pharmamatch retard contains lactose .
P-1570	-0.0016 -0.0007 -0.0011 -0.0042 -0.0079 -0.0142 -0.0130 -0.0018 -0.0147 -0.0048 -0.0089 -0.0011 -0.0011 -0.0014 -0.0010 -0.0017 -0.0004 -0.0023 -0.0014 -0.0012 -0.0009 -0.0009 -0.0145 -0.0135 -0.0145 -0.0135 -0.0013 -0.0011 -0.0014 -0.0010 -0.0015 -0.0005 -0.0015 -0.0013 -0.0012 -0.0006 -0.0008 -0.0021 -0.0039 -0.0015 -0.0008 -0.0023 -0.0014
S-381	29,2 l / Stunde / m2 bis 92,2 l / Stunde / m2 , abhängig vom Geschlecht und vom Alter ( die interindividuelle Variabilität betrug 52,2 % ) .
T-381	Excretion Systemic clearance ranged from 29.2 l / hr / m2 to 92.2 / hr / m2 depending on gender and age ( inter @-@ individual variability was 52.2 % ) .
H-381	-0.04349055141210556	Excretion Systemic clearance ranged from 29.2 l / hr / m2 to 92.2 l / hr / m2 depending on gender and age ( inter @-@ individual variability was 52.2 % ) .
D-381	-0.04349055141210556	Excretion Systemic clearance ranged from 29.2 l / hr / m2 to 92.2 l / hr / m2 depending on gender and age ( inter @-@ individual variability was 52.2 % ) .
P-381	-0.0155 -0.0145 -0.0140 -0.0145 -0.0137 -0.0010 -0.0145 -0.0038 -0.0144 -0.0104 -0.0027 -0.0034 -0.2644 -0.0029 -0.0014 -0.0370 -0.0015 -0.2157 -0.0148 -0.0014 -0.0014 -0.0014 -1.0133 -0.0014 -0.0239 -0.0015 -0.0640 -0.0111 -0.1682 -0.0107 -0.0020 -0.0014 -0.0019 -0.0140 -0.0023 -0.0012 -0.0007 -0.0022 -0.0054 -0.0013 -0.0019 -0.0013 -0.0013 -0.0016 -0.0020 -0.0014
S-1476	Ihre Spritzen Die Spritzen , die mit diesem Arzneimittel mitgeliefert werden , haben eine farbige Nadel- Schutzvorrichtung , die an der Nadel befestigt ist .
T-1476	Your syringes The syringes supplied with this medicine have a coloured needle protection device that is attached to the needle .
H-1476	-0.006092655472457409	Your syringes The syringes supplied with this medicine have a coloured needle protection device that is attached to the needle .
D-1476	-0.006092655472457409	Your syringes The syringes supplied with this medicine have a coloured needle protection device that is attached to the needle .
P-1476	-0.0103 -0.0094 -0.0004 -0.0015 -0.0097 -0.0011 -0.0006 -0.0013 -0.0105 -0.0008 -0.0016 -0.0166 -0.0056 -0.0059 -0.0031 -0.0100 -0.0040 -0.0014 -0.0114 -0.0057 -0.0119 -0.0022 -0.0074 -0.0360 -0.0019 -0.0016 -0.0012 -0.0018 -0.0017
S-760	Achten Sie darauf , dass die Spitze der Nadel sich stets unter der Oberfläche des sterilen Wassers befindet , damit keine Luftbläschen in die Spritze gelangen können .
T-760	Make sure the tip of the needle is always below the surface of the sterile water to help keep any air bubbles from entering the syringe .
H-760	-0.011821350082755089	Make sure the tip of the needle is always below the surface of the sterile water to help keep any air bubbles from entering the syringe .
D-760	-0.011821350082755089	Make sure the tip of the needle is always below the surface of the sterile water to help keep any air bubbles from entering the syringe .
P-760	-0.1170 -0.0012 -0.0129 -0.0059 -0.0016 -0.0019 -0.0439 -0.0011 -0.0024 -0.0428 -0.0512 -0.0015 -0.0020 -0.0016 -0.0031 -0.0021 -0.0005 -0.0013 -0.0175 -0.0147 -0.0140 -0.0152 -0.0107 -0.0007 -0.0007 -0.0060 -0.0088 -0.0027 -0.0015 -0.0003 -0.0002 -0.0017 -0.0015
S-530	führte zur Verabschiedung von 13 Gutachten , die 79 Inhaber von Genehmigungen für das Inverkehrbringen und 136 nationale Zulassungen für die folgenden Anorektika betrafen :
T-530	national marketing authorisations .
H-530	-0.009090437553822994	national marketing authorisations .
D-530	-0.009090437553822994	national marketing authorisations .
P-530	-0.0145 -0.0126 -0.0026 -0.0041 -0.0009 -0.0144 -0.0145
S-1467	EMEA @-@ Jahresbericht 2002 EMEA / MB / 055 / 02 / de / Endgültig Verwendung des speziellen EU @-@ Beitrags für Arzneimittel für seltene Leiden 2002
T-1467	s Protocol assistance s Inspections s Post @-@ authorisation applications
H-1467	-0.022195005789399147	s Protocol assistance s Inspections s Post @-@ authorisation applications
D-1467	-0.022195005789399147	s Protocol assistance s Inspections s Post @-@ authorisation applications
P-1467	-0.0145 -0.0145 -0.0113 -0.0010 -0.0010 -0.0203 -0.0147 -0.0850 -0.0145 -0.0141 -0.0434 -0.0586 -0.0117 -0.0145 -0.0038 -0.0146 -0.0399
S-1015	− Wenn allergische oder anaphylaktoide Reaktionen auftreten , beenden Sie sofort die Infusion , kontaktieren Sie einen Arzt oder suchen Sie sofort eine medizinische Notfalleinrichtung auf .
T-1015	- If allergic or anaphylactic @-@ type reactions occur , stop the infusion immediately and contact a doctor
H-1015	-0.023194238543510437	- If allergic or anaphylactic @-@ type reactions occur , stop the infusion immediately and contact a doctor
D-1015	-0.023194238543510437	- If allergic or anaphylactic @-@ type reactions occur , stop the infusion immediately and contact a doctor
P-1015	-0.0116 -0.0051 -0.0092 -0.0010 -0.0019 -0.0014 -0.0013 -0.0004 -0.0007 -0.1976 -0.0684 -0.0138 -0.0455 -0.0010 -0.0047 -0.0024 -0.0068 -0.0076 -0.0020 -0.0011 -0.0176 -0.0373 -0.0080 -0.0190 -0.0070 -0.1306
S-862	Eine Dosierspritze ( 10 ml mit einer Skalierung in 0,5 ml Schritten ) wird in jeder Packung mitgeliefert , damit Sie Ihre Dosis exakt abmessen können .
T-862	A dosing syringe with a 10 ml graduation is supplied with the pack so you can measure your dose accurately .
H-862	-0.012816434726119041	A dosing syringe with a 10 ml graduation is supplied with the pack so you can measure your dose accurately .
D-862	-0.012816434726119041	A dosing syringe with a 10 ml graduation is supplied with the pack so you can measure your dose accurately .
P-862	-0.0063 -0.0096 -0.1428 -0.0017 -0.0003 -0.0002 -0.0174 -0.0110 -0.0142 -0.0019 -0.0145 -0.0020 -0.0142 -0.0170 -0.0009 -0.0165 -0.0141 -0.0144 -0.0122 -0.0092 -0.0055 -0.0073 -0.0051 -0.0056 -0.0101 -0.0010 -0.0019 -0.0021
S-1254	Die Tabletten sind weiß bis weißlich , rund , flach und tragen auf einer Seite die Markierung &apos; 30 &quot; und auf der anderen Seite die Markierung &apos; AD4 &apos; .
T-1254	The tablets are white to off @-@ white , round , flat and marked <<unk>> 30 <<unk>> on one face , AD4 on the other .
H-1254	-0.05787818506360054	The tablets are white to off @-@ white , round , flat and marked <unk> 30 <unk> on one face , AD4 on the other .
D-1254	-0.05787818506360054	The tablets are white to off @-@ white , round , flat and marked <unk> 30 <unk> on one face , AD4 on the other .
P-1254	-0.0042 -0.0025 -0.0014 -0.0021 -0.0032 -0.0211 -0.0353 -0.0073 -0.0004 -0.0049 -0.0031 -0.0333 -0.0028 -0.0091 -0.0140 -0.0153 -0.0051 -0.0143 -0.0025 -0.0016 -0.7440 -0.4123 -0.0144 -0.0012 -0.0133 -0.0015 -0.0016 -0.3049 -0.0016
S-1474	oberen weiblichen Genitaltrakts , einschließlich Salpingitis und Endometritis ) , ohne einen assoziierten Tuboovarial- oder Beckenabszess .
T-1474	including salpingitis and endometritis ) , without an associated tubo @-@ ovarian or pelvic abscess .
H-1474	-0.0029672938399016857	including salpingitis and endometritis ) , without an associated tubo @-@ ovarian or pelvic abscess .
D-1474	-0.0029672938399016857	including salpingitis and endometritis ) , without an associated tubo @-@ ovarian or pelvic abscess .
P-1474	-0.0145 -0.0018 -0.0005 -0.0009 -0.0007 -0.0016 -0.0002 -0.0006 -0.0012 -0.0011 -0.0015 -0.0103 -0.0040 -0.0030 -0.0006 -0.0027 -0.0013 -0.0141 -0.0040 -0.0145 -0.0000 -0.0022 -0.0019 -0.0004 -0.0009 -0.0007 -0.0002 -0.0005 -0.0016 -0.0014
S-755	Oxidationsmittel in der Natrium ( 99mTc ) pertechnetat @-@ Injektionslösung können die Qualität der zubereiteten Lösung nachteilig beeinflussen .
T-755	Any oxidant present in the sodium pertechnetate ( 99mTc ) solution for injection might adversely affect the quality of the preparation .
H-755	-0.0056977951899170876	Any oxidant present in the sodium pertechnetate ( 99mTc ) solution for injection might adversely affect the quality of the preparation .
D-755	-0.0056977951899170876	Any oxidant present in the sodium pertechnetate ( 99mTc ) solution for injection might adversely affect the quality of the preparation .
P-755	-0.0145 -0.0019 -0.0108 -0.0141 -0.0017 -0.0044 -0.0059 -0.0004 -0.0147 -0.0023 -0.0018 -0.0023 -0.0093 -0.0016 -0.0014 -0.0013 -0.0013 -0.0014 -0.0163 -0.0146 -0.0049 -0.0014 -0.0147 -0.0082 -0.0006 -0.0093 -0.0017 -0.0016 -0.0015 -0.0020 -0.0139 -0.0047 -0.0014
S-950	Osteoporose ist eine Krankheit , die dazu führt , dass Ihre Knochen dünn und brüchig werden - diese Krankheit tritt insbesondere bei Frauen nach der Menopause auf .
T-950	Osteoporosis is a disease that causes your bones to become thin and fragile - this disease is especially common in women after the menopause .
H-950	-0.004348482005298138	Osteoporosis is a disease that causes your bones to become thin and fragile - this disease is especially common in women after the menopause .
D-950	-0.004348482005298138	Osteoporosis is a disease that causes your bones to become thin and fragile - this disease is especially common in women after the menopause .
P-950	-0.0020 -0.0008 -0.0009 -0.0011 -0.0013 -0.0008 -0.0019 -0.0029 -0.0066 -0.0051 -0.0054 -0.0026 -0.0007 -0.0014 -0.0039 -0.0023 -0.0016 -0.0084 -0.0006 -0.0162 -0.0113 -0.0065 -0.0084 -0.0106 -0.0060 -0.0044 -0.0118 -0.0073 -0.0104 -0.0007 -0.0009 -0.0003 -0.0015 -0.0014
S-751	Patienten mit Candida @-@ Endocarditis , Osteomyelitis oder Meningitis und mit einer bekannten C. krusei @-@ Infektion sind nicht untersucht worden .
T-751	Patients with candida endocarditis , osteomyelitis or meningitis and known C. krusei infection have not been studied .
H-751	-0.00397525355219841	Patients with candida endocarditis , osteomyelitis or meningitis and known C. krusei infection have not been studied .
D-751	-0.00397525355219841	Patients with candida endocarditis , osteomyelitis or meningitis and known C. krusei infection have not been studied .
P-751	-0.0022 -0.0009 -0.0158 -0.0102 -0.0022 -0.0009 -0.0025 -0.0011 -0.0004 -0.0004 -0.0015 -0.0013 -0.0008 -0.0009 -0.0011 -0.0006 -0.0005 -0.0046 -0.0007 -0.0012 -0.0007 -0.0006 -0.0100 -0.0142 -0.0009 -0.0144 -0.0010 -0.0008 -0.0046 -0.0224 -0.0017 -0.0015 -0.0132 -0.0019 -0.0015
S-715	Deshalb darf der Test nicht eher verwendet werden , bis vier Wochen ohne systemische antibakterielle Therapie und zwei Wochen nach der letzten Dosis von Antacida verstrichen sind .
T-715	Therefore , the test must not be used until four weeks without systemic antibacterial therapy and two weeks after last dose of acid antisecretory agents .
H-715	-0.007099637761712074	Therefore , the test must not be used until four weeks without systemic antibacterial therapy and two weeks after last dose of acid antisecretory agents .
D-715	-0.007099637761712074	Therefore , the test must not be used until four weeks without systemic antibacterial therapy and two weeks after last dose of acid antisecretory agents .
P-715	-0.0075 -0.0009 -0.0064 -0.0048 -0.0023 -0.0595 -0.0020 -0.0015 -0.0021 -0.0046 -0.0051 -0.0010 -0.0132 -0.0033 -0.0007 -0.0011 -0.0031 -0.0021 -0.0012 -0.0005 -0.0034 -0.0047 -0.0033 -0.0012 -0.0037 -0.0147 -0.0049 -0.0021 -0.0145 -0.0142 -0.0145 -0.0145 -0.0144 -0.0140 -0.0015
S-496	Atorvastatin ( 80 mg täglich ) veränderte die Pharmakokinetik von Prasugrel und seine Thrombozytenaggregationshemmung nicht .
T-496	Atorvastatin ( 80 mg daily ) did not alter the pharmacokinetics of prasugrel and its inhibition of platelet aggregation .
H-496	-0.00640142010524869	Atorvastatin ( 80 mg daily ) did not alter the pharmacokinetics of prasugrel and its inhibition of platelet aggregation .
D-496	-0.00640142010524869	Atorvastatin ( 80 mg daily ) did not alter the pharmacokinetics of prasugrel and its inhibition of platelet aggregation .
P-496	-0.0055 -0.0014 -0.0008 -0.0006 -0.0007 -0.0015 -0.0031 -0.0011 -0.0277 -0.0014 -0.0053 -0.0013 -0.0134 -0.0028 -0.0012 -0.0005 -0.0006 -0.0019 -0.0018 -0.0036 -0.0010 -0.0006 -0.0009 -0.0746 -0.0021 -0.0142 -0.0077 -0.0135 -0.0034 -0.0006 -0.0270 -0.0012 -0.0033 -0.0013 -0.0015 -0.0014
S-1454	Die blutdrucksenkende Wirkung von Aprovel ist innerhalb von 1 @-@ 2 Wochen deutlich nachweisbar , die maximale Wirkung ist 4 @-@ 6 Wochen nach Therapiebeginn erreicht .
T-1454	The blood pressure lowering effect of Aprovel is evident within 1 @-@ 2 weeks , with the maximal effect occurring by 4 @-@ 6 weeks after start of therapy .
H-1454	-0.016252068802714348	The blood pressure lowering effect of Aprovel is evident within 1 @-@ 2 weeks , with the maximal effect occurring by 4 @-@ 6 weeks after start of therapy .
D-1454	-0.016252068802714348	The blood pressure lowering effect of Aprovel is evident within 1 @-@ 2 weeks , with the maximal effect occurring by 4 @-@ 6 weeks after start of therapy .
P-1454	-0.0046 -0.0116 -0.0025 -0.0091 -0.0008 -0.0534 -0.0016 -0.0077 -0.0012 -0.0006 -0.0062 -0.0143 -0.0015 -0.0033 -0.0079 -0.1329 -0.0013 -0.0012 -0.0077 -0.0136 -0.0094 -0.0137 -0.0025 -0.0144 -0.0015 -0.0146 -0.0023 -0.0016 -0.0013 -0.0013 -0.2052 -0.0145 -0.0016 -0.0152 -0.0016 -0.0014
S-1353	Der Impfstoff Advasure darf nur im Rahmen eines Notimpfplanes angewendet werden , der von der zuständigen Behörde eines Mitgliedsstaates nach der Bestätigung der Erkrankung in Übereinstimmung
T-1353	ed The vaccine Advasure can only be used in the framework of an emergency vaccination plan , implemented by the competent authority of a Member State following confirmation of disease , in accordance with Community Legislation on control and eradication of classical swine fever .
H-1353	-0.10862598568201065	ed The vaccine Advasure can be used in the framework of an emergency vaccination plan , implemented by the competent authority of a Member State following confirmation of disease , in accordance with Community Legislation on control and eradication of classical swine fever .
D-1353	-0.10862598568201065	ed The vaccine Advasure can be used in the framework of an emergency vaccination plan , implemented by the competent authority of a Member State following confirmation of disease , in accordance with Community Legislation on control and eradication of classical swine fever .
P-1353	-0.0146 -0.0144 -0.0104 -0.0086 -0.0010 -0.0010 -0.0184 -5.4519 -0.0035 -0.2352 -0.0088 -0.0105 -0.0014 -0.0033 -0.0014 -0.0033 -0.0008 -0.0037 -0.0141 -0.0167 -0.0045 -0.0025 -0.0027 -0.0010 -0.0025 -0.0076 -0.0036 -0.0094 -0.0011 -0.0123 -0.0054 -0.0021 -0.0138 -0.0134 -0.0053 -0.0036 -0.0012 -0.0057 -0.0145 -0.0145 -0.0009 -0.0140 -0.0145 -0.0136 -0.0145 -0.0007 -0.0006 -0.0079 -0.0145 -0.0128 -0.0145 -0.0013 -0.0131 -0.0005 -0.0085 -0.0015
S-1377	Thoraxschmerzen , Dyspnoe , Nasenbluten , Hämoptyse , Pharyngitis , Pleuraeffusion , Pneumonitis .
T-1377	Respiratory , Thoracic and Mediastinal Disorders : chest pain , dyspnoea , epistaxis , haemoptysis , pharyngitis , pleural effusion , pneumonitis
H-1377	-0.01682397723197937	Respiratory , Thoracic and Mediastinal Disorders : chest pain , dyspnoea , epistaxis , haemoptysis , pharyngitis , pleural effusion , pneumonitis
D-1377	-0.01682397723197937	Respiratory , Thoracic and Mediastinal Disorders : chest pain , dyspnoea , epistaxis , haemoptysis , pharyngitis , pleural effusion , pneumonitis
P-1377	-0.0145 -0.0070 -0.0001 -0.0172 -0.0263 -0.0015 -0.0012 -0.0181 -0.0200 -0.0145 -0.0145 -0.0150 -0.0037 -0.0180 -0.0145 -0.0030 -0.0017 -0.0031 -0.0011 -0.0121 -0.0016 -0.0015 -0.0146 -0.0143 -0.0130 -0.0091 -0.0020 -0.0116 -0.0026 -0.0010 -0.0017 -0.0008 -0.0015 -0.0023 -0.0011 -0.0008 -0.0010 -0.0009 -0.0016 -0.0012 -0.0002 -0.0005 -0.0015 -0.0016 -0.0020 -0.0017 -0.0006 -0.0007 -0.0017 -0.0007 -0.5555
S-254	Sollten mehr als 10 % BEROMUN in Ihren Körperkreislauf übertreten ( Leckage ) , so werden die gleichen Maßnahmen eingeleitet , wie sie für die Überdosierung beschrieben wurden .
T-254	If more than 10 % of the BEROMUN reaches the main part of your body ( this is known as systemic leakage ) similar measures as described for dealing with overdose will be carried out by your doctor .
H-254	-0.09888332337141037	If more than 10 % of the BEROMUN reaches the main part of your body ( this is known as systemic leakage ) similar measures as described for overdose will be carried out by your doctor .
D-254	-0.09888332337141037	If more than 10 % of the BEROMUN reaches the main part of your body ( this is known as systemic leakage ) similar measures as described for overdose will be carried out by your doctor .
P-254	-0.0082 -0.0035 -0.0016 -0.0014 -0.0016 -0.0055 -0.0140 -0.0110 -0.0005 -0.0023 -0.0145 -0.0162 -0.0147 -0.0134 -0.0019 -0.0088 -0.0038 -0.0057 -0.0183 -0.0088 -0.0142 -0.0016 -0.0159 -0.0055 -0.0010 -0.0020 -0.0010 -0.0015 -0.0018 -0.0150 -0.0040 -0.0135 -0.0101 -0.0079 -4.0157 -0.0107 -0.0103 -0.0021 -0.0144 -0.0015 -0.1002 -0.0135 -0.0120 -0.0171 -0.0014
S-152	Miralcampo , Nº 7 , Polígono Industrial Miralcampo , 19200 Azuqueca de Henares ( Guadalajara ) , Spanien
T-152	Miralcampo , Nº 7 , Polígono Industrial Miralcampo , 19200 Azuqueca de Henares ( Guadalajara ) , Spain
H-152	-0.00791940838098526	Miralcampo , Nº 7 , Polígono Industrial Miralcampo , 19200 Azuqueca de Henares ( Guadalajara ) , Spain
D-152	-0.00791940838098526	Miralcampo , Nº 7 , Polígono Industrial Miralcampo , 19200 Azuqueca de Henares ( Guadalajara ) , Spain
P-152	-0.0007 -0.0011 -0.0013 -0.0013 -0.0014 -0.0014 -0.0005 -0.0013 -0.0014 -0.0038 -0.0007 -0.0012 -0.0012 -0.0012 -0.0010 -0.0009 -0.0011 -0.0012 -0.0012 -0.0014 -0.0015 -0.0011 -0.0003 -0.0012 -0.0010 -0.0014 -0.0011 -0.0004 -0.0004 -0.2651 -0.0011 -0.0010 -0.0010 -0.0004 -0.0005 -0.0015 -0.0014 -0.0019 -0.0015
S-954	Orphan Europe , Immeuble &quot; Le Wilson &quot; , 70 avenue du Général de Gaulle , F @-@ 92800 Puteaux , Frankreich
T-954	Orphan Europe , Immeuble <<unk>> Le Wilson <<unk>> , 70 avenue du Général de Gaulle , F @-@ 92800 Puteaux , France
H-954	-0.0032819858752191067	Orphan Europe , Immeuble <unk> Le Wilson <unk> , 70 avenue du Général de Gaulle , F @-@ 92800 Puteaux , France
D-954	-0.0032819858752191067	Orphan Europe , Immeuble <unk> Le Wilson <unk> , 70 avenue du Général de Gaulle , F @-@ 92800 Puteaux , France
P-954	-0.0016 -0.0011 -0.0013 -0.0013 -0.0015 -0.0009 -0.0013 -0.0006 -0.0006 -0.0147 -0.0081 -0.0008 -0.0402 -0.0049 -0.0016 -0.0005 -0.0014 -0.0006 -0.0006 -0.0023 -0.0008 -0.0009 -0.0008 -0.0003 -0.0012 -0.0006 -0.0003 -0.0015 -0.0018 -0.0014 -0.0014 -0.0010 -0.0012 -0.0013 -0.0011 -0.0005 -0.0015 -0.0231 -0.0016
S-1723	UMKARTON ( OHNE BLUE BOX ) NUR BÜNDELPACKUNGEN ( 112 TABLETTEN )
T-1723	INTERMEDIATE CARTON ( WITHOUT BLUE BOX ) MULTIPACKS ONLY ( 112 TABLETS )
H-1723	-0.0065839276649057865	INTERMEDIATE CARTON ( WITHOUT BLUE BOX ) MULTIPACKS ONLY ( 112 TABLETS )
D-1723	-0.0065839276649057865	INTERMEDIATE CARTON ( WITHOUT BLUE BOX ) MULTIPACKS ONLY ( 112 TABLETS )
P-1723	-0.0157 -0.0110 -0.0143 -0.0034 -0.0050 -0.0095 -0.0094 -0.0123 -0.0561 -0.0007 -0.0037 -0.0031 -0.0006 -0.0001 -0.0002 -0.0039 -0.0013 -0.0013 -0.0012 -0.0008 -0.0014 -0.0145 -0.0144 -0.0029 -0.0035 -0.0137 -0.0089 -0.0140 -0.0016 -0.0003 -0.0005 -0.0022 -0.0008 -0.0065 -0.0002 -0.0006 -0.0141 -0.0014 -0.0015
S-371	Das Unternehmen stellte die Ergebnisse von Studien zu Abacavir , Lamivudin und Zidovudin zusammengenommen vor , die bei der Entwicklung von Ziagen durchgeführt wurden .
T-371	The company presented the results of studies of abacavir , lamivudine and zidovudine taken together , as carried out during the development of Ziagen .
H-371	-0.021414775401353836	The company presented the results of studies of abacavir , lamivudine and zidovudine taken together , as carried out during the development of Ziagen .
D-371	-0.021414775401353836	The company presented the results of studies of abacavir , lamivudine and zidovudine taken together , as carried out during the development of Ziagen .
P-371	-0.0022 -0.0095 -0.0023 -0.0055 -0.0021 -0.0034 -0.0068 -0.0105 -0.0030 -0.0010 -0.0011 -0.0008 -0.0014 -0.0018 -0.0009 -0.0009 -0.0009 -0.0038 -0.6506 -0.0024 -0.0009 -0.0009 -0.0011 -0.0067 -0.0110 -0.0021 -0.0126 -0.0144 -0.0144 -0.0013 -0.0158 -0.0029 -0.0012 -0.0015 -0.0113 -0.0013 -0.0019 -0.0014
S-1860	Generalisierte Angststörung Die Wirksamkeit von Paroxetin bei der Behandlung der generalisierten Angststörung bei Erwachsenen wurde in einigen Kurzzeit- und Langzeitstudien untersucht .
T-1860	Generalised Anxiety Disorder The efficacy of paroxetine in the treatment of GAD in adults was investigated in some short @-@ term and long @-@ term studies .
H-1860	-0.021606668829917908	Generalised Anxiety Disorder The efficacy of paroxetine in the treatment of GAD in adults was investigated in some short @-@ term and long @-@ term studies .
D-1860	-0.021606668829917908	Generalised Anxiety Disorder The efficacy of paroxetine in the treatment of GAD in adults was investigated in some short @-@ term and long @-@ term studies .
P-1860	-0.0143 -0.0010 -0.0052 -0.0002 -0.0003 -0.0010 -0.0006 -0.0026 -0.0640 -0.0004 -0.0007 -0.0014 -0.0011 -0.0004 -0.0007 -0.2356 -0.0034 -0.0082 -0.0015 -0.0014 -0.0145 -0.0044 -0.0039 -0.0168 -0.0242 -0.2450 -0.0019 -0.0115 -0.0040 -0.0106 -0.0051 -0.0018 -0.0013 -0.0887 -0.0012 -0.0392 -0.0016 -0.0014
S-366	Wie bei anderen Sulfonylharnstoffen basiert dieser Effekt auf einer Verbesserung der Empfindlichkeit der pankreatischen β -Zellen auf den physiologischen Glucosestimulus .
T-366	As with other sulphonylureas , this effect is based on an improvement in responsiveness of pancreatic beta cells to the physiological glucose stimulus .
H-366	-0.008205270394682884	As with other sulphonylureas , this effect is based on an improvement in responsiveness of pancreatic beta cells to the physiological glucose stimulus .
D-366	-0.008205270394682884	As with other sulphonylureas , this effect is based on an improvement in responsiveness of pancreatic beta cells to the physiological glucose stimulus .
P-366	-0.0099 -0.0052 -0.0019 -0.0024 -0.0136 -0.0015 -0.0031 -0.0021 -0.0012 -0.1406 -0.0083 -0.0021 -0.0011 -0.0022 -0.0019 -0.0017 -0.0046 -0.0040 -0.0083 -0.0147 -0.0013 -0.0246 -0.0039 -0.0012 -0.0012 -0.0143 -0.0028 -0.0016 -0.0028 -0.0041 -0.0012 -0.0017 -0.0012 -0.0016 -0.0006 -0.0142 -0.0016 -0.0014
S-593	Aufgrund seiner lipophilen Eigenschaften verteilt sich Doxycyclin problemlos im Tiergewebe , wobei sich das Distributionsvolumen auf 0,53 l / kg beläuft .
T-593	Provided its lipophilic properties doxycycline is easily distributed in animal tissues , showing volumes of distribution of 0.53 l / kg .
H-593	-0.0059053110890090466	Provided its lipophilic properties doxycycline is easily distributed in animal tissues , showing volumes of distribution of 0.53 l / kg .
D-593	-0.0059053110890090466	Provided its lipophilic properties doxycycline is easily distributed in animal tissues , showing volumes of distribution of 0.53 l / kg .
P-593	-0.0150 -0.0066 -0.0139 -0.0021 -0.0006 -0.0013 -0.0006 -0.0032 -0.0141 -0.0008 -0.0013 -0.0009 -0.0017 -0.0071 -0.0121 -0.0107 -0.0025 -0.0010 -0.0079 -0.0022 -0.0155 -0.0007 -0.0012 -0.0076 -0.0145 -0.0145 -0.0008 -0.0041 -0.0226 -0.0054 -0.0162 -0.0015 -0.0026 -0.0014 -0.0007 -0.0019 -0.0015
S-1573	PREZISTA in Kombination mit Ritonavir ist nicht mit allen PIs ( Proteasehemmern ) getestet worden und darf nicht zusammen mit bestimmten PIs eingenommen werden .
T-1573	PREZISTA with ritonavir has not been tested with all PIs ( protease inhibitors ) and should not be used with some PIs .
H-1573	-0.008389618247747421	PREZISTA with ritonavir has not been tested with all PIs ( protease inhibitors ) and should not be used with some PIs .
D-1573	-0.008389618247747421	PREZISTA with ritonavir has not been tested with all PIs ( protease inhibitors ) and should not be used with some PIs .
P-1573	-0.0015 -0.0024 -0.0006 -0.0003 -0.0488 -0.0042 -0.0014 -0.0010 -0.0009 -0.0030 -0.0014 -0.0013 -0.0034 -0.0087 -0.0021 -0.0065 -0.0010 -0.0027 -0.0016 -0.0002 -0.0023 -0.0008 -0.0007 -0.0013 -0.0014 -0.0314 -0.0120 -0.0014 -0.0014 -0.0319 -0.1040 -0.0143 -0.0023 -0.0008 -0.0017 -0.0015
S-1360	Die Lösung kann mit normaler Kochsalzlösung 9 mg / ml ( 0,9 % ) verdünnt werden , um eine für die Verabreichung geeignete Konzentration zu erhalten .
T-1360	Normal sodium chloride solution 9 mg / ml ( 0.9 % ) may be added to dilute to a concentration convenient for administration .
H-1360	-0.005240335129201412	Normal sodium chloride solution 9 mg / ml ( 0.9 % ) may be added to dilute to a concentration convenient for administration .
D-1360	-0.005240335129201412	Normal sodium chloride solution 9 mg / ml ( 0.9 % ) may be added to dilute to a concentration convenient for administration .
P-1360	-0.0145 -0.0005 -0.0141 -0.0019 -0.0018 -0.0002 -0.0001 -0.0013 -0.0074 -0.0143 -0.0006 -0.0015 -0.0016 -0.0018 -0.0024 -0.0012 -0.0014 -0.0015 -0.0129 -0.0016 -0.0137 -0.0034 -0.0133 -0.0003 -0.0004 -0.0141 -0.0143 -0.0099 -0.0145 -0.0018 -0.0027 -0.0039 -0.0020 -0.0016
S-1198	Es lagen 1.302 Fälle ( 23 % ) von bestätigter und 1.603 Fälle ( 28 % ) von unbestätigter Rhabdomyolyse vor .
T-1198	The majority of the reported reactions ( 78 % ) belong to the following COSTART body systems- Musculoskeletal ( 3,417 ; 29 % ) , Body as a whole ( 1,814 ; 16 % ) , Digestive ( 1,663 ; 14 % ) , Metabolic and Nutritional ( 1,354 ; 12 % ) , Nervous ( 914 ; 8 % ) and Urogenital ( 768 ; 7 % ) .
H-1198	-0.15569165349006653	The majority of the reported reactions ( 78 % ) belong to the following COSTART body systems- Musculoskeletal ( 3,417 ; 29 % ) , Body as a whole ( 1,814 ; 16 % ) , Digestive ( 1,663 ; 14 % ) , Metabolic and Nutritional ( 1,354 ; 12 % ) , Nervous ( 914 ; 8 % ) and Urogenital ( 768 ; 7 % ) .
D-1198	-0.15569165349006653	The majority of the reported reactions ( 78 % ) belong to the following COSTART body systems- Musculoskeletal ( 3,417 ; 29 % ) , Body as a whole ( 1,814 ; 16 % ) , Digestive ( 1,663 ; 14 % ) , Metabolic and Nutritional ( 1,354 ; 12 % ) , Nervous ( 914 ; 8 % ) and Urogenital ( 768 ; 7 % ) .
P-1198	-0.0141 -0.0145 -0.0050 -0.0107 -0.0145 -0.0145 -0.0092 -0.0456 -0.0155 -0.0019 -0.0030 -0.0388 -0.0015 -0.0100 -0.0142 -0.0145 -0.0143 -0.0143 -0.0124 -0.0145 -0.0145 -0.0143 -0.0145 -0.0107 -0.0005 -0.0002 -0.0006 -0.0014 -0.0144 -0.0145 -0.2027 -0.0573 -0.0145 -0.1151 -0.0017 -0.0022 -0.0145 -0.0158 -0.0145 -0.0135 -0.0046 -0.0120 -0.0716 -1.1189 -0.2178 -0.0141 -0.7107 -0.0026 -0.0015 -0.0541 -0.0186 -0.0128 -0.0025 -0.0133 -0.3181 -1.2834 -0.2055 -0.0130 -1.3069 -0.0028 -0.0014 -0.1642 -0.0247 -0.0049 -0.0047 -0.0133 -0.0220 -0.0121 -0.0017 -0.0024 -0.0143 -0.5952 -1.3263 -0.1288 -0.0133 -1.5007 -0.0041 -0.0014 -0.3421 -0.0238 -0.0078 -0.0021 -0.0160 -1.0278 -0.1955 -0.0132 -1.5508 -0.0064 -0.0015 -0.5333 -0.0420 -0.0144 -0.0143 -0.0126 -0.0138 -0.6245 -0.2110 -0.0384 -1.2860 -0.0049 -0.0014 -0.0109 -0.0014
S-1939	Die Tatsache , daß die Agentur trotz der kontinuierlichen Zunahme der Anzahl der Anträge im Verlauf des Jahres 1996 in der Lage war , die in der Verordnung ( EWG ) Nr .
T-1939	Despite the steady increase in number of applications during 1996 , the pharmaceutical industry has recognised that the EMEA was able to respect the time limits laid down in Council Regulation ( EEC ) No 2309 / 93 .
H-1939	-0.012853878550231457	Despite the steady increase in number of applications during 1996 , the pharmaceutical industry has recognised that the EMEA was able to respect the time limits laid down in Council Regulation ( EEC ) No 2309 / 93 .
D-1939	-0.012853878550231457	Despite the steady increase in number of applications during 1996 , the pharmaceutical industry has recognised that the EMEA was able to respect the time limits laid down in Council Regulation ( EEC ) No 2309 / 93 .
P-1939	-0.0133 -0.0048 -0.0104 -0.0065 -0.0029 -0.0155 -0.0016 -0.0041 -0.0093 -0.0062 -0.0146 -0.0021 -0.0182 -0.0014 -0.0022 -0.0093 -0.0087 -0.0145 -0.0109 -0.0054 -0.0143 -0.0145 -0.0003 -0.0130 -0.0065 -0.0019 -0.0144 -0.0044 -0.0145 -0.0112 -0.0098 -0.0013 -0.0033 -0.0144 -0.0007 -0.0011 -0.0237 -0.0018 -0.0006 -0.0014 -0.0280 -0.0932 -0.0144 -0.0139 -0.0286 -0.0750 -0.0476 -0.0014
S-284	Schwangerschaftswoche wurde mit dem empfohlenen Dosierungsschema eine niedrige Verschlussrate des Ductus arteriosus festgestellt ( siehe Abschnitt 5.1 ) .
T-284	In preterm newborn infants less than 27 weeks of gestational age , the closure rate of the ductus arteriosus was shown to be low at the recommended dose regimen ( see section 5.1 ) .
H-284	-0.00735367089509964	In preterm newborn infants less than 27 weeks of gestational age , the closure rate of the ductus arteriosus was shown to be low at the recommended dose regimen ( see section 5.1 ) .
D-284	-0.00735367089509964	In preterm newborn infants less than 27 weeks of gestational age , the closure rate of the ductus arteriosus was shown to be low at the recommended dose regimen ( see section 5.1 ) .
P-284	-0.0141 -0.0145 -0.0078 -0.0145 -0.0123 -0.0130 -0.0011 -0.0145 -0.0131 -0.0145 -0.0022 -0.0130 -0.0082 -0.0499 -0.0028 -0.0071 -0.0103 -0.0145 -0.0034 -0.0021 -0.0042 -0.0006 -0.0010 -0.0013 -0.0004 -0.0009 -0.0013 -0.0032 -0.0144 -0.0056 -0.0013 -0.0064 -0.0145 -0.0028 -0.0012 -0.0149 -0.0136 -0.0007 -0.0021 -0.0018 -0.0062 -0.0011 -0.0014 -0.0016 -0.0014 -0.0014
S-1740	Es wurde ein geringgradiger Abfall von Hämoglobin und Hämatokrit ( mittlerer Abfall um etwa 0,05 mMol / l bzw .
T-1740	Small decreases in haemoglobin and haematocrit ( mean decreases of approximately 0.05 mmol / l and 0.16 volume percent , respectively ) were observed .
H-1740	-0.013543269596993923	Small decreases in haemoglobin and haematocrit ( mean decreases of approximately 0.05 mmol / l and 0.16 volume percent , respectively ) were observed .
D-1740	-0.013543269596993923	Small decreases in haemoglobin and haematocrit ( mean decreases of approximately 0.05 mmol / l and 0.16 volume percent , respectively ) were observed .
P-1740	-0.0145 -0.0069 -0.0252 -0.0227 -0.0080 -0.0007 -0.0009 -0.0014 -0.0017 -0.0090 -0.0020 -0.0018 -0.0019 -0.0008 -0.0021 -0.0087 -0.0078 -0.0039 -0.1360 -0.0060 -0.0141 -0.0019 -0.0015 -0.0015 -0.0144 -0.0009 -0.0016 -0.0019 -0.0127 -0.0119 -0.1581 -0.0145 -0.0146 -0.0117 -0.0010 -0.0024 -0.0035 -0.0074 -0.0029 -0.0014
S-251	Die empfohlene Dosis für Alglucosidase alfa liegt bei 20 mg / kg Körpergewicht bei Anwendung einmal alle 2 Wochen als intravenöse Infusion .
T-251	The recommended dosage regimen of alglucosidase alfa is 20 mg / kg of body weight administered once every 2 weeks as an intravenous infusion .
H-251	-0.02605617791414261	The recommended dosage regimen of alglucosidase alfa is 20 mg / kg of body weight administered once every 2 weeks as an intravenous infusion .
D-251	-0.02605617791414261	The recommended dosage regimen of alglucosidase alfa is 20 mg / kg of body weight administered once every 2 weeks as an intravenous infusion .
P-251	-0.0961 -0.0017 -0.0162 -0.0019 -0.0011 -0.2454 -0.0008 -0.2527 -0.0019 -0.0112 -0.0016 -0.0037 -0.0013 -0.0008 -0.0021 -0.0006 -0.0020 -0.0044 -0.0006 -0.0020 -0.0010 -0.1178 -0.0023 -0.0008 -0.0148 -0.0009 -0.0073 -0.0017 -0.0178 -0.0012 -0.0048 -0.0036 -0.0040 -0.0011 -0.0005 -0.0013 -0.0028 -0.0006 -0.2087 -0.0014
S-66	1A2 , 2A6 , 2B6 , 2C8 , 2C9 , 2C19 , 2D6 , 2E1 und 3A4 / 5 .
T-66	1A2 , 2A6 , 2B6 , 2C8 , 2C9 , 2C19 , 2D6 , 2E1 , and 3A4 / 5 .
H-66	-0.05407838523387909	1A2 , 2A6 , 2B6 , 2C8 , 2C9 , 2C19 , 2D6 , 2E1 and 3A4 / 5 .
D-66	-0.05407838523387909	1A2 , 2A6 , 2B6 , 2C8 , 2C9 , 2C19 , 2D6 , 2E1 and 3A4 / 5 .
P-66	-0.0021 -0.0014 -0.0014 -0.0014 -0.0011 -0.0013 -0.0013 -0.0014 -0.0011 -0.0015 -0.0014 -0.0014 -0.0011 -0.0013 -0.0012 -0.0014 -0.0011 -0.0013 -0.0013 -0.0014 -0.0012 -0.0014 -0.0011 -0.0014 -0.0010 -0.0013 -0.0014 -0.0014 -0.0011 -0.0013 -0.0013 -1.8909 -0.1167 -0.0006 -0.0015 -0.0013 -0.0021 -0.0015
S-1515	In kontrollierten klinischen Studien an Diabetikern konnten keine Veränderungen des Blutzuckerspiegels und keine Erhöhung der Inzidenz von Hypoglykämie festgestellt werden .
T-1515	In controlled clinical trials conducted in diabetic patients , no changes of blood glucose level and no increase in the incidence of hypoglycaemia were ascertained .
H-1515	-0.020664285868406296	In controlled clinical trials conducted in diabetic patients , no changes of blood glucose level and no increase in the incidence of hypoglycaemia were ascertained .
D-1515	-0.020664285868406296	In controlled clinical trials conducted in diabetic patients , no changes of blood glucose level and no increase in the incidence of hypoglycaemia were ascertained .
P-1515	-0.0066 -0.0019 -0.0014 -0.2344 -0.0249 -0.0195 -0.0025 -0.0004 -0.0472 -0.0026 -0.0072 -0.0021 -0.0029 -0.0404 -0.0049 -0.2427 -0.0010 -0.0002 -0.0119 -0.0070 -0.0022 -0.0024 -0.0049 -0.0064 -0.0010 -0.0009 -0.0014 -0.0004 -0.0010 -0.0007 -0.0133 -0.0021 -0.0013 -0.0115 -0.0903 -0.0012 -0.0004 -0.0015 -0.0014
S-513	as Eine Fertigspritze enthält 3.000 IE pro 0,3 ml Dosis ( 10.000 IE / ml ) des arzneilich wirksamen Bestandteils Epoetin delta .
T-513	is Pre @-@ filled syringe containing 3,000 IU per 0.3 ml dose ( 10,000 IU / ml ) of the active substance epoetin delta .
H-513	-0.004879722837358713	is Pre @-@ filled syringe containing 3,000 IU per 0.3 ml dose ( 10,000 IU / ml ) of the active substance epoetin delta .
D-513	-0.004879722837358713	is Pre @-@ filled syringe containing 3,000 IU per 0.3 ml dose ( 10,000 IU / ml ) of the active substance epoetin delta .
P-513	-0.0145 -0.0145 -0.0080 -0.0015 -0.0105 -0.0020 -0.0016 -0.0002 -0.0167 -0.0087 -0.0022 -0.0002 -0.0368 -0.0023 -0.0019 -0.0015 -0.0018 -0.0029 -0.0014 -0.0011 -0.0001 -0.0017 -0.0011 -0.0015 -0.0016 -0.0027 -0.0121 -0.0141 -0.0025 -0.0009 -0.0003 -0.0016 -0.0005 -0.0006 -0.0029 -0.0015
S-914	Die absolute Bioverfügbarkeit von Methoxy @-@ Polyethylenglycol @-@ Epoetin beta betrug nach subkutaner Gabe 54 % .
T-914	The absolute bioavailability of methoxy polyethylene glycol @-@ epoetin beta after subcutaneous administration was 54 % .
H-914	-0.00277805351652205	The absolute bioavailability of methoxy polyethylene glycol @-@ epoetin beta after subcutaneous administration was 54 % .
D-914	-0.00277805351652205	The absolute bioavailability of methoxy polyethylene glycol @-@ epoetin beta after subcutaneous administration was 54 % .
P-914	-0.0047 -0.0033 -0.0009 -0.0027 -0.0017 -0.0020 -0.0078 -0.0077 -0.0007 -0.0010 -0.0006 -0.0005 -0.0012 -0.0007 -0.0010 -0.0008 -0.0096 -0.0032 -0.0011 -0.0008 -0.0026 -0.0005 -0.0014 -0.0194 -0.0021 -0.0006 -0.0005 -0.0012 -0.0012 -0.0039 -0.0064 -0.0012 -0.0015 -0.0016 -0.0014
S-1712	Mediane Differenz versus Placebo bei der Veränderung im Vergleich zum Ausgangswert 2 Stratifizierter Wilcoxon @-@ Test für die Differenz versus Placebo .
T-1712	Hodges Lehmann estimate : median difference from placebo in change from baseline 2 Stratified Wilcoxon test for difference from placebo .
H-1712	-0.00518479198217392	Hodges Lehmann estimate : median difference from placebo in change from baseline 2 Stratified Wilcoxon test for difference from placebo .
D-1712	-0.00518479198217392	Hodges Lehmann estimate : median difference from placebo in change from baseline 2 Stratified Wilcoxon test for difference from placebo .
P-1712	-0.0145 -0.0145 -0.0151 -0.0147 -0.0125 -0.0125 -0.0013 -0.0040 -0.0145 -0.0014 -0.0011 -0.0008 -0.0011 -0.0105 -0.0073 -0.0123 -0.0003 -0.0008 -0.0058 -0.0040 -0.0009 -0.0013 -0.0012 -0.0010 -0.0022 -0.0032 -0.0022 -0.0028 -0.0094 -0.0006 -0.0009 -0.0010 -0.0011 -0.0032 -0.0015
S-527	Das Gewebe @-@ Plasma @-@ Verhältnis bewegt sich im Bereich von 2,5 ( Bauchfett ) , 3,7 ( Muskel ) , 4,8 ( Lunge ) bis 36,5 ( Leber ) .
T-527	Tissue to plasma ratios range from 2.5 ( abdominal fat ) , 3.7 ( muscle ) , 4.8 ( lung ) to 36.5 ( liver ) .
H-527	-0.005865465383976698	Tissue to plasma ratios range from 2.5 ( abdominal fat ) , 3.7 ( muscle ) , 4.8 ( lung ) to 36.5 ( liver ) .
D-527	-0.005865465383976698	Tissue to plasma ratios range from 2.5 ( abdominal fat ) , 3.7 ( muscle ) , 4.8 ( lung ) to 36.5 ( liver ) .
P-527	-0.0138 -0.0015 -0.0143 -0.0016 -0.0006 -0.0006 -0.0073 -0.0008 -0.0056 -0.0023 -0.0015 -0.0015 -0.0100 -0.0005 -0.0008 -0.0013 -0.0015 -0.0061 -0.0020 -0.0011 -0.0012 -0.0014 -0.0015 -0.0999 -0.0010 -0.0013 -0.0012 -0.0064 -0.0015 -0.0072 -0.0123 -0.0004 -0.0012 -0.0015 -0.0014 -0.0016 -0.0014
S-458	Es wird angenommen , dass YENTREVE die Kraft des Harnröhrenmuskels erhöht , der Urin zurückhält , wenn Sie lachen , niesen oder sich körperlich betätigen .
T-458	YENTREVE is believed to work by increasing the strength of the muscle that holds back urine when you laugh , sneeze , or perform physical activities .
H-458	-0.01808873564004898	YENTREVE is believed to work by increasing the strength of the muscle that holds back urine when you laugh , sneeze , or perform physical activities .
D-458	-0.01808873564004898	YENTREVE is believed to work by increasing the strength of the muscle that holds back urine when you laugh , sneeze , or perform physical activities .
P-458	-0.0061 -0.0013 -0.0012 -0.0012 -0.0015 -0.0010 -0.0016 -0.0100 -0.0014 -0.0145 -0.0056 -0.0044 -0.0026 -0.0097 -0.0015 -0.0032 -0.0145 -0.0129 -0.0103 -0.0134 -0.0040 -0.0009 -0.0032 -0.0032 -0.0033 -0.0020 -0.0010 -0.0003 -0.0010 -0.4800 -0.0024 -0.0140 -0.0027 -0.0120 -0.0016 -0.0014
S-1449	Basierend auf Daten aus klinischen Studien ( siehe Tabelle 1 ) und basierend auf Langzeiterfahrungen , wird Raptiva für die Anwendung bei Patienten empfohlen , wie sie unter Abschnitt 4.1. beschrieben sind .
T-1449	Based on the clinical development data generated ( see Table 1 ) and long @-@ term experience , Raptiva is recommended for use in patients as defined in section 4.1 .
H-1449	-0.009244329296052456	Based on the clinical development data generated ( see Table 1 ) and long @-@ term experience , Raptiva is recommended for use in patients as defined in section 4.1 .
D-1449	-0.009244329296052456	Based on the clinical development data generated ( see Table 1 ) and long @-@ term experience , Raptiva is recommended for use in patients as defined in section 4.1 .
P-1449	-0.0021 -0.0016 -0.0145 -0.0135 -0.0145 -0.0024 -0.0145 -0.0326 -0.0019 -0.0203 -0.0015 -0.0017 -0.0117 -0.0099 -0.0078 -0.0018 -0.0029 -0.0023 -0.0008 -0.0003 -0.0015 -0.0019 -0.0026 -0.0748 -0.0034 -0.0026 -0.0025 -0.0052 -0.0466 -0.0026 -0.0134 -0.0012 -0.0021 -0.0031 -0.0015
S-1080	Des Weiteren ergeben sich aus diesen Daten keine Hinweise auf ein missbildendes Toxizitätspotential durch Cerezyme für den Fetus , trotz der begrenzten statistischen Nachweise .
T-1080	Furthermore , these data indicate no malformative toxicity for the foetus by Cerezyme , although the statistical evidence is low .
H-1080	-0.01161510031670332	Furthermore , these data indicate no malformative toxicity for the foetus by Cerezyme , although the statistical evidence is low .
D-1080	-0.01161510031670332	Furthermore , these data indicate no malformative toxicity for the foetus by Cerezyme , although the statistical evidence is low .
P-1080	-0.0082 -0.0008 -0.0014 -0.0024 -0.0104 -0.0019 -0.0142 -0.0030 -0.0141 -0.0039 -0.0049 -0.0045 -0.1691 -0.0009 -0.0143 -0.0020 -0.0128 -0.0003 -0.0176 -0.0075 -0.0104 -0.0010 -0.0010 -0.0008 -0.0050 -0.0151 -0.0108 -0.0038 -0.0220 -0.0032 -0.0041 -0.0202 -0.0017 -0.0014
S-1807	Sie dürfen Mycophenolatmofetil Teva nach dem auf dem Umkarton und der Blisterpackung nach &quot; Verwendbar bis &quot; angegebenen Verfallsdatum nicht mehr verwenden .
T-1807	Do not use Mycophenolate mofetil Teva after the expiry date as stated on the blister and carton .
H-1807	-0.04100304841995239	Do not use Mycophenolate mofetil Teva after the expiry date as stated on the blister and carton .
D-1807	-0.04100304841995239	Do not use Mycophenolate mofetil Teva after the expiry date as stated on the blister and carton .
P-1807	-0.0143 -0.0015 -0.0023 -0.0029 -0.0010 -0.0007 -0.0012 -0.0034 -0.0044 -0.0010 -0.0003 -0.0018 -0.0008 -0.0058 -0.0033 -0.0056 -0.0057 -0.0018 -0.6224 -0.0101 -0.0036 -0.0023 -0.0165 -0.4313 -0.0141 -0.0121 -0.0022 -0.0124 -0.0041
S-21	Vorbereitung für das elektronische Einreichen von Anträgen mit dem neuen internationalen Format &quot; Common Technical Document &quot; , Methodik der klinischen Studien nach Veröffentlichung von neuen CPMP @-@ Leitlinien .
T-21	Assessors from accession candidate countries were invited to participate to the trainings as a preparation for the enlargement .
H-21	-0.011630957946181297	Assessors from accession candidate countries were invited to participate to the trainings as a preparation for the enlargement .
D-21	-0.011630957946181297	Assessors from accession candidate countries were invited to participate to the trainings as a preparation for the enlargement .
P-21	-0.0145 -0.0081 -0.0143 -0.0147 -0.0200 -0.0145 -0.0141 -0.0145 -0.0033 -0.0167 -0.0121 -0.0026 -0.0128 -0.0144 -0.0087 -0.0145 -0.0051 -0.0015 -0.0143 -0.0135 -0.0143 -0.0028 -0.0085 -0.0145 -0.0144 -0.0130 -0.0144 -0.0095
S-1346	In klinischen Studien , in denen eine Basis @-@ Bolus @-@ Therapie eingesetzt wurde , waren die Hypoglykämie @-@ Gesamtraten mit Levemir und NPH @-@ Insulin ähnlich .
T-1346	In clinical trials using basal bolus insulin therapy , the overall rates of hypoglycaemia with Levemir and NPH insulin were similar .
H-1346	-0.046453285962343216	In clinical trials using basal bolus insulin therapy , the overall rates of hypoglycaemia with Levemir and NPH insulin were similar .
D-1346	-0.046453285962343216	In clinical trials using basal bolus insulin therapy , the overall rates of hypoglycaemia with Levemir and NPH insulin were similar .
P-1346	-0.0041 -0.0450 -0.8994 -0.0096 -0.0142 -0.0135 -0.0011 -0.0013 -0.0179 -0.0009 -0.0113 -0.0054 -0.0131 -0.0057 -0.0100 -0.0027 -0.0005 -0.0010 -0.0005 -0.0131 -0.0024 -0.0013 -0.0110 -0.0040 -0.0005 -0.0004 -0.0609 -0.0013 -0.0014 -0.0009 -0.0012 -0.0007 -0.0020 -0.0186 -0.4941 -0.0014
S-503	Bei Anwendung von RISPERDAL CONSTA mit Nahrungsmitteln und Getränken Vermeiden Sie das Trinken von Alkohol , wenn RISPERDAL CONSTA bei Ihnen angewendet wird .
T-503	Using RISPERDAL CONSTA with food and drink You should avoid drinking alcohol when using RISPERDAL CONSTA .
H-503	-0.018063301220536232	Using RISPERDAL CONSTA with food and drink You should avoid drinking alcohol when using RISPERDAL CONSTA .
D-503	-0.018063301220536232	Using RISPERDAL CONSTA with food and drink You should avoid drinking alcohol when using RISPERDAL CONSTA .
P-503	-0.0144 -0.2797 -0.0007 -0.0010 -0.0008 -0.0011 -0.0005 -0.0008 -0.0014 -0.0070 -0.0053 -0.0028 -0.1259 -0.0143 -0.0104 -0.0059 -0.0041 -0.0018 -0.0069 -0.0076 -0.0250 -0.0007 -0.0010 -0.0007 -0.0011 -0.0006 -0.0008 -0.0013 -0.0129 -0.0055
S-455	16 Diese Ergebnisse bestätigten sich während der Phase II der Studie , in der die Patienten nach dreiwöchiger Behandlung für die Weiterbehandlung mit Losartan oder mit einem Placebo randomisiert wurden .
T-455	These results were confirmed during period II of the study where patients were randomized to continue losartan or placebo , after three weeks of treatment .
H-455	-0.009090625680983067	These results were confirmed during period II of the study where patients were randomized to continue losartan or placebo , after three weeks of treatment .
D-455	-0.009090625680983067	These results were confirmed during period II of the study where patients were randomized to continue losartan or placebo , after three weeks of treatment .
P-455	-0.0141 -0.0057 -0.0022 -0.0025 -0.0097 -0.0387 -0.0049 -0.0022 -0.0024 -0.0057 -0.0126 -0.0031 -0.0022 -0.0004 -0.1202 -0.0110 -0.0069 -0.0107 -0.0040 -0.0005 -0.0012 -0.0055 -0.0026 -0.0011 -0.0008 -0.0011 -0.0145 -0.0087 -0.0044 -0.0012 -0.0025 -0.0026 -0.0016 -0.0015
S-1734	Geschlecht und ethnische Zugehörigkeit ( Kaukasier , Schwarze , Orientalen ) hatten keinen signifikanten Einfluss auf die pharmakokinetischen Parameter von Micafun- gin .
T-1734	Gender and race ( Caucasian , Black and Oriental ) did not significantly influence the pharmacokinetic parameters of micafungin .
H-1734	-0.0058282059617340565	Gender and race ( Caucasian , Black and Oriental ) did not significantly influence the pharmacokinetic parameters of micafungin .
D-1734	-0.0058282059617340565	Gender and race ( Caucasian , Black and Oriental ) did not significantly influence the pharmacokinetic parameters of micafungin .
P-1734	-0.0052 -0.0005 -0.0019 -0.0144 -0.0018 -0.0008 -0.0019 -0.0002 -0.0102 -0.0014 -0.0041 -0.0150 -0.0031 -0.0008 -0.0022 -0.0080 -0.0014 -0.0181 -0.0472 -0.0048 -0.0016 -0.0005 -0.0005 -0.0021 -0.0015 -0.0006 -0.0014 -0.0020 -0.0112 -0.0145 -0.0144 -0.0017 -0.0019 -0.0015
S-639	Die Organisation dieser Aktivitäten erfolgt in erster Linie über das Programm des &quot; Pan @-@ European Regulatory Forum &quot; ( PERF ) und die verschiedenen Schwerpunktbereiche im Hinblick auf Humanarzneimittel .
T-639	These activities are primarily organised through the Pan @-@ European Regulatory Forum programme ( PERF ) and the different priority action areas relating to human medicines .
H-639	-0.012811601161956787	These activities are primarily organised through the Pan @-@ European Regulatory Forum programme ( PERF ) and the different priority action areas relating to human medicines .
D-639	-0.012811601161956787	These activities are primarily organised through the Pan @-@ European Regulatory Forum programme ( PERF ) and the different priority action areas relating to human medicines .
P-639	-0.0093 -0.0018 -0.0051 -0.0183 -0.0071 -0.0149 -0.0017 -0.0073 -0.0015 -0.0024 -0.0015 -0.0007 -0.0011 -0.0005 -0.0007 -0.0133 -0.0118 -0.0015 -0.0009 -0.0009 -0.0014 -0.0127 -0.0070 -0.0107 -0.0115 -0.0165 -0.0027 -0.0136 -0.0014 -0.0142 -0.0036 -0.2348 -0.0016 -0.0014
S-1199	Bei Anwendung von leicht flüchtigen halogenierten Anästhetika während der Therapie mit indirekten Sympathomimetika kann es perioperativ zu einer akuten Hypertonie kommen .
T-1199	3 Perioperative acute hypertension can occur if volatile halogenated anaesthetics are used during treatment with indirect sympathomimetic agents .
H-1199	-0.005225089844316244	3 Perioperative acute hypertension can occur if volatile halogenated anaesthetics are used during treatment with indirect sympathomimetic agents .
D-1199	-0.005225089844316244	3 Perioperative acute hypertension can occur if volatile halogenated anaesthetics are used during treatment with indirect sympathomimetic agents .
P-1199	-0.0145 -0.0227 -0.0096 -0.0082 -0.0004 -0.0012 -0.0004 -0.0133 -0.0044 -0.0134 -0.0123 -0.0011 -0.0010 -0.0014 -0.0006 -0.0015 -0.0013 -0.0035 -0.0045 -0.0011 -0.0027 -0.0069 -0.0063 -0.0127 -0.0019 -0.0013 -0.0011 -0.0008 -0.0016 -0.0010 -0.0166 -0.0054 -0.0015 -0.0015
S-232	Ein gesundheitliches Risiko besteht u. a. bei Leberkranken , Alkoholkranken , Epileptikern , Patienten mit organischen Erkrankungen des Gehirns , Schwangeren , Stillenden und Kindern .
T-232	To be taken into account in pregnant or breast @-@ feeding women , children and high @-@ risk groups , such as patients with liver disease or epilepsy .
H-232	-0.03213831037282944	To be taken into account in pregnant or breast @-@ feeding women , children and high @-@ risk groups , such as patients with liver disease or epilepsy .
D-232	-0.03213831037282944	To be taken into account in pregnant or breast @-@ feeding women , children and high @-@ risk groups , such as patients with liver disease or epilepsy .
P-232	-0.0145 -0.0138 -0.0145 -0.0027 -0.0048 -0.0142 -0.0145 -0.0144 -0.0129 -0.0042 -0.0011 -0.0063 -0.0281 -0.0099 -0.0322 -0.0145 -0.0101 -0.0016 -0.0142 -0.0135 -0.0128 -0.0016 -0.0137 -0.0085 -0.0033 -0.0070 -0.7337 -0.0144 -0.0003 -0.0010 -0.0066 -0.0140 -0.0016
S-1378	49 Bei einem in Gebrauch befindlichen OptiSet stellen Sie eine Dosis von 2 Einheiten ein , indem Sie den Dosierring vorwärts drehen , bis der Dosierpfeil auf 2 zeigt .
T-1378	In @-@ use OptiSet , select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2 .
H-1378	-0.009544274769723415	In @-@ use OptiSet , select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2 .
D-1378	-0.009544274769723415	In @-@ use OptiSet , select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2 .
P-1378	-0.0146 -0.0145 -0.0022 -0.0005 -0.0016 -0.0088 -0.0144 -0.0060 -0.0062 -0.0023 -0.0050 -0.0028 -0.0027 -0.0048 -0.0023 -0.0059 -0.0886 -0.0016 -0.0145 -0.0004 -0.0025 -0.0655 -0.0010 -0.0023 -0.0144 -0.0028 -0.0008 -0.0061 -0.0044 -0.0020 -0.0020 -0.0018
S-421	Wenn Sie versehentlich zu viele Tabletten eingenommen haben , oder wenn ein anderer oder ein Kind Ihr Arzneimittel eingenommen hat , müssen Sie sich umgehend mit einem Arzt oder Apotheker in Verbindung setzen .
T-421	If you accidentally take too many tablets , or if someone else or a child takes your medicine , talk to a doctor or pharmacist immediately .
H-421	-0.016636228188872337	If you accidentally take too many tablets , or if someone else or a child takes your medicine , talk to a doctor or pharmacist immediately .
D-421	-0.016636228188872337	If you accidentally take too many tablets , or if someone else or a child takes your medicine , talk to a doctor or pharmacist immediately .
P-421	-0.0408 -0.0019 -0.0124 -0.0033 -0.0101 -0.0026 -0.1000 -0.0052 -0.0009 -0.1171 -0.0016 -0.0063 -0.0129 -0.0038 -0.0054 -0.0040 -0.0015 -0.0143 -0.0020 -0.0031 -0.0065 -0.0199 -0.0027 -0.0714 -0.0030 -0.0276 -0.0026 -0.0010 -0.0284 -0.0018 -0.0018
S-278	Eine erhebliche Zunahme der Zahl an Änderungsanträgen ist im Laufe der Zeit zu erwarten , wenn mehr gemeinschaftliche Genehmigungen für das Inverkehrbringen erteilt und entsprechende Präparate auf den Markt gebracht werden .
T-278	A significant growth in the number of variations received is expected as more Community marketing authorisations are granted and products are placed on the market .
H-278	-0.007657412439584732	A significant growth in the number of variations received is expected as more Community marketing authorisations are granted and products are placed on the market .
D-278	-0.007657412439584732	A significant growth in the number of variations received is expected as more Community marketing authorisations are granted and products are placed on the market .
P-278	-0.0084 -0.0084 -0.0146 -0.0039 -0.0026 -0.0016 -0.0014 -0.0145 -0.0133 -0.0173 -0.0097 -0.0074 -0.0129 -0.0062 -0.0039 -0.0110 -0.0041 -0.0013 -0.0010 -0.0048 -0.0083 -0.0124 -0.0124 -0.0093 -0.0317 -0.0013 -0.0015 -0.0012 -0.0018 -0.0014
S-217	EU / 1 / 96 / 005 / 002 CellCept ( 50 Tabletten ) EU / 1 / 96 / 005 / 004 CellCept ( 150 Tabletten )
T-217	( 50 tablets ) ( 150 tablets )
H-217	-0.06233615800738335	( 50 tablets ) ( 150 tablets )
D-217	-0.06233615800738335	( 50 tablets ) ( 150 tablets )
P-217	-0.1177 -0.0116 -0.0015 -0.0024 -0.0027 -0.2625 -0.0142 -0.0015 -0.0023 -0.0025 -0.2668
S-711	Sollte dies der Fall sein , kann Ihr Arzt die Anwendung von FSH und LH abbrechen und die Behandlung mit hCG aussetzen um die Entwicklung eines schwerwiegenderen OHSS zu verhindern .
T-711	If so , your doctor may discontinue the FSH and LH , and abandon the treatment with hCG , to prevent the development of more severe OHSS .
H-711	-0.00972215086221695	If so , your doctor may discontinue the FSH and LH , and abandon the treatment with hCG , to prevent the development of more severe OHSS .
D-711	-0.00972215086221695	If so , your doctor may discontinue the FSH and LH , and abandon the treatment with hCG , to prevent the development of more severe OHSS .
P-711	-0.0054 -0.0649 -0.0022 -0.0025 -0.0036 -0.0394 -0.0113 -0.0006 -0.0092 -0.0147 -0.0010 -0.0030 -0.0015 -0.0010 -0.0139 -0.0038 -0.0145 -0.0011 -0.0111 -0.0060 -0.0037 -0.0032 -0.0013 -0.0010 -0.0932 -0.0090 -0.0067 -0.0049 -0.0025 -0.0014 -0.0066 -0.0083 -0.0016 -0.0007 -0.0018 -0.0017 -0.0015
S-307	14 Eine Intensivierung der Insulintherapie mit einer abrupten Verbesserung der Blutzuckereinstellung kann jedoch mit einer Verschlechterung der diabetischen Retinopathie verbunden sein .
T-307	However , intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with worsening of diabetic retinopathy .
H-307	-0.016752656549215317	However , intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with worsening of diabetic retinopathy .
D-307	-0.016752656549215317	However , intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with worsening of diabetic retinopathy .
P-307	-0.0185 -0.0020 -0.0108 -0.0051 -0.0014 -0.0014 -0.0006 -0.0027 -0.0046 -0.0110 -0.0009 -0.0055 -0.1559 -0.0154 -0.0006 -0.0126 -0.3033 -0.0001 -0.0068 -0.0070 -0.0084 -0.0108 -0.0014 -0.0093 -0.0002 -0.0013 -0.0098 -0.0029 -0.0005 -0.0011 -0.0013 -0.0004 -0.0011 -0.0006 -0.0013 -0.0016 -0.0018
S-1450	Im Jahre 1998 wurde der EMEA eine wachsende Zahl von Verdachtsfällen von schweren unerwünschten Arzneimittelwirkungen zentral zugelassener Präparate gemeldet , die außerhalb der EU aufgetreten waren .
T-1450	In 1998 the EMEA was notified of an increasing number of reports of suspected serious unexpected adverse drug reactions occurring outside the EU for centrally authorised products .
H-1450	-0.005480543710291386	In 1998 the EMEA was notified of an increasing number of reports of suspected serious unexpected adverse drug reactions occurring outside the EU for centrally authorised products .
D-1450	-0.005480543710291386	In 1998 the EMEA was notified of an increasing number of reports of suspected serious unexpected adverse drug reactions occurring outside the EU for centrally authorised products .
P-1450	-0.0042 -0.0011 -0.0130 -0.0069 -0.0007 -0.0013 -0.0044 -0.0034 -0.0010 -0.0025 -0.0081 -0.0034 -0.0017 -0.0014 -0.0145 -0.0037 -0.0131 -0.0082 -0.0155 -0.0061 -0.0005 -0.0117 -0.0084 -0.0003 -0.0145 -0.0010 -0.0039 -0.0025 -0.0098 -0.0141 -0.0041 -0.0003 -0.0011 -0.0062 -0.0013 -0.0112 -0.0018 -0.0014
S-262	Dabei war festzustellen , dass in der Gardasil @-@ Gruppe zwei von fast 8 000 Frauen Genitalwarzen entwickelten und keine Fälle von Krebsvorstufen der Vulva oder Vagina vorkamen .
T-262	Two women out of almost 8,000 in the Gardasil group developed genital warts , and there were no cases of precancerous lesions of the vulva or the vagina .
H-262	-0.005532866809517145	Two women out of almost 8,000 in the Gardasil group developed genital warts , and there were no cases of precancerous lesions of the vulva or the vagina .
D-262	-0.005532866809517145	Two women out of almost 8,000 in the Gardasil group developed genital warts , and there were no cases of precancerous lesions of the vulva or the vagina .
P-262	-0.0144 -0.0136 -0.0055 -0.0013 -0.0114 -0.0030 -0.0064 -0.0018 -0.0007 -0.0009 -0.0008 -0.0010 -0.0032 -0.0026 -0.0008 -0.0009 -0.0004 -0.0004 -0.0219 -0.0043 -0.0072 -0.0469 -0.0016 -0.0051 -0.0015 -0.0100 -0.0028 -0.0004 -0.0139 -0.0001 -0.0070 -0.0021 -0.0011 -0.0021 -0.0017 -0.0155 -0.0028 -0.0010 -0.0019 -0.0014
S-1408	Die Konzentration von Topotecan O @-@ Glucuronid und N @-@ Desmethyl @-@ Topotecan O @-@ Glucuronid im Urin betrug weniger als 2,0 % .
T-1408	The topotecan @-@ O @-@ glucuronide and N @-@ desmethyl topotecan @-@ O @-@ glucuronide in the urine were less than 2.0 % .
H-1408	-0.013179321773350239	The topotecan @-@ O @-@ glucuronide and N @-@ desmethyl topotecan @-@ O @-@ glucuronide in the urine were less than 2.0 % .
D-1408	-0.013179321773350239	The topotecan @-@ O @-@ glucuronide and N @-@ desmethyl topotecan @-@ O @-@ glucuronide in the urine were less than 2.0 % .
P-1408	-0.0038 -0.0145 -0.0021 -0.0018 -0.0014 -0.0144 -0.0074 -0.0026 -0.0009 -0.0015 -0.0012 -0.0012 -0.0023 -0.0042 -0.2803 -0.0026 -0.0008 -0.0010 -0.1102 -0.0016 -0.0012 -0.0013 -0.0056 -0.0011 -0.0015 -0.0009 -0.0014 -0.0013 -0.0012 -0.0136 -0.0148 -0.0009 -0.0010 -0.0107 -0.0068 -0.0015 -0.0013 -0.0014 -0.0026 -0.0014
S-1003	Die Sicherheitsdatenbank aus klinischen Studien umfasste 2.737 CKD @-@ Patienten , von denen 1.789 Patienten mit MIRCERA und 948 mit einem anderen EPO behandelt wurden .
T-1003	The safety data base from clinical trials comprised 2 <<unk>> 737 CKD patients , including 1 <<unk>> 789 patients treated with MIRCERA and 948 with another ESA .
H-1003	-0.016606949269771576	The safety data base from clinical trials comprised 2 <unk> 737 CKD patients , including 1 <unk> 789 patients treated with MIRCERA and 948 with another ESA .
D-1003	-0.016606949269771576	The safety data base from clinical trials comprised 2 <unk> 737 CKD patients , including 1 <unk> 789 patients treated with MIRCERA and 948 with another ESA .
P-1003	-0.0038 -0.0026 -0.0131 -0.0034 -0.0085 -0.0197 -0.4553 -0.0125 -0.0007 -0.0011 -0.0146 -0.0145 -0.0013 -0.0013 -0.0035 -0.0011 -0.0016 -0.0015 -0.0043 -0.0137 -0.0041 -0.0118 -0.0013 -0.0008 -0.0091 -0.0055 -0.0016 -0.0024 -0.0005 -0.0015 -0.0008 -0.0012 -0.0021 -0.0064 -0.0010 -0.0107 -0.0092 -0.0145 -0.0145 -0.0026 -0.0014
S-1435	Zusätzlich könnte während einer langfristigen Behandlung mit der Kombination von Viraferon und Ribavirin ein trockener Mund einen schädigenden Effekt auf die Zähne und die Mundschleimhaut haben .
T-1435	In addition , dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long @-@ term treatment with the combination of Viraferon and ribavirin .
H-1435	-0.015069229528307915	In addition , dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long @-@ term treatment with the combination of Viraferon and ribavirin .
D-1435	-0.015069229528307915	In addition , dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long @-@ term treatment with the combination of Viraferon and ribavirin .
P-1435	-0.0081 -0.0012 -0.0029 -0.0140 -0.0024 -0.0116 -0.0062 -0.0062 -0.0099 -0.0021 -0.0017 -0.0088 -0.0017 -0.0139 -0.0735 -0.0003 -0.0008 -0.0004 -0.0063 -0.1291 -0.0041 -0.0024 -0.1785 -0.0068 -0.0034 -0.0011 -0.0032 -0.0047 -0.0052 -0.0017 -0.0014 -0.0043 -0.0009 -0.0009 -0.0072 -0.0942 -0.0058 -0.0006 -0.0006 -0.0013 -0.0016 -0.0014
S-754	27 / 35 Hersteller , der für die Chargenfreigabe verantwortlich ist Merial Laboratoire Porte des Alpes Rue de l &apos; Aviation F @-@ 69800 Saint Priest Frankreich
T-754	27 / 35 Manufacturing authorisation holder responsible for batch release Merial Laboratoire Porte des Alpes Rue de l &apos;Aviation F @-@ 69800 Saint Priest
H-754	-0.03225312754511833	27 / 35 Manufacturing authorisation holder responsible for batch release Merial Laboratoire Porte des Alpes Rue de l &apos;Aviation F @-@ 69800 Saint Priest
D-754	-0.03225312754511833	27 / 35 Manufacturing authorisation holder responsible for batch release Merial Laboratoire Porte des Alpes Rue de l &apos;Aviation F @-@ 69800 Saint Priest
P-754	-0.0014 -0.0014 -0.3529 -0.0096 -0.0008 -0.5861 -0.0145 -0.0066 -0.0144 -0.0163 -0.0022 -0.0037 -0.2746 -0.0089 -0.0032 -0.0005 -0.0007 -0.0011 -0.0013 -0.0012 -0.0007 -0.0006 -0.0011 -0.0013 -0.0007 -0.0012 -0.0031 -0.0006 -0.0012 -0.0010 -0.0014 -0.0004 -0.0013 -0.0010 -0.0014 -0.0005 -0.0006 -0.0009 -0.0013 -0.0002 -0.0017 -0.0310
S-1478	Der Arzt verschreibt Ihnen Jalra zusätzlich zu anderen Antidiabetika , die Sie bereits einnehmen , falls ein Arzneimittel allein nicht ausreicht , um Ihren Blutzuckerspiegel zu regulieren .
T-1478	Your doctor will prescribe Jalra together with certain other antidiabetic medicines which you will already be taking to control diabetes , if one medicine alone is not enough to control your blood sugar level .
H-1478	-0.02121162787079811	Your doctor will prescribe Jalra together with certain other antidiabetic medicines which you will already be taking to control diabetes , if one medicine alone is not enough to control your blood sugar level .
D-1478	-0.02121162787079811	Your doctor will prescribe Jalra together with certain other antidiabetic medicines which you will already be taking to control diabetes , if one medicine alone is not enough to control your blood sugar level .
P-1478	-0.0110 -0.0017 -0.0055 -0.0016 -0.0010 -0.0024 -0.0013 -0.0009 -0.0181 -0.0014 -0.0266 -0.0165 -0.0302 -0.0019 -0.0006 -0.3251 -0.0078 -0.0083 -0.0138 -0.0018 -0.0633 -0.0082 -0.0055 -0.0037 -0.0160 -0.0137 -0.0213 -0.0115 -0.0099 -0.0075 -0.0081 -0.0034 -0.0034 -0.0024 -0.0086 -0.0018 -0.0125 -0.0159 -0.0023 -0.2049 -0.0082 -0.0016 -0.0014
S-250	Insulin und Rosiglitazon stehen beide mit Flüssigkeitsretention in Zusammenhang , eine gleichzeitige Anwendung könnte das Risiko von Ödemen und einer ischämischen Herzerkrankung erhöhen .
T-250	Insulin and rosiglitazone are both associated with fluid retention , concomitant administration may increase the risk of oedema and could increase the risk of ischaemic heart disease .
H-250	-0.03177052363753319	Insulin and rosiglitazone are both associated with fluid retention , concomitant administration may increase the risk of oedema and could increase the risk of ischaemic heart disease .
D-250	-0.03177052363753319	Insulin and rosiglitazone are both associated with fluid retention , concomitant administration may increase the risk of oedema and could increase the risk of ischaemic heart disease .
P-250	-0.0027 -0.0005 -0.0006 -0.0863 -0.0049 -0.0004 -0.0010 -0.0008 -0.0017 -0.0030 -0.0016 -0.0062 -0.0014 -0.0021 -0.0008 -0.0007 -0.0003 -0.0162 -0.0143 -0.0104 -0.0003 -0.0024 -0.0149 -0.0104 -0.0049 -0.0022 -0.0012 -0.4842 -0.0100 -0.0024 -0.0006 -0.0016 -0.0296 -0.0137 -0.0065 -0.0015 -0.3285 -0.0237 -0.0611 -0.0010 -0.0003 -0.0016 -0.0210 -0.2486 -0.0014
S-303	&quot; Bei einem klinisch und hämodynamisch stabilen Patienten beträgt die Anfangsdosis 48 Stunden nach einem Myokardinfarkt 2,5 mg zweimal täglich für die Dauer von drei Tagen .
T-303	The CHMP , considered that in the absence of substance specific supportive data in this post myocardial infarction ( MI ) 24 hour interval , agreed the following : <<unk>> After 48 hours , following myocardial infarction in a clinically and haemodynamically stable patient , the starting dose is 2.5 mg twice daily for three days .
H-303	-0.014556321315467358	The CHMP , considered that in the absence of substance specific supportive data in this post myocardial infarction ( MI ) 24 hour interval , agreed the following : <unk> After 48 hours , following myocardial infarction in a clinically and haemodynamically stable patient , the starting dose is 2.5 mg twice daily for three days .
D-303	-0.014556321315467358	The CHMP , considered that in the absence of substance specific supportive data in this post myocardial infarction ( MI ) 24 hour interval , agreed the following : <unk> After 48 hours , following myocardial infarction in a clinically and haemodynamically stable patient , the starting dose is 2.5 mg twice daily for three days .
P-303	-0.0143 -0.0168 -0.0145 -0.0143 -0.0145 -0.0145 -0.0139 -0.0140 -0.0145 -0.0014 -0.0145 -0.0145 -0.0145 -0.0145 -0.0142 -0.0143 -0.0145 -0.0139 -0.0005 -0.0005 -0.0013 -0.0060 -0.0002 -0.0202 -0.0855 -0.0096 -0.0119 -0.0818 -0.0531 -0.0144 -0.0144 -0.0014 -0.0043 -0.0145 -0.0142 -0.0143 -0.0131 -0.0445 -0.0145 -0.0144 -0.0026 -0.0101 -0.0154 -0.0150 -0.0004 -0.0003 -0.0011 -0.0014 -0.0003 -0.0610 -0.0328 -0.0097 -0.0098 -0.0010 -0.0046 -0.0128 -0.0002 -0.0014 -0.0003 -0.0019 -0.0017 -0.0026 -0.0121 -0.0057 -0.0106 -0.0031 -0.0049 -0.0057 -0.0011 -0.0046 -0.1717 -0.0026 -0.0114 -0.0014 -0.0016 -0.0014
S-1782	Rötung , Juckreiz , Schwellungen , Blasenbildung ) bemerken , die schneller als normal auftritt , wenn bei Ihnen eine Operation ansteht oder Sie Narkosemittel erhalten sollen .
T-1782	You should also tell your doctor : if you are on a low @-@ salt diet if you have signs such as abnormal thirst , dry mouth , general weakness , drowsiness , muscle pain or cramps , nausea , vomiting , or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide ( contained in CoAprovel ) if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn ( such as redness , itching , swelling , blistering ) occurring more quickly than normal if you are going to have an operation ( surgery ) or be given anaesthetics
H-1782	-0.07234591990709305	You should also tell your doctor : if you are on a low @-@ salt diet if you have signs such as abnormal thirst , dry mouth , drowsiness , muscle pain or cramps , nausea , vomiting , or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide ( contained in CoAprovel ) if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn ( such as redness , itching , swelling , blistering ) occurring more quickly than normal if you are going to have an operation ( surgery ) or be given anaesthetics
D-1782	-0.07234591990709305	You should also tell your doctor : if you are on a low @-@ salt diet if you have signs such as abnormal thirst , dry mouth , drowsiness , muscle pain or cramps , nausea , vomiting , or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide ( contained in CoAprovel ) if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn ( such as redness , itching , swelling , blistering ) occurring more quickly than normal if you are going to have an operation ( surgery ) or be given anaesthetics
P-1782	-0.0144 -0.0142 -0.1128 -0.0997 -0.0074 -0.0058 -0.0207 -0.0125 -0.0098 -0.3352 -0.0141 -0.0123 -0.0144 -0.0141 -0.0145 -0.0010 -0.0145 -0.0038 -0.2430 -0.0145 -0.0180 -0.0015 -0.0315 -0.0142 -0.0145 -0.0028 -0.0046 -0.3631 -0.0140 -0.0035 -1.7845 -0.0109 -0.0014 -0.0000 -0.2876 -1.3168 -0.0129 -0.9105 -0.1197 -0.0073 -0.0257 -0.0148 -0.0001 -0.0727 -0.8076 -0.0004 -0.0015 -0.0064 -0.6896 -0.2646 -0.0143 -0.0148 -0.0144 -0.0144 -0.0119 -0.0386 -0.0113 -0.0145 -0.0119 -0.0263 -0.0146 -0.0148 -0.0145 -0.0120 -0.0082 -0.0011 -0.0119 -0.0038 -0.0035 -0.0001 -0.0139 -0.0145 -0.0039 -0.0145 -0.0145 -0.0145 -0.0145 -0.0078 -0.0510 -0.0057 -0.1701 -0.0120 -0.0343 -0.0151 -0.0006 -0.0156 -0.0056 -0.0123 -0.0148 -0.0131 -0.0142 -0.0151 -0.0144 -0.0126 -0.0144 -0.0060 -0.0203 -0.0143 -0.0014 -0.0117 -0.0006 -0.0255 -0.0027 -0.0016 -0.0434 -0.0029 -0.0015 -0.0748 -0.0045 -0.0016 -0.2384 -0.0647 -0.0043 -0.0119 -0.0048 -0.0039 -0.0039 -0.0145 -0.0054 -0.2390 -0.0142 -0.0047 -0.0065 -0.0103 -0.0032 -0.0256 -0.0142 -0.0039 -0.2772 -0.0144 -0.0096 -0.0051 -0.0037 -0.0113 -0.0090 -0.0650
S-1000	Es wird zusammen mit Cisplatin und 5 @-@ Fluorouracil ( anderen Arzneimitteln gegen Krebs ) angewendet . • Kopf- und Halskrebs im fortgeschrittenen Stadium .
T-1000	It is used with cisplatin and 5 @-@ fluorouracil .
H-1000	-0.021775200963020325	It is used with cisplatin and 5 @-@ fluorouracil .
D-1000	-0.021775200963020325	It is used with cisplatin and 5 @-@ fluorouracil .
P-1000	-0.0043 -0.0019 -0.0041 -0.1238 -0.0020 -0.0010 -0.0011 -0.0014 -0.0017 -0.0018 -0.1724 -0.0028 -0.0011 -0.0008 -0.0010 -0.0005 -0.0557 -0.0145
S-945	Film aus Poly ( ethylenterephthalat ) / Poly ( ethylen @-@ co @-@ vinylacetat ) und silikonisierte Polyesterfolie .
T-945	Backing : polyester / ethylene @-@ vinyl acetate film ; siliconised polyester film .
H-945	-0.011072237975895405	Backing : polyester / ethylene @-@ vinyl acetate film ; siliconised polyester film .
D-945	-0.011072237975895405	Backing : polyester / ethylene @-@ vinyl acetate film ; siliconised polyester film .
P-945	-0.0153 -0.0143 -0.0140 -0.0217 -0.0115 -0.0368 -0.0136 -0.0007 -0.0012 -0.0231 -0.0151 -0.0010 -0.0105 -0.0010 -0.0012 -0.0438 -0.0148 -0.0066 -0.0015 -0.0120 -0.0025 -0.0008 -0.0037 -0.0077 -0.0024
S-1325	Durchstechflaschen aus Klarglas Typ I zu 10 ml für den einmaligen Gebrauch mit Gummistopfen Typ I und Aluminiumverschlüssen mit blauen Schnappdeckeln aus Plastik .
T-1325	Single use 10 ml type 1 clear glass vials with type 1 rubber stoppers and aluminium closures with blue plastic flip off caps .
H-1325	-0.01719721406698227	Single use 10 ml type 1 clear glass vials with type 1 rubber stoppers and aluminium closures with blue plastic flip off caps .
D-1325	-0.01719721406698227	Single use 10 ml type 1 clear glass vials with type 1 rubber stoppers and aluminium closures with blue plastic flip off caps .
P-1325	-0.0145 -0.0108 -0.0165 -0.0009 -0.0168 -0.0139 -0.0067 -0.0016 -0.0026 -0.0017 -0.0035 -0.0139 -0.2454 -0.0020 -0.0897 -0.0049 -0.0018 -0.0013 -0.0028 -0.0117 -0.0014 -0.0047 -0.0043 -0.0015 -0.0145 -0.0037 -0.0145 -0.0047 -0.0018 -0.0018
S-165	Sie dürfen &#91; Neurontin und zugehörige Namen &#93; nach dem auf dem Umkarton und dem Behälter nach &#91; ist national auszufüllen &#93; angegebenen Verfallsdatum nicht mehr verwenden .
T-165	Do not use &#91; Neurontin and associated names &#93; after the expiry date which is stated on the carton after &#91; to be completed nationally &#93; .
H-165	-0.014872872270643711	Do not use &#91; Neurontin and associated names &#93; after the expiry date which is stated on the carton after &#91; to be completed nationally &#93; .
D-165	-0.014872872270643711	Do not use &#91; Neurontin and associated names &#93; after the expiry date which is stated on the carton after &#91; to be completed nationally &#93; .
P-165	-0.0143 -0.0015 -0.0025 -0.0024 -0.0015 -0.0008 -0.0011 -0.0005 -0.0020 -0.0075 -0.0023 -0.0015 -0.0072 -0.0028 -0.0019 -0.0067 -0.0014 -0.3477 -0.0067 -0.0101 -0.0025 -0.0021 -0.0244 -0.0028 -0.0146 -0.0070 -0.0127 -0.0017 -0.0063 -0.0016 -0.0012 -0.0020 -0.0030 -0.0015
S-1981	Adefovirdipivoxil ist ein Dipivaloyloxymethyl @-@ Ester @-@ Prodrug des arzneilich wirksamen Bestandteils Adefovir .
T-1981	Adefovir dipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance adefovir .
H-1981	-0.007424756418913603	Adefovir dipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance adefovir .
D-1981	-0.007424756418913603	Adefovir dipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance adefovir .
P-1981	-0.0021 -0.0010 -0.0010 -0.0106 -0.0010 -0.0118 -0.0011 -0.0004 -0.0012 -0.0011 -0.0016 -0.0018 -0.0019 -0.0016 -0.0013 -0.0019 -0.0014 -0.0015 -0.0014 -0.0004 -0.0007 -0.0023 -0.0034 -0.0023 -0.0055 -0.0024 -0.0134 -0.0143 -0.0138 -0.0009 -0.0009 -0.0009 -0.1441 -0.0014
S-936	Die PSUR @-@ Einreichtermine für Irbesartan Krka Filmtabletten sollen den PSUR @-@ Einreichterminen für das Referenzarzneimittel angeglichen werden .
T-936	The PSUR submission schedule for Irbesartan Krka film @-@ coated tablets should follow the PSUR schedule for the reference medicinal product .
H-936	-0.00666292617097497	The PSUR submission schedule for Irbesartan Krka film @-@ coated tablets should follow the PSUR schedule for the reference medicinal product .
D-936	-0.00666292617097497	The PSUR submission schedule for Irbesartan Krka film @-@ coated tablets should follow the PSUR schedule for the reference medicinal product .
P-936	-0.0046 -0.0027 -0.0010 -0.0012 -0.0099 -0.0010 -0.0145 -0.0037 -0.0105 -0.0001 -0.0005 -0.0011 -0.0010 -0.0006 -0.0047 -0.0504 -0.0145 -0.0006 -0.0295 -0.0011 -0.0114 -0.0146 -0.0060 -0.0032 -0.0009 -0.0012 -0.0147 -0.0042 -0.0026 -0.0026 -0.0114 -0.0026 -0.0015 -0.0017 -0.0014
S-539	Im Allgemeinen wird der Test mit CISH als positiv gewertet , wenn mehr als 5 Kopien des HER2- Gens pro Zellkern in mehr als 50 % der Tumorzellen vorliegen .
T-539	In general , CISH is considered positive if there are more than 5 copies of the HER2 gene per nucleus in greater than 50 % of tumour cells .
H-539	-0.005349240731447935	In general , CISH is considered positive if there are more than 5 copies of the HER2 gene per nucleus in greater than 50 % of tumour cells .
D-539	-0.005349240731447935	In general , CISH is considered positive if there are more than 5 copies of the HER2 gene per nucleus in greater than 50 % of tumour cells .
P-539	-0.0082 -0.0019 -0.0033 -0.0130 -0.0009 -0.0010 -0.0095 -0.0066 -0.0074 -0.0262 -0.0127 -0.0085 -0.0019 -0.0014 -0.0096 -0.0008 -0.0017 -0.0038 -0.0007 -0.0015 -0.0012 -0.0035 -0.0030 -0.0002 -0.0019 -0.0025 -0.0157 -0.0014 -0.0237 -0.0018 -0.0014 -0.0030 -0.0080 -0.0015 -0.0016 -0.0015
S-1626	Eine Dosisreduktion für Patienten , die eine ViraferonPeg Monotherapie mit 0,5 μ g / kg erhalten , muss durch eine Halbierung der verordneten Menge erreicht werden .
T-1626	5 Dose reduction for patients who use 0.5 μ g / kg ViraferonPeg monotherapy must be accomplished by reducing the prescribed volume by one @-@ half .
H-1626	-0.13613873720169067	5 Dose reduction for patients after 0.5 μ g / kg ViraferonPeg monotherapy must be accomplished by reducing the prescribed volume by one @-@ half .
D-1626	-0.13613873720169067	5 Dose reduction for patients after 0.5 μ g / kg ViraferonPeg monotherapy must be accomplished by reducing the prescribed volume by one @-@ half .
P-1626	-0.0145 -0.0145 -0.0102 -0.0025 -0.0054 -0.0018 -4.7472 -0.1075 -0.0120 -0.0019 -0.0014 -0.0009 -0.0059 -0.0010 -0.0009 -0.0011 -0.0010 -0.0010 -0.0033 -0.0016 -0.0007 -0.0083 -0.0014 -0.0144 -0.0012 -0.0021 -0.0137 -0.0036 -0.0045 -0.0009 -0.0148 -0.0064 -0.0151 -0.0088 -0.0021 -0.0019 -0.0015
S-1076	Invega darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen Paliperidon , einen der sonstigen Bestandteile oder gegen Risperidon sind .
T-1076	Invega should not be taken by people who may be hypersensitive ( allergic ) to paliperidone or any of the other ingredients , or to risperidone .
H-1076	-0.03489484265446663	Invega should not be used in people who may be hypersensitive ( allergic ) to paliperidone or any of the other ingredients , or to risperidone .
D-1076	-0.03489484265446663	Invega should not be used in people who may be hypersensitive ( allergic ) to paliperidone or any of the other ingredients , or to risperidone .
P-1076	-0.0045 -0.0006 -0.0013 -0.0091 -0.0015 -0.0014 -1.0318 -0.0050 -0.0353 -0.0029 -0.0044 -0.0025 -0.0159 -0.0007 -0.0036 -0.0020 -0.0008 -0.0015 -0.0016 -0.0041 -0.0004 -0.0004 -0.0001 -0.1008 -0.0049 -0.0038 -0.0072 -0.0222 -0.0103 -0.0276 -0.0038 -0.0066 -0.0029 -0.0009 -0.0003 -0.0001 -0.0017 -0.0014
S-438	Eine klinische Interaktionsstudie mit Midazolam ( Substrat von CYP 3A4 ) zeigt , dass Fulvestrant CYP 3A4 nicht inhibiert .
T-438	A clinical interaction study with midazolam ( substrate of CYP3A4 ) demonstrated that fulvestrant does not inhibit CYP3A4 .
H-438	-0.03172314167022705	A clinical interaction study with midazolam ( substrate of CYP3A4 ) demonstrated that fulvestrant does not inhibit CYP3A4 .
D-438	-0.03172314167022705	A clinical interaction study with midazolam ( substrate of CYP3A4 ) demonstrated that fulvestrant does not inhibit CYP3A4 .
P-438	-0.0040 -0.0012 -0.0059 -0.0013 -0.0019 -0.0105 -0.0054 -0.0008 -0.0010 -0.0008 -0.0010 -0.0018 -0.0070 -0.0011 -0.0014 -0.0709 -0.0015 -0.0012 -1.0653 -0.0013 -0.0011 -0.0015 -0.0145 -0.0020 -0.0022 -0.0009 -0.0020 -0.0044 -0.0014 -0.0013 -0.0005 -0.0005 -0.0015 -0.0013 -0.0113 -0.0011 -0.0011 -0.0019 -0.0015
S-1762	Oktober 2000 erteilte die Europäische Kommission dem Unternehmen GlaxoSmithKline Biologicals s.a. eine Genehmigung für das Inverkehrbringen von Infanrix Hexa in der gesamten Europäischen Union .
T-1762	The European Commission granted a marketing authorisation valid throughout the EU for Infanrix Hexa to GlaxoSmithKline Biologicals s. a. on 23 October 2000 .
H-1762	-0.04177434742450714	The European Commission granted a marketing authorisation valid throughout the EU for Infanrix Hexa to GlaxoSmithKline Biologicals s. a. on 23 October 2000 .
D-1762	-0.04177434742450714	The European Commission granted a marketing authorisation valid throughout the EU for Infanrix Hexa to GlaxoSmithKline Biologicals s. a. on 23 October 2000 .
P-1762	-0.0140 -0.0052 -0.0011 -0.0130 -0.0135 -0.0058 -0.0028 -0.0009 -0.0145 -0.0020 -0.0103 -0.0017 -0.7351 -0.0102 -0.0048 -0.0004 -0.0010 -0.0014 -0.0003 -0.0013 -0.0567 -0.0029 -0.0009 -0.0012 -0.0005 -0.0011 -0.0015 -0.0010 -0.0009 -0.0009 -0.0004 -0.0145 -0.0133 -0.0123 -0.0514 -0.6239 -0.0032 -0.0018 -0.0014
S-1554	Wirkungsweise Micafungin bewirkt eine nicht @-@ kompetitive Hemmung der Synthese von 1,3 @-@ β @-@ D @-@ Glucan , einem Grundbestandteil der Pilzzellwand .
T-1554	Mode of action Micafungin non @-@ competitively inhibits the synthesis of 1,3 @-@ β @-@ D @-@ glucan , an essential component of the fungal cell wall .
H-1554	-0.007902765646576881	Mode of action Micafungin non @-@ competitively inhibits the synthesis of 1,3 @-@ β @-@ D @-@ glucan , an essential component of the fungal cell wall .
D-1554	-0.007902765646576881	Mode of action Micafungin non @-@ competitively inhibits the synthesis of 1,3 @-@ β @-@ D @-@ glucan , an essential component of the fungal cell wall .
P-1554	-0.0131 -0.0014 -0.0023 -0.0052 -0.0010 -0.0005 -0.0019 -0.0146 -0.0016 -0.0045 -0.0004 -0.0027 -0.0007 -0.0007 -0.0023 -0.0008 -0.0008 -0.0011 -0.0014 -0.0009 -0.0014 -0.0003 -0.0014 -0.0010 -0.0014 -0.0017 -0.0016 -0.0021 -0.0148 -0.0070 -0.0048 -0.0011 -0.0378 -0.0034 -0.0020 -0.0004 -0.0073 -0.0015 -0.0015 -0.1722 -0.0014
S-89	Detaillierte Informationen zum Bestandteil Sorbitol ( einem Zucker ) erhalten Sie in Abschnitt 2. unter der Überschrift &quot; Wichtige Informationen über bestimmte sonstige Bestandteile von Tevagrastim &quot; .
T-89	You will find detailed information about the ingredient sorbitol ( a sugar ) in section 2. under the heading <<unk>> Important information about some of the ingredients of Tevagrastim <<unk>> .
H-89	-0.005401611328125	You will find detailed information about the ingredient sorbitol ( a sugar ) in section 2. under the heading <unk> Important information about some of the ingredients of Tevagrastim <unk> .
D-89	-0.005401611328125	You will find detailed information about the ingredient sorbitol ( a sugar ) in section 2. under the heading <unk> Important information about some of the ingredients of Tevagrastim <unk> .
P-89	-0.0116 -0.0077 -0.0039 -0.0035 -0.0011 -0.0159 -0.0044 -0.0128 -0.0005 -0.0003 -0.0008 -0.0004 -0.0005 -0.0020 -0.0031 -0.0009 -0.0016 -0.0022 -0.0094 -0.0107 -0.0032 -0.0021 -0.0012 -0.0145 -0.0042 -0.0006 -0.0012 -0.0079 -0.0071 -0.0143 -0.0137 -0.0016 -0.0163 -0.0050 -0.0125 -0.0007 -0.0006 -0.0044 -0.0008 -0.0180 -0.0018 -0.0018
S-1187	Ísland JANSSEN @-@ CILAG c / o Vistor Hörgatún 2 IS @-@ 210 Garðabær Sími : + 354 535 7000
T-1187	Ísland JANSSEN @-@ CILAG c / o Vistor Hörgatún 2 IS @-@ 210 Garðabær Sími : + 354 535 7000
H-1187	-0.013749003410339355	Ísland JANSSEN @-@ CILAG c / o Vistor Hörgatún 2 IS @-@ 210 Garðabær Sími : + 354 535 7000
D-1187	-0.013749003410339355	Ísland JANSSEN @-@ CILAG c / o Vistor Hörgatún 2 IS @-@ 210 Garðabær Sími : + 354 535 7000
P-1187	-0.0007 -0.0019 -0.0014 -0.0013 -0.0009 -0.0005 -0.0008 -0.0015 -0.0013 -0.0007 -0.0005 -0.0019 -0.0015 -0.0010 -0.0022 -0.0025 -0.0012 -0.0081 -0.0009 -0.0010 -0.0012 -0.2001 -0.1259 -0.0010 -0.0014 -0.0006 -0.0022 -0.0001 -0.0009 -0.0002 -0.0008 -0.0020 -0.0008 -0.0004 -0.0016 -0.0012 -0.0013 -0.0008 -0.0012 -0.2004 -0.0003 -0.0015
S-1186	Die Injektionslösung enthält 10 mg Maropitant pro ml als Maropitant @-@ Citrat @-@ Monohydrat als eine klare , farblose bis leicht gelbliche Lösung .
T-1186	The solution for injection contains 10 mg maropitant per ml as maropitant citrate monohydrate as a clear , colourless to light yellow solution It also contains metacresol ( as preservative ) .
H-1186	-0.025804806500673294	The solution for injection contains 10 mg maropitant per ml as maropitant citrate monohydrate as a clear , colourless to light yellow solution .
D-1186	-0.025804806500673294	The solution for injection contains 10 mg maropitant per ml as maropitant citrate monohydrate as a clear , colourless to light yellow solution .
P-1186	-0.0037 -0.0134 -0.0123 -0.0053 -0.0022 -0.0164 -0.0031 -0.0008 -0.0130 -0.0018 -0.0016 -0.0033 -0.0018 -0.0011 -0.0042 -0.0055 -0.0011 -0.0012 -0.0027 -0.0045 -0.0018 -0.0012 -0.0007 -0.0014 -0.0010 -0.0012 -0.0065 -0.0022 -0.0019 -0.0027 -0.0048 -0.0009 -0.0012 -0.0913 -0.0143 -0.0094 -0.0030 -0.7602 -0.0014
S-1195	Karvea 150 mg Filmtabletten sind weiß bis gebrochen weiß , bikonvex und oval mit Prägung , auf einer Seite ein Herz und auf der anderen Seite die Zahlen 2872 .
T-1195	What Karvea looks like and contents of the pack Karvea 150 mg film @-@ coated tablets are white to off @-@ white , biconvex , and oval @-@ shaped with a heart debossed on one side and the number 2872 engraved on the other side .
H-1195	-0.014975008554756641	What Karvea looks like and contents of the pack Karvea 150 mg film @-@ coated tablets are white to off @-@ white , biconvex , and oval @-@ shaped with a heart debossed on one side and the number 2872 engraved on the other side .
D-1195	-0.014975008554756641	What Karvea looks like and contents of the pack Karvea 150 mg film @-@ coated tablets are white to off @-@ white , biconvex , and oval @-@ shaped with a heart debossed on one side and the number 2872 engraved on the other side .
P-1195	-0.0145 -0.0153 -0.0007 -0.0015 -0.0167 -0.0029 -0.0144 -0.0145 -0.0027 -0.0140 -0.0116 -0.0145 -0.0146 -0.0006 -0.0016 -0.0052 -0.0013 -0.0075 -0.0636 -0.0145 -0.0026 -0.0169 -0.0020 -0.0048 -0.0024 -0.0049 -0.0145 -0.0093 -0.0005 -0.0034 -0.0048 -0.0011 -0.0006 -0.0014 -0.0181 -0.0423 -0.0435 -0.0005 -0.1029 -0.0014 -0.0297 -0.0136 -0.0031 -0.0145 -0.0106 -0.0123 -0.0027 -0.0017 -0.0985 -0.0273 -0.0061 -0.0142 -0.0012 -0.0041 -0.0207 -0.0043 -0.0013 -0.0170 -0.0014 -0.0014 -0.1444 -0.0019 -0.0014
S-1873	Tiefes , beschleunigtes Atmen , Schläfrigkeit und unspezifische Symptome wie Übelkeit , Erbrechen und Magenschmerzen können auf die Entwicklung einer Laktatazidose hinweisen .
T-1873	Deep rapid breathing , drowsiness , and non specific symptoms such as nausea , vomiting and stomach pain , might indicate the development of lactic acidosis .
H-1873	-0.0313611775636673	Deep rapid breathing , drowsiness , and non specific symptoms such as nausea , vomiting and stomach pain , might indicate the development of lactic acidosis .
D-1873	-0.0313611775636673	Deep rapid breathing , drowsiness , and non specific symptoms such as nausea , vomiting and stomach pain , might indicate the development of lactic acidosis .
P-1873	-0.0064 -0.0009 -0.0144 -0.0014 -0.0015 -0.0192 -0.0005 -0.0008 -0.0009 -0.5465 -0.0023 -0.0091 -0.0450 -0.0023 -0.0245 -0.0014 -0.0008 -0.0003 -0.0014 -0.1963 -0.0003 -0.0013 -0.0137 -0.0023 -0.0278 -0.0187 -0.0205 -0.0033 -0.0040 -0.0025 -0.0014 -0.0019 -0.0139 -0.0014 -0.0009 -0.0009 -0.1997 -0.0014
S-1210	Bei erstmaliger Verschreibung sollte der Arzt die Eltern über die Anzeichen , Symptome und Behandlungen einer Hypoglykämie , einschließlich Glucagon @-@ Injektionen , aufklären .
T-1210	At the time of initial prescription , physicians should educate parents on the signs , symptoms and treatment of hypoglycaemia , including injection of glucagon .
H-1210	-0.011779232881963253	At the time of initial prescription , physicians should educate parents on the signs , symptoms and treatment of hypoglycaemia , including injection of glucagon .
D-1210	-0.011779232881963253	At the time of initial prescription , physicians should educate parents on the signs , symptoms and treatment of hypoglycaemia , including injection of glucagon .
P-1210	-0.0133 -0.0123 -0.0103 -0.0021 -0.0065 -0.0067 -0.0039 -0.0143 -0.0038 -0.0017 -0.0121 -0.0011 -0.0031 -0.0147 -0.0048 -0.0022 -0.0016 -0.0009 -0.1524 -0.0136 -0.0032 -0.0005 -0.0009 -0.0005 -0.0127 -0.0019 -0.0013 -0.0128 -0.0540 -0.0129 -0.0435 -0.0042 -0.0016 -0.0009 -0.0005 -0.0019 -0.0014
S-1780	Während der klinischen Prüfungen blieben die supprimierten Testosteronspiegel bei den meisten kleineren Hunden ( &lt; 10 kg ) länger als 12 Monate nach der Implantation erhalten .
T-1780	During clinical trials , most of the smaller size dogs ( &lt; 10 kg ) maintained suppressed levels of testosterone for more than 12 months following implantation .
H-1780	-0.020207582041621208	During clinical trials , most of the smaller size dogs ( &lt; 10 kg ) maintained suppressed levels of testosterone for more than 12 months following implantation .
D-1780	-0.020207582041621208	During clinical trials , most of the smaller size dogs ( &lt; 10 kg ) maintained suppressed levels of testosterone for more than 12 months following implantation .
P-1780	-0.0022 -0.0152 -0.0054 -0.0052 -0.0141 -0.0139 -0.0023 -0.0045 -0.2249 -0.1694 -0.0027 -0.0030 -0.0004 -0.0014 -0.0059 -0.0024 -0.0015 -0.0082 -0.0074 -0.0005 -0.0141 -0.0014 -0.0009 -0.0004 -0.0007 -0.0011 -0.0067 -0.0075 -0.0015 -0.0012 -0.0015 -0.2095 -0.0029 -0.0040 -0.0007 -0.0016 -0.0014
S-988	SonoVue darf bei Patienten , die möglicherweise überempfindlich ( allergisch ) gegen Schwefelhexafluorid oder einen der anderen Bestandteile sind , nicht angewendet werden .
T-988	SonoVue should not be used in people who may be hypersensitive ( allergic ) to sulphur hexafluoride or any of the other ingredients .
H-988	-0.026970593258738518	SonoVue should not be used in people who may be hypersensitive ( allergic ) to sulphur hexafluoride or any of the other ingredients .
D-988	-0.026970593258738518	SonoVue should not be used in people who may be hypersensitive ( allergic ) to sulphur hexafluoride or any of the other ingredients .
P-988	-0.0020 -0.0012 -0.0012 -0.0008 -0.0108 -0.0016 -0.0014 -0.6838 -0.0056 -0.0249 -0.0029 -0.0036 -0.0021 -0.0139 -0.0006 -0.0032 -0.0018 -0.0008 -0.0015 -0.0016 -0.0020 -0.0098 -0.0007 -0.0015 -0.0007 -0.0012 -0.0015 -0.0004 -0.0011 -0.0017 -0.0484 -0.0032 -0.0051 -0.1469 -0.0051 -0.0019 -0.0014
S-115	In der Studie 1899 wurde ein signifikanter Abfall der Sterblichkeit jeglicher Ursache zugunsten von Posaconazol beobachtet &#91; POS 49 / 304 ( 16 % ) vs .
T-115	In Study 1899 , a significant decrease in all cause mortality in favour of posaconazole was observed &#91; POS 49 / 304 ( 16 % ) vs .
H-115	-0.012297114357352257	In Study 1899 , a significant decrease in all cause mortality in favour of posaconazole was observed &#91; POS 49 / 304 ( 16 % ) vs .
D-115	-0.012297114357352257	In Study 1899 , a significant decrease in all cause mortality in favour of posaconazole was observed &#91; POS 49 / 304 ( 16 % ) vs .
P-115	-0.0078 -0.0145 -0.0006 -0.0001 -0.0089 -0.0051 -0.0028 -0.0085 -0.0009 -0.0058 -0.0121 -0.0063 -0.0022 -0.0010 -0.0109 -0.0109 -0.0014 -0.0604 -0.0011 -0.0011 -0.0005 -0.0004 -0.0053 -0.2356 -0.0302 -0.0016 -0.0012 -0.0007 -0.0014 -0.0011 -0.0013 -0.0014 -0.0012 -0.0013 -0.0014 -0.0064 -0.0122 -0.0014
S-932	Am Ende der Hauptstudie hatten 53 % der Patienten , die Exjade erhielten , ausreichend auf die Behandlung angesprochen , verglichen mit 66 % bei den Patienten , die Deferoxamin erhielten .
T-932	At the end of the main study , 53 % of the patients receiving Exjade had shown a sufficient response to treatment , compared with 66 % of the patients receiving deferoxamine .
H-932	-0.02599482797086239	At the end of the main study , 53 % of the patients receiving Exjade had shown a sufficient response to treatment , compared with 66 % of the patients receiving deferoxamine .
D-932	-0.02599482797086239	At the end of the main study , 53 % of the patients receiving Exjade had shown a sufficient response to treatment , compared with 66 % of the patients receiving deferoxamine .
P-932	-0.0114 -0.0020 -0.0032 -0.0014 -0.0016 -0.0026 -0.0048 -0.0034 -0.0009 -0.0017 -0.0015 -0.0123 -0.0024 -0.1094 -0.0035 -0.0012 -0.0019 -0.0052 -0.0144 -0.0093 -0.0057 -0.0020 -0.0226 -0.0067 -0.1494 -0.0021 -0.5688 -0.0009 -0.0013 -0.0186 -0.0122 -0.0019 -0.0093 -0.0121 -0.0009 -0.0008 -0.0012 -0.0015 -0.0014
S-1426	Wie bei anderen Interferonen wurden bei der Behandlung mit Pegasys Hypoglykämie , Hyperglykämie und Diabetes mellitus beobachtet ( siehe Abschnitt 4.8 ) .
T-1426	As with other interferons , hypoglycaemia , hyperglycaemia and diabetes mellitus have been observed with Pegasys ( see section 4.8 ) .
H-1426	-0.01093083992600441	As with other interferons , hypoglycaemia , hyperglycaemia and diabetes mellitus have been observed with Pegasys ( see section 4.8 ) .
D-1426	-0.01093083992600441	As with other interferons , hypoglycaemia , hyperglycaemia and diabetes mellitus have been observed with Pegasys ( see section 4.8 ) .
P-1426	-0.0067 -0.0048 -0.0021 -0.0029 -0.0006 -0.0022 -0.0019 -0.0056 -0.0011 -0.0005 -0.0134 -0.0022 -0.0013 -0.0014 -0.0010 -0.0013 -0.0005 -0.0052 -0.0009 -0.0012 -0.2778 -0.0013 -0.0007 -0.0011 -0.0002 -0.0120 -0.0022 -0.0321 -0.0148 -0.0087 -0.0008 -0.0014 -0.0070 -0.0026 -0.0105 -0.0011 -0.0014 -0.0019 -0.0015 -0.0014
S-879	31 möglicherweise erhöhten Risikos dosisabhängiger Nebenwirkungen kann eine Verringerung der Pioglitazondosierung erforderlich sein , wenn Gemfibrozil gleichzeitig verabreicht wird .
T-879	Since there is a potential for an increase in dose @-@ related adverse events , a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered .
H-879	-0.017736518755555153	Since there is a potential for an increase in dose @-@ related adverse events , a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered .
D-879	-0.017736518755555153	Since there is a potential for an increase in dose @-@ related adverse events , a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered .
P-879	-0.0145 -0.0133 -0.0070 -0.0057 -0.0128 -0.0143 -0.0114 -0.0417 -0.0042 -0.0145 -0.0028 -0.0104 -0.0253 -0.0004 -0.1814 -0.0029 -0.0065 -0.0130 -0.0009 -0.0871 -0.0116 -0.0134 -0.0015 -0.0020 -0.0014 -0.0006 -0.0011 -0.0028 -0.0030 -0.0017 -0.1095 -0.0237 -0.0043 -0.0025 -0.0010 -0.0014 -0.0015 -0.0182 -0.0139 -0.0003 -0.1043 -0.0045 -0.0008 -0.0016 -0.0014
S-291	• Nosokomiale Pneumonie ( einschließlich Beatmungspneumonie ) • Komplizierte intraabdominelle Infektionen • Komplizierte Harnwegsinfektionen .
T-291	• Nosocomial pneumonia ( including ventilator <<unk>> associated pneumonia ) • Complicated intra @-@ abdominal infections • Complicated urinary tract infections
H-291	-0.022095998749136925	• Nosocomial pneumonia ( including ventilator <unk> associated pneumonia ) • Complicated intra @-@ abdominal infections • Complicated urinary tract infections
D-291	-0.022095998749136925	• Nosocomial pneumonia ( including ventilator <unk> associated pneumonia ) • Complicated intra @-@ abdominal infections • Complicated urinary tract infections
P-291	-0.0019 -0.0014 -0.0008 -0.0012 -0.0012 -0.0005 -0.0014 -0.0042 -0.0008 -0.0008 -0.0009 -0.0016 -0.0583 -0.0087 -0.0009 -0.0120 -0.0054 -0.0198 -0.0145 -0.0069 -0.0010 -0.0008 -0.0009 -0.0014 -0.0019 -0.0045 -0.0002 -0.0019 -0.0022 -0.1429 -0.0024 -0.0006 -0.0003 -0.0008 -0.0015 -0.0008 -0.0022 -0.0012 -0.0002 -0.0014 -0.0008 -0.0005 -0.0080 -0.0007 -0.0023 -0.0007 -0.7136
S-1493	Beachten Sie auch die Abschnitte &quot; Ketek darf nicht eingenommen werden &quot; , &quot; Bei Anwendung von anderen Arzneimitteln &quot; und &quot; Verkehrstüchtigkeit und das Bedienen von Maschinen &quot; .
T-1493	impaired hepatic function ) , other medicines containing any of the following active substances : • ketoconazole ( anti fungal treatment ) • a medicine called protease inhibitor ( anti HIV treatment )
H-1493	-0.014096416532993317	impaired hepatic function ) , other medicines containing any of the following active substances : • ketoconazole ( anti fungal treatment ) • a medicine called protease inhibitor ( anti HIV treatment )
D-1493	-0.014096416532993317	impaired hepatic function ) , other medicines containing any of the following active substances : • ketoconazole ( anti fungal treatment ) • a medicine called protease inhibitor ( anti HIV treatment )
P-1493	-0.0348 -0.0141 -0.0145 -0.0136 -0.0133 -0.0140 -0.0146 -0.0179 -0.0144 -0.0048 -0.0055 -0.0174 -0.0143 -0.0136 -0.0074 -0.0124 -0.0145 -0.0127 -0.0002 -0.0154 -0.0145 -0.0145 -0.0046 -0.0136 -0.0123 -0.0031 -0.0125 -0.0145 -0.0742 -0.0057 -0.0029 -0.0144 -0.0034 -0.0174 -0.0146 -0.0144 -0.0141 -0.0146 -0.0145 -0.0143 -0.0016 -0.0012 -0.0110 -0.0078 -0.0136 -0.0574 -0.0138 -0.0029 -0.0182
S-499	AVONEX 30 Mikrogramm Pulver und Lösungsmittel zur Herstellung einer Injektionslösung ( Interferon beta @-@ 1a ) BIO @-@ SET Aufmachung
T-499	AVONEX 30 micrograms powder and solvent for solution for injection ( Interferon beta @-@ 1a ) BIO @-@ SET Presentation
H-499	-0.004001282621175051	AVONEX 30 micrograms powder and solvent for solution for injection ( Interferon beta @-@ 1a ) BIO @-@ SET Presentation
D-499	-0.004001282621175051	AVONEX 30 micrograms powder and solvent for solution for injection ( Interferon beta @-@ 1a ) BIO @-@ SET Presentation
P-499	-0.0022 -0.0017 -0.0011 -0.0012 -0.0010 -0.0034 -0.0065 -0.0108 -0.0090 -0.0106 -0.0010 -0.0018 -0.0058 -0.0145 -0.0141 -0.0033 -0.0011 -0.0023 -0.0158 -0.0006 -0.0014 -0.0010 -0.0014 -0.0015 -0.0013 -0.0014 -0.0015 -0.0045 -0.0013 -0.0009 -0.0015 -0.0007 -0.0011 -0.0134 -0.0013 -0.0022
S-1548	26 Schwerwiege nde psychiatrische Ereignisse wie Depressionen oder Stimmungsänderungen wurden bei Patienten , die ACOMPLIA erhielten , berichtet ( siehe Absatz &quot; WELCHE NEBENWIRKUNGEN
T-1548	Serious psychiatric events including depression or mood changes have been reported in patients taking ACOMPLIA ( see section POSSIBLE SIDE EFFECTS ) .
H-1548	-0.030899275094270706	Serious psychiatric events including depression or mood changes have been reported in patients taking ACOMPLIA ( see section POSSIBLE SIDE EFFECTS ) .
D-1548	-0.030899275094270706	Serious psychiatric events including depression or mood changes have been reported in patients taking ACOMPLIA ( see section POSSIBLE SIDE EFFECTS ) .
P-1548	-0.0145 -0.0016 -0.0009 -0.0012 -0.0053 -0.0294 -0.0007 -0.1291 -0.0034 -0.0027 -0.0248 -0.0017 -0.0810 -0.0039 -0.0031 -0.2368 -0.0015 -0.0010 -0.0006 -0.0015 -0.0007 -0.0023 -0.0024 -0.0129 -0.0145 -0.0131 -0.0133 -0.0032 -0.0064 -0.0178 -0.0114 -0.0168 -0.0061 -0.0023 -0.0018 -0.0079 -0.4956 -0.0015
S-1025	Bei Patienten mit einer Nierenfunktionsstörung in der Anamnese und bei Patienten mit erhöhtem Risiko für eine Nierenfunktionsstörung muss eine häufigere Überwachung der Nierenfunktion erwogen werden .
T-1025	In patients with a history of renal dysfunction or in patients who are at risk for renal dysfunction , consideration must be given to more frequent monitoring of renal function .
H-1025	-0.019512763246893883	In patients with a history of renal dysfunction or in patients who are at risk for renal dysfunction , consideration must be given to more frequent monitoring of renal function .
D-1025	-0.019512763246893883	In patients with a history of renal dysfunction or in patients who are at risk for renal dysfunction , consideration must be given to more frequent monitoring of renal function .
P-1025	-0.0089 -0.0044 -0.0089 -0.0066 -0.0077 -0.0014 -0.0052 -0.0010 -0.2285 -0.0009 -0.0498 -0.0095 -0.0034 -0.0223 -0.0070 -0.0019 -0.0213 -0.0860 -0.0095 -0.0011 -0.0050 -0.0010 -0.0044 -0.0144 -0.0073 -0.0013 -0.0008 -0.0015 -0.0070 -0.0004 -0.0015 -0.0020 -0.0059 -0.0012 -0.0033 -0.1783 -0.0014
S-1398	Zusammenfassend ist festzustellen , dass die Studie 306 ( EUCLID ) schlecht geeignet war , Dokumentation für den Nachweis des beantragten Anspruchs im Hinblick auf beginnende Nephropathie zu liefern .
T-1398	In summary , trial 306 ( EUCLID ) was ill suited to provide the documentation to support the proposed claim in incipient nephropathy .
H-1398	-0.005231228657066822	In summary , trial 306 ( EUCLID ) was ill suited to provide the documentation to support the proposed claim in incipient nephropathy .
D-1398	-0.005231228657066822	In summary , trial 306 ( EUCLID ) was ill suited to provide the documentation to support the proposed claim in incipient nephropathy .
P-1398	-0.0055 -0.0045 -0.0005 -0.0022 -0.0141 -0.0022 -0.0014 -0.0016 -0.0009 -0.0007 -0.0007 -0.0014 -0.0048 -0.0069 -0.0134 -0.0299 -0.0049 -0.0145 -0.0056 -0.0009 -0.0117 -0.0120 -0.0024 -0.0144 -0.0015 -0.0115 -0.0145 -0.0008 -0.0004 -0.0007 -0.0010 -0.0008 -0.0011 -0.0003 -0.0006 -0.0017 -0.0014
S-149	Wenn die Symptome nachlassen und die CK @-@ Spiegel zum Normalwert zurückkehren , kann die Wiederauf- nahme der Statin @-@ Therapie mit der niedrigsten Dosierung und unter engmaschiger Überwachung in Betracht gezogen werden .
T-149	If symptoms resolve and CK levels return to normal , then reintroduction of statin therapy may be considered at the lowest dose and with close monitoring .
H-149	-0.020115485414862633	If symptoms resolve and CK levels return to normal , then reintroduction of statin therapy may be considered at the lowest dose and with close monitoring .
D-149	-0.020115485414862633	If symptoms resolve and CK levels return to normal , then reintroduction of statin therapy may be considered at the lowest dose and with close monitoring .
P-149	-0.0113 -0.0166 -0.0142 -0.0019 -0.0079 -0.0012 -0.0015 -0.0013 -0.0014 -0.0016 -0.0041 -0.3017 -0.1650 -0.0145 -0.0023 -0.0061 -0.0016 -0.0035 -0.0146 -0.0014 -0.0021 -0.0049 -0.0034 -0.0021 -0.0092 -0.0064 -0.0126 -0.0023 -0.0036 -0.0017 -0.0015
S-1399	Die Behandlung aller Genotypen der Erkrankung sollten möglichst frühzeitig eingeleitet werden , um das Gesamtüberleben zu verlängern und Komplikationen wie Leberversagen , Leberkarzinom und Nierenerkrankungen zu verhindern .
T-1399	Treatment of all genotypes of the disease should be initiated as early as possible to increase overall survival and avoid complications such as liver failure , liver cancer and renal disease .
H-1399	-0.017213398590683937	Treatment of all genotypes of the disease should be initiated as early as possible to increase overall survival and avoid complications such as liver failure , liver cancer and renal disease .
D-1399	-0.017213398590683937	Treatment of all genotypes of the disease should be initiated as early as possible to increase overall survival and avoid complications such as liver failure , liver cancer and renal disease .
P-1399	-0.0048 -0.0010 -0.0014 -0.0033 -0.0019 -0.0041 -0.0008 -0.0012 -0.0056 -0.0022 -0.0021 -0.0019 -0.0042 -0.0042 -0.0014 -0.0055 -0.0063 -0.0014 -0.0012 -0.0634 -0.0139 -0.0010 -0.0008 -0.0024 -0.0137 -0.0006 -0.0014 -0.0079 -0.0013 -0.0022 -0.0010 -0.2537 -0.0020 -0.0047 -0.2344 -0.0224 -0.0011 -0.0035 -0.0015 -0.0014
S-446	Hat sich der Ductus arteriosus nach dem ersten Behandlungszyklus noch nicht geschlossen oder wieder geöffnet , kann der Arzt , der Ihr Baby behandelt , beschließen , einen zweiten Behandlungszyklus durchzuführen .
T-446	If after this first course of treatment , the ductus arteriosus is not closed or re @-@ opens , your baby <<unk>> s doctor may decide to give a second course of treatment .
H-446	-0.00719861127436161	If after this first course of treatment , the ductus arteriosus is not closed or re @-@ opens , your baby <unk> s doctor may decide to give a second course of treatment .
D-446	-0.00719861127436161	If after this first course of treatment , the ductus arteriosus is not closed or re @-@ opens , your baby <unk> s doctor may decide to give a second course of treatment .
P-446	-0.0029 -0.0147 -0.0173 -0.0033 -0.0212 -0.0120 -0.0027 -0.0174 -0.0037 -0.0034 -0.0040 -0.0014 -0.0004 -0.0008 -0.0012 -0.0129 -0.0075 -0.0073 -0.0027 -0.0112 -0.0014 -0.0144 -0.0024 -0.0147 -0.0119 -0.0145 -0.0092 -0.0033 -0.0087 -0.0023 -0.0064 -0.0145 -0.0137 -0.0019 -0.0020 -0.0054 -0.0026 -0.0021 -0.0014
S-30	3 Im Ishak @-@ Fibrose @-@ Score bedeutet Verbesserung eine Reduktion des Ishak @-@ Fibrose @-@ Scores ≥ 1 Punkt zwischen Studienbeginn und Woche 52. * p = 0,0024
T-30	3 For Ishak Fibrosis Score , improvement measured as ≥ 1 point reduction in Ishak Fibrosis Score from baseline to week 52 . * p = 0.0024
H-30	-0.004518245346844196	3 For Ishak Fibrosis Score , improvement measured as ≥ 1 point reduction in Ishak Fibrosis Score from baseline to week 52 . * p = 0.0024
D-30	-0.004518245346844196	3 For Ishak Fibrosis Score , improvement measured as ≥ 1 point reduction in Ishak Fibrosis Score from baseline to week 52 . * p = 0.0024
P-30	-0.0059 -0.0141 -0.0104 -0.0009 -0.0018 -0.0090 -0.0010 -0.0017 -0.0033 -0.0009 -0.0072 -0.0035 -0.0145 -0.0103 -0.0145 -0.0022 -0.0024 -0.0130 -0.0095 -0.0018 -0.0009 -0.0015 -0.0013 -0.0009 -0.0018 -0.0025 -0.0008 -0.0135 -0.0145 -0.0002 -0.0042 -0.0034 -0.0013 -0.0019 -0.0011 -0.0009 -0.0012 -0.0018 -0.0011 -0.0010 -0.0015
S-1363	Es ist nicht bekannt , ob Bestandteile dieses Arzneimittels in die Muttermilch von Versuchstieren oder Menschen übergehen ( siehe auch Abschnitt 4.6 für wichtige Daten zur Schwangerschaft und Stillzeit beim Menschen ) .
T-1363	It is not known whether the components of this medicinal product are excreted into experimental animal or human milk ( see section 4.6 for relevant human data on pregnancy and lactation ) .
H-1363	-0.00974865909665823	It is not known whether the components of this medicinal product are excreted into experimental animal or human milk ( see section 4.6 for relevant human data on pregnancy and lactation ) .
D-1363	-0.00974865909665823	It is not known whether the components of this medicinal product are excreted into experimental animal or human milk ( see section 4.6 for relevant human data on pregnancy and lactation ) .
P-1363	-0.0037 -0.0014 -0.0279 -0.0018 -0.0065 -0.0129 -0.0107 -0.0024 -0.0092 -0.0103 -0.0027 -0.0011 -0.0093 -0.0145 -0.0042 -0.0011 -0.0570 -0.0146 -0.0006 -0.0116 -0.0096 -0.0011 -0.0172 -0.0018 -0.0023 -0.0137 -0.0011 -0.0014 -0.0047 -0.0144 -0.0121 -0.0143 -0.0041 -0.0017 -0.0015 -0.0894 -0.0004 -0.0010 -0.0017 -0.0015 -0.0014
S-1969	Im einen Fall zeigten histologische Untersuchungen eine membranöse Glomerulonephritis des Nierenallotransplantats und im anderen Fall eine allergische interstitielle Nephritis .
T-1969	Histology showed a membranous glomerulonephritis of the renal allograft in one case and hypersensitivity interstitial nephritis in the other .
H-1969	-0.005330613814294338	Histology showed a membranous glomerulonephritis of the renal allograft in one case and hypersensitivity interstitial nephritis in the other .
D-1969	-0.005330613814294338	Histology showed a membranous glomerulonephritis of the renal allograft in one case and hypersensitivity interstitial nephritis in the other .
P-1969	-0.0111 -0.0198 -0.0115 -0.0121 -0.0019 -0.0048 -0.0026 -0.0007 -0.0008 -0.0010 -0.0010 -0.0012 -0.0005 -0.0018 -0.0007 -0.0031 -0.0066 -0.0051 -0.0008 -0.0144 -0.0007 -0.0005 -0.0036 -0.0036 -0.0024 -0.0414 -0.0145 -0.0117 -0.0026 -0.0141 -0.0009 -0.0008 -0.0009 -0.0012 -0.0017 -0.0012 -0.0015 -0.0045 -0.0017 -0.0065 -0.0014
S-1339	Zypadhera wird zur Erhaltung der Verbesserung der Symptome bei Patienten mit Schizophrenie angewendet , die mit einem ersten Zyklus von oralem Olanzapin bereits stabilisiert wurden .
T-1339	Zypadhera is used to maintain the improvement in symptoms in patients with schizophrenia who have already been stabilised on an initial course of olanzapine taken by mouth .
H-1339	-0.0143957594409585	Zypadhera is used to maintain the improvement in symptoms in patients with schizophrenia who have already been stabilised on an initial course of olanzapine taken by mouth .
D-1339	-0.0143957594409585	Zypadhera is used to maintain the improvement in symptoms in patients with schizophrenia who have already been stabilised on an initial course of olanzapine taken by mouth .
P-1339	-0.0050 -0.0007 -0.0018 -0.0010 -0.0014 -0.0022 -0.0053 -0.0026 -0.0062 -0.0100 -0.0045 -0.0448 -0.0042 -0.0299 -0.0046 -0.0995 -0.0006 -0.0006 -0.0009 -0.0004 -0.0007 -0.0060 -0.0035 -0.0098 -0.0074 -0.0013 -0.1699 -0.0798 -0.0086 -0.0016 -0.0099 -0.0014 -0.0145 -0.0005 -0.0006 -0.0009 -0.0186 -0.0127 -0.0129 -0.0019 -0.0015
S-1128	se Es wird drin gend empfohlen , bei jeder Ihrer Verabreichung von Viraferon , den Namen und die Chargennummer des Produkts zu dokumentieren , um einen Beleg für die verwendete Charge zu
T-1128	It is strongly recommended that every time you receive a dose of Viraferon the name and batch number of the product are recorded in order to maintain a record of the batches used. i dic
H-1128	-0.030639665201306343	It is strongly recommended that every time you receive a dose of Viraferon the name and batch number of the product are recorded in order to maintain a record of the batches used. i dic
D-1128	-0.030639665201306343	It is strongly recommended that every time you receive a dose of Viraferon the name and batch number of the product are recorded in order to maintain a record of the batches used. i dic
P-1128	-0.0109 -0.0018 -0.0052 -0.0025 -0.0077 -0.0136 -0.0011 -0.0029 -0.0144 -0.0741 -0.0107 -0.0017 -0.0374 -0.0010 -0.0009 -0.0065 -0.0144 -0.0048 -0.0022 -0.0039 -0.3765 -0.0013 -0.0017 -0.0020 -0.0020 -0.0139 -0.0137 -0.0131 -0.0014 -0.0017 -0.0145 -0.0096 -0.0110 -0.0023 -0.0023 -0.0009 -0.5413 -0.0145 -0.0093 -0.0145 -0.0145 -0.0070
S-714	Die Remissionsraten in Woche 8 für die Induktionsdosierung mit 160 / 80 mg und mit 80 / 40 mg waren vergleichbar , unter der Dosierung mit 160 / 80 mg wurden häufiger Nebenwirkungen beobachtet .
T-714	Similar remission rates were observed for the 160 / 80 mg and 80 / 40 mg induction regimens by Week 8 and adverse events were more frequently noted in the 160 / 80 mg group .
H-714	-0.011589844711124897	Similar remission rates were observed for the 160 / 80 mg and 80 / 40 mg induction regimens by Week 8 and adverse events were more frequently noted in the 160 / 80 mg group .
D-714	-0.011589844711124897	Similar remission rates were observed for the 160 / 80 mg and 80 / 40 mg induction regimens by Week 8 and adverse events were more frequently noted in the 160 / 80 mg group .
P-714	-0.0145 -0.0031 -0.0045 -0.0004 -0.0022 -0.0091 -0.0065 -0.0278 -0.0127 -0.0127 -0.0014 -0.0021 -0.0514 -0.0070 -0.0021 -0.0014 -0.0014 -0.0006 -0.0018 -0.0018 -0.0143 -0.0211 -0.0146 -0.0144 -0.0016 -0.0199 -0.0127 -0.0003 -0.1323 -0.0057 -0.0066 -0.0144 -0.0147 -0.0172 -0.0106 -0.0011 -0.0014 -0.0011 -0.0006 -0.0145 -0.0020 -0.0014
S-1893	Omalizumab wurde mit altersabhängiger Abnahme von Blutplättchen bei Primaten in Verbindung gebracht , mit einer höheren relativen Empfindlichkeit bei Jungtieren ( siehe Abschnitt 5.3 ) .
T-1893	Omalizumab has been associated with age @-@ dependent decreases in blood platelets in non @-@ human primates , with a greater relative sensitivity in juvenile animals ( see section 5.3 ) .
H-1893	-0.011772622354328632	Omalizumab has been associated with age @-@ dependent decreases in blood platelets in non @-@ human primates , with a greater relative sensitivity in juvenile animals ( see section 5.3 ) .
D-1893	-0.011772622354328632	Omalizumab has been associated with age @-@ dependent decreases in blood platelets in non @-@ human primates , with a greater relative sensitivity in juvenile animals ( see section 5.3 ) .
P-1893	-0.0016 -0.0010 -0.0003 -0.0009 -0.0010 -0.0060 -0.0013 -0.0034 -0.0014 -0.0024 -0.0022 -0.0152 -0.0140 -0.1911 -0.0048 -0.0138 -0.0009 -0.0004 -0.0463 -0.0198 -0.0146 -0.0021 -0.0127 -0.0017 -0.0010 -0.0146 -0.0067 -0.0141 -0.0736 -0.0013 -0.0034 -0.0008 -0.0072 -0.0086 -0.0002 -0.0130 -0.0052 -0.0017 -0.0018 -0.0106 -0.0011 -0.0014 -0.0017 -0.0015 -0.0014
S-1560	EU / 1 / 00 / 132 / 047 EU / 1 / 00 / 132 / 048 EU / 1 / 00 / 132 / 049 EU / 1 / 00 / 132 / 050
T-1560	EU / 1 / 00 / 132 / 047 EU / 1 / 00 / 132 / 048 EU / 1 / 00 / 132 / 049 EU / 1 / 00 / 132 / 050
H-1560	-0.008477686904370785	EU / 1 / 00 / 132 / 047 EU / 1 / 00 / 132 / 048 EU / 1 / 00 / 132 / 049 EU / 1 / 00 / 132 / 050
D-1560	-0.008477686904370785	EU / 1 / 00 / 132 / 047 EU / 1 / 00 / 132 / 048 EU / 1 / 00 / 132 / 049 EU / 1 / 00 / 132 / 050
P-1560	-0.0016 -0.0016 -0.0013 -0.0015 -0.0014 -0.0014 -0.0010 -0.0013 -0.0014 -0.0012 -0.0009 -0.2797 -0.0015 -0.0013 -0.0014 -0.0013 -0.0014 -0.0010 -0.0013 -0.0014 -0.0012 -0.0019 -0.0011 -0.0015 -0.0013 -0.0014 -0.0013 -0.0013 -0.0009 -0.0013 -0.0014 -0.0011 -0.0007 -0.0014 -0.0015 -0.0013 -0.0015 -0.0013 -0.0014 -0.0010 -0.0013 -0.0014 -0.0012 -0.0455 -0.0014
S-648	Interferon alfa @-@ 2b 3 Mio I.E. / m2 wird dreimal in der Woche ( jeden zweiten Tag ) subkutan verabreicht in Kombination mit Ribavirin Kapseln t lä
T-648	Viraferon is administered subcutaneously at a dose of 3 million IU three times a week ( every other day ) to adult patients , whether administered as monotherapy or in combination with ribavirin .
H-648	-0.01710488460958004	Viraferon is administered subcutaneously at a dose of 3 million IU three times a week ( every other day ) to adult patients , whether administered as monotherapy or in combination with ribavirin .
D-648	-0.01710488460958004	Viraferon is administered subcutaneously at a dose of 3 million IU three times a week ( every other day ) to adult patients , whether administered as monotherapy or in combination with ribavirin .
P-648	-0.0145 -0.0145 -0.0145 -0.0034 -0.0211 -0.0090 -0.0010 -0.0069 -0.0009 -0.0007 -0.0015 -0.1809 -0.0144 -0.0133 -0.0108 -0.0017 -0.0055 -0.0258 -0.0014 -0.0084 -0.2755 -0.0014 -0.0317 -0.0012 -0.0047 -0.0017 -0.0181 -0.0015 -0.0015 -0.0160 -0.0145 -0.0045 -0.0136 -0.0145 -0.0145 -0.0015 -0.0140 -0.0145 -0.0069 -0.0064 -0.0042 -0.0120 -0.0015 -0.0019 -0.0036 -0.0006 -0.0008 -0.0029 -0.0134 -0.0057
S-1434	Es wurden keine schwerwiegenden Nebenwirkungen ( ADRs ) während dieser Studien beobachtet , mit Ausnahme von 2 Ereignissen an aseptischer Meningitis bei 1 Patienten in der US @-@ amerikanischen PID-
T-1434	No serious adverse drug reaction ( ADR ) was observed during the studies , with the exception of two episodes of aseptic meningitis in one patient of the US PID study , which were deemed possibly related to the medicinal product .
H-1434	-0.010405775159597397	No serious adverse drug reaction ( ADR ) was observed during the studies , with the exception of two episodes of aseptic meningitis in one patient of the US PID study , which were deemed possibly related to the medicinal product .
D-1434	-0.010405775159597397	No serious adverse drug reaction ( ADR ) was observed during the studies , with the exception of two episodes of aseptic meningitis in one patient of the US PID study , which were deemed possibly related to the medicinal product .
P-1434	-0.0018 -0.0066 -0.0021 -0.0002 -0.1217 -0.0219 -0.0026 -0.0144 -0.0109 -0.0017 -0.0096 -0.0080 -0.0284 -0.0215 -0.0108 -0.0071 -0.0107 -0.0017 -0.0010 -0.0014 -0.0128 -0.0136 -0.0016 -0.0015 -0.0011 -0.0012 -0.0005 -0.0013 -0.0007 -0.0007 -0.0036 -0.0110 -0.0028 -0.0142 -0.0050 -0.0113 -0.0067 -0.0063 -0.0128 -0.0134 -0.0132 -0.0144 -0.0145 -0.0145 -0.0144 -0.0034 -0.0128 -0.0145 -0.0113 -0.0132 -0.0071 -0.0015
S-1077	Wenn Sie aus irgendeinem Grund eine Blutuntersuchung durchführen lassen , informieren Sie die Person , die Ihnen Blut abnimmt , darüber , dass das Arzneimittel , das Sie gerade anwenden , den Befund beeinflussen kann .
T-1077	Very rare side effects ( affects less than 1 out of 10,000 people ) 51 reduced or damaged blood cells ( increased chance of bleeding , bruising or infection ) a type of anaemia that can be severe and is caused by red blood cells breaking up .
H-1077	-0.09681003540754318	Very rare side effects ( affects less than 1 out as such ) 51 reduced or damaged blood cells ( increased chance of bleeding , bruising or infection ) a type of anaemia that can be severe and is caused by red blood cells breaking up .
D-1077	-0.09681003540754318	Very rare side effects ( affects less than 1 out as such ) 51 reduced or damaged blood cells ( increased chance of bleeding , bruising or infection ) a type of anaemia that can be severe and is caused by red blood cells breaking up .
P-1077	-0.0572 -0.0144 -0.0145 -0.0024 -0.0190 -0.0145 -0.0145 -0.0061 -0.0132 -0.0577 -4.3317 -0.0270 -0.1026 -0.0223 -0.0146 -0.0209 -0.0145 -0.0108 -0.0142 -0.0144 -0.0147 -0.0145 -0.0059 -0.0144 -0.0004 -0.0129 -0.0145 -0.0062 -0.0153 -0.0143 -0.0060 -0.0198 -0.0145 -0.0020 -0.0144 -0.0125 -0.0007 -0.0013 -0.0141 -0.0128 -0.0117 -0.0143 -0.0133 -0.0143 -0.0142 -0.0019 -0.0146 -0.0047 -0.0026 -0.0145 -0.0141 -0.0113 -0.0017
S-1601	Während einer Pandemie @-@ Situation wird die Häufigkeit der Einreichung von regelmäßig aktualisierten Berichten zur Unbedenklichkeit ( PSURs ) gemäß Artikel 24 der ( EU ) - Verordnung Nr .
T-1601	During a pandemic situation , the frequency of submission of periodic safety update reports specified in Article 24 of Regulation ( EC ) No 726 / 2004 will not be adequate for the safety monitoring of a pandemic vaccine for which high levels of exposure are expected within a short period of time .
H-1601	-0.013261553831398487	During a pandemic situation , the frequency of submission of periodic safety update reports specified in Article 24 of Regulation ( EC ) No 726 / 2004 will not be adequate for the safety monitoring of a pandemic vaccine for which high levels of exposure are expected within a short period of time .
D-1601	-0.013261553831398487	During a pandemic situation , the frequency of submission of periodic safety update reports specified in Article 24 of Regulation ( EC ) No 726 / 2004 will not be adequate for the safety monitoring of a pandemic vaccine for which high levels of exposure are expected within a short period of time .
P-1601	-0.0057 -0.0049 -0.0011 -0.0012 -0.0008 -0.0057 -0.0038 -0.0030 -0.0020 -0.0010 -0.0020 -0.0112 -0.0046 -0.0016 -0.0120 -0.1086 -0.0124 -0.0144 -0.0032 -0.0180 -0.0023 -0.0027 -0.0239 -0.0011 -0.0025 -0.0133 -0.0013 -0.0241 -0.0168 -0.0014 -0.0235 -0.1019 -0.0233 -0.0051 -0.0495 -0.0127 -0.0143 -0.0056 -0.0145 -0.0132 -0.0116 -0.0143 -0.0145 -0.0083 -0.0138 -0.0024 -0.0010 -0.0010 -0.0145 -0.0145 -0.0132 -0.0145 -0.0120 -0.0020 -0.0143 -0.0093 -0.0135 -0.0152 -0.0126 -0.0139 -0.0081 -0.0417 -0.0013 -0.0226 -0.0014
S-1486	Irbesartan Winthrop 75 mg Tabletten sind weiß bis gebrochen weiß , bikonvex und oval mit Prägung , auf einer Seite ein Herz und auf der anderen Seite die Zahlen 2771 .
T-1486	What Irbesartan Winthrop looks like and contents of the pack Irbesartan Winthrop 75 mg tablets are white to off @-@ white , biconvex , and oval @-@ shaped with a heart debossed on one side and the number 2771 engraved on the other side .
H-1486	-0.06599917262792587	What Irbesartan Winthrop looks like and contents of the pack Irbesartan Winthrop 75 mg tablets are white to off @-@ white , biconvex , and oval @-@ shaped with a heart debossed on one side and the number 2771 engraved on the other .
D-1486	-0.06599917262792587	What Irbesartan Winthrop looks like and contents of the pack Irbesartan Winthrop 75 mg tablets are white to off @-@ white , biconvex , and oval @-@ shaped with a heart debossed on one side and the number 2771 engraved on the other .
P-1486	-0.1425 -0.0151 -0.0004 -0.0007 -0.0012 -0.0016 -0.0002 -0.0011 -0.0485 -0.0019 -0.0145 -0.0145 -0.0028 -0.0140 -0.0126 -0.0145 -0.0144 -0.0004 -0.0008 -0.0012 -0.0067 -0.0002 -0.0011 -0.0535 -0.0007 -0.0060 -0.0016 -0.0042 -0.0027 -0.0051 -0.0145 -0.0102 -0.0007 -0.0033 -0.0037 -0.0011 -0.0007 -0.0012 -0.0164 -0.0302 -0.0361 -0.0005 -0.0659 -0.0019 -0.0418 -0.0138 -0.0031 -0.0145 -0.0103 -0.0130 -0.0026 -0.0017 -0.0868 -0.0266 -0.0068 -0.0143 -0.0013 -0.0029 -0.0269 -0.0049 -0.0013 -0.0131 -0.0014 -0.0015 -3.4950 -0.0014
S-1971	Unter dem Einfluss des Qualitätsmanagementsystems der EMEA wird das Referat eine zulassungsrechtliche Datenbank entwickeln , um bei der Anleitung der Industrie eine möglichst hohe Konsistenz zu gewährleisten .
T-1971	Based on preliminary forecasts received from industry , a small increase in the number of applications for centralised authorisations is expected with 10 in applications in 2002 Applications for new MRL applications are similarly expected to remain relatively stable with 6 in 2002 Under the impetus of the EMEA quality management system , the Unit will develop a regulatory database that will be used to maximise consistency of guidance to industry .
H-1971	-0.012423189356923103	Based on preliminary forecasts received from industry , a small increase in the number of applications for centralised authorisations is expected with 10 in applications in 2002 Applications for new MRL applications are similarly expected to remain relatively stable with 6 in 2002 Under the impetus of the EMEA quality management system , the Unit will develop a regulatory database that will be used to maximise consistency of guidance to industry .
D-1971	-0.012423189356923103	Based on preliminary forecasts received from industry , a small increase in the number of applications for centralised authorisations is expected with 10 in applications in 2002 Applications for new MRL applications are similarly expected to remain relatively stable with 6 in 2002 Under the impetus of the EMEA quality management system , the Unit will develop a regulatory database that will be used to maximise consistency of guidance to industry .
P-1971	-0.0145 -0.0018 -0.0153 -0.0145 -0.0144 -0.0087 -0.0148 -0.0117 -0.0142 -0.0145 -0.0145 -0.0051 -0.0112 -0.0097 -0.0016 -0.0142 -0.0321 -0.0146 -0.0127 -0.0418 -0.0143 -0.0641 -0.0013 -0.0356 -0.0097 -0.0300 -0.0281 -0.0144 -0.0174 -0.0156 -0.0175 -0.0153 -0.0113 -0.0525 -0.0108 -0.0144 -0.0145 -0.0145 -0.0144 -0.0164 -0.0145 -0.0116 -0.0308 -0.0145 -0.0145 -0.0097 -0.0202 -0.0206 -0.0128 -0.0144 -0.0145 -0.0089 -0.0144 -0.0116 -0.0011 -0.0031 -0.0049 -0.0040 -0.0007 -0.0012 -0.0098 -0.0031 -0.0030 -0.0090 -0.0048 -0.0138 -0.0010 -0.0024 -0.0028 -0.0044 -0.0103 -0.0024 -0.0156 -0.0081 -0.0147 -0.0112 -0.0067 -0.0150 -0.0005 -0.0011 -0.0074 -0.0005 -0.0010 -0.0145 -0.0041 -0.0089 -0.0043 -0.0019 -0.0014
S-1098	EU / 1 / 04 / 285 / 001 EU / 1 / 04 / 285 / 002 EU / 1 / 04 / 285 / 003 EU / 1 / 04 / 285 / 004
T-1098	EU / 1 / 04 / 285 / 001 1 vial of 10ml EU / 1 / 04 / 285 / 002 2 vials of 10ml .
H-1098	-0.017228910699486732	EU / 1 / 04 / 285 / 001 EU / 1 / 04 / 285 / 002 EU / 1 / 04 / 285 / 003 EU / 1 / 04 / 285 / 004
D-1098	-0.017228910699486732	EU / 1 / 04 / 285 / 001 EU / 1 / 04 / 285 / 002 EU / 1 / 04 / 285 / 003 EU / 1 / 04 / 285 / 004
P-1098	-0.3146 -0.0015 -0.0013 -0.0015 -0.0010 -0.0014 -0.0006 -0.0012 -0.0014 -0.0013 -0.0017 -0.4070 -0.0015 -0.0014 -0.0014 -0.0007 -0.0014 -0.0006 -0.0012 -0.0014 -0.0011 -0.0015 -0.0011 -0.0015 -0.0014 -0.0014 -0.0008 -0.0014 -0.0006 -0.0012 -0.0014 -0.0012 -0.0016 -0.0014 -0.0015 -0.0014 -0.0015 -0.0008 -0.0014 -0.0006 -0.0012 -0.0014 -0.0011 -0.0013 -0.0014
S-1990	Wenn ein Patient bereits Johanniskraut einnimmt , sind die Amprenavir- und Ritonavirspiegel und , wenn möglich , die Viruslast zu überprüfen und das Johanniskraut abzusetzen .
T-1990	If a patient is already taking St John <<unk>> s wort , check amprenavir , ritonavir and if possible viral levels and stop St John <<unk>> s wort .
H-1990	-0.007818305864930153	If a patient is already taking St John <unk> s wort , check amprenavir , ritonavir and if possible viral levels and stop St John <unk> s wort .
D-1990	-0.007818305864930153	If a patient is already taking St John <unk> s wort , check amprenavir , ritonavir and if possible viral levels and stop St John <unk> s wort .
P-1990	-0.0081 -0.0044 -0.0011 -0.0047 -0.0105 -0.0057 -0.0117 -0.0257 -0.0145 -0.0022 -0.0061 -0.0026 -0.0092 -0.0127 -0.0015 -0.0144 -0.0053 -0.0164 -0.0038 -0.0058 -0.0049 -0.0030 -0.0103 -0.0130 -0.0017 -0.0140 -0.0141 -0.0044 -0.0093 -0.0145 -0.0021 -0.0144 -0.0028 -0.0028 -0.0024 -0.0015
S-242	5 Auch wenn Reproduktionsstudien an Tieren nur eine begrenzte Voraussage für den Menschen ermöglichen , wird eine Verabreichung während der ersten 3 Schwangerschaftsmonate nicht empfohlen ( siehe Abschnitt 4.4 ) .
T-242	Although animal reproductive studies are not always predictive of the human response , administration is not recommended during the first three months of pregnancy ( see section 4.4 ) .
H-242	-0.04765734821557999	Although animal reproductive studies are not always predictive of the human response , administration is not recommended during the first three months of pregnancy ( see section 4.4 ) .
D-242	-0.04765734821557999	Although animal reproductive studies are not always predictive of the human response , administration is not recommended during the first three months of pregnancy ( see section 4.4 ) .
P-242	-0.0187 -0.0124 -0.0034 -0.5710 -0.0030 -0.0130 -0.0143 -0.0145 -0.0156 -0.0014 -0.0100 -0.0127 -0.0064 -0.0145 -0.0039 -0.0111 -0.0106 -0.0020 -0.0036 -0.0084 -0.0017 -0.0014 -0.8334 -0.0013 -0.0025 -0.0099 -0.0020 -0.0026 -0.0075 -0.0013 -0.0014 -0.0020 -0.0016 -0.0014
S-1415	Bei der Verwendung von InductOs bei Operationen im oberen Bereich der Wirbelsäule ( Nacken ) wurden örtlich begrenzte Schwellungen berichtet , die in manchen Fällen zu Atemschwierigkeiten führten .
T-1415	There have been reports of nerve pain due to localised fluid collection which would require drainage or a surgical procedure to remove the fluid .
H-1415	-0.011801058426499367	There have been reports of nerve pain due to localised fluid collection which would require drainage or a surgical procedure to remove the fluid .
D-1415	-0.011801058426499367	There have been reports of nerve pain due to localised fluid collection which would require drainage or a surgical procedure to remove the fluid .
P-1415	-0.0144 -0.0752 -0.0015 -0.0122 -0.0018 -0.0167 -0.0143 -0.0152 -0.0014 -0.0129 -0.0005 -0.0004 -0.0145 -0.0096 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0138 -0.0014 -0.0133 -0.0142 -0.0144 -0.0017 -0.0015 -0.0103 -0.0123 -0.0119 -0.0089 -0.0142 -0.0005 -0.0125 -0.0072
S-1384	Verkehrstüchtigkeit und das Bedienen von Maschinen Besondere Vorsicht bei der Teilnahme am Straßenverkehr und beim Bedienen von Maschinen ist geboten , wenn Nebenwirkungen wie Schwindelgefühl und unscharfes Sehen auftreten .
T-1384	Driving and using machines Take special care when driving or using machines in case you experience side effects such as dizziness and blurred vision .
H-1384	-0.023027891293168068	Driving and using machines Take special care when driving or using machines in case you experience side effects such as dizziness and blurred vision .
D-1384	-0.023027891293168068	Driving and using machines Take special care when driving or using machines in case you experience side effects such as dizziness and blurred vision .
P-1384	-0.0141 -0.0104 -0.0070 -0.0139 -0.0094 -0.0135 -0.0076 -0.0013 -0.3562 -0.0114 -0.0128 -0.0120 -0.0081 -0.0138 -0.0075 -0.0157 -0.0091 -0.0066 -0.0020 -0.0098 -0.0014 -0.0029 -0.0011 -0.0006 -0.1314 -0.0010 -0.0035 -0.0005 -0.0024 -0.0037
S-1429	≤ 0,2 ‰ bei 10 aufeinander folgenden Messungen ≤ 0,3 ‰ bei 13C in natürlicher Häufigkeit in 10 ml Atemprobenröhr- chen mit 3 % CO2 @-@ Atemkonzentration in der Probe
T-1429	≤ 0.3 ‰ for 13C at natural abundance using a 10 ml breath sample tube with 3 % CO2 breath concentration
H-1429	-0.039762143045663834	≤ 0.2 ‰ for 13C at natural abundance using a 10 ml breath sample tube with 3 % CO2 breath concentration
D-1429	-0.039762143045663834	≤ 0.2 ‰ for 13C at natural abundance using a 10 ml breath sample tube with 3 % CO2 breath concentration
P-1429	-0.0001 -0.0025 -0.8092 -0.0001 -0.0112 -0.0288 -0.0012 -0.0133 -0.0167 -0.0137 -0.0005 -0.0013 -0.0144 -0.0177 -0.0052 -0.0284 -0.0134 -0.0063 -0.0028 -0.0059 -0.0085 -0.0013 -0.0024 -0.0127 -0.0020 -0.0145
S-1999	Missbrauch von MIRCERA durch gesunde Personen kann zu einem exzessiven Anstieg des Hämoglobins führen , der mit lebensbedrohlichen kardiovaskulären Komplikationen einhergehen kann .
T-1999	This may be associated with life @-@ threatening cardiovascular complications .
H-1999	-0.012890676036477089	This may be associated with life @-@ threatening cardiovascular complications .
D-1999	-0.012890676036477089	This may be associated with life @-@ threatening cardiovascular complications .
P-1999	-0.0145 -0.0136 -0.0161 -0.0143 -0.0014 -0.0137 -0.0961 -0.0051 -0.0028 -0.0007 -0.0008 -0.0007 -0.0009 -0.0015 -0.0095 -0.0145
S-210	Wenn Sie eine größere Menge von Procoralan eingenommen haben , als Sie sollten Eine große Menge an Procoralan könnte Sie atemlos oder müde machen , da sich Ihr Herzschlag zu sehr verlangsamt .
T-210	If you take more Procoralan than you should :
H-210	-0.007080320734530687	If you take more Procoralan than you should :
D-210	-0.007080320734530687	If you take more Procoralan than you should :
P-210	-0.0092 -0.0015 -0.0171 -0.0137 -0.0115 -0.0014 -0.0012 -0.0012 -0.0024 -0.0017 -0.0020 -0.0145 -0.0145
S-693	1 @-@ ml @-@ Ampullen , farblos , Glas Typ I , enthalten 1 ml Lösung für einen Vernebler und sind mit drei farbigen Ringen ( pink - rot - rot ) gekennzeichnet .
T-693	1 @-@ ml ampoules , colourless , glass type I , containing 1 ml nebuliser solution , ring coded with three coloured rings ( pink <<unk>> red- red ) .
H-693	-0.01372921746224165	1 @-@ ml ampoules , colourless , glass type I , containing 1 ml nebuliser solution , ring coded with three coloured rings ( pink <unk> red- red ) .
D-693	-0.01372921746224165	1 @-@ ml ampoules , colourless , glass type I , containing 1 ml nebuliser solution , ring coded with three coloured rings ( pink <unk> red- red ) .
P-693	-0.0055 -0.2242 -0.0015 -0.0096 -0.0001 -0.0031 -0.0038 -0.0036 -0.0009 -0.0010 -0.0024 -0.0061 -0.0031 -0.0883 -0.0020 -0.0130 -0.0038 -0.0006 -0.0145 -0.0001 -0.0004 -0.0106 -0.0016 -0.0198 -0.0145 -0.0145 -0.0055 -0.0119 -0.0047 -0.0107 -0.0054 -0.0022 -0.0012 -0.0150 -0.0153 -0.0091 -0.0022 -0.0123 -0.0034 -0.0015
S-858	In Abhängigkeit von der Studiendauer waren alle muskulären Effekte , einschließlich der mikroskopischen Veränderungen , innerhalb von 1 @-@ 3 Monaten nach Beendigung der Dosierung vollständig reversibel .
T-858	Depending on the study duration , all muscle effects , including microscopic changes , were fully reversible within 1 @-@ 3 months following cessation of dosing .
H-858	-0.03658315911889076	Depending on the study duration , all muscle effects , including microscopic changes , were fully reversible within 1 @-@ 3 months following cessation of dosing .
D-858	-0.03658315911889076	Depending on the study duration , all muscle effects , including microscopic changes , were fully reversible within 1 @-@ 3 months following cessation of dosing .
P-858	-0.0042 -0.0010 -0.2722 -0.0051 -0.0113 -0.0038 -0.0014 -0.0040 -0.0026 -0.0122 -0.0026 -0.0192 -0.0123 -0.0030 -0.0005 -0.0010 -0.0017 -0.0021 -0.0038 -0.0241 -0.0084 -0.0011 -0.0004 -0.0010 -0.0041 -0.0093 -0.2057 -0.0014 -0.0015 -0.5550 -0.0144 -0.0000 -0.0014 -0.0020 -0.0065 -0.1870 -0.0016 -0.0014
S-411	Sehr selten wurde von Fällen einer antikörpervermittelten PRCA bei Patienten mit chronischer Niereninsuffizienz berichtet , denen Erythropoetin subkutan gegeben worden war .
T-411	Cases of antibody @-@ mediated PRCA have been very rarely reported in chronic renal failure patients with erythropoietin administered by the subcutaneous route .
H-411	-0.022925488650798798	Cases of antibody @-@ mediated PRCA have been very rarely reported in chronic renal failure patients with erythropoietin administered by the subcutaneous route .
D-411	-0.022925488650798798	Cases of antibody @-@ mediated PRCA have been very rarely reported in chronic renal failure patients with erythropoietin administered by the subcutaneous route .
P-411	-0.0114 -0.0013 -0.0015 -0.0030 -0.0297 -0.0025 -0.0010 -0.0013 -0.0011 -0.0007 -0.0106 -0.0068 -0.0124 -0.0349 -0.0007 -0.0021 -0.0154 -0.0028 -0.0010 -0.4044 -0.0012 -0.0197 -0.0092 -0.0012 -0.0002 -0.0013 -0.0000 -0.0011 -0.0136 -0.0009 -0.0617 -0.0114 -0.0070 -0.0006 -0.0005 -0.0013 -0.2220 -0.0144 -0.0035 -0.0014
S-168	Die übliche Anfangsdosis beträgt 3x täglich eine Pramipexol Teva 0,088 mg Tablette ( eine Tagesdosis von 0,264 mg Pramipexol ) .
T-168	The normal starting dose is one Pramipexole Teva 0.088 mg tablet three times a day ( a daily dose of 0.264 mg of pramipexole ) .
H-168	-0.02388940006494522	The normal starting dose is one Pramipexole Teva 0.088 mg tablet three times a day ( a daily dose of 0.264 mg of pramipexole ) .
D-168	-0.02388940006494522	The normal starting dose is one Pramipexole Teva 0.088 mg tablet three times a day ( a daily dose of 0.264 mg of pramipexole ) .
P-168	-0.0022 -0.0184 -0.0570 -0.0035 -0.0026 -0.0104 -0.0087 -0.0009 -0.0256 -0.0011 -0.0979 -0.0016 -0.0009 -0.0010 -0.0019 -0.0012 -0.0017 -0.0011 -0.0103 -0.0009 -0.5369 -0.0014 -0.0016 -0.0053 -0.0010 -0.0011 -0.0017 -0.0011 -0.0015 -0.0016 -0.0005 -0.0118 -0.0142 -0.0009 -0.0302 -0.0012 -0.0902 -0.0015 -0.0015 -0.0014
S-1617	n Eine Zylinderampulle enthält 30 Millionen I.E. rekombinantes Interferon alfa @-@ 2b hergestellt aus E.coli mittels rekombinanter DNA Technologie , in 1,2 ml .
T-1617	ed One cartridge contains 30 million IU of recombinant interferon alfa @-@ 2b produced in E. coli by recombinant DNA technology , in 1.2 ml .
H-1617	-0.007036120630800724	ed One cartridge contains 30 million IU of recombinant interferon alfa @-@ 2b produced in E. coli by recombinant DNA technology , in 1.2 ml .
D-1617	-0.007036120630800724	ed One cartridge contains 30 million IU of recombinant interferon alfa @-@ 2b produced in E. coli by recombinant DNA technology , in 1.2 ml .
P-1617	-0.0146 -0.0145 -0.0145 -0.0022 -0.0008 -0.0062 -0.0027 -0.0028 -0.0019 -0.0083 -0.0052 -0.0031 -0.0011 -0.0009 -0.0014 -0.0023 -0.0006 -0.0015 -0.0018 -0.0005 -0.0014 -0.0013 -0.0012 -0.0134 -0.1201 -0.0143 -0.0007 -0.0013 -0.0121 -0.0071 -0.0009 -0.0007 -0.0018 -0.0009 -0.0032 -0.0047 -0.0032 -0.0062 -0.0021 -0.0036 -0.0015
S-109	MicardisPlus sollte nicht bei Patienten mit schwerer Nierenfunktionsstörung ( Kreatinin @-@ Clearance &lt; 30 ml / min ) ( siehe Abschnitt 4.3 ) angewandt werden .
T-109	MicardisPlus should not be used in patients with severe renal impairment ( creatinine clearance &lt; 30 ml / min ) ( see section 4.3 ) .
H-109	-0.02445664443075657	MicardisPlus should not be used in patients with severe renal impairment ( creatinine clearance &lt; 30 ml / min ) ( see section 4.3 ) .
D-109	-0.02445664443075657	MicardisPlus should not be used in patients with severe renal impairment ( creatinine clearance &lt; 30 ml / min ) ( see section 4.3 ) .
P-109	-0.0019 -0.0012 -0.0009 -0.0004 -0.0019 -0.0015 -0.0014 -0.6684 -0.0038 -0.0056 -0.2027 -0.0025 -0.0092 -0.0009 -0.0205 -0.0026 -0.0005 -0.0013 -0.0317 -0.0017 -0.0010 -0.0014 -0.0014 -0.0010 -0.0011 -0.0010 -0.0008 -0.0014 -0.0033 -0.0033 -0.0014 -0.0010 -0.0016 -0.0023 -0.0026 -0.0104 -0.0012 -0.0014 -0.0017 -0.0016 -0.0014
S-600	Nederland Serono Benelux BV Tupolevlaan 41 @-@ 61 NL @-@ 1119 NW Schiphol @-@ Rijk Tel : + 3120 @-@ 6582800
T-600	Nederland Serono Benelux BV Tupolevlaan 41 @-@ 61 NL @-@ 1119 NW Schiphol @-@ Rijk Tel : + 3120 @-@ 6582800
H-600	-0.011933729983866215	Nederland Serono Benelux BV Tupolevlaan 41 @-@ 61 NL @-@ 1119 NW Schiphol @-@ Rijk Tel : + 3120 @-@ 6582800
D-600	-0.011933729983866215	Nederland Serono Benelux BV Tupolevlaan 41 @-@ 61 NL @-@ 1119 NW Schiphol @-@ Rijk Tel : + 3120 @-@ 6582800
P-600	-0.0117 -0.0005 -0.0011 -0.0011 -0.0011 -0.0012 -0.0005 -0.0009 -0.0003 -0.0014 -0.0011 -0.0017 -0.0012 -0.0011 -0.0007 -0.0027 -0.0013 -0.0008 -0.2736 -0.0008 -0.0018 -0.0012 -0.0835 -0.0009 -0.0010 -0.0023 -0.0013 -0.0003 -0.1063 -0.0002 -0.0014 -0.0015 -0.0002 -0.0037 -0.0019 -0.0010 -0.0013 -0.0012 -0.0021 -0.0017 -0.0012 -0.0009 -0.0013 -0.0019
S-653	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-653	The patient <<unk>> s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-653	-0.011789567768573761	The patient <unk> s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
D-653	-0.011789567768573761	The patient <unk> s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
P-653	-0.0066 -0.0128 -0.0152 -0.0020 -0.0033 -0.0106 -0.0017 -0.0030 -0.0135 -0.0109 -0.0014 -0.0020 -0.0021 -0.0033 -0.0024 -0.0005 -0.0127 -0.0147 -0.0275 -0.0219 -0.0085 -0.0008 -0.0181 -0.0137 -0.0017 -0.0022 -0.0033 -0.0158 -0.0068 -0.0058 -0.0011 -0.0006 -0.0017 -0.0036 -0.0007 -0.0025 -0.0008 -0.0009 -0.2412 -0.0014 -0.0079 -0.0004 -0.0200 -0.0016 -0.0014
S-1031	Bei Bedarf wird die Agentur für eine eventuelle Einbindung in das biomedizinische Forschungs- und Entwicklungsprogramm der Europäischen Kommission und das von der Generaldirektion XII geführten Netzwerks von Sachverständigen sorgen .
T-1031	Where appropriate the EMEA will assure any necessary liaison with the European Commission <<unk>> s biomedical R &amp; D programme and the European network of experts maintained by Directorate @-@ General XII .
H-1031	-0.01350519247353077	Where appropriate the EMEA will assure any necessary liaison with the European Commission <unk> s biomedical R &amp; D programme and the European network of experts maintained by Directorate @-@ General XII .
D-1031	-0.01350519247353077	Where appropriate the EMEA will assure any necessary liaison with the European Commission <unk> s biomedical R &amp; D programme and the European network of experts maintained by Directorate @-@ General XII .
P-1031	-0.0120 -0.0147 -0.0463 -0.1920 -0.0145 -0.0005 -0.0031 -0.0145 -0.0012 -0.0143 -0.0270 -0.0334 -0.0020 -0.0003 -0.0059 -0.0017 -0.0054 -0.0012 -0.0145 -0.0013 -0.0046 -0.0007 -0.0010 -0.0013 -0.0141 -0.0029 -0.0014 -0.0024 -0.0656 -0.0055 -0.0145 -0.0128 -0.0016 -0.0013 -0.0144 -0.0131 -0.0060 -0.0007 -0.0011 -0.0181 -0.0075 -0.0013 -0.0069 -0.0016 -0.0014
S-678	Xenical Kapseln sind türkis mit Aufdruck &quot; ROCHE XENICAL 120 &quot; und sind in Blisterpackungen und in Glasflaschen mit 21 , 42 oder 84 Kapseln erhältlich .
T-678	Xenical capsules are turquoise with the imprint <<unk>> ROCHE XENICAL 120 <<unk>> and are supplied in blister packs and glass bottles , containing 21 , 42 and 84 capsules .
H-678	-0.02193714678287506	Xenical capsules are turquoise with the imprint <unk> ROCHE XENICAL 120 <unk> and are supplied in blister packs and glass bottles , containing 21 , 42 and 84 capsules .
D-678	-0.02193714678287506	Xenical capsules are turquoise with the imprint <unk> ROCHE XENICAL 120 <unk> and are supplied in blister packs and glass bottles , containing 21 , 42 and 84 capsules .
P-678	-0.0043 -0.0013 -0.0010 -0.0031 -0.0010 -0.0011 -0.0028 -0.0038 -0.0005 -0.0013 -0.0009 -0.0051 -0.0101 -0.0129 -0.0017 -0.0145 -0.0032 -0.0014 -0.0013 -0.0010 -0.0011 -0.0011 -0.0008 -0.0032 -0.0144 -0.0028 -0.0041 -0.0840 -0.0009 -0.0017 -0.0017 -0.3067 -0.0066 -0.0007 -0.0029 -0.0055 -0.0024 -0.0173 -0.0112 -0.0020 -0.0015 -0.0022 -0.5198 -0.0006 -0.0022 -0.0006 -0.0010 -0.0023 -0.0015
S-941	Schnarchen , Schwierigkeiten beim Atmen oder Schlucken , kurzzeitiges Aussetzen der Atmung im Schlaf ( Apnoe ) oder Flüssigkeitsansammlung im Mittelohr sowie Ohrenentzündungen .
T-941	Some signs of enlarged tonsils include : snoring , difficulty breathing or swallowing , sleep apnea ( a condition where breathing stops briefly during sleep ) , or fluid in the middle ear , as well as infections of the ear .
H-941	-0.015214852057397366	Some signs of enlarged tonsils include : snoring , difficulty breathing or swallowing , sleep apnea ( a condition where breathing stops briefly during sleep ) , or fluid in the middle ear , as well as infections of the ear .
D-941	-0.015214852057397366	Some signs of enlarged tonsils include : snoring , difficulty breathing or swallowing , sleep apnea ( a condition where breathing stops briefly during sleep ) , or fluid in the middle ear , as well as infections of the ear .
P-941	-0.0145 -0.0144 -0.0091 -0.0145 -0.0081 -0.0689 -0.0145 -0.0080 -0.0012 -0.0081 -0.0167 -0.0050 -0.0008 -0.0015 -0.0076 -0.0028 -0.0017 -0.0454 -0.0007 -0.0007 -0.0043 -0.0309 -0.0083 -0.0593 -0.0013 -0.0346 -0.0152 -0.0144 -0.0114 -0.0097 -0.0125 -0.0125 -0.1001 -0.0042 -0.0635 -0.0258 -0.0587 -0.0314 -0.0010 -0.0127 -0.0015 -0.0008 -0.0009 -0.0092 -0.0111 -0.0043 -0.0013 -0.0143 -0.0008 -0.0041 -0.0015 -0.0102 -0.0043 -0.0014
S-323	61 Ancylostoma caninum und Uncinaria stenocephala , adulte Stadien von Toxascaris leonina und Trichuris vulpis ) .
T-323	For the treatment and prevention of flea infestation ( Ctenocephalides felis ) , treatment of biting lice ( Trichodectes canis ) , treatment of ear mite infestation ( Otodectes cynotis ) , sarcoptic mange ( caused by Sarcoptes scabiei var. canis ) , demodicosis ( caused by Demodex canis ) , prevention of heartworm disease ( L3 and L4 larvae of Dirofilaria immitis ) , treatment of Angiostrongylus vasorum and treatment of infections with gastrointestinal nematodes ( L4 larvae , immature adults and adults of Toxocara canis , Ancylostoma caninum and Uncinaria stenocephala , adults of Toxascaris leonina and Trichuris vulpis ) .
H-323	-0.06838788092136383	For the treatment and prevention of flea infestation ( Ctenocephalides felis ) , treatment of biting lice ( Trichodectes canis ) , treatment of ear mite infestation ( Otodectes cynotis ) , sarcoptic mange ( caused by Sarcoptes scabiei var. canis ) , demodicosis ( caused by Sarcoptes scabiei var.
D-323	-0.06838788092136383	For the treatment and prevention of flea infestation ( Ctenocephalides felis ) , treatment of biting lice ( Trichodectes canis ) , treatment of ear mite infestation ( Otodectes cynotis ) , sarcoptic mange ( caused by Sarcoptes scabiei var. canis ) , demodicosis ( caused by Sarcoptes scabiei var.
P-323	-0.0154 -0.0133 -0.0141 -0.0148 -0.0143 -0.0006 -0.0069 -0.0176 -0.0122 -0.0144 -0.0005 -0.0058 -0.0141 -0.0145 -0.0145 -0.0145 -0.0142 -0.0028 -0.0144 -0.0226 -0.0144 -0.0262 -0.0087 -0.0145 -0.0102 -0.0386 -0.0145 -0.0067 -0.0170 -0.0362 -0.0044 -0.0145 -0.0145 -0.0145 -0.0457 -0.0155 -0.0116 -0.0166 -0.0373 -0.0053 -0.0212 -0.0145 -0.0145 -0.0197 -0.0039 -0.0090 -0.0159 -0.3396 -0.0145 -0.0145 -0.0145 -0.0600 -0.0145 -0.0145 -0.0101 -0.0091 -0.3593 -0.0123 -0.1398 -0.0145 -0.0140 -0.0106 -0.2366 -0.0017 -0.4810 -0.0127 -0.1415 -0.0156 -0.0120 -0.0145 -0.0144 -0.0234 -0.0134 -0.0144 -0.0302 -0.0109 -0.0105 -0.5387 -0.0145 -0.0145 -0.0063 -0.0085 -0.2533 -0.0018 -1.9831 -0.0036 -0.1637 -0.3949 -0.0016 -0.0141 -0.0145 -0.2222 -0.0105 -0.0015
S-957	Insuman Comb 25 kann mit allen Humaninsulinen von Sanofi @-@ Aventis gemischt werden , AUSSER mit den Insulinen , die speziell für den Einsatz in Insulinpumpen bestimmt sind .
T-957	Insuman Comb 25 may be mixed with all Sanofi @-@ Aventis human insulin preparations , EXCEPT those specially designed for use in insulin pumps .
H-957	-0.005657592322677374	Insuman Comb 25 may be mixed with all Sanofi @-@ Aventis human insulin preparations , EXCEPT those specially designed for use in insulin pumps .
D-957	-0.005657592322677374	Insuman Comb 25 may be mixed with all Sanofi @-@ Aventis human insulin preparations , EXCEPT those specially designed for use in insulin pumps .
P-957	-0.0051 -0.0015 -0.0014 -0.0014 -0.0012 -0.0013 -0.0152 -0.0015 -0.0065 -0.0017 -0.0054 -0.0038 -0.0013 -0.0004 -0.0014 -0.0008 -0.0008 -0.0013 -0.0026 -0.0017 -0.0100 -0.0145 -0.0009 -0.0073 -0.0121 -0.0067 -0.0009 -0.0022 -0.0119 -0.0139 -0.0044 -0.0685 -0.0029 -0.0028 -0.0044 -0.0014 -0.0010 -0.0010 -0.0018 -0.0016
S-1462	Bei Patienten , die bereits mit Diuretika behandelt werden und insbesondere bei solchen , bei denen erst vor kurzem mit der Therapie begonnen wurde , kann es gelegentlich zu einem übermäßigen Blutdruckabfall kommen , wenn Acerbon zusätzlich verabreicht wird .
T-1462	Patients already on diuretics and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure when Zestril is added .
H-1462	-0.03360169753432274	Patients already on diuretics and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure when Zestril is added .
D-1462	-0.03360169753432274	Patients already on diuretics and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure when Zestril is added .
P-1462	-0.0081 -0.0010 -0.0353 -0.0134 -0.0018 -0.0007 -0.1706 -0.0110 -0.0111 -0.0044 -0.0144 -0.0079 -0.0145 -0.0009 -0.3401 -0.0075 -0.0141 -0.0113 -0.0146 -0.0006 -0.0113 -0.0073 -0.0075 -0.0028 -0.0103 -0.0025 -0.0140 -0.4670 -0.0077 -0.0008 -0.0115 -0.0145 -0.0145 -0.0140 -0.0130 -0.0058 -0.0122 -0.0089 -0.0017
S-1934	Dexamethason , Phenytoin , Carbamazepin , Rifampicin , Phenobarbital oder Johanniskraut ) , kann die Imatinib @-@ Konzentration signifikant verringert werden .
T-1934	54 phenytoin , carbamazepine , rifampicin , phenobarbital or Hypericum perforatum , also known as St .
H-1934	-0.147248312830925	54 phenytoin , carbamazepine , rifampicin , phenobarbital , Hypericum perforatum , St .
D-1934	-0.147248312830925	54 phenytoin , carbamazepine , rifampicin , phenobarbital , Hypericum perforatum , St .
P-1934	-0.0145 -0.0146 -0.0099 -0.0013 -0.0031 -0.0090 -0.0062 -0.0014 -0.0007 -0.0003 -0.0012 -0.0015 -0.0013 -0.0009 -0.0012 -0.0011 -0.0377 -0.0016 -0.0012 -0.0007 -0.0008 -0.0014 -0.0003 -4.5438 -0.1052 -0.0045 -0.0097 -0.0060 -0.0180 -0.0144 -0.0116 -0.0123 -0.2165 -0.1936 -0.0394 -0.0141
S-1342	In der Leitlinie CVMP / 627 / 01 und in der GCP @-@ Leitlinie wird darauf hingewiesen , dass das Ansprechen auf die Therapie nach Möglichkeit auf der Grundlage von klinischen und mikrobiologischen Kriterien beurteilt werden muss .
T-1342	The CVMP / 627 / 01 and GCP guideline stated that the response to therapy must be based on clinical and microbiological criteria wherever possible .
H-1342	-0.012898075394332409	The CVMP / 627 / 01 and GCP guideline stated that the response to therapy must be based on clinical and microbiological criteria wherever possible .
D-1342	-0.012898075394332409	The CVMP / 627 / 01 and GCP guideline stated that the response to therapy must be based on clinical and microbiological criteria wherever possible .
P-1342	-0.0130 -0.0116 -0.0012 -0.0006 -0.0025 -0.0012 -0.0010 -0.0014 -0.0010 -0.0092 -0.0071 -0.0015 -0.2753 -0.0133 -0.0041 -0.0105 -0.0145 -0.0019 -0.0110 -0.0051 -0.0027 -0.0107 -0.0102 -0.0083 -0.0142 -0.0120 -0.0043 -0.0017 -0.0008 -0.0011 -0.0011 -0.0021 -0.0153 -0.0009 -0.0017 -0.0017 -0.0015
S-1547	• Schlucken Sie die Tabletten ganz mit einem vollen Glas Wasser . • Nehmen Sie die Tabletten zum Essen oder außerhalb einer Mahlzeit ein . • Die Tabletten dürfen nicht zerkaut , zerteilt oder zerstoßen werden .
T-1547	• Swallow the tablets whole with a full glass of water • Take with or without food • Do not chew , break or crush the tablets .
H-1547	-0.0075022634118795395	• Swallow the tablets whole with a full glass of water • Take with or without food • Do not chew , break or crush the tablets .
D-1547	-0.0075022634118795395	• Swallow the tablets whole with a full glass of water • Take with or without food • Do not chew , break or crush the tablets .
P-1547	-0.0057 -0.0094 -0.0005 -0.0006 -0.0088 -0.0030 -0.0014 -0.0105 -0.0035 -0.0016 -0.0018 -0.0007 -0.0014 -0.0011 -0.0798 -0.0058 -0.0134 -0.0137 -0.0127 -0.0079 -0.0104 -0.0056 -0.0014 -0.0025 -0.0009 -0.0022 -0.0135 -0.0106 -0.0053 -0.0003 -0.0072 -0.0007 -0.0011 -0.0052 -0.0126
S-1029	44 Eine randomisierte , doppelblinde Non @-@ Inferiority @-@ Studie mit Parallelgruppendesign verglich die relative Wirksamkeit von zwei verschiedenen Leflunomid @-@ Erhaltungsdosen , 10 mg und 20 mg täglich .
T-1029	A randomised , double @-@ blind , parallel @-@ group non @-@ inferiority study compared the relative efficacy of two different daily maintenance doses of leflunomide , 10 mg and 20 mg .
H-1029	-0.015351667068898678	A randomised , double @-@ blind , parallel @-@ group non @-@ inferiority study compared the relative efficacy of two different daily maintenance doses of leflunomide , 10 mg and 20 mg .
D-1029	-0.015351667068898678	A randomised , double @-@ blind , parallel @-@ group non @-@ inferiority study compared the relative efficacy of two different daily maintenance doses of leflunomide , 10 mg and 20 mg .
P-1029	-0.0179 -0.0050 -0.0561 -0.0007 -0.0012 -0.0026 -0.0031 -0.0674 -0.0241 -0.0064 -0.0148 -0.0053 -0.0037 -0.0125 -0.0019 -0.0014 -0.0006 -0.0003 -0.0104 -0.0030 -0.0021 -0.0007 -0.0095 -0.0006 -0.0008 -0.0015 -0.0019 -0.0035 -0.0402 -0.0533 -0.0033 -0.0012 -0.0027 -0.0014 -0.0009 -0.0035 -0.0003 -0.0007 -0.0044 -0.0066 -0.3118 -0.0020 -0.0018 -0.0005 -0.0113 -0.0015
S-508	Volibris hebt also die Wirkung von Endothelin auf , so dass sich die Blutgefäße wieder dilatieren ( erweitern ) können , und trägt so dazu bei , dass der Blutdruck absinkt und die Symptome sich bessern .
T-508	By blocking the effect of endothelin , Volibris allows the vessels to dilate ( expand ) , helping to lower the blood pressure and improving symptoms .
H-508	-0.007212238851934671	By blocking the effect of endothelin , Volibris allows the vessels to dilate ( expand ) , helping to lower the blood pressure and improving symptoms .
D-508	-0.007212238851934671	By blocking the effect of endothelin , Volibris allows the vessels to dilate ( expand ) , helping to lower the blood pressure and improving symptoms .
P-508	-0.0144 -0.0143 -0.0049 -0.0119 -0.0016 -0.0020 -0.0010 -0.0013 -0.0045 -0.0046 -0.0099 -0.0011 -0.0001 -0.0123 -0.0088 -0.0144 -0.0008 -0.0022 -0.0019 -0.0001 -0.0193 -0.0138 -0.0016 -0.0263 -0.0143 -0.0056 -0.0078 -0.0184 -0.0033 -0.0007 -0.0035 -0.0141 -0.0068 -0.0022 -0.0027
S-300	Bei Anwendung von Voriconazol bei bereits bestehender Ciclosporin @-@ Therapie wird empfohlen , die Ciclosporin @-@ Dosis zu halbieren und die Ciclosporin @-@ Spiegel sorgfältig zu überwachen .
T-300	When initiating voriconazole in patients already receiving ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored .
H-300	-0.012463589198887348	When initiating voriconazole in patients already receiving ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored .
D-300	-0.012463589198887348	When initiating voriconazole in patients already receiving ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored .
P-300	-0.0095 -0.0145 -0.0033 -0.0100 -0.0003 -0.0003 -0.0007 -0.0117 -0.0143 -0.0137 -0.0105 -0.0058 -0.0007 -0.0005 -0.0007 -0.0118 -0.0176 -0.0015 -0.0025 -0.1210 -0.0035 -0.0057 -0.0008 -0.0005 -0.0007 -0.0101 -0.0047 -0.0051 -0.0019 -0.0011 -0.0281 -0.0141 -0.0006 -0.0005 -0.0007 -0.0092 -0.0144 -0.0097 -0.0017 -0.0010 -0.1569 -0.0015
S-492	Wie bereits oben unter &apos; Besondere Vorsicht bei der Anwendung von VIRAMUNEist erforderlich &quot; erwähnt wurde , sind die wichtigsten Nebenwirkungen von VIRAMUNE starke , lebensgefährliche Hautausschläge und schwerwiegende Leberschädigungen .
T-492	As mentioned in <<unk>> Take special care with VIRAMUNE &apos; , above , the most important side effects of VIRAMUNE are severe and life threatening skin reactions and serious liver damage .
H-492	-0.024607688188552856	As mentioned in <unk> Take special care with VIRAMUNE &apos; , above , the most important side effects of VIRAMUNE are severe and life threatening skin reactions and serious liver damage .
D-492	-0.024607688188552856	As mentioned in <unk> Take special care with VIRAMUNE &apos; , above , the most important side effects of VIRAMUNE are severe and life threatening skin reactions and serious liver damage .
P-492	-0.0024 -0.0103 -0.0348 -0.0145 -0.0145 -0.0128 -0.0018 -0.0129 -0.0109 -0.0012 -0.0010 -0.0013 -0.0035 -0.0104 -0.0110 -0.3606 -0.0036 -0.2379 -0.0284 -0.0071 -0.0065 -0.0036 -0.0111 -0.0018 -0.0011 -0.0009 -0.0014 -0.0014 -0.0040 -0.0036 -0.0131 -0.0044 -0.0699 -0.0120 -0.0148 -0.0046 -0.0626 -0.0099 -0.0038 -0.0191 -0.0016 -0.0014
S-1868	In klinischen Studien zeigten sich unter Einmalgabe von Etoricoxib bis zu einer Dosis von 500 mg sowie unter wiederholter Anwendung von Dosen bis zu 150 mg / Tag über 21 Tage keine bedeutsamen toxischen Wirkungen .
T-1868	In clinical studies , administration of single doses of etoricoxib up to 500 mg and multiple doses up to 150 mg / day for 21 days did not result in significant toxicity .
H-1868	-0.03431534394621849	In clinical studies , administration of single doses of etoricoxib up to 500 mg and multiple doses up to 150 mg / day for 21 days did not result in significant toxicity .
D-1868	-0.03431534394621849	In clinical studies , administration of single doses of etoricoxib up to 500 mg and multiple doses up to 150 mg / day for 21 days did not result in significant toxicity .
P-1868	-0.0084 -0.2409 -0.9497 -0.0091 -0.0145 -0.0020 -0.0197 -0.0105 -0.0007 -0.0028 -0.0231 -0.0025 -0.0007 -0.0005 -0.0011 -0.0063 -0.0014 -0.0093 -0.0008 -0.0062 -0.0143 -0.0022 -0.0007 -0.0089 -0.0014 -0.0013 -0.0005 -0.0029 -0.0018 -0.0086 -0.0014 -0.0014 -0.0105 -0.0014 -0.0169 -0.0015 -0.0037 -0.0134 -0.0263 -0.0039 -0.0066 -0.0014
S-1176	In biologischem Gewebe kann Stickstoffmonoxid mit Superoxid ( O2- ) Peroxynitrit bilden , eine instabile Verbindung , die durch weitere Redoxreaktionen Gewebeschäden hervorrufen kann .
T-1176	In biological tissue , nitric oxide may form peroxynitrite with superoxide ( O2- ) , an unstable compound which may cause tissue damage through further redox reactions .
H-1176	-0.009944694116711617	In biological tissue , nitric oxide may form peroxynitrite with superoxide ( O2- ) , an unstable compound which may cause tissue damage through further redox reactions .
D-1176	-0.009944694116711617	In biological tissue , nitric oxide may form peroxynitrite with superoxide ( O2- ) , an unstable compound which may cause tissue damage through further redox reactions .
P-1176	-0.0038 -0.0028 -0.0017 -0.0095 -0.0056 -0.0024 -0.0007 -0.0005 -0.0140 -0.0033 -0.0143 -0.0016 -0.0009 -0.0012 -0.0012 -0.0010 -0.0082 -0.0030 -0.0007 -0.0046 -0.0041 -0.0037 -0.0018 -0.0014 -0.0027 -0.0033 -0.0013 -0.0009 -0.0011 -0.0119 -0.0099 -0.0049 -0.0025 -0.0018 -0.0199 -0.0046 -0.0012 -0.0015 -0.0016 -0.0028 -0.0004 -0.2619 -0.0014
S-130	nicht abgeklärte Blutung im Genitalbereich unbehandelte Endometriumhyperplasie frühere idiopathische oder bestehende venöse thromboembolische Erkrankungen ( tiefe Venenthrombose , Lungenembolie )
T-130	Undiagnosed genital bleeding Untreated endometrial hyperplasia Previous idiopathic or current venous thromboembolism ( deep venous thrombosis , pulmonary embolism )
H-130	-0.01784326136112213	Undiagnosed genital bleeding Untreated endometrial hyperplasia Previous idiopathic or current venous thromboembolism ( deep venous thrombosis , pulmonary embolism )
D-130	-0.01784326136112213	Undiagnosed genital bleeding Untreated endometrial hyperplasia Previous idiopathic or current venous thromboembolism ( deep venous thrombosis , pulmonary embolism )
P-130	-0.0111 -0.0138 -0.0091 -0.0006 -0.0089 -0.0018 -0.0131 -0.0008 -0.0004 -0.0002 -0.0029 -0.0007 -0.0006 -0.0008 -0.0112 -0.0028 -0.0014 -0.0005 -0.0010 -0.0007 -0.0015 -0.0018 -0.0144 -0.0006 -0.0005 -0.0002 -0.0003 -0.0006 -0.0009 -0.6155 -0.0075 -0.0030 -0.0011 -0.1136 -0.0005 -0.0008 -0.0004 -0.0014 -0.0022 -0.0003 -0.0004 -0.0010 -0.0008 -0.0005 -0.0012 -0.0003 -0.0015 -0.0017
S-1881	Geräte für eine manuelle Beatmung sollten im Falle einer Atemnot oder Apnoe verfügbar sein , wenn Dexmedetomidin und Ketamin nacheinander angewendet werden , um bei Katzen die Narkose einzuleiten .
T-1881	Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats .
H-1881	-0.005276426672935486	Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats .
D-1881	-0.005276426672935486	Equipment for manual ventilation should be available in case of respiratory depression or apnoea when dexmedetomidine and ketamine are used sequentially to induce anaesthesia in cats .
P-1881	-0.0143 -0.0006 -0.0032 -0.0027 -0.0009 -0.0057 -0.0004 -0.0043 -0.0024 -0.0016 -0.0021 -0.0241 -0.0112 -0.0015 -0.0112 -0.0013 -0.0006 -0.0145 -0.0028 -0.0007 -0.0336 -0.0003 -0.0155 -0.0019 -0.0024 -0.0024 -0.0010 -0.0010 -0.0034 -0.0023 -0.0015 -0.0003 -0.0003 -0.0026 -0.0125 -0.0140 -0.0009 -0.0010 -0.0119 -0.0105 -0.0010 -0.0055 -0.0075 -0.0037 -0.0009 -0.0099 -0.0017 -0.0016 -0.0015
S-849	Ischämische Herzkrankheit Unter ischämischen Bedingungen kann sich durch Blockierung des Bradykinin @-@ Rezeptors Typ 2 eine Verschlechterung der Herzfunktion und eine Verminderung der Durchblutung der Herzkranzgefäße ergeben .
T-849	Ischemic heart disease Under ischemic conditions , a deterioration of cardiac function and a decrease in coronary blood flow could theoretically arise from antagonism of bradykinin receptor type 2 .
H-849	-0.03372301161289215	Ischemic heart disease Under ischemic conditions , a deterioration of cardiac function and a decrease in coronary blood flow could theoretically arise from antagonism of bradykinin receptor type 2 .
D-849	-0.03372301161289215	Ischemic heart disease Under ischemic conditions , a deterioration of cardiac function and a decrease in coronary blood flow could theoretically arise from antagonism of bradykinin receptor type 2 .
P-849	-0.0027 -0.0036 -0.0007 -0.0031 -0.0121 -0.0082 -0.0020 -0.0730 -0.0008 -0.0019 -0.0044 -0.0152 -0.0135 -0.0014 -0.6857 -0.0187 -0.0007 -0.0991 -0.0100 -0.0076 -0.0109 -0.0013 -0.1443 -0.0145 -0.0003 -0.0007 -0.0077 -0.0072 -0.0147 -0.1691 -0.0008 -0.1842 -0.0011 -0.0152 -0.0151 -0.0037 -0.0064 -0.0064 -0.0142 -0.0005 -0.0035 -0.0026 -0.0024 -0.0004 -0.0525 -0.0026 -0.0018 -0.0022 -0.0015
S-1329	Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend
T-1329	Invented name Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend
H-1329	-0.023193005472421646	Invented name Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend
D-1329	-0.023193005472421646	Invented name Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend
P-1329	-0.0145 -0.0144 -0.0163 -0.0093 -0.0006 -0.0086 -0.0006 -0.0080 -0.0006 -0.0078 -0.0006 -0.0078 -0.0006 -0.0075 -0.0006 -0.0067 -0.0006 -0.0056 -0.0007 -0.0049 -0.0007 -0.0044 -0.0007 -0.0036 -0.0008 -0.0032 -0.0008 -0.0033 -0.0008 -0.0036 -0.0008 -0.0040 -0.0008 -0.0040 -0.0008 -0.0035 -0.0008 -0.0030 -0.0008 -0.0025 -0.0008 -0.0029 -0.0008 -0.0040 -0.0008 -0.0058 -0.0008 -0.0385 -0.0009 -0.4026 -0.0011 -0.5876
S-236	Tierexperimentelle Untersuchungen deuten jedoch auf ein gewisses Risikopotenzial von Telmisartan für die postnatale Entwicklung der Nachkommen hin wie niedrigeres Körpergewicht , verzögertes Öffnen der Augen und höhere Mortalität .
T-236	There is no evidence of a teratogenic effect , but animal studies indicated some hazardous potential of telmisartan to the postnatal development of the offspring such as lower body weight , delayed eye opening , and higher mortality .
H-236	-0.00936860777437687	There is no evidence of a teratogenic effect , but animal studies indicated some hazardous potential of telmisartan to the postnatal development of the offspring such as lower body weight , delayed eye opening , and higher mortality .
D-236	-0.00936860777437687	There is no evidence of a teratogenic effect , but animal studies indicated some hazardous potential of telmisartan to the postnatal development of the offspring such as lower body weight , delayed eye opening , and higher mortality .
P-236	-0.0144 -0.0078 -0.0144 -0.0079 -0.0129 -0.0122 -0.0145 -0.0143 -0.0117 -0.0080 -0.0026 -0.0105 -0.0140 -0.0079 -0.0053 -0.0045 -0.0152 -0.0124 -0.0145 -0.0122 -0.0058 -0.0013 -0.0099 -0.0105 -0.0011 -0.0008 -0.0006 -0.0015 -0.0185 -0.0118 -0.0073 -0.0006 -0.0014 -0.0016 -0.0016 -0.0129 -0.0012 -0.0006 -0.0159 -0.0014 -0.0051 -0.0017 -0.0011 -0.0014 -0.0018 -0.0084 -0.0015 -0.1468 -0.0035 -0.0057 -0.0008 -0.0010 -0.0020 -0.0014
S-1519	Allgemeine Erkrankungen und Beschwerden am Verabreichungsort Bei einer medianen Nachbeobachtungszeit von 55 Monaten dauerten periphere Ödeme bei 18 von 112 Patientinnen mit peripheren Ödemen am Ende der Chemotherapie an .
T-1519	General disorders and administration site conditions Oedema peripheral was observed to be ongoing at the median follow @-@ up time of 55 months in 18 patients out of the 112 patients with oedema peripheral at the end of the chemotherapy .
H-1519	-0.025859573855996132	General disorders and administration site conditions Oedema peripheral was observed to be ongoing at the median follow @-@ up time of 55 months in 18 patients out of the 112 patients with oedema peripheral at the end of the chemotherapy .
D-1519	-0.025859573855996132	General disorders and administration site conditions Oedema peripheral was observed to be ongoing at the median follow @-@ up time of 55 months in 18 patients out of the 112 patients with oedema peripheral at the end of the chemotherapy .
P-1519	-0.0106 -0.0138 -0.0011 -0.0018 -0.0145 -0.0139 -0.0134 -0.0145 -0.0142 -0.0032 -0.0003 -0.0117 -0.0007 -0.0041 -0.0145 -0.0194 -0.0153 -0.0141 -0.0172 -0.0133 -0.0033 -0.5766 -0.0012 -0.0035 -0.0033 -0.0011 -0.0115 -0.0018 -0.0009 -0.0015 -0.0053 -0.0016 -0.0148 -0.0091 -0.0014 -0.0146 -0.0012 -0.0049 -0.0032 -0.0145 -0.0011 -0.0003 -0.0145 -0.0008 -0.0033 -0.0117 -0.0021 -0.3558 -0.0014 -0.0141 -0.0031 -0.0006 -0.1170 -0.0081 -0.0014
S-394	Rifampicin , benötigen , ist eine Erhöhung der Dosis auf 300 mg unter engmaschiger Überwachung der Verträglichkeit ( einschließlich der Nieren- und Leberfunktion und der Serumelektrolyte ) in Betracht zu ziehen .
T-394	For patients who require concomitant treatment with Tarceva and a potent CYP3A4 inducer such as rifampicin an increase in dose to 300 mg should be considered while their safety ( including renal and liver functions and serum electrolytes ) is closely monitored , and if well tolerated for more than 2 weeks , further increase to 450 mg could be considered with close safety monitoring .
H-394	-0.03055425174534321	For patients who require concomitant treatment with Tarceva and a potent CYP3A4 inducer such as rifampicin an increase in dose to 300 mg should be considered while their safety ( including renal and liver functions and serum electrolytes ) is closely monitored .
D-394	-0.03055425174534321	For patients who require concomitant treatment with Tarceva and a potent CYP3A4 inducer such as rifampicin an increase in dose to 300 mg should be considered while their safety ( including renal and liver functions and serum electrolytes ) is closely monitored .
P-394	-0.0144 -0.0128 -0.0092 -0.0101 -0.0287 -0.0141 -0.0032 -0.0024 -0.0142 -0.0049 -0.0844 -0.0145 -0.0145 -0.0142 -0.0179 -0.0145 -0.0022 -0.0150 -0.0160 -0.0130 -0.0143 -0.0145 -0.0146 -0.0145 -0.0127 -0.0144 -0.0015 -0.0458 -0.0009 -0.0011 -0.0013 -0.0017 -0.0144 -0.0064 -0.0108 -0.0086 -0.0028 -0.0035 -0.0010 -0.0127 -0.0015 -0.0030 -0.0136 -0.0145 -0.0146 -0.0064 -0.0025 -0.0132 -0.0008 -0.0071 -0.2263 -0.0195 -0.0517 -0.0014 -0.0015 -0.0013 -0.0007 -0.0007 -0.0021 -0.0013 -0.0019 -0.0038 -0.0008 -0.0008 -1.1068 -0.0014
S-1851	In dieser Zeit wird sich die Agentur möglicherweise auch neuen Herausforderungen im Hinblick auf die Qualität , Sicherheit und Wirksamkeit von Human- und Tierarzneimitteln in der Europäischen Union stellen und ihren Beitrag zur internationalen Harmonisierung der Prüfbedingungen leisten müssen .
T-1851	During this period , the Agency may also have to face new challenges in relation to the quality , safety and efficacy of medicinal products for human or veterinary use in the European Union and must help achieve international harmonisation of testing requirements .
H-1851	-0.020728113129734993	During this period , the Agency may also have to face new challenges in relation to the quality , safety and efficacy of medicinal products for human or veterinary use in the European Union and must help achieve international harmonisation of testing requirements .
D-1851	-0.020728113129734993	During this period , the Agency may also have to face new challenges in relation to the quality , safety and efficacy of medicinal products for human or veterinary use in the European Union and must help achieve international harmonisation of testing requirements .
P-1851	-0.0056 -0.0040 -0.0093 -0.0119 -0.0028 -0.2016 -0.0113 -0.0097 -0.0107 -0.0016 -0.0100 -0.0043 -0.0012 -0.0111 -0.0131 -0.0014 -0.0023 -0.0009 -0.0014 -0.0012 -0.2250 -0.0827 -0.0004 -0.0008 -0.0015 -0.0091 -0.1618 -0.0012 -0.0023 -0.0009 -0.0134 -0.0010 -0.0010 -0.0007 -0.0039 -0.0014 -0.0145 -0.0011 -0.0060 -0.0144 -0.0144 -0.0138 -0.0053 -0.0008 -0.0015 -0.1188 -0.0071 -0.0136 -0.0014 -0.0014
S-1298	Das Tollwutvirus und attenuierte Tollwutimpfviren akkumulieren gewöhnlich nicht in den Fortpflanzungsorganen ; es ist nicht bekannt , dass sie direkt die Reproduktionsfunktionen beeinflussen .
T-1298	However rabies virus and attenuated rabies vaccine viruses do not usually accumulate in reproductive organs and are not known to directly affect reproductive functions .
H-1298	-0.004702455829828978	However rabies virus and attenuated rabies vaccine viruses do not usually accumulate in reproductive organs and are not known to directly affect reproductive functions .
D-1298	-0.004702455829828978	However rabies virus and attenuated rabies vaccine viruses do not usually accumulate in reproductive organs and are not known to directly affect reproductive functions .
P-1298	-0.0145 -0.0141 -0.0002 -0.0048 -0.0022 -0.0023 -0.0013 -0.0018 -0.0010 -0.0002 -0.0108 -0.0035 -0.0010 -0.0054 -0.0015 -0.0084 -0.0014 -0.0011 -0.0020 -0.0123 -0.0010 -0.0027 -0.0013 -0.0156 -0.0043 -0.0022 -0.0019 -0.0015 -0.0071 -0.0179 -0.0020 -0.0087 -0.0058 -0.0016 -0.0014
S-1502	Bei den Positionserklärungen / Positionspapieren des CPMP handelt es sich um wissenschaftliche Abhandlungen , durch die der aktuelle wissenschaftliche Standpunkt vermittelt werden soll , der EU @-@ weit zu spezifischen Themen eingenommen wird .
T-1502	CPMP position statements / position papers are scientific statements aimed at communicating the current state @-@ of @-@ the @-@ art EU @-@ wide scientific position on a specific topic .
H-1502	-0.019097957760095596	CPMP position statements / position papers are scientific statements aimed at communicating the current state @-@ of @-@ the @-@ art EU @-@ wide scientific position on a specific topic .
D-1502	-0.019097957760095596	CPMP position statements / position papers are scientific statements aimed at communicating the current state @-@ of @-@ the @-@ art EU @-@ wide scientific position on a specific topic .
P-1502	-0.0115 -0.0015 -0.0009 -0.0070 -0.0058 -0.0038 -0.0027 -0.0014 -0.0020 -0.0028 -0.0145 -0.0138 -0.0043 -0.0128 -0.0012 -0.0030 -0.0042 -0.0530 -0.3063 -0.0030 -0.0014 -0.0021 -0.0018 -0.0009 -0.1231 -0.0088 -0.0012 -0.0263 -0.0104 -0.0038 -0.0144 -0.0058 -0.0099 -0.0017 -0.0014
S-72	In der 12 @-@ Wochen- Studie mit Peritonealdialysepatienten wurden im Vergleich zu Patienten , die Calciumacetat erhielten , allerdings vergleichbare Senkungen des iPTH @-@ Spiegels im Serum beobachtet .
T-72	In the 12 week study involving peritoneal dialysis patients however , similar iPTH reductions were seen compared with patients receiving calcium acetate .
H-72	-0.061732713133096695	In the 12 week study involving peritoneal dialysis patients however , similar iPTH reductions were seen compared with patients receiving calcium acetate .
D-72	-0.061732713133096695	In the 12 week study involving peritoneal dialysis patients however , similar iPTH reductions were seen compared with patients receiving calcium acetate .
P-72	-0.0102 -0.0032 -0.0019 -0.0270 -0.0043 -0.0183 -0.0024 -0.0012 -0.0003 -0.0012 -0.0008 -0.0004 -0.0010 -0.0020 -0.1660 -0.1306 -0.0135 -0.0145 -0.0014 -0.0008 -0.0100 -0.0010 -0.0104 -0.2599 -0.1533 -1.0029 -0.0050 -0.1088 -0.0011 -0.0008 -0.2569 -0.0009 -0.0011 -0.0012 -0.0069 -0.0015
S-1504	In klinischen Studien konnte gezeigt werden , dass sich Ihre Chancen , mit dem Rauchen aufzuhören , erhöhen , wenn Sie wie oben beschrieben alle Dosen Ihres Arzneimittels zur richtigen Zeit einnehmen und die empfohlene Behandlungsdauer einhalten .
T-1504	It has been shown in clinical trials that taking all doses of your medicine at the appropriate times and for the recommended duration of treatment described above will increase your chances of stopping smoking .
H-1504	-0.018851300701498985	It has been shown in clinical trials that taking all doses of your medicine at the appropriate times and for the recommended duration of treatment described above will increase your chances of stopping smoking .
D-1504	-0.018851300701498985	It has been shown in clinical trials that taking all doses of your medicine at the appropriate times and for the recommended duration of treatment described above will increase your chances of stopping smoking .
P-1504	-0.0145 -0.0131 -0.0020 -0.0045 -0.0019 -0.0227 -0.2255 -0.0055 -0.0143 -0.0025 -0.0079 -0.0013 -0.0017 -0.0021 -0.0085 -0.0030 -0.0020 -0.0142 -0.0143 -0.0045 -0.0144 -0.0028 -0.0029 -0.0086 -0.0014 -0.0019 -0.0070 -0.0678 -0.0743 -0.0577 -0.0037 -0.0022 -0.0023 -0.0851 -0.0130 -0.0023 -0.0016 -0.0015
S-785	Die Patienten sollten allerdings darüber informiert werden , dass sowohl in Zusammenhang mit der Anwendung von Emtricitabin als auch mit der Anwendung von Tenofovirdisoproxilfumarat über Schwindelgefühle berichtet wurde .
T-785	However , patients should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil fumarate .
H-785	-0.006772528402507305	However , patients should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil fumarate .
D-785	-0.006772528402507305	However , patients should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil fumarate .
P-785	-0.0126 -0.0026 -0.0018 -0.0020 -0.0018 -0.0041 -0.0641 -0.0092 -0.0005 -0.0007 -0.0039 -0.0015 -0.0184 -0.0179 -0.0144 -0.0073 -0.0455 -0.0114 -0.0010 -0.0005 -0.0009 -0.0009 -0.0017 -0.0019 -0.0012 -0.0011 -0.0028 -0.0035 -0.0028 -0.0016 -0.0020 -0.0060 -0.0086 -0.0014 -0.0007 -0.0015 -0.0010 -0.0020 -0.0015
S-1865	Bevor Sie die Spritze aus der Durchstechflasche herausziehen , saugen Sie dieselbe Menge Luft ( 1,5 ml ) wie injiziertes Lösungsmittel an , um den Druck in der Durchstechflasche zu verringern .
T-1865	Before taking the syringe out of the vial , draw in the same amount of air ( 1.5 ml ) as the solvent you injected to reduce the pressure in the vial .
H-1865	-0.0041913799941539764	Before taking the syringe out of the vial , draw in the same amount of air ( 1.5 ml ) as the solvent you injected to reduce the pressure in the vial .
D-1865	-0.0041913799941539764	Before taking the syringe out of the vial , draw in the same amount of air ( 1.5 ml ) as the solvent you injected to reduce the pressure in the vial .
P-1865	-0.0025 -0.0138 -0.0036 -0.0012 -0.0003 -0.0003 -0.0021 -0.0020 -0.0021 -0.0020 -0.0022 -0.0032 -0.0136 -0.0041 -0.0032 -0.0013 -0.0039 -0.0025 -0.0028 -0.0021 -0.0039 -0.0018 -0.0015 -0.0033 -0.0115 -0.0087 -0.0012 -0.0130 -0.0069 -0.0117 -0.0079 -0.0063 -0.0051 -0.0018 -0.0073 -0.0018 -0.0003 -0.0015 -0.0017 -0.0016
S-730	Da das mit Valsartan und das mit der aktuellen Standardtherapie mit einem ACE @-@ Hemmer erzielte klinische Ergebnis durchaus gleichwertig war , nahm der CHMP folgenden harmonisierten Wortlaut für dieses Anwendungsgebiet an :
T-730	Considering the non inferiority in clinical outcome of valsartan compared to current standard treatment , an ACEI , the CHMP adopted the following harmonised wording for this indication :
H-730	-0.03147680684924126	Considering the non inferiority in clinical outcome of valsartan compared to current standard treatment , an ACE , the CHMP adopted the following harmonised wording for this indication :
D-730	-0.03147680684924126	Considering the non inferiority in clinical outcome of valsartan compared to current standard treatment , an ACE , the CHMP adopted the following harmonised wording for this indication :
P-730	-0.0151 -0.0004 -0.0008 -0.0119 -0.0145 -0.0149 -0.0028 -0.0355 -0.0145 -0.0107 -0.0103 -0.0092 -0.0047 -0.0059 -0.0007 -0.0013 -0.0137 -0.1894 -0.0108 -0.0045 -0.0127 -0.0150 -0.0145 -0.0012 -0.6179 -0.1531 -0.0112 -0.0014 -0.0005 -0.0028 -0.0026 -0.0055 -0.0011 -0.0429 -0.0044 -0.0012 -0.0045 -0.0050 -0.0144 -0.0054 -0.0014
S-1175	Viani Diskus ist indiziert für die regelmäßige Behandlung von Asthma bronchiale , bei der die Anwendung von langwirksamem Beta2 @-@ Agonisten und inhalativem Kortikoid in Kombination angezeigt ist :
T-1175	Viani is indicated in the regular treatment of asthma where use of a combination product ( long @-@ acting beta @-@ 2 @-@ agonist and inhaled corticosteroid ) is appropriate :
H-1175	-0.02395053766667843	Viani is indicated in the regular treatment of asthma where use of a combination product ( long @-@ acting beta @-@ 2 @-@ agonist and inhaled corticosteroid ) is appropriate :
D-1175	-0.02395053766667843	Viani is indicated in the regular treatment of asthma where use of a combination product ( long @-@ acting beta @-@ 2 @-@ agonist and inhaled corticosteroid ) is appropriate :
P-1175	-0.0027 -0.0007 -0.0144 -0.0008 -0.7436 -0.0079 -0.0096 -0.0030 -0.0015 -0.0137 -0.0009 -0.0009 -0.0138 -0.0141 -0.0015 -0.0134 -0.0145 -0.0145 -0.0142 -0.0088 -0.0054 -0.0024 -0.0028 -0.0029 -0.0039 -0.0018 -0.0145 -0.0009 -0.0047 -0.0090 -0.0025 -0.0126 -0.0019 -0.0015 -0.0008 -0.0109 -0.0061 -0.0044 -0.0031 -0.0136 -0.0041 -0.0014
S-1296	Bei den Patientinnen ( n = 102 ) mit einem Rezidiv nach 180 Tagen und später betrug die mediane Überlebenszeit im Topotecan + Cisplatin @-@ Arm 9,9 Monate ( 95 % KI :
T-1296	In those ( n = 102 ) with recurrence after 180 days , the median survival in the topotecan plus cisplatin arm was 9.9 months ( 95 % C. I. :
H-1296	-0.004416268784552813	In those ( n = 102 ) with recurrence after 180 days , the median survival in the topotecan plus cisplatin arm was 9.9 months ( 95 % C. I. :
D-1296	-0.004416268784552813	In those ( n = 102 ) with recurrence after 180 days , the median survival in the topotecan plus cisplatin arm was 9.9 months ( 95 % C. I. :
P-1296	-0.0077 -0.0143 -0.0143 -0.0037 -0.0010 -0.0005 -0.0014 -0.0090 -0.0057 -0.0007 -0.0054 -0.0009 -0.0094 -0.0005 -0.0015 -0.0145 -0.0090 -0.0009 -0.0012 -0.0014 -0.0121 -0.0046 -0.0034 -0.0018 -0.0017 -0.0012 -0.0146 -0.0005 -0.0011 -0.0012 -0.0014 -0.0003 -0.0020 -0.0013 -0.0013 -0.0015 -0.0016 -0.0006 -0.0014 -0.0145 -0.0061 -0.0113 -0.0016
S-1545	Wie Eucreas aussieht und Inhalt der Packung Eucreas 50 mg / 850 mg Filmtabletten sind gelbe , ovale Tabletten mit &quot; NVR &quot; auf einer Seite und &quot; SEH &quot; auf der anderen Seite .
T-1545	What Eucreas looks like and contents of the pack Eucreas 50 mg / 850 mg film @-@ coated tablets are yellow , oval tablets with <<unk>> NVR <<unk>> on one side and <<unk>> SEH <<unk>> on the other .
H-1545	-0.03448896110057831	What Eucreas looks like and contents of the pack Eucreas 50 mg / 850 mg film @-@ coated tablets are yellow , oval tablets with <unk> NVR <unk> on one side and <unk> SEH <unk> on the other side .
D-1545	-0.03448896110057831	What Eucreas looks like and contents of the pack Eucreas 50 mg / 850 mg film @-@ coated tablets are yellow , oval tablets with <unk> NVR <unk> on one side and <unk> SEH <unk> on the other side .
P-1545	-0.0131 -0.0016 -0.0014 -0.0015 -0.0025 -0.0015 -0.0021 -0.0087 -0.0009 -0.0018 -0.0060 -0.0038 -0.0047 -0.0012 -0.0015 -0.0057 -0.0006 -0.0015 -0.0010 -0.0914 -0.1407 -0.0060 -0.0955 -0.0145 -0.0018 -0.1471 -0.0018 -0.0020 -0.0009 -0.0092 -0.0032 -0.0006 -0.0070 -0.0011 -0.0020 -0.0149 -0.0039 -0.0007 -0.0142 -0.0019 -0.0016 -0.2146 -0.0016 -0.0037 -0.0066 -0.0014 -0.0057 -0.0043 -0.0014 -0.0015 -0.9613 -0.0016 -0.0014
S-223	NutropinAq ist nicht indiziert für die Langzeitbehandlung von Kindern mit Wachstumsstörungen auf- grund eines genetisch bedingten Prader @-@ Willi @-@ Syndroms , außer sie haben auch einen diagnostizierten Wachstumshormonmangel .
T-223	NutropinAq is not indicated for the long @-@ term treatment of paediatric patients who have growth failure due to genetically confirmed Prader @-@ Willi syndrome , unless they also have a diagnosis of growth hormone deficiency .
H-223	-0.016709187999367714	NutropinAq is not indicated for the long @-@ term treatment of paediatric patients who have growth failure due to genetically confirmed Prader @-@ Willi syndrome , unless they also have a diagnosis of growth hormone deficiency .
D-223	-0.016709187999367714	NutropinAq is not indicated for the long @-@ term treatment of paediatric patients who have growth failure due to genetically confirmed Prader @-@ Willi syndrome , unless they also have a diagnosis of growth hormone deficiency .
P-223	-0.0018 -0.0007 -0.0008 -0.0011 -0.0012 -0.0006 -0.0021 -0.0017 -0.0012 -0.3550 -0.0086 -0.0015 -0.1034 -0.0013 -0.0021 -0.0015 -0.0146 -0.0023 -0.0014 -0.0633 -0.0072 -0.1150 -0.0060 -0.0097 -0.0145 -0.0047 -0.0014 -0.0117 -0.0022 -0.0145 -0.0039 -0.0009 -0.0027 -0.0007 -0.0027 -0.0014 -0.0139 -0.0054 -0.0040 -0.0125 -0.0048 -0.0035 -0.0141 -0.0094 -0.0043 -0.0017 -0.0006 -0.0233 -0.0008 -0.0020 -0.0016 -0.0014
S-574	Hautinfektionen ( Pyodermie- oberflächlich und tief , Wunden , Abszesse ) verursacht durch empfindliche Erreger wie Staphylokokken , E. coli und Proteus mirabilis .
T-574	Dermal infections ( pyoderma <<unk>> superficial and deep , wounds , abscesses ) caused by susceptible strains of Staphylococci , E. coli , and Proteus mirabilis .
H-574	-0.009489735588431358	Dermal infections ( pyoderma <unk> superficial and deep , wounds , abscesses ) caused by susceptible strains of Staphylococci , E. coli , and Proteus mirabilis .
D-574	-0.009489735588431358	Dermal infections ( pyoderma <unk> superficial and deep , wounds , abscesses ) caused by susceptible strains of Staphylococci , E. coli , and Proteus mirabilis .
P-574	-0.0143 -0.0075 -0.0018 -0.0005 -0.0016 -0.0035 -0.0006 -0.0004 -0.0100 -0.0145 -0.0100 -0.0008 -0.0016 -0.0017 -0.0021 -0.0020 -0.0019 -0.0013 -0.0014 -0.0006 -0.0014 -0.0018 -0.0013 -0.0137 -0.0008 -0.0008 -0.0010 -0.0009 -0.0149 -0.0010 -0.0296 -0.0144 -0.0012 -0.0009 -0.0009 -0.0008 -0.0082 -0.0020 -0.0032 -0.0013 -0.0013 -0.2452 -0.0040 -0.0016 -0.0004 -0.0021 -0.0010 -0.0004 -0.0013 -0.0467 -0.0014
S-1021	Κηφισίας 41 @-@ 45 , Κτίριο Β GR @-@ 151 23 Μαρούσι Αθήνα Tηλ : + 30 @-@ 210 @-@ 61 65 100
T-1021	Κηφισίας 41 @-@ 45 , Κτίριο Β GR @-@ 151 23 Μαρούσι Αθήνα Tηλ : + 30 @-@ 210 @-@ 61 65 100
H-1021	-0.015257729217410088	Κηφισίας 41 @-@ 45 , Κτίριο Β GR @-@ 151 23 Μαρούσι Αθήνα Tηλ : + 30 @-@ 210 @-@ 61 65 100
D-1021	-0.015257729217410088	Κηφισίας 41 @-@ 45 , Κτίριο Β GR @-@ 151 23 Μαρούσι Αθήνα Tηλ : + 30 @-@ 210 @-@ 61 65 100
P-1021	-0.0145 -0.0029 -0.0012 -0.0002 -0.0013 -0.0030 -0.0023 -0.0051 -0.0005 -0.2127 -0.1887 -0.0015 -0.0061 -0.0008 -0.0016 -0.0002 -0.0004 -0.0081 -0.0145 -0.0016 -0.0011 -0.2608 -0.0031 -0.0014 -0.0009 -0.0024 -0.0004 -0.0003 -0.0007 -0.0020 -0.0005 -0.0007 -0.0010 -0.0005 -0.0038 -0.0005 -0.0001 -0.0013 -0.0019 -0.0003 -0.0014 -0.0014 -0.0012 -0.0015 -0.0004 -0.0014 -0.0008 -0.0014 -0.0011 -0.0015
S-173	Docetaxel Winthrop ist in Kombination mit Doxorubicin und Cyclophosphamid für die adjuvante Therapie von Patientinnen mit operablem , nodal positivem Brustkrebs angezeigt .
T-173	Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer .
H-173	-0.00936039723455906	Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer .
D-173	-0.00936039723455906	Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer .
P-173	-0.0022 -0.0013 -0.0008 -0.0004 -0.0009 -0.0014 -0.0002 -0.0011 -0.0948 -0.0008 -0.0014 -0.0020 -0.0010 -0.0011 -0.0011 -0.0006 -0.0021 -0.0015 -0.0481 -0.0007 -0.0009 -0.0008 -0.0010 -0.0006 -0.0014 -0.0028 -0.0004 -0.1788 -0.0089 -0.0007 -0.0010 -0.0011 -0.0097 -0.0014 -0.0037 -0.0018 -0.0095 -0.0021 -0.0050 -0.0145 -0.0137 -0.0020 -0.0005 -0.0010 -0.0023 -0.0015
S-450	Ebenso gab es bei den mit Bondronat behandelten Patienten im Vergleich zu Placebo eine 38 % ige Abnahme des Risikos , SREs zu entwickeln ( relatives Risiko 0,62 , p = 0,003 ) .
T-450	There was also a 38 % reduction in the risk of developing an SRE for Bondronat treated patients when compared with placebo ( relative risk 0.62 , p = 0.003 ) .
H-450	-0.023518677800893784	There was also a 38 % reduction in the risk of developing an SRE for Bondronat treated patients when compared with placebo ( relative risk 0.62 , p = 0.003 ) .
D-450	-0.023518677800893784	There was also a 38 % reduction in the risk of developing an SRE for Bondronat treated patients when compared with placebo ( relative risk 0.62 , p = 0.003 ) .
P-450	-0.0120 -0.0069 -0.0035 -0.0020 -0.0016 -0.0023 -0.0097 -0.0030 -0.0034 -0.0013 -0.1158 -0.0021 -0.0145 -0.0027 -0.0016 -0.0068 -0.0144 -0.0143 -0.0012 -0.0145 -0.0127 -0.0146 -0.0023 -0.0498 -0.0006 -0.6687 -0.0026 -0.0012 -0.0007 -0.0012 -0.0025 -0.0012 -0.0010 -0.0063 -0.0023 -0.0019 -0.0011 -0.0012 -0.0011 -0.0005 -0.0014 -0.0015 -0.0014
S-363	Im Falle einer Anwendung von { ( Name ( Phantasiebezeichnung ) } bei stillenden Müttern darf die Creme nicht auf die Brust aufgetragen werden , um eine versehentliche orale Aufnahme durch den Säugling zu vermeiden .
T-363	Breastfeeding mothers may use &lt; Invented Name &gt; but should not apply &lt; Invented Name &gt; to the breast in order to avoid unintentional oral uptake by the newborn .
H-363	-0.009562271647155285	Breastfeeding mothers may use &lt; Invented Name &gt; but should not apply &lt; Invented Name &gt; to the breast in order to avoid unintentional oral uptake by the newborn .
D-363	-0.009562271647155285	Breastfeeding mothers may use &lt; Invented Name &gt; but should not apply &lt; Invented Name &gt; to the breast in order to avoid unintentional oral uptake by the newborn .
P-363	-0.0160 -0.0144 -0.0018 -0.0029 -0.0129 -0.0140 -0.0145 -0.0003 -0.0010 -0.0145 -0.0120 -0.0136 -0.0129 -0.0171 -0.0134 -0.0037 -0.0066 -0.0145 -0.0004 -0.0010 -0.0145 -0.0037 -0.0064 -0.0118 -0.0126 -0.0092 -0.0031 -0.0102 -0.0015 -0.0016 -0.0172 -0.0140 -0.0073 -0.0016 -0.0014 -0.0143 -0.0002 -0.0053 -0.0027 -0.0213 -0.0007 -0.0043 -0.0588
S-1863	Ziconotid , der in Prialt enthaltene Wirkstoff , ist eine Kopie der natürlich vorkommenden Substanz Omega @-@ Conotoxin , die aus dem Gift einer Meeresschneckenart gewonnen wird .
T-1863	The active substance in Prialt , ziconotide , is a copy of a natural substance , omega @-@ conopeptide , extracted from the venom of a type of sea snail .
H-1863	-0.00969703495502472	The active substance in Prialt , ziconotide , is a copy of a natural substance , omega @-@ conopeptide , extracted from the venom of a type of sea snail .
D-1863	-0.00969703495502472	The active substance in Prialt , ziconotide , is a copy of a natural substance , omega @-@ conopeptide , extracted from the venom of a type of sea snail .
P-1863	-0.0132 -0.0046 -0.0130 -0.0082 -0.0113 -0.0005 -0.0034 -0.0105 -0.0011 -0.0017 -0.0004 -0.0036 -0.0016 -0.0018 -0.0029 -0.0014 -0.0142 -0.0136 -0.0048 -0.0098 -0.0020 -0.0006 -0.0051 -0.0017 -0.0529 -0.0145 -0.0143 -0.0029 -0.0141 -0.0009 -0.0461 -0.0056 -0.0065 -0.0003 -0.0018 -0.0037 -0.0144 -0.0013 -0.0110 -0.0027 -0.0014 -0.0901 -0.0015
S-1922	In den vier ursprünglichen gut kontrollierten Studien wurden die gesundheitsbezogene Lebensqualität und die körperliche Funktionsfähigkeit anhand des Index zur körperlichen Funktionseinschränkung ( Health Assessment Questionnaire , HAQ ) bewertet .
T-1922	Health @-@ related quality of life and physical function was assessed using the disability index of the Health Assessment Questionnaire ( HAQ ) in the four original adequate and well @-@ controlled trials , which was a pre @-@ specified primary endpoint at Week 52 in RA study III .
H-1922	-0.048665404319763184	Health @-@ related quality of life and physical function was assessed using the disability index of the Health Assessment Questionnaire ( HAQ ) in the four original adequate and well @-@ controlled trials .
D-1922	-0.048665404319763184	Health @-@ related quality of life and physical function was assessed using the disability index of the Health Assessment Questionnaire ( HAQ ) in the four original adequate and well @-@ controlled trials .
P-1922	-0.0145 -0.0050 -0.0015 -0.0032 -0.0017 -0.0017 -0.0015 -0.0076 -0.0118 -0.0138 -0.0064 -0.0008 -0.0188 -0.0025 -0.0145 -0.0046 -0.0313 -0.0118 -0.0130 -0.0011 -0.0009 -0.0006 -0.0008 -0.0005 -0.0003 -0.0286 -0.0013 -0.0014 -0.0012 -0.0014 -0.0038 -0.0041 -0.0023 -0.0087 -0.0145 -0.0144 -0.0079 -0.0223 -0.0081 -0.0455 -1.7070 -0.0014
S-1065	Nach Markteinführung wurden Fälle von anaphylaktischem Schock / anaphylaktoiden Reaktionen einschließlich Quincke @-@ Ödemen nach der intravitrealen Anwendung von Pegaptanib berichtet .
T-1065	Cases of anaphylaxis / anaphylactoid reactions , including angioedema , have been observed within several hours after the pegaptanib intravitreal administration procedure in the post @-@ marketing experience .
H-1065	-0.014573490247130394	Cases of anaphylaxis / anaphylactoid reactions , including angioedema , have been observed within several hours after the pegaptanib intravitreal administration procedure in the post @-@ marketing experience .
D-1065	-0.014573490247130394	Cases of anaphylaxis / anaphylactoid reactions , including angioedema , have been observed within several hours after the pegaptanib intravitreal administration procedure in the post @-@ marketing experience .
P-1065	-0.0119 -0.0012 -0.0016 -0.0016 -0.0009 -0.0005 -0.0010 -0.0152 -0.0144 -0.0029 -0.0009 -0.0005 -0.0010 -0.0785 -0.0010 -0.0009 -0.0124 -0.0007 -0.0114 -0.0102 -0.0145 -0.0145 -0.0141 -0.0015 -0.0004 -0.0130 -0.0117 -0.0016 -0.2553 -0.0356 -0.0144 -0.0145 -0.0748 -0.0117 -0.0145 -0.0012 -0.0008 -0.0013 -0.0006 -0.0016 -0.0088 -0.0008 -0.0010 -0.0007 -0.0137 -0.0155 -0.0160 -0.0113 -0.0145 -0.0065 -0.0141 -0.0145 -0.0017 -0.0014
S-677	Basierend auf der Analyse von gepoolten , Plazebo @-@ kontrollierten Studien mit insgesamt 1923 Patienten unter SIFROL und 1354 Patienten unter Plazebo , wurden Nebenwirkungen in beiden Gruppen häufig berichtet .
T-677	Based on the analysis of pooled placebo @-@ controlled trials , comprising a total of 1923 patients on SIFROL and 1354 patients on placebo , adverse drug reactions were frequently reported for both groups .
H-677	-0.012218090705573559	Based on the analysis of pooled placebo @-@ controlled trials , comprising a total of 1923 patients on SIFROL and 1354 patients on placebo , adverse drug reactions were frequently reported for both groups .
D-677	-0.012218090705573559	Based on the analysis of pooled placebo @-@ controlled trials , comprising a total of 1923 patients on SIFROL and 1354 patients on placebo , adverse drug reactions were frequently reported for both groups .
P-677	-0.0013 -0.0016 -0.0116 -0.0015 -0.0015 -0.0019 -0.0005 -0.0013 -0.0086 -0.0010 -0.0008 -0.0013 -0.0045 -0.0017 -0.0687 -0.0134 -0.0135 -0.0015 -0.0082 -0.0011 -0.0014 -0.0080 -0.0012 -0.0023 -0.0082 -0.0019 -0.0014 -0.0010 -0.0011 -0.0017 -0.0064 -0.0946 -0.0046 -0.0016 -0.0007 -0.0010 -0.0010 -0.0012 -0.0016 -0.0036 -0.0002 -0.1669 -0.0081 -0.0003 -0.0063 -0.0086 -0.0008 -0.1432 -0.0042 -0.0033 -0.0018 -0.0014
S-357	Veränderungen grenzwertiger Ausgangs @-@ Nüchtern @-@ Gesamtcholesterin @-@ Werte ( 4,39- &lt; 5,17 mmol / l ) zu hohen Werten ( 5,17 mmol / l ) waren sehr häufig .
T-357	Changes in total fasting cholesterol levels from borderline at baseline ( 4.39 - &lt; 5.17 mmol / l ) to high ( 5.17 mmol / l ) were very common .
H-357	-0.00392599031329155	Changes in total fasting cholesterol levels from borderline at baseline ( 4.39 - &lt; 5.17 mmol / l ) to high ( 5.17 mmol / l ) were very common .
D-357	-0.00392599031329155	Changes in total fasting cholesterol levels from borderline at baseline ( 4.39 - &lt; 5.17 mmol / l ) to high ( 5.17 mmol / l ) were very common .
P-357	-0.0043 -0.0005 -0.0012 -0.0084 -0.0110 -0.0127 -0.0018 -0.0020 -0.0005 -0.0007 -0.0133 -0.0136 -0.0133 -0.0006 -0.0004 -0.0139 -0.0144 -0.0006 -0.0037 -0.0029 -0.0080 -0.0103 -0.0007 -0.0007 -0.0011 -0.0011 -0.0014 -0.0013 -0.0010 -0.0009 -0.0014 -0.0038 -0.0015 -0.0016 -0.0033 -0.0087 -0.0009 -0.0012 -0.0011 -0.0012 -0.0008 -0.0014 -0.0011 -0.0014 -0.0031 -0.0040 -0.0066 -0.0016 -0.0014
S-851	Bei Patienten die Hydroxycarbamid in Kombination mit Didanosin , Stavudin und Indinavir erhielten , wurde ein mittlerer Rückgang der CD4 @-@ Zellen von etwa 100 / mm3 festgestellt .
T-851	Patients treated with hydroxycarbamide in combination with didanosine , stavudine , and indinavir showed a median decline in CD4 cells of approximately 100 / mm3 .
H-851	-0.02531038038432598	Patients treated with hydroxycarbamide in combination with didanosine , stavudine , and indinavir showed a median decline in CD4 cells of approximately 100 / mm3 .
D-851	-0.02531038038432598	Patients treated with hydroxycarbamide in combination with didanosine , stavudine , and indinavir showed a median decline in CD4 cells of approximately 100 / mm3 .
P-851	-0.0116 -0.0010 -0.0804 -0.0017 -0.0011 -0.0014 -0.0013 -0.0039 -0.0009 -0.0006 -0.0015 -0.0064 -0.0010 -0.0014 -0.0009 -0.0070 -0.0008 -0.0016 -0.0015 -0.0047 -0.0058 -0.0006 -0.0059 -0.9323 -0.0016 -0.0015 -0.0011 -0.0011 -0.0011 -0.0097 -0.0079 -0.0103 -0.0014 -0.0132 -0.0079 -0.0011 -0.0014 -0.0046 -0.0032 -0.0129 -0.0013 -0.0020 -0.0008 -0.0014 -0.0019 -0.0015
S-1903	In Ermangelung spezifischer klinischer Daten von Patienten mit beeinträchtigter Leber- oder Nierenfunktion wird die Anwendung von Diacomit bei Patienten mit beeinträchtigter Leber- und / oder Nierenfunktion nicht empfohlen .
T-1903	In the absence of specific clinical data in patients with impaired hepatic or renal function , Diacomit is not recommended for use in patients with impaired hepatic and / or renal function .
H-1903	-0.008757947012782097	In the absence of specific clinical data in patients with impaired hepatic or renal function , Diacomit is not recommended for use in patients with impaired hepatic and / or renal function .
D-1903	-0.008757947012782097	In the absence of specific clinical data in patients with impaired hepatic or renal function , Diacomit is not recommended for use in patients with impaired hepatic and / or renal function .
P-1903	-0.0052 -0.0026 -0.0014 -0.0013 -0.0030 -0.0010 -0.0017 -0.0138 -0.0054 -0.0018 -0.0502 -0.0005 -0.0126 -0.0029 -0.0010 -0.0318 -0.0040 -0.0013 -0.0017 -0.0036 -0.0144 -0.0011 -0.0144 -0.0071 -0.0051 -0.0016 -0.0018 -0.0289 -0.0865 -0.0023 -0.0574 -0.0017 -0.0019 -0.0005 -0.0043 -0.0016 -0.0008 -0.0024 -0.0016 -0.0012 -0.0045 -0.0013 -0.0019 -0.0017 -0.0014
S-989	Es gibt keine Erfahrungen in der Subgruppe der Patienten mit einem Körpergewicht über 100 kg und gleichzeitiger mittelgradiger Nierenfunktionseinschränkung ( Kreatinin @-@ Clearance 30 @-@ 50 ml / min ) .
T-989	There is no experience in the subgroup of patients with both high body weight ( &gt; 100 kg ) and moderate renal impairment ( creatinine clearance 30 @-@ 50 ml / min ) .
H-989	-0.017283489927649498	There is no experience in the subgroup of patients with both high body weight ( &gt; 100 kg ) and moderate renal impairment ( creatinine clearance 30 @-@ 50 ml / min ) .
D-989	-0.017283489927649498	There is no experience in the subgroup of patients with both high body weight ( &gt; 100 kg ) and moderate renal impairment ( creatinine clearance 30 @-@ 50 ml / min ) .
P-989	-0.0059 -0.0039 -0.0019 -0.0053 -0.0174 -0.0057 -0.0041 -0.0022 -0.0019 -0.0015 -0.0113 -0.0154 -0.0147 -0.0023 -0.0014 -0.0122 -0.0145 -0.0046 -0.0016 -0.0029 -0.0035 -0.0076 -0.0117 -0.0009 -0.0125 -0.0013 -0.0005 -0.0013 -0.0429 -0.0041 -0.0009 -0.0020 -0.0014 -0.0017 -0.0011 -0.0057 -0.3151 -0.2070 -0.0013 -0.0015 -0.0010 -0.0017 -0.0017 -0.0014
S-1725	Arzneimittel wie Cyclosporin , Mycophenolat @-@ Mofetil und Tacrolimus ( bei Organtransplantationen angewandte Medikamente ) können in ihrer Wirkung durch Renagel abgeschwächt werden .
T-1725	The effects of medicines such as ciclosporin , mycophenolate mofetil and tacrolimus ( medicines used in transplant patients ) may be reduced by Renagel .
H-1725	-0.02047714963555336	The effects of medicines such as ciclosporin , mycophenolate mofetil and tacrolimus ( medicines used in transplant patients ) may be reduced by Renagel .
D-1725	-0.02047714963555336	The effects of medicines such as ciclosporin , mycophenolate mofetil and tacrolimus ( medicines used in transplant patients ) may be reduced by Renagel .
P-1725	-0.0140 -0.0088 -0.0016 -0.0106 -0.0060 -0.0109 -0.0014 -0.0398 -0.0126 -0.0131 -0.0011 -0.0139 -0.0015 -0.0010 -0.0007 -0.0011 -0.0014 -0.0017 -0.0034 -0.0012 -0.0006 -0.5163 -0.0015 -0.0012 -0.0014 -0.0005 -0.0022 -0.0116 -0.0062 -0.0023 -0.0614 -0.0142 -0.0711 -0.0144 -0.0015 -0.0132 -0.0017 -0.0145 -0.0066 -0.0069 -0.0018 -0.0003 -0.0020 -0.0015
S-116	Bei gesunden Probanden wurde im Dosisbereich von 0,05 mg / kg bis 0,20 mg / kg Fasturtec eine deutliche dosisabhängige Abnahme der Harnsäureplasmaspiegel beobachtet .
T-116	In healthy volunteers , a marked dose @-@ related decrease in plasma uric acid levels was observed across the dose range 0.05 mg / kg to 0.20 mg / kg of Fasturtec .
H-116	-0.020257871598005295	In healthy volunteers , a marked dose @-@ related decrease in plasma uric acid levels was observed across the dose range 0.05 mg / kg to 0.20 mg / kg of Fasturtec .
D-116	-0.020257871598005295	In healthy volunteers , a marked dose @-@ related decrease in plasma uric acid levels was observed across the dose range 0.05 mg / kg to 0.20 mg / kg of Fasturtec .
P-116	-0.0059 -0.0023 -0.4903 -0.0083 -0.0047 -0.0140 -0.0045 -0.0036 -0.0143 -0.0052 -0.0009 -0.0065 -0.0145 -0.0003 -0.0008 -0.0131 -0.0010 -0.0012 -0.0028 -0.0038 -0.1832 -0.0155 -0.0047 -0.0054 -0.0026 -0.0141 -0.0014 -0.0008 -0.0014 -0.0008 -0.0176 -0.0014 -0.0015 -0.0006 -0.0015 -0.0006 -0.0123 -0.0004 -0.0018 -0.0009 -0.0012 -0.0018 -0.0014
S-727	HEXAVAC schützt nicht vor invasiven Erkrankungen , die durch andere Serotypen als Haemophilus influenzae Typ b ausgelöst werden , oder vor einer durch andere Erreger verursachten Meningitis .
T-727	HEXAVAC does not protect against invasive diseases due to serotypes other than Haemophilus influenzae type b or against meningitis of other origins .
H-727	-0.008013253100216389	HEXAVAC does not protect against invasive diseases due to serotypes other than Haemophilus influenzae type b or against meningitis of other origins .
D-727	-0.008013253100216389	HEXAVAC does not protect against invasive diseases due to serotypes other than Haemophilus influenzae type b or against meningitis of other origins .
P-727	-0.0011 -0.0010 -0.0013 -0.0012 -0.0010 -0.1728 -0.0013 -0.0036 -0.0026 -0.0012 -0.0007 -0.0008 -0.0040 -0.0160 -0.0014 -0.0028 -0.0017 -0.0012 -0.0034 -0.0016 -0.0076 -0.0016 -0.0014 -0.0006 -0.0011 -0.0011 -0.0006 -0.0017 -0.0033 -0.0095 -0.0069 -0.0136 -0.0053 -0.0013 -0.0008 -0.0007 -0.0171 -0.0057 -0.0150 -0.0174 -0.0018 -0.0016
S-1563	Obwohl Tierstudien keine teratogenen oder embryotoxischen Effekte gezeigt haben , liegen zu Sonata unzureichende klinische Daten vor , um die Sicherheit während der Schwangerschaft und Stillzeit zu beurteilen .
T-1563	Although animal studies have shown no teratogenic or embryotoxic effects , insufficient clinical data 5 are available on Sonata to assess its safety during pregnancy and breastfeeding .
H-1563	-0.020142653957009315	Although animal studies have shown no teratogenic or embryotoxic effects , insufficient clinical data 5 are available on Sonata to assess its safety during pregnancy and breastfeeding .
D-1563	-0.020142653957009315	Although animal studies have shown no teratogenic or embryotoxic effects , insufficient clinical data 5 are available on Sonata to assess its safety during pregnancy and breastfeeding .
P-1563	-0.0038 -0.0052 -0.0013 -0.0036 -0.0088 -0.0018 -0.0007 -0.0011 -0.0013 -0.0011 -0.0013 -0.0017 -0.0025 -0.0008 -0.1126 -0.0009 -0.0008 -0.0013 -0.0070 -0.0024 -0.0090 -0.0022 -0.0011 -0.0163 -0.0204 -0.0136 -0.0024 -0.0122 -0.0010 -0.0010 -0.0050 -0.0132 -0.0141 -0.0008 -0.0019 -0.0013 -0.0023 -0.5589 -0.0011 -0.0049 -0.0017 -0.0014
S-39	45 Wenn bei irgendeiner Indikation im Verlauf der Behandlung mit Viraferon Nebenwirkungen auftreten , ist eine Dosismodifikation vorzunehmen oder die Behandlung vorübergehend abzusetzen , bis sich die Nebenwirkungen wieder zurückgebildet haben .
T-39	42 If adverse events develop during the course of treatment with Viraferon for any indication , modify the dosage or discontinue therapy temporarily until the adverse events abate .
H-39	-0.016494017094373703	42 If adverse events develop during the course of treatment with Viraferon for any indication , modify the dosage or discontinue therapy temporarily until the adverse events abate .
D-39	-0.016494017094373703	42 If adverse events develop during the course of treatment with Viraferon for any indication , modify the dosage or discontinue therapy temporarily until the adverse events abate .
P-39	-0.0148 -0.0083 -0.0136 -0.0002 -0.0270 -0.0144 -0.0099 -0.2107 -0.0011 -0.0014 -0.1690 -0.0037 -0.0060 -0.0009 -0.0009 -0.0067 -0.0093 -0.0021 -0.0006 -0.0020 -0.0139 -0.0084 -0.0039 -0.0173 -0.0017 -0.0012 -0.0032 -0.0135 -0.0002 -0.0205 -0.0067 -0.0353 -0.0085 -0.0021 -0.0002 -0.0016 -0.0145 -0.0007 -0.0021 -0.0016
S-1739	Der primäre Endpunkt war die Kombination aus Schlaganfall , MI ( einschließlich akuter Herztod ) , Herzversagen oder Tod infolge einer anderen kardiovaskulären Ursache ( gemeinsamer Endpunkt ) .
T-1739	The primary end @-@ point was the combination of stroke , MI ( including sudden death ) , heart failure or death from any other cardiovascular cause ( composite end @-@ point ) .
H-1739	-0.013374486938118935	The primary end @-@ point was the combination of stroke , MI ( including sudden death ) , heart failure or death from any other cardiovascular cause ( composite end @-@ point ) .
D-1739	-0.013374486938118935	The primary end @-@ point was the combination of stroke , MI ( including sudden death ) , heart failure or death from any other cardiovascular cause ( composite end @-@ point ) .
P-1739	-0.0021 -0.0072 -0.0264 -0.0305 -0.0042 -0.0018 -0.0098 -0.0014 -0.0016 -0.0012 -0.0016 -0.0041 -0.0018 -0.0017 -0.1115 -0.0145 -0.0139 -0.0039 -0.0015 -0.0050 -0.0005 -0.1824 -0.0016 -0.0072 -0.0116 -0.0017 -0.0011 -0.0007 -0.0008 -0.0007 -0.0017 -0.0015 -0.0145 -0.0108 -0.0127 -0.0273 -0.0081 -0.0014 -0.0015 -0.0014
S-29	Bevor das Arzneimittel auf den Markt kommt , wird der Hersteller von Gliolan in allen Mitgliedstaaten Schulungen für Neurochirurgen einrichten , um sie über den sicheren und effizienten Einsatz des Arzneimittels während der Operation zu informieren .
T-29	Before the medicine is launched , the company that makes Gliolan will set up training courses in all Member States for brain surgeons to inform them about how to use the medicine safely and effectively during surgery .
H-29	-0.007463809102773666	Before the medicine is launched , the company that makes Gliolan will set up training courses in all Member States for brain surgeons to inform them about how to use the medicine safely and effectively during surgery .
D-29	-0.007463809102773666	Before the medicine is launched , the company that makes Gliolan will set up training courses in all Member States for brain surgeons to inform them about how to use the medicine safely and effectively during surgery .
P-29	-0.0037 -0.0070 -0.0108 -0.0077 -0.0271 -0.0104 -0.0037 -0.0145 -0.0123 -0.0113 -0.0070 -0.0010 -0.0015 -0.0018 -0.0084 -0.0037 -0.0036 -0.0078 -0.0342 -0.0026 -0.0028 -0.0012 -0.0303 -0.0145 -0.0015 -0.0004 -0.0011 -0.0060 -0.0094 -0.0008 -0.0012 -0.0103 -0.0132 -0.0091 -0.0035 -0.0072 -0.0081 -0.0028 -0.0015 -0.0128 -0.0027 -0.0048 -0.0015 -0.0014
S-1677	In der klinischen Phase 3 Studie war der Anteil der nicht @-@ CABG @-@ bedingten TIMI @-@ Major- oder TIMI @-@ Minor @-@ Blutungen für Patienten der beiden Gewichtsgruppen wie folgt :
T-1677	In the phase 3 clinical trial , non @-@ CABG @-@ related TIMI major or minor bleeding rates for patients in two weight groups were as follows :
H-1677	-0.005841061007231474	In the phase 3 clinical trial , non @-@ CABG @-@ related TIMI major or minor bleeding rates for patients in two weight groups were as follows :
D-1677	-0.005841061007231474	In the phase 3 clinical trial , non @-@ CABG @-@ related TIMI major or minor bleeding rates for patients in two weight groups were as follows :
P-1677	-0.0032 -0.0205 -0.0097 -0.0020 -0.0017 -0.0201 -0.0045 -0.0139 -0.0016 -0.0015 -0.0005 -0.0006 -0.0073 -0.0069 -0.0013 -0.0011 -0.0014 -0.0061 -0.0045 -0.0143 -0.0087 -0.0022 -0.0096 -0.0154 -0.0040 -0.0040 -0.0169 -0.0027 -0.0025 -0.0026 -0.0034 -0.0008 -0.0016 -0.0014
S-966	In einer pharmakokinetischen Populationsanalyse der Phase @-@ I- und Phase @-@ II @-@ Studiendaten hatte Alter keinen klinisch relevanten Einfluss auf die Pharmakokinetik von Sitagliptin .
T-966	Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data .
H-966	-0.006038771476596594	Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data .
D-966	-0.006038771476596594	Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data .
P-966	-0.0139 -0.0119 -0.0014 -0.0059 -0.0067 -0.0007 -0.0011 -0.0225 -0.0118 -0.0016 -0.0054 -0.0021 -0.0006 -0.0006 -0.0025 -0.0015 -0.0049 -0.0048 -0.0010 -0.0021 -0.0180 -0.0016 -0.0057 -0.0144 -0.0131 -0.0004 -0.0004 -0.0041 -0.0026 -0.0031 -0.0114 -0.0263 -0.0017 -0.0021 -0.0045 -0.0137 -0.0023 -0.0014
S-823	Da die Clearance von QUADRAMET schnell erfolgt , müssen 6 @-@ 12 Stunden nach der Verabreichung keine Vorsichtsmaßnahmen mehr wegen der mit dem Urin ausgeschiedenen Radioaktivität getroffen werden .
T-823	The clearance of QUADRAMET being rapid , the precautions relating to the excreted urinary radioactivity need not be taken after 6 @-@ 12 hours following administration .
H-823	-0.01989261619746685	The clearance of QUADRAMET being rapid , the precautions relating to the excreted urinary radioactivity need not be taken after 6 @-@ 12 hours following administration .
D-823	-0.01989261619746685	The clearance of QUADRAMET being rapid , the precautions relating to the excreted urinary radioactivity need not be taken after 6 @-@ 12 hours following administration .
P-823	-0.0147 -0.0110 -0.0011 -0.0027 -0.0032 -0.0011 -0.0009 -0.0013 -0.0009 -0.0006 -0.0145 -0.0121 -0.0057 -0.0139 -0.0142 -0.0005 -0.0070 -0.0144 -0.0014 -0.0093 -0.0127 -0.0013 -0.0990 -0.0114 -0.0149 -0.0080 -0.0018 -0.0120 -0.0038 -0.0019 -0.0033 -0.0143 -0.0037 -0.3466 -0.0012 -0.0010 -0.0237 -0.0162 -0.0867 -0.0014
S-401	Cetrotide 3 mg verhindert einen vorzeitigen Eisprung , der bei der Hormonbehandlung zur Stimulation der Eierstöcke unerwünscht ist , da sich nur reife Eizellen für die Befruchtung eignen .
T-401	Cetrotide 3 mg inhibits premature ovulation which is undesirable during hormone treatment for ovarian stimulation as only mature egg cells are suitable for fertilisation .
H-401	-0.0057349856942892075	Cetrotide 3 mg inhibits premature ovulation which is undesirable during hormone treatment for ovarian stimulation as only mature egg cells are suitable for fertilisation .
D-401	-0.0057349856942892075	Cetrotide 3 mg inhibits premature ovulation which is undesirable during hormone treatment for ovarian stimulation as only mature egg cells are suitable for fertilisation .
P-401	-0.0026 -0.0011 -0.0013 -0.0039 -0.0030 -0.0007 -0.0194 -0.0002 -0.0012 -0.0065 -0.0009 -0.0008 -0.0011 -0.0146 -0.0019 -0.0061 -0.0037 -0.0018 -0.0120 -0.0054 -0.0096 -0.0066 -0.0096 -0.0063 -0.0003 -0.0020 -0.0008 -0.0007 -0.0388 -0.0013 -0.0005 -0.0136 -0.0019 -0.0032 -0.0027 -0.0283 -0.0025 -0.0093 -0.0017 -0.0015
S-980	3 WIE SIND DOXAGAMMA &#91; UND ANDERE BEZEICHNUNGEN &#93; 4 MG RETARDTABLETTEN EINZUNEHMEN ?
T-980	3 HOW TO TAKE DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
H-980	-0.026279859244823456	3 HOW TO TAKE DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
D-980	-0.026279859244823456	3 HOW TO TAKE DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
P-980	-0.0213 -0.0027 -0.0006 -0.0140 -0.0140 -0.0041 -0.0004 -0.0042 -0.0012 -0.0015 -0.0007 -0.0009 -0.0149 -0.0039 -0.0012 -0.0143 -0.0135 -0.0146 -0.0145 -0.0145 -0.0111 -0.3967 -0.0145 -0.0028 -0.0060 -0.1843 -0.0003 -0.0009 -0.0142 -0.0891 -0.0145 -0.0129 -0.0006 -0.0007 -0.0000 -0.0140 -0.0148 -0.0139 -0.0055 -0.0972
S-321	In Fällen mit einer mittelgradigen Leberinsuffizienz ( Zirrhose , Child @-@ Pugh Klasse A oder B ) , sollte die Anfangsdosis 150 mg / 4 Wochen betragen und nur mit Vorsicht erhöht werden .
T-321	In cases of moderate hepatic insufficiency ( cirrhosis , Child- Pugh Class A or B ) , the starting dose should be 150 mg every 4 weeks and only increased with caution .
H-321	-0.014642806723713875	In cases of moderate hepatic insufficiency ( cirrhosis , Child- Pugh Class A or B ) , the starting dose should be 150 mg every 4 weeks and only increased with caution .
D-321	-0.014642806723713875	In cases of moderate hepatic insufficiency ( cirrhosis , Child- Pugh Class A or B ) , the starting dose should be 150 mg every 4 weeks and only increased with caution .
P-321	-0.0053 -0.0042 -0.0084 -0.0037 -0.0126 -0.0011 -0.0012 -0.0098 -0.0005 -0.0009 -0.0012 -0.0016 -0.0018 -0.0007 -0.0004 -0.0007 -0.0018 -0.0144 -0.0063 -0.0117 -0.0007 -0.0005 -0.0069 -0.0014 -0.0440 -0.0011 -0.0017 -0.0046 -0.0026 -0.0342 -0.0041 -0.0046 -0.0197 -0.0024 -0.0006 -0.3817 -0.0051 -0.0011 -0.0200 -0.0133 -0.0101 -0.0054 -0.0019 -0.0016 -0.0014
S-1117	Bei der Behandlung einer HIV @-@ Infektion kann man nicht immer mit Sicherheit sagen , ob die auftretende Nebenwirkung durch Trizivir oder ein gleichzeitig eingenommenes anderes Arzneimittel oder durch die HIV @-@ Erkrankung selbst verursacht wird .
T-1117	When treating HIV infection , it is not always possible to tell whether some of the side effects that occur are caused by Trizivir , by other medicines you are taking at the same time or by the HIV disease .
H-1117	-0.01375765260308981	When treating HIV infection , it is not always possible to tell whether some of the side effects that occur are caused by Trizivir , by other medicines you are taking at the same time or by the HIV disease .
D-1117	-0.01375765260308981	When treating HIV infection , it is not always possible to tell whether some of the side effects that occur are caused by Trizivir , by other medicines you are taking at the same time or by the HIV disease .
P-1117	-0.0084 -0.0029 -0.0066 -0.0087 -0.0050 -0.0053 -0.0034 -0.0024 -0.0026 -0.0066 -0.0014 -0.0115 -0.0144 -0.0145 -0.0131 -0.0335 -0.0030 -0.0034 -0.0137 -0.0073 -0.0030 -0.0030 -0.0015 -0.0145 -0.0103 -0.0014 -0.0007 -0.0248 -0.0146 -0.0129 -0.0100 -0.2370 -0.0145 -0.0118 -0.0039 -0.0068 -0.0019 -0.0013 -0.0015 -0.0482 -0.0020 -0.0090 -0.0034 -0.0114 -0.0143 -0.0014
S-1708	se Studie ( nach 3 oder 12 Wochen ) mithilfe des so genannten mEASI @-@ Bewertungssystems ( modified Excema Area and Severity Index , ein Bewertungssystem für den Schweregrad und die Ausbreitung
T-1708	ed Protopy was significantly more effective than either of the 2 hydrocortisone preparations at producing improvements in the modified Eczema Area and Severity Index , although it also produced more burning than hydrocortisone .
H-1708	-0.010293765924870968	ed Protopy was significantly more effective than either of the 2 hydrocortisone preparations at producing improvements in the modified Eczema Area and Severity Index , although it also produced more burning than hydrocortisone .
D-1708	-0.010293765924870968	ed Protopy was significantly more effective than either of the 2 hydrocortisone preparations at producing improvements in the modified Eczema Area and Severity Index , although it also produced more burning than hydrocortisone .
P-1708	-0.0145 -0.0145 -0.0145 -0.0145 -0.0144 -0.0145 -0.0139 -0.0091 -0.0123 -0.0150 -0.0140 -0.0075 -0.0145 -0.0145 -0.0141 -0.0093 -0.0054 -0.0145 -0.0046 -0.0144 -0.0145 -0.0146 -0.0058 -0.0107 -0.0145 -0.0012 -0.0143 -0.0145 -0.0006 -0.0045 -0.0015 -0.0004 -0.0012 -0.0013 -0.0137 -0.0145 -0.0132 -0.0148 -0.0147 -0.0137 -0.0145 -0.0141 -0.0146 -0.0018 -0.0014 -0.0012 -0.0099 -0.0027
S-1642	United Kingdom Daiichi Sankyo UK Ltd Chiltern Place , Chalfont Park Gerrards Cross Buckinghamshire , SL9 0BG Tel : + 44 ( 0 ) 1753 893 600
T-1642	United Kingdom Daiichi Sankyo UK Ltd Chiltern Place , Chalfont Park Gerrards Cross Buckinghamshire , SL9 0BG Tel : + 44 ( 0 ) 1753 893 600
H-1642	-0.0017086586449295282	United Kingdom Daiichi Sankyo UK Ltd Chiltern Place , Chalfont Park Gerrards Cross Buckinghamshire , SL9 0BG Tel : + 44 ( 0 ) 1753 893 600
D-1642	-0.0017086586449295282	United Kingdom Daiichi Sankyo UK Ltd Chiltern Place , Chalfont Park Gerrards Cross Buckinghamshire , SL9 0BG Tel : + 44 ( 0 ) 1753 893 600
P-1642	-0.0012 -0.0004 -0.0008 -0.0230 -0.0005 -0.0013 -0.0005 -0.0015 -0.0005 -0.0009 -0.0005 -0.0005 -0.0006 -0.0008 -0.0014 -0.0008 -0.0013 -0.0003 -0.0009 -0.0010 -0.0095 -0.0009 -0.0010 -0.0002 -0.0011 -0.0008 -0.0010 -0.0006 -0.0016 -0.0017 -0.0013 -0.0014 -0.0013 -0.0012 -0.0009 -0.0039 -0.0015 -0.0011 -0.0006 -0.0014 -0.0011 -0.0014 -0.0010 -0.0007 -0.0011 -0.0022 -0.0009 -0.0019
S-1050	EU / 1 / 98 / 085 / 016 @-@ 020 EU / 1 / 98 / 085 / 022 EU / 1 / 98 / 085 / 030 EU / 1 / 98 / 085 / 033
T-1050	EU / 1 / 98 / 085 / 016 @-@ 020 EU / 1 / 98 / 085 / 022 EU / 1 / 98 / 085 / 030 EU / 1 / 98 / 085 / 033
H-1050	-0.007439565844833851	EU / 1 / 98 / 085 / 016 @-@ 020 EU / 1 / 98 / 085 / 022 EU / 1 / 98 / 085 / 030 EU / 1 / 98 / 085 / 033
D-1050	-0.007439565844833851	EU / 1 / 98 / 085 / 016 @-@ 020 EU / 1 / 98 / 085 / 022 EU / 1 / 98 / 085 / 030 EU / 1 / 98 / 085 / 033
P-1050	-0.0016 -0.0015 -0.0013 -0.0014 -0.0008 -0.0014 -0.0015 -0.0008 -0.0014 -0.0010 -0.0011 -0.0014 -0.0011 -0.0013 -0.2986 -0.0015 -0.0013 -0.0014 -0.0007 -0.0014 -0.0012 -0.0007 -0.0014 -0.0011 -0.0012 -0.0013 -0.0015 -0.0013 -0.0014 -0.0007 -0.0014 -0.0012 -0.0006 -0.0014 -0.0013 -0.0014 -0.0016 -0.0015 -0.0013 -0.0014 -0.0007 -0.0015 -0.0012 -0.0008 -0.0014 -0.0011 -0.0011 -0.0014
S-911	Detaillierte Anwendungshinweise für den subkutanen Gebrauch des Produktes werden mit der Gebrauchsinformation ( Abschnitt &quot; Wie Sie Viraferon selbst injizieren &quot; ) bereitgestellt. eim
T-911	The solution should be clear and colourless. lon Detailed instructions for the subcutaneous use of the product are provided with the package leaflet ( refer to <<unk>> How to self inject Viraferon <<unk>> ) .
H-911	-0.006545098032802343	The solution should be clear and colourless. lon Detailed instructions for the subcutaneous use of the product are provided with the package leaflet ( refer to <unk> How to self inject Viraferon <unk> ) .
D-911	-0.006545098032802343	The solution should be clear and colourless. lon Detailed instructions for the subcutaneous use of the product are provided with the package leaflet ( refer to <unk> How to self inject Viraferon <unk> ) .
P-911	-0.0146 -0.0145 -0.0142 -0.0050 -0.0146 -0.0107 -0.0145 -0.0007 -0.0145 -0.0025 -0.0145 -0.0024 -0.0005 -0.0063 -0.0035 -0.0131 -0.0082 -0.0005 -0.0005 -0.0013 -0.0014 -0.0023 -0.0016 -0.0033 -0.0018 -0.0028 -0.0045 -0.0084 -0.0032 -0.0145 -0.0145 -0.0003 -0.0019 -0.0034 -0.0147 -0.0016 -0.0150 -0.0071 -0.0046 -0.0140 -0.0108 -0.0005 -0.0061 -0.0010 -0.0010 -0.0066 -0.0145 -0.0034 -0.0037 -0.0021
S-1419	Die Daten weisen darauf hin , dass Lamotrigin nicht die Pharmakokinetik von Levetiracetam und Levetiracetam nicht die Pharmakokinetik von Lamotrigin beeinflusst .
T-1419	These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine .
H-1419	-0.0055292812176048756	These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine .
D-1419	-0.0055292812176048756	These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine .
P-1419	-0.0143 -0.0024 -0.0061 -0.0018 -0.0057 -0.0012 -0.0006 -0.0012 -0.0095 -0.0013 -0.0720 -0.0031 -0.0013 -0.0006 -0.0008 -0.0012 -0.0015 -0.0047 -0.0004 -0.0010 -0.0003 -0.0009 -0.0013 -0.0042 -0.0454 -0.0383 -0.0006 -0.0011 -0.0003 -0.0008 -0.0017 -0.0030 -0.0014 -0.0102 -0.0021 -0.0007 -0.0010 -0.0006 -0.0008 -0.0014 -0.0018 -0.0010 -0.0006 -0.0012 -0.0015 -0.0014
S-429	Arzneimittel mit Sulfonamidabkömmlingen ( Arzneimittel zur Behandlung von Atemwegs- oder Harnwegsinfektionen ) oder einen der sonstigen Bestandteile von Rasilez HCT sind .
T-429	medicines ( medicines used to treat chest or urinary infections ) or to any of the other ingredients of Rasilez HCT .
H-429	-0.01236774493008852	medicines ( medicines used to treat chest or urinary infections ) or to any of the other ingredients of Rasilez HCT .
D-429	-0.01236774493008852	medicines ( medicines used to treat chest or urinary infections ) or to any of the other ingredients of Rasilez HCT .
P-429	-0.0046 -0.0205 -0.0146 -0.0015 -0.0049 -0.0101 -0.1895 -0.0005 -0.0145 -0.0081 -0.0010 -0.0007 -0.0243 -0.0006 -0.0017 -0.0035 -0.0148 -0.0132 -0.0053 -0.0018 -0.0163 -0.0120 -0.0186 -0.0019 -0.0012 -0.0010 -0.0009 -0.0013 -0.0013 -0.0012 -0.0026 -0.0016
S-598	Die folgenden Informationen basieren auf 2 klinischen Studien , TT01 und TT02 , in denen Savene Patienten gegeben wurde , bei denen es zu einer Extravasation kam und die bereits Chemotherapiezyklen erhielten .
T-598	The following information is based on two clinical studies , TT01 and TT02 , of Savene administered to extravasation patients already receiving cycles of chemotherapeutic agents .
H-598	-0.048246853053569794	The following information is based on two clinical studies , TT01 and TT02 , of Savene administered to extravasation patients already receiving cycles of chemotherapeutic agents .
D-598	-0.048246853053569794	The following information is based on two clinical studies , TT01 and TT02 , of Savene administered to extravasation patients already receiving cycles of chemotherapeutic agents .
P-598	-0.0031 -0.0039 -0.0023 -0.0023 -0.0018 -0.0018 -0.0085 -0.0016 -0.8162 -0.0039 -0.0009 -0.0011 -0.0018 -0.0007 -0.0010 -0.0028 -0.0146 -0.0024 -0.0005 -0.0145 -0.0024 -0.0038 -0.0143 -0.0078 -0.0018 -0.0121 -0.0021 -0.0156 -0.0059 -0.0096 -0.0005 -0.0014 -0.0056 -0.0006 -0.8897 -0.0049 -0.0140 -0.0023 -0.0015
S-1639	Bei Patienten mit symptomatischer Herzinsuffizienz kann ein , durch den Beginn einer Therapie mit ACE @-@ Hemmern ausgelöster , Blutdruckabfall zu einer weiteren Verschlechterung der Nierenfunktion führen .
T-1639	In patients with symptomatic heart failure , hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function .
H-1639	-0.032895416021347046	In patients with symptomatic heart failure , hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function .
D-1639	-0.032895416021347046	In patients with symptomatic heart failure , hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function .
P-1639	-0.0059 -0.0012 -0.1442 -0.0017 -0.0008 -0.0009 -0.0126 -0.0016 -0.0039 -0.0145 -0.0012 -0.0008 -0.0030 -0.0145 -0.0071 -0.0124 -0.0014 -0.0014 -0.0116 -0.0016 -0.0025 -0.4354 -0.0058 -0.0006 -0.0006 -0.0014 -0.0502 -0.0267 -0.0015 -0.0150 -0.0061 -0.0156 -0.0021 -0.0005 -0.0013 -0.5250 -0.0103 -0.0012 -0.0016 -0.0016 -0.0015
S-1993	Sowohl Emtricitabin als auch Tenofovir wirken spezifisch gegen das humane Immundefizienzvirus ( HIV @-@ 1 und HIV @-@ 2 ) sowie gegen das Hepatitis @-@ B @-@ Virus .
T-1993	Both emtricitabine and tenofovir have activity that is specific to human immunodeficiency virus ( HIV @-@ 1 and HIV @-@ 2 ) and hepatitis B virus .
H-1993	-0.023349210619926453	Both emtricitabine and tenofovir have activity that is specific to human immunodeficiency virus ( HIV @-@ 1 and HIV @-@ 2 ) and hepatitis B virus .
D-1993	-0.023349210619926453	Both emtricitabine and tenofovir have activity that is specific to human immunodeficiency virus ( HIV @-@ 1 and HIV @-@ 2 ) and hepatitis B virus .
P-1993	-0.0034 -0.0041 -0.0010 -0.0005 -0.0010 -0.0010 -0.0869 -0.0012 -0.0012 -0.0010 -0.0781 -0.0013 -0.0118 -0.0145 -0.0138 -0.0038 -0.0034 -0.0348 -0.0102 -0.0026 -0.0023 -0.0009 -0.0005 -0.0011 -0.0093 -0.0023 -0.0008 -0.1744 -0.0014 -0.0018 -0.0007 -0.2716 -0.1814 -0.0014 -0.0379 -0.0067 -0.0003 -0.0008 -0.0036 -0.0019 -0.0025 -0.0014
S-566	In kontrollierten klinischen Studien waren Veränderungen der Laborwerte im Zusammenhang mit der Ziagen @-@ Behandlung selten , wobei keine Unterschiede in den Inzidenzen zwischen den mit Ziagen behandelten Patienten und den Kontrollgruppen beobachtet wurden .
T-566	Laboratory abnormalities In controlled clinical studies laboratory abnormalities related to Ziagen treatment were uncommon , with no differences in incidence observed between Ziagen treated patients and the control arms .
H-566	-0.06120039150118828	Laboratory abnormalities In controlled clinical studies laboratory abnormalities related to Ziagen treatment were uncommon , with no differences in incidence observed between Ziagen treated patients and the control arms .
D-566	-0.06120039150118828	Laboratory abnormalities In controlled clinical studies laboratory abnormalities related to Ziagen treatment were uncommon , with no differences in incidence observed between Ziagen treated patients and the control arms .
P-566	-0.0143 -0.0008 -0.0144 -0.0022 -0.0004 -0.0013 -0.6793 -0.0015 -0.0013 -0.7498 -0.0143 -0.0010 -0.0082 -0.0007 -0.0002 -0.0013 -0.7834 -0.0015 -0.0116 -0.0015 -0.0056 -0.0043 -0.0152 -0.0010 -0.0209 -0.0086 -0.0015 -0.0081 -0.0061 -0.0011 -0.1731 -0.0103 -0.0179 -0.0118 -0.0012 -0.0177 -0.0014 -0.0015 -0.0120 -0.0015 -0.0189 -0.0017 -0.0015
S-1731	In Tierexperimenten , in denen die Exposition mit Entacapon deutlich höher war als die therapeutische Exposition , wurden keine offenkundigen teratogenen oder primär fetotoxischen Wirkungen festgestellt .
T-1731	No overt teratogenic or primary foetotoxic effects were observed in animal studies in which the exposure levels of entacapone were markedly higher than the therapeutic exposure levels .
H-1731	-0.0159048642963171	No overt teratogenic or primary foetotoxic effects were observed in animal studies in which the exposure levels of entacapone were markedly higher than the therapeutic exposure levels .
D-1731	-0.0159048642963171	No overt teratogenic or primary foetotoxic effects were observed in animal studies in which the exposure levels of entacapone were markedly higher than the therapeutic exposure levels .
P-1731	-0.0114 -0.0140 -0.0008 -0.0005 -0.0011 -0.0015 -0.0008 -0.0011 -0.0016 -0.0029 -0.0142 -0.0001 -0.0010 -0.0005 -0.0015 -0.0044 -0.0051 -0.1337 -0.0445 -0.0026 -0.0140 -0.0090 -0.0011 -0.0131 -0.0019 -0.0185 -0.0131 -0.0017 -0.0012 -0.0007 -0.3255 -0.0018 -0.0155 -0.0004 -0.0009 -0.0026 -0.0016 -0.0104 -0.0013 -0.0015 -0.0033 -0.0143 -0.0015 -0.0014
S-380	Neuere Untersuchungsergebnisse lassen den Schluss zu , dass der Östrogenrezeptor die Genexpression über mindestens zwei verschiedenartige Wege reguliert , die liganden- , gewebs- und / oder genspezifisch sind .
T-380	Recent data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand- , tissue- , and / or gene @-@ specific .
H-380	-0.011766397394239902	Recent data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand- , tissue- , and / or gene @-@ specific .
D-380	-0.011766397394239902	Recent data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand- , tissue- , and / or gene @-@ specific .
P-380	-0.0052 -0.0013 -0.0144 -0.0133 -0.0021 -0.0043 -0.0114 -0.0009 -0.0006 -0.0008 -0.0013 -0.0009 -0.0016 -0.0144 -0.0032 -0.0011 -0.0012 -0.0010 -0.0125 -0.0037 -0.0012 -0.0072 -0.0129 -0.0012 -0.0052 -0.0010 -0.0137 -0.0019 -0.0023 -0.0134 -0.0014 -0.0014 -0.0084 -0.0022 -0.0007 -0.0013 -0.3194 -0.0078 -0.0015 -0.0013 -0.0009 -0.0162 -0.0086 -0.0016 -0.0014
S-1319	Wie andere zytotoxische Arzneimittel kann Topotecan fetale Schäden verursachen , daher soll Frauen im gebärfähigen Alter angeraten werden , eine Schwangerschaft während der Behandlung mit Topotecan zu vermeiden .
T-1319	As with other cytotoxic medicinal products , topotecan may cause foetal harm and therefore women of child bearing potential should be advised to avoid becoming pregnant during therapy with topotecan .
H-1319	-0.021209586411714554	As with other cytotoxic medicines , topotecan may cause foetal harm and therefore women of child bearing potential should be advised to avoid becoming pregnant during therapy with topotecan .
D-1319	-0.021209586411714554	As with other cytotoxic medicines , topotecan may cause foetal harm and therefore women of child bearing potential should be advised to avoid becoming pregnant during therapy with topotecan .
P-1319	-0.0132 -0.0073 -0.0024 -0.0013 -0.0014 -0.0004 -0.0007 -0.0015 -0.0435 -0.4460 -0.0025 -0.0053 -0.0015 -0.0013 -0.0013 -0.0872 -0.0110 -0.0128 -0.0005 -0.0011 -0.0132 -0.0714 -0.0156 -0.0048 -0.0018 -0.0421 -0.0126 -0.0148 -0.0086 -0.0048 -0.0010 -0.0037 -0.0015 -0.0133 -0.0007 -0.0562 -0.0144 -0.0022 -0.0018 -0.0014 -0.0011 -0.0012 -0.0016 -0.0014
S-151	Wenn die Aufnahme von Nahrung und Getränken unmöglich wird , oder wiederholtes Erbrechen erfolgt , müssen die Patienten angewiesen werden , in die Klinik zur Beurteilung zurückzukehren , und falls nötig , intravenöse Flüssigkeit erhalten .
T-151	If intake of food and / or drink becomes impossible or repeated vomiting occurs , patients should be advised to return to the clinic for evaluation and to receive intravenous fluids if needed .
H-151	-0.03571136295795441	If intake of food and / or drink becomes impossible or repeated vomiting occurs , patients should be advised to return to the clinic for evaluation and to receive intravenous fluids if needed .
D-151	-0.03571136295795441	If intake of food and / or drink becomes impossible or repeated vomiting occurs , patients should be advised to return to the clinic for evaluation and to receive intravenous fluids if needed .
P-151	-0.0054 -0.0118 -0.0083 -0.0033 -0.0019 -0.0036 -0.6577 -0.0011 -0.5775 -0.0028 -0.0024 -0.0860 -0.0124 -0.0029 -0.0003 -0.0013 -0.0028 -0.0008 -0.0017 -0.0098 -0.0142 -0.0018 -0.0138 -0.0014 -0.0014 -0.0096 -0.0034 -0.0028 -0.0039 -0.0093 -0.0008 -0.0008 -0.0464 -0.0140 -0.0079 -0.0055 -0.0011 -0.0005 -0.0013 -0.0007 -0.0298 -0.0146 -0.0250 -0.0015 -0.0015
S-225	Müdigkeit , Fieber , Lethargie , peripheres Ödem , Rigor , Sturz , Brustschmerz , Kältegefühl , Schmerz , ängstliche Nervosität , Schmerz verschlimmert
T-225	Common : fatigue , pyrexia , lethargy , oedema peripheral , rigors , fall , chest pain , feeling cold , pain , feeling jittery , pain exacerbated
H-225	-0.006324059795588255	Common : fatigue , pyrexia , lethargy , oedema peripheral , rigors , fall , chest pain , feeling cold , pain , feeling jittery , pain exacerbated
D-225	-0.006324059795588255	Common : fatigue , pyrexia , lethargy , oedema peripheral , rigors , fall , chest pain , feeling cold , pain , feeling jittery , pain exacerbated
P-225	-0.0145 -0.0019 -0.0130 -0.0142 -0.0012 -0.0006 -0.0017 -0.0510 -0.0049 -0.0120 -0.0003 -0.0016 -0.0017 -0.0010 -0.0017 -0.0011 -0.0015 -0.0164 -0.0006 -0.0002 -0.0142 -0.0009 -0.0073 -0.0033 -0.0105 -0.0144 -0.0016 -0.0065 -0.0017 -0.0017 -0.0034 -0.0015 -0.0133 -0.0020 -0.0016 -0.0032 -0.0017 -0.0145 -0.0145 -0.0011 -0.0004 -0.0051 -0.0123 -0.0141 -0.0005 -0.0020 -0.0025
S-1668	Dies zeigte sich in einer statistisch signifikanten Verbesserung sowohl des IBDQ ( ein krankheitsspezifisches Maß ) als auch des 36- Punkte @-@ Kurzform @-@ Fragebogens ( generischer SF @-@ 36 ) .
T-1668	In ACT 1 and ACT 2 , infliximab improved quality of life , confirmed by statistically significant improvement in both a disease specific measure , IBDQ , and by improvement in the generic 36 @-@ item short form survey SF @-@ 36 .
H-1668	-0.019464584067463875	In ACT 1 and ACT 2 , infliximab improved quality of life , confirmed by statistically significant improvement in both a disease specific measure , IBDQ , and by improvement in the generic 36 @-@ item short form survey SF @-@ 36 .
D-1668	-0.019464584067463875	In ACT 1 and ACT 2 , infliximab improved quality of life , confirmed by statistically significant improvement in both a disease specific measure , IBDQ , and by improvement in the generic 36 @-@ item short form survey SF @-@ 36 .
P-1668	-0.0221 -0.0162 -0.0200 -0.2802 -0.0145 -0.0155 -0.2275 -0.0145 -0.0148 -0.0145 -0.0027 -0.0144 -0.0145 -0.0074 -0.0106 -0.0129 -0.0145 -0.0142 -0.0108 -0.0118 -0.0014 -0.0011 -0.0064 -0.0083 -0.0092 -0.0214 -0.0074 -0.0119 -0.0073 -0.0140 -0.0079 -0.0011 -0.0010 -0.0047 -0.0025 -0.0173 -0.0156 -0.0045 -0.0125 -0.0147 -0.0009 -0.0146 -0.0048 -0.0142 -0.0103 -0.0073 -0.0145 -0.0143 -0.0016 -0.0024 -0.0021 -0.0014
S-1242	Ihr Arzt wird Ihnen Piroxicam nur dann verschreiben , wenn andere nicht @-@ steroidale Antirheumatika ( NSAR ) keine zufriedenstellende Linderung der Beschwerden mit sich gebracht haben .
T-1242	Your doctor will prescribe piroxicam to you only when you have had unsatisfactory relief of symptoms with other non @-@ steroidal anti @-@ inflammatory medicines ( NSAIDs ) . <<unk>> <<unk>> . &#91; &#93; <<unk>>
H-1242	-0.013350807130336761	Your doctor will prescribe piroxicam to you only when you have had unsatisfactory relief of symptoms with other non @-@ steroidal anti @-@ inflammatory medicines ( NSAIDs ) .
D-1242	-0.013350807130336761	Your doctor will prescribe piroxicam to you only when you have had unsatisfactory relief of symptoms with other non @-@ steroidal anti @-@ inflammatory medicines ( NSAIDs ) .
P-1242	-0.0027 -0.0025 -0.0020 -0.0132 -0.0010 -0.0132 -0.0010 -0.0009 -0.0006 -0.0011 -0.0344 -0.0016 -0.0232 -0.0259 -0.0157 -0.0096 -0.0136 -0.0141 -0.0020 -0.0006 -0.0072 -0.0155 -0.0102 -0.0144 -0.0042 -0.0032 -0.0015 -0.0004 -0.0018 -0.0009 -0.0006 -0.0039 -0.0015 -0.0063 -0.0009 -0.0006 -0.0032 -0.0126 -0.0103 -0.0019 -0.0002 -0.0003 -0.0011 -0.0014 -0.0017 -0.3294
S-739	56 Tabletten 98 Tabletten 84 Tabletten 84 Tabletten 30 Tabletten 90 Tabletten 30 Tabletten 90 Tabletten 14 Tabletten 28 Tabletten 28 x 1 Tablette
T-739	14 tablets 28 tablets 28 x 1 tablets 56 tablets 98 tablets 14 tablets 28 tablets 28 x 1 tablets 56 tablets 98 tablets 84 tablets 84 tablets 30 tablets 90 tablets 30 tablets 90 tablets 14 tablets 28 tablets 28 x 1 tablets 30 tablets 56 tablets 90 tablets 98 tablets
H-739	-0.2064531147480011	14 tablets 28 tablets 28 x 1 tablets 56 tablets 98 tablets 14 tablets 28 tablets 28 x 1 tablets 56 tablets 98 tablets 84 tablets 84 tablets 30 tablets 90 tablets 30 tablets 90 tablets 14 tablets 28 tablets 28 x 1 tablets 30 tablets 56 tablets
D-739	-0.2064531147480011	14 tablets 28 tablets 28 x 1 tablets 56 tablets 98 tablets 14 tablets 28 tablets 28 x 1 tablets 56 tablets 98 tablets 84 tablets 84 tablets 30 tablets 90 tablets 30 tablets 90 tablets 14 tablets 28 tablets 28 x 1 tablets 30 tablets 56 tablets
P-739	-0.0161 -0.0025 -0.0102 -0.0343 -0.0037 -0.0119 -0.0246 -0.3994 -0.0014 -0.0014 -0.0085 -0.0604 -0.0012 -0.0108 -0.0064 -0.0014 -0.0117 -0.0159 -0.0021 -0.0124 -0.0098 -0.4127 -0.0110 -0.0140 -0.4044 -0.0014 -0.0018 -0.0091 -0.0371 -0.0019 -0.0115 -0.0438 -0.0018 -0.0121 -0.0175 -0.0017 -0.0121 -1.0458 -0.0018 -0.0117 -1.0708 -0.0016 -0.0099 -0.9124 -0.0018 -0.0102 -1.0631 -0.0021 -0.0115 -1.1181 -0.0031 -0.0107 -1.1811 -0.0030 -0.0127 -0.7430 -0.6838 -0.0126 -0.4471 -0.6281 -0.0021 -0.0019 -0.0104 -0.3991 -0.0043 -0.0103 -1.1804 -0.0088 -0.0097 -2.1987
S-939	Der behandelnde Arzt soll den Patienten untersuchen , um entscheiden zu können , ob die Symptome auf eine neurologische Dysfunktion hinweisen , und falls ja , ob diese Symptome möglicherweise eine PML andeuten können .
T-939	The clinician should evaluate the patient to determine if the symptoms are indicative of neurological dysfunction , and if so , whether these symptoms are possibly suggestive of PML .
H-939	-0.01637178286910057	The clinician should evaluate the patient to determine if the symptoms are indicative of neurological dysfunction , and if so , whether these symptoms are possibly suggestive of PML .
D-939	-0.01637178286910057	The clinician should evaluate the patient to determine if the symptoms are indicative of neurological dysfunction , and if so , whether these symptoms are possibly suggestive of PML .
P-939	-0.0045 -0.0144 -0.0004 -0.0011 -0.0071 -0.0143 -0.0012 -0.0024 -0.0011 -0.0114 -0.0074 -0.0670 -0.0068 -0.0015 -0.0131 -0.0022 -0.0020 -0.0299 -0.0018 -0.1159 -0.0010 -0.0011 -0.2021 -0.0080 -0.0057 -0.0032 -0.0088 -0.0132 -0.0091 -0.0015 -0.0146 -0.0130 -0.0154 -0.0016 -0.0291 -0.0010 -0.0013 -0.0018 -0.0016
S-1411	Bei depressiven Patienten erhöhte Thymanax 25 mg den &quot; Slow Wave Sleep &quot; ohne den REM ( Rapid Eye Movement ) -Schlafanteil oder die REM @-@ Latenz zu verändern .
T-1411	In depressed patients , treatment with Thymanax 25 mg increased slow wave sleep without modification of REM ( Rapid Eye Movement ) sleep amount or REM latency .
H-1411	-0.01624237932264805	In depressed patients , treatment with Thymanax 25 mg increased slow wave sleep without modification of REM ( Rapid Eye Movement ) sleep amount or REM latency .
D-1411	-0.01624237932264805	In depressed patients , treatment with Thymanax 25 mg increased slow wave sleep without modification of REM ( Rapid Eye Movement ) sleep amount or REM latency .
P-1411	-0.0052 -0.0012 -0.0011 -0.0016 -0.0076 -0.1017 -0.0029 -0.1384 -0.0014 -0.0033 -0.0005 -0.0036 -0.0006 -0.0053 -0.0134 -0.0031 -0.0023 -0.0048 -0.0172 -0.0170 -0.2515 -0.0059 -0.0011 -0.0039 -0.0031 -0.0012 -0.0012 -0.0008 -0.0009 -0.0014 -0.0025 -0.0145 -0.0024 -0.0044 -0.0011 -0.0012 -0.0008 -0.0019 -0.0014
S-1007	Eine begrenzte Anzahl ( &gt; 800 ) schwangerer Frauen war während der Schwangerschaft Ritonavir ausgesetzt ; eine sehr begrenzte Zahl ( &lt; 300 ) war während des ersten Trimesters exponiert .
T-1007	A limited number ( &gt; 800 ) of pregnant women were exposed to ritonavir during pregnancy ; a very limited number ( &lt; 300 ) were exposed during the first trimester .
H-1007	-0.004355254117399454	A limited number ( &gt; 800 ) of pregnant women were exposed to ritonavir during pregnancy ; a very limited number ( &lt; 300 ) were exposed during the first trimester .
D-1007	-0.004355254117399454	A limited number ( &gt; 800 ) of pregnant women were exposed to ritonavir during pregnancy ; a very limited number ( &lt; 300 ) were exposed during the first trimester .
P-1007	-0.0020 -0.0137 -0.0024 -0.0151 -0.0015 -0.0006 -0.0015 -0.0027 -0.0020 -0.0013 -0.0030 -0.0007 -0.0017 -0.0026 -0.0014 -0.0011 -0.0009 -0.0025 -0.0020 -0.0502 -0.0019 -0.0112 -0.0034 -0.0013 -0.0128 -0.0111 -0.0003 -0.0013 -0.0006 -0.0014 -0.0081 -0.0011 -0.0013 -0.0021 -0.0013 -0.0011 -0.0009 -0.0008 -0.0016 -0.0014
S-898	Damit die Injektion angenehmer wird , lassen Sie die Fertigspritze für 30 Minuten liegen , so dass sie Raumtemperatur annehmen kann , oder halten Sie die Fertigspritze für einige Minuten 64 vorsichtig in der Hand .
T-898	For a more comfortable injection , let the pre @-@ filled syringe stand for 30 minutes to reach room temperature or hold the pre @-@ filled syringe gently in your hand for a few minutes .
H-898	-0.01027235109359026	For a more comfortable injection , let the pre @-@ filled syringe stand for 30 minutes to reach room temperature or hold the pre @-@ filled syringe gently in your hand for a few minutes .
D-898	-0.01027235109359026	For a more comfortable injection , let the pre @-@ filled syringe stand for 30 minutes to reach room temperature or hold the pre @-@ filled syringe gently in your hand for a few minutes .
P-898	-0.0132 -0.0102 -0.0026 -0.0108 -0.0047 -0.0007 -0.0020 -0.0129 -0.0028 -0.0131 -0.0013 -0.0116 -0.0011 -0.0002 -0.0002 -0.0140 -0.0034 -0.0021 -0.1730 -0.0134 -0.0130 -0.0017 -0.0010 -0.0287 -0.0070 -0.0070 -0.0031 -0.0013 -0.0017 -0.0008 -0.0002 -0.0003 -0.0113 -0.0067 -0.0041 -0.0024 -0.0021 -0.0045 -0.0028 -0.0349 -0.0022 -0.0014
S-271	Hinsichtlich klinischer vertebraler Frakturen ( definiert als Frakturen assoziiert mit Rückenschmerzen und / oder einen Verlust an Körpergröße von mindestens 1 cm ) wurde das relative Risiko um 38 % verringert .
T-271	With respect to clinical vertebral fractures ( defined as fractures associated with back pain and / or a body height loss of at least 1 cm ) , the relative risk was reduced by 38 % .
H-271	-0.003925609402358532	With respect to clinical vertebral fractures ( defined as fractures associated with back pain and / or a body height loss of at least 1 cm ) , the relative risk was reduced by 38 % .
D-271	-0.003925609402358532	With respect to clinical vertebral fractures ( defined as fractures associated with back pain and / or a body height loss of at least 1 cm ) , the relative risk was reduced by 38 % .
P-271	-0.0131 -0.0088 -0.0014 -0.0029 -0.0006 -0.0011 -0.0006 -0.0017 -0.0005 -0.0010 -0.0019 -0.0017 -0.0277 -0.0012 -0.0010 -0.0034 -0.0014 -0.0041 -0.0014 -0.0017 -0.0014 -0.0012 -0.0099 -0.0143 -0.0103 -0.0020 -0.0024 -0.0034 -0.0012 -0.0049 -0.0015 -0.0016 -0.0044 -0.0035 -0.0016 -0.0008 -0.0037 -0.0158 -0.0016 -0.0011 -0.0017 -0.0015 -0.0014
S-90	Die Einjahresdaten aus zwei kombinierten Beobachtungsstudien zeigen für Patienten mit klinischer Abheilung nach einem oder zwei Behandlungszeiträumen eine Rezidivrate von 27 % ( 35 / 128 Patienten ) .
T-90	One @-@ year data from two combined observational studies indicate a recurrence rate of 27 % ( 35 / 128 patients ) in those patients who became clinically clear after one or two courses of treatment .
H-90	-0.007535157259553671	One @-@ year data from two combined observational studies indicate a recurrence rate of 27 % ( 35 / 128 patients ) in those patients who became clinically clear after one or two courses of treatment .
D-90	-0.007535157259553671	One @-@ year data from two combined observational studies indicate a recurrence rate of 27 % ( 35 / 128 patients ) in those patients who became clinically clear after one or two courses of treatment .
P-90	-0.0066 -0.0189 -0.0052 -0.0023 -0.0034 -0.0024 -0.0021 -0.0079 -0.0026 -0.0037 -0.0155 -0.0067 -0.0090 -0.0004 -0.0008 -0.0008 -0.0014 -0.0035 -0.0012 -0.0015 -0.0579 -0.0013 -0.0019 -0.0011 -0.0013 -0.0025 -0.0015 -0.0530 -0.0141 -0.0128 -0.0120 -0.0145 -0.0083 -0.0012 -0.0144 -0.0030 -0.0052 -0.0051 -0.0026 -0.0142 -0.0023 -0.0023 -0.0016 -0.0014
S-105	Veranschlagt sind Mittel zur Deckung des Arbeitgeberbeitrags zur Unfallversicherung und Versicherung gegen Berufskrankheiten sowie der zusätzlichen Ausgaben , die sich aus der Anwendung der einschlägigen Statutsbestimmungen ergeben .
T-105	This appropriation is intended to cover the Agency &apos;s contribution towards insurance against accidents and occupational diseases and the supplementary expenditure arising from the application of the statutory provisions in this area .
H-105	-0.006763202138245106	This appropriation is intended to cover the Agency &apos;s contribution towards insurance against accidents and occupational diseases and the supplementary expenditure arising from the application of the statutory provisions in this area .
D-105	-0.006763202138245106	This appropriation is intended to cover the Agency &apos;s contribution towards insurance against accidents and occupational diseases and the supplementary expenditure arising from the application of the statutory provisions in this area .
P-105	-0.0139 -0.0145 -0.0024 -0.0269 -0.0070 -0.0018 -0.0019 -0.0092 -0.0182 -0.0017 -0.0062 -0.0236 -0.0141 -0.0092 -0.0039 -0.0004 -0.0035 -0.0006 -0.0008 -0.0053 -0.0139 -0.0078 -0.0141 -0.0011 -0.0012 -0.0099 -0.0005 -0.0021 -0.0096 -0.0007 -0.0032 -0.0071 -0.0053 -0.0015 -0.0029 -0.0143 -0.0094 -0.0010 -0.0012 -0.0097 -0.0064 -0.0070 -0.0015 -0.0014
S-1373	Es blockiert erwartungsgemäß alle Wirkungen von Angiotensin II , die über den AT1 @-@ Rezeptor vermittelt werden , unabhängig vom Ursprung oder Syntheseweg von Angiotensin II .
T-1373	It is expected to block all actions of angiotensin @-@ II mediated by the AT1 receptor , regardless of the source or route of synthesis of angiotensin @-@ II .
H-1373	-0.005845160689204931	It is expected to block all actions of angiotensin @-@ II mediated by the AT1 receptor , regardless of the source or route of synthesis of angiotensin @-@ II .
D-1373	-0.005845160689204931	It is expected to block all actions of angiotensin @-@ II mediated by the AT1 receptor , regardless of the source or route of synthesis of angiotensin @-@ II .
P-1373	-0.0066 -0.0111 -0.0023 -0.0015 -0.0020 -0.0037 -0.0136 -0.0030 -0.0039 -0.0009 -0.0010 -0.0008 -0.0013 -0.0861 -0.0027 -0.0058 -0.0013 -0.0069 -0.0023 -0.0010 -0.0014 -0.0041 -0.0004 -0.0017 -0.0076 -0.0067 -0.0013 -0.0061 -0.0112 -0.0019 -0.0139 -0.0021 -0.0111 -0.0016 -0.0006 -0.0024 -0.0041 -0.0010 -0.0013 -0.0012 -0.0013 -0.0088 -0.0102 -0.0016 -0.0014
S-122	Da Mycophenolatmofetil bei Ratten und Kaninchen eine teratogene Wirkung hatte , sollten die Mycophenolatmofetil Teva Kapseln nicht geöffnet oder zerdrückt werden .
T-122	Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbit , Mycophenolate mofetil Teva capsules should not be opened or crushed .
H-122	-0.003538781777024269	Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbit , Mycophenolate mofetil Teva capsules should not be opened or crushed .
D-122	-0.003538781777024269	Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbit , Mycophenolate mofetil Teva capsules should not be opened or crushed .
P-122	-0.0151 -0.0094 -0.0010 -0.0010 -0.0044 -0.0009 -0.0013 -0.0011 -0.0007 -0.0120 -0.0145 -0.0061 -0.0010 -0.0016 -0.0007 -0.0012 -0.0065 -0.0033 -0.0036 -0.0015 -0.0144 -0.0094 -0.0028 -0.0118 -0.0011 -0.0011 -0.0029 -0.0014 -0.0011 -0.0013 -0.0004 -0.0040 -0.0009 -0.0019 -0.0008 -0.0010 -0.0017 -0.0017 -0.0015 -0.0026 -0.0015 -0.0034 -0.0004 -0.0017 -0.0014
S-393	Gleichzeitige Anwendung von Itraconazol ( einem Hemmstoff von CYP3A4 ) und Rosuvastatin führte zu einer 28 % igen Erhöhung der AUC von Rosuvastatin .
T-393	Concomitant administration of itraconazole ( an inhibitor of CYP3A4 ) and rosuvastatin resulted in a 28 % increase in AUC of rosuvastatin .
H-393	-0.05455639958381653	Concurrent administration of itraconazole ( an inhibitor of CYP3A4 ) and rosuvastatin resulted in a 28 % increase in AUC of rosuvastatin .
D-393	-0.05455639958381653	Concurrent administration of itraconazole ( an inhibitor of CYP3A4 ) and rosuvastatin resulted in a 28 % increase in AUC of rosuvastatin .
P-393	-0.0633 -1.9347 -0.0151 -0.0014 -0.0003 -0.0003 -0.0015 -0.0005 -0.0005 -0.0017 -0.0038 -0.0010 -0.0003 -0.0005 -0.0016 -0.0340 -0.0014 -0.0013 -0.3404 -0.0011 -0.0007 -0.0015 -0.0024 -0.0038 -0.0013 -0.0010 -0.0004 -0.0006 -0.0077 -0.0015 -0.0027 -0.0009 -0.0020 -0.0036 -0.0029 -0.0034 -0.0014 -0.0038 -0.0020 -0.0013 -0.0012 -0.0005 -0.0006 -0.0017 -0.0014
S-22	Die notwendigen Verfahren für die Bearbeitung von Befassungen durch den CPMP und das Sekretariat sind zwar etabliert , doch wurden sie bislang ad hoc von Personal aus verschiedenen Bereichen des Referates abgewickelt .
T-22	Whilst the procedures necessary for the CPMP and the Secretariat to handle referrals are in place , they have so far been handled on an ad hoc basis by personnel from the different Sectors of the Unit .
H-22	-0.005370751954615116	Whilst the procedures necessary for the CPMP and the Secretariat to handle referrals are in place , they have so far been handled on an ad hoc basis by personnel from the different Sectors of the Unit .
D-22	-0.005370751954615116	Whilst the procedures necessary for the CPMP and the Secretariat to handle referrals are in place , they have so far been handled on an ad hoc basis by personnel from the different Sectors of the Unit .
P-22	-0.0142 -0.0004 -0.0038 -0.0048 -0.0106 -0.0060 -0.0091 -0.0086 -0.0014 -0.0006 -0.0027 -0.0123 -0.0052 -0.0006 -0.0015 -0.0022 -0.0107 -0.0048 -0.0030 -0.0011 -0.0076 -0.0091 -0.0007 -0.0022 -0.0062 -0.0023 -0.0109 -0.0012 -0.0019 -0.0135 -0.0098 -0.0024 -0.0009 -0.0014 -0.0016 -0.0013 -0.0017 -0.0131 -0.0043 -0.0158 -0.0114 -0.0145 -0.0117 -0.0042 -0.0026 -0.0031 -0.0011 -0.0016 -0.0014
S-1241	EU / 2 / 05 / 054 / 008 12 Pipetten EU / 2 / 05 / 054 / 009 20 Pipetten EU / 2 / 05 / 054 / 010 40 Pipetten
T-1241	EU / 2 / 05 / 054 / 008 12 pipettes EU / 2 / 05 / 054 / 009 20 pipettes EU / 2 / 05 / 054 / 010 40 pipettes EU / 2 / 05 / 054 / 011 80 pipettes
H-1241	-0.047849684953689575	EU / 2 / 05 / 054 / 008 12 pipettes EU / 2 / 05 / 054 / 009 20 pipettes EU / 2 / 05 / 054 / 010 40 pipettes
D-1241	-0.047849684953689575	EU / 2 / 05 / 054 / 008 12 pipettes EU / 2 / 05 / 054 / 009 20 pipettes EU / 2 / 05 / 054 / 010 40 pipettes
P-1241	-0.0103 -0.0015 -0.0015 -0.0015 -0.0011 -0.0014 -0.0017 -0.2136 -0.0014 -0.0015 -0.0013 -0.0022 -0.0064 -0.0016 -0.0007 -0.0011 -0.0015 -0.0014 -0.0015 -0.0010 -0.0014 -0.0015 -0.1344 -0.0014 -0.0015 -0.0013 -0.0013 -0.0027 -0.0008 -0.0006 -0.0010 -0.0014 -0.0014 -0.0015 -0.0010 -0.0014 -0.0013 -0.1471 -0.0014 -0.0015 -0.0012 -0.0020 -0.0030 -0.0009 -0.0007 -1.6331
S-1912	Wenn während der Erhaltungstherapie das Ansprechen verloren ging , war ein Wechsel zu einer höheren Dosierung ( 10 mg / kg ) und / oder einem kürzeren Dosierungsintervall ( alle 8 Wochen ) erlaubt .
T-1912	If response was lost during maintenance treatment , crossing over to a higher dose ( 10 mg / kg ) and / or shorter dosing interval ( q8 weeks ) was allowed .
H-1912	-0.01233949139714241	If response was lost during maintenance treatment , crossing over to a higher dose ( 10 mg / kg ) and / or shorter dosing interval ( q8 weeks ) was allowed .
D-1912	-0.01233949139714241	If response was lost during maintenance treatment , crossing over to a higher dose ( 10 mg / kg ) and / or shorter dosing interval ( q8 weeks ) was allowed .
P-1912	-0.0057 -0.0088 -0.0054 -0.0029 -0.0124 -0.0022 -0.0138 -0.0030 -0.0145 -0.0118 -0.0072 -0.0035 -0.0017 -0.0084 -0.0018 -0.0049 -0.0005 -0.0016 -0.0008 -0.0015 -0.0028 -0.0014 -0.0012 -0.0073 -0.0020 -0.0035 -0.2666 -0.0013 -0.0059 -0.0014 -0.0147 -0.0145 -0.0143 -0.0019 -0.0034 -0.0112 -0.0017 -0.0015
S-267	Jegliche Anzeichen einer Kreislaufüberladung müssen sorgfältig überwacht werden oder es muss der zentrale Venendruck ( ZVD ) gemessen werden ( ein Anstieg des ZVD wurde bei allen behandelten Hunden festgestellt , bei denen dieser gemessen wurde . ) .
T-267	Signs of circulatory overload should be carefully monitored or central venous pressure ( CVP ) measured ( increase in CVP has been recorded in all treated dogs in which it was measured ) .
H-267	-0.008722645230591297	Signs of circulatory overload should be carefully monitored or central venous pressure ( CVP ) measured ( increase in CVP has been recorded in all treated dogs in which it was measured ) .
D-267	-0.008722645230591297	Signs of circulatory overload should be carefully monitored or central venous pressure ( CVP ) measured ( increase in CVP has been recorded in all treated dogs in which it was measured ) .
P-267	-0.0144 -0.0012 -0.0037 -0.0082 -0.0003 -0.0008 -0.0028 -0.0042 -0.0138 -0.0017 -0.0277 -0.0024 -0.0010 -0.0042 -0.0107 -0.0107 -0.0006 -0.0017 -0.0188 -0.0072 -0.0145 -0.0015 -0.0085 -0.0021 -0.0119 -0.0080 -0.0051 -0.0127 -0.0120 -0.0014 -0.0691 -0.0434 -0.0027 -0.0029 -0.0017 -0.0129 -0.0017 -0.0086 -0.0086 -0.0032 -0.0032 -0.0017 -0.0015
S-1393	Heuschnupfen , Nesselsucht ) oder Asthma leiden • Sie bereits früher auf Kontrastmittelinjektionen reagiert haben • Ihre Nieren nicht richtig funktionieren Sollte etwas davon auf Sie zutreffen , wird Ihr Arzt entscheiden , ob die vorgesehene Untersuchung möglich ist oder nicht .
T-1393	18 If any of these apply to you , your doctor will decide whether the intended examination is possible or not .
H-1393	-0.008896207436919212	18 If any of these apply to you , your doctor will decide whether the intended examination is possible or not .
D-1393	-0.008896207436919212	18 If any of these apply to you , your doctor will decide whether the intended examination is possible or not .
P-1393	-0.0145 -0.0143 -0.0228 -0.0046 -0.0277 -0.0144 -0.0024 -0.0020 -0.0035 -0.0038 -0.0017 -0.0022 -0.0085 -0.0083 -0.0103 -0.0142 -0.0094 -0.0030 -0.0053 -0.0072 -0.0016 -0.0085 -0.0144
S-1407	Tierarzneimittel @-@ Zulassungsfragen wurden erfolgreich in der zweiten Phase des Pan @-@ European Regulatory Forum ( PERF II ) angegangen , dem Programm , das zur Vorbereitung der Beitrittsländer aus Mittel- und Osteuropa auf den EU @-@ Beitritt eingerichtet wurde .
T-1407	• Veterinary regulatory affairs were successfully addressed in the second phase of the Pan @-@ European Regulatory Forum
H-1407	-0.006733457092195749	• Veterinary regulatory affairs were successfully addressed in the second phase of the Pan @-@ European Regulatory Forum
D-1407	-0.006733457092195749	• Veterinary regulatory affairs were successfully addressed in the second phase of the Pan @-@ European Regulatory Forum
P-1407	-0.0150 -0.0063 -0.0012 -0.0145 -0.0145 -0.0100 -0.0025 -0.0043 -0.0096 -0.0042 -0.0012 -0.0018 -0.0014 -0.0042 -0.0017 -0.0014 -0.0020 -0.0014 -0.0005 -0.0009 -0.0006 -0.0006 -0.0550
S-464	Sitaxentan @-@ Natrium zeigte jedoch keine Auswirkungen auf die ovulationshemmende Wirkung des oralen Kontrazeptivums , wie sich aus den Plasmaspiegeln an FSH , LH und Progesteron ergab ( siehe Abschnitt 4.4 ) .
T-464	However , sitaxentan sodium did not affect the anti @-@ ovulatory activity of the oral contraceptive as assessed by the plasma concentrations of follicle stimulating hormone ( FSH ) , luteinising hormone ( LH ) , and progesterone ( see section 4.4 ) .
H-464	-0.015290304087102413	However , sitaxentan sodium did not affect the anti @-@ ovulatory activity of the oral contraceptive as assessed by the plasma concentrations of follicle stimulating hormone ( FSH ) , luteinising hormone ( LH ) , and progesterone ( see section 4.4 ) .
D-464	-0.015290304087102413	However , sitaxentan sodium did not affect the anti @-@ ovulatory activity of the oral contraceptive as assessed by the plasma concentrations of follicle stimulating hormone ( FSH ) , luteinising hormone ( LH ) , and progesterone ( see section 4.4 ) .
P-464	-0.0065 -0.0015 -0.0087 -0.0060 -0.0013 -0.0084 -0.0025 -0.0006 -0.0194 -0.0014 -0.0138 -0.0023 -0.0143 -0.0015 -0.0018 -0.0145 -0.0009 -0.0551 -0.0015 -0.0026 -0.0006 -0.0013 -0.0012 -0.0011 -0.0098 -0.0145 -0.0007 -0.0254 -0.0090 -0.0063 -0.0005 -0.0006 -0.0239 -0.0001 -0.0023 -0.0037 -0.0148 -0.0077 -0.0106 -0.0145 -0.0138 -0.0116 -0.0036 -0.0125 -0.0028 -0.0010 -0.3536 -0.0019 -0.0142 -0.0145 -0.0144 -0.0145 -0.0045 -0.0008 -0.0028 -0.0029 -0.0009 -0.0014 -0.2399 -0.0027 -0.0017 -0.0018 -0.0010 -0.0491 -0.0023 -0.0026 -0.0079 -0.0013 -0.0014 -0.0016 -0.0014 -0.0014
S-239	Pro Chemotherapiezyklus wird eine 6 mg Dosis ( ein einzelner Fertigpen ) Neupopeg ( SureClick ) empfohlen , die als subkutane Injektion circa 24 Stunden nach einer zytotoxischen Chemotherapie angewendet wird .
T-239	One 6 mg dose ( a single pre @-@ filled pen ) of Neupopeg ( SureClick ) is recommended for each chemotherapy cycle , administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy .
H-239	-0.01356109231710434	One 6 mg dose ( a single pre @-@ filled pen ) of Neupopeg ( SureClick ) is recommended for each chemotherapy cycle , administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy .
D-239	-0.01356109231710434	One 6 mg dose ( a single pre @-@ filled pen ) of Neupopeg ( SureClick ) is recommended for each chemotherapy cycle , administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy .
P-239	-0.0139 -0.0067 -0.0009 -0.0008 -0.0045 -0.0114 -0.0015 -0.0145 -0.0014 -0.0139 -0.0062 -0.0015 -0.0098 -0.0022 -0.0036 -0.0013 -0.0019 -0.0013 -0.0014 -0.0007 -0.0015 -0.0048 -0.0015 -0.0088 -0.0030 -0.0045 -0.0006 -0.0066 -0.0023 -0.0077 -0.0128 -0.0007 -0.0045 -0.0579 -0.0031 -0.0006 -0.0006 -0.0012 -0.0014 -0.0018 -0.0006 -0.0073 -0.0013 -0.0015 -0.2833 -0.0021 -0.0013 -0.0004 -0.0008 -0.0011 -0.0017 -0.0005 -0.2157 -0.0017 -0.0014
S-1827	Bei gleichzeitiger Anwendung von moderaten CYP3A4 @-@ Inhibitoren wie Erythromycin und Clarithromycin kann eine Dosisanpassung von Vardenafil notwendig sein ( siehe Abschnitt 4.5 und Abschnitt 4.2 ) .
T-1827	Vardenafil dose adjustment might be necessary if moderate CYP 3A4 inhibitors such as erythromycin and clarithromycin , are given concomitantly ( see sections 4.5 and 4.2 ) .
H-1827	-0.033588867634534836	Vardenafil dose adjustment might be necessary if moderate CYP3A4 inhibitors such as erythromycin and clarithromycin , are given concomitantly ( see sections 4.5 and 4.2 ) .
D-1827	-0.033588867634534836	Vardenafil dose adjustment might be necessary if moderate CYP3A4 inhibitors such as erythromycin and clarithromycin , are given concomitantly ( see sections 4.5 and 4.2 ) .
P-1827	-0.0145 -0.0007 -0.0006 -0.0015 -0.0097 -0.0040 -0.0009 -0.0032 -0.0143 -0.0016 -0.0624 -0.0163 -0.0060 -0.0035 -0.0012 -0.8290 -0.0011 -0.0006 -0.0015 -0.0003 -0.0004 -0.0012 -0.0063 -0.0014 -0.0018 -0.0010 -0.0003 -0.0008 -0.0013 -0.0014 -0.0018 -0.0014 -0.0003 -0.0007 -0.0012 -0.0015 -0.0168 -0.0041 -0.0231 -0.0120 -0.0145 -0.0003 -0.0030 -0.0023 -0.0016 -0.4348 -0.0010 -0.0014 -0.0015 -0.0013 -0.0014 -0.0027 -0.2947 -0.0014
S-233	Die nach Gebrauch von Luminity berichteten Nebenwirkungen waren im Allgemeinen in allen klinischen Studien ( insgesamt 2.526 Patienten ) von milder bis mittlerer Intensität , traten innerhalb von Minuten nach der Anwendung auf und verschwanden meistens ohne therapeutische Maßnahmen innerhalb von 15 Minuten .
T-233	The reported adverse reactions following the use of Luminity in pivotal and supportive trials ( total of 2,526 patients ) have generally been mild to moderate in intensity , occur within minutes after administration and usually resolve without therapeutic intervention within 15 minutes .
H-233	-0.020699393004179	The reported adverse reactions following the use of Luminity in pivotal and supportive trials ( total of 2,526 patients ) have generally been mild to moderate in intensity , occur within minutes after administration and usually resolve without therapeutic intervention within 15 minutes .
D-233	-0.020699393004179	The reported adverse reactions following the use of Luminity in pivotal and supportive trials ( total of 2,526 patients ) have generally been mild to moderate in intensity , occur within minutes after administration and usually resolve without therapeutic intervention within 15 minutes .
P-233	-0.0113 -0.0111 -0.0081 -0.0002 -0.0896 -0.0003 -0.0135 -0.0127 -0.0014 -0.0014 -0.0063 -0.0009 -0.0014 -0.0156 -0.0146 -0.0034 -0.0015 -0.0144 -0.0145 -0.0137 -0.0129 -0.0136 -0.0113 -0.0015 -0.0010 -0.0052 -0.0020 -0.0014 -0.0278 -0.0066 -0.0063 -0.0020 -0.0077 -0.0054 -0.0115 -0.0011 -0.0026 -0.0141 -0.0013 -0.0013 -0.1291 -0.0147 -0.0269 -0.0122 -0.0144 -0.0141 -0.0137 -0.0014 -0.0048 -0.0036 -0.0019 -0.4212 -0.0861 -0.0014
S-414	Es liegen keine pharmakokinetischen Daten über Patienten mit Niereninsuffizienz vor ( siehe Abschnitt 4.2 ) , man nimmt jedoch an , dass die Auswirkung einer eingeschränkten Nierenfunktion auf die Ausscheidung von Atazanavir minimal ist .
T-414	There are no pharmacokinetic data available on patients with renal insufficiency ( see section 4.2 ) ; however , the impact of renal impairment on atazanavir elimination is anticipated to be minimal .
H-414	-0.035237155854701996	There are no pharmacokinetic data available on patients with renal insufficiency ( see section 4.2 ) ; however , the impact of renal impairment on atazanavir elimination is anticipated to be minimal .
D-414	-0.035237155854701996	There are no pharmacokinetic data available on patients with renal insufficiency ( see section 4.2 ) ; however , the impact of renal impairment on atazanavir elimination is anticipated to be minimal .
P-414	-0.0072 -0.3163 -0.0015 -0.0023 -0.0005 -0.0005 -0.2694 -0.0017 -0.0698 -0.0723 -0.0044 -0.0021 -0.0019 -0.0012 -0.7688 -0.0006 -0.0006 -0.0011 -0.0018 -0.0020 -0.0106 -0.0012 -0.0014 -0.0019 -0.1250 -0.0035 -0.0032 -0.0061 -0.0126 -0.0020 -0.0350 -0.0012 -0.0050 -0.0032 -0.0007 -0.0012 -0.0031 -0.0134 -0.0006 -0.0008 -0.0011 -0.0009 -0.0123 -0.0012 -0.0018 -0.0145 -0.0015 -0.0013 -0.0020 -0.0015 -0.0015
S-23	Der Impfstoff wird vermischt indem der Inhalt aus der Durchstechflasche mit der Emulsion ( Durchstechflasche B ) mittels einer Spritze entnommen wird und in die Durchstechflasche mit der Suspension ( Durchstechflasche A ) gegeben wird .
T-23	The vaccine is mixed by withdrawing the contents of the vial containing the emulsion ( Vial B ) by means of a syringe and by adding it to the vial containing the suspension ( Vial A ) .
H-23	-0.006080367136746645	The vaccine is mixed by withdrawing the contents of the vial containing the emulsion ( Vial B ) by means of a syringe and by adding it to the vial containing the suspension ( Vial A ) .
D-23	-0.006080367136746645	The vaccine is mixed by withdrawing the contents of the vial containing the emulsion ( Vial B ) by means of a syringe and by adding it to the vial containing the suspension ( Vial A ) .
P-23	-0.0043 -0.0033 -0.0021 -0.0031 -0.0046 -0.0144 -0.0008 -0.0042 -0.0100 -0.0009 -0.0130 -0.0019 -0.0020 -0.0015 -0.0119 -0.0027 -0.0008 -0.0008 -0.0013 -0.0032 -0.0145 -0.0006 -0.0025 -0.0015 -0.0118 -0.0040 -0.0014 -0.0032 -0.0004 -0.0003 -0.0002 -0.0100 -0.0134 -0.0159 -0.0129 -0.0068 -0.0019 -0.0014 -0.0014 -0.0027 -0.0017 -0.0014 -0.0018 -0.0032 -0.0006 -0.0019 -0.0013 -0.0908 -0.0014
S-1605	Bei einem von 65 mit BeneFIX behandelten Patienten ( darunter 9 Patienten , die nur an der Chirurgiestudie teilnahmen ) , die zuvor Plasmaprodukte erhalten hatten , wurde ein klinisch relevanter geringer Hemmkörpertiter nachgewiesen .
T-1605	A clinically relevant , low responding inhibitor was detected in 1 out of 65 BeneFIX patients ( including 9 patients participating only in the surgery study ) who had previously received plasma derived products .
H-1605	-0.007112421095371246	A clinically relevant , low responding inhibitor was detected in 1 out of 65 BeneFIX patients ( including 9 patients participating only in the surgery study ) who had previously received plasma derived products .
D-1605	-0.007112421095371246	A clinically relevant , low responding inhibitor was detected in 1 out of 65 BeneFIX patients ( including 9 patients participating only in the surgery study ) who had previously received plasma derived products .
P-1605	-0.0111 -0.0049 -0.0009 -0.0067 -0.0143 -0.0035 -0.0149 -0.0106 -0.0009 -0.0006 -0.0017 -0.0100 -0.0295 -0.0010 -0.0019 -0.0129 -0.0134 -0.0014 -0.0020 -0.0132 -0.0008 -0.0010 -0.0365 -0.0045 -0.0065 -0.0022 -0.0060 -0.0137 -0.0012 -0.0187 -0.0068 -0.0025 -0.0100 -0.0053 -0.0014 -0.0061 -0.0048 -0.0066 -0.0030 -0.0029 -0.0004 -0.0006 -0.0145 -0.0133 -0.0064 -0.0016 -0.0014
S-1809	Patienten , die bei ihrer letzten vorherigen Behandlung behandlungsrefraktär oder auch nicht behandlungsrefraktär waren , wiesen im VELCADE @-@ Arm eine signifikant längere Gesamtüberlebensdauer sowie eine signifikant höhere Response @-@ Rate auf .
T-1809	Both in patients who were refractory to their last prior therapy and those who were not refractory , overall survival was significantly longer and response rate was significantly higher on the VELCADE arm .
H-1809	-0.007884806953370571	Both in patients who were refractory to their last prior therapy and those who were not refractory , overall survival was significantly longer and response rate was significantly higher on the VELCADE arm .
D-1809	-0.007884806953370571	Both in patients who were refractory to their last prior therapy and those who were not refractory , overall survival was significantly longer and response rate was significantly higher on the VELCADE arm .
P-1809	-0.0168 -0.0144 -0.0090 -0.0053 -0.0070 -0.0077 -0.0007 -0.0006 -0.0005 -0.0144 -0.0136 -0.0122 -0.0103 -0.0131 -0.0055 -0.0111 -0.0026 -0.0044 -0.0054 -0.0114 -0.0008 -0.0006 -0.0006 -0.0129 -0.0143 -0.0011 -0.0111 -0.0024 -0.0337 -0.0069 -0.0108 -0.0128 -0.0092 -0.0037 -0.0227 -0.0329 -0.0029 -0.0016 -0.0010 -0.0014 -0.0006 -0.0013 -0.0004 -0.0017 -0.0015
S-1107	Bei Anwendung von LUMIGAN mit anderen Arzneimitteln Bitte informieren Sie Ihren Arzt oder Apotheker , wenn Sie andere Arzneimittel einnehmen / anwenden bzw. vor kurzem eingenommen / angewendet haben , auch wenn es sich um nicht verschreibungspflichtige Arzneimittel handelt .
T-1107	Please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , even those not prescribed .
H-1107	-0.047858014702796936	Please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , even those not prescribed .
D-1107	-0.047858014702796936	Please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , even those not prescribed .
P-1107	-0.0223 -0.0136 -0.0017 -0.0026 -0.0026 -0.0019 -0.0008 -0.0062 -0.0081 -0.0141 -0.6832 -0.0322 -0.0215 -0.0095 -0.0090 -0.2148 -0.0087 -0.0139 -0.0043 -0.0068 -0.0036 -0.0072 -0.2293 -0.0136 -0.0147 -0.0127 -0.0013 -0.0132 -0.0144
S-1074	Bestätigung : insofern , als daß der Ausschuß seine Arbeit zur Beurteilung von Arzneimitteln auch weiterhin gleichmäßig aufgeteilt sowie seine wissenschaftlichen Gutachten mit Konsens und innerhalb der vorgegebenen Fristen erstellt hat Konsolidierung : in vielerlei Hinsicht , insbesondere in folgenden Punkten :
T-1074	Consolidation in several respects .
H-1074	-0.009899468161165714	Consolidation in several respects .
D-1074	-0.009899468161165714	Consolidation in several respects .
P-1074	-0.0084 -0.0145 -0.0016 -0.0152 -0.0145 -0.0034 -0.0011 -0.0159 -0.0145
S-537	Die Agentur und insbesondere ihre Hauptausschüsse ( Ausschuß für Arzneispezialitäten &#91; CPMP &#93; und Ausschuß für Tierarzneimittel &#91; CVMP &#93; ) haben für die Schnelligkeit und Qualität ihrer wissenschaftlichen Beurteilungen Weltruf erlangt .
T-537	The EMEA and in particular its main committees ( CPMP / CVMP ) have gained a world @-@ wide reputation for the speed and quality of their scientific evaluations .
H-537	-0.0056440276093780994	The EMEA and in particular its main committees ( CPMP / CVMP ) have gained a world @-@ wide reputation for the speed and quality of their scientific evaluations .
D-537	-0.0056440276093780994	The EMEA and in particular its main committees ( CPMP / CVMP ) have gained a world @-@ wide reputation for the speed and quality of their scientific evaluations .
P-537	-0.0035 -0.0350 -0.0132 -0.0004 -0.0069 -0.0074 -0.0012 -0.0026 -0.0035 -0.0028 -0.0009 -0.0034 -0.0122 -0.0013 -0.0007 -0.0149 -0.0120 -0.0014 -0.0006 -0.0077 -0.0038 -0.0087 -0.0089 -0.0106 -0.0088 -0.0082 -0.0010 -0.0017 -0.0040 -0.0033 -0.0014 -0.0016 -0.0015 -0.0071 -0.0010 -0.0129 -0.0012 -0.0016 -0.0014
S-1620	3 Dämpfung des zentralen Nervensystems Wenn Natriumoxybat in Verbindung mit Alkohol oder anderen zentral dämpfenden Mitteln eingenommen wird , kann die dämpfende Wirkung , die Natriumoxybat auf das Zentralnervensystem hat , potenziert werden .
T-1620	CNS depression The combined use of alcohol or any CNS depressant drug with sodium oxybate may result in potentiation of the CNS @-@ depressant effects of sodium oxybate .
H-1620	-0.01207373384386301	CNS depression The combined use of alcohol or any CNS depressant drug with sodium oxybate may result in potentiation of the CNS @-@ depressant effects of sodium oxybate .
D-1620	-0.01207373384386301	CNS depression The combined use of alcohol or any CNS depressant drug with sodium oxybate may result in potentiation of the CNS @-@ depressant effects of sodium oxybate .
P-1620	-0.0158 -0.0009 -0.0145 -0.0145 -0.0145 -0.0142 -0.0015 -0.0246 -0.0254 -0.0145 -0.0145 -0.0005 -0.0144 -0.0023 -0.0298 -0.0349 -0.0593 -0.0064 -0.0007 -0.0030 -0.0017 -0.0012 -0.0372 -0.0143 -0.0016 -0.0145 -0.0132 -0.0489 -0.0045 -0.0116 -0.0003 -0.0143 -0.0113 -0.0039 -0.0023 -0.0128 -0.0112 -0.0087 -0.0006 -0.0017 -0.0012 -0.0013 -0.0030 -0.0035
S-808	Ebenfalls zeigte sich ein stimulierender Effekt auf die Leukozytenproduktion , da die Anzahl der peripheren Blutzellen wie der Neutrophilen , Lymphozyten , Monozyten und Eosinophilen leicht erhöht waren .
T-808	There was also a stimulatory effect on leukocyte production , as peripheral blood counts for neutrophils , lymphocytes , monocytes , and eosinophils were mildly increased .
H-808	-0.024009115993976593	There was also a stimulatory effect on leukocyte production , as peripheral blood counts for neutrophils , lymphocytes , monocytes , and eosinophils were mildly increased .
D-808	-0.024009115993976593	There was also a stimulatory effect on leukocyte production , as peripheral blood counts for neutrophils , lymphocytes , monocytes , and eosinophils were mildly increased .
P-808	-0.0130 -0.0213 -0.0026 -0.0023 -0.0016 -0.1823 -0.0013 -0.0019 -0.0078 -0.0015 -0.0007 -0.0080 -0.0019 -0.0383 -0.0085 -0.0141 -0.0004 -0.0012 -0.0026 -0.0347 -0.0203 -0.0102 -0.0100 -0.0011 -0.0002 -0.0015 -0.0006 -0.0007 -0.0009 -0.0015 -0.0015 -0.0012 -0.0006 -0.0014 -0.0008 -0.7407 -0.0017 -0.0016 -0.0009 -0.0014 -0.0068 -0.0005 -0.0023 -0.0145 -0.0007 -0.0012 -0.0026 -0.0016 -0.0014
S-17	( Hat Ihnen Ihr Arzt mehr als eine Durchstechflasche GONAL @-@ f verordnet , spritzen Sie die Lösung langsam in eine weitere Durchstechflasche mit Pulver ein , bis Sie die vorgeschriebene Anzahl von Durchstechflaschen mit Pulver aufgelöst haben .
T-17	( If you have been prescribed more than one vial of GONAL @-@ f , slowly re @-@ inject the solution into another powder vial , until you have the prescribed number of powder vials dissolved in the solution .
H-17	-0.013690962456166744	( If you have been prescribed more than one vial of GONAL @-@ f , slowly re @-@ inject the solution into another powder vial , until you have the prescribed number of powder vials dissolved in the solution .
D-17	-0.013690962456166744	( If you have been prescribed more than one vial of GONAL @-@ f , slowly re @-@ inject the solution into another powder vial , until you have the prescribed number of powder vials dissolved in the solution .
P-17	-0.0032 -0.0033 -0.0174 -0.0064 -0.0056 -0.0010 -0.0006 -0.0027 -0.0015 -0.0018 -0.0098 -0.0007 -0.0048 -0.0027 -0.0008 -0.0008 -0.0014 -0.0018 -0.0120 -0.0070 -0.0145 -0.0016 -0.0100 -0.0004 -0.0053 -0.0023 -0.0055 -0.0050 -0.0145 -0.0028 -0.0012 -0.0519 -0.0024 -0.0038 -0.0040 -0.0145 -0.0031 -0.0005 -0.0022 -0.0016 -0.0140 -0.0012 -0.0009 -0.0033 -0.0008 -0.0009 -0.4170 -0.0118 -0.0122 -0.0021 -0.0016
S-601	Der mittlere Anstieg der CD4 + -Zellzahl vom Ausgangswert betrug über 48 Wochen 207 Zellen / mm3 und 203 Zellen / mm3 in der Nelfinavir- bzw. der Fosamprenavir / Ritonavir @-@ Gruppe .
T-601	The median increase from baseline in CD4 + cell count over 48 weeks was 207 cells / mm3 and 203 cells / mm3 in the nelfinavir and fosamprenavir / ritonavir groups respectively .
H-601	-0.016261067241430283	The median increase from baseline in CD4 + cell count over 48 weeks was 207 cells / mm3 and 203 cells / mm3 in the nelfinavir and fosamprenavir / ritonavir groups respectively .
D-601	-0.016261067241430283	The median increase from baseline in CD4 + cell count over 48 weeks was 207 cells / mm3 and 203 cells / mm3 in the nelfinavir and fosamprenavir / ritonavir groups respectively .
P-601	-0.0104 -0.0144 -0.0013 -0.0043 -0.1110 -0.0004 -0.0012 -0.0086 -0.0033 -0.0012 -0.0013 -0.0029 -0.0079 -0.0122 -0.0025 -0.0014 -0.0020 -0.0010 -0.0012 -0.0015 -0.0017 -0.0006 -0.0014 -0.0022 -0.0149 -0.0014 -0.0009 -0.0014 -0.0004 -0.0013 -0.0743 -0.0027 -0.0064 -0.0013 -0.0012 -0.0076 -0.0013 -0.0057 -0.0052 -0.0009 -0.0003 -0.0003 -0.0016 -0.0009 -0.0025 -0.0028 -0.0014 -0.0008 -0.0010 -0.0077 -0.5168 -0.0014 -0.0014
S-1585	38 ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG FERTIGSPRITZE MIT ODER OHNE NADEL IN PACKUNGSGRÖßEN ZU 1 , 10
T-1585	35 PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE @-@ FILLED SYRINGE WITH OR WITHOUT NEEDLE , PACK OF 1 , 10
H-1585	-0.008919890969991684	35 PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE @-@ FILLED SYRINGE WITH OR WITHOUT NEEDLE , PACK OF 1 , 10
D-1585	-0.008919890969991684	35 PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE @-@ FILLED SYRINGE WITH OR WITHOUT NEEDLE , PACK OF 1 , 10
P-1585	-0.0152 -0.0145 -0.0087 -0.0033 -0.0137 -0.0095 -0.0095 -0.0143 -0.0145 -0.0129 -0.0125 -0.0128 -0.0157 -0.0082 -0.0049 -0.0034 -0.0017 -0.0069 -0.0143 -0.0137 -0.0063 -0.0016 -0.0065 -0.0146 -0.0145 -0.0255 -0.0145 -0.0142 -0.0143 -0.0223 -0.0023 -0.0031 -0.0017 -0.0143 -0.0071 -0.0003 -0.0089 -0.0040 -0.0005 -0.0015 -0.0007 -0.0013 -0.0001 -0.0125 -0.0135 -0.0005 -0.0063 -0.0142 -0.0127 -0.0025 -0.0170 -0.0147 -0.0027 -0.0129 -0.0026 -0.0009 -0.0051
S-1375	Die Auswirkung einer frühzeitigen Behandlung mit AVONEX , speziell in der Hochrisiko @-@ Gruppe , ist jedoch nicht bekannt , da diese Studie darauf ausgelegt war , die Zeit bis zur Entwicklung eines zweiten Ereignisses zu messen und nicht die Langzeitentwicklung der Erkrankung .
T-1375	However , the impact of early treatment with AVONEX is unknown even in this high @-@ risk subgroup as the study was mainly designed to assess the time to the second event rather than the long @-@ term evolution of the disease .
H-1375	-0.010908691212534904	However , the impact of early treatment with AVONEX is unknown even in this high @-@ risk subgroup as the study was mainly designed to assess the time to the second event rather than the long @-@ term evolution of the disease .
D-1375	-0.010908691212534904	However , the impact of early treatment with AVONEX is unknown even in this high @-@ risk subgroup as the study was mainly designed to assess the time to the second event rather than the long @-@ term evolution of the disease .
P-1375	-0.0087 -0.0123 -0.0022 -0.0144 -0.0015 -0.0037 -0.0031 -0.0022 -0.0015 -0.0017 -0.0010 -0.0012 -0.0008 -0.0164 -0.0327 -0.0608 -0.0039 -0.0144 -0.0018 -0.0183 -0.0166 -0.0145 -0.0064 -0.0177 -0.0110 -0.0061 -0.0036 -0.0313 -0.0149 -0.0016 -0.0138 -0.0049 -0.0033 -0.0116 -0.0116 -0.0138 -0.0033 -0.0136 -0.0014 -0.0051 -0.0046 -0.1053 -0.0014 -0.0140 -0.0009 -0.0023 -0.0021 -0.0027 -0.0017 -0.0014
S-1219	Die Einnahme von Rivastigmin Lösung zum Einnehmen mit einer Mahlzeit verzögert die Resorption ( tmax ) um 74 Minuten , vermindert den Cmax @-@ Wert um 43 % und erhöht den AUC @-@ Wert um etwa 9 % .
T-1219	Administration of rivastigmine oral solution with food delays absorption ( tmax ) by 74 min and lowers Cmax by 43 % and increases AUC by approximately 9 % .
H-1219	-0.015439177863299847	Administration of rivastigmine oral solution with food delays absorption ( tmax ) by 74 min and lowers Cmax by 43 % and increases AUC by approximately 9 % .
D-1219	-0.015439177863299847	Administration of rivastigmine oral solution with food delays absorption ( tmax ) by 74 min and lowers Cmax by 43 % and increases AUC by approximately 9 % .
P-1219	-0.0147 -0.0015 -0.0014 -0.0004 -0.0009 -0.0035 -0.0145 -0.0030 -0.0126 -0.0146 -0.0109 -0.0030 -0.0009 -0.0023 -0.0013 -0.0009 -0.0014 -0.0046 -0.0010 -0.3872 -0.0250 -0.0132 -0.0010 -0.0070 -0.0006 -0.0038 -0.0010 -0.0013 -0.0102 -0.0035 -0.0020 -0.0010 -0.0019 -0.0249 -0.0012 -0.0013 -0.0020 -0.0051
S-1707	Die zweithäufigste ( zumindest möglicherweise therapiebedingte ) Nebenwirkung Ptosis wurde in vergleichbarem Maß berichtet ( 1,9 % bei Xeomin im Vergleich zu 1,8 % bei Botox in der zusammengefassten Probe bzw .
T-1707	1.8 % for Botox in the pooled sample and 6.1 % for Xeomin vs .
H-1707	-0.022595113143324852	1.8 % for Botox in the pooled sample and 6.1 % for Xeomin vs .
D-1707	-0.022595113143324852	1.8 % for Botox in the pooled sample and 6.1 % for Xeomin vs .
P-1707	-0.0146 -0.0204 -0.0027 -0.0138 -0.0091 -0.0008 -0.0015 -0.0093 -0.0053 -0.0144 -0.0005 -0.0013 -0.0012 -0.0101 -0.0164 -0.3806 -0.0015 -0.0028 -0.0086 -0.0024 -0.0010 -0.0017 -0.0146 -0.0160 -0.0145
S-235	Wenn plötzliche , schwere ( anaphylaktische ) Nebenwirkungen auftreten , muss die Injektion sofort abgebrochen werden.Sie müssen sofort Kontakt mit Ihrem Arzt aufnehmen , wenn Sieeins der folgenden Frühsymptome für allergische ( überempfindliche ) Reaktionen haben :
T-235	You must contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitivity ) reactions :
H-235	-0.009429292753338814	You must contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitivity ) reactions :
D-235	-0.009429292753338814	You must contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitivity ) reactions :
P-235	-0.0197 -0.0311 -0.0139 -0.0559 -0.0022 -0.0217 -0.0015 -0.0018 -0.0081 -0.0060 -0.0016 -0.0016 -0.0008 -0.0011 -0.0031 -0.0047 -0.0067 -0.0005 -0.0056 -0.0041 -0.0396 -0.0022 -0.0015 -0.0022 -0.0008 -0.0039 -0.0128
S-1256	Zervikale Dystonie Patienten mit zervikaler Dystonie sollten darauf hingewiesen werden , dass Injektionen von BOTOX milde bis schwere Dysphagien hervorrufen können , mit der Gefahr einer Aspiration und Dyspnoe .
T-1256	Cervical dystonia Patients with cervical dystonia should be informed of the possibility of experiencing dysphagia which may be very mild , but could be severe .
H-1256	-0.011008976958692074	Cervical dystonia Patients with cervical dystonia should be informed of the possibility of experiencing dysphagia which may be very mild , but could be severe .
D-1256	-0.011008976958692074	Cervical dystonia Patients with cervical dystonia should be informed of the possibility of experiencing dysphagia which may be very mild , but could be severe .
P-1256	-0.0015 -0.0011 -0.0009 -0.0098 -0.0010 -0.0010 -0.0122 -0.0009 -0.0410 -0.0015 -0.0009 -0.0008 -0.0008 -0.0009 -0.0006 -0.0020 -0.0016 -0.0138 -0.1299 -0.0019 -0.0139 -0.0172 -0.0145 -0.0145 -0.0024 -0.0014 -0.0006 -0.0143 -0.0122 -0.0105 -0.0147 -0.0010 -0.0232 -0.0141 -0.0144 -0.0106 -0.0040 -0.0133 -0.0083
S-107	150 Verwendete Pens In Verwendung befindliche ( oder als Vorrat mitgeführte ) Fertigpens können maximal 4 Wochen lang bei einer Temperatur von nicht über 25 ° C , vor direkter Hitzeeinwirkung und direktem Licht geschützt , aufbewahrt werden .
T-107	Pre @-@ filled pens in use ( or carried as a spare ) may be stored for a maximum of 4 weeks not above 25 ° C away from direct heat or direct light .
H-107	-0.00879934523254633	Pre @-@ filled pens in use ( or carried as a spare ) may be stored for a maximum of 4 weeks not above 25 ° C away from direct heat or direct light .
D-107	-0.00879934523254633	Pre @-@ filled pens in use ( or carried as a spare ) may be stored for a maximum of 4 weeks not above 25 ° C away from direct heat or direct light .
P-107	-0.0145 -0.0195 -0.0015 -0.0125 -0.0039 -0.0010 -0.0103 -0.0018 -0.0036 -0.0019 -0.0140 -0.0096 -0.0122 -0.0144 -0.0051 -0.0129 -0.0034 -0.0054 -0.0014 -0.0063 -0.0051 -0.0017 -0.0024 -0.0321 -0.0013 -0.0540 -0.0145 -0.0163 -0.0016 -0.0014 -0.0145 -0.0016 -0.0011 -0.0089 -0.0132 -0.0109 -0.0018 -0.0025 -0.0032
S-431	In @-@ vitro @-@ Untersuchungen zum Metabolismus zeigten , dass am Metabolismus von Isotretinoin zu 4 @-@ Oxo @-@ Isotretinoin und Tretinoin mehrere Cytochrom @-@ P @-@ Enzyme beteiligt sind .
T-431	In vitro metabolism studies have demonstrated that several CYP enzymes are involved in the metabolism of isotretinoin to 4 @-@ oxo @-@ isotretinoin and tretinoin .
H-431	-0.00556604191660881	In vitro metabolism studies have demonstrated that several CYP enzymes are involved in the metabolism of isotretinoin to 4 @-@ oxo @-@ isotretinoin and tretinoin .
D-431	-0.00556604191660881	In vitro metabolism studies have demonstrated that several CYP enzymes are involved in the metabolism of isotretinoin to 4 @-@ oxo @-@ isotretinoin and tretinoin .
P-431	-0.0027 -0.0052 -0.0009 -0.0129 -0.0005 -0.0105 -0.0060 -0.0360 -0.0139 -0.0028 -0.0062 -0.0145 -0.0133 -0.0145 -0.0027 -0.0005 -0.0013 -0.0040 -0.0011 -0.0016 -0.0030 -0.0012 -0.0005 -0.0032 -0.0030 -0.0010 -0.0011 -0.0011 -0.0007 -0.0015 -0.0013 -0.0031 -0.0022 -0.0023 -0.0016 -0.0016 -0.0037 -0.0006 -0.0011 -0.0012 -0.0006 -0.0012 -0.0012 -0.0813 -0.0009 -0.0010 -0.0013 -0.0015 -0.0017 -0.0016
S-1950	Basierend auf den konventionellen Studien zur Genotoxizität , Fertilität , Embryo- / Fetusentwicklung , Geburt oder postnataler Entwicklung , und lokalen Verträglichkeit lassen die präklinischen Daten keine besonderen Gefahren für den Menschen erkennen .
T-1950	Preclinical data reveal no special hazard for humans based on conventional studies of genotoxicity , fertility , embryo / foetal development , parturition or post @-@ natal development , and local tolerance .
H-1950	-0.04098489508032799	Preclinical data reveal no special hazard for humans based on conventional studies of genotoxicity , fertility , embryo / foetal development , parturition or post @-@ natal development , and local tolerance .
D-1950	-0.04098489508032799	Preclinical data reveal no special hazard for humans based on conventional studies of genotoxicity , fertility , embryo / foetal development , parturition or post @-@ natal development , and local tolerance .
P-1950	-0.4986 -0.0035 -0.0005 -0.0007 -0.0036 -0.1461 -0.0033 -0.0140 -0.0129 -0.0127 -0.0107 -0.0057 -0.0059 -0.0017 -0.0052 -0.0031 -0.0113 -0.0010 -0.0007 -0.0011 -0.0012 -0.0011 -0.0015 -0.0018 -0.0012 -0.0015 -0.0023 -0.0007 -0.0952 -0.0024 -0.0137 -0.0002 -0.3010 -0.0014 -0.0015 -0.0145 -0.0145 -0.0022 -0.0018 -0.0534 -0.0128 -0.0098 -0.0008 -0.0014 -0.0024 -0.0105 -0.0032 -0.0044 -0.0063 -0.8179 -0.0048 -0.0015
S-1413	Sie sollten Ihrem Arzt sagen , wenn Sie Fluvoxamin ( ein Antidepressivum ) oder Ciprofloxacin ( ein Antibiotikum ) einnehmen , da es notwendig sein kann Ihre OLANZAPIN MYLAN Dosis zu ändern .
T-1413	You should tell your doctor if you are taking fluvoxamine ( an antidepressant ) or ciprofloxacin ( an antibiotic ) , as it may be necessary to change your Olanzapine Mylan dose .
H-1413	-0.004941678140312433	You should tell your doctor if you are taking fluvoxamine ( an antidepressant ) or ciprofloxacin ( an antibiotic ) , as it may be necessary to change your Olanzapine Mylan dose .
D-1413	-0.004941678140312433	You should tell your doctor if you are taking fluvoxamine ( an antidepressant ) or ciprofloxacin ( an antibiotic ) , as it may be necessary to change your Olanzapine Mylan dose .
P-1413	-0.0048 -0.0017 -0.0034 -0.0014 -0.0014 -0.0031 -0.0013 -0.0032 -0.0019 -0.0112 -0.0006 -0.0012 -0.0014 -0.0016 -0.0023 -0.0016 -0.0004 -0.0006 -0.0013 -0.0015 -0.1055 -0.0018 -0.0002 -0.0009 -0.0012 -0.0009 -0.0013 -0.0014 -0.0016 -0.0005 -0.0008 -0.0010 -0.0014 -0.0265 -0.0076 -0.0028 -0.0074 -0.0015 -0.0044 -0.0014 -0.0038 -0.0025 -0.0145 -0.0074 -0.0008 -0.0008 -0.0009 -0.0012 -0.0002 -0.0058 -0.0017 -0.0015
S-274	APTIVUS in Kombination mit niedrig dosiertem Ritonavir senkt die AUC und die Cmax von Ethinylestradiol um 50 % , beeinflusst jedoch die Pharmakokinetik von Norethindron nicht signifikant .
T-274	APTIVUS , co @-@ administered with low dose ritonavir , decreases the AUC and Cmax of ethinyl @-@ oestradiol by 50 % , but does not significantly alter the pharmacokinetic behaviour of norethindrone .
H-274	-0.014858708716928959	APTIVUS , co @-@ administered with low dose ritonavir , decreases the AUC and Cmax of ethinyl @-@ oestradiol by 50 % , but does not significantly alter the pharmacokinetics of norethindrone .
D-274	-0.014858708716928959	APTIVUS , co @-@ administered with low dose ritonavir , decreases the AUC and Cmax of ethinyl @-@ oestradiol by 50 % , but does not significantly alter the pharmacokinetics of norethindrone .
P-274	-0.0014 -0.0012 -0.0006 -0.0008 -0.0407 -0.0185 -0.0014 -0.0112 -0.0011 -0.0077 -0.0050 -0.0114 -0.0038 -0.0039 -0.0015 -0.0011 -0.0043 -0.0144 -0.0020 -0.0117 -0.0010 -0.0010 -0.0017 -0.0580 -0.0007 -0.0025 -0.0005 -0.0015 -0.0037 -0.0624 -0.0158 -0.0017 -0.0003 -0.0018 -0.0018 -0.0029 -0.0019 -0.0169 -0.0047 -0.0063 -0.0014 -0.0039 -0.0479 -0.0052 -0.0012 -0.0007 -0.0011 -0.4094 -0.0015 -0.0010 -0.0008 -0.0013 -0.0080 -0.0018 -0.0015
S-280	Blisterpackungen , Aluminium / Aluminium 10 , 20 , 28 , 30 , 50 , 56 , 98 , 100 , 300 Tabletten , 50 x 1 Tabletten ( Einzeldosen ) , 100 x 1 Tabletten ( Einzeldosen ) .
T-280	Blister packs , aluminium / aluminium 10 , 20 , 28 , 30 , 50 , 56 , 98 , 100 , 300 tablets , EMEA / CPMP / 0540 / 04 50 x 1 tablets ( unit dose ) , 100 x 1 tablets ( unit
H-280	-0.022842159494757652	Blister packs , aluminium / aluminium 10 , 20 , 28 , 30 , 50 , 56 , 98 , 100 , 300 tablets , EMEA / CPMP / 0540 / 04 50 x 1 tablets ( unit dose ) , 100 x 1 tablets ( unit
D-280	-0.022842159494757652	Blister packs , aluminium / aluminium 10 , 20 , 28 , 30 , 50 , 56 , 98 , 100 , 300 tablets , EMEA / CPMP / 0540 / 04 50 x 1 tablets ( unit dose ) , 100 x 1 tablets ( unit
P-280	-0.0066 -0.4741 -0.0067 -0.0011 -0.0029 -0.0039 -0.0058 -0.0016 -0.0039 -0.0015 -0.0032 -0.0014 -0.0012 -0.0014 -0.0011 -0.0014 -0.0012 -0.0014 -0.1048 -0.0014 -0.0010 -0.0014 -0.0008 -0.0014 -0.0010 -0.0014 -0.0010 -0.0020 -0.0013 -0.0015 -0.3330 -0.0145 -0.0035 -0.0142 -0.0229 -0.0144 -0.0145 -0.0140 -0.0674 -0.0144 -0.0969 -0.0146 -0.0217 -0.0023 -0.0017 -0.0018 -0.0021 -0.0071 -0.0145 -0.0141 -0.0020 -0.0047 -0.0108 -0.0015 -0.0015 -0.0015 -0.0014 -0.0015 -0.0025 -0.0145
S-1079	6 D @-@ 63128 Dietzenbach Tel : + 49 ( 0 ) 6074 812160 Eesti Orphan Europe AB Banérgatan 37 S @-@ 115 22 Stockholm Rootsi Tel : + 46 8 545 80 230
T-1079	Eesti Orphan Europe AB Banérgatan 37 S @-@ 115 22 Stockholm Rootsi Tel : + 4 6 8 545 80 230
H-1079	-0.011312768794596195	Eesti Orphan Europe AB Banérgatan 37 S @-@ 115 22 Stockholm Rootsi Tel : + 4 6 8 545 80 230
D-1079	-0.011312768794596195	Eesti Orphan Europe AB Banérgatan 37 S @-@ 115 22 Stockholm Rootsi Tel : + 4 6 8 545 80 230
P-1079	-0.0145 -0.0025 -0.0013 -0.0017 -0.0012 -0.0012 -0.0010 -0.0005 -0.0013 -0.0003 -0.0010 -0.0010 -0.0013 -0.0009 -0.0008 -0.0015 -0.0016 -0.0015 -0.0008 -0.0015 -0.0007 -0.0007 -0.0035 -0.0019 -0.0011 -0.2502 -0.0143 -0.0145 -0.0021 -0.0322 -0.0017 -0.0010 -0.0120
S-893	Verteilung Posaconazol wird langsam resorbiert , bei einem hohen apparenten Verteilungsvolumen ( 1.774 Liter ) langsam eliminiert und ist in hohem Maß an Proteine gebunden ( &gt; 98 % ) , vorwiegend an Serumalbumin .
T-893	Distribution Posaconazole is slowly absorbed and slowly eliminated with a large apparent volume of distribution ( 1,774 litres ) and is highly protein bound ( &gt; 98 % ) , predominantly to serum albumin .
H-893	-0.004640876781195402	Distribution Posaconazole is slowly absorbed and slowly eliminated with a large apparent volume of distribution ( 1,774 litres ) and is highly protein bound ( &gt; 98 % ) , predominantly to serum albumin .
D-893	-0.004640876781195402	Distribution Posaconazole is slowly absorbed and slowly eliminated with a large apparent volume of distribution ( 1,774 litres ) and is highly protein bound ( &gt; 98 % ) , predominantly to serum albumin .
P-893	-0.0108 -0.0010 -0.0036 -0.0010 -0.0012 -0.0005 -0.0014 -0.0024 -0.0057 -0.0042 -0.0008 -0.0127 -0.0086 -0.0020 -0.0007 -0.0139 -0.0042 -0.0128 -0.0145 -0.0142 -0.0058 -0.0026 -0.0016 -0.0054 -0.0012 -0.0007 -0.0043 -0.0093 -0.0013 -0.0015 -0.0133 -0.0049 -0.0116 -0.0140 -0.0064 -0.0015 -0.0009 -0.0006 -0.0014 -0.0014 -0.0029 -0.0102 -0.0006 -0.0020 -0.0104 -0.0007 -0.0032 -0.0002 -0.0009 -0.0014 -0.0015 -0.0015
S-1355	3 Neugeborene ( im Alter von 0 @-@ 1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2 @-@ 12 Jahren ) , Jugendliche ( im Alter von 12 @-@ 16 Jahren ) , Erwachsene ( über 16 Jahre )
T-1355	3 Neonates ( age 0 <<unk>> 1 month ) , infants ( age 1 month <<unk>> 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-1355	-0.05570245534181595	3 Neonates ( age 0 <unk> 1 month ) , infants ( age 1 month <unk> 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
D-1355	-0.05570245534181595	3 Neonates ( age 0 <unk> 1 month ) , infants ( age 1 month <unk> 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
P-1355	-0.0035 -0.0145 -0.0024 -0.0015 -0.0142 -0.0063 -1.1113 -0.0050 -0.0114 -0.0016 -0.0015 -0.0142 -0.0070 -0.0014 -0.0059 -0.0019 -0.0057 -0.0166 -0.0031 -0.1212 -0.0014 -0.0014 -0.0022 -0.0013 -0.0046 -0.0015 -0.0148 -0.0011 -0.3190 -0.0014 -0.0014 -0.0107 -0.0006 -0.0008 -0.0013 -0.0033 -0.0013 -0.3652 -0.0010 -0.3785 -0.0014 -0.0732 -0.0019 -0.0014 -0.0148 -0.0133 -0.0012 -0.2112 -0.0013 -0.0024
S-1224	Bei Männern , mit deren Samen die In @-@ vitro @-@ Befruchtung einer Eizelle wiederholt erfolglos bleibt und bei denen keine andere Erklärung gefunden wird , sollten Kalziumantagonisten wie Nifedipin als mögliche Ursache in Betracht gezogen werden .
T-1224	In those men who are repeatedly unsuccessful in fathering a child by in vitro fertilisation , and where no other explanation can be found , calcium antagonists like nifedipine should be considered as possible causes .
H-1224	-0.011968796141445637	In those men who are repeatedly unsuccessful in fathering a child by in vitro fertilisation , and where no other explanation can be found , calcium antagonists like nifedipine should be considered as possible causes .
D-1224	-0.011968796141445637	In those men who are repeatedly unsuccessful in fathering a child by in vitro fertilisation , and where no other explanation can be found , calcium antagonists like nifedipine should be considered as possible causes .
P-1224	-0.0080 -0.0143 -0.0035 -0.0197 -0.0132 -0.0090 -0.0071 -0.0006 -0.0044 -0.0145 -0.0035 -0.0015 -0.0132 -0.0138 -0.0144 -0.0135 -0.0009 -0.0007 -0.0072 -0.0069 -0.0117 -0.0052 -0.0136 -0.0030 -0.0056 -0.0036 -0.0123 -0.0013 -0.0023 -0.0024 -0.0029 -0.0008 -0.2401 -0.0290 -0.0001 -0.0019 -0.0567 -0.0025 -0.0009 -0.0010 -0.0028 -0.0009 -0.0032 -0.0015 -0.0023 -0.0028 -0.0116 -0.0032 -0.0020 -0.0014
S-305	Als das EPC @-@ Programm vor über 8 Jahren ins Leben gerufen wurde , hatte es zum Ziel , den Nutzen einer frühen Bicalutamid @-@ Therapie im Vergleich zu Placebo als Monotherapie oder zusätzlich zu Operation oder Strahlentherapie zu dokumentieren .
T-305	When the EPC programme was initiated more than 8 years ago , the aim was to document the benefit of early bicalutamide therapy versus placebo as monotherapy or adjuvant therapy to surgery or radiotherapy .
H-305	-0.008821520023047924	When the EPC programme was initiated more than 8 years ago , the aim was to document the benefit of early bicalutamide therapy versus placebo as monotherapy or adjuvant therapy to surgery or radiotherapy .
D-305	-0.008821520023047924	When the EPC programme was initiated more than 8 years ago , the aim was to document the benefit of early bicalutamide therapy versus placebo as monotherapy or adjuvant therapy to surgery or radiotherapy .
P-305	-0.0042 -0.0035 -0.0020 -0.0009 -0.0121 -0.0021 -0.0140 -0.0013 -0.0090 -0.0014 -0.0036 -0.0516 -0.0048 -0.0055 -0.0106 -0.0082 -0.0029 -0.0015 -0.0022 -0.0016 -0.0124 -0.0018 -0.0035 -0.0067 -0.0009 -0.0012 -0.0009 -0.0011 -0.0039 -0.0219 -0.0016 -0.0011 -0.0007 -0.0011 -0.0054 -0.0057 -0.0018 -0.0006 -0.0044 -0.0145 -0.0006 -0.0014 -0.0140 -0.0143 -0.0040 -0.1126 -0.0456 -0.0113 -0.0017 -0.0014
S-1073	Erhöhungen der alkalischen Phosphatase , Amylase und Lipase im Serum können nach einigen Therapiewochen auftreten , die Spiegel sinken innerhalb des ersten oder der ersten beiden Therapiejahre üblicherweise wieder auf hochnormale Werte ab .
T-1073	Elevations of serum alkaline phosphatase , amylase and lipase may occur after a few weeks of treatment , with levels usually returning to high normal within the first one or two years of treatment .
H-1073	-0.022774146869778633	Elevations of serum alkaline phosphatase , amylase and lipase may occur after a few weeks of treatment , with levels usually returning to high normal within the first one or two years of treatment .
D-1073	-0.022774146869778633	Elevations of serum alkaline phosphatase , amylase and lipase may occur after a few weeks of treatment , with levels usually returning to high normal within the first one or two years of treatment .
P-1073	-0.0094 -0.0043 -0.0053 -0.3433 -0.0145 -0.0023 -0.0024 -0.0009 -0.0014 -0.0011 -0.0008 -0.0004 -0.0008 -0.0017 -0.0007 -0.0010 -0.0010 -0.0061 -0.4714 -0.0017 -0.0007 -0.0078 -0.0045 -0.0031 -0.0066 -0.0028 -0.0014 -0.0037 -0.0104 -0.0178 -0.0141 -0.0029 -0.0088 -0.0120 -0.0017 -0.0141 -0.0096 -0.0136 -0.0026 -0.0016 -0.0312 -0.0270 -0.0064 -0.0023 -0.0069 -0.0064 -0.0015 -0.0014
S-453	Lediglich für Broiler , die über 9 Zyklen jährlich behandelt wurden , und nur , wenn die Einstreu auf Weideland ausgebracht wurde , könnte ein nicht vertretbares Risiko für Pflanzen entstehen ( Risikoquotient ( RQ ) &gt; 1 ) .
T-453	Only for broilers treated for 9 cycles per year and only when litter is spread on grassland could there be an unacceptable risk for plants ( Risk Quotient ( RQ ) value &gt; 1 ) .
H-453	-0.007389779202640057	Only for broilers treated for 9 cycles per year and only when litter is spread on grassland could there be an unacceptable risk for plants ( Risk Quotient ( RQ ) value &gt; 1 ) .
D-453	-0.007389779202640057	Only for broilers treated for 9 cycles per year and only when litter is spread on grassland could there be an unacceptable risk for plants ( Risk Quotient ( RQ ) value &gt; 1 ) .
P-453	-0.0064 -0.0128 -0.0010 -0.0005 -0.0076 -0.0110 -0.0101 -0.0023 -0.0006 -0.0080 -0.0022 -0.0166 -0.0044 -0.0120 -0.0118 -0.0010 -0.0102 -0.0090 -0.0102 -0.0129 -0.0049 -0.0048 -0.0092 -0.0098 -0.0050 -0.0030 -0.0066 -0.0015 -0.0487 -0.0034 -0.0016 -0.0099 -0.0012 -0.0109 -0.0011 -0.0017 -0.0006 -0.0037 -0.0023 -0.0018 -0.0014 -0.0353 -0.0226 -0.0015 -0.0014 -0.0016 -0.0014
S-1901	Nach der Behandlung mit Clostridium botulinum Toxin Typ A wurde in seltenen Fällen über plötzliche Todesfälle berichtet , die gelegentlich mit Dysphagie , Pneumonie und / oder anderen Schwächezuständen assoziiert waren .
T-1901	There have been rare spontaneous reports of death , sometimes associated with dysphagia , pneumonia and / or other significant debility , after treatment with botulinum toxin type A .
H-1901	-0.011168568395078182	There have been rare spontaneous reports of death , sometimes associated with dysphagia , pneumonia and / or other significant debility , after treatment with botulinum toxin type A .
D-1901	-0.011168568395078182	There have been rare spontaneous reports of death , sometimes associated with dysphagia , pneumonia and / or other significant debility , after treatment with botulinum toxin type A .
P-1901	-0.0145 -0.0390 -0.0033 -0.0092 -0.0146 -0.0003 -0.0012 -0.0141 -0.0022 -0.0075 -0.0138 -0.0125 -0.0055 -0.0015 -0.0012 -0.0002 -0.0010 -0.0009 -0.0017 -0.0015 -0.0006 -0.0008 -0.0003 -0.2388 -0.0020 -0.0012 -0.0016 -0.0152 -0.0169 -0.0139 -0.0070 -0.0080 -0.0057 -0.0020 -0.0145 -0.0012 -0.0016 -0.0011 -0.0005 -0.0013 -0.0036 -0.0023 -0.0039 -0.0015
S-1618	Verkehrstüchtigkeit und das Bedienen von Maschinen Sie dürfen sich nicht an das Steuer eines Fahrzeugs setzen oder Maschinen bedienen , wenn Sie nach der Behandlung mit IONSYS das Krankenhaus verlassen , weil das Schmerzmittel manche Menschen benommen oder schläfrig macht .
T-1618	Driving and using machines Do not drive or operate machines when you leave hospital after using IONSYS because the painkiller leaves some people feeling dizzy or drowsy .
H-1618	-0.006474060472100973	Driving and using machines Do not drive or operate machines when you leave hospital after using IONSYS because the painkiller leaves some people feeling dizzy or drowsy .
D-1618	-0.006474060472100973	Driving and using machines Do not drive or operate machines when you leave hospital after using IONSYS because the painkiller leaves some people feeling dizzy or drowsy .
P-1618	-0.0140 -0.0080 -0.0053 -0.0140 -0.0076 -0.0141 -0.0013 -0.0144 -0.0091 -0.0154 -0.0100 -0.0083 -0.0072 -0.0045 -0.0088 -0.0036 -0.0132 -0.0033 -0.0011 -0.0014 -0.0013 -0.0011 -0.0113 -0.0044 -0.0093 -0.0008 -0.0004 -0.0005 -0.0137 -0.0060 -0.0025 -0.0124 -0.0101 -0.0009 -0.0043 -0.0082 -0.0006 -0.0007 -0.0020 -0.0039
S-783	Arzneilich wirksame Bestandteile Protein dO ( nicht toxisches Deletionsderivat des dermonekrotischen Toxins von Pasteurella multocida ) Inaktivierte Bordetella bronchiseptica Zellen 1
T-783	Protein dO ( non @-@ toxic deletion derivative of Pasteurella multocida ) dermonecrotic toxin )
H-783	-0.004148559179157019	Protein dO ( non @-@ toxic deletion derivative of Pasteurella multocida ) dermonecrotic toxin )
D-783	-0.004148559179157019	Protein dO ( non @-@ toxic deletion derivative of Pasteurella multocida ) dermonecrotic toxin )
P-783	-0.0145 -0.0008 -0.0021 -0.0013 -0.0022 -0.0052 -0.0060 -0.0032 -0.0006 -0.0009 -0.0021 -0.0006 -0.0013 -0.0018 -0.0016 -0.0138 -0.0008 -0.0014 -0.0004 -0.0009 -0.0010 -0.0016 -0.0008 -0.0145 -0.0148 -0.0020 -0.0021 -0.0052 -0.0013 -0.0012 -0.0015 -0.0145 -0.0149
S-294	Für HPV @-@ 18 war der Unterschied zwischen Impfstoff- und Kontrollgruppen bezüglich CIN2 + -Läsionen und persistierender Infektion über einen Zeitraum von 12 Monaten ( TVC @-@ 1 @-@ Kohorte ) statistisch nicht signifikant .
T-294	However , in a pre @-@ specified analysis ( TVC @-@ 2 ) that was identical to the
H-294	-0.03182700276374817	However , in a pre @-@ specified analysis ( TVC @-@ 2 ) that was identical to the
D-294	-0.03182700276374817	However , in a pre @-@ specified analysis ( TVC @-@ 2 ) that was identical to the
P-294	-0.0145 -0.0021 -0.0135 -0.0145 -0.0145 -0.0014 -0.0145 -0.0084 -0.0145 -0.0148 -0.0091 -0.0014 -0.0027 -0.4896 -0.0129 -0.0145 -0.0119 -0.0145 -0.0008 -0.0068 -0.0087 -0.0145
S-968	Poly ( vinylalkohol ) ; Titandioxid ; Macrogol ; Talkum ; entölte Phospholipide aus Sojabohnen ; Indigocarmin , Aluminiumsalz ( E132 ) .
T-968	40 The coating : polyvinyl alcohol , titanium dioxide , macrogol , talc , soya lecithin , indigo carmine aluminium lake ( E132 )
H-968	-0.00946543738245964	40 The coating : polyvinyl alcohol , titanium dioxide , macrogol , talc , soya lecithin , indigo carmine aluminium lake ( E132 )
D-968	-0.00946543738245964	40 The coating : polyvinyl alcohol , titanium dioxide , macrogol , talc , soya lecithin , indigo carmine aluminium lake ( E132 )
P-968	-0.0337 -0.0147 -0.0210 -0.0117 -0.0144 -0.0142 -0.0104 -0.0004 -0.0030 -0.0132 -0.0018 -0.0009 -0.0010 -0.0013 -0.0006 -0.0021 -0.0047 -0.0012 -0.0025 -0.0013 -0.0033 -0.0007 -0.0085 -0.0060 -0.0143 -0.0129 -0.0145 -0.0145 -0.0098 -0.0134 -0.0043 -0.0119 -0.0044 -0.0016 -0.0340 -0.0037 -0.0404 -0.0304 -0.0031 -0.0014 -0.0014 -0.0016 -0.0170
S-973	Eine altersbedingte Verminderung der renalen Clearance verbunden mit einer Zunahme der AUC @-@ Werte ist bei älteren Patienten zu bedenken ( siehe hierzu den obigen Absatz &quot; Patienten mit eingeschränkter Nierenfunktion &quot; sowie Abschnitt 5.2 ) .
T-973	2 should be considered in elderly patients ( see <<unk>> Use in patients with renal impairment <<unk>> above and section 5.2 ) .
H-973	-0.010873554274439812	2 should be considered in elderly patients ( see <unk> Use in patients with renal impairment <unk> above and section 5.2 ) .
D-973	-0.010873554274439812	2 should be considered in elderly patients ( see <unk> Use in patients with renal impairment <unk> above and section 5.2 ) .
P-973	-0.0145 -0.0340 -0.0056 -0.0068 -0.0092 -0.0135 -0.0014 -0.0140 -0.0033 -0.0145 -0.0145 -0.0143 -0.0142 -0.0016 -0.0548 -0.0009 -0.0051 -0.0011 -0.0005 -0.0013 -0.0143 -0.0136 -0.0065 -0.0137 -0.0015 -0.0016 -0.0182 -0.0086 -0.0120
S-1914	Die Bioverfügbarkeit ist geringer , wenn Ciprofloxacin zusammen mit Aluminium- und / oder Magnesiumhydroxid @-@ haltigen Antazida und Calcium- oder Eisensalzen angewendet wird .
T-1914	The bioavailability is lower if antacids that contain aluminium and / or magnesium hydroxide , and calcium and iron salts are used concomitantly .
H-1914	-0.01616242341697216	The bioavailability is lower if antacids that contain aluminium and / or magnesium hydroxide , and calcium and iron salts are used concomitantly .
D-1914	-0.01616242341697216	The bioavailability is lower if antacids that contain aluminium and / or magnesium hydroxide , and calcium and iron salts are used concomitantly .
P-1914	-0.0081 -0.0016 -0.0011 -0.0030 -0.0090 -0.1635 -0.0161 -0.0008 -0.0021 -0.0145 -0.0026 -0.0046 -0.0060 -0.0020 -0.0016 -0.0012 -0.0026 -0.0010 -0.0011 -0.0010 -0.0010 -0.0012 -0.0130 -0.0099 -0.0018 -0.0007 -0.2726 -0.0189 -0.0022 -0.0010 -0.0014 -0.0028 -0.0078 -0.0152 -0.0140 -0.0062 -0.0023 -0.0132 -0.0015
S-838	Wenn Janumet mit einem Sulfonylharnstoff kombiniert wird , kann es jedoch zu einer Unterzuckerung ( Hypoglykämie ) kommen und Ihr Arzt wird möglicherweise die Dosis Ihres Sulfonylharnstoffes reduzieren .
T-838	When Janumet is used with a sulphonylurea medicine , low blood sugar can occur and your doctor may reduce the dose of your sulphonylurea .
H-838	-0.007978364825248718	When Janumet is used with a sulphonylurea medicine , low blood sugar can occur and your doctor may reduce the dose of your sulphonylurea .
D-838	-0.007978364825248718	When Janumet is used with a sulphonylurea medicine , low blood sugar can occur and your doctor may reduce the dose of your sulphonylurea .
P-838	-0.0139 -0.0018 -0.0007 -0.0011 -0.0014 -0.0154 -0.0188 -0.0066 -0.0027 -0.0136 -0.0014 -0.0024 -0.0038 -0.0015 -0.0225 -0.0145 -0.0035 -0.0144 -0.0107 -0.0024 -0.0137 -0.0062 -0.0341 -0.0024 -0.0014 -0.0690 -0.0028 -0.0054 -0.0042 -0.0019 -0.0018 -0.0015 -0.0075 -0.0011 -0.0011 -0.0035 -0.0011 -0.0012 -0.0038 -0.0025
S-1691	Während des Beurteilungsprozesses wird es verstärkte Möglichkeiten für den Dialog zwischen den Antragstellern und ihren Sachverständigen einerseits und dem Berichterstatter , dem Mitberichterstatter , den europäischen Sachverständigen und dem EMEA @-@ Produktteam andererseits geben .
T-1691	During the evaluation process there will be increased opportunity for dialogue between applicants and their experts with the rapporteur , co @-@ rapporteur , the European experts and the EMEA product team .
H-1691	-0.008148281835019588	During the evaluation process there will be increased opportunity for dialogue between applicants and their experts with the rapporteur , co @-@ rapporteur , the European experts and the EMEA product team .
D-1691	-0.008148281835019588	During the evaluation process there will be increased opportunity for dialogue between applicants and their experts with the rapporteur , co @-@ rapporteur , the European experts and the EMEA product team .
P-1691	-0.0060 -0.0018 -0.0057 -0.0008 -0.0009 -0.0016 -0.0112 -0.0020 -0.0054 -0.0075 -0.0142 -0.0026 -0.0015 -0.0042 -0.0096 -0.0004 -0.0013 -0.0017 -0.0015 -0.0039 -0.0363 -0.0033 -0.0011 -0.0011 -0.0019 -0.0021 -0.0065 -0.1243 -0.0006 -0.0011 -0.0022 -0.0021 -0.0244 -0.0121 -0.0016 -0.0364 -0.0030 -0.0026 -0.0008 -0.0012 -0.0026 -0.0019 -0.0042 -0.0014
S-1014	6 Wechselwirkungen bei serologischen Untersuchungen Nach Infusion von Immunglobulin kann es durch den vorübergehenden Anstieg der verschiedenen , passiv übertragenen Antikörper im Blut des Patienten zu falsch positiven Testergebnissen bei serologischen Untersuchungen kommen .
T-1014	Interference with serological testing After infusion of immunoglobulin the transitory rise of the various passively transferred antibodies in the patients blood may result in misleading positive results in serological testing .
H-1014	-0.024967672303318977	Interference with serological testing After infusion of immunoglobulin the transitory rise of the various passively transferred antibodies in the patients blood may result in misleading positive results in serological testing .
D-1014	-0.024967672303318977	Interference with serological testing After infusion of immunoglobulin the transitory rise of the various passively transferred antibodies in the patients blood may result in misleading positive results in serological testing .
P-1014	-0.0143 -0.4317 -0.0141 -0.0019 -0.0031 -0.0140 -0.0074 -0.0088 -0.0033 -0.0040 -0.0017 -0.0008 -0.0006 -0.0010 -0.0016 -0.0132 -0.0137 -0.0008 -0.3074 -0.0118 -0.0839 -0.0098 -0.0114 -0.0085 -0.0014 -0.0092 -0.0121 -0.0008 -0.0031 -0.0023 -0.0197 -0.0060 -0.0085 -0.0123 -0.0015 -0.0145 -0.0136 -0.0090 -0.0119 -0.0108 -0.0021 -0.0014 -0.0108 -0.0019 -0.0017
S-735	Hypertonie vom Grad 4 ( eine hypertensive Krise ) trat bei bis zu 1,0 % der Patienten unter Avastin und Chemotherapie auf , verglichen mit bis zu 0,2 % bei Patienten , die mit Chemotherapie allein behandelt wurden .
T-735	Grade 4 hypertension ( hypertensive crisis ) occurred in up to 1.0 % of patients treated with Avastin and chemotherapy compared to up to 0.2 % of patients treated with the same chemotherapy alone .
H-735	-0.023443007841706276	Grade 4 hypertension ( hypertensive crisis ) occurred in up to 1.0 % of patients treated with Avastin and chemotherapy compared to up to 0.2 % of patients treated with the same chemotherapy alone .
D-735	-0.023443007841706276	Grade 4 hypertension ( hypertensive crisis ) occurred in up to 1.0 % of patients treated with Avastin and chemotherapy compared to up to 0.2 % of patients treated with the same chemotherapy alone .
P-735	-0.0013 -0.0010 -0.0048 -0.0011 -0.0001 -0.0018 -0.0107 -0.0013 -0.0006 -0.0062 -0.0014 -0.0086 -0.0019 -0.0028 -0.0013 -0.0044 -0.0012 -0.0017 -0.0014 -0.0048 -0.0123 -0.0016 -0.0009 -0.0004 -0.0013 -0.0022 -0.0205 -0.0005 -0.1230 -0.2339 -0.5307 -0.0059 -0.0014 -0.0010 -0.0014 -0.0012 -0.0104 -0.0060 -0.0019 -0.0019 -0.0328 -0.0144 -0.0126 -0.0005 -0.0421 -0.0028 -0.0017 -0.0014
S-388	Myelosuppression Die Behandlung mit Tasigna ist mit Thrombozytopenie , Neutropenie und Anämie assoziiert ( National Cancer Institute Common Toxicity Criteria Grad 3 @-@ 4 ) .
T-388	Myelosuppression Treatment with Tasigna is associated with ( National Cancer Institute Common Toxicity Criteria grade 3 @-@ 4 ) thrombocytopenia , neutropenia and anaemia .
H-388	-0.0068512167781591415	Myelosuppression Treatment with Tasigna is associated with ( National Cancer Institute Common Toxicity Criteria grade 3 @-@ 4 ) thrombocytopenia , neutropenia and anaemia .
D-388	-0.0068512167781591415	Myelosuppression Treatment with Tasigna is associated with ( National Cancer Institute Common Toxicity Criteria grade 3 @-@ 4 ) thrombocytopenia , neutropenia and anaemia .
P-388	-0.0041 -0.0029 -0.0051 -0.0012 -0.0006 -0.0007 -0.0014 -0.0029 -0.0007 -0.0011 -0.0019 -0.0039 -0.0005 -0.0004 -0.0027 -0.0006 -0.0014 -0.0150 -0.0117 -0.0005 -0.0007 -0.0039 -0.0013 -0.0008 -0.0010 -0.0006 -0.0013 -0.0009 -0.0006 -0.0137 -0.0016 -0.2302 -0.0014 -0.0014 -0.0043 -0.0010 -0.0004 -0.0006 -0.0011 -0.0005 -0.0015 -0.0010 -0.0006 -0.0009 -0.0005 -0.0060 -0.0020 -0.0121 -0.0003 -0.0012 -0.0020 -0.0015
S-924	Nach der Applikation am Auge betrug die mittlere steady @-@ state Plasmakonzentration Cmax für Nepafenac 0,310 ± 0,104 ng / ml und für Amfenac 0,422 ± 0,121 ng / ml .
T-924	The mean steady @-@ state plasma Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng / ml and 0.422 ± 0.121 ng / ml , respectively , following ocular administration .
H-924	-0.09249789267778397	The mean steady @-@ state plasma Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng / ml and 0.422 ± 0.121 ng / ml , following ocular administration .
D-924	-0.09249789267778397	The mean steady @-@ state plasma Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng / ml and 0.422 ± 0.121 ng / ml , following ocular administration .
P-924	-0.0137 -0.0042 -0.0055 -0.0023 -0.0009 -0.0029 -0.0004 -0.0006 -0.0143 -0.0006 -0.0143 -0.0134 -0.0037 -0.0021 -0.0011 -0.0005 -0.0147 -0.0141 -0.0086 -0.0004 -0.0004 -0.0150 -0.0068 -0.0571 -0.0014 -0.0005 -0.0035 -0.0006 -0.0010 -0.0012 -0.0015 -0.0014 -0.0047 -0.0024 -0.0012 -0.0011 -0.0005 -0.0016 -0.0011 -0.0015 -0.0011 -0.0011 -0.0015 -0.0007 -0.0145 -4.4358 -0.0144 -0.0002 -0.0138 -0.0104 -0.0015
S-578	Die durchschnittliche Änderung im Gesamtcholesterin betrug mit Orlistat 60 mg -2,4 % ( Ausgangswert 5,20 mmol / l ) und mit Placebo + 2,8 % ( Ausgangswert 5,26 mmol / l ) .
T-578	The mean relative change in total cholesterol was -2.4 % for orlistat 60 mg ( baseline 5.20 mmol / l ) and + 2.8 % for placebo ( baseline 5.26 mmol / l ) .
H-578	-0.003505392698571086	The mean relative change in total cholesterol was -2.4 % for orlistat 60 mg ( baseline 5.20 mmol / l ) and + 2.8 % for placebo ( baseline 5.26 mmol / l ) .
D-578	-0.003505392698571086	The mean relative change in total cholesterol was -2.4 % for orlistat 60 mg ( baseline 5.20 mmol / l ) and + 2.8 % for placebo ( baseline 5.26 mmol / l ) .
P-578	-0.0065 -0.0080 -0.0278 -0.0155 -0.0066 -0.0052 -0.0006 -0.0005 -0.0007 -0.0063 -0.0143 -0.0026 -0.0013 -0.0014 -0.0140 -0.0058 -0.0003 -0.0033 -0.0121 -0.0008 -0.0028 -0.0008 -0.0013 -0.0056 -0.0018 -0.0012 -0.0010 -0.0010 -0.0014 -0.0037 -0.0014 -0.0023 -0.0023 -0.0011 -0.0012 -0.0013 -0.0036 -0.0008 -0.0011 -0.0007 -0.0012 -0.0018 -0.0002 -0.0007 -0.0009 -0.0040 -0.0011 -0.0010 -0.0009 -0.0014 -0.0015 -0.0014 -0.0017 -0.0014
S-587	Bei Macaca mulatta ( Rhesus @-@ Affen ) konnte man für Interferon alfa @-@ 2b nach Gabe des 90- und 180fachen der empfohlenen intramuskulären oder subkutanen Dosis von
T-587	Interferon alfa @-@ 2b has been shown to have abortifacient effects in Macaca mulatta ( rhesus monkeys ) at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU / m2 .
H-587	-0.006918408442288637	Interferon alfa @-@ 2b has been shown to have abortifacient effects in Macaca mulatta ( rhesus monkeys ) at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU / m2 .
D-587	-0.006918408442288637	Interferon alfa @-@ 2b has been shown to have abortifacient effects in Macaca mulatta ( rhesus monkeys ) at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU / m2 .
P-587	-0.0143 -0.0008 -0.0014 -0.0026 -0.0008 -0.0014 -0.0013 -0.0012 -0.0141 -0.0038 -0.0090 -0.0026 -0.0142 -0.0145 -0.0144 -0.0119 -0.0077 -0.0119 -0.0117 -0.0077 -0.0134 -0.0018 -0.0015 -0.0016 -0.0013 -0.0014 -0.0091 -0.0018 -0.0009 -0.0014 -0.0041 -0.0011 -0.0014 -0.0143 -0.0045 -0.0047 -0.0024 -0.0032 -0.0041 -0.0023 -0.0015 -0.0558 -0.0009 -0.0006 -0.0027 -0.0018 -0.0005 -0.0006 -0.0014 -0.0015 -0.0115 -0.0067 -0.0144 -0.0145 -0.0145 -0.0124 -0.0140 -0.0145 -0.0198 -0.0022
S-615	Wird das Produkt nicht wie in dieser Fachinformation beschrieben verwendet , kann dies zu einer Prävalenz Fluorochinolon @-@ resistenter Bakterien und einer reduzierten Wirksamkeit der Behandlung mit anderen Chinolonen aufgrund potentieller Kreuzresistenz führen .
T-615	2 / 64 Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance .
H-615	-0.008027033880352974	2 / 64 Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance .
D-615	-0.008027033880352974	2 / 64 Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance .
P-615	-0.0145 -0.0459 -0.0145 -0.0144 -0.0048 -0.0067 -0.0027 -0.0145 -0.0128 -0.0022 -0.0065 -0.0138 -0.0139 -0.0034 -0.0137 -0.0145 -0.0115 -0.0103 -0.0376 -0.0028 -0.0020 -0.0003 -0.0009 -0.0017 -0.0135 -0.0025 -0.0013 -0.0015 -0.0143 -0.0106 -0.0010 -0.0134 -0.0082 -0.0013 -0.0018 -0.0143 -0.0042 -0.0164 -0.0152 -0.0009 -0.0038 -0.0188 -0.0009 -0.0016 -0.0083 -0.0024 -0.0030 -0.0019 -0.0015 -0.0015 -0.0014 -0.0056 -0.0014 -0.0140 -0.0041 -0.0063 -0.0028 -0.0122 -0.0026 -0.0014
S-191	Ein Patient , der im Rahmen eines Compassionate @-@ Use @-@ Programms behandelt wurde , starb nach Gabe von Chemotherapeutika zur Senkung der Leukozytenzahl an einem Zerebralinfarkt infolge der Leukozytose .
T-191	One patient treated under a compassionate use program died from cerebral infarct due to leukocytosis , following treatment with chemotherapeutic medicinal products to lower WBC count .
H-191	-0.030093375593423843	One patient treated under a compassionate use program died from cerebral infarct due to leukocytosis , following treatment with chemotherapeutic medicines to lower WBC count .
D-191	-0.030093375593423843	One patient treated under a compassionate use program died from cerebral infarct due to leukocytosis , following treatment with chemotherapeutic medicines to lower WBC count .
P-191	-0.0119 -0.0015 -0.0093 -0.0195 -0.0053 -0.0075 -0.0006 -0.0009 -0.0017 -0.0060 -0.0032 -0.0122 -0.0131 -0.0008 -0.0010 -0.0044 -0.0004 -0.1002 -0.0127 -0.0014 -0.0011 -0.0027 -0.0005 -0.0007 -0.0010 -0.0181 -0.0123 -0.0142 -0.0028 -0.0023 -0.0005 -0.0113 -0.0460 -0.0144 -0.8659 -0.0080 -0.0159 -0.0153 -0.0033 -0.0111 -0.0017 -0.0015
S-110	Die Umstellung des Patienten auf die Behandlung mit &lt; Phantasiebezeichnung &gt; sollte mit Vorsicht durchgeführt werden , insbesondere , wenn anzunehmen ist , dass die Nebennierenfunktion durch eine frühere systemische Kortikoidbehandlung beeinträchtigt ist .
T-110	Parque Tecnologico de Madrid , Calle Severo Ochoa 2 , 28760 , Tres Cantos , Madrid
H-110	-0.020687231793999672	Parque Tecnologico de Madrid , Calle Severo Ochoa 2 , 28760 , Tres Cantos , Madrid
D-110	-0.020687231793999672	Parque Tecnologico de Madrid , Calle Severo Ochoa 2 , 28760 , Tres Cantos , Madrid
P-110	-0.0145 -0.0145 -0.0145 -0.0137 -0.0143 -0.0137 -0.0143 -0.0147 -0.0145 -0.0135 -0.0144 -0.0144 -0.0145 -0.0137 -0.0839 -0.0144 -0.0042 -0.1228 -0.0094 -0.0288 -0.0146 -0.0147 -0.0111 -0.0299 -0.0145 -0.0144 -0.0145 -0.0118 -0.0179 -0.0145
S-1323	Die anfängliche Infusionsrate sollte nicht mehr als 0,25 mg pro Minute ( 15 mg pro Stunde ) betragen , um das Risiko infusionsbedingter Nebenwirkungen herabzusetzen , und kann bei nachfolgenden Infusionen allmählich erhöht werden .
T-1323	The starting infusion rate should be no more than 0.25 mg per minute ( 15 mg per hour ) to reduce the risk of infusion @-@ related side effects .
H-1323	-0.02856927178800106	The starting infusion rate should be no more than 0.25 mg per minute ( 15 mg per hour ) to reduce the risk of infusion @-@ related side effects .
D-1323	-0.02856927178800106	The starting infusion rate should be no more than 0.25 mg per minute ( 15 mg per hour ) to reduce the risk of infusion @-@ related side effects .
P-1323	-0.0048 -0.0160 -0.0112 -0.0012 -0.0017 -0.0019 -0.1018 -0.0034 -0.0055 -0.0015 -0.0017 -0.0031 -0.0013 -0.0098 -0.0055 -0.0017 -0.0017 -0.0008 -0.0022 -0.0011 -0.0015 -0.0502 -0.0053 -0.0024 -0.0010 -0.2716 -0.0078 -0.0010 -0.0028 -0.1188 -0.1211 -0.0027 -0.1944 -0.0130
S-241	Die ersten Besuche im Zusammenhang mit einem gemeinsamen Auditprogramm zur Beurteilung des Systems der GMP @-@ Einhaltung der Mitgliedstaaten im Hinblick auf die Harmonisierung und Verbesserung der Leistungsfähigkeit der europäischen Inspektionsdienste wurden in der zweiten Hälfte 2002 initiiert .
T-241	rapporteurship for the database of clinical trials and suspected unexpected adverse reactions reporting , the latter being foreseen as a EudraVigilance module .
H-241	-0.01244477741420269	rapporteurship for the database of clinical trials and suspected unexpected adverse reactions reporting , the latter being foreseen as a EudraVigilance module .
D-241	-0.01244477741420269	rapporteurship for the database of clinical trials and suspected unexpected adverse reactions reporting , the latter being foreseen as a EudraVigilance module .
P-241	-0.0145 -0.0010 -0.0419 -0.0144 -0.0061 -0.0142 -0.0087 -0.0159 -0.0142 -0.0145 -0.0128 -0.0151 -0.0145 -0.0146 -0.0140 -0.0061 -0.0141 -0.0020 -0.0167 -0.0144 -0.0136 -0.0155 -0.0124 -0.0145 -0.0010 -0.0142 -0.0099 -0.0145 -0.0145 -0.0145 -0.0145 -0.0127 -0.0060 -0.0145 -0.0023 -0.0127 -0.0032
S-1259	NovoNorm kann auch bei Patienten mit Typ @-@ 2 @-@ Diabetes angewendet werden , deren Blutglukosespiegel in der Regel gut durch eine Diät eingestellt ist , bei denen es jedoch zeitweilig zu einem Verlust der Blutzuckerkontrolle kommt .
T-1259	NovoNorm can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet , but are experiencing temporary loss of blood glucose control .
H-1259	-0.03459962084889412	NovoNorm can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet , but are experiencing temporary loss of blood glucose control .
D-1259	-0.03459962084889412	NovoNorm can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet , but are experiencing temporary loss of blood glucose control .
P-1259	-0.0034 -0.0010 -0.0012 -0.0015 -0.0171 -0.0275 -0.0013 -0.0051 -0.8375 -0.0141 -0.0018 -0.0017 -0.0015 -0.0068 -0.0021 -0.0147 -0.0009 -0.0007 -0.0045 -0.0022 -0.0089 -0.0143 -0.0064 -0.0150 -0.0138 -0.0064 -0.0046 -0.0143 -0.0143 -0.0107 -0.0035 -0.1656 -0.0045 -0.1139 -0.0009 -0.0005 -0.0015 -0.0019 -0.0019
S-692	Die chelatbildende Eigenschaft ist wahrscheinlich auch für die gesteigerte Ausscheidung von Eisen und Zink über den Harntrakt und die verringerte Serumkonzentration von Calcium verantwortlich , wie in einigen wenigen Studien beschrieben wird .
T-692	The chelating property is probably also responsible for an increased urinary excretion of iron and zinc and a decreased serum concentration of calcium as described in a few studies .
H-692	-0.03592173010110855	The chelating property is probably also responsible for an increased urinary excretion of iron and zinc and a decreased serum concentration of calcium as described in a few studies .
D-692	-0.03592173010110855	The chelating property is probably also responsible for an increased urinary excretion of iron and zinc and a decreased serum concentration of calcium as described in a few studies .
P-692	-0.0059 -0.0003 -0.0090 -0.0090 -0.0033 -0.0106 -0.0252 -0.0278 -0.0013 -0.0138 -0.0059 -0.0146 -0.0008 -0.0073 -0.0007 -0.0021 -0.0015 -0.0011 -0.0014 -0.0010 -0.0012 -0.0149 -0.0085 -0.0087 -0.8006 -0.0022 -0.0014 -0.0022 -0.0016 -0.0012 -0.0007 -0.3111 -0.0126 -0.0053 -0.0017 -0.0069 -0.0050 -0.0018 -0.1050 -0.0015
S-3	Typ @-@ 2 @-@ Diabetes ist eine Krankheit , bei der die Bauchspeicheldrüse nicht genügend Insulin zur Reduzierung des Glukosespiegels im Blut ( Blutzuckerspiegel ) produziert oder der Körper Insulin nicht wirksam nutzen kann .
T-3	Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively .
H-3	-0.004999521654099226	Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively .
D-3	-0.004999521654099226	Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively .
P-3	-0.0010 -0.0017 -0.0008 -0.0016 -0.0030 -0.0040 -0.0052 -0.0011 -0.0016 -0.0030 -0.0004 -0.0011 -0.0045 -0.0013 -0.0143 -0.0039 -0.0007 -0.0008 -0.0023 -0.0163 -0.0113 -0.0130 -0.0014 -0.0022 -0.0006 -0.0006 -0.0020 -0.0203 -0.0012 -0.0408 -0.0142 -0.0020 -0.0009 -0.0088 -0.0043 -0.0014 -0.0082 -0.0012 -0.0005 -0.0034 -0.0015 -0.0015
S-1783	Wurde bereits zum Zeitpunkt der Geburt gegen Hepatitis B geimpft , kann Infanrix Penta ab dem Alter von 6 Wochen anstelle ergänzender Dosen eines Hepatitis @-@ B @-@ Impfstoffes verabreicht werden .
T-1783	Where a dose of hepatitis B vaccine is given at birth , Infanrix Penta can be used as a replacement for supplementary doses of hepatitis B vaccine from the age of six weeks .
H-1783	-0.005784784909337759	Where a dose of hepatitis B vaccine is given at birth , Infanrix Penta can be used as a replacement for supplementary doses of hepatitis B vaccine from the age of six weeks .
D-1783	-0.005784784909337759	Where a dose of hepatitis B vaccine is given at birth , Infanrix Penta can be used as a replacement for supplementary doses of hepatitis B vaccine from the age of six weeks .
P-1783	-0.0144 -0.0132 -0.0145 -0.0042 -0.0122 -0.0004 -0.0007 -0.0015 -0.0137 -0.0105 -0.0134 -0.0051 -0.0024 -0.0023 -0.0036 -0.0004 -0.0012 -0.0012 -0.0008 -0.0014 -0.0073 -0.0018 -0.0161 -0.0137 -0.0057 -0.0128 -0.0031 -0.0100 -0.0034 -0.0012 -0.0020 -0.0010 -0.0023 -0.0099 -0.0005 -0.0007 -0.0037 -0.0038 -0.0093 -0.0111 -0.0016 -0.0014 -0.0202 -0.0014 -0.0039 -0.0014
S-1533	Filgrastim ( rekombinanter Methionin @-@ Humangranulozyten @-@ koloniestimulierender Faktor ) wird durch rekombinante DNA @-@ Technologie in Escherichia coli K802 hergestellt .
T-1533	Filgrastim ( recombinant methionyl human granulocyte @-@ colony stimulating factor ) is produced in Escherichia coli K802 by recombinant DNA technology .
H-1533	-0.022385373711586	Filgrastim ( recombinant methionyl human granulocyte @-@ colony stimulating factor ) is produced in Escherichia coli K802 by recombinant DNA technology .
D-1533	-0.022385373711586	Filgrastim ( recombinant methionyl human granulocyte @-@ colony stimulating factor ) is produced in Escherichia coli K802 by recombinant DNA technology .
P-1533	-0.0013 -0.0014 -0.0034 -0.0009 -0.0017 -0.0025 -0.0011 -0.0006 -0.0016 -0.0015 -0.0006 -0.0012 -0.4117 -0.0038 -0.0060 -0.0014 -0.0010 -0.0009 -0.0030 -0.0153 -0.0069 -0.0013 -0.0037 -0.0762 -0.0013 -0.0014 -0.0019 -0.0374 -0.1775 -0.0018 -0.0003 -0.0004 -0.0009 -0.0009 -0.0012 -0.0017 -0.0011 -0.0008 -0.0100 -0.0028 -0.0009 -0.0006 -0.0015 -0.0009 -0.0021 -0.2542 -0.0014
S-944	Dies ist wahrscheinlich auf eine Überlagerung von Nebenwirkungen und dem in der frühen Behandlungsphase nicht beherrschten Krankheitsprozess sowie auf die zahllosen Arzneimittel zurückzuführen , die zur Kontrolle der Symptome und des Krankheitsgeschehens erforderlich sind .
T-944	This is probably due to the confounding of adverse events by the uncontrolled disease process early on in the treatment course and the myriad concomitant medicinal products required to control symptoms and morbidity .
H-944	-0.029889637604355812	This is probably due to the confounding of adverse events by the uncontrolled disease process early on in the treatment course and the myriad concomitant medicinal products required to control symptoms and morbidity .
D-944	-0.029889637604355812	This is probably due to the confounding of adverse events by the uncontrolled disease process early on in the treatment course and the myriad concomitant medicinal products required to control symptoms and morbidity .
P-944	-0.0036 -0.0039 -0.0064 -0.0048 -0.0015 -0.0125 -0.0144 -0.0142 -0.0004 -0.0102 -0.0129 -0.0004 -0.1110 -0.0158 -0.0044 -0.0121 -0.0023 -0.0024 -0.0034 -0.0140 -0.0094 -0.0038 -0.0117 -0.0036 -0.0144 -0.0100 -0.0070 -0.0116 -0.0003 -0.0008 -0.0153 -0.0085 -0.0033 -0.0017 -0.0063 -0.9592 -0.0029 -0.0113 -0.0415 -0.0024 -0.0059 -0.0016 -0.0144 -0.0014 -0.0028 -0.0016 -0.0014
S-1928	ZWISCHENPACKUNGEN DER MEHRFACHPACKUNGEN ( OHNE BLUE BOX ) MIT PVC / PCTFE @-@ BLISTERPACKUNGEN
T-1928	INTERMEDIATE CARTON OF MULTIPACKS ( WITHOUT BLUE BOX ) CONTAINING PVC / PCTFE BLISTERS
H-1928	-0.007436075713485479	INTERMEDIATE CARTON OF MULTIPACKS ( WITHOUT BLUE BOX ) CONTAINING PVC / PCTFE BLISTERS
D-1928	-0.007436075713485479	INTERMEDIATE CARTON OF MULTIPACKS ( WITHOUT BLUE BOX ) CONTAINING PVC / PCTFE BLISTERS
P-1928	-0.0120 -0.0065 -0.0142 -0.0027 -0.0120 -0.0053 -0.0324 -0.0140 -0.0171 -0.0145 -0.0439 -0.0019 -0.0112 -0.0005 -0.0051 -0.0007 -0.0142 -0.0115 -0.0138 -0.0038 -0.0026 -0.0006 -0.0002 -0.0001 -0.0033 -0.0010 -0.0012 -0.0012 -0.0009 -0.0015 -0.0145 -0.0069 -0.0117 -0.0008 -0.0113 -0.0082 -0.0017 -0.0021 -0.0017 -0.0012 -0.0012 -0.0012 -0.0105 -0.0040 -0.0119 -0.0041 -0.0064
S-1054	Aripiprazol wirkt vermutlich vor allem als &quot; partieller Agonist &quot; für die Rezeptoren für die Neurotransmitter Dopamin und 5 @-@ Hydroxytryptamin ( auch Serotonin genannt ) .
T-1054	Aripiprazole is thought to act mainly by being a <<unk>> partial agonist <<unk>> for the receptors for the neurotransmitters dopamine and 5 @-@ hydroxytryptamine ( also called serotonin ) .
H-1054	-0.006994941271841526	Aripiprazole is thought to act mainly by being a <unk> partial agonist <unk> for the receptors for the neurotransmitters dopamine and 5 @-@ hydroxytryptamine ( also called serotonin ) .
D-1054	-0.006994941271841526	Aripiprazole is thought to act mainly by being a <unk> partial agonist <unk> for the receptors for the neurotransmitters dopamine and 5 @-@ hydroxytryptamine ( also called serotonin ) .
P-1054	-0.0022 -0.0008 -0.0014 -0.0007 -0.0001 -0.0061 -0.0086 -0.0019 -0.0081 -0.0118 -0.0561 -0.0143 -0.0031 -0.0164 -0.0035 -0.0004 -0.0009 -0.0146 -0.0049 -0.0059 -0.0037 -0.0005 -0.0375 -0.0077 -0.0036 -0.0022 -0.0008 -0.0005 -0.0013 -0.0006 -0.0028 -0.0014 -0.0004 -0.0005 -0.0015 -0.0016 -0.1173 -0.0004 -0.0012 -0.0012 -0.0009 -0.0005 -0.0014 -0.0021 -0.0024 -0.0033 -0.0094 -0.0012 -0.0011 -0.0010 -0.0014 -0.0014 -0.0015 -0.0014
S-1035	Der mittlere iPTH- Ausgangswert in den drei Studien lag bei 733 und 683 pg / ml ( 77,8 und 72,4 pmol / l ) für die Cinacalcet- bzw. die Placebogruppen .
T-1035	Mean baseline iPTH concentrations across the 3 studies were 733 and 683 pg / ml ( 77.8 and 72.4 pmol / l ) for the cinacalcet and placebo groups , respectively .
H-1035	-0.012685389257967472	Mean baseline iPTH concentrations across the 3 studies were 733 and 683 pg / ml ( 77.8 and 72.4 pmol / l ) for the cinacalcet and placebo groups , respectively .
D-1035	-0.012685389257967472	Mean baseline iPTH concentrations across the 3 studies were 733 and 683 pg / ml ( 77.8 and 72.4 pmol / l ) for the cinacalcet and placebo groups , respectively .
P-1035	-0.0120 -0.0011 -0.0131 -0.0009 -0.0094 -0.0053 -0.0006 -0.0145 -0.0003 -0.0007 -0.0156 -0.0044 -0.0144 -0.0033 -0.0041 -0.0021 -0.0010 -0.0026 -0.0014 -0.0006 -0.0018 -0.0011 -0.0015 -0.0012 -0.0018 -0.0018 -0.0030 -0.0013 -0.0017 -0.0011 -0.0012 -0.0014 -0.0014 -0.0010 -0.0011 -0.0015 -0.0031 -0.0044 -0.0273 -0.0031 -0.0091 -0.0012 -0.0011 -0.0058 -0.0031 -0.0047 -0.0012 -0.0011 -0.0006 -0.0014 -0.0045 -0.4897 -0.0024 -0.0016 -0.0014
S-16	3 ml Lösung in einer Patrone aus Glas ( Glasart 1 ) , mit einem Kolben ( Brombutylgummi ) und einem Stopfen ( Brombutylgummi / Polyisopren ) in einem Umkarton .
T-16	3 ml solution in a cartridge ( type 1 glass ) , with a plunger ( bromobutyl ) and a stopper ( bromobutyl / polyisoprene ) in a carton .
H-16	-0.009015592746436596	3 ml solution in a cartridge ( type 1 glass ) , with a plunger ( bromobutyl ) and a stopper ( bromobutyl / polyisoprene ) in a carton .
D-16	-0.009015592746436596	3 ml solution in a cartridge ( type 1 glass ) , with a plunger ( bromobutyl ) and a stopper ( bromobutyl / polyisoprene ) in a carton .
P-16	-0.0037 -0.0008 -0.0143 -0.0030 -0.0034 -0.0096 -0.0010 -0.0009 -0.0145 -0.0100 -0.0083 -0.0107 -0.0020 -0.0055 -0.0057 -0.0053 -0.0136 -0.0010 -0.0014 -0.0025 -0.0079 -0.0122 -0.0026 -0.1099 -0.0017 -0.0039 -0.0071 -0.0015 -0.0014 -0.0010 -0.0014 -0.0020 -0.0014 -0.1032 -0.0019 -0.0004 -0.0009 -0.0005 -0.0015 -0.0029 -0.0044 -0.0117 -0.0014 -0.0043 -0.0016
S-77	Da die arzneilich wirksamen Bestandteile von Trizivir möglicherweise die DNA @-@ Replikation hemmen , stellt jede Anwendung , besonders während der ersten 3 Schwangerschaftsmonate , ein mögliches Risiko für den Fetus dar .
T-77	As the active substances of Trizivir may inhibit DNA replication any use , especially during the first trimester , presents a potential risk to the foetus .
H-77	-0.027941593900322914	As the active substances of Trizivir may inhibit DNA replication any use , especially during the first trimester , presents a potential risk to the foetus .
D-77	-0.027941593900322914	As the active substances of Trizivir may inhibit DNA replication any use , especially during the first trimester , presents a potential risk to the foetus .
P-77	-0.0125 -0.0035 -0.0117 -0.0144 -0.0007 -0.0063 -0.0250 -0.0069 -0.0640 -0.0009 -0.0059 -0.0074 -0.0006 -0.0006 -0.0021 -0.0014 -0.0007 -0.0013 -0.0177 -0.0089 -0.0102 -0.0113 -0.0040 -0.0018 -0.0013 -0.8047 -0.0007 -0.0014 -0.0113 -0.0127 -0.0031 -0.0064 -0.0019 -0.0126 -0.0019 -0.0131 -0.0002 -0.0233 -0.0016 -0.0016
S-1170	Amitraz ist ein Monoamin @-@ Oxidase @-@ Inhibitor ( MOAI ) ; daher sollten Personen , die MOAI @-@ haltige Medikamente nehmen , besonders vorsichtig beim Umgang mit diesem Tierarzneimittel sein .
T-1170	37 / 39 Amitraz is a monoamine oxidase inhibitor ( MOAI ) ; therefore , people taking MOAI @-@ containing medication should take particular care when handling this product .
H-1170	-0.007150328252464533	37 / 39 Amitraz is a monoamine oxidase inhibitor ( MOAI ) ; therefore , people taking MOAI @-@ containing medication should take particular care when handling this product .
D-1170	-0.007150328252464533	37 / 39 Amitraz is a monoamine oxidase inhibitor ( MOAI ) ; therefore , people taking MOAI @-@ containing medication should take particular care when handling this product .
P-1170	-0.0155 -0.0144 -0.0146 -0.0073 -0.0007 -0.0026 -0.0011 -0.0015 -0.0015 -0.0012 -0.0012 -0.0007 -0.0009 -0.0013 -0.0006 -0.0011 -0.0005 -0.0005 -0.0012 -0.0017 -0.0013 -0.0012 -0.0012 -0.0014 -0.0367 -0.0036 -0.0099 -0.0159 -0.0072 -0.0128 -0.0013 -0.0015 -0.0076 -0.0018 -0.0204 -0.0019 -0.0132 -0.0171 -0.0019 -0.0611 -0.0127 -0.0016 -0.0145 -0.0024 -0.0015
S-1874	6 gekennzeichnet ist , einer lysosomalen Hydrolase , die die Hydrolyse terminaler α -L @-@ iduronischer Rückstände von Dermatansulfat und Heparansulfat katalysiert .
T-1874	Reduced or absent α -L @-@ iduronidase activity results in the accumulation of the GAGs , dermatan sulfate and heparan sulfate in many cell types and tissues .
H-1874	-0.020238464698195457	Reduced or absent α -L @-@ iduronidase activity results in the accumulation of the GAGs , dermatan sulfate and heparan sulfate in many cell types and tissues .
D-1874	-0.020238464698195457	Reduced or absent α -L @-@ iduronidase activity results in the accumulation of the GAGs , dermatan sulfate and heparan sulfate in many cell types and tissues .
P-1874	-0.0145 -0.0141 -0.0144 -0.0145 -0.0129 -0.0145 -0.0282 -0.0021 -0.0123 -0.0043 -0.0005 -0.0143 -0.0145 -0.0138 -0.0161 -0.0145 -0.0113 -0.0113 -0.0145 -0.0011 -0.0029 -0.0137 -0.0147 -0.0145 -0.0144 -0.0129 -0.0145 -0.0028 -0.0068 -0.0027 -0.1042 -0.0038 -0.0022 -0.0005 -0.0042 -0.0010 -0.0571 -0.0134 -0.0145 -0.0145 -0.0082 -0.1430 -0.0145 -0.0004 -0.0012 -0.2233 -0.0017
S-402	In dieser Studie wurde Ferkeln aus jedem Wurf jeder einzelnen Sau Blut entnommen und auf Antikörper gegen das Pasteurella @-@ multocida @-@ Toxin sowie Bordetella bronchiseptica getestet .
T-402	In this study , blood was taken from piglets in each litter born from each sow , and tested for antibodies to Pasteurella multocida toxin and Bordetella bronchiseptica .
H-402	-0.007543415762484074	In this study , blood was taken from piglets in each litter born from each sow , and tested for antibodies to Pasteurella multocida toxin and Bordetella bronchiseptica .
D-402	-0.007543415762484074	In this study , blood was taken from piglets in each litter born from each sow , and tested for antibodies to Pasteurella multocida toxin and Bordetella bronchiseptica .
P-402	-0.0039 -0.0027 -0.0021 -0.0076 -0.0109 -0.0038 -0.0365 -0.0018 -0.0172 -0.0006 -0.0111 -0.0099 -0.0033 -0.0006 -0.0147 -0.0137 -0.0050 -0.0076 -0.0006 -0.0131 -0.0055 -0.0120 -0.0027 -0.0021 -0.0007 -0.0193 -0.0116 -0.0007 -0.0013 -0.0005 -0.0042 -0.0010 -0.0012 -0.0012 -0.0014 -0.0026 -0.0890 -0.0018 -0.0010 -0.0015 -0.0005 -0.0006 -0.0006 -0.0015 -0.0272 -0.0004 -0.0018 -0.0015
S-683	Nach der Injektion können die Schweine für bis zu zwei Tage eine um 1,4 ° C erhöhte Körpertemperatur haben , einige Tiere auch um bis zu 2,5 ° C , was jedoch nicht länger als 24 Stunden nach der Injektion andauern sollte .
T-683	Following injection , pigs may have an increased body temperature of 1.4 ° C for up to two days , and in some pigs of up to 2.5 ° C , but this should not last more than 24 hours after the injection .
H-683	-0.0072478740476071835	Following injection , pigs may have an increased body temperature of 1.4 ° C for up to two days , and in some pigs of up to 2.5 ° C , but this should not last more than 24 hours after the injection .
D-683	-0.0072478740476071835	Following injection , pigs may have an increased body temperature of 1.4 ° C for up to two days , and in some pigs of up to 2.5 ° C , but this should not last more than 24 hours after the injection .
P-683	-0.0139 -0.0118 -0.0010 -0.0046 -0.0098 -0.0016 -0.0080 -0.0046 -0.0107 -0.0086 -0.0017 -0.0009 -0.0041 -0.0046 -0.0016 -0.0015 -0.0076 -0.0020 -0.0013 -0.0185 -0.0013 -0.0150 -0.0080 -0.0140 -0.0019 -0.0144 -0.0016 -0.0143 -0.0057 -0.0013 -0.0009 -0.0014 -0.0016 -0.0044 -0.0079 -0.0046 -0.0031 -0.0048 -0.0095 -0.0100 -0.0014 -0.0011 -0.0013 -0.0720 -0.0126 -0.0012 -0.0005 -0.0191 -0.0014
S-203	Besondere Patientengruppen Patienten mit Niereninsuffizienz Bei Patienten mit leichter oder mäßiger Niereninsuffizienz ( Kreatinin @-@ Clearance ≥ 30 ml / min ) ist keine Dosisanpassung erforderlich .
T-203	Special Populations Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment where creatinine clearance is equal or greater than 30 ml / min .
H-203	-0.019143035635352135	Special Populations Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment where creatinine clearance is equal or greater than 30 ml / min .
D-203	-0.019143035635352135	Special Populations Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment where creatinine clearance is equal or greater than 30 ml / min .
P-203	-0.0058 -0.0145 -0.0056 -0.0080 -0.0008 -0.0052 -0.0044 -0.0012 -0.1727 -0.0006 -0.0011 -0.0013 -0.0092 -0.0059 -0.0027 -0.0007 -0.0016 -0.0079 -0.3579 -0.0125 -0.0017 -0.0017 -0.0032 -0.0021 -0.0011 -0.0011 -0.0013 -0.0054 -0.0003 -0.0005 -0.0014 -0.1968 -0.0040 -0.0008 -0.0014 -0.0016 -0.0011 -0.0011 -0.0141 -0.0145 -0.0144 -0.0081 -0.0019 -0.0015 -0.0023 -0.0015 -0.0012 -0.0308 -0.0016
S-20	Gadoversetamid ist ein Chelat , das Gadolinium - das paramagnetische Eigenschaften besitzt und für die kontrastverstärkende Wirkung in der MRT verantwortlich ist - und den Liganden Versetamid enthält .
T-20	Gadoversetamide is a chelate containing gadolinium - which has paramagnetic properties and is responsible for the contrast enhancement effect in MRI - and the ligand versetamide .
H-20	-0.007127222139388323	Gadoversetamide is a chelate containing gadolinium - which has paramagnetic properties and is responsible for the contrast enhancement effect in MRI - and the ligand versetamide .
D-20	-0.007127222139388323	Gadoversetamide is a chelate containing gadolinium - which has paramagnetic properties and is responsible for the contrast enhancement effect in MRI - and the ligand versetamide .
P-20	-0.0014 -0.0010 -0.0019 -0.0007 -0.0004 -0.0014 -0.0018 -0.0015 -0.0006 -0.0043 -0.0191 -0.0006 -0.0000 -0.0007 -0.0011 -0.0137 -0.0052 -0.0041 -0.0012 -0.0008 -0.0012 -0.0008 -0.0011 -0.0016 -0.0036 -0.0025 -0.0020 -0.0264 -0.0071 -0.0008 -0.0052 -0.0201 -0.0012 -0.0055 -0.0043 -0.0032 -0.0024 -0.0029 -0.0021 -0.0049 -0.0004 -0.0069 -0.0007 -0.0015 -0.0008 -0.0008 -0.0015 -0.1746 -0.0015
S-1801	Wenn der Östradiolspiegel höher als 5500 pg / ml ( 20000 pmol / l ) ist und wenn insgesamt 40 oder mehr Follikel vorliegen , kann es erforderlich sein , auf die hCG @-@ Anwendung zu verzichten .
T-1801	When the estradiol level is &gt; 5500 pg / ml ( 20000 pmol / l ) and when there are 40 or more follicles in total , it may be necessary to withhold hCG administration .
H-1801	-0.004602463915944099	When the estradiol level is &gt; 5500 pg / ml ( 20000 pmol / l ) and when there are 40 or more follicles in total , it may be necessary to withhold hCG administration .
D-1801	-0.004602463915944099	When the estradiol level is &gt; 5500 pg / ml ( 20000 pmol / l ) and when there are 40 or more follicles in total , it may be necessary to withhold hCG administration .
P-1801	-0.0147 -0.0082 -0.0097 -0.0003 -0.0007 -0.0031 -0.0027 -0.0146 -0.0042 -0.0034 -0.0017 -0.0015 -0.0016 -0.0015 -0.0022 -0.0119 -0.0028 -0.0026 -0.0010 -0.0011 -0.0014 -0.0032 -0.0015 -0.0059 -0.0114 -0.0088 -0.0081 -0.0061 -0.0023 -0.0016 -0.0010 -0.0007 -0.0012 -0.0085 -0.0028 -0.0029 -0.0056 -0.0029 -0.0017 -0.0040 -0.0041 -0.0144 -0.0035 -0.0126 -0.0014 -0.0010 -0.0138 -0.0021 -0.0016
S-1955	Wichtige Informationen über bestimmte sonstige Bestandteile von Infanrix hexa Sagen Sie Ihrem Arzt , wenn Ihr Kind eine allergische Reaktion gegen Neomycin oder Polymyxin ( Antibiotika ) gezeigt hat .
T-1955	Important information about some of the ingredients of Infanrix hexa Please tell your doctor if your child has had an allergic reaction to neomycin and polymyxin ( antibiotics ) .
H-1955	-0.024042245000600815	Important information about some of the ingredients of Infanrix hexa Please tell your doctor if your child has had an allergic reaction to neomycin and polymyxin ( antibiotics ) .
D-1955	-0.024042245000600815	Important information about some of the ingredients of Infanrix hexa Please tell your doctor if your child has had an allergic reaction to neomycin and polymyxin ( antibiotics ) .
P-1955	-0.0014 -0.0007 -0.0012 -0.0064 -0.0050 -0.0141 -0.0139 -0.0021 -0.0159 -0.0040 -0.0020 -0.0005 -0.0012 -0.0013 -0.0027 -0.0012 -0.0013 -0.0155 -0.0127 -0.0015 -0.0019 -0.0019 -0.0563 -0.0019 -0.0026 -0.0131 -0.0026 -0.0008 -0.0005 -0.0010 -0.0023 -0.0017 -0.0009 -0.0011 -0.0015 -0.0016 -0.9357 -0.0022 -0.0007 -0.0010 -0.0009 -0.0020 -0.0043 -0.0019 -0.0007 -0.0279 -0.0014 -0.0019 -0.0014
S-1034	Im Kühlschrank lagern ( 2 ° C - 8 ° C ) Nicht einfrieren Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen Nach Anbruch : nicht im Kühlschrank oder über 25 ° C aufbewahren
T-1034	Store in a refrigerator ( 2 ° C - 8 ° C ) Do not freeze Keep the vial in the outer carton in order to protect from light During use : do not refrigerate or store above 25 ° C
H-1034	-0.006130505353212357	Store in a refrigerator ( 2 ° C - 8 ° C ) Do not freeze Keep the vial in the outer carton in order to protect from light During use : do not refrigerate or store above 25 ° C
D-1034	-0.006130505353212357	Store in a refrigerator ( 2 ° C - 8 ° C ) Do not freeze Keep the vial in the outer carton in order to protect from light During use : do not refrigerate or store above 25 ° C
P-1034	-0.0049 -0.0034 -0.0137 -0.0049 -0.0006 -0.0009 -0.0017 -0.0024 -0.0024 -0.0016 -0.0013 -0.0505 -0.0013 -0.0010 -0.0012 -0.0018 -0.0032 -0.0015 -0.0043 -0.0137 -0.0050 -0.0033 -0.0022 -0.0037 -0.0067 -0.0145 -0.0008 -0.0119 -0.0019 -0.0141 -0.0024 -0.0015 -0.0048 -0.0144 -0.0023 -0.0145 -0.0145 -0.0051 -0.0077 -0.0014 -0.0139 -0.0010 -0.0007 -0.0013 -0.0029 -0.0103 -0.0106 -0.0019 -0.0013 -0.0015 -0.0181
S-1138	Veranschlagt sind Mittel für : - die Entschädigung bei Beendigung des Dienstverhältnisses eines Beamten auf Probe im Fall offensichtlich unzulänglicher Leistungen ; - die Vergütung bei Kündigung des Vertrages des betroffenen Mitarbeiters durch die Agentur .
T-1138	This appropriation covers : <<unk>> allowances in the event of dismissal of a probationary official for obvious inadequacy , <<unk>> allowances in the event of cancellation by the Agency of the contract of a relevant staff member .
H-1138	-0.008523618802428246	This appropriation covers : <unk> allowances in the event of dismissal of a probationary official for obvious inadequacy , <unk> allowances in the event of cancellation by the Agency of the contract of a relevant staff member .
D-1138	-0.008523618802428246	This appropriation covers : <unk> allowances in the event of dismissal of a probationary official for obvious inadequacy , <unk> allowances in the event of cancellation by the Agency of the contract of a relevant staff member .
P-1138	-0.0143 -0.0144 -0.0030 -0.0519 -0.0037 -0.0145 -0.0145 -0.0110 -0.0011 -0.0129 -0.0063 -0.0050 -0.0032 -0.0143 -0.0101 -0.0015 -0.0095 -0.0102 -0.0145 -0.0002 -0.0013 -0.0095 -0.0130 -0.0133 -0.0086 -0.0107 -0.0123 -0.0138 -0.0054 -0.0143 -0.0071 -0.0011 -0.0071 -0.0026 -0.0022 -0.0046 -0.0135 -0.0008 -0.0013 -0.0069 -0.0016 -0.0081 -0.0018 -0.0068 -0.0045 -0.0028 -0.0189 -0.0142 -0.0134 -0.0023 -0.0020 -0.0015
S-81	Darunavir und Ritonavir hemmen CYP3A4 ; daher ist mit einem Anstieg der Plasmakonzentrationen von Calciumantagonisten zu rechnen , welche CYP3A4 @-@ Substrate sind .
T-81	Darunavir and ritonavir inhibit CYP3A4 and as a result can be expected to increase the plasma concentrations of calcium channel antagonists , which are CYP3A4 substrates .
H-81	-0.01779123768210411	Darunavir and ritonavir inhibit CYP3A4 and as a result can be expected to increase the plasma concentrations of calcium channel antagonists , which are CYP3A4 substrates .
D-81	-0.01779123768210411	Darunavir and ritonavir inhibit CYP3A4 and as a result can be expected to increase the plasma concentrations of calcium channel antagonists , which are CYP3A4 substrates .
P-81	-0.0014 -0.0010 -0.0006 -0.0012 -0.1312 -0.0031 -0.0013 -0.0006 -0.0010 -0.0026 -0.0006 -0.0008 -0.0020 -0.0012 -0.3140 -0.0010 -0.0006 -0.0972 -0.0146 -0.0078 -0.0034 -0.0152 -0.0019 -0.0013 -0.0026 -0.0056 -0.0094 -0.0035 -0.0005 -0.0006 -0.0090 -0.0004 -0.0007 -0.0016 -0.0018 -0.0006 -0.0012 -0.0547 -0.0108 -0.0001 -0.0021 -0.0087 -0.0022 -0.0017 -0.0023 -0.0012 -0.0013 -0.0011 -0.0007 -0.0012 -0.0007 -0.0036 -0.2239 -0.0014
S-1636	Interferon alfa @-@ 2b , Injektionslösung ( 13 subkutane Injektionen von jeweils 3 Mio I.E. ) dar , die in suizidaler Absicht an einem Tag von einem Patienten angewendet worden war .
T-1636	In clinical trials with Rebetol used in combination with peginterferon alfa @-@ 2b or interferon alfa @-@ 2b , the maximum overdose reported was a total dose of 10 g of Rebetol ( 50 x 200 mg capsules ) and 39 MIU of interferon alfa @-@ 2b ( 13 subcutaneous injections of 3 MIU each ) taken in one day by a patient in an attempt at suicide .
H-1636	-0.019131161272525787	In clinical trials with Rebetol used in combination with peginterferon alfa @-@ 2b or interferon alfa @-@ 2b , the maximum overdose reported was a total dose of 10 g of Rebetol ( 50 x 200 mg capsules ) and 39 MIU of interferon alfa @-@ 2b ( 13 subcutaneous injections of 3 MIU each ) taken in one day by a patient in an attempt at suicide .
D-1636	-0.019131161272525787	In clinical trials with Rebetol used in combination with peginterferon alfa @-@ 2b or interferon alfa @-@ 2b , the maximum overdose reported was a total dose of 10 g of Rebetol ( 50 x 200 mg capsules ) and 39 MIU of interferon alfa @-@ 2b ( 13 subcutaneous injections of 3 MIU each ) taken in one day by a patient in an attempt at suicide .
P-1636	-0.0145 -0.0158 -0.0085 -0.0145 -0.0145 -0.0145 -0.0145 -0.0127 -0.0146 -0.0132 -0.0132 -0.0021 -0.0148 -0.0145 -0.0145 -0.0029 -0.0023 -0.0036 -0.0008 -0.0016 -0.0016 -0.0011 -0.5225 -0.0138 -0.0013 -0.0017 -0.0085 -0.0379 -0.0016 -0.0041 -0.0015 -0.3727 -0.0129 -0.0145 -0.0145 -0.0011 -0.0145 -0.0102 -0.0149 -0.0124 -0.0145 -0.0018 -0.0152 -0.0145 -0.0116 -0.0147 -0.0108 -0.0021 -0.0081 -0.0131 -0.0155 -0.0150 -0.0153 -0.0076 -0.0151 -0.0015 -0.0290 -0.0047 -0.0468 -0.0145 -0.0145 -0.0005 -0.0109 -0.0144 -0.0012 -0.0019 -0.0049 -0.0220 -0.0016 -0.0021 -0.0011 -0.0130 -0.0208 -0.0122 -0.0012 -0.0007 -0.0012 -0.0016 -0.0053 -0.0043 -0.0090 -0.0066 -0.0145 -0.0002 -0.0047 -0.0016 -0.0432 -0.0118 -0.0053 -0.0022 -0.0134 -0.0075 -0.0036 -0.0143 -0.0113 -0.0050 -0.0145 -0.0019 -0.0632 -0.0014
S-53	Die Häufigkeiten sind wie folgt definiert : sehr häufig : ≥ 1 / 10 , häufig : ≥ 1 / 100 und &lt; 1 / 10 , gelegentlich : ≥ 1 / 1.000 und &lt; 1 / 100 , selten : ≥ 1 / 10.000 und &lt; 1 / 1.000 , sehr selten : &lt; 1 / 10.000 .
T-53	The frequency is defined as follows : very common : ≥ 1 / 10 , common : ≥ 1 / 100 and &lt; 1 / 10 , uncommon : ≥ 1 / 1,000 and &lt; 1 / 100 , rare : ≥ 1 / 10,000 and &lt; 1 / 1,000 , very rare : ≤ 1 / 10,000 .
H-53	-0.0059243617579340935	The frequency is defined as follows : very common : ≥ 1 / 10 , common : ≥ 1 / 100 and &lt; 1 / 10 , uncommon : ≥ 1 / 1,000 and &lt; 1 / 100 , rare : ≥ 1 / 10,000 and &lt; 1 / 1,000 , very rare : ≤ 1 / 10,000 .
D-53	-0.0059243617579340935	The frequency is defined as follows : very common : ≥ 1 / 10 , common : ≥ 1 / 100 and &lt; 1 / 10 , uncommon : ≥ 1 / 1,000 and &lt; 1 / 100 , rare : ≥ 1 / 10,000 and &lt; 1 / 1,000 , very rare : ≤ 1 / 10,000 .
P-53	-0.0089 -0.0045 -0.0132 -0.0101 -0.0035 -0.0037 -0.0068 -0.0015 -0.0033 -0.0070 -0.0029 -0.0002 -0.0015 -0.0015 -0.0015 -0.0033 -0.0120 -0.0014 -0.0003 -0.0015 -0.0015 -0.0009 -0.0021 -0.0213 -0.0021 -0.0013 -0.0014 -0.0015 -0.0015 -0.0022 -0.0145 -0.0012 -0.0014 -0.0005 -0.0014 -0.0014 -0.0062 -0.0017 -0.0551 -0.0011 -0.0013 -0.0013 -0.0015 -0.0012 -0.0016 -0.0074 -0.0013 -0.0004 -0.0013 -0.0014 -0.0031 -0.0017 -0.0286 -0.0011 -0.0012 -0.0014 -0.0014 -0.0039 -0.0019 -0.0093 -0.0016 -0.0014 -0.1111 -0.0016 -0.0014 -0.0013 -0.0016 -0.0014
S-897	NierenfunktionsstörungDie Pharmakokinetik von Bortezomib wird bei Patienten mit leichter bis mäßiger Nierenfunktionsstörung ( CrCl ( Kreatinin @-@ Clearance ) &gt; 20 ml / min / 1,73 m2 ) nicht beeinflusst ; daher sind Dosisanpassungen bei diesen Patienten nicht notwendig .
T-897	Renal impairment The pharmacokinetics of bortezomib are not influenced in patients with mild to moderate renal impairment ( CCl &gt; 20 ml / min / 1.73 m2 ) ; therefore , dose adjustments are not necessary for these patients .
H-897	-0.024592960253357887	Renal impairment The pharmacokinetics of bortezomib are not influenced in patients with mild to moderate renal impairment ( CCl &gt; 20 ml / min / 1.73 m2 ) ; therefore , dose adjustments are not necessary for these patients .
D-897	-0.024592960253357887	Renal impairment The pharmacokinetics of bortezomib are not influenced in patients with mild to moderate renal impairment ( CCl &gt; 20 ml / min / 1.73 m2 ) ; therefore , dose adjustments are not necessary for these patients .
P-897	-0.0098 -0.0012 -0.0145 -0.0010 -0.0002 -0.0091 -0.0086 -0.0026 -0.0006 -0.0008 -0.0021 -0.0017 -0.0015 -0.0009 -0.0007 -0.0007 -0.0019 -0.0056 -0.0042 -0.0213 -0.0008 -0.0193 -0.0017 -0.0019 -0.0023 -0.0059 -0.0007 -0.0015 -0.0013 -0.0105 -0.0004 -0.0004 -0.0014 -0.0214 -0.0145 -0.0144 -0.0106 -0.0019 -0.0021 -0.0014 -0.0010 -0.0016 -0.0025 -0.0027 -0.0171 -0.0017 -0.0264 -0.0116 -0.0928 -0.1489 -0.0026 -0.0008 -0.6755 -0.0074 -0.0024 -0.1491 -0.1299 -0.0185 -0.0015 -0.0015 -0.0014
S-1859	Dem CHMP zufolge zeigten zwar die Wirksamkeitsdaten einen statistisch signifikanten Unterschied der SPID30 zu Gunsten von Rapinyl im Vergleich zu Placebo , doch sollten die primären Endpunkte die Bewertung des Unterschiedes der Schmerzintensität auf einer einfachen Skala und zur Definition von Respondern umfassen .
T-1859	The CHMP considered that while the efficacy data showed statistically significant difference in favour of Rapinyl versus placebo on SPID 30 , the CHMP considered that the primary endpoints should include the assessment of pain intensity difference by simple scale and to define responder .
H-1859	-0.027318881824612617	The CHMP considered that while the efficacy data showed statistically significant difference in favour of Rapinyl versus placebo on SPID 30 , the CHMP considered that the primary endpoints should include the assessment of pain intensity difference by simple scale and to define responder .
D-1859	-0.027318881824612617	The CHMP considered that while the efficacy data showed statistically significant difference in favour of Rapinyl versus placebo on SPID 30 , the CHMP considered that the primary endpoints should include the assessment of pain intensity difference by simple scale and to define responder .
P-1859	-0.0127 -0.0020 -0.0005 -0.0148 -0.0018 -0.0089 -0.0119 -0.0019 -0.0006 -0.0009 -0.0011 -0.0049 -0.0140 -0.0012 -0.0012 -0.0008 -0.0103 -0.0088 -0.0145 -0.0015 -0.0143 -0.0013 -0.0010 -0.0138 -0.0013 -0.0011 -0.0008 -0.0012 -0.0144 -0.0029 -0.2193 -0.0058 -0.0026 -0.0077 -0.4886 -0.0008 -0.0144 -0.0038 -0.0094 -0.5829 -0.0045 -0.0014 -0.0037 -0.0032 -0.0127 -0.0058 -0.0015 -0.0121 -0.0015 -0.0069 -0.0181 -0.0136 -0.0053 -0.0039 -0.0138 -0.0036 -0.0031 -0.0142 -0.0072 -0.0014
S-277	Die klinische Entwicklung des Gelbfieber @-@ Impfstoffs war Bestandteil der Entwicklung eines stabilisierten lebenden , attenuierten Gelbfieber @-@ Impfstoffs , der aus dem Gebrauchsimpfgut IP / F2 extrahiert wurde , und des Validierungsprozesses für das neue Gebrauchsimpfgut PV26 .
T-277	The clinical development of the yellow fever vaccine has been part of the development of a stabilized live attenuated yellow fever vaccine , derived from the working seed IP / F2 , and the validation process of a new working seed , PV26 .
H-277	-0.011859720572829247	The clinical development of the yellow fever vaccine has been part of the development of a stabilized live attenuated yellow fever vaccine , derived from the working seed IP / F2 , and the validation process of a new working seed , PV26 .
D-277	-0.011859720572829247	The clinical development of the yellow fever vaccine has been part of the development of a stabilized live attenuated yellow fever vaccine , derived from the working seed IP / F2 , and the validation process of a new working seed , PV26 .
P-277	-0.0044 -0.0047 -0.0014 -0.0019 -0.0031 -0.0043 -0.0012 -0.0008 -0.0014 -0.0124 -0.0027 -0.0064 -0.0014 -0.0024 -0.0029 -0.0020 -0.0023 -0.0050 -0.1724 -0.0074 -0.0050 -0.0017 -0.0016 -0.0008 -0.0014 -0.0009 -0.0010 -0.0122 -0.0147 -0.0014 -0.0015 -0.0054 -0.0145 -0.0145 -0.0012 -0.0014 -0.0013 -0.2256 -0.0054 -0.0021 -0.0069 -0.0017 -0.0011 -0.0020 -0.0198 -0.0180 -0.0027 -0.0144 -0.0069 -0.0139 -0.0029 -0.0014 -0.0020 -0.0029 -0.0014
S-965	Eine Immunantwort auf Osigraft sollte in Erwägung gezogen werden , und in Fällen , in denen Verdacht auf eine unerwünschte Wirkung mit immunologischem Hintergrund besteht , und auch in Fällen , in denen Osigraft unwirksam ist , sollte mit einem entsprechenden Test auf Vorhandensein von Antikörpern im Serum geprüft werden .
T-965	An immune response to Osigraft should be considered and appropriate tests for the presence of antibodies in serum should be performed in cases where an immune @-@ mediated undesirable effect is suspected , including cases where Osigraft is ineffective .
H-965	-0.007015208713710308	An immune response to Osigraft should be considered and appropriate tests for the presence of antibodies in serum should be performed in cases where an immune @-@ mediated undesirable effect is suspected , including cases where Osigraft is ineffective .
D-965	-0.007015208713710308	An immune response to Osigraft should be considered and appropriate tests for the presence of antibodies in serum should be performed in cases where an immune @-@ mediated undesirable effect is suspected , including cases where Osigraft is ineffective .
P-965	-0.0024 -0.0020 -0.0013 -0.0019 -0.0083 -0.0010 -0.0007 -0.0013 -0.0017 -0.0014 -0.0022 -0.0622 -0.0145 -0.0103 -0.0128 -0.0066 -0.0005 -0.0016 -0.0016 -0.0007 -0.0025 -0.0081 -0.0024 -0.0027 -0.0014 -0.0127 -0.0049 -0.0034 -0.0040 -0.0124 -0.0138 -0.0140 -0.0144 -0.0016 -0.0131 -0.0066 -0.0038 -0.0046 -0.0028 -0.0007 -0.0216 -0.0537 -0.0108 -0.0037 -0.0022 -0.0010 -0.0007 -0.0015 -0.0021 -0.0047 -0.0015 -0.0016 -0.0016
S-1431	Eine Studie im Steady state wurde an 46 Patienten mit leichter ( n = 17 ; Ishak Score 1 @-@ 2 ) , mäßiger ( n = 20 ; Ishak Score 3 @-@ 4 ) oder schwerer ( n = 9 ; Ishak Score 5 @-@ 6 , 8 Patienten mit Child @-@ Pugh A bzw .
T-1431	Hepatic dysfunction : A steady state study comparing 46 patients with mild ( n = 17 :
H-1431	-0.016974402591586113	Hepatic dysfunction : A steady state study comparing 46 patients with mild ( n = 17 :
D-1431	-0.016974402591586113	Hepatic dysfunction : A steady state study comparing 46 patients with mild ( n = 17 :
P-1431	-0.0148 -0.0140 -0.0126 -0.0145 -0.0016 -0.0142 -0.0132 -0.0106 -0.0059 -0.0025 -0.0172 -0.0092 -0.0117 -0.0032 -0.0032 -0.0078 -0.0020 -0.0707 -0.0012 -0.0009 -0.1281 -0.0145
S-738	REYATAZ + Ritonavir war vergleichbar wirksam ( nicht schlechter als ) wie Lopinavir + Ritonavir bei dieser Erhebungs @-@ Methode ( zeitgemittelter Unterschied &#91; time @-@ averaged difference &#93; von 0,13 ; 97,5 % Konfidenzintervall &#91; -0,12 ; 0,39 &#93; ) .
T-738	REYATAZ + ritonavir was similar ( non @-@ inferior ) to lopinavir + ritonavir on this efficacy measure ( time @-@ averaged difference of 0.13 , 97.5 % confidence interval &#91; -0.12 , 0.39 &#93; ) .
H-738	-0.005398528650403023	REYATAZ + ritonavir was similar ( non @-@ inferior ) to lopinavir + ritonavir on this efficacy measure ( time @-@ averaged difference of 0.13 , 97.5 % confidence interval &#91; -0.12 , 0.39 &#93; ) .
D-738	-0.005398528650403023	REYATAZ + ritonavir was similar ( non @-@ inferior ) to lopinavir + ritonavir on this efficacy measure ( time @-@ averaged difference of 0.13 , 97.5 % confidence interval &#91; -0.12 , 0.39 &#93; ) .
P-738	-0.0031 -0.0012 -0.0008 -0.0005 -0.0016 -0.0052 -0.0015 -0.0008 -0.0010 -0.0040 -0.0142 -0.0243 -0.0145 -0.0071 -0.0033 -0.0002 -0.0163 -0.0070 -0.0149 -0.0035 -0.0139 -0.0005 -0.0009 -0.0020 -0.0006 -0.0012 -0.0007 -0.0010 -0.0151 -0.0027 -0.0145 -0.0002 -0.0007 -0.0141 -0.0022 -0.0030 -0.0053 -0.0008 -0.0018 -0.0020 -0.0047 -0.0020 -0.0012 -0.0152 -0.0051 -0.0009 -0.0014 -0.0011 -0.0024 -0.0006 -0.0014 -0.0012 -0.0012 -0.0013 -0.0724 -0.0015 -0.0007 -0.0018 -0.0017 -0.0021 -0.0014
S-624	HERSTELLER DER WIRKSTOFFE BIOLOGISCHEN URSPRUNGS UND INHABER DER HERSTELLUNGSERLAUBNIS , DER FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST
T-624	MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
H-624	-0.019825460389256477	MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
D-624	-0.019825460389256477	MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
P-624	-0.0067 -0.0024 -0.0011 -0.0003 -0.0003 -0.0004 -0.0005 -0.2649 -0.0016 -0.0008 -0.0100 -0.0145 -0.0012 -0.0012 -0.0019 -0.0009 -0.0034 -0.0006 -0.1408 -0.0123 -0.0000 -0.0142 -0.1768 -0.0125 -0.0078 -0.0077 -0.0078 -0.0063 -0.0013 -0.0144 -0.0037 -0.0005 -0.0004 -0.0000 -0.0008 -0.0014 -0.2086 -0.0145 -0.0032 -0.0008 -0.0143 -0.0122 -0.0079 -0.0147 -0.0138 -0.0143 -0.0103 -0.0011 -0.0011 -0.0018 -0.0007 -0.0012 -0.0055 -0.0007 -0.0144 -0.0144 -0.0144 -0.0134 -0.0139 -0.0034 -0.0035 -0.1036
S-1572	Im Rahmen der randomisierten Studie MN302 wurden 999 Patienten mit aktiver rheumatoider Arthritis mit 20 mg / Tag Leflunomid ( n = 501 ) oder 7,5 mg / Woche Methotrexat mit einer Steigerung auf 15 mg / Woche ( n = 498 ) behandelt .
T-1572	Study MN302 randomised 999 subjects with active rheumatoid arthritis to leflunomide 20 mg / day ( n = 501 ) or methotrexate at 7.5 mg / week increasing to 15 mg / week ( n = 498 ) .
H-1572	-0.009711978957057	Study MN302 randomised 999 subjects with active rheumatoid arthritis to leflunomide 20 mg / day ( n = 501 ) or methotrexate at 7.5 mg / week increasing to 15 mg / week ( n = 498 ) .
D-1572	-0.009711978957057	Study MN302 randomised 999 subjects with active rheumatoid arthritis to leflunomide 20 mg / day ( n = 501 ) or methotrexate at 7.5 mg / week increasing to 15 mg / week ( n = 498 ) .
P-1572	-0.0145 -0.0008 -0.0017 -0.0021 -0.0012 -0.0014 -0.0120 -0.2181 -0.0006 -0.0012 -0.0016 -0.0008 -0.0145 -0.0025 -0.0019 -0.0032 -0.0007 -0.0008 -0.0009 -0.0003 -0.0016 -0.0008 -0.0007 -0.0142 -0.0145 -0.0008 -0.0065 -0.0006 -0.0007 -0.0079 -0.0006 -0.0016 -0.0023 -0.0020 -0.0558 -0.0010 -0.0013 -0.0014 -0.0015 -0.0027 -0.0055 -0.0011 -0.0015 -0.0012 -0.0010 -0.0145 -0.0024 -0.0005 -0.0015 -0.0013 -0.0131 -0.0020 -0.0026 -0.0005 -0.0015 -0.0012 -0.0014 -0.1600 -0.0011 -0.0013 -0.0006 -0.0014 -0.0038 -0.0015
S-1182	Zur Prophylaxe und Behandlung von Fieber , Schüttelfrost und anderen grippeähnlichen Begleitsymptomen der Beromun @-@ Behandlung können vor der ILP Paracetamol ( oral oder als Zäpfchen ) oder ein anderes Analgetikum / Antipyretikum verabreicht werden .
T-1182	4 Prophylaxis and treatment of fever , chills and other influenza @-@ like symptoms associated with Beromun administration , can be achieved by pre @-@ ILP administration of paracetamol ( oral or by suppository ) or an alternative analgesic / antipyretic .
H-1182	-0.011779909953474998	4 Prophylaxis and treatment of fever , chills and other influenza @-@ like symptoms associated with Beromun administration , can be achieved by pre @-@ ILP administration of paracetamol ( oral or by suppository ) or an alternative analgesic / antipyretic .
D-1182	-0.011779909953474998	4 Prophylaxis and treatment of fever , chills and other influenza @-@ like symptoms associated with Beromun administration , can be achieved by pre @-@ ILP administration of paracetamol ( oral or by suppository ) or an alternative analgesic / antipyretic .
P-1182	-0.0145 -0.0239 -0.0010 -0.0016 -0.0008 -0.0020 -0.0052 -0.0031 -0.0029 -0.0023 -0.0009 -0.0017 -0.0018 -0.0002 -0.3379 -0.0023 -0.0088 -0.0004 -0.0014 -0.0023 -0.0017 -0.0121 -0.0125 -0.0016 -0.0052 -0.0008 -0.0008 -0.0145 -0.0141 -0.0141 -0.0043 -0.0145 -0.0083 -0.0145 -0.0017 -0.0116 -0.1235 -0.0138 -0.0067 -0.0050 -0.0013 -0.0008 -0.0009 -0.0002 -0.0021 -0.0058 -0.0022 -0.0145 -0.0007 -0.0005 -0.0000 -0.0044 -0.0060 -0.0029 -0.0146 -0.0140 -0.0022 -0.0011 -0.0011 -0.0013 -0.0025 -0.0049 -0.0006 -0.0016 -0.0009 -0.0046 -0.0015
S-49	Diese vorangegangenen Behandlungen schlossen Kortikosteroide ( 98 % aller Patienten ) , Immunglobuline ( 97 % ) , Rituximab ( 71 % ) , Danazol ( 37 % ) , zytotoxische Therapien ( 68 % ) und Azathioprin ( 24 % ) ein .
T-49	Prior treatments included corticosteroids ( 98 % of all patients ) , immunoglobulins ( 97 % ) , rituximab ( 71 % ) , danazol ( 37 % ) , cytotoxic therapies ( 68 % ) , and azathioprine ( 24 % ) .
H-49	-0.026867929846048355	Prior treatments included corticosteroids ( 98 % of all patients ) , immunoglobulins ( 97 % ) , rituximab ( 71 % ) , danazol ( 37 % ) , cytotoxic therapies ( 68 % ) and azathioprine ( 24 % ) .
D-49	-0.026867929846048355	Prior treatments included corticosteroids ( 98 % of all patients ) , immunoglobulins ( 97 % ) , rituximab ( 71 % ) , danazol ( 37 % ) , cytotoxic therapies ( 68 % ) and azathioprine ( 24 % ) .
P-49	-0.0150 -0.0007 -0.0062 -0.0141 -0.0015 -0.0010 -0.0010 -0.0004 -0.0010 -0.0008 -0.0014 -0.0007 -0.0014 -0.0037 -0.0165 -0.0024 -0.0014 -0.0505 -0.0010 -0.0008 -0.0004 -0.0009 -0.0043 -0.0013 -0.0006 -0.0012 -0.0014 -0.0014 -0.0010 -0.0002 -0.0006 -0.0011 -0.0010 -0.0013 -0.0012 -0.0011 -0.0014 -0.0014 -0.0004 -0.0006 -0.6345 -0.0013 -0.0008 -0.0011 -0.0014 -0.0014 -0.0018 -0.0014 -0.0004 -0.0007 -0.0017 -0.0051 -0.0010 -0.0013 -0.0007 -0.0011 -0.0014 -0.9692 -0.0005 -0.0007 -0.0963 -0.0010 -0.0032 -0.0009 -0.0013 -0.0010 -0.0011 -0.0014 -0.0015 -0.0014
S-1759	Der CHMP schloss außerdem , dass Protopic nicht bei Erwachsenen oder Kindern mit geschwächtem Immunsystem eingesetzt und nicht auf Läsionen aufge- tragen werden sollte , die als möglicherweise maligne oder prämaligne zu betrachten sind , und eine zu Behandlungsbeginn vorhandene Lymphadenopathie untersucht und unter Beobachtung gehalten werden sollte .
T-1759	Additionally , the CHMP concluded that Protopic should not be used in immunocompromised adults or children and that Protopic should not be applied to lesions that are considered to be potentially malignant or pre @-@ malignant and that lymphadenopathy present at initiation of therapy should be investigated and kept under review .
H-1759	-0.0062104081735014915	Additionally , the CHMP concluded that Protopic should not be used in immunocompromised adults or children and that Protopic should not be applied to lesions that are considered to be potentially malignant or pre @-@ malignant and that lymphadenopathy present at initiation of therapy should be investigated and kept under review .
D-1759	-0.0062104081735014915	Additionally , the CHMP concluded that Protopic should not be used in immunocompromised adults or children and that Protopic should not be applied to lesions that are considered to be potentially malignant or pre @-@ malignant and that lymphadenopathy present at initiation of therapy should be investigated and kept under review .
P-1759	-0.0146 -0.0009 -0.0043 -0.0032 -0.0012 -0.0006 -0.0025 -0.0020 -0.0039 -0.0008 -0.0013 -0.0017 -0.0015 -0.0014 -0.0471 -0.0055 -0.0520 -0.0101 -0.0044 -0.0018 -0.0025 -0.0024 -0.0028 -0.0088 -0.0139 -0.0144 -0.0006 -0.0014 -0.0016 -0.0017 -0.0015 -0.0049 -0.0055 -0.0037 -0.0005 -0.0087 -0.0097 -0.0093 -0.0123 -0.0017 -0.0062 -0.0008 -0.0008 -0.0012 -0.0018 -0.0130 -0.0013 -0.0009 -0.0004 -0.0011 -0.0168 -0.0051 -0.0109 -0.0016 -0.0007 -0.0011 -0.0007 -0.0020 -0.0105 -0.0029 -0.0262 -0.0019 -0.0095 -0.0253 -0.0015 -0.0016 -0.0103 -0.0015 -0.0094 -0.0006 -0.0142 -0.0015 -0.0014
S-1637	Die Plasma @-@ Clearance von oralem Olanzapin ist bei Frauen niedriger ( 18,9 l / Std ) als bei Männern ( 27,3 l / Std ) , und bei Nichtrauchern ( 18,6 l / Std ) niedriger als bei Rauchern ( 27,7 l / Std ) .
T-1637	Olanzapine plasma clearance after oral olanzapine is lower in females ( 18.9 l / hr ) versus males ( 27.3 l / hr ) , and in non @-@ smokers ( 18.6 l / hr ) versus smokers ( 27.7 l / hr ) .
H-1637	-0.017561141401529312	Olanzapine plasma clearance after oral olanzapine is lower in females ( 18.9 l / hr ) versus males ( 27.3 l / hr ) , and in non @-@ smokers ( 18.6 l / hr ) versus smokers ( 27.7 l / hr ) .
D-1637	-0.017561141401529312	Olanzapine plasma clearance after oral olanzapine is lower in females ( 18.9 l / hr ) versus males ( 27.3 l / hr ) , and in non @-@ smokers ( 18.6 l / hr ) versus smokers ( 27.7 l / hr ) .
P-1637	-0.0123 -0.0145 -0.0014 -0.0004 -0.0010 -0.0090 -0.0008 -0.0008 -0.0015 -0.0013 -0.0146 -0.0059 -0.0140 -0.0004 -0.0003 -0.0010 -0.0051 -0.0027 -0.0041 -0.0712 -0.0005 -0.0016 -0.0030 -0.0019 -0.0056 -0.0015 -0.0554 -0.0015 -0.0402 -0.0050 -0.0013 -0.0013 -0.0008 -0.0014 -0.1804 -0.0014 -0.0001 -0.0013 -0.1293 -0.0026 -0.0139 -0.0042 -0.0092 -0.0038 -0.0008 -0.0014 -0.0006 -0.2019 -0.1447 -0.0014 -0.0001 -0.0014 -0.0141 -0.0069 -0.0011 -0.0014 -0.0007 -0.0013 -0.1109 -0.0014 -0.0001 -0.0014 -0.0015 -0.0014
S-1153	48 Allgemeine Erkrankungen und Beschwerden am Verabreichungsort Reaktionen an der Einstichstelle waren in der Regel schwach ausgeprägt und äußerten sich in Hyperpigmentierungen , Entzündungen , Hautrötungen oder Hauttrockenheit , Phlebitis oder Extravasaten und Venenschwellungen .
T-1153	Infusion site reactions were generally mild and consisted of hyper pigmentation , inflammation , redness or dryness of the skin , phlebitis or extravasation and swelling of the vein .
H-1153	-0.006326218601316214	Infusion site reactions were generally mild and consisted of hyper pigmentation , inflammation , redness or dryness of the skin , phlebitis or extravasation and swelling of the vein .
D-1153	-0.006326218601316214	Infusion site reactions were generally mild and consisted of hyper pigmentation , inflammation , redness or dryness of the skin , phlebitis or extravasation and swelling of the vein .
P-1153	-0.0145 -0.0145 -0.0014 -0.0067 -0.0005 -0.0048 -0.0055 -0.0129 -0.0063 -0.0145 -0.0015 -0.0076 -0.0142 -0.0008 -0.0095 -0.0009 -0.0038 -0.0015 -0.0016 -0.0007 -0.0018 -0.0015 -0.0099 -0.0010 -0.0034 -0.0048 -0.0006 -0.0014 -0.0272 -0.0039 -0.0011 -0.0017 -0.0018 -0.0009 -0.0013 -0.0007 -0.0026 -0.0015 -0.0090 -0.0011 -0.0142 -0.0577 -0.0101 -0.0015 -0.0037 -0.0018 -0.0040 -0.0133 -0.0036 -0.0057
S-1357	Wenn neue Informationen erhalten werden , die sich auf die gegenwärtige Sicherheitsspezifikation , den Pharmakovigilanzplan oder Aktivitäten zur Risikominimierung auswirken können Innerhalb von 60 Tagen , wenn ein wichtiger ( Pharmakovigilanz- oder Risikominimierungs- ) Meilenstein erreicht wurde auf Anfrage der EMEA
T-1357	In addition , an updated RMP should be submitted : • When new information is received that may impact on the current Safety Specification , Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important ( pharmacovigilance or risk minimisation ) milestone being reached • At the request of the EMEA
H-1357	-0.007008668500930071	In addition , an updated RMP should be submitted : • When new information is received that may impact on the current Safety Specification , Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important ( pharmacovigilance or risk minimisation ) milestone being reached • At the request of the EMEA
D-1357	-0.007008668500930071	In addition , an updated RMP should be submitted : • When new information is received that may impact on the current Safety Specification , Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important ( pharmacovigilance or risk minimisation ) milestone being reached • At the request of the EMEA
P-1357	-0.0153 -0.0145 -0.0047 -0.0145 -0.0145 -0.0145 -0.0144 -0.0141 -0.0035 -0.0142 -0.0145 -0.0172 -0.0175 -0.0074 -0.0016 -0.0080 -0.0068 -0.0060 -0.0070 -0.0113 -0.0213 -0.0348 -0.0031 -0.0144 -0.0058 -0.0014 -0.0023 -0.0053 -0.0005 -0.0009 -0.0006 -0.0002 -0.0008 -0.0013 -0.0013 -0.0301 -0.0105 -0.0089 -0.0091 -0.0014 -0.0026 -0.0125 -0.0072 -0.0013 -0.0015 -0.0094 -0.0105 -0.0019 -0.0034 -0.0078 -0.0010 -0.0003 -0.0010 -0.0009 -0.0056 -0.0008 -0.0042 -0.0010 -0.0012 -0.0014 -0.0015 -0.0007 -0.0058 -0.0078 -0.0142 -0.0141 -0.0079 -0.0010 -0.0014 -0.0060 -0.0012 -0.0006 -0.0013 -0.0042
S-689	Folgepackung Faltschachtel mit entweder 2 Blisterpackungen zu 14 x 1 mg Vareniclin @-@ Filmtabletten oder 4 Blisterpackungen mit 14 x 1 mg Vareniclin @-@ Filmtabletten oder 8 Blisterpackungen mit 14 x 1 mg Vareniclin @-@ Filmtabletten
T-689	Maintenance pack Carton Pack containing 2 blister packs of 14 x 1 mg varenicline film @-@ coated tablets or 4 blister packs of 14 x 1 mg varenicline film @-@ coated tablets or 8 blister packs of 14 x 1 mg varenicline film @-@ coated tablets
H-689	-0.04637643322348595	Maintenance pack Carton Pack containing 2 blisters of 14 x 1 mg varenicline film @-@ coated tablets or 4 blister packs of 14 x 1 mg varenicline film @-@ coated tablets or 8 blister packs of 14 x 1 mg varenicline film @-@ coated tablets
D-689	-0.04637643322348595	Maintenance pack Carton Pack containing 2 blisters of 14 x 1 mg varenicline film @-@ coated tablets or 4 blister packs of 14 x 1 mg varenicline film @-@ coated tablets or 8 blister packs of 14 x 1 mg varenicline film @-@ coated tablets
P-689	-0.0145 -0.0074 -0.0112 -0.0148 -0.0025 -0.0696 -0.0116 -0.0478 -0.0145 -0.0065 -1.9919 -0.0059 -0.0091 -0.0010 -0.0027 -0.0007 -0.0120 -0.0013 -0.0009 -0.0140 -0.0028 -0.0355 -0.0145 -0.0013 -0.0377 -0.0014 -0.0046 -0.0017 -0.0003 -0.3869 -0.0061 -0.0007 -0.0065 -0.0012 -0.0016 -0.0015 -0.0006 -0.0012 -0.0012 -0.0010 -0.0119 -0.0020 -0.0026 -0.0018 -0.0005 -0.0059 -0.0012 -0.0026 -0.0022 -0.0003 -0.3848 -0.0034 -0.0008 -0.0034 -0.0011 -0.0015 -0.0014 -0.0007 -0.0008 -0.0012 -0.0011 -0.0108 -0.0017 -0.0018 -0.0010 -0.0005 -0.0011 -0.0013 -0.0022
S-1499	In beiden Studien waren die Ausgangskrankheitsmerkmale generell in allen Behandlungsgruppen einheitlich , mit einem mittleren PASI @-@ Ausgangsscore von 17 bis 18 und einer mittleren Ausgangs @-@ Body Surface Area ( BSA ) ≥ 20 und einem mittleren Dermatology Life Quality Index ( DLQI ) zwischen 10 und 12 .
T-1499	In both studies , baseline disease characteristics were generally consistent across all treatment groups with a median baseline PASI score from 17 to 18 and median baseline Body Surface Area ( BSA ) ≥ 20 , median Dermatology Life Quality Index ( DLQI ) range from 10 to 12 .
H-1499	-0.008576116524636745	In both studies , baseline disease characteristics were generally consistent across all treatment groups with a median baseline PASI score from 17 to 18 and median baseline Body Surface Area ( BSA ) ≥ 20 , median Dermatology Life Quality Index ( DLQI ) range from 10 to 12 .
D-1499	-0.008576116524636745	In both studies , baseline disease characteristics were generally consistent across all treatment groups with a median baseline PASI score from 17 to 18 and median baseline Body Surface Area ( BSA ) ≥ 20 , median Dermatology Life Quality Index ( DLQI ) range from 10 to 12 .
P-1499	-0.0042 -0.0106 -0.0046 -0.0068 -0.0143 -0.0007 -0.0036 -0.0060 -0.0011 -0.0031 -0.0083 -0.0099 -0.0329 -0.0023 -0.0014 -0.0017 -0.0164 -0.0095 -0.0121 -0.0014 -0.0277 -0.0005 -0.0041 -0.0953 -0.0013 -0.0004 -0.0188 -0.0017 -0.0421 -0.0012 -0.0309 -0.0146 -0.0016 -0.0050 -0.0008 -0.0059 -0.0014 -0.0009 -0.0006 -0.0011 -0.0017 -0.0007 -0.0014 -0.0004 -0.0010 -0.0985 -0.0147 -0.0013 -0.0044 -0.0027 -0.0018 -0.0009 -0.0034 -0.0011 -0.0005 -0.0013 -0.0007 -0.0012 -0.0013 -0.0014 -0.0145 -0.0060 -0.0013 -0.0015 -0.0016 -0.0015 -0.0014
S-1591	Kuvan wird zur Behandlung einer Hyperphenylalaninämie ( HPA , hoher Phenylalaninspiegel im Blut ) bei Patienten mit den angeborenen Erkrankungen Phenylketonurie ( PKU ) oder Tetrahydrobiopterin ( BH4 ) -Mangel angewendet .
T-1591	Kuvan is used to treat hyperphenylalaninaemia ( HPA , high levels of phenylalanine in the blood ) in patients with the genetic disorders phenylketonuria ( PKU ) or tetrahydrobiopterin ( BH4 ) deficiency .
H-1591	-0.005941981915384531	Kuvan is used to treat hyperphenylalaninaemia ( HPA , high levels of phenylalanine in the blood ) in patients with the genetic disorders phenylketonuria ( PKU ) or tetrahydrobiopterin ( BH4 ) deficiency .
D-1591	-0.005941981915384531	Kuvan is used to treat hyperphenylalaninaemia ( HPA , high levels of phenylalanine in the blood ) in patients with the genetic disorders phenylketonuria ( PKU ) or tetrahydrobiopterin ( BH4 ) deficiency .
P-1591	-0.0013 -0.0003 -0.0021 -0.0033 -0.0055 -0.0010 -0.0019 -0.0009 -0.0007 -0.0011 -0.0012 -0.0145 -0.0108 -0.0007 -0.0013 -0.0016 -0.0015 -0.0006 -0.0358 -0.0027 -0.0056 -0.0014 -0.0015 -0.0005 -0.0009 -0.0011 -0.0044 -0.0016 -0.0256 -0.0012 -0.0015 -0.0018 -0.0037 -0.0690 -0.0117 -0.0144 -0.0099 -0.0011 -0.0017 -0.0006 -0.0003 -0.0008 -0.0003 -0.0012 -0.0016 -0.0015 -0.0014 -0.0020 -0.0015 -0.1127 -0.0011 -0.0007 -0.0009 -0.0011 -0.0007 -0.0008 -0.0014 -0.0012 -0.0013 -0.0012 -0.0014 -0.0048 -0.0004 -0.0012 -0.0017 -0.0014
S-1681	144 Bei älteren Patienten mit Demenz kann es bei der Einnahme von Olanzapin zu Schlaganfall , Lungenentzündung , Harninkontinenz , Stürzen , extremer Müdigkeit , optischen Halluzinationen , Erhöhung der Körpertemperatur , Hautrötung und Schwierigkeiten beim Gehen kommen .
T-1681	While taking olanzapine , elderly patients with dementia may suffer from stroke , pneumonia , urinary incontinence , falls , extreme tiredness , visual hallucinations , a rise in body temperature , redness of the skin and have trouble walking .
H-1681	-0.004222008865326643	While taking olanzapine , elderly patients with dementia may suffer from stroke , pneumonia , urinary incontinence , falls , extreme tiredness , visual hallucinations , a rise in body temperature , redness of the skin and have trouble walking .
D-1681	-0.004222008865326643	While taking olanzapine , elderly patients with dementia may suffer from stroke , pneumonia , urinary incontinence , falls , extreme tiredness , visual hallucinations , a rise in body temperature , redness of the skin and have trouble walking .
P-1681	-0.0145 -0.0034 -0.0007 -0.0005 -0.0010 -0.0012 -0.0097 -0.0088 -0.0063 -0.0045 -0.0008 -0.0083 -0.0117 -0.0144 -0.0117 -0.0015 -0.0010 -0.0003 -0.0004 -0.0005 -0.0014 -0.0010 -0.0007 -0.0012 -0.0003 -0.0010 -0.0014 -0.0026 -0.0015 -0.0009 -0.0097 -0.0004 -0.0011 -0.0014 -0.0053 -0.0003 -0.0011 -0.0006 -0.0009 -0.0014 -0.0143 -0.0109 -0.0021 -0.0028 -0.0010 -0.0016 -0.0075 -0.0011 -0.0116 -0.0021 -0.0015 -0.0057 -0.0200 -0.0186 -0.0013 -0.0018 -0.0014
S-1326	Emtricitabin @-@ resistente Viren mit der M184V / I @-@ Mutation waren kreuzresistent gegenüber Lamivudin , blieben aber empfindlich gegenüber Didanosin , Stavudin , Tenofovir , Zalcitabin und Zidovudin .
T-1326	Emtricitabine @-@ resistant viruses with the M184V / I mutation were cross @-@ resistant to lamivudine , but retained sensitivity to didanosine , stavudine , tenofovir , zalcitabine and zidovudine .
H-1326	-0.019578583538532257	Emtricitabine @-@ resistant viruses with the M184V / I mutation were cross @-@ resistant to lamivudine , but retained sensitivity to didanosine , stavudine , tenofovir , zalcitabine , and zidovudine .
D-1326	-0.019578583538532257	Emtricitabine @-@ resistant viruses with the M184V / I mutation were cross @-@ resistant to lamivudine , but retained sensitivity to didanosine , stavudine , tenofovir , zalcitabine , and zidovudine .
P-1326	-0.0015 -0.0009 -0.0005 -0.0010 -0.0011 -0.0043 -0.0012 -0.0008 -0.0034 -0.0009 -0.0042 -0.0030 -0.0023 -0.0012 -0.0016 -0.1571 -0.0014 -0.0999 -0.0011 -0.0014 -0.0037 -0.0038 -0.0032 -0.0048 -0.0008 -0.0020 -0.0019 -0.0011 -0.0010 -0.0011 -0.0020 -0.0075 -0.0025 -0.0145 -0.0010 -0.0064 -0.0006 -0.0016 -0.0001 -0.0069 -0.0008 -0.0011 -0.0015 -0.0056 -0.0073 -0.0011 -0.0039 -0.0014 -0.0005 -0.0013 -0.0008 -0.1035 -0.0012 -0.0015 -0.0019 -0.0010 -0.0005 -0.0009 -0.0011 -0.7501 -0.0770 -0.0029 -0.0010 -0.0010 -0.0012 -0.0029 -0.0015 -0.0014
S-1301	Sucrose , Natriumdihydrogenphosphat @-@ Monohydrat , Dinatriumhydrogenphosphat @-@ Dihydrat , Methionin , Polysorbat 20 , konzentrierte Phosphorsäure und Natriumhydroxid Eine Fertigspritze mit Lösungsmittel enthält :
T-1301	One pre @-@ filled syringe of solvent contains :
H-1301	-0.00736174127086997	One pre @-@ filled syringe of solvent contains :
D-1301	-0.00736174127086997	One pre @-@ filled syringe of solvent contains :
P-1301	-0.0171 -0.0131 -0.0014 -0.0100 -0.0092 -0.0007 -0.0003 -0.0142 -0.0041 -0.0020 -0.0050 -0.0040 -0.0150
S-837	Bei Anwendung von RISPERDAL CONSTA mit anderen Arzneimitteln Bitte informieren Sie Ihren Arzt oder Apotheker , wenn Sie andere Arzneimittel einnehmen / anwenden oder vor kurzem eingenommen / angewendet haben , auch wenn es sich um nicht verschreibungspflichtige Arzneimittel und pflanzliche Arzneimittel handelt .
T-837	Using other medicines Please tell your doctor or pharmacist if you are using or have recently used any other medicines , including medicines obtained without a prescription and herbal medicines .
H-837	-0.058035265654325485	Using other medicines Please tell your doctor or pharmacist if you are using or have recently used any other medicines , including medicines obtained without a prescription and herbal medicines .
D-837	-0.058035265654325485	Using other medicines Please tell your doctor or pharmacist if you are using or have recently used any other medicines , including medicines obtained without a prescription and herbal medicines .
P-837	-0.0289 -0.3487 -0.0023 -0.2272 -0.0122 -0.0306 -0.0016 -0.0029 -0.0021 -0.0017 -0.0009 -0.0020 -0.0014 -0.0062 -0.6622 -0.0793 -0.0192 -0.0120 -0.3161 -0.0658 -0.0046 -0.0044 -0.0027 -0.0036 -0.2380 -0.0149 -0.0047 -0.0176 -0.0133 -0.0101 -0.0005 -0.0417 -0.0016 -0.0010 -0.0058 -0.0031 -0.0044 -0.0103
S-512	Tevagrastim , das r @-@ metHuG @-@ CSF ( Filgrastim ) enthält , führt innerhalb von 24 Stunden nach Anwendung zu einer deutlichen Steigerung der Anzahl neutrophiler Granulozyten im peripheren Blut , begleitet von gering ausgeprägter Erhöhung der Anzahl von Monozyten .
T-512	Tevagrastim containing r @-@ metHuG @-@ CSF ( filgrastim ) causes marked increases in peripheral blood neutrophil counts within 24 hours , with minor increases in monocytes .
H-512	-0.01340900082141161	Tevagrastim containing r @-@ metHuG @-@ CSF ( filgrastim ) causes marked increases in peripheral blood neutrophil counts within 24 hours , with minor increases in monocytes .
D-512	-0.01340900082141161	Tevagrastim containing r @-@ metHuG @-@ CSF ( filgrastim ) causes marked increases in peripheral blood neutrophil counts within 24 hours , with minor increases in monocytes .
P-512	-0.0048 -0.0009 -0.0008 -0.0028 -0.0010 -0.0110 -0.0019 -0.3134 -0.0014 -0.0007 -0.0010 -0.0026 -0.0008 -0.0012 -0.0032 -0.0019 -0.0009 -0.0026 -0.0012 -0.0015 -0.0151 -0.0145 -0.0109 -0.0022 -0.0145 -0.0007 -0.0012 -0.0029 -0.0042 -0.0034 -0.0004 -0.0051 -0.0144 -0.0115 -0.0016 -0.0017 -0.0898 -0.0141 -0.0140 -0.0062 -0.0018 -0.0079 -0.0007 -0.0007 -0.0278 -0.0042 -0.0034
S-1442	FRAGEN UND ANTWORTEN ZUR RÜCKNAHME DES ANTRAGS AUF ÄNDERUNG DER GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN von NUTROPINAQ
T-1442	QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE APPLICATION FOR A CHANGE TO THE MARKETING AUTHORISATION for NUTROPINAQ
H-1442	-0.015495320782065392	QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE APPLICATION FOR A CHANGE TO THE MARKETING AUTHORISATION for NUTROPINAQ
D-1442	-0.015495320782065392	QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE APPLICATION FOR A CHANGE TO THE MARKETING AUTHORISATION for NUTROPINAQ
P-1442	-0.0043 -0.0006 -0.0002 -0.0012 -0.0004 -0.0024 -0.0008 -0.0099 -0.0016 -0.0079 -0.0006 -0.0124 -0.0039 -0.0145 -0.0113 -0.0145 -0.0113 -0.0131 -0.0140 -0.0129 -0.0016 -0.0202 -0.0186 -0.0046 -0.0011 -0.0008 -0.0005 -0.0130 -0.0009 -0.0288 -0.0047 -0.0012 -0.0013 -0.0164 -0.0062 -0.0145 -0.0042 -0.0080 -0.0081 -0.2094 -0.0044 -0.0019 -0.0134 -0.0080 -0.0010 -0.2593 -0.0022 -0.0021 -0.0011 -0.0014 -0.0014 -0.0014 -0.0014 -0.0008 -0.0502
S-1383	Dosis , Dosierungsbereich und Behandlungsintervalle Zur Behandlung von Blutungen und zur Prophylaxe von Blutungen bei invasiven und chirurgischen Eingriffen wird eine Dosis von 15 @-@ 30 µg pro kg Körpergewicht alle 4 @-@ 6 Stunden bis zum Erreichen einer Hämostase empfohlen .
T-1383	3 Dose , dose range and dose interval The recommended dose range for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 15 - 30 μ g per kg body weight every 4 - 6 hours until haemostasis is achieved .
H-1383	-0.029410796239972115	3 Dose , dose range and dose interval The recommended dose range for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 15 - 30 μ g per kg body weight every 4 - 6 hours until haemostasis is achieved .
D-1383	-0.029410796239972115	3 Dose , dose range and dose interval The recommended dose range for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 15 - 30 μ g per kg body weight every 4 - 6 hours until haemostasis is achieved .
P-1383	-0.0146 -0.0148 -0.0125 -0.0038 -0.0124 -0.0031 -0.3466 -0.0142 -0.0026 -0.0149 -0.0139 -0.0043 -0.0090 -0.0366 -0.0385 -0.0130 -0.0028 -0.0071 -0.0011 -0.0147 -0.0162 -0.0159 -0.0334 -0.0036 -0.0008 -0.0014 -0.0045 -0.0006 -0.0097 -0.0151 -0.0069 -0.0005 -0.0149 -0.0126 -0.0067 -0.0021 -0.0010 -0.0060 -0.0024 -0.0027 -0.1551 -0.0026 -0.0274 -0.0027 -0.0234 -0.0750 -0.0801 -0.0009 -0.0049 -0.0016 -0.6631 -0.0014 -0.0016 -0.0143 -0.0114 -0.0004 -0.0002 -0.0003 -0.0070 -0.0092 -0.0016 -0.0015
S-306	Idiopathische , Thrombozytopenische Purpura ( ITP ) Zur Behandlung einer akuten Episode 0,8 @-@ 1 g / kg KG am 1.Tag , evtl. einmalige Wiederholung innerhalb von 3 Tagen , oder jeweils 0,4 g / kg KG an zwei bis fünf aufeinander folgenden Tagen .
T-306	Idiopathic Thrombocytopenic Purpura ( ITP ) For the treatment of an acute episode , 0.8 @-@ 1 g / kg BW on day one , which may be repeated once within 3 days , or 0.4 g / kg BW daily for two to five days .
H-306	-0.010249423794448376	Idiopathic Thrombocytopenic Purpura ( ITP ) For the treatment of an acute episode , 0.8 @-@ 1 g / kg BW on day one , which may be repeated once within 3 days , or 0.4 g / kg BW daily for two to five days .
D-306	-0.010249423794448376	Idiopathic Thrombocytopenic Purpura ( ITP ) For the treatment of an acute episode , 0.8 @-@ 1 g / kg BW on day one , which may be repeated once within 3 days , or 0.4 g / kg BW daily for two to five days .
P-306	-0.0030 -0.0011 -0.0010 -0.0006 -0.0011 -0.0125 -0.0005 -0.0004 -0.0007 -0.0007 -0.0020 -0.0020 -0.0005 -0.0018 -0.0014 -0.0014 -0.0012 -0.2326 -0.0014 -0.0085 -0.0102 -0.0015 -0.0014 -0.0056 -0.0015 -0.0007 -0.0019 -0.0143 -0.0054 -0.0014 -0.0744 -0.0031 -0.0012 -0.0015 -0.0007 -0.0145 -0.0037 -0.0112 -0.0126 -0.0072 -0.0144 -0.0084 -0.0022 -0.0025 -0.0030 -0.0073 -0.0250 -0.0014 -0.0592 -0.0013 -0.0030 -0.0017 -0.0009 -0.0015 -0.0007 -0.0144 -0.0148 -0.0071 -0.0042 -0.0030 -0.0094 -0.0137 -0.0071 -0.0015
S-1447	Am Ende dieser Studie ( Woche 12 ) normalisierte sich das Serum @-@ IGF @-@ I bei 9,7 % , 38,5 % , 75 % und 82 % der Personen , die 14 mit Plazebo , SOMAVERT 10 mg / Tag , 15 mg / Tag beziehungsweise 20 mg / Tag , behandelt wurden .
T-1447	The serum IGF @-@ 1 was normalised at the end of the study ( week 12 ) in 9.7 % , 38.5 % , 75 % and 82 % of subjects treated with placebo , 10 mg / day , 15 mg / day or 20 mg / day SOMAVERT respectively .
H-1447	-0.01805911213159561	The serum IGF @-@ 1 was normalised at the end of the study ( week 12 ) in 9.7 % , 38.5 % , 75 % and 82 % of subjects treated with placebo , 10 mg / day , 15 mg / day or 20 mg / day SOMAVERT respectively .
D-1447	-0.01805911213159561	The serum IGF @-@ 1 was normalised at the end of the study ( week 12 ) in 9.7 % , 38.5 % , 75 % and 82 % of subjects treated with placebo , 10 mg / day , 15 mg / day or 20 mg / day SOMAVERT respectively .
P-1447	-0.0216 -0.0107 -0.0017 -0.0023 -0.0011 -0.0024 -0.2461 -0.0142 -0.0130 -0.0013 -0.0083 -0.0062 -0.0084 -0.0016 -0.0115 -0.0033 -0.0022 -0.0016 -0.0013 -0.0014 -0.0058 -0.0016 -0.0012 -0.3616 -0.0015 -0.0240 -0.0012 -0.0014 -0.0012 -0.0015 -0.0007 -0.0012 -0.1782 -0.0004 -0.0011 -0.0017 -0.0123 -0.0097 -0.0021 -0.0013 -0.0012 -0.0006 -0.0012 -0.0022 -0.0145 -0.0393 -0.0019 -0.0023 -0.0026 -0.0009 -0.0005 -0.0015 -0.0013 -0.0981 -0.0012 -0.0005 -0.0014 -0.0013 -0.0131 -0.0007 -0.0013 -0.0007 -0.0127 -0.0017 -0.0015
S-367	EU / 1 / 04 / 279 / 030 EU / 1 / 04 / 279 / 031 EU / 1 / 04 / 279 / 032 EU / 1 / 04 / 279 / 033 EU / 1 / 04 / 279 / 034 EU / 1 / 04 / 279 / 035
T-367	1 / 2 EU / 1 / 04 / 279 / 028 EU / 1 / 04 / 279 / 029 EU / 1 / 04 / 279 / 030 EU / 1 / 04 / 279 / 031 EU / 1 / 04 / 279 / 032 EU / 1 / 04 / 279 / 033 EU / 1 / 04 / 279 / 034 EU / 1 / 04 / 279 / 035
H-367	-0.03477611765265465	EU / 1 / 04 / 279 / 030 EU / 1 / 04 / 279 / 031 EU / 1 / 04 / 279 / 032 EU / 1 / 04 / 279 / 033 EU / 1 / 04 / 279 / 034 EU / 1 / 04 / 279 / 035
D-367	-0.03477611765265465	EU / 1 / 04 / 279 / 030 EU / 1 / 04 / 279 / 031 EU / 1 / 04 / 279 / 032 EU / 1 / 04 / 279 / 033 EU / 1 / 04 / 279 / 034 EU / 1 / 04 / 279 / 035
P-367	-0.3454 -0.0015 -0.0013 -0.0014 -0.0010 -0.0014 -0.0008 -0.0011 -0.0014 -0.0015 -0.2698 -0.3250 -0.0015 -0.0014 -0.0014 -0.0007 -0.0014 -0.0008 -0.0012 -0.0014 -0.0015 -0.0013 -0.0012 -0.0015 -0.0014 -0.0014 -0.0007 -0.0014 -0.0008 -0.0012 -0.0014 -0.0014 -0.0045 -0.0013 -0.0015 -0.0014 -0.0014 -0.0007 -0.0014 -0.0008 -0.0011 -0.0014 -0.0012 -0.0010 -0.0013 -0.0015 -0.0014 -0.0014 -0.0007 -0.0014 -0.0008 -0.0012 -0.0014 -0.0012 -0.0075 -0.0014 -0.0015 -0.0014 -0.0014 -0.0007 -0.0014 -0.0007 -0.0012 -0.0014 -0.0012 -1.3018 -0.0014
S-872	Während der Behandlung mit Rapamune sollten Patienten , die einen HMG @-@ CoA @-@ Reduktaseinhibitor und / oder ein Fibrat erhalten bezüglich der möglichen Entwicklung einer Rhabdomyolyse und anderer Nebenwirkungen so überwacht werden , wie in der Fachinformation zum jeweiligen Präparat beschrieben .
T-872	During Rapamune therapy , patients administered an HMG @-@ CoA reductase inhibitor and / or fibrate , should be monitored for the possible development of rhabdomyolysis and other adverse effects as described in the respective Summary of Product Characteristics of these agents .
H-872	-0.007699624169617891	During Rapamune therapy , patients administered an HMG @-@ CoA reductase inhibitor and / or fibrate , should be monitored for the possible development of rhabdomyolysis and other adverse effects as described in the respective Summary of Product Characteristics of these agents .
D-872	-0.007699624169617891	During Rapamune therapy , patients administered an HMG @-@ CoA reductase inhibitor and / or fibrate , should be monitored for the possible development of rhabdomyolysis and other adverse effects as described in the respective Summary of Product Characteristics of these agents .
P-872	-0.0043 -0.0138 -0.0012 -0.0002 -0.0167 -0.0035 -0.0027 -0.0433 -0.1209 -0.0094 -0.0012 -0.0014 -0.0008 -0.0038 -0.0015 -0.0011 -0.0032 -0.0004 -0.0003 -0.0004 -0.0010 -0.0003 -0.0008 -0.0011 -0.0017 -0.0014 -0.0012 -0.0078 -0.0013 -0.0022 -0.0178 -0.0040 -0.0017 -0.0033 -0.0009 -0.0052 -0.0078 -0.0113 -0.0018 -0.0014 -0.0018 -0.0006 -0.0008 -0.0013 -0.0009 -0.0016 -0.0008 -0.0022 -0.0024 -0.0122 -0.0005 -0.0554 -0.0067 -0.0220 -0.0017 -0.0027 -0.0144 -0.0146 -0.0006 -0.0121 -0.0142 -0.0145 -0.0019 -0.0010 -0.0010 -0.0009 -0.0214 -0.0145 -0.0144 -0.0017 -0.0015
S-1962	EU / 1 / 97 / 030 / 035 EU / 1 / 97 / 030 / 057 EU / 1 / 97 / 030 / 058 EU / 1 / 97 / 030 / 086 EU / 1 / 97 / 030 / 091 EU / 1 / 97 / 030 / 096
T-1962	EU / 1 / 97 / 030 / 086 EU / 1 / 97 / 030 / 035 EU / 1 / 97 / 030 / 057 EU / 1 / 97 / 030 / 091 EU / 1 / 97 / 030 / 096 EU / 1 / 97 / 030 / 058
H-1962	-0.051661986857652664	EU / 1 / 97 / 030 / 086 EU / 1 / 97 / 030 / 035 EU / 1 / 97 / 030 / 057 EU / 1 / 97 / 030 / 091 EU / 1 / 97 / 030 / 096 EU / 1 / 97 / 030 / 058
D-1962	-0.051661986857652664	EU / 1 / 97 / 030 / 086 EU / 1 / 97 / 030 / 035 EU / 1 / 97 / 030 / 057 EU / 1 / 97 / 030 / 091 EU / 1 / 97 / 030 / 096 EU / 1 / 97 / 030 / 058
P-1962	-0.0018 -0.0016 -0.0013 -0.0015 -0.0006 -0.0014 -0.0013 -0.0012 -0.0014 -0.0012 -0.6089 -0.0022 -0.0016 -0.0014 -0.0015 -0.0006 -0.0014 -0.0013 -0.0012 -0.0014 -0.0013 -0.2229 -0.0014 -0.0016 -0.0013 -0.0015 -0.0005 -0.0014 -0.0012 -0.0012 -0.0014 -0.0013 -0.5518 -0.0013 -0.0015 -0.0013 -0.0015 -0.0006 -0.0014 -0.0012 -0.0020 -0.0014 -0.0013 -0.5234 -0.0016 -0.0016 -0.0014 -0.0015 -0.0005 -0.0014 -0.0012 -0.0013 -0.0014 -0.0013 -0.1628 -0.7277 -0.0025 -0.0016 -0.0015 -0.0011 -0.0017 -0.0012 -0.0017 -0.0016 -0.0013 -0.2577 -0.3251
S-1512	EU / 1 / 99 / 127 / 027 EU / 1 / 99 / 127 / 028 EU / 1 / 99 / 127 / 029 EU / 1 / 99 / 127 / 030 EU / 1 / 99 / 127 / 043 EU / 1 / 99 / 127 / 044
T-1512	EU / 1 / 99 / 127 / 027 EU / 1 / 99 / 127 / 028 EU / 1 / 99 / 127 / 029 EU / 1 / 99 / 127 / 030 EU / 1 / 99 / 127 / 043 EU / 1 / 99 / 127 / 044
H-1512	-0.006004787515848875	EU / 1 / 99 / 127 / 027 EU / 1 / 99 / 127 / 028 EU / 1 / 99 / 127 / 029 EU / 1 / 99 / 127 / 030 EU / 1 / 99 / 127 / 043 EU / 1 / 99 / 127 / 044
D-1512	-0.006004787515848875	EU / 1 / 99 / 127 / 027 EU / 1 / 99 / 127 / 028 EU / 1 / 99 / 127 / 029 EU / 1 / 99 / 127 / 030 EU / 1 / 99 / 127 / 043 EU / 1 / 99 / 127 / 044
P-1512	-0.3185 -0.0016 -0.0013 -0.0015 -0.0007 -0.0014 -0.0011 -0.0012 -0.0014 -0.0013 -0.0011 -0.0014 -0.0016 -0.0014 -0.0015 -0.0006 -0.0014 -0.0010 -0.0012 -0.0014 -0.0011 -0.0009 -0.0013 -0.0015 -0.0013 -0.0015 -0.0006 -0.0014 -0.0010 -0.0012 -0.0014 -0.0013 -0.0027 -0.0014 -0.0015 -0.0013 -0.0015 -0.0007 -0.0014 -0.0010 -0.0012 -0.0014 -0.0013 -0.0012 -0.0014 -0.0016 -0.0014 -0.0015 -0.0006 -0.0014 -0.0010 -0.0012 -0.0014 -0.0015 -0.0011 -0.0014 -0.0015 -0.0013 -0.0015 -0.0006 -0.0014 -0.0010 -0.0012 -0.0015 -0.0012 -0.0007 -0.0014
S-51	Die Wirksamkeit und die Unbedenklichkeit von Paxene ( 175 mg / m2 über 3 Stunden in dreiwöchigen Abständen wiederholt ) bei Ovarialkarzinom im fortgeschrittenen Stadium wurden bei 120 Frauen in einer multizentrischen , unverblindeten erweiterten Phase @-@ II @-@ Studie untersucht .
T-51	The efficacy and safety of Paxene ( 175 mg / m ² over 3 hours repeated at 3 @-@ week intervals ) in advanced metastatic ovarian cancer were investigated in 120 women in a multicentre , open @-@ label extended Phase II trial .
H-51	-0.016051894053816795	The efficacy and safety of Paxene ( 175 mg / m ² over 3 hours repeated at 3 @-@ week intervals ) in advanced metastatic ovarian cancer were investigated in 120 women in a multicentre , open @-@ label extended Phase II trial .
D-51	-0.016051894053816795	The efficacy and safety of Paxene ( 175 mg / m ² over 3 hours repeated at 3 @-@ week intervals ) in advanced metastatic ovarian cancer were investigated in 120 women in a multicentre , open @-@ label extended Phase II trial .
P-51	-0.0053 -0.0047 -0.0005 -0.0007 -0.0017 -0.0010 -0.0018 -0.0013 -0.0011 -0.0020 -0.0036 -0.0090 -0.0004 -0.0015 -0.5080 -0.0025 -0.0153 -0.0065 -0.0034 -0.0094 -0.0059 -0.0080 -0.0357 -0.0051 -0.0018 -0.0012 -0.0014 -0.0036 -0.0025 -0.0155 -0.0011 -0.0005 -0.0045 -0.0004 -0.0011 -0.0037 -0.0115 -0.0205 -0.0017 -0.0019 -0.0017 -0.0019 -0.0024 -0.0050 -0.0004 -0.0110 -0.0017 -0.0027 -0.0069 -0.0033 -0.0001 -0.0131 -0.0098 -0.0047 -0.0183 -0.1230 -0.0015
S-582	Patienten , die zuvor bereits andere Arzneimittel zur Behandlung der HIV @-@ Infektion eingenommen haben , sollte Viread nur verordnet werden , nachdem sich der Arzt die antiviralen Arzneimittel , die der Patient zuvor eingenommen hat , angesehen oder die Wahrscheinlichkeit des Ansprechens des Virus auf antivirale Arzneimittel überprüft hat .
T-582	For patients who have taken medicines to treat HIV infection before , doctors should only prescribe Viread once they have looked at the antiviral medicines the patient has taken before or the likelihood of the virus <<unk>> s response to antiviral medicines .
H-582	-0.0068715219385921955	For patients who have taken medicines to treat HIV infection before , doctors should only prescribe Viread once they have looked at the antiviral medicines the patient has taken before or the likelihood of the virus <unk> s response to antiviral medicines .
D-582	-0.0068715219385921955	For patients who have taken medicines to treat HIV infection before , doctors should only prescribe Viread once they have looked at the antiviral medicines the patient has taken before or the likelihood of the virus <unk> s response to antiviral medicines .
P-582	-0.0177 -0.0048 -0.0230 -0.0052 -0.0144 -0.0145 -0.0068 -0.0121 -0.0031 -0.0041 -0.0121 -0.0078 -0.0031 -0.0159 -0.0017 -0.0098 -0.0038 -0.0013 -0.0079 -0.0009 -0.0137 -0.0104 -0.0021 -0.0133 -0.0022 -0.0058 -0.0031 -0.0008 -0.0030 -0.0060 -0.0087 -0.0098 -0.0013 -0.0036 -0.0118 -0.0111 -0.0068 -0.0141 -0.0040 -0.0007 -0.0005 -0.0029 -0.0049 -0.0012 -0.0145 -0.0130 -0.0075 -0.0014 -0.0046 -0.0008 -0.0024 -0.0084 -0.0101 -0.0019 -0.0015
S-1200	Injektions- knopf ge- drückt und zählen Sie langsam bis 5. • Der Pen ist korrekt entlüf- tet , wenn Insu- lin als dünner Strahl aus der Nadel austritt . • Tritt kein In- sulin aus , wie- derholen Sie die Schritte 2B bis 2D .
T-1200	• Priming is complete when a stream of insulin appears from the needle tip . • If a stream of insulin does not appear , repeat priming steps 2B thru 2D .
H-1200	-0.016635848209261894	• Priming is complete when a stream of insulin appears from the needle tip . • If a stream of insulin does not appear , repeat priming steps 2B thru 2D .
D-1200	-0.016635848209261894	• Priming is complete when a stream of insulin appears from the needle tip . • If a stream of insulin does not appear , repeat priming steps 2B thru 2D .
P-1200	-0.0143 -0.0145 -0.0142 -0.0135 -0.0144 -0.0116 -0.0142 -0.0145 -0.0023 -0.0017 -0.0004 -0.0145 -0.0078 -0.0027 -0.0011 -0.0013 -0.1411 -0.0576 -0.0016 -0.0033 -0.0141 -0.0144 -0.0026 -0.0033 -0.0006 -0.0069 -0.0014 -0.0143 -0.0046 -0.0129 -0.0148 -0.0110 -0.0035 -0.0023 -0.0012 -0.2055 -0.0009 -0.0011 -0.0010 -0.0052 -0.0136
S-1582	Unter den Patienten mit Neovaskularisationen infolge von pathologischer Myopie hatten nach 12 Monaten 86 % der mit Visudyne behandelten Patienten ein um weniger als 15 Buchstaben verschlechtertes Sehvermögen , verglichen mit 67 % der mit Placebo behandelten Patienten .
T-1582	For patients with neovascularisation caused by pathologic myopia , after 12 months , 86 % of the Visudyne @-@ treated patients had a loss of less than 15 letters compared with 67 % of the placebo @-@ treated patients .
H-1582	-0.02244635485112667	For patients with neovascularisation caused by pathologic myopia , after 12 months , 86 % of the Visudyne @-@ treated patients had a loss of less than 15 letters compared with 67 % of the placebo @-@ treated patients .
D-1582	-0.02244635485112667	For patients with neovascularisation caused by pathologic myopia , after 12 months , 86 % of the Visudyne @-@ treated patients had a loss of less than 15 letters compared with 67 % of the placebo @-@ treated patients .
P-1582	-0.0217 -0.0040 -0.0049 -0.0036 -0.0009 -0.0010 -0.0043 -0.0121 -0.0051 -0.0134 -0.0015 -0.0017 -0.0325 -0.0014 -0.0006 -0.0010 -0.0007 -0.0044 -0.0981 -0.0012 -0.0014 -0.0103 -0.1441 -0.0016 -0.0018 -0.0124 -0.0102 -0.0011 -0.0007 -0.0009 -0.0541 -0.0009 -0.0014 -0.0067 -0.0133 -0.0140 -0.0667 -0.0143 -0.0015 -0.0015 -0.0033 -0.0139 -0.6263 -0.0007 -0.0013 -0.0154 -0.0106 -0.0012 -0.0012 -0.0008 -0.0013 -0.0033 -0.0005 -0.0016 -0.0015 -0.0014
S-324	Schläfrigkeit ( Lethargie ) , Tremor , Nachtschweiß , Paniksymptome , Schluckauf , Ärger , Ruhelosigkeit ( Dysphorie ) , Verstimmung , Suizidgedanken , Aggressivität oder aggressives Verhalten , Hypoglykämie n
T-324	ge Uncommon side effects , that affect less than 1 per 100 but more than1 per 1000 , that have occurred in patients on ACOMPLIA include : lon Sleepiness ( lethargy ) , tremor , night sweats , panic symptoms , hiccups , anger , restlessness ( dysphoria ) , emotional disorder , suicidal thoughts , aggressiveness or aggressive behaviour , hypoglycaemia ( low blood sugar ) .
H-324	-0.041913628578186035	ge Uncommon side effects , that affect less than 1 per 100 but more than1 per 1000 , that have occurred in patients on ACOMPLIA include : lon Sleepiness ( lethargy ) , tremor , night sweats , panic symptoms , hiccups , anger , restlessness ( dysphoria ) , emotional disorder , suicidal thoughts , aggressiveness or aggressive behaviour , hypoglycaemia .
D-324	-0.041913628578186035	ge Uncommon side effects , that affect less than 1 per 100 but more than1 per 1000 , that have occurred in patients on ACOMPLIA include : lon Sleepiness ( lethargy ) , tremor , night sweats , panic symptoms , hiccups , anger , restlessness ( dysphoria ) , emotional disorder , suicidal thoughts , aggressiveness or aggressive behaviour , hypoglycaemia .
P-324	-0.0145 -0.0145 -0.0145 -0.0145 -0.0023 -0.0137 -0.0145 -0.0278 -0.0145 -0.0054 -0.0135 -0.0778 -0.0148 -0.0209 -0.0142 -0.0145 -0.0138 -0.0046 -0.0143 -0.0162 -0.0144 -0.0362 -0.0142 -0.0074 -0.0144 -0.0146 -0.0145 -0.0143 -0.0145 -0.0143 -0.0145 -0.0145 -0.0124 -0.0145 -0.0145 -0.0142 -0.0028 -0.0038 -0.0116 -0.0068 -0.0010 -0.0017 -0.0011 -0.0015 -0.0030 -0.0033 -0.0006 -0.0025 -0.0020 -0.0009 -0.0023 -0.0032 -0.0018 -0.0017 -0.0056 -0.0016 -0.0018 -0.0003 -0.0010 -0.0017 -0.0063 -0.0018 -0.0008 -0.0003 -0.0011 -0.2382 -0.0011 -0.0004 -0.0004 -0.0014 -0.0018 -0.0147 -0.0144 -0.1083 -0.0026 -0.0006 -0.0031 -0.0020 -0.0024 -0.0040 -0.0006 -0.1207 -0.0014 -0.0076 -0.1033 -0.0021 -0.0012 -0.0007 -0.0126 -0.0019 -0.0011 -2.5898 -0.0015
S-664	Die Daten von 145 Patienten , die in zwei Langzeitstudien täglich 10 , 15 oder 20 mg erhielten , zeigen mittlere Pegvisomant- Serumkonzentrationen ( ± SD ) von ungefähr 8800 ± 6300 , 13200 ± 8000 und 15600 ± 10300 ng / ml .
T-664	The data from 145 patients in two long @-@ term studies who received daily doses of 10 , 15 , or 20 mg , demonstrate pegvisomant mean serum concentrations ( ± SD ) of approximately 8800 ± 6300 , 13200 ± 8000 and 15600 ± 10300 ng / ml , respectively .
H-664	-0.03805038332939148	The data from 145 patients in two long @-@ term studies who received daily doses of 10 , 15 , or 20 mg , demonstrate pegvisomant mean serum concentrations ( ± SD ) of approximately 8800 ± 6300 , 13200 ± 8000 and 15600 ± 10300 ng / ml .
D-664	-0.03805038332939148	The data from 145 patients in two long @-@ term studies who received daily doses of 10 , 15 , or 20 mg , demonstrate pegvisomant mean serum concentrations ( ± SD ) of approximately 8800 ± 6300 , 13200 ± 8000 and 15600 ± 10300 ng / ml .
P-664	-0.0121 -0.0021 -0.0108 -0.0012 -0.0013 -0.0017 -0.0272 -0.0032 -0.0021 -0.0166 -0.0014 -0.0026 -0.0180 -0.0308 -0.0163 -0.0144 -0.0017 -0.0016 -0.0111 -0.0017 -0.0011 -0.2180 -0.0173 -0.0025 -0.0007 -0.0144 -0.0170 -0.0144 -0.0023 -0.0029 -0.0009 -0.0033 -0.0151 -0.0032 -0.0015 -0.0035 -0.0003 -0.0008 -0.0018 -0.0005 -0.0014 -0.0011 -0.0014 -0.0023 -0.0076 -0.0029 -0.0007 -0.0005 -0.0012 -0.0009 -0.0014 -0.0029 -0.0009 -0.0004 -0.0006 -0.0141 -0.0014 -0.0006 -0.0004 -0.0020 -0.0008 -0.0010 -0.0010 -0.0015 -0.0016 -1.9979 -0.0014
S-581	Zusätzlich hemmte Rosiglitazon die ovarielle Östradiol- und Progesteronsynthese und erniedrigte die Plasmaspiegel dieser Hormone , mit Auswirkungen auf den Östrus / Menstruationszyklus und die Fertilität ( siehe Abschnitt 4.4 ) .
T-581	In addition , rosiglitazone inhibited ovarian oestradiol and progesterone synthesis and lowered plasma levels of these hormones resulting in effects on oestrus / menstrual cycles and fertility ( see section 4.4 ) .
H-581	-0.006029819138348103	In addition , rosiglitazone inhibited ovarian oestradiol and progesterone synthesis and lowered plasma levels of these hormones resulting in effects on oestrus / menstrual cycles and fertility ( see section 4.4 ) .
D-581	-0.006029819138348103	In addition , rosiglitazone inhibited ovarian oestradiol and progesterone synthesis and lowered plasma levels of these hormones resulting in effects on oestrus / menstrual cycles and fertility ( see section 4.4 ) .
P-581	-0.0082 -0.0015 -0.0035 -0.0064 -0.0005 -0.0010 -0.0009 -0.0015 -0.0023 -0.0011 -0.0018 -0.0047 -0.0041 -0.0016 -0.0113 -0.0013 -0.0006 -0.0014 -0.0025 -0.0016 -0.0013 -0.0007 -0.0010 -0.0088 -0.0006 -0.0007 -0.0359 -0.0098 -0.0006 -0.0096 -0.0004 -0.0005 -0.0119 -0.0021 -0.0045 -0.0008 -0.0009 -0.0012 -0.0145 -0.0015 -0.0102 -0.0017 -0.0125 -0.0010 -0.0058 -0.0025 -0.0008 -0.0002 -0.0028 -0.0130 -0.0008 -0.1361 -0.0011 -0.0011 -0.0020 -0.0024 -0.0076 -0.0012 -0.0013 -0.0018 -0.0015 -0.0014
S-1792	Die gleichzeitige Anwendung von Tenofovirdisoproxilfumarat und Didanosin führt zu einem Anstieg der systemischen Exposition von Didanosin um 40 @-@ 60 % , wodurch das Risiko für Didanosin @-@ bedingte unerwünschte Ereignisse erhöht sein könnte .
T-1792	Co @-@ administration of tenofovir disoproxil fumarate and didanosine results in a 40 @-@ 60 % increase in systemic exposure to didanosine that may increase the risk for didanosine @-@ related adverse events .
H-1792	-0.01778072863817215	Co @-@ administration of tenofovir disoproxil fumarate and didanosine results in a 40 @-@ 60 % increase in systemic exposure to didanosine that may increase the risk of didanosine @-@ related adverse events .
D-1792	-0.01778072863817215	Co @-@ administration of tenofovir disoproxil fumarate and didanosine results in a 40 @-@ 60 % increase in systemic exposure to didanosine that may increase the risk of didanosine @-@ related adverse events .
P-1792	-0.0543 -0.0014 -0.0137 -0.0021 -0.0017 -0.0010 -0.0011 -0.0026 -0.0038 -0.0015 -0.0014 -0.0018 -0.0044 -0.0098 -0.0007 -0.0007 -0.0014 -0.0011 -0.0051 -0.0006 -0.0065 -0.0008 -0.0025 -0.0131 -0.0015 -0.0078 -0.0015 -0.0891 -0.0012 -0.0019 -0.0042 -0.0033 -0.0033 -0.0008 -0.0012 -0.0038 -0.0298 -0.0003 -0.0042 -0.0010 -0.0016 -0.0151 -0.0091 -0.0046 -0.0021 -0.0012 -0.6491 -0.0006 -0.0043 -0.0009 -0.0062 -0.0049 -0.0370 -0.0019 -0.0007 -0.0007 -0.0018 -0.0015
S-1534	Informieren Sie Ihren Arzt , wenn Sie irgendein anderes Immunsuppressivum oder eine Phototherapie ( dabei wird Ihr Körper mit speziellem ultraviolettem ( UV ) Licht behandelt ) erhalten , während Sie STELARA anwenden , das auch eine Auswirkung auf Ihr Immunsystem hat .
T-1534	Tell your doctor if you are receiving any other immunosuppressant or phototherapy ( when your body is treated with specific ultraviolet ( UV ) light ) while using STELARA , which may also decrease the activity of your immune system .
H-1534	-0.007416159380227327	Tell your doctor if you are receiving any other immunosuppressant or phototherapy ( when your body is treated with specific ultraviolet ( UV ) light ) while using STELARA , which may also decrease the activity of your immune system .
D-1534	-0.007416159380227327	Tell your doctor if you are receiving any other immunosuppressant or phototherapy ( when your body is treated with specific ultraviolet ( UV ) light ) while using STELARA , which may also decrease the activity of your immune system .
P-1534	-0.1369 -0.0009 -0.0017 -0.0018 -0.0035 -0.0017 -0.0123 -0.0117 -0.0022 -0.0025 -0.0025 -0.0007 -0.0007 -0.0008 -0.0012 -0.0195 -0.0014 -0.0034 -0.0037 -0.0009 -0.0022 -0.0138 -0.0057 -0.0018 -0.0023 -0.0037 -0.0019 -0.0140 -0.0013 -0.0010 -0.0008 -0.0008 -0.0035 -0.0015 -0.0467 -0.0013 -0.0057 -0.0015 -0.0042 -0.0081 -0.0015 -0.0010 -0.0011 -0.0014 -0.0063 -0.0023 -0.0144 -0.0138 -0.0166 -0.0008 -0.0108 -0.0141 -0.0017 -0.0067 -0.0009 -0.0014 -0.0019 -0.0015
S-1714	Wenn Sie die Anwendung von Helixate NexGen 1000 I.E. vergessen haben • Injizieren Sie sofort die nächste Dosis und setzen Sie dann die Behandlung wie vom Arzt verordnet fort . • Wenden Sie nicht die doppelte Dosis an , wenn Sie die vorherige Anwendung vergessen haben .
T-1714	If you forget to use Helixate NexGen 1000 IU : • Proceed with the next administration immediately and continue at regular intervals as advised by your doctor . • Do not take a double dose to make up for a forgotten doses .
H-1714	-0.007590441964566708	If you forget to use Helixate NexGen 1000 IU : • Proceed with the next administration immediately and continue at regular intervals as advised by your doctor . • Do not take a double dose to make up for a forgotten doses .
D-1714	-0.007590441964566708	If you forget to use Helixate NexGen 1000 IU : • Proceed with the next administration immediately and continue at regular intervals as advised by your doctor . • Do not take a double dose to make up for a forgotten doses .
P-1714	-0.0027 -0.0013 -0.0106 -0.0013 -0.0111 -0.0021 -0.0011 -0.0012 -0.0012 -0.0016 -0.0009 -0.0014 -0.0017 -0.0026 -0.0011 -0.0144 -0.0144 -0.0125 -0.0145 -0.0067 -0.0010 -0.0109 -0.0104 -0.0063 -0.0144 -0.0073 -0.0076 -0.0032 -0.0145 -0.0142 -0.0041 -0.0007 -0.0037 -0.0145 -0.0012 -0.0018 -0.0014 -0.0586 -0.0012 -0.0015 -0.0012 -0.0072 -0.0145 -0.0026 -0.0007 -0.0145 -0.0145 -0.0144 -0.0015 -0.0145 -0.0144 -0.0144 -0.0149 -0.0022 -0.0033
S-1943	In diesen Studien betrug die Dosis von Efavirenz einmal täglich 600 mg ; die Dosis von Indinavir , wenn es mit Efavirenz angewendet wurde , war alle 8 Stunden 1.000 mg und wenn es ohne Efavirenz eingesetzt wurde , alle 8 Stunden 800 mg .
T-1943	In these studies the dose of efavirenz was 600 mg once daily ; the dose of indinavir was 1,000 mg every 8 hours when used with efavirenz and 800 mg every 8 hours when used without efavirenz .
H-1943	-0.00666602049022913	In these studies the dose of efavirenz was 600 mg once daily ; the dose of indinavir was 1,000 mg every 8 hours when used with efavirenz and 800 mg every 8 hours when used without efavirenz .
D-1943	-0.00666602049022913	In these studies the dose of efavirenz was 600 mg once daily ; the dose of indinavir was 1,000 mg every 8 hours when used with efavirenz and 800 mg every 8 hours when used without efavirenz .
P-1943	-0.0026 -0.0275 -0.0027 -0.0109 -0.0016 -0.0017 -0.0076 -0.0005 -0.0012 -0.0013 -0.0023 -0.0083 -0.0015 -0.0014 -0.0019 -0.1284 -0.0157 -0.0043 -0.0016 -0.0014 -0.0013 -0.0007 -0.0009 -0.0010 -0.0150 -0.0045 -0.0008 -0.0049 -0.0022 -0.0012 -0.0081 -0.0084 -0.0020 -0.0016 -0.0006 -0.0012 -0.0006 -0.0013 -0.0516 -0.0003 -0.0007 -0.0035 -0.0013 -0.0010 -0.0056 -0.0051 -0.0019 -0.0015 -0.0006 -0.0012 -0.0008 -0.0016 -0.0014 -0.0015
S-320	Eine Erhöhung des Cholesterin- oder Triglyceridspiegels wurde mit einer Thiaziddiuretika- Behandlung in Verbindung gebracht , wobei aber unter einer Dosis von 12,5 mg , wie in CoAprovel enthalten , nur geringe oder keine derartigen Effekte berichtet wurden .
T-320	Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy ; however at the 12.5 mg dose contained in CoAprovel , minimal or no effects were reported .
H-320	-0.00919696781784296	Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy ; however at the 12.5 mg dose contained in CoAprovel , minimal or no effects were reported .
D-320	-0.00919696781784296	Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy ; however at the 12.5 mg dose contained in CoAprovel , minimal or no effects were reported .
P-320	-0.0126 -0.0006 -0.0380 -0.0884 -0.0018 -0.0007 -0.0009 -0.0169 -0.0011 -0.0008 -0.0014 -0.0006 -0.0668 -0.0052 -0.0074 -0.0014 -0.0042 -0.0014 -0.0034 -0.0018 -0.0003 -0.0017 -0.0016 -0.0005 -0.0056 -0.0138 -0.0495 -0.0058 -0.0161 -0.0142 -0.0075 -0.0026 -0.0008 -0.0018 -0.0137 -0.0017 -0.0016 -0.0019 -0.0011 -0.0005 -0.0044 -0.0151 -0.0026 -0.0016 -0.0143 -0.0100 -0.0013 -0.0019 -0.0015
S-473	Bei der Behandlung der akuten Abstoßung hat sich gezeigt , dass das Therapieschema mit Tacrolimus entweder ein signifikant verbessertes histologisches Endomyokardbiopsie @-@ Grading der Abstoßung oder ein Abklingen der Abstoßung bewirkte .
T-473	In treatment of acute rejection the therapeutic regimen with tacrolimus has been proven to provide either a significantly improved histological endomyocardial biopsy grading of rejection or a resolution of rejection .
H-473	-0.005400427617132664	In treatment of acute rejection the therapeutic regimen with tacrolimus has been proven to provide either a significantly improved histological endomyocardial biopsy grading of rejection or a resolution of rejection .
D-473	-0.005400427617132664	In treatment of acute rejection the therapeutic regimen with tacrolimus has been proven to provide either a significantly improved histological endomyocardial biopsy grading of rejection or a resolution of rejection .
P-473	-0.0099 -0.0138 -0.0019 -0.0037 -0.0006 -0.0010 -0.0009 -0.0139 -0.0140 -0.0015 -0.0090 -0.0010 -0.0054 -0.0068 -0.0012 -0.0013 -0.0007 -0.0118 -0.0064 -0.0152 -0.0033 -0.0140 -0.0126 -0.0150 -0.0062 -0.0027 -0.0005 -0.0026 -0.0003 -0.0133 -0.0011 -0.0004 -0.0008 -0.0022 -0.0009 -0.0002 -0.0029 -0.0014 -0.0099 -0.0093 -0.0004 -0.0018 -0.0087 -0.0144 -0.0109 -0.0052 -0.0003 -0.0017 -0.0015
S-212	Bezüglich der Mortalität ( 9,5 verglichen mit 9,9 Monaten ) und der progressionsfreien Überlebenszeit ( 5,1 verglichen mit 5,0 Monaten ) bestand kein Unterschied zwischen der Therapie mit Cisplatin / Paclitaxel und der Therapie mit Cisplatin / Teniposid .
T-212	5.0 months ) with cisplatin / paclitaxel vs cisplatin / tenoposide .
H-212	-0.017956512048840523	5.0 months ) with cisplatin / paclitaxel vs cisplatin / tenoposide .
D-212	-0.017956512048840523	5.0 months ) with cisplatin / paclitaxel vs cisplatin / tenoposide .
P-212	-0.0145 -0.0909 -0.0025 -0.0071 -0.0145 -0.0145 -0.0008 -0.0008 -0.0014 -0.0036 -0.0004 -0.0012 -0.0005 -0.0011 -0.0145 -0.0093 -0.0010 -0.0009 -0.0013 -0.0017 -0.0012 -0.2313 -0.0142 -0.0144 -0.0089 -0.0145
S-1405	Die mit &gt; 10 % Häufigkeit beobachteten Nebenwirkungen bei Erwachsenen , die mit Ribavir in Kapseln in Kombination mit Interferon alfa @-@ 2b oder pegyliertem Interferon alfa @-@ 2b ein Jahr lang behandelt wurden , wurden ebenfalls bei Kindern und Jugendlichen beobachtet .
T-1405	Adverse reactions reported with a &gt; 10 % incidence in adult patients treated with ribavirin capsules in combination with interferon alfa @-@ 2b or pegylated interferon alfa @-@ 2b for one year have also been reported in children and adolescents .
H-1405	-0.029618967324495316	Adverse reactions reported with a &gt; 10 % incidence in adult patients treated with ribavir capsules in combination with interferon alfa @-@ 2b or pegylated interferon alfa @-@ 2b for one year have also been reported in children and adolescents .
D-1405	-0.029618967324495316	Adverse reactions reported with a &gt; 10 % incidence in adult patients treated with ribavir capsules in combination with interferon alfa @-@ 2b or pegylated interferon alfa @-@ 2b for one year have also been reported in children and adolescents .
P-1405	-0.0108 -0.0034 -0.0105 -0.0003 -0.0140 -0.0080 -0.0104 -0.0077 -0.0012 -0.0017 -0.0088 -0.0011 -0.0052 -0.0338 -0.0036 -0.0046 -0.0021 -0.0078 -0.0006 -0.9930 -0.0013 -0.0183 -0.0007 -0.0017 -0.0053 -0.0009 -0.0014 -0.0471 -0.0006 -0.0013 -0.0015 -0.0007 -0.0013 -0.0013 -0.0013 -0.2056 -0.0025 -0.0007 -0.0003 -0.0206 -0.0007 -0.0013 -0.0016 -0.0008 -0.0013 -0.0011 -0.0011 -0.0029 -0.0116 -0.0014 -0.0139 -0.0388 -0.0014 -0.0545 -0.0870 -0.0320 -0.1347 -0.0022 -0.0008 -0.0010 -0.0015 -0.0014
S-553	Die Wirksamkeit von Clopidogrel BMS als Gerinnungshemmer ( Antikoagulans ) wurde in einer Studie ( CAPRIE ) an etwa 19 000 Patienten mit Atherothrombose untersucht , in der sie mit der Wirksamkeit von Aspirin verglichen wurde .
T-553	The effectiveness of Clopidogrel BMS as an anticoagulant was compared with that of aspirin in a study called CAPRIE including around 19,000 patients with atherothrombosis .
H-553	-0.013359898701310158	The effectiveness of Clopidogrel BMS as an anticoagulant was compared with that of aspirin in a study called CAPRIE including around 19,000 patients with atherothrombosis .
D-553	-0.013359898701310158	The effectiveness of Clopidogrel BMS as an anticoagulant was compared with that of aspirin in a study called CAPRIE including around 19,000 patients with atherothrombosis .
P-553	-0.0045 -0.0250 -0.0009 -0.0014 -0.0107 -0.0008 -0.0011 -0.0004 -0.0009 -0.0030 -0.0012 -0.0035 -0.0053 -0.0032 -0.0010 -0.0005 -0.0025 -0.0010 -0.0064 -0.2585 -0.1379 -0.0140 -0.0014 -0.0017 -0.0008 -0.0013 -0.0043 -0.0026 -0.0034 -0.0151 -0.0027 -0.0012 -0.0006 -0.0006 -0.0149 -0.0126 -0.0041 -0.0055 -0.0017 -0.0441 -0.0006 -0.0141 -0.0043 -0.0016 -0.0010 -0.0021 -0.0016
S-1428	Kombinationen mit anderen Antimykotika Die kombinierte Anwendung von Antimykotika dürfte die Wirksamkeit von Posaconazol oder der anderen Therapien nicht beeinträchtigen ; es liegen jedoch derzeit keine klinischen Daten vor , die einen zusätzlichen Nutzen einer Kombinationstherapie belegen .
T-1428	Combination with other antifungal agents The use of combination antifungal therapies should not decrease the efficacy of either posaconazole or the other therapies ; however , there is currently no clinical evidence that combination therapy will provide an added benefit .
H-1428	-0.015942689031362534	Combination with other antifungal agents The use of combination antifungal therapies should not decrease the efficacy of either posaconazole or the other therapies ; however , there is currently no clinical evidence that combination therapy will provide an added benefit .
D-1428	-0.015942689031362534	Combination with other antifungal agents The use of combination antifungal therapies should not decrease the efficacy of either posaconazole or the other therapies ; however , there is currently no clinical evidence that combination therapy will provide an added benefit .
P-1428	-0.0052 -0.0139 -0.0031 -0.0019 -0.0077 -0.0006 -0.0009 -0.0110 -0.0060 -0.0065 -0.0140 -0.0026 -0.0145 -0.0065 -0.0013 -0.0007 -0.0078 -0.0147 -0.0011 -0.0089 -0.0019 -0.0145 -0.0008 -0.0019 -0.0635 -0.0006 -0.0008 -0.0015 -0.2140 -0.0853 -0.0010 -0.0012 -0.0005 -0.0006 -0.0017 -0.0080 -0.0025 -0.0050 -0.0009 -0.0228 -0.0092 -0.0042 -0.0364 -0.1196 -0.0097 -0.0014 -0.0021 -0.1000 -0.0136 -0.0144 -0.0017 -0.0142 -0.0106 -0.0142 -0.0096 -0.0025 -0.0017 -0.0014
S-501	14 Das Einhalten des Dosier- und Diätschemas , die korrekte Insulinverabreichung und das Erkennen von Symptomen einer Hypoglykämie durch den Patienten sind von zentraler Bedeutung , um das Risiko einer Hypoglykämie zu senken .
T-501	Adherence of the patient to the dosage and dietary regimen , correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia .
H-501	-0.06945568323135376	Adherence to the dosage and dietary regimen , correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia .
D-501	-0.06945568323135376	Adherence to the dosage and dietary regimen , correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia .
P-501	-0.0317 -0.0004 -0.0029 -1.6916 -0.0046 -0.3999 -0.3168 -0.0016 -0.0018 -0.0110 -0.0025 -0.0113 -0.0029 -0.0120 -0.0104 -0.0059 -0.0007 -0.0019 -0.1413 -0.0144 -0.0039 -0.0122 -0.0010 -0.0005 -0.0132 -0.0025 -0.0014 -0.0020 -0.0166 -0.0120 -0.0069 -0.0086 -0.0024 -0.0015 -0.2204 -0.0008 -0.0009 -0.0005 -0.0059 -0.0014 -0.0013 -0.0022 -0.0028
S-1272	Bei der Umstellung von einem anderen Phosphatbinder auf Renagel wird Ihr Arzt möglicherweise eine engmaschige Überwachung des Bicarbonat @-@ Spiegels in Ihrem Blut in Erwägung ziehen , da Renagel zu einem Absinken des Bicarbonat @-@ Spiegels führen kann .
T-1272	When you switch from another phosphate binder to Renagel , your doctor might consider monitoring the levels of bicarbonate in your blood more closely because Renagel may decrease the levels of bicarbonate .
H-1272	-0.01049144845455885	When you switch from another phosphate binder to Renagel , your doctor might consider monitoring the levels of bicarbonate in your blood more closely because Renagel may decrease the levels of bicarbonate .
D-1272	-0.01049144845455885	When you switch from another phosphate binder to Renagel , your doctor might consider monitoring the levels of bicarbonate in your blood more closely because Renagel may decrease the levels of bicarbonate .
P-1272	-0.0094 -0.0151 -0.0059 -0.0031 -0.0096 -0.0009 -0.0189 -0.0011 -0.0010 -0.0012 -0.0018 -0.0021 -0.0019 -0.0004 -0.0038 -0.0021 -0.0023 -0.2090 -0.0035 -0.0137 -0.0087 -0.0138 -0.0020 -0.0039 -0.0015 -0.0006 -0.0015 -0.0016 -0.0026 -0.0014 -0.0141 -0.0010 -0.0163 -0.0013 -0.0017 -0.0004 -0.0743 -0.0164 -0.0009 -0.0094 -0.0089 -0.0018 -0.0047 -0.0017 -0.0007 -0.0012 -0.0030 -0.0017
S-543	Neurologische Ereignisse Während der Behandlungsperiode erlitten 4 Patienten ( 2 % ) in der R @-@ CHOP @-@ Gruppe , alle mit kardiovaskulären Risikofaktoren , einen thromboembolischen zerebrovaskulären Zwischenfall während des ersten Behandlungszyklus .
T-543	Neurologic events During the treatment period , four patients ( 2 % ) treated with R @-@ CHOP , all with cardiovascular risk factors , experienced thromboembolic cerebrovascular accidents during the first treatment cycle .
H-543	-0.007245013024657965	Neurologic events During the treatment period , four patients ( 2 % ) treated with R @-@ CHOP , all with cardiovascular risk factors , experienced thromboembolic cerebrovascular accidents during the first treatment cycle .
D-543	-0.007245013024657965	Neurologic events During the treatment period , four patients ( 2 % ) treated with R @-@ CHOP , all with cardiovascular risk factors , experienced thromboembolic cerebrovascular accidents during the first treatment cycle .
P-543	-0.0056 -0.0601 -0.0042 -0.0049 -0.0042 -0.0041 -0.0064 -0.0025 -0.0047 -0.0133 -0.0013 -0.0023 -0.0019 -0.0013 -0.0014 -0.0145 -0.0126 -0.0048 -0.0018 -0.0009 -0.0007 -0.0050 -0.0023 -0.0051 -0.0009 -0.0005 -0.0008 -0.0007 -0.0009 -0.0010 -0.0027 -0.0120 -0.0108 -0.0003 -0.0008 -0.0011 -0.1083 -0.0018 -0.0006 -0.0018 -0.0012 -0.0010 -0.0007 -0.0145 -0.0007 -0.0217 -0.0032 -0.0021 -0.0140 -0.0036 -0.0017 -0.0014
S-199	21 Intravenöse Infusion Ceftriaxon Tyrol Pharma / und zugehörige Namen ( siehe Anhang I ) / 1 g Pulver zur Herstellung einer Injektions- oder Infusionslösung ist in einer der folgenden calciumfreien Infusionslösungen zu lösen :
T-199	Intravenous infusion Ceftriaxone Tyrol Pharma and associated names ( See Annex I ) 1 g powder for solution for injection or infusion should be dissolved in one of the following calcium @-@ free infusion solutions :
H-199	-0.022860173135995865	Intravenous infusion Ceftriaxone Tyrol Pharma and associated names ( See Annex I ) 1 g powder for solution for injection or infusion should be dissolved in one of the following calcium @-@ free infusion solutions :
D-199	-0.022860173135995865	Intravenous infusion Ceftriaxone Tyrol Pharma and associated names ( See Annex I ) 1 g powder for solution for injection or infusion should be dissolved in one of the following calcium @-@ free infusion solutions :
P-199	-0.0143 -0.0010 -0.0005 -0.0013 -0.0051 -0.0008 -0.0054 -0.0003 -0.0008 -0.0005 -0.0342 -0.0005 -0.0006 -0.0012 -0.0007 -0.1814 -0.0092 -0.0027 -0.0019 -0.4755 -0.0095 -0.0012 -0.0249 -0.0015 -0.0240 -0.0017 -0.0037 -0.0076 -0.0617 -0.0127 -0.0025 -0.0018 -0.0035 -0.0058 -0.0009 -0.0140 -0.0013 -0.0109 -0.0007 -0.0011 -0.0078 -0.0095 -0.0014 -0.0019 -0.0013 -0.0063 -0.0013 -0.2770 -0.0059 -0.0028 -0.0068 -0.0008 -0.0017 -0.0021 -0.0014
S-1532	Intravenöse Anwendung von Insulin Die intravenöse Injektion von Insulin lispro muss gemäß der üblichen klinischen Praxis für intravenö- se Injektionen erfolgen , zum Beispiel durch einen intravenösen Bolus oder durch ein Infusionssystem .
T-1532	Intravenous injection of insulin lispro should be carried out following normal clinical practise for intravenous injections , for example by an intravenous bolus or by an infusion system .
H-1532	-0.005068369675427675	Intravenous injection of insulin lispro should be carried out following normal clinical practise for intravenous injections , for example by an intravenous bolus or by an infusion system .
D-1532	-0.005068369675427675	Intravenous injection of insulin lispro should be carried out following normal clinical practise for intravenous injections , for example by an intravenous bolus or by an infusion system .
P-1532	-0.0018 -0.0010 -0.0006 -0.0015 -0.0138 -0.0068 -0.0053 -0.0017 -0.0004 -0.0070 -0.0007 -0.0013 -0.0138 -0.0047 -0.0125 -0.0014 -0.0219 -0.0128 -0.0027 -0.0145 -0.0030 -0.0037 -0.0045 -0.0011 -0.0006 -0.0016 -0.0018 -0.0117 -0.0195 -0.0069 -0.0030 -0.0106 -0.0103 -0.0031 -0.0010 -0.0007 -0.0013 -0.0007 -0.0011 -0.0023 -0.0096 -0.0048 -0.0021 -0.0024 -0.0011 -0.0016 -0.0017
S-1968	Gelegentlich - im Allgemeinen bei älteren Personen und aus Gründen , die noch nicht vollständig geklärt sind - wird das Virus wieder aktiv , und die Patienten erkranken an Gürtelrose , einem schmerzhaften Hautausschlag mit Blasenbildung , der in der Regel an einer bestimmten Stelle des Körpers auftritt .
T-1968	Sometimes , generally in older people , and for reasons which are not fully understood , the virus becomes active again , and the patient develops shingles , a painful , blistering rash typically in one part of the body .
H-1968	-0.007962710224092007	Sometimes , generally in older people , and for reasons which are not fully understood , the virus becomes active again , and the patient develops shingles , a painful , blistering rash typically in one part of the body .
D-1968	-0.007962710224092007	Sometimes , generally in older people , and for reasons which are not fully understood , the virus becomes active again , and the patient develops shingles , a painful , blistering rash typically in one part of the body .
P-1968	-0.0134 -0.0109 -0.0122 -0.0035 -0.0265 -0.0033 -0.0128 -0.0080 -0.0021 -0.0010 -0.0128 -0.0064 -0.0057 -0.0090 -0.0053 -0.0019 -0.0020 -0.0005 -0.0117 -0.0017 -0.0028 -0.0855 -0.0033 -0.0112 -0.0078 -0.0108 -0.0013 -0.0023 -0.0004 -0.0009 -0.0020 -0.0023 -0.0008 -0.0155 -0.0005 -0.0081 -0.0080 -0.0004 -0.0144 -0.0143 -0.0123 -0.0111 -0.0014 -0.0020 -0.0010 -0.0017 -0.0015
S-787	Im Allgemeinen wurde die Suszeptibilität gegen Atazanavir aufrechterhalten ( 83 % der Isolate zeigten eine &lt; 2,5 @-@ fache Veränderung der EC50 ) bei Isolaten , die nicht gegenüber mehr als 2 Proteaseinhibitoren resistent waren .
T-787	In general , susceptibility to atazanavir was retained ( 83 % of isolates displayed &lt; 2.5 fold change in EC50 ) among isolates resistant to no more than 2 protease inhibitors .
H-787	-0.004341738764196634	In general , susceptibility to atazanavir was retained ( 83 % of isolates displayed &lt; 2.5 fold change in EC50 ) among isolates resistant to no more than 2 protease inhibitors .
D-787	-0.004341738764196634	In general , susceptibility to atazanavir was retained ( 83 % of isolates displayed &lt; 2.5 fold change in EC50 ) among isolates resistant to no more than 2 protease inhibitors .
P-787	-0.0071 -0.0020 -0.0072 -0.0021 -0.0001 -0.0004 -0.0012 -0.0006 -0.0029 -0.0015 -0.0007 -0.0017 -0.0021 -0.0010 -0.0025 -0.0181 -0.0007 -0.0020 -0.0006 -0.0014 -0.0018 -0.0078 -0.0041 -0.0141 -0.0132 -0.0007 -0.0012 -0.0019 -0.0141 -0.0038 -0.0031 -0.0026 -0.0019 -0.0019 -0.0340 -0.0023 -0.0016 -0.0140 -0.0007 -0.0018 -0.0090 -0.0015 -0.0015 -0.0228 -0.0018 -0.0003 -0.0014 -0.0004 -0.0007 -0.0011 -0.0015 -0.0014
S-1372	Die Hauptmetabolite beim Menschen sind N @-@ 3,5 @-@ Dimethyl- Gludantan , ein Isomerengemisch von 4- und 6 @-@ Hydroxy @-@ Memantin , sowie 1 @-@ Nitroso @-@ 3,5- Dimethyl @-@ Adamantan .
T-1372	Main human metabolites are N @-@ 3,5 @-@ dimethyl @-@ gludantan , the isomeric mixture of 4- and 6 @-@ hydroxy @-@ memantine , and 1 @-@ nitroso @-@ 3,5 @-@ dimethyl @-@ adamantane .
H-1372	-0.015166248194873333	Main human metabolites are N @-@ 3,5 @-@ dimethyl @-@ gludantan , the isomeric mixture of 4- and 6 @-@ hydroxy @-@ memantine , and 1 @-@ nitroso @-@ 3,5 @-@ dimethyl @-@ adamantane .
D-1372	-0.015166248194873333	Main human metabolites are N @-@ 3,5 @-@ dimethyl @-@ gludantan , the isomeric mixture of 4- and 6 @-@ hydroxy @-@ memantine , and 1 @-@ nitroso @-@ 3,5 @-@ dimethyl @-@ adamantane .
P-1372	-0.0140 -0.0127 -0.0008 -0.0007 -0.0006 -0.0026 -0.0007 -0.0014 -0.0022 -0.0017 -0.0019 -0.0008 -0.0074 -0.0044 -0.0007 -0.0094 -0.0011 -0.0407 -0.0024 -0.0148 -0.0032 -0.0012 -0.0096 -0.0024 -0.0009 -0.0034 -0.0113 -0.0029 -0.0018 -0.0013 -0.2608 -0.0005 -0.0515 -0.0046 -0.0006 -0.0013 -0.0055 -0.0610 -0.0061 -0.0017 -0.2493 -0.0018 -0.0009 -0.0020 -0.0015 -0.0067 -0.0017 -0.0007 -0.0007 -0.0012 -0.0014 -0.0022 -0.0031 -0.0009 -0.0349 -0.0015 -0.0015
S-745	Indirekt kommt es zu einer Reduzierung des Plasmavolumens mit anschließender Zunahme von Plasmareninaktivität und Aldosteronsekretion sowie einer verstärkten Ausscheidung von Kalium und einer verminderten Kaliumkonzentration im Serum .
T-745	26 approximately equal extent , and indirectly by this diuretic action reducing plasma volume , with consequent increases in plasma renin activity , aldosterone secretion and urinary potassium loss , and a decrease in serum potassium .
H-745	-0.02587546594440937	26 approximately equal extent , and indirectly by this diuretic action reducing plasma volume , with consequent increases in plasma renin activity , aldosterone secretion and urinary potassium loss , and a decrease in serum potassium .
D-745	-0.02587546594440937	26 approximately equal extent , and indirectly by this diuretic action reducing plasma volume , with consequent increases in plasma renin activity , aldosterone secretion and urinary potassium loss , and a decrease in serum potassium .
P-745	-0.0145 -0.0166 -0.0151 -0.0145 -0.0142 -0.0159 -0.0131 -0.0018 -0.0145 -0.0142 -0.0144 -0.0144 -0.0036 -0.0144 -0.0145 -0.0110 -0.0006 -0.0005 -0.0007 -0.0123 -0.0136 -0.0139 -0.0019 -0.0134 -0.0047 -0.0029 -0.0006 -0.0061 -0.0145 -0.0143 -0.0052 -0.3394 -0.0020 -0.0011 -0.0009 -0.0013 -0.0007 -0.0193 -0.0846 -0.0145 -0.0109 -0.0120 -0.0007 -0.1337 -0.0158 -0.0125 -0.0102 -0.0108 -0.0065 -0.4759 -0.0025 -0.0102 -0.0018 -0.0026 -0.0003 -0.0012 -0.0159 -0.0015
S-1933	Die gleichzeitige Verabreichung von Ketoconazol , ein bekannter starker Hemmer von CYP 3A4 , führt nicht zu einer Hemmung der Ausscheidung von Paclitaxel bei Patienten ; deshalb können beide Arzneimittel ohne Dosisanpassung zusammen verabreicht werden .
T-1933	Concurrent administration of ketoconazole , a known potent inhibitor of CYP3A4 , does not inhibit the elimination of paclitaxel in patients ; thus , both medicinal products may be administered together without dosage adjustment .
H-1933	-0.04363519698381424	Concurrent administration of ketoconazole , a known potent inhibitor of CYP3A4 , does not inhibit the elimination of paclitaxel in patients ; thus , both medicinal products may be administered together without dosage adjustment .
D-1933	-0.04363519698381424	Concurrent administration of ketoconazole , a known potent inhibitor of CYP3A4 , does not inhibit the elimination of paclitaxel in patients ; thus , both medicinal products may be administered together without dosage adjustment .
P-1933	-0.0137 -0.6289 -0.0034 -0.0015 -0.0010 -0.0014 -0.0015 -0.0005 -0.0003 -0.0019 -0.0029 -0.0028 -0.0084 -0.0015 -0.0014 -0.0005 -0.0007 -0.0013 -0.0334 -0.0015 -0.0012 -0.8734 -0.0013 -0.0009 -0.0023 -0.0034 -0.0013 -0.0074 -0.0011 -0.0007 -0.0047 -0.0134 -0.0009 -0.0014 -0.0005 -0.0011 -0.0009 -0.0015 -0.0036 -0.0020 -0.0929 -0.0136 -0.0065 -0.0081 -0.0050 -0.7338 -0.0015 -0.0115 -0.0014 -0.0064 -0.0008 -0.0056 -0.0030 -0.1280 -0.0020 -0.0012 -0.0029 -0.0005 -0.0027 -0.0015 -0.0014
S-1844	Eine höhere oder niedrigere Anfangsdosis kann von Ihrem Arzt entsprechend Ihren Bedürfnissen empfohlen werden . • Je nachdem , wie Sie auf die Behandlung ansprechen , kann Ihr Arzt die Dosierung später erhöhen oder senken . • Die maximale empfohlene Tagesdosis beträgt 30 mg / kg Körpergewicht .
T-1844	A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs . • Depending on how you respond to treatment , your doctor may later adjust your treatment to a higher or lower dose . • The maximum recommended daily dose is 30 mg per kilogram body weight .
H-1844	-0.018024681136012077	A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs . • Depending on how you respond to treatment , your doctor may later adjust your treatment to a higher or lower dose . • The maximum recommended daily dose is 30 mg / kg body weight .
D-1844	-0.018024681136012077	A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs . • Depending on how you respond to treatment , your doctor may later adjust your treatment to a higher or lower dose . • The maximum recommended daily dose is 30 mg / kg body weight .
P-1844	-0.0036 -0.0014 -0.0012 -0.0013 -0.0035 -0.0034 -0.0016 -0.0013 -0.0020 -0.0014 -0.0013 -0.0012 -0.0137 -0.1156 -0.0016 -0.0146 -0.0146 -0.0010 -0.0180 -0.0022 -0.0015 -0.0008 -0.0015 -0.0055 -0.0014 -0.0044 -0.0014 -0.0041 -0.0018 -0.0014 -0.0010 -0.0048 -0.0106 -0.0149 -0.0014 -0.0147 -0.0171 -0.0141 -0.0142 -0.0033 -0.0016 -0.0015 -0.0116 -0.0035 -0.0023 -0.0032 -0.0010 -0.0030 -0.0007 -0.0022 -0.0015 -0.0038 -0.0006 -0.6087 -0.0010 -0.0889 -0.0007 -0.0014 -0.0021
S-933	Ελλάδα Nycomed Hellas SA 196 Λεωφόρος Κηφισίας GR @-@ 15231 Χαλάνδρι , Aθήνα Τηλ : + 30 210 672 9570
T-933	Ελλάδα Nycomed Hellas SA 196 Λεωφόρος Κηφισίας GR @-@ 15231 Χαλάνδρι , Aθήνα Τηλ : + 30 210 672 9570
H-933	-0.006247779820114374	Ελλάδα Nycomed Hellas SA 196 Λεωφόρος Κηφισίας GR @-@ 15231 Χαλάνδρι , Aθήνα Τηλ : + 30 210 672 9570
D-933	-0.006247779820114374	Ελλάδα Nycomed Hellas SA 196 Λεωφόρος Κηφισίας GR @-@ 15231 Χαλάνδρι , Aθήνα Τηλ : + 30 210 672 9570
P-933	-0.0141 -0.0001 -0.0013 -0.0005 -0.0005 -0.0002 -0.0004 -0.0000 -0.0004 -0.0014 -0.0007 -0.0031 -0.0014 -0.0144 -0.0014 -0.0009 -0.0008 -0.0020 -0.0004 -0.0002 -0.0003 -0.0047 -0.0017 -0.0018 -0.0005 -0.0004 -0.0013 -0.0011 -0.0015 -0.0012 -0.0010 -0.2758 -0.0018 -0.0011 -0.0009 -0.0145 -0.0006 -0.0004 -0.0012 -0.0005 -0.0020 -0.0003 -0.0006 -0.0015 -0.0041 -0.0019 -0.0052 -0.0006 -0.0002 -0.0014 -0.0015 -0.0005 -0.0014 -0.0013 -0.0011 -0.0005 -0.0014 -0.0006 -0.0010 -0.0012 -0.0009 -0.0015
S-733	Wenn der Zielblutdruck ( &lt; 140 / 90 mmHg ) nicht erreicht wurde , wurde zunächst Hydrochlorothiazid ( 12,5 mg ) zugegeben und dann gegebenenfalls die Losartan- oder Atenolol @-@ Dosis auf 100 mg einmal täglich erhöht .
T-733	If goal blood pressure ( &lt; 140 / 90 mmHg ) was not reached , hydrochlorothiazide ( 12.5 mg ) was added first and , if needed , the dose of losartan or atenolol was then increased to 100 mg once daily .
H-733	-0.015297085046768188	If goal blood pressure ( &lt; 140 / 90 mmHg ) was not reached , hydrochlorothiazide ( 12.5 mg ) was added first and , if needed , the dose of losartan or atenolol was then increased to 100 mg once daily .
D-733	-0.015297085046768188	If goal blood pressure ( &lt; 140 / 90 mmHg ) was not reached , hydrochlorothiazide ( 12.5 mg ) was added first and , if needed , the dose of losartan or atenolol was then increased to 100 mg once daily .
P-733	-0.0074 -0.0145 -0.0015 -0.0010 -0.0036 -0.0010 -0.0005 -0.0012 -0.0008 -0.0013 -0.0014 -0.0015 -0.0011 -0.0012 -0.0014 -0.0047 -0.0018 -0.0066 -0.0022 -0.0051 -0.0012 -0.0007 -0.0013 -0.0005 -0.0016 -0.0002 -0.0009 -0.0022 -0.0012 -0.0019 -0.0008 -0.0015 -0.0021 -0.0077 -0.0086 -0.0141 -0.0134 -0.0053 -0.0139 -0.0014 -0.0079 -0.0127 -0.0020 -0.0006 -0.0005 -0.0019 -0.0576 -0.0140 -0.0014 -0.0008 -0.0043 -0.2968 -0.1878 -0.0018 -0.0015 -0.0007 -0.0024 -0.1796 -0.0014 -0.0014
S-187	Bei Patienten , die Panretin Gel viermal täglich auftrugen , schien die Inzidenz von mit der Gabe des Arzneimittels assoziierten Hautstörungen , Hautgeschwüren , Schmerzen , und Ausschlägen größer zu sein als bei Patienten , die das Arzneimittel seltener auftrugen .
T-187	The incidence of drug @-@ related skin disorder , skin ulcer , pain and rash appeared to be greater in patients applying Panretin gel four times daily than in those applying it less frequently .
H-187	-0.0169305931776762	The incidence of drug @-@ related skin disorder , skin ulcer , pain and rash appeared to be greater in patients applying Panretin gel four times daily than in those applying it less frequently .
D-187	-0.0169305931776762	The incidence of drug @-@ related skin disorder , skin ulcer , pain and rash appeared to be greater in patients applying Panretin gel four times daily than in those applying it less frequently .
P-187	-0.0142 -0.0012 -0.0009 -0.0015 -0.0147 -0.0047 -0.0085 -0.0034 -0.0141 -0.0016 -0.0051 -0.0021 -0.0148 -0.0016 -0.0031 -0.0676 -0.0029 -0.0398 -0.0075 -0.0048 -0.0013 -0.0512 -0.0035 -0.0052 -0.0127 -0.0066 -0.0010 -0.0008 -0.0104 -0.0047 -0.0017 -0.3068 -0.0226 -0.0038 -0.0151 -0.0096 -0.0128 -0.0024 -0.0046 -0.0016 -0.0018
S-1831	Da die Dosis für jeden Patienten individuell auf Basis von Wirksamkeits- und Unbedenklichkeitsparametern titriert wird , ist keine zusätzliche Dosisanpassung abhängig vom Grad der Leberinsuffizienz notwendig ( siehe Abschnitt 4.2 und 4.4 ) .
T-1831	( see sections 4.2 and 4.4 ) .
H-1831	-0.007548216264694929	( see sections 4.2 and 4.4 ) .
D-1831	-0.007548216264694929	( see sections 4.2 and 4.4 ) .
P-1831	-0.0187 -0.0114 -0.0169 -0.0014 -0.0016 -0.0019 -0.0013 -0.0013 -0.0034 -0.0105 -0.0146
S-1487	Die Mitgliedsstaaten müssen mit dem Inhaber der Genehmigung für das Inverkehrbringen ( MAH ) die Einzelheiten der Implementierung einer Überwachungsstudie nach Markteinführung in jedem einzelnen Mitgliedsstaat vereinbaren und gewährleisten , dass die Einrichtung dieser Studie vor dem Inverkehrbringen des Arzneimittels abgeschlossen ist .
T-1487	The Member States shall agree details of the implementation of the post @-@ marketing surveillance study in each member state with the MAH and ensure that it is put in place prior to marketing of the product .
H-1487	-0.0069319140166044235	The Member States shall agree details of the implementation of the post @-@ marketing surveillance study in each member state with the MAH and ensure that it is put in place prior to marketing of the product .
D-1487	-0.0069319140166044235	The Member States shall agree details of the implementation of the post @-@ marketing surveillance study in each member state with the MAH and ensure that it is put in place prior to marketing of the product .
P-1487	-0.0135 -0.0028 -0.0016 -0.0151 -0.0020 -0.0144 -0.0089 -0.0072 -0.0048 -0.0031 -0.0139 -0.0043 -0.0025 -0.0127 -0.0104 -0.0029 -0.0051 -0.0021 -0.0139 -0.0022 -0.0032 -0.0015 -0.0145 -0.0010 -0.0092 -0.0060 -0.0022 -0.0138 -0.0029 -0.0144 -0.0083 -0.0014 -0.0113 -0.0014 -0.0128 -0.0109 -0.0020 -0.0136 -0.0018 -0.0014
S-55	Da Reproduktionsstudien am Tier nicht immer aussagekräftig für die Reaktion beim Menschen sind , sollte die Gabe von Herceptin während der Schwangerschaft vermieden werden , es sei denn , der potentielle Nutzen für die Mutter überwiegt das potentielle Risiko für den Föten .
T-55	As animal reproduction studies are not always predictive of human response , Herceptin should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus .
H-55	-0.023414531722664833	As animal reproduction studies are not always predictive of human response , Herceptin should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus .
D-55	-0.023414531722664833	As animal reproduction studies are not always predictive of human response , Herceptin should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus .
P-55	-0.0101 -0.0071 -0.0027 -0.6961 -0.0017 -0.0068 -0.0017 -0.0024 -0.0145 -0.0009 -0.0050 -0.0118 -0.0092 -0.0021 -0.0114 -0.0003 -0.0005 -0.0060 -0.0432 -0.0014 -0.0042 -0.0009 -0.0123 -0.0034 -0.0016 -0.0081 -0.0197 -0.0024 -0.0455 -0.0020 -0.0004 -0.0010 -0.0038 -0.0015 -0.0016 -0.0140 -0.0016 -0.0095 -0.0003 -0.0115 -0.0016 -0.0019
S-703	Aktive Immunisierung von Pferden ab einem Lebensalter von 6 Monaten gegen Pferdeinfluenza , um die klinischen Symptome und die Virusausscheidung nach der Infektion zu vermindern sowie aktive Immunisierung gegen Tetanus , um Todesfälle zu vermeiden .
T-703	Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection , and active immunisation against tetanus to prevent mortality .
H-703	-0.009513869881629944	Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection , and active immunisation against tetanus to prevent mortality .
D-703	-0.009513869881629944	Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection , and active immunisation against tetanus to prevent mortality .
P-703	-0.0067 -0.0010 -0.0022 -0.0251 -0.0052 -0.0020 -0.0082 -0.0192 -0.0015 -0.0051 -0.0012 -0.0052 -0.0116 -0.0005 -0.0014 -0.0006 -0.0013 -0.0121 -0.0060 -0.0053 -0.0144 -0.0383 -0.0108 -0.0068 -0.0007 -0.0017 -0.0066 -0.0020 -0.0311 -0.0055 -0.0022 -0.0026 -0.0026 -0.0310 -0.0008 -0.0002 -0.0012 -0.0151 -0.0150 -0.0142 -0.0013 -0.0821 -0.0015
S-549	Wenn die gebrauchsfertige Zubereitung nicht sofort eingesetzt wird , betragen Aufbewahrungszeiten und - bedingungen normalerweise nicht länger als 24 Stunden bei 2 ° C - 8 ° C ( Kühlschrank ) , sofern die Rekonstitution nicht unter kontrollierten und validierten aseptischen Bedingungen erfolgt ist .
T-549	If not used immediately , in @-@ use storage times and conditions prior to use would normally not be longer than 24 hours at 2 ° C - 8 ° C ( refrigerator ) , unless reconstitution has taken place in controlled and validated aseptic conditions .
H-549	-0.00861417967826128	If not used immediately , in @-@ use storage times and conditions prior to use would normally not be longer than 24 hours at 2 ° C - 8 ° C ( refrigerator ) , unless reconstitution has taken place in controlled and validated aseptic conditions .
D-549	-0.00861417967826128	If not used immediately , in @-@ use storage times and conditions prior to use would normally not be longer than 24 hours at 2 ° C - 8 ° C ( refrigerator ) , unless reconstitution has taken place in controlled and validated aseptic conditions .
P-549	-0.0094 -0.0143 -0.0117 -0.0031 -0.0032 -0.0144 -0.0145 -0.0131 -0.0127 -0.0090 -0.0017 -0.0019 -0.0368 -0.0014 -0.0093 -0.0694 -0.0092 -0.0088 -0.0124 -0.0073 -0.0017 -0.0018 -0.0016 -0.0499 -0.0030 -0.0023 -0.0022 -0.0327 -0.0014 -0.0012 -0.0012 -0.0018 -0.0067 -0.0005 -0.0008 -0.0024 -0.0016 -0.0233 -0.0053 -0.0093 -0.0014 -0.0094 -0.0135 -0.0010 -0.0157 -0.0038 -0.0027 -0.0028 -0.0006 -0.0011 -0.0007 -0.0012 -0.0023 -0.0017 -0.0015
S-1144	Keppra 100 mg / ml Lösung zum Einnehmen enthält Methyl -4- hydroxybenzoat ( E218 ) und Propyl -4- hydroxybenzoat ( E216 ) , das allergische Reaktionen hervorrufen kann ( möglicherweise verzögert ) .
T-1144	Keppra 100 mg / ml oral solution includes methyl parahydroxybenzoate ( E218 ) and propyl parahydroxybenzoate ( E216 ) which may cause allergic reactions ( possibly delayed ) .
H-1144	-0.004683553706854582	Keppra 100 mg / ml oral solution includes methyl parahydroxybenzoate ( E218 ) and propyl parahydroxybenzoate ( E216 ) which may cause allergic reactions ( possibly delayed ) .
D-1144	-0.004683553706854582	Keppra 100 mg / ml oral solution includes methyl parahydroxybenzoate ( E218 ) and propyl parahydroxybenzoate ( E216 ) which may cause allergic reactions ( possibly delayed ) .
P-1144	-0.0021 -0.0006 -0.0007 -0.0032 -0.0005 -0.0015 -0.0010 -0.0145 -0.0036 -0.0652 -0.0023 -0.0014 -0.0146 -0.0145 -0.0105 -0.0126 -0.0040 -0.0015 -0.0012 -0.0007 -0.0013 -0.0017 -0.0015 -0.0014 -0.0013 -0.0015 -0.0023 -0.0008 -0.0009 -0.0019 -0.0047 -0.0015 -0.0066 -0.0012 -0.0012 -0.0008 -0.0007 -0.0013 -0.0015 -0.0012 -0.0011 -0.0010 -0.0014 -0.0104 -0.0118 -0.0078 -0.0096 -0.0006 -0.0114 -0.0005 -0.0029 -0.0026 -0.0047 -0.0017 -0.0019 -0.0015
S-1817	In der Studie , bei der Sitagliptin zusätzlich zu Glimepirid und Meformin gegeben wurden , wurde der HbA1c @-@ Wert nach 24 Wochen um 0,59 % gesenkt , während er bei Patienten , die zusätzlich Placebo erhielten , um 0,30 % stieg .
T-1817	In the study where sitagliptin was added to glimepiride and metformin , the levels of HbA1c were reduced by 0.59 % after 24 weeks , compared with an increase of 0.30 % in the patients adding placebo .
H-1817	-0.014783169142901897	In the study where sitagliptin was added to glimepiride and metformin , the levels of HbA1c were reduced by 0.59 % after 24 weeks , compared with an increase of 0.30 % in the patients adding placebo .
D-1817	-0.014783169142901897	In the study where sitagliptin was added to glimepiride and metformin , the levels of HbA1c were reduced by 0.59 % after 24 weeks , compared with an increase of 0.30 % in the patients adding placebo .
P-1817	-0.0031 -0.0024 -0.0035 -0.0128 -0.0073 -0.0033 -0.0006 -0.0019 -0.0021 -0.0115 -0.0022 -0.0011 -0.0009 -0.0009 -0.0005 -0.0015 -0.0160 -0.0006 -0.0019 -0.0026 -0.0066 -0.0145 -0.0019 -0.0025 -0.0011 -0.0016 -0.0013 -0.0013 -0.0038 -0.0080 -0.0023 -0.0015 -0.0010 -0.0022 -0.0087 -0.0018 -0.0011 -0.0116 -0.0126 -0.5103 -0.0129 -0.0032 -0.0014 -0.0012 -0.0013 -0.0013 -0.0538 -0.0159 -0.0098 -0.0441 -0.0034 -0.0010 -0.0006 -0.0012 -0.0028 -0.0015
S-1892	Bei vier weiteren Testpersonen , denen 10,5 mg 14C @-@ Saquinavir intravenös gegeben wurde , konnten innerhalb von 4 Tagen nach der Anwendung 81 % der intravenös gegebenen , radioaktiv markierten Dosis im Stuhl und 3 % im Urin nachgewiesen werden .
T-1892	In an additional four subjects administered 10.5 mg 14C @-@ saquinavir intravenously , 81 % and 3 % of the intravenously administered radioactivity was recovered in faeces and urine , respectively , within 4 days of dosing .
H-1892	-0.012637742795050144	In an additional four subjects administered 10.5 mg 14C @-@ saquinavir intravenously , 81 % and 3 % of the intravenously administered radioactivity was recovered in faeces and urine , respectively , within 4 days of dosing .
D-1892	-0.012637742795050144	In an additional four subjects administered 10.5 mg 14C @-@ saquinavir intravenously , 81 % and 3 % of the intravenously administered radioactivity was recovered in faeces and urine , respectively , within 4 days of dosing .
P-1892	-0.0112 -0.0144 -0.0016 -0.0062 -0.0029 -0.0166 -0.0860 -0.0042 -0.0047 -0.0010 -0.0070 -0.0013 -0.0027 -0.0088 -0.0010 -0.0010 -0.0009 -0.0030 -0.0011 -0.0004 -0.0010 -0.0045 -0.0013 -0.0014 -0.0164 -0.0015 -0.0012 -0.0053 -0.0049 -0.0096 -0.0009 -0.0006 -0.1763 -0.0083 -0.0008 -0.0064 -0.0142 -0.0142 -0.0149 -0.0071 -0.0125 -0.0002 -0.0025 -0.0024 -0.0094 -0.0012 -0.0177 -0.0135 -0.0020 -0.0228 -0.0062 -0.0012 -0.1399 -0.0160 -0.0027 -0.0020 -0.0014
S-1719	Bei der Entscheidung , ob das Stillen fortgeführt bzw. unterbrochen wird oder die Immunisierung mit Twinrix Erwachsene fortgeführt bzw. unterbrochen wird , sollte der Vorteil des Stillens für das Kind gegenüber dem Nutzen einer Impfung mit Twinrix Erwachsene für die Mutter abgewogen werden .
T-1719	A decision on whether to continue / discontinue breast- feeding or to continue / discontinue therapy with Twinrix Adult should be made taking into account the benefit of breast @-@ feeding to the child and the benefit of Twinrix Adult therapy to the woman .
H-1719	-0.010097507387399673	A decision on whether to continue / discontinue breast- feeding or to continue / discontinue therapy with Twinrix Adult should be made taking into account the benefit of breast @-@ feeding to the child and the benefit of Twinrix Adult therapy to the woman .
D-1719	-0.010097507387399673	A decision on whether to continue / discontinue breast- feeding or to continue / discontinue therapy with Twinrix Adult should be made taking into account the benefit of breast @-@ feeding to the child and the benefit of Twinrix Adult therapy to the woman .
P-1719	-0.0144 -0.0049 -0.0104 -0.0025 -0.0045 -0.0026 -0.0302 -0.0109 -0.0009 -0.0318 -0.0021 -0.0235 -0.0060 -0.0058 -0.0099 -0.0032 -0.0070 -0.0043 -0.0005 -0.0145 -0.0036 -0.0016 -0.0010 -0.0010 -0.0014 -0.0085 -0.0780 -0.0043 -0.0078 -0.0046 -0.0145 -0.0048 -0.0274 -0.0022 -0.0123 -0.0077 -0.0122 -0.0484 -0.0018 -0.0098 -0.0024 -0.0037 -0.0164 -0.0048 -0.0077 -0.0070 -0.0113 -0.0009 -0.0009 -0.0014 -0.0012 -0.0077 -0.0145 -0.0034 -0.0019 -0.0533 -0.0027 -0.0015
S-375	Bei Probanden war die gleichzeitige Gabe von Febuxostat und Naproxen 250 mg 2 x täglich mit einem Anstieg der Febuxostatexposition ( Cmax 28 % , AUC 41 % und t1 / 2 26 % ) assoziiert .
T-375	In healthy subjects concomitant use of febuxostat and naproxen 250mg BID was associated with an increase in febuxostat exposure ( Cmax 28 % , AUC 41 % and t1 / 2 26 % ) .
H-375	-0.006356607191264629	In healthy subjects concomitant use of febuxostat and naproxen 250mg BID was associated with an increase in febuxostat exposure ( Cmax 28 % , AUC 41 % and t1 / 2 26 % ) .
D-375	-0.006356607191264629	In healthy subjects concomitant use of febuxostat and naproxen 250mg BID was associated with an increase in febuxostat exposure ( Cmax 28 % , AUC 41 % and t1 / 2 26 % ) .
P-375	-0.0060 -0.0145 -0.0440 -0.0142 -0.0126 -0.0004 -0.0017 -0.0129 -0.0015 -0.0100 -0.0081 -0.0010 -0.0009 -0.0005 -0.0015 -0.0028 -0.0011 -0.0008 -0.0009 -0.0010 -0.0135 -0.0007 -0.0008 -0.0505 -0.0145 -0.0447 -0.0027 -0.0015 -0.0060 -0.0024 -0.0062 -0.0019 -0.0018 -0.0010 -0.0008 -0.0030 -0.0019 -0.0046 -0.0027 -0.0024 -0.0005 -0.0014 -0.0012 -0.0015 -0.0007 -0.0008 -0.0006 -0.0011 -0.0060 -0.0014 -0.0018 -0.0015 -0.0402 -0.0016 -0.0011 -0.0024 -0.0031 -0.0014
S-1485	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Wirksamkeit von Tasigna , auch wenn es nicht direkt mit einer anderen Behandlung verglichen wurde , hinreichend nachgewiesen worden und mit der eines anderen Arzneimittels derselben Klasse vergleichbar ist .
T-1485	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that , even though it was not directly compared to any other treatment , the effectiveness of Tasigna had been demonstrated sufficiently and was the same as that of another medicine in the same class .
H-1485	-0.02772401086986065	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that , even though it was not directly compared to any other treatment , the effectiveness of Tasigna had been demonstrated sufficiently and was the same as that of another medicine in the same class .
D-1485	-0.02772401086986065	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that , even though it was not directly compared to any other treatment , the effectiveness of Tasigna had been demonstrated sufficiently and was the same as that of another medicine in the same class .
P-1485	-0.0024 -0.0007 -0.7985 -0.0009 -0.0003 -0.0006 -0.0012 -0.0012 -0.0008 -0.0013 -0.0023 -0.0006 -0.0005 -0.0014 -0.4953 -0.0014 -0.0129 -0.0101 -0.0122 -0.0165 -0.0127 -0.0013 -0.0035 -0.0048 -0.0075 -0.0223 -0.0025 -0.0013 -0.0015 -0.0128 -0.0316 -0.0009 -0.0014 -0.0015 -0.0007 -0.0003 -0.0121 -0.0018 -0.0143 -0.0073 -0.0004 -0.0009 -0.0033 -0.0081 -0.0150 -0.0025 -0.0017 -0.0065 -0.0015 -0.0180 -0.0057 -0.0056 -0.0017 -0.0008 -0.0025 -0.0016 -0.0014
S-1284	Die Konjugation des PEG @-@ Bestandteiles ( bis- &#91; Monomethoxy @-@ Polyethylenglykol &#93; ) an Interferon alfa @-@ 2a bildet das pegylierte Interferon alfa @-@ 2a ( Pegasys ) .
T-1284	The conjugation of PEG reagent ( bis @-@ monomethoxypolyethylene glycol ) to interferon alfa @-@ 2a forms a pegylated interferon alfa @-@ 2a ( Pegasys ) .
H-1284	-0.007382468786090612	The conjugation of PEG reagent ( bis @-@ monomethoxypolyethylene glycol ) to interferon alfa @-@ 2a forms a pegylated interferon alfa @-@ 2a ( Pegasys ) .
D-1284	-0.007382468786090612	The conjugation of PEG reagent ( bis @-@ monomethoxypolyethylene glycol ) to interferon alfa @-@ 2a forms a pegylated interferon alfa @-@ 2a ( Pegasys ) .
P-1284	-0.0058 -0.0051 -0.0008 -0.0017 -0.0015 -0.0016 -0.0137 -0.0004 -0.0145 -0.0025 -0.0020 -0.0108 -0.0130 -0.0149 -0.0015 -0.0010 -0.1403 -0.0145 -0.0100 -0.0045 -0.0012 -0.0009 -0.0007 -0.0016 -0.0011 -0.0014 -0.0009 -0.0062 -0.0044 -0.0837 -0.0006 -0.0015 -0.0014 -0.0009 -0.0014 -0.0012 -0.0014 -0.0109 -0.0142 -0.0039 -0.0006 -0.0001 -0.0025 -0.0007 -0.0013 -0.0019 -0.0009 -0.0013 -0.0011 -0.0013 -0.0017 -0.0017 -0.0007 -0.0011 -0.0015 -0.0017 -0.0014
S-690	Abacavir hat auch in vitro gezeigt , dass es die Metabolisierung , die über die Enzyme CYP 3A4 , CYP 2C9 oder CYP 2D6 vermittelt wird , in klinisch relevanten Konzentrationen nicht hemmt .
T-690	Abacavir has also been shown in vitro not to inhibit CYP 3A4 , CYP 2C9 or CYP 2D6 enzymes at clinically relevant concentrations .
H-690	-0.03805413469672203	Abacavir has also been shown in vitro not to inhibit CYP 3A4 , CYP 2C9 or CYP 2D6 enzymes at clinically relevant concentrations .
D-690	-0.03805413469672203	Abacavir has also been shown in vitro not to inhibit CYP 3A4 , CYP 2C9 or CYP 2D6 enzymes at clinically relevant concentrations .
P-690	-0.0028 -0.0010 -0.0012 -0.0011 -0.0060 -0.0052 -0.0140 -0.0029 -0.0154 -0.0009 -0.0008 -0.0179 -0.0013 -0.0043 -0.0008 -0.0006 -0.0145 -0.0017 -0.5408 -0.0041 -0.0009 -0.0016 -0.0025 -0.0013 -0.5240 -0.0011 -0.0015 -0.0013 -0.0927 -0.0016 -0.0013 -0.4664 -0.0011 -0.0011 -0.0014 -0.0126 -0.0029 -0.0013 -0.0132 -0.0008 -0.0011 -0.0047 -0.0041 -0.0003 -0.0007 -0.0078 -0.0018
S-1797	Operationen zur Fusion der unteren Wirbelsäule Wenn Sie starke Schmerzen durch eine beschädigte Bandscheibe im unteren Bereich Ihres Rückens haben und andere Behandlungen nicht effektiv waren , kann es sein , dass Sie für eine Operation zur Fusion der unteren Wirbelsäule in Betracht kommen .
T-1797	Lower back spine fusion surgery If you have a lot of pain from a damaged disc in your lower back and other treatments have not proved effective , you may be considered for lower back spine fusion surgery .
H-1797	-0.03426271677017212	Lower back spine fusion surgery If you have a lot of pain from a damaged disc in your lower back and other treatments have not proved effective , you may be considered for lower back spine fusion surgery .
D-1797	-0.03426271677017212	Lower back spine fusion surgery If you have a lot of pain from a damaged disc in your lower back and other treatments have not proved effective , you may be considered for lower back spine fusion surgery .
P-1797	-0.0098 -0.0008 -0.0144 -0.1479 -0.0058 -0.1820 -0.0090 -0.0038 -0.0018 -0.0077 -0.0137 -0.0141 -0.0014 -0.0016 -0.0121 -0.0046 -0.0017 -0.0091 -0.0035 -0.0035 -0.0228 -0.0015 -0.0025 -0.0069 -0.0023 -0.0030 -0.0049 -0.0047 -0.0146 -0.0024 -0.0022 -0.0036 -0.0043 -0.0045 -0.0124 -0.0041 -0.0046 -0.0124 -0.3617 -0.0054 -0.4573 -0.0016 -0.1172 -0.0019
S-1899	Obgleich Änderungen der Plasmakonzentrationen anderer Antiepileptika durch Lamotrigin beschrieben wurden , konnte in kontrollierten Studien kein Einfluss von Lamotrigin auf die Plasmakonzentrationen gleichzeitig verabreichter Antiepileptika festgestellt werden .
T-1899	Although changes in the plasma concentrations of other AEDs have been reported , controlled studies have shown no evidence that lamotrigine affects the plasma concentrations of concomitant AEDs .
H-1899	-0.005929213482886553	Although changes in the plasma concentrations of other AEDs have been reported , controlled studies have shown no evidence that lamotrigine affects the plasma concentrations of concomitant AEDs .
D-1899	-0.005929213482886553	Although changes in the plasma concentrations of other AEDs have been reported , controlled studies have shown no evidence that lamotrigine affects the plasma concentrations of concomitant AEDs .
P-1899	-0.0035 -0.0049 -0.0140 -0.0120 -0.0034 -0.0005 -0.0006 -0.0099 -0.0005 -0.0009 -0.0016 -0.0018 -0.0183 -0.0145 -0.0015 -0.0117 -0.0015 -0.0137 -0.0132 -0.0121 -0.0079 -0.0061 -0.0131 -0.0024 -0.0157 -0.0151 -0.0108 -0.0012 -0.0008 -0.0013 -0.0127 -0.0047 -0.0028 -0.0005 -0.0005 -0.0044 -0.0006 -0.0009 -0.0018 -0.0102 -0.0128 -0.0003 -0.0059 -0.0037 -0.0040 -0.0015 -0.0017 -0.0014
S-912	Rauchen Aus In @-@ vitro @-@ Studien mit Enzymen der menschlichen Leber geht hervor , dass Paliperidon kein Substrat von CYP1A2 ist ; Rauchen sollte daher keinen Einfluss auf die Pharmakokinetik von Paliperidon haben .
T-912	Smoking Status Based on in vitro studies utilising human liver enzymes , paliperidone is not a substrate for CYP1A2 ; smoking should , therefore , not have an effect on the pharmacokinetics of paliperidone .
H-912	-0.019377121701836586	Smoking Status Based on in vitro studies utilising human liver enzymes , paliperidone is not a substrate for CYP1A2 ; smoking should , therefore , not have an effect on the pharmacokinetics of paliperidone .
D-912	-0.019377121701836586	Smoking Status Based on in vitro studies utilising human liver enzymes , paliperidone is not a substrate for CYP1A2 ; smoking should , therefore , not have an effect on the pharmacokinetics of paliperidone .
P-912	-0.0104 -0.0013 -0.0145 -0.0140 -0.0017 -0.0025 -0.0015 -0.0009 -0.0031 -0.0209 -0.0132 -0.0092 -0.0013 -0.0006 -0.0005 -0.0013 -0.0041 -0.0054 -0.0006 -0.0005 -0.0002 -0.0029 -0.0019 -0.0021 -0.0031 -0.0009 -0.0021 -0.2404 -0.0018 -0.0014 -0.2808 -0.0011 -0.0014 -0.0014 -0.0727 -0.0083 -0.0040 -0.0165 -0.0017 -0.0015 -0.0071 -0.0164 -0.0071 -0.0110 -0.0017 -0.0066 -0.0016 -0.0007 -0.0007 -0.2900 -0.0016 -0.0018 -0.0009 -0.0005 -0.0003 -0.0017 -0.0015
S-1394	Grundlage für die Befassung waren Abweichungen in der von verschiedenen EU @-@ Mitgliedstaaten genehmigten Zusammenfassung der Merkmale des Arzneimittels , einschließlich Qualitätsaspekten von Remeron und damit verbundenen Bezeichnungen , in Bezug auf die Behandlung von Major @-@ Depression- Episoden .
T-1394	The basis for referral was that there were divergences in the Summaries of Product Characteristics ( SPC ) including quality aspects of Remeron and associated names approved across EU Member States , with respect to treatment of major depressive episodes .
H-1394	-0.014698943123221397	The basis for referral was that there were divergences in the Summaries of Product Characteristics ( SPC ) including quality aspects of Remeron and associated names approved across EU Member States , with respect to treatment of major depressive episodes .
D-1394	-0.014698943123221397	The basis for referral was that there were divergences in the Summaries of Product Characteristics ( SPC ) including quality aspects of Remeron and associated names approved across EU Member States , with respect to treatment of major depressive episodes .
P-1394	-0.0039 -0.0144 -0.0071 -0.0099 -0.0031 -0.0058 -0.0145 -0.0129 -0.0081 -0.0139 -0.0007 -0.0009 -0.0038 -0.0025 -0.0144 -0.0376 -0.0071 -0.0271 -0.0145 -0.0099 -0.0005 -0.0004 -0.0008 -0.0011 -0.1871 -0.0144 -0.0136 -0.0329 -0.0921 -0.0058 -0.0029 -0.0021 -0.0025 -0.0011 -0.0015 -0.0018 -0.0090 -0.0126 -0.0175 -0.1067 -0.0104 -0.0027 -0.0012 -0.0120 -0.0166 -0.0107 -0.0014 -0.0135 -0.0023 -0.0012 -0.0111 -0.0033 -0.0008 -0.0015 -0.0014
S-660	In plazebokontrollierten Studien mit RISPERDAL in dieser Patientenpopulation lag die Mortalitätsinzidenz bei den mit RISPERDAL behandelten Patienten bei 4,0 % verglichen mit 3,1 % bei den Patienten unter Plazebo .
T-660	In placebo @-@ controlled trials with RISPERDAL in this population , the incidence of mortality was 4.0 % for RISPERDAL @-@ treated patients compared to 3.1 % for placebo @-@ treated patients .
H-660	-0.026895390823483467	In placebo @-@ controlled trials with RISPERDAL in this population , the incidence of mortality was 4.0 % for RISPERDAL @-@ treated patients compared with 3.1 % for placebo @-@ treated patients .
D-660	-0.026895390823483467	In placebo @-@ controlled trials with RISPERDAL in this population , the incidence of mortality was 4.0 % for RISPERDAL @-@ treated patients compared with 3.1 % for placebo @-@ treated patients .
P-660	-0.0025 -0.1683 -0.0011 -0.0006 -0.0014 -0.0037 -0.0018 -0.0106 -0.0099 -0.0023 -0.0008 -0.0009 -0.0008 -0.0012 -0.0022 -0.0029 -0.0128 -0.0061 -0.0087 -0.0129 -0.0009 -0.0014 -0.0024 -0.0008 -0.0117 -0.0014 -0.0012 -0.0019 -0.0347 -0.0137 -0.0009 -0.0010 -0.0008 -0.0012 -0.0078 -0.0008 -0.0020 -0.1011 -0.8963 -0.0009 -0.0014 -0.0013 -0.0434 -0.0059 -0.0011 -0.0008 -0.0013 -0.0039 -0.0007 -0.0015 -0.0015 -0.0014
S-788	Primäre Hypercholesterinämie und gemischte Hypercholesterinämie In Vergleichsstudien zur Wirksamkeit und Unbedenklichkeit von Simvastatin an Patienten mit Hypercholesterinämie führte eine Behandlung mit 10 mg , 20 mg , 40 mg und 80 mg Simvastatin pro Tag zu mittleren Senkungen von LDL @-@ Cholesterin um 30 % , 38 % , 41 % und 47 % .
T-788	Primary Hypercholesterolaemia and Combined Hyperlipidaemia In studies comparing the efficacy and safety of simvastatin 10 , 20 , 40 and 80 mg daily in patients with hypercholesterolemia , the mean reductions of LDL @-@ C were 30 , 38 , 41 and 47 % , respectively .
H-788	-0.0390498973429203	Primary Hypercholesterolaemia and Combined Hyperlipidaemia In studies comparing the efficacy and safety of simvastatin 10 , 20 , 40 and 80 mg daily in patients with hypercholesterolemia , the mean reductions of LDL @-@ C were 30 , 38 , 41 and 47 % , respectively .
D-788	-0.0390498973429203	Primary Hypercholesterolaemia and Combined Hyperlipidaemia In studies comparing the efficacy and safety of simvastatin 10 , 20 , 40 and 80 mg daily in patients with hypercholesterolemia , the mean reductions of LDL @-@ C were 30 , 38 , 41 and 47 % , respectively .
P-788	-0.0060 -0.0003 -0.2640 -0.0009 -0.6308 -0.0013 -0.0036 -0.0641 -0.0029 -0.0013 -0.0034 -0.0144 -0.0129 -0.0006 -0.0018 -0.0009 -0.8086 -0.0145 -0.0142 -0.0108 -0.0013 -0.0053 -0.0142 -0.0075 -0.0024 -0.0026 -0.0106 -0.0005 -0.0009 -0.0017 -0.0009 -0.0016 -0.0026 -0.0008 -0.0005 -0.0006 -0.0006 -0.0177 -0.2155 -0.0017 -0.0770 -0.0013 -0.0677 -0.0014 -0.0013 -0.0131 -0.0091 -0.0071 -0.0019 -0.0032 -0.0031 -0.0017 -0.0007 -0.0945 -0.0013 -0.0023 -0.0132 -0.0139 -0.0067 -0.0008 -0.0373 -0.0020 -0.0459 -0.0144 -0.0176 -0.0107 -0.0021 -0.3055 -0.0008 -0.0525 -0.0008 -0.0649 -0.0009 -0.0031 -0.0154 -0.0007 -0.0015 -0.0014
S-1134	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Tyverb in Kombination mit Capecitabin zur Behandlung von Patientinnen mit fortgeschrittenem oder metastasierendem Brustkrebs , deren Tumore ErbB2 ( HER2 ) überexprimieren , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Tyverb zu erteilen .
T-1134	The Committee recommended that Tyverb be given marketing authorisation .
H-1134	-0.05924005061388016	The Committee recommended that Tyverb be given marketing authorisation .
D-1134	-0.05924005061388016	The Committee recommended that Tyverb be given marketing authorisation .
P-1134	-0.0025 -0.0012 -0.7343 -0.0044 -0.0067 -0.0034 -0.0018 -0.0118 -0.0133 -0.0135 -0.0080 -0.0008 -0.0131 -0.0145
S-1717	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 47 E @-@ mail : mail @ emea.europa.eu http : / / www.emea.europa.eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Zwei Feldstudien wurden an Hunden in Tierarztpraxen in verschiedenen europäischen Ländern und unterschiedlichen Regionen durchgeführt .
T-1717	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 47 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Prac @-@ tic shown during the studies ?
H-1717	-0.019937293604016304	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 47 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Prac @-@ tic shown during the studies ?
D-1717	-0.019937293604016304	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 47 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Prac @-@ tic shown during the studies ?
P-1717	-0.0036 -0.0010 -0.0014 -0.0012 -0.0014 -0.0007 -0.0014 -0.0005 -0.0010 -0.0009 -0.0014 -0.0006 -0.2340 -0.0011 -0.0014 -0.0004 -0.0012 -0.0006 -0.0009 -0.0028 -0.1467 -0.0006 -0.0014 -0.0007 -0.0009 -0.0003 -0.2401 -0.0004 -0.2353 -0.0145 -0.0097 -0.0010 -0.0014 -0.0015 -0.0015 -0.0693 -0.0123 -0.0027 -0.0010 -0.1977 -0.0004 -0.2393 -0.0117 -0.0144 -0.0007 -0.0015 -0.0007 -0.0017 -0.0014 -0.0021 -0.0012 -0.0013 -0.0014 -0.0012 -0.0010 -0.0013 -0.0013 -0.0008 -0.0014 -0.0060 -0.0011 -0.0014 -0.0020 -0.0339 -0.0017 -0.0012 -0.0010 -0.0015 -0.0010 -0.0009 -0.0018 -0.0015 -0.0086 -0.0145 -0.0145 -0.0126 -0.0145 -0.0145 -0.0108 -0.0144 -0.0144 -0.0145 -0.0081 -0.0142 -0.0106 -0.0122
S-1250	Bei Ratten wurde bei gleichzeitiger Anwendung von Salmeterolxinafoat und Fluticason @-@ 17 @-@ propionat in Dosierungen , die bekanntlich mit Kortikoid- induzierten Anomalien verbunden sind , ein erhöhtes Auftreten von Transpositionen der Nabelschnurarterien ( Arteria umbilicaris ) sowie unvollständige Ossifikation des Os occipitale festgestellt .
T-1250	Following co @-@ administration , increased incidences of transposed umbilical artery and incomplete ossification of occipital bone were found in rats at doses associated with known glucocorticoid @-@ induced abnormalities .
H-1250	-0.02248629927635193	Following co @-@ administration , increased incidences of transposed umbilical artery and incomplete ossification of occipital bone were found in rats at doses associated with known glucocorticoid @-@ induced abnormalities .
D-1250	-0.02248629927635193	Following co @-@ administration , increased incidences of transposed umbilical artery and incomplete ossification of occipital bone were found in rats at doses associated with known glucocorticoid @-@ induced abnormalities .
P-1250	-0.0145 -0.0145 -0.0013 -0.0114 -0.5251 -0.0141 -0.0116 -0.2325 -0.0012 -0.0015 -0.0134 -0.0143 -0.0133 -0.0013 -0.0002 -0.0013 -0.0086 -0.0111 -0.0145 -0.0070 -0.0016 -0.0005 -0.0007 -0.0028 -0.0140 -0.0005 -0.0026 -0.0097 -0.0075 -0.1015 -0.0027 -0.0010 -0.0144 -0.0032 -0.0085 -0.0105 -0.0016 -0.0145 -0.0145 -0.0111 -0.0021 -0.0033 -0.0006 -0.0014 -0.0046 -0.0038 -0.0005 -0.0104 -0.0006 -0.0004 -0.0013 -0.0122 -0.0144
S-283	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Intanza zur Influenzaprophylaxe bei Erwachsenen bis 59 Jahre und Personen ab 60 Jahren - insbesondere bei Personen , die ein erhöhtes Risiko für influenzabedingte Komplikationen aufweisen - gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Intanza zu erteilen .
T-283	The Committee recommended that Intanza be given marketing authorisation .
H-283	-0.06069169193506241	The Committee recommended that Intanza be given marketing authorisation .
D-283	-0.06069169193506241	The Committee recommended that Intanza be given marketing authorisation .
P-283	-0.0024 -0.0012 -0.7519 -0.0049 -0.0141 -0.0004 -0.0014 -0.0106 -0.0135 -0.0143 -0.0056 -0.0008 -0.0139 -0.0145
S-743	Eine 12 @-@ monatige Studie ( &quot; Gaining Optimal Asthma Control &quot; , GOAL ) an 3416 erwachsenen und jugendlichen Patienten mit persistierendem Asthma bronchiale verglich die Sicherheit und Wirksamkeit von Seretide mit dem inhalativen Kortikoid Fluticasonpropionat allein , um zu prüfen , ob die Zielkriterien des Asthmamanagements erreichbar sind .
T-743	A twelve month study ( Gaining Optimal Asthma ControL , GOAL ) , in 3416 adult and adolescent patients with persistent asthma , compared the safety and efficacy of Seretide versus inhaled corticosteroid ( Fluticasone Propionate ) alone to determine whether the goals of asthma management were achievable .
H-743	-0.016542740166187286	A twelve month study ( Gaining Optimal Asthma ControL , GOAL ) , in 3416 adult and adolescent patients with persistent asthma , compared the safety and efficacy of Seretide versus inhaled corticosteroid ( Fluticasone Propionate ) alone to determine whether the goals of asthma management were achievable .
D-743	-0.016542740166187286	A twelve month study ( Gaining Optimal Asthma ControL , GOAL ) , in 3416 adult and adolescent patients with persistent asthma , compared the safety and efficacy of Seretide versus inhaled corticosteroid ( Fluticasone Propionate ) alone to determine whether the goals of asthma management were achievable .
P-743	-0.0047 -0.0142 -0.0004 -0.0010 -0.0575 -0.0052 -0.0029 -0.0040 -0.0003 -0.0025 -0.0010 -0.0014 -0.0010 -0.0011 -0.0145 -0.0145 -0.0033 -0.0009 -0.0013 -0.0014 -0.0258 -0.0140 -0.0047 -0.0011 -0.0036 -0.0016 -0.0054 -0.0006 -0.0012 -0.0012 -0.0772 -0.0034 -0.0008 -0.0141 -0.0009 -0.0009 -0.0098 -0.0019 -0.0033 -0.0010 -0.0014 -0.7908 -0.0006 -0.0007 -0.0014 -0.0139 -0.0016 -0.0127 -0.0144 -0.0090 -0.0105 -0.0015 -0.0014 -0.0008 -0.0150 -0.0044 -0.0145 -0.0085 -0.0013 -0.0005 -0.0049 -0.0124 -0.0013 -0.0001 -0.0030 -0.0044 -0.0335 -0.0107 -0.0074 -0.0052 -0.0143 -0.0055 -0.0039 -0.0009 -0.0006 -0.0007 -0.0096 -0.0075 -0.0005 -0.0016 -0.0014
S-935	Die Patienten wurden randomisiert , entweder pegyliertes Interferon alfa @-@ 2b ( 100 oder 150 µg / Woche gewichtsbasiert ) plus Ribavirin ( 800- 1.200 mg / Tag gewichtsbasiert ) oder IntronA ( 3 Mio I.E. dreimal in der Woche ) plus Ribavirin ( 800- 1.200 mg / Tag gewichtsbasiert ) zu erhalten .
T-935	Patients were randomized to receive either pegylated interferon alfa @-@ 2b ( 100 or 150 µg / week based on weight ) plus ribavirin ( 800 @-@ 1,200 mg / day based on weight ) or IntronA ( 3 MIU TIW ) plus ribavirin ( 800 @-@ 1,200 mg / day based on weight ) .
H-935	-0.0078084757551550865	Patients were randomized to receive either pegylated interferon alfa @-@ 2b ( 100 or 150 µg / week based on weight ) plus ribavirin ( 800 @-@ 1,200 mg / day based on weight ) or IntronA ( 3 MIU TIW ) plus ribavirin ( 800 @-@ 1,200 mg / day based on weight ) .
D-935	-0.0078084757551550865	Patients were randomized to receive either pegylated interferon alfa @-@ 2b ( 100 or 150 µg / week based on weight ) plus ribavirin ( 800 @-@ 1,200 mg / day based on weight ) or IntronA ( 3 MIU TIW ) plus ribavirin ( 800 @-@ 1,200 mg / day based on weight ) .
P-935	-0.0033 -0.0010 -0.0018 -0.0002 -0.0769 -0.0086 -0.0095 -0.0021 -0.0015 -0.0036 -0.0005 -0.0001 -0.0014 -0.0006 -0.0014 -0.0014 -0.0005 -0.0014 -0.0012 -0.0011 -0.0014 -0.0017 -0.0021 -0.0098 -0.0226 -0.0012 -0.0015 -0.0013 -0.0144 -0.0022 -0.0012 -0.0017 -0.0028 -0.0014 -0.0009 -0.0008 -0.0016 -0.0013 -0.0012 -0.0061 -0.0079 -0.0012 -0.0005 -0.0014 -0.0014 -0.0129 -0.0015 -0.0013 -0.0015 -0.0019 -0.0014 -0.0008 -0.0013 -0.0013 -0.0015 -0.0279 -0.0004 -0.1948 -0.0145 -0.1105 -0.0011 -0.0010 -0.0008 -0.0005 -0.0014 -0.0013 -0.0012 -0.0018 -0.0026 -0.0009 -0.0005 -0.0014 -0.0013 -0.0115 -0.0016 -0.0013 -0.0013 -0.0023 -0.0015
S-538	Rebetol ist in Kombination mit Interferon alfa @-@ 2b indiziert zur Behandlung von erwachsenen Patienten mit chronischer Hepatitis C , die nicht vorbehandelt sind , ohne Leberdekompensation sind , erhöhte Alanin @-@ Aminotransferase @-@ Werte ( ALT @-@ Werte ) haben und die Serum @-@ HCV @-@ RNA @-@ positiv sind ( siehe Abschnitt 4.4 ) .
T-538	Rebetol is indicated , in combination with interferon alfa @-@ 2b , for the treatment of adult patients with chronic hepatitis C , not previously treated , without liver decompensation , with elevated alanine aminotransferase ( ALT ) , who are positive for serum HCV @-@ RNA ( see section 4.4 ) .
H-538	-0.014922618865966797	Rebetol is indicated , in combination with interferon alfa @-@ 2b , for the treatment of adult patients with chronic hepatitis C , not previously treated , without liver decompensation , with elevated alanine aminotransferase ( ALT ) , who are positive for serum HCV @-@ RNA ( see section 4.4 ) .
D-538	-0.014922618865966797	Rebetol is indicated , in combination with interferon alfa @-@ 2b , for the treatment of adult patients with chronic hepatitis C , not previously treated , without liver decompensation , with elevated alanine aminotransferase ( ALT ) , who are positive for serum HCV @-@ RNA ( see section 4.4 ) .
P-538	-0.0015 -0.0028 -0.0009 -0.0010 -0.0170 -0.0006 -0.0162 -0.0050 -0.0008 -0.0015 -0.5371 -0.0006 -0.0013 -0.0016 -0.0006 -0.0014 -0.0012 -0.0011 -0.0016 -0.0401 -0.0049 -0.0015 -0.0015 -0.0032 -0.0023 -0.0713 -0.0017 -0.0008 -0.0004 -0.0007 -0.0011 -0.0275 -0.0145 -0.0074 -0.0012 -0.0028 -0.0098 -0.0035 -0.0006 -0.0045 -0.0018 -0.0091 -0.0016 -0.0012 -0.0082 -0.0010 -0.0033 -0.0022 -0.0097 -0.0015 -0.0010 -0.0026 -0.0007 -0.0005 -0.0160 -0.0021 -0.0012 -0.0017 -0.0219 -0.0147 -0.0057 -0.0145 -0.0026 -0.0009 -0.0017 -0.0018 -0.0013 -0.2171 -0.0131 -0.0014 -0.0006 -0.0023 -0.0017 -0.0099 -0.0013 -0.0013 -0.0015 -0.0015 -0.0014
S-868	13 Sehr selten ( &lt; 1 / 10000 ) wurden bei Patienten , die Pegfilgrastim nach einer zytotoxischen Chemotherapie erhielten , bei Untersuchungen der Leberfunktionswerte ( liver function tests ( LFTS ) , Erhöhungen der ALAT ( Alanin @-@ Aminotransferase ) oder der ASAT ( Aspartat @-@ Aminotransferase ) beobachtet .
T-868	Very rare ( &lt; 1 / 10,000 ) elevations in liver function tests ( LFTs ) for ALT ( alanine aminotransferase ) or AST ( aspartate aminotransferase ) , have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy .
H-868	-0.011495775543153286	Very rare ( &lt; 1 / 10,000 ) elevations in liver function tests ( LFTs ) for ALT ( alanine aminotransferase ) or AST ( aspartate aminotransferase ) , have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy .
D-868	-0.011495775543153286	Very rare ( &lt; 1 / 10,000 ) elevations in liver function tests ( LFTs ) for ALT ( alanine aminotransferase ) or AST ( aspartate aminotransferase ) , have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy .
P-868	-0.0148 -0.0493 -0.0025 -0.0006 -0.0005 -0.0011 -0.0017 -0.0018 -0.0097 -0.0014 -0.0143 -0.0213 -0.0101 -0.0071 -0.0007 -0.0069 -0.0024 -0.0011 -0.0004 -0.1087 -0.0014 -0.0381 -0.0165 -0.0146 -0.0023 -0.0021 -0.0010 -0.0045 -0.0020 -0.0051 -0.0014 -0.0013 -0.0031 -0.0007 -0.0005 -0.0015 -0.0120 -0.0021 -0.0146 -0.0015 -0.0014 -0.0017 -0.0007 -0.0011 -0.0028 -0.0011 -0.0009 -0.0016 -0.0008 -0.0005 -0.0014 -0.0148 -0.0138 -0.0019 -0.0459 -0.0025 -0.0059 -0.1735 -0.0163 -0.0035 -0.0014 -0.0009 -0.0013 -0.0027 -0.0011 -0.0081 -0.0019 -0.0013 -0.0024 -0.0009 -0.0013 -0.0016 -0.0005 -0.1701 -0.0019 -0.0015
S-281	12 a ) unter Verwendung von Tabelle 2 bei Patienten , die einer Opioid @-@ Rotation bedürfen ( Umstellungverhältnis von oralem Morphin zu transdermalem Fentanyl 150 : 1 ) a ) unter Verwendung von Tabelle 3 bei Patienten unter stabiler und gut verträglicher Opioidtherapie ( Umstellungverhältnis von oralem Morphin zu transdermalem Fentanyl 100 : 1 )
T-281	12 b ) using Table 3 for patients on stable and well tolerated opioid therapy ( conversion ratio of oral morphine to transdermal fentanyl equal to 100 : 1 )
H-281	-0.019992303103208542	12 b ) using Table 3 for patients on stable and well tolerated opioid therapy ( conversion ratio of oral morphine to transdermal fentanyl equal to 100 : 1 )
D-281	-0.019992303103208542	12 b ) using Table 3 for patients on stable and well tolerated opioid therapy ( conversion ratio of oral morphine to transdermal fentanyl equal to 100 : 1 )
P-281	-0.0025 -0.0182 -0.0015 -0.0107 -0.0056 -0.3630 -0.0103 -0.0018 -0.0207 -0.0098 -0.0025 -0.0039 -0.0063 -0.0031 -0.0025 -0.0011 -0.0005 -0.0062 -0.0024 -0.0102 -0.0005 -0.0017 -0.0085 -0.0008 -0.0009 -0.0009 -0.0625 -0.0036 -0.0011 -0.0008 -0.2122 -0.0024 -0.0006 -0.0006 -0.0010 -0.0146 -0.0097 -0.0149 -0.0023 -0.0014 -0.0017 -0.0145
S-1925	in Insulininfusionspumpen wenn der Penfill oder das Gerät , das den Penfill enthält , fallen gelassen wurde , beschädigt oder zerdrückt ist ; es besteht die Gefahr des Auslaufens von Insulin wenn es nicht korrekt aufbewahrt worden ist oder eingefroren war ( siehe 6 Wie ist Protaphane aufzubewahren ? ) wenn es nach dem Resuspendieren nicht gleichmäßig weiß und trübe ist .
T-1925	In insulin infusion pumps If Penfill or the device containing Penfill is dropped , damaged or crushed there is a risk of leakage of insulin If it hasn <<unk>> t been stored correctly or been frozen ( see 6 How to store Protaphane ) If it <<unk>> s not uniformly white and cloudy when it <<unk>> s resuspended .
H-1925	-0.008081100881099701	In insulin infusion pumps If Penfill or the device containing Penfill is dropped , damaged or crushed there is a risk of leakage of insulin If it hasn <unk> t been stored correctly or been frozen ( see 6 How to store Protaphane ) If it <unk> s not uniformly white and cloudy when it <unk> s resuspended .
D-1925	-0.008081100881099701	In insulin infusion pumps If Penfill or the device containing Penfill is dropped , damaged or crushed there is a risk of leakage of insulin If it hasn <unk> t been stored correctly or been frozen ( see 6 How to store Protaphane ) If it <unk> s not uniformly white and cloudy when it <unk> s resuspended .
P-1925	-0.0128 -0.0031 -0.0007 -0.0023 -0.0007 -0.0012 -0.0008 -0.0147 -0.0145 -0.0018 -0.0044 -0.0068 -0.0054 -0.0049 -0.0068 -0.0009 -0.0141 -0.0009 -0.0271 -0.0014 -0.1284 -0.0023 -0.0004 -0.0125 -0.0056 -0.0037 -0.0028 -0.0044 -0.0099 -0.0033 -0.0015 -0.0032 -0.0012 -0.0009 -0.0140 -0.0055 -0.0269 -0.0186 -0.0041 -0.0013 -0.0079 -0.0013 -0.0073 -0.0009 -0.0018 -0.0142 -0.0023 -0.0017 -0.0027 -0.0025 -0.0042 -0.0047 -0.0072 -0.0019 -0.0017 -0.0004 -0.0383 -0.0076 -0.0058 -0.0145 -0.0086 -0.0015 -0.0089 -0.0003 -0.0015 -0.0013 -0.0025 -0.0046 -0.0006 -0.0191 -0.0117 -0.0144 -0.0124 -0.0145 -0.0056 -0.0003 -0.0161 -0.0016
S-1370	EU / 1 / 08 / 456 / 008 EU / 1 / 08 / 456 / 009 EU / 1 / 08 / 456 / 010 EU / 1 / 08 / 456 / 011 EU / 1 / 08 / 456 / 012 EU / 1 / 08 / 456 / 013 EU / 1 / 08 / 456 / 014 EU / 1 / 08 / 456 / 016
T-1370	EU / 1 / 08 / 456 / 008 EU / 1 / 08 / 456 / 009 EU / 1 / 08 / 456 / 010 EU / 1 / 08 / 456 / 011 EU / 1 / 08 / 456 / 012 EU / 1 / 08 / 456 / 013 EU / 1 / 08 / 456 / 014 EU / 1 / 08 / 456 / 016
H-1370	-0.008255554363131523	EU / 1 / 08 / 456 / 008 EU / 1 / 08 / 456 / 009 EU / 1 / 08 / 456 / 010 EU / 1 / 08 / 456 / 011 EU / 1 / 08 / 456 / 012 EU / 1 / 08 / 456 / 013 EU / 1 / 08 / 456 / 014 EU / 1 / 08 / 456 / 016
D-1370	-0.008255554363131523	EU / 1 / 08 / 456 / 008 EU / 1 / 08 / 456 / 009 EU / 1 / 08 / 456 / 010 EU / 1 / 08 / 456 / 011 EU / 1 / 08 / 456 / 012 EU / 1 / 08 / 456 / 013 EU / 1 / 08 / 456 / 014 EU / 1 / 08 / 456 / 016
P-1370	-0.3367 -0.0015 -0.0013 -0.0015 -0.0012 -0.0014 -0.0012 -0.0007 -0.0015 -0.0015 -0.0014 -0.2863 -0.0016 -0.0014 -0.0015 -0.0011 -0.0014 -0.0011 -0.0007 -0.0014 -0.0013 -0.0012 -0.0012 -0.0015 -0.0014 -0.0015 -0.0010 -0.0014 -0.0011 -0.0007 -0.0014 -0.0017 -0.0014 -0.0013 -0.0015 -0.0014 -0.0015 -0.0009 -0.0014 -0.0011 -0.0007 -0.0014 -0.0017 -0.0013 -0.0013 -0.0016 -0.0014 -0.0015 -0.0009 -0.0014 -0.0011 -0.0007 -0.0015 -0.0016 -0.0012 -0.0014 -0.0015 -0.0014 -0.0015 -0.0008 -0.0014 -0.0011 -0.0007 -0.0014 -0.0015 -0.0011 -0.0014 -0.0015 -0.0014 -0.0015 -0.0008 -0.0014 -0.0012 -0.0007 -0.0014 -0.0015 -0.0010 -0.0014 -0.0015 -0.0014 -0.0015 -0.0009 -0.0014 -0.0012 -0.0007 -0.0015 -0.0017 -0.0012 -0.0014
S-1521	Die empfohlene Dosierung von Firazyr ist eine Injektion ( 3 ml , 30 mg ) , subkutan ( unter die Haut ) verabreicht , sobald Sie feststellen , dass sich die Attacke Ihres hereditären Angioödems moderat oder stark verschlimmert ( beispielsweise verstärkte Hautschwellungen , die besonders das Gesicht und den Hals betreffen , oder stärkere Bauchschmerzen ) .
T-1521	The recommended dose of Firazyr is one injection ( 3 ml , 30 mg ) applied subcutaneously ( under the skin ) as soon as you notice the attack of hereditary angioedema becoming moderately or severely worse ( for example increased skin swelling , particularly affecting the face and neck , or increasing tummy pain ) .
H-1521	-0.006464548874646425	The recommended dose of Firazyr is one injection ( 3 ml , 30 mg ) applied subcutaneously ( under the skin ) as soon as you notice the attack of hereditary angioedema becoming moderately or severely worse ( for example increased skin swelling , particularly affecting the face and neck , or increasing tummy pain ) .
D-1521	-0.006464548874646425	The recommended dose of Firazyr is one injection ( 3 ml , 30 mg ) applied subcutaneously ( under the skin ) as soon as you notice the attack of hereditary angioedema becoming moderately or severely worse ( for example increased skin swelling , particularly affecting the face and neck , or increasing tummy pain ) .
P-1521	-0.0279 -0.0024 -0.0113 -0.0087 -0.0081 -0.0008 -0.0005 -0.0015 -0.0016 -0.0141 -0.0020 -0.0005 -0.0024 -0.0046 -0.0030 -0.0019 -0.0022 -0.0010 -0.0015 -0.0144 -0.0208 -0.0004 -0.0003 -0.0014 -0.1199 -0.0020 -0.0035 -0.0019 -0.0011 -0.0014 -0.0098 -0.0016 -0.0013 -0.0019 -0.0109 -0.0136 -0.0100 -0.0019 -0.0160 -0.0006 -0.0008 -0.0014 -0.0010 -0.0002 -0.0014 -0.0004 -0.0112 -0.0081 -0.0010 -0.0016 -0.0103 -0.0068 -0.0015 -0.0067 -0.0029 -0.0108 -0.0075 -0.0012 -0.0014 -0.0053 -0.0094 -0.0047 -0.0027 -0.0014 -0.0016 -0.0043 -0.0024 -0.0058 -0.0145 -0.0153 -0.0015 -0.0043 -0.0015 -0.0014 -0.0014
S-722	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Isentress bei einer Verabreichung in Kombination mit anderen antiretroviralen Arzneimitteln , im Rahmen der Behandlung einer HIV @-@ 1 @-@ Infektion bei vorbehandelten erwachsenen Patienten mit nachgewiesener HIV @-@ 1 @-@ Replikation trotz kontinuierlicher antiretroviraler Therapie gegenüber den Risiken überwiegen .
T-722	The Committee for Medicinal Products for Human Use ( CHMP ) decided that Isentress <<unk>> s benefits , when taken in combination with other antiretroviral medicinal products , outweigh its risks for the treatment of HIV @-@ 1 infection in treatment @-@ experienced adult patients with evidence of HIV @-@ 1 replication despite ongoing antiretroviral therapy .
H-722	-0.034479569643735886	The Committee for Medicinal Products for Human Use ( CHMP ) decided that Isentress <unk> s benefits , when taken in combination with other antiretroviral medicinal products , outweigh its risks for the treatment of HIV @-@ 1 infection in treatment @-@ experienced adult patients with evidence of HIV @-@ 1 replication despite ongoing antiretroviral therapy .
D-722	-0.034479569643735886	The Committee for Medicinal Products for Human Use ( CHMP ) decided that Isentress <unk> s benefits , when taken in combination with other antiretroviral medicinal products , outweigh its risks for the treatment of HIV @-@ 1 infection in treatment @-@ experienced adult patients with evidence of HIV @-@ 1 replication despite ongoing antiretroviral therapy .
P-722	-0.0025 -0.0013 -0.8256 -0.0010 -0.0006 -0.0005 -0.0012 -0.0012 -0.0010 -0.0010 -0.0021 -0.0006 -0.0004 -0.0014 -0.4711 -0.0018 -0.0144 -0.0007 -0.0006 -0.0146 -0.0079 -0.0063 -0.0137 -0.0053 -0.0148 -0.0050 -0.0017 -0.0014 -0.0065 -0.0056 -0.0010 -0.0007 -0.0012 -0.0074 -0.9051 -0.0016 -0.0052 -0.0065 -0.0023 -0.0137 -0.0028 -0.0145 -0.0110 -0.0015 -0.0014 -0.0036 -0.0020 -0.0016 -0.0056 -0.0022 -0.0145 -0.0102 -0.0144 -0.0059 -0.0010 -0.0082 -0.0143 -0.0021 -0.0026 -0.0016 -0.0014 -0.0024 -0.0009 -0.0012 -0.0095 -0.0127 -0.0022 -0.0010 -0.0011 -0.0011 -0.0028 -0.0019 -0.0014
S-1764	Es könnte ein anderer LHRH @-@ Agonist verwendet werden , jedoch ist dies in Anbetracht der von dem Antragsteller vorgelegten Metaanalyse überflüssig , da eine Orchiektomie bei Verfügbarkeit von reversiblen Methoden inakzeptabel ist , DES veraltet ist und nichtsteroidale Antiandrogene bei Einsatz als Monotherapie eine geringere Wirksamkeit zeigen können .
T-1764	Another LHRH agonist could be used , but this is superfluous considering the meta @-@ analysis presented by Applicant , orchidectomy is not acceptable when reversible methods are available , DES is obsolete and non @-@ steroidal anti @-@ androgens may have inferior efficacy when used as monotherapy .
H-1764	-0.006938248872756958	Another LHRH agonist could be used , but this is superfluous considering the meta @-@ analysis presented by Applicant , orchidectomy is not acceptable when reversible methods are available , DES is obsolete and non @-@ steroidal anti @-@ androgens may have inferior efficacy when used as monotherapy .
D-1764	-0.006938248872756958	Another LHRH agonist could be used , but this is superfluous considering the meta @-@ analysis presented by Applicant , orchidectomy is not acceptable when reversible methods are available , DES is obsolete and non @-@ steroidal anti @-@ androgens may have inferior efficacy when used as monotherapy .
P-1764	-0.0090 -0.0015 -0.0007 -0.0008 -0.0006 -0.0010 -0.0070 -0.0018 -0.0027 -0.0205 -0.0086 -0.0058 -0.0038 -0.0091 -0.0004 -0.0015 -0.0147 -0.0018 -0.0027 -0.0030 -0.0096 -0.0006 -0.0116 -0.0015 -0.0150 -0.0045 -0.0010 -0.0253 -0.0214 -0.0032 -0.0145 -0.0065 -0.0005 -0.0054 -0.0102 -0.0026 -0.0140 -0.0022 -0.0009 -0.0007 -0.0037 -0.0020 -0.0017 -0.0018 -0.0010 -0.0012 -0.0020 -0.0102 -0.0003 -0.0005 -0.1286 -0.0051 -0.0148 -0.0005 -0.0025 -0.0012 -0.0005 -0.0172 -0.0013 -0.0010 -0.0008 -0.0015 -0.0039 -0.0127 -0.0152 -0.0013 -0.0259 -0.0040 -0.0005 -0.0007 -0.0095 -0.0022 -0.0039 -0.0046 -0.0015 -0.0047 -0.0016 -0.0015
S-1631	Obwohl die Transplantationsquote kein Studien @-@ Endpunkt war , erhielten 10 / 61 Patienten ( 16 % ) eine HSCT nach der Behandlung mit Clofarabin ( 3 nach Erreichen einer VR , 2 nach einer VRp , 3 nach einer PR , 1 Patient , der vom IRRP als Behandlungsfehlschlag eingestuft wurde und 1 , der vom IRRP als nicht beurteilbar betrachtet wurde ) .
T-1631	Although transplantation rate was not a study endpoint , 10 / 61 patients ( 16 % ) went on to receive a HSCT after treatment with clofarabine ( 3 after achieving a CR , 2 after a CRp , 3 after a PR , 1 patient that was considered a treatment failure by the IRRP and 1 that was considered not evaluable by the IRRP ) .
H-1631	-0.010357290506362915	Although transplantation rate was not a study endpoint , 10 / 61 patients ( 16 % ) went on to receive a HSCT after treatment with clofarabine ( 3 after achieving a CR , 2 after a CRp , 3 after a PR , 1 patient that was considered a treatment failure by the IRRP and 1 that was considered not evaluable by the IRRP ) .
D-1631	-0.010357290506362915	Although transplantation rate was not a study endpoint , 10 / 61 patients ( 16 % ) went on to receive a HSCT after treatment with clofarabine ( 3 after achieving a CR , 2 after a CRp , 3 after a PR , 1 patient that was considered a treatment failure by the IRRP and 1 that was considered not evaluable by the IRRP ) .
P-1631	-0.0056 -0.0109 -0.0224 -0.0097 -0.0024 -0.0021 -0.0050 -0.0089 -0.0030 -0.0167 -0.0020 -0.0022 -0.0018 -0.0009 -0.0019 -0.0015 -0.0016 -0.0013 -0.0014 -0.0154 -0.0081 -0.0032 -0.0021 -0.0138 -0.0039 -0.0016 -0.0009 -0.0043 -0.0095 -0.0017 -0.0030 -0.0013 -0.0010 -0.0019 -0.0015 -0.0018 -0.0029 -0.0139 -0.0114 -0.0145 -0.0133 -0.0028 -0.0015 -0.0014 -0.0084 -0.0169 -0.0145 -0.0014 -0.0013 -0.0016 -0.0103 -0.0026 -0.0017 -0.0015 -0.0035 -0.0134 -0.0050 -0.0127 -0.0076 -0.0094 -0.0005 -0.0018 -0.0082 -0.0012 -0.0012 -0.2262 -0.0060 -0.0016 -0.0056 -0.0026 -0.0099 -0.0128 -0.0121 -0.0030 -0.0014 -0.0030 -0.0004 -0.0012 -0.1962 -0.0016 -0.0016 -0.0014
S-1464	Der Inhaber der Genehmigung für das Inverkehrbringen verpflichtet sich , die im Pharmakovigilanz- Plan aufgeführten Studien und zusätzlichen Pharmakovigilanz @-@ Maßnahmen , wie in Version 5.0 des in Modul 1.8.2 des Zulassungsantrags aufgeführten Risikomanagementplans ( RMP ) vereinbart , sowie entsprechend jeder nachfolgenden durch den CHMP angenommenen Aktualisierung des RMP , durchzuführen .
T-1464	The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan , as agreed in version 5.0 of the Risk Management Plan ( RMP ) presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP .
H-1464	-0.013691428117454052	The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan , as agreed in version 5.0 of the Risk Management Plan ( RMP ) presented in Module 1.8.2 of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP .
D-1464	-0.013691428117454052	The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan , as agreed in version 5.0 of the Risk Management Plan ( RMP ) presented in Module 1.8.2 of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP .
P-1464	-0.0028 -0.0165 -0.0145 -0.0137 -0.0013 -0.0048 -0.0140 -0.0048 -0.0053 -0.0099 -0.0079 -0.0043 -0.0007 -0.0006 -0.0008 -0.0013 -0.0131 -0.0191 -0.0017 -0.0028 -0.0075 -0.0003 -0.0008 -0.0008 -0.0003 -0.0008 -0.0011 -0.0013 -0.0110 -0.0021 -0.0071 -0.0040 -0.0078 -0.0015 -0.0014 -0.0016 -0.0027 -0.0028 -0.0011 -0.0013 -0.0007 -0.0544 -0.0031 -0.0011 -0.0014 -0.0239 -0.0017 -0.0098 -0.0008 -0.0021 -0.0030 -0.6193 -0.0017 -0.0018 -0.0136 -0.0001 -0.0088 -0.0011 -0.0036 -0.0004 -0.0013 -0.0123 -0.0142 -0.0017 -0.0128 -0.0095 -0.0031 -0.0035 -0.0006 -0.0143 -0.0056 -0.0066 -0.0013 -0.0004 -0.0020 -0.0016
S-480	Bei derartigen Fällen sollte das Vorhandensein von Antikörpern untersucht werden , und die Behandlung sollte abgesetzt werden , falls diese in einem Bestätigungstest nach 6 Wochen positiv bleiben , da persistierende Antikörper mit einer erheblich verminderten Wirksamkeit von TYSABRI und einer erhöhten Häufigkeit von Überempfindlichkeitsreaktionen einhergehen ( siehe Abschnitt 4.8 ) .
T-480	In these cases the presence of antibodies should be evaluated and if these remain positive in a confirmatory test after 6 weeks , treatment should be discontinued , as persistent antibodies are associated with a substantial decrease in efficacy of TYSABRI and an increased incidence of hypersensitivity reactions ( see section 4.8 ) .
H-480	-0.007425263524055481	In these cases the presence of antibodies should be evaluated and if these remain positive in a confirmatory test after 6 weeks , treatment should be discontinued , as persistent antibodies are associated with a substantial decrease in efficacy of TYSABRI and an increased incidence of hypersensitivity reactions ( see section 4.8 ) .
D-480	-0.007425263524055481	In these cases the presence of antibodies should be evaluated and if these remain positive in a confirmatory test after 6 weeks , treatment should be discontinued , as persistent antibodies are associated with a substantial decrease in efficacy of TYSABRI and an increased incidence of hypersensitivity reactions ( see section 4.8 ) .
P-480	-0.0056 -0.0240 -0.0039 -0.0104 -0.0015 -0.0013 -0.0013 -0.0009 -0.0016 -0.0013 -0.0235 -0.0013 -0.0038 -0.0205 -0.0138 -0.0064 -0.0021 -0.0052 -0.0032 -0.0133 -0.0060 -0.0008 -0.0019 -0.0076 -0.0337 -0.0013 -0.0100 -0.0257 -0.0021 -0.0020 -0.0109 -0.0002 -0.0722 -0.0174 -0.0014 -0.0018 -0.0063 -0.0009 -0.0035 -0.0066 -0.0014 -0.0097 -0.0143 -0.0093 -0.0018 -0.0026 -0.0127 -0.0005 -0.0009 -0.0022 -0.0022 -0.0013 -0.0014 -0.0013 -0.0005 -0.0015 -0.0202 -0.0070 -0.0613 -0.0126 -0.0009 -0.0014 -0.0011 -0.0012 -0.0005 -0.0062 -0.0009 -0.0016 -0.0019 -0.0119 -0.0010 -0.0013 -0.0019 -0.0015 -0.0014
S-229	Ammonaps kann außerdem zu Appetitverlust , einem abnormen Säuregehalt im Blut , Depressionen , Reizbarkeit , Kopfschmerzen , Ohnmacht , Flüssigkeitsretention , Geschmacksstörungen oder Geschmacksaversion , Bauchschmerzen , Erbrechen , Übelkeit , Verstopfung , Hautausschlag , unangenehmem Körpergeruch oder Gewichtszunahme führen .
T-229	Ammonaps may also cause decreased appetite , abnormal blood acidity , depression , irritability , headache , fainting , fluid retention , bad taste or taste aversion , abdominal pain , vomiting , nausea , constipation , rash , unpleasant body odour , or weight gain .
H-229	-0.013496781699359417	Ammonaps may also cause decreased appetite , abnormal blood acidity , depression , irritability , headache , fainting , fluid retention , bad taste or taste aversion , abdominal pain , vomiting , nausea , constipation , rash , unpleasant body odour , or weight gain .
D-229	-0.013496781699359417	Ammonaps may also cause decreased appetite , abnormal blood acidity , depression , irritability , headache , fainting , fluid retention , bad taste or taste aversion , abdominal pain , vomiting , nausea , constipation , rash , unpleasant body odour , or weight gain .
P-229	-0.0018 -0.0005 -0.0140 -0.0555 -0.0019 -0.0108 -0.0143 -0.0203 -0.0007 -0.0008 -0.0017 -0.0025 -0.0006 -0.0104 -0.0040 -0.0017 -0.0015 -0.0010 -0.0015 -0.0008 -0.0009 -0.0015 -0.0005 -0.0005 -0.0072 -0.0014 -0.0012 -0.0074 -0.0011 -0.0015 -0.0020 -0.0011 -0.0005 -0.0003 -0.0015 -0.0149 -0.0010 -0.0027 -0.0111 -0.0082 -0.0017 -0.0015 -0.0079 -0.0006 -0.0008 -0.0012 -0.0014 -0.1316 -0.0003 -0.0012 -0.0015 -0.0007 -0.0002 -0.0015 -0.0008 -0.0003 -0.0006 -0.0012 -0.0014 -0.0118 -0.0016 -0.2540 -0.0053 -0.0012 -0.0015 -0.0006 -0.0132 -0.3119 -0.0091 -0.0018 -0.0009 -0.0015 -0.0014
S-24	EU / 1 / 07 / 415 / 027 ( 14 Tabletten ) EU / 1 / 07 / 415 / 028 ( 28 Tabletten ) EU / 1 / 07 / 415 / 029 ( 35 Tabletten ) EU / 1 / 07 / 415 / 030 ( 56 Tabletten ) EU / 1 / 07 / 415 / 031 ( 70 Tabletten )
T-24	EU / 1 / 07 / 415 / 027 ( 14 tablets ) EU / 1 / 07 / 415 / 028 ( 28 tablets ) EU / 1 / 07 / 415 / 029 ( 35 tablets ) EU / 1 / 07 / 415 / 030 ( 56 tablets ) EU / 1 / 07 / 415 / 031 ( 70 tablets )
H-24	-0.08350333571434021	( 14 tablets ) EU / 1 / 07 / 415 / 028 ( 28 tablets ) EU / 1 / 07 / 415 / 029 ( 35 tablets ) EU / 1 / 07 / 415 / 030 ( 56 tablets ) EU / 1 / 07 / 415 / 031 ( 70 tablets )
D-24	-0.08350333571434021	( 14 tablets ) EU / 1 / 07 / 415 / 028 ( 28 tablets ) EU / 1 / 07 / 415 / 029 ( 35 tablets ) EU / 1 / 07 / 415 / 030 ( 56 tablets ) EU / 1 / 07 / 415 / 031 ( 70 tablets )
P-24	-4.2465 -1.0046 -0.0019 -0.0016 -0.0017 -0.3193 -0.0016 -0.0014 -0.0014 -0.0010 -0.0014 -0.0013 -0.0011 -0.0014 -0.0012 -0.0012 -0.0584 -0.0952 -0.0012 -0.0016 -0.0014 -0.0019 -0.0015 -0.0014 -0.0014 -0.0008 -0.0014 -0.0011 -0.0012 -0.0014 -0.0012 -0.0030 -0.0014 -0.0342 -0.0010 -0.0014 -0.0014 -0.0017 -0.0015 -0.0014 -0.0014 -0.0009 -0.0014 -0.0012 -0.0010 -0.0014 -0.0013 -0.0013 -0.0013 -0.0008 -0.0009 -0.0018 -0.0014 -0.0016 -0.0015 -0.0014 -0.0014 -0.0008 -0.0014 -0.0012 -0.0010 -0.0014 -0.0015 -0.0008 -0.0014 -0.0011 -0.0008 -0.0019 -0.0014 -0.0016
S-432	Bei der Verabreichung von hohen Überdosierungen von Robenacoxib ( 4 , 12 oder 20 mg / kg / Tag über 6 Wochen ) an gesunde , junge Katzen im Alter von 7 @-@ 8 Monaten wurden keine Anzeichen von Toxizität , und hier auch keine gastrointestinalen , renalen oder hepatischen Toxizitäten und auch kein Einfluss auf die Blutungszeit gezeigt .
T-432	In healthy young cats aged 7 @-@ 8 months , oral robenacoxib administered at high overdoses ( 4 , 12 , or 20 mg / kg / day for 6 weeks ) did not produce any signs of toxicity , including no evidence of any gastrointestinal , kidney or liver toxicity and no effect on bleeding time .
H-432	-0.01984151266515255	In healthy young cats aged 7 @-@ 8 months , oral robenacoxib administered at high overdoses ( 4 , 12 , or 20 mg / kg / day for 6 weeks ) did not produce any signs of toxicity , including no evidence of any gastrointestinal , kidney or liver toxicity and no effect on bleeding time .
D-432	-0.01984151266515255	In healthy young cats aged 7 @-@ 8 months , oral robenacoxib administered at high overdoses ( 4 , 12 , or 20 mg / kg / day for 6 weeks ) did not produce any signs of toxicity , including no evidence of any gastrointestinal , kidney or liver toxicity and no effect on bleeding time .
P-432	-0.0123 -0.0145 -0.0104 -0.0014 -0.0141 -0.0033 -0.2782 -0.0011 -0.0022 -0.0099 -0.0145 -0.0144 -0.0113 -0.0011 -0.0004 -0.0011 -0.0144 -0.0019 -0.0106 -0.0070 -0.0147 -0.0097 -0.0199 -0.0037 -0.0019 -0.0015 -0.0013 -0.1766 -0.0292 -0.0019 -0.0007 -0.0015 -0.0012 -0.0021 -0.0019 -0.0090 -0.0049 -0.0011 -0.0016 -0.0131 -0.0016 -0.0174 -0.0056 -0.0091 -0.0017 -0.0013 -0.0007 -0.0009 -0.0531 -0.0134 -0.0168 -0.2545 -0.0037 -0.0241 -0.1996 -0.0076 -0.0002 -0.0007 -0.0007 -0.0016 -0.0165 -0.0007 -0.0094 -0.0153 -0.0056 -0.0240 -0.0013 -0.0661 -0.0043 -0.0110 -0.0027 -0.0059 -0.0007 -0.0055 -0.0021 -0.0015
S-1180	Es zeigte sich insgesamt keine signifikante Auswirkung auf das Kupfergleichgewicht , eine geringfügige Wechselwirkung von Zink mit Chelatbildnern ( Penicillamin und Trientin ) konnte jedoch nachgewiesen werden ; hierbei traten im Vergleich zu einer Zink @-@ Monotherapie eine verringerte Kupferausscheidung im Stuhl , aber eine erhöhte Ausscheidung von Kupfer im Urin auf .
T-1180	They showed no significant overall effect on copper balance although mild interaction of zinc with chelators ( penicillamine and trientine ) could be detected with decreased faecal but increased urinary copper excretion as compared with zinc alone .
H-1180	-0.029367918148636818	They showed no significant overall effect on copper balance although mild interaction of zinc with chelators ( penicillamine and trientine ) could be detected with decreased faecal but increased urinary copper excretion as compared with zinc alone .
D-1180	-0.029367918148636818	They showed no significant overall effect on copper balance although mild interaction of zinc with chelators ( penicillamine and trientine ) could be detected with decreased faecal but increased urinary copper excretion as compared with zinc alone .
P-1180	-0.0145 -0.0095 -0.0040 -0.0063 -0.0153 -0.0161 -0.0017 -0.0077 -0.0011 -0.0035 -0.0856 -0.0145 -0.0037 -0.0851 -0.0082 -0.0008 -0.0011 -0.0084 -0.0003 -0.0319 -0.0020 -0.0009 -0.0010 -0.0015 -0.0017 -0.0018 -0.0128 -0.0073 -0.0015 -0.0014 -0.0129 -0.0018 -0.0133 -0.0013 -0.0141 -0.0137 -0.1301 -0.0248 -0.0002 -0.0318 -0.1969 -0.0027 -0.0245 -0.0065 -0.1282 -0.0009 -0.0080 -0.0004 -0.0023 -0.0140 -0.0022 -0.6605 -0.0024 -0.0011 -0.0162 -0.0069 -0.0049
S-31	Sehr häufig ( ≥ 1 / 10 ) , häufig ( ≥ 1 / 100 bis &lt; 1 / 10 ) , gelegentlich ( ≥ 1 / 1.000 bis &lt; 1 / 100 ) , selten ( ≥ 1 / 10.000 bis &lt; 1 / 1.000 ) , sehr selten &lt; 1 / 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-31	Frequency categories are defined according to the following convention : very common ( ≥ 1 / 10 ) , common ( ≥ 1 / 100 to &lt; 1 / 10 ) , uncommon ( ≥ 1 / 1,000 to &lt; 1 / 100 ) , rare ( ≥ 1 / 10,000 to &lt; 1 / 1,000 ) , very rare ( &lt; 1 / 10,000 ) , not known ( cannot be calculated from the available data ) .
H-31	-0.007563868071883917	Frequency categories are defined according to the following convention : very common ( ≥ 1 / 10 ) , common ( ≥ 1 / 100 to &lt; 1 / 10 ) , uncommon ( ≥ 1 / 1,000 to &lt; 1 / 100 ) , rare ( ≥ 1 / 10,000 to &lt; 1 / 1,000 ) , very rare ( &lt; 1 / 10,000 ) , not known ( cannot be calculated from the available data ) .
D-31	-0.007563868071883917	Frequency categories are defined according to the following convention : very common ( ≥ 1 / 10 ) , common ( ≥ 1 / 100 to &lt; 1 / 10 ) , uncommon ( ≥ 1 / 1,000 to &lt; 1 / 100 ) , rare ( ≥ 1 / 10,000 to &lt; 1 / 1,000 ) , very rare ( &lt; 1 / 10,000 ) , not known ( cannot be calculated from the available data ) .
P-31	-0.0487 -0.0004 -0.0045 -0.0145 -0.0122 -0.0145 -0.0144 -0.0015 -0.0123 -0.0149 -0.0145 -0.0067 -0.0101 -0.0073 -0.0041 -0.0002 -0.0015 -0.0015 -0.0017 -0.0018 -0.0026 -0.0097 -0.0014 -0.0004 -0.0015 -0.0014 -0.0010 -0.0074 -0.0006 -0.0016 -0.0012 -0.0014 -0.0015 -0.0015 -0.0014 -0.0015 -0.0148 -0.0007 -0.0014 -0.0004 -0.0014 -0.0014 -0.0559 -0.0016 -0.0006 -0.0010 -0.0013 -0.0013 -0.0015 -0.1257 -0.0014 -0.0015 -0.0359 -0.0014 -0.0004 -0.0014 -0.0014 -0.0120 -0.0015 -0.0006 -0.0011 -0.0013 -0.0012 -0.0014 -0.0101 -0.0015 -0.0017 -0.0509 -0.0024 -0.0148 -0.0092 -0.0008 -0.0016 -0.0014 -0.0014 -0.0012 -0.0015 -0.0165 -0.0124 -0.0022 -0.0019 -0.0145 -0.0013 -0.0137 -0.0016 -0.0134 -0.0127 -0.0049 -0.0022 -0.0016 -0.0021 -0.0014
S-1721	Reaktionen im Zusammenhang mit der Infusion Bei der Infusion von intravenösem Voriconazol kam es bei gesunden Probanden zu anaphylaktoiden Reaktionen wie Flush , Fieber , Schwitzen , Tachykardie , Engegefühl im Brustkorb , Atemnot , Schwächegefühl , Übelkeit , Juckreiz und Hautausschlag .
T-1721	Infusion @-@ Related Reactions During infusion of the intravenous formulation of voriconazole in healthy subjects , anaphylactoid @-@ type reactions , including flushing , fever , sweating , tachycardia , chest tightness , dyspnoea , faintness , nausea , pruritus and rash have occurred .
H-1721	-0.013793067075312138	Infusion @-@ Related Reactions During infusion of the intravenous formulation of voriconazole in healthy subjects , anaphylactoid @-@ type reactions , including flushing , fever , sweating , tachycardia , chest tightness , dyspnoea , faintness , nausea , pruritus and rash have occurred .
D-1721	-0.013793067075312138	Infusion @-@ Related Reactions During infusion of the intravenous formulation of voriconazole in healthy subjects , anaphylactoid @-@ type reactions , including flushing , fever , sweating , tachycardia , chest tightness , dyspnoea , faintness , nausea , pruritus and rash have occurred .
P-1721	-0.0140 -0.0098 -0.0039 -0.0144 -0.0020 -0.0007 -0.0138 -0.0072 -0.0094 -0.0057 -0.0147 -0.0068 -0.0004 -0.0008 -0.0013 -0.0145 -0.0025 -0.0096 -0.0007 -0.0004 -0.0003 -0.0006 -0.0135 -0.0016 -0.3314 -0.0086 -0.0029 -0.0008 -0.0005 -0.0005 -0.0903 -0.0007 -0.0031 -0.0656 -0.0144 -0.0881 -0.0005 -0.0144 -0.0122 -0.0010 -0.0134 -0.0015 -0.0294 -0.0008 -0.0015 -0.0025 -0.0017 -0.0015 -0.0008 -0.0009 -0.0012 -0.0009 -0.0002 -0.0015 -0.0023 -0.0019 -0.0003 -0.0013 -0.0014 -0.0192 -0.0004 -0.0139 -0.0013 -0.0015 -0.0146 -0.0430 -0.0010 -0.0014 -0.0014 -0.0004 -0.0015 -0.0316 -0.0008 -0.0007 -0.0009 -0.1122 -0.0068 -0.0013 -0.0145 -0.0110 -0.0016 -0.0014
S-1091	30 Tadalafil ( 10 mg und 20 mg ) hatte weder eine klinisch signifikante Wirkung auf die Bioverfügbarkeit ( AUC ) von S @-@ Warfarin oder R @-@ Warfarin ( CYP2C9 Substrat ) , noch hatte Tadalafil einen Einfluss auf eine mittels Warfarin eingestellte Prothrombin @-@ Zeit .
T-1091	Tadalafil ( 10 mg and 20 mg ) had no clinically significant effect on exposure ( AUC ) to S @-@ warfarin or R @-@ warfarin ( CYP2C9 substrate ) , nor did tadalafil affect changes in prothrombin time induced by warfarin .
H-1091	-0.014360854402184486	Tadalafil ( 10 mg and 20 mg ) had no clinically significant effect on exposure ( AUC ) to S @-@ warfarin or R @-@ warfarin ( CYP2C9 substrate ) , nor did tadalafil affect changes in prothrombin time induced by warfarin .
D-1091	-0.014360854402184486	Tadalafil ( 10 mg and 20 mg ) had no clinically significant effect on exposure ( AUC ) to S @-@ warfarin or R @-@ warfarin ( CYP2C9 substrate ) , nor did tadalafil affect changes in prothrombin time induced by warfarin .
P-1091	-0.0129 -0.0010 -0.0010 -0.0007 -0.0009 -0.0127 -0.0044 -0.2607 -0.0023 -0.0017 -0.0004 -0.0032 -0.0158 -0.0059 -0.0017 -0.0010 -0.0013 -0.0015 -0.0017 -0.0145 -0.0135 -0.0017 -0.0010 -0.0015 -0.0114 -0.0050 -0.0085 -0.0019 -0.0009 -0.0014 -0.0024 -0.0014 -0.0014 -0.0011 -0.0007 -0.0013 -0.0018 -0.0022 -0.0013 -0.3082 -0.0011 -0.0014 -0.0013 -0.0025 -0.0013 -0.0013 -0.0015 -0.0108 -0.0035 -0.0060 -0.0130 -0.0010 -0.0009 -0.0006 -0.0011 -0.0086 -0.0842 -0.0027 -0.1267 -0.0006 -0.0008 -0.0014 -0.0065 -0.0144 -0.0022 -0.0027 -0.0014 -0.0009 -0.0012 -0.0026 -0.0017
S-623	Unter den Patienten , denen 1000 mg Rituximab ohne Glukokortikoid @-@ Prämedikation verabreicht wurden , erlitten 18 von 65 ( 28 % ) eine akute Infusionsreaktion , verglichen mit 24 von 127 Patienten ( 19 % ) , die eine intravenöse Prämedikation mit einem Glukokortikoid erhalten hatten .
T-623	Of the patients who received 1000 mg rituximab without premedication with glucocorticoids , 18 / 65 ( 28 % ) experienced an acute infusion reaction , compared with 24 / 127 ( 19 % ) in patients given intravenous glucocorticoid premedication , respectively .
H-623	-0.023350484669208527	Of the patients who received 1000 mg rituximab without premedication with glucocorticoids , 18 / 65 ( 28 % ) experienced an acute infusion reaction , compared with 24 / 127 ( 19 % ) in patients given intravenous glucocorticoid premedication , respectively .
D-623	-0.023350484669208527	Of the patients who received 1000 mg rituximab without premedication with glucocorticoids , 18 / 65 ( 28 % ) experienced an acute infusion reaction , compared with 24 / 127 ( 19 % ) in patients given intravenous glucocorticoid premedication , respectively .
P-623	-0.0174 -0.0091 -0.0060 -0.0171 -0.0276 -0.0096 -0.0010 -0.0069 -0.0002 -0.0005 -0.0011 -0.0011 -0.0036 -0.0164 -0.0035 -0.0135 -0.0013 -0.0020 -0.0013 -0.0014 -0.0006 -0.0187 -0.0017 -0.0016 -0.0151 -0.0010 -0.0017 -0.0235 -0.0013 -0.0014 -0.0076 -0.0044 -0.0006 -0.0005 -0.0056 -0.0013 -0.0053 -0.1401 -0.0018 -0.5723 -0.0011 -0.0032 -0.0008 -0.0011 -0.0121 -0.0011 -0.0011 -0.0014 -0.0145 -0.0086 -0.0496 -0.0110 -0.0012 -0.0006 -0.0013 -0.0142 -0.0015 -0.0016 -0.0014 -0.0015 -0.0124 -0.0061 -0.0055 -0.4482 -0.0138 -0.0018 -0.0014
S-1963	• Ausbau der wissenschaftlichen Beratung sowie im Zusammenhang damit weitere Bereitstellung technischer und organisatorischer Unterstützung auf hohem Qualitätsniveau ; • Optimierung der Ressourcen für die wissenschaftliche Beratung des CPMP und seiner Arbeitsgruppen durch Ermittlung der jeweiligen Fachkenntnisse der Mitglieder und Durchführung entsprechender Arbeitssitzungen ; • Unterstützung des multidisziplinären Ansatzes bei der Erörterung neuer Therapiekonzepte ( z .
T-1963	• to optimise the resources for scientific advice of the CPMP and its working parties by identifying areas of specific expertise of members and arranging working sessions accordingly ;
H-1963	-0.008770016953349113	• to optimise the resources for scientific advice of the CPMP and its working parties by identifying areas of specific expertise of members and arranging working sessions accordingly ;
D-1963	-0.008770016953349113	• to optimise the resources for scientific advice of the CPMP and its working parties by identifying areas of specific expertise of members and arranging working sessions accordingly ;
P-1963	-0.0036 -0.0141 -0.0145 -0.0005 -0.0065 -0.0118 -0.0088 -0.0065 -0.0053 -0.0135 -0.0311 -0.0016 -0.0013 -0.0005 -0.0017 -0.0027 -0.0053 -0.0133 -0.0049 -0.0058 -0.0085 -0.0145 -0.0033 -0.0142 -0.0044 -0.0058 -0.0130 -0.0022 -0.0143 -0.0012 -0.0129 -0.0058 -0.0144 -0.0017 -0.0272 -0.0191
S-471	Insgesamt wurde durch die Daten aus dem nicht klinischen und klinischen Entwicklungsprogramm , das mit Unterstützung der wissenschaftlichen Beratung konzipiert wurde , hinlänglich nachgewiesen , dass auf ein Dosisverhältnis von 1 : 1 zwischen Xeomin und Botox in Bezug auf Wirksamkeit und Sicherheit geschlossen werden kann und die Übernahme der für Botox festgelegten Dosierung hinreichend gerechtfertigt ist .
T-471	Taken altogether , the data from the non @-@ clinical and clinical development program , which has been designed with support of Scientific Advice , provided sufficient evidence that a 1 : 1 dose ratio between Xeomin and Botox with respect to efficacy and safety can be concluded and the adoption of the dosage which has been established for Botox is adequately justified .
H-471	-0.005156128667294979	Taken altogether , the data from the non @-@ clinical and clinical development program , which has been designed with support of Scientific Advice , provided sufficient evidence that a 1 : 1 dose ratio between Xeomin and Botox with respect to efficacy and safety can be concluded and the adoption of the dosage which has been established for Botox is adequately justified .
D-471	-0.005156128667294979	Taken altogether , the data from the non @-@ clinical and clinical development program , which has been designed with support of Scientific Advice , provided sufficient evidence that a 1 : 1 dose ratio between Xeomin and Botox with respect to efficacy and safety can be concluded and the adoption of the dosage which has been established for Botox is adequately justified .
P-471	-0.0139 -0.0011 -0.0146 -0.0048 -0.0081 -0.0030 -0.0044 -0.0021 -0.0050 -0.0057 -0.0008 -0.0022 -0.0010 -0.0015 -0.0126 -0.0067 -0.0107 -0.0122 -0.0014 -0.0098 -0.0023 -0.0138 -0.0119 -0.0155 -0.0006 -0.0055 -0.0031 -0.0020 -0.0141 -0.0071 -0.0029 -0.0098 -0.0068 -0.0117 -0.0063 -0.0014 -0.0066 -0.0044 -0.0048 -0.0044 -0.0022 -0.0008 -0.0014 -0.0014 -0.0017 -0.0003 -0.0011 -0.0144 -0.0062 -0.0014 -0.0079 -0.0005 -0.0010 -0.0016 -0.0006 -0.0070 -0.0014 -0.0091 -0.0043 -0.0128 -0.0016 -0.0007 -0.0014 -0.0023 -0.0087 -0.0013 -0.0014 -0.0145 -0.0109 -0.0013 -0.0122 -0.0020 -0.0019 -0.0005 -0.0011 -0.0025 -0.0134 -0.0011 -0.0024 -0.0015 -0.0014
S-1770	Protaminsulfat m @-@ Cresol destilliert &#91; 1,76 mg / ml &#93; Phenol &#91; 0,80 mg / ml &#93; Glycerol Dinatriumhydrogenphosphat 7 H2O Zinkoxid Wasser für Injektionszwecke Salzsäure und Natriumhydroxid können für die Einstellung des pH auf 7,0 bis 7,8 verwendet werden .
T-1770	Protamine sulphate m @-@ cresol &#91; 1.76 mg / ml &#93; Phenol &#91; 0.80 mg / ml &#93; 79 Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 <<unk>> 7.8 .
H-1770	-0.013695224188268185	Protamine sulphate m @-@ cresol &#91; 1.76 mg / ml &#93; Phenol &#91; 0.80 mg / ml &#93; 79 Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 <unk> 7.8 .
D-1770	-0.013695224188268185	Protamine sulphate m @-@ cresol &#91; 1.76 mg / ml &#93; Phenol &#91; 0.80 mg / ml &#93; 79 Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 <unk> 7.8 .
P-1770	-0.0031 -0.0057 -0.0044 -0.1125 -0.0011 -0.0016 -0.2153 -0.0077 -0.0006 -0.0210 -0.0144 -0.0041 -0.0014 -0.0005 -0.0015 -0.0007 -0.0013 -0.0071 -0.0014 -0.0011 -0.0275 -0.0020 -0.0013 -0.0006 -0.0015 -0.0004 -0.0013 -0.0278 -0.0140 -0.0013 -0.0013 -0.0155 -0.0104 -0.0145 -0.0119 -0.0011 -0.0190 -0.2739 -0.0031 -0.0212 -0.0143 -0.0024 -0.0015 -0.0013 -0.0007 -0.0011 -0.0033 -0.0047 -0.0042 -0.0017 -0.0143 -0.0076 -0.0008 -0.0009 -0.0006 -0.0004 -0.0011 -0.0012 -0.0251 -0.0042 -0.0006 -0.0007 -0.0004 -0.0012 -0.0133 -0.0014 -0.0022 -0.0462 -0.0054 -0.0008 -0.0118 -0.0009 -0.0058 -0.0034 -0.0014 -0.0414 -0.0041 -0.0015 -0.0040 -0.0016
S-214	Die gleichzeitige Anwendung von Vardenafil mit starken CYP3A4 @-@ Inhibitoren wie zum Beispiel Itraconazol und Ketoconazol ( orale Darreichungsform ) sollte vermieden werden , da bei Kombination dieser Arzneimittel sehr hohe Plasmakonzentrationen von Vardenafil erreicht werden ( siehe Abschnitte 4.5 und 4.3 ) .
T-214	Concomitant use of vardenafil with potent CYP 3A4 inhibitors such as itraconazole and ketoconazole ( oral form ) should be avoided as very high plasma concentrations of vardenafil are reached if the medicinal products are combined ( see sections 4.5 and 4.3 ) .
H-214	-0.02119901031255722	Concomitant use of vardenafil with potent CYP3A4 inhibitors such as itraconazole and ketoconazole ( oral form ) should be avoided as very high plasma concentrations of vardenafil are reached if the medicinal products are combined ( see sections 4.5 and 4.3 ) .
D-214	-0.02119901031255722	Concomitant use of vardenafil with potent CYP3A4 inhibitors such as itraconazole and ketoconazole ( oral form ) should be avoided as very high plasma concentrations of vardenafil are reached if the medicinal products are combined ( see sections 4.5 and 4.3 ) .
P-214	-0.0122 -0.4103 -0.0004 -0.0016 -0.0056 -0.0015 -0.0026 -0.0007 -0.0008 -0.0010 -0.0034 -0.0112 -0.0015 -0.0019 -0.0012 -0.7695 -0.0011 -0.0006 -0.0012 -0.0006 -0.0004 -0.0011 -0.0308 -0.0014 -0.0002 -0.0007 -0.0015 -0.0006 -0.0004 -0.0021 -0.0004 -0.0013 -0.0016 -0.0006 -0.0004 -0.0019 -0.0016 -0.0091 -0.0022 -0.0014 -0.0014 -0.0008 -0.0923 -0.0093 -0.0013 -0.0050 -0.0005 -0.0005 -0.0046 -0.0004 -0.0008 -0.0015 -0.0011 -0.0006 -0.0008 -0.0010 -0.0053 -0.0157 -0.0221 -0.0138 -0.0139 -0.0974 -0.0026 -0.0021 -0.0048 -0.0029 -0.0018 -0.0070 -0.0009 -0.0014 -0.0015 -0.0012 -0.0013 -0.0019 -0.0015 -0.0014
S-249	Besondere Patientengruppen Patienten mit Niereninsuffizienz Bei Patienten mit leichter oder mäßiger Niereninsuffizienz mit einem Serumkreatinin @-@ Wert ≤ 200 µmol / l ( 2,3 mg / dl ) oder einer Kreatinin @-@ Clearance ( gemessen oder geschätzt ) ≥ 30 ml / min ist keine Dosisanpassung erforderlich .
T-249	Special Populations Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment where serum creatinine is equal or below 200 μ mol / l ( 2.3 mg / dl ) or where creatinine clearance ( measured or estimated ) is equal or greater than 30 ml / min .
H-249	-0.009220436215400696	Special Populations Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment where serum creatinine is equal or below 200 μ mol / l ( 2.3 mg / dl ) or where creatinine clearance ( measured or estimated ) is equal or greater than 30 ml / min .
D-249	-0.009220436215400696	Special Populations Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment where serum creatinine is equal or below 200 μ mol / l ( 2.3 mg / dl ) or where creatinine clearance ( measured or estimated ) is equal or greater than 30 ml / min .
P-249	-0.0064 -0.0145 -0.0056 -0.0078 -0.0009 -0.0063 -0.0045 -0.0011 -0.1457 -0.0006 -0.0011 -0.0013 -0.0133 -0.0056 -0.0029 -0.0006 -0.0015 -0.0066 -0.2535 -0.0103 -0.0023 -0.0018 -0.0023 -0.0021 -0.0011 -0.0008 -0.0013 -0.0046 -0.0004 -0.0005 -0.0013 -0.0143 -0.0023 -0.0016 -0.0016 -0.0011 -0.0014 -0.0016 -0.0113 -0.0145 -0.0144 -0.0169 -0.0073 -0.0213 -0.0027 -0.0009 -0.0014 -0.0022 -0.0021 -0.0029 -0.0017 -0.0009 -0.0015 -0.0027 -0.0015 -0.0028 -0.0140 -0.0030 -0.0008 -0.0014 -0.0014 -0.0004 -0.0012 -0.0075 -0.0008 -0.0016 -0.0019 -0.0015 -0.0081 -0.0128 -0.0062 -0.0122 -0.0017 -0.0008 -0.0035 -0.0014 -0.0010 -0.0019 -0.0016
S-1866	Nebenwirkungen , die zu einem Absetzen von Doribax führten , waren Übelkeit ( 0,1 % ) , Diarrhö ( 0,1 % ) , Pruritus ( 0,1 % ) , mykotische Infektion der Vulva ( 0,1 % ) , Erhöhung der Leberenzyme ( 0,2 % ) und Hautausschlag ( 0,2 % ) .
T-1866	Adverse drug reactions that led to Doribax discontinuation were nausea ( 0.1 % ) , diarrhoea ( 0.1 % ) , pruritus ( 0.1 % ) , vulvomycotic infection ( 0.1 % ) , hepatic enzyme increased ( 0.2 % ) and rash ( 0.2 % ) .
H-1866	-0.00777861475944519	Adverse drug reactions that led to Doribax discontinuation were nausea ( 0.1 % ) , diarrhoea ( 0.1 % ) , pruritus ( 0.1 % ) , vulvomycotic infection ( 0.1 % ) , hepatic enzyme increased ( 0.2 % ) and rash ( 0.2 % ) .
D-1866	-0.00777861475944519	Adverse drug reactions that led to Doribax discontinuation were nausea ( 0.1 % ) , diarrhoea ( 0.1 % ) , pruritus ( 0.1 % ) , vulvomycotic infection ( 0.1 % ) , hepatic enzyme increased ( 0.2 % ) and rash ( 0.2 % ) .
P-1866	-0.0120 -0.0003 -0.0161 -0.0071 -0.0005 -0.0102 -0.0067 -0.0017 -0.0128 -0.0008 -0.0008 -0.0015 -0.0126 -0.0036 -0.0017 -0.0174 -0.0008 -0.0003 -0.0013 -0.0019 -0.0014 -0.0013 -0.0015 -0.0015 -0.0013 -0.0003 -0.0066 -0.0007 -0.0014 -0.0010 -0.0014 -0.0011 -0.0014 -0.0015 -0.0013 -0.0001 -0.0002 -0.0013 -0.0014 -0.0010 -0.0014 -0.0011 -0.0014 -0.0014 -0.0146 -0.0111 -0.0145 -0.0066 -0.0009 -0.0023 -0.0030 -0.0013 -0.0010 -0.0014 -0.0011 -0.0014 -0.0015 -0.0145 -0.0012 -0.0008 -0.0009 -0.0329 -0.0018 -0.0143 -0.0015 -0.0009 -0.0014 -0.0012 -0.0014 -0.3209 -0.0069 -0.0006 -0.0020 -0.0009 -0.0014 -0.0012 -0.0014 -0.0014 -0.0014
S-179	Eine allergische Reaktion kann sich durch juckende Hautausschläge , Atemnot oder Anschwellen des Gesichts oder der Zunge äußern . • wenn bei Ihnen / Ihrem Kind schon einmal eine allergische Reaktion auf eine frühere Impfung gegen Hepatitis A oder Hepatitis B aufgetreten ist . • wenn Sie / Ihr Kind eine schwere Infektion mit Fieber haben / hat .
T-179	Signs of an allergic reaction may include itchy skin rash , shortness of breath and swelling of the face or tongue . • if you have / your child has previously had an allergic reaction to any vaccine against hepatitis A or hepatitis B diseases . • if you have / your child has a severe infection with a high temperature .
H-179	-0.019922398030757904	Signs of an allergic reaction may include itchy skin rash , shortness of breath and swelling of the face or tongue . • if you have / your child has previously had an allergic reaction to any vaccine against hepatitis A or hepatitis B diseases . • if you have / your child has a severe infection with a high temperature .
D-179	-0.019922398030757904	Signs of an allergic reaction may include itchy skin rash , shortness of breath and swelling of the face or tongue . • if you have / your child has previously had an allergic reaction to any vaccine against hepatitis A or hepatitis B diseases . • if you have / your child has a severe infection with a high temperature .
P-179	-0.0145 -0.0116 -0.0052 -0.0067 -0.0014 -0.0005 -0.0013 -0.0116 -0.0054 -0.0058 -0.0039 -0.0102 -0.0052 -0.0159 -0.0020 -0.0117 -0.0008 -0.0014 -0.0003 -0.5320 -0.0017 -0.0010 -0.0019 -0.0029 -0.0024 -0.0025 -0.0006 -0.0005 -0.0606 -0.0021 -0.0055 -0.0063 -0.0135 -0.2246 -0.0117 -0.0013 -0.0129 -0.1270 -0.0045 -0.0016 -0.0005 -0.0005 -0.0014 -0.0014 -0.0145 -0.0145 -0.0065 -0.0019 -0.0004 -0.0007 -0.0013 -0.1551 -0.0010 -0.0004 -0.0007 -0.0058 -0.0184 -0.0234 -0.0023 -0.0011 -0.0025 -0.0132 -0.0154 -0.0059 -0.0016 -0.0047 -0.0113 -0.0044 -0.0060 -0.0020 -0.0108 -0.0178 -0.0107 -0.0018 -0.0015
S-1768	11 Andere medizinisch relevante Folgeerscheinungen einer Überdosierung sind Delirium , Krampfanfälle , Koma , mögliches malignes neuroleptisches Syndrom , Atemdepression , Aspiration , Hypertonie oder Hypotonie , Herzarrhythmien ( &lt; 2 % der Fälle von Überdosierung ) und Herz - Atemstillstand .
T-1768	Other medically significant sequelae of overdose include delirium , convulsion , coma , possible neuroleptic malignant syndrome , respiratory depression , aspiration , hypertension or hypotension , cardiac arrhythmias ( &lt; 2 % of overdose cases ) and cardiopulmonary arrest .
H-1768	-0.008760793134570122	Other medically significant sequelae of overdose include delirium , convulsion , coma , possible neuroleptic malignant syndrome , respiratory depression , aspiration , hypertension or hypotension , cardiac arrhythmias ( &lt; 2 % of overdose cases ) and cardiopulmonary arrest .
D-1768	-0.008760793134570122	Other medically significant sequelae of overdose include delirium , convulsion , coma , possible neuroleptic malignant syndrome , respiratory depression , aspiration , hypertension or hypotension , cardiac arrhythmias ( &lt; 2 % of overdose cases ) and cardiopulmonary arrest .
P-1768	-0.0160 -0.0025 -0.0008 -0.0209 -0.0145 -0.0048 -0.0004 -0.0033 -0.0079 -0.0038 -0.0070 -0.0005 -0.0010 -0.0302 -0.0015 -0.0138 -0.0004 -0.0141 -0.0018 -0.0021 -0.0016 -0.0015 -0.0045 -0.0141 -0.0031 -0.0011 -0.0012 -0.0181 -0.0097 -0.0129 -0.0101 -0.0007 -0.0016 -0.0027 -0.0005 -0.0010 -0.0013 -0.0014 -0.0005 -0.0008 -0.0015 -0.0013 -0.0005 -0.1238 -0.0016 -0.0003 -0.0009 -0.0020 -0.0015 -0.0054 -0.0009 -0.0004 -0.0006 -0.0053 -0.0045 -0.0015 -0.0015 -0.0004 -0.0014 -0.0016 -0.0016 -0.0016 -0.0038 -0.0010 -0.0014 -0.0014 -0.2198 -0.0023 -0.0156 -0.0110 -0.0003 -0.0003 -0.0014 -0.0016 -0.0014
S-829	In einer dieser Studien ließ sich - nach einer initialen Dosis von 1,0 mg / kg alle 2 Wochen für einen Zeitraum von 6 Monaten - bei einigen Patienten die GL @-@ 3 @-@ Clearance in bestimmten Zelltypen mit 0,3 mg / kg alle 2 Wochen möglicherweise aufrecht erhalten ; die langfristige klinische Bedeutung dieser Beobachtung ist jedoch nicht geklärt ( siehe Abschnitt 5.1 ) .
T-829	In one of these studies , after an initial dose of 1.0 mg / kg every 2 weeks for 6 months , 0.3 mg / kg every 2 weeks may maintain clearance of GL @-@ 3 in certain cell types in some patients ; however , the long term clinical relevance of these findings has not been established ( see section 5.1 ) .
H-829	-0.010940046049654484	In one of these studies , after an initial dose of 1.0 mg / kg every 2 weeks for 6 months , 0.3 mg / kg every 2 weeks may maintain clearance of GL @-@ 3 in certain cell types in some patients ; however , the long term clinical relevance of these findings has not been established ( see section 5.1 ) .
D-829	-0.010940046049654484	In one of these studies , after an initial dose of 1.0 mg / kg every 2 weeks for 6 months , 0.3 mg / kg every 2 weeks may maintain clearance of GL @-@ 3 in certain cell types in some patients ; however , the long term clinical relevance of these findings has not been established ( see section 5.1 ) .
P-829	-0.0040 -0.0071 -0.0036 -0.0032 -0.0066 -0.0044 -0.0158 -0.0043 -0.0007 -0.0019 -0.0022 -0.0035 -0.0015 -0.0004 -0.0015 -0.0008 -0.0022 -0.0129 -0.0010 -0.0027 -0.0136 -0.0017 -0.0023 -0.0220 -0.0018 -0.0003 -0.0014 -0.0006 -0.0144 -0.0018 -0.0010 -0.0103 -0.0136 -0.0146 -0.0013 -0.0121 -0.0046 -0.0015 -0.0023 -0.0015 -0.0023 -0.0057 -0.0020 -0.0015 -0.0037 -0.0045 -0.0015 -0.0166 -0.0263 -0.0064 -0.0129 -0.0020 -0.3638 -0.0021 -0.0120 -0.0010 -0.0015 -0.0437 -0.0142 -0.0110 -0.0024 -0.0029 -0.0109 -0.0020 -0.0021 -0.0115 -0.0012 -0.0014 -0.0018 -0.0014 -0.0014
S-640	Aus dem gleichen Grund wird die gleichzeitige Verabreichung sowohl eines potenten CYP3A4 @-@ Inhibitors ( wie Ketoconazol , Itraconazol und Ritonavir ) als auch eines CYP2C9 @-@ Inhibitors ( wie Voriconazol ) mit Tracleer nicht empfohlen ( siehe Abschnitt 4.4 ) .
T-640	For the same reason , concomitant administration of both a potent CYP3A4 inhibitor ( such as ketoconazole , itraconazole and ritonavir ) and a CYP2C9 inhibitor ( such as voriconazole ) with Tracleer is not recommended ( see section 4.4 ) .
H-640	-0.014079708606004715	For the same reason , concomitant administration of both a potent CYP3A4 inhibitor ( such as ketoconazole , itraconazole and ritonavir ) and a CYP2C9 inhibitor ( such as voriconazole ) with Tracleer is not recommended ( see section 4.4 ) .
D-640	-0.014079708606004715	For the same reason , concomitant administration of both a potent CYP3A4 inhibitor ( such as ketoconazole , itraconazole and ritonavir ) and a CYP2C9 inhibitor ( such as voriconazole ) with Tracleer is not recommended ( see section 4.4 ) .
P-640	-0.0045 -0.0016 -0.0014 -0.0019 -0.0050 -0.0135 -0.0099 -0.0003 -0.0022 -0.0027 -0.0046 -0.0097 -0.0041 -0.0016 -0.0015 -0.0016 -0.0012 -0.7026 -0.0014 -0.0007 -0.0012 -0.0006 -0.0009 -0.0012 -0.0015 -0.0027 -0.0013 -0.0008 -0.0014 -0.0016 -0.0005 -0.0003 -0.0014 -0.0002 -0.0013 -0.0016 -0.0005 -0.0003 -0.2441 -0.0010 -0.0012 -0.0014 -0.0009 -0.0014 -0.0018 -0.0078 -0.0015 -0.0012 -0.0013 -0.0011 -0.0013 -0.0011 -0.0010 -0.0007 -0.0007 -0.0012 -0.0013 -0.0010 -0.0014 -0.0005 -0.0007 -0.0004 -0.0005 -0.0014 -0.0036 -0.0110 -0.0009 -0.0015 -0.0026 -0.0015 -0.0024 -0.0017 -0.0017 -0.0093 -0.0012 -0.0013 -0.0020 -0.0014 -0.0014
S-608	Bitte beachten Sie die entsprechende Fachinformation der antiretroviralen Arzneimittel , die gleichzeitig mit der HCV @-@ Behandlung angewendet werden , um die für jedes Produkt spezifischen Toxizitätsreaktionen sowie die mögliche Überlagerung von Toxizitätsreaktionen mit denen von Ribavirin und Peginterferon alfa @-@ 2b erkennen und behandeln zu können .
T-608	Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Ribavirin and peginterferon alfa @-@ 2b .
H-608	-0.03723796829581261	Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Ribavirin and peginterferon alfa @-@ 2b .
D-608	-0.03723796829581261	Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Ribavirin and peginterferon alfa @-@ 2b .
P-608	-0.0031 -0.0101 -0.0016 -0.0034 -0.0155 -0.0150 -0.0008 -0.0091 -0.0171 -0.0145 -0.0016 -0.0010 -0.0011 -0.0013 -0.0109 -0.0112 -0.0120 -0.0011 -0.0006 -0.0010 -0.0105 -0.9310 -0.0029 -0.0122 -0.0035 -0.0436 -0.0014 -0.0388 -0.0299 -0.0228 -0.0017 -0.0058 -0.0014 -0.1501 -0.0131 -0.0803 -0.0145 -0.0048 -0.0138 -0.0015 -0.0114 -0.7762 -0.0117 -0.0076 -0.1131 -0.0016 -0.0023 -0.0144 -0.0091 -0.0087 -0.0144 -0.0079 -0.0064 -0.0010 -0.0090 -0.2231 -0.0032 -0.0048 -0.0144 -0.0006 -0.0009 -0.0016 -0.0021 -0.0178 -0.0016 -0.0006 -0.0005 -0.0013 -0.0016 -0.0004 -0.0014 -0.0012 -0.0011 -0.0025 -0.0016
S-627	Der Anteil der Patienten , bei denen die Nachuntersuchung keinerlei Anzeichen für Virusaktivitäten im Blut ergab , betrug bei den HBeAg @-@ positiven Patienten unter Pegasys 32 % und bei denen unter Lamivudin 22 % ; bei den HBeAg @-@ negativen Patienten waren es 43 % unter Pegasys und 29 % unter Lamivudin .
T-627	The proportions of patients with no signs of viral activity in their blood at follow- up were 32 % with Pegasys and 22 % with lamivudine in the HBeAg @-@ positive patients , and 43 % with Pegasys and 29 % with lamivudine in the HBeAg @-@ negative patients .
H-627	-0.007492115721106529	The proportions of patients with no signs of viral activity in their blood at follow- up were 32 % with Pegasys and 22 % with lamivudine in the HBeAg @-@ positive patients , and 43 % with Pegasys and 29 % with lamivudine in the HBeAg @-@ negative patients .
D-627	-0.007492115721106529	The proportions of patients with no signs of viral activity in their blood at follow- up were 32 % with Pegasys and 22 % with lamivudine in the HBeAg @-@ positive patients , and 43 % with Pegasys and 29 % with lamivudine in the HBeAg @-@ negative patients .
P-627	-0.0051 -0.0301 -0.0025 -0.0024 -0.0031 -0.0137 -0.0024 -0.0094 -0.0017 -0.0061 -0.0019 -0.0030 -0.0377 -0.0020 -0.0121 -0.0145 -0.0044 -0.0144 -0.0014 -0.0036 -0.0011 -0.0021 -0.0178 -0.0085 -0.0011 -0.0011 -0.0077 -0.0010 -0.0014 -0.0018 -0.0141 -0.0010 -0.0009 -0.0010 -0.0026 -0.0121 -0.0091 -0.0041 -0.0018 -0.0012 -0.0013 -0.0055 -0.0024 -0.0085 -0.0085 -0.1294 -0.0660 -0.0013 -0.0017 -0.0020 -0.0009 -0.0012 -0.0017 -0.0007 -0.0012 -0.0016 -0.0134 -0.0008 -0.0010 -0.0013 -0.0033 -0.0041 -0.0021 -0.0019 -0.0016 -0.0012 -0.0014 -0.0021 -0.0033 -0.0020 -0.0016 -0.0014
S-1895	Aufgrund der Möglichkeit des Absinkens der Voriconazol @-@ Konzentrationen sollte die gleichzeitige Anwendung von Voriconazol und niedrig dosiertem Ritonavir ( 100 mg zweimal täglich ) wie in Kaletra enthalten , vermieden werden , es sei denn , die Nutzen / Risiko Abwägung bei dem Patienten rechtfertigt die Anwendung von Voriconazol .
T-1895	Voriconazole : due to the potential for reduced voriconazole concentrations , co @-@ administration of voriconazole and low dose ritonavir ( 100 mg twice daily ) as contained in Kaletra should be avoided unless an assessment of the benefit / risk to patient justifies the use of voriconazole .
H-1895	-0.009045046754181385	Voriconazole : due to the potential for reduced voriconazole concentrations , co @-@ administration of voriconazole and low dose ritonavir ( 100 mg twice daily ) as contained in Kaletra should be avoided unless an assessment of the benefit / risk to patient justifies the use of voriconazole .
D-1895	-0.009045046754181385	Voriconazole : due to the potential for reduced voriconazole concentrations , co @-@ administration of voriconazole and low dose ritonavir ( 100 mg twice daily ) as contained in Kaletra should be avoided unless an assessment of the benefit / risk to patient justifies the use of voriconazole .
P-1895	-0.0150 -0.0009 -0.0005 -0.0004 -0.0144 -0.0142 -0.0014 -0.0036 -0.0151 -0.0076 -0.0142 -0.0062 -0.0008 -0.0006 -0.0004 -0.0065 -0.0003 -0.0007 -0.0046 -0.0144 -0.0014 -0.0122 -0.0715 -0.0020 -0.0008 -0.0005 -0.0004 -0.0064 -0.0017 -0.0094 -0.0023 -0.0019 -0.0034 -0.0008 -0.0045 -0.0047 -0.0008 -0.0029 -0.1002 -0.0019 -0.0077 -0.0055 -0.0016 -0.0019 -0.0012 -0.0006 -0.0024 -0.0015 -0.0010 -0.0139 -0.0145 -0.0096 -0.0015 -0.0088 -0.0110 -0.0060 -0.0013 -0.0138 -0.0144 -0.0046 -0.0012 -0.0061 -0.0034 -0.0015 -0.0018 -0.0008 -0.0005 -0.0005 -0.1414 -0.0015
S-769	Hypromellose ( E 464 ) Titandioxid ( E171 ) Macrogol 6000 Glycerol ( E 422 ) Magnesiumstearat ( E 470 B ) Eisen ( III ) -hydroxid @-@ oxid x H2O ( E 172 ) Eisen ( III ) -oxid ( E 172 )
T-769	Film @-@ coating Hypromellose ( E 464 ) Titanium dioxide ( E171 ) Macrogol 6000 Glycerol ( E 422 ) Magnesium stearate ( E 470 B ) Yellow iron oxide ( E172 ) Red iron oxide ( E172 )
H-769	-0.02160155028104782	Film @-@ coating Hypromellose ( E 464 ) Titanium dioxide ( E171 ) Macrogol 6000 Glycerol ( E 422 ) Magnesium stearate ( E 470 B ) Yellow iron oxide ( E172 ) Red iron oxide ( E172 )
D-769	-0.02160155028104782	Film @-@ coating Hypromellose ( E 464 ) Titanium dioxide ( E171 ) Macrogol 6000 Glycerol ( E 422 ) Magnesium stearate ( E 470 B ) Yellow iron oxide ( E172 ) Red iron oxide ( E172 )
P-769	-0.3520 -0.0225 -0.0144 -0.0082 -0.0136 -0.1760 -0.0009 -0.0018 -0.0007 -0.0018 -0.1853 -0.0024 -0.0014 -0.0014 -0.0025 -0.0008 -0.0012 -0.0054 -0.0006 -0.0014 -0.1230 -0.0011 -0.0013 -0.0014 -0.0011 -0.0010 -0.0012 -0.0011 -0.0005 -0.0094 -0.0009 -0.0009 -0.0500 -0.0013 -0.0458 -0.0012 -0.0011 -0.0013 -0.0011 -0.0008 -0.0008 -0.1604 -0.0008 -0.0013 -0.0012 -0.0013 -0.0372 -0.0013 -0.0011 -0.0010 -0.0013 -0.0145 -0.0081 -0.0140 -0.0223 -0.0075 -0.0162 -0.0036 -0.0023 -0.0015 -0.0522 -0.0119 -0.0051 -0.0035 -0.0204 -0.0022 -0.0024 -0.0014 -0.0537
S-1987	Daher ist bei der Behandlung von Patienten mit kongenitalem oder in der Familie aufgetretenem QT @-@ Verlängerungssyndrom , bei Patienten mit bekanntermaßen erworbener Verlängerung des QT @-@ Intervalls sowie bei Patienten , die mit einem QTc @-@ Verlängerung induzierenden Arzneimittel behandelt werden , Vorsicht geboten ( siehe auch Abschnitt 4.5 ) .
T-1987	3 when treating patients with a history of congenital or a family history of long QT syndrome , in patients with known acquired QT interval prolongation , and in patients treated with drugs affecting the QTc interval ( see section 4.5 also ) .
H-1987	-0.017251821234822273	3 when treating patients with a history of congenital or a family history of long QT syndrome , in patients with known acquired QT interval prolongation , and in patients treated with drugs affecting the QTc interval ( see section 4.5 also ) .
D-1987	-0.017251821234822273	3 when treating patients with a history of congenital or a family history of long QT syndrome , in patients with known acquired QT interval prolongation , and in patients treated with drugs affecting the QTc interval ( see section 4.5 also ) .
P-1987	-0.0149 -0.0395 -0.0137 -0.0043 -0.0476 -0.0466 -0.0143 -0.0016 -0.0506 -0.0005 -0.0004 -0.0036 -0.0143 -0.0025 -0.0015 -0.0014 -0.0208 -0.0131 -0.0147 -0.0136 -0.0009 -0.0154 -0.0143 -0.0023 -0.0049 -0.0075 -0.0053 -0.0117 -0.0017 -0.0094 -0.0005 -0.0111 -0.0026 -0.0028 -0.0084 -0.0451 -0.0084 -0.0036 -0.0066 -0.0020 -0.0145 -0.0145 -0.0132 -0.0079 -0.0107 -0.0012 -0.0145 -0.0016 -0.0060 -0.0022 -0.0133 -0.0011 -0.0015 -0.3901 -0.0033 -0.0021 -0.0014
S-454	Bei Empfängern einer Lebertransplantation , die von Anfang an Mycophenolatmofetil und Tacrolimus erhielten , wurden die AUC und die Cmax von MPA , dem aktiven Metaboliten von Mycophenolatmofetil , durch die gleichzeitige Verabreichung von Tacrolimus nicht signifikant beeinflusst .
T-454	5 Tacrolimus : in liver transplant recipients initiated on mycophenolate mofetil and tacrolimus , the AUC and C max of MPA , the active metabolite of mycophenolate mofetil , were not significantly affected by trough tacrolimus level .
H-454	-0.007572535891085863	5 Tacrolimus : in liver transplant recipients initiated on mycophenolate mofetil and tacrolimus , the AUC and C max of MPA , the active metabolite of mycophenolate mofetil , were not significantly affected by trough tacrolimus level .
D-454	-0.007572535891085863	5 Tacrolimus : in liver transplant recipients initiated on mycophenolate mofetil and tacrolimus , the AUC and C max of MPA , the active metabolite of mycophenolate mofetil , were not significantly affected by trough tacrolimus level .
P-454	-0.0145 -0.0156 -0.0035 -0.0015 -0.0017 -0.0010 -0.0142 -0.0143 -0.0116 -0.0011 -0.0316 -0.0009 -0.0011 -0.0149 -0.0069 -0.0143 -0.0047 -0.0007 -0.0011 -0.0052 -0.0007 -0.0008 -0.0010 -0.0007 -0.0024 -0.0011 -0.0012 -0.0013 -0.0007 -0.0030 -0.0077 -0.0018 -0.0025 -0.0016 -0.0695 -0.0138 -0.0038 -0.0015 -0.0013 -0.0025 -0.0028 -0.0008 -0.0016 -0.0007 -0.0010 -0.0040 -0.0007 -0.0010 -0.0013 -0.0032 -0.0015 -0.0007 -0.0010 -0.0003 -0.0019 -0.0029 -0.0014 -0.0010 -0.0086 -0.0026 -0.0302 -0.0141 -0.0008 -0.0341 -0.0011 -0.0013 -0.0009 -0.0717 -0.0555 -0.0016
S-1663	In Studien zur RA war die Häufigkeit von schwerwiegenden Infektionen , einschließlich Pneumonie , bei Patienten , die Infliximab in Kombination mit Methotrexat erhielten höher als bei Patienten , die Methotrexat allein erhielten , insbesondere bei Dosierungen von 6 mg / kg oder höher ( siehe Abschnitt 4.4 ) .
T-1663	In RA clinical studies , the incidence of serious infections including pneumonia was higher in infliximab plus methotrexate treated patients compared with methotrexate alone especially at doses of 6 mg / kg or greater ( see section 4.4 ) .
H-1663	-0.023220244795084	In RA clinical studies , the incidence of serious infections including pneumonia was higher in infliximab plus methotrexate treated patients compared with methotrexate alone especially at doses of 6 mg / kg or greater ( see section 4.4 ) .
D-1663	-0.023220244795084	In RA clinical studies , the incidence of serious infections including pneumonia was higher in infliximab plus methotrexate treated patients compared with methotrexate alone especially at doses of 6 mg / kg or greater ( see section 4.4 ) .
P-1663	-0.0030 -0.0025 -0.0015 -0.0160 -0.0174 -0.0040 -0.0069 -0.0068 -0.0009 -0.0016 -0.0069 -0.0021 -0.0007 -0.0716 -0.0012 -0.0006 -0.0007 -0.0003 -0.0031 -0.0568 -0.0150 -0.0165 -0.0003 -0.0009 -0.0011 -0.0145 -0.0004 -0.0011 -0.0014 -0.0013 -0.0011 -0.0146 -0.0064 -0.0467 -0.8552 -0.0125 -0.0011 -0.0014 -0.0015 -0.0009 -0.0122 -0.0144 -0.0075 -0.0024 -0.1121 -0.0022 -0.0037 -0.0006 -0.0015 -0.0008 -0.0020 -0.0133 -0.0017 -0.0018 -0.0110 -0.0011 -0.0013 -0.0021 -0.0015 -0.0014
S-1675	10 ml der Lösung enthalten 2,44 g Gadofosveset Trinatriumsalz in einer Durchstechflasche 15 ml der Lösung enthalten 3,66 g Gadofosveset Trinatriumsalz in einer Durchstechflasche 20 ml der Lösung enthalten 4,88 g Gadofosveset Trinatriumsalz in einer Durchstechflasche .
T-1675	20 ml solution contains 4.88 g of gadofosveset trisodium in a vial .
H-1675	-0.00821278803050518	20 ml solution contains 4.88 g of gadofosveset trisodium in a vial .
D-1675	-0.00821278803050518	20 ml solution contains 4.88 g of gadofosveset trisodium in a vial .
P-1675	-0.0164 -0.0018 -0.0145 -0.0086 -0.0114 -0.0422 -0.0012 -0.0142 -0.0079 -0.0009 -0.0027 -0.0007 -0.0008 -0.0013 -0.0143 -0.0030 -0.0017 -0.0136 -0.0035 -0.0004 -0.0006 -0.0128 -0.0145
S-143	Bei einer Exposition , die geringer war als die unter therapeutischen Dosen beim Menschen erzielte Exposition , führte die Behandlung mit Posaconazol zu Veränderungen am Skelettsystem und skelettalen Missbildungen , Dystokie , Verlängerung der Gestationszeit , einer verminderten mittleren Größe der Nachkommen und reduzierter postnataler Lebensfähigkeit .
T-143	At exposures lower than those obtained at therapeutic doses in humans , posaconazole caused skeletal variations and malformations , dystocia , increased length of gestation , reduced mean litter size and postnatal viability .
H-143	-0.011194770224392414	At exposures lower than those obtained at therapeutic doses in humans , posaconazole caused skeletal variations and malformations , dystocia , increased length of gestation , reduced mean litter size and postnatal viability .
D-143	-0.011194770224392414	At exposures lower than those obtained at therapeutic doses in humans , posaconazole caused skeletal variations and malformations , dystocia , increased length of gestation , reduced mean litter size and postnatal viability .
P-143	-0.0096 -0.0142 -0.0019 -0.0009 -0.0075 -0.0016 -0.0075 -0.0109 -0.0131 -0.0064 -0.0013 -0.0026 -0.0005 -0.0038 -0.0039 -0.0019 -0.0124 -0.0010 -0.0012 -0.0004 -0.0005 -0.0144 -0.0133 -0.0006 -0.0007 -0.1240 -0.0145 -0.0043 -0.0884 -0.0113 -0.0011 -0.0014 -0.0017 -0.0014 -0.0015 -0.0040 -0.0015 -0.0142 -0.0202 -0.0015 -0.0015 -0.0172 -0.0047 -0.0118 -0.0119 -0.0146 -0.0132 -0.0020 -0.1036 -0.0149 -0.0005 -0.0013 -0.0024 -0.0009 -0.0017 -0.0016
S-882	Spezifischere Methoden als die EKG @-@ Messung zur Evaluierung und Überwachung der Herzfunktion sind die Messung der linksventrikulären Auswurffraktion durch Echokardiographie oder vorzugsweise durch die quantitative Radionuklidventrikulographie / Herzbinnenraumszintigraphie ( MUGA ) .
T-882	More specific methods for the evaluation and monitoring of cardiac functions as compared to ECG are a measurement of left ventricular ejection fraction by echocardiography or preferably by Multigated Angiography ( MUGA ) .
H-882	-0.016154535114765167	More specific methods for the evaluation and monitoring of cardiac functions as compared to ECG are a measurement of left ventricular ejection fraction by echocardiography or preferably by Multigated Angiography ( MUGA ) .
D-882	-0.016154535114765167	More specific methods for the evaluation and monitoring of cardiac functions as compared to ECG are a measurement of left ventricular ejection fraction by echocardiography or preferably by Multigated Angiography ( MUGA ) .
P-882	-0.0049 -0.0017 -0.0024 -0.0375 -0.0116 -0.0039 -0.0011 -0.0007 -0.0019 -0.0024 -0.0013 -0.0055 -0.0005 -0.1186 -0.0147 -0.0120 -0.4164 -0.0038 -0.0012 -0.0120 -0.0145 -0.0109 -0.0264 -0.0012 -0.0015 -0.0055 -0.0004 -0.0011 -0.0012 -0.0054 -0.0015 -0.0005 -0.0018 -0.0080 -0.0013 -0.0015 -0.0003 -0.0012 -0.0009 -0.0538 -0.0076 -0.0013 -0.0079 -0.0245 -0.0145 -0.0145 -0.0145 -0.0109 -0.0050 -0.0100 -0.0068 -0.0028 -0.0015 -0.0007 -0.0015 -0.0024 -0.0015
S-1059	Nach 16 Behandlungswochen wiesen 77 % der Erwachsenen , die Ziagen zusammen mit Lamivudin und Zidovudin einnahmen , Viruslasten unter 400 Kopien / ml auf ( 67 von 87 ) , im Vergleich zu 38 % der Erwachsenen , denen nur Lamivudin und Zidovudin verabreicht wurde ( 33 von 86 ) .
T-1059	After 16 weeks of treatment , 77 % of the adults taking Ziagen with lamivudine and zidovudine had viral loads below 400 copies / ml ( 67 out of 87 ) , compared with 38 % of the adults taking lamivudine and zidovudine alone ( 33 out of 86 ) .
H-1059	-0.010124138556420803	After 16 weeks of treatment , 77 % of the adults taking Ziagen with lamivudine and zidovudine had viral loads below 400 copies / ml ( 67 out of 87 ) , compared with 38 % of the adults taking lamivudine and zidovudine alone ( 33 out of 86 ) .
D-1059	-0.010124138556420803	After 16 weeks of treatment , 77 % of the adults taking Ziagen with lamivudine and zidovudine had viral loads below 400 copies / ml ( 67 out of 87 ) , compared with 38 % of the adults taking lamivudine and zidovudine alone ( 33 out of 86 ) .
P-1059	-0.0069 -0.0020 -0.0013 -0.0026 -0.0015 -0.0041 -0.0009 -0.0017 -0.0014 -0.0123 -0.0022 -0.0101 -0.0099 -0.0012 -0.0110 -0.0095 -0.0011 -0.0009 -0.0012 -0.0046 -0.0015 -0.0029 -0.0009 -0.0010 -0.0012 -0.0070 -0.0058 -0.0035 -0.0032 -0.0353 -0.0010 -0.0012 -0.0022 -0.0025 -0.0015 -0.0004 -0.0092 -0.0014 -0.0006 -0.0016 -0.1449 -0.0032 -0.3024 -0.0010 -0.0011 -0.0015 -0.0066 -0.0012 -0.0149 -0.0118 -0.0010 -0.0010 -0.0014 -0.0059 -0.0016 -0.0014 -0.0009 -0.0010 -0.0012 -0.0071 -0.0070 -0.0014 -0.0009 -0.0018 -0.0014 -0.0006 -0.0014 -0.0014 -0.0014
S-1271	Einige Arzneimittel verringern die Wirksamkeit von Bridion → Es ist sehr wichtig , dass Sie Ihrem Anästhesisten mitteilen , wenn Sie vor kurzem • Toremifen ( zur Behandlung von Brustkrebs ) • Flucloxacillin ( ein Antibiotikum ) • Fusidinsäure ( ein Antibiotikum ) eingenommen haben .
T-1271	25 Some medicines reduce the effect of Bridion → It is especially important that you tell your anaesthetist if you have recently taken : • toremifene ( used to treat breast cancer ) . • flucloxacillin ( an antibiotic ) . • fusidic acid ( an antibiotic ) .
H-1271	-0.006654973607510328	25 Some medicines reduce the effect of Bridion → It is especially important that you tell your anaesthetist if you have recently taken : • toremifene ( used to treat breast cancer ) . • flucloxacillin ( an antibiotic ) . • fusidic acid ( an antibiotic ) .
D-1271	-0.006654973607510328	25 Some medicines reduce the effect of Bridion → It is especially important that you tell your anaesthetist if you have recently taken : • toremifene ( used to treat breast cancer ) . • flucloxacillin ( an antibiotic ) . • fusidic acid ( an antibiotic ) .
P-1271	-0.0150 -0.0144 -0.0029 -0.0045 -0.0080 -0.0026 -0.0495 -0.0015 -0.0050 -0.0008 -0.0006 -0.0028 -0.0020 -0.0568 -0.0016 -0.0174 -0.0018 -0.0052 -0.0018 -0.0014 -0.0092 -0.0006 -0.0024 -0.0023 -0.0014 -0.0050 -0.0041 -0.0038 -0.0180 -0.0048 -0.0126 -0.0002 -0.0009 -0.0133 -0.0003 -0.0016 -0.0119 -0.1027 -0.0007 -0.0013 -0.0007 -0.0015 -0.0340 -0.0009 -0.0008 -0.0014 -0.0010 -0.0010 -0.0009 -0.0012 -0.0014 -0.0042 -0.0008 -0.0006 -0.0010 -0.0015 -0.0020 -0.0028 -0.0008 -0.0009 -0.0019 -0.0011 -0.0015 -0.0026 -0.0005 -0.0007 -0.0008 -0.0017 -0.0015 -0.0015
S-533	Es könnten Symptome auftreten , die Sie selbst nicht bemerken , wie Stimmungs- oder Verhaltensveränderungen , Gedächtnislücken , Sprech- oder Kommunikationsschwierigkeiten , die Ihr Arzt möglicherweise näher überprüfen muss , um eine PML auszuschließen . • Zeigen Sie den Patientenpass und diese Packungsbeilage jedem Arzt , der Sie behandelt , nicht nur Ihrem Neurologen .
T-533	They might see new symptoms that you might not notice such as changes in mood or behaviour , memory lapses , speech and communication difficulties , which your doctor may need to investigate further to rule out PML . • Show the Alert Card and this package leaflet to any doctor involved with your treatment , not only to your neurologist .
H-533	-0.00993443839251995	They might see new symptoms that you might not notice such as changes in mood or behaviour , memory lapses , speech and communication difficulties , which your doctor may need to investigate further to rule out PML . • Show the Alert Card and this package leaflet to any doctor involved with your treatment , not only to your neurologist .
D-533	-0.00993443839251995	They might see new symptoms that you might not notice such as changes in mood or behaviour , memory lapses , speech and communication difficulties , which your doctor may need to investigate further to rule out PML . • Show the Alert Card and this package leaflet to any doctor involved with your treatment , not only to your neurologist .
P-533	-0.0145 -0.0124 -0.0146 -0.0147 -0.0018 -0.0075 -0.0031 -0.0138 -0.0021 -0.0073 -0.0144 -0.0015 -0.0091 -0.0492 -0.0016 -0.1081 -0.0087 -0.0017 -0.0031 -0.0131 -0.0013 -0.0019 -0.0109 -0.0139 -0.0012 -0.0050 -0.0079 -0.0049 -0.0033 -0.0033 -0.0981 -0.0044 -0.0017 -0.0140 -0.0057 -0.0071 -0.0039 -0.0017 -0.0010 -0.0013 -0.0017 -0.0025 -0.0082 -0.0104 -0.0145 -0.0143 -0.0129 -0.0027 -0.0081 -0.0120 -0.0118 -0.0005 -0.0007 -0.0020 -0.0068 -0.0076 -0.0145 -0.0124 -0.0079 -0.0055 -0.0025 -0.0018 -0.0130 -0.0137 -0.0072 -0.0009 -0.0005 -0.0009 -0.0018 -0.0016
S-1371	Probleme beim Gehen , Taubheitsgefühl im Gesicht , an Armen und Beinen , Sehprobleme , Müdigkeit , Gleichgewichtsstörungen oder Benommenheit , Probleme mit Blase und Darm , Denk- und Konzentrationsstörungen , Depressionen , akute oder chronische Schmerzen , Sexualstörungen , Steifigkeit und Verkrampfung der Muskeln .
T-1371	Symptoms can include ; walking problems , numbness in the face , arms or legs , problems seeing things , tiredness , feeling off @-@ balance or light headed , bladder and bowel problems , difficulty in thinking and concentrating , depression , acute or chronic pain , sexual problems , and stiffness and muscle spasms .
H-1371	-0.022559700533747673	Symptoms can include ; walking problems , numbness in the face , arms or legs , problems seeing things , tiredness , feeling off @-@ balance or light headed , bladder and bowel problems , difficulty in thinking and concentrating , depression , acute or chronic pain , sexual problems , and stiffness and muscle spasms .
D-1371	-0.022559700533747673	Symptoms can include ; walking problems , numbness in the face , arms or legs , problems seeing things , tiredness , feeling off @-@ balance or light headed , bladder and bowel problems , difficulty in thinking and concentrating , depression , acute or chronic pain , sexual problems , and stiffness and muscle spasms .
P-1371	-0.0145 -0.0003 -0.0157 -0.0014 -0.0215 -0.0149 -0.0088 -0.0077 -0.0004 -0.0006 -0.0010 -0.0149 -0.0039 -0.0013 -0.0018 -0.0015 -0.8181 -0.0008 -0.0064 -0.0130 -0.0144 -0.0145 -0.0039 -0.0093 -0.0006 -0.0013 -0.0020 -0.0145 -0.0145 -0.0144 -0.0004 -0.0216 -0.0137 -0.0145 -0.0033 -0.0112 -0.0003 -0.0040 -0.0114 -0.0002 -0.0026 -0.2204 -0.0128 -0.0112 -0.0041 -0.0767 -0.0059 -0.0012 -0.0020 -0.0021 -0.0015 -0.0016 -0.0007 -0.0033 -0.0006 -0.0044 -0.0016 -0.0072 -0.0121 -0.0019 -0.0365 -0.0415 -0.0006 -0.0013 -0.0034 -0.0061 -0.0121 -0.0041 -0.0009 -0.0018 -0.0014
S-866	Die wichtigsten Nebenwirkungen von INVANZ ( die bei 1 bis 10 von 100 Patienten zu beobachten waren ) sind Kopfschmerzen , Diarrhöe ( Durchfall ) , Nausea ( Übelkeit ) , Erbrechen , Hautausschlag ( einschließlich Windelausschlag bei Kindern ) , Juckreiz , Probleme an der Injektionsstelle ( einschließlich Schmerzen ) .
T-866	The main side effects of INVANZ ( seen in 1 to 10 patients in 100 ) are headache , diarrhoea , nausea ( feeling sick ) , vomiting , rash ( including nappy rash in children ) , itching , problems at the site where the medicine was injected ( including pain ) .
H-866	-0.039522502571344376	The main side effects of INVANZ ( seen in 1 to 10 patients in 100 ) are headache , diarrhoea , nausea ( feeling sick ) , vomiting , rash ( including nappy rash in children ) , itching , problems at the site where the medicine was injected ( including pain ) .
D-866	-0.039522502571344376	The main side effects of INVANZ ( seen in 1 to 10 patients in 100 ) are headache , diarrhoea , nausea ( feeling sick ) , vomiting , rash ( including nappy rash in children ) , itching , problems at the site where the medicine was injected ( including pain ) .
P-866	-0.0049 -0.0350 -0.0124 -0.0023 -0.0912 -0.0016 -0.0013 -0.0007 -0.0145 -0.0019 -0.0121 -0.0016 -0.6831 -0.0164 -0.0014 -0.0134 -0.0139 -0.0036 -0.0070 -0.0093 -0.0012 -0.0005 -0.0042 -0.0018 -0.0013 -0.0002 -0.0100 -0.0008 -0.3097 -0.0001 -0.0001 -0.8410 -0.0397 -0.0170 -0.0017 -0.0534 -0.2625 -0.0003 -0.0012 -0.0015 -0.0179 -0.0021 -0.0016 -0.0135 -0.0126 -0.0017 -0.0005 -0.0017 -0.0036 -0.0073 -0.0014 -0.0015 -0.0559 -0.0025 -0.0535 -0.0121 -0.0032 -0.0032 -0.0445 -0.0414 -0.0036 -0.0145 -0.0088 -0.0088 -0.0021 -0.0022 -0.0019 -0.0016 -0.0015 -0.0021 -0.0014
S-531	Poloxamer 188 , Sucrose , Methionin , Natriumdihydrogenphosphat @-@ 1H2O , Natriummonohydrogenphosphat @-@ Dihydrat , m @-@ Cresol , Phosphorsäure 85 % , Natriumhydroxid und Wasser für Injektionszwecke
T-531	Poloxamer 188 , sucrose , methionine , sodium dihydrogen phosphate monohydrate , disodium phosphate dihydrate , m @-@ cresol , concentrated phosphoric acid , sodium hydroxide and water for injections .
H-531	-0.027317745611071587	Poloxamer 188 , sucrose , methionine , sodium dihydrogen phosphate monohydrate , disodium phosphate dihydrate , m @-@ cresol , concentrated phosphoric acid , sodium hydroxide and water for injections .
D-531	-0.027317745611071587	Poloxamer 188 , sucrose , methionine , sodium dihydrogen phosphate monohydrate , disodium phosphate dihydrate , m @-@ cresol , concentrated phosphoric acid , sodium hydroxide and water for injections .
P-531	-0.0036 -0.0009 -0.0010 -0.0019 -0.0011 -0.0012 -0.0016 -0.0042 -0.2325 -0.0005 -0.0015 -0.0031 -0.0004 -0.0012 -0.3714 -0.0015 -0.0019 -0.0007 -0.0012 -0.0011 -0.0023 -0.0018 -0.0027 -0.0009 -0.1324 -0.0023 -0.0017 -0.0133 -0.0009 -0.0165 -0.0143 -0.3697 -0.0012 -0.0144 -0.1077 -0.0010 -0.0237 -0.1863 -0.0013 -0.0020 -0.0055 -0.0976 -0.0012 -0.0006 -0.0062 -0.0016 -0.0148 -0.0015 -0.0033 -0.0007 -0.0025 -0.0010 -0.0015 -0.0134 -0.0039 -0.0005 -0.0035 -0.0006 -0.0011 -0.0133 -0.0059 -0.0032 -0.0020 -0.0138 -0.0735 -0.0015
S-1306	Orale Dreifach @-@ Kombinationstherapie Die Anwendung von Rosiglitazon in der oralen Dreifach @-@ Kombinationstherapie zusammen mit Metformin und Sulfonylharnstoffen kann mit einem erhöhten Risiko einer Flüssigkeitsretention und einer Herzinsuffizienz sowie einer Hypoglykämie verbunden sein ( siehe Abschnitt 4.8 ) .
T-1306	Triple oral therapy The use of rosiglitazone in triple oral therapy , in combination with metformin and a sulphonylurea , may be associated with increased risks for fluid retention and heart failure , as well as hypoglycaemia ( see section 4.8 ) .
H-1306	-0.01699855923652649	Triple oral therapy The use of rosiglitazone in triple oral therapy , in combination with metformin and a sulphonylurea , may be associated with increased risks for fluid retention and heart failure , as well as hypoglycaemia ( see section 4.8 ) .
D-1306	-0.01699855923652649	Triple oral therapy The use of rosiglitazone in triple oral therapy , in combination with metformin and a sulphonylurea , may be associated with increased risks for fluid retention and heart failure , as well as hypoglycaemia ( see section 4.8 ) .
P-1306	-0.0142 -0.0079 -0.0104 -0.0086 -0.0036 -0.0015 -0.0042 -0.0003 -0.0010 -0.0009 -0.0016 -0.0053 -0.0109 -0.0012 -0.0035 -0.0138 -0.0145 -0.0062 -0.0013 -0.0015 -0.0002 -0.0015 -0.0016 -0.0465 -0.0106 -0.0135 -0.0020 -0.0025 -0.0038 -0.0014 -0.0339 -0.0070 -0.0078 -0.0045 -0.0016 -0.0014 -0.0141 -0.0121 -0.5148 -0.0027 -0.0007 -0.0006 -0.0003 -0.0719 -0.0071 -0.0007 -0.1481 -0.0077 -0.0111 -0.0014 -0.0013 -0.0010 -0.0006 -0.0133 -0.0029 -0.0013 -0.0017 -0.0021 -0.0109 -0.0011 -0.0014 -0.0018 -0.0015 -0.0014
S-1647	Jede Packung KOGENATE Bayer 2000 I.E. enthält eine Durchstechflasche und eine Fertigspritze mit separat beigefügten Spritzenstempel , sowie einem Adapter für die Durchstechflasche , ein Venenpunktionsbesteck , zwei Alkoholtupfer , zwei Trockentupfer und zwei Pflaster .
T-1647	Each pack of KOGENATE Bayer 2000 IU contains a vial and a pre @-@ filled syringe with a separate plunger rod , as well as a vial adapter , a venipuncture set , two alcohol swabs , two dry swabs and two plasters .
H-1647	-0.016885284334421158	Each pack of KOGENATE Bayer 2000 IU contains a vial and a pre @-@ filled syringe with a separate plunger rod , as well as a vial adapter , a venipuncture set , two alcohol swabs , two dry swabs and two plasters .
D-1647	-0.016885284334421158	Each pack of KOGENATE Bayer 2000 IU contains a vial and a pre @-@ filled syringe with a separate plunger rod , as well as a vial adapter , a venipuncture set , two alcohol swabs , two dry swabs and two plasters .
P-1647	-0.0029 -0.0140 -0.0033 -0.0031 -0.0012 -0.0013 -0.0008 -0.0004 -0.0010 -0.0003 -0.0012 -0.0020 -0.0145 -0.0049 -0.0110 -0.0044 -0.0009 -0.0052 -0.0053 -0.0051 -0.0014 -0.0055 -0.0011 -0.0002 -0.0003 -0.0038 -0.0120 -0.0066 -0.0145 -0.0042 -0.0165 -0.0094 -0.0122 -0.0069 -0.0014 -0.0225 -0.0084 -0.0009 -0.0014 -0.4255 -0.0016 -0.0088 -0.0015 -0.0144 -0.0008 -0.0023 -0.0077 -0.0016 -0.0027 -0.0107 -0.0087 -0.0003 -0.0015 -0.0013 -0.0028 -0.0033 -0.0003 -0.1570 -0.0032 -0.0103 -0.0031 -0.1809 -0.0015
S-1261	Verlaufsstudien zeigten ebenfalls , dass bei Patienten , bei denen im ersten Jahr nach der Transplantation eine akute Abstoßungsreaktion auftrat , während der 5 @-@ Jahres @-@ Follow- up @-@ Periode mehr Transplantatverluste und Todesfälle vorkamen , als bei Patienten , bei denen keine Abstoßungsreaktion auftrat .
T-1261	Extension studies also showed that patients who experienced an acute rejection episode during the first year after transplantation experienced more graft losses and deaths over the five @-@ year follow @-@ up period than patients who had no rejection .
H-1261	-0.006675217766314745	Extension studies also showed that patients who experienced an acute rejection episode during the first year after transplantation experienced more graft losses and deaths over the five @-@ year follow @-@ up period than patients who had no rejection .
D-1261	-0.006675217766314745	Extension studies also showed that patients who experienced an acute rejection episode during the first year after transplantation experienced more graft losses and deaths over the five @-@ year follow @-@ up period than patients who had no rejection .
P-1261	-0.0145 -0.0143 -0.0031 -0.0080 -0.0056 -0.0017 -0.0062 -0.0061 -0.0080 -0.0088 -0.0012 -0.0005 -0.0019 -0.0006 -0.0146 -0.0129 -0.0021 -0.0022 -0.0015 -0.0139 -0.0043 -0.0030 -0.0087 -0.0049 -0.0104 -0.0006 -0.0105 -0.0016 -0.0072 -0.0340 -0.0020 -0.0110 -0.0114 -0.0035 -0.0012 -0.0022 -0.0012 -0.0022 -0.0198 -0.0080 -0.0041 -0.0126 -0.0052 -0.0011 -0.0003 -0.0135 -0.0016
S-1333	Sprechen Sie bitte mit Ihrem Arzt darüber . - Es ist nicht bekannt , ob MIRCERA bei Patienten mit Hämoglobinbildungsstörungen ( Hämoglobinopathien ) , gegenwärtigen Blutungen oder Blutungen in der Vorgeschichte , Anfallserkrankungen oder mit einer hohen Anzahl von Blutplättchen eine andersartige Wirkung entfaltet .
T-1333	( disorders associated with abnormal haemoglobin ) , past or present bleeding , seizures or with a high blood platelet count .
H-1333	-0.01084873080253601	( disorders associated with abnormal haemoglobin ) , past or present bleeding , seizures or with a high blood platelet count .
D-1333	-0.01084873080253601	( disorders associated with abnormal haemoglobin ) , past or present bleeding , seizures or with a high blood platelet count .
P-1333	-0.0145 -0.0145 -0.0011 -0.0146 -0.0015 -0.0145 -0.0017 -0.0120 -0.0003 -0.0005 -0.0038 -0.0145 -0.0127 -0.0142 -0.0799 -0.0008 -0.0299 -0.0016 -0.0051 -0.0023 -0.0074 -0.0015 -0.0338 -0.0121 -0.0070 -0.0022 -0.0143 -0.0023 -0.0004 -0.0110 -0.0005 -0.0112 -0.0145
S-362	Im Vergleich mit einem Diuretikum ( Hydrochlorothiazid - HCTZ ) senkte 300 mg Enviage nach einer 12 @-@ wöchigen Behandlung den systolischen / diastolischen Blutdruck um 17,0 / 12,3 mmHg gegenüber 14,4 / 10,5 mmHg unter 25 mg HCTZ .
T-362	Compared to a diuretic ( hydrochlorothiazide - HCTZ ) , Enviage 300 mg lowered systolic / diastolic blood pressure by 17.0 / 12.3 mmHg , compared to 14.4 / 10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment .
H-362	-0.023182585835456848	Compared to a diuretic ( hydrochlorothiazide - HCTZ ) , Enviage 300 mg lowered systolic / diastolic blood pressure by 17.0 / 12.3 mmHg , compared to 14.4 / 10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment .
D-362	-0.023182585835456848	Compared to a diuretic ( hydrochlorothiazide - HCTZ ) , Enviage 300 mg lowered systolic / diastolic blood pressure by 17.0 / 12.3 mmHg , compared to 14.4 / 10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment .
P-362	-0.0103 -0.0010 -0.9053 -0.0049 -0.0022 -0.0004 -0.0009 -0.0025 -0.0020 -0.0011 -0.0005 -0.0013 -0.0006 -0.0016 -0.0001 -0.0009 -0.0045 -0.0015 -0.0015 -0.0021 -0.0008 -0.0014 -0.0058 -0.0140 -0.0008 -0.0014 -0.0034 -0.0007 -0.0103 -0.0011 -0.0030 -0.0012 -0.0005 -0.0019 -0.0009 -0.0005 -0.0006 -0.0010 -0.0021 -0.0010 -0.0038 -0.0030 -0.0015 -0.0015 -0.0013 -0.0016 -0.0010 -0.0012 -0.0011 -0.0151 -0.0057 -0.5990 -0.0011 -0.0013 -0.0014 -0.0019 -0.0014 -0.0008 -0.0013 -0.0012 -0.0144 -0.0126 -0.0014 -0.0024 -0.0006 -0.0143 -0.0009 -0.0089 -0.0029 -0.0020 -0.0050 -0.0035 -0.0015 -0.0014
S-833	Die klinischen Wirkungen bzw. die Pharmakokinetik von Cetirizin bei Kindern mit Niereninsuffizienz wurden bislang nicht untersucht , der Inhaber der Genehmigung für das Inverkehrbringen räumte aber ein , dass die derzeitige Formulierung nicht gänzlich korrekt ist , weil das Alter des Patienten die Clearance bestimmt und daher von Bedeutung ist .
T-833	For children with renal impairment , the clinical effects or the pharmacokinetics of cetirizine have never been tested but the MAH agreed that the current wording is not entirely correct since the age of the patient is important as it determines its clearance .
H-833	-0.01889757253229618	For children with renal impairment , the clinical effects or the pharmacokinetics of cetirizine have never been tested but the MAH agreed that the current wording is not entirely correct since the age of the patient is important as it determines its clearance .
D-833	-0.01889757253229618	For children with renal impairment , the clinical effects or the pharmacokinetics of cetirizine have never been tested but the MAH agreed that the current wording is not entirely correct since the age of the patient is important as it determines its clearance .
P-833	-0.0152 -0.0105 -0.0022 -0.0052 -0.0010 -0.4374 -0.0007 -0.0008 -0.0014 -0.0057 -0.0064 -0.0020 -0.0044 -0.0131 -0.0150 -0.0006 -0.0006 -0.0007 -0.0014 -0.0016 -0.0010 -0.0014 -0.0008 -0.0075 -0.0035 -0.0049 -0.1845 -0.0060 -0.1471 -0.0136 -0.0024 -0.0157 -0.0143 -0.0145 -0.0026 -0.0032 -0.0042 -0.0145 -0.0010 -0.0044 -0.0028 -0.0083 -0.0045 -0.0578 -0.0032 -0.0053 -0.0023 -0.0018 -0.0020 -0.0142 -0.0142 -0.0129 -0.0057 -0.0032 -0.0012 -0.0144 -0.0013 -0.0013 -0.0031 -0.0014
S-244	Ribavirin Teva ist in Kombination mit Interferon alfa @-@ 2b indiziert zur Behandlung von erwachsenen Patienten mit chronischer Hepatitis C , die zunächst auf eine Interferon alfa- Monotherapie angesprochen haben ( mit Normalisierung der ALT @-@ Werte am Ende der Behandlung ) , jedoch später einen Rückfall erlitten haben .
T-244	Additionally , Ribavirin Teva is indicated , in combination with peginterferon alfa @-@ 2b , for the treatment of adult patients with chronic hepatitis C who have failed previous treatment with interferon alpha
H-244	-0.04357319697737694	Additionally , Ribavirin Teva is indicated , in combination with interferon alfa @-@ 2b , for the treatment of adult patients with chronic hepatitis C who have failed previous treatment with interferon alpha
D-244	-0.04357319697737694	Additionally , Ribavirin Teva is indicated , in combination with interferon alfa @-@ 2b , for the treatment of adult patients with chronic hepatitis C who have failed previous treatment with interferon alpha
P-244	-0.0182 -0.0005 -0.0027 -0.0114 -0.0007 -0.0005 -0.0012 -0.0013 -0.0008 -0.0410 -0.0007 -0.0162 -0.0055 -0.0008 -0.0015 -1.3840 -0.0006 -0.0014 -0.0014 -0.0005 -0.0014 -0.0012 -0.0010 -0.0017 -0.0398 -0.0044 -0.0018 -0.0015 -0.0030 -0.0020 -0.0852 -0.0019 -0.0009 -0.0004 -0.0006 -0.0014 -0.0267 -0.0105 -0.0148 -0.0145 -0.0130 -0.0124 -0.0061 -0.0007 -0.0013 -0.0018 -0.3768 -0.0014 -0.0159
S-1543	Diese Blutbildveränderungen traten vermehrt bei hohen Dosierungen ( 1200- 1500 mg / Tag ) auf sowie bei Patienten im fortgeschrittenen Stadium der Erkrankung ( besonders , wenn die Knochenmarkreserve vor Behandlungsbeginn vermindert war ) und insbesondere bei CD4- Zellwerten von unter 100 / mm ³ ( siehe Abschnitt 4.4 ) .
T-1543	These occurred more frequently at higher dosages ( 1200 @-@ 1500 mg / day ) and in patients with advanced HIV disease ( especially when there is poor bone marrow reserve prior to treatment ) , and particularly in patients with CD4 cell counts less than 100 / mm3 ( see section 4.4 ) .
H-1543	-0.020187903195619583	These occurred more frequently at higher dosages ( 1200 @-@ 1500 mg / day ) and in patients with advanced HIV disease ( especially when there is poor bone marrow reserve prior to treatment ) , and particularly in patients with CD4 cell counts less than 100 / mm3 ( see section 4.4 ) .
D-1543	-0.020187903195619583	These occurred more frequently at higher dosages ( 1200 @-@ 1500 mg / day ) and in patients with advanced HIV disease ( especially when there is poor bone marrow reserve prior to treatment ) , and particularly in patients with CD4 cell counts less than 100 / mm3 ( see section 4.4 ) .
P-1543	-0.0059 -0.0145 -0.0120 -0.0082 -0.0106 -0.0148 -0.0017 -0.5458 -0.1532 -0.0020 -0.0007 -0.0669 -0.0014 -0.0005 -0.0016 -0.0024 -0.0014 -0.0427 -0.0034 -0.0041 -0.0120 -0.0037 -0.0145 -0.0135 -0.0047 -0.0104 -0.0116 -0.0142 -0.0191 -0.0145 -0.0013 -0.0007 -0.0002 -0.0043 -0.0074 -0.0014 -0.0097 -0.0047 -0.0358 -0.0046 -0.0127 -0.0099 -0.0132 -0.0025 -0.0031 -0.0013 -0.0038 -0.0140 -0.0668 -0.0015 -0.0011 -0.0016 -0.0126 -0.0041 -0.0018 -0.0019 -0.0103 -0.0012 -0.0013 -0.0020 -0.0015 -0.0014
S-1604	In den meisten klinischen Studien wurden im Vergleich zu Plazebo eine Reduktion der Gesamtplasma @-@ Triglyzeride und der freien Fettsäuren und ein Anstieg der HDL @-@ Cholesterinspiegel sowie geringfügig , jedoch klinisch nicht signifikant erhöhte LDL @-@ Cholesterinspiegel beobachtet .
T-1604	In most clinical trials , reduced total plasma triglycerides and free fatty acids , and increased HDL- cholesterol levels were observed as compared to placebo , with small , but not clinically significant increases in LDL @-@ cholesterol levels .
H-1604	-0.040530577301979065	In most clinical trials , reduced total plasma triglycerides and free fatty acids , and increased HDL- cholesterol levels were observed as compared with placebo , with small , but not clinically significant increases in LDL @-@ cholesterol levels .
D-1604	-0.040530577301979065	In most clinical trials , reduced total plasma triglycerides and free fatty acids , and increased HDL- cholesterol levels were observed as compared with placebo , with small , but not clinically significant increases in LDL @-@ cholesterol levels .
P-1604	-0.0089 -0.0039 -0.0017 -0.8796 -0.0060 -0.0145 -0.0070 -0.0024 -0.0008 -0.0008 -0.0006 -0.0006 -0.0018 -0.0002 -0.0598 -0.0524 -0.0020 -0.0020 -0.0009 -0.0008 -0.0011 -0.0128 -0.0668 -0.0464 -0.0049 -0.0827 -0.0098 -0.0081 -0.0007 -0.0005 -0.0056 -0.0180 -0.0491 -0.0165 -0.0543 -0.8985 -0.0013 -0.0012 -0.0007 -0.0012 -0.0050 -0.0149 -0.0136 -0.0116 -0.0045 -0.0076 -0.0016 -0.0009 -0.0009 -0.0113 -0.0038 -0.0018 -0.0067 -0.0066 -0.0044 -0.0006 -0.0004 -0.0053 -0.0016 -0.0014
S-1973	Die gleichzeitige Einnahme zusammen mit einer fett- und eiweißreichen Mahlzeit , die Milchprodukte beinhaltete , reduzierte die Bioverfügbarkeit ( Fläche unter der Kurve = AUC ) des in ORACEA enthaltenen Doxycyclins um etwa 20 % und die Spitzenplasmaspiegel um 43 % .
T-1973	Coadministration with a high @-@ fat , high @-@ protein meal that included dairy products reduced the bioavailability ( AUC ) of doxycycline from ORACEA by about 20 % and reduced the peak plasma level by 43 % .
H-1973	-0.0071572717279195786	Coadministration with a high @-@ fat , high @-@ protein meal that included dairy products reduced the bioavailability ( AUC ) of doxycycline from ORACEA by about 20 % and reduced the peak plasma level by 43 % .
D-1973	-0.0071572717279195786	Coadministration with a high @-@ fat , high @-@ protein meal that included dairy products reduced the bioavailability ( AUC ) of doxycycline from ORACEA by about 20 % and reduced the peak plasma level by 43 % .
P-1973	-0.0143 -0.0145 -0.0224 -0.0027 -0.0075 -0.0087 -0.0010 -0.0089 -0.0025 -0.0019 -0.0004 -0.0032 -0.0131 -0.0082 -0.0022 -0.0004 -0.0121 -0.0047 -0.0064 -0.0019 -0.0014 -0.0043 -0.0145 -0.0010 -0.0101 -0.0018 -0.0141 -0.0008 -0.0018 -0.0009 -0.0094 -0.0027 -0.0144 -0.0011 -0.0007 -0.0004 -0.0020 -0.0310 -0.0011 -0.0019 -0.0433 -0.0192 -0.0263 -0.0039 -0.0021 -0.0005 -0.0005 -0.0229 -0.0019 -0.0016 -0.0013 -0.0016 -0.0016
S-774	Neoclarityn 2,5 mg Tabletten wurden nicht an pädiatrischen Patienten untersucht , in Verbindung mit den Dosisfindungsstudien bei Kindern unterstützen jedoch die pharmakokinetischen Daten für Neoclarityn Schmelztabletten die Verwendung der 2,5 mg Dosierung bei Kindern von 6 bis 11 Jahren .
T-774	Neoclarityn 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics , the pharmacokinetics data for Neoclarityn orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age .
H-774	-0.03778725489974022	Neoclarityn 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics , the pharmacokinetic data for Neoclarityn orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age .
D-774	-0.03778725489974022	Neoclarityn 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics , the pharmacokinetic data for Neoclarityn orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age .
P-774	-0.0015 -0.0012 -0.0006 -0.0015 -0.0010 -0.0011 -0.0036 -0.0006 -0.0036 -0.0017 -0.0319 -0.0015 -0.0012 -0.1434 -0.0013 -0.0060 -0.0138 -0.0005 -0.0005 -0.0015 -0.0017 -0.1434 -0.0127 -0.0107 -0.0005 -0.0015 -0.0065 -0.0071 -0.0095 -0.0029 -0.0039 -0.0652 -0.0009 -0.0006 -0.8797 -0.0060 -0.0095 -0.0015 -0.0005 -0.0004 -0.5766 -0.0017 -0.0032 -0.0023 -0.0012 -0.0006 -0.0013 -0.0013 -0.0011 -0.0145 -0.0142 -0.0145 -0.0083 -0.0144 -0.0012 -0.0015 -0.0113 -0.0039 -0.0021 -0.0015 -0.0047 -0.0013 -0.0005 -0.0115 -0.0028 -0.0160 -0.0004 -0.0003 -0.3395 -0.0124 -0.0170 -0.0649 -0.0012 -0.0015 -0.4100 -0.0013 -0.0015 -0.0014
S-1505	Kopfschmerzen2 Schwindel , Parästhesie , Geschmacksstörungen , Hypästhesie Migräne , Schläfrigkeit , Synkope , periphere Neuropathie , Gedächtnisschwäche , Ischiasbeschwerden , &quot; Restless Leg Syndrom &quot; , Tremor , Hirnblutung
T-1505	Headache2 Dizziness , paraesthesia , taste disturbance , hypoaesthesia Migraine , somnolence , syncope , peripheral neuropathy , memory impairment , sciatica , restless leg syndrome , tremor , cerebral haemorrhage
H-1505	-0.003518593031913042	Headache2 Dizziness , paraesthesia , taste disturbance , hypoaesthesia Migraine , somnolence , syncope , peripheral neuropathy , memory impairment , sciatica , restless leg syndrome , tremor , cerebral haemorrhage
D-1505	-0.003518593031913042	Headache2 Dizziness , paraesthesia , taste disturbance , hypoaesthesia Migraine , somnolence , syncope , peripheral neuropathy , memory impairment , sciatica , restless leg syndrome , tremor , cerebral haemorrhage
P-1505	-0.0052 -0.0004 -0.0001 -0.0145 -0.0013 -0.0037 -0.0004 -0.0016 -0.0015 -0.0145 -0.0016 -0.0007 -0.0004 -0.0015 -0.0099 -0.0129 -0.0139 -0.0023 -0.0014 -0.0145 -0.0115 -0.0016 -0.0006 -0.0069 -0.0012 -0.0180 -0.0022 -0.0143 -0.0049 -0.0000 -0.0016 -0.0015 -0.0020 -0.0006 -0.0015 -0.0007 -0.0008 -0.0014 -0.0004 -0.0006 -0.0006 -0.0014 -0.0057 -0.0112 -0.0009 -0.0007 -0.0018 -0.0014 -0.0005 -0.0053 -0.0004 -0.0038 -0.0043 -0.0012 -0.0007 -0.0019 -0.0007 -0.0015 -0.0004 -0.0006 -0.0023 -0.0017 -0.0072 -0.0002 -0.0008 -0.0093 -0.0009 -0.0003 -0.0022 -0.0018
S-196	EU / 1 / 08 / 458 / 001 EU / 1 / 08 / 458 / 002 EU / 1 / 08 / 458 / 003 EU / 1 / 08 / 458 / 004 EU / 1 / 08 / 458 / 005 EU / 1 / 08 / 458 / 006 EU / 1 / 08 / 458 / 007 EU / 1 / 08 / 458 / 008 EU / 1 / 08 / 458 / 009 EU / 1 / 08 / 458 / 010 EU / 1 / 08 / 458 / 011 EU / 1 / 08 / 458 / 012 EU / 1 / 08 / 458 / 013 EU / 1 / 08 / 458 / 014
T-196	17 EU / 1 / 08 / 458 / 008 EU / 1 / 08 / 458 / 009 EU / 1 / 08 / 458 / 010 EU / 1 / 08 / 458 / 011 EU / 1 / 08 / 458 / 012 EU / 1 / 08 / 458 / 013 EU / 1 / 08 / 458 / 014
H-196	-0.011142873205244541	EU / 1 / 08 / 458 / 001 EU / 1 / 08 / 458 / 002 EU / 1 / 08 / 458 / 003 EU / 1 / 08 / 458 / 004 EU / 1 / 08 / 458 / 005 EU / 1 / 08 / 458 / 006 EU / 1 / 08 / 458 / 007 EU / 1 / 08 / 458 / 008 EU / 1 / 08 / 458 / 009 EU / 1 / 08 / 458 / 010 EU / 1 / 08 / 458 / 011 EU / 1 / 08 / 458 / 012 EU / 1 / 08 / 458 / 013 EU / 1 / 08 / 458 / 014
D-196	-0.011142873205244541	EU / 1 / 08 / 458 / 001 EU / 1 / 08 / 458 / 002 EU / 1 / 08 / 458 / 003 EU / 1 / 08 / 458 / 004 EU / 1 / 08 / 458 / 005 EU / 1 / 08 / 458 / 006 EU / 1 / 08 / 458 / 007 EU / 1 / 08 / 458 / 008 EU / 1 / 08 / 458 / 009 EU / 1 / 08 / 458 / 010 EU / 1 / 08 / 458 / 011 EU / 1 / 08 / 458 / 012 EU / 1 / 08 / 458 / 013 EU / 1 / 08 / 458 / 014
P-196	-0.8652 -0.0015 -0.0013 -0.0015 -0.0012 -0.0014 -0.0011 -0.0007 -0.0015 -0.0014 -0.3047 -0.3306 -0.0016 -0.0014 -0.0015 -0.0012 -0.0014 -0.0011 -0.0008 -0.0014 -0.0012 -0.0016 -0.0012 -0.0016 -0.0014 -0.0015 -0.0011 -0.0014 -0.0011 -0.0008 -0.0014 -0.0012 -0.0023 -0.0012 -0.0016 -0.0014 -0.0015 -0.0010 -0.0014 -0.0010 -0.0007 -0.0014 -0.0011 -0.0024 -0.0012 -0.0016 -0.0014 -0.0015 -0.0010 -0.0014 -0.0011 -0.0007 -0.0014 -0.0011 -0.0016 -0.0012 -0.0015 -0.0014 -0.0015 -0.0010 -0.0014 -0.0010 -0.0008 -0.0014 -0.0012 -0.0015 -0.0012 -0.0015 -0.0013 -0.0015 -0.0010 -0.0014 -0.0010 -0.0007 -0.0014 -0.0013 -0.0015 -0.0012 -0.0015 -0.0013 -0.0015 -0.0009 -0.0014 -0.0011 -0.0007 -0.0014 -0.0013 -0.0015 -0.0013 -0.0015 -0.0014 -0.0015 -0.0009 -0.0014 -0.0011 -0.0008 -0.0015 -0.0013 -0.0014 -0.0013 -0.0015 -0.0014 -0.0015 -0.0009 -0.0014 -0.0011 -0.0009 -0.0015 -0.0021 -0.0013 -0.0014 -0.0015 -0.0014 -0.0015 -0.0009 -0.0014 -0.0011 -0.0009 -0.0015 -0.0018 -0.0011 -0.0015 -0.0015 -0.0014 -0.0015 -0.0009 -0.0015 -0.0010 -0.0007 -0.0014 -0.0016 -0.0012 -0.0017 -0.0015 -0.0014 -0.0015 -0.0009 -0.0014 -0.0011 -0.0008 -0.0015 -0.0018 -0.0291 -0.0018 -0.0015 -0.0014 -0.0015 -0.0009 -0.0015 -0.0010 -0.0007 -0.0015 -0.0018 -0.0010 -0.0014
S-1040	EU / 1 / 96 / 022 / 002 ZYPREXA - 2,5 mg - überzogene Tabletten - 28 Tabletten in einer Packung EU / 1 / 96 / 022 / 019 ZYPREXA - 2,5 mg - überzogene Tabletten - 56 Tabletten in einer Packung EU / 1 / 96 / 022 / 023 - ZYPREXA - 2,5 mg - überzogene Tabletten - 35 Tabletten in einer Packung EU / 1 / 96 / 022 / 029 - ZYPREXA - 2,5 mg - überzogene Tabletten - 70 Tabletten in einer Packung
T-1040	EU / 1 / 96 / 022 / 029 - ZYPREXA - 2.5 mg - coated tablets - 70 tablets , per box .
H-1040	-0.03328651562333107	EU / 1 / 96 / 022 / 002 - ZYPREXA - 2.5 mg - coated tablets - 70 tablets , per box .
D-1040	-0.03328651562333107	EU / 1 / 96 / 022 / 002 - ZYPREXA - 2.5 mg - coated tablets - 70 tablets , per box .
P-1040	-0.0033 -0.0015 -0.0013 -0.0014 -0.0006 -0.0014 -0.0012 -0.0010 -0.0014 -0.3737 -0.0014 -0.0145 -0.0134 -0.0014 -0.0005 -0.0008 -0.0013 -0.0048 -0.0131 -0.0008 -0.0037 -0.0135 -0.0011 -0.0074 -0.0143 -0.0855 -0.4697 -0.0040 -0.0237 -0.0145 -0.0123 -0.0143 -0.0146 -0.0146
S-1772	29 Häufig auftretende Nebenwirkungen ( betreffen mehr als 1 von 100 Personen ) : • Schwellungen an Armen und Beinen • Schlaflosigkeit • verstopfte Nase und Nasenbluten • Zahnfleischbluten • Übelkeit und / oder Erbrechen , Schwierigkeiten beim Stuhlgang , Magenschmerzen , Magenverstimmung und Durchfall • Hitzewallungen • Muskelkrämpfe • Schwindelgefühl • Müdigkeit • längere Blutgerinnungszeit • Gelbfärbung der Haut oder der Augen ( Gelbsucht ) oder anhaltende Übelkeit und / oder Erbrechen können auf eine Veränderung der Leberfunktion hinweisen
T-1772	Common side effects ( likely to affect more than 1 in every 100 people ) : • swelling in the arms and legs • being unable to sleep • blocked nose and nosebleeds • bleeding from the gums • feeling and / or being sick , difficulty in passing stools , stomach ache , indigestion and diarrhoea • flushed • cramp in muscles • dizziness • feeling tired • your blood may take longer to clot . • yellowing of the skin or eyes ( jaundice ) and persistent nausea and / or vomiting may indicate changes in liver function
H-1772	-0.009636010974645615	Common side effects ( likely to affect more than 1 in every 100 people ) : • swelling in the arms and legs • being unable to sleep • blocked nose and nosebleeds • bleeding from the gums • feeling and / or being sick , difficulty in passing stools , stomach ache , indigestion and diarrhoea • flushed • cramp in muscles • dizziness • feeling tired • your blood may take longer to clot . • yellowing of the skin or eyes ( jaundice ) and persistent nausea and / or vomiting may indicate changes in liver function
D-1772	-0.009636010974645615	Common side effects ( likely to affect more than 1 in every 100 people ) : • swelling in the arms and legs • being unable to sleep • blocked nose and nosebleeds • bleeding from the gums • feeling and / or being sick , difficulty in passing stools , stomach ache , indigestion and diarrhoea • flushed • cramp in muscles • dizziness • feeling tired • your blood may take longer to clot . • yellowing of the skin or eyes ( jaundice ) and persistent nausea and / or vomiting may indicate changes in liver function
P-1772	-0.0146 -0.0012 -0.0090 -0.0011 -0.0024 -0.0145 -0.0029 -0.0025 -0.0046 -0.0014 -0.0027 -0.0045 -0.1476 -0.0009 -0.0043 -0.0015 -0.0043 -0.0008 -0.0062 -0.0010 -0.0161 -0.0126 -0.0019 -0.0019 -0.0007 -0.0026 -0.0145 -0.0142 -0.0013 -0.0081 -0.0034 -0.0142 -0.0028 -0.0022 -0.0054 -0.0030 -0.0003 -0.0000 -0.0034 -0.0018 -0.0032 -0.0006 -0.0145 -0.0026 -0.0019 -0.0008 -0.0027 -0.0298 -0.0188 -0.0017 -0.0013 -0.0180 -0.0142 -0.0110 -0.0048 -0.0131 -0.0124 -0.0141 -0.0002 -0.0033 -0.0024 -0.0212 -0.0016 -0.0146 -0.0000 -0.0013 -0.0042 -0.0009 -0.0004 -0.0102 -0.0003 -0.0017 -0.0141 -0.0141 -0.0145 -0.0145 -0.0135 -0.0084 -0.0130 -0.0033 -0.0098 -0.0007 -0.0007 -0.0024 -0.0141 -0.0055 -0.0040 -0.0145 -0.0049 -0.0143 -0.0145 -0.0028 -0.0022 -0.0051 -0.0003 -0.0144 -0.0006 -0.0020 -0.0007 -0.0003 -0.0022 -0.0033 -0.0012 -0.1233 -0.0569 -0.0016 -0.0004 -0.0001 -0.0001 -0.0007 -0.0014 -0.0710 -0.0066 -0.0016 -0.0006 -0.0003 -0.0015 -0.0014 -0.0012 -0.0312 -0.0002 -0.0013 -0.0054 -0.0034 -0.0097 -0.0111 -0.0018 -0.0008 -0.1269
S-1251	65 Kinder Die empfohlene intravenöse Kinderdosis ergibt sich aus einer gepoolten pharmakokinetischen Populationsanalyse der Daten von 82 immungeschwächten , pädiatrischen Patienten im Alter von 2 bis &lt; 12 Jahren , die an drei Pharmakokinetikstudien teilnahmen ( intravenöse Einzeldosen von 3 mg und 4 mg / kg KG zweimal täglich ; intravenöse Mehrfachdosen von 3 , 4 , 6 und 8 mg / kg KG zweimal täglich ; orale Mehrfachdosen der Suspension von 4 mg und 6 mg / kg KG zweimal täglich ) .
T-1251	Paediatrics The recommended intravenous dose in paediatric patients is based on a population pharmacokinetic analysis of data pooled from 82 immunocompromised paediatric patients aged 2 to &lt; 12 years old who were evaluated in three pharmacokinetic studies ( examining single intravenous doses of 3 and 4 mg / kg twice daily , multiple intravenous doses of 3 , 4 , 6 and 8 mg / kg twice daily and multiple oral suspension doses of 4 and 6 mg / kg twice daily ) .
H-1251	-0.0248469989746809	Paediatrics The recommended intravenous dose in paediatric patients is based on a population pharmacokinetic analysis of data pooled from 82 immunocompromised paediatric patients aged 2 to &lt; 12 years old who were evaluated in three pharmacokinetic studies ( examining single intravenous doses of 3 and 4 mg / kg twice daily , multiple intravenous doses of 3 , 4 , 6 and 8 mg / kg twice daily and multiple oral suspension doses of 4 and 6 mg / kg twice daily ) .
D-1251	-0.0248469989746809	Paediatrics The recommended intravenous dose in paediatric patients is based on a population pharmacokinetic analysis of data pooled from 82 immunocompromised paediatric patients aged 2 to &lt; 12 years old who were evaluated in three pharmacokinetic studies ( examining single intravenous doses of 3 and 4 mg / kg twice daily , multiple intravenous doses of 3 , 4 , 6 and 8 mg / kg twice daily and multiple oral suspension doses of 4 and 6 mg / kg twice daily ) .
P-1251	-0.0145 -0.0007 -0.0002 -0.8780 -0.0139 -0.0026 -0.0067 -0.0014 -0.0005 -0.0013 -0.0025 -0.0143 -0.0144 -0.0009 -0.0008 -0.3087 -0.0106 -0.0061 -0.0126 -0.0018 -0.0077 -0.0147 -0.0154 -0.0005 -0.0003 -0.0022 -0.0158 -0.0055 -0.0047 -0.0147 -0.0004 -0.0012 -0.0060 -0.0006 -0.0013 -0.0020 -0.0025 -0.0008 -0.0135 -0.0004 -0.0002 -0.0014 -0.0017 -0.0111 -0.0028 -0.0231 -0.0014 -0.0003 -0.0010 -0.0012 -0.0051 -0.0262 -0.0209 -0.0141 -0.0145 -0.0016 -0.0058 -0.0027 -0.0057 -0.0012 -0.0004 -0.0498 -0.0171 -0.0022 -0.0193 -0.0055 -0.0134 -0.0037 -0.0012 -0.0005 -0.0011 -0.0014 -0.0009 -0.0043 -0.0037 -0.5195 -0.0017 -0.0005 -0.0014 -0.0008 -0.0128 -0.1103 -0.0545 -0.0036 -0.0033 -0.0011 -0.0005 -0.0011 -0.0009 -0.0007 -0.0027 -0.0014 -0.0014 -0.0013 -0.0015 -0.0013 -0.1860 -0.0012 -0.0008 -0.0014 -0.0006 -0.0031 -0.0019 -0.0394 -0.0052 -0.0010 -0.0142 -0.0012 -0.0010 -0.0018 -0.0014 -0.2359 -0.0014 -0.0005 -0.0015 -0.0005 -0.0027 -0.1072 -0.0019 -0.0015 -0.0014
S-724	In den plazebokontrollierten Studien mit RISPERDAL wurde bei älteren Patienten mit Demenz , die mit Furosemid plus Risperidon behandelt wurden , eine höhere Mortalitätsinzidenz ( 7,3 % ; mittleres Alter 89 Jahre , Altersspanne 75 @-@ 97 Jahre ) im Vergleich zu Patienten , die Risperidon allein ( 3,1 % ; mittleres Alter 84 Jahre , Altersspanne 70 @-@ 96 Jahre ) oder Furosemid allein ( 4,1 % ; mittleres Alter 80 Jahre , Altersspanne 67 @-@ 90 Jahre ) erhalten hatten , beobachtet .
T-724	In the RISPERDAL placebo @-@ controlled trials in elderly patients with dementia , a higher incidence of mortality was observed in patients treated with furosemide plus risperidone ( 7.3 % ; mean age 89 years , range 75 @-@ 97 ) when compared to patients treated with risperidone alone ( 3.1 % ; mean age 84 years , range 70 @-@ 96 ) or furosemide alone ( 4.1 % ; mean age 80 years , range 67 @-@ 90 ) .
H-724	-0.028670839965343475	In the RISPERDAL placebo @-@ controlled trials in elderly patients with dementia , a higher incidence of mortality was observed in patients treated with furosemide plus risperidone ( 7.3 % ; mean age 89 years , range 75 @-@ 97 ) when compared with patients treated with risperidone alone ( 3.1 % ; mean age 84 years , range 70 @-@ 96 ) or furosemide alone ( 4.1 % ; mean age 80 years , range 67 @-@ 90 ) .
D-724	-0.028670839965343475	In the RISPERDAL placebo @-@ controlled trials in elderly patients with dementia , a higher incidence of mortality was observed in patients treated with furosemide plus risperidone ( 7.3 % ; mean age 89 years , range 75 @-@ 97 ) when compared with patients treated with risperidone alone ( 3.1 % ; mean age 84 years , range 70 @-@ 96 ) or furosemide alone ( 4.1 % ; mean age 80 years , range 67 @-@ 90 ) .
P-724	-0.0034 -0.0529 -0.0270 -0.0007 -0.0009 -0.0008 -0.0010 -0.0010 -0.0009 -0.0008 -0.0014 -0.0030 -0.0021 -0.0131 -0.0143 -0.0121 -0.0097 -0.0343 -0.0006 -0.0359 -0.0144 -0.0322 -0.0063 -0.0010 -0.0804 -0.0024 -0.0008 -0.0111 -0.0444 -0.0333 -0.0064 -0.0091 -0.0015 -0.0012 -0.0013 -0.0006 -0.0009 -0.0061 -0.0019 -0.0009 -0.0004 -0.0002 -0.0016 -0.0016 -0.0013 -0.0013 -0.0035 -0.0007 -0.0015 -0.0007 -0.0030 -0.0022 -0.0125 -0.0019 -0.1715 -0.0006 -0.4184 -0.0906 -0.0003 -0.7911 -0.0037 -0.0354 -0.0018 -0.0024 -0.0009 -0.0005 -0.0002 -0.0007 -0.0013 -0.0017 -0.0014 -0.0011 -0.0067 -0.0005 -0.0014 -0.0005 -0.0118 -0.0015 -0.0051 -0.0006 -0.1829 -0.0009 -0.3777 -0.0026 -0.0020 -0.0013 -0.0008 -0.0012 -0.0006 -0.0013 -0.0009 -0.0014 -0.0010 -0.0861 -0.0006 -0.0013 -0.0009 -0.0208 -0.0014 -0.0054 -0.0005 -0.0015 -0.0012 -0.2856 -0.0015 -0.0014
S-1755	Infektionen des Herzens , Infektion des äußeren Ohrs Erkrankungen des Blutes : schwerwiegende Abnahme der roten Blutzellen , der weißen Blutzellen und der Blutplättchen Erkrankungen des Immunsystems : schwerwiegende allergische Reaktionen , systemischer Lupus erythematodes ( eine Krankheit , bei der der Körper seine eigenen Zellen angreift ) , rheumatoide Arthritis ( eine Autoimmunerkrankung ) Endokrine Erkrankungen : diabetische Ketoazidose , eine Komplikation bei unkontrolliertem Diabetes Psychiatrische Erkrankungen :
T-1755	Diabetic ketacidosis , a complication of uncontrolled diabetes Psychiatric disorders :
H-1755	-0.024524027481675148	Diabetic ketacidosis , a complication of uncontrolled diabetes Psychiatric disorders :
D-1755	-0.024524027481675148	Diabetic ketacidosis , a complication of uncontrolled diabetes Psychiatric disorders :
P-1755	-0.0142 -0.0145 -0.0035 -0.0145 -0.4111 -0.0007 -0.0007 -0.0104 -0.0132 -0.0014 -0.0013 -0.0072 -0.0021 -0.0013 -0.0011 -0.0100 -0.0026 -0.0012 -0.0112 -0.0010 -0.0020 -0.0145
S-1345	Bei der gleichzeitigen Anwendung von Tenofovirdisoproxilfumarat mit Emtricitabin , Lamivudin , Indinavir , Efavirenz , Nelfinavir , Saquinavir ( Ritonavir geboostert ) , Methadon , Ribavirin , Rifampicin , Tacrolimus oder dem hormonellen Verhütungsmittel Norgestimat / Ethinylestradiol zeigten sich keine klinisch signifikanten pharmakokinetischen Wechselwirkungen .
T-1345	There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil fumarate was co @-@ administered with emtricitabine , lamivudine , indinavir , efavirenz , nelfinavir , saquinavir ( ritonavir boosted ) , methadone , ribavirin , rifampicin , tacrolimus , or the hormonal contraceptive norgestimate / ethinyl oestradiol .
H-1345	-0.009493188001215458	There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil fumarate was co @-@ administered with emtricitabine , lamivudine , indinavir , efavirenz , nelfinavir , saquinavir ( ritonavir boosted ) , methadone , ribavirin , rifampicin , tacrolimus , or the hormonal contraceptive norgestimate / ethinyl oestradiol .
D-1345	-0.009493188001215458	There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil fumarate was co @-@ administered with emtricitabine , lamivudine , indinavir , efavirenz , nelfinavir , saquinavir ( ritonavir boosted ) , methadone , ribavirin , rifampicin , tacrolimus , or the hormonal contraceptive norgestimate / ethinyl oestradiol .
P-1345	-0.0134 -0.3794 -0.0017 -0.0013 -0.0009 -0.0015 -0.0015 -0.0008 -0.0003 -0.0017 -0.0034 -0.0080 -0.0109 -0.0080 -0.0011 -0.0010 -0.0032 -0.0026 -0.0017 -0.0011 -0.0019 -0.0063 -0.0095 -0.0007 -0.0007 -0.0014 -0.0011 -0.0021 -0.0209 -0.0014 -0.0046 -0.0011 -0.0017 -0.0083 -0.0011 -0.0004 -0.0008 -0.0009 -0.0014 -0.0017 -0.0009 -0.0009 -0.0010 -0.0008 -0.0014 -0.0010 -0.0005 -0.0006 -0.0012 -0.0014 -0.0017 -0.0004 -0.0014 -0.0002 -0.0023 -0.0015 -0.0010 -0.0012 -0.0009 -0.0004 -0.0010 -0.0015 -0.0005 -0.0009 -0.0017 -0.0008 -0.0017 -0.0033 -0.0014 -0.0006 -0.0010 -0.0043 -0.0034 -0.0017 -0.0014 -0.0010 -0.0009 -0.0678 -0.0015 -0.0007 -0.0006 -0.0004 -0.0074 -0.0015 -0.0005 -0.0008 -0.0008 -0.0008 -0.0088 -0.0016 -0.0007 -0.0011 -0.0012 -0.0003 -0.2972 -0.0051 -0.0031 -0.0015 -0.0115 -0.0011 -0.0022 -0.0006 -0.0020 -0.0027 -0.0023 -0.0014 -0.0018 -0.0018 -0.0002 -0.0018 -0.0030 -0.1002 -0.0100 -0.0003 -0.0019 -0.0016 -0.0015
S-1437	14 Retardtabletten - EU / 1 / 07 / 395 / 072 - weiß 28 Retardtabletten - EU / 1 / 07 / 395 / 035 - weiß 30 Retardtabletten - EU / 1 / 07 / 395 / 036 - weiß 49 Retardtabletten - EU / 1 / 07 / 395 / 037 - weiß 56 Retardtabletten - EU / 1 / 07 / 395 / 038 - weiß 98 Retardtabletten - EU / 1 / 07 / 395 / 039 - weiß
T-1437	14 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 072 - WHITE 28 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 031 - WHITE 30 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 032 - WHITE 49 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 033 - WHITE 56 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 034 - WHITE 98 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 035 - WHITE
H-1437	-0.030395248904824257	14 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 072 - WHITE 28 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 035 - WHITE 30 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 036 - WHITE 49 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 037 - WHITE 56 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 038 - WHITE 98 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 039 - WHITE
D-1437	-0.030395248904824257	14 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 072 - WHITE 28 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 035 - WHITE 30 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 036 - WHITE 49 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 037 - WHITE 56 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 038 - WHITE 98 prolonged @-@ release tablets - EU / 1 / 07 / 395 / 039 - WHITE
P-1437	-0.0037 -0.0145 -0.0144 -0.0013 -0.0135 -0.0013 -0.0020 -0.0071 -0.0044 -0.0019 -0.0016 -0.0013 -0.0015 -0.0010 -0.0015 -0.0011 -0.0009 -0.0015 -0.0017 -0.0009 -0.0966 -0.0146 -0.0005 -0.0011 -0.0018 -0.0145 -0.0000 -0.0008 -0.0016 -0.0000 -0.0029 -0.0056 -0.0014 -0.0010 -0.0015 -0.0015 -0.0015 -0.0009 -0.0014 -0.0011 -0.0009 -0.0014 -0.0015 -2.4286 -0.3951 -0.0030 -0.0018 -0.0009 -0.0009 -0.0136 -0.0000 -0.0006 -0.0014 -0.0000 -0.0026 -0.0058 -0.0013 -0.0011 -0.0015 -0.0015 -0.0015 -0.0009 -0.0015 -0.0010 -0.0009 -0.0015 -0.0017 -0.0751 -0.3196 -0.0009 -0.0011 -0.0010 -0.0036 -0.0135 -0.0000 -0.0005 -0.0013 -0.0000 -0.0022 -0.0052 -0.0013 -0.0012 -0.0015 -0.0015 -0.0015 -0.0009 -0.0014 -0.0011 -0.0011 -0.0015 -0.0015 -0.0297 -0.3379 -0.0012 -0.0007 -0.0010 -0.3034 -0.0131 -0.0000 -0.0008 -0.0013 -0.0000 -0.0023 -0.0042 -0.0013 -0.0015 -0.0016 -0.0015 -0.0015 -0.0008 -0.0015 -0.0012 -0.0010 -0.0015 -0.0016 -0.0031 -0.0013 -0.0012 -0.0008 -0.0011 -0.0487 -0.0137 -0.0000 -0.0010 -0.0012 -0.0000 -0.0028 -0.0034 -0.0019 -0.0015 -0.0016 -0.0017 -0.0016 -0.0008 -0.0015 -0.0012 -0.0011 -0.0015 -0.0016 -0.0012 -0.0017 -0.0028 -0.0010 -0.0009 -0.0567
S-198	In der Atorvastatin @-@ Gruppe verringerte sich das LDL @-@ C von einem Ausgangswert von 150 mg / dl ± 28 ( 3,89 mmol / l ± 0,7 ) auf durchschnittlich 78,9 mg / dl ± 30 ( 2,04 mmol / l ± 0,8 ) , in der Pravastatin- Gruppe von 150 mg / dl ± 26 ( 3,89 mmol / l ± 0,7 ) auf 110 mg / dl ± 26 ( 2,85 mmol / l ± 0,7 ) ( p &lt; 0,0001 ) .
T-198	In the atorvastatin group , LDL @-@ C was reduced to a mean of 2.04 mmol / L ± 0.8 ( 78.9 mg / dl ± 30 ) from baseline 3.89 mmol / l ± 0.7 ( 150 mg / dl ± 28 ) and in the pravastatin group , LDL @-@ C was reduced to a mean of 2.85 mmol / l ± 0.7 ( 110 mg / dl ± 26 ) from baseline 3.89 mmol / l ± 0.7 ( 150 mg / dl ± 26 ) ( p &lt; 0.0001 ) .
H-198	-0.007704730145633221	In the atorvastatin group , LDL @-@ C was reduced to a mean of 2.04 mmol / L ± 0.8 ( 78.9 mg / dl ± 30 ) from baseline 3.89 mmol / l ± 0.7 ( 150 mg / dl ± 28 ) and in the pravastatin group , LDL @-@ C was reduced to a mean of 2.85 mmol / l ± 0.7 ( 110 mg / dl ± 26 ) from baseline 3.89 mmol / l ± 0.7 ( 150 mg / dl ± 26 ) ( p &lt; 0.0001 ) .
D-198	-0.007704730145633221	In the atorvastatin group , LDL @-@ C was reduced to a mean of 2.04 mmol / L ± 0.8 ( 78.9 mg / dl ± 30 ) from baseline 3.89 mmol / l ± 0.7 ( 150 mg / dl ± 28 ) and in the pravastatin group , LDL @-@ C was reduced to a mean of 2.85 mmol / l ± 0.7 ( 110 mg / dl ± 26 ) from baseline 3.89 mmol / l ± 0.7 ( 150 mg / dl ± 26 ) ( p &lt; 0.0001 ) .
P-198	-0.0069 -0.0018 -0.0001 -0.0008 -0.0004 -0.0009 -0.0036 -0.0063 -0.0035 -0.0126 -0.0016 -0.0014 -0.0136 -0.0058 -0.0147 -0.0134 -0.0030 -0.0044 -0.0207 -0.0023 -0.0014 -0.0023 -0.0009 -0.0009 -0.0014 -0.3382 -0.0010 -0.0022 -0.0014 -0.0479 -0.0134 -0.0013 -0.0014 -0.0007 -0.0014 -0.0079 -0.0006 -0.0013 -0.0047 -0.0237 -0.0141 -0.0007 -0.0145 -0.0006 -0.0012 -0.0009 -0.0008 -0.0014 -0.0052 -0.0004 -0.0024 -0.0013 -0.0102 -0.0019 -0.0006 -0.0015 -0.0026 -0.0005 -0.0009 -0.0014 -0.0110 -0.0098 -0.0015 -0.0003 -0.0010 -0.0005 -0.0005 -0.0016 -0.0136 -0.0143 -0.0023 -0.0019 -0.0012 -0.0082 -0.0051 -0.0113 -0.0168 -0.0007 -0.0030 -0.0154 -0.0070 -0.0012 -0.0009 -0.0009 -0.0014 -0.0029 -0.0005 -0.0010 -0.0014 -0.0271 -0.0026 -0.0006 -0.0014 -0.0024 -0.0004 -0.0017 -0.0364 -0.0075 -0.0145 -0.0007 -0.0139 -0.0006 -0.0012 -0.0009 -0.0008 -0.0014 -0.0020 -0.0005 -0.0010 -0.0014 -0.0176 -0.0172 -0.0006 -0.0014 -0.0021 -0.0004 -0.0006 -0.0250 -0.0058 -0.0217 -0.0005 -0.0005 -0.0013 -0.0015 -0.0008 -0.0013 -0.0014 -0.0017 -0.0014
S-309	Wenn Ambirix im zweiten Lebensjahr in Form einer getrennten Injektion gleichzeitig mit einem kombinierten Diphtherie- , Tetanus- , azellulärem Pertussis- , inaktiviertem Poliomyelitis- und Haemophilus influenzae Typ b @-@ Impfstoff ( DTPa @-@ IPV / Hib ) oder mit einem kombinierten Masern- Mumps @-@ Röteln @-@ Impfstoff verabreicht wurde , war die Immunantwort auf alle Antigene ausreichend ( siehe Abschnitt 5.1 ) .
T-309	When Ambirix was administered concomitantly with , but as a separate injection to a combined diphtheria , tetanus , acellular pertussis , inactivated poliomyelitis and Haemophilus influenzae type b vaccine ( DTPa @-@ IPV / Hib ) or with a combined Measles @-@ Mumps @-@ Rubella vaccine in the second year of life , immune responses to all antigens were satisfactory ( see section 5.1 )
H-309	-0.009963952004909515	When Ambirix was administered concomitantly with , but as a separate injection to a combined diphtheria , tetanus , acellular pertussis , inactivated poliomyelitis and Haemophilus influenzae type b vaccine ( DTPa @-@ IPV / Hib ) or with a combined Measles @-@ Mumps @-@ Rubella vaccine in the second year of life , immune responses to all antigens were satisfactory ( see section 5.1 ) .
D-309	-0.009963952004909515	When Ambirix was administered concomitantly with , but as a separate injection to a combined diphtheria , tetanus , acellular pertussis , inactivated poliomyelitis and Haemophilus influenzae type b vaccine ( DTPa @-@ IPV / Hib ) or with a combined Measles @-@ Mumps @-@ Rubella vaccine in the second year of life , immune responses to all antigens were satisfactory ( see section 5.1 ) .
P-309	-0.0088 -0.0010 -0.0010 -0.0013 -0.0030 -0.0053 -0.0009 -0.0138 -0.0229 -0.0009 -0.0025 -0.0152 -0.0152 -0.0142 -0.0140 -0.0095 -0.0023 -0.0024 -0.0005 -0.0145 -0.0142 -0.0044 -0.0051 -0.0008 -0.0002 -0.0005 -0.0029 -0.0010 -0.0003 -0.0013 -0.0014 -0.0024 -0.0006 -0.0006 -0.0032 -0.0005 -0.0023 -0.0013 -0.0047 -0.0034 -0.0012 -0.0014 -0.0006 -0.0008 -0.0013 -0.0006 -0.0004 -0.0180 -0.0120 -0.0010 -0.0014 -0.0004 -0.0012 -0.0007 -0.0006 -0.0032 -0.0038 -0.0159 -0.0035 -0.0015 -0.0012 -0.0013 -0.0013 -0.0014 -0.0016 -0.0004 -0.2760 -0.0015 -0.0007 -0.0010 -0.0014 -0.0073 -0.0081 -0.0079 -0.0024 -0.0144 -0.0003 -0.0003 -0.0126 -0.0054 -0.0005 -0.0016 -0.0041 -0.0001 -0.0011 -0.0128 -0.0056 -0.0023 -0.0015 -0.0026 -0.0022 -0.0023 -0.0140 -0.0180 -0.0025 -0.0027 -0.0047 -0.0008 -0.0021 -0.0142 -0.0004 -0.0015 -0.0019 -0.0115 -0.0011 -0.0014 -0.0018 -0.3525 -0.0014
S-382	Wenn Sie von einer oralen Verhütungspille auf EVRA wechseln Wenn Sie von einer oralen Verhütungspille auf EVRA wechseln : • Warten Sie ab , bis Sie Ihre Periode bekommen • Kleben Sie Ihr erstes Pflaster innerhalb der ersten 24 Stunden Ihrer Periode auf Wenn das Pflaster nach Tag 1 Ihrer Periode aufgeklebt wird , müssen Sie : • zusätzlich ein nicht @-@ hormonelles Verhütungsmittel bis zum Tag 8 , an dem Sie Ihr Pflaster wechseln , verwenden .
T-382	If the patch is applied after Day 1 of your period , you should : • Use a non @-@ hormonal contraceptive until Day 8 when you change your patch .
H-382	-0.0066732317209243774	If the patch is applied after Day 1 of your period , you should : • Use a non @-@ hormonal contraceptive until Day 8 when you change your patch .
D-382	-0.0066732317209243774	If the patch is applied after Day 1 of your period , you should : • Use a non @-@ hormonal contraceptive until Day 8 when you change your patch .
P-382	-0.0076 -0.0151 -0.0122 -0.0018 -0.0088 -0.0134 -0.0087 -0.0126 -0.0051 -0.0036 -0.0024 -0.0034 -0.0054 -0.0037 -0.0141 -0.0052 -0.0026 -0.0144 -0.0082 -0.0022 -0.0190 -0.0009 -0.0044 -0.0010 -0.0037 -0.0012 -0.0011 -0.0117 -0.0079 -0.0015 -0.0138 -0.0033 -0.0047 -0.0049 -0.0012 -0.0018 -0.0063 -0.0145
S-1041	Veranschlagt sind Mittel zur Deckung der Kosten für Einstellungsverfahren , insbesondere der Kosten für Veröffentlichungen , der Reisekosten sowie der Kosten für die Unfallversicherung der einberufenen Stellenbewerber ; der Kosten , die in direktem Zusammenhang mit der Vorbereitung und Durchführung von Einstellungsprüfungen stehen ( Miete für Räumlichkeiten , Mobiliar und Maschinen , Kosten für Verschiedenes , Vergütungen für die Vorbereitung und Korrektur von Prüfungsarbeiten usw. ) , sowie der Kosten für die ärztliche Untersuchung vor der Einstellung .
T-1041	This appropriation is intended to cover expenditure arising from recruitment procedures , and in particular publication costs , travel costs and accident insurance for candidates called for examinations and interviews , costs directly linked to the promotion and organisation of group recruitment tests ( hire of rooms , furniture , machines and miscellaneous equipment , fees for the preparation and correction of tests , etc . ) , as well as pre @-@ recruitment medical examinations .
H-1041	-0.01852082833647728	This appropriation is intended to cover expenditure arising from recruitment procedures , and in particular publication costs , travel costs and accident insurance for candidates called for examinations and interviews , costs directly linked to the promotion and organisation of group recruitment tests ( hire of rooms , furniture , machines and miscellaneous equipment , fees for the preparation and correction of tests , etc . ) , as well as pre @-@ recruitment medical examinations .
D-1041	-0.01852082833647728	This appropriation is intended to cover expenditure arising from recruitment procedures , and in particular publication costs , travel costs and accident insurance for candidates called for examinations and interviews , costs directly linked to the promotion and organisation of group recruitment tests ( hire of rooms , furniture , machines and miscellaneous equipment , fees for the preparation and correction of tests , etc . ) , as well as pre @-@ recruitment medical examinations .
P-1041	-0.0141 -0.0144 -0.0024 -0.0250 -0.0067 -0.0019 -0.0016 -0.0145 -0.0005 -0.0025 -0.0146 -0.0007 -0.0029 -0.0041 -0.0050 -0.0035 -0.0141 -0.0043 -0.0010 -0.0125 -0.0076 -0.0585 -0.0019 -0.0083 -0.0214 -0.0120 -0.0011 -0.0133 -0.0133 -0.0134 -0.0138 -0.0145 -0.0015 -0.0616 -0.0150 -0.0553 -0.0087 -0.0073 -0.0114 -0.0019 -0.0091 -0.0824 -0.0035 -0.0138 -0.0014 -0.0147 -0.0095 -0.0105 -0.0018 -0.0141 -0.0022 -0.0137 -0.0018 -0.0041 -0.5040 -0.0141 -0.1976 -0.0108 -0.0004 -0.0003 -0.0012 -0.0016 -0.0013 -0.0084 -0.0284 -0.0140 -0.0037 -0.0130 -0.0733 -0.0021 -0.0034 -0.0014 -0.0014 -0.0141 -0.0136 -0.0015 -0.0020 -0.0015 -0.0253 -0.0099 -0.0062 -0.0014 -0.0135 -0.0014 -0.0045 -0.0038 -0.0124 -0.0008 -0.0022 -0.0014
S-1683	Schwindel ( selten , beim Aufstehen oder aus dem Bett steigen ) , Müdigkeit , Palpitationen ( spürbar starker Herzschlag , der schneller oder unregelmäßiger als normal sein kann ) , Übelkeit , Erbrechen , Magenschmerzen , Magenverstimmung , Durchfall und Blähungen , Anämie ( geringfügige Abnahme der Zahl roter Blutkörperchen und Eisenmangel ) , unzureichende Flüssigkeitsausscheidung ( einschließlich Schwellung Ihrer Fußgelenke ) oder Ausschlag .
T-1683	Dizziness ( rarely when standing up or getting out of bed ) , tiredness , palpitations ( awareness of a forceful heartbeat which may be rapid or irregular ) , nausea , diarrhoea , stomach pain , indigestion and wind , vomiting , anaemia ( a small reduction in red blood cell count and iron deficiency ) , fluid retention ( including swelling of your ankles ) or rash .
H-1683	-0.03401746600866318	Dizziness ( rarely when standing up or getting out of bed ) , tiredness , palpitations ( awareness of a forceful heartbeat which may be rapid or irregular ) , nausea , diarrhoea , stomach pain , indigestion and wind , vomiting , anaemia ( a small reduction in red blood cell count and iron deficiency ) , fluid retention ( including swelling of your ankles ) or rash .
D-1683	-0.03401746600866318	Dizziness ( rarely when standing up or getting out of bed ) , tiredness , palpitations ( awareness of a forceful heartbeat which may be rapid or irregular ) , nausea , diarrhoea , stomach pain , indigestion and wind , vomiting , anaemia ( a small reduction in red blood cell count and iron deficiency ) , fluid retention ( including swelling of your ankles ) or rash .
P-1683	-0.0062 -0.0005 -0.0010 -0.0015 -0.0125 -0.0134 -0.0141 -0.0025 -0.0177 -0.0050 -0.0015 -0.0014 -0.0007 -0.0014 -0.0022 -0.0104 -0.0006 -0.0012 -0.0018 -0.0010 -0.0008 -0.0036 -0.0015 -0.0146 -0.0020 -0.0072 -0.0145 -0.0006 -0.0008 -0.0044 -0.0007 -0.0127 -0.0094 -0.0017 -0.0144 -0.0017 -0.0052 -0.0007 -0.0059 -0.0013 -0.0009 -0.0003 -0.0014 -0.6694 -0.0117 -0.0092 -0.0004 -0.2554 -0.1049 -0.0131 -0.2673 -0.1607 -0.0001 -0.0013 -0.8788 -0.0145 -0.0066 -0.0199 -0.0004 -0.0013 -0.0052 -0.0150 -0.0088 -0.0003 -0.0013 -0.0018 -0.0093 -0.0101 -0.0120 -0.0026 -0.0022 -0.0016 -0.0121 -0.0056 -0.0577 -0.0017 -0.0006 -0.0002 -0.0013 -0.0015 -0.0017 -0.0143 -0.0013 -0.0143 -0.0079 -0.0019 -0.0050 -0.0010 -0.0009 -0.0047 -0.0052 -0.0032 -0.0003 -0.0014 -0.4299 -0.0106 -0.0018 -0.0924 -0.0014
S-1757	Obwohl es keine Anzeichen dafür gibt , dass die Inzidenz kongenitaler Anomalien bei Kindern , deren Mütter &lt; Zocord &gt; oder einen anderen eng verwandten HMG @-@ CoA @-@ Reduktase @-@ Inhibitor eingenommen hatten , von der in der Gesamtpopulation beobachteten abweicht , kann eine Behandlung der Mutter mit Simvastatin beim Fetus die Spiegel der Mevalonsäure senken , welche als Vorstufe der Cholesterinsynthese eine Rolle spielt .
T-1757	Although there is no evidence that the incidence of congenital anomalies in offspring of patients taking &lt; Zocord &gt; or another closely related HMG @-@ CoA reductase inhibitor differs from that observed in the general population , maternal treatment with &lt; Zocord &gt; may reduce the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis .
H-1757	-0.00690259225666523	Although there is no evidence that the incidence of congenital anomalies in offspring of patients taking &lt; Zocord &gt; or another closely related HMG @-@ CoA reductase inhibitor differs from that observed in the general population , maternal treatment with &lt; Zocord &gt; may reduce the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis .
D-1757	-0.00690259225666523	Although there is no evidence that the incidence of congenital anomalies in offspring of patients taking &lt; Zocord &gt; or another closely related HMG @-@ CoA reductase inhibitor differs from that observed in the general population , maternal treatment with &lt; Zocord &gt; may reduce the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis .
P-1757	-0.0061 -0.0021 -0.0037 -0.0015 -0.0048 -0.0048 -0.0030 -0.0009 -0.0008 -0.1370 -0.0018 -0.0005 -0.0005 -0.0155 -0.0015 -0.0007 -0.0013 -0.0039 -0.0166 -0.0014 -0.0295 -0.0145 -0.0312 -0.0020 -0.0006 -0.0011 -0.0027 -0.0011 -0.0005 -0.0009 -0.0025 -0.0091 -0.0011 -0.0008 -0.0016 -0.0015 -0.0008 -0.0094 -0.0016 -0.0012 -0.0025 -0.0004 -0.0005 -0.0005 -0.0010 -0.0003 -0.0009 -0.0016 -0.0089 -0.0017 -0.0017 -0.0114 -0.0024 -0.0108 -0.0022 -0.0118 -0.0015 -0.0015 -0.0103 -0.0002 -0.0013 -0.0116 -0.0021 -0.0169 -0.0005 -0.0009 -0.0034 -0.0012 -0.0005 -0.0007 -0.0126 -0.0111 -0.0120 -0.0157 -0.0002 -0.0824 -0.0057 -0.0014 -0.0026 -0.0010 -0.0144 -0.0133 -0.0084 -0.0050 -0.0030 -0.0007 -0.0014 -0.0088 -0.0024 -0.0007 -0.0006 -0.0224 -0.0113 -0.0015 -0.0008 -0.0009 -0.0016 -0.0014
S-793	13 Der PDCO gelangte ausgehend von seiner Entscheidung über das Pädiatriehandbuch GINA 2006 und den Beiträgen von Experten zu dem Schluss , dass pharmakokinetische Daten über Asthma @-@ Patienten im Alter von 2 bis 5 Jahren wegen eines Mangels an klinischen Daten über Asthma @-@ Patienten im Alter von 6 Monaten bis 2 Jahren nicht auf jüngere Patienten im Alter von 6 Monaten bis 2 Jahren , die dieselben Symptome aufweisen , extrapoliert werden können .
T-793	The PDCO , basing its decision on the GINA paediatric handbook 2006 and expert intervention , concluded that , due to a shortage of clinical data in patients aged 6 months <<unk>> 2 years with asthma , pharmacokinetic data from patients aged 2 @-@ 5 years diagnosed with asthma cannot be extrapolated to younger patients aged 6 months- 2 years presenting with the same symptoms .
H-793	-0.020138097926974297	The PDCO , basing its decision on the GINA paediatric handbook 2006 and expert intervention , concluded that , due to a shortage of clinical data in patients aged 6 months <unk> 2 years with asthma , pharmacokinetic data from patients aged 2 @-@ 5 years diagnosed with asthma cannot be extrapolated to younger patients aged 6 months- 2 years presenting with the same symptoms .
D-793	-0.020138097926974297	The PDCO , basing its decision on the GINA paediatric handbook 2006 and expert intervention , concluded that , due to a shortage of clinical data in patients aged 6 months <unk> 2 years with asthma , pharmacokinetic data from patients aged 2 @-@ 5 years diagnosed with asthma cannot be extrapolated to younger patients aged 6 months- 2 years presenting with the same symptoms .
P-793	-0.0157 -0.0025 -0.0012 -0.0007 -0.0113 -0.0144 -0.0011 -0.0025 -0.0026 -0.0022 -0.0024 -0.0126 -0.0015 -0.0013 -0.0145 -0.0010 -0.0005 -0.0032 -0.0058 -0.0005 -0.0041 -0.0079 -0.0116 -0.0144 -0.0037 -0.0165 -0.0014 -0.0133 -0.0068 -0.0014 -0.0056 -0.0136 -0.0017 -0.0010 -0.0021 -0.0177 -0.0132 -0.0119 -0.0060 -0.0990 -0.2965 -0.0074 -0.0024 -0.0129 -0.0018 -0.0011 -0.0008 -0.0036 -0.0026 -0.0005 -0.0004 -0.2991 -0.0017 -0.0141 -0.0116 -0.0036 -0.0045 -0.0123 -0.0017 -0.0020 -0.0145 -0.0054 -0.0047 -0.0010 -0.0008 -0.0043 -0.0014 -0.0003 -0.0006 -0.0011 -0.0004 -0.0013 -0.0067 -0.0017 -0.0022 -0.0061 -0.0031 -0.5767 -0.0050 -0.0046 -0.0015 -0.0019 -0.0141 -0.0309 -0.0658 -0.0012 -0.0012 -0.0018 -0.0015
S-1956	&quot; Invasiv &quot; bedeutet , dass sich der Pilz in Gewebe und Blutgefäße ausgebreitet hat ; • Vorbeugung einer Infektion mit Candida bei Patienten , die sich einer Knochenmarktransplantation unterziehen ( zur Behandlung von Knochenmark- oder Blutkrankheiten oder bestimmten Arten von Krebs ) , oder wenn eine Neutropenie ( niedrige Anzahl von Neutrophilen , einer Art weißer Blutkörperchen ) von 10 oder mehr Tagen zu erwarten ist .
T-1956	Mycamine is used in babies , children and adults in the following situations : • to treat invasive candidiasis ( a type of fungal infection caused by a yeast @-@ like fungus called Candida ) . <<unk>> Invasive <<unk>> means that the fungus has spread into tissue and blood vessels ; • to prevent infection with Candida in patients who are having a bone marrow transplant ( to treat bone marrow or blood problems , or certain types of cancer ) or who are expected to have neutropenia ( low levels of neutrophils , a type of white blood cell ) for 10 days or more .
H-1956	-0.02798072248697281	Mycamine is used in babies , children and adults in the following situations : • to treat invasive candidiasis ( a type of fungal infection caused by a yeast @-@ like fungus called Candida ) . <unk> Invasive <unk> means that the fungus has spread into tissue and blood vessels ; • to prevent infection with Candida in patients who are having a bone marrow transplant ( to treat bone marrow or blood problems , or certain types of cancer ) or who are expected to have neutropenia ( low levels of neutrophils , a type of white blood cell ) for 10 days or more .
D-1956	-0.02798072248697281	Mycamine is used in babies , children and adults in the following situations : • to treat invasive candidiasis ( a type of fungal infection caused by a yeast @-@ like fungus called Candida ) . <unk> Invasive <unk> means that the fungus has spread into tissue and blood vessels ; • to prevent infection with Candida in patients who are having a bone marrow transplant ( to treat bone marrow or blood problems , or certain types of cancer ) or who are expected to have neutropenia ( low levels of neutrophils , a type of white blood cell ) for 10 days or more .
P-1956	-0.0145 -0.0145 -0.0145 -0.0133 -0.0144 -0.0175 -0.0145 -0.0205 -0.0140 -0.0086 -0.0082 -0.0190 -0.0118 -0.0144 -0.0138 -0.0032 -0.0023 -0.0143 -0.0170 -0.0145 -0.0010 -0.0011 -0.0145 -0.0015 -0.6683 -0.5411 -0.0013 -0.0134 -0.0128 -0.0124 -0.0017 -0.0105 -0.0002 -0.5791 -0.0097 -0.0132 -0.0017 -0.0121 -0.0145 -0.0004 -0.0143 -0.0117 -0.0124 -0.0003 -0.5272 -0.0150 -0.0137 -0.0014 -0.0011 -0.0053 -0.0136 -0.0150 -0.0098 -0.0010 -0.0011 -0.0145 -0.0046 -0.0072 -0.0046 -0.0021 -0.0003 -0.2784 -0.0023 -0.0030 -0.0120 -0.0114 -0.0019 -0.0016 -0.0009 -0.0007 -0.0243 -0.0019 -0.0060 -0.0013 -0.0068 -0.0029 -0.0037 -0.0012 -0.0009 -0.0020 -0.0022 -0.0137 -0.0119 -0.0145 -0.0078 -0.0009 -0.0010 -0.0003 -0.0006 -0.2515 -0.0021 -0.0094 -0.0006 -0.0022 -0.0013 -0.0004 -0.0060 -0.0012 -0.0145 -0.1310 -0.0026 -0.0027 -0.0027 -0.0013 -0.0010 -0.0015 -0.0508 -0.0142 -0.0062 -0.0114 -0.0017 -0.0093 -0.0016 -0.0007 -0.0013 -0.0005 -0.0020 -0.0085 -0.0110 -0.0014 -0.0012 -0.0075 -0.0022 -0.0002 -0.0024 -0.0035 -0.0032 -0.0013 -0.0013 -0.0029 -0.0104 -0.0022 -0.0111 -0.0032 -0.0081 -0.0015 -0.0033 -0.0020 -0.0014
S-643	Dabei wurden Fälle von APL @-@ Differenzierungssyndrom ( 3 ) , Leukozytose ( 3 ) , QT- Verlängerung ( 4 , davon 1 mit Torsade de Pointes ) , Vorhofflimmern / Vorhofflattern ( 1 ) , Hyperglykämie ( 2 ) und verschiedene schwerwiegende Nebenwirkungen , die mit Blutungen , Infektionen , Schmerzen , Diarrhoe oder Übelkeit verbunden waren , TRISENOX zugeschrieben .
T-643	Those serious adverse reactions attributed to TRISENOX included APL differentiation syndrome ( 3 ) , leukocytosis ( 3 ) , prolonged QT interval ( 4 , 1 with torsade de pointes ) , atrial fibrillation / atrial flutter ( 1 ) , hyperglycaemia ( 2 ) and a variety of serious adverse reactions related to haemorrhage , infections , pain , diarrhoea , nausea .
H-643	-0.01187293604016304	Those serious adverse reactions attributed to TRISENOX included APL differentiation syndrome ( 3 ) , leukocytosis ( 3 ) , prolonged QT interval ( 4 , 1 with torsade de pointes ) , atrial fibrillation / atrial flutter ( 1 ) , hyperglycaemia ( 2 ) and a variety of serious adverse reactions related to haemorrhage , infections , pain , diarrhoea , nausea .
D-643	-0.01187293604016304	Those serious adverse reactions attributed to TRISENOX included APL differentiation syndrome ( 3 ) , leukocytosis ( 3 ) , prolonged QT interval ( 4 , 1 with torsade de pointes ) , atrial fibrillation / atrial flutter ( 1 ) , hyperglycaemia ( 2 ) and a variety of serious adverse reactions related to haemorrhage , infections , pain , diarrhoea , nausea .
P-643	-0.0145 -0.0145 -0.0090 -0.0005 -0.0246 -0.0003 -0.0145 -0.0095 -0.0019 -0.0074 -0.0007 -0.0014 -0.0014 -0.0009 -0.0117 -0.0068 -0.0011 -0.0024 -0.0010 -0.0016 -0.0021 -0.0006 -0.0014 -0.0014 -0.0014 -0.0015 -0.0009 -0.0014 -0.0005 -0.0006 -0.0010 -0.0014 -0.0013 -0.0014 -0.0015 -0.0145 -0.0042 -0.0021 -0.0037 -0.0015 -0.0145 -0.0128 -0.0018 -0.0014 -0.0049 -0.0088 -0.0114 -0.0027 -0.0016 -0.0012 -0.0012 -0.0051 -0.0015 -0.0016 -0.0850 -0.0017 -0.0012 -0.0011 -0.0008 -0.0004 -0.0007 -0.0038 -0.0102 -0.0013 -0.0007 -0.0019 -0.0016 -0.0014 -0.0014 -0.1168 -0.0012 -0.0013 -0.0005 -0.0131 -0.0032 -0.0013 -0.0014 -0.0014 -0.0014 -0.0075 -0.0129 -0.0098 -0.0014 -0.0075 -0.0040 -0.0003 -0.0066 -0.0006 -0.0132 -0.0016 -0.0164 -0.0016 -0.0002 -0.0066 -0.0014 -0.0109 -0.0006 -0.0015 -0.0013 -0.0015 -0.0014 -0.0002 -0.0096 -0.0004 -0.6460 -0.0153 -0.0003 -0.0167 -0.0014
S-1283	Die häufigsten Nebenwirkungen von Azopt ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Dysgeusie ( bitterer oder ungewöhnlicher Geschmack im Mund ) , Kopfschmerzen , Blepharitis ( Entzündung der Augenlider ) , verschwommenes Sehen , Augenreizung , Augenschmerzen , trockenes Auge , Augenausfluss , Augenjucken , Fremdkörpergefühl im Auge , okuläre Hyperämie ( rotes Auge ) und Mundtrockenheit .
T-1283	The most common side effects with Azopt ( seen in between 1 and 10 patients in 100 ) are dysgeusia ( a bitter or unusual taste in the mouth ) , headache , blepharitis ( inflammation of the eyelids ) , blurred vision , eye irritation , eye pain , dry eye , eye discharge , eye pruritus ( itching ) , sensation of a foreign body in the eyes , ocular hyperaemia ( red eye ) and dry mouth .
H-1283	-0.02239096723496914	The most common side effects with Azopt ( seen in between 1 and 10 patients in 100 ) are dysgeusia ( a bitter or unusual taste in the mouth ) , headache , blepharitis ( inflammation of the eyelids ) , blurred vision , eye irritation , eye pain , dry eye , eye discharge , eye pruritus , sensation of a foreign body in the eyes , ocular hyperaemia ( red eye ) and dry mouth .
D-1283	-0.02239096723496914	The most common side effects with Azopt ( seen in between 1 and 10 patients in 100 ) are dysgeusia ( a bitter or unusual taste in the mouth ) , headache , blepharitis ( inflammation of the eyelids ) , blurred vision , eye irritation , eye pain , dry eye , eye discharge , eye pruritus , sensation of a foreign body in the eyes , ocular hyperaemia ( red eye ) and dry mouth .
P-1283	-0.0036 -0.0047 -0.0038 -0.0112 -0.0018 -0.1013 -0.0082 -0.0002 -0.0021 -0.0129 -0.0016 -0.6776 -0.0021 -0.0052 -0.0017 -0.0128 -0.0124 -0.0023 -0.0069 -0.0057 -0.0084 -0.0033 -0.0036 -0.0003 -0.0014 -0.0134 -0.0017 -0.0018 -0.0027 -0.0022 -0.0027 -0.0015 -0.0009 -0.0015 -0.0016 -0.0008 -0.0005 -0.0041 -0.0016 -0.0009 -0.0008 -0.0010 -0.0008 -0.0021 -0.0018 -0.0007 -0.0014 -0.0018 -0.0021 -0.0024 -0.0002 -0.0012 -0.0015 -0.0014 -0.0006 -0.0018 -0.0005 -0.0015 -0.0026 -0.0006 -0.0014 -0.0015 -0.0014 -0.0025 -0.0015 -0.0005 -0.0012 -0.0015 -0.0058 -0.0011 -0.0006 -0.0011 -0.2684 -0.0127 -0.0146 -0.0012 -0.0020 -0.0007 -0.5255 -0.0142 -0.0021 -0.0019 -0.0130 -0.0004 -0.0026 -0.0026 -0.0015 -0.0143 -0.2534 -0.0009 -0.0002 -0.0010 -0.0138 -0.0003 -0.0012 -0.0017 -0.0018 -0.0010 -0.0015 -0.1890 -0.0017 -0.0006 -0.0016 -0.0014
S-260	76 Wochen für Patienten , die mit Efavirenz + Zidovudin + Lamivudin , Efavirenz + Indinavir oder Indinavir + Zidovudin + Lamivudin behandelt wurden ) zeigten , dass bei einer Therapie über 24 Wochen hinaus die Inzidenzen von erstmalig auftretenden ZNS @-@ Symptomen bei mit Efavirenz behandelten Patienten generell denen in der Kontrollgruppe ähnlich waren .
T-260	Analysis of long @-@ term data from a clinical study ( median follow @-@ up 180 weeks , 102 weeks and 76 weeks for patients treated with efavirenz + zidovudine + lamivudine , efavirenz + indinavir , and indinavir + zidovudine + lamivudine , respectively ) showed that , beyond 24 weeks of therapy , the incidences of new @-@ onset nervous system symptoms among efavirenz @-@ treated patients were generally similar to those in the control arm .
H-260	-0.016188204288482666	Analysis of long @-@ term data from a clinical study ( median follow @-@ up 180 weeks , 102 weeks and 76 weeks for patients treated with efavirenz + zidovudine + lamivudine , efavirenz + indinavir , and indinavir + zidovudine + lamivudine , respectively ) showed that , beyond 24 weeks of therapy , the incidences of new @-@ onset nervous system symptoms among efavirenz @-@ treated patients were generally similar to those in the control arm .
D-260	-0.016188204288482666	Analysis of long @-@ term data from a clinical study ( median follow @-@ up 180 weeks , 102 weeks and 76 weeks for patients treated with efavirenz + zidovudine + lamivudine , efavirenz + indinavir , and indinavir + zidovudine + lamivudine , respectively ) showed that , beyond 24 weeks of therapy , the incidences of new @-@ onset nervous system symptoms among efavirenz @-@ treated patients were generally similar to those in the control arm .
P-260	-0.0145 -0.0051 -0.0102 -0.0149 -0.0035 -0.0031 -0.0144 -0.0113 -0.0141 -0.0138 -0.0138 -0.0145 -0.0146 -0.0050 -0.0141 -0.0027 -0.0013 -0.0145 -0.0103 -0.1731 -0.0146 -0.0087 -0.2050 -0.0090 -0.0012 -0.0623 -0.0020 -0.0027 -0.0016 -0.0031 -0.0005 -0.0015 -0.0005 -0.0035 -0.0016 -0.0035 -0.0011 -0.0009 -0.0009 -0.0041 -0.0013 -0.0015 -0.0011 -0.0009 -0.0012 -0.0049 -0.0014 -0.0011 -0.0005 -0.0013 -0.0005 -0.0019 -0.0014 -0.0008 -0.0006 -0.0008 -0.0009 -0.2947 -0.0144 -0.0011 -0.0008 -0.0005 -0.0009 -0.0013 -0.0019 -0.0011 -0.0010 -0.0011 -0.0071 -0.0014 -0.0015 -0.0009 -0.0010 -0.0011 -0.0052 -0.0455 -0.0031 -0.0539 -0.0057 -0.0021 -0.0131 -0.0143 -0.0012 -0.0014 -0.0119 -0.0095 -0.0020 -0.0061 -0.0008 -0.3465 -0.0012 -0.0015 -0.0145 -0.0160 -0.0045 -0.0018 -0.0157 -0.0023 -0.0020 -0.0168 -0.0142 -0.0009 -0.0015 -0.0012 -0.0026 -0.0094 -0.0005 -0.0012 -0.0045 -0.0047 -0.0016 -0.0197 -0.0022 -0.0038 -0.0021 -0.0012 -0.2028 -0.0015 -0.0014
S-592	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea.eu.int http : / / www.emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged wird aus einem Bakterium gewonnen , in das ein Gen ( DNA ) eingebracht wurde , wodurch es zur Bildung des Hormons angeregt wird .
T-592	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea. eu. int http : / / www. emea. eu. int © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Preotact for up to 2 years , and their bone density was measured .
H-592	-0.015637947246432304	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea. eu. int http : / / www. emea. eu. int © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Preotact for up to 2 years , and their bone density was measured .
D-592	-0.015637947246432304	( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea. eu. int http : / / www. emea. eu. int © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Preotact for up to 2 years , and their bone density was measured .
P-592	-0.0032 -0.0010 -0.0014 -0.0013 -0.0014 -0.0006 -0.0013 -0.0005 -0.0011 -0.0007 -0.0013 -0.0006 -0.2440 -0.0012 -0.0014 -0.0004 -0.0012 -0.0005 -0.0009 -0.0030 -0.1527 -0.0006 -0.0014 -0.0008 -0.0009 -0.0002 -0.2160 -0.0008 -0.1592 -0.0005 -0.0006 -0.0014 -0.0015 -0.0015 -0.0404 -0.0131 -0.0026 -0.0006 -0.1493 -0.0010 -0.0680 -0.0006 -0.0005 -0.0011 -0.0007 -0.0013 -0.0010 -0.0017 -0.0011 -0.0014 -0.0014 -0.0013 -0.0011 -0.0013 -0.0014 -0.0007 -0.0013 -0.0073 -0.0010 -0.0014 -0.0019 -0.0476 -0.0017 -0.0014 -0.0011 -0.0015 -0.0009 -0.0008 -0.0014 -0.0014 -0.0076 -0.0145 -0.0145 -0.0145 -0.0145 -0.0145 -0.0024 -0.0143 -0.0059 -0.0142 -0.0143 -0.0145 -0.0145 -0.0119 -0.0009 -0.0144 -0.0141 -0.0147 -0.0079
S-1212	Evista darf nicht von Frauen eingenommen werden , die : • schwanger werden könnten ; • ein Blutgerinnsel haben oder hatten , einschließlich tiefer Venenthrombose und Lungenembolie ( Blutgerinnsel in der Lunge ) ; • eine Lebererkrankung , eine schwere Nierenerkrankung , ungeklärte Gebärmutterblutungen oder ein Endometriumkarzinom ( Gebärmutterschleimhautkrebs ) haben .
T-1212	Evista should not be used in women who : • could become pregnant ; • have or have had any blood clot disorders , including deep vein thrombosis and pulmonary embolism ( a blood clot in the lungs ) ; • have liver disease , severe kidney disease , unexplained bleeding from the womb or endometrial cancer ( cancer of the lining of the womb ) .
H-1212	-0.014187310822308064	Evista should not be used in women who : • could become pregnant ; • have or have had any blood clot disorders , including deep vein thrombosis and pulmonary embolism ( a blood clot in the lungs ) ; • have liver disease , severe kidney disease , unexplained bleeding from the womb or endometrial cancer ( cancer of the lining of the womb ) .
D-1212	-0.014187310822308064	Evista should not be used in women who : • could become pregnant ; • have or have had any blood clot disorders , including deep vein thrombosis and pulmonary embolism ( a blood clot in the lungs ) ; • have liver disease , severe kidney disease , unexplained bleeding from the womb or endometrial cancer ( cancer of the lining of the womb ) .
P-1212	-0.0034 -0.0009 -0.0004 -0.0080 -0.0014 -0.0013 -0.0673 -0.0938 -0.0034 -0.0022 -0.0039 -0.0008 -0.0118 -0.0051 -0.0008 -0.0096 -0.0009 -0.0018 -0.0042 -0.0107 -0.0038 -0.0149 -0.0035 -0.0050 -0.0007 -0.0156 -0.0009 -0.0348 -0.0567 -0.0013 -0.0762 -0.0006 -0.0002 -0.0007 -0.0009 -0.0026 -0.0005 -0.0004 -0.0009 -0.0009 -0.0006 -0.0012 -0.0004 -0.1172 -0.0124 -0.0038 -0.0012 -0.0004 -0.0022 -0.0015 -0.0117 -0.0006 -0.0014 -0.1040 -0.0008 -0.0016 -0.0014 -0.0036 -0.0022 -0.0036 -0.0137 -0.0006 -0.0012 -0.0017 -0.0024 -0.0022 -0.0145 -0.0012 -0.0118 -0.0020 -0.0125 -0.0013 -0.1156 -0.0028 -0.0002 -0.0033 -0.0063 -0.2821 -0.0070 -0.0014 -0.0020 -0.0212 -0.0014 -0.0019 -0.0217 -0.0013 -0.0016 -0.0019 -0.0014
S-261	In klinischen Studien wurden die Antikörperantworten einen Monat nach der Gabe von zwei Dosen sowie nach Abschluss einer Grundimmunisierung mit insgesamt drei Dosen Menitorix ( gleichzeitig verabreicht mit DTPa @-@ HBV @-@ IPV- oder DTPa @-@ IPV @-@ Impfstoffen ) , verabreicht an 814 Säuglinge und Kleinkinder ungefähr in Monat 2 , 3 und 4 oder Monat 2 , 4 und 6 , bewertet .
T-261	Clinical trials have evaluated the antibody responses at one month after two doses and after completion of a 3 @-@ dose primary vaccination course of Menitorix ( co @-@ administered with DTPa @-@ HBV- IPV or DTPa @-@ IPV vaccines ) given at approximately 2 , 3 , 4 months or 2 , 4 , 6 months to 814 infants .
H-261	-0.03248260170221329	Clinical trials have evaluated the antibody responses at one month after two doses and after completion of a 3 @-@ dose primary vaccination course of Menitorix ( co @-@ administered with DTPa @-@ HBV @-@ IPV or DTPa @-@ IPV vaccines ) given at approximately 2 , 3 , 4 months or 2 , 4 , 6 months to 814 infants .
D-261	-0.03248260170221329	Clinical trials have evaluated the antibody responses at one month after two doses and after completion of a 3 @-@ dose primary vaccination course of Menitorix ( co @-@ administered with DTPa @-@ HBV @-@ IPV or DTPa @-@ IPV vaccines ) given at approximately 2 , 3 , 4 months or 2 , 4 , 6 months to 814 infants .
P-261	-0.0147 -0.0019 -0.1094 -0.0144 -0.0068 -0.0012 -0.0105 -0.0043 -0.0406 -0.0026 -0.0139 -0.0131 -0.0024 -0.0058 -0.0113 -0.0023 -0.0009 -0.0072 -0.0100 -0.0090 -0.0043 -0.0015 -0.0128 -0.0145 -0.0111 -0.0007 -0.0132 -0.0137 -0.0013 -0.0128 -0.0094 -0.0039 -0.0010 -0.0005 -0.0012 -0.0031 -0.0140 -0.0014 -0.0029 -0.0007 -0.0023 -0.0043 -0.0012 -0.0013 -0.0014 -0.0069 -0.0004 -0.7433 -0.0019 -0.0081 -0.2067 -0.0025 -0.0013 -0.0013 -0.0013 -0.0013 -0.0017 -0.0006 -0.2370 -0.0023 -0.0012 -0.0018 -0.0140 -0.0136 -0.0076 -0.0140 -0.0033 -0.0014 -0.5621 -0.0559 -0.0162 -0.0064 -0.0109 -0.0015 -0.0014 -0.1045 -0.0779 -0.0024 -0.0070 -0.0009 -0.0012 -0.0032 -0.0038 -0.2142 -0.0016
S-1274	CRIXIVAN kann gleichzeitig mit einer Reihe anderer , häufig bei HIV @-@ Infektionen eingesetzten Arzneimitteln eingenommen werden ( Zidovudin , Didanosin , Lamivudin , Stavudin , Chinidin , Cimetidin , Clarithromycin , Isoniazid , Fluconazol , Trimethoprim / Sulfamethoxazol und Methadon ) .
T-1274	CRIXIVAN may be taken with a number of medicines that are commonly used in HIV infection ( zidovudine , didanosine , lamivudine , stavudine , quinidine , cimetidine , clarithromycin , isoniazid , fluconazole , trimethoprim / sulfamethoxazole , methadone ) .
H-1274	-0.013270190916955471	CRIXIVAN may be taken with a number of medicines that are commonly used in HIV infection ( zidovudine , didanosine , lamivudine , stavudine , quinidine , cimetidine , clarithromycin , isoniazid , fluconazole , trimethoprim / sulfamethoxazole , methadone ) .
D-1274	-0.013270190916955471	CRIXIVAN may be taken with a number of medicines that are commonly used in HIV infection ( zidovudine , didanosine , lamivudine , stavudine , quinidine , cimetidine , clarithromycin , isoniazid , fluconazole , trimethoprim / sulfamethoxazole , methadone ) .
P-1274	-0.0028 -0.0008 -0.0011 -0.0007 -0.0008 -0.0162 -0.0014 -0.0093 -0.0370 -0.0035 -0.0069 -0.0014 -0.0142 -0.0028 -0.0143 -0.0024 -0.0049 -0.0018 -0.1431 -0.0053 -0.0083 -0.0030 -0.0041 -0.0010 -0.0009 -0.0010 -0.0004 -0.0014 -0.0002 -0.0061 -0.0008 -0.0009 -0.0014 -0.0009 -0.0010 -0.0009 -0.0012 -0.0013 -0.0014 -0.0040 -0.0050 -0.0010 -0.0023 -0.0014 -0.0005 -0.0007 -0.0012 -0.0014 -0.0016 -0.0011 -0.0013 -0.0013 -0.0004 -0.0014 -0.0013 -0.0001 -0.0005 -0.0008 -0.0057 -0.0014 -0.0021 -0.0006 -0.0074 -0.0027 -0.0014 -0.0007 -0.0012 -0.0005 -0.0002 -0.0014 -0.0249 -0.0007 -0.0010 -0.0008 -0.0015 -0.0015 -0.0110 -0.0006 -0.0019 -0.0002 -0.0012 -0.0007 -0.0004 -0.7439 -0.0175 -0.0008 -0.0202 -0.0016 -0.0028 -0.0014
S-548	Zusammenfassung der Merkmale des Arzneimittels , Abschnitt 4.8 - Nebenwirkungen Der Inhaber der Genehmigung für das Inverkehrbringen wurde aufgefordert , Unterschiede zwi- schen den unerwünschten Ereignissen , die in den national genehmigten Zusammenfassungen der Merkmale des Arzneimittels und der CDS des Inhabers der Genehmigung für das Inverkehrbrin- gen aufgelistet sind , zu ermitteln und den Abschnitt 4.8 gemäß den MedDRA @-@ Organsystemklassen zu gestalten .
T-548	10 SPC Section 4.8 - Undesirable effects The MAH was asked to identify differences between the listed adverse events in the nationally approved SPCs and the MAH <<unk>> s CDS , and to organise Section 4.8 according to the MedDRA system organ class .
H-548	-0.008870963007211685	10 SPC Section 4.8 - Undesirable effects The MAH was asked to identify differences between the listed adverse events in the nationally approved SPCs and the MAH <unk> s CDS , and to organise Section 4.8 according to the MedDRA system organ class .
D-548	-0.008870963007211685	10 SPC Section 4.8 - Undesirable effects The MAH was asked to identify differences between the listed adverse events in the nationally approved SPCs and the MAH <unk> s CDS , and to organise Section 4.8 according to the MedDRA system organ class .
P-548	-0.0145 -0.0147 -0.0125 -0.0145 -0.0010 -0.0078 -0.0476 -0.0043 -0.0143 -0.0115 -0.0035 -0.0122 -0.0060 -0.0148 -0.0143 -0.0142 -0.0096 -0.0016 -0.0073 -0.0086 -0.0077 -0.0074 -0.0200 -0.0050 -0.0009 -0.0011 -0.0041 -0.0039 -0.0033 -0.0015 -0.0054 -0.0145 -0.0145 -0.0084 -0.0112 -0.0115 -0.0144 -0.0037 -0.0145 -0.0064 -0.0134 -0.0063 -0.0144 -0.0029 -0.0051 -0.0144 -0.0019 -0.0101 -0.0006 -0.0010 -0.0015 -0.0097 -0.0016 -0.0038 -0.0064 -0.0009 -0.0013 -0.0145 -0.0197 -0.0151 -0.0036 -0.0080
S-1746	Durst , Austrocknung , Bluthochdruck , Migräne , geschwollene Drüsen , Hautausschlag , Menstruationsstörungen , vermindertes Interesse am Sex , Vaginalprobleme , Schmerzen in der Brust , Hodenschmerzen , Schilddrüsenprobleme , Zahnfleischrötung , Mundtrockenheit , Rötung oder Entzündung im Bereich des Mundes oder der Zunge , Zahnschmerzen oder Zahnprobleme , Herpes Simplex ( Fieberbläschen ) , Geschmacksveränderungen , Magenverstimmung , Verdauungsstörungen , Verstopfung , Lebervergrößerung ( Leberprobleme , manchmal schwerwiegend ) , dünner Stuhl , Bettnässen bei Kindern , Entzündung der Nebenhöhlen , Bronchitis , Schmerzen am Auge , Probleme am Tränenkanal , 488 Bindehautentzündung ( &quot; Rötung am Auge &quot; ) , körperliche Unruhe , Schläfrigkeit , Schlafwandeln , Verhaltensstörungen , Nervosität , verstopfte oder laufende Nase , Niesen , schnelles Atmen , Blässe , Hautrötung , Bluterguss , hohe Kälteempfindlichkeit der Finger und Zehen , Haut- oder Nagelprobleme , Psoriasis ( neu oder verschlimmert ) , vermehrtes Schwitzen , vermehrter Harndrang , leichtes Zittern , vermindertes Tastgefühl , Arthritis .
T-1746	Commonly reported side effects ( at least 1 in every 100 patients , but less than 1 in every 10 patients ) : thirst , dehydration , high blood pressure , migraines , swollen glands , flushing , menstrual problems , decreased sexual drive , vaginal problem , breast pain , pain in testicle , problems with thyroid gland , red gums , dry mouth , red or sore mouth or tongue , tooth ache or tooth disorder , herpes simplex ( fever blisters ) , taste change , upset stomach , dyspepsia ( heartburn ) , constipation , enlargement of <<unk>> 432 liver ( liver problems , sometimes severe ) , loose stools , bedwetting in children , inflammation of the sinuses , bronchitis , eye pain , problem with your tear ducts , conjunctivitis ( <<unk>> pink eye <<unk>> ) , agitation , sleepiness , sleepwalking , problem with behaviour , nervousness , stuffy or runny nose , sneezing , rapid breathing , pale or reddened skin , bruising , fingers and toes very sensitive to cold , problem with skin or nails , psoriasis ( new or worsened ) , increased sweating , increased need to pass urine , fine shaking movements , decreased sensitivity to touch , arthritis .
H-1746	-0.12496127188205719	Commonly reported side effects ( at least 1 in every 100 patients , but less than 1 in every 10 patients ) : thirst , dehydration , high blood pressure , migraines , swollen glands , flushing , menstrual problems , decreased sexual drive , vaginal problem , breast pain , pain in testicle , problems with thyroid gland , red gums , dry mouth , red or sore mouth or tongue , tooth ache or tooth disorder , herpes simplex ( fever blisters ) , taste change , upset stomach , dyspepsia ( heartburn ) , constipation , enlargement of <unk> 432 liver ( liver problems , sometimes severe ) , loose stools , bedwetting in children , inflammation of the sinuses , bronchitis ( fever blisters ) , eye pain , problem with your tear ducts , conjunctivitis ( <unk> pink eye <unk>
D-1746	-0.12496127188205719	Commonly reported side effects ( at least 1 in every 100 patients , but less than 1 in every 10 patients ) : thirst , dehydration , high blood pressure , migraines , swollen glands , flushing , menstrual problems , decreased sexual drive , vaginal problem , breast pain , pain in testicle , problems with thyroid gland , red gums , dry mouth , red or sore mouth or tongue , tooth ache or tooth disorder , herpes simplex ( fever blisters ) , taste change , upset stomach , dyspepsia ( heartburn ) , constipation , enlargement of <unk> 432 liver ( liver problems , sometimes severe ) , loose stools , bedwetting in children , inflammation of the sinuses , bronchitis ( fever blisters ) , eye pain , problem with your tear ducts , conjunctivitis ( <unk> pink eye <unk>
P-1746	-0.0145 -0.0079 -0.0144 -0.0144 -0.0017 -0.0198 -0.0145 -0.0087 -0.0143 -0.0127 -0.0140 -0.0141 -0.0139 -0.1439 -0.0142 -0.0145 -0.0076 -0.0122 -0.0051 -0.0103 -0.0148 -0.0129 -0.1225 -0.0194 -0.0019 -0.0016 -0.0021 -0.0024 -0.0004 -0.0005 -0.0011 -0.2345 -0.0069 -0.0013 -0.0008 -0.0015 -0.0010 -0.0006 -0.4816 -0.0015 -0.0014 -0.0006 -0.0004 -0.0003 -0.0015 -0.0346 -0.0038 -0.0061 -0.0021 -0.0004 -0.0028 -0.0117 -0.0014 -0.0105 -0.1008 -0.0140 -0.0145 -0.0017 -0.0003 -0.0008 -0.0144 -0.0015 -0.0140 -0.0022 -0.0014 -0.0145 -0.0060 -0.0114 -0.0007 -0.0146 -0.0019 -0.0143 -0.0034 -0.0036 -0.0011 -0.0007 -0.0014 -0.0100 -0.0015 -0.0021 -0.0143 -0.0006 -0.0036 -0.0014 -0.0027 -0.0006 -0.0015 -0.0146 -0.0093 -0.0145 -0.0031 -0.0082 -0.0091 -0.0007 -0.0005 -0.0092 -0.0106 -0.0004 -0.0145 -0.2293 -0.0099 -0.0006 -0.0150 -0.0015 -0.0029 -0.0007 -0.0002 -0.0014 -0.0011 -0.0896 -0.0141 -0.0040 -0.0048 -0.0016 -0.0014 -0.0015 -0.0136 -0.0135 -0.0015 -0.0041 -0.0008 -0.0618 -0.0154 -0.0062 -0.0069 -0.0016 -0.7376 -0.0148 -0.0016 -0.0032 -0.1072 -0.0126 -0.0006 -0.0006 -0.0016 -0.0016 -0.0093 -0.0005 -0.0328 -0.0058 -0.0203 -0.0145 -0.0146 -0.0143 -0.0022 -0.0029 -0.0066 -0.0029 -0.0012 -0.0041 -0.0016 -0.0015 -0.0145 -0.0010 -0.0004 -0.0016 -0.0116 -0.0003 -0.0005 -0.0043 -0.0020 -0.1481 -0.0144 -0.0008 -0.0016 -0.0016 -0.0075 -0.0011 -0.0015 -0.2803 -0.0003 -0.0013 -0.0005 -2.3660 -0.1226 -0.0013 -0.0143 -0.0030 -0.0018 -0.0015 -0.0082 -0.0036 -0.0016 -0.0143 -0.0071 -0.0147 -0.0136 -0.0003 -0.0121 -0.0017 -0.0118 -0.0003 -0.0029 -0.0004 -0.0002 -0.0020 -0.0154 -0.0150 -0.0121 -0.0145 -18.7064
S-541	EU / 1 / 07 / 427 / 011 - Olanzapin Teva - 10 mg - Filmtabletten - 7 Tabletten in einer Packung EU / 1 / 07 / 427 / 012 - Olanzapin Teva - 10 mg - Filmtabletten - 28 Tabletten in einer Packung EU / 1 / 07 / 427 / 013 - Olanzapin Teva - 10 mg - Filmtabletten - 30 Tabletten in einer Packung EU / 1 / 07 / 427 / 041 - Olanzapin Teva - 10 mg - Filmtabletten - 35 Tabletten in einer Packung EU / 1 / 07 / 427 / 014 - Olanzapin Teva - 10 mg - Filmtabletten - 50 Tabletten in einer Packung EU / 1 / 07 / 427 / 015 - Olanzapin Teva - 10 mg - Filmtabletten - 56 Tabletten in einer Packung EU / 1 / 07 / 427 / 051 - Olanzapin Teva - 10 mg - Filmtabletten - 70 Tabletten in einer Packung
T-541	EU / 1 / 07 / 427 / 011 <<unk>> Olanzapine Teva <<unk>> 10 mg <<unk>> film @-@ coated tablets <<unk>> 7 tablets , per box EU / 1 / 07 / 427 / 012 <<unk>> Olanzapine Teva <<unk>> 10 mg <<unk>> film @-@ coated tablets <<unk>> 28 tablets , per box EU / 1 / 07 / 427 / 013 <<unk>> Olanzapine Teva <<unk>> 10 mg <<unk>> film @-@ coated tablets <<unk>> 30 tablets , per box EU / 1 / 07 / 427 / 041 <<unk>> Olanzapine Teva <<unk>> 10 mg <<unk>> film @-@ coated tablets <<unk>> 35 tablets , per box EU / 1 / 07 / 427 / 014 <<unk>> Olanzapine Teva <<unk>> 10 mg <<unk>> film @-@ coated tablets <<unk>> 50 tablets , per box
H-541	-0.026124807074666023	EU / 1 / 07 / 427 / 011 <unk> Olanzapine Teva <unk> 10 mg <unk> film @-@ coated tablets <unk> 7 tablets , per box EU / 1 / 07 / 427 / 012 <unk> Olanzapine Teva <unk> 10 mg <unk> film @-@ coated tablets <unk> 28 tablets , per box EU / 1 / 07 / 427 / 013 <unk> Olanzapine Teva <unk> 10 mg <unk> film @-@ coated tablets <unk> 30 tablets , per box EU / 1 / 07 / 427 / 041 <unk> Olanzapine Teva <unk> 10 mg <unk> film @-@ coated tablets <unk> 35 tablets , per box
D-541	-0.026124807074666023	EU / 1 / 07 / 427 / 011 <unk> Olanzapine Teva <unk> 10 mg <unk> film @-@ coated tablets <unk> 7 tablets , per box EU / 1 / 07 / 427 / 012 <unk> Olanzapine Teva <unk> 10 mg <unk> film @-@ coated tablets <unk> 28 tablets , per box EU / 1 / 07 / 427 / 013 <unk> Olanzapine Teva <unk> 10 mg <unk> film @-@ coated tablets <unk> 30 tablets , per box EU / 1 / 07 / 427 / 041 <unk> Olanzapine Teva <unk> 10 mg <unk> film @-@ coated tablets <unk> 35 tablets , per box
P-541	-0.0018 -0.0015 -0.0013 -0.0014 -0.0009 -0.0014 -0.0012 -0.0010 -0.0014 -0.0016 -0.0015 -0.4464 -0.0117 -0.0009 -0.0011 -0.0008 -0.0042 -0.0015 -0.0008 -0.0150 -0.0129 -0.0013 -0.0137 -0.0129 -0.0313 -0.0145 -0.0008 -0.0360 -0.0048 -0.0154 -0.0093 -0.0075 -0.0135 -0.0145 -0.0120 -0.0143 -0.0032 -0.0016 -0.0016 -0.0015 -0.0009 -0.0014 -0.0012 -0.0010 -0.0015 -0.0015 -0.0013 -0.0050 -0.0095 -0.0008 -0.0011 -0.0007 -0.0016 -0.0011 -0.0008 -0.0047 -0.0026 -0.0013 -0.0018 -0.0066 -0.0031 -0.0014 -0.0008 -0.0097 -0.0016 -0.0084 -0.0022 -0.0059 -0.0117 -0.0035 -0.0018 -0.0088 -0.0433 -0.0016 -0.0016 -0.0015 -0.0008 -0.0014 -0.0011 -0.0010 -0.0015 -0.0014 -0.0011 -0.0100 -0.0089 -0.0009 -0.0013 -0.0007 -0.0012 -0.0012 -0.0009 -0.0049 -0.0025 -0.0008 -0.0031 -0.0035 -0.0023 -0.0019 -0.0006 -0.0024 -0.0029 -0.0049 -0.0031 -0.0038 -0.0132 -0.0023 -0.0016 -0.0101 -0.1428 -0.0021 -0.0016 -0.0015 -0.0009 -0.0014 -0.0011 -0.0010 -0.0015 -0.0017 -0.0009 -0.0122 -0.0064 -0.0010 -0.0013 -0.0008 -0.0018 -0.0012 -0.0010 -0.0059 -0.0030 -0.0012 -0.0053 -0.0028 -0.0024 -0.0010 -0.0007 -0.0032 -0.0016 -0.0039 -0.0099 -0.0039 -0.0135 -0.0028 -0.0015 -0.0094 -2.5635
S-1387	Anämie , verminderte Anzahl der sogenannten Blutplättchen , die zur Blutgerinnung dienen , verminderte Anzahl einiger Arten von weißen Blutzellen , Vergrößerung der Lymphknoten Allergische Reaktion Hohe Blutspiegel von Glukose ( Blutzucker ) Gefühls- oder Bewegungsstörungen , ( unwillkürliches ) Zittern , Krampfanfälle Herzrhythmusstörungen einschließlich schneller Herzschlag ( Palpitationen ) , anormale Werte bei Herzuntersuchungen ( wie EKGs , die den Herzrhythmus aufzeichnen ) Hoher oder niedriger Blutdruck Bauchspeicheldrüsenentzündung Leberentzündung , Leberschaden , Gelbsucht ( Gelbfärbung der Haut oder der Augen ) Nierenfunktionsstörungen , Nierenversagen Menstruationsstörungen Verschwommenes Sehen Haarausfall , Juckreiz Geschwüre im Mund Frösteln , generelles Unwohlsein oder Schwächegefühl Schmerzen am ganzen Körper , einschließlich in Muskeln oder Gelenken , Rückenschmerzen Flüssigkeitsretention , veränderte Arzneimittelspiegel .
T-1387	Anaemia , low numbers of cells called platelets that help the blood to clot , low numbers of some types of white blood cells , enlargement of lymph glands Allergic reaction High blood levels of glucose Disturbances in feeling or moving , tremor , fits Heart rhythm problems including very fast heartbeat ( palpitations ) , abnormal findings on heart tests ( like ECGs that show heart rhythm ) High or low blood pressure Inflammation of the pancreas Inflammation of liver , liver damage , jaundice ( yellow colour of the skin or the eyes ) Problems with kidney function , failure of the kidneys Menstrual disorder Blurred vision Hair loss , itching Mouth ulcers 29 Shivering , generally feeling unwell or weak Scattered body pain , including in muscles and joints , back pain Fluid retention , altered medicine levels .
H-1387	-0.011654187925159931	Anaemia , low numbers of cells called platelets that help the blood to clot , low numbers of some types of white blood cells , enlargement of lymph glands Allergic reaction High blood levels of glucose Disturbances in feeling or moving , tremor , fits Heart rhythm problems including very fast heartbeat ( palpitations ) , abnormal findings on heart tests ( like ECGs that show heart rhythm ) High or low blood pressure Inflammation of the pancreas Inflammation of liver , liver damage , jaundice ( yellow colour of the skin or the eyes ) Problems with kidney function , failure of the kidneys Menstrual disorder Blurred vision Hair loss , itching Mouth ulcers 29 Shivering , generally feeling unwell or weak Scattered body pain , including in muscles and joints , back pain Fluid retention , altered medicine levels .
D-1387	-0.011654187925159931	Anaemia , low numbers of cells called platelets that help the blood to clot , low numbers of some types of white blood cells , enlargement of lymph glands Allergic reaction High blood levels of glucose Disturbances in feeling or moving , tremor , fits Heart rhythm problems including very fast heartbeat ( palpitations ) , abnormal findings on heart tests ( like ECGs that show heart rhythm ) High or low blood pressure Inflammation of the pancreas Inflammation of liver , liver damage , jaundice ( yellow colour of the skin or the eyes ) Problems with kidney function , failure of the kidneys Menstrual disorder Blurred vision Hair loss , itching Mouth ulcers 29 Shivering , generally feeling unwell or weak Scattered body pain , including in muscles and joints , back pain Fluid retention , altered medicine levels .
P-1387	-0.0108 -0.0055 -0.0003 -0.0014 -0.0022 -0.0146 -0.0146 -0.0014 -0.0145 -0.0068 -0.0020 -0.0004 -0.0037 -0.0110 -0.0135 -0.0141 -0.0016 -0.0103 -0.0070 -0.0005 -0.0040 -0.0138 -0.0078 -0.0015 -0.0071 -0.0031 -0.0014 -0.0017 -0.0281 -0.0101 -0.0017 -0.0038 -0.0005 -0.0207 -0.0014 -0.0046 -0.0065 -0.0143 -0.0008 -0.0028 -0.0008 -0.0036 -0.0022 -0.0036 -0.0049 -0.0014 -0.0011 -0.0010 -0.0006 -0.1714 -0.0004 -0.0069 -0.0014 -0.0117 -0.0134 -0.0023 -0.0143 -0.0042 -0.0138 -0.0014 -0.0116 -0.0120 -0.0145 -0.0062 -0.0072 -0.0047 -0.0136 -0.0190 -0.0145 -0.0056 -0.0078 -0.0027 -0.0019 -0.0013 -0.0018 -0.0025 -0.0015 -0.0023 -0.0007 -0.0005 -0.0145 -0.0150 -0.0062 -0.0109 -0.0014 -0.0128 -0.0027 -0.0017 -0.0014 -0.0047 -0.0145 -0.0129 -0.0035 -0.0041 -0.0016 -0.0019 -0.0015 -0.0022 -0.0013 -0.0010 -0.0143 -0.0001 -0.0010 -0.0015 -0.0016 -0.0336 -0.0031 -0.0008 -0.0013 -0.0145 -0.0006 -0.0008 -0.0012 -0.0089 -0.0745 -0.0017 -0.0047 -0.0023 -0.0016 -0.0004 -0.0002 -0.0001 -0.0010 -0.0015 -0.0141 -0.0141 -0.0019 -0.0067 -0.0008 -0.2336 -0.0878 -0.0011 -0.0014 -0.0145 -0.0005 -0.0107 -0.0023 -0.0098 -0.0017 -0.0030 -0.0142 -0.0076 -0.0097 -0.0145 -0.0073 -0.0001 -0.0103 -0.0005 -0.0087 -0.0141 -0.0043 -0.0009 -0.0001 -0.0033 -0.0006 -0.0008 -0.0015 -0.0009 -0.0026 -0.0145 -0.0002 -0.0006 -0.0016 -0.0009 -0.0145 -0.0145 -0.0081 -0.0020 -0.0144 -0.0096 -0.0078 -0.0005 -0.0077 -0.0140 -0.0145 -0.0144 -0.0140 -0.0069 -0.0069 -0.0062 -0.0087 -0.0020 -0.5252 -0.0005 -0.0005 -0.0020 -0.0079 -0.0038 -0.0071 -0.0006 -0.0009 -0.0002 -0.0017 -0.0045 -0.0006 -0.0141 -0.0017 -0.1051 -0.0014
S-736	Dies gilt insbesondere für folgende Arzneimittel : • Antiarrhythmika - Arzneimittel gegen unregelmäßigen Herzschlag ; • Chloroquin , Halofantrin , Clarithromycin , Haloperidol , Methadon - Arzneimittel , die unerwünschte Auswirkungen auf die Herzfunktion haben können ; • Ketoconazol , Itraconazol , Voriconazol , Moxifloxacin , Clarithromycin , Telithromycin - Arzneimittel gegen Infektionskrankheiten ; • Ritonavir - ein Arzneimittel aus der Gruppe der so genannten Antiproteasen , angewendet zur HIV @-@ Behandlung ; • Carbamazepin , Phenobarbital , Phenytoin - Arzneimittel gegen Epilepsie ; • Rifampicin - ein Arzneimittel gegen Tuberkulose ; • Johanniskraut - ein pflanzliches Präparat unter anderem gegen Depressionen ( anderer Name :
T-736	This includes in particular : • antiarrhythmics <<unk>> used to treat irregular heart beat ; • chloroquine , halofantrine , clarithromycin , haloperidol , methadone - medicines that may have an unwanted effect on the function of the heart ; • ketoconazole , itraconazole , voriconazole , moxifloxacin , clarithromycin , telithromycin <<unk>> used to treat infections ; • ritonavir <<unk>> a medicine from the class <<unk>> antiproteases <<unk>> used to treat HIV ; • carbamazepine , phenobarbital , phenytoin <<unk>> used to treat epilepsy ; • rifampicin <<unk>> used to treat tuberculosis ; • St .
H-736	-0.005688347388058901	This includes in particular : • antiarrhythmics <unk> used to treat irregular heart beat ; • chloroquine , halofantrine , clarithromycin , haloperidol , methadone - medicines that may have an unwanted effect on the function of the heart ; • ketoconazole , itraconazole , voriconazole , moxifloxacin , clarithromycin , telithromycin <unk> used to treat infections ; • ritonavir <unk> a medicine from the class <unk> antiproteases <unk> used to treat HIV ; • carbamazepine , phenobarbital , phenytoin <unk> used to treat epilepsy ; • rifampicin <unk> used to treat tuberculosis ; • St .
D-736	-0.005688347388058901	This includes in particular : • antiarrhythmics <unk> used to treat irregular heart beat ; • chloroquine , halofantrine , clarithromycin , haloperidol , methadone - medicines that may have an unwanted effect on the function of the heart ; • ketoconazole , itraconazole , voriconazole , moxifloxacin , clarithromycin , telithromycin <unk> used to treat infections ; • ritonavir <unk> a medicine from the class <unk> antiproteases <unk> used to treat HIV ; • carbamazepine , phenobarbital , phenytoin <unk> used to treat epilepsy ; • rifampicin <unk> used to treat tuberculosis ; • St .
P-736	-0.0062 -0.0140 -0.0063 -0.0010 -0.0050 -0.0011 -0.0099 -0.0002 -0.0003 -0.0091 -0.0146 -0.0145 -0.0130 -0.0028 -0.0050 -0.0006 -0.0141 -0.0114 -0.0045 -0.0007 -0.0010 -0.0003 -0.0012 -0.0011 -0.0006 -0.0022 -0.0006 -0.0012 -0.0006 -0.0016 -0.0657 -0.0014 -0.0029 -0.0002 -0.0006 -0.0011 -0.0033 -0.0015 -0.0003 -0.0001 -0.0003 -0.0025 -0.0013 -0.0010 -0.0094 -0.0754 -0.0041 -0.0058 -0.0068 -0.0059 -0.0046 -0.0125 -0.0111 -0.0129 -0.0033 -0.0015 -0.0139 -0.0132 -0.0014 -0.0016 -0.0008 -0.0311 -0.0007 -0.0002 -0.0015 -0.0014 -0.0005 -0.0003 -0.0015 -0.0004 -0.0011 -0.0015 -0.0005 -0.0005 -0.0014 -0.0004 -0.0002 -0.0006 -0.0005 -0.0014 -0.0013 -0.0008 -0.0005 -0.0012 -0.0009 -0.0015 -0.0014 -0.0025 -0.0001 -0.0006 -0.0012 -0.0019 -0.0019 -0.0003 -0.0167 -0.0002 -0.0005 -0.0012 -0.0020 -0.1032 -0.0138 -0.0053 -0.0019 -0.0018 -0.0140 -0.0015 -0.0008 -0.0016 -0.0012 -0.0009 -0.0009 -0.0190 -0.0105 -0.0135 -0.0108 -0.0043 -0.0141 -0.0185 -0.0098 -0.0011 -0.0018 -0.0009 -0.0140 -0.0038 -0.0383 -0.0012 -0.0006 -0.0018 -0.0010 -0.0016 -0.0016 -0.0005 -0.0005 -0.0010 -0.0024 -0.0006 -0.0007 -0.0010 -0.0017 -0.0001 -0.0017 -0.0006 -0.0010 -0.0013 -0.0040 -0.0204 -0.0116 -0.0064 -0.0026 -0.0029 -0.0005 -0.0011 -0.0008 -0.0013 -0.0010 -0.0010 -0.0011 -0.0009 -0.0007 -0.0073 -0.0139 -0.0135 -0.0067 -0.0034 -0.0015 -0.0006 -0.0013 -0.0004 -0.0010 -0.0018 -0.0016 -0.0107 -0.0338 -0.0145
S-1696	• Behandlung von Ulcus duodeni und Ulcus ventriculi • Behandlung der Refluxösophagitis • Prophylaxe der Refluxösophagitis • Eradikation von Helicobacter pylori ( H. pylori ) in Kombination mit einer geeigneten antibiotischen Therapie zur Behandlung von H. pylori bedingten Ulzera • Behandlung von NSAR @-@ assoziierten gutartigen Ulcus ventriculi und Ulcus duodeni bei Patienten , die eine Langzeittherapie mit NSAR benötigen • Prophylaxe von NSAR @-@ assoziierten Ulcus ventriculi und Ulcus duodeni bei Risikopatienten ( siehe Abschnitt 4.2 ) , die eine Langzeittherapie mit NSAR benötigen • Symptomatische gastro @-@ ösophageale Refluxkrankheit • Zollinger @-@ Ellison @-@ Syndrom .
T-1696	• Treatment of duodenal and gastric ulcer • Treatment of reflux oesophagitis • Prophylaxis of reflux oesophagitis • Eradication of Helicobacter pylori ( H. pylori ) concurrently given with appropriate antibiotic therapy for treatment of H.pylori @-@ associated ulcers • Treatment of NSAID @-@ associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment • Prophylaxis of NSAID @-@ associated gastric ulcers and duodenal ulcers in patients at risk ( see section 4.2 ) requiring continued therapy • Symptomatic gastroesophageal reflux disease • Zollinger @-@ Ellison syndrome .
H-1696	-0.008770364336669445	• Treatment of duodenal and gastric ulcer • Treatment of reflux oesophagitis • Prophylaxis of reflux oesophagitis • Eradication of Helicobacter pylori ( H. pylori ) concurrently given with appropriate antibiotic therapy for treatment of H.pylori @-@ associated ulcers • Treatment of NSAID @-@ associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment • Prophylaxis of NSAID @-@ associated gastric ulcers and duodenal ulcers in patients at risk ( see section 4.2 ) requiring continued therapy • Symptomatic gastroesophageal reflux disease • Zollinger @-@ Ellison syndrome .
D-1696	-0.008770364336669445	• Treatment of duodenal and gastric ulcer • Treatment of reflux oesophagitis • Prophylaxis of reflux oesophagitis • Eradication of Helicobacter pylori ( H. pylori ) concurrently given with appropriate antibiotic therapy for treatment of H.pylori @-@ associated ulcers • Treatment of NSAID @-@ associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment • Prophylaxis of NSAID @-@ associated gastric ulcers and duodenal ulcers in patients at risk ( see section 4.2 ) requiring continued therapy • Symptomatic gastroesophageal reflux disease • Zollinger @-@ Ellison syndrome .
P-1696	-0.0017 -0.0046 -0.0025 -0.0013 -0.0014 -0.0061 -0.0005 -0.0005 -0.0068 -0.0092 -0.0145 -0.0488 -0.0010 -0.0082 -0.0162 -0.0069 -0.0030 -0.0018 -0.0011 -0.0014 -0.0018 -0.0010 -0.0030 -0.0144 -0.0004 -0.0011 -0.0009 -0.0014 -0.0010 -0.0012 -0.0059 -0.0012 -0.0012 -0.0007 -0.0008 -0.0014 -0.0014 -0.0010 -0.0013 -0.0022 -0.0006 -0.0007 -0.0008 -0.0014 -0.0008 -0.0013 -0.0035 -0.0011 -0.0015 -0.0014 -0.0044 -0.0008 -0.0006 -0.0009 -0.0013 -0.0009 -0.0006 -0.0012 -0.0024 -0.0013 -0.0008 -0.0005 -0.0012 -0.0014 -0.0210 -0.0130 -0.0145 -0.0071 -0.0099 -0.0008 -0.0005 -0.0017 -0.0054 -0.0050 -0.0128 -0.0014 -0.0142 -0.0050 -0.0005 -0.0014 -0.0053 -0.0142 -0.0023 -0.0034 -0.0008 -0.0015 -0.0022 -0.0012 -0.0011 -0.0014 -0.0011 -0.0138 -0.0070 -0.0039 -0.0022 -0.0007 -0.0002 -0.0013 -0.0145 -0.0133 -0.0009 -0.0130 -0.0021 -0.0010 -0.0007 -0.0062 -0.0010 -0.0199 -0.0004 -0.0044 -0.0020 -0.0129 -0.0145 -0.0537 -0.0074 -0.0094 -0.0113 -0.0013 -0.0030 -0.0013 -0.0013 -0.0009 -0.0011 -0.0015 -0.0004 -0.0055 -0.0027 -0.0024 -0.0021 -0.0145 -0.2096 -0.0008 -0.0142 -0.0045 -0.0003 -0.0021 -0.0044 -0.0011 -0.0006 -0.0132 -0.0007 -0.0021 -0.0006 -0.0025 -0.0110 -0.0030 -0.0029 -0.0064 -0.0019 -0.0097 -0.0012 -0.0014 -0.0022 -0.0095 -0.0137 -0.0358 -0.0152 -0.0007 -0.0018 -0.0013 -0.0002 -0.1903 -0.0003 -0.0011 -0.0003 -0.0006 -0.0018 -0.0016 -0.0006 -0.0016 -0.0038 -0.0019 -0.0001 -0.0005 -0.0019 -0.0004 -0.0017 -0.0027 -0.0005 -0.3833 -0.0014
S-809	Wenn Sie noch andere Arzneimittel anwenden , ist bei Ihnen möglicherweise eine engmaschige Überwachung erforderlich da die Wirkungen von Yondelis dadurch herabgesetzt ( Beispiele sind Rifampicin @-@ haltige Arzneimittel ( gegen bakterielle Infektionen ) , Phenobarbital ( gegen Epilepsie ) , Johanniskraut ( Hypericum perforatum , ein pflanzliches Mittel gegen Depressionen ) ) oder verstärkt ( Beispiele sind Ketoconazol @-@ haltige oder Fluconazol @-@ haltige Mittel ( gegen Pilzinfektionen ) , Ritonavir ( gegen HIV @-@ Infektionen ) , Clarithromycin ( gegen bakterielle Infektionen , Ciclosporin ( Hemmung der Körperabwehr ) oder Verapamil ( gegen hohen Blutdruck und Herzerkrankungen ) werden können .
T-809	If you use other medicines , you may need to be closely monitored as the effects of Yondelis might be decreased ( examples are medicines containing rifampicin ( for bacterial infections ) , phenobarbital ( for epilepsy ) or St. John <<unk>> s Wort ( Hypericum perforatum , herbal medicine for depression ) ) or increased ( examples are medicines containing ketoconazole or fluconazole ( for fungal infections ) , ritonavir ( for HIV infection ) , clarithromycin ( for bacterial infections ) , ciclosporin ( inhibit the defensive system of the body ) or verapamil ( for high blood pressure and heart conditions ) ) as a result .
H-809	-0.03262946009635925	If you use other medicines , you may need to be closely monitored as the effects of Yondelis might be decreased ( examples are medicines containing rifampicin ( for bacterial infections ) , phenobarbital ( for epilepsy ) or St. John <unk> s Wort ( Hypericum perforatum , herbal medicine for depression ) ) or increased ( examples are medicines containing ketoconazole or fluconazole ( for fungal infections ) , ritonavir ( for HIV infection ) , clarithromycin ( for bacterial infections ) , ciclosporin ( inhibit the defensive system of the body ) or verapamil ( for high blood pressure and heart conditions ) as a result .
D-809	-0.03262946009635925	If you use other medicines , you may need to be closely monitored as the effects of Yondelis might be decreased ( examples are medicines containing rifampicin ( for bacterial infections ) , phenobarbital ( for epilepsy ) or St. John <unk> s Wort ( Hypericum perforatum , herbal medicine for depression ) ) or increased ( examples are medicines containing ketoconazole or fluconazole ( for fungal infections ) , ritonavir ( for HIV infection ) , clarithromycin ( for bacterial infections ) , ciclosporin ( inhibit the defensive system of the body ) or verapamil ( for high blood pressure and heart conditions ) as a result .
P-809	-0.0066 -0.0443 -0.0275 -0.0050 -0.0025 -0.2795 -0.0048 -0.0072 -0.0051 -0.0063 -0.0085 -0.0065 -0.0074 -0.0015 -0.0011 -0.0141 -0.0127 -0.0026 -0.0018 -0.0023 -0.0010 -0.0009 -0.0014 -0.0142 -0.0026 -0.0152 -0.0011 -0.0021 -0.0019 -0.0095 -0.0074 -0.0034 -0.0021 -0.0012 -0.0011 -0.0011 -0.0007 -0.0025 -0.0015 -0.0081 -0.0008 -0.0006 -0.0007 -0.0020 -0.0005 -0.0014 -0.1260 -0.0003 -0.0006 -0.0008 -0.0014 -0.0002 -0.0013 -0.0020 -0.0013 -0.0003 -0.0012 -0.0006 -0.0014 -0.8207 -0.0078 -0.0016 -0.0145 -0.0019 -0.0093 -0.0014 -0.0072 -0.0016 -0.0011 -0.0014 -0.0013 -0.0010 -0.0010 -0.0010 -0.0017 -0.0174 -0.0010 -0.0138 -0.0040 -0.0010 -0.0014 -0.3370 -0.3935 -0.0123 -0.0013 -0.0016 -0.0063 -0.0104 -0.0042 -0.0015 -0.0003 -0.0015 -0.0016 -0.0004 -0.0002 -0.2095 -0.0008 -0.0013 -0.0003 -0.0002 -0.0013 -0.0022 -0.0030 -0.0003 -0.0016 -0.0014 -0.0003 -0.0014 -0.0839 -0.0022 -0.0012 -0.0007 -0.0009 -0.0013 -0.0035 -0.0006 -0.0170 -0.0015 -0.1244 -0.0037 -0.0002 -0.0007 -0.0008 -0.0022 -0.0013 -0.0033 -0.0006 -0.0006 -0.0007 -0.0020 -0.0005 -0.7039 -0.0699 -0.0055 -0.0008 -0.0010 -0.0007 -0.0088 -0.0014 -0.0117 -0.0101 -0.0140 -0.0079 -0.0145 -0.0050 -0.0115 -0.0014 -0.0007 -0.0014 -0.1135 -0.0019 -0.0016 -0.0004 -0.0009 -0.0013 -0.0040 -0.0017 -0.0006 -0.0008 -0.0016 -0.0033 -0.0518 -0.0014 -1.5804 -0.0083 -0.0020 -0.0018 -0.0014
S-350	Es darf bei Patienten mit schwerer Leberkrankheit oder bei Patienten , die eines der folgenden Arzneimittel einnehmen , nicht angewendet werden : Astemizol , Terfenadin ( gebräuchlich zur Behandlung von Allergiesymptomen ; diese Arzneimittel sind möglicherweise auch ohne Verschreibung erhältlich ) ; Dihydroergotamin , Ergotamin , Ergonovin , Methylergonovin ( gegen Migräne ) ; Midazolam , Triazolam ( zur Linderung von Angst- oder Schlafstörungen ) ; Pimozid ( gegen bestimmte psychische Störungen ) ; Cisaprid ( gegen Magenprobleme ) , Bepridil ( gegen Herzerkrankungen ) ; Johanniskraut ( ein pflanzliches Präparat zur Behandlung von Depressionen ) .
T-350	It must not be used in patients with severe liver disease or who are taking any of the following medicines : <<unk>> astemizole , terfenadine ( commonly used to treat allergy symptoms - these medicines may be available without prescription ) ; <<unk>> dihydroergotamine , ergotamine , ergonovine , methylergonovine ( used to treat migraine headache ) ; <<unk>> midazolam , triazolam ( used to relieve anxiety or difficulty sleeping ) ; <<unk>> pimozide ( used to treat mental illnesses ) ; <<unk>> cisapride ( used to relieve certain stomach problems ) ; <<unk>> bepridil ( used to treat angina ) ; <<unk>> St John <<unk>> s wort ( a herbal preparation used to treat depression ) .
H-350	-0.01807636208832264	It must not be used in patients with severe liver disease or who are taking any of the following medicines : <unk> astemizole , terfenadine ( commonly used to treat allergy symptoms - these medicines may be available without prescription ) ; <unk> dihydroergotamine , ergotamine , ergonovine , methylergonovine ( used to treat migraine headache ) ; <unk> midazolam , triazolam ( used to relieve anxiety or difficulty sleeping ) ; <unk> pimozide ( used to treat mental illnesses ) ; <unk> cisapride ( used to relieve certain stomach problems ) ; <unk> bepridil ( used to treat angina ) ; <unk> St John <unk> s wort ( a herbal preparation used to treat depression ) .
D-350	-0.01807636208832264	It must not be used in patients with severe liver disease or who are taking any of the following medicines : <unk> astemizole , terfenadine ( commonly used to treat allergy symptoms - these medicines may be available without prescription ) ; <unk> dihydroergotamine , ergotamine , ergonovine , methylergonovine ( used to treat migraine headache ) ; <unk> midazolam , triazolam ( used to relieve anxiety or difficulty sleeping ) ; <unk> pimozide ( used to treat mental illnesses ) ; <unk> cisapride ( used to relieve certain stomach problems ) ; <unk> bepridil ( used to treat angina ) ; <unk> St John <unk> s wort ( a herbal preparation used to treat depression ) .
P-350	-0.0044 -0.1314 -0.0014 -0.0013 -0.4123 -0.0036 -0.0287 -0.2255 -0.0054 -0.0455 -0.0283 -0.0661 -0.0148 -0.0095 -0.0061 -0.0417 -0.0016 -0.0018 -0.0008 -0.0021 -0.0032 -0.0016 -0.0145 -0.0068 -0.0110 -0.0041 -0.0005 -0.0258 -0.0026 -0.0005 -0.0045 -0.0026 -0.0018 -0.0100 -0.0011 -0.0062 -0.0010 -0.0102 -0.0008 -0.0014 -0.0008 -0.0182 -0.0083 -0.0025 -0.2407 -0.0038 -0.0119 -0.0032 -0.0031 -0.0057 -0.0020 -0.0025 -0.0127 -0.0024 -0.0009 -0.0012 -0.0008 -0.0017 -0.0015 -0.0048 -0.0008 -0.0016 -0.0014 -0.0030 -0.0011 -0.0010 -0.0669 -0.0015 -0.0010 -0.0097 -0.0013 -0.0010 -0.0010 -0.0007 -0.0361 -0.0017 -0.0101 -0.0071 -0.0404 -0.0008 -0.0003 -0.4459 -0.0583 -0.0004 -0.0132 -0.0587 -0.0014 -0.0056 -0.0012 -0.0009 -0.0008 -0.0009 -0.0014 -0.0016 -0.0027 -0.0005 -0.0008 -0.0013 -0.0016 -0.0079 -0.0028 -0.0112 -0.0009 -0.0005 -0.0036 -0.0143 -0.0007 -0.0017 -0.0011 -0.0031 -0.0043 -0.0007 -0.0051 -0.0129 -0.0040 -0.0020 -0.0059 -0.0053 -0.1020 -0.0144 -0.0144 -0.0007 -0.0015 -0.0023 -0.0053 -0.0050 -0.0009 -0.0012 -0.0003 -0.0020 -0.0036 -0.0050 -0.1968 -0.0008 -0.0148 -0.0068 -0.0045 -0.0014 -0.0108 -0.0002 -0.0033 -0.0020 -0.0009 -0.0022 -0.0024 -0.0039 -0.0037 -0.1708 -0.0152 -0.0144 -0.0139 -0.0016 -0.0009 -0.0118 -0.0146 -0.0145 -0.0012 -0.0075 -0.0021 -0.0123 -0.0021 -0.0007 -0.0110 -0.0057 -0.0030 -0.0049 -0.0016 -0.0014 -0.0019 -0.0014
S-558	• Nierenerkrankung oder Nierentransplantation ; • Nierenarterienstenose ( Verengung der zu einer oder beiden Nieren führenden Blutgefäße ) ; • Lebererkrankung ; • Herzbeschwerden ; • erhöhte Aldosteronspiegel ( Wasser und Salzretention im Körper einhergehend mit einem Ungleichgewicht von verschiedenen Mineralstoffen im Blut ) ; • niedriger Blutdruck ( Hypotonie ) , der bei Dehydrierung ( übermäßiger Flüssigkeitsverlust des Körpers ) , Salzmangel infolge einer Diuretikabehandlung ( &quot; Entwässerungstabletten &quot; ) , salzarmer Kost , Durchfall oder Erbrechen auftreten kann ; • erhöhte Kaliumspiele im Blut ; • Diabetes mellitus .
T-558	48 • Renal artery stenosis ( narrowing of the blood vessels to one or both kidneys ) . • Liver disease . • Heart trouble . • Raised aldosterone levels ( water and salt retention in the body along with imbalance of various blood minerals ) . • Low blood pressure ( hypotension ) , likely to occur if you are dehydrated ( excessive loss of body water ) or have salt deficiency due to diuretic therapy ( &apos; water tablets &apos; ) , low @-@ salt diet , diarrhoea , or vomiting . • Elevated potassium levels in your blood . • Diabetes .
H-558	-0.011552534997463226	48 • Renal artery stenosis ( narrowing of the blood vessels to one or both kidneys ) . • Liver disease . • Heart trouble . • Raised aldosterone levels ( water and salt retention in the body along with imbalance of various blood minerals ) . • Low blood pressure ( hypotension ) , likely to occur if you are dehydrated ( excessive loss of body water ) or have salt deficiency due to diuretic therapy ( &apos; water tablets &apos; ) , low @-@ salt diet , diarrhoea , or vomiting . • Elevated potassium levels in your blood . • Diabetes .
D-558	-0.011552534997463226	48 • Renal artery stenosis ( narrowing of the blood vessels to one or both kidneys ) . • Liver disease . • Heart trouble . • Raised aldosterone levels ( water and salt retention in the body along with imbalance of various blood minerals ) . • Low blood pressure ( hypotension ) , likely to occur if you are dehydrated ( excessive loss of body water ) or have salt deficiency due to diuretic therapy ( &apos; water tablets &apos; ) , low @-@ salt diet , diarrhoea , or vomiting . • Elevated potassium levels in your blood . • Diabetes .
P-558	-0.0145 -0.0145 -0.0143 -0.0013 -0.0147 -0.0063 -0.0057 -0.0011 -0.0010 -0.0020 -0.0037 -0.0009 -0.0017 -0.0093 -0.0049 -0.0008 -0.0007 -0.0145 -0.0042 -0.0013 -0.0052 -0.0038 -0.0454 -0.0002 -0.0015 -0.3779 -0.0009 -0.0085 -0.0006 -0.0024 -0.0078 -0.0009 -0.0029 -0.0139 -0.0038 -0.0014 -0.0151 -0.0004 -0.0056 -0.0014 -0.0006 -0.0011 -0.0058 -0.0028 -0.0043 -0.0018 -0.0030 -0.0014 -0.0004 -0.0022 -0.0016 -0.0014 -0.0143 -0.0014 -0.0125 -0.0083 -0.0020 -0.0058 -0.0166 -0.0028 -0.0012 -0.0011 -0.0020 -0.0211 -0.0011 -0.0045 -0.0018 -0.0009 -0.0068 -0.0019 -0.0003 -0.0009 -0.0020 -0.0014 -0.0100 -0.0145 -0.0064 -0.0084 -0.0237 -0.0128 -0.0120 -0.0049 -0.0021 -0.0015 -0.0032 -0.0040 -0.0111 -0.0014 -0.0137 -0.0143 -0.0015 -0.0609 -0.0108 -0.0128 -0.0018 -0.0003 -0.0028 -0.0106 -0.0014 -0.0029 -0.0018 -0.0033 -0.0140 -0.0365 -0.0154 -0.0148 -0.0049 -0.0015 -0.0163 -0.0016 -0.0637 -0.0096 -0.0098 -0.0019 -0.0113 -0.0147 -0.0015 -0.0004 -0.0099 -0.0004 -0.1919 -0.0040 -0.0150 -0.0003 -0.0012 -0.0078 -0.0053 -0.0145 -0.0060 -0.0012 -0.0092 -0.0001 -0.0012 -0.0089 -0.0018 -0.0957 -0.0015 -0.0018 -0.0075 -0.0021 -0.0252 -0.0014
Generate valid with beam=5: BLEU4 = 94.39, 98.9/98.0/97.3/96.7 (BP=0.966, ratio=0.966, syslen=36885, reflen=38173)
